PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Kim, SY; Senatorov, VV; Morrissey, CS; Lippmann, K; Vazquez, O; Milikovsky, DZ; Gu, F; Parada, I; Prince, DA; Becker, AJ; Heinemann, U; Friedman, A; Kaufer, D				Kim, Soo Young; Senatorov, Vladimir V., Jr.; Morrissey, Christapher S.; Lippmann, Kristina; Vazquez, Oscar; Milikovsky, Dan Z.; Gu, Feng; Parada, Isabel; Prince, David A.; Becker, Albert J.; Heinemann, Uwe; Friedman, Alon; Kaufer, Daniela			TGF beta signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults	SCIENTIFIC REPORTS			English	Article							BLOOD-BRAIN-BARRIER; INJURED EPILEPTOGENIC NEOCORTEX; MARKED NEUROPROTECTIVE EFFICACY; FAST-SPIKING INTERNEURONS; ACUTE ISCHEMIC-STROKE; EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; ACQUIRED EPILEPSY; ALBUMIN THERAPY; VISUAL-CORTEX	Brain damage due to stroke or traumatic brain injury (TBI), both leading causes of serious long-term disability, often leads to the development of epilepsy. Patients who develop post-injury epilepsy tend to have poor functional outcomes. Emerging evidence highlights a potential role for blood-brain barrier (BBB) dysfunction in the development of post-injury epilepsy. However, common mechanisms underlying the pathological hyperexcitability are largely unknown. Here, we show that comparative transcriptome analyses predict remodeling of extracellular matrix (ECM) as a common response to different types of injuries. ECM-related transcriptional changes were induced by the serum protein albumin via TGF beta signaling in primary astrocytes. In accordance with transcriptional responses, we found persistent degradation of protective ECM structures called perineuronal nets (PNNs) around fast-spiking inhibitory interneurons, in a rat model of TBI as well as in brains of human epileptic patients. Exposure of a naive brain to albumin was sufficient to induce the transcriptional and translational upregulation of molecules related to ECM remodeling and the persistent breakdown of PNNs around fast-spiking inhibitory interneurons, which was contingent on TGF beta signaling activation. Our findings provide insights on how albumin extravasation that occurs upon BBB dysfunction in various brain injuries can predispose neural circuitry to the development of chronic inhibition deficits.	[Kim, Soo Young; Morrissey, Christapher S.; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Senatorov, Vladimir V., Jr.; Vazquez, Oscar; Kaufer, Daniela] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Lippmann, Kristina; Heinemann, Uwe] Charite Univ Med Berlin, Inst Neurophysiol, D-10117 Berlin, Germany; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Cognit & Brain Sci, IL-84105 Beer Sheva, Israel; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Physiol, IL-84105 Beer Sheva, Israel; [Milikovsky, Dan Z.; Friedman, Alon] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Cell Biol, IL-84105 Beer Sheva, Israel; [Gu, Feng; Parada, Isabel; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Becker, Albert J.] Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; [Friedman, Alon] Dalhousie Univ, Dept Med Neurosci, Halifax, NS B3H 4R2, Canada; [Kaufer, Daniela] Canadian Inst Adv Res CIFAR, Program Child & Brain Dev, Toronto, ON M5G 1Z8, Canada; [Lippmann, Kristina] Univ Leipzig, Carl Ludwig Inst Physiol, D-04315 Leipzig, Germany		Kim, SY; Kaufer, D (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.; Kaufer, D (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.; Kaufer, D (corresponding author), Canadian Inst Adv Res CIFAR, Program Child & Brain Dev, Toronto, ON M5G 1Z8, Canada.	sooykim29@gmail.com; danielak@berkeley.edu	Kim, Soo Young/K-2083-2012; Lippmann, Kristina/AAA-6709-2019; Becker, Albert J/F-6248-2012	Kim, Soo Young/0000-0002-2111-4619; Lippmann, Kristina/0000-0001-7719-0437; Milikovsky, Dan Z/0000-0002-4826-5273	NARSAD Young Investigator Grant Award; Siebel Stem Cell Postdoctoral Fellowship; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 39579, NS 082644, NS 090076, T32-AG00266, 2R56NS066005-05A1]; CURE (Citizens United for Research in Epilepsy) Prevention of Acquired Epilepsies Grant Award; German Research Foundation Grant Cluster of Excellence [DFG-EXC257 NeuroCure, DFG-HE1128/18-1, GRK 1123]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000266] Funding Source: NIH RePORTER	We wish to dedicate this paper in memory of our co-author, Dr. Uwe Heinemann, who passed away during the work on this manuscript. Uwe was a role model, a wonderful colleague and a dear friend to us. We thank Dr. Yunyong Ma, Delina T. Meharenna, and Min-Sun Jun for technical assistance, Dr. Justin Y. Choi in the Functional Genomics Lab at UC Berkeley for the help with microarray analysis, and Dr. DeAnna L. Adkins for helpful comments on the manuscript. This work is supported by NARSAD Young Investigator Grant Award and Siebel Stem Cell Postdoctoral Fellowship (to S.Y.K.), the US National Institutes of Health grant NS 39579, NS 082644, and NS 090076 (to D.A.P.), T32-AG00266 (to C.S.M.), 2R56NS066005-05A1 (to D.K.), CURE (Citizens United for Research in Epilepsy) Prevention of Acquired Epilepsies Grant Award (to A.F. and D.K.), and the German Research Foundation Grant Cluster of Excellence DFG-EXC257 NeuroCure (to U.H.), DFG-HE1128/18-1 (to U.H. and A.F.), and GRK 1123 (K.L.).	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Asher RA, 2000, J NEUROSCI, V20, P2427; Balami JS, 2011, LANCET NEUROL, V10, P357, DOI 10.1016/S1474-4422(10)70313-6; Bar-Klein G, 2014, ANN NEUROL, V75, P864, DOI 10.1002/ana.24147; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Beurdeley M, 2012, J NEUROSCI, V32, P9429, DOI 10.1523/JNEUROSCI.0394-12.2012; Bien CG, 2007, NEUROLOGY, V69, P1236, DOI 10.1212/01.wnl.0000276946.08412.ef; BRUCKNER G, 1993, GLIA, V8, P183, DOI 10.1002/glia.440080306; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cammarota M, 2013, J PHYSIOL-LONDON, V591, P807, DOI 10.1113/jphysiol.2012.238154; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Dityatev A, 2010, TRENDS NEUROSCI, V33, P503, DOI 10.1016/j.tins.2010.08.003; Fauser S, 2004, ACTA NEUROPATHOL, V108, P272, DOI 10.1007/s00401-004-0889-0; Gaudet AD, 2014, EXP NEUROL, V258, P24, DOI 10.1016/j.expneurol.2013.11.020; Geirsson A, 2012, CIRCULATION, V126, pS189, DOI 10.1161/CIRCULATIONAHA.111.082610; Geissler M, 2013, J NEUROSCI, V33, P7742, DOI 10.1523/JNEUROSCI.3275-12.2013; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hsieh T. H., 2016, CEREB CORTEX; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Kann O, 2011, BRAIN, V134, P345, DOI 10.1093/brain/awq333; Kim HT, 2015, CELL REP, V13, P990, DOI 10.1016/j.celrep.2015.09.075; Kim S. Y., 2016, J NEUROSCIENCE RES; Kim SY, 2016, J NEUROSCI RES, V94, P794, DOI 10.1002/jnr.23758; Kim SY, 2012, EPILEPSIA, V53, P37, DOI 10.1111/j.1528-1167.2012.03701.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Librizzi L, 2012, ANN NEUROL, V72, P82, DOI 10.1002/ana.23567; Lippmann K., 2016, J CEREBRAL BLOOD FLO; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Martin RH, 2016, STROKE, V47, P2355, DOI 10.1161/STROKEAHA.116.012825; McFarland BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078728; McMillin M. A., 2015, LAB INVEST; Mercado-Gomez O, 2014, EPILEPSY RES, V108, P1694, DOI 10.1016/j.eplepsyres.2014.09.019; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Pollock E, 2014, NEUROBIOL DIS, V70, P21, DOI 10.1016/j.nbd.2014.06.003; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Raabe A, 2012, EPILEPSIA, V53, P539, DOI 10.1111/j.1528-1167.2012.03405.x; Rankin- Gee E. K., 2015, EPILEPSIA; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rossi S, 2011, BRAIN BEHAV IMMUN, V25, P947, DOI 10.1016/j.bbi.2010.10.004; Salar S, 2016, NEUROBIOL DIS, V91, P155, DOI 10.1016/j.nbd.2016.03.008; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sorg BA, 2016, J NEUROSCI, V36, P11459, DOI 10.1523/JNEUROSCI.2351-16.2016; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Sugiyama S, 2008, CELL, V134, P508, DOI 10.1016/j.cell.2008.05.054; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Upchurch K, 2010, SEIZURE-EUR J EPILEP, V19, P120, DOI 10.1016/j.seizure.2009.11.006; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Weissberg I, 2015, NEUROBIOL DIS, V78, P115, DOI 10.1016/j.nbd.2015.02.029; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wu M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155730; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu Q, 2000, GENE DEV, V14, P163; Yutsudo N., 2015, EXP NEUROL; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	75	41	41	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 9	2017	7								7711	10.1038/s41598-017-07394-3			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD1KC	WOS:000407295200010	28794441	gold, Green Published			2022-02-06	
J	Esnault, P; Cardinale, M; Boret, H; D'Aranda, E; Montcriol, A; Bordes, J; Prunet, B; Joubert, C; Dagain, A; Goutorbe, P; Kaiser, E; Meaudre, E				Esnault, Pierre; Cardinale, Mickael; Boret, Henry; D'Aranda, Erwan; Montcriol, Ambroise; Bordes, Julien; Prunet, Bertrand; Joubert, Christophe; Dagain, Arnaud; Goutorbe, Philippe; Kaiser, Eric; Meaudre, Eric			Blunt cerebrovascular injuries in severe traumatic brain injury: incidence, risk factors, and evolution	JOURNAL OF NEUROSURGERY			English	Article						blunt cerebrovascular injury; traumatic brain injury; cervical artery dissection; anticoagulation therapy	CAROTID ARTERIAL INJURIES; COMPUTED-TOMOGRAPHY; SCREENING CRITERIA; EARLY-DIAGNOSIS; ANTICOAGULATION; DISSECTIONS	OBJECTIVE Blunt cerebrovascular injuries (BCVIs) affect approximately 1% of patients with blunt trauma. An antithrombotic or anticoagulation therapy is recommended to prevent the occurrence or recurrence of neurovascular events. This treatment has to be carefully considered after severe traumatic brain injury (TBI), due to the risk of intracranial hemorrhage expansion. Thus, the physician in charge of the patient is confronted with a hemorrhagic and ischemic risk. The main objective of this study was to determine the incidence of BCVI after severe TBI. METHODS The authors conducted a prospective, observational, single-center study including all patients with severe TBI admitted in the trauma center. Diagnosis of BCVI was performed using a 64-channel multidetector CT. Characteristics of the patients, CT scan results, and outcomes were collected. A multivariate logistic regression model was developed to determine the risk factors of BCVI. Patients in whom BCVI was diagnosed were treated with systemic anticoagulation. RESULTS In total, 228 patients with severe TBI who were treated over a period of 7 years were included. The incidence of BCVI was 9.2%. The main risk factors were as follows: motorcycle crash (OR 8.2, 95% CI 1.9-34.8), fracture involving the carotid canal (OR 11.7, 95% CI 1.7-80.9), cervical spine injury (OR 13.5, 95% CI 3.1-59.4), thoracic trauma (OR 7.3, 95% CI 1.1-51.2), and hepatic lesion (OR 13.3, 95% CI 2.1-84.5). Among survivors, 82% of patients with BCVI received systemic anticoagulation therapy, beginning at a median of Day 1.5. The overall stroke rate was 19%. One patient had an intracranial hemorrhagic complication. CONCLUSIONS Blunt cerebrovascular injuries are frequent after severe TBI (incidence 9.2%). The main risk factors are high-velocity lesions and injuries near cervical arteries.	[Esnault, Pierre; Cardinale, Mickael; Boret, Henry; D'Aranda, Erwan; Montcriol, Ambroise; Bordes, Julien; Prunet, Bertrand; Goutorbe, Philippe; Kaiser, Eric; Meaudre, Eric] St Anne Mil Hosp, Intens Care Unit, Toulon, France; [Joubert, Christophe; Dagain, Arnaud] St Anne Mil Hosp, Dept Neurosurg, Toulon, France; [Dagain, Arnaud; Kaiser, Eric; Meaudre, Eric] Ecole Val de Grace, French Mil Hlth Serv, Acad Unit, Paris, France		Esnault, P (corresponding author), Hop Instruct Armees St Anne, Serv Reanimat Brules, Blvd St Anne, F-83000 Toulon, France.	pierre.esnault@gmail.com	Esnault, Pierre/AAN-5792-2020; Joubert, Christophe/AAU-4807-2020	dagain, arnaud/0000-0001-8416-1976			Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; Arthurs ZM, 2008, INJURY, V39, P1232, DOI 10.1016/j.injury.2008.02.042; Bauer D, 2008, J NEUROTRAUM, V25, P276; Bauer Derek, 2015, Semin Neurol, V35, pe14, DOI 10.1055/s-0035-1549095; Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS87; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Burlew CC, 2011, SURG CLIN N AM, V91, P217, DOI 10.1016/j.suc.2010.10.004; Burlew CC, 2010, CURR OPIN CRIT CARE, V16, P587, DOI 10.1097/MCC.0b013e32833ee8b4; Callcut RA, 2012, J TRAUMA ACUTE CARE, V72, P338, DOI 10.1097/TA.0b013e318243d978; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Franz RW, 2012, J AM COLL SURGEONS, V214, P313, DOI 10.1016/j.jamcollsurg.2011.11.012; Fusco MR, 2011, NEUROSURGERY, V68, P517, DOI 10.1227/NEU.0b013e3181fe2fda; Jacobson LE, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0040-7; Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKinney A, 2007, EUR J RADIOL, V62, P385, DOI 10.1016/j.ejrad.2007.01.008; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Mundinger GS, 2013, J ORAL MAXIL SURG, V71, P2092, DOI 10.1016/j.joms.2013.07.005; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Sliker CW, 2008, RADIOGRAPHICS, V28, P1689, DOI 10.1148/rg.286085521; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146	35	41	44	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2017	127	1					16	22		10.3171/2016.4.JNS152600			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EY6JB	WOS:000404087500003	27471889				2022-02-06	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Single-task and dual-task tandem gait test performance after concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Tandem gait; Locomotion; Balance; Concussion; Mild traumatic brain injury; Dual-task	SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; EXECUTIVE FUNCTION; POSTURAL CONTROL; BALANCE CONTROL; ADOLESCENTS; ATTENTION	Objectives: To compare single-task and dual-task tandem gait test performance between athletes after concussion with controls on observer-timed, spatio-temporal, and center-of-mass (COM) balance control measurements. Design: Ten participants (19.0 +/- 5.5 years) were prospectively identified and completed a tandem gait test protocol within 72 h of concussion and again 1 week, 2 weeks, 1 month, and 2 months post-injury. Seven uninjured controls (20.0 +/- 4.5 years) completed the same protocol in similar time increments. Methods: Tandem gait test trials were performed with (dual-task) and without (single-task) concurrently performing a cognitive test as whole-body motion analysis was performed. Outcome variables included test completion time, average tandem gait velocity, cadence, and whole-body COM frontal plane displacement. Results: Concussion participants took significantly longer to complete the dual-task tandem gait test than controls throughout the first 2 weeks post-injury (mean time = 16.4 [95% CI: 13.4-19.4] vs. 10.1 [95% CI: 6.4-13.7] seconds; p = 0.03). Single-task tandem gait times were significantly lower 72 h post-injury (p = 0.04). Dual-task cadence was significantly lower for concussion participants than controls (89.5 [95% CI: 68.6-110.4] vs. 127.0 [95% CI: 97.4-156.6] steps/minute; p = 0.04). Moderately-high to high correlations between tandem gait test time and whole-body COM medial-lateral displacement were detected at each time point during dual-task gait (r(s) = 0.70-0.93; p = 0.03-0.001). Conclusions: Adding a cognitive task during the tandem gait test resulted in longer detectable deficits post-concussion compared to the traditional single-task tandem gait test. As a clinical tool to assess dynamic motor function, tandem gait may assist with return to sport decisions after concussion. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu		Chou, Li-Shan/0000-0002-2777-7034	Department of Defense-TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	Funding for the data collection of this work was supported by the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would also like to acknowledge Mr. Quinn Peterson, Mr. Michael Kado, Ms. Madison Murray, and Ms. Rachel Klas for their assistance with data collection.	Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Hanninen T, 2016, J SCI MED SPORT, V19, P636, DOI 10.1016/j.jsams.2015.08.005; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Winter D, 2009, BIOMECHANICS MOTOR C, Vfourth, P86; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265	23	41	41	3	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2017	20	7					622	626		10.1016/j.jsams.2016.11.020			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FA2FI	WOS:000405255800003	28169147				2022-02-06	
J	Sompol, P; Furman, JL; Pleiss, MM; Kraner, SD; Artiushin, IA; Batten, SR; Quintero, JE; Simmerman, LA; Beckett, TL; Lovell, MA; Murphy, MP; Gerhardt, GA; Norris, CM				Sompol, Pradoldej; Furman, Jennifer L.; Pleiss, Melanie M.; Kraner, Susan D.; Artiushin, Irina A.; Batten, Seth R.; Quintero, Jorge E.; Simmerman, Linda A.; Beckett, Tina L.; Lovell, Mark A.; Murphy, M. Paul; Gerhardt, Greg A.; Norris, Christopher M.			Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in A beta-Bearing Mice	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; astrocytes; calcineurin; dementia; glutamate; hyperexcitability	POSTSYNAPTICALLY SILENT SYNAPSES; GLIAL GLUTAMATE TRANSPORTER; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; AMYLOID-BETA; NEURONAL-ACTIVITY; SYNAPTIC FUNCTION; TRANSGENIC MICE	Hyperexcitable neuronal networks are mechanistically linked to the pathologic and clinical features of Alzheimer's disease (AD). Astrocytes are a primary defense against hyperexcitability, but their functional phenotype duringADis poorly understood. Here, we found that activated astrocytes in the5xFADmousemodel were strongly associated with proteolysis of the protein phosphatase calcineurin (CN) and the elevated expression of the CN-dependent transcription factor nuclear factor of activated T cells 4 (NFAT4). Intrahippocampal injections of adeno-associated virus vectors containing the astrocyte-specific promoter Gfa2 and the NFAT inhibitory peptide VIVIT reduced signs of glutamate-mediated hyperexcitability in 5xFAD mice, measured in vivo with microelectrode arrays and ex vivo brain slices, using whole-cell voltage clamp. VIVIT treatment in 5xFAD mice led to increased expression of the astrocytic glutamate transporter GLT-1 and to attenuated changes in dendrite morphology, synaptic strength, and NMDAR-dependent responses. The results reveal astrocytic CN/NFAT4 as a key pathologic mechanism for driving glutamate dysregulation and neuronal hyperactivity during AD.	[Sompol, Pradoldej; Kraner, Susan D.; Artiushin, Irina A.; Beckett, Tina L.; Lovell, Mark A.; Murphy, M. Paul; Norris, Christopher M.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Furman, Jennifer L.; Pleiss, Melanie M.; Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA; [Batten, Seth R.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Dept Neurosci, Lexington, KY 40536 USA; [Batten, Seth R.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Simmerman, Linda A.] Univ Kentucky, Coll Arts & Sci, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lovell, Mark A.] Univ Kentucky, Coll Arts & Sci, Dept Chem, Lexington, KY 40536 USA; [Murphy, M. Paul] Univ Kentucky, Coll Arts & Sci, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA		Norris, CM (corresponding author), Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA.	cnorr2@uky.edu		Kraner, Susan/0000-0002-1062-4007	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG027297, AG051945, AG000242-20]; The Hazel Embry Research Trust; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG027297, R01AG027297, R21AG051945, T32AG000242] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants AG027297 and AG051945 to C.M.N. and Grant AG000242-20 to P.S.; and The Hazel Embry Research Trust. We thank Drs. Eric M. Blalock and Richard Kryscio for conceptual and statistical input.	Abdul HM, 2011, AGING CELL, V10, P103, DOI 10.1111/j.1474-9726.2010.00645.x; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Aida T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036853; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Andreasson KI, 2016, J NEUROCHEM, V138, P653, DOI 10.1111/jnc.13667; ANDREW RD, 1994, NEUROSCIENCE, V62, P371, DOI 10.1016/0306-4522(94)90372-7; Armbruster M, 2016, J NEUROSCI, V36, P10404, DOI 10.1523/JNEUROSCI.2066-16.2016; Audrain M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0070-y; Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Bakker A, 2012, NEURON, V74, P467, DOI 10.1016/j.neuron.2012.03.023; Bomben V, 2014, NEUROBIOL AGING, V35, P2091, DOI 10.1016/j.neurobiolaging.2014.03.029; Bouvier DS, 2015, J ALZHEIMERS DIS, V45, P1001, DOI 10.3233/JAD-143156; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Busche MA, 2015, BIOESSAYS, V37, P624, DOI 10.1002/bies.201500004; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Dallas M, 2007, J NEUROSCI, V27, P3946, DOI 10.1523/JNEUROSCI.5030-06.2007; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Fleming TM, 2011, J PHYSIOL-LONDON, V589, P3929, DOI 10.1113/jphysiol.2011.207340; Fontana ACK, 2016, J NEUROTRAUM, V33, P1073, DOI 10.1089/neu.2015.4079; Fontana R, 2017, NEUROBIOL AGING, V50, P64, DOI 10.1016/j.neurobiolaging.2016.10.027; Furman JL, 2016, J NEUROSCI, V36, P1502, DOI 10.1523/JNEUROSCI.1930-15.2016; Furman JL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0158-7; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; Gong HY, 2016, INT J MOL MED, V38, P943, DOI 10.3892/ijmm.2016.2663; Gray BC, 2006, BIOCHEM SOC T, V34, P51, DOI 10.1042/BST0340051; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Grienberger C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1783; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hascup KN, 2011, NEUROPSYCHOPHARMACOL, V36, P1769, DOI 10.1038/npp.2011.60; Hascup KN, 2007, FRONT NEUROENG, V1, P407; Hefendehl JK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13441; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Huang YHH, 2004, CURR OPIN NEUROBIOL, V14, P346, DOI 10.1016/j.conb.2004.05.007; Hudry E, 2012, J NEUROSCI, V32, P3176, DOI 10.1523/JNEUROSCI.6439-11.2012; Hunsberger HC, 2015, J NEUROCHEM, V132, P169, DOI 10.1111/jnc.12967; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kellner V, 2014, NEUROBIOL AGING, V35, P1982, DOI 10.1016/j.neurobiolaging.2014.04.001; Kim JH, 2016, EXP MOL PATHOL, V100, P1, DOI 10.1016/j.yexmp.2015.11.005; Kim SY, 2003, J NEUROCHEM, V86, P1458, DOI 10.1046/j.1471-4159.2003.01958.x; Kuchibhotla KV, 2009, SCIENCE, V323, P1211, DOI 10.1126/science.1169096; Lacey CJ, 2012, J NEUROSCI, V32, P11067, DOI 10.1523/JNEUROSCI.5604-11.2012; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lim D, 2013, GLIA, V61, P1134, DOI 10.1002/glia.22502; Liu F, 2005, J BIOL CHEM, V280, P37755, DOI 10.1074/jbc.M507475200; Mallolas J, 2006, J EXP MED, V203, P711, DOI 10.1084/jem.20051979; Malm TM, 2015, NEUROTHERAPEUTICS, V12, P81, DOI 10.1007/s13311-014-0316-8; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; Matveeva EA, 2012, EPILEPSIA, V53, P157, DOI 10.1111/j.1528-1167.2011.03345.x; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Meeker KD, 2015, J ALZHEIMERS DIS, V45, P509, DOI 10.3233/JAD-142304; Miller EM, 2015, J NEUROSCI METH, V252, P75, DOI 10.1016/j.jneumeth.2015.01.018; Miller EM, 2014, PSYCHOPHARMACOLOGY, V231, P3019, DOI 10.1007/s00213-014-3479-4; Minkeviciene R, 2009, J NEUROSCI, V29, P3453, DOI 10.1523/JNEUROSCI.5215-08.2009; Moidunny S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0613-8; Mookherjee P, 2011, J ALZHEIMERS DIS, V26, P447, DOI 10.3233/JAD-2011-110503; Murphy MP, 2007, NEUROBIOL DIS, V27, P301, DOI 10.1016/j.nbd.2007.06.002; Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010; Noebels J, 2011, EPILEPSIA, V52, P39, DOI 10.1111/j.1528-1167.2010.02909.x; Norris CM, 2006, J NEUROPHYSIOL, V96, P2488, DOI 10.1152/jn.00593.2005; Norris CM, 2016, EXP NEUROL, V276, P5, DOI 10.1016/j.expneurol.2015.11.006; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Nudmamud-Thanoi S, 2006, NEUROTOXICOLOGY, V27, P623, DOI 10.1016/j.neuro.2006.01.012; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oberheim NA, 2012, METHODS MOL BIOL, V814, P23, DOI 10.1007/978-1-61779-452-0_3; Padurariu M, 2012, PSYCHIAT DANUB, V24, P152; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Peskind ER, 2006, AM J GERIAT PSYCHIAT, V14, P704, DOI 10.1097/01.JGP.0000224350.82719.83; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Pleiss MM, 2016, BBA-MOL BASIS DIS, V1862, P1521, DOI 10.1016/j.bbadis.2016.05.007; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Prow NA, 2008, J NEUROCHEM, V105, P1276, DOI 10.1111/j.1471-4159.2008.05230.x; Putcha D, 2011, J NEUROSCI, V31, P17680, DOI 10.1523/JNEUROSCI.4740-11.2011; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reese LC, 2008, AGING CELL, V7, P824, DOI 10.1111/j.1474-9726.2008.00434.x; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rojanathammanee L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0255-2; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Sametsky EA, 2010, NEUROBIOL AGING, V31, P813, DOI 10.1016/j.neurobiolaging.2008.05.029; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Schallier A, 2011, J ALZHEIMERS DIS, V24, P287, DOI 10.3233/JAD-2011-101005; Scholl M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16404; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Scimemi A, 2013, J NEUROSCI, V33, P5312, DOI 10.1523/JNEUROSCI.5274-12.2013; Selkirk JV, 2005, EUR J NEUROSCI, V21, P3217, DOI 10.1111/j.1460-9568.2005.04162.x; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shioda N, 2006, J NEUROCHEM, V98, P310, DOI 10.1111/j.1471-4159.2006.03874.x; Simpson JE, 2010, NEUROBIOL AGING, V31, P578, DOI 10.1016/j.neurobiolaging.2008.05.015; Siskova Z, 2014, NEURON, V84, P1023, DOI 10.1016/j.neuron.2014.10.024; Spires TL, 2004, REV NEUROSCIENCE, V15, P267, DOI 10.1515/REVNEURO.2004.15.4.267; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Tackenberg C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.129; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tian RJ, 2010, J NEUROPATH EXP NEUR, V69, P335, DOI 10.1097/NEN.0b013e3181d3cb52; Vossel KA, 2016, ANN NEUROL, V80, P858, DOI 10.1002/ana.24794; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xu MJ, 2016, PHYSIOL BEHAV, V167, P265, DOI 10.1016/j.physbeh.2016.09.018; Yokokura M, 2017, J CEREBR BLOOD F MET, V37, P877, DOI 10.1177/0271678X16646788; Zumkehr J, 2015, NEUROBIOL AGING, V36, P2260, DOI 10.1016/j.neurobiolaging.2015.04.005	110	41	42	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 21	2017	37	25					6132	6148		10.1523/JNEUROSCI.0877-17.2017			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EY2IJ	WOS:000403791500015	28559377	Green Published, Bronze			2022-02-06	
J	Baillieul, S; Chacaroun, S; Doutreleau, S; Detante, O; Pepin, JL; Verges, S				Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Detante, O.; Pepin, J. L.; Verges, S.			Hypoxic conditioning and the central nervous system: A new therapeutic opportunity for brain and spinal cord injuries?	EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						Central nervous system; conditioning; hypoxia; neurobiology; neuroprotection; physiology	TRANSIENT ISCHEMIC ATTACKS; PERMANENT CEREBRAL-ISCHEMIA; INTERMITTENT HYPOXIA; HIPPOCAMPAL NEUROGENESIS; FUNCTIONAL RECOVERY; HYPOBARIC HYPOXIA; MEMORY IMPAIRMENT; RANDOMIZED-TRIAL; MOTOR FUNCTION; IN-VITRO	Central nervous system diseases are among the most disabling in the world. Neuroprotection and brain recovery from either acute or chronic neurodegeneration still represent a challenge in neurology and neurorehabilitation as pharmacology treatments are often insufficiently effective. Conditioning the central nervous system has been proposed as a potential non-pharmacological neuro-therapeutic. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism to increase resistance to the same or even different noxious stimuli given above the threshold of damage. Hypoxic conditioning has been investigated in several cellular and preclinical models and is now recognized as inducing endogenous mechanisms of neuroprotection. Ischemic, traumatic, or chronic neurodegenerative diseases can benefit from hypoxic conditioning strategies aiming at preventing the deleterious consequences or reducing the severity of the pathological condition (preconditioning) or aiming at inducing neuroplasticity and recovery (postconditioning) following central nervous system injury. Hypoxic conditioning can consist in single (sustained) or cyclical (intermittent, interspersed by short period of normoxia) hypoxia stimuli which duration range from few minutes to several hours and that can be repeated over several days or weeks. This mini-review addresses the existing evidence regarding the use of hypoxic conditioning as a potential innovating neuro-therapeutic modality to induce neuroprotection, neuroplasticity and brain recovery. This mini-review also emphasizes issues which remain to be clarified and future researches to be performed in the field.	[Baillieul, S.; Doutreleau, S.; Pepin, J. L.] CHU Grenoble Alpes, Physiol Sleep & Exercise Dept, F-38042 Grenoble, France; [Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Pepin, J. L.; Verges, S.] INSERM, U1042, F-38042 Grenoble, France; [Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Pepin, J. L.; Verges, S.] Univ Grenoble Alpes, Lab HP2, F-38042 Grenoble, France; [Detante, O.] CHU Grenoble Alpes, Pole Psychiat Neurol, Stroke Unit, F-38042 Grenoble, France; [Detante, O.] Grenoble Inst Neurosci, Inserm U 836, F-38042 Grenoble, France		Baillieul, S (corresponding author), CHU Grenoble Alpes, Physiol Sleep & Exercise Dept, F-38042 Grenoble, France.; Baillieul, S (corresponding author), INSERM, U1042, F-38042 Grenoble, France.; Baillieul, S (corresponding author), Univ Grenoble Alpes, Lab HP2, F-38042 Grenoble, France.	sbaillieul@chu-grenoble.fr	Verges, Samuel/M-7040-2014; Detante, Olivier/M-1737-2014; Sebastien, BAILLIEUL/M-7143-2015	Verges, Samuel/0000-0002-0831-9222; Sebastien, BAILLIEUL/0000-0002-2348-6918; DOUTRELEAU, Stephane/0000-0001-8816-0356; Pepin, Jean Louis/0000-0003-3832-2358	Fond de Dotation Agir pour les maladies chroniques	We thank the "Fond de Dotation Agir pour les maladies chroniques'' for financial support regarding our research in the field of hypoxic conditioning.	Arboix A, 2004, CEREBROVASC DIS, V18, P304, DOI 10.1159/000080356; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Borlongan CV, 2015, FUTUR NEUROL, V10, P313, DOI 10.2217/FNL.15.27; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Chacaroun S, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00675; Coppel J, 2015, EXTREME PHYSIOL MED, V4, DOI 10.1186/s13728-014-0021-6; DAHL NA, 1964, AM J PHYSIOL, V207, P452, DOI 10.1152/ajplegacy.1964.207.2.452; Della Morte David, 2008, J Stroke Cerebrovasc Dis, V17, P257, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.004; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Dezfulian C, 2013, TRANSL STROKE RES, V4, P19, DOI 10.1007/s12975-012-0224-3; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gidday JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00042; Gonzalez-Rothi EJ, 2015, J APPL PHYSIOL, V119, P1455, DOI 10.1152/japplphysiol.00235.2015; Hayes HB, 2014, NEUROLOGY, V82, P104, DOI 10.1212/01.WNL.0000437416.34298.43; Hoshino T, 2013, J STROKE CEREBROVASC, V22, P260, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.010; Hougaard KD, 2014, STROKE, V45, P159, DOI 10.1161/STROKEAHA.113.001346; Johnston SC, 2004, STROKE, V35, P2680, DOI 10.1161/01.STR.0000143322.20491.0f; Komnenov D, 2016, J APPL PHYSIOL, V121, P545, DOI 10.1152/japplphysiol.00448.2016; Kushwah N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149309; Leconte C, 2009, STROKE, V40, P3349, DOI 10.1161/STROKEAHA.109.557314; Li SJ, 2017, PROG NEUROBIOL, V157, P79, DOI 10.1016/j.pneurobio.2017.01.001; Lin AM, 2003, ANN NY ACAD SCI, V993, P95; Lin AMY, 2003, ANN NY ACAD SCI, V993, P168, DOI 10.1111/j.1749-6632.2003.tb07527.x; Lovett-Barr MR, 2012, J NEUROSCI, V32, P3591, DOI 10.1523/JNEUROSCI.2908-11.2012; Lukyanova LD, 2013, B EXP BIOL MED+, V154, P597, DOI 10.1007/s10517-013-2008-5; Lynch M, 2017, J SPINAL CORD MED, V40, P295, DOI 10.1080/10790268.2016.1142137; Manukhina E B, 2010, Neurosci Behav Physiol, V40, P737, DOI 10.1007/s11055-010-9320-6; Manukhina EB, 2016, EXP BIOL MED, V241, P1351, DOI 10.1177/1535370216649060; Meng R, 2015, NEUROTHERAPEUTICS, V12, P667, DOI 10.1007/s13311-015-0358-6; Meng R, 2012, NEUROLOGY, V79, P1853, DOI 10.1212/WNL.0b013e318271f76a; Miller BA, 2001, NEUROREPORT, V12, P1663, DOI 10.1097/00001756-200106130-00030; Millet GP, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00224; Moisan A, 2016, CELL TRANSPLANT, V25, P2157, DOI 10.3727/096368916X691132; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Navarrete-Opazo A, 2015, EXP NEUROL, V266, P1, DOI 10.1016/j.expneurol.2015.02.007; Navarrete-Opazo A, 2017, J NEUROTRAUM, V34, P1803, DOI 10.1089/neu.2016.4478; Navarrete-Opazo A, 2016, ARCH CLIN NEUROPSYCH, V31, P332, DOI 10.1093/arclin/acw012; Prosser-Loose EJ, 2015, J NEUROTRAUM, V32, P1403, DOI 10.1089/neu.2014.3789; Qiao YX, 2015, J MOL NEUROSCI, V55, P923, DOI 10.1007/s12031-014-0447-8; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Rybnikova E A, 2008, Neurosci Behav Physiol, V38, P721, DOI 10.1007/s11055-008-9038-x; Rybnikova E, 2008, J NEUROCHEM, V106, P1450, DOI 10.1111/j.1471-4159.2008.05516.x; Rybnikova E, 2007, NEUROSCI LETT, V417, P234, DOI 10.1016/j.neulet.2007.02.048; Rybnikova E, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00388; Rybnikova E, 2009, NEUROSCI RES, V65, P360, DOI 10.1016/j.neures.2009.08.013; Schaller B, 2005, NEUROSCI LETT, V377, P206, DOI 10.1016/j.neulet.2004.12.004; Schega L, 2013, GERONTOLOGY, V59, P316, DOI 10.1159/000350927; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stowe AM, 2011, ANN NEUROL, V69, P975, DOI 10.1002/ana.22367; Studer L, 2000, J NEUROSCI, V20, P7377; Tarumi T, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00006; Tester NJ, 2014, AM J RESP CRIT CARE, V189, P57, DOI 10.1164/rccm.201305-0848OC; Trumbower RD, 2012, NEUROREHAB NEURAL RE, V26, P163, DOI 10.1177/1545968311412055; Tsai YW, 2013, J CEREBR BLOOD F MET, V33, P764, DOI 10.1038/jcbfm.2013.15; Tsai YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024001; Verges S, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00058; Vetrovoy OV, 2017, BIOCHEMISTRY-MOSCOW+, V82, P392, DOI 10.1134/S000629791703018X; Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A; Weih M, 1999, STROKE, V30, P1851, DOI 10.1161/01.STR.30.9.1851; Yang Y, 2013, NEUROCHEM RES, V38, P123, DOI 10.1007/s11064-012-0899-6; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075; Zhu XH, 2010, J NEUROSCI, V30, P12653, DOI 10.1523/JNEUROSCI.6414-09.2010; Zhu YL, 2007, INVEST OPHTH VIS SCI, V48, P1735, DOI 10.1167/iovs.06-1037	70	41	45	1	13	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1535-3702	1535-3699		EXP BIOL MED	Exp. Biol. Med.	JUN	2017	242	11					1198	1206		10.1177/1535370217712691			9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	EX0PS	WOS:000402923900010	28585890	Green Published			2022-02-06	
J	Li, X; Pan, YP; Chen, G; Yu, HY				Li, Xiang; Pan, Yongping; Chen, Gong; Yu, Haoyong			Multi-modal control scheme for rehabilitation robotic exoskeletons	INTERNATIONAL JOURNAL OF ROBOTICS RESEARCH			English	Article						Rehabilitation robotic exoskeleton; robot control; series elastic actuator; singular perturbation approach	FLEXIBLE-JOINT ROBOTS; IMPEDANCE CONTROL; ADAPTIVE-CONTROL; AIDED NEUROREHABILITATION; GAIT REHABILITATION; MECHANICAL DESIGN; MANIPULATORS; COMPLIANT; COMPENSATION; ASSISTANCE	In the past few decades, a variety of rehabilitation robotic exoskeletons have been developed for patients with stroke and traumatic brain injury, which can assist therapists and potentially improve the functional outcomes. Many robotic exoskeleton systems adopted series elastic actuators, which are known to offer a number of advantages over rigid actuators, such as high force/torque fidelity, low output impedance, intrinsic compliance, and tolerance to shocks. While several control schemes have been proposed for robotic exoskeletons driven by series elastic actuators, existing methods are limited at high level, by assuming a perfect inner control loop. Due to the nonlinearity in robot dynamics, changing interaction forces, etc., the stability of the overall system consisting of both the robot dynamics and the actuator dynamics may not be guaranteed. This paper presents a multi-modal control scheme for rehabilitation robotic exoskeletons. Three control modes are smoothly integrated into the controller, where the robot-assisted mode allows the human to exert voluntary efforts within a desired region, the robot-dominant mode is activated to correct the movement of the human when the robot is outside the region, and the safety-stop mode is to stop the robot whenever the interaction force is too large which may result in injuries. By using the regional position and force feedback, the proposed controller achieves the paradigm of "assist-as-needed" and also guarantees the safety of the human. The development of the proposed controller follows the singular perturbation approach, and the stability of the overall system is rigorously proved by using Tikhonov's theorem. Experimental results in both upper-limb and lower-limb exoskeleton systems are presented to demonstrate the effectiveness of the proposed control method.	[Li, Xiang] Chinese Univ Hong Kong, Dept Mech & Automat Engn, Hong Kong, Hong Kong, Peoples R China; [Pan, Yongping; Chen, Gong; Yu, Haoyong] Natl Univ Singapore, Dept Biomed Engn, Singapore, Singapore		Yu, HY (corresponding author), EA 02-02,9 Engn Dr 1, Singapore 117575, Singapore.	bieyhy@nus.edu.sg	Pan, Yongping/B-3511-2012	Pan, Yongping/0000-0002-8587-6065	Engineering Design and Innovation Center, National University of Singapore, SingaporeNational University of Singapore [R-261-503-002-133]; Science and Engineering Research Council, Agency for Science, Technology and Research (A*STAR), SingaporeAgency for Science Technology & Research (ASTAR) [1421480015]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Seed Fund of the Engineering Design and Innovation Center, National University of Singapore, Singapore under Grant no. R-261-503-002-133, and in part by the Science and Engineering Research Council, Agency for Science, Technology and Research (A*STAR), Singapore under Grant no. 1421480015.	Agarwal P, 2015, INT J ROBOT RES, V34, P1747, DOI 10.1177/0278364915598388; Aguirre-Ollinger G, 2012, IEEE T NEUR SYS REH, V20, P68, DOI 10.1109/TNSRE.2011.2176960; Albu-Schaffer A, 2007, INT J ROBOT RES, V26, P23, DOI 10.1177/0278364907073776; Arimoto S., 1996, CONTROL THEORY NONLI; Asbeck AT, 2015, INT J ROBOT RES, V34, P744, DOI 10.1177/0278364914562476; Banala SK, 2009, IEEE T NEUR SYS REH, V17, P2, DOI 10.1109/TNSRE.2008.2008280; Blaya JA, 2004, IEEE T NEUR SYS REH, V12, P24, DOI 10.1109/TNSRE.2003.823266; Cai LL, 2006, IEEE INT CONF ROBOT, P3504, DOI 10.1109/ROBOT.2006.1642237; Cheah CC, 2007, IEEE T ROBOT, V23, P1260, DOI 10.1109/TRO.2007.909808; Cheah C. C., 2015, TASK SPACE SENSORY F; Cheah CC, 1998, IEEE T ROBOTIC AUTOM, V14, P452, DOI 10.1109/70.678454; Chen G, 2016, MECH MACH THEORY, V103, P51, DOI 10.1016/j.mechmachtheory.2016.04.012; Chen WH, 2000, IEEE T IND ELECTRON, V47, P932, DOI 10.1109/41.857974; De Luca A, 2005, AUTOMATICA, V41, P1809, DOI 10.1016/j.automatica.2005.05.009; Dollar AM, 2008, IEEE T ROBOT, V24, P144, DOI 10.1109/TRO.2008.915453; Duschau-Wicke A, 2010, IEEE T NEUR SYS REH, V18, P38, DOI 10.1109/TNSRE.2009.2033061; Fleerkotte BM, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-26; Haddadin S, 2008, 2008 IEEE/RSJ INTERNATIONAL CONFERENCE ON ROBOTS AND INTELLIGENT SYSTEMS, VOLS 1-3, CONFERENCE PROCEEDINGS, P3356, DOI 10.1109/IROS.2008.4650764; Haddadin S, 2010, INT J SOC ROBOT, V2, P235, DOI 10.1007/s12369-010-0053-z; Haghighi R, 2012, AUTOMATICA, V48, P2526, DOI 10.1016/j.automatica.2012.03.028; HOGAN N, 1985, J DYN SYST-T ASME, V107, P1, DOI 10.1115/1.3140702; Huang J, 2015, IEEE T AUTOM SCI ENG, V12, P1257, DOI 10.1109/TASE.2015.2466634; Kazerooni H, 2005, IEEE INT CONF ROBOT, P4353; KELLER U, 2013, P IEEE 13 INT C REH, P1; KHALIL HK, 1992, NONLINEAR SYSTEMS; Kong KC, 2006, IEEE-ASME T MECH, V11, P428, DOI 10.1109/TMECH.2006.878550; Krebs HI, 2007, IEEE T NEUR SYS REH, V15, P327, DOI 10.1109/TNSRE.2007.903899; LEWIS FL, 1993, CONTROL ROBOT END EF; Li X, 2014, IEEE T CONTR SYST T, V22, P1032, DOI 10.1109/TCST.2013.2293498; Li X, 2013, AUTOMATICA, V49, P1614, DOI 10.1016/j.automatica.2013.02.067; Liu C, 2008, AUTOMATICA, V44, P1806, DOI 10.1016/j.automatica.2007.10.039; LOZANO R, 1992, IEEE T AUTOMAT CONTR, V37, P174, DOI 10.1109/9.121619; Meng XL, 2014, IEEE T BIO-MED ENG, V61, P892, DOI 10.1109/TBME.2013.2291910; Michmizos KP, 2012, P IEEE RAS-EMBS INT, P1081, DOI 10.1109/BioRob.2012.6290705; Ott C, 2008, IEEE T ROBOT, V24, P416, DOI 10.1109/TRO.2008.915438; Park JH, 2001, IEEE T ROBOTIC AUTOM, V17, P870, DOI 10.1109/70.976014; ParraVega V, 1995, INT J SYST SCI, V26, P2263, DOI 10.1080/00207729508929166; Patel RV, 2009, IEEE-ASME T MECH, V14, P575, DOI 10.1109/TMECH.2008.2009637; Pehlivan AU, 2016, IEEE T ROBOT, V32, P113, DOI 10.1109/TRO.2015.2503726; Petit F, 2015, IEEE ROBOT AUTOM MAG, V22, P37, DOI 10.1109/MRA.2015.2476576; PRATT GA, 1995, IROS '95 - 1995 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS: HUMAN ROBOT INTERACTION AND COOPERATIVE ROBOTS, PROCEEDINGS, VOL 1, P399, DOI 10.1109/IROS.1995.525827; Ronsse R, 2011, IEEE T BIO-MED ENG, V58, P1001, DOI 10.1109/TBME.2010.2089629; Roy A, 2009, IEEE T ROBOT, V25, P569, DOI 10.1109/TRO.2009.2019783; Slotine J.-J. E, 1991, APPL NONLINEAR CONTR, V199; SPONG MW, 1995, AUTOMATICA, V31, P585, DOI 10.1016/0005-1098(95)98487-Q; Sulzer JS, 2009, IEEE T ROBOT, V25, P539, DOI 10.1109/TRO.2009.2019788; Vanderborght B, 2009, INT J ROBOT RES, V28, P90, DOI 10.1177/0278364908095333; Veneman JF, 2007, IEEE T NEUR SYS REH, V15, P379, DOI 10.1109/TNSRE.2007.903919; Whittle MW., 2003, GAIT ANAL INTRO; Wolbrecht ET, 2008, IEEE T NEUR SYS REH, V16, P286, DOI 10.1109/TNSRE.2008.918389; Yamada Y, 1997, IEEE-ASME T MECH, V2, P230, DOI 10.1109/3516.653047; Yu HY, 2015, IEEE T ROBOT, V31, P1089, DOI 10.1109/TRO.2015.2457314; Yu HY, 2013, MECHATRONICS, V23, P1072, DOI 10.1016/j.mechatronics.2013.08.004; Yu HY, 2003, AUTON ROBOT, V15, P53, DOI 10.1023/A:1024488717009; Zhang JJ, 2015, IEEE T ROBOT, V31, P233, DOI 10.1109/TRO.2015.2392451; [No title captured]; [No title captured]; [No title captured]	58	41	42	11	122	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0278-3649	1741-3176		INT J ROBOT RES	Int. J. Robot. Res.	JUN	2017	36	5-7					759	777		10.1177/0278364917691111			19	Robotics	Science Citation Index Expanded (SCI-EXPANDED)	Robotics	EZ4IV	WOS:000404677700016					2022-02-06	
J	Orendorff, R; Peck, AJ; Zheng, B; Shirazi, SN; Ferguson, RM; Khandhar, AP; Kemp, SJ; Goodwill, P; Krishnan, KM; Brooks, GA; Kaufer, D; Conolly, S				Orendorff, Ryan; Peck, Austin J.; Zheng, Bo; Shirazi, Shawn N.; Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Goodwill, Patrick; Krishnan, Kannan M.; Brooks, George A.; Kaufer, Daniela; Conolly, Steven			First in vivo traumatic brain injury imaging via magnetic particle imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						traumatic brain injury; magnetic particle imaging; iron nanoparticles; tracer imaging	INTERSTITIAL FLUID; CLEARANCE; BIODISTRIBUTION; NANOPARTICLES; SYSTEM; IMPACT; MRI	Emergency room visits due to traumatic brain injury (TBI) is common, but classifying the severity of the injury remains an open challenge. Some subjective methods such as the Glasgow Coma Scale attempt to classify traumatic brain injuries, as well as some imaging based modalities such as computed tomography and magnetic resonance imaging. However, to date it is still difficult to detect and monitor mild to moderate injuries. In this report, we demonstrate that the magnetic particle imaging (MPI) modality can be applied to imaging TBI events with excellent contrast. MPI can monitor injected iron nanoparticles over long time scales without signal loss, allowing researchers and clinicians to monitor the change in blood pools as the wound heals.	[Orendorff, Ryan; Zheng, Bo; Conolly, Steven] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Peck, Austin J.; Shirazi, Shawn N.; Brooks, George A.; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.] LodeSpin Labs LLC, Seattle, WA USA; [Goodwill, Patrick] Magnet Insight Inc, Alameda, CA USA; [Krishnan, Kannan M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA; [Conolly, Steven] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA		Conolly, S (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.; Conolly, S (corresponding author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.	sconolly@berkeley.edu	Goodwill, Patrick/AAB-8825-2022	Goodwill, Patrick/0000-0003-4240-1956; Khandhar, Amit/0000-0003-4049-1855	Keck FoundationW.M. Keck Foundation [009323]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EB019458, 1R24MH106053, 2R42EB013520-02A1]; UC DiscoveryUniversity of California System; NSF GRFPNational Science Foundation (NSF)NSF - Office of the Director (OD); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R42EB013520, R01EB019458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24MH106053] Funding Source: NIH RePORTER	We are grateful for funding support from the Keck Foundation Grant 009323, NIH 1R01EB019458, NIH 1R24MH106053, and a UC Discovery Grant. LodeSpin Labs is also grateful for NIH 2R42EB013520-02A1. Ryan Orendorff would like to thank the NSF GRFP for funding support.	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; BRADBURY MWB, 1981, AM J PHYSIOL, V240, pF329, DOI 10.1152/ajprenal.1981.240.4.F329; Ferguson RM, 2015, IEEE T MED IMAGING, V34, P1077, DOI 10.1109/TMI.2014.2375065; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808; Goodwill PW, 2011, IEEE T MED IMAGING, V30, P1581, DOI 10.1109/TMI.2011.2125982; Goodwill PW, 2010, IEEE T MED IMAGING, V29, P1851, DOI 10.1109/TMI.2010.2052284; Jain TK, 2008, MOL PHARMACEUT, V5, P316, DOI 10.1021/mp7001285; Kemp SJ, 2016, RSC ADV, V6, P77452, DOI 10.1039/c6ra12072e; Keselman P, 2016, WORLD MOL IM C; Konkle JJ, 2013, BIOMED ENG-BIOMED TE, V58, P565, DOI 10.1515/bmt-2012-0062; Konkle JJ, 2013, IEEE T MED IMAGING, V32, P338, DOI 10.1109/TMI.2012.2227121; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee Bruce, 2005, NeuroRx, V2, P372; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu K, 2013, IEEE T MED IMAGING, V32, P1565, DOI 10.1109/TMI.2013.2257177; Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656; Mathieu E, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-35; Reimer P, 2003, EUR RADIOL, V13, P1266, DOI 10.1007/s00330-002-1721-7; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saritas EU, 2013, J MAGN RESON, V229, P116, DOI 10.1016/j.jmr.2012.11.029; Stacul F, 2011, EUR RADIOL, V21, P2527, DOI 10.1007/s00330-011-2225-0; Tay ZW., 2016, WORLD MOL IM C; TEASDALE G, 1974, LANCET, V2, P81; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zheng B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14055	31	41	45	4	19	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	MAY 7	2017	62	9					3501	3509		10.1088/1361-6560/aa52ad			9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Radiology, Nuclear Medicine & Medical Imaging	ES0JL	WOS:000399212500007	28378708	Green Accepted			2022-02-06	
J	Jennings, RM; Burtner, JJ; Pellicer, JF; Nair, DK; Bradford, MC; Shaffer, M; Uspal, NG; Tieder, JS				Jennings, Rebecca M.; Burtner, Jennifer J.; Pellicer, Joseph F.; Nair, Deepthi K.; Bradford, Miranda C.; Shaffer, Michele; Uspal, Neil G.; Tieder, Joel S.			Reducing Head CT Use for Children With Head Injuries in a Community Emergency Department	PEDIATRICS			English	Article							CLINICAL DECISION-SUPPORT; COMPUTED-TOMOGRAPHY; TRAUMA; IMPLEMENTATION; CERTIFICATION; MAINTENANCE; CARE; IMPROVEMENT; MODEL; RULE	BACKGROUND AND OBJECTIVE: Clinical decision rules have reduced use of computed tomography (CT) to evaluate minor pediatric head injury in pediatric emergency departments (EDs). CT use remains high in community EDs, where the majority of children seek medical care. We sought to reduce the rate of CT scans used to evaluate pediatric head injury from 29% to 20% in a community ED. METHODS: We evaluated a quality improvement (QI) project in a community ED aimed at decreasing the use of head CT scans in children by implementing a validated head trauma prediction rule for traumatic brain injury. A multidisciplinary team identified key drivers of CT use and implemented decision aids to improve the use of prediction rules. The team identified and mitigated barriers. An affiliated children's hospital offered Maintenance of Certification credit and QI coaching to participants. We used statistical process control charts to evaluate the effect of the intervention on monthly CT scan rates and performed a Wald test of equivalence to compare preintervention and postintervention CT scan proportions. RESULTS: The baseline period (February 2013-July 2014) included 695 patients with a CT scan rate of 29.2% (95% confidence interval, 25.8%32.6%). The postintervention period (August 2014-October 2015) included 651 patients with a CT scan rate of 17.4% (95% confidence interval, 14.5%-20.2%, P <.01). Barriers included targeting providers with variable pediatric experience and parental imaging expectations. CONCLUSIONS: We demonstrate that a Maintenance of Certification QI project sponsored by a children's hospital can facilitate evidence-based pediatric care and decrease the rate of unnecessary CT use in a community setting.	[Jennings, Rebecca M.; Tieder, Joel S.] Seattle Childrens Hosp, Div Gen Pediat & Hosp Med, Seattle, WA USA; [Jennings, Rebecca M.; Nair, Deepthi K.; Bradford, Miranda C.; Shaffer, Michele; Tieder, Joel S.] Seattle Childrens Hosp, Div Emergency Med, Seattle, WA USA; [Burtner, Jennifer J.; Pellicer, Joseph F.] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA; [Uspal, Neil G.] Providence St Peter Hosp, Emergency Dept, Olympia, WA USA		Jennings, RM (corresponding author), M-S FA 2-115,POB 5371, Seattle, WA 98145 USA.	rebecca.jennings@seattlechildrens.org			Seattle Children's Hospital Academic Enrichment Fund	All phases of this study were supported by Seattle Children's Hospital Academic Enrichment Fund.	Ambroggio L, 2013, PEDIATRICS, V131, pE1623, DOI 10.1542/peds.2012-2635; Ballard DW, 2013, ACAD EMERG MED, V20, P352, DOI 10.1111/acem.12109; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Benneyan JC, 1998, INT J QUAL HEALTH C, V10, P69, DOI 10.1093/intqhc/10.1.69; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Boucher Nathan A, 2015, Perm J, V19, P90, DOI 10.7812/TPP/14-095; Box G. E. P., 2008, TIME SERIES ANAL FOR; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Cook DA, 2015, JAMA INTERN MED, V175, P35, DOI 10.1001/jamainternmed.2014.5437; Gausche-Hill M, 2007, PEDIATRICS, V120, P1229, DOI 10.1542/peds.2006-3780; Gorzkowski JA, 2014, PEDIATRICS, V134, P747, DOI 10.1542/peds.2014-0316; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Huber P., 1967, P 5 BERK S MATH STAT; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Jerardi E, 2013, PEDIATRICS, V132, pE749, DOI 10.1542/peds.2013-0720; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Kurowski EM, 2015, PEDIATRICS, V135, pE1052, DOI 10.1542/peds.2014-2077; Levinson W, 2010, NEW ENGL J MED, V362, P948, DOI 10.1056/NEJMclde0911205; Li J, 2015, ACAD MED, V90, P303, DOI 10.1097/ACM.0000000000000547; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nishijima DK, 2015, ANN EMERG MED, V65, P72, DOI 10.1016/j.annemergmed.2014.08.019; Rogers AJ, 2013, PEDIATRICS, V132, pE356, DOI 10.1542/peds.2013-0299; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Trochim W, 2011, CTS-CLIN TRANSL SCI, V4, P153, DOI 10.1111/j.1752-8062.2011.00291.x; [Version 5.2; Version 5.3 Version 5.4 The Joint Commission], SPEC MAN NAT HOSP IN; WA State Hospital Association, 100K CHILD CAMP; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wylie MC, 2014, PEDIATR EMERG CARE, V30, P680, DOI 10.1097/PEC.0000000000000227	33	41	41	1	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2017	139	4							e20161349	10.1542/peds.2016-1349			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	ER2CU	WOS:000398602400003	28255067	Bronze			2022-02-06	
J	Li, D; Liu, N; Zhao, HH; Zhang, X; Kawano, H; Liu, L; Zhao, L; Li, HP				Li, Dan; Liu, Nan; Zhao, Hai-Hua; Zhang, Xu; Kawano, Hitoshi; Liu, Lu; Zhao, Liang; Li, Hong-Peng			Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain injury; Sirt1; ERK pathway; JNK pathway; p38MAPK pathway; Astrocyte activation	FIBRILLARY ACIDIC PROTEIN; KINASE SIGNALING PATHWAY; OXIDATIVE STRESS; MITOCHONDRIAL-FUNCTION; HISTONE DEACETYLASE; REACTIVE GLIOSIS; NITRIC-OXIDE; P38 MAPK; INHIBITION; EXPRESSION	Background: Astrocyte activation is a hallmark of traumatic brain injury resulting in neurological dysfunction or death for an overproduction of inflammatory cytokines and glial scar formation. Both the silent mating type information (Sirt1) expression and mitogen-activated protein kinase ( MAPK) signal pathway activation represent a promising therapeutic target for several models of neurodegenerative diseases. We investigated the potential effects of Sirt1 upregulation and MAPK pathway pharmacological inhibition on astrocyte activation in vitro and in vivo. Moreover, we attempted to confirm the underlying interactions between Sirt1 and MAPK pathways in astrocyte activation after brain injury. Methods: The present study employs an interleukin-1 beta IL-1 beta) stimulated primary cortical astrocyte model in vitro and a nigrostriatal pathway injury model in vivo to mimic the astrocyte activation induced by traumatic brain injury. The activation of GFAP, Sirt1, and MAPK pathways were detected by Western blot; astrocyte morphological hypertrophy was assessed using immunofluorescence staining; in order to explore the neuroprotective effect of regulation Sirt1 expression and MAPK pathway activation, the motor and neurological function tests were assessed after injury. Results: GFAP level and morphological hypertrophy of astrocytes are elevated after injury in vitro or in vivo. Furthermore, the expressions of phosphorylated extracellular regulated protein kinases p-ERK), phosphorylated c-Jun N-terminal kinase p-JNK), and phosphorylated p38 activation p- p38) are upregulated, but the Sirt1 expression is downregulated. Overexpression of Sirt1 significantly increases the p- ERK expression and reduces the p-JNK and p- p38 expressions. Inhibition of ERK, JNK, or p38 activation respectively with their inhibitors significantly elevated the Sirt1 expression and attenuated the astrocyte activation. Both the overproduction of Sirt1 and inhibition of ERK, JNK, or p38 activation can alleviate the astrocyte activation, thereby improving the neurobehavioral function according to the modified neurological severity scores mNSS) and balance latency test. C onclusions: Thus, Sirt1 plays a protective role against astrocyte activation, which may be associated with the regulation of the MAPK pathway activation induced by brain injury in vitro and in vivo.	[Li, Dan; Liu, Nan; Zhao, Hai-Hua; Zhang, Xu; Liu, Lu; Zhao, Liang; Li, Hong-Peng] China Med Univ, Dept Human Anat, Coll Basic Med Sci, Shenyang, Peoples R China; [Kawano, Hitoshi] Teikyo Heisei Univ, Dept Hlth & Dietet, Fac Hlth & Med Sci, Tokyo 1708445, Japan		Li, HP (corresponding author), China Med Univ, Dept Human Anat, Coll Basic Med Sci, Shenyang, Peoples R China.	hpli@cmu.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [NSFC-81171248]	This research was supported by the National Natural Science Foundation of China (NSFC) (belongs to Hong-Peng Li), Grant No: NSFC-81171248.	Armstead WM, 2012, NEUROL RES, V34, P530, DOI 10.1179/1743132812Y.0000000039; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Bellaver B, 2015, NEUROCHEM RES, V40, P1600, DOI 10.1007/s11064-015-1636-8; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chang HM, 2009, J PINEAL RES, V47, P211, DOI 10.1111/j.1600-079X.2009.00704.x; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Cheng YD, 2016, APOPTOSIS, V21, P905, DOI 10.1007/s10495-016-1258-x; Cheng Y, 2014, J NEUROIMMUNOL, V269, P38, DOI 10.1016/j.jneuroim.2014.02.001; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; Donmez G, 2012, TRENDS PHARMACOL SCI, V33, P494, DOI 10.1016/j.tips.2012.05.007; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Falchi M, 2010, ARCH ITAL BIOL, V148, P389, DOI 10.4449/aib.v148i4.1241; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guan QH, 2006, BRAIN RES, V1092, P36, DOI 10.1016/j.brainres.2006.03.086; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Guo WJ, 2011, J NEUROSCI RES, V89, P1723, DOI 10.1002/jnr.22725; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Huang WY, 2015, J CELL PHYSIOL, V230, P2461, DOI 10.1002/jcp.24981; Jiang T, 2014, AGING CELL, V13, P1059, DOI 10.1111/acel.12268; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/S0006-8993(96)00417-9; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Lennmyr F, 2003, ACTA NEUROL SCAND, V108, P339, DOI 10.1034/j.1600-0404.2003.00129.x; Li D, 2017, BRAIN RES, V1654, P1, DOI 10.1016/j.brainres.2016.10.013; Li D, 2016, BRAIN RES, V1648, P90, DOI 10.1016/j.brainres.2016.07.008; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5; Nemoto W, 2015, NEUROPHARMACOLOGY, V99, P221, DOI 10.1016/j.neuropharm.2015.07.022; Paraiso A, 2013, MOL NEUROBIOL, V48, P681, DOI 10.1007/s12035-013-8459-x; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Pousset F, 2001, J NEUROCHEM, V79, P726, DOI 10.1046/j.1471-4159.2001.00569.x; Qu Y, 2012, NEUROSCI LETT, V525, P168, DOI 10.1016/j.neulet.2012.07.025; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Shen T, 2013, INT J CARDIOL, V168, P3704, DOI 10.1016/j.ijcard.2013.06.018; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sticozzi C, 2013, NEUROSCIENCE, V252, P367, DOI 10.1016/j.neuroscience.2013.07.061; Tang BL, 2008, MOL ASPECTS MED, V29, P187, DOI 10.1016/j.mam.2007.02.001; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Wang LW, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-175; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wu CY, 2008, J NEUROCHEM, V105, P1499, DOI 10.1111/j.1471-4159.2008.05318.x; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zhou XM, 2014, J NEUROSCI RES, V92, P714, DOI 10.1002/jnr.23359; Zhu W, 2016, IMMUNOPHARM IMMUNOT, V38, P205, DOI 10.3109/08923973.2016.1168433	67	41	47	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 29	2017	14								67	10.1186/s12974-017-0841-6			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	EP9BS	WOS:000397669300001	28356158	Green Published, gold			2022-02-06	
J	Amorini, AM; Lazzarino, G; Di Pietro, V; Signoretti, S; Lazzarino, G; Belli, A; Tavazzi, B				Amorini, Angela Maria; Lazzarino, Giacomo; Di Pietro, Valentina; Signoretti, Stefano; Lazzarino, Giuseppe; Belli, Antonio; Tavazzi, Barbara			Severity of experimental traumatic brain injury modulates changes in concentrations of cerebral free amino acids	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						cerebral free amino acids; excitotoxicity; high performance liquid chromatography; methyl-cycle; N-acetylaspartate; mild traumatic brain injury; severe traumatic brain injury	N-ACETYLASPARTATE; CEREBROSPINAL-FLUID; RAT-BRAIN; MASS-SPECTROMETRY; METABOLIC-CHANGES; CANAVANS-DISEASE; TEMPORAL WINDOW; INBORN-ERRORS; FATTY-ACIDS; MOUSE MODEL	In this study, concentrations of free amino acids (FAA) and amino group containing compounds (AGCC) following graded diffuse traumatic brain injury (mild TBI, mTBI; severe TBI, sTBI) were evaluated. After 6, 12, 24, 48 and 120 hr aspartate (Asp), glutamate (Glu), asparagine (Asn), serine (Ser), glutamine (Gln), histidine (His), glycine (Gly), threonine (Thr), citrulline (Cit), arginine (Arg), alanine (Ala), taurine (Tau), caminobutyrate (GABA), tyrosine (Tyr), S-adenosylhomocysteine (SAH), L-cystathionine (L-Cystat), valine (Val), methionine (Met), tryptophane (Trp), phenylalanine (Phe), isoleucine (Ile), leucine (Leu), ornithine (Orn), lysine (Lys), plus N-acetylaspartate (NAA) were determined in whole brain extracts (n = 6 rats at each time for both TBI levels). Sham-operated animals (n = 6) were used as controls. Results demonstrated that mTBI caused modest, transient changes in NAA, Asp, GABA, Gly, Arg. Following sTBI, animals showed profound, long-lasting modifications of Glu, Gln, NAA, Asp, GABA, Ser, Gly, Ala, Arg, Citr, Tau, Met, SAH, L-Cystat, Tyr and Phe. Increase in Glu and Gln, depletion of NAA and Asp increase, suggested a link between NAA hydrolysis and excitotoxicity after sTBI. Additionally, sTBI rats showed net imbalances of the Glu-Gln/GABA cycle between neurons and astrocytes, and of the methyl-cycle (demonstrated by decrease in Met, and increase in SAH and L-Cystat), throughout the post-injury period. Besides evidencing new potential targets for novel pharmacological treatments, these results suggest that the force acting on the brain tissue at the time of the impact is the main determinant of the reactions ignited and involving amino acid metabolism.	[Amorini, Angela Maria; Lazzarino, Giacomo; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Neurosci & Ophthalmol Grp, Birmingham, W Midlands, England; [Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, Div Med Biochem, Catania, Italy; [Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res Surg Reconstruct, Birmingham B15 2TH, W Midlands, England; [Belli, Antonio] Queen Elizabeth Hosp, Microbiol Res Ctr, Birmingham B15 2TH, W Midlands, England		Lazzarino, G (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Div Med Biochem, Catania, Italy.	lazzarig@unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279; Lazzarino, Giacomo/0000-0003-1639-0966; AMORINI, Angela Maria/0000-0003-3525-9955	Catholic University of Rome the University of Catania; University of Birmingham	This work has been funded in part by research funds of the Catholic University of Rome (BT) the University of Catania (Giuseppe L) and the University of Birmingham (AB).	Amorini AM, 2012, MOL CELL BIOCHEM, V359, P205, DOI 10.1007/s11010-011-1015-y; Amorini AM, 2016, BBA-MOL BASIS DIS, V1862, P679, DOI 10.1016/j.bbadis.2016.01.023; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bame M, 2014, BBA-MOL BASIS DIS, V1842, P79, DOI 10.1016/j.bbadis.2013.10.004; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Baslow MH, 2013, BIOCHIMIE, V95, P946, DOI 10.1016/j.biochi.2012.10.023; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Baslow MH, 2010, AMINO ACIDS, V39, P1139, DOI 10.1007/s00726-010-0656-6; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Cai XJ, 2015, MOL MED REP, V11, P1715, DOI 10.3892/mmr.2014.2947; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chan CY, 2013, ADV EXP MED BIOL, V775, P45, DOI 10.1007/978-1-4614-6130-2_4; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Choe KY, 2012, J NEUROSCI, V32, P12518, DOI 10.1523/JNEUROSCI.1380-12.2012; Clark JF, 2006, MED HYPOTHESES, V67, P506, DOI 10.1016/j.mehy.2006.02.047; Cooper AJL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6020016; Dash PK, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00036; De Simone R, 2013, BBA-MOL BASIS DIS, V1832, P650, DOI 10.1016/j.bbadis.2013.02.001; Di Pietro V, 2014, MOL MED, V20, P147, DOI 10.2119/molmed.2013.00153; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; ERECINSKA M, 1984, BRAIN RES, V304, P9, DOI 10.1016/0006-8993(84)90857-6; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gu F, 2015, CURR OPIN CLIN NUTR, V18, P89, DOI 10.1097/MCO.0000000000000134; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gundersen V, 2015, PHYSIOL REV, V95, P695, DOI 10.1152/physrev.00024.2014; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hui H, 2016, NEUROCHEM INT, V94, P23, DOI 10.1016/j.neuint.2016.02.002; Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meunier CNJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151233; Oenarto J, 2014, ARCH BIOCHEM BIOPHYS, V560, P59, DOI 10.1016/j.abb.2014.06.024; Olsen GM, 2015, NEUROCHEM INT, V88, P47, DOI 10.1016/j.neuint.2014.11.006; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Panzaa F, 2009, J ALZHEIMERS DIS, V16, P467, DOI 10.3233/JAD-2009-1012; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perez-Neri I, 2007, J CHROMATOGR B, V851, P250, DOI 10.1016/j.jchromb.2006.10.047; Pu BF, 2015, MOL MED REP, V12, P3704, DOI 10.3892/mmr.2015.3830; Purins K, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00064; Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0; Rae C, 2012, NEUROCHEM RES, V37, P2541, DOI 10.1007/s11064-012-0847-5; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Schneider BL, 2016, J NEUROTRAUM, V33, P1614, DOI 10.1089/neu.2015.4190; Seki Y, 2005, NEUROCHEM RES, V30, P123, DOI 10.1007/s11064-004-9693-4; Sekine A, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0826-9; Shin SS, 2015, J NEUROTRAUM, V32, P1429, DOI 10.1089/neu.2014.3445; Shnitko TA, 2016, PSYCHOPHARMACOLOGY, V233, P2045, DOI 10.1007/s00213-016-4259-0; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; SINGH AK, 1988, J CHROMATOGR-BIOMED, V425, P245, DOI 10.1016/0378-4347(88)80029-X; Singhal NK, 2015, J NEUROSCI, V35, P15170, DOI 10.1523/JNEUROSCI.4349-14.2015; Song Y, 2008, NEUROSCI LETT, V445, P53, DOI 10.1016/j.neulet.2008.08.058; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Suchy J, 2010, NEUROMOL MED, V12, P86, DOI 10.1007/s12017-009-8089-7; Surendran S, 2003, J CHILD NEUROL, V18, P611, DOI 10.1177/08830738030180090701; Surendran S, 2003, BRAIN RES BULL, V61, P427, DOI 10.1016/S0361-9230(03)00158-8; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vitvitsky V, 2011, J BIOL CHEM, V286, P32002, DOI 10.1074/jbc.M111.253344; WALLWORK JC, 1983, J NUTR, V113, P47, DOI 10.1093/jn/113.1.47; Pinto MCX, 2015, NEUROPHARMACOLOGY, V89, P274, DOI 10.1016/j.neuropharm.2014.10.003; Zhuo JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136151	74	41	41	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1582-4934			J CELL MOL MED	J. Cell. Mol. Med.	MAR	2017	21	3					530	542		10.1111/jcmm.12998			13	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	EP5KP	WOS:000397417700011	27696676	Green Published, gold			2022-02-06	
J	Cottle, JE; Hall, EE; Patel, K; Barnes, KP; Ketcham, CJ				Cottle, Jordan E.; Hall, Eric E.; Patel, Kirtida; Barnes, Kenneth P.; Ketcham, Caroline J.			Concussion Baseline Testing: Preexisting Factors, Symptoms, and Neurocognitive Performance	JOURNAL OF ATHLETIC TRAINING			English	Article						neurocognitive testing; ImPACT; return to play	TEST-RETEST RELIABILITY; SPORT CONCUSSION; UNITED-STATES; HIGH-SCHOOL; IMPACT; PREVALENCE; DEPRESSION; MIGRAINE; SCORES; ADHD	Context: Neurocognitive test scores are often considered an important aspect of concussion management. To best use these data, clinicians must understand potential factors that may influence baseline performance on these tests. Objective: To determine preexisting factors that may influence performance on the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: A total of 486 National Collegiate Athletic Association Division I collegiate student-athletes. Main Outcome Measure(s): To determine neurocognitive functioning and total symptom score at baseline, ImPACT was administered. Outcomes were verbal memory, visual memory, visual motor speed, reaction time, and total symptom score. A self-report demographic section at the beginning of ImPACT was used to gather information concerning previous treatment for headaches, migraines, and psychiatric conditions; diagnosis of attention-deficit/hyperactivity disorder; and exposure to previous strenuous exercise. We conducted multivariate analyses of variance to determine if the ImPACT composite and total symptom scores differed according to preexisting factors (P < .0083). Results: Sex showed an effect on verbal memory (P = .001), visual motor speed (P < .001), and reaction time (P = .006), with women performing better than men. A previous diagnosis of attention-deficit/hyperactivity disorder affected visual motor speed (P = .008). Previous treatment for headaches (P < .001), migraines (P = .001), a psychiatric condition (P < .001), or a diagnosis ofattention-deficit/hyperactivity disorder (P < .001) all showed effects on the total symptom score. Strenuous exercise did not affect neurocogntive performance or total symptom score. Conclusions: Based on our findings and the previous literature, we suggest that many preexisting factors influence baseline neurocognitive data. Baseline testing is an important aspect of concussion management. Sports medicine professionals should be cognizant of these factors when developing concussion-management protocols.	[Cottle, Jordan E.; Hall, Eric E.; Ketcham, Caroline J.] Elon Univ, Dept Exercise Sci, 2525 Campus Box, Elon, NC 27244 USA; [Patel, Kirtida] Elon Univ, Dept Athlet, Elon, NC USA; [Barnes, Kenneth P.] Greensboro Orthopaed, Greensboro, NC USA		Hall, EE (corresponding author), Elon Univ, Dept Exercise Sci, 2525 Campus Box, Elon, NC 27244 USA.	ehall@elon.edu		Ketcham, Caroline/0000-0002-6713-130X	American Medical Society for Sports Medicine	This research was supported by a grant from the American Medical Society for Sports Medicine (K.P.B., E.E.H., coinvestigators).	Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown CN, 2007, J ATHL TRAINING, V42, P515; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; DeMars C. E., 2013, RES PRACTICE ASSESSM, V8, P69; Doose-Grunefeld S, 2015, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00003; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gil-Gouveia R, 2016, PAIN PHYSICIAN, V19, pE137; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Mrazik M, 2013, J ATHL TRAINING, V48, P654, DOI 10.4085/1062-6050-48.3.19; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Smitherman TA, 2013, HEADACHE, V53, P427, DOI 10.1111/head.12074; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Substance Abuse and Mental Health Services Administration, RES 2013 NAT SURV DR; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	29	41	41	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2017	52	2					77	81		10.4085/1062-6050-51.12.21			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	EP2IW	WOS:000397207600001	28071936	Green Published, Bronze			2022-02-06	
J	Menzel, L; Kleber, L; Friedrich, C; Hummel, R; Dangel, L; Winter, J; Schmitz, K; Tegeder, I; Schafer, MKE				Menzel, Lutz; Kleber, Lisa; Friedrich, Carina; Hummel, Regina; Dangel, Larissa; Winter, Jennifer; Schmitz, Katja; Tegeder, Irmgard; Schaefer, Michael K. E.			Progranulin Protects Against Exaggerated Axonal Injury and Astrogliosis Following Traumatic Brain Injury	GLIA			English	Article						traumatic brain injury; progranulin; astrocytes; TNF alpha; neuroinflammation	ACTIVATED MICROGLIA; PATHOLOGICAL CONDITIONS; ASTROCYTE ACTIVATION; TNF RECEPTORS; GROWTH-FACTOR; WHITE-MATTER; EXPRESSION; MUTATIONS; INFLAMMATION; RESPONSES	In response to traumatic brain injury (TBI) microglia/macrophages and astrocytes release inflammatory mediators with dual effects on secondary brain damage progression. The neurotrophic and anti-inflammatory glycoprotein progranulin (PGRN) attenuates neuronal damage and microglia/macrophage activation in brain injury but mechanisms are still elusive. Here, we studied histopathology, neurology and gene expression of inflammatory markers in PGRN-deficient mice (Grn(-/-)) 24 h and 5 days after experimental TBI. Grn(-/-) mice displayed increased perilesional axonal injury even though the overall brain tissue loss and neurological consequences were similar to wild-type mice. Brain inflammation was elevated in Grn(-/-) mice as reflected by increased transcription of pro-inflammatory cytokines TNF alpha, IL-1, IL-6, and decreased transcription of the anti-inflammatory cytokine IL-10. However, numbers of Iba1(+) microglia/macrophages and immigrated CD45(+) leukocytes were similar at perilesional sites while determination of IgG extravasation suggested stronger impairment of blood brain barrier integrity in Grn(-/-) compared to wild-type mice. Most strikingly, Grn(-/-) mice displayed exaggerated astrogliosis 5 days after TBI as demonstrated by anti-GFAP immunohistochemistry and immunoblot. GFAP(+) astrocytes at perilesional sites were immunolabelled for iNOS and TNF alpha suggesting that pro-inflammatory activation of astrocytes was attenuated by PGRN. Accordingly, recombinant PGRN (rPGRN) attenuated LPS- and cytokine-evoked iNOS and TNF alpha mRNA expression in cultured astrocytes. Moreover, intracerebroventricular administration of rPGRN immediately before trauma reduced brain damage and neurological deficits, and restored normal levels of cytokine transcription, axonal injury and astrogliosis 5 days after TBI in Grn(-/-) mice. Our results show that endogenous and recombinant PGRN limit axonal injury and astrogliosis and suggest therapeutic potential of PGRN in TBI.	[Menzel, Lutz; Kleber, Lisa; Friedrich, Carina; Hummel, Regina; Dangel, Larissa; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Winter, Jennifer] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Human Genet, Mainz, Germany; [Winter, Jennifer; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Focus Program Translat Neurosci FTN, Mainz, Germany; [Schmitz, Katja; Tegeder, Irmgard] Goethe Univ Hosp, Clin Pharmacol, Frankfurt, Germany		Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1,Bld 505, Mainz, Germany.; Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Focus Program Translat Neurosci, Langenbeckstr 1,Bld 505, Mainz, Germany.	michael.schaefer@unimedizin-mainz.de	Tegeder, Irmgard/AAM-2246-2020	Tegeder, Irmgard/0000-0001-7524-8025; Menzel, Lutz/0000-0002-3816-6255	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC1080]	The autors gratefully acknowledge the technical assistance of Wiesia Bobkiewicz and Tobias Hirnet (Department of Anesthesiology, UMC Mainz, Germany) and Annett Haussler (Clinical Pharmacology, Goethe-University Hospital, Frankfurt, Germany). This study was supported by the Deutsche Forschungsgemeinschaft (CRC1080, project B6 to M.K.E.S. and project A9 to I.T.).	Abudara V, 2015, GLIA, V63, P795, DOI 10.1002/glia.22785; Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Caesar M, 2014, GLIA, V62, P1075, DOI 10.1002/glia.22663; Chen X, 2013, J NEUROSCI, V33, P9202, DOI 10.1523/JNEUROSCI.5336-12.2013; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; de Munain AL, 2008, BIOL PSYCHIAT, V63, P946, DOI 10.1016/j.biopsych.2007.08.015; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; Etemadi N, 2013, IMMUNOL CELL BIOL, V91, P661, DOI 10.1038/icb.2013.53; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Gass J, 2006, HUM MOL GENET, V15, P2988, DOI 10.1093/hmg/ddl241; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Jackman K, 2013, J NEUROSCI, V33, P19579, DOI 10.1523/JNEUROSCI.4318-13.2013; Jin X, 2016, J BIOCH, V8; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kim JY, 2010, NAT NEUROSCI, V13, P180, DOI 10.1038/nn.2471; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Li BL, 2003, MOL BRAIN RES, V111, P155, DOI 10.1016/S0169-328X(03)00025-1; Li B, 2015, CRIT CARE MED, V43, pE304, DOI 10.1097/CCM.0000000000001096; Lim HY, 2012, J CELL MOL MED, V16, P708, DOI 10.1111/j.1582-4934.2011.01350.x; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Liu Z, 2015, PROG NEUROBIOL, V9, P30001; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Medina S, 2002, FREE RADICAL RES, V36, P1179, DOI 10.1080/107157602100006445; Milani D, 2003, J NEUROCHEM, V86, P126, DOI 10.1046/j.1471-4159.2003.01805.x; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Petkau TL, 2016, NEUROSCIENCE, V315, P175, DOI 10.1016/j.neuroscience.2015.12.006; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phulwani NK, 2008, J IMMUNOL, V181, P3841, DOI 10.4049/jimmunol.181.6.3841; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Schafer M, 2014, CELL TISSUE RES, V357, P395, DOI 10.1007/s00441-014-1807-y; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Schaible EV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071056; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Tian QY, 2014, METHODS MOL BIOL, V1155, P163, DOI 10.1007/978-1-4939-0669-7_14; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Toklu HZ, 2015, OXIDATIVE STRESS BRA; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Vercellino M, 2011, MULT SCLER J, V17, P1194, DOI 10.1177/1352458511406164; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang BC, 2015, PROTEIN CELL, V6, P792, DOI 10.1007/s13238-015-0213-x; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang XK, 2003, MOL PHARMACOL, V64, P833, DOI 10.1124/mol.64.4.833; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wes PD, 2016, GLIA; Wilson CM, 2009, INT J RADIAT ONCOL, V74, P934, DOI 10.1016/j.ijrobp.2009.02.035; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao YP, 2013, BIOMATERIALS, V34, P6412, DOI 10.1016/j.biomaterials.2013.05.030; Zhu SS, 2013, BRAIN RES, V1530, P54, DOI 10.1016/j.brainres.2013.07.023	86	41	41	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2017	65	2					278	292		10.1002/glia.23091			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK1ER	WOS:000393669100005	27778404				2022-02-06	
J	Reis, PA; Alexandre, PCB; D'Avila, JC; Siqueira, LD; Antunes, B; Estato, V; Tibirica, EV; Verdonk, F; Sharshar, T; Chretien, F; Castro-Faria-Neto, HC; Bozza, FA				Reis, Patricia A.; Alexandre, Pedro C. B.; D'Avila, Joana C.; Siqueira, Luciana D.; Antunes, Barbara; Estato, Vanessa; Tibirica, Eduardo V.; Verdonk, Franck; Sharshar, Tarek; Chretien, Fabrice; Castro-Faria-Neto, Hugo C.; Bozza, Fernando A.			Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Statin; Cognition; Sepsis; Neuroinflammation; Endothelium	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; ROSUVASTATIN; MORTALITY; THERAPY; DISEASE; MODEL; RATS	Acute brain dysfunction is a frequent condition in sepsis patients and is associated with increased mortality and long-term neurocognitive consequences. Impaired memory and executive function are common findings in sepsis survivors. Although neuroinflammation and blood-brain barrier dysfunction have been associated with acute brain dysfunction and its consequences, no specific treatments are available that prevent cognitive impairment after sepsis. Experimental sepsis was induced in Swiss Webster mice by intraperitoneal injection of cecal material (5 mg/kg, 500 mu L). Control groups (n = 5/group each experiment) received 500 mu L of saline. Support therapy recover (saline 0.9%, 1 mL and imipenem 30 mg/kg) were applied (6, 24 and 48 h post injection, n = 5-10/group, each experiment), together or not with additive orally treatment with statins (atorvastatin/simvastatin 20 mg/kg b.w.). Survival rate was monitored at 6, 24 and 48 h. In a setting of experiments, animals were euthanized at 6 and 24 h after induction for biochemical, immunohistochemistry and intravital analysis. Statins did not prevented mortality in septic mice, however survivors presented lower clinical score. At another setting of experiments, after 15 days, mice survivors from fecal supernatant peritoneal sepsis presented cognitive dysfunction for contextual hippocampal and aversive amygdala-dependent memories, which was prevented by atorvastatin/simvastatin treatment. Systemic and brain tissue levels of proinflammatory cytokines/chemokines and activation of microglial were lower in septic mice treated with statins. Brain lipid peroxidation and myeloperoxidase levels were also reduced by statins treatment. Intravital examination of the brain vessels of septic animals revealed decreased functional capillary density and increased rolling and adhesion of leukocytes, and blood flow impairment, which were reversed by treatment with statins. In addition, treatment with statins restored the cholinergic vasodilator response due to sepsis. Taken together, these data demonstrated that statins reverse microvascular dysfunction and reduce neuroinflammation during sepsis, preventing the development of long-term cognitive decline. (C) 2016 Elsevier Inc. All rights reserved.	[Reis, Patricia A.; Alexandre, Pedro C. B.; D'Avila, Joana C.; Siqueira, Luciana D.; Castro-Faria-Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, Rio De Janeiro, Brazil; [Antunes, Barbara; Estato, Vanessa; Tibirica, Eduardo V.] Fiocruz MS, Inst Oswaldo Cruz, Lab Cardiovasc Invest, Rio De Janeiro, Brazil; [Verdonk, Franck; Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France; [Bozza, Fernando A.] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil; [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil; [Castro-Faria-Neto, Hugo C.] Univ Estacio Sa, Fac Med, Rio De Janeiro, Brazil		Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FiOCRUZ, Evandro Chagas Natl Inst Infect Dis, Lab Crit Care, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.	fernando.bozza@ipec.fiocruz.br	Bozza, Fernando A/A-2618-2013; Verdonk, Franck/AAG-8997-2021; Sharshar, Tarek/ABF-4117-2021; d'Avila, Joana/L-8970-2013; Chretien, fabrice B/D-4035-2018; Estato, Vanessa/AAJ-9060-2020	Bozza, Fernando A/0000-0003-4878-0256; Verdonk, Franck/0000-0001-7061-5594; d'Avila, Joana/0000-0002-2045-0813; Chretien, fabrice B/0000-0002-2794-1383; 	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrasilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), BrasilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), BrasilFundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Institute Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), Brasil; Fundacao Oswaldo Cruz, Brasil and Institute Pasteur, France	This work was supported by grants from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasil, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasil, Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brasil, Institute Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), Brasil, Fundacao Oswaldo Cruz, Brasil and Institute Pasteur, France. HCCFN is a fellow on the program Pesquisa Produtividade from Universidade Estacio de Sa.	Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1; Bozza FA, 2010, J CEREBR BLOOD F MET, V30, P440, DOI 10.1038/jcbfm.2009.215; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Jukema JW, 2012, J AM COLL CARDIOL, V60, P875, DOI 10.1016/j.jacc.2012.07.007; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kwok JMF, 2013, VASC PHARMACOL, V58, P21, DOI 10.1016/j.vph.2012.10.003; Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218; Londono D, 2011, J IMMUNOL, V186, P7176, DOI 10.4049/jimmunol.1100060; Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195; Moraes CA, 2014, MOL NEUROBIOL; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Needham DM, 2016, LANCET RESP MED, V4, P203, DOI 10.1016/S2213-2600(16)00005-9; Pesic S, 2002, PHARMACOLOGY, V64, P182, DOI 10.1159/000056169; Quevedo J, 1999, LEARN MEMORY, V6, P600, DOI 10.1101/lm.6.6.600; Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Tralhao AFR, 2014, POSTGRAD MED, V126, DOI 10.3810/pgm.2014.11.2832; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Sharshar T, 2016, LANCET RESP MED, V4, P169, DOI 10.1016/S2213-2600(16)00028-X; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d; Yasuda H, 2006, KIDNEY INT, V69, P1535, DOI 10.1038/sj.ki.5000300; Yende S, 2016, CRIT CARE MED, V44, P1461, DOI 10.1097/CCM.0000000000001658	37	41	43	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	FEB	2017	60						293	303		10.1016/j.bbi.2016.11.006			11	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	EH6UA	WOS:000391908200030	27833044				2022-02-06	
J	Wammes, JD; Good, TJ; Fernandes, MA				Wammes, Jeffrey D.; Good, Tyler J.; Fernandes, Myra A.			Autobiographical and episodic memory deficits in mild traumatic brain injury	BRAIN AND COGNITION			English	Article						Mild traumatic brain injury; Concussion; Aging; Episodic memory; Semantic memory; Autobiographical memory	DIFFUSE AXONAL INJURY; NEUROPSYCHOLOGICAL OUTCOMES; HEAD-INJURY; COGNITIVE SEQUELAE; CONCUSSION; SPORTS; LONG; ABNORMALITIES; RECOLLECTION; METAANALYSIS	Those who have suffered a concussion, otherwise known as a mild traumatic brain injury (mTBI), often complain of lingering memory problems. However, there is little evidence in the behavioral literature reliably demonstrating memory deficits. Thus, in the present study, cognitive profiles including measures of general executive functioning and processing speed, as well as episodic and semantic memory were collected in younger and older adult participants with or without a remote (>1 year prior to testing) mTBI. We first investigated whether there were observable episodic and autobiographical memory impairments associated with mTBI within an otherwise healthy' young group. Next, because previous work had demonstrated some overlap in patterns of behavioral impairment in normally aging adults and younger adults with a history of mTBI (e.g. Ozen, Fernandes, Clark, & Roy, 2015), we sought to determine whether these groups displayed similar cognitive profiles. Lastly, we conducted an exploratory analysis to test whether having suffered an mTBI might exacerbate age-related cognitive decline. Results showed the expected age-related decline in episodic memory performance, coupled with a relative preservation of semantic memory in older adults. Importantly, this pattern was also present in younger adults with a history of remote mTBI. No differences were observed across older adult groups based on mTBI status. Logistic regression analyses, using each measure in our battery as a predictor, successfully classified mTBI status in younger participants with a high degree of specificity (79.5%). These results indicate that those who have had an mTBI demonstrate a distinct cognitive signature, characterized by impairment in episodic and autobiographical memory, coupled with a relative preservation of semantic memory. (C) 2016 Elsevier Inc. All rights reserved.	[Wammes, Jeffrey D.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada; [Good, Tyler J.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Good, Tyler J.] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada		Wammes, JD (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	jwammes@uwaterloo.ca		Wammes, Jeffrey/0000-0002-8923-5441	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was funded by a scholarship from the Natural Science and Engineering Research Council (NSERC) awarded to author J.W.; and an NSERC Discovery grant awarded to author M.F. The authors would like to thank Jingwen Cao for her dedication to helping us complete this project.	ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Alves W., 1992, PHYS MED REHABIL STA, V6, P21; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Army Individual Test Battery, 1944, MAN DIR SCOR; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BORNSTEIN RA, 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Bradley M. M., 1999, PSYCHOLOGY C, VC-1, P1; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Bucur B, 2008, NEUROBIOL AGING, V29, P1070, DOI 10.1016/j.neurobiolaging.2007.02.008; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 1997, NEUROREPORT, V8, P3479, DOI 10.1097/00001756-199711100-00013; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christiansen K., 2016, NEUROIMAGE; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Court, 1989, MILL HILL VOCABULARY; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Douet V, 2015, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00343; Dritschel BH, 1998, BRAIN INJURY, V12, P875; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Farber M., 1994, SPORTS ILLUSTRATED; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kausler D. H., 1994, LEARNING MEMORY NORM, P276; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kinnunen K. M., 2010, BRAIN, V347; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIGHT LL, 1991, ANNU REV PSYCHOL, V42, P333, DOI 10.1146/annurev.ps.42.020191.002001; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McRae K, 2005, BEHAV RES METHODS, V37, P547, DOI 10.3758/BF03192726; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITCHELL DB, 1989, J EXP PSYCHOL LEARN, V15, P31, DOI 10.1037/0278-7393.15.1.31; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nyberg L, 1996, J GERONTOL B-PSYCHOL, V51, pP234, DOI 10.1093/geronb/51B.4.P234; Ozen LJ, 2015, AGING NEUROPSYCHOL C, V22, P517, DOI 10.1080/13825585.2014.993584; Ozen LJ, 2013, BRAIN INJURY, V27, P1244, DOI 10.3109/02699052.2013.804207; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Ozen LJ, 2010, J INT NEUROPSYCH SOC, V16, P556, DOI 10.1017/S1355617710000202; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Piolino P, 2006, PSYCHOL AGING, V21, P510, DOI 10.1037/0882-7974.21.3.510; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rasmussen KW, 2014, J NEUROPSYCHOL, V8, P34, DOI 10.1111/jnp.12003; Raven J. C., 1958, USING MILL HILL VOCA; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reuter-Lorenz PA, 2008, CURR DIR PSYCHOL SCI, V17, P177, DOI 10.1111/j.1467-8721.2008.00570.x; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rudebeck SR, 2009, J NEUROSCI, V29, P14987, DOI 10.1523/JNEUROSCI.4707-09.2009; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Steffener J, 2009, BRAIN IMAGING BEHAV, V3, P142, DOI 10.1007/s11682-008-9056-x; Stirling DP, 2010, TRENDS MOL MED, V16, P160, DOI 10.1016/j.molmed.2010.02.002; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; van Rijn, 1995, CELEX LEXICAL DATABA; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verhaeghen P, 2003, PSYCHOL AGING, V18, P332, DOI 10.1037/0882-7974.18.2.332; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wittenbrook JM, 1941, J NERV MENT DIS, V94, P170, DOI 10.1097/00005053-194194020-00004; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhuang L, 2012, J ALZHEIMERS DIS, V29, P629, DOI 10.3233/JAD-2012-111766	107	41	41	3	43	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	FEB	2017	111						112	126		10.1016/j.bandc.2016.11.004			15	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	EI3CC	WOS:000392366300013	27886529				2022-02-06	
J	Ritter, AC; Wagner, AK; Fabio, A; Pugh, MJ; Walker, WC; Szaflarski, JP; Zafonte, RD; Brown, AW; Hammond, FM; Bushnik, T; Johnson-Greene, D; Shea, T; Krellman, JW; Rosenthal, JA; Dreer, LE				Ritter, Anne C.; Wagner, Amy K.; Fabio, Anthony; Pugh, Mary Jo; Walker, William C.; Szaflarski, Jerzy P.; Zafonte, Ross D.; Brown, Allen W.; Hammond, Flora M.; Bushnik, Tamara; Johnson-Greene, Douglas; Shea, Timothy; Krellman, Jason W.; Rosenthal, Joseph A.; Dreer, Laura E.			Incidence and risk factors of posttraumatic seizures following traumatic brain injury: A Traumatic Brain Injury Model Systems Study	EPILEPSIA			English	Article						Epilepsy; Prophylaxis; Relative risk; TBI Model Systems; Epidemiology	HEAD-INJURY; EPILEPSY DEVELOPMENT; GENETIC-VARIATION; EPIDEMIOLOGY; REHABILITATION; ASSOCIATIONS; HOSPITALIZATION; MULTICENTER; DEFINITION; MECHANISMS	ObjectiveDetermine incidence of posttraumatic seizure (PTS) following traumatic brain injury (TBI) among individuals with moderate-to-severe TBI requiring rehabilitation and surviving at least 5 years. MethodsUsing the prospective TBI Model Systems National Database, we calculated PTS incidence during acute hospitalization, and at years 1, 2, and 5 postinjury in a continuously followed cohort enrolled from 1989 to 2000 (n = 795). Incidence rates were stratified by risk factors, and adjusted relative risk (RR) was calculated. Late PTS associations with immediate (<24 h), early (24 h-7 day), or late seizures (>7 day) versus no seizure prior to discharge from acute hospitalization was also examined. ResultsPTS incidence during acute hospitalization was highest immediately (<24 h) post-TBI (8.9%). New onset PTS incidence was greatest between discharge from inpatient rehabilitation and year 1 (9.2%). Late PTS cumulative incidence from injury to year 1 was 11.9%, and reached 20.5% by year 5. Immediate/early PTS RR (2.04) was increased for those undergoing surgical evacuation procedures. Late PTS RR was significantly greater for individuals who self-identified as a race other than black/white (year 1 RR = 2.22), and for black individuals (year 5 RR = 3.02) versus white individuals. Late PTS was greater for individuals with subarachnoid hemorrhage (year 1 RR = 2.06) and individuals age 23-32 (year 5 RR = 2.43) and 33-44 (year 5 RR = 3.02). Late PTS RR years 1 and 5 was significantly higher for those undergoing surgical evacuation procedures (RR: 3.05 and 2.72, respectively). SignificanceIn this prospective, longitudinal, observational study, PTS incidence was similar to that in studies published previously. Individuals with immediate/late seizures during acute hospitalization have increased late PTS risk. Race, intracranial pathologies, and neurosurgical procedures also influenced PTS RR. Further studies are needed to examine the impact of seizure prophylaxis in high-risk subgroups and to delineate contributors to race/age associations on long-term seizure outcomes.	[Ritter, Anne C.; Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Ritter, Anne C.; Wagner, Amy K.] Univ Pittsburgh, Phys Med & Rehabil, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Pugh, Mary Jo] South Texas Vet Hlth Care Syst Polytrauma Rehabi, San Antonio, TX USA; [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, UAB Stn, Birmingham, AL 35294 USA; [Zafonte, Ross D.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Bushnik, Tamara] NYU, Sch Med, Rusk Rehabil, New York, NY USA; [Johnson-Greene, Douglas] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Shea, Timothy; Rosenthal, Joseph A.; Dreer, Laura E.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Krellman, Jason W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763; Fabio, Anthony/0000-0002-6808-4939; Bushnik, Tamara/0000-0003-3328-257X; Brown, Allen W./0000-0001-7228-3351	NIDILRRUnited States Department of Health & Human Services [90DP0041, 90DP0038, 90DP0036, 90DP0033]; Polytrauma Rehabilitation Center Traumatic Brain Injury Model System; Department of Veterans Affairs (VA)US Department of Veterans Affairs; NIDILRRUnited States Department of Health & Human Services	The National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) supported the collection of original data for this manuscript. The contents of this manuscript were developed under grants NIDILRR Grants 90DP0041 (AKW, ACR), NIDILRR 90DP0038 (JWK), 90DP0036 (FH), 90DP0033 (WCW), and the Polytrauma Rehabilitation Center Traumatic Brain Injury Model System (MJP). The Polytrauma Rehabilitation Center TBI Model System is a funded collaboration between the Department of Veterans Affairs (VA) and NIDILRR. NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of the VA, NIDILRR, ACL, or HHS, and endorsement of this content by the Federal Government should not be assumed.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 2013, R LANG ENV STAT COMP; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Brasure M, 2012, COMP EFFECTIVENESS R; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; DESAI BT, 1983, ANN EMERG MED, V12, P543, DOI 10.1016/S0196-0644(83)80294-7; Diamond ML, 2015, EPILEPSIA, V56, P1198, DOI 10.1111/epi.13044; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2012, EPILEPSY BEHAV, V24, P304, DOI 10.1016/j.yebeh.2012.04.128; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kjellstr?m, 2006, BASIC EPIDEMIOLOGY; Krellman JW, 2014, ARCH PHYS MED REHAB, V95, P633, DOI 10.1016/j.apmr.2013.10.016; Kumar RG, 2016, J HEAD TRAU IN PRESS; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Liu SS, 2016, NEUROPSYCH DIS TREAT, V12, P1425, DOI 10.2147/NDT.S107905; Najafi Mohammad Reza, 2015, Adv Biomed Res, V4, P82, DOI 10.4103/2277-9175.156640; Oluwole OSA, 2011, BRAIN INJURY, V25, P980, DOI 10.3109/02699052.2011.589798; Pretz CR, 2015, ARCH PHYS MED REHAB, V96, P746, DOI 10.1016/j.apmr.2014.09.025; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Ritter AC, 2016, EPILEPSIA, V57, P1503, DOI 10.1111/epi.13470; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Szaflarski M, 2006, EPILEPSY BEHAV, V9, P243, DOI 10.1016/j.yebeh.2006.05.011; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Walker WC, 2015, J HEAD TRAUMA REHAB, V30, P231, DOI 10.1097/HTR.0000000000000127; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	50	41	44	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	DEC	2016	57	12					1968	1977		10.1111/epi.13582			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EF5EI	WOS:000390353100004	27739577	Green Submitted			2022-02-06	
J	Shahim, P; Linemann, T; Inekci, D; Karsdal, MA; Blennow, K; Tegner, Y; Zetterberg, H; Henriksen, K				Shahim, Pashtun; Linemann, Thomas; Inekci, Dilek; Karsdal, Morten Asser; Blennow, Kaj; Tegner, Yelverton; Zetterberg, Henrik; Henriksen, Kim			Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players	JOURNAL OF NEUROTRAUMA			English	Article						ice hockey; serum biomarkers; sports-related concussion; tau fragments	TRAUMATIC BRAIN-INJURY; BIOMARKERS	The diagnosis of sports-related concussion is mainly based on subjective clinical symptoms and neuropsychological tests. Therefore, reliable brain injury biomarkers to assess when it is safe to return to play are highly desirable. The overall objective of this study was to evaluate the utility of two newly described tau fragments for diagnosis and prognosis of sports-related concussions. This multi-center prospective cohort study involved all 12 teams of the top professional ice hockey league in Sweden. A total of 288 players consented to participate in the study. Thirty-five players sustained concussions, of whom 28 underwent repeated blood samplings at 1, 12, 36, and 144 h after the trauma, or when the player returned to play (7 to > 90 days). There was no significant increase in the levels of Tau-A in post-concussion samples compared with preseason values. However, serum levels of Tau-C were significantly higher in post-concussion samples compared with preseason. Further, levels of Tau-A correlated with the duration of post-concussive symptoms. Tau-A in serum, which is newly discovered biomarker, could be used to predict when it is safe to return to play after a sports-related concussion.	[Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden; [Linemann, Thomas; Inekci, Dilek; Karsdal, Morten Asser; Henriksen, Kim] Nord Biosci, Biomarkers & Res, Herlev, Denmark; [Tegner, Yelverton] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Queen Sq, London, England		Henriksen, K (corresponding author), Nord Biosci AS, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.	kh@nordicbioscience.com		Karsdal, Morten/0000-0001-5026-8740; Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Centrum for Idrottsforskning; Emil and Maria Palm Foundation; Danish Research Foundation (Den Danske Forskningsfond); Danish Ministry for Science, Technology, and Education	We thank all study participants and the teams for contributing to this research. The study was supported by grants from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Centrum for Idrottsforskning, and the Emil and Maria Palm Foundation. Kim Henriksen and Thomas Linemann have received funding from the Danish Research Foundation (Den Danske Forskningsfond). Dilek Inekci is funded by the Danish Ministry for Science, Technology, and Education.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Henriksen K, 2015, J ALZHEIMERS DIS, V43, P1331, DOI 10.3233/JAD-140984; Henriksen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064990; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Wang Y, 2012, Int J Alzheimers Dis, V2012, P209409, DOI 10.1155/2012/209409; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399	17	41	42	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					1995	1999		10.1089/neu.2014.3741			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300002	25621407	Green Submitted			2022-02-06	
J	Silverberg, ND; Iverson, GL; McCrea, M; Apps, JN; Hammeke, TA; Thomas, DG				Silverberg, Noah D.; Iverson, Grant L.; McCrea, Michael; Apps, Jennifer N.; Hammeke, Thomas A.; Thomas, Danny G.			Activity-Related Symptom Exacerbations After Pediatric Concussion	JAMA PEDIATRICS			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; BED REST; ADOLESCENTS; CHILDREN; RECOVERY; EXERCISE; TRIAL; YOUTH	IMPORTANCE Recovery from concussion generally follows a trajectory of gradual improvement, but symptoms can abruptly worsen with exertion. This phenomenon is poorly understood. OBJECTIVES To characterize the incidence, course, and clinical significance of symptom exacerbations (spikes) in children after concussion. DESIGN, SETTING, AND PARTICIPANTS This secondary analysis of clinical trial data analyzes 63 eligible participants prospectively recruited from an emergency department who were asked to complete a postconcussion symptom scale and record their activities in a structured diary for the next 10 days. They completed standardized assessments of symptoms (postconcussion symptom scale), cognition (Immediate Post-Concussion Assessment and Cognitive Testing), and balance (Balance Error Scoring System) 10 days following the injury. Eligible participants were aged 11 to 18 years and sustained a concussion (according to the Centers for Disease Control and Prevention criteria) that did not result in an abnormal computed tomography scan or require hospital admission. The trial was conducted from May 2010 to December 2012, and the analysis was conducted from November 2015 to February 2016. MAIN OUTCOME AND MEASURE The occurrence of symptom spikes, defined as an increase of 10 or more points on the postconcussion symptom scale over consecutive days. RESULTS Of the 63 participants, there were 41 boys (65.1%) and 22 girls (34.9%), and the mean (SD) age was 13.8 (1.8) years. Symptom spikes occurred in one-third of the sample (20 participants [31.7%]). Symptom spikes tended to partially resolve within 24 hours. An abrupt increase in mental activity (ie, returning to school and extracurricular activities) from one day to the next increased the risk of a symptom spike (relative risk, 0.81; 95% CI, 0.21-3.21), but most symptom spikes were not preceded by a documented increase in physical or mental activity. Patients with symptom spikes were initially more symptomatic in the emergency department and throughout the observation period but did not differ from the group without symptom spikes on cognition or balance 10 days following injury. CONCLUSIONS AND RELEVANCE Certain patients appeared susceptible to high and variable symptom reporting. Symptom spikes may not themselves be detrimental to recovery. The present findings support clinical guidelines for adolescents to return to school and activities gradually after concussion.	[Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Silverberg, Noah D.; Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Silverberg, Noah D.; Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp, Children Sports Concuss Program, Boston, MA USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Clement J Zablocki VA Med Ctr, Milwaukee, WI 53226 USA; [Apps, Jennifer N.; Hammeke, Thomas A.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [Thomas, Danny G.] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA		Thomas, DG (corresponding author), Childrens Hosp Wisconsin, Dept Pediat, Emergency Med, Corp Ctr, 999 N 92nd St,Ste C550, Milwaukee, WI 53226 USA.	dthomas@mcw.edu		Iverson, Grant/0000-0001-7348-9570; Thomas, Danny/0000-0002-7470-9835	Injury Research Center of the Medical College of Wisconsin; Vancouver Coastal Health Research Institute; Mooney-Reed Charitable Foundation	Dr Thomas received the Advancing A Healthier Wisconsin Seed Grant from the Injury Research Center of the Medical College of Wisconsin. Dr Silverberg received salary support from the Vancouver Coastal Health Research Institute. Dr Iverson received funding from the Mooney-Reed Charitable Foundation.	ANDREASSEN J, 1957, ACTA MED SCAND, V158, P239; [Anonymous], HEADS UP HLTH CAR PR; Aubry M, 2002, BRIT J SPORT MED, V36, P6; Balasundaram AP, 2013, PHYS THER SPORT, V14, P253, DOI 10.1016/j.ptsp.2013.06.002; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bratteby LE, 1997, EUR J CLIN NUTR, V51, P585, DOI 10.1038/sj.ejcn.1600449; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley T, J HEAD TRAUMA REHABI, DOI [10.1097/HRT.0000000000000165, DOI D10.1097/HRT.0000000000000165]; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dematteo C, 2015, MED SCI SPORT EXER, V47, P2283, DOI 10.1249/MSS.0000000000000682; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Henry CJK, 2004, AM J HUM BIOL, V16, P346, DOI 10.1002/ajhb.20022; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; Silverberg ND, 2016, CLIN J SPORT MED, V26, P226, DOI 10.1097/JSM.0000000000000241; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	32	41	41	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	OCT	2016	170	10					946	953		10.1001/jamapediatrics.2016.1187			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DZ2AB	WOS:000385643000013	27479847	Bronze			2022-02-06	
J	Kerr, ZY; Simon, JE; Grooms, DR; Roos, KG; Cohen, RP; Dompier, TP				Kerr, Zachary Y.; Simon, Janet E.; Grooms, Dustin R.; Roos, Karen G.; Cohen, Randy P.; Dompier, Thomas P.			Epidemiology of Football Injuries in the National Collegiate Athletic Association, 2004-2005 to 2008-2009	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						college football; injury rates; practice seasons; scrimmages	SURVEILLANCE SYSTEM; UNITED-STATES; HIGH-SCHOOL; SPORTS; YOUTH; CONCUSSION; PLAYERS; PROGRAM	Background: Research has found that injury rates in football are higher in competition than during practice. However, there is little research on the association between injury rates and type of football practices and how these specific rates compare with those in competitions. Purpose: This study utilized data from the National Collegiate Athletic Association Injury Surveillance System (NCAA ISS) to describe men's collegiate football practice injuries (academic years 2004-2005 to 2008-2009) in 4 event types: competitions, scrimmages, regular practices, and walkthroughs. Study Design: Descriptive epidemiological study. Methods: Football data during the 2004-2005 to 2008-2009 academic years were analyzed. Annually, an average of 60 men's football programs provided data (9.7% of all universities sponsoring football). Injury rates per 1000 athlete-exposures (AEs), injury rate ratios (RRs), 95% CIs, and injury proportions were reported. Results: The NCAA ISS captured 18,075 football injuries. Most injuries were reported in regular practices (55.9%), followed by competitions (38.8%), scrimmages (4.4%), and walkthroughs (0.8%). Most AEs were reported in regular practices (77.6%), followed by walkthroughs (11.5%), competitions (8.6%), and scrimmages (2.3%). The highest injury rate was found in competitions (36.94/1000 AEs), followed by scrimmages (15.7/1000 AEs), regular practices (5.9/1000 AEs), and walkthroughs (0.6/1000 AEs). These rates were all significantly different from one another. Distributions of injury location and diagnoses were similar across all 4 event types, with most injuries occurring at the lower extremity (56.0%) and consisting of sprains and strains (50.6%). However, injury mechanisms varied. The proportion of injuries due to player contact was greatest in scrimmages (66.8%), followed by regular practices (48.5%) and walkthroughs (34.9%); in contrast, the proportion of injuries due to noncontact/overuse was greatest in walkthroughs (41.7%), followed by regular practices (35.6%) and scrimmages (21.9%). Conclusion: Injury rates were the highest in competitions but then varied by the type of practice event, with higher practice injury rates reported in scrimmage. In addition, greater proportions of injuries were reported in regular practices, and greater proportions of exposures were reported in regular practices and walkthroughs. Efforts to minimize injury in all types of practice events are essential to mitigating injury incidence related to both contact and noncontact.	[Roos, Karen G.; Dompier, Thomas P.] Sports Injury Res & Prevent Inc, Datalys Ctr, Indianapolis, IN USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA; [Simon, Janet E.; Grooms, Dustin R.] Ohio Univ, Sch Appl Hlth Sci & Wellness, Div Athlet Training, Athens, OH 45701 USA; [Grooms, Dustin R.] Ohio Univ, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA; [Dompier, Thomas P.] Univ Arizona, Athlet Training, Tucson, AZ USA		Kerr, ZY (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu	Grooms, Dustin/AAO-8917-2021	Grooms, Dustin/0000-0001-6102-8224			Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bizzini M, 2015, BRIT J SPORT MED, V49, P577, DOI 10.1136/bjsports-2015-094765; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; DURANT RH, 1991, AM J DIS CHILD, V145, P1119, DOI 10.1001/archpedi.1991.02160100051022; ESPN, IV LEAG LIM FULL CON; ESPN, PAC 12 LIM CONT PRAC; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Martens R, 1974, Exerc Sport Sci Rev, V2, P155; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Collegiate Athletic Association, FOOTB PRACT GUID; National Collegiate Athletic Association, STUD ATHL PART 1981; Oxendine J.B., 1970, QUEST MONOGR, V13, P23, DOI [DOI 10.1080/00336297.1970.10519673, 10.1080/00336297.1970.10519673]; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009; Steiner ME, 2016, SPORTS HEALTH, V8, P217, DOI 10.1177/1941738115626689; Swanik C, 2015, J ATHL TRAINING, V50, P1100, DOI 10.4085/1062-6050-50.10.08	25	41	41	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	SEP	2016	4	9							2325967116664500	10.1177/2325967116664500			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DZ0RL	WOS:000385547300001	27635412	Green Published, Green Accepted, gold			2022-02-06	
J	Wang, WZ; Li, HG; Yu, JT; Hong, M; Zhou, J; Zhu, L; Wang, Y; Luo, M; Xia, Z; Yang, ZJ; Tang, T; Ren, P; Huang, X; Wang, J				Wang, Wenzhu; Li, Haigang; Yu, Jintao; Hong, Michael; Zhou, Jing; Zhu, Lin; Wang, Yang; Luo, Min; Xia, Zian; Yang, Zeng-Jin; Tang, Tao; Ren, Ping; Huang, Xi; Wang, Jian			Protective Effects of Chinese Herbal Medicine Rhizoma drynariae in Rats After Traumatic Brain Injury and Identification of Active Compound	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Rhizoma drynariae; Traumatic brain injury; UPLC	CHAIHU-SHUGAN-SAN; INTRACEREBRAL HEMORRHAGE; SIGNALING PATHWAY; MERANZIN HYDRATE; HEAD-INJURY; MICE; CELL; TRANSPLANTATION; PROGESTERONE; NRF2	Traumatic brain injury (TBI) is a leading cause of death and disability in the USA. Effective therapeutic strategies for TBI are needed, and increasing attention is turning toward traditional herbal medicine. Rhizoma drynariae is a traditional Chinese medicine that has immunomodulatory and anti-inflammatory effects. Here, using the controlled cortical impact model of TBI in rats, we examined whether oral administration of R. drynariae can reduce TBI-induced brain injury in rats. We also identified the likely active compound among its four major phytochemicals in decoction. We found that post-treatment with R. drynariae decreased brain lesion volume, improved neurologic and cognitive function, and reduced anxiety- and depression-like behaviors. These changes were accompanied by reduced blood levels of IL-6 and increased IL-10. R. drynariae treatment also reversed the TBI-induced decrease in blood monocyte numbers and percentage of blood CD3 and CD4 T lymphocytes while inhibiting microglial/macrophage activation. Furthermore, by using ultra performance liquid chromatography and comparing retention times with authentic standards, we identified eriodictyol as the putative active compound of R. drynariae extract in the blood of rats with TBI. These novel findings indicate that the traditional Chinese herbal medicine R. drynariae protects brain against TBI-induced brain injury, possibly via immune-promoting, anti-inflammatory, and neuroprotective effects. Eriodictyol could be its active compound.	[Wang, Wenzhu; Li, Haigang; Zhou, Jing; Zhu, Lin; Wang, Yang; Luo, Min; Xia, Zian; Tang, Tao; Huang, Xi] Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Wang, Wenzhu; Hong, Michael; Yang, Zeng-Jin; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA; [Yu, Jintao] Cent S Univ, Xiangya Hosp, Dept Otolaryngol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Ren, Ping] Cent S Univ, Xiangya Hosp, Off Good Clin Practice, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Huang, Xi] Nanjing Univ Tradit Chinese Med, Inst TCM Related Depress Comorbid, 138 Xianling Rd, Nanjing 210064, Jiangsu, Peoples R China		Huang, X (corresponding author), Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.; Huang, X (corresponding author), Nanjing Univ Tradit Chinese Med, Inst TCM Related Depress Comorbid, 138 Xianling Rd, Nanjing 210064, Jiangsu, Peoples R China.	huangx59@163.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Hai-Gang/0000-0003-2346-6527	NSFCNational Natural Science Foundation of China (NSFC) [81072967]; National Key Clinical Specialist Vocational School of TCM encephalopathy; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; China Scholarship Council Joint PhD Training award (CSC)China Scholarship Council [201406370078]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This work was supported by grants from NSFC (No. 81072967), the fund from National Key Clinical Specialist Vocational School of TCM encephalopathy, and NIH (R01NS078026, R01AT007317). Wenzhu Wang is the recipient of the China Scholarship Council Joint PhD Training award (CSC NO. 201406370078). We thank Jiarui Wang and Claire Levine for assistance with this manuscript.	An HJ, 2012, NAT PROD COMMUN, V7, P905; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Anuja GI, 2010, J ETHNOPHARMACOL, V132, P456, DOI 10.1016/j.jep.2010.08.038; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Fogaca MV, 2015, PHARMACOL BIOCHEM BE, V129, P7, DOI 10.1016/j.pbb.2014.11.013; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Gao Y, 2008, CHIN J MED CHEM, V8, P284; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Huang W, 2012, PHARMAZIE, V67, P586, DOI 10.1691/ph.2012.1142; Jing X, 2013, TOXICOL APPL PHARM, V273, P672, DOI 10.1016/j.taap.2013.10.018; Li M, 2015, CHINESE MED J-PEKING, V128, P1072, DOI 10.4103/0366-6999.155094; Lou HY, 2012, NEUROCHEM INT, V61, P251, DOI 10.1016/j.neuint.2012.05.013; Ma HD, 2013, CLIN REV ALLERG IMMU, V44, P229, DOI 10.1007/s12016-012-8332-0; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Qiu XJ, 2011, J ETHNOPHARMACOL, V137, P205, DOI 10.1016/j.jep.2011.05.009; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Shang ZhenPing, 2010, Practical Pharmacy and Clinical Remedies, V13, P262; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Taylor AE, 2011, BRIT J SPORT MED, V45, P1243, DOI 10.1136/bjsports-2011-090024; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060; Wang HC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/720870; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2015, BRAIN BEHAV IMMUN, V43, P172, DOI 10.1016/j.bbi.2014.07.022; Wang JP, 2014, BEHAV BRAIN RES, V265, P171, DOI 10.1016/j.bbr.2014.02.033; Wang WZ, 2012, J ETHNOPHARMACOL, V142, P300, DOI 10.1016/j.jep.2012.04.031; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Wang Y, 2012, CURR TOP MED CHEM, V12, P1356, DOI 10.2174/156802612801319034; Warner N, 2010, CURR OPIN OPHTHALMOL, V21, P459, DOI 10.1097/ICU.0b013e32833f00c9; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Xie Y, 2013, NEUROPHARMACOLOGY, V67, P318, DOI 10.1016/j.neuropharm.2012.10.003; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	48	41	41	1	35	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	SEP	2016	53	7					4809	4820		10.1007/s12035-015-9385-x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DS3JI	WOS:000380678600043	26334614	Green Accepted			2022-02-06	
J	Bharadwaj, VN; Lifshitz, J; Adelson, PD; Kodibagkar, VD; Stabenfeldt, SE				Bharadwaj, Vimala N.; Lifshitz, Jonathan; Adelson, P. David; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.			Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size	SCIENTIFIC REPORTS			English	Article							BARRIER PERMEABILITY; SMALL MOLECULES; BIODISTRIBUTION; SURFACE; CORTEX; MOUSE; DRUG; TIME; RAT; METABOLISM	Nanoparticle (NP) based therapeutic and theranostic agents have been developed for various diseases, yet application to neural disease/ injury is restricted by the blood-brain-barrier (BBB). Traumatic brain injury (TBI) results in a host of pathological alterations, including transient breakdown of the BBB, thus opening a window for NP delivery to the injured brain tissue. This study focused on investigating the spatiotemporal accumulation of different sized NPs after TBI. Specifically, animal cohorts sustaining a controlled cortical impact injury received an intravenous injection of PEGylated NP cocktail (20, 40, 100, and 500 nm, each with a unique fluorophore) immediately (0 h), 2 h, 5 h, 12 h, or 23 h after injury. NPs were allowed to circulate for 1 h before perfusion and brain harvest. Confocal microscopy demonstrated peak NP accumulation within the injury penumbra 1 h post-injury. An inverse relationship was found between NP size and their continued accumulation within the penumbra. NP accumulation preferentially occurred in the primary motor and somatosensory areas of the injury penumbra as compared to the parietal association and visual area. Thus, we characterized the accumulation of particles up to 500 nm at different times acutely after injury, indicating the potential of NP-based TBI theranostics in the acute period after injury.	[Bharadwaj, Vimala N.; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85281 USA; [Lifshitz, Jonathan; Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Lifshitz, Jonathan; Adelson, P. David] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA		Kodibagkar, VD; Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85281 USA.	vikram.kodibagkar@asu.edu; sarah.stabenfeldt@asu.edu	Adelson, David/W-2083-2019; Bharadwaj, Vimala/AAV-1040-2021	Bharadwaj, Vimala/0000-0002-6243-0861	FLINN Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2HD084067]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	Authors would like to thank CLAS-Life Sciences Electron Microscope Lab and Bioimaging facility/Keck division (Arizona State University) for the use of transmission electron microscope and confocal laser scanning microscope, respectively. We thank Karthik Nambiar and David Lowry for the technical assistance in acquiring TEM images. We would also like to thank Dr. Dierdre Meldrum for the use of dynamic light scattering instrument. We would like to extend our thanks to Amanda Witten for assistance with the Figure 1 and Supplementary Figure 1. This study was supported by the FLINN Foundation (S.E.S., V.D.K., J.L., P.D.A.) and NIH (1DP2HD084067; SES).	Adelson PD, 1998, ACT NEUR S, V71, P104; Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Ban Y, 1997, Mol Vis, V3, P18; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669; Bryan-Hancock C, 2010, INJURY PREV, V16, pA17, DOI 10.1136/ip.2010.029215.61; Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/nnano.2011.166, 10.1038/NNANO.2011.166]; Cai WB, 2007, SMALL, V3, P1840, DOI 10.1002/smll.200700351; Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dorr A, 2007, NEUROIMAGE, V35, P1409, DOI 10.1016/j.neuroimage.2006.12.040; Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Herculano-Houzel S, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00035; Jin AY, 2009, CONTRAST MEDIA MOL I, V4, P305, DOI 10.1002/cmmi.292; Kim CK, 2009, NANOSCALE, V1, P61, DOI 10.1039/b9nr00112c; KLEIN B, 1986, AM J PHYSIOL, V251, pH1333, DOI 10.1152/ajpheart.1986.251.6.H1333; Kobeissy F.H., 2015, NANOPARTICLES NEUROT, DOI [10.1517/14728210902769601, DOI 10.1517/14728210902769601]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w; Lipka J, 2010, BIOMATERIALS, V31, P6574, DOI 10.1016/j.biomaterials.2010.05.009; Liu DF, 2014, NANOSCALE, V6, P15161, DOI 10.1039/c4nr03942d; LIU DX, 1992, BIOCHIM BIOPHYS ACTA, V1104, P95, DOI 10.1016/0005-2736(92)90136-A; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Masserini M, 2013, ISRN BIOCH, V2013; Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018; Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001; Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6; Nishiyama N, 2015, ENCY POLYM NANOMATER, P1958, DOI DOI 10.1007/978-3-642-29648-2_226; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Pham LDD, 2012, GLIA, V60, P875, DOI 10.1002/glia.22320; Phinikaridou A, 2012, CIRCULATION, V126, P707, DOI 10.1161/CIRCULATIONAHA.112.092098; Ping XJ, 2014, J NEUROTRAUM, V31, P1172, DOI 10.1089/neu.2013.3147; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Sawyer AJ, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/1/016013; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thermo Fisher Scientific, FLUOR SPECTRAVIEWER; Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011; TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yamamoto Y, 2001, J CONTROL RELEASE, V77, P27, DOI 10.1016/S0168-3659(01)00451-5; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155	56	41	42	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 22	2016	6								29988	10.1038/srep29988			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6SS	WOS:000380032200001	27444615	Green Accepted, Green Submitted, Green Published, gold			2022-02-06	
J	Zhao, YH; Gibb, SL; Zhao, J; Moore, AN; Hylin, MJ; Menge, T; Xue, HS; Baimukanova, G; Potter, D; Johnson, EM; Holcomb, JB; Cox, CS; Dash, PK; Pati, S				Zhao, Yuhai; Gibb, Stuart L.; Zhao, Jing; Moore, Anthony N.; Hylin, Michael J.; Menge, Tyler; Xue, Hasen; Baimukanova, Gyulnar; Potter, Daniel; Johnson, Evan M.; Holcomb, John B.; Cox, Charles S., Jr.; Dash, Pramod K.; Pati, Shibani			Wnt3a, a Protein Secreted by Mesenchymal Stem Cells Is Neuroprotective and Promotes Neurocognitive Recovery Following Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cells; Wnt3a; Traumatic brain injury; Neuroprotection; Neurogenesis	ADULT HIPPOCAMPAL NEUROGENESIS; PATTERN SEPARATION; DENTATE GYRUS; OBJECT RECOGNITION; NEURONS; MICE; TRANSPLANTATION; ACTIVATION; MEMORY; TSG-6	Intravenous administration of bone marrow derived mesenchymal stem cells (MSCs) has been shown to reduce blood brain barrier compromise and improve neurocognition following traumatic brain injury (TBI). These effects occur in the absence of engraftment and differentiation of these cells in the injured brain. Recent studies have shown that soluble factors produced by MSCs mediate a number of the therapeutic effects. In this study, we sought to determine if intravenous administration of MSCs (IV-MSCs) could enhance hippocampal neurogenesis following TBI. Our results demonstrate that IV-MSC treatment attenuates loss of neural stem cells and promotes hippocampal neurogenesis in TBI injured mice. As Wnt signaling has been implicated in neurogenesis, we measured circulating Wnt3a levels in serum following IV-MSC administration and found a significant increase in Wnt3a. Concurrent with this increase, we detected increased activation of the Wnt/beta-catenin signaling pathway in hippocampal neurons. Furthermore, IV recombinant Wnt3a treatment provided neuroprotection, promoted neurogenesis, and improved neurocognitive function in TBI injured mice. Taken together, our results demonstrate a role for Wnt3a in the therapeutic potential of MSCs and identify Wnt3a as a potential stand-alone therapy or as part of a combination therapeutic strategy for the treatment of TBI.	[Zhao, Yuhai] Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA USA; [Gibb, Stuart L.; Menge, Tyler; Baimukanova, Gyulnar; Potter, Daniel; Dash, Pramod K.] Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA; [Gibb, Stuart L.; Baimukanova, Gyulnar; Potter, Daniel] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Zhao, Jing; Moore, Anthony N.; Hylin, Michael J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hylin, Michael J.; Pati, Shibani] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA		Pati, S (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	SPati@bloodsystems.org	Hylin, Michael/U-2878-2019	holcomb, john/0000-0001-8312-9157; Dash, Pramod/0000-0001-6746-1002	Blood Systems Research Institute	We thank Scott Holmes for graphic work and Dr. Peng, Zhanglong for assistance in imaging data analysis. TIRR Foundation Mission Connect and intramural grant funding from Blood Systems Research Institute supported this work.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Burke SN, 2010, BEHAV NEUROSCI, V124, P559, DOI 10.1037/a0020893; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dhamdhere GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083650; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012; Grigorian AS, 2011, B EXP BIOL MED+, V150, P551, DOI 10.1007/s10517-011-1187-1; Hylin MJ, 2013, LEARN MEMORY, V20, P267, DOI 10.1101/lm.030197.112; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Maltman DJ, 2011, NEUROCHEM INT, V59, P347, DOI 10.1016/j.neuint.2011.06.008; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Oh SH, 2015, CELL TRANSPLANT, V24, P1097, DOI 10.3727/096368914X679237; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tfilin M, 2010, MOL PSYCHIATR, V15, P1164, DOI 10.1038/mp.2009.110; Varela-Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Yan YF, 2014, NEURAL REGEN RES, V9, P798, DOI 10.4103/1673-5374.131596; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	50	41	43	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2016	34	5					1263	1272		10.1002/stem.2310			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	DL8MU	WOS:000375896900012	26840479	Bronze			2022-02-06	
J	Morganti, JM; Riparip, LK; Chou, A; Liu, S; Gupta, N; Rosi, S				Morganti, Josh M.; Riparip, Lara-Kirstie; Chou, Austin; Liu, Sharon; Gupta, Nalin; Rosi, Susanna			Age exacerbates the CCR2/5-mediated neuroinflammatory response to traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglia; Macrophage; CCR2; Chemokine; Antagonist; Aging; Neurotrauma	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NADPH OXIDASE; ALTERNATIVE ACTIVATION; SPINAL-CORD; MICROGLIA; RECRUITMENT; NEUROTOXICITY; FRACTALKINE; CHEMOKINES; RECOVERY	Background: Traumatic brain injury (TBI) is a major risk factor for the development of multiple neurodegenerative diseases, including Alzheimer's disease (AD) and numerous recent reports document the development of dementia after TBI. Age is a significant factor in both the risk of and the incidence of acquired brain injury. TBI-induced inflammatory response is associated with activation of brain resident microglia and accumulation of infiltrating monocytes, which plays a pivotal role in chronic neurodegeneration and loss of neurological function after TBI. Despite the extensive clinical evidence implicating neuroinflammation with the TBI-related sequelae, the specific role of these different myeloid cells and the influence of age on TBI-initiated innate immune response remain unknown and poorly studied. Methods: We used gene profiling and pathway analysis to define the effect of age on inflammatory response at the time of injury. The recruitment of peripheral CCR2(+) macrophages was delineated using the CX3CR1(GFP/+)CCR2(RFP/+) reporter mouse. These responses were examined in the context of CCR2/5 antagonism using cenicriviroc. Results: Unsupervised gene clustering and pathway analysis revealed that age predisposes exacerbated inflammatory response related to the recruitment and activation of peripheral monocytes to the injured brain. Using a unique reporter animal model able to discriminate resident versus peripherally derived myeloid cells, we demonstrate that in the aged brain, there is an increased accumulation of peripherally derived CCR2(+) macrophages after TBI compared to young animals. Exaggerated recruitment of this population of cells was associated with an augmented inflammatory response in the aged TBI animals. Targeting this cellular response with cenicriviroc, a dual CCR2/5 antagonist, significantly ameliorated injury-induced sequelae in the aged TBI animals. Conclusions: Importantly, these findings demonstrate that peripheral monocytes play a non-redundant and contributing role to the etiology of trauma-induced inflammatory sequelae in the aged brain.	[Morganti, Josh M.; Riparip, Lara-Kirstie; Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Morganti, Josh M.; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA; [Liu, Sharon; Gupta, Nalin; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Gupta, Nalin] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA		Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.	susanna.rosi@ucsf.edu	Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Chou, Austin/0000-0003-4328-5811	National Institute Of Neurological Disorders And StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32NS090805, R21NS087458, R21AG042016]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458, F32NS090805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke and National Institute on Aging of the National Institutes of Health under award numbers F32NS090805 (J.M.M.), R21NS087458 (S.R.); R21AG042016 (S.R.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Balboa L, 2011, J LEUKOCYTE BIOL, V90, P69, DOI 10.1189/jlb.1010577; Blanpain C, 1999, BLOOD, V94, P1899; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hernandes MS, 2012, CURR NEUROPHARMACOL, V10, P321, DOI 10.2174/157015912804143540; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Inadera H, 1999, J INTERF CYTOK RES, V19, P1179, DOI 10.1089/107999099313127; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Mildner A, 2009, BRAIN, V132, P2487, DOI 10.1093/brain/awp144; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti JM, 2012, J NEUROSCI, V32, P14592, DOI 10.1523/JNEUROSCI.0539-12.2012; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Takahashi M, 2009, J IMMUNOL, V183, P3463, DOI 10.4049/jimmunol.0802812; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	43	41	42	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 18	2016	13								80	10.1186/s12974-016-0547-1			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DJ5YB	WOS:000374285600002	27090212	Green Published, gold			2022-02-06	
J	Janova, H; Bottcher, C; Holtman, IR; Regen, T; van Rossum, D; Gotz, A; Ernst, AS; Fritsche, C; Gertig, U; Saiepour, N; Gronke, K; Wrzos, C; Ribes, S; Rolfes, S; Weinstein, J; Ehrenreich, H; Pukrop, T; Kopatz, J; Stadelmann, C; Salinas-Riester, G; Weber, MS; Prinz, M; Bruck, W; Eggen, BJL; Boddeke, HWGM; Priller, J; Hanisch, UK				Janova, Hana; Boettcher, Chotima; Holtman, Inge R.; Regen, Tommy; van Rossum, Denise; Goetz, Alexander; Ernst, Anne-Sophie; Fritsche, Christin; Gertig, Ulla; Saiepour, Nasrin; Gronke, Konrad; Wrzos, Claudia; Ribes, Sandra; Rolfes, Simone; Weinstein, Jonathan; Ehrenreich, Hannelore; Pukrop, Tobias; Kopatz, Jens; Stadelmann, Christine; Salinas-Riester, Gabriela; Weber, Martin S.; Prinz, Marco; Brueck, Wolfgang; Eggen, Bart J. L.; Boddeke, Hendrikus W. G. M.; Priller, Josef; Hanisch, Uwe-Karsten			CD14 is a key organizer of microglial responses to CNS infection and injury	GLIA			English	Article						chemokines; cytokines; inflammation; monocytes; neutrophils; Toll-like receptor; damage	RECEPTOR 4; I INTERFERON; BRAIN; CELLS; LPS; INFLAMMATION; ACTIVATION; LIPOPOLYSACCHARIDE; RECRUITMENT; MACROPHAGES	Microglia, innate immune cells of the CNS, sense infection and damage through overlapping receptor sets. Toll-like receptor (TLR) 4 recognizes bacterial lipopolysaccharide (LPS) and multiple injury-associated factors. We show that its co-receptor CD14 serves three non-redundant functions in microglia. First, it confers an up to 100-fold higher LPS sensitivity compared to peripheral macrophages to enable efficient proinflammatory cytokine induction. Second, CD14 prevents excessive responses to massive LPS challenges via an interferon -mediated feedback. Third, CD14 is mandatory for microglial reactions to tissue damage-associated signals. In mice, these functions are essential for balanced CNS responses to bacterial infection, traumatic and ischemic injuries, since CD14 deficiency causes either hypo- or hyperinflammation, insufficient or exaggerated immune cell recruitment or worsened stroke outcomes. While CD14 orchestrates functions of TLR4 and related immune receptors, it is itself regulated by TLR and non-TLR systems to thereby fine-tune microglial damage-sensing capacity upon infectious and non-infectious CNS challenges.	[Janova, Hana; Regen, Tommy; van Rossum, Denise; Goetz, Alexander; Ernst, Anne-Sophie; Fritsche, Christin; Gertig, Ulla; Saiepour, Nasrin; Gronke, Konrad; Wrzos, Claudia; Ribes, Sandra; Stadelmann, Christine; Weber, Martin S.; Brueck, Wolfgang; Hanisch, Uwe-Karsten] Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Boettcher, Chotima; Rolfes, Simone; Priller, Josef] Charite, Dept Neuropsychiat, D-10117 Berlin, Germany; [Holtman, Inge R.; Rolfes, Simone; Priller, Josef] Charite, Lab Mol Psychiat, D-10117 Berlin, Germany; [Holtman, Inge R.; Eggen, Bart J. L.; Boddeke, Hendrikus W. G. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Sect Med Physiol, NL-9713 AW Groningen, Netherlands; [Regen, Tommy] Johannes Gutenberg Univ Mainz, Inst Mol Med, D-55131 Mainz, Germany; [van Rossum, Denise] Sartorius Stedim Biotech GmbH, D-37079 Gottingen, Germany; [Weinstein, Jonathan] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Ehrenreich, Hannelore] Max Planck Inst Expt Med, Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany; [Pukrop, Tobias] Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; [Kopatz, Jens] Univ Bonn, Dept Neural Regenerat, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany; [Salinas-Riester, Gabriela] Univ Gottingen, Transcriptome Anal Lab, D-37077 Gottingen, Germany; [Prinz, Marco] Univ Freiburg, Inst Neuropathol, D-79106 Freiburg, Germany; [Prinz, Marco] Univ Freiburg, BIOSS Ctr Biol Signaling, D-79106 Freiburg, Germany; [Hanisch, Uwe-Karsten] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04103 Leipzig, Germany		Janova, H (corresponding author), Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	janova.hana@seznam.cz	Holtman, Inge R./AAE-8655-2020	Ehrenreich, Hannelore/0000-0001-8371-5711; Priller, Josef/0000-0001-7596-0979; Weinstein, Jonathan/0000-0001-6080-9758; Ernst, Anne-Sophie/0000-0003-1483-5781; Bottcher, Chotima/0000-0002-6226-586X; Holtman, Inge R./0000-0001-9752-4756; Stadelmann, Christine/0000-0003-1766-5458; Regen, Tommy/0000-0002-7275-3330	German Research Council (DFG)German Research Foundation (DFG) [SFB/TRR43, FOR1336]; NeuroCure; DZNEHelmholtz Association; BIH; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS065008, R01NS076620] Funding Source: NIH RePORTER	German Research Council (DFG, SFB/TRR43, UKH, JP, WB; FOR1336, JP, MP, UKH; NeuroCure, DZNE, and BIH, JP.	Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Cauwels A, 1999, J IMMUNOL, V162, P4762; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Esen N, 2014, GLIA, V62, P1452, DOI 10.1002/glia.22692; Gangloff SC, 2005, J IMMUNOL, V175, P3940, DOI 10.4049/jimmunol.175.6.3940; Garin A, 2010, IMMUNITY, V33, P84, DOI 10.1016/j.immuni.2010.07.005; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Pagano M, 2011, FRONT BIOSCI-LANDMRK, V16, P698, DOI 10.2741/3713; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Regen T, 2011, BRAIN BEHAV IMMUN, V25, P957, DOI 10.1016/j.bbi.2010.10.009; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sahay B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000687; Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409; Scheibe F, 2012, J CEREBR BLOOD F MET, V32, P1578, DOI 10.1038/jcbfm.2012.55; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Triantafilou M, 2004, BIOCHEM J, V381, P527, DOI 10.1042/BJ20040172; Trotta T, 2014, J NEUROIMMUNOL, V268, P1, DOI 10.1016/j.jneuroim.2014.01.014; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742; Zanoni I, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00032; Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118	35	41	41	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2016	64	4					635	649		10.1002/glia.22955			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DD8CX	WOS:000370153300012	26683584				2022-02-06	
J	Decq, P; Gault, N; Blandeau, M; Kerdraon, T; Berkal, M; ElHelou, A; Dusfour, B; Peyrin, JC				Decq, Philippe; Gault, Nathalie; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa; ElHelou, Amine; Dusfour, Bernard; Peyrin, Jean-Claude			Long-term consequences of recurrent sports concussion	ACTA NEUROCHIRURGICA			English	Article						Concussion; Rugby; Depression; Cognitive disorder; Headache	CHRONIC TRAUMATIC ENCEPHALOPATHY; MODIFIED TELEPHONE INTERVIEW; INTERNATIONAL-CONFERENCE; HIGH-SCHOOL; AGREEMENT STATEMENT; CONSENSUS STATEMENT; ALZHEIMERS-DISEASE; TICS-M; FOOTBALL; EPIDEMIOLOGY	Recurrent concussions are suspected to promote the development of long-term neurological disorders. The study was designed to assess the prevalence of major depressive disorder, mild cognitive disorders and headache in a population of retired high-level sportsmen and rugby players and to study the link between scores evaluating these disorders and the number of reported concussions (RCs). A total of 239 retired rugby players (RRPs) and 138 other retired sportsmen (ORSs) who had reached the French national or international championship level between 1985 and 1990 filled in a self-administered questionnaire describing their sociodemographic data, comorbidities and reported history of RC. A phone interview was then conducted using validated questionnaires for the detection of major depressive disorder (PHQ-9), mild cognitive disorders (F-TICS-m) and headache (HIT-6). RRPs reported a higher number of RCs than ORSs (p < 0.001). A higher rate of major depressive disorder (PHQ-9 score > 9) was observed among RRPs compared to ORSs (9% versus 6%) (p = 0.04), and the PHQ-9 score increased with the number of RCs regardless of the type of sport (p = 0.026). A higher rate of mild cognitive disorders (TICS-m score a parts per thousand currency sign30) was observed in RRPs compared to ORSs (57% versus 40%, p = 0.005), but no association was found with the number of RC. The HIT-6 score increased with the number of RCs (p = 0.019) More than 20 years after the end of their career, RRPs present higher rates of depression and lower F-TICS-m scores in favor of mild cognitive impairment compared with ORSs. PHQ-9 and HIT-6 scores were significantly associated with the number of RCs.	[Decq, Philippe; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa] Arts & Metiers ParisTech, Georges Charpak Human Biomecan Inst, Paris, France; [Gault, Nathalie] Beaujon Hosp, AP HP, Epidemiol & Clin Res Dept, Clichy, France; [Decq, Philippe; Blandeau, Mathias; Kerdraon, Tristan; Berkal, Miassa] Beaujon Hosp, AP HP, Dept Neurosurg, Clichy, France; [ElHelou, Amine] Inst Cerveau & Moelle Epiniere, Paris, France; [Dusfour, Bernard] Ligue Natl Rugby, Paris, France; [Peyrin, Jean-Claude] Federat Francaise Rugby, Marcoussis, France; [Decq, Philippe] Rene Diderot Paris 7 Med Univ, Paris, France		Decq, P (corresponding author), Arts & Metiers ParisTech, Georges Charpak Human Biomecan Inst, Paris, France.; Decq, P (corresponding author), Beaujon Hosp, AP HP, Dept Neurosurg, Clichy, France.; Decq, P (corresponding author), Rene Diderot Paris 7 Med Univ, Paris, France.	philippe.decq@aphp.fr	Helou, Amine El/AAN-6827-2020; GAULT, Nathalie/Y-9693-2019	GAULT, Nathalie/0000-0002-9913-9760; Blandeau, Mathias/0000-0002-7727-7580	Federation Francaise de Rugby (FFR); la Ligue Nationale de Rugby (LNR)	The Federation Francaise de Rugby (FFR) and la Ligue Nationale de Rugby (LNR) provided financial support in the form of research technician funding. The sponsor had no role in the design or conduct of this research.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cook SE, 2009, J GERIATR PSYCH NEUR, V22, P103, DOI 10.1177/0891988708328214; Critchley M, 1949, PUNCH DRUNK SYNDROME; Decq P, 2011, J TRAUMATOLOGIE SPOR, V28, P227; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lacoste L., 2009, NPG NEUROLOGIE PSYCH, V9, P17, DOI DOI 10.1016/J.NPG.2008.06.009; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Martin M, 2004, J CLIN EPIDEMIOL, V57, P1271, DOI 10.1016/j.jclinepi.2004.05.004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P265, DOI 10.1080/13803395.2015.1004303; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rothman K.J., 2008, Modern epidemiology, V3rd; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Thomas Anterion C, 2001, REV NEUROL, V157, P1377; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vercambre MN, 2010, INT J GERIATR PSYCH, V25, P1142, DOI 10.1002/gps.2447; Yang M, 2011, CEPHALALGIA, V31, P357, DOI 10.1177/0333102410379890; Zuithoff NPA, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-98	40	41	41	2	53	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2016	158	2					289	300		10.1007/s00701-015-2681-4			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DB6DK	WOS:000368603400012	26711286	Green Published			2022-02-06	
J	Liu, W; Soderlund, K; Senseney, JS; Joy, D; Yeh, PH; Ollinger, J; Sham, EB; Liu, T; Wang, Y; Oakes, TR; Riedy, G				Liu, Wei; Soderlund, Karl; Senseney, Justin S.; Joy, David; Yeh, Ping-Hong; Ollinger, John; Sham, Elyssa B.; Liu, Tian; Wang, Yi; Oakes, Terrence R.; Riedy, Gerard			Imaging Cerebral Microhemorrhages in Military Service Members with Chronic Traumatic Brain Injury	RADIOLOGY			English	Article							SUSCEPTIBILITY; MICROBLEEDS; LESIONS	Purpose: To detect cerebral microhemorrhages in military service members with chronic traumatic brain injury by using susceptibility-weighted magnetic resonance (MR) imaging. The longitudinal evolution of microhemorrhages was monitored in a subset of patients by using quantitative susceptibility mapping. Materials and Methods: The study was approved by the Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA guidelines. All participants underwent two-dimensional conventional gradient-recalled-echo MR imaging and three-dimensional flow-compensated multiecho gradient-recalled-echo MR imaging (processed to generate susceptibility-weighted images and quantitative susceptibility maps), and a subset of patients underwent follow-up imaging. Microhemorrhages were identified by two radiologists independently. Comparisons of microhemorrhage number, size, and magnetic susceptibility derived from quantitative susceptibility maps between baseline and follow-up imaging examinations were performed by using the paired t test. Results: Among the 603 patients, cerebral microhemorrhages were identified in 43 patients, with six excluded for further analysis owing to artifacts. Seventy-seven percent (451 of 585) of the microhemorrhages on susceptibility-weighted images had a more conspicuous appearance than on gradient-recalled-echo images. Thirteen of the 37 patients underwent follow-up imaging examinations. In these patients, a smaller number of microhemorrhages were identified at follow-up imaging compared with baseline on quantitative susceptibility maps (mean +/- standard deviation, 9.8 microhemorrhages +/- 12.8 vs 13.7 microhemorrhages +/- 16.6; P = .019). Quantitative susceptibility mapping-derived quantitative measures of microhemorrhages also decreased over time: -0.85 mm(3) per day +/- 1.59 for total volume (P = .039) and -0.10 parts per billion per day +/- 0.14 for mean magnetic susceptibility (P = .016). Conclusion: The number of microhemorrhages and quantitative susceptibility mapping-derived quantitative measures of microhemorrhages all decreased over time, suggesting that hemosiderin products undergo continued, subtle evolution in the chronic stage. (C) RSNA, 2015	[Liu, Wei; Soderlund, Karl; Senseney, Justin S.; Joy, David; Yeh, Ping-Hong; Ollinger, John; Sham, Elyssa B.; Oakes, Terrence R.; Riedy, Gerard] Walter Reed Natl Mil Med Ctr, NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA; [Joy, David; Oakes, Terrence R.; Riedy, Gerard] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Joy, David] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Liu, Tian; Wang, Yi] Cornell Univ, Dept Biomed Engn, New York, NY 10021 USA; [Liu, Wei; Sham, Elyssa B.] NorthTide Grp, Sterling, VA USA		Riedy, G (corresponding author), Walter Reed Natl Mil Med Ctr, NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA.; Riedy, G (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.	gerard.p.riedy.civ@mail.mil		Joy, David/0000-0001-9941-9538	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300606]; Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074437]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB013443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072370] Funding Source: NIH RePORTER	Supported by Center for Neuroscience and Regenerative Medicine grant no. 300606 and Congressionally Directed Medical Research Programs grant no. PT074437.	Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Mori N, 2008, INVEST RADIOL, V43, P574, DOI 10.1097/RLI.0b013e31817fb432; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; National Center for Injury Prevention and Control, REP C MILD TRAUM BRA; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zhang J, 2014, P 22 M INT SOC MAGN; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022	22	41	41	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2016	278	2					536	545		10.1148/radiol.2015150160			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	DO3SQ	WOS:000377702200028	26371749	Bronze, Green Accepted			2022-02-06	
J	Barker-Collo, S; Jones, K; Theadom, A; Starkey, N; Dowell, A; McPherson, K; Ameratunga, S; Dudley, M; Te Ao, B; Feigin, V				Barker-Collo, Suzanne; Jones, Kelly; Theadom, Alice; Starkey, Nicola; Dowell, Anthony; McPherson, Kathryn; Ameratunga, Shanthi; Dudley, Margaret; Te Ao, Braden; Feigin, Valery		BIONIC Res Grp	Neuropsychological outcome and its correlates in the first year after adult mild traumatic brain injury: A population- based New Zealand study	BRAIN INJURY			English	Article							DEPRESSION FOLLOWING MILD; CONCUSSION SYMPTOMS QUESTIONNAIRE; COGNITIVE FAILURES QUESTIONNAIRE; HEAD-INJURY; CONSTRUCT-VALIDITY; HOSPITAL ANXIETY; CULTURAL-BIAS; SCALE; RELIABILITY; DEFICITS		[Barker-Collo, Suzanne] Univ Auckland, Fac Sci, Sch Psychol, Auckland 1141, New Zealand; [Jones, Kelly; Theadom, Alice; Te Ao, Braden; Feigin, Valery] Auckland Univ Technol, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Fac Arts & Social Sci, Sch Psychol, Hamilton, New Zealand; [Dowell, Anthony] Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Hlth & Rehabil Res Inst, Person Ctr Res Ctr, Auckland, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1141, New Zealand; [Dudley, Margaret] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand		Barker-Collo, S (corresponding author), Univ Auckland, Sch Psychol, Clin Training Programme, Tamaki Campus,Private Bag 92019, Auckland 1141, New Zealand.	s.barker-collo@auckland.ac.nz	Feigin, Valery/AAF-2313-2019; Starkey, Nicola/AAJ-3795-2020; Jones, Kelly/I-5199-2019	Starkey, Nicola/0000-0002-4370-8186; Te Ao, Braden/0000-0002-1050-200X; McPherson, Kath/0000-0003-0487-8497; Theadom, Alice/0000-0003-0351-6216; Ameratunga, Shanthi/0000-0001-8042-2251; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kathryn/0000-0003-1240-8882	New Zealand Health Research CouncilHealth Research Council of New Zealand	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was funded by the New Zealand Health Research Council.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arciniegas, 2000, Curr Treat Options Neurol, V2, P169; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arfanakisa K, 2003, AM J NEURORADIOL, V23, P792; Barker-Collo S, 2002, CLIN NEUROPSYCHOL, V16, P290, DOI 10.1076/clin.16.3.290.13856; Barker-Collo SL, 2001, APHASIOLOGY, V15, P85, DOI 10.1080/02687040042000124; Barker-Collo S, 2008, NEW ZEAL J PSYCHOL, V37, P53; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blouin JSM, 2012, INT ENCY REHABILITAT; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Emerson E, 2012, TIZARD LEARN DISABIL, V17, P139, DOI 10.1108/13595471211240988; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finkelstein E, 2006, INCIDENCE EC BURDEN; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GRIGSBY J, 1992, PERCEPT MOTOR SKILL, V74, P883, DOI 10.2466/PMS.74.3.883-892; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri CT, 2004, AM NEUR ASS ANN M BA; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Heilman KM, 2003, CLIN NEUROPSYCHOLOGY; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbird MR, 1998, AM J PSYCHIAT, V156, P374; Horowitz SH, 2014, STATE LEARNING DISAB; Johnson LG, 2008, MEDSCAPE J MED, V10, P327; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KAYE K, 1990, J AM GERIATR SOC, V38, P1304, DOI 10.1111/j.1532-5415.1990.tb03452.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Michopoulos Ioannis, 2008, Ann Gen Psychiatry, V7, P4, DOI 10.1186/1744-859X-7-4; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ogden J. A., 2003, BRAIN IMPAIR, V4, P122, DOI [10.1375/brim.4.2.122.27026, DOI 10.1375/BRIM.4.2.122.27026]; Ogden JA, 1997, NEW ZEAL J PSYCHOL, V26, P2; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2013, EUR J NEUROL, V20, P1135, DOI 10.1111/ene.12099; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wallace JC, 2004, PERS INDIV DIFFER, V37, P307, DOI 10.1016/j.paid.2003.09.005; Willemsen-van Son A, 2009, J REHABILITATION MED, V41, P521; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	41	41	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC 6	2015	29	13-14					1604	1616		10.3109/02699052.2015.1075143			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CY8LL	WOS:000366659800011	26382561				2022-02-06	
J	Ahmadzadeh, H; Smith, DH; Shenoy, VB				Ahmadzadeh, Hossein; Smith, Douglas H.; Shenoy, Vivek B.			Mechanical Effects of Dynamic Binding between Tau Proteins on Microtubules during Axonal Injury	BIOPHYSICAL JOURNAL			English	Article							BRAIN-INJURY; DEFORMATION; TRANSPORT; STRAIN; DAMAGE; BIOMECHANICS; ORGANIZATION; DENDRITES; BREAKING; SINGLE	The viscoelastic nature of axons plays a key role in their selective vulnerability to damage in traumatic brain injury (TBI). Experimental studies have shown that although axons can tolerate 100% strain under slow loading rates, even strain as small as 5% can rupture microtubules (MTs) during the fast loading velocities relevant to TBI. Here, we developed a computational model to examine rate-dependent behavior related to dynamic interactions between MTs and the MT-associated protein tau under varying strains and strain rates. In the model, inverted pairs of tau proteins can dynamically cross-link parallel MTs via the respective MT-binding domain of each tau. The model also incorporates realistic thermodynamic breaking and reformation of the bonds between the connected tau proteins as they respond to mechanical stretch. With simulated stretch of the axon, the model shows that despite the highly dynamic nature of binding and unbinding events, under fast loading rates relevant to TBI, large tensile forces can be transmitted to the MTs that can lead to mechanical rupture of the MT cylinder, in agreement with experimental observations and as inferred in human TBI. In contrast, at slow loading rates, the progressive breaking and reformation of the bonds between the tau proteins facilitate the extension of axons up to similar to 100% strain without any microstructural damage. The model also predicts that under fast loading rates, individual MTs detach from MT bundles via sequential breaking of the tau-tau bonds. Finally, the model demonstrates that longer MTs are more susceptible to mechanical rupture, whereas short MTs are more prone to detachment from the MT bundle, leading to disintegration of the axonal MT ultrastructure. Notably, the predictions from the model are in excellent agreement with the findings of the recent in vitro mechanical testing of micropatterned neuronal cultures.	[Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Shenoy, VB (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.	vshenoy@seas.upenn.edu	Shenoy, Vivek/ABD-5075-2021		National Institute of Biomedical Imaging and Bioengineering of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB017753]; U.S. National Science FoundationNational Science Foundation (NSF) [CMMI-1312392]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-N5038104, R01 NS092389, P01-NS056202]; U.S. Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB017753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P01NS056202] Funding Source: NIH RePORTER	This study was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award number R01EB017753, and by U.S. National Science Foundation grant CMMI-1312392 (to V.B.S.), National Institutes of Health grants R01-N5038104, R01 NS092389, and P01-NS056202, and U.S. Department of Defense grant PT110785 (to D.H.S.).	AAMODT EJ, 1986, J CELL BIOL, V103, P23, DOI 10.1083/jcb.103.1.23; Ackbarow T, 2007, P NATL ACAD SCI USA, V104, P16410, DOI 10.1073/pnas.0705759104; Ackbarow T, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/3/035111; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Baas PW, 2004, J NEUROBIOL, V58, P3, DOI 10.1002/neu.10281; Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BRAY D, 1981, J NEUROCYTOL, V10, P589, DOI 10.1007/BF01262592; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Dolle JP, 2013, LAB CHIP, V13, P432, DOI 10.1039/c2lc41063j; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Faul M, 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fournier AJ, 2014, FASEB J, V28, P5277, DOI 10.1096/fj.14-251942; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Hinrichs MH, 2012, J BIOL CHEM, V287, P38559, DOI 10.1074/jbc.M112.369785; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Jerusalem A, 2014, BIOMECH MODEL MECHAN, V13, P883, DOI 10.1007/s10237-013-0543-7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Konzack S, 2007, J NEUROSCI, V27, P9916, DOI 10.1523/JNEUROSCI.0927-07.2007; Kuznetsov IA, 2015, MATH MED BIOL, V32, P263, DOI 10.1093/imammb/dqu003; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Makrides V, 2004, P NATL ACAD SCI USA, V101, P6746, DOI 10.1073/pnas.0400992101; McVicker DP, 2014, CYTOSKELETON, V71, P184, DOI 10.1002/cm.21163; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Ouyang H, 2013, J BIOL ENG, V7, DOI 10.1186/1754-1611-7-21; Phillips R., 2012, PHYS BIOL CELL; Price, 2005, BASIC NEUROCHEMISTRY; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Ross JL, 2004, P NATL ACAD SCI USA, V101, P12910, DOI 10.1073/pnas.0402928101; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scholz T, 2014, CELL MOL LIFE SCI, V71, P3139, DOI 10.1007/s00018-014-1610-7; Sendek A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104965; Shahpasand K, 2012, J NEUROSCI, V32, P2430, DOI 10.1523/JNEUROSCI.5927-11.2012; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tamura A, 2007, STAPP CAR CRASH JO, V51, P139; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Xu K, 2013, SCIENCE, V339, P452, DOI 10.1126/science.1232251; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	59	41	42	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0006-3495	1542-0086		BIOPHYS J	Biophys. J.	DEC 1	2015	109	11					2328	2337		10.1016/j.bpj.2015.09.010			10	Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics	CX8CG	WOS:000365929500013	26636944	Green Published, Bronze			2022-02-06	
J	Baker, JG; Leddy, JJ; Darling, SR; Rieger, BP; Mashtare, TL; Sharma, T; Willer, BS				Baker, John G.; Leddy, John J.; Darling, Scott R.; Rieger, Brian P.; Mashtare, Terry L.; Sharma, Tania; Willer, Barry S.			Factors Associated With Problems for Adolescents Returning to the Classroom After Sport-Related Concussion	CLINICAL PEDIATRICS			English	Article						return to learn; sport-related concussion; school problems; symptoms; computer testing; recovery time	SYMPTOMS; RELIABILITY; MANAGEMENT; RECOVERY; ZURICH; PLAY	The primary objective of this study was to determine factors in the clinic setting associated with concussion-related problems in the school setting. A total of 91 student athletes, 13 to 19 years old, completed the SCAT2 and computerized testing during their initial visit to the clinic. During a follow-up telephone interview, one-third reported problems with return to school. The presence of problems reported in school was associated with severity of concussion as represented by recovery time and the overall number of symptoms at the first clinic visit. Gender, age, and previous concussions were not associated with school problems. Athletes with computerized test scores below the ninth percentile were more likely to report school problems. The current study offers some descriptive information for clinicians and ideas for future research related to adolescent athletes with concussion and problems with return to the classroom.	[Baker, John G.; Leddy, John J.; Darling, Scott R.; Mashtare, Terry L.; Sharma, Tania; Willer, Barry S.] SUNY Buffalo, Buffalo, NY 14214 USA; [Rieger, Brian P.] SUNY Upstate Med Univ, Phys Med & Rehabil, Syracuse, NY 13210 USA		Baker, JG (corresponding author), SUNY Buffalo, UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	jgbaker@buffalo.edu			Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills Team Physician Fund; Buffalo Sabres Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund, and the Buffalo Sabres Foundation.	Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, BRIT J SPORT MED S1, V43, pi85; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Piland SG, 2003, J ATHL TRAINING, V38, P104; Pontifex MB, 2012, RES Q EXERCISE SPORT, V83, P553; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	18	41	41	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	SEP	2015	54	10					961	968		10.1177/0009922815588820			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CP6PF	WOS:000360009000005	26084537				2022-02-06	
J	Pearce, AJ; Hoy, K; Rogers, MA; Corp, DT; Davies, CB; Maller, JJ; Fitzgerald, PB				Pearce, Alan J.; Hoy, Kate; Rogers, Mark A.; Corp, Daniel T.; Davies, Charlotte B.; Maller, Jerome J.; Fitzgerald, Paul B.			Acute motor, neurocognitive and neurophysiological change following concussion injury in Australian amateur football. A prospective multimodal investigation	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Transcranial magnetic stimulation; Motor cortex inhibition; Sports concussion; Australian football	TRANSCRANIAL MAGNETIC STIMULATION; SPORT-RELATED CONCUSSION; BRAIN-INJURY; LONG-TERM; INHIBITION; CORTEX; TASKS	Objectives: This multimodal study investigated the motor, neurocognitive and neurophysiological responses following a sports related concussion injury in the acute-phase (up to 10 days) in sub-elite Australian football players. Design: Between-group, repeated measures. Methods: Over the course of one season (six months), 43 male players from one football club (25.1 +/- 4.5 years) were assessed for fine motor dexterity, visuomotor reaction time, implicit learning and attention. Motor cortex excitability and inhibition were assessed using transcranial magnetic stimulation. Results: Of the 43 players, eight suffered concussion injuries, and were compared to 15 non-concussed players (active control) who returned for follow up testing. Post-concussion assessments using the aforementioned tests were carried out at 48 and 96 h, and 10 days. Compared to the non-concussed players, those who suffered concussion showed slowed fine dexterity (P = 0.02), response (P = 0.02) and movement times (P = 0.01) 48 h post-Concussion. Similarly, attentional performance was reduced in the concussed group at all time points (48h: P<0.01; 96h: P<0.01; and 10 days: P = 0.02) post-concussion. TMS revealed significantly increased corticospinal inhibition at 48 (P = 0.04) and 96 h post concussion (P = 0.02) with significant correlations between increased corticospinal inhibition and response (r = 0.48; P < 0.01), movement time (r = 0.42; P = 0.02), and attention performance (r = 0.44; P = 0.01). Conclusions: This study has demonstrated that acutely concussed Australian football players show abnormalities in motor, cognitive and neurophysiological measures with variable rates of recovery. These. findings suggest that measuring the recovery of concussed athletes should incorporate a range of testing modalities rather than relying on one area of measurement in determining return to play. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Pearce, Alan J.; Rogers, Mark A.; Corp, Daniel T.; Davies, Charlotte B.] Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] Monash Univ, Alfred & Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia		Pearce, AJ (corresponding author), Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic, Australia.	alan.pearce@deakin.edu.au	Pearce, Alan J/W-1195-2018; Fitzgerald, Paul B/A-1225-2008; Maller, Jerome J/H-4963-2014	Pearce, Alan J/0000-0002-9264-9880; Fitzgerald, Paul B/0000-0003-4217-8096; Maller, Jerome J/0000-0003-4685-1508; Corp, Daniel/0000-0003-2435-077X; Hoy, Kate/0000-0003-0694-9674; Rogers, Mark/0000-0002-6808-9545	Smart Head Play; NHMRC fellowshipNational Health and Medical Research Council of Australia; NHMRC Practitioner FellowshipNational Health and Medical Research Council of Australia [606907]; Cervel Neurotech	This study was supported, in part, by a seeding grant from Smart Head Play. JM is supported by a NHMRC fellowship. PBF is supported by a NHMRC Practitioner Fellowship (606907). PBF has received equipment for research from MagVenture A/S, Medtronic Ltd., Cervel Neurotech and Brainsway Ltd., and commercial funding for research from Cervel Neurotech. The authors sincerely thank Mr. Matthew Gray and the Hampton Rovers amateur football club for assistance with participant recruitment, and Ms Hannah Drury for advice with neuropsychological tests.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; Chipchase L, 2012, CLIN NEUROPHYSIOL, V123, P1698, DOI 10.1016/j.clinph.2012.05.003; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hermens HJ., 1999, EUROPEAN RECOMMENDAT; Killane I, 2013, IEEE ENG MED BIO, P6397, DOI 10.1109/EMBC.2013.6611018; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Rossini PM, 2013, FRONT NEUROSCI, P207; Sandberg M.A., 2011, ENCY CLIN NEUROPSYCH, P480, DOI [10.1007/978-0-387-79948-3_169, DOI 10.1007/978-0-387-79948-3_169]; Schlogl A, 2002, P 5 INT WORKSH PRES; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004	30	41	41	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2015	18	5					500	506		10.1016/j.jsams.2014.07.010			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CP9AM	WOS:000360186100002	25104044				2022-02-06	
J	Wilde, EA; Bouix, S; Tate, DF; Lin, AP; Newsome, MR; Taylor, BA; Stone, JR; Montier, J; Gandy, SE; Biekman, B; Shenton, ME; York, G				Wilde, Elisabeth A.; Bouix, Sylvain; Tate, David F.; Lin, Alexander P.; Newsome, Mary R.; Taylor, Brian A.; Stone, James R.; Montier, James; Gandy, Samuel E.; Biekman, Brian; Shenton, Martha E.; York, Gerald			Advanced neuroimaging applied to veterans and service personnel with traumatic brain injury: state of the art and potential benefits	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Magnetic resonance imaging; Diffusion tensor imaging; fMRI; Positron emission tomography; Magnetic resonance spectroscopy; Veteran	MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; POSTTRAUMATIC-STRESS-DISORDER; CEREBRAL-BLOOD-FLOW; DIFFUSE AXONAL INJURY; SPORTS-RELATED CONCUSSION; WHITE-MATTER ABNORMALITIES; AFGHANISTAN WAR VETERANS; MEDIAL TEMPORAL-LOBES; PITTSBURGH COMPOUND-B	Traumatic brain injury (TBI) remains one of the most prevalent forms of morbidity among Veterans and Service Members, particularly for those engaged in the conflicts in Iraq and Afghanistan. Neuroimaging has been considered a potentially useful diagnostic and prognostic tool across the spectrum of TBI generally, but may have particular importance in military populations where the diagnosis of mild TBI is particularly challenging, given the frequent lack of documentation on the nature of the injuries and mixed etiologies, and highly comorbid with other disorders such as post-traumatic stress disorder, depression, and substance misuse. Imaging has also been employed in attempts to understand better the potential late effects of trauma and to evaluate the effects of promising therapeutic interventions. This review surveys the use of structural and functional neuroimaging techniques utilized in military studies published to date, including the utilization of quantitative fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), volumetric analysis, diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), positron emission tomography (PET), magnetoencephalography (MEG), task-based and resting state functional MRI (fMRI), arterial spin labeling (ASL), and magnetic resonance spectroscopy (MRS). The importance of quality assurance testing in current and future research is also highlighted. Current challenges and limitations of each technique are outlined, and future directions are discussed.	[Wilde, Elisabeth A.; Newsome, Mary R.; Taylor, Brian A.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Biekman, Brian] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Sch Med, Boston, MA 02115 USA; [Tate, David F.] Univ Missouri St Louis, Missouri Inst Mental Hlth, Berkeley, MO USA; [Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Ctr Clin Spect, Sch Med, Boston, MA 02115 USA; [Lin, Alexander P.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA; [Montier, James] Univ Virginia Hlth Syst, Dept Radiol & Med Imaging, Dept Neurol Surg, Charlottesville, VA USA; [Gandy, Samuel E.] Icahn Sch Med, Ctr Cognit Hlth, New York, NY USA; [Gandy, Samuel E.] Icahn Sch Med, NFL Neurol Ctr, New York, NY USA; [Gandy, Samuel E.] James J Peters VA Med Ctr, Div Neurol, New York, NY USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA; [York, Gerald] San Antonio Mil Med Ctr, Def Vet Brain Injury Ctr, Ft Sam Houston, TX USA		Wilde, EA (corresponding author), Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.	ewilde@bcm.edu	Shenton, Martha/V-8780-2019; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; Taylor, Brian/0000-0001-9745-1075	US Department of Veterans AffairsUS Department of Veterans Affairs; VA MERIT review grant programUS Department of Veterans Affairs [1I01RX000684-01A2, 1I01RX001062-01A1, 1 I01 RX000928:]; VA SPIRE program [VA 1 I21RX001565, VA 1 I21RX001608]; Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-10-1-0835, X81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337]; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0025]; United States Army Medical Research Acquisition Activity (USAMRAA) [W81XWH-09-2-0160]; Chronic Effects Neurotrauma Consortium (CENC) [PT108802-SC106187, 1W81XWH-13-2-0095]; Alzheimer's Drug Discovery Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002174, I21RX001608, I01RX000684] Funding Source: NIH RePORTER	The authors recognize the support of the US Department of Veterans Affairs (EAW, BAT, SG, MRN, MES, SG), the VA MERIT review grant program (1I01RX000684-01A2: SG, 1I01RX001062-01A1: EAW, MRN, and 1 I01 RX000928: MES, SB), and VA SPIRE program (VA 1 I21RX001565 BAT, and VA 1 I21RX001608 MRN); the Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) (W81XWH-10-1-0835: APL; X81XWH-07-CC-CSDoD: MES, SB), the National Institutes of Health (R01-NS078337: APL, MES, SB), Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC; W81XWH-13-2-0025: DFT), United States Army Medical Research Acquisition Activity (USAMRAA; W81XWH-09-2-0160: JRS, SG), the Chronic Effects Neurotrauma Consortium (CENC; PT108802-SC106187 and 1W81XWH-13-2-0095), and the Alzheimer's Drug Discovery Foundation (SG). We also wish to thank Rhonda O'Donovan for her assistance in manuscript preparation.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197; Amann M, 2015, NEUROIMAGE, V108, P87, DOI 10.1016/j.neuroimage.2014.12.045; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barker JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117101; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Brown S, 2003, J NEUROPSYCH CLIN N, V15, P367, DOI 10.1176/appi.neuropsych.15.3.367; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Callaghan MF, 2014, NEUROBIOL AGING, V35, P1862, DOI 10.1016/j.neurobiolaging.2014.02.008; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Choe AS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00290; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; da Costa L, 2015, J NEUROL NEUROSUR PS, V86, P1008, DOI 10.1136/jnnp-2014-308571; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Descoteaux M, 2011, MED IMAGE ANAL, V15, P603, DOI 10.1016/j.media.2010.07.001; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Dortch RD, 2013, NEUROIMAGE, V64, P640, DOI 10.1016/j.neuroimage.2012.08.047; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Folkersma H, 2009, J NUCL MED, V50, P1975, DOI 10.2967/jnumed.109.067512; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Franklin TR, 2012, DRUG ALCOHOL DEPEN, V125, P60, DOI 10.1016/j.drugalcdep.2012.03.016; Freeman TW, 1998, MAGNET RESON MED, V40, P66, DOI 10.1002/mrm.1910400110; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gholipour A, 2011, IEEE ENG MED BIO, P6997, DOI 10.1109/IEMBS.2011.6091769; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Haacke Em RW., 2013, CEREBRAL BLOOD FLOW, P75; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Harrison NA, 2015, BIOL PSYCHIAT, V78, P49, DOI 10.1016/j.biopsych.2014.09.023; Hartkamp NS, 2014, CURR OPIN NEUROL, V27, P42, DOI 10.1097/WCO.0000000000000051; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Huang H, 2008, MAGN RESON IMAGING, V26, P1294, DOI 10.1016/j.mri.2008.03.005; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Ito R, 2002, NEUROIMAG CLIN N AM, V12, P1, DOI 10.1016/S1052-5149(03)00067-4; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim J, 2012, PSYCHOPHARMACOLOGY, V222, P47, DOI 10.1007/s00213-011-2622-8; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kimbrell T, 2005, PSYCHIAT RES-NEUROIM, V140, P91, DOI 10.1016/j.pscychresns.2005.07.001; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; LaConte SM, 2007, HUM BRAIN MAPP, V28, P1033, DOI 10.1002/hbm.20326; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin A. P., 2010, 96 SCI ASS ANN M RAD; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lin YC, 2015, BRAIN CONNECT, V5, P401, DOI 10.1089/brain.2014.0245; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Logan G. D., 2000, ATTENTION PERFORM, P653; Lopez-Larson Melissa, 2013, Front Psychiatry, V4, P83, DOI 10.3389/fpsyt.2013.00083; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maikusa N, 2013, MED PHYS, V40, DOI 10.1118/1.4801913; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Maksimovskiy Arkadiy L, 2014, J Alcohol Drug Depend, V2, P144; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Mascalchi M, 2014, J MAGN RESON IMAGING, V40, P360, DOI 10.1002/jmri.24355; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mutsaerts HJMM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104108; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Newbould RD, 2014, NEUROIMAGE-CLIN, V4, P641, DOI 10.1016/j.nicl.2014.02.004; Newsome MR, 2015, NEUROIMAGE-CLIN, V8, P543, DOI 10.1016/j.nicl.2015.04.024; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Niedermeyer E., 2005, ELECTROENCEPHALOGRAP; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Oz G, 2014, RADIOLOGY, V270, P658, DOI 10.1148/radiol.13130531; Pagani E, 2008, NEUROL SCI, V29, pS290, DOI 10.1007/s10072-008-1001-7; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Ruthotto L, 2012, PHYS MED BIOL, V57, P5715, DOI 10.1088/0031-9155/57/18/5715; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sokunbi MO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00392; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Symms M, 2004, J NEUROL NEUROSUR PS, V75, P1235, DOI 10.1136/jnnp.2003.032714; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tormenti M, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12282; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Wang DJJ, 2013, NEUROIMAGE-CLIN, V3, P1, DOI 10.1016/j.nicl.2013.06.017; Wang XJ, 2014, NMR BIOMED, V27, P843, DOI 10.1002/nbm.3129; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Wang Z, 2014, HUM BRAIN MAPP, V35, P2869, DOI 10.1002/hbm.22445; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wolf ME, 2014, J NEUROIMAGING, V24, P453, DOI 10.1111/jon.12064; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yoo RE, 2015, STROKE, V46, P564, DOI 10.1161/STROKEAHA.114.007797; Yuan H, 2014, BRAIN CONNECT, V4, P690, DOI 10.1089/brain.2014.0262; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zaharchuk G, 2010, MAGN RESON MED, V63, P1548, DOI 10.1002/mrm.22329; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049; Zhang K, 2014, J CEREBR BLOOD F MET, V34, P1373, DOI 10.1038/jcbfm.2014.92; Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197; Zivadinov R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091098	191	41	41	2	34	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					367	402		10.1007/s11682-015-9444-y			36	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR8LQ	WOS:000361604300003	26350144	Green Accepted			2022-02-06	
J	Salvador, E; Burek, M; Forster, C				Salvador, Ellaine; Burek, Malgorzata; Foerster, CarolaY.			Stretch and/or oxygen glucose deprivation (OGD) in an in vitro traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blood brain barrier; cEND; astrocytes; traumatic brain injury; cell stretch; oxygen-glucose deprivation; calcium level	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; ENDOTHELIAL-CELLS; RECEPTOR ANTAGONIST; BARRIER PROPERTIES; TIGHT JUNCTIONS; NERVOUS-SYSTEM; EXPRESSION; INTERLEUKIN-1; INHIBITION	The blood-brain barrier (BBB), made up of endothelial cells of capillaries in the brain, maintains the microenvironment of the central nervous system. During ischemia and traumatic brain injury (TBI), cellular disruption leading to mechanical insult results to the BBB being compromised. Oxygen glucose deprivation (OGD) is the most commonly used in vitro model for ischemia. On the other hand, stretch injury is currently being used to model TBI in vitro. In this paper, the two methods are used alone or in combination, to assess their effects on cerebrovascular endothelial cells cEND in the presence or absence of astrocytic factors. Applying severe stretch and/or OGD to cEND cells in our experiments resulted to cell swelling and distortion. Damage to the cells induced release of lactate dehydrogenase enzyme (LDH) and nitric oxide (NO) into the cell culture medium. In addition, mRNA expression of inflammatory markers interleukin (I L)-6, IL-1 alpha chemokine (C-C motif) ligand 2 (CCL2) and tumor necrosis factor (TNF)-alpha also increased. These events could lead to the opening of calcium ion channels resulting to excitotoxicity. This could be demonstrated by increased calcium level in OGD-subjected cEND cells incubated with astrocyte-conditioned medium. Furthermore, reduction of cell membrane integrity decreased tight junction proteins claudin-5 and occludin expression. In addition, permeability of the endothelial cell monolayer increased. Also, since cell damage requires an increased uptake of glucose, expression of glucose transporter glut1 was found to increase at the mRNA level after OGD. Overall, the effects of OGD on cEND cells appear to be more prominent than that of stretch with regards to TJ proteins, NO, glutl expression, and calcium level. Astrocytes potentiate these effects on calcium level in cEND cells. Combining both methods to model TBI in vitro shows a promising improvement to currently available models.	[Salvador, Ellaine; Burek, Malgorzata; Foerster, CarolaY.] Univ Wurzburg, Zentrum Operat Med, Klin & Poliklin Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany		Forster, C (corresponding author), Univ Wurzburg, Zentrum Operat Med, Klin & Poliklin Anesthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	foerster_c@ukw.de	Burek, Malgorzata/AAF-3283-2021	Burek, Malgorzata/0000-0001-6148-2195	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German Research Foundation (DFG) [FO 315/4-]; European Union Seventh Framework Programme (FP7) [HEALTH-F2-2009-241778]	We thank Dr. Winfried Neuhaus of the Department of Pharmaceutical Chemistry, University of Vienna for the helpful discussions. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under grant number FO 315/4- and the European Union Seventh Framework Programme (FP7/2007-2013) under Grant agreement No. HEALTH-F2-2009-241778 (to CF and MB).	Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Atlee J, 2007, COMPLICATIONS ANESTH; Audus K.L., 1991, TARGETED DRUG DELIVE, P43, DOI [10. 1007/978-3-642-75862-1_3, DOI 10.1007/978-3-642-75862-1_3]; AUDUS KL, 1990, PHARM RES-DORDR, V7, P435, DOI 10.1023/A:1015800312910; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044; Blecharz KG, 2014, BIOL CELL, V106, DOI 10.1111/boc.201300083; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; Brockmann K, 2009, BRAIN DEV-JPN, V31, P545, DOI 10.1016/j.braindev.2009.02.008; Burek M., 2013, J STEROIDS HORMONAL, V5, P1, DOI [10.4172/2157-7536.1000128, DOI 10.4172/2157-7536.1000128]; Burek M, 2012, JOVE-J VIS EXP, DOI 10.3791/4022; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ceruti S, 2011, NEUROCHEM INT, V59, P259, DOI 10.1016/j.neuint.2011.05.013; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cheung J. Y., 1986, NEW ENGL J MED, V314, P314; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; DINARELLO CA, 1991, BLOOD, V77, P1627; Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Espinoza-Rojo Monica, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P317; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Forstermann U, 1998, FASEB J, V12, P773; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gidday JM, 1999, J NEUROTRAUM, V16, P27, DOI 10.1089/neu.1999.16.27; Gray H., 2011, ANN QUEENSTOWN UPDAT, P51; Guo XL, 2005, BIOCHEM GENET, V43, P175, DOI 10.1007/s10528-005-1510-5; Haslam G, 2000, CYTOTECHNOLOGY, V32, P63, DOI 10.1023/A:1008121125755; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jowers CT, 2013, J NEUROSCI METH, V218, P1, DOI 10.1016/j.jneumeth.2013.04.020; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Munaron L, 2000, J CELL PHYSIOL, V185, P454, DOI 10.1002/1097-4652(200012)185:3<454::AID-JCP17>3.0.CO;2-A; Neuhaus W, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00352; Neuhaus W, 2012, NEUROSCI LETT, V506, P44, DOI 10.1016/j.neulet.2011.10.045; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Silwedel C, 2006, J NEUROIMMUNOL, V179, P37, DOI 10.1016/j.jneuroim.2006.06.019; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Vandamme W, 2004, J NEUROCHEM, V88, P411, DOI 10.1046/j.1471-4159.2003.02163.x; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolterbeek HT, 2005, ASSAY DRUG DEV TECHN, V3, P675, DOI 10.1089/adt.2005.3.675; Yu AS, 2010, AM J PHYSIOL-CELL PH, V299, pC1277, DOI 10.1152/ajpcell.00296.2010; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299	65	41	41	2	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 21	2015	9								323	10.3389/fncel.2015.00323			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP8WS	WOS:000360176300001	26347611	Green Published, gold			2022-02-06	
J	Haghighi, F; Ge, YC; Chen, S; Xin, YR; Umali, MU; De Gasperi, R; Sosa, MAG; Ahlers, ST; Elder, GA				Haghighi, Fatemeh; Ge, Yongchao; Chen, Sean; Xin, Yurong; Umali, Michelle U.; De Gasperi, Rita; Sosa, Miguel A. Gama; Ahlers, Stephen T.; Elder, Gregory A.			Neuronal DNA Methylation Profiling of Blast-Related Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast overpressure; DNA methylation; epigenetic; sleep disturbance; traumatic brain injury	SLEEP DISTURBANCE; INTRACRANIAL-PRESSURE; N-ACETYLTRANSFERASE; MOUSE MODEL; RAT MODEL; EXPOSURE; EXPRESSION; MICE; GENE; INCREASES	Long-term molecular changes in the brain resulting from blast exposure may be mediated by epigenetic changes, such as deoxyribonucleic acid (DNA) methylation, that regulate gene expression. Aberrant regulation of gene expression is associated with behavioral abnormalities, where DNA methylation bridges environmental signals to sustained changes in gene expression. We assessed DNA methylation changes in the brains of rats exposed to three 74.5kPa blast overpressure events, conditions that have been associated with long-term anxiogenic manifestations weeks or months following the initial exposures. Rat frontal cortex eight months post-exposure was used for cell sorting of whole brain tissue into neurons and glia. We interrogated DNA methylation profiles in these cells using Expanded Reduced Representation Bisulfite Sequencing. We obtained data for millions of cytosines, showing distinct methylation profiles for neurons and glia and an increase in global methylation in neuronal versus glial cells (p<10(-7)). We detected DNA methylation perturbations in blast overpressure-exposed animals, compared with sham blast controls, within 458 and 379 genes in neurons and glia, respectively. Differentially methylated neuronal genes showed enrichment in cell death and survival and nervous system development and function, including genes involved in transforming growth factor and nitric oxide signaling. Functional validation via gene expression analysis of 30 differentially methylated neuronal and glial genes showed a 1.2 fold change in gene expression of the serotonin N-acetyltransferase gene (Aanat) in blast animals (p<0.05). These data provide the first genome-based evidence for changes in DNA methylation induced in response to multiple blast overpressure exposures. In particular, increased methylation and decreased gene expression were observed in the Aanat gene, which is involved in converting serotonin to the circadian hormone melatonin and is implicated in sleep disturbance and depression associated with traumatic brain injury.	[Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA; [De Gasperi, Rita; Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; [Haghighi, Fatemeh; Chen, Sean; Xin, Yurong; Umali, Michelle U.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Haghighi, Fatemeh; De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Ge, Yongchao; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Dept Neurotrauma, Silver Spring, MD USA		Haghighi, F (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Floor 10,Room 10-70D, New York, NY 10029 USA.	fatemeh.haghighi@mssm.edu	Ge, Yongchao/AAG-9317-2021	Ge, Yongchao/0000-0001-6448-5703	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award [1I01RX000996-01];  [MH094774]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH094774] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000996, I01RX001705] Funding Source: NIH RePORTER	This work was supported by MH094774 and the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The study protocol was reviewed and approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee in compliance with all applicable Federal regulations governing the protection of animals in research.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Akalin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002781; Archer SN, 2010, SLEEP, V33, P695, DOI 10.1093/sleep/33.5.695; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Baracchi F, 2008, BRAIN BEHAV IMMUN, V22, P982, DOI 10.1016/j.bbi.2008.02.001; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beuckmann CT, 2003, J NEUROSCI, V23, P6793; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen LC, 2003, BRAIN RES, V973, P214, DOI 10.1016/S0006-8993(03)02484-3; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Comuzzie AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051954; Curie T, 2013, SLEEP, V36, P311, DOI 10.5665/sleep.2440; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Dodt Matthias, 2012, Biology (Basel), V1, P895, DOI 10.3390/biology1030895; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fang JD, 1998, AM J PHYSIOL-REG I, V274, pR655, DOI 10.1152/ajpregu.1998.274.3.R655; Faul M, 2010, TRAUMATIC BRAIN INJU; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Garrett-Bakelman FE, 2015, JOVE-J VIS EXP, DOI 10.3791/52246; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Horbelt D, 2012, INT J BIOCHEM CELL B, V44, P469, DOI 10.1016/j.biocel.2011.12.013; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Kozlenkov A, 2014, NUCLEIC ACIDS RES, V42, P109, DOI 10.1093/nar/gkt838; Krieglstein K, 2011, TRENDS NEUROSCI, V34, P421, DOI 10.1016/j.tins.2011.06.002; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lundberg J, 2009, NEUROSCI LETT, V457, P8, DOI 10.1016/j.neulet.2009.03.105; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; Matevossian A., 2008, J VIS EXP; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Mitchell AC, 2012, NEUROBIOL DIS, V45, P3, DOI 10.1016/j.nbd.2011.06.001; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Morairty SR, 2013, P NATL ACAD SCI USA, V110, P20272, DOI 10.1073/pnas.1314762110; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schober ME, 2012, J NEUROTRAUM, V29, P2075, DOI 10.1089/neu.2011.2276; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Soria V, 2010, J PINEAL RES, V49, P35, DOI 10.1111/j.1600-079X.2010.00763.x; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Xin YR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011357; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061; Zheng WP, 2002, CURR MED CHEM, V9, P1187, DOI 10.2174/0929867023370013	74	41	41	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1200	1209		10.1089/neu.2014.3640			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400003	25594545	Green Published			2022-02-06	
J	Hammond, FM; Barrett, RS; Shea, T; Seel, RT; McAlister, TW; Kaelin, D; Ryser, DK; Corrigan, JD; Cullen, N; Horn, SD				Hammond, Flora M.; Barrett, Ryan S.; Shea, Timothy; Seel, Ronald T.; McAlister, Thomas W.; Kaelin, Darryl; Ryser, David K.; Corrigan, John D.; Cullen, Nora; Horn, Susan D.			Psychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amantadine; Antidepressive agents; Antipsychotic agents; Brain injuries; Central nervous system stimulants; Drug therapy; Medication therapy management; Patient care; Physician's practice patterns; Polypharmacy; Rehabilitation	PLACEBO-CONTROLLED TRIAL; PROPENSITY ADJUSTMENT; METHYLPHENIDATE; AMANTADINE; HALOPERIDOL; AGITATION; RECOVERY; SEQUELAE	Objective: To describe psychotropic medication administration patterns during inpatient rehabilitation for traumatic brain injury (TBI) and their relation to patient preinjury and injury characteristics. Design: Prospective observational cohort. Setting: Multiple acute inpatient rehabilitation units or hospitals. Participants: Individuals with TBI (N=2130; complicated mild, moderate, or severe) admitted for inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measures: Not applicable. Results: Most frequently administered were narcotic analgesics (72% of sample), followed by antidepressants (67%), anticonvulsants (47%), anxiolytics (33%), hypnotics (30%), stimulants (28%), antipsychotics (25%), antiparkinson agents (25%), and miscellaneous psychotropics (18%). The psychotropic agents studied were administered to 95% of the sample, with 8.5% receiving only 1 and 31.8% receiving >= 6. Degree of psychotropic medication administration varied widely between sites. Univariate analyses indicated younger patients were more likely to receive anxiolytics, antidepressants, antiparkinson agents, stimulants, antipsychotics, and narcotic analgesics, whereas those older were more likely to receive anticonvulsants and miscellaneous psychotropics. Men were more likely to receive antipsychotics. All medication classes were less likely administered to Asians and more likely administered to those with more severe functional impairment. Use of anticonvulsants was associated with having seizures at some point during acute care or rehabilitation stays. Narcotic analgesics were more likely for those with history of drug abuse, history of anxiety and depression (premorbid or during acute care), and severe pain during rehabilitation. Psychotropic medication administration increased rather than decreased during the course of inpatient rehabilitation in each of the medication categories except for narcotics. This observation was also true for medication administration within admission functional levels (defined by cognitive FIM scores), except for those with higher admission FIM cognitive scores. Conclusions: Many psychotropic medications are used during inpatient rehabilitation. In general, lower admission FIM cognitive score groups were administered more of the medications under investigation compared with those with higher cognitive function at admission. Considerable site variation existed regarding medications administered. The current investigation provides baseline data for future studies of effectiveness. (C) 2015 by the American Congress of Rehabilitation Medicine	[Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.; McAlister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Barrett, Ryan S.; Horn, Susan D.] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Shea, Timothy; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Seel, Ronald T.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Kaelin, Darryl] Univ Louisville, Sch Med, Louisville, KY 40292 USA; [Kaelin, Darryl] Frazier Rehabil Inst, Louisville, KY USA; [Ryser, David K.] Intermt Med Ctr, Salt Lake City, UT USA; [Cullen, Nora] Toronto Rehabil Inst, Toronto, ON, Canada		Hammond, FM (corresponding author), 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com		Cullen, Nora/0000-0001-6359-9418	National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Balon R, 2006, AM J PSYCHIAT, V163, P1504, DOI 10.1176/appi.ajp.163.9.1504; Bhalerao, 2010, BCMEDJ, V53, P26, DOI [10.1089/scd.2015.0160, DOI 10.1089/SCD.2015.0160]; Bogner J, 2015, ARCH PHYS MED REHAB, V96, pS274, DOI 10.1016/j.apmr.2015.04.020; Burnett DM, 1999, NEUROREHABILITATION, V13, P165; Corrigan JD, 2015, ARCH PHYS MED REHAB, V96, pS209, DOI 10.1016/j.apmr.2015.03.026; EDWARDS JG, 2004, SEMINARS CLIN PSYCHO, P573; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Forchheimer MB, 2011, ARCH PHYS MED REHAB, V92, P419, DOI 10.1016/j.apmr.2010.08.029; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS304, DOI 10.1016/j.apmr.2014.11.030; Leon AC, 2007, STAT MED, V26, P110, DOI 10.1002/sim.2458; Leon AC, 2007, STAT MED, V26, P2650, DOI 10.1002/sim.2732; Madeira G, 2007, LARYNGOL OTOL RHINOL, V128, P145; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Murphy MP, 2014, REHABIL NURS, V39, P113, DOI 10.1002/rnj.89; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Ontario Neurotrauma Foundation, EV BAS REV MOD SEV A; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Schneider WN, 1999, BRAIN INJURY, V13, P863; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS197, DOI 10.1016/j.apmr.2015.02.034; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2010, EUR J PHYS REHAB MED, V46, P557; Yasseen B, 2008, BRAIN INJURY, V22, P752, DOI 10.1080/02699050802320132; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014	34	41	41	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S256	S273		10.1016/j.apmr.2015.01.025			18	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100008	26212402	Green Accepted			2022-02-06	
J	Rocque, M				Rocque, Michael			The lost concept: The (re)emerging link between maturation and desistance from crime	CRIMINOLOGY & CRIMINAL JUSTICE			English	Article						Crime theory; desistance; historical perspectives; life-course criminology; maturation	TRAUMATIC BRAIN-INJURY; LIFE-COURSE; ANTISOCIAL-BEHAVIOR; AGE-DIFFERENCES; ADOLESCENCE; CHILDHOOD; PERSONALITY; PERSISTENT; MARRIAGE; MATURITY	Research on desistance or the process of ceasing criminal behavior has increased in recent years. This work has revealed a large number of factors that are related to desistance. To date, these explanations have been generally perceived as mutually exclusive and/or competitive. Interestingly, while research on desistance from crime has been a recent focus, certain work had examined crime over the life-course as far back as the early 20th century. In particular, the Gluecks offered one of the earliest theories of desistance, focusing on maturation. Their maturation theory was somewhat tautological and not well specified. However, the Gluecks were clear that further work was needed in order to specify what maturation means and how it relates to crime. In this article, five domains of maturation are articulated drawing on the literature in the life-course and developmental fields. It is argued that this new framework may help advance the criminological work on desistance.	Bates Coll, Dept Sociol, Lewiston, ME 04240 USA		Rocque, M (corresponding author), Bates Coll, Dept Sociol, 265 Pettengill Hall, Lewiston, ME 04240 USA.	mrocque@bates.edu					Adams K., 2004, DEV THEORIES CRIME D; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Beaver KM, 2008, SOC SCI RES, V37, P736, DOI 10.1016/j.ssresearch.2007.11.003; Bersani B, 2009, J QUANT CRIMINOL, V25, P3, DOI 10.1007/s10940-008-9056-4; Block J., 1971, LIVES TIME; Blonigen DM, 2008, J PERS, V76, P229, DOI 10.1111/j.1467-6494.2007.00485.x; Blonigen DM, 2010, CLIN PSYCHOL REV, V30, P89, DOI 10.1016/j.cpr.2009.10.001; Blonigen DM, 2006, J ABNORM PSYCHOL, V115, P85, DOI 10.1037/0021-843X.115.1.85; Bottoms Anthony., 2004, HOWARD J CRIMINAL JU, V43, P368, DOI 10.1111/j.1468-2311.2004.00336.x; Byrne JM, 2008, VICTIMS OFFENDERS, V3, P319, DOI 10.1080/15564880802338435; Casey BJ, 2008, ANN NY ACAD SCI, V1124, P111, DOI 10.1196/annals.1440.010; Caspi A, 2005, ANNU REV PSYCHOL, V56, P453, DOI 10.1146/annurev.psych.55.090902.141913; Cauffman E, 2000, BEHAV SCI LAW, V18, P741, DOI 10.1002/bsl.416; Collins R. E., 2004, J OFFENDER REHABIL, V39, P1; DANNEFER D, 1984, AM SOCIOL REV, V49, P100, DOI 10.2307/2095560; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Diamond A, 1997, MONOGR SOC RES CHILD, V62, P1; Dmitrieva J, 2012, DEV PSYCHOPATHOL, V24, P1073, DOI 10.1017/S0954579412000545; Farrall S., 2006, UNDERSTANDING DESIST; Farrall S, 2011, AUST NZ J CRIMINOL, V44, P218, DOI 10.1177/0004865811405136; Farrington DP, 2009, AGGRESSIVE BEHAV, V35, P150, DOI 10.1002/ab.20296; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Finlay A, 2010, HDB RES CIVIC ENGAGE, P277, DOI DOI 10.1002/9780470767603.CH11; GIBBONS DC, 1970, SOC SERV REV, V44, P22, DOI 10.1086/642483; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giordano PC, 2002, AM J SOCIOL, V107, P990, DOI 10.1086/343191; Giordano PC, 2007, AM J SOCIOL, V112, P1603, DOI 10.1086/512710; Glueck S, 1937, LATER CRIMINAL CAREE; GLUECK S, 1968, DELINQUENTS NONDELIN; Glueck S., 1970, TYPOLOGY JUVENILE OF; Glueck S., 1940, JUVENILE DELINQUENTS; GLUECK S, 1943, CRIMINAL CAREERS RET; Glueck S., 1964, VENTURES CRIMINOLOGY, P306; Glueck S., 1974, DELINQUENCY CRIME PA; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gottfredson M. R., 1990, GEN THEORY CRIME; Gove WR, 1985, GENDER LIFE COURSE, P115; Graham J., 1995, YOUNG PEOPLE CRIME R; GREEN EJ, 1984, ADV CHEM SER, P1; GREENBERG DF, 1977, CONTEMP CRISES, V1, P189, DOI 10.1007/BF00728871; GREENBERGER E, 1974, J YOUTH ADOLESCENCE, V3, P329, DOI 10.1007/BF02214746; GREENBERGER E, 1975, J YOUTH ADOLESCENCE, V4, P127, DOI 10.1007/BF01537437; Greenberger E, 1986, TEENAGERS WORK PSYCH; Hammersley R, 2008, DRUGS AND CRIME, V2; HIRSCHI T, 1983, AM J SOCIOL, V89, P552, DOI 10.1086/227905; Hirschi T., 1969, CAUSES DELINQUENCY; HOGAN DP, 1986, ANNU REV SOCIOL, V12, P109, DOI 10.1146/annurev.so.12.080186.000545; Iselin AMR, 2009, LAW HUMAN BEHAV, V33, P455, DOI 10.1007/s10979-008-9160-x; Kazemian L, 2009, HANDB SOCIOL SOC RES, P277, DOI 10.1007/978-1-4419-0245-0_15; Kort-Butler LA, 2015, JUSTICE Q, V32, P381, DOI 10.1080/07418825.2013.770547; Laub J.H., 2003, SHARED BEGINNINGS DI; Laub JH, 2001, CRIME JUSTICE, V28, P1, DOI 10.1086/652208; LAUB JH, 1991, AM J SOCIOL, V96, P1402, DOI 10.1086/229691; LeBel TP, 2008, EUR J CRIMINOL, V5, P131, DOI 10.1177/1477370807087640; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; MARTINSON R, 1974, PUBLIC INTEREST, P22; Maruna S, 2004, PSYCHOL CRIME LAW, V10, P271, DOI 10.1080/10683160410001662762; Maruna S, 2011, PUNISHM SOC, V13, P3, DOI 10.1177/1462474510385641; Massoglia M, 2010, AM J SOCIOL, V116, P543, DOI 10.1086/653835; MATZA D, 1964, DELINQUENCY DRIFT; McAdams DP, 1998, GENERATIVITY AND ADULT DEVELOPMENT, P7, DOI 10.1037/10288-001; Modecki KL, 2008, LAW HUMAN BEHAV, V32, P78, DOI 10.1007/s10979-007-9087-7; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Monahan KC, 2009, DEV PSYCHOL, V45, P1654, DOI 10.1037/a0015862; Nagin D.S., 2005, GROUP BASED MODELING; Navalta CP, 2006, J NEUROPSYCH CLIN N, V18, P45, DOI 10.1176/appi.neuropsych.18.1.45; Paternoster R, 2009, J CRIM LAW CRIM, V99, P1103; Paternoster R, 2009, J QUANT CRIMINOL, V25, P103, DOI 10.1007/s10940-009-9065-y; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Pulkkinen L, 2009, AGGRESSIVE BEHAV, V35, P117, DOI 10.1002/ab.20297; Restak RM., 2001, SECRET LIFE BRAIN; Rocque M, 2012, J CRIM JUST, V40, P306, DOI 10.1016/j.jcrimjus.2012.05.003; Rumgay J., 2004, HOWARD J, V43, P405, DOI DOI 10.1111/J.1468-2311.2004.00338.X; Sampson R.J., 1993, CRIME MAKING PATHWAY; Sampson RJ, 2006, CRIMINOLOGY, V44, P465, DOI 10.1111/j.1745-9125.2006.00055.x; Savolainen J, 2009, BRIT J CRIMINOL, V49, P285, DOI 10.1093/bjc/azn084; Shanahan M.J., 2005, FRONTIER ADULTHOOD T; Shapland J, 2011, PUNISHM SOC, V13, P256, DOI 10.1177/1462474511404334; SHOVER N, 1985, AGING CRIMINALS; Sohoni T, 2014, J CRIME JUSTICE, V37, P155, DOI 10.1080/0735648X.2012.759884; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spear L., 2007, ADOLESCENT PSYCHOPAT, P9, DOI DOI 10.1093/ACPR0F:0S0/9780195306255.003.0001; Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002; Steinberg L, 2009, CHILD DEV, V80, P28, DOI 10.1111/j.1467-8624.2008.01244.x; Sutherland EH, 1937, HARVARD LAW REV, V51, P184, DOI 10.2307/1333300; Sweeten G, 2013, J YOUTH ADOLESCENCE, V42, P921, DOI 10.1007/s10964-013-9926-4; Uggen C., 2003, HDB LIFE COURSE, P311; Uggen C, 2010, CRIMINOL PUBLIC POL, V9, P725, DOI 10.1111/j.1745-9133.2010.00666.x; Vaske J, 2011, J CRIM JUST, V39, P90, DOI 10.1016/j.jcrimjus.2010.12.006; Vaughn MG, 2014, CRIM BEHAV MENT HEAL, V24, P188, DOI 10.1002/cbm.1900; Walsh A, 2009, CRIMINOL JUST STUD, P154; Warr M, 1998, CRIMINOLOGY, V36, P183, DOI 10.1111/j.1745-9125.1998.tb01246.x; WILKINS LT, 1969, YALE LAW J, V78, P731, DOI 10.2307/795026; Wilson J. Q., 1985, CRIME HUMAN NATURE; Wootton B, 1962, SOCIAL SCI SOCIAL PA; YAMAGUCHI K, 1985, AM J SOCIOL, V90, P1284, DOI 10.1086/228211; [No title captured]	99	41	42	0	27	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1748-8958	1748-8966		CRIMINOL CRIM JUSTIC	Crimnol. Crim. Justice	JUL	2015	15	3					340	360		10.1177/1748895814547710			21	Criminology & Penology	Social Science Citation Index (SSCI)	Criminology & Penology	CL0AX	WOS:000356601900008					2022-02-06	
J	Jacotte-Simancas, A; Costa-Miserachs, D; Coll-Andreu, M; Torras-Garcia, M; Borlongan, CV; Portell-Cortes, I				Jacotte-Simancas, Alejandra; Costa-Miserachs, David; Coll-Andreu, Margalida; Torras-Garcia, Meritxell; Borlongan, Cesar V.; Portell-Cortes, Isabel			Effects of Voluntary Physical Exercise, Citicoline, and Combined Treatment on Object Recognition Memory, Neurogenesis, and Neuroprotection after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis and neuroprotection; voluntary physical exercise; traumatic brain injury; object recognition memory; citicoline	CLOSED-HEAD INJURY; GROWTH-FACTOR; NEUROTROPHIC FACTOR; CDP-CHOLINE; HIPPOCAMPAL; TERM; COMBINATION; DYSFUNCTION; MECHANISMS; COGNITION	The biochemical and cellular events that lead to secondary neural damage after traumatic brain injury (TBI) contribute to long-term disabilities, including memory deficits. There is a need to search for single and/or combined treatments aimed at reducing these TBI-related disfunctions. The effects of citicoline and of voluntary physical exercise in a running wheel (3 weeks), alone or in combination, on TBI-related short-term (3 h) and long-term (24 h) object recognition memory (ORM) deficits and on neurogenesis and neuroprotection were examined using a rodent model of TBI (controlled cortical impact injury). Citicoline improved memory deficits at the two times tested, while physical exercise only in the long-term test. Physical exercise had a clear neuroprotective effect as indicated by reduced interhemispheric differences in hippocampal formation and lateral ventricle volumes and in density of mature neurons in the hilus of the dentate gyrus and the perirhinal cortex. Physical exercise also increased cell proliferation and neurogenesis in the granular cell layer of the dentate gyrus. Some degree of neuroprotection of citicoline was suggested by reduced interhemispheric differences in the volume of the hippocampal formation. Contrary to what was expected, the effects of citicoline and physical exercise did not sum up. Further, a negative interference between both treatments was found in several behavioral and histological variables. The promising profiles of both treatments as therapeutic tools in TBI when applied singly underscore the need to perform further works looking for other combined treatment regimens that increase the benefit of each treatment alone.	[Jacotte-Simancas, Alejandra; Costa-Miserachs, David; Coll-Andreu, Margalida; Torras-Garcia, Meritxell; Portell-Cortes, Isabel] Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, E-08193 Barcelona, Spain; [Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL USA		Costa-Miserachs, D (corresponding author), Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, E-08193 Barcelona, Spain.	David.Costa@uab.cat	Torras-Garcia, Meritxell/K-9068-2014; Costa-Miserachs, David/N-2794-2019; Costa-Miserachs, David/E-1318-2011; Coll-Andreu, Margalida/C-9119-2011; Portell-Cortes, Isabel/C-5991-2011	Torras-Garcia, Meritxell/0000-0003-2511-8788; Costa-Miserachs, David/0000-0001-5781-0774; Costa-Miserachs, David/0000-0001-5781-0774; Coll-Andreu, Margalida/0000-0003-4106-2606; Portell-Cortes, Isabel/0000-0002-7710-0101	Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [BES 2008_007827, SEJ2006-14226-PSIC]; Ministerio de Ciencia y TecnologiaSpanish GovernmentEuropean Commission [PSI 2009-08034]	A.J.S. was a recipient of a pre-doctoral fellowship from the Ministerio de Educacion y Ciencia (BES 2008_007827).; This work was supported by the Ministerio de Educacion y Ciencia (SEJ2006-14226-PSIC) and by the Ministerio de Ciencia y Tecnologia (PSI 2009-08034).	Aasebo IEJ, 2011, EUR J NEUROSCI, V33, P1094, DOI 10.1111/j.1460-9568.2011.07608.x; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Brown MW, 2012, NEUROPSYCHOLOGIA, V50, P3122, DOI 10.1016/j.neuropsychologia.2012.07.034; Bustamante A, 2012, J NEUROCHEM, V123, P217, DOI 10.1111/j.1471-4159.2012.07891.x; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Chen MF, 2013, J PHYSIOL-LONDON, V591, P985, DOI 10.1113/jphysiol.2012.241125; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Clarke JR, 2010, P NATL ACAD SCI USA, V107, P2652, DOI 10.1073/pnas.0915059107; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Fehrenbach E, 2006, SPORTS MED, V36, P373, DOI 10.2165/00007256-200636050-00001; Ferreira AFB, 2011, BRAIN RES, V1425, P111, DOI 10.1016/j.brainres.2011.10.004; Fioravanti M, 2006, CLIN INTERV AGING, V1, P247, DOI 10.2147/ciia.2006.1.3.247; Fogelman D, 2012, PM&R, V4, P908, DOI 10.1016/j.pmrj.2012.09.028; Garcia-Capdevila S, 2009, BEHAV BRAIN RES, V202, P162, DOI 10.1016/j.bbr.2009.03.020; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Halldorsson JG, 2012, BRAIN INJURY, V26, P1, DOI 10.3109/02699052.2011.635359; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kim JS, 2008, J RADIAT RES, V49, P517, DOI 10.1269/jrr.08020; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marques-Aleixo I, 2012, PROG NEUROBIOL, V99, P149, DOI 10.1016/j.pneurobio.2012.08.002; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Qian K, 2014, NEUROCHEM RES, V39, P1206, DOI 10.1007/s11064-014-1299-x; Ratey JJ, 2011, REV NEUROSCIENCE, V22, P171, DOI 10.1515/RNS.2011.017; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Secades JJ, 2011, REV NEUROLOGIA, V52, pS1, DOI 10.33588/rn.52S02.2010787; Seo HS, 2010, PHARMACOL BIOCHEM BE, V94, P588, DOI 10.1016/j.pbb.2009.11.015; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Snyder JS, 2009, HIPPOCAMPUS, V19, P898, DOI 10.1002/hipo.20552; Takasaki K, 2011, J PHARMACOL SCI, V116, P232, DOI 10.1254/jphs.11013FP; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Yang M, 2010, NEUROBIOL LEARN MEM, V93, P487, DOI 10.1016/j.nlm.2010.01.006; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	58	41	42	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					739	751		10.1089/neu.2014.3502			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200009	25144903	Green Submitted			2022-02-06	
J	Pandya, JD; Grondin, R; Yonutas, HM; Haghnazar, H; Gash, DM; Zhang, ZM; Sullivan, PG				Pandya, Jignesh D.; Grondin, Richard; Yonutas, Heather M.; Haghnazar, Hamed; Gash, Don M.; Zhang, Zhiming; Sullivan, Patrick G.			Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging	NEUROBIOLOGY OF AGING			English	Article						Aging; Alzheimer's disease; Brain; Calcium buffering; Mitochondria; Mitochondrial permeability transition pore; Pyruvate dehydrogenase complex enzyme activity; Parkinsonism; Parkinson's disease; Respiration; Rhesus monkeys	TRAUMATIC BRAIN-INJURY; FREE-RADICAL THEORY; AGE-RELATED-CHANGES; SPINAL-CORD; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; RESPIRATORY-CHAIN; COGNITIVE DECLINE; PROCESSING SPEED	Altered mitochondrial function in the basal ganglia has been hypothesized to underlie cellular senescence and promote age-related motor decline. We tested this hypothesis in a nonhuman primate model of human aging. Six young (6-8 years old) and 6 aged (20-25 years old) female Rhesus monkeys (Macaca mulatta) were behaviorally characterized from standardized video records. Additionally, we measured mitochondrial bioenergetics along with calcium buffering capacity in the substantia nigra and putamen (PUT) from both age groups. Our results demonstrate that the aged animals had significantly reduced locomotor activity and movement speed compared with younger animals. Moreover, aged monkeys had significantly reduced ATP synthesis capacity (in substantia nigra and PUT), reduced pyruvate dehydrogenase activity (in PUT), and reduced calcium buffering capacity (in PUT) compared with younger animals. Furthermore, this age-related decline in mitochondrial function in the basal ganglia correlated with decline in motor function. Overall, our results suggest that drug therapies designed to enhance altered mitochondrial function may help improve motor deficits in the elderly. (C) 2015 Elsevier Inc. All rights reserved.	[Pandya, Jignesh D.; Yonutas, Heather M.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Coll Med, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Grondin, Richard; Yonutas, Heather M.; Haghnazar, Hamed; Gash, Don M.; Zhang, Zhiming; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Chandler Coll Med, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Chandler Coll Med, 475 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	patsull@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 48191]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) chair endowment funds; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant NS 48191 and Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) chair endowment funds (to PGS).	Alexeyev MF, 2009, FEBS J, V276, P5768, DOI 10.1111/j.1742-4658.2009.07269.x; Allum JHJ, 2002, J PHYSIOL-LONDON, V542, P643, DOI 10.1113/jphysiol.2001.015644; Andersen AH, 1999, BRAIN RES, V829, P90, DOI 10.1016/S0006-8993(99)01343-8; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; BACHEVALIER J, 1991, NEUROBIOL AGING, V12, P99, DOI 10.1016/0197-4580(91)90048-O; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; Bishop NA, 2010, NATURE, V464, P529, DOI 10.1038/nature08983; Bjorklund A, 2010, PROG BRAIN RES, V184, P133, DOI 10.1016/S0079-6123(10)84007-5; Blalock EM, 2010, J NEUROSCI, V30, P6058, DOI 10.1523/JNEUROSCI.3956-09.2010; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Brody H., 1975, CLIN MORPHOLOGIC NEU, p[221, xi]; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Calabrese V, 2004, IN VIVO, V18, P245; Capitanio JP, 2008, LANCET, V371, P1126, DOI 10.1016/S0140-6736(08)60489-4; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Cass WA, 2007, NEUROBIOL AGING, V28, P258, DOI 10.1016/j.neurobiolaging.2005.12.010; CHAGNON P, 1995, NEUROREPORT, V6, P711, DOI 10.1097/00001756-199503270-00002; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039; Curtis RG, 2015, AGING NEUROPSYCHOL C, V22, P42, DOI 10.1080/13825585.2014.888392; DENTON RM, 1988, J CARDIOVASC PHARM, V12, pS69; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Emborg ME, 2007, ILAR J, V48, P339, DOI 10.1093/ilar.48.4.339; Emborg ME, 1998, J COMP NEUROL, V401, P253; Erickson KI, 2010, J NEUROSCI, V30, P5368, DOI 10.1523/JNEUROSCI.6251-09.2010; Fields RD, 2010, SCIENCE, V330, P768, DOI 10.1126/science.1199139; Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187; Freeman WM, 2009, NEUROSCIENCE, V159, P183, DOI 10.1016/j.neuroscience.2008.12.004; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; Gavilan MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010; Geddes JW, 2009, EXP NEUROL, V218, P169, DOI 10.1016/j.expneurol.2009.05.011; GERHARDT GA, 1995, NEUROBIOL AGING, V16, P939, DOI 10.1016/0197-4580(95)02013-6; Gerhardt GA, 2002, J NEUROCHEM, V80, P168, DOI 10.1046/j.0022-3042.2001.00684.x; Glisky E.L., 2007, BRAIN AGING MODELS M; Glover A, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-43; GRACE AA, 1983, NEUROSCIENCE, V10, P317, DOI 10.1016/0306-4522(83)90136-7; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536; Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009; HANSFORD RG, 1978, BIOCHEM J, V170, P285, DOI 10.1042/bj1700285; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Harman D, 1955, AGING THEORY BASED F; Harman D, 2006, ANN NY ACAD SCI, V1067, P454, DOI 10.1196/annals.1354.065; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Head E, 2009, EXP NEUROL, V220, P171, DOI 10.1016/j.expneurol.2009.08.014; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; IRWIN I, 1994, NEURODEGENERATION, V3, P251; Jemmerson R, 2005, ANTIOXID REDOX SIGN, V7, P1158, DOI 10.1089/ars.2005.7.1158; Jin KL, 2010, AGING DIS, V1, P72; Kann O, 2007, AM J PHYSIOL-CELL PH, V292, pC641, DOI 10.1152/ajpcell.00222.2006; Kelly DP, 2011, NATURE, V470, P342, DOI 10.1038/nature09896; Khaliq ZM, 2010, J NEUROSCI, V30, P7401, DOI 10.1523/JNEUROSCI.0143-10.2010; KING FA, 1988, SCIENCE, V240, P1475, DOI 10.1126/science.3287624; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Mosharov EV, 2009, NEURON, V62, P218, DOI 10.1016/j.neuron.2009.01.033; Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nicholls DG, 2004, J BIOENERG BIOMEMBR, V36, P277, DOI 10.1023/B:JOBB.0000041753.52832.f3; Nilsson J, 2014, J INT NEUROPSYCH SOC, V20, P262, DOI 10.1017/S1355617713001458; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Pandya JD, 2011, BRAIN RES, V1384, P151, DOI 10.1016/j.brainres.2011.01.102; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PARADIES G, 1991, BIOCHIM BIOPHYS ACTA, V1070, P180, DOI 10.1016/0005-2736(91)90161-Z; Parihar MS, 2007, AM J PHYSIOL-CELL PH, V292, pC8, DOI 10.1152/ajpcell.00232.2006; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pawlowski TL, 2009, BRAIN RES, V1256, P101, DOI 10.1016/j.brainres.2008.12.039; Poon HF, 2006, NEUROBIOL AGING, V27, P1020, DOI 10.1016/j.neurobiolaging.2005.05.014; Puopolo M, 2007, J NEUROSCI, V27, P645, DOI 10.1523/JNEUROSCI.4341-06.2007; Readnower R.D., 2011, INT J ALZHEIMERS DIS, V2011, P1, DOI [10.4061/2011/104545, DOI 10.4061/2011/104545]; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; Serper M, 2014, HEALTH SERV RES, V49, P1249, DOI 10.1111/1475-6773.12154; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Silver I, 1998, ADV EXP MED BIOL, V454, P7; Sinnegger-Brauns MJ, 2009, MOL PHARMACOL, V75, P407, DOI 10.1124/mol.108.049981; Sonntag WE, 1999, J GERONTOL A-BIOL, V54, pB521, DOI 10.1093/gerona/54.12.B521; SOONG NW, 1992, NAT GENET, V2, P318; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Surmeier DJ, 2011, NEUROSCIENCE, V198, P221, DOI 10.1016/j.neuroscience.2011.08.045; Surmeier DJ, 2007, LANCET NEUROL, V6, P933, DOI 10.1016/S1474-4422(07)70246-6; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Tzagoloff, 1967, METHOD ENZYMOL, V10, P245; Uusi-Rasi K, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-12; VanGuilder HD, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00008; Vina J, 2007, IUBMB LIFE, V59, P249, DOI 10.1080/15216540601178067; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Walton A, 2006, NEUROBIOL AGING, V27, P1477, DOI 10.1016/j.neurobiolaging.2005.08.003; WAN B, 1989, J BIOL CHEM, V264, P13430; Weinert BT, 2003, J APPL PHYSIOL, V95, P1706, DOI 10.1152/japplphysiol.00288.2003; Welmer AK, 2014, J GERONTOL A-BIOL, V69, P1503, DOI 10.1093/gerona/glu047; WHO, 2011, GLOB HLTH AG; Wilson CJ, 2000, J NEUROPHYSIOL, V83, P3084, DOI 10.1152/jn.2000.83.5.3084; Wolfgang MJ, 2002, TRENDS BIOTECHNOL, V20, P479, DOI 10.1016/S0167-7799(02)02052-8; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Zhang ZM, 2000, J GERONTOL A-BIOL, V55, pB473, DOI 10.1093/gerona/55.10.B473	118	41	43	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAY	2015	36	5					1903	1913		10.1016/j.neurobiolaging.2015.01.018			11	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Neurosciences & Neurology	CI9PA	WOS:000355100900012	25726361				2022-02-06	
J	Stergiopoulos, V; Cusi, A; Bekele, T; Skosireva, A; Latimer, E; Schutz, C; Fernando, I; Rourke, SB				Stergiopoulos, V.; Cusi, A.; Bekele, T.; Skosireva, A.; Latimer, E.; Schuetz, C.; Fernando, I.; Rourke, S. B.			Neurocognitive impairment in a large sample of homeless adults with mental illness	ACTA PSYCHIATRICA SCANDINAVICA			English	Article						cognition; homeless persons; mental disorders; neuropsychology	TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSIVE DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL IMPAIRMENT; EXECUTIVE FUNCTION; TEST BATTERY; RISK-FACTORS; ILL PERSONS; SCHIZOPHRENIA	ObjectiveThis study examines neurocognitive functioning in a large, well-characterized sample of homeless adults with mental illness and assesses demographic and clinical factors associated with neurocognitive performance. MethodA total of 1500 homeless adults with mental illness enrolled in the At Home Chez Soi study completed neuropsychological measures assessing speed of information processing, memory, and executive functioning. Sociodemographic and clinical data were also collected. Linear regression analyses were conducted to examine factors associated with neurocognitive performance. ResultsApproximately half of our sample met criteria for psychosis, major depressive disorder, and alcohol or substance use disorder, and nearly half had experienced severe traumatic brain injury. Overall, 72% of participants demonstrated cognitive impairment, including deficits in processing speed (48%), verbal learning (71%) and recall (67%), and executive functioning (38%). The overall statistical model explained 19.8% of the variance in the neurocognitive summary score, with reduced neurocognitive performance associated with older age, lower education, first language other than English or French, Black or Other ethnicity, and the presence of psychosis. ConclusionHomeless adults with mental illness experience impairment in multiple neuropsychological domains. Much of the variance in our sample's cognitive performance remains unexplained, highlighting the need for further research in the mechanisms underlying cognitive impairment in this population.	[Stergiopoulos, V.; Cusi, A.; Skosireva, A.; Fernando, I.; Rourke, S. B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City, Toronto, ON M5B 1W8, Canada; [Stergiopoulos, V.; Rourke, S. B.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Bekele, T.; Rourke, S. B.] Ontario HIV Treatment Network, Toronto, ON, Canada; [Latimer, E.] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada; [Latimer, E.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Schuetz, C.] Univ British Columbia, Dept Psychiat, Inst Mental Hlth, Vancouver, BC, Canada		Stergiopoulos, V (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	stergiopoulosv@smh.ca		Latimer, Eric/0000-0002-4485-1056; Bekele, Tsegaye/0000-0002-8735-5941	Health Canada	The authors would like to thank Jayne Barker (2008-11), Ph.D., Cameron Keller (2011-12), and Catharine Hume (2012-present) Mental Health Commission of Canada At Home/Chez Soi National Project Leads, Paula Goering, Ph.D., the National Research Lead, the National Research Team, the five site research teams, the Site Coordinators, and the numerous service and housing providers, as well as persons with lived experience, who have contributed to this project and the research. This research has been made possible through a financial contribution from Health Canada. The views expressed herein solely represent the authors.	American Psychiatric Association, 1994, DIGAN STAT MAN MENT; Amorim P, 1998, EUR PSYCHIAT, V13, P26, DOI 10.1016/S0924-9338(97)86748-X; Andersen J, 2014, DISABIL REHABIL, V36, P2210, DOI 10.3109/09638288.2014.895870; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Boothroyd RA, 2008, ADM POLICY MENT HLTH, V35, P370, DOI 10.1007/s10488-008-0179-6; Bousman CA, 2010, J NERV MENT DIS, V198, P790, DOI 10.1097/NMD.0b013e3181f97dff; Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; Burra TA, 2009, CAN J PSYCHIAT, V54, P123, DOI 10.1177/070674370905400210; Caplan B, 2006, SCHIZOPHR RES, V83, P77, DOI 10.1016/j.schres.2005.11.013; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Caton CLM, 2005, AM J PUBLIC HEALTH, V95, P1753, DOI 10.2105/AJPH.2005.063321; City of Toronto, 2013, STREET NEEDS ASS; Conrad K J, 2001, Ment Health Serv Res, V3, P141, DOI 10.1023/A:1011571531303; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cotman A, 1997, J COGN REHABIL, V15, P16; Culhane DP, 2001, J EPIDEMIOL COMMUN H, V55, P515, DOI 10.1136/jech.55.7.515; Dickinson D, 2007, ARCH GEN PSYCHIAT, V64, P532, DOI 10.1001/archpsyc.64.5.532; Diez-Roux AV, 1999, AM J PUBLIC HEALTH, V89, P302, DOI 10.2105/AJPH.89.3.302; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Eberle Planning and Research, 2013, VANC HOM COUNT 2013; Fazel S, 2008, PLOS MED, V5, P1670, DOI 10.1371/journal.pmed.0050225; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; Folsom D, 2002, ACTA PSYCHIAT SCAND, V105, P404, DOI 10.1034/j.1600-0447.2002.02209.x; Geddes J R, 1996, Health Bull (Edinb), V54, P276; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; GOLDBERG TE, 1993, AM J PSYCHIAT, V150, P1355; Gonzalez EA, 2001, J NERV MENT DIS, V189, P176, DOI 10.1097/00005053-200103000-00006; Green MF, 2006, J CLIN PSYCHIAT, V67, P3, DOI 10.4088/JCP.1006e12; Greenwood RM, 2005, AM J COMMUN PSYCHOL, V36, P223, DOI 10.1007/s10464-005-8617-z; Harvey PD, 2009, J CLIN EXP NEUROPSYC, V31, P462, DOI 10.1080/13803390802251386; Heaton R. K., 2004, REVISED COMPREHENSIV; HEATON RK, 1986, NEUROPSYCHOLOGICAL A, P100; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Highley JL, 2008, TRAUMATIC BRAIN INJU; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; Hwang SW, 2001, CAN MED ASSOC J, V164, P229; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; Kurtz MM, 2009, NEUROPSYCHOLOGY, V23, P551, DOI 10.1037/a0016277; Lee RSC, 2012, J AFFECT DISORDERS, V140, P113, DOI 10.1016/j.jad.2011.10.023; Leung WW, 2008, J INT NEUROPSYCH SOC, V14, P479, DOI 10.1017/S1355617708080600; Newbold K.B., 2010, CAN ISSUES, P28; Norman MA, 2011, J CLIN EXP NEUROPSYC, V33, P793, DOI 10.1080/13803395.2011.559157; Pluck G, 2012, CAN J BEHAV SCI, V44, P9, DOI 10.1037/a0025382; Pluck G, 2011, BRIT J CLIN PSYCHOL, V50, P33, DOI 10.1348/014466510X490253; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Raphael-Greenfield E, 2012, OCCUP THER INT, V19, P135, DOI 10.1002/oti.1328; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riley ED, 2007, J URBAN HEALTH, V84, P415, DOI 10.1007/s11524-006-9153-3; Robertson MJ, 1996, ANNU REV PUBL HEALTH, V17, P311; Schaefer J, 2013, SCHIZOPHR RES, V150, P42, DOI 10.1016/j.schres.2013.07.009; Schuitevoerder S, 2013, J ANXIETY DISORD, V27, P550, DOI 10.1016/j.janxdis.2013.01.001; Schutt RK, 2007, SCHIZOPHRENIA BULL, V33, P1388, DOI 10.1093/schbul/sbm037; Seidman LJ, 2003, PSYCHIAT SERV, V54, P905, DOI 10.1176/appi.ps.54.6.905; Seidman LJ, 1997, J NERV MENT DIS, V185, P3, DOI 10.1097/00005053-199701000-00002; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; Statistics Canada, 2006, 2006 CENS CAN VIS MI; Statistics Canada, 2006, 2006 CENS CAN POP AB; Stergiopoulos V, 2011, J NERV MENT DIS, V199, P854, DOI 10.1097/NMD.0b013e3182349cfc; TEESSON M, 1993, HOSP COMMUNITY PSYCH, V44, P1187; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; van Holst Ruth Janke, 2011, Curr Drug Abuse Rev, V4, P42; Wagner S, 2012, ACTA PSYCHIAT SCAND, V125, P281, DOI 10.1111/j.1600-0447.2011.01762.x; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237; Wechsler D, 1981, WECHSLER ADULT INTEL; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	72	41	41	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-690X	1600-0447		ACTA PSYCHIAT SCAND	Acta Psychiatr. Scand.	APR	2015	131	4					256	268		10.1111/acps.12391			13	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	CD5SC	WOS:000351147200007	25604122				2022-02-06	
J	Dawes, AJ; Sacks, GD; Cryer, HG; Gruen, JP; Preston, C; Gorospe, D; Cohen, M; McArthur, DL; Russell, MM; Maggard-Gibbons, M; Ko, CY				Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Gruen, J. Peter; Preston, Christy; Gorospe, Deidre; Cohen, Marilyn; McArthur, David L.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.		Los Angeles Cty Trauma Consortium	Intracranial pressure monitoring and inpatient mortality in severe traumatic brain injury: A propensity score-matched analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Traumatic brain injury; intracranial pressure monitoring; mortality; propensity score	EVIDENCE-BASED GUIDELINES; UNITED-STATES; CARE; HOSPITALIZATION; IMPROVEMENT; MANAGEMENT; OUTCOMES	BACKGROUND: Although intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI) is recommended by the Brain Trauma Foundation, the benefits remain controversial. We sought to determine the impact of ICP monitor placement on inpatient mortality within a regional trauma system after correcting for selection bias through propensity score matching. METHODS: Data were collected on all severe TBI cases presenting to 14 trauma centers during the 2-year study period (2009-2010). Inclusion criteria were as follows: blunt injury, Glasgow Coma Scale (GCS) score of 8 or lower in the emergency department, and abnormal intracranial findings on head computed tomography (CT). Two separate multivariate logistic regression models were used to predict ICP monitor placement and inpatient mortality after controlling for demographics, severity of injury, comorbidities, and TBI-specific variables (GCS score, pupil reactivity, international normalized ratio, and nine specific head CT findings). To account for selection bias, we developed a propensity score-matched model to estimate the "true'' effect of ICP monitoring on in-hospital mortality. RESULT: A total of 844 patients met inclusion criteria; 22 died on arrival to the emergency department. Inpatient mortality was 38.8%; 46.0% of the patients underwent ICP monitor placement. Unadjusted mortality rates were significantly lower in the ICP monitoring group (30.7% vs. 45.7%, p < 0.001). ICP monitor placement was positively associated with CT findings of subdural hematoma, intraparenchymal contusion, and mass effect and negatively associated with age, alcoholism, and elevated international normalized ratio. After adjusting for selection bias via propensity score matching, ICP monitor placement was associated with an 8.3 percentage point reduction in the risk-adjusted mortality rate. CONCLUSION: ICP monitor placement occurred in only 46% of eligible patients but was associated with significantly decreased mortality after adjusting for baseline risk profile and the propensity to undergo monitoring. As the individual impact of ICP monitoring may vary, future efforts must determine who stands to benefit from invasive monitoring techniques. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)	[Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Cohen, Marilyn; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Dawes, Aaron J.; Sacks, Greg D.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA; [Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Gruen, J. Peter] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA; [Preston, Christy; Gorospe, Deidre] Cty Los Angeles, Dept Hlth Serv, Emergency Med Serv Agcy, Los Angeles, CA USA		Dawes, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ronald Reagan UCLA Med Ctr, 757 Westwood Plaza B7-11, Los Angeles, CA 90095 USA.	adawes@mednet.ucla.edu	Dawes, Aaron/I-1680-2019	Dawes, Aaron/0000-0003-4574-6765	VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program	A.J.D. was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; DRAKE C, 1993, BIOMETRICS, V49, P1231, DOI 10.2307/2532266; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Guo Shenyang, 2010, PROPENSITY SCORE ANA; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shafi S, 2014, J NEUROSURG, V120, P773, DOI 10.3171/2013.12.JNS132151; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Veterans Health Initiative, 2010, TRAUMATIC BRAIN INJU, P1	24	41	45	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2015	78	3					492	501		10.1097/TA.0000000000000559			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CE8DQ	WOS:000352072000011	25710418				2022-02-06	
J	Nathan, DE; Oakes, TR; Yeh, PH; French, LM; Harper, JF; Liu, W; Wolfowitz, RD; Wang, B; Graner, JL; Riedy, G				Nathan, Dominic E.; Oakes, Terrence R.; Yeh, Ping Hong; French, Louis M.; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Graner, John L.; Riedy, Gerard			Exploring Variations in Functional Connectivity of the Resting State Default Mode Network in Mild Traumatic Brain Injury	BRAIN CONNECTIVITY			English	Article						default mode network; dual-regression ICA; exploratory biomarkers of mild TBI; goodness-of-fit measure; neuropsychological assessments of mTBI; resting state fMRI	POSTTRAUMATIC-STRESS-DISORDER; CINGULATE CORTEX; CHRONIC PAIN; ACTIVATION; VETERANS; DEPRESSION; DIAGNOSIS; MILITARY; MEMORY; FMRI	A definitive diagnosis of mild traumatic brain injury (mTBI) is difficult due to the absence of biomarkers in standard clinical imaging. The brain is a complex network of interconnected neurons and subtle changes can modulate key networks of cognitive function. The resting state default mode network (DMN) has been shown to be sensitive to changes induced by pathology. This study seeks to determine whether quantitative measures of the DMN are sensitive in distinguishing mTBI subjects. Resting state functional magnetic resonance imaging data were obtained for healthy (n = 12) and mTBI subjects (n = 15). DMN maps were computed using dual-regression Independent Component Analysis (ICA). A goodness-of-fit (GOF) index was calculated to assess the degree of spatial specificity and sensitivity between healthy controls and mTBI subjects. DMN regions and neuropsychological assessments were examined to identify potential relationships. The resting state DMN maps indicate an increase in spatial coactivity in mTBI subjects within key regions of the DMN. Significant coactivity within the cerebellum and supplementary motor areas of mTBI subjects were also observed. This has not been previously reported in seed-based resting state network analysis. The GOF suggested the presence of high variability within the mTBI subject group, with poor sensitivity and specificity. The neuropsychological data showed correlations between areas of coactivity within the resting state network in the brain with a number of measures of emotion and cognitive functioning. The poor performance of the GOF highlights the key challenge associated with mTBI injury: the high variability in injury mechanisms and subsequent recovery. However, the quantification of the DMN using dual-regression ICA has potential to distinguish mTBI from healthy subjects, and provide information on the relationship of aspects of cognitive and emotional functioning with their potential neural correlates.	[Nathan, Dominic E.; Yeh, Ping Hong; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan] Henry Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Nathan, Dominic E.; Yeh, Ping Hong; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Riedy, Gerard] Natl Capital Neuroimaging Consortium, Bethesda, MD USA; [Nathan, Dominic E.; Wolfowitz, Rachel D.; Riedy, Gerard] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Nathan, Dominic E.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Nathan, Dominic E.; Oakes, Terrence R.; Yeh, Ping Hong; Harper, Jamie F.; Liu, Wei; Wolfowitz, Rachel D.; Wang, Bin Quan; Graner, John L.; Riedy, Gerard] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Dept Neuroimaging, Bethesda, MD USA; [French, Louis M.; Riedy, Gerard] Ctr Neurosci & Regenerat Med, Rockville, MD USA		Riedy, G (corresponding author), Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Natl Capital NeuroImaging Consortium, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	gerard.p.riedy.civ@mail.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [300606-07.01-60855]; Congressional Directed Medical Research Programs [W81XWH-08-2-0165]	We are grateful to Cara Olson, PhD, Research Assistant Professor and Biostatistics Consultant at the Uniformed Services University of the Health Sciences for assistance with the statistics, Jacob Hershorin, MS, psychometrist at the National Intrepid Center of Excellence, Walter Reed National Military Medical Center for assistance with analysis of the clinical assessment data, and Anthony Panettiere, MD, Neurologist at the National Intrepid Center of Excellence, Walter Reed National Military Medical Center. The views expressed in this article are solely those of the authors and do not reflect official policy of the United States Department of Defense, United States Military, or the United States Government. This research was supported by Center for Neuroscience and Regenerative Medicine (CNRM), (G.R., Henry M. Jackson Foundation Award Number: 300606-07.01-60855) and the Congressional Directed Medical Research Programs (G.R., CDMRP Award Number: W81XWH-08-2-0165).	Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Beckmann C.F., 2009, 15 ANN M ORG HUM BRA; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chikazoe J, 2007, J COGNITIVE NEUROSCI, V19, P69, DOI 10.1162/jocn.2007.19.1.69; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Faul M, 2010, TRAUMATIC BRAIN INJU; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hyvarinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Koch W, 2012, NEUROBIOL AGING, V33, P466, DOI 10.1016/j.neurobiolaging.2010.04.013; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lane RD, 1998, J COGNITIVE NEUROSCI, V10, P525, DOI 10.1162/089892998562924; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Marx E, 2004, NEUROIMAGE, V21, P1818, DOI 10.1016/j.neuroimage.2003.12.026; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrella JR, 2011, NEUROLOGY, V76, P511, DOI 10.1212/WNL.0b013e31820af94e; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rapoport M, 2000, J NEUROPSYCH CLIN N, V12, P193, DOI 10.1176/appi.neuropsych.12.2.193; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Seminowicz DA, 2007, J NEUROPHYSIOL, V97, P3651, DOI 10.1152/jn.01210.2006; Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Snell RS, 2009, CLIN NEUROANATOMY; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vlassenko A, 2004, J NEUROPSYCH CLIN N, V16, P360, DOI 10.1176/appi.neuropsych.16.3.360; Whitfield-Gabrieli S, 2009, P NATL ACAD SCI USA, V106, P1279, DOI 10.1073/pnas.0809141106; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yan CG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005743; Zoroya G., 2009, 360000 VETERANS MAY; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080; [No title captured]	64	41	43	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2158-0014	2158-0022		BRAIN CONNECT	Brain Connect.	MAR	2015	5	2					102	114		10.1089/brain.2014.0273			13	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	VG7FN	WOS:000448192300004	25222050				2022-02-06	
J	Mayeux, JP; Teng, SX; Katz, PS; Gilpin, NW; Molina, PE				Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.			Traumatic brain injury induces neuroinflammation and neuronal degeneration that is associated with escalated alcohol self-administration in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Alcohol; Self-administration; Neuroinflammation; Anxiety	DRUG-USE; STRESS; ANXIETY; RECEPTOR; ACTIVATION; DEPRESSION; DISORDERS; SYMPTOMS; SEQUELAE; RISK	Background: Traumatic brain injury (TBI) affects millions of people each year and is characterized by direct tissue injury followed by a neuroinflammatory response. The post-TBI recovery period can be associated with a negative emotional state characterized by alterations in affective behaviors implicated in the development of Alcohol Use Disorder in humans. The aim of this study was to test the hypothesis that post-TBI neuroinflammation is associated with behavioral dysfunction, including escalated alcohol intake. Methods: Adult male Wistar rats were trained to self-administer alcohol prior to counterbalanced assignment into naive, craniotomy, and TBI groups by baseline drinking. TBI was produced by lateral fluid percussion (LFP; >2 ATM; 25 ms). Alcohol drinking and neurobehavioral function were measured at baseline and following TBI in all experimental groups. Markers of neuroinflammation (GFAP and ED1) and neurodegeneration (FJC) were determined by fluorescence histochemistry in brains excised at sacrifice 19 days post-TBI. Results: The cumulative increase in alcohol intake over the 15 days post-TBI was greater in TBI animals compared to naive controls. A higher rate of pre-injury alcohol intake was associated with a greater increase in post-injury alcohol intake in both TBI and craniotomy animals. Immediately following TBI, both TBI and craniotomy animals exhibited greater neurobehavioral dysfunction compared to naive animals. GFAP, IBA-1, ED1, and FJC immunoreactivity at 19 days post-TBI was significantly higher in brains from TBI animals compared to both craniotomy and naive animals. Conclusions: These results show an association between post-TBI escalation of alcohol drinking and marked localized neuroinflammation at the site of injury. Moreover, these results highlight the relevance of baseline alcohol preference in determining post-TBI alcohol drinking. Further investigation to determine the contribution of neuroinflammation to increased alcohol drinking post-TBI is warranted. (C) 2014 Elsevier B.V. All rights reserved.	[Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; [Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, New Orleans, LA 70112 USA		Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7205, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Gilpin, Nicholas/V-1266-2019; Molina, Patricia E./AAK-9814-2021	Molina, Patricia E./0000-0002-3598-384X	 [T-32 AA007577];  [F30 AA022838];  [LEQSF-EPS(2012)-PFUND-283]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007577, F30AA022838] Funding Source: NIH RePORTER	The authors thank Rebecca Gonzales for editorial assistance, Drs. Scott Edwards and Liz Simon for scientific discussions during the preparation of this manuscript, Dr. Luis Del Valle for guidance with brain IHC imaging, and John Maxi and Renata Impastato for assistance with animal surgeries. This research was supported by T-32 AA007577, F30 AA022838, and LEQSF-EPS(2012)-PFUND-283.	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Breese GR, 2005, ALCOHOL CLIN EXP RES, V29, P185, DOI 10.1097/01.ALC.0000153544.83656.3C; CDC, 2003, REP C MILD TRAUM BRA; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; EDVINSSO.L, 1972, ACTA PATH MICRO IM A, VA 80, P134; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kushner MG, 1999, AM J PSYCHIAT, V156, P723; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1996, LAB INVEST, V74, P315; Miller SC, 2013, AM J PSYCHIAT, V170, P383, DOI 10.1176/appi.ajp.2012.12010126; Moller C, 1997, ALCOHOL CLIN EXP RES, V21, P656, DOI 10.1111/j.1530-0277.1997.tb03818.x; Moonat S, 2012, ALCOHOL RES-CURR REV, V34, P495; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V130, P63, DOI 10.1111/j.1748-1716.1987.tb08112.x; ONAIVI ES, 1989, PROG NEURO-PSYCHOPH, V13, P963, DOI 10.1016/0278-5846(89)90047-X; Osterndorff-Kahanek E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059870; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; POHORECKY LA, 1991, ALCOHOL CLIN EXP RES, V15, P438, DOI 10.1111/j.1530-0277.1991.tb00543.x; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Primeaux SD, 2006, ALCOHOL CLIN EXP RES, V30, P791, DOI 10.1111/j.1530-0277.2006.00092.x; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Roltsch EA, 2014, NEUROPHARMACOLOGY, V79, P83, DOI 10.1016/j.neuropharm.2013.11.005; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI 10.1007/BF02246268; STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q; Taylor AN, 2013, J NEUROTRAUM, V30, P1250, DOI 10.1089/neu.2012.2847; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Zamora-Martinez ER, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00024	45	41	41	1	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2015	279						22	30		10.1016/j.bbr.2014.10.053			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AZ5IO	WOS:000348255200004	25446758	Green Accepted			2022-02-06	
J	Gosseries, O; Sarasso, S; Casarotto, S; Boly, M; Schnakers, C; Napolitani, M; Bruno, MA; Ledoux, D; Tshibanda, JF; Massimini, M; Laureys, S; Rosanova, M				Gosseries, Olivia; Sarasso, Simone; Casarotto, Silvia; Boly, Melanie; Schnakers, Caroline; Napolitani, Martino; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Massimini, Marcello; Laureys, Steven; Rosanova, Mario			On the Cerebral Origin of EEG Responses to TMS: Insights From Severe Cortical Lesions	BRAIN STIMULATION			English	Article						Transcranial magnetic stimulation; Electroencephalography; Brain-injury; Biological artifacts	TRANSCRANIAL MAGNETIC STIMULATION; EFFECTIVE CONNECTIVITY; VEGETATIVE STATE; RECOVERY; COMA; BREAKDOWN	Background: Transcranial magnetic stimulation combined with electroencephalography (TMS/EEG) represents a valuable tool to probe cortical excitability and connectivity. Although several procedures have been devised to abolish TMS-related artifacts, direct evidence that it is possible to record TMS-evoked potentials (TEPs) that purely reflect cortical responses to TMS are still lacking. Objective: To demonstrate that when TMS is delivered on a human head with intact nerves, scalp and ocular muscles, TEPs are present only if a functional portion of cortex is targeted and is absent otherwise. Methods: We performed extensive navigated TMS/EEG mappings in three vegetative state patients and in eight healthy controls. Patients were selected based on the extension of their cortical lesions as revealed by structural/functional imaging: the cerebral cortex was globally damaged in Patient 1 due to cerebral anoxia, Patient 2 showed a traumatic damage affecting one cerebral hemisphere, while Patient 3 was characterized by one left sided and one right-sided focal ischemic lesion. Results: In Patient 1, TMS performed at any targeted cortical site did not elicit statistically significant TEPs. In Patient 2, TEPs were absent when the damaged hemisphere was targeted, while were present over the healthy side. In Patient 3, significant TEPs were absent when cortical lesions were targeted and present otherwise. Significant TEPs were always present in healthy controls. Conclusions: These findings suggest that, provided that appropriate experimental procedures are employed, TEPs are genuine cortical responses detectable only when preserved cortical tissue is stimulated. Hence, a dependable assessment of cortical excitability and connectivity in brain-injured patients requires the use of neuronavigated TMS. (C) 2015 Elsevier Inc. All rights reserved.	[Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Liege, Belgium; [Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven; Rosanova, Mario] Univ Liege, Dept Neurol, Liege, Belgium; [Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven; Rosanova, Mario] Univ Hosp Liege, Liege, Belgium; [Gosseries, Olivia] Univ Wisconsin, Postle Lab, Madison, WI USA; [Gosseries, Olivia] Univ Wisconsin, Dept Psychiat & Psychol, Ctr Sleep & Consciousness, Madison, WI USA; [Sarasso, Simone; Casarotto, Silvia; Napolitani, Martino; Massimini, Marcello; Rosanova, Mario] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, I-20122 Milan, Italy; [Massimini, Marcello] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy; [Rosanova, Mario] FERB Onlus, Fdn Europea Ric Biomed, Milan, Italy		Rosanova, M (corresponding author), Univ Milan, Hosp Luigi Sacco, Dept Biomed & Clin Sci L Sacco, Via GB Grassi 74, I-20122 Milan, Italy.	mario.rosanova@unimi.it	Ledoux, Didier/ABA-8401-2021; Laureys, Steven/AAN-2097-2021; Casarotto, Silvia/F-1251-2015; Gosseries, Olivia/AAB-6469-2020; Sarasso, Simone/C-7817-2012; Laureys, Steven/A-3349-2011; Casarotto, Silvia/Q-9402-2019; Rosanova, Mario/S-8440-2017; Massimini, Marcello/T-8115-2017	Ledoux, Didier/0000-0002-9314-6564; Laureys, Steven/0000-0002-3096-3807; Casarotto, Silvia/0000-0002-7548-7664; Gosseries, Olivia/0000-0001-9011-7496; Sarasso, Simone/0000-0001-9984-4710; Casarotto, Silvia/0000-0002-7548-7664; Rosanova, Mario/0000-0001-7486-7617; Massimini, Marcello/0000-0003-2271-957X; Boly, Melanie/0000-0001-9584-0907	James S. McDonnell Foundation Scholar Award; EUEuropean Commission [FP7-ICT-2011-9, 600806]; Public Utility Foundation; Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Belgian American Educational Foundation; Wallonie Bruxelles International; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH095984]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH095984] Funding Source: NIH RePORTER	This study was funded by James S. McDonnell Foundation Scholar Award 2013, EU grant FP7-ICT-2011-9, n. 600806 " Corticonics" and PRIN 2010 to MM; Public Utility Foundation " Universite Europeenne du Travail"; Belgian National Funds for Scientific Research (FNRS); Belgian American Educational Foundation and Wallonie Bruxelles International. OG and MAB are Postdoctoral Researchers and SL is Research Director at FNRS. OG received support from NIH grant MH095984 to Bradley R. Postle and from Giulio Tononi.	Ammermann H, 2007, J NEUROL SCI, V260, P65, DOI 10.1016/j.jns.2007.03.026; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Casali AG, 2010, NEUROIMAGE, V49, P1459, DOI 10.1016/j.neuroimage.2009.09.026; Corthout E, 2000, NEUROREPORT, V11, P2345, DOI 10.1097/00001756-200008030-00003; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Ilmoniemi RJ, 2010, BRAIN TOPOGR, V22, P233, DOI 10.1007/s10548-009-0123-4; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Komssi S, 2007, NEUROREPORT, V18, P13, DOI 10.1097/WNR.0b013e328011b89a; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Lv J, 2007, MED ENG PHYS, V29, P191, DOI 10.1016/j.medengphy.2006.03.001; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; McCubbin J, 2008, J NEUROSCI METH, V168, P265, DOI 10.1016/j.jneumeth.2007.10.003; Miniussi C, 2010, BRAIN TOPOGR, V22, P249, DOI 10.1007/s10548-009-0083-8; Mutanen T, 2013, BRAIN STIMUL, V6, P371, DOI 10.1016/j.brs.2012.07.005; Nikouline V, 1999, CLIN NEUROPHYSIOL, V110, P1325, DOI 10.1016/S1388-2457(99)00070-X; Rogasch NC, 2013, HUM BRAIN MAPP, V34, P1652, DOI 10.1002/hbm.22016; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; TERBRAACK EM, 2013, BRAIN TOPOGR; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Veniero D, 2009, CLIN NEUROPHYSIOL, V120, P1392, DOI 10.1016/j.clinph.2009.04.023; Virtanen J, 1999, MED BIOL ENG COMPUT, V37, P322, DOI 10.1007/BF02513307; Ziemann U, 2011, NEUROSCIENTIST, V17, P368, DOI 10.1177/1073858410390225	29	41	42	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JAN-FEB	2015	8	1					142	149		10.1016/j.brs.2014.10.008			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX1ZA	WOS:000346741700018	25481074	Green Published			2022-02-06	
J	Lopez-Rodriguez, AB; Siopi, E; Finn, DP; Marchand-Leroux, C; Garcia-Segura, LM; Jafarian-Tehrani, M; Viveros, MP				Lopez-Rodriguez, Ana Belen; Siopi, Eleni; Finn, David P.; Marchand-Leroux, Catherine; Garcia-Segura, Luis M.; Jafarian-Tehrani, Mehrnaz; Viveros, Maria-Paz			CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice	CEREBRAL CORTEX			English	Article						cannabinoid system; diffuse axonal injury; microglial activation; minocycline; neuroprotection; traumatic brain injury	CLOSED-HEAD INJURY; FOCAL CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; PROTECTS NEURONS; KAPPA-B; EDEMA; EXPRESSION; CELLS; NEUROINFLAMMATION; INVOLVEMENT	Traumatic brain injury (TBI) and its consequences represent one of the leading causes of death in young adults. This lesion mediates glial activation and the release of harmful molecules and causes brain edema, axonal injury, and functional impairment. Since glial activation plays a key role in the development of this damage, it seems that controlling it could be beneficial and could lead to neuroprotective effects. Recent studies show that minocycline suppresses microglial activation, reduces the lesion volume, and decreases TBI-induced locomotor hyperactivity up to 3 months. The endocannabinoid system (ECS) plays an important role in reparative mechanisms and inflammation under pathological situations by controlling some mechanisms that are shared with minocycline pathways. We hypothesized that the ECS could be involved in the neuroprotective effects of minocycline. To address this hypothesis, we used a murine TBI model in combination with selective CB1 and CB2 receptor antagonists (AM251 and AM630, respectively). The results provided the first evidence for the involvement of ECS in the neuroprotective action of minocycline on brain edema, neurological impairment, diffuse axonal injury, and microglial activation, since all these effects were prevented by the CB1 and CB2 receptor antagonists.	[Lopez-Rodriguez, Ana Belen; Viveros, Maria-Paz] Univ Complutense Madrid, Fac Biol, Dept Anim Physiol Anim Physiol 2, Inst Invest Sanitaria,Hosp Clin San Carlos IdISSC, E-28040 Madrid, Spain; [Siopi, Eleni; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale,EA4475, Paris, France; [Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Sorbonne Paris Cite, UFR Biomed St Peres, CNRS,UMR 8194, Paris, France; [Finn, David P.] Natl Univ Ireland Galway, NCBES Neurosci Cluster, Sch Med, Galway, Ireland; [Finn, David P.] Natl Univ Ireland Galway, Ctr Pain Res, Galway, Ireland; [Lopez-Rodriguez, Ana Belen; Garcia-Segura, Luis M.] CSIC, Inst Cajal, E-28002 Madrid, Spain		Viveros, MP (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Anim Physiol Anim Physiol 2, Calle Jose Antonio Novais 2, E-28040 Madrid, Spain.	pazviver@bio.ucm.es	Garcia-Segura, Luis M/U-3711-2017; Lopez-Rodriguez, Ana Belen/A-8384-2015; Lopez-Rodriguez, Ana Belen/H-3631-2017; MARCHAND-LEROUX, Catherine/L-7453-2017; Viveros, Maria-Paz/S-6855-2016	Garcia-Segura, Luis M/0000-0002-2450-2916; Lopez-Rodriguez, Ana Belen/0000-0002-0747-7966; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Viveros, Maria-Paz/0000-0002-4119-4636; Finn, David/0000-0001-6186-621X; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	GRUPOS UCM-BSCH [951579]; Delegacion del Gobierno para el Plan Nacional sobre Drogas [Orden SAS/1250/2009]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; Redes tematicas de Investigacion Cooperativa en salud, Red de Trastornos Adictivos [RD06/0001/1013, RD2012/0028/0021]; Ministerio de Economia y Competividad, Spain [BFU2011-30217-C03-01]; nonprofitable organization "Fondation des Gueules cassees"	This work has been supported by GRUPOS UCM-BSCH 951579; Delegacion del Gobierno para el Plan Nacional sobre Drogas (Orden SAS/1250/2009); Instituto de Salud Carlos III; Redes tematicas de Investigacion Cooperativa en salud, Red de Trastornos Adictivos (RD06/0001/1013 and RD2012/0028/0021) to M.P.V.; Ministerio de Economia y Competividad, Spain (BFU2011-30217-C03-01) to L.M.G.S., and the nonprofitable organization "Fondation des Gueules cassees" to E.S. and M.J.T.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Boto GR, 2009, NEUROSURG REV, V32, P343, DOI 10.1007/s10143-008-0178-9; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; Chin CL, 2008, BRIT J PHARMACOL, V153, P367, DOI 10.1038/sj.bjp.0707506; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chu LS, 2010, LIFE SCI, V86, P170, DOI 10.1016/j.lfs.2009.12.001; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Dirikoc S, 2007, J NEUROSCI, V27, P9537, DOI 10.1523/JNEUROSCI.1942-07.2007; Diz-Chaves Y, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-71; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Esposito G, 2001, J NEUROCHEM, V78, P835, DOI 10.1046/j.1471-4159.2001.00465.x; Ferretti MT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-62; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fowler CJ, 2010, EXP NEUROL, V224, P37, DOI 10.1016/j.expneurol.2010.03.021; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gonzalez JC, 2007, EUR J NEUROSCI, V26, P2481, DOI 10.1111/j.1460-9568.2007.05873.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HERKENHAM M, 1992, ANN NY ACAD SCI, V654, P19, DOI 10.1111/j.1749-6632.1992.tb25953.x; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; Kozela E, 2011, BRIT J PHARMACOL, V163, P1507, DOI 10.1111/j.1476-5381.2011.01379.x; Kozela E, 2010, J BIOL CHEM, V285, P1616, DOI 10.1074/jbc.M109.069294; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Marco EM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00063; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Tolon RM, 2009, BRAIN RES, V1283, P148, DOI 10.1016/j.brainres.2009.05.098; Markovic DS, 2011, BRAIN BEHAV IMMUN, V25, P624, DOI 10.1016/j.bbi.2011.01.015; Marmarou A, 2003, ACT NEUR S, V86, P7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McLaughlin PJ, 2003, BEHAV PHARMACOL, V14, P583, DOI 10.1097/00008877-200312000-00002; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Micale V, 2007, PHARMACOL RES, V56, P382, DOI 10.1016/j.phrs.2007.09.008; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paulsen K, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-33; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Romero-Perez D, 2008, J AM COLL CARDIOL, V52, P1086, DOI 10.1016/j.jacc.2008.06.028; Roth P, 2000, Crit Care Nurs Q, V23, P14; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Sarne Y, 2011, BRIT J PHARMACOL, V163, P1391, DOI 10.1111/j.1476-5381.2011.01280.x; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Soares HD, 1995, J NEUROSCI, V15, P8223; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; TOMINAGA T, 1989, STROKE, V20, P513, DOI 10.1161/01.STR.20.4.513; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; WEIBEL ER, 1979, STEREOLOGICAL METHOD; World Health Organization, 2006, WORLD HLTH REPORT 20; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	88	41	43	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JAN	2015	25	1					35	45		10.1093/cercor/bht202			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY2KA	WOS:000347417600004	23960212	Bronze, Green Submitted			2022-02-06	
J	Fujii, M; Sherchan, P; Soejima, Y; Hasegawa, Y; Flores, J; Doycheva, D; Zhang, JH				Fujii, Mutsumi; Sherchan, Prativa; Soejima, Yoshiteru; Hasegawa, Yu; Flores, Jerry; Doycheva, Desislava; Zhang, John H.			Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats	EXPERIMENTAL NEUROLOGY			English	Article						Cannabinoid receptor type 2; JWH133; Subarachnoid hemorrhage; Apoptosis; Brain edema; CREB	TRAUMATIC BRAIN-INJURY; CB2 RECEPTOR; PROTEIN; MODEL; CREB; INVOLVEMENT; DYSFUNCTION; INHIBITION; EXPRESSION; INDUCTION	Early brain injury (EBI) which comprises of vasogenic edema and apoptotic cell death is an important component of subarachnoid hemorrhage (SAH) pathophysiology. This study evaluated whether cannabinoid receptor type 2 (CB2R) agonist, JWH133, attenuates EBI after SAH and whether CB2R stimulation reduces pro-apoptotic caspase-3 via up-regulation of cAMP response element-binding protein (CREB)-Bcl-2 signaling pathway. Male Sprague-Dawley rats (n = 123) were subjected to SAN by endovascular perforation. Rats received vehicle or JWH133 at 1 h after SAH. Neurological deficits and brain water content were evaluated at 24 h after SAN. Western blot was performed to quantify phosphorylated CREB (pCREB), Bcl-2, and cleaved caspase-3 levels. Neuronal cell death was evaluated with terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling staining. Additionally, CREB siRNA was administered to manipulate the proposed pathway. JWH133 (1.0 mg/kg) improved neurological deficits and reduced brain water content in left hemisphere 24 h after SAN. JWH133 significantly increased activated CREB (pCREB) and Bcl-2 levels and significantly decreased cleaved caspase-3 levels in left hemisphere 24 h after SAH. CREB siRNA reversed the effects of treatment. TUNEL positive neurons in the cortex were reduced with JWH133 treatment. Thus, CB2R stimulation attenuated EBI after SAN possibly through activation of pCREB-Bcl-2 pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Fujii, Mutsumi; Sherchan, Prativa; Soejima, Yoshiteru; Hasegawa, Yu; Flores, Jerry; Doycheva, Desislava; Zhang, John H.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Neurosurg, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92354 USA		Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Dept Neurosurg, 11234 Anderson St, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com		Zhang, John H./0000-0002-4319-4285; Doycheva, Desislava/0000-0001-7795-5989; Sherchan, Prativa/0000-0002-2909-283X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS081740, NS082184]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS082184, R01NS081740] Funding Source: NIH RePORTER	This research was supported by NIH grant NS081740 and NS082184 to Dr. Zhang.	Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Bahjat FR, 2013, TRANSL STROKE RES, V4, P89, DOI 10.1007/s12975-012-0223-4; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Borner C, 2009, J BIOL CHEM, V284, P35450, DOI 10.1074/jbc.M109.006338; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Choi IY, 2013, AM J PATHOL, V182, P928, DOI 10.1016/j.ajpath.2012.11.024; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; Fujii M, 2012, NEUROCHEM INT, V60, P327, DOI 10.1016/j.neuint.2011.12.014; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Glass M, 1999, MOL PHARMACOL, V56, P1362, DOI 10.1124/mol.56.6.1362; Ichiki T, 2006, ARTERIOSCL THROM VAS, V26, P449, DOI 10.1161/01.ATV.0000196747.79349.d1; Lapchak PA, 2013, TRANSL STROKE RES, V4, P328, DOI 10.1007/s12975-012-0200-y; Liu GM, 2006, J BIOL CHEM, V281, P29479, DOI 10.1074/jbc.M600579200; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Murikinati S, 2010, FASEB J, V24, P788, DOI 10.1096/fj.09-141275; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228; Onaivi ES, 2012, J PSYCHOPHARMACOL, V26, P92, DOI 10.1177/0269881111400652; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Peters M, 2009, GENES BRAIN BEHAV, V8, P320, DOI 10.1111/j.1601-183X.2009.00474.x; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Simard JM, 2012, TRANSL STROKE RES, V3, pS155, DOI 10.1007/s12975-012-0166-9; Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004; Suzuki H, 2010, STROKE, V41, P1783, DOI 10.1161/STROKEAHA.110.586537; Tajiri N, 2013, TRANSL STROKE RES, V4, P308, DOI 10.1007/s12975-012-0241-2; Tokudome T, 2004, ENDOCRINOLOGY, V145, P2458, DOI 10.1210/en.2003-1322; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yamamoto W, 2008, EUR J PHARMACOL, V583, P56, DOI 10.1016/j.ejphar.2008.01.010; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	36	41	44	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						396	403		10.1016/j.expneurol.2014.07.005			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR4AX	WOS:000343531500042	25058046	Green Accepted			2022-02-06	
J	Weber, DJ; Gracon, ASA; Ripsch, MS; Fisher, AJ; Cheon, BM; Pandya, PH; Vittal, R; Capitano, ML; Kim, Y; Allette, YM; Riley, AA; McCarthy, BP; Territo, PR; Hutchins, GD; Broxmeyer, HE; Sandusky, GE; White, FA; Wilkes, DS				Weber, Daniel J.; Gracon, Adam S. A.; Ripsch, Matthew S.; Fisher, Amanda J.; Cheon, Bo M.; Pandya, Pankita H.; Vittal, Ragini; Capitano, Maegan L.; Kim, Youngsong; Allette, Yohance M.; Riley, Amanda A.; McCarthy, Brian P.; Territo, Paul R.; Hutchins, Gary D.; Broxmeyer, Hal E.; Sandusky, George E.; White, Fletcher A.; Wilkes, David S.			The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation	SCIENCE TRANSLATIONAL MEDICINE			English	Article							GLYCATION END-PRODUCTS; MOBILITY GROUP BOX-1; THERAPEUTIC TARGET; RECEPTOR DOMAIN; RAGE; INFLAMMATION; ACTIVATION; MIGRATION; CONTRIBUTES; APOPTOSIS	Traumatic brain injury (TBI) results in systemic inflammatory responses that affect the lung. This is especially critical in the setting of lung transplantation, where more than half of donor allografts are obtained postmortem from individuals with TBI. The mechanism by which TBI causes pulmonary dysfunction remains unclear but may involve the interaction of high-mobility group box-1 (HMGB1) protein with the receptor for advanced glycation end products (RAGE). To investigate the role of HMGB1 and RAGE in TBI-induced lung dysfunction, RAGE-sufficient (wild-type) or RAGE-deficient (RAGE(-/-)) C57BL/6 mice were subjected to TBI through controlled cortical impact and studied for cardiopulmonary injury. Compared to control animals, TBI induced systemic hypoxia, acute lung injury, pulmonary neutrophilia, and decreased compliance (a measure of the lungs' ability to expand), all of which were attenuated in RAGE(-/-) mice. Neutralizing systemic HMGB1 induced by TBI reversed hypoxia and improved lung compliance. Compared to wild-type donors, lungs from RAGE(-/-) TBI donors did not develop acute lung injury after transplantation. In a study of clinical transplantation, elevated systemic HMGB1 in donors correlated with impaired systemic oxygenation of the donor lung before transplantation and predicted impaired oxygenation after transplantation. These data suggest that the HMGB1-RAGE axis plays a role in the mechanism by which TBI induces lung dysfunction and that targeting this pathway before transplant may improve recipient outcomes after lung transplantation.	[Weber, Daniel J.; Gracon, Adam S. A.; Fisher, Amanda J.; Pandya, Pankita H.; Vittal, Ragini; White, Fletcher A.; Wilkes, David S.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA; [Weber, Daniel J.; Gracon, Adam S. A.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Ripsch, Matthew S.; Fisher, Amanda J.; Cheon, Bo M.; Kim, Youngsong; Allette, Yohance M.; White, Fletcher A.] Indiana Univ Sch Med, Dept Anesthesia, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Pandya, Pankita H.; Vittal, Ragini; Capitano, Maegan L.; Broxmeyer, Hal E.; Wilkes, David S.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Riley, Amanda A.; McCarthy, Brian P.; Territo, Paul R.; Hutchins, Gary D.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Sandusky, George E.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA		Wilkes, DS (corresponding author), Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA.	dwilkes@iupui.edu	VITTAL, RAGINI/AAE-9052-2020; White, Fletcher/F-3203-2015	White, Fletcher/0000-0002-8408-9262	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL096845]; National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P01AI084853, R01 DK100905]; Indiana Spinal Cord and Brain Injury Research Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL109288, R01HL112669, R01HL096845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P01AI056097, P01AI084853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK100905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM077229] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002209] Funding Source: NIH RePORTER	Funding: This work was supported by NIH grants R01 HL096845 and National Institute of Allergy and Infectious Diseases P01AI084853 to D. S. W., and R01 DK100905 and Indiana Spinal Cord and Brain Injury Research Fund to F.A.W.	Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bhangoo S, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-38; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bierhaus A, 2004, J CLIN INVEST, V114, P1741, DOI 10.1172/JCI200418058; Bittle GJ, 2013, J HEART LUNG TRANSPL, V32, P760, DOI 10.1016/j.healun.2013.04.012; Bopp C, 2008, CRIT CARE, V12, DOI 10.1186/cc6164; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Buckley ST, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/917108; Christie JD, 2009, AM J RESP CRIT CARE, V180, P1010, DOI 10.1164/rccm.200901-0118OC; Cypel M, 2013, CURR OPIN ORGAN TRAN, V18, P513, DOI 10.1097/MOT.0b013e328365191b; Cypel M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000266; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Fan L, 2011, AM J TRANSPLANT, V11, P911, DOI 10.1111/j.1600-6143.2011.03482.x; Feldman P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-180; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hreggvidsdottir HS, 2012, MOL MED, V18, P224, DOI 10.2119/molmed.2011.00327; Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Iori V, 2013, NEUROBIOL DIS, V58, P102, DOI 10.1016/j.nbd.2013.03.006; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kreissl MC, 2006, J NUCL MED, V47, P974; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; PROFANT M, 1978, SIAM J APPL MATH, V34, P666, DOI 10.1137/0134053; Putranto EW, 2013, INT J MOL MED, V32, P938, DOI 10.3892/ijmm.2013.1467; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Qin YH, 2009, J IMMUNOL, V183, P6244, DOI 10.4049/jimmunol.0900390; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Raman KG, 2006, AM J PHYSIOL-GASTR L, V291, pG556, DOI 10.1152/ajpgi.00055.2006; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; Rouhiainen Ari, 2013, Methods Mol Biol, V963, P239, DOI 10.1007/978-1-62703-230-8_15; Rouze NC, 2004, IEEE T NUCL SCI, V51, P757, DOI 10.1109/TNS.2004.829738; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Sharma AK, 2013, AM J TRANSPLANT, V13, P2255, DOI 10.1111/ajt.12368; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sirois CM, 2013, J EXP MED, V210, P2447, DOI 10.1084/jem.20120201; Soon VC, 2007, IEEE NUCL SCI CONF R, P3468, DOI 10.1109/NSSMIC.2007.4436877; Studholme C, 1998, P SOC PHOTO-OPT INS, V3338, P132, DOI 10.1117/12.310835; Toshchakov VY, 2011, J IMMUNOL, V186, P4819, DOI 10.4049/jimmunol.1002424; Toshchakov VU, 2005, J IMMUNOL, V175, P494, DOI 10.4049/jimmunol.175.1.494; Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Zoelen MAD, 2009, SHOCK, V31, P280, DOI 10.1097/SHK.0b013e318186262d; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010; Wu XJ, 2013, MOL CELL BIOCHEM, V380, P249, DOI 10.1007/s11010-013-1680-0; Yang D, 2007, J LEUKOCYTE BIOL, V81, P59, DOI 10.1189/jlb.0306180; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Zampell JC, 2011, AM J PHYSIOL-CELL PH, V300, pC1107, DOI 10.1152/ajpcell.00378.2010; Zandarashvili L, 2013, J BIOL CHEM, V288, P11621, DOI 10.1074/jbc.M113.449942	63	41	43	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	SEP 3	2014	6	252							252ra124	10.1126/scitranslmed.3009443			12	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	AO4KD	WOS:000341305400008	25186179	Green Accepted, Green Submitted			2022-02-06	
J	Lee, JH; Wei, L; Gu, XH; Wei, Z; Dix, TA; Yu, SP				Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Wei, Zheng; Dix, Thomas A.; Yu, Shan Ping			Therapeutic Effects of Pharmacologically Induced Hypothermia against Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; hypothermia; inflammation; neurotensin analogue; sensorimotor function; traumatic brain injury	CONTROLLED CORTICAL IMPACT; TRANSIENT GLOBAL-ISCHEMIA; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INFLAMMATORY RESPONSE; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; PHASE-II; STROKE	Preclinical and clinical studies have shown therapeutic potential of mild-to-moderate hypothermia for treatments of stroke and traumatic brain injury (TBI). Physical cooling in humans, however, is usually slow, cumbersome, and necessitates sedation that prevents early application in clinical settings and causes several side effects. Our recent study showed that pharmacologically induced hypothermia (PIH) using a novel neurotensin receptor 1 (NTR1) agonist, HPI-201 (also known as ABS-201), is efficient and effective in inducing therapeutic hypothermia and protecting the brain from ischemic and hemorrhagic stroke in mice. The present investigation tested another second-generation NTR1 agonist, HPI-363, for its hypothermic and protective effect against TBI. Adult male mice were subjected to controlled cortical impact (CCI) (velocity = 3 m/sec, depth = 1.0 mm, contact time = 150 msec) to the exposed cortex. Intraperitoneal administration of HPI-363 (0.3 mg/kg) reduced body temperature by 3-5 degrees C within 30-60 min without triggering a shivering defensive reaction. An additional two injections sustained the hypothermic effect in conscious mice for up to 6 h. This PIH treatment was initiated 15, 60, or 120 min after the onset of TBI, and significantly reduced the contusion volume measured 3 days after TBI. HPI-363 attenuated caspase-3 activation, Bax expression, and TUNEL-positive cells in the pericontusion region. In blood-brain barrier assessments, HPI-363 ameliorated extravasation of Evans blue dye and immunoglobulin G, attenuated the MMP-9 expression, and decreased the number of microglia cells in the post-TBI brain. HPI-363 decreased the mRNA expression of tumor necrosis factor-a and interleukin-1 beta (IL-1 beta), but increased IL-6 and IL-10 levels. Compared with TBI control mice, HPI-363 treatments improved sensorimotor functional recovery after TBI. These findings suggest that the second generation NTR-1 agonists, such as HPI-363, are efficient hypothermic-inducing compounds that have a strong potential in the management of TBI.	[Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Wei, Zheng; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut Inc, Mt Pleasant, MI USA		Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073378, NS0458710, NS075338, NS062097]; VA Merit grant; American Heart Association (AHA)American Heart Association [12GRNT12060222]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS073378, R01NS062097, R21NS075338, R42NS073378] Funding Source: NIH RePORTER	This work was supported by the NIH grants NS073378 (TAD and SPY), NS0458710 (SPY), NS075338 (LW), NS062097 (LW), a VA Merit grant (SPY), the American Heart Association (AHA) grant 12GRNT12060222 (SPY), and the AHA Established Investigator Award (LW).	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Arcure Jess, 2009, J Spec Oper Med, V9, P22; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Demetrius L, 2005, EMBO REP, V6, pS39, DOI 10.1038/sj.embor.7400422; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Guluma KZ, 2008, NEUROCRIT CARE, V8, P42, DOI 10.1007/s12028-007-9009-z; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Heegaard W, 1997, ACAD EMERG MED, V4, P33, DOI 10.1111/j.1553-2712.1997.tb03640.x; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kida H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068877; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Leon LR, 2006, J APPL PHYSIOL, V100, P1400, DOI 10.1152/japplphysiol.01040.2005; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lundberg George D, 2008, Medscape J Med, V10, P212; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Stewart CR, 2010, PEDIATR CRIT CARE ME, V11, P109, DOI 10.1097/PCC.0b013e3181b01042; SYDENHAM E, 2009, COCHRANE DATABASE SY; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tsuchiya D, 2002, J CEREBR BLOOD F MET, V22, P1231, DOI 10.1097/01.wcb.0000037995.34930.F5; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Won SM, 2011, EXP MOL MED, V43, P121, DOI 10.3858/emm.2011.43.2.020; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	79	41	41	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2014	31	16					1417	1430		10.1089/neu.2013.3251			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AN4DB	WOS:000340536700005	24731132	Green Published			2022-02-06	
J	Heo, J; Park, SQ; Cho, SJ; Chang, JC; Park, HK				Heo, Juneyoung; Park, Sukh Que; Cho, Sung Jin; Chang, Jae Chil; Park, Hyung-ki			Evaluation of simultaneous cranioplasty and ventriculoperitoneal shunt procedures Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; ventriculoperitoneal shunt; complication; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; SUBARACHNOID HEMORRHAGE; COMPLICATIONS; HEMICRANIECTOMY; INFARCTION	Object. Some patients with severe brain swelling treated with decompressive craniectomy may develop hydrocephalus. Consequently, these patients require cranioplasty and a ventriculoperitoneal (VP) shunt to relieve the hydrocephalus. However, there is no consensus as to the timing of the cranioplasty and VP shunt placement in patients requiring both. The authors assessed the results of performing cranioplasty and VP shunt placement at the same time in patients with cranial defects and hydrocephalus. Methods. A retrospective review was performed of 51 patients who had undergone cranioplasty and VP shunt operations after decompressive craniectomy for refractory intracranial hypertension between 2003 and 2012 at the authors' institution. Patient characteristics, data on whether the operations were performed simultaneously, brain bulging, hydrocephalus, cranial defect size, and complications were analyzed. Results. The overall complication rate was 43% (22 of 51 patients). In 32 cases, cranioplasty and VP shunt placement were performed at the same time. Complications included subdural hematoma, subdural fluid collection, and infection. The group undergoing cranioplasty and VP shunt placement at the same time had higher complication rates than the group undergoing the procedures at different times (56% vs 21%, respectively). The severity of complications was also greater in the former group. Patients with severe brain bulging had higher complication rates than did those without brain bulging (51% vs 0%, respectively). Cranial defect size, severity of hydrocephalus, indication for decompressive craniectomy, age, sex, and interval between decompressive craniectomy and subsequent operation did not affect complication rates. Conclusions. Patients undergoing cranioplasty and VP shunt placement at the same time had higher complication rates, especially those with severe brain bulging.	[Heo, Juneyoung; Park, Sukh Que; Cho, Sung Jin; Chang, Jae Chil; Park, Hyung-ki] Soonchunhyang Univ, Seoul Hosp, Dept Neurosurg, Seoul 140743, South Korea		Park, SQ (corresponding author), Soonchunhyang Univ, Seoul Hosp, Dept Neurosurg, 657 Hannam Dong, Seoul 140743, South Korea.	drcolor@schmc.ac.kr			Soonchunhyang University	This work was supported by the Soonchunhyang University Research Fund.	Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Fodstad H, 1979, Acta Neurochir Suppl (Wien), V28, P514; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marion DW, 2006, NEUROSURGERY, V58, P655; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Zhou Qing, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P254	20	41	43	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2014	121	2					313	318		10.3171/2014.2.JNS131480			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AL9PK	WOS:000339473000012	24655097				2022-02-06	
J	Carlozzi, NE; Tulsky, DS; Chiaravalloti, ND; Beaumont, JL; Weintraub, S; Conway, K; Gershon, RC				Carlozzi, Noelle E.; Tulsky, David S.; Chiaravalloti, Nancy D.; Beaumont, Jennifer L.; Weintraub, Sandra; Conway, Kevin; Gershon, Richard C.			NIH Toolbox Cognitive Battery (NIHTB-CB): The NIHTB Pattern Comparison Processing Speed Test	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						NIHTB; Processing speed; Pattern Comparison Processing Speed Test; Cognition; Neuropsychological assessment; Mental processes; Outcomes assessment (health care)	TRAUMATIC BRAIN-INJURY; CHRONIC-FATIGUE-SYNDROME; MULTIPLE-SCLEROSIS; WORKING-MEMORY; SEX-DIFFERENCES; GENERAL INTELLIGENCE; AGE-DIFFERENCES; HEAD-INJURY; ADULT AGE; LIFE-SPAN	The NIH Toolbox (NIHTB) Pattern Comparison Processing Speed Test was developed to assess processing speed within the NIHTB for the Assessment of Neurological Behavior and Function Cognition Battery (NIHTB-CB). This study highlights validation data collected in adults ages 18-85 on this measure and reports descriptive data, test-retest reliability, construct validity, and preliminary work creating a composite index of processing speed. Results indicated good test-retest reliability. There was also evidence for both convergent and discriminant validity; the Pattern Comparison Processing Speed Test demonstrated moderate significant correlations with other processing speed tests (i.e., WAIS-IV Coding, Symbol Search and Processing Speed Index), small significant correlations with measures of working memory (i.e., WAIS-IV Letter-Number Sequencing and PASAT), and non-significant correlations with a test of vocabulary comprehension (i.e., PPVT-IV). Finally, analyses comparing and combining scores on the NIHTB Pattern Comparison Processing Speed Test with other measures of simple reaction time from the NIHTB-CB indicated that a Processing Speed Composite score performed better than any test examined in isolation. The NIHTB Pattern Comparison Processing Speed Test exhibits several strengths: it is appropriate for use across the lifespan (ages, 3-85 years), it is short and easy to administer, and it has high construct validity.	[Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Tulsky, David S.] NYU, Rusk Inst, Dept Rehabil Med, Dept Orthoped Surg,Dept Gen Med, New York, NY USA; [Tulsky, David S.] Kessler Fdn, Neuropsychol & Neurosci Lab, Spinal Cord Injury Lab, West Orange, NJ USA; [Chiaravalloti, Nancy D.] Kessler Fdn, Traumat Brain Injury Lab, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Beaumont, Jennifer L.; Gershon, Richard C.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Weintraub, Sandra] Northwestern Univ, Dept Psychiat & Cognit Neurol, Chicago, IL 60611 USA; [Weintraub, Sandra] Northwestern Univ, Alzheimers Dis Ctr, Chicago, IL 60611 USA; [Conway, Kevin] NIDA, Washington, DC USA		Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	Beaumont, Jennifer/AAA-2825-2020	Beaumont, Jennifer/0000-0002-1484-260X; Tulsky, David/0000-0002-4335-4509; Chiaravalloti, Nancy/0000-0003-2943-7567; Conway, Kevin/0000-0002-7638-339X	Blueprint for Neuroscience Research, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHS-N-260-2006-00007-C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL085766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR057943, U01AR057929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077946, R03NS065194, U01NS056975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013854, R01AG032088, RC2AG036498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [N44AA002006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC008552] Funding Source: NIH RePORTER	This study is funded in whole or in part with Federal funds from the Blueprint for Neuroscience Research, National Institutes of Health, under Contract No. HHS-N-260-2006-00007-C. The authors do not have any conflicts of interest to report.	Ball K., 2008, INFORM PROCESSING SP; Barker-Collo SL, 2006, ARCH CLIN NEUROPSYCH, V21, P167, DOI 10.1016/j.acn.2005.08.008; Bell NL, 2001, J CLIN PSYCHOL, V57, P417, DOI 10.1002/jclp.1024; Camarata S, 2006, INTELLIGENCE, V34, P231, DOI 10.1016/j.intell.2005.12.001; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2013, MONOGR SOC RES CHILD, V78, P88, DOI 10.1111/mono.12036; CERELLA J, 1994, ACTA PSYCHOL, V86, P109, DOI 10.1016/0001-6918(94)90002-7; Chaytor N, 2004, J INT NEUROPSYCH SOC, V10, P489, DOI 10.1017/S1355617704104013; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Coyle TR, 2011, PSYCHOL SCI, V22, P1265, DOI 10.1177/0956797611418243; Crowe SF, 2000, ASSESSMENT, V7, P113, DOI 10.1177/107319110000700202; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; DeLuca J, 2004, J INT NEUROPSYCH SOC, V10, P101; DeLuca J., 2008, INFORM PROCESSING SP; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63; Denegar C.R., 1993, J SPORT REHABIL, V2, P35, DOI 10.1123/jsr.2.1.35.; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Dunn, 2007, PPVT 4 PEABODY PICTU; Finkel SI, 2004, INT J GERIATR PSYCH, V19, P9, DOI 10.1002/gps.998; FLAVELL JH, 1992, DEV PSYCHOL, V28, P998, DOI 10.1037/0012-1649.28.6.998; Forn C, 2013, BRAIN COGNITION, V82, P152, DOI 10.1016/j.bandc.2013.04.003; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Genova HM, 2009, J INT NEUROPSYCH SOC, V15, P383, DOI 10.1017/S1355617709090535; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALE S, 1990, CHILD DEV, V61, P653, DOI 10.1111/j.1467-8624.1990.tb02809.x; Han SD, 2012, J INT NEUROPSYCH SOC, V18, P39, DOI 10.1017/S1355617711001299; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Hinkley LBN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039804; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; JENSEN AR, 1993, CURRENT DIRECTIONS P, V0002, P00053, DOI [DOI 10.1111/1467-8721.EP10770697, DOI 10.1111/1467-8721.ep10770697]; JENSEN AR, 1982, MODEL INTELLIGENCE; KAIL R, 1991, DEV PSYCHOL, V27, P259, DOI 10.1037/0012-1649.27.2.259; KAIL RV, 2008, INFORM PROCESSING SP; Kalmar JH, 2008, INFORM PROCESSING SP; Kochunov P, 2010, NEUROIMAGE, V49, P1190, DOI 10.1016/j.neuroimage.2009.09.052; Leavitt VM, 2012, MULT SCLER J, V18, P409, DOI 10.1177/1352458511423651; Lengenfelder J, 2006, ARCH CLIN NEUROPSYCH, V21, P229, DOI 10.1016/j.acn.2005.12.001; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Llorente AM, 1998, J CLIN EXP NEUROPSYC, V20, P60, DOI 10.1076/jcen.20.1.60.1489; Mabbott D.J., 2005, ORG HUM BRAIN MAPP T; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Majeres RL, 1999, MEM COGNITION, V27, P246, DOI 10.3758/BF03211409; Majeres RL, 1997, PERCEPT MOTOR SKILL, V85, P1243, DOI 10.2466/pms.1997.85.3f.1243; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; O'Brien AR, 2008, INFORM PROCESSING SP; Posthuma D., 2008, INFORM PROCESSING SP; Ready RE, 2011, AM J ALZHEIMERS DIS, V26, P463, DOI 10.1177/1533317511421921; SALTHOUSE TA, 1991, PSYCHOL AGING, V6, P118, DOI 10.1037/0882-7974.6.1.118; SALTHOUSE TA, 1993, DEV PSYCHOL, V29, P722, DOI 10.1037/0012-1649.29.4.722; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Salthouse TA, 1990, HDB PSYCHOL AGING, P310, DOI 10.1016/B978-0-12-101280-9.50024-3; Salthouse TimothyA., 1985, HDB PSYCHOL AGING, V2nd ed., P400; Sasson E, 2012, BRAIN STRUCT FUNCT, V217, P503, DOI 10.1007/s00429-011-0344-7; Sawamoto N, 2002, J NEUROSCI, V22, P5198, DOI 10.1523/JNEUROSCI.22-12-05198.2002; SCHAIE KW, 1994, AM PSYCHOL, V49, P304, DOI 10.1037/0003-066X.49.4.304; SCHAIE KW, 1989, PSYCHOL AGING, V4, P443, DOI 10.1037/0882-7974.4.4.443; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SIEGEL LS, 1994, INT J BEHAV DEV, P109; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; Smith AM, 2012, J NEUROL SCI, V312, P131, DOI 10.1016/j.jns.2011.08.003; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Takeuchi H, 2011, J NEUROSCI, V31, P12139, DOI 10.1523/JNEUROSCI.2948-11.2011; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; TULSKY DS, 2003, CLIN INTERPRETATION; van Duinkerken E, 2012, DIABETES, V61, P1814, DOI 10.2337/db11-1358; van Duinkerken E, 2009, DIABETES, V58, P2335, DOI 10.2337/db09-0425; Vernon P. A, 1987, SPEED INFORM PROCESS; VERNON PA, 1983, INTELLIGENCE, V7, P53, DOI 10.1016/0160-2896(83)90006-5; Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562; Wechsler D., 2008, WECHSLER ADULT INTEL; Weintraub S., J INT NEURO IN PRESS; Yakovlev PI, 1967, REGIONAL DEV BRAIN E; Ystad M, 2011, NEUROIMAGE, V55, P24, DOI 10.1016/j.neuroimage.2010.11.016; Zelazo P.D., J INT NEUROPSYCHOLOG; Zimprich D, 2002, PSYCHOL AGING, V17, P690, DOI 10.1037/0882-7974.17.4.690	83	41	42	3	29	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2014	20	6					630	641		10.1017/S1355617714000319			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AL7PH	WOS:000339326300007	24960594	Green Accepted			2022-02-06	
J	Spittle, AJ; Thompson, DK; Brown, NC; Treyvaud, K; Cheong, JLY; Lee, KJ; Pace, CC; Olsen, J; Allinson, LG; Morgan, AT; Seal, M; Eeles, A; Judd, F; Doyle, LW; Anderson, PJ				Spittle, Alicia J.; Thompson, Deanne K.; Brown, Nisha C.; Treyvaud, Karli; Cheong, Jeanie L. Y.; Lee, Katherine J.; Pace, Carmen C.; Olsen, Joy; Allinson, Leesa G.; Morgan, Angela T.; Seal, Marc; Eeles, Abbey; Judd, Fiona; Doyle, Lex W.; Anderson, Peter J.			Neurobehaviour between birth and 40 weeks' gestation in infants born < 30 weeks' gestation and parental psychological wellbeing: predictors of brain development and child outcomes	BMC PEDIATRICS			English	Article						Preterm; Neurobehaviour; Magnetic resonance imaging; Neurodevelopment; Parent mental health; Parent-child interaction	INTENSIVE-CARE-UNIT; PRETERM INFANTS; WEIGHT INFANTS; EMOTIONAL AVAILABILITY; POSTPARTUM DEPRESSION; PREMATURE-INFANTS; MOTOR DEVELOPMENT; HOSPITAL ANXIETY; RISK-FACTORS; TERM	Background: Infants born < 30 weeks' gestation are at increased risk of long term neurodevelopmental problems compared with term born peers. The predictive value of neurobehavioural examinations at term equivalent age in very preterm infants has been reported for subsequent impairment. Yet there is little knowledge surrounding earlier neurobehavioural development in preterm infants prior to term equivalent age, and how it relates to perinatal factors, cerebral structure, and later developmental outcomes. In addition, maternal psychological wellbeing has been associated with child development. Given the high rate of psychological distress reported by parents of preterm children, it is vital we understand maternal and paternal wellbeing in the early weeks and months after preterm birth and how this influences the parent-child relationship and children's outcomes. Therefore this study aims to examine how 1) early neurobehaviour and 2) parental mental health relate to developmental outcomes for infants born preterm compared with infants born at term. Methods/Design: This prospective cohort study will describe the neurobehaviour of 150 infants born at < 30 weeks' gestational age from birth to term equivalent age, and explore how early neurobehavioural deficits relate to brain growth or injury determined by magnetic resonance imaging, perinatal factors, parental mental health and later developmental outcomes measured using standardised assessment tools at term, one and two years' corrected age. A control group of 150 healthy term-born infants will also be recruited for comparison of outcomes. To examine the effects of parental mental health on developmental outcomes, both parents of preterm and term-born infants will complete standardised questionnaires related to symptoms of anxiety, depression and post-traumatic stress at regular intervals from the first week of their child's birth until their child's second birthday. The parent-child relationship will be assessed at one and two years' corrected age. Discussion: Detailing the trajectory of infant neurobehaviour and parental psychological distress following very preterm birth is important not only to identify infants most at risk, further understand the parental experience and highlight potential times for intervention for the infant and/or parent, but also to gain insight into the effect this has on parent-child interaction and child development.	[Spittle, Alicia J.; Thompson, Deanne K.; Brown, Nisha C.; Treyvaud, Karli; Cheong, Jeanie L. Y.; Lee, Katherine J.; Pace, Carmen C.; Olsen, Joy; Allinson, Leesa G.; Seal, Marc; Eeles, Abbey; Doyle, Lex W.; Anderson, Peter J.] Murdoch Childrens Res Inst, Victorian Infant Brain Studies, Parkville, Vic 3052, Australia; [Spittle, Alicia J.; Allinson, Leesa G.] Univ Melbourne, Sch Hlth Sci, Dept Physiotherapy, Carlton, Vic 3053, Australia; [Spittle, Alicia J.; Cheong, Jeanie L. Y.; Judd, Fiona] Royal Womens Hosp, Serv Neonatol, Parkville, Vic 3052, Australia; [Thompson, Deanne K.; Treyvaud, Karli; Lee, Katherine J.; Morgan, Angela T.; Seal, Marc; Doyle, Lex W.; Anderson, Peter J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Cheong, Jeanie L. Y.; Olsen, Joy; Doyle, Lex W.; Anderson, Peter J.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; [Pace, Carmen C.] Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3010, Australia; [Morgan, Angela T.] Murdoch Childrens Res Inst, Language & Literacy Grp, Parkville, Vic 3052, Australia		Spittle, AJ (corresponding author), Murdoch Childrens Res Inst, Victorian Infant Brain Studies, 4th Floor,Flemington Rd, Parkville, Vic 3052, Australia.	alicia.spittle@mcri.edu.au	Thompson, Deanne/W-7177-2019; Anderson, Peter J/B-6839-2015; Olsen, Jorn/F-8801-2015; Anderson, Peter John/O-5302-2019; Seal, Marc L/J-9290-2019; Lee, Katherine J/A-2519-2016; Thompson, Deanne K/A-9502-2018; Morgan, Angela/J-5235-2017	Thompson, Deanne/0000-0001-8017-5756; Anderson, Peter J/0000-0001-7430-868X; Olsen, Jorn/0000-0001-7462-5140; Anderson, Peter John/0000-0001-7430-868X; Seal, Marc L/0000-0002-8396-140X; Thompson, Deanne K/0000-0001-8017-5756; Morgan, Angela/0000-0003-1147-7405; Spittle, Alicia/0000-0002-6535-661X; Brown, Nisha/0000-0002-2953-8045; Cheong, Jeanie/0000-0001-5901-0455; Doyle, Lex/0000-0002-7667-7312	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1024516]; Victorian Government's Operational Infrastructure Support Program; Early Career Fellowship [1053767]; Centre for Clinical Research Excellence [546519]; Centre for Research Excellence [1060733]; Senior Research Fellowship [628371]	This study is funded by grants from the National Health and Medical Research Council (NHMRC: Project Grant 1024516; Early Career Fellowship 1053767; Centre for Clinical Research Excellence 546519; Centre for Research Excellence 1060733, Senior Research Fellowship 628371). The Murdoch Childrens Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program.; We would like to acknowledge Merilyn Bear, Emma McInnes, Brenda Argus, Bernice Mills and Nicole vander Linden for their input into recruitment of infants and their families for this study.	Abidin, 1995, PARENTING STRESS IND; Als H, 2004, PEDIATRICS, V113, P846, DOI 10.1542/peds.113.4.846; AMIELTISON C, 2001, FETAL NEONATAL NEURO, P99; Bayley N., 2005, BAYLEY SCALES INFANT; Bigsby R, 1996, INFANT BEHAV DEV, V19, P295, DOI 10.1016/S0163-6383(96)90030-2; Biringen Z, 2000, AM J ORTHOPSYCHIAT, V70, P104, DOI 10.1037/h0087711; Biringen Z., 2008, EMOTIONAL AVAILABILI, V4 th; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bornstein MH, 2006, INFANCY, V10, P1, DOI 10.1207/s15327078in1001_1; Brown NC, 2014, CURR PEDIAT IN PRESS; Brown NC, 2006, PEDIATRICS, V118, P2461, DOI 10.1542/peds.2006-0880; Brown NC, 2009, J PEDIATR-US, V155, P32, DOI 10.1016/j.jpeds.2009.01.038; Burns Y R, 1989, Aust J Physiother, V35, P141, DOI 10.1016/S0004-9514(14)60503-1; Carter A. S., 2000, INFANT TODDLER UNPUB; Carter JD, 2005, ARCH DIS CHILD-FETAL, V90, P109, DOI 10.1136/adc.2003.031641; Cheong JLY, 2009, AM J NEURORADIOL, V30, P623, DOI 10.3174/ajnr.A1399; Costa P. T., 1992, REVISED NEO PERSONAL; Daily DK, 2005, NEONATAL NETW, V24, P15, DOI 10.1891/0730-0832.24.1.15; Danks M, 2012, EARLY HUM DEV, V88, P637, DOI 10.1016/j.earlhumdev.2012.01.010; Davis Leigh, 2003, Int J Nurs Pract, V9, P374, DOI 10.1046/j.1440-172X.2003.00447.x; Dubowitz L, 1998, J PEDIATR-US, V133, P406, DOI 10.1016/S0022-3476(98)70279-3; DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893; Dunn W, 2002, INFANT TODDLER SENSO; Eadie PA, 2010, INT J LANG COMM DIS, V45, P572, DOI 10.3109/13682820903277944; Easterbrooks M A, 2000, Attach Hum Dev, V2, P123; Eeles AL, 2013, DEV MED CHILD NEUROL, V55, P314, DOI 10.1111/j.1469-8749.2012.04434.x; Einspieler C., 2004, PRECHTLS METHOD QUAL, V167; Endler NS., 1999, COPING INVENTORY STR, V2nd ed; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fenson L., 1993, MACARTHUR BATES COMM; Ferrari F, 2012, J MATERN-FETAL NEO M, V25, P2154, DOI 10.3109/14767058.2012.696164; Forcada-Guex M, 2006, PEDIATRICS, V118, pE107, DOI 10.1542/peds.2005-1145; Goldberg L.R., 1999, PERSONALITY PSYCHOL, VVol. 7, P7; Gray RF, 2004, PEDIATRICS, V114, P736, DOI 10.1542/peds.2003-1150-L; Gui L, 2012, MED IMAGE ANAL, V16, P1565, DOI 10.1016/j.media.2012.07.006; Hadders-Algra M, 2010, DEV MED CHILD NEUROL, V52, P87, DOI 10.1111/j.1469-8749.2009.03305.x; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hilferty F, 2009, IMPLICATIONS POVERY; Holditch-Davis D, 2003, JOGNN, V32, P161, DOI 10.1177/0884217503252035; Huppi PS, 1996, PEDIATR RES, V39, P895; Jeng SF, 1998, EARLY HUM DEV, V51, P235, DOI 10.1016/S0378-3782(98)00035-8; JOHNSTON C, 1989, J CLIN CHILD PSYCHOL, V18, P167, DOI 10.1207/s15374424jccp1802_8; Kidokoro H, 2013, AM J NEURORADIOL, V34, P2208, DOI 10.3174/ajnr.A3521; Kuklisova-Murgasova M, 2011, NEUROIMAGE, V54, P2750, DOI 10.1016/j.neuroimage.2010.10.019; Lambrenos K, 1996, ARCH DIS CHILD, V74, P115, DOI 10.1136/adc.74.2.115; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Lester BM, 2004, PEDIATRICS, V113, P641; Lester BM, 2004, PEDIATRICS, V113, P634; Miles MS, 2007, J DEV BEHAV PEDIATR, V28, P36, DOI 10.1097/01.DBP.0000257517.52459.7a; Milgrom J, 2010, PEDIATR RES, V67, P330, DOI 10.1203/PDR.0b013e3181cb8e2f; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nomura Y, 2002, J AM ACAD CHILD PSY, V41, P402, DOI 10.1097/00004583-200204000-00012; O'Hara MW, 2013, ANNU REV CLIN PSYCHO, V9, P379, DOI 10.1146/annurev-clinpsy-050212-185612; Pinelli J, 2000, Neonatal Netw, V19, P27; Pinelli J, 2008, J NEONATAL NURSING, V14, P156, DOI DOI 10.1016/J.JNN.2008.03.015; Piper M., 1994, MOTOR ASSESSMENT DEV; Pridham K, 2005, RES NURS HEALTH, V28, P252, DOI 10.1002/nur.20073; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roberts G, 2008, J PAEDIATR CHILD H, V44, P276, DOI 10.1111/j.1440-1754.2007.01251.x; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Saigal S, 2003, ARCH PEDIAT ADOL MED, V157, P261, DOI 10.1001/archpedi.157.3.261; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Shah DK, 2006, PEDIATR RES, V60, P97, DOI 10.1203/01.pdr.0000220324.27597.f0; Shields-Poe D, 1997, Neonatal Netw, V16, P29; SKUSE D, 1995, DYSPHAGIA, V10, P192, DOI 10.1007/BF00260976; Smyser CD, 2010, CEREB CORTEX, V20, P2852, DOI 10.1093/cercor/bhq035; Spittle AJ, 2008, DEV MED CHILD NEUROL, V50, P254, DOI 10.1111/j.1469-8749.2008.02025.x; Spittle AJ, 2013, DEV MED CHILD NEUROL, V55, P448, DOI 10.1111/dmcn.12049; Spittle AJ, 2009, PEDIATRICS, V123, P512, DOI 10.1542/peds.2008-0590; Thompson DK, 2008, ANN NEUROL, V63, P642, DOI 10.1002/ana.21367; Thompson DK, 2007, BRAIN, V130, P667, DOI 10.1093/brain/awl277; Thompson DK, 2011, NEUROIMAGE, V55, P479, DOI 10.1016/j.neuroimage.2010.12.025; Tronick E, 2013, J CHILD ADOL PS NURS, V26, P193, DOI 10.1111/jcap.12042; Vigod SN, 2010, BJOG-INT J OBSTET GY, V117, P540, DOI 10.1111/j.1471-0528.2009.02493.x; Volpe J. J., 2008, NEUROLOGY NEWBORN; WALLACE IF, 1995, J DEV BEHAV PEDIATR, V16, P309; Weathers F, 1996, MEASUREMENT STRESS T; Woodward LJ, 2006, NEW ENGL J MED, V355, P685, DOI 10.1056/NEJMoa053792; Zelkowitz P, 2007, INFANT MENT HEALTH J, V28, P296, DOI 10.1002/imhj.20137; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	81	41	42	1	42	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	APR 24	2014	14								111	10.1186/1471-2431-14-111			13	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AG7IA	WOS:000335590400001	24758605	Green Published, gold			2022-02-06	
J	Kim, SY; Shim, MS; Kim, KY; Weinreb, RN; Wheeler, LA; Ju, WK				Kim, S. Y.; Shim, M. S.; Kim, K-Y; Weinreb, R. N.; Wheeler, L. A.; Ju, W-K			Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury	CELL DEATH & DISEASE			English	Article						cyclosporin A; retinal ischemia; retinal ganglion cell; cyclophilin D; mitochondrial DNA; mitochondrial transcription factor A	PERMEABILITY TRANSITION PORE; TRAUMATIC BRAIN-INJURY; ADENINE-NUCLEOTIDE TRANSLOCASE; RAT RETINA; TRANSCRIPTION FACTOR; TRANSIENT ISCHEMIA; REPERFUSION INJURY; CEREBRAL-ISCHEMIA; NEURONAL DEATH; INFARCT SIZE	Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury. However, the molecular mechanisms underlying CypD/MPTP opening-mediated cell death in ischemic retinal injury induced by acute intraocular pressure (IOP) elevation remain unknown. We observed the first direct evidence that acute IOP elevation significantly upregulated CypD protein expression in ischemic retina at 12 h. However, CsA prevented the upregulation of CypD protein expression and promoted retinal ganglion cell (RGC) survival against ischemic injury. Moreover, CsA blocked apoptotic cell death by decreasing cleaved caspase-3 protein expression in ischemic retina. Of interest, although the expression level of Bcl-xL protein did not show a significant change in ischemic retina treated with vehicle or CsA at 12 h, ischemic damage induced the reduction of Bcl-xL immunoreactivity in RGCs. More importantly, CsA preserved Bcl-xL immunoreactivity in RGCs of ischemic retina. In parallel, acute IOP elevation significantly increased phosphorylated Bad (pBad) at Ser112 protein expression in ischemic retina at 12 h. However, CsA significantly preserved pBad protein expression in ischemic retina. Finally, acute IOP elevation significantly increased mitochondrial transcription factor A (Tfam) protein expression in ischemic retina at 12 h. However, CsA significantly preserved Tfam protein expression in ischemic retina. Studies on mitochondrial DNA (mtDNA) content in ischemic retina showed that there were no statistically significant differences in mtDNA content among control and ischemic groups treated with vehicle or CsA. Therefore, these results provide evidence that the activation of CypD-mediated MPTP opening is associated with the apoptotic pathway and the mitochondrial alteration in RGC death of ischemic retinal injury. On the basis of these observations, our findings suggest that CsA-mediated CypD inhibition may provide a promising therapeutic potential for protecting RGCs against ischemic injury-mediated mitochondrial dysfunction.	[Kim, S. Y.; Shim, M. S.; Weinreb, R. N.; Ju, W-K] Univ Calif San Diego, Lab Opt Nerve Biol, Dept Ophthalmol, Hamilton Glaucoma Ctr, La Jolla, CA 92037 USA; [Kim, K-Y] Univ Calif San Diego, Ctr Res Biol Syst, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92037 USA; [Kim, K-Y] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92037 USA; [Wheeler, L. A.] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA USA		Ju, WK (corresponding author), Univ Calif San Diego, Lab Opt Nerve Biol, Dept Ophthalmol, Hamilton Glaucoma Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.	danielju@glaucoma.ucsd.edu		Kim, Sang Yeop/0000-0002-5781-9039	Allergan Inc.AbbVieAllergan; National Institute Health [EY018658, P30EY022589]; Research to Prevent Blindness (New York, NY, USA)Research to Prevent Blindness (RPB); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY018658, P30EY022589] Funding Source: NIH RePORTER	This work was supported, in part, by funding provided by an Allergan Inc. (WKJ), the National Institute Health Grants EY018658 (WKJ) and P30EY022589 (Vision Research Core Grant) and an unrestricted grant from Research to Prevent Blindness (New York, NY, USA).	ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Chen H, 2001, STROKE, V32, P2382, DOI 10.1161/hs1001.097099; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739, DOI 10.2174/138161206775474242; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Cui Q, 2007, NEUROSCIENCE, V146, P986, DOI 10.1016/j.neuroscience.2007.02.034; Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gouriou Y, 2011, BIOCHIMIE, V93, P2060, DOI 10.1016/j.biochi.2011.08.001; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Hokari M, 2010, NEUROPATHOLOGY, V30, P401, DOI 10.1111/j.1440-1789.2009.01086.x; Javadov S, 2007, CELL PHYSIOL BIOCHEM, V20, P1, DOI 10.1159/000103747; Javadov S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00076; Ju WK, 2000, J NEUROPATH EXP NEUR, V59, P241, DOI 10.1093/jnen/59.3.241; Ju WK, 2000, NEUROSCI LETT, V283, P133, DOI 10.1016/S0304-3940(00)00931-9; Ju WK, 2011, METHODS MOL BIOL, V740, P149, DOI 10.1007/978-1-61779-108-6_16; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lee D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047098; Leger PL, 2011, EXP NEUROL, V230, P58, DOI 10.1016/j.expneurol.2010.06.009; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046498; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; Martin LJ, 2011, TOXICOL PATHOL, V39, P220, DOI 10.1177/0192623310389475; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Ngo HB, 2011, NAT STRUCT MOL BIOL, V18, P1290, DOI 10.1038/nsmb.2159; Nucci C, 2007, INT REV NEUROBIOL, V82, P397, DOI 10.1016/S0074-7742(07)82022-8; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Park SW, 2011, INVEST OPHTH VIS SCI, V52, P2837, DOI 10.1167/iovs.09-5010; Piao Y, 2012, BBA-GEN SUBJECTS, V1820, P577, DOI 10.1016/j.bbagen.2011.08.007; Rao VK, 2014, BBA-MOL BASIS DIS, V1842, P1267, DOI 10.1016/j.bbadis.2013.09.003; Russo R, 2008, PROG BRAIN RES, V173, P575, DOI 10.1016/S0079-6123(08)01139-4; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino Hiroyuki, 2013, Acta Neurochir Suppl, V118, P311, DOI 10.1007/978-3-7091-1434-6_61; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vander Heiden MG, 1999, MOL CELL, V3, P159; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Wurm A, 2011, PROG RETIN EYE RES, V30, P324, DOI 10.1016/j.preteyeres.2011.06.001; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Yuen CM, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-141	60	41	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2014	5								e1105	10.1038/cddis.2014.80			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AE1TW	WOS:000333754100009	24603333	Green Published, gold			2022-02-06	
J	Kjeldgaard, D; Forchhammer, H; Teasdale, T; Jensen, RH				Kjeldgaard, Dorte; Forchhammer, Hysse; Teasdale, Tom; Jensen, Rigmor H.			Chronic post-traumatic headache after mild head injury: A descriptive study	CEPHALALGIA			English	Article						Chronic post-traumatic headache; brain concussion; Quality of Life; SF-36; Rivermead Post Concussion Symptoms Questionnaire; Harvard Trauma Questionnaire	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; STRESS-DISORDER; CHRONIC PAIN; QUESTIONNAIRE; POPULATION; PREVALENCE; INSTRUMENT; DISABILITY; MIGRAINE	Background The aetiology behind chronic post-traumatic headache (CPTH) after mild head injury is unclear and management is complicated. In order to optimize treatment strategies we aimed to characterize a CPTH population. Methods Ninety patients with CPTH and 45 patients with chronic primary headaches were enrolled from the Danish Headache Center. All patients were interviewed about demographic and headache data. They completed the Harvard Trauma Questionnaire (HTQ), Rivermead Post Concussion Symptoms Questionnaire, SF-36 and a headache diary. Results The CPTH group experienced more cognitive (p<0.001) and somatic symptoms (p=0.048) and rated their self-perceived health as more affected in terms of physical function (p=0.036), physical role function (p=0.012) and social function (p=0.012) than the control group. Surprisingly, 31% of the CPTH group had a score equal to or above the cut-off score for having post-traumatic stress disorder (PTSD) according to the HTQ. In terms of demographics and headache, the groups were comparable except the CPTH group were more often without affiliation to the labour market (p<0.001). Conclusions The loss of work capacity and high levels of disability for the CPTH patients suggests directions for further research into what important factors are embedded in the patients' PTSD symptoms and might explain their prolonged illness.	[Kjeldgaard, Dorte; Jensen, Rigmor H.] Univ Copenhagen, Danish Headache Ctr, DK-2600 Glostrup, Denmark; [Forchhammer, Hysse] Univ Copenhagen, Dept Neurol, DK-2600 Glostrup, Denmark; [Teasdale, Tom] Univ Copenhagen, Dept Psychol, DK-2600 Glostrup, Denmark		Jensen, RH (corresponding author), Univ Copenhagen, Glostrup Hosp, Danish Headache Ctr, Nrd Ringvej 69, DK-2600 Glostrup, Denmark.	rigmor.jensen@regionh.dk			LundbeckLundbeck Corporation [R67-A6507]; Helsefonden [2099B033]	The research received grants from Lundbeck (R67-A6507) and Helsefonden (2099B033).	Aaseth K, 2008, CEPHALALGIA, V28, P705, DOI 10.1111/j.1468-2982.2008.01577.x; American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN, V4th; Andersen TE, 2012, SCAND J PAIN, V3, P39, DOI 10.1016/j.sjpain.2011.10.001; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P991, DOI 10.1016/S0895-4356(98)00091-2; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Ifergane G, 2009, EUR J INTERN MED, V20, P182, DOI 10.1016/j.ejim.2008.05.001; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jensen R, 2011, CEPHALALGIA, V31, P1549, DOI 10.1177/0333102411424212; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lanteri-Minet M, 2011, CEPHALALGIA, V31, P837, DOI 10.1177/0333102411398400; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Linde M, 2012, EUR J NEUROL, V19, P703, DOI 10.1111/j.1468-1331.2011.03612.x; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Marcus DA, 2003, HEADACHE, V43, P117, DOI 10.1046/j.1526-4610.2003.03028.x; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Vargas BB, 2012, CURR OPIN NEUROL, V25, P284, DOI 10.1097/WCO.0b013e3283535bf5; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; Ware JE, 2001, QUAL LIFE RES, V10, P405, DOI 10.1023/A:1012588218728; Zasler ND, 2011, J HEAD TRAUMA REHAB, V26, P397, DOI 10.1097/HTR.0b013e31822721f8; Zeeberg P, 2005, CEPHALALGIA, V25, P1159, DOI 10.1111/j.1468-2982.2005.00980.x	34	41	42	0	23	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	MAR	2014	34	3					191	200		10.1177/0333102413505236			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	303OS	WOS:000330684500005	24045573				2022-02-06	
J	Kierans, AS; Kirov, II; Gonen, O; Haemer, G; Nisenbaum, E; Babb, JS; Grossman, RI; Lui, YW				Kierans, Andrea S.; Kirov, Ivan I.; Gonen, Oded; Haemer, Gillian; Nisenbaum, Eric; Babb, James S.; Grossman, Robert I.; Lui, Yvonne W.			Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury	NEUROLOGY			English	Article							PROTON MR SPECTROSCOPY; RELAXATION-TIMES; BASAL GANGLIA; MICRODIALYSIS; METABOLISM; REDUCTION; THALAMUS; CHILDREN; SYSTEM	Objective:To obtain quantitative neurometabolite measurements, specifically myoinositol (mI) and glutamate plus glutamine (Glx), markers of glial and neuronal excitation, in deep gray matter structures after mild traumatic brain injury (mTBI) using proton magnetic resonance spectroscopy (H-1-MRS) and to compare these measurements against normal healthy control subjects.Methods:This study approved by the institutional review board is Health Insurance Portability and Accountability Act compliant. T1-weighted MRI and multi-voxel H-1-MRS imaging were acquired at 3 tesla from 26 patients with mTBI an average of 22 days postinjury and from 13 age-matched healthy controls. Two-way analysis of variance was used to compare patients and controls for mean N-acetylaspartate, choline, creatine (Cr), Glx, and mI levels as well as the respective ratios to Cr within the caudate, globus pallidus, putamen, and thalamus.Results:Quantitative putaminal mI was higher in patients with mTBI compared with controls (p = 0.02). Quantitative neurometabolite ratios of putaminal mI and Glx relative to Cr, mI/Cr, and Glx/Cr were also higher among patients with mTBI compared with controls (p = 0.01 and 0.02, respectively). No other differences in neurometabolite levels or ratios were observed in any other brain region evaluated.Conclusion:Increased putaminal mI, mI/Cr, and Glx/Cr in patients after mTBI compared with control subjects supports the notion of a complex glial and excitatory response to injury without concomitant neuronal loss, evidenced by preserved N-acetylaspartate levels in this region.	[Kierans, Andrea S.; Kirov, Ivan I.; Gonen, Oded; Haemer, Gillian; Nisenbaum, Eric; Babb, James S.; Grossman, Robert I.; Lui, Yvonne W.] NYU, Sch Med, Dept Radiol, New York, NY 10003 USA		Lui, YW (corresponding author), NYU, Sch Med, Dept Radiol, New York, NY 10003 USA.	Yvonne.lui@nyumc.org	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Babb, James/0000-0003-1798-1186; Gonen, Oded/0000-0002-3148-2028	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1RR029893, RO1 NS039135, EB01015, RO1 NS050520]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050520, R01NS039135] Funding Source: NIH RePORTER	Supported in part by the following federal grants from the NIH: 1UL1RR029893, RO1 NS039135, EB01015, and RO1 NS050520.	Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Choi CH, 2006, MAGN RESON MED, V56, P971, DOI 10.1002/mrm.21055; DU YPP, 1994, JMRI-J MAGN RESON IM, V4, P733, DOI 10.1002/jmri.1880040517; Ell SW, 2012, HORIZON NEUROSCIENCE, P29; Faul M, 2010, TRAUMATIC BRAIN INJU; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Fudge JL, 2003, J NEUROPSYCH CLIN N, V15, P306, DOI 10.1176/appi.neuropsych.15.3.306; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Goelman G, 2007, MAGN RESON MED, V58, P167, DOI 10.1002/mrm.21251; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Grahn JA, 2009, BEHAV BRAIN RES, V199, P53, DOI 10.1016/j.bbr.2008.11.020; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; HU J, 1995, J MAGN RESON SER B, V108, P213, DOI 10.1006/jmrb.1995.1126; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2008, MAGN RESON MED, V60, P790, DOI 10.1002/mrm.21715; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	39	41	41	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 11	2014	82	6					521	528		10.1212/WNL.0000000000000105			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH9VW	WOS:000336493900013	24401686	Green Published			2022-02-06	
J	Ritfeld, GJ; Rauck, BM; Novosat, TL; Park, D; Patel, P; Roos, RAC; Wang, YD; Oudega, M				Ritfeld, Gaby J.; Rauck, Britta M.; Novosat, Tabitha L.; Park, Daewon; Patel, Pavan; Roos, Raymund A. C.; Wang, Yadong; Oudega, Martin			The effect of a polyurethane-based reverse thermal gel on bone marrow stromal cell transplant survival and spinal cord repair	BIOMATERIALS			English	Article						Spinal cord injury; Cell therapy; ESHU; Antioxidant; Neuroprotection; Repair	TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; STEM-CELLS; ADULT-RATS; REGENERATIVE MEDICINE; SCHWANN-CELLS; IN-VITRO; CONTUSION; THERAPY; SYSTEM	Cell therapy for nervous tissue repair is limited by low transplant survival. We investigated the effects of a polyurethane-based reverse thermal gel, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU) on bone marrow stromal cell (BMSC) transplant survival and repair using a rat model of spinal cord contusion. Transplantation of BMSCs in ESHU at three days post-contusion resulted in a 3.5-fold increase in BMSC survival at one week post-injury and a 66% increase in spared nervous tissue volume at four weeks post-injury. These improvements were accompanied by enhanced hindlimb motor and sensorimotor recovery. In vitro, we found that ESHU protected BMSCs from hydrogen peroxide-mediated death, resulting in a four-fold increase in BMSC survival with two-fold fewer BMSCs expressing the apoptosis marker, caspase 3 and the DNA oxidation marker, 8-oxo-deoxyguanosine. We argue that ESHU protected BMSCs transplanted is a spinal cord contusion from death thereby augmenting their effects on neuroprotection leading to improved behavioral restoration. The data show that the repair effects of intraneural BMSC transplants depend on the degree of their survival and may have a widespread impact on cell-based regenerative medicine. (C) 2013 Elsevier Ltd. All rights reserved.	[Ritfeld, Gaby J.; Novosat, Tabitha L.; Patel, Pavan; Oudega, Martin] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Park, Daewon; Oudega, Martin] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Rauck, Britta M.; Wang, Yadong; Oudega, Martin] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA; [Wang, Yadong] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Rauck, Britta M.; Wang, Yadong] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA; [Park, Daewon] Univ Colorado Denver, Dept Bioengn, Aurora, CO USA; [Ritfeld, Gaby J.; Roos, Raymund A. C.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands		Oudega, M (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, W1452 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	yaw20@pitt.edu; moudega@pitt.edu	Ritfeld, Gaby/AAW-2039-2021; Wang, Yadong/AAC-3381-2020; Park, Daewon/W-8128-2019	Wang, Yadong/0000-0003-2067-382X; Patel, Pavan/0000-0002-7387-2083	LUMC [30229/5000]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32EB003392-07]; NSFNational Science Foundation (NSF) [DMR-1206589]; Department of Physical Medicine and Rehabilitation at the University of Pittsburgh; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB003392] Funding Source: NIH RePORTER	Financial support was provided by LUMC (grant #30229/5000) to GJR, NIH 5T32EB003392-07 (BR), NSF #DMR-1206589 (YW), and the Department of Physical Medicine and Rehabilitation at the University of Pittsburgh.	Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bernardo ME, 2012, BONE MARROW TRANSPL, V47, P164, DOI 10.1038/bmt.2011.81; Bolton DAE, 2006, BEHAV BRAIN RES, V168, P272, DOI 10.1016/j.bbr.2005.11.017; Bonilla C, 2012, J TRAUMA ACUTE CARE, V72, P1203, DOI 10.1097/TA.0b013e318248bdcf; Boyce RW, 2010, TOXICOL PATHOL, V38, P1011, DOI 10.1177/0192623310385140; Brodbeck WG, 2002, CYTOKINE, V18, P311, DOI 10.1006/cyto.2002.1048; BUNGE RP, 1993, ADV NEUROL, V59, P75; Caplan Al, 2009, J PATHOL, V217, P318; Christenson EM, 2004, J BIOMED MATER RES A, V70A, P245, DOI 10.1002/jbm.a.30067; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO;2-C; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Friberg TR, 2012, ARVO ANN M 2012; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596; Hill CE, 2007, EUR J NEUROSCI, V26, P1433, DOI 10.1111/j.1460-9568.2007.05771.x; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ichim TE, 2010, CELL IMMUNOL, V260, P75, DOI 10.1016/j.cellimm.2009.10.006; Joosten EAJ, 2004, J NEUROSCI RES, V77, P127, DOI 10.1002/jnr.20088; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kawabori M, 2013, NEUROPATHOLOGY, V33, P140, DOI 10.1111/j.1440-1789.2012.01335.x; Kigerl KA, 2012, EXP NEUROL, V233, P333, DOI 10.1016/j.expneurol.2011.10.025; Kong QM, 2010, CELL MOL LIFE SCI, V67, P1817, DOI 10.1007/s00018-010-0277-y; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Lankhorst AJ, 1999, NEUROSCI RES COMMUN, V24, P135; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McBane JE, 2007, J BIOMED MATER RES A, V82A, P984, DOI 10.1002/jbm.a.31263; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Okano H, 2013, CIRC RES, V112, P523, DOI 10.1161/CIRCRESAHA.111.256149; Oudega M, 2007, ACTA PHYSIOL, V189, P181, DOI 10.1111/j.1748-1716.2006.01658.x; Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384; Park D, 2011, BIOMATERIALS, V32, P777, DOI 10.1016/j.biomaterials.2010.09.044; Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043; Ritfeld GJ, 2012, CELL TRANSPLANT, V21, P1561, DOI 10.3727/096368912X640484; Ritfeld GJ, 2010, NEUROREPORT, V21, P221, DOI 10.1097/WNR.0b013e32833677cd; Ruff CA, 2010, PANMINERVA MED, V52, P125; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301; Siriphorn A, 2010, J NEUROCHEM, V115, P864, DOI 10.1111/j.1471-4159.2010.06770.x; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Tewarie RDSN, 2009, J NEUROTRAUM, V26, P2313, DOI 10.1089/neu.2009.0987; Tschope C, 2011, CURR PHARM DESIGN, V17, P3295, DOI 10.2174/138161211797904136; Wu Liqin, 2012, Central Nervous System Agents in Medicinal Chemistry, V12, P122; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Zhang YJ, 2012, J NEUROL SCI, V313, P64, DOI 10.1016/j.jns.2011.09.027; Zou JP, 2012, INT J LOW EXTR WOUND, V11, P244, DOI 10.1177/1534734612463935	54	41	47	0	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	FEB	2014	35	6					1924	1931		10.1016/j.biomaterials.2013.11.062			8	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	AA3UD	WOS:000331018700015	24331711	Green Accepted			2022-02-06	
J	Li, H; Wu, W; Sun, Q; Liu, M; Li, W; Zhang, XS; Zhou, ML; Hang, CH				Li, Hua; Wu, Wei; Sun, Qing; Liu, Ming; Li, Wei; Zhang, Xiang-sheng; Zhou, Meng-liang; Hang, Chun-hua			Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage	BRAIN RESEARCH			English	Article						Receptor for advanced glycation end-product; Nuclear factor kappa B; Subarachnoid hemorrhage; Inflammation	TRAUMATIC BRAIN-INJURY; RESPONSE PROTEIN 88; ALZHEIMERS-DISEASE; CEREBRAL VASOSPASM; RAGE RECEPTOR; MOUSE MODEL; BETA; INFLAMMATION; ASTROCYTES; LIGANDS	Convincing evidence indicates that inflammation contributes to the adverse prognosis of subarachnoid hemorrhage (SAH). Some pro-inflammatory molecules such as high mobility group protein 1, S100 family of proteins, beta-amyloid peptide, and macrophage antigen complex 1 have been involved in the damaging inflammation process following SAH. The receptor for advanced glycation end-products (RAGE) is a transmembrane receptor that senses these molecules and plays central role in inflammatory processes. This study aimed to determine the expression and cell distribution of RAGE in the brain cortex after SAH. Male Sprague-Dawley rats were randomly divided into sham group and SAN groups at 6 h, 12 h and on day 1, day 2 and day 3 (n=6 for each subgroup). SAN groups suffered experimental SAN by injection of 0.3 ml autologous blood into the prechiasmatic cistern. RAGE expression was measured by Western blot, real-time PCR, immunohistochemistry and immunofluorescence. Nuclear expression of p65 protein, the major subunit of nuclear factor kappa B, was also detected. Our data demonstrated that the expression levels of RAGE and nuclear p65 protein were both markedly increased after SAN. Moreover, there was a significant positive correlation between the expression of RAGE and that of p65 protein. Double immunofluorescence staining showed that RAGE was expressed by neuron and microglia rather than astrocyte after SAH. These results suggest that RAGE may be directly involved in the inflammatory response after SAN, and there might be important implications for further studies using specific RAGE antagonists to decrease inflammation-mediated brain injury following SAH. (C) 2013 Elsevier B.V. All rights reserved.	[Li, Hua; Wu, Wei; Sun, Qing; Li, Wei; Zhou, Meng-liang; Hang, Chun-hua] Nanjing Univ, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Ming] Southern Med Univ Guangzhou, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing, Jiangsu, Peoples R China; [Zhang, Xiang-sheng] Second Mil Med Univ Shanghai, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing, Jiangsu, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Sch Med, Dept Neurosurg, Jinling Hosp, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com	Li, Wei/ABE-4301-2021	Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170]; Nature Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]; Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China [CXZZ12_0067]	The authors acknowledge the support for this study by Grants from the National Natural Science Foundation, China (No. 81171170) and Nature Science Foundation of Jiangsu Province, China (BK2010459) and Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China (CXZZ12_0067).	Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chavakis T, 2004, MICROBES INFECT, V6, P1219, DOI 10.1016/j.micinf.2004.08.004; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Fritz G, 2011, TRENDS BIOCHEM SCI, V36, P625, DOI 10.1016/j.tibs.2011.08.008; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Larysz-Brysz M, 2012, CURR NEUROVASC RES, V9, P159, DOI 10.2174/156720212801619045; Lefranc F, 2005, NEUROPATH APPL NEURO, V31, P649, DOI 10.1111/j.1365-2990.2005.00682.x; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li W, 2012, NEUROL SCI; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Lin L, 2009, FRONT BIOSCI-LANDMRK, V14, P1403, DOI 10.2741/3315; Ma L, 2004, BRAIN RES, V1018, P10, DOI 10.1016/j.brainres.2004.05.052; Ma L, 2003, BRAIN RES, V966, P167, DOI 10.1016/S0006-8993(02)04149-5; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Ponath G, 2007, J NEUROIMMUNOL, V184, P214, DOI 10.1016/j.jneuroim.2006.12.011; Pradilla G, 2004, J NEUROSURG, V101, P88, DOI 10.3171/jns.2004.101.1.0088; Pradilla G, 2010, NEUROSURG CLIN N AM, V21, P365, DOI 10.1016/j.nec.2009.10.008; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Schmidt AM, 2009, CURR OPIN INVEST DR, V10, P672; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Sun Q, 2013, BRAIN RES, V1520, P134, DOI 10.1016/j.brainres.2013.05.010; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Venti M, 2012, FRONT NEUROL NEUROSC, V30, P149, DOI 10.1159/000333625; Xie JL, 2013, CELL SIGNAL, V25, P2185, DOI 10.1016/j.cellsig.2013.06.013; YAN SD, 1994, J BIOL CHEM, V269, P9889; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; You WC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/786242; Zhou ML, 2007, J CEREBR BLOOD F MET, V27, P1583, DOI 10.1038/sj.jcbfm.9600456	36	41	46	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 16	2014	1543						315	323		10.1016/j.brainres.2013.11.023			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	300VE	WOS:000330491300035	24291745				2022-02-06	
J	Bhullar, IS; Johnson, D; Paul, JP; Kerwin, AJ; Tepas, JJ; Frykberg, ER				Bhullar, Indermeet S.; Johnson, Donald; Paul, Julia P.; Kerwin, Andrew J.; Tepas, Joseph J., III; Frykberg, Eric R.			More harm than good: Antiseizure prophylaxis after traumatic brain injury does not decrease seizure rates but may inhibit functional recovery	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Phenytoin; antiseizure prophylaxis; functional outcome; traumatic brain injury	SEVERE HEAD-INJURY; POSTTRAUMATIC EPILEPSY; PHENYTOIN	BACKGROUND: The purposes of this study were to examine the current Brain Trauma Foundation recommendation for antiseizure prophylaxis with phenytoin during the first 7 days after traumatic brain injury (TBI) in preventing seizures and to determine if this medication affects functional recovery at discharge. METHODS: The records of adult (age >= 18 years) patients with blunt severe TBI who remained in the hospital at least 7 days after injury were retrospectively reviewed from January 2008 to January 2010. Clinical seizure rates during the first 7 days after injury and functional outcome at discharge were compared for the two groups based on antiseizure prophylaxis, no prophylaxis (NP) versus phenytoin prophylaxis (PP). Statistical analysis was performed using chi(2). RESULTS: A total of 93 adult patients who met the previously mentioned criteria were identified (43 [46%] NP group vs. 50 [54%] PP group). The two groups were well matched. Contrary to expectation, more seizures occurred in the PP group as compared with the NP group; however, this did not reach significance (PP vs. NP, 2 [4%] vs. 1 [2.3%], p = 1). There was no significant difference in the two groups (PP vs. NP) as far as disposition are concerned, mortality caused by head injury (4 [8%] vs. 3 [7%], p = 1), discharge home (16 [32%] vs. 17 [40%], p = 0.7), and discharge to rehabilitation (30 [60%] vs. 23 [53%], p = 0.9). However, with PP, there was a significantly longer hospital stay (PP vs. NP, 36 vs. 25 days, p = 0.04) and significantly worse functional outcome at discharge based on Glasgow Outcome Scale (GOS) score (PP vs. NP, 2.9 vs. 3.4, p < 0.01) and modified Rankin Scale score (2.3 +/- 1.7 vs. 3.1 +/- 1.5, p = 0.02). CONCLUSION: PP may not decrease early posttraumatic seizure and may suppress functional outcome after blunt TBI. These results need to be verified with randomized studies before recommending changes in clinical practice and do not apply to penetrating trauma. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Bhullar, Indermeet S.; Paul, Julia P.; Kerwin, Andrew J.; Frykberg, Eric R.] Univ Florida, Coll Med, Div Acute Care Surg, Jacksonville, FL 32209 USA; [Johnson, Donald] Univ Florida, Coll Med, Div Pharm, Jacksonville, FL 32209 USA; [Tepas, Joseph J., III] Univ Florida, Coll Med, Div Pediat, Jacksonville, FL 32209 USA		Bhullar, IS (corresponding author), Univ Florida, Coll Med, Surg Intens Care Unit, 655 West 8th St, Jacksonville, FL 32209 USA.	Indermeet.bhullar@jax.ufl.edu					Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Dauch WA, 1996, ZBL NEUROCHIR, V57, P190; Debenham S, 2011, CAN J NEUROL SCI, V38, P896, DOI 10.1017/S031716710001249X; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Faul M, 2010, TRAUMATIC BRAIN INJU; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HARUDA F, 1979, NEUROLOGY, V29, P1480, DOI 10.1212/WNL.29.11.1480; HENDRICK EB, 1968, J TRAUM, V8, P547; Jacka MJ, 2007, CAN J NEUROL SCI, V34, P307, DOI 10.1017/S0317167100006727; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; Rowbotham GF, 1942, ACUTE INJURIES HEAD; Sahin S, 2008, CLIN NEUROPHARMACOL, V31, P93, DOI 10.1097/WNF.0b013e31806ad6cb; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	30	41	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					54	60		10.1097/TA.0b013e3182aafd15			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200012	24368357				2022-02-06	
J	Cusimano, MD; Chipman, M; Donnelly, P; Hutchison, MG				Cusimano, Michael D.; Chipman, Mary; Donnelly, Peter; Hutchison, Michael G.			Effectiveness of an educational video on concussion knowledge in minor league hockey players: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Ice hockey; Injury Prevention; Concussion; Head injuries; Intervention effectiveness	YOUTH ICE HOCKEY; RUGBY UNION; INJURY PREVENTION; RISK-FACTORS; INTERVENTIONS; RULES	Background With the heightened awareness of concussions in all sports, the development and implementation of effective prevention strategies are necessary. Education has been advocated as an effective injury prevention intervention. Purpose To examine the effectiveness of the Smart Hockey: More Safety, More Fun' video on knowledge transfer among minor league hockey players. Study Design Cluster-randomised controlled trial. Methods A total of 267 participants from two age divisions and competitive levels were assigned to either a video or no-video group. The video was shown (or not shown) to the entire team as a result of random assignment. To evaluate the effectiveness of the educational video, questionnaires specific to concussion knowledge and players' attitudes and behaviours were completed. Results There was a significant increase in the players' concussion knowledge scores immediately following exposure to the video (F(1,103)=27.00, p<0.001). However, concussion knowledge at 2months was not significantly different between the video and no-video groups, after controlling for prior knowledge level, age and competitive level (F(1,115)=0.41, p=0.523). Similarly, players' attitudes and behaviour scores at 2months did not differ between groups (F(1,115)=0.41, p=0.507). Conclusions We were able to show that a single viewing of an educational video in hockey could immediately improve knowledge about concussion but that this effect was transient and lost at 2-month follow-up. Future prevention endeavours in hockey and other sports should attempt to incorporate strategies and modalities to enhance knowledge retention.	[Cusimano, Michael D.] Univ Toronto, Div Neurosurg, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Chipman, Mary] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5B 1W8, Canada; [Donnelly, Peter; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5B 1W8, Canada		Cusimano, MD (corresponding author), Univ Toronto, Div Neurosurg, Injury Prevent Res Off, St Michaels Hosp, 3,30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Ontario Neurotrauma Foundation [ONF-02006-O]; Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]	This study was funded by the Ontario Neurotrauma Foundation (# ONF-02006-O) and Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research (# TIR-103946). The funding organisations had no role in the design of the study and the collection, analysis and interpretation of the data.	BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Biasca N., 2005, EUR J TRAUMA, V31, P105, DOI [10.1007/s00068-005-1050-z, DOI 10.1007/S00068-005-1050-Z]; Bjornson GL, 1997, CAN J PUBLIC HEALTH, V88, P405, DOI 10.1007/BF03403916; Braslow A, 1997, RESUSCITATION, V34, P207, DOI 10.1016/S0300-9572(97)01096-4; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cusimano MD, 2013, CAN MED ASSOC J, V185, pE57, DOI 10.1503/cmaj.112017; Cusimano Michael D, 2011, Open Med, V5, pe57; Cusimano MD, 2010, NEUROSURGERY, V67, P1404, DOI 10.1227/NEU.0b013e3181f209f1; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Freimuth VS, 1997, HEALTH EDUC BEHAV, V24, P555, DOI 10.1177/109019819702400504; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Gianotti SM, 2009, J SCI MED SPORT, V12, P371, DOI 10.1016/j.jsams.2008.01.002; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; HockeyCanada, 2009, HOCK CAN ANN REP; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCauley J, 2003, ACAD MED, V78, P518, DOI 10.1097/00001888-200305000-00017; Mugno D A, 1985, Can J Appl Sport Sci, V10, P26; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377	32	41	41	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					141	U153		10.1136/bjsports-2012-091660			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	276KK	WOS:000328749000017	23918445				2022-02-06	
J	Wang, JW; Wang, HD; Cong, ZX; Zhou, XM; Xu, JG; Jia, Y; Ding, Y				Wang, Jia-Wei; Wang, Han-Dong; Cong, Zi-Xiang; Zhou, Xiao-Ming; Xu, Jian-Guo; Jia, Yue; Ding, Yu			Puerarin ameliorates oxidative stress in a rodent model of traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Puerarin; Oxidative stress; Akt	SPINAL-CORD-INJURY; PC12 CELLS; SIGNALING PATHWAY; SUBARACHNOID HEMORRHAGE; ANTIOXIDANT THERAPIES; INDUCED NEUROTOXICITY; ISOFLAVONE PUERARIN; CEREBRAL-ISCHEMIA; HYDROGEN-PEROXIDE; ESTROGEN-RECEPTOR	Background: A wealth of evidence has suggested that oxidative stress is involved in the secondary brain injury after traumatic brain injury (TBI). Recently, numerous in vivo and in vitro studies were reported that puerarin could inhibit oxidative stress through the activation of phosphatidylinositol 3-kinase (PI3K)-Akt pathway. It is unknown, however, whether puerarin can provide neuroprotection and reduce oxidative stress after TBI. The present study investigated the effects of puerarin on the TBI-induced neurodegeneration, oxidative stress, and the possible role of PI3K-Akt pathway in the neuroprotection of puerarin, in a rat model of TBI. Materials and methods: Rats were randomly distributed into various subgroups undergoing the sham surgery or TBI procedures. Puerarin (200 mg/kg) was given intraperitoneally at 10 min before injury and PI3K-Akt pathway inhibitor LY294002 was also administered intra-cerebroventricular in one subgroup. All rats were killed at 24 h after TBI for examination. Results: Our data indicated that puerarin could significantly reduce TBI-induced neuronal degeneration, accompanied by the partial restoration of the redox disturbance and enhanced expression of phospho-Akt in the pericontusional cortex after TBI. Moreover, PI3K-Akt pathway inhibitor LY294002 could partially abrogate the neuroprotection of puerarin in rats with TBI. Conclusions: These results indicate that puerarin can ameliorate oxidative neurodegeneration after TBI, at least in part, through the activation of PI3K-Akt pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Wang, Jia-Wei; Wang, Han-Dong; Cong, Zi-Xiang; Xu, Jian-Guo; Jia, Yue; Ding, Yu] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Xiao-Ming] Second Mil Med Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Key Subject of Jiangsu Province [X4200722]	We would like to thank Miss Zhe Zhang for her expert technical assistance. This work was supported by grants from National Natural Science Foundation of China (no. 81070974) and the Key Subject of Jiangsu Province (X4200722).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; [Anonymous], 2008, J NEUROTRAUM, V25, P513; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Benedict AL, 2012, J NEUROTRAUM, V29, P2576, DOI 10.1089/neu.2012.2474; Bo J, 2005, NEUROSCI RES, V53, P183, DOI 10.1016/j.neures.2005.06.014; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-9; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cherdshewasart W, 2008, PHYTOMEDICINE, V15, P38, DOI 10.1016/j.phymed.2007.07.058; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; De Wilde A, 2006, J CELL PHYSIOL, V209, P786, DOI 10.1002/jcp.20767; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003; Ersahin M, 2009, J PINEAL RES, V46, P324, DOI 10.1111/j.1600-079X.2009.00664.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez-Gomez FJ, 2006, NEUROBIOL DIS, V24, P296, DOI 10.1016/j.nbd.2006.07.005; Gao L, 2009, NEUROL RES, V31, P402, DOI 10.1179/174313209X444017; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Guerra MC, 2000, LIFE SCI, V67, P2997, DOI 10.1016/S0024-3205(00)00885-7; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hwang YP, 2008, TOXICOL APPL PHARM, V233, P371, DOI 10.1016/j.taap.2008.09.006; Jiang B, 2003, CELL BIOL INT, V27, P1025, DOI 10.1016/j.cellbi.2003.09.007; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kim H, 2005, NEUROL RES, V27, P287, DOI 10.1179/016164105X25234; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kurella E, 1997, ANN NY ACAD SCI, V834, P661, DOI 10.1111/j.1749-6632.1997.tb52344.x; Li JM, 2010, EUR J PHARMACOL, V649, P195, DOI 10.1016/j.ejphar.2010.09.045; Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maiese K, 2012, INT J MOL SCI, V13, P13830, DOI 10.3390/ijms131113830; MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Penetar DM, 2012, DRUG ALCOHOL DEPEN, V126, P251, DOI 10.1016/j.drugalcdep.2012.04.012; Robillard JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020676; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Streck EL, 2001, NEUROCHEM RES, V26, P1195, DOI 10.1023/A:1013907104585; Vitale DC, 2013, EUR J DRUG METAB PH, V38, P15, DOI 10.1007/s13318-012-0112-y; Wang CX, 2006, NEUROL RES, V28, P436, DOI 10.1179/016164106X115044; Wang Jia-Wei, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P164; Wang Q, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004196.pub2; Wong KH, 2011, J ETHNOPHARMACOL, V134, P584, DOI 10.1016/j.jep.2011.02.001; Xing GH, 2011, BRAIN RES BULL, V85, P212, DOI 10.1016/j.brainresbull.2011.03.024; Xiong FL, 2006, EUR J PHARMACOL, V529, P1, DOI 10.1016/j.ejphar.2005.10.024; Xu XH, 2005, PLANTA MED, V71, P585, DOI 10.1055/s-2005-871261; Xu XH, 2007, J ETHNOPHARMACOL, V113, P421, DOI 10.1016/j.jep.2007.06.012; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang HY, 2008, CELL BIOL INT, V32, P1230, DOI 10.1016/j.cellbi.2008.07.006; Zhang Q, 2012, CELL BIOL INT, V36, P419, DOI 10.1042/CBI20100900; Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s-2007-967168; Zhu GQ, 2012, NEUROCHEM INT, V60, P400, DOI 10.1016/j.neuint.2012.01.003; Zou Y, 2013, FREE RADICAL RES, V47, P55, DOI 10.3109/10715762.2012.742518	65	41	46	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JAN	2014	186	1					328	337		10.1016/j.jss.2013.08.027			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	274TJ	WOS:000328628800057	24079811				2022-02-06	
J	Ling, JM; Klimaj, S; Toulouse, T; Mayer, AR				Ling, Josef M.; Klimaj, Stefan; Toulouse, Trent; Mayer, Andrew R.			A prospective study of gray matter abnormalities in mild traumatic brain injury	NEUROLOGY			English	Article							CORTICAL IMPACT INJURY; AXONAL INJURY; TIME-COURSE; ENCEPHALOPATHY; NEUROPATHOLOGY; PERFORMANCE; ANISOTROPY; INTEGRITY; RECOVERY; ATROPHY	Objective: To examine the underlying pathophysiology of mild traumatic brain injury through changes in gray matter diffusion and atrophy during the semiacute stage. Methods: Fifty patients and 50 sex-, age-, and education-matched controls were evaluated with a clinical and neuroimaging battery approximately 14 days postinjury, with 26 patients returning for follow-up 4 months postinjury. Clinical measures included tests of attention, processing speed, executive function, working memory, memory, and self-reported postconcussive symptoms. Measures of diffusion (fractional anisotropy [FA], mean diffusivity) and atrophy were obtained for cortical and subcortical structures to characterize effects of injury as a function of time. Results: Patients reported more cognitive, somatic, and emotional complaints during the semiacute injury phase, which were significantly reduced 4 months postinjury. Patients showed evidence of increased FA in the bilateral superior frontal cortex during the semiacute phase, with the left superior frontal cortex remaining elevated 4 months postinjury. There were no significant differences between patients and matched controls on neuropsychological testing or measures of gray matter atrophy/mean diffusivity at either time point. Conclusions: Increased cortical FA is largely consistent with an emerging animal literature of gray matter abnormalities after neuronal injury. Potential mechanistic explanations for increased FA include cytotoxic edema or reactive gliosis. In contrast, there was no evidence of cortical or subcortical atrophy in the current study, suggesting that frank neuronal or neuropil loss does not occur early in the chronic disease course for patients with typical mild traumatic brain injury.	[Ling, Josef M.; Klimaj, Stefan; Toulouse, Trent; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87108 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87108 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Supported by the NIH (R24-HD050836, R21-NS064464-01A1, and 3 R21 NS064464-01S1 to A.R.M.).	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Halassa MM, 2007, J NEUROSCI, V27, P6473, DOI 10.1523/JNEUROSCI.1419-07.2007; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wright MJ, 2013, BRAIN IMAGING B 0501; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	37	41	42	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 10	2013	81	24					2121	2127		10.1212/01.wnl.0000437302.36064.b1			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AA0FZ	WOS:000330772300015	24259552	Green Published			2022-02-06	
J	Colvin, JD; Thurm, C; Pate, BM; Newland, JG; Hall, M; Meehan, WP				Colvin, Jeffrey D.; Thurm, Cary; Pate, Brian M.; Newland, Jason G.; Hall, Matt; Meehan, William P., III			Diagnosis and acute management of patients with concussion at children's hospitals	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; COMPUTED-TOMOGRAPHY; CONSENSUS STATEMENT; HEAD-INJURY; EMERGENCY; PREDICTION; IMPACT; EPIDEMIOLOGY	Objectives To describe the number of hospital admissions for concussion at paediatric hospitals in the USA. To describe the use of imaging and medications for acute concussion paediatric patients. Design Cross-sectional study. Setting Children's hospitals participating in the Pediatric Health Information System in the USA during a 10-year period. Patients All emergency department (ED) visits and inpatient admissions with the primary diagnosis of concussion, defined as International Classification of Diseases, Ninth Revision, Clinical Modification codes for: (1) concussion, (2) postconcussion syndrome or (3) skull fracture without mention of intracranial injury with concussion. Main outcome measures The proportion of concussion patients who were hospitalised, underwent imaging or received medication, and the adjusted costs of visits for concussion. Results The number of ED visits for concussion increased between 2001 and 2010 (2126 (0.36% of all ED visits) vs 4967 (0.62% of all ED visits); p<0.001), while the number of admissions remained stable. Of ED visits for concussion, 59.9% received CT and 47.7% received medications or intravenous fluids. Non-narcotic analgesics were the most common medication administered. Adjusted costs of patient visits were significantly higher when imaging was obtained (US$695, IQR US$472-$1009, vs US$191, IQR US$114-$287). An ED visit with CT, however, cost less than a hospitalisation without CT (US$1907, IQR US$1292-$3770). Conclusions Although the number of ED patients diagnosed with concussion has increased, the number admitted has remained stable. Concussion patients at paediatric hospitals in the USA commonly undergo CT imaging and receive medication.	[Colvin, Jeffrey D.; Pate, Brian M.] Univ Missouri, Childrens Mercy Hosp & Clin, Div Pediat Hosp Med, Dept Pediat, Kansas City, MO 64110 USA; [Thurm, Cary; Hall, Matt] Childrens Hosp Assoc, Dept Informat, Overland Pk, KS USA; [Newland, Jason G.] Univ Missouri, Dept Pediat, Div Infect Dis, Childrens Mercy Hosp & Clin, Kansas City, MO 64110 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA		Colvin, JD (corresponding author), Childrens Mercy Hosp, Sect Pediat Hosp Med, 2401 Gillham Rd, Kansas City, MO 64108 USA.	jdcolvin@cmh.edu	Colvin, Jeffrey/L-5492-2019; Hall, Matt/AAT-1349-2021	Hall, Matt/0000-0001-7778-5887	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Dr Meehan is supported by award T32 HD040128-06A1 from the National Institutes of Health.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bowser B., 2007, NEWSHOUR; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Carson J, 2006, CAN FAM PHYSICIAN, V52, P756; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Dalt L, 2005, EUR J PEDIATR, V165, P142; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fackelmann K., 2003, US TODAY; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hendry SJ, 2005, ARCH DIS CHILD, V90, P629, DOI 10.1136/adc.2004.049502; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lueke L, 2011, J LEGAL MED, V32, P483, DOI 10.1080/01947648.2011.632710; MacMullan J., 2007, BOSTON GLOBE; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2011, ACAD EMERG MED, V18, P906, DOI 10.1111/j.1553-2712.2011.01154.x; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; MEADOWS B, 2007, PEOPLE MAGAZINE 1008, P107; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schwarz Alan, 2007, NY TIMES; Shah SS, 2011, J HOSP MED, V6, P256, DOI 10.1002/jhm.872; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Truman CD, 2002, CAN J PUBLIC HEALTH, V93, P41, DOI 10.1007/BF03404416; Weiss AK, 2011, PEDIATRICS, V127, pE255, DOI 10.1542/peds.2010-0983; Williams A, 2009, ARCH DIS CHILD, V94, P817, DOI 10.1136/adc.2008.149823; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	47	41	41	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	DEC	2013	98	12					934	938		10.1136/archdischild-2012-303588			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	292JG	WOS:000329897400006	23852997	Bronze			2022-02-06	
J	Finnanger, TG; Skandsen, T; Andersson, S; Lydersen, S; Vik, A; Indredavik, M				Finnanger, Torun Gangaune; Skandsen, Toril; Andersson, Stein; Lydersen, Stian; Vik, Anne; Indredavik, Marit			Differentiated patterns of cognitive impairment 12 months after severe and moderate traumatic brain injury	BRAIN INJURY			English	Article						Craniocerebral trauma; deficits; executive function; longitudinal studies; memory deficits; neurobehavioural signs and symptoms; outcome assessment	CLOSED-HEAD-INJURY; RECOVERY; PERFORMANCE; SPEED; RECOMMENDATIONS; ASSOCIATION; EDUCATION; TESTS; SCALE	Objective: To assess cognitive function at 12 months after moderate and severe traumatic brain injury (TBI) separately, as well as improvement from 3 to 12 months and relationship to global outcome. Methods: Cognitive function among patients with moderate (n = 30, Glasgow Coma Scale score (GCS) 9-3) and severe traumatic brain injury (n = 20, GCS score <= 8), recruited from an unselected neurosurgical cohort, all with MRI performed in the early phase were assessed with a neuropsychological test battery and Glasgow Outcome Scale Extended. Healthy volunteers (n = 47) matched for age, gender and years of education served as controls. Results: Executive function was reduced at 12-months post-injury in patients with both moderate and severe TBI. However, motor function, processing speed and memory were reduced only among patients with severe TBI. Both patients with moderate and severe TBI improved their processing speed and visual memory. Patients with moderate TBI also improved motor function, while patients with severe TBI also improved executive function. Conclusion: Differentiating between patients with moderate and severe TBI yields a more accurate description of cognitive deficits and their improvement over time. Further, executive dysfunction and attention problems affected the ability to resume independent living and employment regardless of injury severity and age.	[Finnanger, Torun Gangaune; Lydersen, Stian; Indredavik, Marit] Norwegian Univ Sci & Technol, Reg Ctr Child & Youth Mental Hlth & Child Welfare, N-7034 Trondheim, Norway; [Finnanger, Torun Gangaune; Indredavik, Marit] Univ Trondheim Hosp, Dept Child & Adolescent Psychiat, St Olavs Hosp, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, Clin Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, N-7034 Trondheim, Norway; [Andersson, Stein] Univ Oslo, Dept Psychol, Oslo, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Neuroclinic, Trondheim, Norway		Finnanger, TG (corresponding author), Norwegian Univ Sci & Technol, Reg Ctr Child & Youth Mental Hlth & Child Welfare, N-7034 Trondheim, Norway.	torun.g.finnanger@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Norwegian ExtraFoundation for Health and Rehabilitation [2010/2/0105]; Central Norway Regional Health Authority (RHA) [47063700]; Norwegian University of Science and Technology (NTNU) [47063700]; SINTEF Unimed Innovation Research FundSINTEF [09/9603]	The authors report no conflicts of interest. This work was supported by the Norwegian ExtraFoundation for Health and Rehabilitation (first author, grant number 2010/2/0105); the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (first author, grant number 47063700); and SINTEF Unimed Innovation Research Fund (first author, grant number 09/9603).	Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Cohen J., 2013, STAT POWER ANAL BEHA; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Conners C. K., 2000, CONNERS CONTINUOUS P; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gardner M.J, 2000, STAT CONFIDENCE; Grissom Robert J, 2005, EFFECT SIZES RES BRO; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Matthews CG., 1964, INSTRUCTION MANUAL A; Meyers JE., 1995, REY COMPLEX FIGURE T; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack TA, 2000, BRAIN INJURY, V14, P987; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paolo AM, 1998, ARCH CLIN NEUROPSYCH, V13, P333, DOI 10.1016/S0887-6177(97)00018-8; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Rentz DM, 2004, NEUROPSYCHOLOGY, V18, P38, DOI 10.1037/0894-4105.18.1.38; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rosner B, 2011, FUNDAMENTALS BIOSTAT; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 1982, SYMBOL DIGIT MODALIT; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Strong CAH, 2008, J CLIN EXP NEUROPSYC, V30, P885, DOI 10.1080/13803390701858224; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Trahan DE, 1988, CONTINOUS VISUAL MEM; Wechsler C., 1997, WECHSLER ADULT INTEL; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfson, 1993, HALSTEAD REITAN NEUR; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	61	41	45	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2013	27	13-14					1606	1616		10.3109/02699052.2013.831127			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	259BW	WOS:000327503400016	24102501				2022-02-06	
J	Joseph, B; Pandit, V; Sadoun, M; Larkins, CG; Kulvatunyou, N; Tang, A; Mino, M; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Sadoun, Moutamn; Larkins, Christopher G.; Kulvatunyou, Narong; Tang, Andrew; Mino, Matthew; Friese, Randall S.; Rhee, Peter			A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	43rd Annual Meeting of the Western-Trauma-Association	MAR 03-08, 2013	Snowmass, CO	Western Trauma Assoc		Anti-platelet therapy; platelet transfusion; traumatic brain injury; platelet function; VerifyNow platelet function assay	BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; ELDERLY-PATIENTS; TRANSFUSION; DYSFUNCTION; RESISTANCE; ASPIRIN; AGENTS; MODEL	BACKGROUND: Platelet transfusion is increasingly used in patients with traumatic intracranial hemorrhage (ICH) on aspirin therapy to minimize the progression of ICH. We hypothesized (null) that platelet transfusion in this cohort of patients does not improve platelet function. METHODS: We performed a prospective interventional trail on patients with traumatic ICH on daily high-dose (325 mg) aspirin therapy. All patients received one pack of apheresis platelets. Blood samples were collected before and 1 hour after platelet transfusion. Platelet function was assessed using Verify Now Platelet Function Assay, and a cutoff of greater than 550 aspirin reaction units was used to define functioning platelets (FP). RESULTS: Twenty-eight patients were enrolled in the study. On presentation, 79% (22 of 28) of the patients had nonfunctioning platelets (NFPs), and transfusion of platelets did not improve platelet function as 81% (18 of 22) still had NFP. Of the 22 patients, 4 converted from NFP to FP after transfusion. There was no difference in the progression of ICH (37.5% vs. 30%, p = 0.7) or neurosurgical intervention (12.5% vs. 15%, p = 0.86) between patients with FP and NFP after platelet transfusion. CONCLUSION: Administration of one pack of apheresis platelet did not improve platelet function. In our study, progression of ICH and the need for neurosurgical intervention were independent of platelet function. Further randomized clinical trials are required to assess both the dose dependence effect and role of platelet transfusion in patients on antiplatelet therapy with traumatic ICH. (Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Pandit, Viraj; Sadoun, Moutamn; Larkins, Christopher G.; Kulvatunyou, Narong; Tang, Andrew; Mino, Matthew; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Acute Care Surg, 1501 N Campbell Ave,Rm 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; COLEMAN J, 2004, POINT CARE, V3, P77; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Faul M, 2010, TRAUMATIC BRAIN INJU; Feher G, 2009, CLIN GENET, V75, P1, DOI 10.1111/j.1399-0004.2008.01105.x; Greer DM, 2010, CNS DRUGS, V24, P1027, DOI 10.2165/11539160-000000000-00000; Joseph B, AM SURG IN PRESS; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Toyoda K, 2005, NEUROLOGY, V65, P1000, DOI 10.1212/01.wnl.0000179178.37713.69; van Werkum JW, 2008, PLATELETS, V19, P479, DOI 10.1080/09537100802317918; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	19	41	43	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2013	75	6					990	994		10.1097/TA.0b013e3182a96591			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	300IR	WOS:000330458100012	24256671				2022-02-06	
J	Shi, J; Longo, FM; Massa, SM				Shi, Jian; Longo, Frank M.; Massa, Stephen M.			A Small Molecule p75(NTR) Ligand Protects Neurogenesis After Traumatic Brain Injury	STEM CELLS			English	Article						Traumatic brain injury; Neurotrophin; Neurogenesis; Hippocampus	P75 NEUROTROPHIN RECEPTOR; CELL-ADHESION MOLECULE; REGULATES HIPPOCAMPAL NEUROGENESIS; NERVE GROWTH-FACTOR; DENTATE GYRUS; UP-REGULATION; EXPRESSION PATTERNS; FUNCTIONAL RECOVERY; PROGENITOR CELLS; NEWBORN NEURONS	The p75 neurotrophin receptor (p75(NTR)) influences the proliferation, survival, and differentiation of neuronal precursors and its expression is induced in injured brain, where it regulates cell survival. Here, we test the hypotheses that pharmacologic modulation of p75(NTR) signaling will promote neural progenitor survival and proliferation, and improve outcomes of traumatic brain injury (TBI). LM11A-31, an orally available, blood-brain barrier-permeant small-molecule p75(NTR) signaling modulator, significantly increased proliferation and survival, and decreased JNK phosphorylation, in hippocampal neural stem/progenitor cells in culture expressing wild-type p75(NTR), but had no effect on cells expressing a mutant neurotrophin-unresponsive form of the receptor. The compound also enhanced the production of mature neurons from adult hippocampal neural progenitors in vitro. In vivo, intranasal administration of LM11A-31 decreased postinjury hippocampal and cortical neuronal death, neural progenitor cell death, gliogenesis, and microglial activation, and enhanced long-term hippocampal neurogenesis and reversed spatial memory impairments. LM11A-31 diminished the postinjury increase of SOX2-expressing early progenitor cells, but protected and increased the proliferation of endogenous polysialylated-neural cell adhesion molecule positive intermediate progenitors, and restored the long-term production of mature granule neurons. These findings suggest that modulation of p75(NTR) actions using small molecules such as LM11A-31 may constitute a potent therapeutic strategy for TBI. Stem Cells2013;31:2561-2574	[Shi, Jian; Massa, Stephen M.] Dept Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA USA; [Shi, Jian; Massa, Stephen M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Massa, SM (corresponding author), San Francisco VA Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	Stephen.Mas-sa@ucsf.edu			Department of DefenseUnited States Department of Defense [DOD DAMD17-03-1-0532]; Veterans AdministrationUS Department of Veterans Affairs	These studies were supported by the Department of Defense (DOD DAMD17-03-1-0532 to SMM); and the Veterans Administration (SMM).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bernabeu RO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-136; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Catts VS, 2008, EUR J NEUROSCI, V28, P883, DOI 10.1111/j.1460-9568.2008.06390.x; Colditz MJ, 2010, EXP BRAIN RES, V200, P161, DOI 10.1007/s00221-009-1947-6; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Diarra Adama, 2009, Biochem Biophys Res Commun, V390, P352, DOI 10.1016/j.bbrc.2009.09.116; Dougherty KD, 1999, J COMP NEUROL, V407, P77, DOI 10.1002/(SICI)1096-9861(19990428)407:1<77::AID-CNE6>3.0.CO;2-S; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Galvao RP, 2008, J NEUROSCI, V28, P13368, DOI 10.1523/JNEUROSCI.2918-08.2008; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gascon E, 2005, EUR J NEUROSCI, V21, P69, DOI 10.1111/j.1460-9568.2004.03849.x; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gu Yan, 2013, Curr Top Behav Neurosci, V15, P31, DOI 10.1007/7854_2012_217; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; James SE, 2008, NEUROTOXICOLOGY, V29, P605, DOI 10.1016/j.neuro.2008.04.008; Kaneko N, 2006, GENES CELLS, V11, P1145, DOI 10.1111/j.1365-2443.2006.01010.x; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Knowles JK, 2013, NEUROBIOL AGING, V34, P2052, DOI 10.1016/j.neurobiolaging.2013.02.015; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Longo FM, 2008, CNS NEUROL DISORD-DR, V7, P63, DOI 10.2174/187152708783885093; Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024; Lopez-Fernandez MA, 2007, J NEUROSCI, V27, P4552, DOI 10.1523/JNEUROSCI.0396-07.2007; Luikart BW, 2012, BEHAV BRAIN RES, V227, P348, DOI 10.1016/j.bbr.2011.03.048; Maric D, 1998, METHODS, V16, P247, DOI 10.1006/meth.1998.0682; Markram K, 2007, NEUROSCIENCE, V144, P788, DOI 10.1016/j.neuroscience.2006.10.024; Massa SM, 2006, J NEUROSCI, V26, P5288, DOI 10.1523/JNEUROSCI.3547-05.2006; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Meeker RB, 2012, J NEUROIMMUNE PHARM, V7, P388, DOI 10.1007/s11481-011-9325-0; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MRZLJAK L, 1993, CEREB CORTEX, V3, P133, DOI 10.1093/cercor/3.2.133; Namba T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025303; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; NYAKAS C, 1987, BRAIN RES BULL, V18, P533, DOI 10.1016/0361-9230(87)90117-1; Pehar M, 2006, EUR J NEUROSCI, V24, P1575, DOI 10.1111/j.1460-9568.2006.05040.x; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Seki T, 2002, J NEUROSCI RES, V70, P327, DOI 10.1002/jnr.10387; Seki T, 1999, J COMP NEUROL, V410, P115, DOI 10.1002/(SICI)1096-9861(19990719)410:1<115::AID-CNE10>3.0.CO;2-C; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Sotthibundhu A, 2009, NEUROBIOL AGING, V30, P1975, DOI 10.1016/j.neurobiolaging.2008.02.004; Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Van der Borght K, 2005, BEHAV NEUROSCI, V119, P926, DOI 10.1037/0735-7044.119.4.926; Van Hoesen GW, 1999, ANN NY ACAD SCI, V877, P575; Venero C, 2006, EUR J NEUROSCI, V23, P1585, DOI 10.1111/j.1460-9568.2006.04663.x; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Yang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003604; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267; Young KM, 2007, J NEUROSCI, V27, P5146, DOI 10.1523/JNEUROSCI.0654-07.2007; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang JS, 2007, NAT NEUROSCI, V10, P77, DOI 10.1038/nn1816; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	76	41	45	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	NOV	2013	31	11					2561	2574		10.1002/stem.1516			14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	252QY	WOS:000327025600025	23940017	Bronze			2022-02-06	
J	Ley, EJ; Short, SS; Liou, DZ; Singer, MB; Mirocha, J; Melo, N; Bukur, M; Salim, A				Ley, Eric J.; Short, Scott S.; Liou, Douglas Z.; Singer, Matthew B.; Mirocha, James; Melo, Nicolas; Bukur, Marko; Salim, Ali			Gender impacts mortality after traumatic brain injury in teenagers	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Pediatric; traumatic brain injury; gender; puberty	DATA-BANK; IMPROVED OUTCOMES; CLINICAL-TRIALS; PROGESTERONE; INSURANCE; CHILDREN; WOMEN; AGE	BACKGROUND: Gender may influence outcomes following traumatic brain injury (TBI) although the mechanism is unknown. Animal TBI studies suggest that gender differences in endogenous hormone production may be the source. Limited retrospective clinical studies on gender present varied conclusions. Pediatric patients represent a unique population as pubescent children experience up-regulation of endogenous hormones that varies dramatically by gender. Younger children do not have these hormonal differences. The aim of this study was to compare pubescent and prepubescent females with males after isolated TBI to identify independent predictors of mortality. METHODS: We performed a retrospective review of the National Trauma Data Bank Research Data Sets from 2007 and 2008 looking at all blunt trauma patients 18 years or younger who required hospital admission after isolated, moderate-to-severe TBI, defined as head Abbreviated Injury Scale (AIS) score 3 or greater. We excluded all individuals with AIS score of 3 or greater for any other region to limit the confounding effect of comorbidities. Based on the median age of menarche, we defined two age groups as follows: prepubescent (0-12 years) and pubescent (912 years). Analysis was performed to compare trauma profiles and outcomes between groups. Our primary outcome measure was in-hospital mortality. RESULTS: A total of 20,280 patients met inclusion criteria; 10,135 were prepubescent, and 10,145 were pubescent. Overall mortality was 6.9%, and lower mortality was noted among prepubescent patients compared with pubescent (5.2% vs. 8.6%, p < 0.0001). Although female gender did not predict reduced mortality in the prepubescent cohort (adjusted odds ratio, 1.05; 95% confidence interval, 0.85-1.30; p = 0.63), female gender was associated with reduced mortality in the pubescent (adjusted odds ratio, 0.78; 95% confidence interval, 0.65-0.93; p = 0.007). CONCLUSION: In contrast to prepubescent female gender, pubescent female gender predicts reduced mortality following isolated, moderate-to-severe TBI. Endogenous hormonal differences may be a contributing factor and require further investigation. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Ley, Eric J.; Short, Scott S.; Liou, Douglas Z.; Singer, Matthew B.; Melo, Nicolas; Bukur, Marko; Salim, Ali] Cedars Sinai Med Ctr, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Mirocha, James] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Mirocha, James] Cedars Sinai Med Ctr, Dept Biostat, Los Angeles, CA 90048 USA		Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215 NT, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Bukur, Marko/0000-0002-1850-7147			Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Anderson SE, 2005, J PEDIATR-US, V147, P753, DOI 10.1016/j.jpeds.2005.07.016; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Haider AH, 2012, J AM COLL SURGEONS, V214, P756, DOI 10.1016/j.jamcollsurg.2011.12.013; Junpeng M., 2011, COCHRANE DB SYST REV, V1; Kelley BG, 2011, MOL CELL NEUROSCI, V48, P137, DOI 10.1016/j.mcn.2011.07.002; Kochanek Kenneth D, 2011, Natl Vital Stat Rep, V60, P1; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Phillips B, 2008, J TRAUMA, V64, P768, DOI 10.1097/TA.0b013e3181620152; Ringdal KG, 2013, INJURY, V44, P29, DOI 10.1016/j.injury.2011.12.024; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Singer MB, 2013, J TRAUMA ACUTE CARE, V74, P312, DOI 10.1097/TA.0b013e31826fc899; Singh M, 2013, NEUROSCIENCE, V239, P84, DOI 10.1016/j.neuroscience.2012.09.056; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46	21	41	44	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2013	75	4					682	686		10.1097/TA.0b013e31829d024f			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	300IK	WOS:000330457400020	24064883				2022-02-06	
J	Turner, RC; Naser, ZJ; Logsdon, AF; DiPasquale, KH; Jackson, GJ; Robson, MJ; Gettens, RTT; Matsumoto, RR; Huber, JD; Rosen, CL				Turner, Ryan C.; Naser, Zachary J.; Logsdon, Aric F.; DiPasquale, Kenneth H.; Jackson, Garrett J.; Robson, Matthew J.; Gettens, Robert T. T.; Matsumoto, Rae R.; Huber, Jason D.; Rosen, Charles L.			Modeling clinically relevant blast parameters based on scaling principles produces functional & histological deficits in rats	EXPERIMENTAL NEUROLOGY			English	Article						Blast injury; Shock tube; Blast duration; Traumatic brain injury; Neural injury	TRAUMATIC BRAIN-INJURY; AXONAL INJURY; MOUSE MODEL; AIR-BLAST; MECHANISMS; MICROGLIA; ACTIVATION; STRESS	Blast-induced traumatic brain injury represents a leading cause of injury in modem warfare with injury pathogenesis poorly understood. Preclinical models of blast injury remain poorly standardized across laboratories and the clinical relevance unclear based upon pulmonary injury scaling laws. Models capable of high peak overpressures and of short duration may better replicate clinical exposure when scaling principles are considered. In this work we demonstrate a tabletop shock tube model capable of high peak overpressures and of short duration. By varying the thickness of the polyester membrane, peak overpressure can be controlled. We used membranes with a thickness of 0.003, 0.005, 0.007, and 0.010 in to generate peak reflected overpressures of 31.47, 50.72, 72.05, and 90.10 PSI, respectively. Blast exposure was shown to decrease total activity and produce neural degeneration as indicated by fluoro-jade B staining. Similarly, blast exposure resulted in increased glial activation as indicated by an increase in the number of glial fibrillary acidic protein expressing astrocytes compared to control within the corpus callosum, the region of greatest apparent injury following blast exposure. Similar findings were observed with regard to activated microglia, some of which displayed phagocytic-like morphology within the corpus callosum following blast exposure, particularly with higher peak overpressures. Furthermore, hematoxylin and eosin staining showed the presence of red blood cells within the parenchyma and red, swollen neurons following blast injury. Exposure to blast with 90.10 PSI peak reflected overpressure resulted in immediate mortality associated with extensive intracranial bleeding. This work demonstrates one of the first examples of blast-induced brain injury in the rodent when exposed to a blast wave scaled from human exposure based on scaling principles derived from pulmonary injury lethality curves. (C) 2013 Elsevier Inc. All rights reserved.	[Turner, Ryan C.; Naser, Zachary J.; Jackson, Garrett J.; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Turner, Ryan C.; Naser, Zachary J.; Logsdon, Aric F.; DiPasquale, Kenneth H.; Jackson, Garrett J.; Robson, Matthew J.; Matsumoto, Rae R.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; DiPasquale, Kenneth H.; Robson, Matthew J.; Matsumoto, Rae R.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Gettens, Robert T. T.] Western New England Univ, Coll Engn, Dept Biomed Engn, Springfield, MA USA		Rosen, CL (corresponding author), W Virginia Univ, Sch Med, Dept Neurosurg, Hlth Sci Ctr, 1 Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Robson, Matthew/H-3127-2013	Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174, 5RO1-NS061954, DA013978]; West Virginia University Department of Neurosurgery; American Society for Quality, Biomedical Division; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM008174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA013978] Funding Source: NIH RePORTER	The authors would like to thank Nicholas St. John for contributing to the design of the blast model, Brandon P. Lucke-Wold for his assistance with preliminary experiments, and Ms. Diana Richardson of the National Institute of Occupational Safety and Health (NIOSH) for her assistance in tissue preparation. The authors would also like to thank Mr. James Edward Robson and Mr. Peter Bennett for their assistance in model construction. The authors are also grateful to Dr. Kymberly Gyure for her assistance with neuropathological examination. This work was supported by grant funding provided to Ryan C. Turner (5T32GM08174), Jason D. Huber (5RO1-NS061954), and Rae R. Matsumoto (DA013978) by the National Institutes of Health. The West Virginia University Department of Neurosurgery also funded this work. Funding was also provided to Dr. Robert T.T. Gettens by the American Society for Quality, Biomedical Division in the form of the Dr. Richard J. Schlesinger Grant for construction of the blast model.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cemak I., 2010, J CEREB BLOOD FLOW M, V30, P255; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Covey Dana C, 2010, J Surg Orthop Adv, V19, P8; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Duckworth JL, 2012, PATHOPHYSIOLOGY, V20, P23; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hyde D, 2004, CONVENTIONAL WEAPONS; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, NEUROSCI LETT, V522, P47, DOI 10.1016/j.neulet.2012.06.012; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9	41	41	42	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2013	248						520	529		10.1016/j.expneurol.2013.07.008			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261SJ	WOS:000327684600053	23876514				2022-02-06	
J	Chiu, SL; Osternig, L; Chou, LS				Chiu, Shiu-Ling; Osternig, Louis; Chou, Li-Shan			Concussion induces gait inter-joint coordination variability under conditions of divided attention and obstacle crossing	GAIT & POSTURE			English	Article						Concussion; Gait; Obstacle avoidance; Attention; Inter-joint coordination	TRAUMATIC BRAIN-INJURY; BIMANUAL COORDINATION; BALANCE; WALKING; TASK; PERFORMANCE; COLLEGIATE; LOCOMOTION; MOVEMENTS; CAPACITY	This study investigated the effect of concussion on the pattern and variability of inter-joint coordination during level walking (Level), obstacle crossing (OB), and walking with a concurrent cognitive test (ATT). Gait analyses of 23 concussed and 23 matched healthy adults were performed. Continuous relative phase (CRP), derived from phase angles of two adjacent joints, was used to assess inter-joint coordination. Cross-correlation measures and root-mean-square (RMS) differences were used to compare CRP patterns of the Level condition to those of OB and ATT conditions, respectively. Deviation phase (DP) was used to evaluate variability of inter-joint coordination for each task. For hip-knee and knee-ankle CRP patterns, RMS differences between OB and Level and between ATT and Level in concussed subjects were significantly greater than those of healthy adults. No significant group differences were detected for the cross-correlation measures of hip-knee and knee-ankle CRP patterns. In stance phase, a significant task effect on DP values was detected in hip-knee inter-joint coordination. For knee-ankle inter-joint coordination, concussed subjects showed significantly greater DP values than healthy controls during OB and ATT. In swing phase, concussed individuals showed greater DP values in hip-knee and knee-ankle inter-joint coordination compared to healthy controls. The findings suggest that the ability to modulate inter-joint coordination patterns when accommodating to gait perturbations is affected by concussion. (C) 2013 Elsevier B.V. All rights reserved.	[Chiu, Shiu-Ling; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu					[Anonymous], 1995, GAIT POSTURE; Barela JA, 2000, HUM MOVEMENT SCI, V19, P251, DOI 10.1016/S0167-9457(00)00014-2; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BURGESSLIMERICK R, 1993, J BIOMECH, V26, P91, DOI 10.1016/0021-9290(93)90617-N; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chiu SL, 2012, J BIOMECH, V45, P275, DOI 10.1016/j.jbiomech.2011.10.028; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Cordo PJ, 2004, PROG BRAIN RES, V143, P29, DOI 10.1016/S0079-6123(03)43003-3; Drew T, 2008, BRAIN RES REV, V57, P199, DOI 10.1016/j.brainresrev.2007.07.017; Faul M, 2010, TRAUMATIC BRAIN INJU; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hamill J, 1999, CLIN BIOMECH, V14, P297, DOI 10.1016/S0268-0033(98)90092-4; Holtzer R, 2011, J GERONTOL A-BIOL, V66, P879, DOI 10.1093/gerona/glr068; HURMUZLU Y, 1994, J BIOMECH, V27, P1495, DOI 10.1016/0021-9290(94)90199-6; Kelly JP, 1997, NEUROLOGY, V48, P581; Lacquaniti F, 1997, ARCH ITAL BIOL, V135, P353; Lu TW, 2008, GAIT POSTURE, V27, P309, DOI 10.1016/j.gaitpost.2007.04.007; Matthews A, 2006, NEUROSCI LETT, V400, P172, DOI 10.1016/j.neulet.2006.02.043; McFadyen BJ, 1997, EXP BRAIN RES, V114, P500, DOI 10.1007/PL00005659; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Monno A, 2002, ACTA PSYCHOL, V110, P187, DOI 10.1016/S0001-6918(02)00033-1; PATLA AE, 1991, J EXP PSYCHOL HUMAN, V17, P603, DOI 10.1037/0096-1523.17.3.603; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Zackowski KM, 2002, EXP BRAIN RES, V146, P511, DOI 10.1007/s00221-002-1191-9	30	41	42	0	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2013	38	4					717	722		10.1016/j.gaitpost.2013.03.010			6	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	231MV	WOS:000325421900029	23578796				2022-02-06	
J	Noe, N; Dillon, L; Lellek, V; Diaz, F; Hida, A; Moraes, CT; Wenz, T				Noe, Natalie; Dillon, Lloye; Lellek, Veronika; Diaz, Francisca; Hida, Aline; Moraes, Carlos T.; Wenz, Tina			Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy	MITOCHONDRION			English	Article						Bezafibrate; CNS; PPAR/PGC-1 alpha; Mitochondrial encephalopathy	GAMMA AGONIST ROSIGLITAZONE; RECEPTOR-ALPHA ACTIVATION; TRAUMATIC BRAIN-INJURY; PGC-1-ALPHA; FENOFIBRATE; BIOGENESIS; NEUROPROTECTION; RESVERATROL; DEFICIENCY; MICROGLIA	Mitochondrial dysfunction frequently affects the central nervous system. Here, we investigated the effect of bezafibrate treatment on neuronal mitochondrial function and its impact on the progression of a mitochondrial encephalopathy. We used a murine model with a forebrain-specific cytochrome c oxidase deficiency caused by conditional deletion of the COX10 gene. In this mouse model, bezafibrate-administration improved the phenotype of the mice associated with an increase in mitochondrial proteins and mitochondrial ATP generating capacity. Bezafibrate-treatment also attenuated astrogliosis and decreased the level of inflammatory markers in the affected tissues. Overall, bezafibrate had a neuroprotective effect in this mouse model of mitochondrial encephalopathy. These findings imply that bezafibrate might be a promising therapeutic agent for the treatment of neurodegenerative disease associated with mitochondrial dysfunction. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Noe, Natalie; Lellek, Veronika; Wenz, Tina] Univ Cologne, Inst Genet, D-50674 Cologne, Germany; [Noe, Natalie; Lellek, Veronika; Wenz, Tina] Univ Cologne, Cluster Excellence Cellular Stress Responses Agi, D-50674 Cologne, Germany; [Dillon, Lloye; Diaz, Francisca; Hida, Aline; Moraes, Carlos T.; Wenz, Tina] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; [Moraes, Carlos T.; Wenz, Tina] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA		Wenz, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47A, D-50674 Cologne, Germany.	tina.wenz@uni-koeln.de	Moraes, Carlos/AAT-3818-2021	Dillon, Lloye/0000-0002-5118-1126	Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [AG036871, EY10804, NS079965]; Muscular Dystrophy AssociationMuscular Dystrophy Association; United Mitochondrial Disease Foundation; Emmy-Nother-Programme of the German Research Society (DFG)German Research Foundation (DFG) [WE4108/3-1]; Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG036871] Funding Source: NIH RePORTER	Our work is supported by the Public Health Service grants AG036871, EY10804, and NS079965 and by the Muscular Dystrophy Association. Dr. Wenz was supported by a fellowship from the United Mitochondrial Disease Foundation, the Emmy-Nother-Programme of the German Research Society (DFG, WE4108/3-1) as well as the Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD).	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Beal M Flint, 2007, Novartis Found Symp, V287, P183; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Deplanque D, 2003, J NEUROSCI, V23, P6264; Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307; Diaz F, 2012, HUM MOL GENET, V21, P5066, DOI 10.1093/hmg/dds350; Dillon LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044335; Dillon LM, 2012, HUM MOL GENET, V21, P2288, DOI 10.1093/hmg/dds049; DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302; DiMauro S, 2009, BBA-MOL BASIS DIS, V1792, P1159, DOI 10.1016/j.bbadis.2008.10.015; Djouadi F, 2011, CELL METAB, V14, P715, DOI 10.1016/j.cmet.2011.11.003; Dumont M, 2012, HUM MOL GENET, V21, P5091, DOI 10.1093/hmg/dds355; Feinstein Douglas L, 2003, Diabetes Technol Ther, V5, P67, DOI 10.1089/152091503763816481; Fukui H, 2007, P NATL ACAD SCI USA, V104, P14163, DOI 10.1073/pnas.0705738104; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Johri A, 2012, HUM MOL GENET, V21, P1124, DOI 10.1093/hmg/ddr541; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kreisler A, 2007, BRAIN RES, V1135, P77, DOI 10.1016/j.brainres.2006.12.011; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Mudo G, 2012, CELL MOL LIFE SCI, V69, P1153, DOI 10.1007/s00018-011-0850-z; Mysiorek C, 2009, CURR NEUROVASC RES, V6, P181, DOI 10.2174/156720209788970081; O'Rourke F, 2004, CAN MED ASSOC J, V170, P1123, DOI 10.1503/cmaj.1031185; Pallas M, 2009, CURR NEUROVASC RES, V6, P70, DOI 10.2174/156720209787466019; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Ryan MJ, 2004, HYPERTENSION, V43, P661, DOI 10.1161/01.HYP.0000116303.71408.c2; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-14; Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011; Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911; Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006; Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51	41	41	41	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	SEP	2013	13	5			SI		417	426		10.1016/j.mito.2012.12.003			10	Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Genetics & Heredity	210YF	WOS:000323870600005	23261681	Green Accepted			2022-02-06	
J	Zhang, L; Zhang, F; Weng, ZF; Brown, BN; Yan, HQ; Ma, XM; Vosler, PS; Badylak, SF; Dixon, CE; Cui, XT; Chen, J				Zhang, Ling; Zhang, Feng; Weng, Zhongfang; Brown, Bryan N.; Yan, Hongqu; Ma, Xiecheng Michelle; Vosler, Peter S.; Badylak, Stephen F.; Dixon, C. Edward; Cui, Xinyan Tracy; Chen, Jun			Effect of an Inductive Hydrogel Composed of Urinary Bladder Matrix Upon Functional Recovery Following Traumatic Brain Injury	TISSUE ENGINEERING PART A			English	Article							CONTROLLED CORTICAL IMPACT; EXTRACELLULAR-MATRIX; BIOLOGIC SCAFFOLDS; MACROPHAGE PHENOTYPE; COGNITIVE FUNCTION; PROGENITOR CELLS; TRANSPLANTATION; TISSUE; FGF-2; RECONSTRUCTION	Traumatic brain injury (TBI) is a major public health problem with no effective clinical treatment. Use of bioactive scaffold materials has been shown to be a promising strategy for tissue regeneration and repair in a number of injury models. Of these scaffold materials, urinary bladder matrix (UBM) derived from porcine bladder tissue, has demonstrated desirable properties for supporting and promoting the growth of neural cells in vitro, suggesting its potential as a scaffold for brain tissue repair in the treatment of TBI. Herein we evaluate the biocompatibility of UBM within brain tissue and the effects of UBM delivery upon functional outcome following TBI. A hydrogel form of UBM was injected into healthy rat brains for 1, 3, and 21 days to examine the tissue response to UBM. Multiple measures of tissue injury, including reactive astrocytosis, microglial activation, and neuron degeneration showed that UBM had no deleterious effects on normal brain. Following TBI, the brains were evaluated histologically and behaviorally between sham-operated controls and UBM- and vehicle-treated groups. Application of UBM reduced lesion volume and attenuated trauma-induced myelin disruption. Importantly, UBM treatment resulted in significant neurobehavioral recovery following TBI as demonstrated by improvements in vestibulomotor function; however, no differences in cognitive recovery were observed between the UBM- and vehicle-treated groups. The present study demonstrated that UBM is not only biocompatible within the brain tissue, but also can exert protective effects upon injured brain.	[Zhang, Ling; Cui, Xinyan Tracy] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA; [Zhang, Feng; Weng, Zhongfang; Vosler, Peter S.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Dept Neurol, Pittsburgh, PA 15261 USA; [Brown, Bryan N.; Badylak, Stephen F.; Cui, Xinyan Tracy] Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15261 USA; [Yan, Hongqu; Ma, Xiecheng Michelle; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Badylak, Stephen F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA		Cui, XT (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA.	xic11@pitt.edu; chenj2@upmc.edu		Vosler, Peter/0000-0002-7689-5539; Badylak, Stephen/0000-0003-3555-0689; Cui, Xinyan/0000-0002-0470-2005	Department of Defense Concept AwardUnited States Department of Defense [PT073219]; NSFNational Science Foundation (NSF) [0748001]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048] Funding Source: NIH RePORTER	We acknowledge the financial support provided by the Department of Defense Concept Award PT073219 (J.C.), NSF Career Award 0748001 (X.T.C.).	Agrawal V, 2009, J TISSUE ENG REGEN M, V3, P590, DOI 10.1002/term.200; Badylak SF, 2004, TRANSPL IMMUNOL, V12, P367, DOI 10.1016/j.trim.2003.12.016; Badylak SF, 2007, BIOMATERIALS, V28, P3587, DOI 10.1016/j.biomaterials.2007.04.043; Basu A, 2002, GLIA, V40, P109, DOI 10.1002/glia.10118; Brennan EP, 2008, J TISSUE ENG REGEN M, V2, P491, DOI 10.1002/term.123; Brown B, 2006, TISSUE ENG, V12, P519, DOI 10.1089/ten.2006.12.519; Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031; Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Crapo PM, 2012, BIOMATERIALS, V33, P3539, DOI 10.1016/j.biomaterials.2012.01.044; Daly KA, 2009, TISSUE ENG PT A, V15, P3877, DOI [10.1089/ten.tea.2009.0089, 10.1089/ten.TEA.2009.0089]; DeQuach JA, 2011, TISSUE ENG PT A, V17, P2583, DOI [10.1089/ten.tea.2010.0724, 10.1089/ten.TEA.2010.0724]; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Freytes DO, 2008, BIOMATERIALS, V29, P1630, DOI 10.1016/j.biomaterials.2007.12.014; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hodde JP, 2001, WOUNDS, V13, P195; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; Liu CY, 2003, NEUROSURGERY, V52, P1154, DOI 10.1227/01.NEU.0000057747.93237.8F; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; Marcal H, 2012, REGEN MED, V7, P159, DOI [10.2217/RME.12.6, 10.2217/rme.12.6]; Marra KG, 2008, PLAST RECONSTR SURG, V121, P1153, DOI 10.1097/01.prs.0000305517.93747.72; MENEI P, 1993, BIOMATERIALS, V14, P470, DOI 10.1016/0142-9612(93)90151-Q; Ortuzar N, 2011, J NEURAL TRANSM, V118, P135, DOI 10.1007/s00702-010-0496-2; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwartz M, 2010, BRAIN BEHAV IMMUN, V24, P1054, DOI 10.1016/j.bbi.2010.01.010; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; WOERLY S, 1990, BIOMATERIALS, V11, P97, DOI 10.1016/0142-9612(90)90123-8; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zantop T, 2006, J ORTHOP RES, V24, P1299, DOI 10.1002/jor.20071	39	41	42	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341			TISSUE ENG PT A	Tissue Eng. Part A	SEP	2013	19	17-18					1909	1918		10.1089/ten.tea.2012.0622			10	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering; Materials Science	190ES	WOS:000322322600003	23596981	Green Published			2022-02-06	
J	Asl, SZ; Khaksari, M; Khachki, AS; Shahrokhi, N; Nourizade, S				Asl, Saleh Zahedi; Khaksari, Mohammad; Khachki, Ali Siahposht; Shahrokhi, Nader; Nourizade, Shahla			Contribution of estrogen receptors alpha and beta in the brain response to traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; propyl pyrazole triol; diarylpropionitrile; estrogen receptor; neuroprotection	SEX STEROID-HORMONES; AGED FEMALE RATS; ER-ALPHA; INTRACRANIAL-PRESSURE; CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE; OVARIECTOMIZED RATS; GLOBAL-ISCHEMIA; CELL-DEATH; IN-VIVO	Object. Although there is evidence that estradiol has neuroprotective effects after traumatic brain injury (TBI) in female rats, it is unclear which estrogen receptor (ER) subtype, ER alpha or ER beta, mediates this effect. The authors therefore examined the roles of the different ERs in this effect. Here the authors used the ER alpha selective agonist propyl pyrazole trio! (PPT) and the ER beta selective agonist diarylpropionitrile (DPN) alone and in combination in female rats to investigate this question. Methods. Before the ovariectomized animals were injured using the Marmarou TBI technique, they were randomly divided into the following 9 groups: control, sham, TBI, vehicle, El (physiological dose of 17-beta estradiol), E2 (pharmacological dose of 17-beta estradiol), PPT, DPN, and PPT+DPN. Levels of blood-brain barrier (BBB) disruption (5 hours) and water content (24 hours) were evaluated after TBI. In groups receiving drugs or vehicle, treatment was administered as a single dose intraperitoneally 30 minutes after induction of TBI. Results. Results showed that brain edema or brain water content after TBI was lower (p < 0.001) in the E2, PPT, DPN, and PPT+DPN groups than it was in the vehicle group. After trauma, the Evans blue dye content or BBB permeability was significantly higher in the TBI and vehicle groups (p < 0.001) than in the E2, PPT, DPN, and PPT+DPN groups. The inhibitory effects of PPT+DPN on brain water content, neurological scores, and Evans blue dye content were the highest for all groups. Although both PPT and DPN increased neurological scores after TBI, PPT appears to be more effective in increasing neurological scores. Conclusions. Neuroprotective effects of estradiol on brain edema, BBB permeability, and neurological scores are mediated through both ER alpha and ER beta. This may suggest a therapeutic potential in the brain trauma for ER-specific agonists.	[Asl, Saleh Zahedi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, Tehran, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Physiol Res Ctr, Kerman 7614715977, Iran; [Khachki, Ali Siahposht; Shahrokhi, Nader] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman 7614715977, Iran; [Nourizade, Shahla] Urmia Univ Med Sci, Orumiyeh, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, 22 Bahman Blvd, Kerman 7614715977, Iran.	Khaksar38@yahoo.co.uk	Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019	Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Physiology Research Center of Kerman University of Medical Sciences; Endocrine Research Center of Shahid Beheshti University of Medical Sciences	The present study was financially supported by the Physiology Research Center of Kerman University of Medical Sciences and the Endocrine Research Center of Shahid Beheshti University of Medical Sciences.	Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gonzales KL, 2008, ENDOCRINOLOGY, V149, P4615, DOI 10.1210/en.2008-0511; Gorres BK, 2011, J PHYSIOL-LONDON, V589, P2041, DOI 10.1113/jphysiol.2010.199018; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewis DK, 2008, J NEUROIMMUNOL, V195, P47, DOI 10.1016/j.jneuroim.2008.01.006; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mazzucco CA, 2006, NEUROSCIENCE, V141, P1793, DOI 10.1016/j.neuroscience.2006.05.032; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ogura E, 2008, PEPTIDES, V29, P456, DOI 10.1016/j.peptides.2007.11.007; Patkar S, 2011, NEUROSCI RES, V71, P78, DOI 10.1016/j.neures.2011.05.006; Santollo J, 2009, PHYSIOL BEHAV, V97, P193, DOI 10.1016/j.physbeh.2009.02.021; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Sarvari M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-82; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sharma PK, 2006, NEUROBIOL AGING, V27, P880, DOI 10.1016/j.neurobiolaging.2005.04.003; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Smith JA, 2011, NEUROCHEM RES, V36, P1587, DOI 10.1007/s11064-010-0336-7; Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Szymczak S, 2006, HIPPOCAMPUS, V16, P453, DOI 10.1002/hipo.20172; Thammacharoen S, 2009, BRAIN RES, V1268, P88, DOI 10.1016/j.brainres.2009.02.067; Tiwari-Woodruff S, 2009, J NEUROL SCI, V286, P81, DOI 10.1016/j.jns.2009.04.023; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Walf AA, 2008, NEUROBIOL LEARN MEM, V89, P513, DOI 10.1016/j.nlm.2008.01.008; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Xia Y, 2009, NEUROSCIENCE, V162, P292, DOI 10.1016/j.neuroscience.2009.04.068; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	59	41	41	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					353	361		10.3171/2013.4.JNS121636			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400015	23724987				2022-02-06	
J	DeMuro, JP; Simmons, S; Jax, J; Gianelli, SM				DeMuro, Jonas P.; Simmons, Susan; Jax, Judy; Gianelli, Scott M.			Application of the shock index to the prediction of need for hemostasis intervention	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							MASSIVE TRANSFUSION; HEART-RATE; TRAUMA; UTILITY; RESUSCITATION; PATIENT	Introduction: The traditional method to identify hemorrhage after trauma has been vital signs-based. More recent attempts have used mathematical prediction models, but these are limited by the need for additional data including a Focused Assessment with Sonography for Trauma exam, or an arterial blood gas. Shock Index (SI) is the mathematical relationship of the heart rate divided by the systolic blood pressure; the cutoff of >0.9 has been associated with bleeding. Methods: A total of 4292 trauma patients were identified in database over an 11 year period. Inclusion criteria included age >16 years and initial presentation to our trauma center. Patients were excluded for incomplete data, traumatic brain injury, or transfer leaving 4277 patients for analysis. Patients were further subdivided by age, and by mechanism of injury (blunt versus penetrating). Finally, patients were divided into bleeding versus nonbleeding, and the SI formula was applied to their initial hospital vital signs. Results: Across our dataset, using the standard SI cutoff of >0.9 as the threshold for bleeding, the sensitivity is 54.5%, with a specificity of 93.6%. In the geriatric subanalysis, there was no difference for sensitivity between the age groups, but SI is more specific in the older patients. There was no difference in sensitivity using SI in blunt versus penetrating. Lowering the SI to >= 0.8 increases the sensitivity to 76.1%, with a specificity of 87.4%. Conclusion: SI, at a lowered threshold of >= 0.8, can be used to identify trauma patients that will require intervention for hemostasis. (C) 2013 Elsevier Inc. All rights reserved.	[DeMuro, Jonas P.; Simmons, Susan; Jax, Judy] Winthrop Univ Hosp, Div Trauma & Crit Care, Dept Surg, Mineola, NY 11501 USA; [Gianelli, Scott M.] SUNY Stony Brook, Sch Marine & Atmospher Sci, Suffolk, NY USA		DeMuro, JP (corresponding author), Winthrop Univ Hosp, Div Trauma & Crit Care, Dept Surg, Mineola, NY 11501 USA.	jdemuro@winthrop.org					Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Chico-Fernandez M, 2011, MED INTENSIVA, V35, P546, DOI 10.1016/j.medin.2011.06.010; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Gaarder C, 2009, J TRAUMA, V67, P323, DOI 10.1097/TA.0b013e3181a4ed27; Heffernan DS, 2010, J TRAUMA, V69, P813, DOI 10.1097/TA.0b013e3181f41af8; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; Pasquier P, 2012, AM J SURG, V204, P812, DOI 10.1016/j.amjsurg.2011.10.022; Rady MY, 1996, AM J EMERG MED, V14, P218, DOI 10.1016/S0735-6757(96)90136-9; RODEHEFFER RJ, 1984, CIRCULATION, V69, P203, DOI 10.1161/01.CIR.69.2.203; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Yussof Shah Jahan Mohd, 2012, Med J Malaysia, V67, P406; Zarzaur BL, 2010, J TRAUMA, V68, P1134, DOI 10.1097/TA.0b013e3181d87488	16	41	43	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	AUG	2013	31	8					1260	1263		10.1016/j.ajem.2013.05.027			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	201SN	WOS:000323163400021	23806728				2022-02-06	
J	Borich, M; Makan, N; Boyd, L; Virji-Babul, N				Borich, Michael; Makan, Nadia; Boyd, Lara; Virji-Babul, Naznin			Combining Whole-Brain Voxel-Wise Analysis with In Vivo Tractography of Diffusion Behavior after Sports-Related Concussion in Adolescents: A Preliminary Report	JOURNAL OF NEUROTRAUMA			English	Article						adolescents; concussion; diffusion tensor imaging, mild traumatic brain injury; tract-based spatial statistics, tractography	WHITE-MATTER INTEGRITY; INJURY; ANISOTROPY; RECOVERY; MRI; AGE	We have previously shown that sports-related concussion in adolescents is associated with changes in whole-brain properties of white-matter pathways. Here, we assess local changes within these pathways. Twelve adolescents with a clinical diagnosis of subacute concussion and 10 healthy adolescents matched for age, gender, and physical activity completed magnetic resonance imaging scanning. Voxel-wise tract-based spatial statistics and tractography were performed to assess local changes in diffusion-based measures of microstructural properties of white-matter pathways (fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity) between the two groups. Fractional anisotropy values were higher for the concussed group in multiple cluster regions using tract-based spatial statistics, primarily in frontal white-matter regions, including the anterior corona radiata bilaterally. Using these regions of altered diffusion characteristics to seed fiber tractography, significantly reduced axial diffusivity in tracts passing through these areas were detected in the concussed group (p = 0.04). A trend toward reduced mean and radial diffusivity in the concussed group was also observed within the same reconstructed tracts. Diffusion behavior within these tracts was significantly correlated with an assessment of concussion status (Sports Concussion Assessment Tool 2). Fractional anisotropy within the reconstructed tracts was not significantly different between the two groups. These results suggest that subacute concussion in adolescents is associated with altered diffusion properties within regional white-matter tissue and along reconstructed fiber pathways. Combining voxel-wise analysis with fiber tractography provides an alternative objective approach to evaluate and identify subtle changes in white-matter fiber integrity after concussion.	[Borich, Michael; Makan, Nadia; Boyd, Lara; Virji-Babul, Naznin] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada		Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Borich, Michael Robert/E-1683-2011	Borich, Michael Robert/0000-0002-0469-6282; Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund from the University of British Columbia; Brain Research Center at the University of British Columbia	This research was supported by the Martha Piper Research Fund from the University of British Columbia, and the Brain Research Center at the University of British Columbia. The authors thank BC Hockey for their support and all the participants, trainers, and coaches who took part in this study. The authors also thank Dr. Alex Rauscher for his assistance with the MRI protocol.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leemans A, 2009, P 17 ANN M INT SOC M; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K., 2011, MRI ATLAS HUMAN WHIT, V2nd Edn.; Reetz K, 2012, NEUROIMAGE, V63, P517, DOI 10.1016/j.neuroimage.2012.07.009; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3	32	41	41	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1243	1249		10.1089/neu.2012.2818			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100004	23406264				2022-02-06	
J	Shirazi-Zand, Z; Ahmad-Molaei, L; Motamedi, F; Naderi, N				Shirazi-Zand, Zahra; Ahmad-Molaei, Leila; Motamedi, Fereshteh; Naderi, Nima			The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice	EPILEPSY & BEHAVIOR			English	Article						Cannabidiol; Paxilline; Pentylenetetrazole; Maximal electroshock; Seizure	CA2+-ACTIVATED K+ CHANNELS; CLOSED-HEAD INJURY; ACTION-POTENTIAL REPOLARIZATION; RAT-BRAIN; AFTER-HYPERPOLARIZATION; SPIKE REPOLARIZATION; CULTURED HIPPOCAMPAL; DRUG-INTERACTIONS; CALCIUM-CHANNELS; CANNABINOIDS	Cannabidiol is a nonpsychoactive member of phytocannabinoids that produces various pharmacological effects that are not mediated through putative CB1/CB2 cannabinoid receptors and their related effectors. In this study, we examined the effect of the i.c.v. administration of potassium BK channel blocker paxilline alone and in combination with cannabidiol in protection against pentylenetetrazol (PTZ)-and maximal electroshock (MES)-induced seizure in mice. In the PTZ-induced seizure model, i.c.v. administration of cannabidiol caused a significant increase in seizure threshold compared with the control group. Moreover, while i.c.v. administration of various doses of paxilline did not produce significant change in the VIZ-induced seizure threshold in mice, coadministration of cannabidiol and paxilline attenuated the antiseizure effect of cannabidiol in VIZ-induced tonic seizures. In the MES model of seizure, both cannabidiol and paxilline per se produced significant increase in percent protection against electroshock-induced seizure. However, coadministration of cannabidiol and paxilline did not produce significant interaction in their antiseizure effect in the MES test. The results of the present study showed a protective effect of cannabidiol in both PTZ and MES models of seizure. These results suggested a BK channel-mediated antiseizure action of cannabidiol in PTZ model of seizure. However, such an interaction might not exist in MES-induced convulsion. (C) 2013 Elsevier Inc. All rights reserved.	[Shirazi-Zand, Zahra; Ahmad-Molaei, Leila; Motamedi, Fereshteh; Naderi, Nima] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran 1996835113, Iran; [Naderi, Nima] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Tehran 1996835113, Iran		Naderi, N (corresponding author), Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, 2660 Vali E Asr Ave,POB 14155-6153, Tehran 1996835113, Iran.	naderi@sbmu.ac.ir	Naderi, Nima/U-5410-2018	Naderi, Nima/0000-0003-4591-8918; Motamedi, Fereshteh/0000-0003-4030-8627	Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Iran	This work was supported by a grant from the Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Iran.	ADAMS PR, 1982, NATURE, V296, P746, DOI 10.1038/296746a0; ALGER BE, 1988, J PHYSIOL-LONDON, V399, P191; BENOWITZ NL, 1980, CLIN PHARMACOL THER, V28, P115, DOI 10.1038/clpt.1980.139; Bhattacharyya S, 2009, ARCH GEN PSYCHIAT, V66, P442, DOI 10.1001/archgenpsychiatry.2009.17; BLATZ AL, 1984, J GEN PHYSIOL, V84, P1, DOI 10.1085/jgp.84.1.1; Brenner R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573; Brenowitz SD, 2003, J NEUROSCI, V23, P6373; Brew HM, 2007, J NEUROPHYSIOL, V98, P1501, DOI 10.1152/jn.00640.2006; CARLINI EA, 1973, J PHARM PHARMACOL, V25, P664, DOI 10.1111/j.2042-7158.1973.tb10660.x; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Castaldo P, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0003.2002; CAULFIELD MP, 1992, BRIT J PHARMACOL, V106, P231, DOI 10.1111/j.1476-5381.1992.tb14321.x; CHESHER GB, 1974, PSYCHOPHARMACOLOGIA, V37, P255, DOI 10.1007/BF00421539; CONSROE P, 1981, J CLIN PHARMACOL, V21, pS428, DOI 10.1002/j.1552-4604.1981.tb02623.x; CONSROE P, 1982, EUR J PHARMACOL, V83, P293, DOI 10.1016/0014-2999(82)90264-3; CONSROE PF, 1975, JAMA-J AM MED ASSOC, V234, P306, DOI 10.1001/jama.234.3.306; CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI 10.1159/000137430; Drysdale AJ, 2006, NEUROPHARMACOLOGY, V50, P621, DOI 10.1016/j.neuropharm.2005.11.008; Drysdale AJ, 2003, CURR MED CHEM, V10, P2719, DOI 10.2174/0929867033456387; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; ELLISON JM, 1990, J CLIN PSYCHIAT, V51, P439; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Esposito G, 2006, NEUROSCI LETT, V399, P91, DOI 10.1016/j.neulet.2006.01.047; Faber ESL, 2003, J PHYSIOL-LONDON, V552, P483, DOI 10.1113/jphysiol.2003.050120; FRAGOSOVELOZ J, 1990, EUR J PHARMACOL, V178, P275, DOI 10.1016/0014-2999(90)90106-G; GENNINGS C, 1990, J PHARMACOL EXP THER, V252, P208; Gordon E, 2001, EPILEPSIA, V42, P1266, DOI 10.1046/j.1528-1157.2001.19301.x; Gu N, 2007, J PHYSIOL-LONDON, V580, P859, DOI 10.1113/jphysiol.2006.126367; GUIMARAES FS, 1994, GEN PHARMACOL, V25, P161, DOI 10.1016/0306-3623(94)90027-2; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356, DOI 10.1152/jn.2000.84.5.2356; Hayase T, 2001, Nihon Arukoru Yakubutsu Igakkai Zasshi, V36, P596; HOLLISTER LE, 1973, EXPERIENTIA, V29, P825, DOI 10.1007/BF01946311; Holmes GL, 2008, PEDIATR NEUROL, V38, P151, DOI 10.1016/j.pediatrneurol.2007.09.008; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Jones NA, 2010, J PHARMACOL EXP THER, V332, P569, DOI 10.1124/jpet.109.159145; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; KARLER R, 1981, J CLIN PHARMACOL, V21, pS437, DOI 10.1002/j.1552-4604.1981.tb02624.x; KARLER R, 1989, NEUROPHARMACOLOGY, V28, P775, DOI 10.1016/0028-3908(89)90166-4; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Lastres-Becker I, 2005, NEUROBIOL DIS, V19, P96, DOI 10.1016/j.nbd.2004.11.009; Leweke FM, 2000, PHARMACOL BIOCHEM BE, V66, P175, DOI 10.1016/S0091-3057(00)00201-X; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K; Lutz B, 2004, BIOCHEM PHARMACOL, V68, P1691, DOI 10.1016/j.bcp.2004.07.007; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MECHOULAM R, 1963, TETRAHEDRON, V19, P2073, DOI 10.1016/0040-4020(63)85022-X; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Netzeband JG, 1999, J NEUROSCI, V19, P8765, DOI 10.1523/JNEUROSCI.19-20-08765.1999; Paxinos G., 2008, MOUSE BRAIN STEREOTA; PEREZREY.M, 1973, EXPERIENTIA, V29, P1009; Pertwee RG, 2004, PHARM THERAPEUTIC PO; Raffaelli G, 2004, J PHYSIOL-LONDON, V557, P147, DOI 10.1113/jphysiol.2004.062661; Rho JM, 1999, DEV NEUROSCI-BASEL, V21, P320, DOI 10.1159/000017381; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Ryan D, 2009, J NEUROSCI, V29, P2053, DOI 10.1523/JNEUROSCI.4212-08.2009; SAH PAJ, 1992, J NEUROPHYSIOL, V68, P1834, DOI 10.1152/jn.1992.68.5.1834; Sanchez M, 1996, NEUROPHARMACOLOGY, V35, P963, DOI 10.1016/0028-3908(96)00137-2; Sartorius T, 2006, ABSTR SOC NEUROSCI, pD23; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; Scuderi C, 2009, PHYTOTHER RES, V23, P597, DOI 10.1002/ptr.2625; SEGAL M, 1984, J NEUROSCI, V4, P604; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Sheehan JJ, 2009, EPILEPSIA, V50, P711, DOI 10.1111/j.1528-1167.2008.01888.x; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shruti S, 2008, NEUROBIOL DIS, V30, P323, DOI 10.1016/j.nbd.2008.02.002; Sim-Selley LJ, 2002, J PHARMACOL EXP THER, V303, P36, DOI 10.1124/jpet.102.035618; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; STORM JF, 1987, BRAIN RES, V435, P387, DOI 10.1016/0006-8993(87)91631-3; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TURKANIS SA, 1977, PSYCHOPHARMACOLOGY, V52, P207, DOI 10.1007/BF00439112; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; Usami N, 1998, CHEM PHARM BULL, V46, P1462; van der Stelt M, 2005, EMBO J, V24, P3026, DOI 10.1038/sj.emboj.7600784; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallace MJ, 2001, EUR J PHARMACOL, V428, P51, DOI 10.1016/S0014-2999(01)01243-2; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Womack MD, 2002, EUR J NEUROSCI, V16, P1214, DOI 10.1046/j.1460-9568.2002.02171.x	84	41	41	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	JUL	2013	28	1					1	7		10.1016/j.yebeh.2013.03.009			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	164QB	WOS:000320423500001	23644464				2022-02-06	
J	Carter, L; Russell, PN; Helton, WS				Carter, Leonie; Russell, Paul N.; Helton, William S.			Target predictability, sustained attention, and response inhibition	BRAIN AND COGNITION			English	Article						Near-infrared spectroscopy; Executive control; Response inhibition; Sustained attention; Vigilance	TRAUMATIC BRAIN-INJURY; SIGNAL-REGULARITY; TASK; VIGILANCE; PERFORMANCE; SENSITIVITY; SALIENCE; FAILURES; STIMULI; THOUGHT	We examined whether the sustained attention to response task is a better measure of response inhibition or sustained attention. Participants performed a number detection task for 37.3 min using either a Sustained Attention to Response Task (SARI; high Go low No-Go) or a more traditionally formatted vigilance task (TFT; high No-Go low Go) response format. Participants performed these tasks using either a regular fixed ordered stimuli set (1-9, sequentially repeated), in which the target number appeared predictably, or a random order (1-9, random presentation), in which the target number appeared at random. We utilized functional near infrared spectroscopy (fNIRS) to measure cerebral oxygenation levels in the right and left frontal areas. We also used post-task participant reports of arousal, and conscious thoughts occurring during the tasks. Performance differed for the both response format and target predictability. Greater right than left frontal hemisphere activation occurred in the TFT than the SART with time-on-task. In addition, the SARI response format resulted in elevated self-reports of task-related thoughts than the TFT response format. The results suggest the SARI, random or fixed ordered, places high response inhibition, not necessarily sustained attention, demands on participants. Elevated levels of task-related thoughts during the SART format condition in comparison to the TFT condition does not appear to be in accord with the claim that the SART induces mindlessness. (C) 2013 Elsevier Inc. All rights reserved.	[Carter, Leonie; Russell, Paul N.; Helton, William S.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand		Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	Deak_Helton@canterbury.ac.nz					Aaslid R., 1986, TRANSCRANIAL DOPPLER, P39; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bengson JJ, 2012, NEUROIMAGE, V59, P1534, DOI 10.1016/j.neuroimage.2011.08.034; Bonnefond A, 2010, BEHAV BRAIN RES, V211, P185, DOI 10.1016/j.bbr.2010.03.030; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Cheyne JA, 2009, COGNITION, V111, P98, DOI 10.1016/j.cognition.2008.12.009; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Davies DR., 1982, PSYCHOL VIGILANCE; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Hart S.G., 2002, ERGONOMICS DESIGN, V10, DOI [https://doi.org/10.1177/106480460201000103, DOI 10.1177/106480460201000103]; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2007, J CLIN EXP NEUROPSYC, V29, P545, DOI 10.1080/13803390600814757; Helton WS, 2012, HUM FACTORS, V54, P189, DOI 10.1177/0018720811430503; Helton WS, 2011, CONSCIOUS COGN, V20, P1732, DOI 10.1016/j.concog.2011.02.011; Helton WS, 2011, HUM FACTORS, V53, P132, DOI 10.1177/0018720811401385; Helton WS, 2011, EXP BRAIN RES, V209, P401, DOI 10.1007/s00221-011-2563-9; Helton WS, 2011, PSYCHOL RES-PSYCH FO, V75, P384, DOI 10.1007/s00426-010-0316-1; Helton WS, 2010, BRAIN COGNITION, V74, P75, DOI 10.1016/j.bandc.2010.06.008; Helton WS, 2010, NEUROPSYCHOLOGIA, V48, P1683, DOI 10.1016/j.neuropsychologia.2010.02.014; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Helton WS, 1999, CURR PSYCHOL, V18, P311, DOI 10.1007/s12144-999-1006-2; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Matthews G., 1999, PERS PSYCHOL EUR, V7, P335, DOI DOI 10.1177/154193120404801107; Matthews G, 2002, EMOTION, V2, P315, DOI 10.1037//1528-3542.2.4.315; Maxwell SE., 1990, DESIGNING EXPT ANAL; McVay JC, 2009, J EXP PSYCHOL LEARN, V35, P196, DOI 10.1037/a0014104; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connor C, 2011, NEUROPSYCHOLOGY, V25, P535, DOI 10.1037/a0022767; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ossowski U, 2011, CONSCIOUS COGN, V20, P1649, DOI 10.1016/j.concog.2011.08.015; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Stevenson H, 2011, BRAIN COGNITION, V77, P215, DOI 10.1016/j.bandc.2011.08.007; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm J. S., 1984, SUSTAINED ATTENTION; WARM JS, 1992, B PSYCHONOMIC SOC, V30, P297; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	50	41	42	1	39	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	JUN	2013	82	1					35	42		10.1016/j.bandc.2013.02.002			8	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	130AH	WOS:000317884600005	23501702				2022-02-06	
J	Gatson, JW; Warren, V; Abdelfattah, K; Wolf, S; Hynan, LS; Moore, C; Diaz-Arrastia, R; Minei, JP; Madden, C; Wigginton, JG				Gatson, Joshua Wayne; Warren, Victoria; Abdelfattah, Kareem; Wolf, Steven; Hynan, Linda S.; Moore, Carol; Diaz-Arrastia, Ramon; Minei, Joseph P.; Madden, Christopher; Wigginton, Jane G.			Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						amyloid oligomers; amyloid-beta 42; biomarkers cerebrospinal fluid; traumatic brain injury	PRECURSOR PROTEIN IMMUNOREACTIVITY; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; HUMANS; DEPOSITION; APOPTOSIS; SCALE; RAT; NEURODEGENERATION	Object. Traumatic brain injury (TBI) is known to be a risk factor for Alzheimer-like dementia. In previous studies, an increase in P-amyloid (A beta) monomers, such as beta-amyloid 42 (A beta 42), in the CSF of patients with TBI has been shown to correlate with a decrease in amyloid plaques in the brain and improved neurological outcomes. In this study, the authors hypothesized that the levels of toxic high-molecular-weight beta-amyloid oligomers are increased in the brain and are detectable within the CSF of TBI patients with poor neurological outcomes. Methods. Samples of CSF were collected from 18 patients with severe TBI (Glasgow Coma Scale Scores 3-8) and a ventriculostomy. In all cases the CSF was collected within 72 hours of injury. The CSF levels of neuron-specific enolase (NSE) and A beta 42 were measured using enzyme-linked immunosorbent assay. The levels of high-molecular-weight p-amyloid oligomers were measured using Western blot analysis. Results. Patients with good outcomes showed an increase in the levels of CSF A beta 42 (p = 0.003). Those with bad outcomes exhibited an increase in CSF levels of p-amyloid oligomers (p = 0.009) and NSE (p = 0.001). In addition, the CSF oligomer levels correlated with the scores on the extended Glasgow Outcome Scale (r = 0.89, p = 0.0001), disability rating scale scores (r = 0.77, p = 0.005), CSF A(342 levels (r = 0.42, p = 0.12), and CSF NSE levels (r = 0.70, p = 0.004). Additionally, the receiver operating characteristic curve yielded an area under the curve for P-amyloid oligomers of 0.8750 +/- 0.09. Conclusions. Detection of P-amyloid oligomers may someday become a useful clinical tool for determining injury severity and neurological outcomes in patients with TBI.	[Gatson, Joshua Wayne; Warren, Victoria; Abdelfattah, Kareem; Wolf, Steven; Hynan, Linda S.; Minei, Joseph P.; Madden, Christopher; Wigginton, Jane G.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Moore, Carol; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA		Gatson, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsw.edu	Hynan, Linda S/P-6473-2016	Wigginton, Jane/0000-0002-8561-3492; Hynan, Linda/0000-0002-4642-7769; Wolf, Steven/0000-0003-2972-3440; Diaz-Arrastia, Ramon/0000-0001-6051-3594			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chen YN, 2006, BIOCHEM BIOPH RES CO, V341, P1, DOI 10.1016/j.bbrc.2005.12.150; Cizas P, 2010, ARCH BIOCHEM BIOPHYS, V496, P84, DOI 10.1016/j.abb.2010.02.001; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Ferretti MT, 2012, NEUROBIOL AGING, V33, P1329, DOI 10.1016/j.neurobiolaging.2011.01.007; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klaver AC, 2011, J NEUROSCI METH, V195, P249, DOI 10.1016/j.jneumeth.2010.12.001; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Liao CW, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-84; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomasevic G, 2010, J NEUROSCI RES, V88, P3414, DOI 10.1002/jnr.22491; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan Q, 2003, J NEUROSCI, V23, P7504	49	41	41	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1336	1342		10.3171/2013.2.JNS121771			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400034	23540266				2022-02-06	
J	Wolf, H; Frantal, S; Pajenda, GS; Salameh, O; Widhalm, H; Hajdu, S; Sarahrudi, K				Wolf, Harald; Frantal, Sophie; Pajenda, Gholam S.; Salameh, Olivia; Widhalm, Harald; Hajdu, Stefan; Sarahrudi, Kambiz			Predictive value of neuromarkers supported by a set of clinical criteria in patients with mild traumatic brain injury: S100B protein and neuron-specific enolase on trial	JOURNAL OF NEUROSURGERY			English	Article						computed tomography scanning; adult brain injury; assessment tool; guideline; neuromarker; traumatic brain injury	MINOR HEAD-INJURY; FIBRILLARY ACIDIC PROTEIN; COMPUTED-TOMOGRAPHY; INTRACRANIAL LESIONS; SCREENING TOOL; SERUM-LEVELS; S-100B; MARKERS; DAMAGE; ANTICOAGULATION	Object. The role of the neuromarkers S100B protein and neuron-specific enolase (NSE) in minor head injury is well established. Moreover, there are sensitive decision rules available in the literature to identify clinically important brain lesions. However, it is not clear if using the biomarkers has an influence on the predictability of the decision rule. The purpose of this study was to determine if a set of preclinical and clinical parameters combined with 2 neuromarker levels could serve as reliable guidance for accurate diagnosis. Methods. Prospective evaluation of a cohort of head trauma patients with Glasgow Coma Scale scores of 13-15 was performed at an academic, Level I trauma center. Blood samples and cranial CT studies were obtained for all patients within 3 hours after injury. The hypothesis of the study was whether the combination of an increase of S100B and NSE levels in serum and other defined risk factors are associated with a pathological finding on CT. A forward stepwise logistic regression model was used. Results. The study included 107 head trauma patients with a mean age of 59 +/- 23 years. Twenty-five patients (23.4%) had traumatic lesions on CT. Eight patients underwent craniotomy. The analysis provided a model with good overall accuracy for discriminating cases with clinically important brain injury, including the 6 variables of S100B, NSE, nausea, amnesia, vomiting, and loss of consciousness. The area under the curve (AUC) was 0.88 (0.83-0.93). The receiver operating characteristic curve plots detecting clinically important brain injury for the single variables of S100B and NSE showed an AUC of 0.63 and 0.64, respectively. Conclusions. The integration of the neuromarker panel as part of a diagnostic rule including the high-risk factors of nausea, vomiting, amnesia, and loss of consciousness is safe and reliable in determining a diagnosis, pending the availability of more brain-specific neuromarkers.	[Wolf, Harald; Pajenda, Gholam S.; Salameh, Olivia; Widhalm, Harald; Hajdu, Stefan; Sarahrudi, Kambiz] Med Univ Vienna, Dept Trauma Surg, AKH Wien, A-1090 Vienna, Austria; [Frantal, Sophie] Med Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria		Wolf, H (corresponding author), Med Univ Vienna, Dept Trauma Surg, AKH Wien, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Harald.Wolf@meduniwien.ac.at	Widhalm, Harald/ABE-8863-2020	Widhalm, Harald/0000-0001-9739-6176; Aschacher, Olivia/0000-0002-2321-156X			Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Karni A, 2001, AM SURGEON, V67, P1098; Lange RT, 2010, J TRAUMA, V68, P1065, DOI 10.1097/TA.0b013e3181bb9890; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Munoz-Sanchez MA, 2009, BRAIN INJURY, V23, P39, DOI 10.1080/02699050802590346; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Nessen SC, 2008, WAR SURG AFGHANISTAN, P431; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vogel T, 2008, UNFALLCHIRURG, V111, P898, DOI 10.1007/s00113-008-1502-0; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	33	41	45	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1298	1303		10.3171/2013.1.JNS121181			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400028	23451906				2022-02-06	
J	Ekmark-Lewen, S; Flygt, J; Kiwanuka, O; Meyerson, BJ; Lewen, A; Hillered, L; Marklund, N				Ekmark-Lewen, Sara; Flygt, Johanna; Kiwanuka, Olivia; Meyerson, Bengt J.; Lewen, Anders; Hillered, Lars; Marklund, Niklas			Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes	JOURNAL OF NEUROINFLAMMATION			English	Article						Astrocytes; beta-amyloid precursor protein (beta-APP); Central fluid percussion injury; Diffuse traumatic axonal injury; Inflammatory response; Functional outcome; Mouse	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; EXPERIMENTAL BRAIN-INJURY; CONCENTRIC SQUARE FIELD; VASCULAR-PERMEABILITY; CONTUSION TRAUMA; UP-REGULATION; WHITE-MATTER; HEAD-INJURY	Background: Diffuse traumatic axonal injury (TAI), a common consequence of traumatic brain injury, is associated with high morbidity and mortality. Inflammatory processes may play an important role in the pathophysiology of TAI. In the central fluid percussion injury (cFPI) TAI model in mice, the neuroinflammatory and astroglial response and behavioral changes are unknown. Methods: Twenty cFPI injured and nine sham-injured mice were used, and the neuroinflammatory and astroglial response was evaluated by immunohistochemistry at 1, 3 and 7 days post-injury. The multivariate concentric square field test (MCSF) was used to compare complex behavioral changes in mice subjected to cFPI (n = 16) or sham injury (n = 10). Data was analyzed using non-parametric statistics and principal component analysis (MCSF data). Results: At all post-injury time points, beta-amyloid precursor protein (beta-APP) immunoreactivity revealed widespread bilateral axonal injury and IgG immunostaining showed increased blood-brain barrier permeability. Using vimentin and glial fibrillary acidic protein (GFAP) immunohistochemistry, glial cell reactivity was observed in cortical regions and important white matter tracts peaking at three days post-injury. Only vimentin was increased post-injury in the internal capsule and only GFAP in the thalamus. Compared to sham-injured controls, an increased number of activated microglia (MAC-2), infiltrating neutrophils (GR-1) and T-cells (CD3) appearing one day after TAI (P<0.05 for all cell types) was observed in subcortical white matter. In the MCSF, the behavioral patterns including general activity and exploratory behavior differed between cFPI mice and sham-injured controls. Conclusions: Traumatic axonal injury TAI resulted in marked bilateral astroglial and neuroinflammatory responses and complex behavioral changes. The cFPI model in mice appears suitable for the study of injury mechanisms, including neuroinflammation, and the development of treatments targeting TAI.	[Ekmark-Lewen, Sara; Flygt, Johanna; Kiwanuka, Olivia; Lewen, Anders; Hillered, Lars; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden; [Meyerson, Bengt J.] Uppsala Univ, Dept Neurosci, Biomed Ctr, Div Pharmacol, S-71523 Uppsala, Sweden		Marklund, N (corresponding author), Uppsala Univ, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626; Hillered, Lars/0000-0002-2808-9292; Kiwanuka, Olivia/0000-0003-3562-5513	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Uppsala University Hospital; Selander Foundation; Ahlen Foundation	This work was funded by grants from Swedish Research Council, The Swedish Brain Foundation, Uppsala University Hospital, The Selander Foundation and The Ahlen Foundation.The authors would like to acknowledge Dr John T. Povlishock and Dr John Greer for hands-on (to NM) technical information about the cFPI model.	AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Bignami A., 1991, DISCUSS NEUROSCI, V111, P9; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ekmark-Lewen S, 2010, J NEUROTRAUM, V27, P1643, DOI 10.1089/neu.2009.0953; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Eriksson L, 2006, MOL DIVERS, V10, P187, DOI 10.1007/s11030-006-9026-4; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Johansson E., 2006, MULTI MEGAVARIATE 1; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lindbom L, 2003, CHEM IMMUNOL, V83, P146; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maruichi K, 2009, NEUROPATHOLOGY, V29, P422, DOI 10.1111/j.1440-1789.2008.00995.x; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meyerson BJ, 2006, BEHAV BRAIN RES, V168, P100, DOI 10.1016/j.bbr.2005.10.020; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.3.CO;2-5; Pekny M, 1999, NEUROCHEM RES, V24, P1357, DOI 10.1023/A:1022572304626; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pittella JEH, 2004, ARQ NEURO-PSIQUIAT, V62, P406, DOI 10.1590/S0004-282X2004000300007; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Roman E, 2006, HORM BEHAV, V50, P736, DOI 10.1016/j.yhbeh.2006.06.016; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	90	41	47	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 4	2013	10								44	10.1186/1742-2094-10-44			19	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	143FQ	WOS:000318852600001	23557178	gold, Green Published			2022-02-06	
J	Guo, H; Zhao, Z; Yang, Q; Wang, M; Bell, RD; Wang, S; Chow, N; Davis, TP; Griffin, JH; Goldman, SA; Zlokovic, BV				Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Bell, Robert D.; Wang, Su; Chow, Nienwen; Davis, Thomas P.; Griffin, John H.; Goldman, Steven A.; Zlokovic, Berislav V.			An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR(1)-Akt Pathway	JOURNAL OF NEUROSCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; STEM-CELLS; BRAIN; ANTICOAGULANT; DIFFERENTIATION; PROLIFERATION; NEUROGENESIS; MIGRATION; MODULATION; RECEPTOR-1	Activated protein C (APC) is a protease with anticoagulant and cell-signaling activities. In the CNS, APC and its analogs with reduced anticoagulant activity but preserved cell signaling activities, such as 3K3A-APC, exert neuroprotective, vasculoprotective, and anti-inflammatory effects. Murine APC promotes subependymal neurogenesis in rodents in vivo after ischemic and traumatic brain injury. Whether human APC can influence neuronal production from resident progenitor cells in humans is unknown. Here we show that 3K3A-APC, but not S360A-APC (an enzymatically inactive analog of APC), stimulates neuronal mitogenesis and differentiation from fetal human neural stem and progenitor cells (NPCs). The effects of 3K3A-APC on proliferation and differentiation were comparable to those obtained with fibroblast growth factor and brain-derived growth factor, respectively. Its promoting effect on neuronal differentiation was accompanied by inhibition of astroglial differentiation. In addition, 3K3A-APC exerted modest anti-apoptotic effects during neuronal production. These effects appeared to be mediated through specific protease activated receptors (PARs) and sphingosine-1-phosphate receptors (S1PRs), in that siRNA-mediated inhibition of PARs 1-4 and S1PRs 1-5 revealed that PAR1, PAR3, and S1PR(1) are required for the neurogenic effects of 3K3A-APC. 3K3A-APC activated Akt, a downstream target of S1PR(1), which was inhibited by S1PR(1), PAR1, and PAR3 silencing. Adenoviral transduction of NPCs with a kinase-defective Akt mutant abolished the effects of 3K3A-APC on NPCs, confirming a key role of Akt activation in 3K3A-APC-mediated neurogenesis. Therefore, APC and its pharmacological analogs, by influencing PAR and S1PR signals in resident neural progenitor cells, may be potent modulators of both development and repair in the human CNS.	[Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Zlokovic, Berislav V.] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Ctr Neurodegenerat & Regenerat, Los Angeles, CA 90089 USA; [Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Zlokovic, Berislav V.] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90089 USA; [Bell, Robert D.] Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Rochester, NY 14642 USA; [Bell, Robert D.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Wang, Su; Goldman, Steven A.] Univ Rochester, Med Ctr, Dept Neurol, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Chow, Nienwen] ZZ Biotech LLC, Rochester, NY 14642 USA; [Davis, Thomas P.] Univ Arizona, Dept Med Pharmacol, Coll Med, Blood Brain Barrier Res Lab, Tucson, AZ 85724 USA; [Griffin, John H.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA		Zlokovic, BV (corresponding author), Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Room 101,1501 San Pablo St, Los Angeles, CA 90089 USA.	zlokovic@usc.edu	davis, thomas p/F-3244-2015; zhao, zhen/A-2080-2012	davis, thomas p/0000-0001-8465-4973; zhao, zhen/0000-0001-8967-5570; Goldman, Steven/0000-0002-5498-4303; Griffin, John/0000-0002-4302-2547	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL52246, R01NS75345, R01NS39559]; New York Stem Cell Research Board; National Cancer Institute Cancer Center Shared Grant [5P30 CA014089]; University of Southern California Provost Funds; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014089] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063290, R01HL052246, R37HL052246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075345, R01NS039559] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grant #HL63290 to B.Z., Grant #HL52246 to J.H.G., and Grants #R01NS75345 to R01NS39559 to S. G.), as well as by the New York Stem Cell Research Board. We thank Dr. Robert Freeman(University of Rochester Medical Center, Rochester, NY) for providing the Ad. AktK179A construct, Dr. Joe G.N. Garcia (University of Chicago, Chicago, IL) for providing the Ad. EDG1 construct, and Dr. Abhay Sagare and Theresa Barrett for technical help and discussion. The flow cytometry study and cell cycle analysis were performed at the University of Southern California Broad California Institute of Restorative Medicine Center Flow Cytometry Core Facility, which is supported by the National Cancer Institute Cancer Center Shared Grant 5P30 CA014089 and the University of Southern California Provost Funds.	Breunig JJ, 2007, CELL STEM CELL, V1, P612, DOI 10.1016/j.stem.2007.11.008; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Deane R, 2009, J CEREBR BLOOD F MET, V29, P25, DOI 10.1038/jcbfm.2008.117; Durbec Pascale, 2008, V438, P213, DOI 10.1007/978-1-59745-133-8_18; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Goldman SA, 1997, J NEUROBIOL, V32, P554, DOI 10.1002/(SICI)1097-4695(19970605)32:6<554::AID-NEU2>3.0.CO;2-Z; Goldman SA, 2001, HIGH YIELD SELECTION; Griffin JH, 2012, INT J HEMATOL, V95, P333, DOI 10.1007/s12185-012-1059-0; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Guo HA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-13; Guo H, 2009, J NEUROCHEM, V109, P116, DOI 10.1111/j.1471-4159.2009.05921.x; Guo H, 2009, EUR J NEUROSCI, V29, P1119, DOI 10.1111/j.1460-9568.2009.06664.x; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Jossin Y, 2007, MOL CELL BIOL, V27, P7113, DOI 10.1128/MCB.00928-07; Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kim WR, 2011, DEV GROWTH DIFFER, V53, P225, DOI 10.1111/j.1440-169X.2010.01226.x; Kimura A, 2007, STEM CELLS, V25, P115, DOI 10.1634/stemcells.2006-0223; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kong H, 2008, J CELL SCI, V121, P4029, DOI 10.1242/jcs.035758; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Nakamura M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020717; Okada Y, 2008, STEM CELLS, V26, P3086, DOI 10.1634/stemcells.2008-0293; Otaegi G, 2006, J CELL SCI, V119, P2739, DOI 10.1242/jcs.03012; Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Sakayori N, 2011, GENES CELLS, V16, P778, DOI 10.1111/j.1365-2443.2011.01527.x; Saxe JP, 2007, CHEM BIOL, V14, P1019, DOI 10.1016/j.chembiol.2007.07.016; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Silva A, 2009, J NEUROSCI RES, V87, P1986, DOI 10.1002/jnr.22041; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wang S, 2010, J NEUROSCI, V30, P14635, DOI 10.1523/JNEUROSCI.1729-10.2010; Wang YM, 2012, STROKE, V43, P2444, DOI 10.1161/STROKEAHA.112.658997; Wang YM, 2009, STROKE, V40, P1864, DOI 10.1161/STROKEAHA.108.536680; Williams PD, 2012, CURR PHARM DESIGN, V18, P4215; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zlokovic BV, 2011, TRENDS NEUROSCI, V34, P198, DOI 10.1016/j.tins.2011.01.005	58	41	43	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 3	2013	33	14					6181	+		10.1523/JNEUROSCI.4491-12.2013			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	120QP	WOS:000317186800031	23554499	Green Accepted, Bronze, Green Published			2022-02-06	
J	Russo, E; di Paola, ED; Gareri, P; Siniscalchi, A; Labate, A; Gallelli, L; Citraro, R; De Sarro, G				Russo, Emilio; di Paola, Eugenio Donato; Gareri, Pietro; Siniscalchi, Antonio; Labate, Angelo; Gallelli, Luca; Citraro, Rita; De Sarro, Giovambattista			Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice	PHARMACOLOGICAL RESEARCH			English	Article						Epilepsy; Cholesterol; Statins; Anticonvulsant potency; Pharmacodynamic; AEDs; Drug-drug Interaction	HIPPOCAMPAL CELL-DEATH; ACID-INDUCED SEIZURES; HYPERKINETIC MOVEMENT-DISORDERS; DEEP PREPIRIFORM CORTEX; TEMPORAL-LOBE EPILEPSY; NITRIC-OXIDE SYNTHASE; CORTICAL-NEURONS; INDUCED EXCITOTOXICITY; ATORVASTATIN TREATMENT; NEUROLOGICAL DEFICIT	It is known that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both the primary and the secondary prevention of ischemic heart disease. Increasing evidence indicates that statins have protective effects in several neurological diseases including stroke, cerebral ischemia, Parkinson disease, multiple sclerosis, traumatic brain injury and epilepsy. The aim of the present research was to evaluate the effects of some HMG-CoA reductase inhibitors (i.e. lovastatin, simvastatin, atorvastatin, fluvastatin and pravastatin) commonly used for the treatment of hypercholesterolemia in the DBA/2 mice, an animal model of generalized tonic-clonic seizures. Furthermore, the co-administration of these compounds with some antiepileptic drugs (AEDs; i.e. carbamazepine, diazepam, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate and valproate) was studied in order to identify possible positive pharmacological interactions. Simvastatin only was active against both the tonic and clonic phase of audiogenic seizures, whereas the other statins tested were only partially effective against the tonic phase with the following order of potency: lovastatin > fluvastatin > atorvastatin; pravastatin was completely ineffective up to the dose of 150 mg/kg. The co-administration of ineffective doses of all statins with AEDs generally increased the potency of the latter reducing their ED50 values. In particular, simvastatin was the most active in potentiating the activity of AEDs and the combinations of statins with carbamazepine, diazepam, felbamate, lamotrigine, topiramate and valproate were the most favorable, whereas, the co-administrations with the other AEDs studied was in most cases neutral. The increase in potency was generally associated with an enhancement of motor impairment (TD50); however, the therapeutic index (TD50/ED50) of combined treatment of AEDs with statins was predominantly more favorable than control. Statins administration did not significantly affect the total plasma but, in some cases, it increased the free plasma levels and the brain concentrations of some of the AEDs studied (i.e. carbamazepine, diazepam, phenytoin and valproate); however, these alterations where not statistically significant. Therefore, with the exception of the latter compounds, we might exclude pharmacokinetic interactions and conclude that for the most of AEDs, potentiation was of pharmacodynamic nature. In conclusion, simvastatin, fluvastatin, lovastatin and atorvastatin showed an additive anticonvulsant effect when co-administered with some AEDs, most notably carbamazepine, diazepam, felbamate, lamotrigine, topiramate and valproate, implicating a possible therapeutic relevance of such drug combinations. The present results suggest that statins, besides the beneficial cardiovascular effects, might be able to affect brain areas, which might participate in the regulation of seizure susceptibility. (C) 2013 Published by Elsevier Ltd.	[Russo, Emilio; di Paola, Eugenio Donato; Gareri, Pietro; Gallelli, Luca; Citraro, Rita; De Sarro, Giovambattista] Magna Graecia Univ Catanzaro, Clin Pharmacol Unit, Dept Hlth Sci, Sch Med, I-88100 Catanzaro, Italy; [Siniscalchi, Antonio] Annunziata Hosp, Neurol Unit, Dept Neurosci, Cosenza, Italy; [Labate, Angelo] Magna Graecia Univ Catanzaro, Sch Med, Inst Neurol, I-88100 Catanzaro, Italy		De Sarro, G (corresponding author), Magna Graecia Univ Catanzaro, Clin Pharmacol Unit, Dept Hlth Sci, Sch Med, Viale Europa, I-88100 Catanzaro, Italy.	desarro@unicz.it	Russo, Emilio/G-5241-2010; Siniscalchi, Antonio/H-7143-2019; gallelli, luca/A-5180-2011; Pietro, Gareri/K-6102-2016	Russo, Emilio/0000-0002-1279-8123; gallelli, luca/0000-0003-0858-7902; Pietro, Gareri/0000-0003-4277-3426; Labate, Angelo/0000-0002-8827-7324; De Sarro, Giovambattista/0000-0002-7629-6579; Citraro, Rita/0000-0001-6746-6751	Italian Ministry of Education, University and Research (MIUR, Cofin, Rome)Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN); National Research Council (CNR, Rome)Consiglio Nazionale delle Ricerche (CNR)	This work was supported by the Italian Ministry of Education, University and Research (MIUR, Cofin 2007, Rome) and the National Research Council (CNR, Rome). Both were not involved in study design, collection, analysis and interpretation of data.	Bialer M, 2010, EPILEPSY RES, V92, P89, DOI 10.1016/j.eplepsyres.2010.09.001; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Candrilli SD, 2010, EPILEPSY RES, V91, P260, DOI 10.1016/j.eplepsyres.2010.07.021; Canevini MP, 2010, EPILEPSIA, V51, P797, DOI 10.1111/j.1528-1167.2010.02520.x; Citraro R, 2011, EPILEPSY RES, V95, P60, DOI 10.1016/j.eplepsyres.2011.02.013; Comparato C, 2001, NUTR METAB CARDIOVAS, V11, P328; Corsini A, 2007, VASC HEALTH RISK MAN, V3, P611; De Luca G, 2005, PHARMACOL BIOCHEM BE, V81, P47, DOI 10.1016/j.pbb.2005.02.012; De Luca G, 2006, PHARMACOL BIOCHEM BE, V85, P804, DOI 10.1016/j.pbb.2006.11.016; De Sarro G, 1998, EUR J PHARMACOL, V349, P179, DOI 10.1016/S0014-2999(98)00193-9; De Sarro G, 2002, EUR J PHARMACOL, V442, P205, DOI 10.1016/S0014-2999(02)01536-4; De Sarro G, 2000, EUR J PHARMACOL, V394, P275, DOI 10.1016/S0014-2999(00)00086-8; De Sarro G, 2012, PHARMACOL RES, V65, P285, DOI 10.1016/j.phrs.2011.11.005; DESARRO G, 1993, EUR J PHARMACOL, V230, P151, DOI 10.1016/0014-2999(93)90797-L; DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503; di Paola ED, 2007, EPILEPSY RES, V75, P112, DOI 10.1016/j.eptepsyres.2007.04.008; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Etminan M, 2010, NEUROLOGY, V75, P1496, DOI 10.1212/WNL.0b013e3181f96253; Fischer W, 2004, BASIC CLIN PHARMACOL, V94, P79, DOI 10.1111/j.1742-7843.2004.pto940205.x; Funck VR, 2011, EPILEPSIA, V52, P2094, DOI 10.1111/j.1528-1167.2011.03261.x; Gambardella Antonio, 2008, Neuropsychiatr Dis Treat, V4, P33; Gidal BE, 2009, NEUROLOGY, V72, P419, DOI 10.1212/01.wnl.0000341789.77291.8d; Gitto R, 2007, BIOORGAN MED CHEM, V15, P5417, DOI 10.1016/j.bmc.2007.05.059; Golomb BA, 2008, NEUROLOGY, V70, P2349, DOI 10.1212/01.wnl.0000317006.87071.b1; GUILLOT F, 1993, J CARDIOVASC PHARM, V21, P339, DOI 10.1097/00005344-199302000-00022; Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4; Holtzman CW, 2006, PHARMACOTHERAPY, V26, P1601, DOI 10.1592/phco.26.11.1601; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Labate A, 2012, EPILEPTIC DISORD, V14, P163, DOI 10.1684/epd.2012.0497; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee DK, 2012, CELL PHYSIOL BIOCHEM, V30, P499, DOI 10.1159/000341433; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Lee SH, 2008, J NEUROL SCI, V275, P64, DOI 10.1016/j.jns.2008.07.029; Levy RH, 2007, INT REV NEUROBIOL, V81, P235, DOI 10.1016/S0074-7742(06)81015-9; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; Meldrum BS, 1997, EPILEPSIA, V38, pS7, DOI 10.1111/j.1528-1157.1997.tb05204.x; Moezi L, 2012, EPILEPSY BEHAV, V23, P399, DOI 10.1016/j.yebeh.2012.02.001; Moldrich RX, 2003, EUR J PHARMACOL, V476, P3, DOI 10.1016/S0014-2999(03)02149-6; Monetti M, 2007, PHARMACOL RES, V55, P441, DOI 10.1016/j.phrs.2007.02.001; Naval NS, 2009, NEUROL RES, V31, P425, DOI 10.1179/174313208X353686; Pelaia G, 2012, CELL PROLIFERAT, V45, P557, DOI 10.1111/j.1365-2184.2012.00846.x; Piermartiri TCB, 2010, EXP NEUROL, V226, P274, DOI 10.1016/j.expneurol.2010.08.030; Piermartiri TCB, 2009, NEUROTOX RES, V16, P106, DOI 10.1007/s12640-009-9057-6; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Russo E, 2004, NEUROPHARMACOLOGY, V46, P865, DOI 10.1016/j.neuropharm.2003.11.028; Russo E, 2004, BRIT J PHARMACOL, V141, P285, DOI 10.1038/sj.bjp.0705617; Russo E, 2013, NEUROPHARMACOLOGY, V64, P371, DOI 10.1016/j.neuropharm.2012.06.039; Russo E, 2010, EPILEPSIA, V51, P1560, DOI 10.1111/j.1528-1167.2009.02400.x; Selley ML, 2005, BRAIN RES, V1037, P1, DOI 10.1016/j.brainres.2004.02.083; Serbanescu I, 2004, J LIPID RES, V45, P2038, DOI 10.1194/jlr.M400097-JLR200; Shimamura M, 2007, STROKE, V38, P3251, DOI 10.1161/STROKEAHA.107.485045; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Siniscalchi A, 2012, PHARMACOL RES, V65, P171, DOI 10.1016/j.phrs.2011.09.003; Siniscalchi A, 2010, CURR NEUROPHARMACOL, V8, P359, DOI 10.2174/157015910793358187; Siniscalchi Antonio, 2011, Ann Pharmacother, V45, pe33, DOI 10.1345/aph.1Q013; Siniscalchi A, 2012, PHARMACOL REP, V64, P24, DOI 10.1016/S1734-1140(12)70727-2; Stepien KM, 2012, EUR J PHARMACOL, V674, P20, DOI 10.1016/j.ejphar.2011.10.030; TURPIN JC, 1991, DEV NEUROSCI-BASEL, V13, P304, DOI 10.1159/000112177; Uzum G, 2010, EPILEPSY BEHAV, V19, P284, DOI 10.1016/j.yebeh.2010.07.024; van Vliet EA, 2011, EPILEPSIA, V52, P1319, DOI 10.1111/j.1528-1167.2011.03073.x; Wang Q, 2008, NEUROSCIENCE, V154, P1100, DOI 10.1016/j.neuroscience.2008.04.026; Wang Q, 2009, EXP NEUROL, V216, P132, DOI 10.1016/j.expneurol.2008.11.016; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Zacco A, 2003, J NEUROSCI, V23, P11104	69	41	41	0	19	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	APR	2013	70	1					1	12		10.1016/j.phrs.2012.12.002			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	117BG	WOS:000316926500001	23253428				2022-02-06	
J	Hines, DJ; Haydon, PG				Hines, Dustin J.; Haydon, Philip G.			Inhibition of a SNARE-Sensitive Pathway in Astrocytes Attenuates Damage following Stroke	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; SYNAPTIC-TRANSMISSION; MOLECULAR-MECHANISMS; IN-VIVO; DEPENDENT NEURODEGENERATION; GLUTAMATE RELEASE; NEURONAL-ACTIVITY; NMDA ANTAGONISTS; CLINICAL-TRIALS; MOTOR CORTEX	A strong body of research has defined the role of excitotoxic glutamate in animal models of brain ischemia and stroke; however, clinical trials of glutamate receptor antagonists have demonstrated their limited capacity to prevent brain damage following ischemia. We propose that astrocyte-neuron signaling represents an important modulatory target that may be useful in mediating damage following stroke. To assess the impact of astrocyte signaling on damage following stroke, we have used the astrocyte-specific dominant-negative SNARE mouse model (dnSNARE). Recent findings have shown that the astrocytic SNARE signaling pathway can affect neuronal excitability by regulating the surface expression of NMDA receptors. Using focal photothrombosis via the Rose Bengal method, as well as excitotoxic NMDA lesions, we show that dnSNARE animals exhibited a sparing of damaged tissue quantified using Nissl and NeuN staining. At the same time point, animals were also tested in behavioral tasks that probe the functional integrity of stroke- or lesion-damaged motor and somatosensory areas. We found that dnSNARE mice performed significantly better than littermate controls on rung walk and adhesive dot removal tasks following lesion. Together, our results demonstrate the important role of astrocytic signaling under ischemic conditions. Drugs targeting astrocyte signaling have a potential benefit for the outcome of stroke in human patients by limiting the spread of damage.	[Hines, Dustin J.; Haydon, Philip G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA		Haydon, PG (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	philip.haydon@tufts.edu	Hines, Dustin/AAC-6394-2021	Hines, Dustin/0000-0003-2952-9824	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS037585, R01 MH095385]; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH095385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054770, R01NS037585] Funding Source: NIH RePORTER	This work was supported by NIH Grants R01 NS037585, R01 MH095385 to P. G. H., and by grants from The Heart and Stroke Foundation of Canada to D.J.H..	Aarts Michelle M, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403007087; Aguado F, 2002, J NEUROSCI, V22, P9430; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 1998, J NEUROSCI, V18, P6822; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Barber Philip A, 2003, Adv Neurol, V92, P151; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Brown CE, 2010, J CEREBR BLOOD F MET, V30, P783, DOI 10.1038/jcbfm.2009.241; Deng QD, 2011, GLIA, V59, P1084, DOI 10.1002/glia.21181; Ding SH, 2009, GLIA, V57, P767, DOI 10.1002/glia.20804; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Farr TD, 2006, J NEUROSCI METH, V153, P104, DOI 10.1016/j.jneumeth.2005.10.011; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fellin T, 2009, P NATL ACAD SCI USA, V106, P15037, DOI 10.1073/pnas.0906419106; GINSBERG MD, 1994, ANN NEUROL, V36, P553, DOI 10.1002/ana.410360402; Halassa MM, 2009, NEURON, V61, P213, DOI 10.1016/j.neuron.2008.11.024; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kim SH, 2006, MOL PHARMACOL, V69, P691, DOI 10.1124/mol.105.016428; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1602/neurorx.1.1.101; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Oliet SHR, 2004, GLIA, V47, P258, DOI 10.1002/glia.20032; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Tennant KA, 2011, CEREB CORTEX, V21, P865, DOI 10.1093/cercor/bhq159; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Zorec R, 2012, ASN NEURO, V4, P103, DOI 10.1042/AN20110061	40	41	44	0	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 6	2013	33	10					4234	4240		10.1523/JNEUROSCI.5495-12.2013			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	103OB	WOS:000315926300003	23467341	Green Published, Green Accepted, Bronze			2022-02-06	
J	Almenawer, SA; Bogza, I; Yarascavitch, B; Sne, N; Farrokhyar, F; Murty, N; Reddy, K				Almenawer, Saleh A.; Bogza, Iulia; Yarascavitch, Blake; Sne, Niv; Farrokhyar, Forough; Murty, Naresh; Reddy, Kesava			The Value of Scheduled Repeat Cranial Computed Tomography After Mild Head Injury: Single-Center Series and Meta-analysis	NEUROSURGERY			English	Article						Follow-up CT; Intracranial hemorrhage; Meta-analysis; Mild head injury; Repeat computed tomography	TRAUMATIC BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; CT-SCAN; RADIATION; UTILITY; PROGRESSION; RISK; MANAGEMENT; CANCER; RULE	BACKGROUND: After an initial computed tomography (CT) scan revealing intracranial hemorrhage resulting from traumatic brain injury, a standard of care in many trauma centers is to schedule a repeat CT scan to rule out possible progression of bleed. OBJECTIVE: To evaluate the utility of routine follow-up CT in changing the management of mild head injury patients despite clinical stability, although repeat imaging is indicated to assess a deteriorating patient. METHODS: The trauma database at our institution was retrospectively reviewed and the literature was searched to identify patients after mild head injury with positive initial CT finding and scheduled repeat scan. Patients were divided into 2 groups for comparison. Group A included patients who had intervention based on neurological examination changes. Group B comprised patients requiring a change in management according to CT results exclusively. The meta-analysis of the present cohort and included articles was performed with a random-effects model. RESULTS: Overall, 15 studies and 445 patients met our eligibility criteria, totaling 2693 patients. Intervention rates of groups A and B were 2.7% (95% confidence interval, 1.7-3.9; P = .003) and 0.6% (95% confidence interval, 0.3-1; P = .21), respectively. The statistical difference between both intervention rates was clinically significant with P < .001. CONCLUSION: The available evidence indicates that it is unnecessary to schedule a repeat CT scan after mild head injury when patients are unchanged or improving neurologically. In the absence of supporting data, we question the value of routine follow-up imaging given the associated accumulative increase in cost and risks.	[Almenawer, Saleh A.; Bogza, Iulia; Yarascavitch, Blake; Murty, Naresh; Reddy, Kesava] McMaster Univ, Div Neurosurg, Hamilton, ON, Canada; [Sne, Niv; Farrokhyar, Forough] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada		Almenawer, SA (corresponding author), 100 Main St E,Ste 42B, Hamilton, ON L8N 3W4, Canada.	Dr_menawer@hotmail.com	Reddy, Kesava/AAR-8866-2021; Farrokhyar, Forough/AAQ-6005-2021; Yarascavitch, Blake/AAR-8800-2021	Farrokhyar, Forough/0000-0001-9928-9016; Yarascavitch, Blake/0000-0003-1810-1267			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Huynh T, 2006, AM SURGEON, V72, P1162; Kalender WA, 2006, PHYS MED BIOL, V51, pR29, DOI 10.1088/0031-9155/51/13/R03; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Khaldi A, 2010, J NEUROSURG, V113, P1021, DOI 10.3171/2009.11.JNS081048; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Pauwels EKJ, 2011, ACTA RADIOL, V52, P767, DOI 10.1258/ar.2011.100496; Peace K, 2010, J NEUROSCI NURS, V42, P109, DOI 10.1097/JNN.0b013e3181ce5c5b; Roka Y B, 2008, Nepal Med Coll J, V10, P225; Schuster R, 2005, AM SURGEON, V71, P701; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sifri ZC, 2011, J TRAUMA, V71, P1605, DOI 10.1097/TA.0b013e31822b3728; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; TEASDALE G, 1974, LANCET, V2, P81; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f	41	41	41	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2013	72	1					56	62		10.1227/NEU.0b013e318276f899			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	060II	WOS:000312769400027	23254767				2022-02-06	
J	Asemota, AO; George, BP; Bowman, SM; Haider, AH; Schneider, EB				Asemota, Anthony O.; George, Benjamin P.; Bowman, Steven M.; Haider, Adil H.; Schneider, Eric B.			Causes and Trends in Traumatic Brain Injury for United States Adolescents	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; head trauma; pediatric brain injury; TBI	OUTCOMES; PREVALENCE; ADULTS; IMPACT	Traumatic brain injury (TBI) is a leading cause of death and disability among United States adolescents. The authors sought to determine causes and trends for TBI-related hospitalizations in the United States adolescent population (10-19 years). The authors identified common causes and trends of adolescent TBI, overall and within 2-year age categories, using hospitalization data from 2005 to 2009 in the Nationwide Inpatient Sample. The leading cause of adolescent TBI overall was motor vehicle occupant accidents (35%), which are also the leading cause in the 14-15, 16-17, and 18-19 year age groups. Falls were the cause of most TBI in the 10-11 year (23%) and 12-13 year (20%) age groups. For both unintentional and intentional mechanisms of injury, there was evidence of increasing hospitalizations with increasing age. From 2005 to 2009, the overall annual incidence of adolescent TBI hospitalizations decreased 21% from an estimated 75.5-59.3 per 100,000 (p < 0.001). These rates declined for mild, moderate, and severe TBI, and decreased for 2-year age groups, except for the 18-19 year-old group. For TBI attributable to motor vehicle occupants, rates declined 27% from 27.6 to 20.2 per 100,000 (p < 0.001). Motor vehicle occupant injuries account for 42% of in-hospital mortality from adolescent TBI; however, firearms are the most lethal mechanism with 46% proportional mortality among victims of firearm-related TBI. Rates of adolescent TBI-related hospitalizations have decreased overall. Motor vehicle accidents and firearms were identified as leading causes of injury and mortality for adolescent TBI, and represent potential targets for intervention.	[Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21287 USA; [Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Bowman, Steven M.] Natl Univ, Dept Community Hlth, Technol & Hlth Sci Ctr, San Diego, CA USA		Asemota, AO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	aasemota@jhsph.edu		George, Benjamin/0000-0001-9966-5632			Agency for Healthcare Research and Quality, 2009, INTR HCUP NAT INP SA; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; [Anonymous], 1997, ICDMAP 90 INJ SEV CO; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barrett M., 2010, HCUP METHODS SERIES, Vx0023; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; Finklestein EA., 2006, INCIDENCE EC BURDEN; Haider AH, 2011, J PEDIATR SURG, V46, P1557, DOI 10.1016/j.jpedsurg.2011.04.055; HUIZINGA D, 2000, COOCCURENCE DELINQUE; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ruggles S, 2010, INTEGRATED PUBLIC US; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; U.S. Department of Transportation, 2012, TRAFF VOL TRENDS; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	26	41	44	1	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					67	75		10.1089/neu.2012.2605			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000001	22989254				2022-02-06	
S	Beauchamp, MH; Anderson, V		Dulac, O; Lassonde, M; Sarnat, HB		Beauchamp, M. H.; Anderson, V.			Cognitive and psychopathological sequelae of pediatric traumatic brain injury	PEDIATRIC NEUROLOGY, PT II	Handbook of Clinical Neurology		English	Article; Book Chapter							EXECUTIVE FUNCTIONS; PERSONALITY-CHANGE; SKILLS; CHILDREN; PREDICTORS; ADOLESCENTS; OUTCOMES; MIND; DISORDER		[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Anderson, V.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, V.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, V.] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia		Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Ayr LK, 2005, J INT NEUROPSYCH SOC, V11, P249, DOI 10.1017/S1355617705050307; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Kenny DT, 2007, CONT ISSUES CRIME JU, V107, P1; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Morgan AT, 2010, CHILD CARE HLTH DEV, V36, P44, DOI 10.1111/j.1365-2214.2009.00961.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nybo T, 2005, ACTA NEUROL SCAND, V112, P338, DOI 10.1111/j.1600-0404.2005.00489.x; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; RUTTER M, 1983, DEV NEUROPSYCHIATRY; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; TEASDALE G, 1974, LANCET, V2, P81; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Verger K, 2000, BRAIN INJURY, V14, P495; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535	39	41	41	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0072-9752		978-0-444-62699-8; 978-0-444-52910-7	HAND CLINIC			2013	112						913	920					8	Clinical Neurology; Pediatrics	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Pediatrics	BA6KI	WOS:000337167400015	23622301				2022-02-06	
J	Ennis, N; Rosenbloom, BN; Canzian, S; Topolovec-Vranic, J				Ennis, Naomi; Rosenbloom, Brittany N.; Canzian, Sonya; Topolovec-Vranic, Jane			Depression and anxiety in parent versus spouse caregivers of adult patients with traumatic brain injury: A systematic review	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Depression; Anxiety; Traumatic brain injury; Systematic review; Caregivers	SEVERE HEAD-INJURY; PSYCHOLOGICAL DISTRESS; RELATIVES; INDIVIDUALS; TBI; REHABILITATION; ADJUSTMENT; BURDEN; HEALTH; IMPACT	A systematic review of studies which evaluated depression and anxiety in parent versus spouse caregivers of adults with traumatic brain injury (TBI) was conducted. Demographic variables of the TBI patients and caregivers, study design, measurement tools used, and outcomes reported were collected. Twenty-four studies met the inclusion criteria and were evaluated for methodological quality. While the majority of studies revealed no significant differences between caregiver types on measures of depression and/or anxiety, there was a great deal of variation in methodology and quality between the studies. Overall, high levels of caregiver distress were exposed, regardless of caregiver type (parent versus spouse). There is a need for qualitative and quantitative research designs in order to elucidate the factors that put caregivers at risk for depression and anxiety.	[Ennis, Naomi; Rosenbloom, Brittany N.; Canzian, Sonya; Topolovec-Vranic, Jane] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Topolovec-Vranic, Jane] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada		Topolovec-Vranic, J (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St,Bond 4-016, Toronto, ON M5B 1W8, Canada.	topolovec-vranicj@smh.ca	Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212	Ontario Neurotrauma Foundation [2008-ABI-THC-600]	Funding was provided by the Ontario Neurotrauma Foundation (2008-ABI-THC-600).	Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; Florian V., 1989, BRAIN INJURY, V3, P210, DOI 10.3109/02699058909029637; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Layman DE, 2005, BRAIN INJURY, V19, P909, DOI 10.1080/02699050500109928; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Phelan SM, 2011, DISABIL HEALTH J, V4, P177, DOI 10.1016/j.dhjo.2011.03.003; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Zeigler E A, 1999, J Neurosci Nurs, V31, P106	48	41	44	2	28	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 1	2013	23	1					1	18		10.1080/09602011.2012.712871			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	096BD	WOS:000315377800001	22897335				2022-02-06	
J	Hours, M; Chossegros, L; Charnay, P; Tardy, H; Nhac-Vu, HT; Boisson, D; Luaute, J; Laumon, B				Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Boisson, Dominique; Luaute, Jacques; Laumon, Bernard			Outcomes one year after a road accident: Results from the ESPARR cohort	ACCIDENT ANALYSIS AND PREVENTION			English	Article						ESPARR; France; Cohort study; One year follow-up; Road accident; Outcome	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; FOLLOW-UP; TRAFFIC ACCIDENTS; MAJOR TRAUMA; PSYCHOLOGICAL TRAUMA; SOCIAL-CONSEQUENCES; IMPROVES ACCURACY; SEVERITY SCORE	Objective: Reducing the rates of death, trauma and sequelae associated with road accidents is the prime goal of road safety authorities, and success requires having data on victims' outcomes in the long term. The present study examined the outcome of adult road accident victims one year after their accident. Design: A follow-up study. Methods: The cohort comprised 886 injured road-accident victims, aged >= 16 years, and living in the Rhone administrative Departement, France (taken from the ESPARR Cohort). Data were collected on victim characteristics at the time of crash, and self-reported outcomes one year later. The population of respondents at the one-year questionnaire follow-up was divided into two categories according to injury severity, as mild-to-moderate (M.AIS <3) or severe (M.AIS 3+). Qualitative variables were compared between these 2 groups using Chi(2) or Fisher exact tests. Results: At one year post-accident, 45% of the mild-to-moderate injury group versus only 20% of severely injured subjects reported full recovery of health (p <0.001). 20% of the cohort, as a whole, reported permanent pain. More than half of the severely injured subjects reported that the accident had had an impact on the everyday life of their family; this was twice as many as in the mild-to-moderate injury group (55% vs. 22%). Most of the severely injured reported impact on leisure, projects and emotional life: 20% reported relational difficulties in the couple, 16% reported impaired sexual life, and the rate of separation was significantly higher than in the mild-to-moderate injury group (5% vs. 1%; p <0.001). Mean time off work was significantly longer in the severe injury group: 245 +/- 158 days vs. 75 +/- 104 days (p <0.001); and 32% of the severe injury group (p <0.001) who had stopped work had not returned at 1 year, compared to 5% of the mild-to-moderate injury group. Conclusions: One year after a road accident, the consequences for victims remain significant. In terms of physical impact, pain frequently persists, impairing daily life for many. There is an elevated rate of chronic PTSD (post-traumatic stress disorder) and a non-negligible impact on affective and occupational life. (C) 2012 Elsevier Ltd. All rights reserved.	[Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Boisson, Dominique; Luaute, Jacques; Laumon, Bernard] Univ Lyon, F-69622 Lyon, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] IFSTTAR, UMRESTTE, F-69675 Bron, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] Univ Lyon 1, UMRESTTE, F-69373 Lyon, France; [Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Hoang-Thy Nhac-Vu; Laumon, Bernard] Henry Gabrielle Hosp, Hosp Civils Lyon, Rehabil & Phys Med Unit, F-69230 St Genis Laval, France		Hours, M (corresponding author), IFSTTAR, UMRESTTE, 25 Ave Francois Mitterrand, F-69675 Bron, France.	martine.hours@ifsttar.fr; laetitia.chossegros@ifsttar.fr; pierrette.charnay@ifsttar.fr; helene.tardy@ifsttar.fr; vu.hoang-thy-nhac@ifsttar.fr; dominique.boisson@chu-lyon.fr; jacques.luaute@chu-lyon.fr; bernard.laumon@ifsttar.fr	Luaute, jacques/H-4618-2017; TARDY, HELENE/AAE-6287-2019	Luaute, jacques/0000-0002-6387-9572; TARDY, HELENE/0000-0001-8351-9825			AAAM, 1990, ABBREVIATED INJURY S, P74; Amoros E, 2006, ACCIDENT ANAL PREV, V38, P627, DOI 10.1016/j.aap.2005.11.006; ANDERSSON AL, 1994, SCAND J SOC MED, V22, P299, DOI 10.1177/140349489402200409; Andersson AL, 1997, INJURY, V28, P539, DOI 10.1016/S0020-1383(97)00083-1; Association for the Advancement of Automotive Medicine (AAAM), 1994, INJ IMP SCAL, P66; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Calmels P., 1996, Annales de Readaptation et de Medecine Physique, V39, P241; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Chossegros L, 2011, ACCIDENT ANAL PREV, V43, P471, DOI 10.1016/j.aap.2010.10.004; Currens JAB, 2000, INJURY, V31, P99, DOI 10.1016/S0020-1383(99)00246-6; De Mey-Guillard C, 2005, ENCEPHALE, V31, P76; DiGallo A, 1996, BRIT J PSYCHIAT, V169, P405, DOI 10.1192/bjp.169.4.405; Edwards P, 2007, J CLIN EPIDEMIOL, V60, P417, DOI 10.1016/j.jclinepi.2006.06.021; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Frommberger UH, 1998, EUR ARCH PSY CLIN N, V248, P316, DOI 10.1007/s004060050057; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Jeavons S, 2000, J TRAUMA STRESS, V13, P359, DOI 10.1023/A:1007797904536; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; Laumon B, 1997, 41 ANN P ASS ADV AUT, P127; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McClure RJ, 1996, ACCIDENT ANAL PREV, V28, P443, DOI 10.1016/0001-4575(96)00012-7; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Schluter PJ, 2006, ANZ J SURG, V76, P886, DOI 10.1111/j.1445-2197.2006.03900.x; Soderstrom CA, 1997, J TRAUMA, V43, P925; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; van der Sluis CK, 1998, INJURY, V29, P277, DOI 10.1016/S0020-1383(97)00198-8; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Wise EK, 2010, ARCH PHYS MED REHAB, V91, P1357, DOI 10.1016/j.apmr.2010.06.009; Yang Z, 2010, INJURY, V41, P226, DOI 10.1016/j.injury.2009.10.019; Yao SN, 2003, ENCEPHALE, V29, P232	45	41	41	0	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2013	50						92	102		10.1016/j.aap.2012.03.037			11	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	079SD	WOS:000314191600012	23200444				2022-02-06	
J	Linden, MA; Braiden, HJ; Miller, S				Linden, Mark A.; Braiden, Hannah-Jane; Miller, Sarah			Educational professionals' understanding of childhood traumatic brain injury	BRAIN INJURY			English	Article						Education; traumatic brain injury; children; misconceptions	COMMON MISCONCEPTIONS; CAUSAL ATTRIBUTIONS; FOLLOW-UP; CHILDREN; ATTITUDES; SURVIVORS; TERM; PREVALENCE; PREDICTORS; BEHAVIOR	Primary objectives: To determine the understanding of educational professionals around the topic of childhood brain injury and explore the factor structure of the Common Misconceptions about Traumatic Brain Injury Questionnaire (CM-TBI). Research design: Cross-sectional postal survey. Methods and procedures: The CM-TBI was posted to all educational establishments in one region of the UK. One representative from each school was asked to complete and return the questionnaire (n = 388). Main outcomes and results: Differences were demonstrated between those participants who knew someone with a brain injury and those who did not, with a similar pattern being shown for those educators who had taught a child with brain injury. Participants who had taught a child with brain injury demonstrated greater knowledge in areas such as seatbelts/prevention, brain damage, brain injury sequelae, amnesia, recovery and rehabilitation. Principal components analysis suggested the existence of four factors and the discarding of half the original items of the questionnaire. Conclusions: In the first European study to explore this issue, it is highlighted that teachers are ill-prepared to cope with children who have sustained a brain injury. Given the importance of a supportive school environment in return to life following hospitalization, the lack of understanding demonstrated by teachers in this research may significantly impact on a successful return to school.	[Linden, Mark A.] Queens Univ Belfast, Sch Nursing & Midwifery, Belfast BT9 7BL, Antrim, North Ireland; [Braiden, Hannah-Jane] Western Educ & Lib Board, Omagh, North Ireland; [Miller, Sarah] Queens Univ Belfast, Sch Educ, Belfast BT9 7BL, Antrim, North Ireland		Linden, MA (corresponding author), Queens Univ Belfast, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.linden@qub.ac.uk	Linden, Mark/L-7754-2019	Linden, Mark/0000-0002-3832-4102	Southern Health and Social Care trust	This research was supported by a grant from the Southern Health and Social Care trust. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Bjorkman T, 2008, SCAND J CARING SCI, V22, P170, DOI 10.1111/j.1471-6712.2007.00509.x; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Costello A., 2005, PAN PACIFIC MANAGEME, V10, P1, DOI DOI 10.7275/JYJ1-4868; Crothers IR, 2007, BRAIN INJURY, V21, P47, DOI 10.1080/02699050601149054; Deidrick KKM, 2005, PREV SCH FAIL, V49, P23, DOI 10.3200/PSFL.49.4.23-33; Department of Education Northern Ireland, 2011, COD PRACT ID ASS SPE; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Lehr E., 1990, REHABILITATION I CHI; Linden MA, 2006, ARCH CLIN NEUROPSYCH, V21, P763, DOI 10.1016/j.acn.2006.08.010; Linden MA, 2010, BRAIN INJURY, V24, P642, DOI 10.3109/02699051003601689; Linden M, 2012, J ADV NURS, V68, P1359, DOI 10.1111/j.1365-2648.2011.05848.x; Linden MA, 2012, NURS RES, V61, P58, DOI 10.1097/NNR.0b013e31823ca253; Linden MA, 2011, INT J NURS STUD, V48, P62, DOI 10.1016/j.ijnurstu.2010.05.011; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McClure J, 2011, REHABIL PSYCHOL, V56, P85, DOI 10.1037/a0023354; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; Pappadis MR, 2011, J HEAD TRAUMA REHAB, V26, P301, DOI 10.1097/HTR.0b013e3181e7832b; Parker JG, 1993, ADV PERSONAL RELATIO, P195; Parkin AE., 1996, AUSTR OCCUPATIONAL T, V43, P133; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Redpath SJ, 2010, BRAIN INJURY, V24, P802, DOI 10.3109/02699051003709623; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sevigny R, 1999, INT J SOC PSYCHIATR, V45, P41, DOI 10.1177/002076409904500106; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Stranmillis University College, 2012, PROSP ENTR 2012; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369	42	41	41	1	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					92	102		10.3109/02699052.2012.722262			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300010	23252440	Green Published			2022-02-06	
J	Luoto, TM; Tenovuo, O; Kataja, A; Brander, A; Ohman, J; Iverson, GL				Luoto, Teemu M.; Tenovuo, Olli; Kataja, Anneli; Brander, Antti; Ohman, Juha; Iverson, Grant L.			Who Gets Recruited in Mild Traumatic Brain Injury Research?	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; selection bias; traumatic brain injury	COLLABORATING-CENTER; TASK-FORCE; CLINICAL-TRIALS; BIAS; RECOMMENDATIONS; SYMPTOMS; MODERATE; IMPACT	Selection bias, common in traumatic brain injury research, limits the clinical usefulness and generalizability of study findings. The purpose of this study was to examine the effect of different inclusion and exclusion criteria on patient enrollment, and the implications for generalizability, in a mild traumatic brain injury (MTBI) study. The study was conducted at the emergency department (ED) of Tampere University Hospital. Our aim was to study outcome from MTBI in patients who do not have pre-existing conditions or other confounding factors. For this, all consecutive patients with acute head trauma (n = 1344) were screened. The study design included three inclusion criteria and nine exclusion criteria. The World Health Organization Collaborating Center for Neurotrauma Task Force criteria for MTBI were used. Of all patients screened, 934 (69.5%) fulfilled the MTBI criteria. For those fulfilling the MTBI criteria, various inclusion and exclusion criteria were applied in order to yield those eligible for the outcome study. Applying these criteria excluded 95.1% of MTBI patients, leaving only 46 patients in the final sample. The final sample and the excluded patients with MTBI significantly differed in age, mechanism of injury, and injury severity characteristics. Many studies recruit fundamentally biased samples that are not generalizable to the population of persons who sustain an MTBI. Studying carefully selected samples is often necessary to address specific research questions, but such studies have serious limitations in terms of translating research findings into clinical practice.	[Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland; [Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland; [Tenovuo, Olli] Turku Univ, Cent Hosp, Turku, Finland; [Kataja, Anneli; Brander, Antti] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, FI-33521 Tampere, Finland; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada		Luoto, TM (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	teemu.luoto@pshp.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Eldridge S, 2009, BMJ-BRIT MED J, V339, pb4006; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; HOLDEN G, 1993, SOC WORK HEALTH CARE, V19, P1, DOI 10.1300/J010v19n02_01; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Poyry T, 2012, J HEAD TRAUMA REHABI; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sica GT, 2006, RADIOLOGY, V238, P780, DOI 10.1148/radiol.2383041109; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slieker FJA, 2008, NEUROSURGERY, V62, P1321, DOI 10.1227/01.neu.0000333304.79931.4d	23	41	41	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					11	16		10.1089/neu.2012.2611			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300003	22909262				2022-02-06	
J	Lutkenhoff, ES; McArthur, DL; Hua, X; Thompson, PM; Vespa, PM; Monti, MM				Lutkenhoff, Evan S.; McArthur, David L.; Hua, Xue; Thompson, Paul M.; Vespa, Paul M.; Monti, Martin M.			Thalamic atrophy in antero-medial and dorsal nuclei correlates with six-month outcome after severe brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Thalamus; Tensor brain morphometry; Magnetic resonance imaging	MEDIODORSAL NUCLEUS; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; HIPPOCAMPAL ATROPHY; NEURONAL-ACTIVITY; FLUID-PERCUSSION; GROWTH-PATTERNS; LIMBIC CORTEX; SERIAL MRI; ROBUST	The primary and secondary damage to neural tissue inflicted by traumatic brain injury is a leading cause of death and disability. The secondary processes, in particular, are of great clinical interest because of their potential susceptibility to intervention. We address the dynamics of tissue degeneration in cortico-subcortical circuits after severe brain injury by assessing volume change in individual thalamic nuclei over the first six-months post-injury in a sample of 25 moderate to severe traumatic brain injury patients. Using tensor-based morphometry, we observed significant localized thalamic atrophy over the six-month period in antero-dorsal limbic nuclei as well as in medio-dorsal association nuclei. Importantly, the degree of atrophy in these nuclei was predictive, even after controlling for full-brain volume change, of behavioral outcome at six-months post-injury. Furthermore, employing a data-driven decision tree model, we found that physiological measures, namely the extent of atrophy in the anterior thalamic nucleus, were the most predictive variables of whether patients had regained consciousness by six-months, followed by behavioral measures. Overall, these findings suggest that the secondary non-mechanical degenerative processes triggered by severe brain injury are still ongoing after the first week post-trauma and target specifically antero-medial and dorsal thalamic nuclei. This result therefore offers a potential window of intervention, and a specific target region, in agreement with the view that specific cortico-thalamo-cortical circuits are crucial to the maintenance of large-scale network neural activity and thereby the restoration of cognitive function after severe brain injury. (C) 2013 The Authors. Published by Elsevier Inc.	[Lutkenhoff, Evan S.; Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [McArthur, David L.; Vespa, Paul M.; Monti, Martin M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, BIRC, Los Angeles, CA 90095 USA; [Hua, Xue; Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA; [Thompson, Paul M.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; [Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA		Monti, MM (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	monti@psych.ucla.edu	Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867; Monti, Martin M/0000-0001-5511-3780			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.0.CO;2-P; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BANERJEE PK, 1994, EPILEPSY RES, V17, P193, DOI 10.1016/0920-1211(94)90050-7; Bekinschtein TA, 2008, J NEUROL NEUROSUR PS, V79, P826, DOI 10.1136/jnnp.2007.132738; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Cachier P, 2000, LECT NOTES COMPUT SC, V1935, P472; Chan HM, 2003, PROC CVPR IEEE, P570; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung MK, 2003, NEUROIMAGE, V18, P198, DOI 10.1016/S1053-8119(02)00017-4; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; Cipolotti L, 2008, NEUROPSYCHOLOGIA, V46, P2745, DOI 10.1016/j.neuropsychologia.2008.05.009; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Dumont JR, 2012, NEUROSCIENCE, V224, P81, DOI 10.1016/j.neuroscience.2012.08.027; Dupire A, 2013, HIPPOCAMPUS, V23, P392, DOI 10.1002/hipo.22098; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fox NC, 2000, ARCH NEUROL-CHICAGO, V57, P339, DOI 10.1001/archneur.57.3.339; Fox NC, 1996, BRAIN, V119, P2001, DOI 10.1093/brain/119.6.2001; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; Fox NC, 1997, J MAGN RESON IMAGING, V7, P1069, DOI 10.1002/jmri.1880070620; Freeborough PA, 1997, IEEE T MED IMAGING, V16, P623, DOI 10.1109/42.640753; Freeborough PA, 1996, J COMPUT ASSIST TOMO, V20, P1012, DOI 10.1097/00004728-199611000-00030; Furnkranz J, 1997, MACH LEARN, V27, P139, DOI 10.1023/A:1007329424533; GABRIEL M, 1983, BEHAV NEUROSCI, V97, P675, DOI 10.1037/0735-7044.97.5.675; Ge YL, 2000, RADIOLOGY, V214, P665, DOI 10.1148/radiology.214.3.r00mr30665; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hampstead BM, 2009, CLIN NEUROPSYCHOL, V23, P1232, DOI 10.1080/13854040902936679; HERKENHAM M, 1980, SCIENCE, V207, P532, DOI 10.1126/science.7352263; Hua X, 2011, NEUROIMAGE, V57, P5, DOI 10.1016/j.neuroimage.2011.01.079; Hua X, 2010, NEUROBIOL AGING, V31, P1463, DOI 10.1016/j.neurobiolaging.2010.04.033; Hua X, 2010, NEUROIMAGE, V51, P63, DOI 10.1016/j.neuroimage.2010.01.104; Hua X, 2009, HUM BRAIN MAPP, V30, P209, DOI 10.1002/hbm.20498; Ishwaran H., 2009, ENCY MED DECISION MA, P323; Jank W, 2010, FRONT ARTIF INTEL AP, V218, P137, DOI 10.3233/978-1-60750-633-1-137; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; KAITZ SS, 1981, J COMP NEUROL, V195, P527, DOI 10.1002/cne.901950309; Kang EK, 2012, J REHABIL MED, V44, P346, DOI 10.2340/16501977-0947; Kato K, 2008, NEUROL MED-CHIR, V48, P285, DOI 10.2176/nmc.48.285; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lemieux L, 1998, Med Image Anal, V2, P227, DOI 10.1016/S1361-8415(98)80021-2; Leow A, 2005, LECT NOTES COMPUT SC, V3565, P493; Leow A, 2005, NEUROIMAGE, V24, P910, DOI 10.1016/j.neuroimage.2004.09.022; Leow AD, 2007, IEEE T MED IMAGING, V26, P822, DOI 10.1109/TMI.2007.892646; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Lu PH, 2011, J ALZHEIMERS DIS, V23, P433, DOI 10.3233/JAD-2010-101398; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; Mierswa I., 2006, P 12 ACM SIGKDD INT, DOI DOI 10.1145/1150402.1150531; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; O'Brien JT, 2001, NEUROLOGY, V56, P1386, DOI 10.1212/WNL.56.10.1386; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; QUINLAN JR, 1987, INT J MAN MACH STUD, V27, P221, DOI 10.1016/S0020-7373(87)80053-6; Rex DE, 2003, NEUROIMAGE, V19, P1033, DOI 10.1016/S1053-8119(03)00185-X; Rey D, 2002, MED IMAGE ANAL, V6, P163, DOI 10.1016/S1361-8415(02)00056-7; ROBERTSON RT, 1981, J COMP NEUROL, V195, P501, DOI 10.1002/cne.901950308; Rokach L, 2005, IEEE T SYST MAN CY C, V35, P476, DOI 10.1109/TSMCC.2004.843247; Rotaru DC, 2005, J COMP NEUROL, V490, P220, DOI 10.1002/cne.20661; Saunders RC, 2005, EXP BRAIN RES, V167, P1, DOI 10.1007/s00221-005-2361-3; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sherman SM, 2001, EXPLORING THALAMUS; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; STREET JO, 1988, AM STAT, V42, P152, DOI 10.2307/2684491; Studholme C, 2001, MICCAI, P41; TEASDALE G, 1974, LANCET, V2, P81; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Van Der Werf YD, 2003, CORTEX, V39, P1047, DOI 10.1016/S0010-9452(08)70877-3; van Groen T, 2002, BEHAV BRAIN RES, V136, P329, DOI 10.1016/S0166-4328(02)00199-7; van Huijzen, 2008, HUMAN CENTRAL NERVOU; Wang L, 2003, NEUROIMAGE, V20, P667, DOI 10.1016/S1053-8119(03)00361-6; Watanabe Y, 2004, J NEUROPHYSIOL, V92, P1738, DOI 10.1152/jn.00994.2003; Watanabe Y, 2012, NEUROSCI BIOBEHAV R, V36, P134, DOI 10.1016/j.neubiorev.2011.05.003; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson SL, 1998, LANCET, V352, P485, DOI 10.1016/S0140-6736(05)79220-5; Woods RP, 2003, NEUROIMAGE, V18, P769, DOI 10.1016/S1053-8119(03)00019-3; Yamamoto T, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.04.010; Yanovsky Igor, 2008, Conf Comput Vis Pattern Recognit Workshops, V2008, DOI 10.1109/CVPRW.2008.4562988; Yanovsky I, 2009, MED IMAGE ANAL, V13, P679, DOI 10.1016/j.media.2009.06.002; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	100	41	43	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2013	3						396	404		10.1016/j.nicl.2013.09.010			9	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V37LI	WOS:000209276900043	24273723	Green Published, gold			2022-02-06	
J	Turner-Stokes, L; Siegert, RJ				Turner-Stokes, Lynne; Siegert, Richard J.			A comprehensive psychometric evaluation of the UK FIM plus FAM	DISABILITY AND REHABILITATION			English	Article						Extended activities of daily living; factor analysis; Mokken analysis; neurological rehabilitation; psychometrics; UK FIM plus FAM	FUNCTIONAL ASSESSMENT MEASURE; TRAUMATIC BRAIN-INJURY; INTERRATER RELIABILITY; INDEPENDENCE MEASURE; SCALE ANALYSIS; REHABILITATION; PERFORMANCE; DISABILITY; FIM+FAM; UTILITY	Purpose: To evaluate the psychometric properties of the UK FIM + FAM. Methods: (a) A systematic literature review integrating the evidence for psychometric qualities of both the original and UK versions, and (b) exploratory and confirmatory factor analysis of admission/discharge data from an inpatient general neuro-rehabilitation cohort using parametric and non-parametric techniques. A prospective cohort of 459 patients with a male: female ratio of 57: 43 and mean age of 44.5 (SD 14.3) years participated in this study. Results: Seven published articles together demonstrated acceptable utility, concurrent validity, inter-rater reliability and responsiveness of the UK FIM + FAM. Factor analysis demonstrated that all items loaded high (40.58) on the first principal component and distinct motor and cognitive factors emerged after rotation. A four-factor solution also demonstrated four distinct, interpretable dimensions (Physical, Psychosocial, Communication and Extended Activities of Everyday Living (EADL)). Mokken analysis of the second data set confirmed these dimensions. Cronbach's alpha s were 0.97 and 0.96 for the motor and cognitive domains and 0.90-0.97 for the subscales. Analysis of responsiveness demonstrated "large" effect sizes (0.86-1.29). Conclusions: The UK FIM + FAM, including the newer EADL module, is a valid, reliable scale of functional independence. It has high internal consistency in two domains and four subscales and is responsive to changes occurring in a general inpatient neuro-rehabilitation population.	[Turner-Stokes, Lynne; Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med, London SE5 9PJ, England; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England; [Siegert, Richard J.] Auckland Univ Technol, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand; [Siegert, Richard J.] Auckland Univ Technol, Sch Rehabil & Occupat Studies, Auckland, New Zealand		Turner-Stokes, L (corresponding author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, Bessemer Rd,Denmark Hill, London SE5 9PJ, England.	lynne.turner-stokes@dial.pipex.com	Siegert, Richard J./K-2030-2019; Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	National Institute for Health Research in England (NIHR)National Institute for Health Research (NIHR) [RP-PG-0407-10185]; Dunhill Medical TrustDunhill Medical Trust; Luff Foundation; National Institute for Health ResearchNational Institute for Health Research (NIHR) [RP-PG-0407-10185] Funding Source: researchfish	Outcome measurement is a specific research interest of our centre. The UK FIM + FAM were both developed through this department, but is disseminated free of charge to trained users. Neither of the authors has any personal financial interests in the work undertaken or the findings reported. This manuscript presents independent research commissioned by the National Institute for Health Research in England (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10185). The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Financial support for the preparation of this manuscript was also provided by the Dunhill Medical Trust and the Luff Foundation.	Alcott D, 1997, DISABIL REHABIL, V19, P355, DOI 10.3109/09638289709166551; Cohen J., 2013, STAT POWER ANAL BEHA; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hobart JC, 2001, NEUROLOGY, V57, P639, DOI 10.1212/WNL.57.4.639; Jorge LL, 2011, INT J REHABIL RES, V34, P89, DOI 10.1097/MRR.0b013e32833ba55f; Law J, 2009, DISABIL REHABIL, V31, P825, DOI 10.1080/09638280802355049; Linn R T, 1999, J Outcome Meas, V3, P339; LOEVINGER J, 1948, PSYCHOL BULL, V45, P507, DOI 10.1037/h0055827; McPherson K, 1997, NEUROPSYCHOL REHABIL, V7, P241, DOI 10.1080/713755530; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pett MA., 2003, MAKING SENSE FACTOR; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Siegert RJ, 2010, J REHABIL MED, V42, P936, DOI 10.2340/16501977-0602; SIJTSMA K, 2002, MEASUREMENT METHODS, V5; Sijtsma K., 2000, MSP5 WINDOWS PROGRAM; Tabachnick B.G., 2001, USING MULTIVARIATE S; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Tesio L, 1998, J Outcome Meas, V2, P79; Thompson B., 2004, EXPLORATORY CONFIRMA; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 2012, DISABIL REHABIL, V34, P1871, DOI 10.3109/09638288.2012.670033; Turner-Stokes L, 2012, CLIN REHABIL, V26, P264, DOI 10.1177/0269215511417467; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; van Schuur WH, 2003, POLIT ANAL, V11, P139, DOI 10.1093/pan/mpg002; Wilson FC, 2009, NEUROREHABILITATION, V24, P377, DOI 10.3233/NRE-2009-0492; [No title captured]	38	41	42	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	22					1885	1895		10.3109/09638288.2013.766271			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	230PW	WOS:000325355400005	23384240	hybrid, Green Published			2022-02-06	
J	Zhang, LY; Makwana, R; Sharma, S				Zhang, Liying; Makwana, Rahul; Sharma, Sumit			Brain response to primary blast wave using validated finite element models of human head and advanced combat helmet	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; primary blast; finite element model; advanced combat helmet model; human head model; intracranial pressure; brain strain and strain rate; head protection		Blast-induced traumatic brain injury has emerged as a "signature injury" in combat casualty care. Present combat helmets are designed primarily to protect against ballistic and blunt impacts, but the current issue with helmets is protection concerning blasts. In order to delineate the blast wave attenuating capability of the Advanced Combat Helmet (ACH), a finite element (FE) study was undertaken to evaluate the head response against blast loadings with and without helmet using a partially validated FE model of the human head and ACH. Four levels of overpressures (0.27-0.66 MPa) from the Bowen's lung iso-damage threshold curves were used to simulate blast insults. Effectiveness of the helmet with respect to head orientation was also investigated. The resulting biomechanical responses of the brain to blast threats were compared for human head with and without the helmet. For all Bowen's cases, the peak intracranial pressures (ICP) in the head ranged from 0.68 to 1.8 MPa in the coup cortical region. ACH was found to mitigate ICP in the head by 10-35%. Helmeted head resulted in 30% lower average peak brain strains and product of strain and strain rate. Among three blast loading directions with ACH, highest reduction in peak ICP (44%) was due to backward blasts whereas the lowest reduction in peak ICP and brain strains was due to forward blast (27%). The biomechanical responses of a human head to primary blast insult exhibited directional sensitivity owing to the different geometry contours and coverage of the helmet construction and asymmetric anatomy of the head. Thus, direction-specific tolerances are needed in helmet design in order to offer omni-directional protection for the human head. The blasts of varying peak overpressures and durations that are believed to produce the same level of lung injury produce different levels of mechanical responses in the brain, and hence "iso-damage" curves for brain injury are likely different than the Bowen curves for lung injury.	[Zhang, Liying; Makwana, Rahul; Sharma, Sumit] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA		Zhang, LY (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI USA.; Zhang, LY (corresponding author), Wayne State Univ, Bioengn Ctr, 818 West Hancock St, Detroit, MI 48201 USA.	lzhang@wayne.edu	MAKWANA, RAHUL/H-9629-2019		Department of Defence [W81XWH-08-1-0678]	This work was partially supported by a Department of Defence award W81XWH-08-1-0678.	Aare M, 2007, INT J IMPACT ENG, V34, P596, DOI 10.1016/j.ijimpeng.2005.08.001; Allsop D, 1988, P 32 STAPP CAR CRASH; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bir C, 2011, TECHNICAL REPORT; Bowen IG, 1968, DASA2113 DEP DEF DEF; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; Defense Manpower Data Center, 2011, GLOB WAR TERR CAUS M; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of the Army, 2008, 10847020410 DEP ARM; Dobratz B. M., 1985, LLNL EXPLOSIVES HDB; Duetekom MJ, 1999, P 18 INT S BALL; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Galford JE, 1969, 69BHF6; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; King AI, 2003, P BIOM IMP, P1; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Li JZ, 2010, IFMBE PROC, V31, P1518, DOI 10.1007/978-3-642-14515-5_387; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McEntire BJ, 2005, 200512 USAARL; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W C, 2011, LLNLSR471496, DOI 10.2172/1021058; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Nyquist G. W., 1986, P 30 STAPP CAR CRASH; Sewell RGS, 1979, TP5920 NAV WEAP CTR; Sharma S, 2011, P INJ BIOM S; Stevenson C, 2009, J MIL VETERANS HEALT, V17, P17; Takhounts EG, 2004, STAPP CAR CRASH J, V47, P107; Trosseille X., 1992, P 36 STAPP CAR CRASH; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Ward C, 1980, P 24 STAPP CAR CRASH; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Xin X, 2009, INTERACTION BLAST HE; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L., 2003, P 2003 SUMM BIOENG C, P137; Zhang L, 2010, TECHNICAL REPORT; Zhang LH, 2008, 2008 PROCEEDINGS OF INFORMATION TECHNOLOGY AND ENVIRONMENTAL SYSTEM SCIENCES: ITESS 2008, VOL 1, P123; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	49	41	42	2	14	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								88	10.3389/fneur.2013.00088			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000087	23935591	Green Published, gold			2022-02-06	
J	De Beaumont, L; Henry, LC; Gosselin, N				De Beaumont, Louis; Henry, Luke C.; Gosselin, Nadia			Long-term functional alterations in sports concussion	NEUROSURGICAL FOCUS			English	Article						sports concussion; neurophysiology; long-term effect; cognition; motor function; neuropsychology	HUMAN MOTOR CORTEX; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; PAIRED ASSOCIATIVE STIMULATION; GABA(B) RECEPTOR AGONIST; ELECTROPHYSIOLOGICAL ABNORMALITIES; MULTIPLE CONCUSSIONS; CEREBRAL CONCUSSION; POSTURAL CONTROL; NCAA CONCUSSION	In this review the authors discuss persistent and cumulative alterations in both cognitive and motor function after sports concussions detected with some of the newest, most sophisticated brain investigation techniques. Ranging from subclinical neurophysiological alterations in young concussed athletes to quantifiable cognitive and motor function declines in former athletes in late adulthood with concussions sustained decades earlier, this review is also intended to provide new insights into the neuropathophysiology of sports concussion. (http://thejns.org/doi/abs/10.3171/2012.9.FOCUS12278)	[De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada; [De Beaumont, Louis; Gosselin, Nadia] Montreal Sacred Heart Hosp, Res Ctr, Montreal, PQ, Canada; [Henry, Luke C.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA		De Beaumont, L (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Michel Sarrazin Hall,CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	louis.de.beaumont@umontreal.ca					Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Allen JS, 2005, AM J HUM BIOL, V17, P673, DOI 10.1002/ajhb.20439; Barbeau E, 2004, NEUROLOGY, V62, P1317, DOI 10.1212/01.WNL.0000120548.24298.DB; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Carrillo C, 2010, J CLIN MICROBIOL, V48, P4094, DOI 10.1128/JCM.01081-10; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; Craik FIM., 1999, HDB AGING COGNITION, V2nd; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DONCHIN E, 1966, IEEE T BIO-MED ENG, VBM13, P131, DOI 10.1109/TBME.1966.4502423; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hollister JR, 2008, VIROLOGY, V373, P411, DOI 10.1016/j.virol.2007.12.019; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Koop MM, 2008, MOVEMENT DISORD, V23, P1262, DOI 10.1002/mds.22077; Lefaucheur JP, 2006, MOVEMENT DISORD, V21, P1350, DOI 10.1002/mds.20966; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; POLICH J, 1988, J CLIN NEUROPHYSIOL, V5, P287, DOI 10.1097/00004691-198807000-00004; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Restivo DA, 2004, FUNCT NEUROL, V19, P37; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; Spiers MV., 2001, PRINCIPLES NEUROPSYC; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Tremblay S, 2012, CEREB CORTEX; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004	71	41	41	3	57	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E8	10.3171/2012.9.FOCUS12278			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500009	23199431	Bronze			2022-02-06	
J	Jha, MK; Jeon, S; Suk, K				Jha, Mithilesh Kumar; Jeon, Sangmin; Suk, Kyoungho			Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders	CURRENT NEUROPHARMACOLOGY			English	Article						Aerobic glycolysis; neuro-metabolic disorders; neuronal-glial interaction; oxidative phosphorylation; pyruvate dehydrogenase complex; pyruvate dehydrogenase kinase	TRAUMATIC BRAIN-INJURY; ACTIVATED RECEPTOR-ALPHA; HUMAN SKELETAL-MUSCLE; ALZHEIMERS-DISEASE; ENERGY-METABOLISM; MITOCHONDRIAL DYSFUNCTION; AEROBIC GLYCOLYSIS; LACTATE SHUTTLE; IN-VIVO; PHOSPHORYLATION SITES	Metabolism is involved directly or indirectly in all processes conducted in living cells. The brain, popularly viewed as a neuronal-glial complex, gets most of its energy from the oxygen-dependent metabolism of glucose, and the mitochondrial pyruvate dehydrogenase complex (PDC) plays a key regulatory role during the oxidation of glucose. Pyruvate dehydrogenase kinase (also called PDC kinase or PDK) is a kinase that regulates glucose metabolism by switching off PDC. Four isoforms of PDKs with tissue specific activities have been identified. The metabolisms of neurons and glial cells, especially, those of astroglial cells, are interrelated, and these cells function in an integrated fashion. The energetic coupling between neuronal and astroglial cells is essential to meet the energy requirements of the brain in an efficient way. Accumulating evidence suggests that alterations in the PDKs and/or neuron-astroglia metabolic interactions are associated with the development of several neurological disorders. Here, the authors review the results of recent research efforts that have shed light on the functions of PDKs in the nervous system, particularly on neuron-glia metabolic interactions and neuro-metabolic disorders.	[Jha, Mithilesh Kumar; Jeon, Sangmin; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, Taegu 700422, South Korea		Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, 680 Gukchaebosang St, Taegu 700422, South Korea.	ksuk@knu.ac.kr		Jha, Mithilesh Kumar/0000-0002-9526-0053	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [2011-0028240]; Korean Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A111345]	This work was supported by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (2011-0028240). This study was also supported by a grant of the Korean Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345).	Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2007, GLIA, V55, P1272, DOI 10.1002/glia.20360; Balmaceda-Aguilera C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032409; Barros LF, 2007, GLIA, V55, P1222, DOI 10.1002/glia.20375; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Blass JP, 2000, ANN NY ACAD SCI, V924, P170; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bonvento G, 2005, J CEREBR BLOOD F MET, V25, P1394, DOI 10.1038/sj.jcbfm.9600127; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Dang CV, 2008, ERNST SCHERING FOUND, V4, P35, DOI 10.1007/2789_2008_088; DeKosky ST, 1996, NEURODEGENERATION, V5, P417, DOI 10.1006/neur.1996.0056; Denton R M, 1979, Essays Biochem, V15, P37; Denton RM, 1996, ADV ENZYME REGUL, V36, P183, DOI 10.1016/0065-2571(95)00020-8; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; Di RM, 2010, CHINESE MED J-PEKING, V123, P2358, DOI 10.3760/cma.j.issn.0366-6999.2010.17.014; DIENEL GA, 1988, J BIOL CHEM, V263, P19697; Dienel GA, 2004, NEUROCHEM INT, V45, P321, DOI 10.1016/j.neuint.2003.10.011; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gandhi GK, 2009, J NEUROCHEM, V111, P522, DOI 10.1111/j.1471-4159.2009.06333.x; Genc S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-162; Gibson GE, 2010, J ALZHEIMERS DIS, V20, pS591, DOI 10.3233/JAD-2010-100336; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; Hattori N, 2003, J NUCL MED, V44, P1709; Hauptmann S, 2009, NEUROBIOL AGING, V30, P1574, DOI 10.1016/j.neurobiolaging.2007.12.005; Hertz L, 2002, INT REV NEUROBIOL, V51, P1, DOI 10.1016/S0074-7742(02)51003-5; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Holness MJ, 2002, BIOCHEM J, V364, P687, DOI 10.1042/bj20011841; Huang BL, 2003, DIABETES, V52, P1371, DOI 10.2337/diabetes.52.6.1371; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; KATOHSEMBA R, 1988, CELL TISSUE RES, V252, P133; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Laurencikiene J, 2008, CANCER RES, V68, P9247, DOI 10.1158/0008-5472.CAN-08-1343; LeBlanc PJ, 2004, J PHYSIOL-LONDON, V557, P559, DOI 10.1113/jphysiol.2003.058263; Leybaert L, 2005, J CEREBR BLOOD F MET, V25, P2, DOI 10.1038/sj.jcbfm.9600001; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lovell MA, 2000, FREE RADICAL BIO MED, V29, P714, DOI 10.1016/S0891-5849(00)00346-4; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Mangia S, 2011, J CEREBR BLOOD F MET, V31, P1346, DOI 10.1038/jcbfm.2011.29; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Mangia S, 2009, J CEREBR BLOOD F MET, V29, P441, DOI 10.1038/jcbfm.2008.134; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MATSUMOTO K, 1995, BIOCHEM BIOPH RES CO, V209, P95, DOI 10.1006/bbrc.1995.1475; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mosconi L, 2005, EUR J NUCL MED MOL I, V32, P486, DOI [10.1007/s00259-008-1039-z, 10.1007/s00259-005-1762-7]; Mosconi L, 2009, NEUROLOGY, V72, P513, DOI 10.1212/01.wnl.0000333247.51383.43; Mosconi L, 2008, NEUROBIOL AGING, V29, P676, DOI 10.1016/j.neurobiolaging.2006.12.008; Nakai N, 2000, LIFE SCI, V68, P497, DOI 10.1016/S0024-3205(00)00947-4; Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001; Nehlig A, 2007, GLIA, V55, P1238, DOI 10.1002/glia.20376; Nicholson RM, 2010, BRAIN RES, V1347, P179, DOI 10.1016/j.brainres.2010.05.084; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Occhipinti R, 2009, J NEUROPHYSIOL, V101, P2528, DOI 10.1152/jn.90377.2008; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pan James G, 2007, Sci STKE, V2007, ppe14; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Peters SJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE980, DOI 10.1152/ajpendo.1998.275.6.E980; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; Pratico D, 2004, J ALZHEIMERS DIS, V6, P385; PRIESTMAN DA, 1994, BIOCHEM J, V300, P659, DOI 10.1042/bj3000659; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002; REED LJ, 1990, J BIOL CHEM, V265, P8971; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smallbone K, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-6; Smolle M, 2006, J BIOL CHEM, V281, P19772, DOI 10.1074/jbc.M601140200; Spriet LL, 2004, J APPL PHYSIOL, V96, P2082, DOI 10.1152/japplphysiol.01318.2003; Stacpoole P.W., 2012, AGING CELL; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263; Sugden MC, 1997, J MOL CELL CARDIOL, V29, P1867, DOI 10.1006/jmcc.1997.0425; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Sugden MC, 2001, DIABETES, V50, P2729, DOI 10.2337/diabetes.50.12.2729; Sugden MC, 2001, BIOCHEM SOC T, V29, P272, DOI 10.1042/0300-5127:0290272; Sun LJ, 2006, MITOCHONDRION, V6, P136, DOI 10.1016/j.mito.2006.04.003; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3; Tokmakov A.A., 2011, J MOL MODEL; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wang J, 2009, SCI CHINA SER C, V52, P1003, DOI 10.1007/s11427-009-0140-2; Wang Z, 2009, ENDOCR J, V56, P1019, DOI 10.1507/endocrj.K09E-178; Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Wynn RM, 2008, J BIOL CHEM, V283, P25305, DOI 10.1074/jbc.M802249200; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x; Zhou QQ, 2009, FEBS LETT, V583, P1132, DOI 10.1016/j.febslet.2009.02.043	141	41	42	0	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2012	10	4					393	403					11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	048KH	WOS:000311909700010	23730261	Green Submitted, Green Published			2022-02-06	
J	Kalonia, H; Mishra, J; Kumar, A				Kalonia, Harikesh; Mishra, Jitendriya; Kumar, Anil			Targeting Neuro-Inflammatory Cytokines and Oxidative Stress by Minocycline Attenuates Quinolinic-Acid-Induced Huntington's Disease-Like Symptoms in Rats	NEUROTOXICITY RESEARCH			English	Article						Minocycline; Neurotoxicity; Oxidative stress; Proinflammatory cytokines; Quinolinic acid	FOCAL CEREBRAL-ISCHEMIA; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; BEHAVIORAL ALTERATIONS; MOLECULAR-MECHANISMS; PARKINSONS-DISEASE	Recent experimental and clinical reports support the fact that the minocycline exhibits significant neuroprotective activity in neurodegenerative diseases. However, its mechanism of neuroprotection is still far from our understanding. Besides, minocycline does not always produce neuroprotective effect. Therefore, this study has been designed to explore the possible mechanism of minocycline in experimental model of HD in rats. Intrastriatal administration of quinolinic acid caused a significant reduction in body weight, motor dysfunction (impaired locomotor activity, rotarod performance, and beam walk test), oxidative damage (as evidenced by increase in lipid peroxidation, nitrite concentration, and depletion of super oxide dismutase and catalase), increased TNF-alpha and IL-6 levels as compared to the sham-treated animals. Minocycline (25, 50, and 100 mg/kg) treatment (for 21 days) significantly improved body weight, locomotor activity, rotarod performance, balance beam walk performance, oxidative defense, attenuated TNF-alpha and IL-6 levels as compared to quinolinic-acid (QA)-treated animals. This study provides evidence that minocycline might have neuroprotective effect against QA-induced Huntington-like behavioral, biochemical alterations, and neuroinflammation in rats.	[Kalonia, Harikesh; Mishra, Jitendriya; Kumar, Anil] Panjab Univ, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Div Pharmacol, Chandigarh 160014, India		Kumar, A (corresponding author), Panjab Univ, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Div Pharmacol, Chandigarh 160014, India.	kumaruips@yahoo.com	KUMAR, ANIL -/D-7471-2011; Kalonia, Harikesh/AAZ-7182-2021	KUMAR, ANIL -/0000-0002-9506-6197; 	University Grant Commission (U.G.C.), New DelhiUniversity Grants Commission, India	The Research Fellowship in Science for Meritorious Student (Harikesh Kalonia) of the University Grant Commission (U.G.C.), New Delhi, is gratefully acknowledged.	Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Amori L, 2009, NEUROSCIENCE, V159, P196, DOI 10.1016/j.neuroscience.2008.11.055; Appel SH, 2009, J CLIN INVEST, V119, P13, DOI 10.1172/JCI38096; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Bizat N, 2003, J NEUROSCI, V23, P5020; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Browne SE, 2002, INT REV NEUROBIOL, V53, P243; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chu LS, 2010, LIFE SCI, V86, P170, DOI 10.1016/j.lfs.2009.12.001; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Ganzella M, 2006, NEUROSCI RES, V55, P397, DOI 10.1016/j.neures.2006.05.003; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jiang WL, 2009, NEUROCHEM INT, V55, P601, DOI 10.1016/j.neuint.2009.06.001; Kalonia H, 2010, NEUROTOXICOLOGY, V31, P195, DOI 10.1016/j.neuro.2009.12.008; Kalonia H, 2009, NEUROSCI BULL, V25, P343, DOI 10.1007/s12264-009-0513-3; Kalonia H, 2009, INDIAN J EXP BIOL, V47, P880; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Kulkarni S K, 1999, HDB EXPT PHARM; Leblhuber F, 1998, CLIN CHEM LAB MED, V36, P747, DOI 10.1515/CCLM.1998.132; Lim D, 2008, J BIOL CHEM, V283, P5780, DOI 10.1074/jbc.M704704200; Lin CH, 2001, LIFE SCI, V69, P2503, DOI 10.1016/S0024-3205(01)01330-3; Liu XD, 2009, ARCH ORAL BIOL, V54, P1143, DOI 10.1016/j.archoralbio.2009.09.006; Luck H, 1971, METHODS ENZYMATIC AN; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Milakovic T, 2006, J BIOL CHEM, V281, P34785, DOI 10.1074/jbc.M603845200; Minghetti L, 2007, J NEUROPATH EXP NEUR, V66, P363, DOI 10.1097/nen.0b013e3180517477; Mishra MK, 2009, NEUROCHEM INT, V54, P464, DOI 10.1016/j.neuint.2009.01.022; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Rossato JI, 2002, NEUROSCI LETT, V318, P137, DOI 10.1016/S0304-3940(01)02504-6; Sanchez AME, 2008, ARCH MED RES, V39, P265, DOI 10.1016/j.arcmed.2007.11.011; Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Song C, 2003, J BIOL CHEM, V278, P33364, DOI 10.1074/jbc.M304240200; Stolp HB, 2009, NEUROPATH APPL NEURO, V35, P132, DOI 10.1111/j.1365-2990.2008.01005.x; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Tzeng Shun-Fen, 2005, Current Drug Targets - Inflammation and Allergy, V4, P335, DOI 10.2174/1568010054022051; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang XM, 2006, BIOCHEM BIOPH RES CO, V340, P1023, DOI 10.1016/j.bbrc.2005.12.125; Wellington CL, 2003, CLIN NEUROSCI RES, V3, P129, DOI 10.1016/S1566-2772(03)00055-0; WILLS ED, 1966, BIOCHEM J, V99, P667, DOI 10.1042/bj0990667; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	82	41	41	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428			NEUROTOX RES	Neurotox. Res.	NOV	2012	22	4					310	320		10.1007/s12640-012-9315-x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	008OM	WOS:000308966400006	22392362				2022-02-06	
J	Ryan, CG; Thompson, RE; Temkin, NR; Crane, PK; Ellenbogen, RG; Elmore, JG				Ryan, Christina G.; Thompson, Rachel E.; Temkin, Nancy R.; Crane, Paul K.; Ellenbogen, Richard G.; Elmore, Joann G.			Acute traumatic subdural hematoma: Current mortality and functional outcomes in adult patients at a Level I trauma center	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Acute subdural hematoma; traumatic brain injury; subdural hematoma; mortality	INJURY; SCORE	BACKGROUND: Existing data on outcomes following subdural hematoma have provided limited information on medical complications and functional outcomes. Mortality rates previously reported range from 22% to 66%. METHODS: This is a retrospective cohort study of prospectively collected data from a trauma registry in Washington State from 2005 through 2008. Patients were categorized by surgical evacuation status with the hypothesis that those undergoing evacuation represented a more severe injury. RESULTS: The 1,427 patients included in the study had a mean age of 58 years, and most of them were male (63%). Glasgow Coma Scale (GCS) score on presentation was greater than 12 in 58%; the average Injury Severity Score (ISS) was 27.5. Mean length of stay was 9.6 days (range, 1-110), with 40% spending 2 or more days in the intensive care unit. Twenty-eight percent experienced medical complications. At discharge, 94% had GCS score of 13 or greater. Independence with expression, feeding, and locomotion at discharge was noted for 92%, 81%, and 43%, respectively. Inpatient mortality was 16% and did not differ significantly between the evacuated group (15%) and the nonevacuated group (17%). CONCLUSION: This large cohort of patients with acute traumatic subdural hematoma demonstrated a lower mortality rate than those of previous reports, including among patients requiring surgical evacuation (J Trauma Acute Care Surg. 2012;73: 1348-1352). (J Trauma Acute Care Surg. 2012;73:1348-1354. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Ryan, Christina G.; Thompson, Rachel E.; Crane, Paul K.; Elmore, Joann G.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Ryan, Christina G.; Thompson, Rachel E.; Temkin, Nancy R.; Ellenbogen, Richard G.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Elmore, Joann G.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA		Ryan, CG (corresponding author), Univ Washington, Harborview Med Ctr, Hosp Med, 325 9th Ave,Box 359780, Seattle, WA 98104 USA.	cgilmore@uw.edu	Crane, Paul K/C-8623-2014	Crane, Paul/0000-0003-4278-7465	National Cancer Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [2 KO5 CA104699-06]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K05CA104699] Funding Source: NIH RePORTER	This work was supported by the National Cancer Institute at the National Institutes of Health (2 KO5 CA104699-06 to J.G.E.).	Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; [Anonymous], 2006, ICD 9 CM INT CLASS D; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Committee on Medical Aspect of Automotive Safety, 1971, JAMA-J AM MED ASSOC, V215, P277; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Dent DL, 1995, J TRAUMA, V39, P42; Depreitere B, 2003, ACTA NEUROCHIR, V145, P541, DOI 10.1007/s00701-003-0020-7; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; JENNETT B, 1976, LANCET, V1, P1031; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Tallon JM, 2008, CAN J SURG, V51, P339; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014	14	41	42	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73	5					1348	1353		10.1097/TA.0b013e31826fcb30			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	043VF	WOS:000311577100056	23117390	Green Accepted			2022-02-06	
J	Hohl, A; Gullo, JD; Silva, CCP; Bertotti, MM; Felisberto, F; Nunes, JC; de Souza, B; Petronilho, F; Soares, FMS; Prediger, RDS; Dal-Pizzol, F; Linhares, MN; Walz, R				Hohl, Alexandre; Gullo, Jackson da Silva; Pestana Silva, Claudia Carvalho; Bertotti, Melina More; Felisberto, Francine; Nunes, Jean Costa; de Souza, Bruna; Petronilho, Fabricia; Schneider Soares, Flavia Mahatma; Schroder Prediger, Rui Daniel; Dal-Pizzol, Felipe; Linhares, Marcelo Neves; Walz, Roger			Plasma levels of oxidative stress biomarkers and hospital mortality in severe head injury: A multivariate analysis	JOURNAL OF CRITICAL CARE			English	Article						Traumatic brain injury; Prognosis; TBARS; Carbonyl; Oxidative stress; Hospital mortality	TRAUMATIC BRAIN-INJURY; COMA DATA-BANK; LIPID-PEROXIDATION; WISTAR RATS; KAINIC ACID; CNS INJURY; MECHANISMS; STROKE; IMPACT; CITY	Introduction: The association between biomarkers of oxidative stress and the prognosis of patients with traumatic brain injury (TBI) remains inconclusive. Objective: The objective was to investigate the association between plasma levels of lipid peroxidation (thiobarbituric acid reactive species [TBARS]) and protein oxidation (carbonyl) biomarkers and the hospital mortality of patients with severe TBI. Methods: Plasma levels of TBARS and carbonyl were determined in 79 consecutive patients with severe TBI (Glasgow Coma Scale [GCS] <= 8) at a median of 12 hours (interquartile range [IQ] 25-75, 6.5-19.0), 30 hours (IQ 25-75, 24.7-37.0), and 70 (IQ 25-75, 55.0-78.5) hours after TBI and were compared with age-and sex-matched controls. The association between the TBARS and carbonyl levels and the hospital mortality was analyzed by multiple logistic regression analysis. Results: The mean age of patients was 34.8 years. Eighty-six percent were male. The TBARS and carbonyl levels were significantly higher in patients than in controls. There was a trend (P = .09) for higher plasma levels of TBARS and carbonyl proteins at 12 hours, but not at 30 or 70 hours, after trauma in nonsurvivors than in survivors. These findings were not confirmed after the adjustments by multiple logistic regression analysis. The final model showed a higher adjusted odds ratio for death for patients with admission GCS lower than 5 (odds ratio [OR] = 4.04; 95% confidence interval [CI], 1.33-12.13; P = .01) than those with higher GCS scores. Abnormal pupils were also associated with higher mortality (OR = 3.97; 95% CI, 1.22-12.13; P = .02). There was a nonsignificant trend for association between glucose greater than or equal to 150 mm/dL in the first 12 hours and death than levels between 70 and 149 mg/dL (OR = 2.92; 95% CI, 0.96-9.02; P = .06). Conclusions: Plasma levels of TBARS and carbonyl increase significantly in the first 70 hours after severe TBI but are not independently associated with the hospital mortality. (C) 2012 Elsevier Inc. All rights reserved.	[Hohl, Alexandre; de Souza, Bruna; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, HU, Florianopolis, SC, Brazil; [Hohl, Alexandre; Gullo, Jackson da Silva; Pestana Silva, Claudia Carvalho; Bertotti, Melina More; Nunes, Jean Costa; Schneider Soares, Flavia Mahatma; Schroder Prediger, Rui Daniel; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas CeNAp, Univ Hosp, Florianopolis, SC, Brazil; [Felisberto, Francine; Petronilho, Fabricia; Dal-Pizzol, Felipe] Univ Extremo Sul Catarinense, Lab Fisiopatol Expt, Unidade Acad Ciencias Saude, Criciuma, SC, Brazil; [Schroder Prediger, Rui Daniel] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Florianopolis, SC, Brazil; [Bertotti, Melina More; Linhares, Marcelo Neves] HGCR, Serv Neurocirurgia, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Walz, Roger] HGCR, Ctr Epilepsia Estado Santa Catarina CEPESC, Florianopolis, SC, Brazil		Walz, R (corresponding author), UFSC, Dept Clin Med, Univ Hosp, 3 Andar,Campus Univ, Trindade Florianopolis, SC, Brazil.		Prediger, Rui D/C-4036-2013; Petronilho, Fabricia/D-8822-2013; Prediger, Rui Daniel/AAV-3419-2020; Walz, Roger/K-9096-2013; Dal-Pizzol, Felipe/F-2756-2015; Neurociencia, Inct/I-1011-2013; Diaz, Alexandre Paim/AAD-8323-2019; Hohl, Alexandre/R-9269-2019	Prediger, Rui D/0000-0002-7547-6463; Prediger, Rui Daniel/0000-0002-7547-6463; Walz, Roger/0000-0002-9875-6687; Dal-Pizzol, Felipe/0000-0003-3003-8977; Diaz, Alexandre Paim/0000-0002-6591-6648; Hohl, Alexandre/0000-0002-8073-5837; Mahatma Schneider Soares, Flavia/0000-0001-5968-1312	Brazilian Council for Scientific and Technologic Development, Brazil; Foundation for Scientific Research and Technology of the State of Santa Catarina	This work was supported by the Brazilian Council for Scientific and Technologic Development, Brazil and the Foundation for Scientific Research and Technology of the State of Santa Catarina. The technical support for biological sample collection came from Laboratorio Biomedico (Florianopolis) under the Pharm. Saulo Correia de Mello supervision.	Dal-Pizzol F, 2000, NEUROSCI LETT, V291, P179, DOI 10.1016/S0304-3940(00)01409-9; Dal-Pizzol F, 2007, METAB BRAIN DIS, V22, P25, DOI 10.1007/s11011-006-9033-2; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Grotto D, 2007, J PHARMACEUT BIOMED, V43, P619, DOI 10.1016/j.jpba.2006.07.030; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Klamt F, 2001, FREE RADICAL BIO MED, V30, P1137; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nayak CD, 2007, INDIAN J MED SCI, P381; Nayak C, 2007, CLIN CHEM LAB MED, V45, P629, DOI 10.1515/CCLM.2007.123; Nayak CD, 2008, NEUROL INDIA, V56, P31, DOI 10.4103/0028-3886.39309; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Perel P, 2006, BMC MED INFORM DECIS, P38; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Petronilho F., 2009, J SURG RES; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Schwarzbold M, 2008, NEUROPSYCH DIS TREAT, P1176; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0	29	41	43	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	OCT	2012	27	5							523.e11	10.1016/j.jcrc.2011.06.007			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025PP	WOS:000310204300025	21803537	hybrid			2022-02-06	
J	Kwiatt, ME; Patel, MS; Ross, SE; Lachant, MT; MacNew, HG; Ochsner, MG; Norwood, SH; Speier, L; Kozar, R; Gerber, JA; Rowell, S; Krishnakumar, S; Livingston, DH; Manis, G; Haan, JM				Kwiatt, Michael E.; Patel, Mitul S.; Ross, Steven E.; Lachant, Mary T.; MacNew, Heather G.; Ochsner, M. Gage; Norwood, Scott H.; Speier, LaDonna; Kozar, Rosemary; Gerber, Jonathan A.; Rowell, Susan; Krishnakumar, Sheetal; Livingston, David H.; Manis, George; Haan, James M.			Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; venous thromboembolism prophylaxis; low-molecular weight heparin	INTERMITTENT PNEUMATIC COMPRESSION; INTRACRANIAL HEMORRHAGE; ENOXAPARIN; THROMHOEMBOLISM; MANAGEMENT	BACKGROUND: Venous thromboembolism (VTE) is a significant risk in trauma patients. Although low-molecular weight heparin (LMWH) is effective in VTE prophylaxis, its use for patients with traumatic intracranial hemorrhage remains controversial. The purpose of this study was to evaluate the safety of LMWH for VTE prophylaxis in blunt intracranial injury. METHODS: We conducted a retrospective multicenter study of LMWH chemoprophylaxis on patients with intracranial hemorrhage caused by blunt trauma. Patients with brain Abbreviated Injury Scale score of 3 or higher, age 18 years or older, and at least one repeated head computed tomographic scan were included. Patients with previous VTE; on preinjury anticoagulation; hospitalized for less than 48 hours; on heparin for VTE prophylaxis; or required emergent thoracic, abdominal, or vascular surgery at admission were excluded. Patients were divided into two groups: those who received LMWH and those who did not. The primary outcome was progression of intracranial hemorrhage on repeated head computed tomographic scan. RESULTS: The study included 1,215 patients, of which 220 patients (18.1%) received LMWH and 995 (81.9%) did not. Hemorrhage progression occurred in 239 of 995 control subjects and 93 of 220 LMWH patients (24% vs. 42%, p < 0.001). Hemorrhage progression occurred in 32 patients after initiating LMWH (14.5%). Nine of these patients (4.1%) required neurosurgical intervention for hemorrhage progression. CONCLUSION: Patients receiving LMWH were at higher risk for hemorrhage progression. We were unable to demonstrate safety of LMWH for VTE prophylaxis in patients with brain injury. The risk of using LMWH may exceed its benefit. (J Trauma Acute Care Surg. 2012; 73: 625-628. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Kwiatt, Michael E.; Patel, Mitul S.; Ross, Steven E.; Lachant, Mary T.] Cooper Univ Hosp, Off Surg Educ, Camden, NJ 08103 USA; [Livingston, David H.; Manis, George] Univ Med & Dent New Jersey, New Jersey Univ Hosp, Newark, NJ USA; [MacNew, Heather G.; Ochsner, M. Gage] Mem Univ Med Ctr, Savannah, GA USA; [Norwood, Scott H.; Speier, LaDonna] E Texas Med Ctr, Tyler, TX USA; [Kozar, Rosemary; Gerber, Jonathan A.] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Rowell, Susan; Krishnakumar, Sheetal] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Haan, James M.] Via Christi Reg Med Ctr, Wichita, KS USA		Kwiatt, ME (corresponding author), Cooper Univ Hosp, Off Surg Educ, 3 Cooper Plaza,Suite 411, Camden, NJ 08103 USA.	kwiatt-michael@cooperhealth.edu	Rowell, Susan/S-7480-2019	MacNew, Heather/0000-0002-8417-837X			Adams RC, 2008, J TRAUMA, V65, P300, DOI 10.1097/TA.0b013e31817cf744; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 1994, NEW ENGL J MED, V42, P456; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Ginzburg E, 2003, BRIT J SURG, V90, P1338, DOI 10.1002/bjs.4309; Huseynova K, 2009, J AM COLL SURGEONS, V208, P547, DOI 10.1016/j.jamcollsurg.2009.01.002; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Patel NY, 2000, J TRAUMA, V49, P132; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87	19	41	46	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					625	628		10.1097/TA.0b013e318265cab9			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	009TK	WOS:000309047900014	22929493				2022-02-06	
J	Bouvier, D; Fournier, M; Dauphin, JB; Amat, F; Ughetto, S; Labbe, A; Sapin, V				Bouvier, Damien; Fournier, Mathilde; Dauphin, Jean-Benoit; Amat, Flore; Ughetto, Sylvie; Labbe, Andre; Sapin, Vincent			Serum S100B Determination in the Management of Pediatric Mild Traumatic Brain Injury	CLINICAL CHEMISTRY			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; CHILDREN; PROTEIN; MULTICENTER; FAMILY; ADULTS	BACKGROUND: The place of serum S100B measurement in mild traumatic brain injury (mTBI) management is still controversial. Our prospective study aimed to evaluate its utility in the largest child cohort described to date. METHODS: Children younger than 16 years presenting at a pediatric emergency department within 3 h after TBI were enrolled prospectively for blood sampling to determine serum S100B concentrations. The following information was collected: TBI severity determined by using the Masters classification [1: minimal or Glasgow Coma Scale (GCS) 15, 2: mild or GCS 13-15, and 3: severe or GCS <13]; whether hospitalized or not; good or bad clinical evolution (CE); whether cranial computed tomography (CCT) was prescribed; and related presence (CCT+) or absence (CCT-) of lesions. RESULTS: For the 446 children enrolled, the median concentrations of S100B were 0.21, 0.31, and 0.44 mu g/L in Masters groups 1, 2, and 3, respectively, with a statistically significant difference between these groups (P < 0.05). In Masters group 2, 65 CCT scans were carried out. Measurement of S100B identified patients as CCT+ with 100% (95% CI 85-100) sensitivity and 33% (95% CI 20-50) specificity. Of the 424 children scored Masters 1 or 2, 21 presented "bad CE." S100B identified bad CE patients with 100% (95% CI 84-100) sensitivity and 36% (95% CI 31-41) specificity. Of the 242 children hospitalized, 81 presented an S100B concentration within the reference interval. CONCLUSIONS: Serum S100B determination during the first 3 h of management of children with mTBI has the potential to reduce the number of CCT scans, thereby avoiding unnecessary irradiation, and to save hospitalization costs. (c) 2012 American Association for Clinical Chemistry	[Bouvier, Damien; Fournier, Mathilde; Sapin, Vincent] Clermont Ferrand Teaching Hosp, Dept Biochem, Clermont Ferrand, France; [Dauphin, Jean-Benoit; Amat, Flore; Labbe, Andre] Clermont Ferrand Teaching Hosp, Dept Paediat Emergency, Clermont Ferrand, France; [Ughetto, Sylvie] Clermont Ferrand Teaching Hosp, Dept Med Informat, Clermont Ferrand, France		Sapin, V (corresponding author), CHU Gabriel Montpied, Ctr Biol, Lab Biochim Med, Rue Montalembert, F-63000 Clermont Ferrand, France.	vsapin@chu-clermontferrand.fr		Bouvier, Damien/0000-0002-2707-4320			Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bergman DA, 1999, PEDIATRICS, V104, P1407; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; Bouvier D, 2011, CLIN BIOCHEM, V44, P927, DOI 10.1016/j.clinbiochem.2011.05.004; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10185; Floret D, 2006, ARCH PEDIATRIE, V13, P528, DOI 10.1016/j.arcped.2006.03.017; Hall EJ, 2009, PEDIATR RADIOL, V39, pS57, DOI 10.1007/s00247-008-1027-2; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	25	41	42	0	7	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147	1530-8561		CLIN CHEM	Clin. Chem.	JUL	2012	58	7					1116	1122		10.1373/clinchem.2011.180828			7	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	970AA	WOS:000306099300011	22529109	Bronze			2022-02-06	
J	Yuan, F; Ding, J; Chen, H; Guo, Y; Wang, G; Gao, WW; Chen, SW; Tian, HL				Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li			Predicting outcomes after traumatic brain injury: The development and validation of prognostic models based on admission characteristics	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Prognostic models; prediction; traumatic brain injury; validation; outcome	ISCHEMIC-STROKE; HEAD-INJURY; D-DIMER; CALCIUM; IMPACT; HEMORRHAGE	BACKGROUND: Early estimation of prognosis for the patient with traumatic brain injury is an important factor in making treatment decisions, resource allocation, classify patients, or communicating with family. We aimed to develop and validate practical prognostic models for mortality at 30 days and for 6 months unfavorable outcome after moderate and severe traumatic brain injury. METHODS: Retrospectively collected data from our department were used to develop prognostic models for outcome. We developed four prognostic models based on admission predictors with logistic regression analysis. The performance of models was assessed with respect to discrimination and calibration. Discriminative ability was evaluated with C statistic, equal to the area under the receiver operating characteristic curve. Calibrative ability was assessed with the Hosmer-Lemeshow test (H-L test). The internal validity of models was evaluated with the bootstrap re-sampling technique. We validated three of the models in an external series of 203 patients that collected from another research center. Discrimination and calibration were further assessed to indicate the performance of the models in external patients. RESULTS: Logistic regression showed that age, pupillary reactivity, motor Glasgow Coma Score, computed tomography characters, glucose, hemoglobin, D-dimer, serum calcium, and intracranial pressure were independent prognostic factors of outcome. The models discriminated well in the development patients (C statistic 0.709-0.939). We extensively validate three of the models. Internal validation showed no overoptimism in any of the models' predictive C statistics. External validity was much better (C statistic 0.844-0.902). Calibration was also good (H-L tests, p > 0.05). Computer-based calculator that based on prognostic models was developed for clinical use. CONCLUSION: Our validated prognostic models have good performance and are generalizable to be used to predict outcome of new patients. We recommend the use of prognostic models to complement clinical decision making. (J Trauma Acute Care Surg. 2012; 73: 137-145. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai, Peoples R China		Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai, Peoples R China.	tianhengli1964@yahoo.com.cn			Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1412500]	Supported in part by a grant from the Shanghai Science and Technology Committee (Grant 10JC1412500).	Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Brain Trauma Foundation. American Association of Neurological Surgeons & Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pi, DOI DOI 10.1089/NEU.2007.9999; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Ovbiagele B, 2006, NEUROLOGY, V67, P170, DOI 10.1212/01.wnl.0000223629.07811.ae; Ovbiagele B, 2008, STROKE, V39, P2231, DOI 10.1161/STROKEAHA.107.513499; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Steyerberg, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Tymianski Michael, 1996, Neurosurgery (Baltimore), V38, P1176, DOI 10.1097/00006123-199606000-00028; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	25	41	48	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					137	145		10.1097/TA.0b013e31824b00ac			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	979JU	WOS:000306814100020	22743383				2022-02-06	
J	Luo, P; Chen, T; Zhao, YB; Xu, HX; Huo, K; Zhao, MM; Yang, YF; Fei, Z				Luo, Peng; Chen, Tao; Zhao, Yongbo; Xu, Haoxiang; Huo, Kai; Zhao, Mingming; Yang, Yuefan; Fei, Zhou			Protective effect of Homer 1a against hydrogen peroxide-induced oxidative stress in PC12 cells	FREE RADICAL RESEARCH			English	Article						reactive oxygen species; mitochondria; apoptosis; antioxidant; postsynaptic density; calcium homeostasis	METABOTROPIC GLUTAMATE RECEPTORS; SYNAPTIC PLASTICITY; GENE-EXPRESSION; TRAUMATIC BRAIN; CYTOCHROME-C; MOUSE MODEL; PROTEIN; FAMILY; MITOCHONDRIA; APOPTOSIS	Oxidative stress-induced cell damage is involved in many neurological diseases. Homer protein, as an important scaffold protein at postsynaptic density, regulates synaptic structure and function. Here, we reported that hydrogen peroxide (H2O2) induced the expression of Homer 1a. Down-regulation of Homer 1a with a specific small interfering RNA (siRNA) exacerbated H2O2-induced cell injury. Up-regulation of Homer 1a by lentivirus transfection did not affect the anti-oxidant activity, but significantly reduced the reactive oxygen species (ROS) production and lipid peroxidation after H2O2-induced oxidative stress. Overexpression of Homer 1a attenuated the loss of mitochondrial membrane potential (MMP) and ATP production induced by H2O2, and subsequently inhibited mitochondrial dysfunction-induced cytochrome c release, increase of Bax/Bcl-2 ratio and caspase-9/caspase-3 activity. Furthermore, in the presence of BAPTA-AM, an intracellular free-calcium (Ca2+) chelator, overexpression of Homer 1a had no significant effects on H2O2-induced oxidative stress. These results suggest that Homer 1a has protective effects against H2O2-induced oxidative stress by reducing ROS accumulation and activation of mitochondrial apoptotic pathway, and these protective effects are dependent on the regulation of intracellular Ca2+ homeostasis.	[Luo, Peng; Chen, Tao; Zhao, Yongbo; Xu, Haoxiang; Huo, Kai; Zhao, Mingming; Yang, Yuefan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 15 Changle Xi Rd, Xian 710032, Peoples R China.	feizhou@fmmu.edu.cn	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093]; 863 High-Tech ProjectNational High Technology Research and Development Program of China [2009AA02Z419]	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article. The work was supported by National Natural Science Foundation of China (No. 30670796, No. 30930093) and the 863 High-Tech Project (2009AA02Z419).	Ageta H, 2001, MOL BRAIN RES, V97, P186, DOI 10.1016/S0169-328X(01)00303-5; Avery SV, 2011, BIOCHEM J, V434, P201, DOI 10.1042/BJ20101695; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Chen M, 2007, J BIOL CHEM, V282, P33888, DOI 10.1074/jbc.M702969200; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Denisova NA, 1999, FREE RADICAL BIO MED, V27, P1292, DOI 10.1016/S0891-5849(99)00163-X; Dickey CA, 2003, J NEUROSCI, V23, P5219; Dietrich JB, 2007, SYNAPSE, V61, P587, DOI 10.1002/syn.20412; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Gleichmann M, 2011, ANTIOXID REDOX SIGN, V14, P1261, DOI 10.1089/ars.2010.3386; Govek EE, 2004, NAT NEUROSCI, V7, P364, DOI 10.1038/nn1210; Guerrero AD, 2008, APOPTOSIS, V13, P177, DOI 10.1007/s10495-007-0139-8; Hernandez-Garcia D, 2010, FREE RADICAL BIO MED, V49, P130, DOI 10.1016/j.freeradbiomed.2010.03.020; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401-011-0921-0; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Knackstedt LA, 2010, J NEUROSCI, V30, P7984, DOI 10.1523/JNEUROSCI.1244-10.2010; Kwon SH, 2011, NEUROCHEM INT, V58, P533, DOI 10.1016/j.neuint.2011.01.012; Li RC, 2008, BRAIN RES, V1190, P159, DOI 10.1016/j.brainres.2007.11.022; Li SY, 2010, FREE RADICAL BIO MED, V48, P597, DOI 10.1016/j.freeradbiomed.2009.12.004; Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011; Maroto R, 1997, J NEUROCHEM, V69, P514; Marrone DF, 2008, J NEUROSCI, V28, P1030, DOI 10.1523/JNEUROSCI.4235-07.2008; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; McCoy MK, 2012, ANTIOXID REDOX SIGN, V16, P869, DOI [10.1089/ars.2011.4019, 10.1089/ars.2011.4074]; McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011; Miletic G, 2009, ANESTH ANALG, V109, P2000, DOI 10.1213/ANE.0b013e3181beea9b; Oberst A, 2008, CELL DEATH DIFFER, V15, P1139, DOI 10.1038/cdd.2008.65; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olmez I, 2012, NEUROCHEM INT, V60, P208, DOI 10.1016/j.neuint.2011.11.009; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Potschka H, 2002, EUR J NEUROSCI, V16, P2157, DOI 10.1046/j.1460-9568.2002.02265.x; Rezvani K, 2007, J NEUROSCI, V27, P10508, DOI 10.1523/JNEUROSCI.3353-07.2007; Roselli F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006011; Sanchez-Gallego JI, 2010, FREE RADICAL BIO MED, V48, P1444, DOI 10.1016/j.freeradbiomed.2010.02.034; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; Tappe A, 2006, NAT MED, V12, P677, DOI 10.1038/nm1406; Tiago T, 2011, CELL CALCIUM, V49, P174, DOI 10.1016/j.ceca.2011.01.009; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Twiddy D, 2004, J BIOL CHEM, V279, P19665, DOI 10.1074/jbc.M311388200; von Bernhardi R, 2012, ANTIOXID REDOX SIGN, V16, P974, DOI 10.1089/ars.2011.4082; Worley PF, 2007, CELL CALCIUM, V42, P363, DOI 10.1016/j.ceca.2007.05.007; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yano M, 2005, NEUROSCIENCE, V132, P855, DOI 10.1016/j.neuroscience.2004.12.019; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Zhang SH, 2010, J MOL NEUROSCI, V40, P311, DOI 10.1007/s12031-009-9285-5	52	41	41	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.	JUN	2012	46	6					766	776		10.3109/10715762.2012.678340			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939RW	WOS:000303832700007	22435683				2022-02-06	
J	Piao, CS; Loane, DJ; Stoica, BA; Li, SH; Hanscom, M; Cabatbat, R; Blomgren, K; Faden, AI				Piao, Chun-Shu; Loane, David J.; Stoica, Bogdan A.; Li, Shihong; Hanscom, Marie; Cabatbat, Rainier; Blomgren, Klas; Faden, Alan I.			Combined inhibition of cell death induced by apoptosis inducing factor and caspases provides additive neuroprotection in experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Apoptosis inducing factor; Caspase; Cyclophilin A	INDEPENDENT PROGRAMMED NECROSIS; OXYGEN-GLUCOSE DEPRIVATION; CYCLOPHILIN-A; CEREBRAL-ISCHEMIA; NEURONAL DEATH; HISTONE H2AX; POLY(ADP-RIBOSE) POLYMERASE; NEUROLOGICAL DYSFUNCTION; RHEUMATOID-ARTHRITIS; HYPOXIA-ISCHEMIA	Neuronal programmed cell death (PCD) contributes to delayed tissue damage after traumatic brain injury (TBI). Both caspase-dependent and caspase-independent mechanisms have been implicated, with the latter including apoptosis inducing factor (AIF). The peptidyl-proplyl isomerase Cyclophilin A (CypA) transports AIF from the cytosol to the nucleus, a key step for AIF-dependent cell death. We compared the effects of single versus combined inhibition of caspase and AIF pathways in a mouse controlled cortical impact (CCI) model, by examining the effects of CypA gene knockout (CypA(-/-)), caspase inhibition with a pan-caspase inhibitor (boc-aspartyl(oMe)-fluoromethylketone, BAF), or combined modulation. TBI caused caspase activation as well as translocation of AIF to the nucleus. Markers of caspase activation including caspase-specific fodrin cleavage fragments and number of FLIVO-positive cells were reduced in BAF-treated CypA(+/+) mice, whereas markers of AIF activation including AIF/H2AX interaction and AIF translocation to the nucleus were attenuated in CypA(-/-) mice. Each single intervention, (CypA(-/-) or BAF-treated CypA(+/+)) reduced the number of apoptotic cells (TUNEL-positive) in the cortex and improved long-term sensorimotor function; CypA(-/-) also attenuated microglial activation after injury. Importantly, BAF-treated CypA(-/-) mice, showed greater effects than either intervention alone on multiple outcomes including: reduction in TUNEL-positive cells, decrease in neuroinflammation, improved motor and cognitive recovery, and attenuation of lesion volume and neuronal loss in the hippocampus. Using two in vitro neuronal cell death models known to induce AIF-mediated PCD, we also showed that neurons from CypA(-/-) animals were protected and that effects were unrelated to caspase activation. These data indicate that AIF-mediated and caspase-dependent pathways contribute independently and in parallel to secondary injury after TBI, and suggest that combined therapeutic strategies directed at multiple PCD pathways may provide superior neuroprotection than those directed at single mechanisms. (C) 2012 Elsevier Inc. All rights reserved.	[Piao, Chun-Shu; Loane, David J.; Stoica, Bogdan A.; Li, Shihong; Hanscom, Marie; Cabatbat, Rainier; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Blomgren, Klas] Univ Gothenburg, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden; [Faden, Alan I.] Karolinska Inst, Karolinska Univ Hosp Q2 07, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Organized Res, Dept Anesthesiol, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Organized Res, Dept Anesthesiol, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Blomgren, Klas/0000-0002-0476-7271; Hanscom, Marie/0000-0001-8308-135X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 RO1 NS0618839]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER	We thank Michael Murray II, Michael Dinizo, Stephanie Custer, Kelly Wilson, and Nicole Hockenbury for expert technical assistance. This work is supported by NIH grant 1 RO1 NS0618839.	Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Baritaud M, 2010, CELL CYCLE, V9, P3166, DOI 10.4161/cc.9.16.12552; Boulos S, 2007, NEUROBIOL DIS, V25, P54, DOI 10.1016/j.nbd.2006.08.012; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colgan J, 2005, J IMMUNOL, V174, P6030, DOI 10.4049/jimmunol.174.10.6030; Conti AC, 1998, J NEUROSCI, V18, P5663; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; El Ghouzzi V, 2007, J NEUROPATH EXP NEUR, V66, P838, DOI 10.1097/NEN.0b013e318148b822; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hilton G.D., 2008, J CEREB BLOOD FLOW M; Joza N, 2009, ANN NY ACAD SCI, V1171, P2, DOI 10.1111/j.1749-6632.2009.04681.x; Kabadi S.V., 2011, NEUROTHERAPEUTICS; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kim H, 2005, CLIN IMMUNOL, V116, P217, DOI 10.1016/j.clim.2005.05.004; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Osato K, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.63; Piao CS, 2009, J CEREBR BLOOD F MET, V29, P759, DOI 10.1038/jcbfm.2008.168; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; RINK A, 1995, AM J PATHOL, V147, P1575; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Satoh K, 2008, CIRCULATION, V117, P3088, DOI 10.1161/CIRCULATIONAHA.107.756106; Satoh K, 2009, NAT MED, V15, P649, DOI 10.1038/nm.1958; Seizer P, 2011, ARTERIOSCL THROM VAS, V31, P1377, DOI 10.1161/ATVBAHA.111.225771; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki J, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/916514; Thal SE, 2011, NEUROSCI LETT, V499, P1, DOI 10.1016/j.neulet.2011.05.016; Tomita T, 2006, INT J MOL MED, V18, P257; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Wei YA, 2010, ATHEROSCLEROSIS, V213, P415, DOI 10.1016/j.atherosclerosis.2010.09.033; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	64	41	44	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2012	46	3					745	758		10.1016/j.nbd.2012.03.018			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	950DK	WOS:000304629300024	22426396	Green Accepted			2022-02-06	
J	Cameron, KL; Marshall, SW; Sturdivant, RX; Lincoln, AE				Cameron, Kenneth L.; Marshall, Stephen W.; Sturdivant, Rodney X.; Lincoln, Andrew E.			Trends in the Incidence of Physician-Diagnosed Mild Traumatic Brain Injury among Active Duty U.S. Military Personnel between 1997 and 2007	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; mild traumatic brain injury; military; trends	POSTTRAUMATIC-STRESS-DISORDER; MEDICAL SURVEILLANCE; SERVICE MEMBERS; CONCUSSION; SPORTS; COMBAT; RECOMMENDATIONS; EPIDEMIOLOGY; DISLOCATION; DEPLOYMENT	Mild traumatic brain injury (mTBI) has been described as the most common form of traumatic brain injury within military populations; however, few epidemiologic studies have examined incidence rates for mTBI in this population. The objective of this study was to examine trends in the incidence of mTBI among active-duty U. S. service members between 1997 and 2007. Specifically, we were interested in evaluating trends in the incidence rates in relation to the initiation of combat operations in Iraq and Afghanistan. A retrospective cohort study was conducted utilizing data extracted from the Defense Medical Surveillance System to identify all incident cases of mTBI within the study population. The primary outcome of interest was the incidence rate of mTBI per 1000 person-years. Multivariable Poisson regression was used to analyze the data. There were 98,012 mTBI cases and 14,956,955 person-years of follow-up, for an overall incidence rate of 6.55 (95% CI 6.51,6.59) per 1000 person-years. There was a steady increase in the mTBI rate over time. The average change in the mTBI rate was 8.5% (95% CI 8.2%, 8.8%) per year; however, the rate rose dramatically in the last 2 years of the study period. Overall, for 2006-2007 versus 1997-2005, the rate ratio was 1.61 (95% CI 1.58,1.65). The greatest increase in the rate of mTBI was observed among those serving in Iraq, who experienced a 38.4% (95% CI 35.4%, 41.1%) annual increase in new cases. The observed increase in the incidence of mTBI in this population has significant policy implications in terms of allocating appropriate health care resources.	[Cameron, Kenneth L.] US Mil Acad, Keller Army Hosp, West Point, NY 10996 USA; [Sturdivant, Rodney X.] US Mil Acad, Dept Math Sci, West Point, NY 10996 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Lincoln, Andrew E.] Union Mem Hosp, MedStar Hlth Res Inst, Baltimore, MD USA		Cameron, KL (corresponding author), US Mil Acad, Keller Army Hosp, 900 Washington Rd, West Point, NY 10996 USA.	kenneth.cameron@amedd.army.mil		Marshall, Stephen/0000-0002-2664-9233; Cameron, Kenneth/0000-0002-6276-4482	Congressionally Directed Medical Research Program's Post-Traumatic Stress Disorder and Traumatic Brain Injury Research Program [W81XWH-08-2-0152]	The views and opinions expressed are those of the authors and do not represent the official policy of the U.S. Army, Department of Defense, or the U. S. government. We would like to thank Dr. Angie Eick-Cost and her staff from the Armed Forces Health Surveillance Center for assisting our research team with data acquisition. We would also like to acknowledge the U.S. service members on active duty during the study period between 1997 and 2007 for their selfless commitment to serve our nation. Finally, we would like to recognize the active-duty and civilian providers and support staff that coordinated and delivered the medical care for this cohort throughout the military health system. This project was supported by the Congressionally Directed Medical Research Program's Post-Traumatic Stress Disorder and Traumatic Brain Injury Research Program Award no. W81XWH-08-2-0152.	Army Medical Surveillance Activity, 2004, DEF MED EP DAT US GU; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brundage JF, 2000, MIL MED, V165, P505, DOI 10.1093/milmed/165.7.505; Cameron KL, 2010, J ATHL TRAINING, V45, P29, DOI 10.4085/1062-6050-45.1.29; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chrisman S.P., 2011, CLIN PEDIAT PHILA; Ciminera P, 2007, AM J TROP MED HYG, V76, P275, DOI 10.4269/ajtmh.2007.76.275; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hsiao M, 2010, AM J SPORT MED, V38, P1997, DOI 10.1177/0363546510371423; Joint Improvised Explosive Device Defeat Organization, 2008, ANN REP FY 2008 DEP, P1; Joint Improvised Explosive Device Defeat Organization, 2007, AIDS EP UPD, P1; Jones BH, 2010, AM J PREV MED, V38, pS42, DOI 10.1016/j.amepre.2009.10.014; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrea M.A, 2008, MILD TRAUMATIC BRAIN, P153; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Owens BD, 2009, J BONE JOINT SURG AM, V91A, P791, DOI 10.2106/JBJS.H.00514; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson ALG, 2009, SOC PSYCH PSYCH EPID, V44, P473, DOI 10.1007/s00127-008-0461-7	39	41	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1313	1321		10.1089/neu.2011.2168			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600004	22332633				2022-02-06	
J	Chen, T; Cao, L; Dong, WP; Luo, P; Liu, WB; Qu, Y; Fei, Z				Chen, Tao; Cao, Lei; Dong, WenPeng; Luo, Peng; Liu, WenBo; Qu, Yan; Fei, Zhou			Protective Effects of mGluR5 Positive Modulators Against Traumatic Neuronal Injury Through PKC-Dependent Activation of MEK/ERK Pathway	NEUROCHEMICAL RESEARCH			English	Article						Neuroprotective effect; Traumatic brain injury; ERK; PKC	METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-KINASE-C; BRAIN-INJURY; IN-VITRO; CORTICAL-NEURONS; ANTAGONISTS MPEP; MAP KINASES; CELLS; RAT; PHARMACOLOGY	Several previous studies utilizing selective pharmacological antagonists have demonstrated that type 5 metabotropic glutamate receptors (mGluR5) are potential therapeutic targets for the treatment of numerous disorders of the central nervous system, but the role of mGluR5 activation in traumatic brain injury (TBI) is not fully understood. Here in an in vitro TBI model, the mGluR5 agonist (RS)-2-chloro-5- hydroxyphenylglycine (CHPG) and the positive allosteric modulators 3-cyano-N-(1,3- diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB) were used to investigate the neuroprotective potency of mGluR5 activation. Data showed that CHPG and CDPPB suppressed the increase of LDH release and caspase-3 activation induced by traumatic neuronal injury in a dose-dependent manner, and the salutary effects were also present when these compounds were added 1 h after injury. Western blot was used to examine the activation of three members of mitogen-activated protein kinases: extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 kinase (p38). CHPG and CDPPB enhanced the activation of ERK after traumatic neuronal injury, and PD98059 and U0126, two selective MEK/ERK inhibitors, partly revised the protective effects. Furthermore, we also investigated the role of protein kinase C (PKC) in CHPG and CDPPB-induced neuroprotection. With the pretreatment of chelerythrine chloride, a PKC inhibitor, the surpressing effects of CHPG and CDPPB on traumatic injury-evoked LDH release and caspase-3 activation were blocked. All of these findings extended the protective role of mGluR5 activation in an in vitro model of TBI and suggested that these protective effects might be mediated by the PKC-dependent activation of MEK/ERK pathway. These results may have important implications for the development of mGluR5 modulators to treat TBI.	[Chen, Tao; Luo, Peng; Liu, WenBo; Qu, Yan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Cao, Lei] Xi An Jiao Tong Univ, Xian Cent Hosp, Dept Neurol Dis, Xian 710032, Shaanxi, Peoples R China; [Dong, WenPeng] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Cardiovasc Surg, Guangzhou 510010, Guangdong, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China.	zhoufei@fmmu.edu.cn		Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093]	This work was financially supported by the National Natural Science Foundation of China (No. 30930093).	Bhave G, 2004, J NEUROBIOL, V61, P88, DOI 10.1002/neu.20083; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013, DOI 10.1097/00004647-200109000-00001; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; D'Antoni S, 2008, NEUROCHEM RES, V33, P2436, DOI 10.1007/s11064-008-9694-9; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Flor PJ, 2002, ADV EXP MED BIOL, V513, P197; Gold MS, 2005, NEUROSIGNALS, V14, P147, DOI 10.1159/000087653; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kew JNC, 2005, PSYCHOPHARMACOLOGY, V179, P4, DOI 10.1007/s00213-005-2200-z; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Liu F, 2005, J NEUROCHEM, V95, P1363, DOI 10.1111/j.1471-4159.2005.03474.x; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morin N, 2010, NEUROPHARMACOLOGY, V58, P981, DOI 10.1016/j.neuropharm.2009.12.024; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Parmentier-Batteur S, 2012, NEUROPHARMACOLOGY, V62, P1453, DOI 10.1016/j.neuropharm.2010.11.013; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Sugano T, 2006, J NEUROCHEM, V98, P20, DOI 10.1111/j.1471-4159.2006.03846.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	36	41	42	1	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2012	37	5					983	990		10.1007/s11064-011-0691-z			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	920LC	WOS:000302404900010	22228200				2022-02-06	
J	Theeler, BJ; Flynn, FG; Erickson, JC				Theeler, Brett J.; Flynn, Frederick G.; Erickson, Jay C.			Chronic Daily Headache in U.S. Soldiers After Concussion	HEADACHE			English	Article						mild traumatic brain injury; concussion; posttraumatic headache; military	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; PREVALENCE; VETERANS; MIGRAINE; RISK; IRAQ	Objective.-To determine the prevalence and characteristics of, and factors associated with, chronic daily headache (CDH) in U.S. soldiers after a deployment-related concussion. Methods.-A cross-sectional, questionnaire-based study was conducted with a cohort of 978 U.S. soldiers who screened positive for a deployment-related concussion upon returning from Iraq or Afghanistan. All soldiers underwent a clinical evaluation at the Madigan Traumatic Brain Injury Program that included a history, physical examination, 13-item self-administered headache questionnaire, and a battery of cognitive and psychological assessments. Soldiers with CDH, defined as headaches occurring on 15 or more days per month for the previous 3 months, were compared to soldiers with episodic headaches occurring less than 15 days per month. Results.-One hundred ninety-six of 978 soldiers (20%) with a history of deployment-related concussion met criteria for CDH and 761 (78%) had episodic headache. Soldiers with CDH had a median of 27 headache days per month, and 46/196 (23%) reported headaches occurring every day. One hundred seven out of 196 (55%) soldiers with CDH had onset of headaches within 1 week of head trauma and thereby met the time criterion for posttraumatic headache (PTHA) compared to 253/761 (33%) soldiers with episodic headache. Ninety-seven out of 196 (49%) soldiers with CDH used abortive medications to treat headache on 15 or more days per month for the previous 3 months. One hundred thirty out of 196 (66%) soldiers with CDH had headaches meeting criteria for migraine compared to 49% of soldiers with episodic headache. The number of concussions, blast exposures, and concussions with loss of consciousness was not significantly different between soldiers with and without CDH. Cognitive performance was also similar for soldiers with and without CDH. Soldiers with CDH had significantly higher average scores on the posttraumatic stress disorder (PTSD) checklist compared to soldiers with episodic headaches. Forty-one percent of soldiers with CDH screened positive for PTSD compared to only 18% of soldiers with episodic headache. Conclusions.-The prevalence of CDH in returning U.S. soldiers after a deployment-related concussion is 20%, or 4- to 5-fold higher than that seen in the general U.S. population.CDH following a concussion usually resembles chronic migraine and is associated with onset of headaches within the first week after concussion. The mechanism and number of concussions are not specifically associated with CDH as compared to episodic headache. In contrast, PTSD symptoms are strongly associated with CDH, suggesting that traumatic stress may be an important mediator of headache chronification. These findings justify future studies examining strategies to prevent and treat CDH in military service members following a concussive injury.	[Theeler, Brett J.] 187th Med Battal, AMEDD Student Detachment, Ft Sam Houston, TX 78234 USA; [Erickson, Jay C.] USA, Med Corps, Madigan Army Med Ctr, Dept Med,Neurol Serv, Austin, TX USA; [Flynn, Frederick G.] Madigan Traumat Brain Injury Program, Ft Lewis, WA USA		Theeler, BJ (corresponding author), 187th Med Battal, AMEDD Student Detachment, Ft Sam Houston, TX 78234 USA.	btheeler@hotmail.com					[Anonymous], 2009, Medical Surveillance Montly Report, V16, P2; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton RB, 2011, HEADACHE, V51, P77, DOI 10.1111/j.1526-4610.2011.01954.x; Mathew NT, 2009, HEADACHE, V49, P1466, DOI 10.1111/j.1526-4610.2009.01566.x; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Ruff RL, 2010, F1000 MED REP, V2, P1; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Scher AI, 2008, HEADACHE, V48, P16, DOI 10.1111/j.1526-4610.2007.00970.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	24	41	41	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAY	2012	52	5					732	738		10.1111/j.1526-4610.2012.02112.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	936NA	WOS:000303595900004	22404747				2022-02-06	
J	Kabadi, SV; Stoica, BA; Loane, DJ; Byrnes, KR; Hanscom, M; Cabatbat, RM; Tan, MT; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Byrnes, Kimberly R.; Hanscom, Marie; Cabatbat, Rainier M.; Tan, Ming T.; Faden, Alan I.			Cyclin D1 Gene Ablation Confers Neuroprotection in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cell cycle; controlled cortical impact; cyclin D1; neuroinflammation; neuroprotection	CONTROLLED CORTICAL IMPACT; NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; IN-VITRO; OBJECT RECOGNITION; DEPENDENT KINASES; SPATIAL MEMORY; CNS INJURY	Cell cycle activation (CCA) is one of the principal secondary injury mechanisms following brain trauma, and it leads to neuronal cell death, microglial activation, and neurological dysfunction. Cyclin D1 (CD1) is a key modulator of CCA and is upregulated in neurons and microglia following traumatic brain injury (TBI). In this study we subjected CD1-wild-type (CD1(+/+)) and knockout (CD1(-/-)) mice to controlled cortical impact (CCI) injury to evaluate the role of CD1 in post-traumatic neurodegeneration and neuroinflammation. As early as 24 h post-injury, CD1(+/+) mice showed markers of CCA in the injured hemisphere, including increased CD1, E2F1, and proliferating cell nuclear antigen (PCNA), as well as increased Fluoro-Jade B staining, indicating neuronal degeneration. Progressive neuronal loss in the hippocampus was observed through 21 days post-injury in these mice, which correlated with a decline in cognitive function. Microglial activation in the injured hemisphere peaked at 7 days post-injury, with sustained increases at 21 days. In contrast, CD1(-/-) mice showed reduced CCA and neurodegeneration at 24 h, as well as improved cognitive function, attenuated hippocampal neuronal cell loss, decreased lesion volume, and cortical microglial activation at 21 days post-injury. These findings indicate that CD1-dependent CCA plays a significant role in the neuroinflammation, progressive neurodegeneration, and related neurological dysfunction resulting from TBI. Our results further substantiate the proposed role of CCA in post-traumatic secondary injury, and suggest that inhibition of CD1 may be a key therapeutic target for TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Hanscom, Marie; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Hanscom, Marie; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Byrnes, Kimberly R.; Cabatbat, Rainier M.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Tan, Ming T.] Univ Maryland, Greenebaum Canc Ctr, Div Biostat, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Organized Res Ctr, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Hanscom, Marie/0000-0001-8308-135X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	We thank Kelly Wilson, Nicole Hockenbury, Michael Dinizo, David Knipp, and Michael Murray for expert technical assistance. This work was supported by a grant from the National Institutes of Health (R01 NS052568).	Akirav I, 2006, CEREB CORTEX, V16, P1759, DOI 10.1093/cercor/bhj114; Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Piao Chun-Shu, 2012, NEUROBIOLOGY DIS; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.3.CO;2-8; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Small DL, 2001, BRAIN RES, V900, P26, DOI 10.1016/S0006-8993(01)02102-3; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Verdaguer E, 2004, J PHARMACOL EXP THER, V308, P609, DOI 10.1124/jpet.103.057497; Yang Y, 2003, J NEUROSCI, V23, P2557; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	53	41	41	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					813	+		10.1089/neu.2011.1980			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900010	21895533	Green Published			2022-02-06	
J	Bansal, V; Ryu, SY; Lopez, N; Allexan, S; Krzyzaniak, M; Eliceiri, B; Baird, A; Coimbra, R				Bansal, Vishal; Ryu, Seok Yong; Lopez, Nicole; Allexan, Sarah; Krzyzaniak, Michael; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul			Vagal Stimulation Modulates Inflammation through a Ghrelin Mediated Mechanism in Traumatic Brain Injury	INFLAMMATION			English	Article						traumatic brain injury; inflammation; vagus nerve; ghrelin; neuroenteric axis	INTESTINAL DYSFUNCTION; ORGAN DYSFUNCTION; NERVOUS-SYSTEM; RELEASE; ACETYLCHOLINE; CYTOKINES; PEPTIDE; SEPSIS; LEPTIN; TNF	Traumatic brain injury (TBI) releases a cascade of inflammatory cytokines. Vagal nerve stimulation (VNS) and ghrelin have known anti-inflammatory effects; furthermore, ghrelin release is stimulated by acetylcholine. We hypothesized VNS decreases post-TBI inflammation through a ghrelin-mediated mechanism. TBI was created in five groups of mice: sham, TBI, TBI/ghrelin, TBI/VNS, and TBI/VNS/ghrelin receptor antagonist (GRa). Serum and tissue ghrelin, and serum TNF-alpha were measured. Ghrelin increased following VNS 2 h post-TBI compared to sham or TBI. At 6 h, TBI and TBI/VNS/GRa had increased TNF-alpha compared to sham while TBI/VNS and TBI/ghrelin had TNF-alpha level comparable to sham. The highest ghrelin was measured in stomach where TBI decreased ghrelin in contrast to an increase by VNS. In conclusion, VNS increased serum ghrelin and decreased TNF-alpha following TBI. This was abrogated with GRa. Our data suggests that ghrelin plays an important role in the anti-inflammatory effects of VNS following TBI.	[Bansal, Vishal; Ryu, Seok Yong; Lopez, Nicole; Allexan, Sarah; Krzyzaniak, Michael; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Dept Emergency Med, Sanggye Paik Hosp, Seoul, South Korea		Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Baird, Andrew/0000-0003-0027-9905; Lopez, Nicole/0000-0002-4807-7360	Inje Research and Scholarship Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	This research was supported in part by the 2009 Inje Research and Scholarship Foundation.	Acampa M, 2008, NEUROSCI LETT, V432, P69, DOI 10.1016/j.neulet.2007.12.030; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; German J, 2009, ENDOCRINOLOGY, V150, P4502, DOI 10.1210/en.2009-0445; Hosoda H, 2008, REGUL PEPTIDES, V146, P12, DOI 10.1016/j.regpep.2007.07.005; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kemp CD, 2008, AM SURGEON, V74, P866; Koch A, 2010, CRIT CARE, V14, DOI 10.1186/cc9029; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1; Li Y, 2007, CURR MED CHEM, V14, P2554, DOI 10.2174/092986707782023334; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Shrestha YB, 2009, PEPTIDES, V30, P1187, DOI 10.1016/j.peptides.2009.02.001; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vaughan T, 2010, MOL IMMUNOL, V47, P2515, DOI 10.1016/j.molimm.2010.06.006; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Waseern T, 2008, SURGERY, V143, P334, DOI 10.1016/j.surg.2007.09.039; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	31	41	46	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	FEB	2012	35	1					214	220		10.1007/s10753-011-9307-7			7	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	896FM	WOS:000300550900025	21360048	Green Published, hybrid, Green Submitted			2022-02-06	
J	Berdichevsky, Y; Dzhala, V; Mail, M; Staley, KJ				Berdichevsky, Yevgeny; Dzhala, Volodymyr; Mail, Michelle; Staley, Kevin J.			Interictal spikes, seizures and ictal cell death are not necessary for post-traumatic epileptogenesis in vitro	NEUROBIOLOGY OF DISEASE			English	Article						Epilepsy; Epileptogenesis; Traumatic brain injury; Phenytoin; Neuronal death; Activity; Interictal; Ictal	TEMPORAL-LOBE EPILEPSY; ORGANOTYPIC SLICE CULTURES; INDUCED STATUS EPILEPTICUS; HEAD-INJURY; ANTIEPILEPTIC DRUGS; DENTATE GYRUS; CYTO-TOXICITY; GRANULE CELLS; AXONAL INJURY; BRAIN-INJURY	Clinical studies indicate that phenytoin prevents acute post-traumatic seizures but not subsequent post-traumatic epilepsy. We explored this phenomenon using organotypic hippocampal slice cultures as a model of severe traumatic brain injury. Hippocampal slices were cultured for up to eight weeks, during which acute and chronic electrical recordings revealed a characteristic evolution of spontaneous epileptiform discharges, including interictal spikes, seizure activity and electrical status epilepticus. Cell death exhibited an early peak immediately following slicing, and a later secondary peak that coincided with the peak of seizure-like activity. The secondary peak in neuronal death was abolished by either blockade of glutamatergic transmission with kynurenic acid or by elimination of ictal activity and status epilepticus with phenytoin. Withdrawal of kynurenic acid or phenytoin was followed by a sharp increase in spontaneous seizure activity. Phenytoin's anticonvulsant and neuroprotective effects failed after four weeks of continuous administration. These data support the clinical findings that after brain injury, anticonvulsants prevent seizures but not epilepsy or the development of anticonvulsant resistance. We extend the clinical data by showing that secondary neuronal death is correlated with ictal but not interictal activity, and that blocking all three of these sequelae of brain injury does not prevent epileptogenesis in this in vitro model. (C) 2011 Elsevier Inc. All rights reserved.	[Berdichevsky, Yevgeny; Dzhala, Volodymyr; Mail, Michelle; Staley, Kevin J.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA		Staley, KJ (corresponding author), MGH Neurol, CNY 114,Room 2600,114 16th St, Charlestown, MA 02129 USA.	kstaley@partners.org		Berdichevsky, Yevgeny/0000-0001-7539-601X	National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Epilepsy Foundation (EFA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072258, R01NS077908] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke (NINDS) and Epilepsy Foundation (EFA).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1974, Electroencephalogr Clin Neurophysiol, V37, P538; Ben-Ari Y, 2010, EPILEPSY CURR, V10, P118, DOI 10.1111/j.1535-7511.2010.01376.x; Berdichevsky Y, 2009, J NEUROSCI METH, V178, P59, DOI 10.1016/j.jneumeth.2008.11.016; Berg AT, 2008, CURR OPIN NEUROL, V21, P173, DOI 10.1097/WCO.0b013e3282f36ccd; Bernhardt BC, 2009, NEUROLOGY, V72, P1747, DOI 10.1212/01.wnl.0000345969.57574.f5; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Buckmaster PS, 2004, EPILEPSIA, V45, P452, DOI 10.1111/j.0013-9580.2004.67103.x; Chatrian GE, 1974, ELECTROENCEPHALOGR C, V37, P521; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DUNCAN JS, 1987, EPILEPSIA, V28, P259, DOI 10.1111/j.1528-1157.1987.tb04216.x; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fuerst D, 2003, ANN NEUROL, V53, P413, DOI 10.1002/ana.10509; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Giblin KA, 2010, NEUROSCIENTIST, V16, P253, DOI 10.1177/1073858409354385; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRONDAHL TO, 1993, J NEUROSURG, V78, P938, DOI 10.3171/jns.1993.78.6.0938; Haut SR, 2002, EPILEPSIA, V43, P711, DOI 10.1046/j.1528-1157.2002.26401.x; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Jefferys JGR, 2003, EPILEPSIA, V44, P44, DOI 10.1111/j.0013-9580.2003.12004.x; JENNETT B, 1973, LANCET, V2, P652; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kobayashi M, 2003, J NEUROSCI, V23, P2440; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; MELDRUM BS, 1973, EXPERIENTIA, V29, P561, DOI 10.1007/BF01926665; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P10, DOI 10.1001/archneur.1973.00490190028002; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rocha Luisa L, 2007, Epilepsy Curr, V7, P77, DOI 10.1111/j.1535-7511.2007.00178.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; SEGAL MM, 1994, J NEUROPHYSIOL, V72, P1874, DOI 10.1152/jn.1994.72.4.1874; Shinnar S, 2010, NEUROLOGY, V74, P624, DOI 10.1212/WNL.0b013e3181d0ce5b; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; Staley K, 2005, NEUROSCIENTIST, V11, P272, DOI 10.1177/1073858405278239; STEWARD O, 1978, BRAIN RES, V149, P216, DOI 10.1016/0006-8993(78)90601-7; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Sutula TP, 2007, PROG BRAIN RES, V163, P541, DOI 10.1016/S0079-6123(07)63029-5; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; White AM, 2006, J NEUROSCI METH, V152, P255, DOI 10.1016/j.jneumeth.2005.09.014; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	64	41	41	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	FEB	2012	45	2					774	785		10.1016/j.nbd.2011.11.001			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	881QC	WOS:000299500200012	22115940	Green Accepted			2022-02-06	
J	Anderson, V; Catroppa, C; Godfrey, C; Rosenfeld, JV				Anderson, Vicki; Catroppa, Cathy; Godfrey, Celia; Rosenfeld, Jeffrey V.			Intellectual Ability 10 Years after Traumatic Brain Injury in Infancy and Childhood: What Predicts Outcome?	JOURNAL OF NEUROTRAUMA			English	Article						children; intelligence; recovery of function; traumatic brain injury	CLOSED HEAD-INJURY; NEUROBEHAVIORAL RECOVERY; ACADEMIC-ACHIEVEMENT; SOCIAL OUTCOMES; SHORT-TERM; CHILDREN; TBI; ADOLESCENTS; AGE; PLASTICITY	The long-term consequences of child traumatic brain injury (TBI) are poorly understood, but there are indications of ongoing deterioration in skills with time since injury. This study investigated outcomes up to 10 years post-injury, to determine the influences of injury severity, injury age, and environment. The study design was prospective and longitudinal. Participants included consecutive admissions to the Royal Children's Hospital, Melbourne, Australia. Children sustaining TBI between 2 and 12 years of age (n = 76) were recruited on admission and divided according to injury severity (mild, moderate, and severe) and injury age (2-7 years and 8-12 years). Cognitive abilities were evaluated using standard measures of intellectual function (IQ) acutely and at 12 months, 30 months, and 10 years post-injury. At 10 years, mean IQs for survivors fell within the low average to average range. There were no significant effects of injury severity, injury age, or time since injury. In contrast, elevated rates of impairment were identified in association with severe TBI (global deficits), and early injury (non-verbal deficits). Impairments in processing speed were related to injury severity and age at injury. Predictors of 10-year outcome included pre-injury and social factors, injury age, and family function. Child survivors of serious TBI are at elevated risk of cognitive impairment, with recovery continuing into the third year post-injury. However, between 30 months and 10 years post-insult, children appear to make appropriate developmental gains, contrary to the speculation that these children "grow into their deficits.''	[Anderson, Vicki; Catroppa, Cathy; Godfrey, Celia] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 	Australian National Heath and Medical Research Council; Victorian Government	This research was supported by grants from the Australian National Heath and Medical Research Council and the Victorian Government Operational Infrastructure Support Program.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 2011, BRAIN, DOI [10.1093/brain//awr103, DOI 10.1093/BRAIN//AWR103]; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bayley N., 1969, BAYLEY SCALES INFANT; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Daniel A., 1983, POWER PRIVILEGE PRES; DENNIS M, 2007, COGNITIVE RESERVE TH, P53; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 1999, BRAIN INJURY, V13, P759; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Romema S., SOCIAL OUTC IN PRESS; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Walsh K., 1985, NEUROPSYCHOLOGY CLIN; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 1989, MANUAL PRESCHOOL PRI; Yeates K. O., 2006, BEHAVIOUR, V14, P141; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; [No title captured]; [No title captured]	62	41	41	1	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					143	153		10.1089/neu.2011.2012			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300017	22022835				2022-02-06	
J	Jones, A; Ingram, MV; Ben-Porath, YS				Jones, Alvin; Ingram, M. Victoria; Ben-Porath, Yossef S.			Scores on the MMPI-2-RF Scales as a Function of Increasing Levels of Failure on Cognitive Symptom Validity Tests in a Military Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory-2-Restructured Form; MMPI-2-RF; Symptom validity tests; Military sample	PERSONAL-INJURY LITIGANTS; RESTRUCTURED CLINICAL RC; TRAUMATIC BRAIN-INJURY; REPEATABLE BATTERY; EVALUATION CONTEXT; FORENSIC SETTINGS; EFFORT INDEX; PERFORMANCE; VALIDATION; DISABILITY	This research examined associations between the full range of Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) validity and substantive scales and increasing levels of cognitive symptom validity test (SVT) failure in a sample of 501 military members who completed a neuropsychological evaluation primarily for mild traumatic brain injury resulting from a closed head injury and blast exposure or heat injury. SVT failure was associated with significant linear increases in all of the over-reporting MMPI-2-RF validity scales and most of the substantive scales. For the validity scales, all over-reporting scales had large effect sizes (ESs) when comparing a group that failed no SVTs with a group that failed three SVTs. A comparison between these two groups for the substantive scales revealed the largest ESs for scales related to somatic/cognitive complaints and emotional dysfunction. RBS (Response Bias Scale) had the largest ES of all scales (d = 1.69), followed by FBS-r (Symptom Validity Scale; d = 1.34), AXY (Anxiety, d = 1.21), and COG (Cognitive Complaints, d = 1.19). The scales related to behavioral dysfunction had the smallest ESs of all of the substantive scales, and there were no significant associations between the vast majority of these scales and SVT failure. With respect to clinically significant elevations, those who did not fail SVTs had clinically significant elevations only on COG and NUC (Neurological Complaints), and MLS (Malaise) approached clinical significance. For those who failed SVTs, RBS was the only over-reporting scale that was elevated across all failure groups. Those who failed any SVT had clinically significant elevations on COG, MLS, NUC, and AXY. Those who failed three SVTs had additional elevations on scales related to emotional dysfunction.	[Jones, Alvin] Womack Army Med Ctr, Dept Med, Neurol Serv, Ft Bragg, NC 28310 USA; [Ingram, M. Victoria] Womack Army Med Ctr, Dept Behav Hlth, Ft Bragg, NC 28310 USA; [Ben-Porath, Yossef S.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA		Jones, A (corresponding author), Womack Army Med Ctr, Dept Med, Neurol Serv, 2817 Riley Rd,Bldg 4-2817, Ft Bragg, NC 28310 USA.	alvin.jones@amedd.army.mil					Arbisi PA, 2008, J PERS ASSESS, V90, P122, DOI 10.1080/00223890701845146; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Butcher JN, 2001, MMPI 2 MANUAL ADM SC; Cohen J., 2013, STAT POWER ANAL BEHA; Department of Veterans Affairs, 2009, VA DOD CLIN PRACT GU; Gervais RO, 2011, J PERS ASSESS, V93, P508, DOI 10.1080/00223891.2011.594132; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P473, DOI 10.1093/arclin/acq052; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Green P., 2003, GREENS WORD MEMORY T; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Harkness AR, 2012, PSYCHOL ASSESSMENT, V24, P432, DOI 10.1037/a0025830; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P158, DOI 10.1080/13825580601025916; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Jones A, 2011, CLIN NEUROPSYCHOL, V25, P1207, DOI 10.1080/13854046.2011.600726; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Randolph C., 1998, REPEATABLE BATTERY A; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TYDECKS S, 2006, INT J FORENSIC PSYCH, V0001, P00029; Wallace A, 2005, ASSESSMENT, V12, P290, DOI 10.1177/1073191105276250; Wygant DB, 2005, ARCH CLIN NEUROPSYCH, V20, P892; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	38	41	42	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	5					790	815		10.1080/13854046.2012.693202			26	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	970EU	WOS:000306111700003	22709365				2022-02-06	
J	Potter, S; Brown, RG				Potter, Seb; Brown, Richard G.			Cognitive behavioural therapy and persistent post-concussional symptoms: Integrating conceptual issues and practical aspects in treatment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Post-concussion syndrome; Cognitive-behavioural therapy	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; MEDICALLY UNEXPLAINED SYMPTOMS; STIMULUS-INDEPENDENT THOUGHT; CHRONIC-FATIGUE-SYNDROME; EMOTIONAL RISK-FACTORS; POSTCONCUSSION-SYNDROME; NEUROPSYCHOLOGICAL REHABILITATION; MISERABLE MINORITY	This paper seeks to integrate research findings in mild traumatic brain injury (MTBI) around three central themes relevant to psychological therapies for persistent post-concussional symptoms (PCS). These are (1) the relative lack of symptom specificity, (2) the extent to which subjective (but not necessarily objective) cognitive difficulties predominate, and (3) the role of psychological (especially cognitive-behavioural) processes in the evolution and maintenance of symptoms. Evidence-based models guiding cognitive-behavioural therapy (CBT) for similar symptoms in other clinical groups are considered in relation to persistent PCS, as well as some of the practical considerations in applying CBT with this client group. Outstanding research issues are identified and discussed, including the opportunities and risks of combining CBT and cognitive rehabilitation approaches.	[Potter, Seb] S London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Brain Injury Unit, London SE5 8AZ, England; [Brown, Richard G.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England		Potter, S (corresponding author), S London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	s.potter@iop.kcl.ac.uk	Brown, Richard G/A-9599-2010	Brown, Richard G/0000-0001-9021-0172; Potter, Sebastian/0000-0002-2173-9870	NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust (SLaM); Institute of Psychiatry, King's College London	The authors would like to thank Ionie Lyon for her assistance in preparing this manuscript. The authors acknowledge support from the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust (SLaM) and Institute of Psychiatry, King's College London.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck AT., 1979, COGNITIVE THERAPY DE; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blatt SJ, 1998, J CONSULT CLIN PSYCH, V66, P423, DOI 10.1037/0022-006X.66.2.423; Blenkiron P, 2005, BEHAV COGN PSYCHOTH, V33, P45, DOI 10.1017/S1352465804001766; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Boone K. B., 2008, CLIN NEUROPSYCHOL, V23, P1016; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; Clark DM., 2001, INT HDB SOCIAL ANXIE, P405; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Deale A, 1998, J PSYCHOSOM RES, V45, P77, DOI 10.1016/S0022-3999(98)00021-X; Deary V, 2007, CLIN PSYCHOL REV, V27, P781, DOI 10.1016/j.cpr.2007.07.002; Deikman Arthur J., 1969, ALTERED STATES CONSC; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Erichsen JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fairburn CG, 1999, ARCH GEN PSYCHIAT, V56, P468, DOI 10.1001/archpsyc.56.5.468; Fennell M.J.V., 1998, ADV PSYCHIAT TREATME, V4, P296, DOI [DOI 10.1192/APT.4.5.296, 10.1192/apt.4.5.296]; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Frank J. D., 1982, PSYCHOTHERAPY RES BE, P5; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fry, 1989, PSYCHOL HELPLESSNESS, P339, DOI DOI 10.1016/S0166-4115(08)60986-3; Gass C. S., 1992, PSYCHOL ASSESSMENT, V4, P272; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson G. L., 2010, BRAIN INJURY, P1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P295, DOI 10.1037/0022-006X.64.2.295; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirk J., 1989, COGNITIVE BEHAV THER, P13; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lilenfeld LR, 1998, ARCH GEN PSYCHIAT, V55, P603, DOI 10.1001/archpsyc.55.7.603; Lipsitt, 2001, HYPOCHONDRIASIS MODE, P202; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MASTERS RSW, 1993, PERS INDIV DIFFER, V14, P655, DOI 10.1016/0191-8869(93)90113-H; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Matthews Gerald, 2000, HUMAN PERFORMANCE CO; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McGrath J., 2004, OXFORD GUIDE BEHAV E, P331; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Nezu AM, 2001, BEHAV THER, V32, P537, DOI 10.1016/S0005-7894(01)80035-6; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Padesky C., 1990, INT COGNITIVE THERAP, V6, P13; PADESKY CA, 1994, CLIN PSYCHOL PSYCHOT, V1, P267, DOI 10.1002/cpp.5640010502; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Potter S., 2010, BRAIN INJURY, V24, P205; Potter S., 2008, BRAIN INJURY S1, V22, P66; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Riley GA, 2010, NEUROPSYCHOL REHABIL, V20, P869, DOI 10.1080/09602011.2010.503041; Rimes KA, 2010, J PSYCHOSOM RES, V68, P285, DOI 10.1016/j.jpsychores.2009.09.014; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Schmidt AJM, 2003, BEHAV RES THER, V41, P1243, DOI 10.1016/S0005-7967(03)00155-4; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Shafran R, 2002, BEHAV RES THER, V40, P773, DOI 10.1016/S0005-7967(01)00059-6; Smith AM, 2000, SPORTS MED, V30, P423, DOI 10.2165/00007256-200030060-00004; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell DL, 2008, J CLIN EXP NEUROPSYC, V2, P1; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Sullivan MJL, 2008, J OCCUP REHABIL, V18, P249, DOI 10.1007/s10926-008-9140-5; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; TEASDALE JD, 1993, EUR J COGN PSYCHOL, V5, P417, DOI 10.1080/09541449308520128; TEASDALE JD, 1995, MEM COGNITION, V23, P551, DOI 10.3758/BF03197257; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Todd D, 1998, FORENSIC EXAMINER, V7, P14; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Veale D., 2003, ADV PSYCHIAT TREATME, V9, P258, DOI DOI 10.1192/APT.9.4.258; Wells A., 1997, COGNITIVE THERAPY AN; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1993, ICD 10 CLASS MENT BE; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010; [No title captured]	140	41	41	0	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	1					1	25		10.1080/09602011.2011.630883			25	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	920KO	WOS:000302403500001	22175238				2022-02-06	
J	Sheth, KN; Nutter, T; Stein, DM; Scalea, TM; Bernat, JL				Sheth, Kevin N.; Nutter, Tyree; Stein, Deborah M.; Scalea, Thomas M.; Bernat, James L.			Autoresuscitation after asystole in patients being considered for organ donation	CRITICAL CARE MEDICINE			English	Article						donation after circulatory death; organ donation; traumatic brain injury	LIVER-TRANSPLANTATION; CARDIAC DEATH; DONORS; SURVIVAL	Objectives: A fundamental issue in organ donation after circulatory death is the determination of death. There are limited data regarding the incidence and timing of autoresuscitation after asystole. Prevailing guidelines suggest a 2- to 5-min observation after mechanical asystole before the declaration of death. This study tested the hypothesis that a 2-min observation period after asystole is sufficient for the declaration of death in patients being considered for organ donation after circulatory death. Design: Single-center observational study using prospectively collected data. Setting: University hospital, Level I trauma center. Patients: Those patients identified by the organ donation registry that underwent organ donation after circulatory death from 2000 to 2008, during which time the institutional protocol required a 5-min observation period. Interventions: None. Measurements and Main Results: Documentation of medical history, serial Glasgow Coma Scale scores, time of extubation, and time to asystole, hypotension, pulseless electrical activity, and declaration of death were ascertained. Seventy-three patients were identified. The most common mechanism of injury was traumatic brain injury, and eight patients were aged <18 yrs. Patients had a mean Glasgow Coma Scale score of 5 on admission and were taken to organ donation after circulatory death an average of 6.6 days after admission. The average time from extubation to death was 22 mins. No patients exhibited autoresuscitation during the 5-min waiting observation period, including the first 2 mins after asystole. Conclusions: The absence of autoresuscitation in our series suggests that a 2-min observation period is sufficient for the determination of death after cardiac arrest, including patients younger than 18 yrs. These data may inform practice guidelines. (Crit Care Med 2012; 40:158-161)	[Sheth, Kevin N.] Univ Maryland, Med Ctr, Dept Neurol Neurosurg & Emergency Med, Baltimore, MD 21201 USA; [Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Scalea, Thomas M.] Shock Trauma & Anesthesiol Res Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Bernat, James L.] Dartmouth Hitchcock Med Ctr, Dept Neurol, Lebanon, NH 03766 USA		Sheth, KN (corresponding author), Univ Maryland, Med Ctr, Dept Neurol Neurosurg & Emergency Med, Baltimore, MD 21201 USA.	ksheth@som.umaryland.edu		Stein, Deborah/0000-0003-3683-3963	American Academy of Neurology	Dr. Sheth received grant support from the American Academy of Neurology. The remaining authors have not disclosed any potential conflicts of interest.	Abt PL, 2004, ANN SURG, V239, P87, DOI 10.1097/01.sla.0000103063.82181.2c; Antommaria AHM, 2009, JAMA-J AM MED ASSOC, V301, P1902, DOI 10.1001/jama.2009.637; Bernat JL, 2008, NEW ENGL J MED, V359, P669, DOI 10.1056/NEJMp0804161; Bernat JL, 2010, CRIT CARE MED, V38, P963, DOI 10.1097/CCM.0b013e3181c58916; Boucek MM, 2008, NEW ENGL J MED, V359, P709, DOI 10.1056/NEJMoa0800660; Caplan Arthur L., 1993, Kennedy Institute of Ethics Journal, V3, P251; Curfman GD, 2008, NEW ENGL J MED, V359, P749, DOI 10.1056/NEJMe0805480; DeVita M A, 2001, Prog Transplant, V11, P58; DeVita MA, 2000, CRIT CARE MED, V28, P1709, DOI 10.1097/00003246-200006000-00002; DeVita MA, 2001, CRIT CARE MED, V29, P1826; Herdman R, 1998, KENNEDY INST ETHIC J, V8, P83; Hornby K, 2010, CRIT CARE MED, V38, P1246, DOI 10.1097/CCM.0b013e3181d8caaa; *I MED, 2000, 0309066417 I MED; Jackson A, 2008, J HEART LUNG TRANSPL, V27, P348, DOI 10.1016/j.healun.2007.12.006; Kootstra G, 2002, WORLD J SURG, V26, P181; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2965; Lee KW, 2006, TRANSPLANTATION, V82, P1683, DOI 10.1097/01.tp.0000250936.73034.98; President's Council on Bioethics, 2008, CONTR DET DEATH; Wijdicks EFM, 2004, NEUROLOGY, V62, P673, DOI 10.1212/WNL.62.4.673; XIAO F, 1995, CRIT CARE MED S, V23, pA17; YOUNGNER SJ, 1993, JAMA-J AM MED ASSOC, V269, P2769, DOI 10.1001/jama.269.21.2769	21	41	42	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					158	161		10.1097/CCM.0b013e31822f0b2a			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KO	WOS:000298379800023	21926577				2022-02-06	
J	Smith, RL; Lin, JC; Adelson, PD; Kochanek, PM; Fink, EL; Wisniewski, SR; Bayir, H; Tyler-Kabara, EC; Clark, RSB; Brown, SD; Bell, MJ				Smith, Rebecca L.; Lin, John C.; Adelson, P. David; Kochanek, Patrick M.; Fink, Ericka L.; Wisniewski, Stephen R.; Bayir, Huelya; Tyler-Kabara, Elizabeth C.; Clark, Robert S. B.; Brown, S. Danielle; Bell, Michael J.			Relationship between hyperglycemia and outcome in children with severe traumatic brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; hyperglycemia; outcome	SEVERE HEAD-INJURY; INSULIN THERAPY PROTECTS; BLOOD-GLUCOSE CONTROL; PERIOPERATIVE HYPERGLYCEMIA; ADMISSION HYPERGLYCEMIA; MODERATE HYPOTHERMIA; INFECTIONS; MORTALITY; SURGERY; STRICT	Objective: To determine the relationship between hyperglycemia and outcome in infants and children after severe traumatic brain injury. Design: Retrospective review of a prospectively collected Pediatric Neurotrauma Registry. Setting and Patients: Children admitted after severe traumatic brain injury (postresuscitation Glasgow Coma Scale <= 8) were studied (1999-2004). A subset of children (n = 28) were concurrently enrolled in a randomized, controlled clinical trial of early hypothermia for neuroprotection. Interventions: Demographic data, serum glucose concentrations, and outcome assessments were collected. Methods and Main Results: Children (n = 57) were treated with a standard traumatic brain injury protocol. Exogenous glucose was withheld for 48 hrs after injury unless hypoglycemia was observed (blood glucose <70 mg/dL). Early (first 48 hrs) and Late (49-168 hrs) time periods were defined and mean blood glucose concentrations were calculated. Additionally, children were categorized based on peak blood glucose concentrations during each time period (normal, blood glucose <150 mg/dL; mild hyperglycemia, blood glucose <= 200 mg/dL; severe hyperglycemia, blood glucose >200 mg/dL). In the Late period, an association between elevated mean serum glucose concentration and outcome was observed (133.5 +/- 5.6 mg/dL in the unfavorable group vs. 115.4 +/- 4.1 mg/dL in favorable group, p = .02). This association continued to be significant after correcting for injury severity, age, and exposure to insulin (p = .03). Similarly, in the Late period, children within the severe hyperglycemia group had decreased incidence of good outcome compared to children within the other glycemic groups (% good outcome: normal, 61.9%; mild hyperglycemia, 73.7%; severe hyperglycemia, 33.3%; p = .05). However, when adjusted for exposure to insulin, this relationship was no longer statistically significant. Conclusions: In children with severe traumatic brain injury, hyperglycemia beyond the initial 48 hrs is associated with poor outcome. This relationship was observed in both our analysis of mean blood glucose concentrations as well as among the patients with episodic severe hyperglycemia. This observation suggests a relationship between hyperglycemia and outcome from traumatic brain injury. However, only a prospective study can answer the important question of whether manipulating serum glucose concentration can improve outcome after traumatic brain injury in children. (Pediatr Crit Care Med 2012; 13:85-91)	[Smith, Rebecca L.; Kochanek, Patrick M.; Fink, Ericka L.; Bayir, Huelya; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth C.; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol & Biostat, Pittsburgh, PA 15260 USA; [Smith, Rebecca L.; Kochanek, Patrick M.; Fink, Ericka L.; Bayir, Huelya; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Lin, John C.] Wilford Hall, Dept Pediat, San Antonio, TX USA; [Adelson, P. David; Brown, S. Danielle] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA		Smith, RL (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	smithr3@upmc.edu	Smith, Rebecca L/N-5911-2014; Adelson, David/W-2083-2019; Fink, Ericka/AAU-9792-2021; Tyler-Kabara, Elizabeth/H-4930-2013; Kochanek, Patrick M/D-2371-2015	Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Fink, Ericka/0000-0002-3683-4571	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040686]; Cyberonics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Supported, in part, by a grant from NIH (T32 HD040686) to Dr. Smith.; Dr. Adelson is employed with Phoenix Children's Hospital; has consulted for Traumtec, Inc; received honoraria/speaking fees from Cyberonics; and received grant support from the NIH. The remaining authors have not disclosed any potential conflicts of interest.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Ambiru S, 2008, J HOSP INFECT, V68, P230, DOI 10.1016/j.jhin.2007.12.002; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Klein GW, 2008, J PEDIATR-US, V153, P379, DOI 10.1016/j.jpeds.2008.04.012; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; LUNDGREN J, 1991, EXP BRAIN RES, V84, P91; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Paret G, 1999, J ACCID EMERG MED, V16, P186; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; Preissig CM, 2009, PEDIATR CARDIOL, V30, P1098, DOI 10.1007/s00246-009-9512-4; Ramos M, 2008, ANN SURG, V248, P585, DOI 10.1097/SLA.0b013e31818990d1; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Sharma D, 2009, ANESTH ANALG, V108, P81, DOI 10.1213/ane.0b013e31818a6f32; Ulate KP, 2008, PEDIATRICS, V122, pE898, DOI 10.1542/peds.2008-0871; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vriesendorp TM, 2004, EUR J VASC ENDOVASC, V28, P520, DOI 10.1016/j.ejvs.2004.08.006; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; Yates AR, 2006, PEDIATR CRIT CARE ME, V7, P351, DOI 10.1097/01.PCC.0000227755.96700.98; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22	35	41	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2012	13	1					85	91		10.1097/PCC.0b013e3182192c30			7	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	875YT	WOS:000299073000026	21499170	Green Accepted			2022-02-06	
J	Takahashi, N; Higuchi, T; Shiotani, M; Hirose, Y; Shibuya, H; Yamanouchi, H; Hashidate, H; Funayama, K				Takahashi, Naoya; Higuchi, Takeshi; Shiotani, Motoi; Hirose, Yasuo; Shibuya, Hiroyuki; Yamanouchi, Haruo; Hashidate, Hideki; Funayama, Kazuhisa			The effectiveness of postmortem multidetector computed tomography in the detection of fatal findings related to cause of non-traumatic death in the emergency department	EUROPEAN RADIOLOGY			English	Article						Postmortem CT; Emergency department; Postmortem imaging; Forensic imaging; Sudden death	MINIMALLY INVASIVE AUTOPSY; CONVENTIONAL AUTOPSY; IMAGING FINDINGS; VIRTUAL AUTOPSY; CT; INJURY; MRI; ANGIOGRAPHY; HEMORRHAGE; EXPERIENCE	To investigate the diagnostic performance of postmortem multidetector computed tomography (PMMDCT) for the detection of fatal findings related to causes of non-traumatic death in the emergency department (ED). 494 consecutive cases of clinically diagnosed non-traumatic death in ED involving PMMDCT were enrolled. The fatal findings were detected on PMMDCT and classified as definite or possible findings. These findings were confirmed by autopsy in 20 cases. The fatal findings were detected in 188 subjects (38.1%) including 122 with definite (24.7%) and 66 with possible finding (13.4%). Definite findings included 21 cases of intracranial vascular lesions, 84 with intra-thoracic haemorrhage, 13 with retroperitoneal haemorrhage and one with oesophagogastric haemorrhage. In three patients who had initially been diagnosed with non-traumatic death, PMMDCT revealed fatal traumatic findings. Two definite findings (two haemopericardiums) and seven possible findings (two intestinal obstructions, one each of multiple liver tumours central pulmonary artery dilatation, pulmonary congestion, peritoneal haematoma, and brain oedema) were confirmed by autopsy. The causes of death were not determined in cases with possible findings without autopsy. PMMDCT is a feasible tool for detecting morphological fatal findings in non-traumatic death in ED. It is important to know the ability and limitation of PMMDCT. aEuro cent Postmortem multi-detector CT (MDCT) can reveal the cause of non-traumatic death. aEuro cent Postmortem MDCT is quick and can be widely available. aEuro cent Postmortem MDCT is acceptable to those relatives who object to invasive autopsy. aEuro cent MDCT cannot establish the cause of death in all patients.	[Takahashi, Naoya; Higuchi, Takeshi; Shiotani, Motoi] Niigata City Gen Hosp, Dept Diagnost Radiol, Chuo Ku, Niigata 9501197, Japan; [Hirose, Yasuo] Niigata City Gen Hosp, Dept Emergency & Crit Care, Niigata 9501197, Japan; [Shibuya, Hiroyuki; Hashidate, Hideki] Niigata City Gen Hosp, Dept Pathol, Niigata 9501197, Japan; [Yamanouchi, Haruo; Funayama, Kazuhisa] Niigata Univ, Dept Community Prevent Med, Div Legal Med, Grad Sch Med & Dent Sci, Niigata, Japan		Takahashi, N (corresponding author), Niigata City Gen Hosp, Dept Diagnost Radiol, Chuo Ku, 463-7 Shumoku, Niigata 9501197, Japan.	nandtr@gmail.com					Anon J, 2008, J MAGN RESON IMAGING, V28, P823, DOI 10.1002/jmri.21495; Bolliger SA, 2008, EUR RADIOL, V18, P273, DOI 10.1007/s00330-007-0737-4; Bolliger SA, 2010, AM J ROENTGENOL, V195, P1051, DOI 10.2214/AJR.10.4600; Christe A, 2008, EUR RADIOL, V18, P283, DOI 10.1007/s00330-007-0745-4; Christe A, 2009, J TRAUMA, V66, P1302, DOI 10.1097/TA.0b013e31818c1441; Harcke HT, 2008, AM J ROENTGENOL, V190, pW106, DOI 10.2214/AJR.07.2754; Hoey BA, 2007, J TRAUMA, V63, P979, DOI 10.1097/TA.0b013e318154011f; Iino M, 2010, J FORENSIC SCI, V55, P1251, DOI 10.1111/j.1556-4029.2010.01430.x; Jackowski C, 2011, EUR RADIOL, V21, P70, DOI 10.1007/s00330-010-1884-6; Leth Peter Mygind, 2007, Forensic Sci Med Pathol, V3, P65, DOI 10.1385/FSMP:3:1:65; Levy AD, 2006, RADIOLOGY, V240, P522, DOI 10.1148/radiol.2402050972; Loughrey MB, 2000, ULSTER MED J, V69, P83; Mitka M, 2007, JAMA-J AM MED ASSOC, V298, P392, DOI 10.1001/jama.298.4.392; Mushtaq F, 2005, EMERG MED J, V22, P718, DOI 10.1136/emj.2004.018721; Oyake Yuji, 2006, Radiat Med, V24, P493, DOI 10.1007/s11604-006-0061-y; Quigley M, 2003, EMERG MED J, V20, P349, DOI 10.1136/emj.20.4.349; Rieger M, 2009, J TRAUMA, V66, P648, DOI 10.1097/TA.0b013e31816275f3; Roberts ISD, 2003, HISTOPATHOLOGY, V42, P424, DOI 10.1046/j.1365-2559.2003.01614.x; Ross S, 2008, AM J ROENTGENOL, V190, P1380, DOI 10.2214/AJR.07.3082; Scholing M, 2009, EUR RADIOL, V19, P2333, DOI 10.1007/s00330-009-1440-4; Shiotani S, 2008, RADIAT MED, V26, P253, DOI 10.1007/s11604-007-0223-6; Shiotani Seiji, 2004, Radiat Med, V22, P405; Shiotani S, 2011, LEGAL MED-TOKYO, V13, P151, DOI 10.1016/j.legalmed.2010.12.008; Shojania KG, 2008, NEW ENGL J MED, V358, P873, DOI 10.1056/NEJMp0707996; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Sochor MR, 2008, J TRAUMA, V65, P659, DOI 10.1097/TA.0b013e3181238d66; Takahashi N, 2010, AM J ROENTGENOL, V195, pW388, DOI 10.2214/AJR.10.4442; Takahashi N, 2009, JPN J RADIOL, V27, P316, DOI 10.1007/s11604-009-0340-5; Uchigasaki S., 2007, RECHTSMEDIZIN, V17, P19, DOI [10.1007/s00194-006-0409-8, DOI 10.1007/S00194-006-0409-8]; Watts Geoff, 2010, BMJ, V341, pc6600, DOI 10.1136/bmj.c6600; Weustink AC, 2009, RADIOLOGY, V250, P897, DOI 10.1148/radiol.2503080421; Yamazaki K, 2006, FORENSIC SCI INT, V162, P163, DOI 10.1016/j.forsciint.2006.06.020; Yen K, 2007, FORENSIC SCI INT, V173, P21, DOI 10.1016/j.forsciint.2007.01.027	33	41	42	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994			EUR RADIOL	Eur. Radiol.	JAN	2012	22	1					152	160		10.1007/s00330-011-2248-6			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	857UX	WOS:000297749100016	21861187				2022-02-06	
J	Talving, P; Lustenberger, T; Lam, L; Inaba, K; Mohseni, S; Plurad, D; Green, DJ; Demetriades, D				Talving, Peep; Lustenberger, Thomas; Lam, Lydia; Inaba, Kenji; Mohseni, Shahin; Plurad, David; Green, Donald J.; Demetriades, Demetrios			Coagulopathy After Isolated Severe Traumatic Brain Injury in Children	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Traumatic brain injury; Children; Pediatric; Coagulopathy; Outcome; Risk factor; Mortality	SEVERE HEAD-INJURY; COAGULATION; ADOLESCENTS; DISORDERS	Introduction: Few previous studies have been conducted on the severe traumatic brain injury (sTBI)-associated coagulopathy in children. The purpose of this study was to evaluate the incidence and risk factors of sTBI coagulopathy in a pediatric cohort and to evaluate its impact on outcomes. Methods: Retrospective analysis of pediatric patients (younger than 18 years) sustaining isolated sTBI [head Abbreviated Injury Scale (AIS) score >= 3 and extracranial injuries AIS score <3]. Criteria for sTBI-associated coagulopathy included thrombocytopenia (platelet count <100,000 per mm(3)) and/or elevated international normalized ratio >1.2 and/or prolonged activated partial thromboplastin time >36 seconds. Incidence and risk factors of sTBI coagulopathy and its impact on in-hospital outcomes were analyzed. Results: Overall, 42.8% (n = 137) of the 320 patients studied developed coagulopathy, with increasing incidence in a stepwise fashion with escalating head AIS score (31.1, 46.2, and 88.6% for head AIS score 3, 4, and 5, respectively; p < 0.001). Depressed GCS, increasing age, an ISS >= 16, and brain contusions/lacerations were independently associated with the presence of coagulopathy. The case fatality rate was 7.8% (n = 25); 17.5% versus 0.5% in coagulopathic versus noncoagulopathic patients, respectively. After logistic regression to adjust for confounders, no statistical significant mortality difference in patients with and without coagulopathy was noted (adjusted p = 0.912). Conclusions: Incidence of coagulopathy in children suffering isolated sTBI is exceedingly high at 40% and reflect the head injury severity. A low GCS, increasing age, ISS >= 16 and intraparenchymal lesions proved to be independently associated with TBI coagulopathy.	[Talving, Peep; Lustenberger, Thomas; Lam, Lydia; Inaba, Kenji; Mohseni, Shahin; Plurad, David; Green, Donald J.; Demetriades, Demetrios] Univ So Calif, Div Acute Care Surg Trauma Emergency Surg & Surg, Dept Surg, Keck Sch Med,Med Ctr, Los Angeles, CA 90033 USA		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles Cty Gen Hosp LAC USC, 1200 N State St,C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	INABA, KENJI/AAC-8532-2020; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI 10.1590/S0021-75572007000400014; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jakob H, 2010, EUR J TRAUMA EMERG S, V36, P325, DOI 10.1007/s00068-010-1125-3; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	21	41	41	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1205	1210		10.1097/TA.0b013e31820d151d			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849IG	WOS:000297118600026	21427617				2022-02-06	
J	Widome, R; Laska, MN; Gulden, A; Fu, SS; Lust, K				Widome, Rachel; Laska, Melissa Nelson; Gulden, Ashley; Fu, Steven S.; Lust, Katherine			Health Risk Behaviors of Afghanistan and Iraq War Veterans Attending College	AMERICAN JOURNAL OF HEALTH PROMOTION			English	Article						Veterans; Young Adult; Tobacco; Substance Abuse; Obesity; Safety; Prevention Research	TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; CIGARETTE-SMOKING; YOUNG-ADULTS; BODY-WEIGHT; UNITED-STATES; ALCOHOL-USE; TOBACCO USE; OBESITY; PREVALENCE	Purpose. The population of military veterans attending college is rapidly growing as veterans return from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF). We sought to describe patterns of student veterans' health-related behaviors and how they might differ from their nonveteran peers. Design. We analyzed data from the 2008 Boynton College Student Health Survey (CSHS). Setting. CSHS participants completed an anonymous online survey. Subjects. The CSHS sampled students (n = 8651) attending public, private, 2-year, and 4-year postsecondary educational institutions in Minnesota. Measures. The CSHS included items on substance use (including alcohol and tobacco), safety, nutrition, and physical activity. Analysis. We described demographics of OEF/OIF veteran, non-OEF/OIF veteran, and nonveteran students and used Poisson regression to compute adjusted relative risks (ARRs) with 95 % confidence intervals (CIs) to characterize associations between veteran status and health behaviors. Results. After controlling for demographics, veteran students reported more safety-, tobacco-, and alcohol-related risk behaviors compared to nonveteran students. For instance, compared to the nonveteran reference group, the ARR for past year smokeless tobacco use and physical fighting among for OEF/OIF veterans was 1.76 (95 % CI = 1.31-2.35) and 1.48 (95 % CI = 1.22-1.79) respectively. Veteran and nonveteran students display similar weight-related behaviors, though OEF/OIF veteran students were more likely to engage in strengthening exercises. Conclusions. There are specific health risk behaviors that are particularly relevant for veterans attending postsecondary institutions. As veterans enroll in postsecondary education, there is a unique window of opportunity far health promotion in this population. (Am J Health Promot 2011;26[2]:101-108.)	[Widome, Rachel; Gulden, Ashley; Fu, Steven S.] Minneapolis VA Med Ctr, CCDOR, Minneapolis, MN 55417 USA; [Widome, Rachel; Fu, Steven S.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Laska, Melissa Nelson] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Lust, Katherine] Univ Minnesota, Boynton Hlth Serv, Minneapolis, MN USA		Widome, R (corresponding author), Minneapolis VA Med Ctr, CCDOR, 1 Vet Dr 152-2E, Minneapolis, MN 55417 USA.	chel@umn.edu		Laska, Melissa/0000-0002-3836-0269; Fu, Steven/0000-0002-2246-9825	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54 CA116849, U54CA116849] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA116849] Funding Source: NIH RePORTER		Almond N, 2008, MIL MED, V173, P544, DOI 10.7205/MILMED.173.6.544; Bondurant S, 2009, COMB TOB US MIL VET; Bray RM, 2006, RTI7841106FR; Butler SM, 2004, AM J HEALTH BEHAV, V28, P24, DOI 10.5993/AJHB.28.1.3; Centers for Disease Control and Prevention, 2009 STAT LOC YOUTH; COOK A, 2005, PYRAMID SERVINGS INT; DALTON A, 2006, HLTH SERVICES VA SUB; DeBate RD, 2001, ADOLESCENCE, V36, P819; Driskell JA, 2005, J AM DIET ASSOC, V105, P798, DOI 10.1016/j.jada.2005.02.004; FEIGELMAN W, 1994, PREV MED, V23, P235, DOI 10.1006/pmed.1994.1032; Ferreira I, 2005, ARCH INTERN MED, V165, P42, DOI 10.1001/archinte.165.1.42; Forgas LB, 1996, MIL MED, V161, P165, DOI 10.1093/milmed/161.3.165; Gordon-Larsen P, 2004, AM J PREV MED, V27, P277, DOI 10.1016/j.amepre.2004.07.006; Hajhosseini L, 2006, J AM COLL NUTR, V25, P123, DOI 10.1080/07315724.2006.10719522; Hammond D, 2005, TOB CONTROL, V14, P181, DOI 10.1136/tc.2004.009621; Heron M, NAT VIT STAT REP, V58, P1; Hoffman DJ, 2006, J AM COLL HEALTH, V55, P41, DOI 10.3200/JACH.55.1.41-46; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm-Denoma JM, 2008, HEALTH PSYCHOL, V27, pS3, DOI 10.1037/0278-6133.27.1.S3; Huang TTK, 2003, J AM COLL HEALTH, V52, P83, DOI 10.1080/07448480309595728; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jacobson IG, 2009, AM J EPIDEMIOL, V169, P415, DOI 10.1093/aje/kwn366; Kaly PW, 2002, J COLL STUDENT DEV, V43, P838; Kang H., 2009, ANAL VA HLTH CARE UT; Karney B. R., 2008, INVISIBLE WOUNDS WAR, P119; Kiefe CI, 2001, AM J PUBLIC HEALTH, V91, P213, DOI 10.2105/AJPH.91.2.213; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; KLEVENS RM, 1995, AM J PREV MED, V11, P245, DOI 10.1016/S0749-3797(18)30453-7; LaBrie JW, 2008, ARCH SEX BEHAV, V37, P330, DOI 10.1007/s10508-007-9195-y; Lloyd-Richardson EE, 2009, PREV MED, V48, P256, DOI 10.1016/j.ypmed.2008.12.009; McCracken Melissa, 2007, Prev Chronic Dis, V4, pA25; McKinney WP, 1997, PUBLIC HEALTH REP, V112, P212; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Morrell HER, 2008, AM J ADDICTION, V17, P181, DOI 10.1080/10550490802019899; Morrow ML, 2006, OBESITY, V14, P1438, DOI 10.1038/oby.2006.163; Nelson KM, 2006, J GEN INTERN MED, V21, P915, DOI 10.1007/BF02743137; Nelson MC, 2008, OBESITY, V16, P2205, DOI 10.1038/oby.2008.365; Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005; Office of Statistics and Programming NCfIPaCCfDCaP, 2009, WISQUARS 2006 UN INJ; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Paeratakul S, 2003, J AM DIET ASSOC, V103, P1332, DOI 10.1016/S0002-8223(03)01086-1; Peterson AL, 2007, MIL MED, V172, P1300, DOI 10.7205/MILMED.172.12.1300; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Racette SB, 2005, J AM COLL HEALTH, V53, P245, DOI 10.3200/JACH.53.6.245-251; Racette SB, 2008, J NUTR EDUC BEHAV, V40, P39, DOI 10.1016/j.jneb.2007.01.001; Raudenbush S.W., 2002, HIERACHICAL LINEAR M; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI 10.1001/jama.284.6.699; Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sewall M., 2010, CHRON HIGHER EDUC, V56, pA20; Smith B, 2008, AM J PREV MED, V35, P539, DOI 10.1016/j.amepre.2008.07.009; Sutfin EL, 2009, NICOTINE TOB RES, V11, P444, DOI 10.1093/ntr/ntp006; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; Vander Weg MW, 2008, ADDICT BEHAV, V33, P69, DOI 10.1016/j.addbeh.2007.07.005; WAGNER TH, 2007, PSYCHOL SERVICES, V0004; Wechsler H, 1998, JAMA-J AM MED ASSOC, V280, P1673, DOI 10.1001/jama.280.19.1673	57	41	41	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0890-1171	2168-6602		AM J HEALTH PROMOT	Am. J. Health Promot.	NOV-DEC	2011	26	2					101	108		10.4278/ajhp.090826-QUAN-278			8	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	846WR	WOS:000296934400006	22040391	Green Accepted			2022-02-06	
J	Zhao, JB; Li, GZ; Zhang, Y; Su, XF; Hang, CH				Zhao, Jinbing; Li, Guangzhao; Zhang, Yang; Su, Xingfen; Hang, Chunhua			The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats	CYTOKINE			English	Article						JAK2; STAT3; Anti-apoptotic; Recombinant human erythropoietin; Traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; JAK-STAT PATHWAY; TRANSCRIPTION FACTORS; INCREASED EXPRESSION; SIGNALING PATHWAY; JAK/STAT PATHWAY; CORTICAL-NEURONS; CELL-DEATH; ACTIVATION; RECEPTOR	Previous studies indicate that administration of recombinant human erythropoietin (rhEPO) protects cortical neurons following traumatic brain injury (TBI). The mechanisms of rhEPO's neuroprotection are complex and interacting, including anti-apoptosis. Here we aim to demonstrate the role of janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway on the anti-apoptotic effect of rhEPO in Feeney free falling TBI model. Activation of JAK2/STAT3 in pericontusional cortex was analyzed among rats in Sham, TBI, TBI + rhEPO, TBI + rhEPO + AG490 groups (rhEPO: 5000 U/kg day; JAK2 inhibitor AG490: 5 mg/kg day, intraperitoneal) through Western blotting, electrophoretic mobility shift assay. Bcl-2 and Bcl-xl expression (Q-PCR, Western blotting) and cell apoptosis (TUNEL) in pericontusional cortex were also detected in each group. As a result, we found that TBI could activate JAK2 and STAT3, and increase cell apoptosis in pericontusional cortex. RhEPO enhanced the expression of p-JAK2 and p-STAT3, up-regulated the mRNA and protein levels of Bcl-2 and Bcl-xl, followed by increased cell survival. Moreover, AG490 attenuated rhEPO's neuroprotection by down-regulating rhEPO-induced activation of JAK2/STAT3, and inhibiting Bcl-2 and Bcl-xl. These results suggest the essential role of JAK2/STAT3 pathway on the anti-apoptotic benefit of post-TBI rhEPO treatment. (C) 2011 Elsevier Ltd. All rights reserved.	[Zhao, Jinbing; Zhang, Yang; Su, Xingfen; Hang, Chunhua] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu Provinc, Peoples R China; [Li, Guangzhao; Hang, Chunhua] So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Provinc, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Provinc, Peoples R China.	hang.neurosurgery@gmail.com			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2010459]; Jiangsu Province "333 High-Level Personnel Training Project" [BRA2010196]; Nanjing Military Command, China	This study was supported by Natural Science Foundation of Jiangsu Province (BK2010459), Jiangsu Province "333 High-Level Personnel Training Project" (BRA2010196) and Medical and Health Research Fund of Nanjing Military Command, China. We appreciate the help of Gen-bao Feng for his technical assistance.	Arishima Y, 2006, SPINE, V31, P2432, DOI 10.1097/01.brs.0000239124.41410.7a; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bolli R, 2003, TRENDS CARDIOVAS MED, V13, P72, DOI 10.1016/S1050-1738(02)00230-X; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chen G, 2009, CYTOKINE, V45, P162, DOI 10.1016/j.cyto.2008.11.015; Cotena S, 2008, PANMINERVA MED, V50, P185; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Gorina R, 2005, J NEUROCHEM, V92, P505, DOI 10.1111/j.1471-4159.2004.02878.x; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masamune A, 2005, WORLD J GASTROENTERO, V11, P3385, DOI 10.3748/wjg.v11.i22.3385; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Osuka K, 2006, BRAIN RES, V1072, P1, DOI 10.1016/j.brainres.2005.12.003; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Seki Y, 2000, CIRC RES, V87, P12, DOI 10.1161/01.RES.87.1.12; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Spandou E, 2004, BRAIN RES, V1021, P167, DOI 10.1016/j.brainres.2004.06.057; Tacchini L, 2002, BIOCHEM PHARMACOL, V63, P139, DOI 10.1016/S0006-2952(01)00836-X; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	43	41	43	2	13	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666			CYTOKINE	Cytokine	NOV	2011	56	2					343	350		10.1016/j.cyto.2011.07.018			8	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	837OX	WOS:000296214200031	21843949				2022-02-06	
J	Berry, C; Ley, EJ; Margulies, DR; Mirocha, J; Bukur, M; Malinoski, D; Salim, A				Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Mirocha, James; Bukur, Marko; Malinoski, Darren; Salim, Ali			Correlating the Blood Alcohol Concentration with Outcome after Traumatic Brain Injury: Too Much Is Not a Bad Thing	AMERICAN SURGEON			English	Article; Proceedings Paper	22nd Annual Scientific Meeting of the Southern California Chapter of the American-College-of-Surgeons	JAN 21-23, 2011	Santa Barbara, CA	Amer Coll Surg			SERUM ETHANOL LEVELS; MORTALITY; LEVEL; RISK; INTOXICATION; ASSOCIATION; SEVERITY; MODERATE; RAT	Although recent evidence suggests a beneficial effect of alcohol for patients with traumatic brain injury (TB!), the level of alcohol that confers the protective effect is unknown. Our objective was to investigate the relationship between admission blood alcohol concentration (BAC) and outcomes in patients with isolated moderate to severe TBI. From 2005 to 2009, the Los Angeles County Trauma Database was queried for all patients >= 14 years of age with isolated moderate to severe TBI and admission serum alcohol levels. Patients were then stratified into four levels based on admission BAC: None (0 mg/dL), low (0-100 mg/dL), moderate (100-230 mg/dL), and high (>= 230 mg/dL). Demographics, patient characteristics, and outcomes were compared across levels. In evaluating 3794 patients, the mortality rate decreased with increasing BAC levels (linear trend P < 0.0001). In determining the relationship between BAC and mortality, multivariable logistic regression analysis demonstrated a high BAC level was significantly protective (adjusted odds ratio 0.55; 95% confidence interval: 0.38-0.8; P = 0.002). In the largest study to date, a high (>= 230 mg/dL) admission BAC was independently associated with improved survival in patients with isolated moderate to severe TBI. Additional research is warranted to investigate the potential therapeutic implications.	[Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Mirocha, James; Bukur, Marko; Malinoski, Darren; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020	Bukur, Marko/0000-0002-1850-7147			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Berry C, 2010, AM SURGEON, V76, P1067; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813	21	41	41	0	8	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	OCT	2011	77	10					1416	1419					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	829ED	WOS:000295558600033	22127102				2022-02-06	
J	Ley, EJ; Clond, MA; Singer, MB; Shouhed, D; Salim, A				Ley, Eric J.; Clond, Morgan A.; Singer, Matt B.; Shouhed, Daniel; Salim, Ali			IL6 Deficiency Affects Function After Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; controlled cortical impact; behavioral testing; cytokine; heat shock protein; IL6; HSP70; HSP 72; IL1 beta	INTERLEUKIN-1 RECEPTOR ANTAGONIST; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; MICE; IL-6; CYTOKINE; IMPACT; CORRELATE; SEVERITY; KNOCKOUT	Objective. Interleukin-6 (IL6) is a major inflammatory mediator and one of the first cytokines produced after traumatic brain injury (TBI). This study evaluates early behavioral changes and acute inflammation after TBI in IL6 knock-out mice using electromagnetic controlled cortical impact. Methods. IL6 knock-out (KO) and C57BL/6 (WT) male mice were subjected to TBI or sham injury (n = 6 mice per group) using electromagnetic controlled cortical impact. Behavioral deficits were tested by standard performance tests. Brain IL1 beta expression was measured by ELISA and HSP70 expression was measured by Western blot. Results. After TBI, KO showed reduced performance on the neuroscreen compared with wild type (KO 3.2 +/- 0.7 versus WT 4.7 +/- 0.2 points, P = 0.007), less exploratory activity in the open field test (KO 1090.2 +/- 1799.2 versus WT 5636.8 +/- 1291.8 regions explored per hour, P = 0.003) less rearing behavior in the open field test (KO 36.4 +/- 79.2 versus WT 346.5 +/- 18.5 rearing per hour, P = 0.0006), reduced travel on the rotarod (KO 3.5 +/- 4.0 versus WT 13.0 +/- 4.0 cm, P = 0.0109), and reduced time balanced on the rotarod (KO 15.0 +/- 11.5 versus WT 36.2 +/- 5.9 s, P = 0.0109). After TBI, IL6 knock-out mice had significantly elevated IL1 beta (KO 58.16 +/- 17.54 versus WT 14.98 +/- 8.33 pg/mL, P = 0.003 and nonsignificantly increased HSP70 levels (KO 0.93 +/- 0.96 versus WT 0.68 +/- 0.97, P = 0.77). Conclusion. IL6 deficiency after TBI is associated with poor behavior performance, and appears to affect expression of IL1 beta and, possibly, HSP70. (C) 2011 Elsevier Inc. All rights reserved.	[Ley, Eric J.; Clond, Morgan A.; Singer, Matt B.; Shouhed, Daniel; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA		Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Clond, Morgan/0000-0002-3036-4193	American Association for the Surgery of Trauma Research and Education Foundation	The authors acknowledge support in part for this study by a grant from the American Association for the Surgery of Trauma Research and Education Foundation.	Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Howell JM, 2006, PROTEOMICS, V6, P2050, DOI 10.1002/pmic.200500517; Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mannick JA, 2002, J AM COLL SURGEONS, V194, P104, DOI 10.1016/S1072-7515(01)01123-1; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	28	41	41	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	OCT	2011	170	2					253	256		10.1016/j.jss.2011.03.006			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	823NH	WOS:000295128600024	21529825				2022-02-06	
J	McAllister, TW; McDonald, BC; Flashman, LA; Ferrell, RB; Tosteson, TD; Yanofsky, NN; Grove, MR; Saykin, AJ				McAllister, Thomas W.; McDonald, Brenna C.; Flashman, Laura A.; Ferrell, Richard B.; Tosteson, Tor D.; Yanofsky, Norman N.; Grove, Margaret R.; Saykin, Andrew J.			Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: Altered working memory and BOLD response	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; Alpha-2 adrenergic agonist; Working memory; Functional MRI; Guanfacine	CORTICAL COGNITIVE FUNCTION; PREFRONTAL CORTEX; ALPHA-2 ANTAGONIST; AGED RATS; PERFORMANCE; AGONIST; MECHANISMS; DEFICITS; REVERSAL; MONKEYS	Alterations in working memory (WM) are common after traumatic brain injury (TBI). Frontal catecholaminergic systems, including the alpha-2 adrenergic system, modulate WM function and may be affected in TBI. We hypothesized that administration of an alpha-2 adrenergic agonist might improve WM after mild TBI (MTBI). Thirteen individuals with MTBI 1 month after injury and 14 healthy controls (HC) were challenged with guanfacine and placebo prior to administration of a verbal WM functional MRI task. Guanfacine was associated with improved WM performance in the MTBI but not the HC group. On guanfacine the MTBI group showed increased activation within a WM task-specific region of interest. Findings are consistent with the hypothesis that alterations in WM after MTBI may be improved with the alpha-2 agonist guanfacine. (C) 2011 Elsevier B.V. All rights reserved.	[McAllister, Thomas W.; McDonald, Brenna C.; Flashman, Laura A.; Ferrell, Richard B.; Grove, Margaret R.; Saykin, Andrew J.] Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH USA; [McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN USA; [Tosteson, Tor D.] Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH USA; [Yanofsky, Norman N.] Dartmouth Med Sch, Sect Emergency Med, Lebanon, NH USA		McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532; Ferrell, Richard/0000-0002-7492-210X	NIDRR [H133G70031, H133000136]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS40472-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER	This research was supported in part by NIDRR Grants H133G70031 and H133000136 and NIH Grant R01 NS40472-01. The authors would like to thank Brian Greenlee and Kaloyan Tanev, Neuropsychiatry Fellows, James Ford and Heather Pixley, Department of Psychiatry, and Robert Ferranti, Alice Davison, Shreve Soule and Robert Shaffer, Department of Radiology, for their assistance on this project.	Anticevic A, 2010, NEUROIMAGE, V49, P2638, DOI 10.1016/j.neuroimage.2009.11.008; Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; ARNSTEN AFT, 1988, J NEUROSCI, V8, P4287; Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448; Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; ARNSTEN AFT, 1985, SCIENCE, V230, P1273, DOI 10.1126/science.2999977; Avery RA, 2000, NEUROPSYCHOPHARMACOL, V23, P240, DOI 10.1016/S0893-133X(00)00111-1; Barth AMI, 2008, J NEUROPHYSIOL, V99, P394, DOI 10.1152/jn.00943.2007; BARTUS RT, 1978, J GERONTOL, V33, P858, DOI 10.1093/geronj/33.6.858; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Birnbaum S, 1999, BIOL PSYCHIAT, V46, P1266, DOI 10.1016/S0006-3223(99)00138-9; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAI JX, 1993, BRAIN RES, V614, P191; CARLSON S, 1992, BEHAV NEURAL BIOL, V58, P113, DOI 10.1016/0163-1047(92)90327-Z; Chen KW, 2004, NEUROIMAGE, V22, P134, DOI 10.1016/j.neuroimage.2004.01.002; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clerkin SM, 2009, BIOL PSYCHIAT, V66, P307, DOI 10.1016/j.biopsych.2009.04.013; Crossley NA, 2009, HUM BRAIN MAPP, V30, P4129, DOI 10.1002/hbm.20834; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKAPLAN EXECUTIV; First M., 1997, STRUCTURED CLIN INTE; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gordon M., 1986, GORDON DIAGNOSTIC SY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI [10.1016/S1053-8119(18)31587-8, DOI 10.1016/S1053-8119(18)31587-8]; HUNT RD, 1995, J AM ACAD CHILD PSY, V34, P50, DOI 10.1097/00004583-199501000-00013; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P119, DOI 10.1016/S0893-133X(98)00055-4; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LUINE V, 1990, BRAIN RES, V537, P271, DOI 10.1016/0006-8993(90)90368-L; McAllister T. W., 2008, COGNITIVE NEUROREHAB, P298; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Nejad AB, 2011, WORLD J BIOL PSYCHIA, V12, P271, DOI 10.3109/15622975.2010.556199; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Rama P, 1996, PHARMACOL BIOCHEM BE, V55, P415, DOI 10.1016/S0091-3057(96)00111-6; Ramos BP, 2006, LEARN MEMORY, V13, P770, DOI 10.1101/lm.298006; Reitan R.M., 1993, HALSTEADREITAN NEURO; SIRVIO J, 1991, BEHAV NEURAL BIOL, V56, P101, DOI 10.1016/0163-1047(91)90327-M; Steere JC, 1997, BEHAV NEUROSCI, V111, P883; Strauss E., 1998, COMPENDIUM NEUROPSYC, P447; Tanila H, 1996, BRAIN RES BULL, V40, P117, DOI 10.1016/0361-9230(96)00026-3; The Psychological Corporation, 1997, WAIS 3 WECHSL AD INT; Tomasi D, 2006, HUM BRAIN MAPP, V27, P694, DOI 10.1002/hbm.20211; Wang M, 2007, CELL, V129, P397, DOI 10.1016/j.cell.2007.03.015; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME	58	41	42	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		107	114		10.1016/j.ijpsycho.2011.06.022			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600012	21767584	Green Accepted			2022-02-06	
J	Gao, JH; Hu, J; Buckley, T; White, K; Hass, C				Gao, Jianbo; Hu, Jing; Buckley, Thomas; White, Keith; Hass, Chris			Shannon and Renyi Entropies to Classify Effects of Mild Traumatic Brain Injury on Postural Sway	PLOS ONE			English	Article							COLLEGIATE FOOTBALL PLAYERS; CONCUSSION ASSESSMENT; TIME-SERIES; HEAD-INJURY; STABILITY; ENCEPHALOPATHY; COMPLEXITY; DEFICITS; IMPACT	Background: Mild Traumatic Brain Injury (mTBI) has been identified as a major public and military health concern both in the United States and worldwide. Characterizing the effects of mTBI on postural sway could be an important tool for assessing recovery from the injury. Methodology/Principal Findings: We assess postural sway by motion of the center of pressure (COP). Methods for data reduction include calculation of area of COP and fractal analysis of COP motion time courses. We found that fractal scaling appears applicable to sway power above about 0.5 Hz, thus fractal characterization is only quantifying the secondary effects (a small fraction of total power) in the sway time series, and is not effective in quantifying long-term effects of mTBI on postural sway. We also found that the area of COP sensitively depends on the length of data series over which the COP is obtained. These weaknesses motivated us to use instead Shannon and Renyi entropies to assess postural instability following mTBI. These entropy measures have a number of appealing properties, including capacity for determination of the optimal length of the time series for analysis and a new interpretation of the area of COP. Conclusions: Entropy analysis can readily detect postural instability in athletes at least 10 days post-concussion so that it appears promising as a sensitive measure of effects of mTBI on postural sway. Availability: The programs for analyses may be obtained from the authors.	[Gao, Jianbo] PMB Intelligence LLC, W Lafayette, IN USA; [Hu, Jing] Affymetrix Inc, Santa Clara, CA USA; [Buckley, Thomas] Georgia So Univ, Grad Athlet Training Program, Statesboro, GA 30460 USA; [White, Keith] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA; [Hass, Chris] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA		Gao, JH (corresponding author), PMB Intelligence LLC, W Lafayette, IN USA.	jbgao@pmbintelligence.com	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; White, Keith/0000-0002-4442-5743	Army Research Office [56382LSJDO, W911NF-10-1-0425]; Div Of Civil, Mechanical, & Manufact InnNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1031958] Funding Source: National Science Foundation	This work was supported in part by Army Research Office grants #56382LSJDO and #W911NF-10-1-0425. The views expressed herein are those of the authors and do not reflect the views of the Army Research Office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amoud H, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-12; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gao J., 2007, MULTISCALE ANAL COMP; Gao JB, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016117; Gao JB, 2011, PLOS ONE IN PRESS; Gao JB, 2010, IEEE SIGNAL PROC LET, V17, P237, DOI 10.1109/LSP.2009.2037773; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu J, 2009, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2009/02/P02066; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mandelbrot BB., 1982, FRACTAL GEOMETRY NAT; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Thurner S, 2002, AUDIOL NEURO-OTOL, V7, P240, DOI 10.1159/000063740; Tung WW, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.046210; Valovich TC, 2003, J ATHL TRAINING, V38, P51	37	41	41	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2011	6	9							e24446	10.1371/journal.pone.0024446			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CN	WOS:000294803100033	21931720	Green Submitted, gold, Green Published			2022-02-06	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Linden, CV; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Geurts, Monique; Linden, Catharine Vander; Smits-Engelsman, Bouwien C. M.; Sunaert, Stefan; Swinnen, Stephan P.			Correlations Between White Matter Integrity and Motor Function in Traumatic Brain Injury Patients	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						diffuse axonal injury; traumatic brain injury rehabilitation; fractional anisotropy; motor skills; pediatric brain injury	MOVEMENT ASSESSMENT BATTERY; DIFFUSION-TENSOR MRI; CORPUS-CALLOSUM; AXONAL INJURY; HEAD-INJURY; BEHAVIOR RELATIONSHIPS; CEREBELLAR ATROPHY; MUTUAL INFORMATION; CHILDREN; MILD	Background. Deterioration of motor function is one of several clinical manifestations following traumatic brain injury (TBI) in children and adolescents. Objective. To investigate the relationship between white matter (WM) integrity using diffusion tensor imaging (DTI) and motor functioning in young TBI patients. Methods. A group with moderate to severe TBI (n = 24) and a control group (n = 17) were scanned using DTI along with standard anatomical scans. Using ExploreDTI software, WM regions/tracts that carry efferent output (motor) from the brain were evaluated, as well as the corpus callosum, brainstem, internal capsule, and subcortical WM structures. Motor function was assessed using the Movement Assessment Battery for Children (M-ABC), consisting of manual dexterity, ball skills, and static and dynamic balance items. Results. TBI patients were less successful on the M-ABC than the controls and showed lower WM fractional anisotropy (FA) in the corpus callosum, anterior corona radiata, corticospinal tract, and cerebellum. Decreased FA was associated with lower motor performance in the TBI group but not in the control group. Conclusion. This study provides evidence for a structural alteration of motor pathways and regions in children and adolescents with TBI that are correlated with motor functioning. Further studies may be able to identify therapeutic targets and monitor the effects of new interventions.	[Caeyenberghs, Karen] Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, B-3001 Heverlee, Belgium; [Leemans, Alexander] Cardiff Univ, Cardiff, S Glam, Wales; [Leemans, Alexander] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Linden, Catharine Vander] Ghent Univ Hosp, B-9000 Ghent, Belgium; [Smits-Engelsman, Bouwien C. M.] Univ Professionals, Breda, Netherlands		Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Sunaert, Stefan/E-8031-2011	Leemans, Alexander/0000-0002-9306-6126; Sunaert, Stefan/0000-0002-1177-4680; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation-Flanders (FWO)FWO [7.0004.05, G.0482.010]	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: Support for this study was provided through a grant from the Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05 and G.0482.010). Karen Caeyenberghs is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Arfanakis K, 2002, MAGNET RESON MED, V47, P354, DOI 10.1002/mrm.10046; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Croce RV, 2001, PERCEPT MOTOR SKILL, V93, P275, DOI 10.2466/pms.2001.93.1.275; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Foulder-Hughes L., 2003, BRIT J OCCUPATIONAL, V66, P9; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Greenwood R, 2002, J NEUROL NEUROSUR PS, V73, pI8; HAZRATI LN, 1992, BRAIN RES, V585, P267, DOI 10.1016/0006-8993(92)91216-2; Hsu JL, 2010, NEUROIMAGE, V49, P32, DOI 10.1016/j.neuroimage.2009.08.031; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LeBihan D, 1995, NMR BIOMED, V8, P375; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, P INT SOC MAG RESON; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Smits-Engelsman BCM, 1998, HUM MOVEMENT SCI, V17, P699, DOI 10.1016/S0167-9457(98)00019-0; Smits-Engelsman BCM, 2008, PHYS THER, V88, P286, DOI 10.2522/ptj.20070068; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Sterr A, 2010, NEUROREHAB NEURAL RE, V24, P413, DOI 10.1177/1545968309348310; Sugden, 1992, MOVEMENT ASSESSMENT; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; van Hartingsveldt Margo J, 2005, Occup Ther Int, V12, P1, DOI 10.1002/oti.11; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; Van Hecke W, 2010, J MAGN RESON IMAGING, V31, P1492, DOI 10.1002/jmri.22198; Van Hecke W, 2009, NEUROIMAGE, V46, P692, DOI 10.1016/j.neuroimage.2009.02.032; Van Waelvelde H, 2007, CLIN REHABIL, V21, P465, DOI 10.1177/0269215507074052; Verhoeven JS, 2010, HUM BRAIN MAPP, V31, P470, DOI 10.1002/hbm.20880; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	66	41	42	0	31	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2011	25	6					492	502		10.1177/1545968310394870			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	774KL	WOS:000291384200001	21427274				2022-02-06	
J	Bohman, LE; Heuer, GG; Macyszyn, L; Maloney-Wilensky, E; Frangos, S; Le Roux, PD; Kofke, A; Levine, JM; Stiefel, MF				Bohman, Leif-Erik; Heuer, Gregory G.; Macyszyn, Lukascz; Maloney-Wilensky, Eileen; Frangos, Suzanne; Le Roux, Peter D.; Kofke, Andrew; Levine, Joshua M.; Stiefel, Michael F.			Medical Management of Compromised Brain Oxygen in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Brain tissue oxygen pressure; Brain hypoxia; Intracranial pressure; Cerebral perfusion pressure; Outcome; Traumatic brain injury; Head injury; Monitoring	CEREBRAL PERFUSION-PRESSURE; BLOOD-CELL TRANSFUSION; TISSUE OXYGEN; INTRACRANIAL-PRESSURE; REGIONAL OXYGENATION; HYPERTONIC SALINE; METABOLISM; AUGMENTATION; HYPERTENSION	Background Brain tissue oxygen (PbtO(2)) monitoring is used in severe traumatic brain injury (TBI) patients. How brain reduced PbtO(2) should be treated and its response to treatment is not clearly defined. We examined which medical therapies restore normal PbtO(2) in TBI patients. Methods Forty-nine (mean age 40 +/- A 19 years) patients with severe TBI (Glasgow Coma Scale [GCS] a parts per thousand currency sign 8) admitted to a University-affiliated, Level I trauma center who had at least one episode of compromised brain oxygen (PbtO(2) < 25 mmHg for > 10 min), were retrospectively identified from a prospective observational cohort study. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbtO(2) were monitored continuously. Episodes of compromised PbtO(2) and brain hypoxia (PbtO(2) < 15 mmHg for > 10 min) and the medical interventions that improved PbtO(2) were identified. Results Five hundred and sixty-four episodes of compromised PbtO2 were identified from 260 days of PbtO2 monitoring. Medical management used in a "cause-directed" manner successfully reversed 72% of the episodes of compromised PbtO(2), defined as restoration of a "normal" PbtO(2) (i.e. a parts per thousand yen25 mmHg). Ventilator manipulation, CPP augmentation, and sedation were the most frequent interventions. Increasing FiO(2) restored PbtO(2) 80% of the time. CPP augmentation and sedation were effective in 73 and 66% of episodes of compromised brain oxygen, respectively. ICP reduction using mannitol was effective in 73% of treated episodes, though was used only when PbtO(2) was compromised in the setting of elevated ICP. Successful medical treatment of brain hypoxia was associated with decreased mortality. Survivors (n = 38) had a 71% rate of response to treatment and non-survivors (n = 11) had a 44% rate of response (P = 0.01). Conclusion Reduced PbtO(2) may occur in TBI patients despite efforts to maintain CPP. Medical interventions other than those to treat ICP and CPP can improve PbtO(2). This may increase the number of therapies for severe TBI in the ICU.	[Bohman, Leif-Erik; Heuer, Gregory G.; Macyszyn, Lukascz; Maloney-Wilensky, Eileen; Frangos, Suzanne; Le Roux, Peter D.; Kofke, Andrew; Levine, Joshua M.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, Andrew; Levine, Joshua M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Stiefel, Michael F.] New York Med Coll, Westchester Med Ctr, Dept Neurosurg, Div NeuroTrauma, Valhalla, NY 10595 USA		Bohman, LE (corresponding author), Univ Penn, Dept Neurosurg, 3 Silverstein Pavilion,3400 Spruce St, Philadelphia, PA 19104 USA.	Leif-Erik.Bohman@uphs.upenn.edu		Bohman, Leif-Erik/0000-0002-3889-9328	Integra Foundation; Integra Neurosciences; Mary Elisabeth Groff Surgical and Medical Research Trust	This article was supported by Research Grants from the Integra Foundation (PDL), Integra Neurosciences (PDL), and the Mary Elisabeth Groff Surgical and Medical Research Trust (PDL). PDL is a member of Integra's Speaker's Bureau.	Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P1; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESTNUT RM, 2000, HEAD INJURY, P229; Dhar R, 2009, STROKE, V40, P3039, DOI 10.1161/STROKEAHA.109.556159; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRACIAS VH, 2004, J TRAUMA, V56, P72; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Ledwith MB, 2010, J NEUROSCI NURS, V42, P280, DOI 10.1097/JNN.0b013e3181ecafd4; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McCarthy MC, 2009, SURGERY, V146, P585, DOI 10.1016/j.surg.2009.06.059; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Procaccio F, 2000, J Neurosurg Sci, V44, P11; Radolovich DK, 2010, ANESTH ANALG, V110, P165, DOI 10.1213/ANE.0b013e3181c0722f; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	43	41	41	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					361	369		10.1007/s12028-011-9526-7			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800006	21394543				2022-02-06	
J	Seifert, S; Pannell, M; Uckert, W; Farber, K; Kettenmann, H				Seifert, Stefanie; Pannell, Maria; Uckert, Wolfgang; Faerber, Katrin; Kettenmann, Helmut			Transmitter- and hormone-activated Ca2+ responses in adult microglia/brain macrophages in situ recorded after viral transduction of a recombinant Ca2+ sensor	CELL CALCIUM			English	Article						Microglia; Calcium; ATP; Endothelin-1; Serotonin; Substance P; Histamine; Neuropeptides; Neurotransmitter; Neurohormone; Stab wound	HISTAMINERGIC NEURON SYSTEM; TRAUMATIC BRAIN-INJURY; SUBSTANCE-P; BORRELIA-BURGDORFERI; RECEPTOR EXPRESSION; MURINE MICROGLIA; NEUROPATHIC PAIN; P2X(7) RECEPTOR; CEREBRAL-CORTEX; UP-REGULATION	In vitro studies show that microglia, the resident immune cells of the brain, express neurotransmitter and neuropeptide receptors which are linked to Ca2+ signaling. Here we describe an approach to obtain Ca2+ recordings from microglia in situ. We injected a retrovirus encoding a calcium sensor into the cortex of mice 2 days after stimulation of microglial proliferation by a stab wound injury. Microglial cells were identified with tomato lectin in acute slices prepared 3, 6, 21 and 42 days after the injury. The membrane current profile and the ameboid morphology indicated that microglial cells were activated at day 6 while at day 42 they resembled resting microglia. We recorded transient Ca2+ responses to application of ATP, endothelin-1, substance P. histamine and serotonin. The fluorescence amplitude of ATP was increased only at day 6 compared to other time points, while responses to all other ligands did not vary. Only half of the microglial cells that responded to ATP also responded to endothelin-1, serotonin and histamine. Substance P. in contrast, showed a complete overlap with the ATP responding microglial population at day 6, at day 42 this population was reduced to 55%. Cultured cells were less responsive to these ligands. This study shows that in situ microglia consist of heterogeneous populations with respect to their sensitivity to neuropeptides and -transmitters. (C) 2011 Elsevier Ltd. All rights reserved.	[Seifert, Stefanie; Pannell, Maria; Kettenmann, Helmut] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Faerber, Katrin] Univ Wurzburg, Inst Mol Infect Biol, D-97080 Wurzburg, Germany		Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	kettenmann@mdc-berlin.de	Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291	Transregio SFB [TR 43]; DFG graduate schoolGerman Research Foundation (DFG) [1258]	N1-GCaMP2 vector was a gift from Juchini Nakai (Saitama University Brain Science Institute, Saitama, Japan). CX3CR1-GFP mice were provided by Stefan Kaufmann, Max Planck Institut fur Infektionsbiologie. Berlin originally obtained from Skirball Institute of Biomolecular Medicine and Howard Hughes Medical Institute New York University Medical Center, New York. This work was supported by Transregio SFB TR 43 and the DFG graduate school 1258.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Agnati LF, 2010, BRAIN RES REV, V64, P137, DOI 10.1016/j.brainresrev.2010.03.003; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Block ML, 2006, FASEB J, V20, P251, DOI 10.1096/fj.05-4553com; Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chauhan VS, 2008, J IMMUNOL, V180, P8241, DOI 10.4049/jimmunol.180.12.8241; COLTON CA, 1993, ADV NEUROL, V59, P321; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engels B, 2003, HUM GENE THER, V14, P1155, DOI 10.1089/104303403322167993; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Inoue K, 2009, INT REV NEUROBIOL, V85, P159, DOI 10.1016/S0074-7742(09)85012-5; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Katoh Y, 2001, NEUROSCI LETT, V305, P181, DOI 10.1016/S0304-3940(01)01835-3; KESSLER IM, 2005, SURG NEUROL S1, V64, P2; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kreutzberg GW, 1968, ACTA NEUROPATH    S4, V4, P141; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li JJ, 2010, NEUROSCIENCE, V167, P665, DOI 10.1016/j.neuroscience.2010.02.062; Maeda K, 1997, GERONTOLOGY, V43, P11; Mahe C, 2005, NEUROPHARMACOLOGY, V49, P40, DOI 10.1016/j.neuropharm.2005.01.025; Marek GJ, 1998, BIOL PSYCHIAT, V44, P1118, DOI 10.1016/S0006-3223(98)00036-5; MARTIN FC, 1993, J NEUROIMMUNOL, V42, P53, DOI 10.1016/0165-5728(93)90212-H; McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3; Moller T, 1997, NEUROREPORT, V8, P2127; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007; PRELL GD, 1986, ANNU REV NEUROSCI, V9, P209; Rasley A, 2004, J IMMUNOL, V172, P5707, DOI 10.4049/jimmunol.172.9.5707; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Tsuda M, 2008, GLIA, V56, P579, DOI 10.1002/glia.20641; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Vruwink M, 2001, J COMP NEUROL, V441, P288, DOI 10.1002/cne.1413; WADA H, 1991, BRAIN RES BULL, V27, P367, DOI 10.1016/0361-9230(91)90126-5; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; WATANABE T, 1984, BRAIN RES, V295, P13, DOI 10.1016/0006-8993(84)90811-4; Werry EL, 2006, J NEUROCHEM, V99, P924, DOI 10.1111/j.1471-4159.2006.04133.x; Wu CY, 2009, NEUROSCIENCE, V158, P1500, DOI 10.1016/j.neuroscience.2008.11.043; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	51	41	41	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4160	1532-1991		CELL CALCIUM	Cell Calcium	JUN	2011	49	6					365	375		10.1016/j.ceca.2011.03.005			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	791KL	WOS:000292664000002	21536328				2022-02-06	
J	Skandsen, T; Kvistad, KA; Solheim, O; Lydersen, S; Strand, IH; Vik, A				Skandsen, Toril; Kvistad, Kjell Arne; Solheim, Ole; Lydersen, Stian; Strand, Ingrid Haavde; Vik, Anne			Prognostic Value of Magnetic Resonance Imaging in Moderate and Severe Head Injury: A Prospective Study of Early MRI Findings and One-Year Outcome	JOURNAL OF NEUROTRAUMA			English	Article						cohort study; craniocerebral trauma; Glasgow Outcome Scale; magnetic resonance imaging; treatment outcome	TRAUMATIC BRAIN-INJURY; PRACTICAL SCALE; STEM; CLASSIFICATION; DAMAGE; CONSCIOUSNESS; PREDICTION; MECHANISM; RECOVERY; LESIONS	The clinical benefit of early magnetic resonance imaging (MRI) in severe and moderate head injury is unclear. We sought to explore the prognostic value of the depth of lesions depicted with early MRI, and also to describe the prevalence and impact of traumatic brainstem lesions. In a cohort of 159 consecutive patients with moderate to severe head injury (age 5-65 years and surviving the acute phase) admitted to a regional level 1 trauma center, 106 (67%) were examined with MRI within 4 weeks post-injury. Depth of lesions in MRI was categorized as: hemisphere level, central level, and brainstem injury (BSI). The outcome measure was Glasgow Outcome Scale Extended (GOSE) 12 months post-injury. Forty-six percent of patients with severe injuries and 14% of patients with moderate injuries had BSI. In severe head injury, central or brainstem lesions in MRI, together with higher Rotterdam CT score, pupillary dilation, and secondary adverse events were significantly associated with a worse outcome in age-adjusted analyses. Bilateral BSI was strongly associated with a poor outcome in severe injury, with positive and negative predictive values of 0.86 and 0.88, respectively. In moderate injury, only age was significantly associated with outcome in multivariable analyses. Limitations of the current study include lack of blinded outcome evaluations and insufficient statistical power to assess the added prognostic value of MRI when combined with clinical information. We conclude that in patients with severe head injury surviving the acute phase, depth of lesion on the MRI was associated with outcome, and in particular, bilateral brainstem injury was strongly associated with poor outcomes. In moderate head injury, surprisingly, there was no association between MRI findings and outcome when using the GOSE score as outcome measure.	[Skandsen, Toril] Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Imaging, Fac Med, Trondheim, Norway; [Lydersen, Stian] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Unit Appl Clin Res, Trondheim, Norway; [Kvistad, Kjell Arne; Strand, Ingrid Haavde] Univ Trondheim Hosp, Dept Diagnost Imaging, St Olavs Hosp, N-7006 Trondheim, Norway; [Solheim, Ole; Vik, Anne] Univ Trondheim Hosp, Dept Neurosurg, St Olavs Hosp, N-7006 Trondheim, Norway		Skandsen, T (corresponding author), Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Solheim, Ole/0000-0002-5954-4817	Liaison Committee	We wish to thank neuroradiologist Mari Folvik (M. F.) for evaluation of MRI scans, and neuroradiologist Jana Rydland (J.R.) for her contribution to the reliability evaluation; Beate Holmqvist Karlsen, Otto Aarhaug, and Brit Sorum for participating in management of the database and the GOSE interviews; Kent Goran Moen for his work with the data files; the residents at the neurosurgical department for collection of the injury-related variables; the staff at the MRI unit for their cooperation with the MRI examinations; Toril Skandsen (T. S.) and Ole Solheim (O.S.) have received research grants from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), T. S. during the whole study period, and O.S. during the period of manuscript preparation.	Altman D.G., 1999, PRACTICAL STAT MED R; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENTRY LR, 2002, HEAD TRAUMA; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MITCHELL DE, 1973, LANCET, V2, P215; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	32	41	41	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					691	699		10.1089/neu.2010.1590			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100270	21401308				2022-02-06	
J	Paterniti, I; Melani, A; Cipriani, S; Corti, F; Mello, T; Mazzon, E; Esposito, E; Bramanti, P; Cuzzocrea, S; Pedata, F				Paterniti, Irene; Melani, Alessia; Cipriani, Sara; Corti, Francesca; Mello, Tommaso; Mazzon, Emanuela; Esposito, Emanuela; Bramanti, Placido; Cuzzocrea, Salvatore; Pedata, Felicita			Selective adenosine A(2A) receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects	JOURNAL OF NEUROINFLAMMATION			English	Article							EVOKED GLUTAMATE RELEASE; TRAUMATIC BRAIN-INJURY; AMINO-ACIDS; IN-VIVO; INDEPENDENT MECHANISMS; INDUCED EXCITOTOXICITY; COMPRESSION INJURY; CEREBRAL-ISCHEMIA; CELL-ACTIVATION; FOCAL ISCHEMIA	Background: Permanent functional deficits following spinal cord injury (SCI) arise both from mechanical injury and from secondary tissue reactions involving inflammation. Enhanced release of adenosine and glutamate soon after SCI represents a component in the sequelae that may be responsible for resulting functional deficits. The role of adenosine A(2A) receptor in central ischemia/trauma is still to be elucidated. In our previous studies we have demonstrated that the adenosine A(2A) receptor-selective agonist CGS21680, systemically administered after SCI, protects from tissue damage, locomotor dysfunction and different inflammatory readouts. In this work we studied the effect of the adenosine A(2A) receptor antagonist SCH58261, systemically administered after SCI, on the same parameters. We investigated the hypothesis that the main action mechanism of agonists and antagonists is at peripheral or central sites. Methods: Spinal trauma was induced by extradural compression of SC exposed via a four-level T5-T8 laminectomy in mouse. Three drug-dosing protocols were utilized: a short-term systemic administration by intraperitoneal injection, a chronic administration via osmotic minipump, and direct injection into the spinal cord. Results: SCH58261, systemically administered (0.01 mg/kg intraperitoneal. 1, 6 and 10 hours after SCI), reduced demyelination and levels of TNF-alpha, Fas-L, PAR, Bax expression and activation of JNK mitogen-activated protein kinase (MAPK) 24 hours after SCI. Chronic SCH58261 administration, by mini-osmotic pump delivery for 10 days, improved the neurological deficit up to 10 days after SCI. Adenosine A(2A) receptors are physiologically expressed in the spinal cord by astrocytes, microglia and oligodendrocytes. Soon after SCI (24 hours), these receptors showed enhanced expression in neurons. Both the A(2A) agonist and antagonist, administered intraperitoneally, reduced expression of the A(2A) receptor, ruling out the possibility that the neuroprotective effects of the A(2A) agonist are due to A(2A) receptor desensitization. When the A(2A) antagonist and agonist were centrally injected into injured SC, only SCH58261 appeared neuroprotective, while CGS21680 was ineffective. Conclusions: Our results indicate that the A(2A) antagonist protects against SCI by acting on centrally located A(2A) receptors. It is likely that blockade of A(2A) receptors reduces excitotoxicity. In contrast, neuroprotection afforded by the A(2A) agonist may be primarily due to peripheral effects.	[Melani, Alessia; Cipriani, Sara; Corti, Francesca; Pedata, Felicita] Univ Florence, Dept Pharmacol, I-50121 Florence, Italy; [Paterniti, Irene; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; [Mazzon, Emanuela; Esposito, Emanuela; Bramanti, Placido; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Mello, Tommaso] Univ Florence, Gastroenterol Unit, Dept Clin Pathophysiol, I-50121 Florence, Italy		Pedata, F (corresponding author), Univ Florence, Dept Pharmacol, I-50121 Florence, Italy.	felicita.pedata@unifi.it	Mazzon, Emanuela/AAL-4334-2020; Mello, Tommaso/I-4715-2012; Mello, Tommaso/AAO-7831-2021; Bramanti, Placido/K-5117-2016	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; mazzon, emanuela/0000-0002-5073-717X; Pedata, Felicita/0000-0002-6841-3712	IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy; Italian Ministry of HealthMinistry of Health, Italy	This investigation was supported by grants from IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy and Italian Ministry of Health.	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Back SA, 2006, MENT RETARD DEV D R, V12, P129, DOI 10.1002/mrdd.20107; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Bronstein JM, 2000, J NEUROSCI RES, V60, P284, DOI 10.1002/(SICI)1097-4547(20000501)60:3<284::AID-JNR2>3.3.CO;2-K; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2008, CURR PHARM DESIGN, V14, P1490, DOI 10.2174/138161208784480126; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; CHOUKE RA, 2008, MOL MED, V14, P116; Corsi C, 1999, NEUROREPORT, V10, P687, DOI 10.1097/00001756-199903170-00005; Corsi C, 2000, NEUROREPORT, V11, P2591, DOI 10.1097/00001756-200008030-00048; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2010, J BIOL REG HOMEOS AG, V24, P73; Genovese T, 2009, SHOCK, V32, P578, DOI 10.1097/SHK.0b013e3181a20792; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Jurewicz A, 2006, GLIA, V53, P158, DOI 10.1002/glia.20249; Lappas CM, 2006, J EXP MED, V203, P2639, DOI 10.1084/jem.20061097; Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Matute C, 2002, EUR J PHARMACOL, V447, P239, DOI 10.1016/S0014-2999(02)01847-2; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McAdoo DJ, 2000, BRAIN RES, V854, P152, DOI 10.1016/S0006-8993(99)02333-1; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Melani A, 2006, BRAIN RES, V1073, P470, DOI 10.1016/j.brainres.2005.12.010; Melani A, 2003, BRAIN RES, V959, P243, DOI 10.1016/S0006-8993(02)03753-8; Melani A, 2009, BRAIN, V132, P1480, DOI 10.1093/brain/awp076; Minei JP, 2002, J TRAUMA, V53, P229; Mirabet M, 1999, J CELL SCI, V112, P491; Miyazaki N, 2008, PFLUG ARCH EUR J PHY, V457, P441, DOI 10.1007/s00424-008-0542-1; Monopoli A, 1998, J PHARMACOL EXP THER, V285, P9; Moreno-Flores Maria Teresa, 2006, Recent Pat CNS Drug Discov, V1, P55, DOI 10.2174/157488906775245264; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Pintor A, 2001, EUR J PHARMACOL, V421, P177, DOI 10.1016/S0014-2999(01)01058-5; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Reece TB, 2004, J SURG RES, V121, P130, DOI 10.1016/j.jss.2004.04.006; Rivlin A S, 1978, Surg Neurol, V10, P38; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROKKAS CK, 1994, ANN THORAC SURG, V58, P312, DOI 10.1016/0003-4975(94)92200-4; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Sebastiao AM, 2009, BRIT J PHARMACOL, V158, P15, DOI 10.1111/j.1476-5381.2009.00157.x; Sitkovsky MV, 2003, BIOCHEM PHARMACOL, V65, P493, DOI 10.1016/S0006-2952(02)01548-4; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; Wirkner K, 2004, NEUROPHARMACOLOGY, V46, P994, DOI 10.1016/j.neuropharm.2004.01.008; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yin KJ, 2005, NEUROBIOL DIS, V20, P881, DOI 10.1016/j.nbd.2005.05.026; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; Zocchi C, 1996, BRIT J PHARMACOL, V117, P1381, DOI 10.1111/j.1476-5381.1996.tb15296.x	68	41	43	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 12	2011	8								31	10.1186/1742-2094-8-31			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	765EY	WOS:000290687400001	21486435	Green Published, gold			2022-02-06	
J	Ljungqvist, J; Nilsson, D; Ljungberg, M; Sorbo, A; Esbjornsson, E; Eriksson-Ritzen, C; Skoglund, T				Ljungqvist, Johan; Nilsson, Daniel; Ljungberg, Maria; Sorbo, Ann; Esbjornsson, Eva; Eriksson-Ritzen, Catherine; Skoglund, Thomas			Longitudinal study of the diffusion tensor imaging properties of the corpus callosum in acute and chronic diffuse axonal injury	BRAIN INJURY			English	Article						Traumatic brain injury; axonal injury; MRI; outcome measures	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; NEUROPSYCHOMETRIC TESTS; WALLERIAN DEGENERATION; CORTICOSPINAL TRACT; WATER DIFFUSION; SERIAL CHANGES; ACUTE MILD; FOLLOW-UP; ANISOTROPY	Background: Magnetic resonance diffusion tensor imaging (MR-DTI) is used increasingly to detect diffuse axonal injury (DAI) after traumatic brain injury (TBI). Primary objective: The primary objective was to investigate the changes in the diffusion properties of the corpus callosum in the acute phase and 6 months after TBI and to examine the correlation between DTI parameters and clinical outcome. Research design: Longitudinal prospective study. Methods and procedures: MR-DTI was performed in eight patients with suspected DAI within 11 days and at 6 months post-injury. Six controls were also examined. Fractional anisotropy (FA), trace and parallel and perpendicular diffusivity of the corpus callosum were analysed. The main outcome was the extended Glasgow Outcome Scale score, assessed at 6 months. Main outcomes and results: A significant reduction in FA in the corpus callosum was seen in the acute phase in patients compared with the healthy controls. There was no significant change in the parallel or perpendicular eigenvalues or trace. At 6 months, a significant reduction in FA and a significant increase in trace and perpendicular eigenvalues were noticed compared with controls. Conclusions: The diffusion properties of the corpus callosum correlated with clinical outcome in this longitudinal investigation.	[Ljungqvist, Johan; Nilsson, Daniel; Eriksson-Ritzen, Catherine; Skoglund, Thomas] Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden; [Ljungberg, Maria] Sahlgrens Univ Hosp, MR Ctr, SE-41345 Gothenburg, Sweden; [Sorbo, Ann] Uddevalla Cent Hosp, Dept Neurol & Rehabil, Uddevalla, Sweden; [Esbjornsson, Eva] Sahlgrens Univ Hosp, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden		Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se	Nilsson, Daniel/AAF-3868-2020	Sorbo, Ann/0000-0002-6744-6942	Health and Medical Care Committee of Vastra Gotaland; Foundation for Medical Imaging	This work was supported by grants from the Health and Medical Care Committee of Vastra Gotaland and the Foundation for Medical Imaging in Memory of Erik Lysholm.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7; Good P., 2000, PERMUTATION TESTS PR; Gulani V, 2001, MAGNET RESON MED, V45, P191, DOI 10.1002/1522-2594(200102)45:2<191::AID-MRM1025>3.0.CO;2-9; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kanaan RA, 2006, PSYCHIAT RES-NEUROIM, V146, P73, DOI 10.1016/j.pscychresns.2005.11.002; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim M, 2006, NEUROIMAGE, V32, P1243, DOI 10.1016/j.neuroimage.2006.06.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Prigatano GP, 1993, BNI Q, V9, P2; Prigatano GP, 2008, BNI SCREEN HIGHER CE; Rosenstein LD., 1995, ADM SCORING MANUAL B; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Takahashi S, 2002, NEUROSCI LETT, V332, P45, DOI 10.1016/S0304-3940(02)00914-X; Wakamoto H, 2006, J CHILD NEUROL, V21, P566, DOI 10.1177/08830738060210071401; Werring DJ, 2000, BRAIN, V123, P1667, DOI 10.1093/brain/123.8.1667; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	43	41	42	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2011	25	4					370	378		10.3109/02699052.2011.558038			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600006	21355671				2022-02-06	
J	Arbisi, PA; Polusny, MA; Erbes, CR; Thuras, P; Reddy, MK				Arbisi, Paul A.; Polusny, Melissa A.; Erbes, Christopher R.; Thuras, Paul; Reddy, Madhavi K.			The Minnesota Multiphasic Personality Inventory-2 Restructured Form in National Guard Soldiers Screening Positive for Posttraumatic Stress Disorder and Mild Traumatic Brain Injury	PSYCHOLOGICAL ASSESSMENT			English	Article						Minnesota Multiphasic Personality Inventory-2 Restructured Form; blast injury; mild traumatic brain injury; posttraumatic stress disorder; assessment	INTERNALIZING SUBTYPES; INCREMENTAL VALIDITY; ANXIETY DISORDERS; SYMPTOM INVENTORY; MMPI-2 SCORES; RC SCALES; PTSD; IRAQ; TBI; VETERANS	The Minnesota Multiphasic Personality Inventory-2 Restructured Form (MMPI-2 RF) was administered to 251 National Guard soldiers who had recently returned from deployment to Iraq. Soldiers were also administered questionnaires to identify posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). On the basis of responses to the screening instruments, the National Guard soldiers who produced a valid MMPI-2 RF were classified into four groups: 21 soldiers who screened positive for PTSD only, 33 soldiers who screened positive for mTBI only, 9 soldiers who screened positive for both conditions, and 166 soldiers who did not screen positive for either condition. Results showed that the MMPI-2 RF was able to differentiate across the groups with the MMPI-2 RF specific problem scale Anxiety adding incrementally to MMPI-2 Restructured Clinical scales in predicting PTSD. Both MMPI-2 RC 1 (Somatic Complaints) and MMPI-2 RF head pain complaints predicted mTBI screen but did not add incrementally to each other. Of note, all of the MMPI-2 RF validity scales associated with overreporting, including Symptom Validity-Revised (FBS-r), were not significantly elevated in the mTBI group. These findings support the use of the MMPI-2 RF in assessing PTSD in non-treatment-seeking veterans. This further suggests that a positive screen for mTBI alone is not associated with significant emotional disturbance.	[Arbisi, Paul A.] Minneapolis Vet Affairs Med Ctr, Psychol Serv 116B, Minneapolis, MN 55417 USA; [Arbisi, Paul A.; Polusny, Melissa A.; Erbes, Christopher R.; Thuras, Paul; Reddy, Madhavi K.] Univ Minnesota, Dept Psychiat, Sch Med, St Paul, MN USA; [Arbisi, Paul A.] Univ Minnesota, Dept Psychol, St Paul, MN USA		Arbisi, PA (corresponding author), Minneapolis Vet Affairs Med Ctr, Psychol Serv 116B, 1 Vet Dr, Minneapolis, MN 55417 USA.	paul.arbisi@va.gov	Polusny, Melissa/X-8158-2019; Polusny, Melissa Anderson/N-8112-2014	Polusny, Melissa/0000-0002-4932-305X; Polusny, Melissa Anderson/0000-0002-4932-305X; Reddy, Madhavi/0000-0002-4513-9909			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; ARBISI PA, 2004, 112 ANN CONV AM PSYC; Arbisi PA, 2008, J PERS ASSESS, V90, P122, DOI 10.1080/00223890701845146; Arbisi PA, 2010, ASSESSMENT, V17, P406, DOI 10.1177/1073191110376163; Archer RP, 2006, J PERS ASSESS, V87, P84, DOI 10.1207/s15327752jpa8701_07; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Clark LA., 1996, SCHEDULE NONADAPTIVE; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Efendov AA, 2008, PSYCHOL ASSESSMENT, V20, P317, DOI 10.1037/a0013870; Gamez W, 2007, J ANXIETY DISORD, V21, P526, DOI 10.1016/j.janxdis.2006.08.003; Greenblatt RL, 1999, J CLIN PSYCHOL, V55, P217, DOI 10.1002/(SICI)1097-4679(199902)55:2<217::AID-JCLP9>3.0.CO;2-I; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jaycox, 2008, INVISIBLE WOUNDS WAR; Jones E, 2006, PHILOS T R SOC B, V361, P533, DOI 10.1098/rstb.2006.1814; KEANE TM, 1984, J CONSULT CLIN PSYCH, V52, P888, DOI 10.1037/0022-006X.52.5.888; Kehle SM, 2010, J TRAUMA STRESS, V23, P33, DOI 10.1002/jts.20480; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lyons JA, 1999, J TRAUMA STRESS, V12, P175, DOI 10.1023/A:1024710803042; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, CLIN PSYCHOL-SCI PR, V10, P373, DOI 10.1093/clipsy/bpg040; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; PENK WE, 2005, MMPI 2 PRACTITIONERS, P121; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Watson D, 2005, J ABNORM PSYCHOL, V114, P522, DOI 10.1037/0021-843X.114.4.522; Weathers F.W., 1993, 9 ANN C ISTSS; Wolf EJ, 2008, PSYCHOL ASSESSMENT, V20, P327, DOI 10.1037/a0012948; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	47	41	41	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2011	23	1					203	214		10.1037/a0021339			12	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	729KT	WOS:000287949200017	21381845				2022-02-06	
J	West, LK; Curtis, KL; Greve, KW; Bianchini, KJ				West, Laura K.; Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.			Memory in traumatic brain injury: The effects of injury severity and effort on the Wechsler Memory Scale-III	JOURNAL OF NEUROPSYCHOLOGY			English	Article							MALINGERED NEUROCOGNITIVE DYSFUNCTION; DIGIT RECOGNITION TEST; MILD HEAD TRAUMA; CLASSIFICATION ACCURACY; HEALTHY-ADULTS; TEST-SCORES; WMS-III; INDICATORS; EXAGGERATION; METAANALYSIS	This study examined the effects of traumatic brain injury (TBI) on Wechsler Memory Scale-III (WMS-III) performance. Since poor effort potentially contaminates results, effort was explicitly assessed and controlled using two well-validated cognitive validity indicators, the Portland Digit Recognition Test (PDRT) and Reliable Digit Span (RDS). Participants were 44 mild TBI patients with good effort, 48 mild TBI patients with poor effort, and 40 moderate-severe TBI patients with good effort. A dose-response relationship between injury severity and WMS-III performance was demonstrated. Effect size calculations showed that the good effort mild TBI patients did not differ from normal (average Cohen's d = 0.07) while moderate-severe TBI had a moderate effect on VVMS-III scores (average Cohen's d = -0.52). Consistent with previous literature, the moderate-severe TBI group scored the lowest on WMS-III Visual indices. Effort had a larger effect than injury severity on WMS-III scores (average Cohen's d = -1.27). Clinical implications of these findings are discussed.	[West, Laura K.; Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Curtis KL, 2006, ARCH CLIN NEUROPSYCH, V21, P544; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Doane BM, 2005, CLIN NEUROPSYCHOL, V19, P99, DOI 10.1080/13854040490524100; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 1996, WORD MEMORY TEST USE; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lange RT, 2006, J CLIN EXP NEUROPSYC, V28, P294, DOI 10.1080/13803390490918156; Langeluddecke PM, 2005, J CLIN EXP NEUROPSYC, V27, P576, DOI 10.1080/13803390490918372; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Lipsey M. W., 2000, PRACTICAL METAANALYS, V49; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REY A, 1964, EXAMIN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; SCHERER M, 2005, FORENSIC NEUROPSYCHO, P237; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WECHSLER MEMORY SCAL; WECHSLER DA, 1997, WAIS 3 WMS 2 TECHNIC	54	41	41	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	MAR	2011	5		1				114	125		10.1348/174866410X521434			12	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	739NK	WOS:000288724600006	21366889				2022-02-06	
J	Kelso, ML; Scheff, NN; Scheff, SW; Pauly, JR				Kelso, Matthew L.; Scheff, Nicole N.; Scheff, Stephen W.; Pauly, James R.			Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Autoradiography; Morris water maze; Controlled cortical impact; Rat	FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; MICROGLIAL ACTIVATION; IN-VIVO; NEUROPROTECTION; RECEPTORS; RAT; TETRACYCLINES; IMPAIRMENT; DAMAGE	The biochemical sequelae that follow traumatic brain injury (TBI) are numerous and affect many different brain functions at different points of time as the secondary cascades progress. The complexity of the resulting pathophysiology is such that a singular therapeutic intervention may not provide adequate benefit and a combination of drugs targeting different pathways may be needed. Two of the most widely studied injury mechanisms are oxidative stress and inflammation. Numerous studies have suggested that pharmacological agents targeting either of these pathways may produce an improvement in histological and functional outcome measures. We hypothesized that combining melatonin, a potent antioxidant, with minocycline, a bacteriostatic agent that also inhibit microglia, would provide better neuroprotection than either agent used alone. To test this hypothesis, we subjected anesthetized adult male rats to a 1.5 mm controlled cortical impact and administered melatonin or vehicle in the acute post-injury period followed by daily minocycline or vehicle injections beginning the following day in a 2 x 2 study design. The animals were allowed to recover for 5 days before undergoing Morris water maze (MWM) testing to assess cognitive functioning following injury. There was no significant difference in MWM performance between the vehicle, melatonin, minocycline, or combination treatments. Following sacrifice and histological examination for neuroprotection, we did not observe a significant difference between the groups in the amount of cortical tissue that was spared nor was there a significant difference in [H-3]-PK11195 binding, a marker for activated microglia. These results suggest that neither drug has therapeutic efficacy, however dosing and/or administration issues may have played a role. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Kelso, Matthew L.; Scheff, Nicole N.; Pauly, James R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA; [Kelso, Matthew L.; Scheff, Stephen W.; Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Kelso, ML (corresponding author), Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, 986045 Nebraska Med Ctr, Omaha, NE 68198 USA.	mkelso@unmc.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG021981, AG21981, R01 AG021981-05] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42196, R01 NS042196, R01 NS042196-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER		Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; GUSEVA MV, 2008, J NEUROTRAUMA; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; HIGASHIDA T, 2010, J NEUROSURG; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Ucar T, 2005, ACTA NEUROL SCAND, V112, P163, DOI 10.1111/j.1600-0404.2005.00463.x; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	29	41	44	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 13	2011	488	1					60	64		10.1016/j.neulet.2010.11.003			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	716UA	WOS:000286997800013	21056621	Green Accepted			2022-02-06	
B	Iverson, GL; Lange, RT		Schoenberg, MR; Scott, JG		Iverson, Grant L.; Lange, Rael T.			Mild Traumatic Brain Injury	LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH			English	Article; Book Chapter							MINOR HEAD-INJURY; SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; TERM BENZODIAZEPINE USE; OPERATION DESERT-STORM; VOLUNTARY EXERCISE; POSTCONCUSSION-SYNDROME; PROFESSIONAL FOOTBALL; NEUROTROPHIC FACTOR	Mild traumatic brain injuries (MTBI) are heterogeneous. This injury falls on a broad spectrum, from very mild neurometabolic changes in the brain with rapid recovery to permanent problems due to structural brain damage. It is incorrect to assume that MTBIs cannot cause permanent brain damage and it is incorrect to assume that MTBIs typically cause permanent brain damage. This is a highly individualized injury most people recover relatively quickly and fully. However, some people have long-term problems. These long-term problems can be caused or maintained by multiple factors. Brain damage, although possible, is probably not the root cause of long-term problems in most patients. Instead, a diverse set of pre-existing and co-occurring conditions and factors likely cause and/or maintain symptoms and problems in most patients (e.g., personality characteristics; preexisting health and mental health problems; co-morbid chronic pain, depression, anxiety disorders; social psychological factors; and litigation). It is important to carefully consider a multitude of factors that can cause or maintain symptom reporting long after an MTBI before concluding that a person is likely to have permanent damage to the function of his or her brain.	[Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Coquitlam, BC, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada		Iverson, GL (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	giverson@interchange.ubc.ca; rlange@dvbic.org					Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; Barker MJ, 2004, CNS DRUGS, V18, P37, DOI 10.2165/00023210-200418010-00004; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carey ME, 1998, MIL MED, V163, P581, DOI 10.1093/milmed/163.9.581; CAREY ME, 1982, ACTA CHIR SCAND, P351; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Drazen JM, 2005, NEW ENGL J MED, V352, P2121, DOI 10.1056/NEJMe048332; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LAHMEYER HW, 1987, J PSYCHIAT RES, V21, P1, DOI 10.1016/0022-3956(87)90004-5; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Mead GE, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004366.pub6, 10.1002/14651858.CD004366.pub4]; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Paniak C, 2000, BRAIN INJURY, V14, P219; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; Peleg K, 2006, J AM COLL SURGEONS, V202, P643, DOI 10.1016/j.jamcollsurg.2005.12.019; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Pietropaolo S, 2008, BEHAV BRAIN RES, V192, P42, DOI 10.1016/j.bbr.2008.03.014; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sosin DM, 1996, BRAIN INJURY, V10, P47; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	125	41	41	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-0-387-70703-7				2011							697	719		10.1007/978-0-387-76978-3_22	10.1007/978-0-387-76978-3		23	Clinical Neurology; Neurosciences; Psychology	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Psychology	BTF43	WOS:000286799800022					2022-02-06	
J	Miller, JB; Millis, SR; Rapport, LJ; Bashem, JR; Hanks, RA; Axelrod, BN				Miller, Justin B.; Millis, Scott R.; Rapport, Lisa J.; Bashem, Jesse R.; Hanks, Robin A.; Axelrod, Bradley N.			Detection of Insufficient Effort Using the Advanced Clinical Solutions for the Wechsler Memory Scale, Fourth Edition	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Malingering; Assessment; Neuropsychology; Logistic regression	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; RESPONSE BIAS; PERFORMANCE; INDICATORS; NAN	This study investigated the ability of the Wechsler Memory Scale-4th Edition (WMS-IV) and the Advanced Clinical Solutions (ACS) package including the new Word Choice test (WCT) to distinguish poor performance due to intentional response bias among simulators of traumatic brain injury (TBI) from poor performance due to actual TBI. Participants were 45 survivors of moderate to severe TBI and 39 healthy adult coached to simulate TBI. Logistic regression indicated that a five-variable model containing all the ACS variables and a single-variable model using only the WCT were statistically reliable. Comparing predictive accuracy of each model found that adding the WCT to the ACS increased predictive accuracy. Diagnostic efficiency for the full ACS model was considered "excellent" according to interpretive guidelines.	[Miller, Justin B.; Hanks, Robin A.] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Axelrod, Bradley N.] Vet Affairs Med Ctr, John D Dingell Dept, Detroit, MI USA		Miller, JB (corresponding author), Wayne State Univ, Sch Med, 7th Floor,5057 Woodward Ave, Detroit, MI 48202 USA.	Justin.b.miller@gmail.com		Rapport, Lisa/0000-0001-8014-9523; Miller, Justin B./0000-0002-4439-6604	National Institute on Disability and Rehabilitation Research [H133A080044]; US Department of EducationUS Department of Education; Del Harder foundation, Detroit, Michigan	The study was supported in part by grant number H133A080044 through the National Institute on Disability and Rehabilitation Research, the US Department of Education, and the Del Harder foundation, Detroit, Michigan.	Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Green P., 2008, NONVERBAL MED SYMPTO; Green P., 2005, MED SYMPTOM VALIDITY; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hardin JW., 2007, GEN LINEAR MODELS EX; Harrell FE Jr, 2017, REGRESSION MODELING; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hosmer DW., 2000, APPL LOGISTIC REGRES; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P3; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; MILGRAM S, 1963, J ABNORM PSYCHOL, V67, P371, DOI 10.1037/h0040525; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MILLIS SR, 2008, NEUROPSYCHOLOGY MALI, P21; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; *PEARS ED I, 2008, WECHSL MEM SCAL CLIN; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Steyerberg E. W., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, 10. 1007/978-0-387-77244-8., DOI 10.1007/978-0-387-77244-8]; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	38	41	41	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					160	172		10.1080/13854046.2010.533197			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100011	21253964				2022-02-06	
J	Guilfoyle, MR; Seeley, HM; Corteen, E; Harkin, C; Richards, H; Menon, DK; Hutchinson, PJ				Guilfoyle, Mathew R.; Seeley, Helen M.; Corteen, Elizabeth; Harkin, Christine; Richards, Hugh; Menon, David K.; Hutchinson, Peter J.			Assessing Quality of Life after Traumatic Brain Injury: Examination of the Short Form 36 Health Survey	JOURNAL OF NEUROTRAUMA			English	Article						outcome assessment; quality of life; SF-36; traumatic brain injury; validation	AMYOTROPHIC-LATERAL-SCLEROSIS; SURVEY SF-36; SURVEY QUESTIONNAIRE; MULTIPLE-SCLEROSIS; SCALING ASSUMPTIONS; OUTCOME MEASURE; RELIABILITY; VALIDITY; STROKE; TESTS	Measuring health-related quality of life (HRQoL) has an important role in the comprehensive assessment of patient recovery following traumatic brain injury (TBI). We examined the validity of domain and summary scores derived from the Medical Outcomes Survey 36-Item Short Form Health Questionnaire (SF-36) as outcome measures for TBI in a prospective study of 514 patients with a range of functional impairment (Glasgow Outcome Scale-Extended [GOSE] scores 3-8). Item scaling criteria for the eight domain scores were tested and principal component analysis was used to examine if physical and mental component summary scores were valid. External validity was assessed by comparison with GOSE. Mean response, variance, and distribution of the items were largely equivalent, and item-own scale correlations corrected for overlap all exceeded the threshold for equivalent contribution to domain scores and convergent validity. All corrected item-own scale correlations were greater than the respective item-other correlations indicating no scaling failures, and reliability coefficients for the domain scores were high and substantially more than the inter-domain correlations. Overall, criteria for summing items into domain scores were satisfied, and there was a significant relationship of increasing score with more favorable GOSE class across all domains. However, there were floor and/or ceiling effects in four of the eight domains, and principal component analysis of the domain scores demonstrated only a unidimensional structure to the data. We conclude that individual SF-36 domain scores are valid measures of HRQoL in TBI patients, but that the physical and mental component summaries should be interpreted with caution.	[Guilfoyle, Mathew R.; Seeley, Helen M.; Corteen, Elizabeth; Harkin, Christine; Richards, Hugh; Hutchinson, Peter J.] Addenbrookes Hosp, Acad Dept Neurosurg, Cambridge CB2 2QQ, England; [Menon, David K.] Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England		Guilfoyle, MR (corresponding author), Addenbrookes Hosp, Acad Dept Neurosurg, Box 167,Hills Rd, Cambridge CB2 2QQ, England.	mathew.guilfoyle@addenbrookes.nhs.uk		Corteen, Elizabeth/0000-0002-3069-9655	Philip King Royal College of Surgeons of England; Academy of Medical Sciences Health Foundation; U.K. Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Specialist Biomedical Research Centre; Evelyn Trust; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0601025, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	M.R.G. is supported by the Philip King Royal College of Surgeons of England Research Fellowship. P.J.H. is supported by an Academy of Medical Sciences Health Foundation Senior Surgical Scientist Fellowship. D.K.M. is supported by the U.K. Medical Research Council, the National Institute of Health Research Specialist Biomedical Research Centre, and the Evelyn Trust.	Baron R, 2006, SPINE, V31, P2575, DOI 10.1097/01.brs.0000240694.83621.52; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Dallmeijer AJ, 2007, J REHABIL MED, V39, P163, DOI 10.2340/16501977-0024; Edwards SGM, 2002, BRIT MED J, V324, P1493, DOI 10.1136/bmj.324.7352.1493; Fayers PM, 2005, ASSESSING QUALITY LI; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Hagell P, 2008, J NEUROL, V255, P246, DOI 10.1007/s00415-008-0708-y; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; Hobart J, 2001, J NEUROL NEUROSUR PS, V71, P363, DOI 10.1136/jnnp.71.3.363; Hobart JC, 2002, STROKE, V33, P1348, DOI 10.1161/01.STR.0000015030.59594.B3; Jacoby A, 1999, QUAL LIFE RES, V8, P351, DOI 10.1023/A:1008902728574; Jenkinson C, 2002, J NEUROL, V249, P178, DOI 10.1007/PL00007861; JENKINSON C, 1996, UK SF 36 ANAL INTERP; Likert R., 1932, ARCH PSYCHOL, V22, P1; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; O'Mahony PG, 1998, AGE AGEING, V27, P19, DOI 10.1093/ageing/27.1.19; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	26	41	41	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2173	2181		10.1089/neu.2010.1353			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400007	20939701				2022-02-06	
J	Ribbe, K; Friedrichs, H; Begemann, M; Grube, S; Papiol, S; Kastner, A; Gerchen, MF; Ackermann, V; Tarami, A; Treitz, A; Flogel, M; Adler, L; Aldenhoff, JB; Becker-Emner, M; Becker, T; Czernik, A; Dose, M; Folkerts, H; Freese, R; Gunther, R; Herpertz, S; Hesse, D; Kruse, G; Kunze, H; Franz, M; Lohrer, F; Maier, W; Mielke, A; Muller-Isberner, R; Oestereich, C; Pajonk, FG; Pollmacher, T; Schneider, U; Schwarz, HJ; Kroner-Herwig, B; Havemann-Reinecke, U; Frahm, J; Stuhmer, W; Falkai, P; Brose, N; Nave, KA; Ehrenreich, H				Ribbe, Katja; Friedrichs, Heidi; Begemann, Martin; Grube, Sabrina; Papiol, Sergi; Kaestner, Anne; Gerchen, Martin F.; Ackermann, Verena; Tarami, Asieh; Treitz, Annika; Floegel, Marlene; Adler, Lothar; Aldenhoff, Josef B.; Becker-Emner, Marianne; Becker, Thomas; Czernik, Adelheid; Dose, Matthias; Folkerts, Here; Freese, Roland; Guenther, Rolf; Herpertz, Sabine; Hesse, Dirk; Kruse, Gunther; Kunze, Heinrich; Franz, Michael; Loehrer, Frank; Maier, Wolfgang; Mielke, Andreas; Mueller-Isberner, Ruediger; Oestereich, Cornelia; Pajonk, Frank-Gerald; Pollmaecher, Thomas; Schneider, Udo; Schwarz, Hans-Joachim; Kroener-Herwig, Birgit; Havemann-Reinecke, Ursula; Frahm, Jens; Stuehmer, Walter; Falkai, Peter; Brose, Nils; Nave, Klaus-Armin; Ehrenreich, Hannelore			The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients	BMC PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; GENDER-DIFFERENCES; RATING-SCALE; COGNITIVE PERFORMANCE; PSYCHOTIC DISORDERS; SEX-DIFFERENCES; 1ST-EPISODE; NEUROCOGNITION; DETERMINANTS; ASSOCIATION	Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of >= 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Gottingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia. Methods: For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected. Results: The corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail. Conclusions: The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding 'the schizophrenias' through exploring the contribution of genetic variation to the schizophrenic phenotypes.	[Ribbe, Katja; Friedrichs, Heidi; Begemann, Martin; Grube, Sabrina; Papiol, Sergi; Kaestner, Anne; Gerchen, Martin F.; Ackermann, Verena; Tarami, Asieh; Treitz, Annika; Floegel, Marlene; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Aldenhoff, Josef B.] Hosp Psychiat & Psychotherapy, Ctr Integrat Psychiat, Kiel, Germany; [Becker-Emner, Marianne] Karl Jaspers Hosp, Bad Zwischenahn, Germany; [Becker, Thomas] Univ Ulm, Dist Hosp Gunzburg, Dept Psychiat 2, D-89069 Ulm, Germany; [Czernik, Adelheid] Hosp Fulda, Dept Psychiat & Psychotherapy, Fulda, Germany; [Dose, Matthias] Isar Amper Hosp, Dept Psychiat & Psychotherapy, Taufkirchen, Vils, Germany; [Folkerts, Here] Reinhard Nieter Hosp, Dept Psychiat & Psychotherapy, Wilhelmshaven, Germany; [Freese, Roland] Vitos Hosp Forens Psychiat Eltville, Eltville, Germany; [Guenther, Rolf] Vitos Hosp Psychiat & Psychotherapy Merxhausen, Kassel, Germany; [Herpertz, Sabine] Univ Rostock, Dept Psychiat & Psychotherapy, D-2500 Rostock 1, Germany; [Hesse, Dirk] Hosp Forens Psychiat, Moringen, Germany; [Kruse, Gunther] Reg Hosp Hannover, Hosp Psychiat & Psychotherapy Langenhagen, Hannover, Germany; [Kunze, Heinrich; Franz, Michael] Vitos Hosp Psychiat & Psychotherapy, Bad Emstal Merxhausen, Germany; [Loehrer, Frank] Addict Hosp Am Waldsee, Rieden, Germany; [Maier, Wolfgang] Univ Med Ctr Bonn, Dept Psychiat & Psychotherapy, Bonn, Germany; [Mielke, Andreas] Vitos Hosp Psychiat & Psychotherapy Merxhausen, Hofgeismar, Germany; [Mueller-Isberner, Ruediger] Vitos Haina Forens Psychiat Hosp, Haina, Germany; [Oestereich, Cornelia] Reg Hosp Hannover, Dept Psychiat & Psychotherapy, Wunstorf, Germany; [Pajonk, Frank-Gerald] Dr K Fontheims Hosp Mental Hlth, Liebenburg, Germany; [Pollmaecher, Thomas] Hosp Ingolstadt, Dept Psychiat & Psychotherapy, Ingolstadt, Germany; [Schneider, Udo] Hosp Lubbecke, Dept Psychiat & Psychotherapy, Lubeck, Germany; [Schwarz, Hans-Joachim] Hosp Psychiat & Psychotherapy, Rickling, Germany; [Kroener-Herwig, Birgit] Univ Gottingen, Georg Elias Muller Inst Psychol, D-37075 Gottingen, Germany; [Havemann-Reinecke, Ursula; Falkai, Peter] Univ Med Ctr Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany; [Frahm, Jens] Max Planck Inst Biophys Chem, Biomed NMR Res GmbH, D-37075 Gottingen, Germany; [Stuehmer, Walter] Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany; [Brose, Nils] Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; [Nave, Klaus-Armin] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany		Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Becker, Thomas/O-9769-2014; Herpertz, Sabine C/AAW-4885-2020; Falkai, Peter/E-3273-2017; Nave, Klaus-Armin/C-8883-2011; Stuehmer, Walter/A-2176-2009	Becker, Thomas/0000-0001-8179-1219; Herpertz, Sabine C/0000-0001-9676-1928; Falkai, Peter/0000-0003-2873-8667; Papiol, Sergi/0000-0001-9366-8728; Frahm, Jens/0000-0002-8279-884X; Ehrenreich, Hannelore/0000-0001-8371-5711; Gerchen, Martin Fungisai/0000-0003-3071-5296	Max Planck SocietyMax Planck SocietyFoundation CELLEX; DFG-Research Center for Molecular Physiology of the Brain (CMBP)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG-Research Center for Molecular Physiology of the Brain (CMBP). We are indebted to all patients for their participation in the GRAS (Gottingen Research Association for Schizophrenia) study and to all colleagues in the collaborating centers who contributed to the GRAS data collection.	Aleman A, 2003, ARCH GEN PSYCHIAT, V60, P565, DOI 10.1001/archpsyc.60.6.565; Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Aschenbrenner S., 2000, REGENSBURGER WORTFLU; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Barnes TRE, 2003, J PSYCHOPHARMACOL, V17, P365, DOI 10.1177/0269881103174013; Bartels C, 2008, NEUROMUSCULAR DISORD, V18, P398, DOI 10.1016/j.nmd.2008.02.005; Begemann M, 2010, ARCH GEN PSYCHIAT, V67, P879, DOI 10.1001/archgenpsychiatry.2010.107; Blom G, 1958, STAT ESTIMATES TRANS; Calkins ME, 2007, SCHIZOPHRENIA BULL, V33, P33, DOI 10.1093/schbul/sbl044; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Cardno AG, 2000, AM J MED GENET, V97, P12, DOI 10.1002/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.3.CO;2-L; CASTLE DJ, 1994, PSYCHOL MED, V24, P41, DOI 10.1017/S0033291700026817; CHAPMAN RL, 1948, PSYCHOMETRIKA, V13, P175; CHEN EYH, 1995, PSYCHIAT RES, V56, P183, DOI 10.1016/0165-1781(95)02535-2; Crowley JJ, 2008, AM J MED GENET B, V147B, P1298, DOI 10.1002/ajmg.b.30727; DAVIS JM, 1976, ARCH GEN PSYCHIAT, V33, P858; Dominguez MD, 2009, PSYCHOL BULL, V135, P157, DOI 10.1037/a0014415; DUAN J, BRAIN RES B; Ehrenreich H, 2001, EUR ARCH PSY CLIN N, V251, P149, DOI 10.1007/s004060170034; Fleischhacker WW, 2005, SCHIZOPHR RES, V78, P147, DOI 10.1016/j.schres.2005.06.004; Franke G.H., 2000, BRIEF SYMPTOM INVENT; Franzek E, 1998, AM J PSYCHIAT, V155, P76, DOI 10.1176/ajp.155.1.76; Gaite L, 2005, COMPR PSYCHIAT, V46, P440, DOI 10.1016/j.comppsych.2005.03.006; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; GOTTESMAN II, 1967, P NATL ACAD SCI USA, V58, P199, DOI 10.1073/pnas.58.1.199; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Guy W., 1976, CLIN GLOBAL IMPRESSI; Hafner H, 2000, ACTA PSYCHIAT SCAND, V102, P44, DOI 10.1034/j.1600-0447.2000.00008.x; Hafner H, 1998, SOC PSYCH PSYCH EPID, V33, P380, DOI 10.1007/s001270050069; Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P222, DOI 10.1034/j.1600-0447.2003.00064.x; Helmstaedter C., 2001, VERBALER LERN MERKFA; Henry JM, 2010, PSYCHIAT SERV, V61, P264, DOI 10.1176/ps.2010.61.3.264; Hoff AL, 1998, AM J PSYCHIAT, V155, P1437, DOI 10.1176/ajp.155.10.1437; Horn W, 1983, LEISTUNGSPRUFSYSTEM; Israel N, 2010, AM J COMMUN PSYCHOL, V46, P49, DOI 10.1007/s10464-010-9326-9; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Karayiorgou M, 2004, AM J MED GENET B, V124B, P20, DOI 10.1002/ajmg.b.20090; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; KESSLER J, 1999, DEMEZ TEST DT; Kraepelin E., 1899, PSYCHIAT LEHRBUCH ST, V6th; Krampe H, 2008, AMYOTROPH LATERAL SC, V9, P99, DOI 10.1080/17482960701875805; Kupfer J., 2001, TORONTO ALEXITHYMIE; Larsen TK, 1996, SCHIZOPHRENIA BULL, V22, P257, DOI 10.1093/schbul/22.2.257; Laux LG., 1981, STATE TRAIT ANGSTINV; LEHRL S, 1995, ACTA NEUROL SCAND, V91, P335, DOI 10.1111/j.1600-0404.1995.tb07018.x; Lehrl S., 1999, MEHRFACH WORTSCHATZ; Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3; Lichtenstein P, 2009, LANCET, V373, P234, DOI 10.1016/S0140-6736(09)60072-6; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; LOUGHLAND C, AUSTR NZ J PSYCHIAT; Loughland CM, 2004, PSYCHIAT RES, V125, P117, DOI 10.1016/j.psychres.2003.11.002; Loughland CM, 2001, AUST NZ J PSYCHIAT, V35, P660, DOI 10.1080/0004867010060516; McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001; Moriarty PJ, 2001, SCHIZOPHRENIA BULL, V27, P103, DOI 10.1093/oxfordjournals.schbul.a006850; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; PINHEIRO AP, 2009, AUSTR NZ J PSYCHIAT, V41, P169; Price GW, 2006, BIOL PSYCHIAT, V60, P1, DOI 10.1016/j.biopsych.2005.09.010; Puig O, 2008, PSYCHIAT RES, V158, P11, DOI 10.1016/j.psychres.2007.04.017; Riecher-Rossler A, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.00011.x; RILEY B, 2003, SCHIZOPHRENIA; Schennach-Wolff R, 2009, SCHIZOPHR RES, V113, P210, DOI 10.1016/j.schres.2009.05.032; Seeman MV, 2009, SCHIZOPHRENIA BULL, V35, P937, DOI 10.1093/schbul/sbn023; Seeman MV, 2004, AM J PSYCHIAT, V161, P1324, DOI 10.1176/appi.ajp.161.8.1324; SEEMAN MV, 1990, SCHIZOPHRENIA BULL, V16, P185, DOI 10.1093/schbul/16.2.185; Simpson G.M., 1970, ACTA PSYCHIAT SCAND, V212, pS11; SIMPSON GM, 1979, PSYCHOPHARMACOLOGY, V64, P171, DOI 10.1007/BF00496058; Stroup TS, 2003, SCHIZOPHRENIA BULL, V29, P15, DOI 10.1093/oxfordjournals.schbul.a006986; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; Sullivan PF, 2007, BIOL PSYCHIAT, V61, P902, DOI 10.1016/j.biopsych.2006.07.036; Tewes U., 1991, HAMBURG WECHSLER INT, V2nd; Thorup A, 2007, J NERV MENT DIS, V195, P396, DOI 10.1097/01.nmd.0000253784.59708.dd; TORO PA, 1995, J CONSULT CLIN PSYCH, V63, P280, DOI 10.1037/0022-006X.63.2.280; War Department, 1944, ARM IND TEST BATT MA; Weiser M, 2000, SCHIZOPHR RES, V45, P185, DOI 10.1016/S0920-9964(99)00190-5; Wittchen H., 1997, SKID I STRUKTURIERTE; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Zimmermann P., 1993, TESTBATTERIE AUFMERK	81	41	41	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-244X		BMC PSYCHIATRY	BMC Psychiatry	NOV 10	2010	10								91	10.1186/1471-244X-10-91			20	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	695DM	WOS:000285350800001	21067598	Green Published, gold			2022-02-06	
J	Luchetti, S; Bossers, K; Frajese, GV; Swaab, DF				Luchetti, Sabina; Bossers, Koen; Frajese, Giovanni Vanni; Swaab, Dick F.			Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson's Disease	BRAIN PATHOLOGY			English	Article						3 alpha lpha-hydroxysteroid dehydrogenase; 5 alpha lphareductase; GABA-A receptors; gene expression; neurosteroids; Parkinson's disease	INDUCED DOPAMINE DEPLETION; TRAUMATIC BRAIN-INJURY; DEHYDROEPIANDROSTERONE DHEA; PREGNENOLONE-SULFATE; GENE-EXPRESSION; PROGESTERONE METABOLITES; CELL-DEATH; HIPPOCAMPAL-NEURONS; RECEPTOR PLASTICITY; PROTEIN EXPRESSION	There is emerging evidence from animal studies for a neuroprotective role of sex steroids in neurodegenerative diseases, but studies in human brain are lacking. We have carried out an extensive study of the neurosteroid biosynthetic pathways in substantia nigra (SN), caudate nucleus (CN) and putamen (PU) of 7 Parkinson's disease (PD) patients and 7 matched controls. The mRNA levels of 37 genes including neurosteroid biosynthetic enzymes, hormone receptors and the neurosteroid-modulated gamma-amino-butyric acid -A (GABA-A) receptor subunits were analyzed by quantitative PCR (qPCR). In the SN, we found downregulation of 5 alpha-reductase type 1 (5 alpha-R1), sulfotransferase 2B1 (SULT2B1) and some GABA-A receptor subunits (alpha 4, beta 1) while in the CN, upregulation of 3 alpha-hydroxysteroid dehydrogenase type 3 (3 alpha-HSD3) and alpha 4 GABA-A receptor subunit (22-fold) was observed. No significant differences were found in the PU. These data imply an involvement of pregnane steroids and changes in GABAergic neurotransmission in the neurodegenerative process and suggest that neurosteroids may deserve further investigation as potential therapeutic agents in PD.	[Luchetti, Sabina; Bossers, Koen; Swaab, Dick F.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuropsychiat Disorders, NL-1105 BA Amsterdam, Netherlands; [Luchetti, Sabina] Santa Lucia Fdn, Inst Sci, Ist Dermopat Immacolata IDI IRCCS, Rome, Italy; [Frajese, Giovanni Vanni] Univ Roma Tor Vergata, Endocrinol lab, Dept Internal Med, Rome, Italy; [Frajese, Giovanni Vanni] Univ Cassino, Fac Motor Sci, I-03043 Cassino, Italy		Luchetti, S (corresponding author), Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuropsychiat Disorders, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	s.luchetti@nin.knaw.nl	Bossers, Koen/I-4002-2013	Bossers, Koen/0000-0002-0272-4518; Swaab, Dick/0000-0002-9665-7845			Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Biggio F, 2006, PHARMACOL BIOCHEM BE, V84, P545, DOI 10.1016/j.pbb.2006.07.002; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O; Bossers K, 2009, BRAIN PATHOL, V19, P91, DOI 10.1111/j.1750-3639.2008.00171.x; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Callier S, 2000, SYNAPSE, V37, P245, DOI 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Calon F, 2003, MOVEMENT DISORD, V18, P241, DOI 10.1002/mds.10343; Carter RB, 1997, J PHARMACOL EXP THER, V280, P1284; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; D'Astous M, 2003, SYNAPSE, V47, P10, DOI 10.1002/syn.10145; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Do Rego JL, 2009, FRONT NEUROENDOCRIN, V30, P259, DOI 10.1016/j.yfrne.2009.05.006; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Follesa P, 2000, MOL PHARMACOL, V57, P1262; Garcia-Segura LM, 2006, NEUROENDOCRINOLOGY, V84, P275, DOI 10.1159/000097485; Gerlach M, 1996, BRAIN RES, V741, P142, DOI 10.1016/S0006-8993(96)00915-8; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gillies GE, 2010, HORM BEHAV, V57, P23, DOI 10.1016/j.yhbeh.2009.06.002; Grandbois M, 2000, NEUROREPORT, V11, P343, DOI 10.1097/00001756-200002070-00024; Gulinello M, 2001, BRAIN RES, V910, P55, DOI 10.1016/S0006-8993(01)02565-3; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Horak M, 2004, J NEUROSCI, V24, P10318, DOI 10.1523/JNEUROSCI.2099-04.2004; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kask K, 2009, PHARMACOL BIOCHEM BE, V92, P608, DOI 10.1016/j.pbb.2009.02.014; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KISH SJ, 1986, ANN NEUROL, V20, P26, DOI 10.1002/ana.410200106; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lovick TA, 2005, NEUROSCIENCE, V131, P397, DOI 10.1016/j.neuroscience.2004.11.010; Luchetti S, 2006, J NEUROSCI METH, V153, P290, DOI 10.1016/j.jneumeth.2005.11.005; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Morissette M, 2008, MOL CELL ENDOCRINOL, V290, P60, DOI 10.1016/j.mce.2008.04.008; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Nohria V, 2007, NEUROTHERAPEUTICS, V4, P102, DOI 10.1016/j.nurt.2006.11.003; PERRY TL, 1983, J NEUROCHEM, V40, P1120, DOI 10.1111/j.1471-4159.1983.tb08102.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pieribone VA, 2007, EPILEPSIA, V48, P1870, DOI 10.1111/j.1528-1167.2007.01182.x; Ramirez AD, 2003, NEUROENDOCRINOLOGY, V77, P223, DOI 10.1159/000070277; RINNE JO, 1988, NEUROSCI LETT, V94, P182, DOI 10.1016/0304-3940(88)90292-3; Sanna E, 2009, J NEUROSCI, V29, P1755, DOI 10.1523/JNEUROSCI.3684-08.2009; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shirakawa H, 2005, EUR J NEUROSCI, V21, P2329, DOI 10.1111/j.1460-9568.2005.04079.x; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; WU FS, 1991, MOL PHARMACOL, V40, P333	63	41	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	SEP	2010	20	5					945	951		10.1111/j.1750-3639.2010.00396.x			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	635BA	WOS:000280629400007	20406233	Green Published			2022-02-06	
J	Lojovich, JM				Lojovich, Jeanne M.			The Relationship Between Aerobic Exercise and Cognition: Is Movement Medicinal?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aerobic exercise; brain injury; cognition; memory; rehabilitation	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; BLOOD-FLOW; PHYSICAL-ACTIVITY; CONTUSION INJURY; GROWTH-FACTOR; UP-REGULATION; MOTOR CORTEX	Each year approximately 1.5 million individuals sustain traumatic brain injuries often resulting in difficulties in memory and executive function that limit independence. Aerobic exercise not only has been found to impact cardiovascular systems but has also shown benefits to brain function itself and specifically in the domain of memory and learning. Recent evidence is shedding light on the mechanisms possibly impacting cognitive performance following the participation in exercise. Literature has demonstrated increased hemodynamics within the brain, changes in neurotransmitters, and increasing levels of brain-derived neurotrophic factor that stimulates neurogenesis, and resistance to further injury. This review article explores the current literature and the possibility of exercise acting as an adjunct treatment to enhance the effectiveness of cognitive rehabilitation.	Univ Minnesota, Program Phys Therapy, Minneapolis, MN 55455 USA		Lojovich, JM (corresponding author), Univ Minnesota, Program Phys Therapy, MMC 388,420 Delaware St SE, Minneapolis, MN 55455 USA.	jablo005@umn.edu					Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Calof Anne L., 1995, Current Opinion in Neurobiology, V5, P19, DOI 10.1016/0959-4388(95)80082-4; Christensen LOD, 2000, EXP BRAIN RES, V135, P66, DOI 10.1007/s002210000493; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Edelberg JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS1199, DOI 10.2741/1166; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Gonzalez-Alonso J, 2004, J PHYSIOL-LONDON, V557, P331, DOI 10.1113/jphysiol.2004.060574; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gruber O, 2003, NEUROIMAGE, V19, P797, DOI 10.1016/S1053-8119(03)00089-2; Hassett LM, 2007, BRAIN INJURY, V21, P1069, DOI 10.1080/02699050701630375; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413, DOI 10.1152/jappl.1996.81.1.413; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Ide K, 1999, J APPL PHYSIOL, V87, P1604, DOI 10.1152/jappl.1999.87.5.1604; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; JEZZARD P, 2002, FUNCTIONAL MRI INTRO, P12; Johnson RA, 2003, NEUROSCIENCE, V121, P1, DOI 10.1016/S0306-4522(03)00422-6; Jorgensen L G, 1995, Acta Physiol Scand Suppl, V625, P1; JORGENSEN LG, 1992, J APPL PHYSIOL, V72, P1123, DOI 10.1152/jappl.1992.72.3.1123; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kleim JA, 2002, BRAIN RES, V934, P1, DOI 10.1016/S0006-8993(02)02239-4; Komulainen P, 2008, NEUROBIOL LEARN MEM, V90, P596, DOI 10.1016/j.nlm.2008.07.014; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lu B, 2000, PROG BRAIN RES, V128, P231; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nyberg L, 2003, NEUROPSYCHOLOGIA, V41, P371, DOI 10.1016/S0028-3932(02)00168-9; Pott F, 1996, ACTA PHYSIOL SCAND, V158, P349, DOI 10.1046/j.1365-201X.1996.564325000.x; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Ranganath C, 2005, J COGNITIVE NEUROSCI, V17, P994, DOI 10.1162/0898929054475118; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SPIRDUSO WW, 1980, J GERONTOL, V35, P850, DOI 10.1093/geronj/35.6.850; Sutoo D, 1996, PHYSIOL BEHAV, V60, P177, DOI 10.1016/0031-9384(96)00011-X; Sutoo D, 2003, NEUROBIOL DIS, V13, P1, DOI 10.1016/S0969-9961(03)00030-5; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454	63	41	42	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					184	192		10.1097/HTR.0b013e3181dc78cd			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300005	20473092				2022-02-06	
J	Thapa, A; Chandra, SP; Sinha, S; Sreenivas, V; Sharma, BS; Tripathi, M				Thapa, Amit; Chandra, Sarat P.; Sinha, Sumit; Sreenivas, V.; Sharma, Bhawani S.; Tripathi, Manjari			Post-traumatic seizures-A prospective study from a tertiary level trauma center in a developing country	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Post-traumatic seizure; Traumatic brain injury; Glasgow coma scale	PENETRATING HEAD-INJURY; BRAIN-INJURY; RISK-FACTORS; EPILEPSY; EPIDEMIOLOGY; PROPHYLAXIS; POPULATION; PREVENTION; CHILDREN; ADULTS	Rationale: No large studies till date are available from India on post-traumatic seizures (PTS). Methods: This is a prospective observational study of 520 patients with traumatic brain injury (TBI) (July 2007-2008). Patients admitted after 24 h of injury, with Glasgow coma scale (GCS) <= 4 were excluded. Results: At a median follow-up of 386 days, 59(11.4%) patients developed PTS. Incidence of immediate, early and late onset seizure were 6.5%, 2.1% and 2.7% respectively. In children, incidence of PTS was 18.3%. On univariate analysis, females, of age <10 years, with associated medical problems and with delayed loss of consciousness and poor GCS (<9), following fall from height, had significantly higher odds of PTS. On multivariate analysis, the risk of PTS was 3.7 times higher in patients who had fallen from height, 4.4 times higher in associated medical problems, and 3.7 times higher in severe head injury (GCS < 9) at presentation. PTS was associated with poor Glasgow outcome score and higher incidence of behavioral abnormality on follow up. 32% patient with PTS developed recurrent delayed seizures. Seizure recurrence was significantly higher in late onset PTS. PTS affected overall outcome of the patients in severe head injury. Conclusion: The risk of PTS was higher in patients who sustained fall from height, in GCS <9, and associated medical problems. About 1/3rd of the patients with early PTS developed recurrent delayed seizures. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Chandra, Sarat P.] All India Inst Med Sci, Dept Neurosurg, CN Ctr, New Delhi 110029, India; [Tripathi, Manjari] All India Inst Med Sci, Dept Neurol, New Delhi 110029, India; [Sreenivas, V.] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India; [Thapa, Amit; Chandra, Sarat P.; Sinha, Sumit; Sreenivas, V.; Sharma, Bhawani S.; Tripathi, Manjari] All India Inst Med Sci, Dept Trauma Ctr, New Delhi 110029, India		Chandra, SP (corresponding author), All India Inst Med Sci, Dept Neurosurg, CN Ctr, Room 607,6th Floor, New Delhi 110029, India.	saratpchandra@gmail.com	Thapa, Amit/L-3769-2013	Thapa, Amit/0000-0003-1896-3115			AARABI B, 2000, NEUROSURG FOCUS, V15, P8; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; Marchal C, 1999, Rev Prat, V49, P383; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Pagni CA, 2005, ACT NEUR S, V93, P27; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; TREIMAN DM, 1993, EPILEPSIA, V34, pS17, DOI 10.1111/j.1528-1157.1993.tb05919.x; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Wang HC, 2008, J TRAUMA, V64, P883, DOI 10.1097/TA.0b013e31804a7fa4; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiedemayer H, 2002, BRAIN INJURY, V16, P323, DOI 10.1080/02699050110102077; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YABLON SA, 2003, PHYS MED REHAB STATE, V15, P301	35	41	41	0	2	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	MAY	2010	19	4					211	216		10.1016/j.seizure.2010.02.004			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	598ZG	WOS:000277878700002	20202866	Bronze			2022-02-06	
J	Melcer, T; Walker, GJ; Galarneau, M; Belnap, B; Konoske, P				Melcer, Ted; Walker, G. Jay; Galarneau, Michael; Belnap, Brian; Konoske, Paula			Midterm Health and Personnel Outcomes of Recent Combat Amputees	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; OPERATION ENDURING FREEDOM; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; HETEROTOPIC OSSIFICATION; MILITARY PERSONNEL; IRAQI-FREEDOM; VIETNAM-WAR; AMPUTATIONS; AFGHANISTAN	Objective: Warfighters who sustained combat amputations in Operation Enduring Freedom or Operation Iraqi Freedom (OEF/OIF) have unique challenges during rehabilitation. This study followed their outcomes. Methods: Subjects were 382 U.S. warfighters with major limb amputations utter combat injury in OEF/OIF between 2001 and 2005. Outcome measures were diagnoses, treatment codes, and personnel events captured by health and personnel data-bases during 24 months postinjury. Results: Most patients had multiple complications generally within 30 days postinjury (e.g., infections, anemia), with important exceptions (e.g., heterotopic ossification). Lower limb amputees had 50% more complications than upper limb amputees. Two-thirds of patients had a mental health disorder (e.g.. adjustment, post-traumatic stress disorder), with rates of major disorder categories between 18% and 25%. Over 80% of patients used physical and occupational therapy. prosthetic/orthotic services. and psychiatric care. Conclusions: Combat amputees had a complex set of outcomes supporting the continued need for military amputee care programs.	[Melcer, Ted; Galarneau, Michael; Konoske, Paula] USN, Hlth Res Ctr, San Diego, CA 92106 USA; [Walker, G. Jay] Sci Applicat Int Corp, San Diego, CA 92121 USA; [Belnap, Brian] USN, San Diego Med Ctr, Comprehens Combat & Complex Casualty Care Naval M, San Diego, CA 92134 USA		Melcer, T (corresponding author), USN, Hlth Res Ctr, Dept 161,Bldg 331,140 Sylvester Rd, San Diego, CA 92106 USA.				Office of the Assistant Secretary of Defense (Health Affairs); U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Marine Corps Systems Command; Office of Naval ResearchOffice of Naval Research	This work was funded by the Office of the Assistant Secretary of Defense (Health Affairs), U.S. Army Medical Research and Materiel Command, Marine Corps Systems Command, and the Office of Naval Research.	Andersen Romney C, 2006, J Am Acad Orthop Surg, V14, pS24; Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; COVEY D, 2005, INSTR COURSE LECT, V57, P65; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Dougherty PJ, 2003, J TRAUMA, V54, P718, DOI 10.1097/01.TA.0000046260.16866.A9; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; FISCHER H, CRS REPORT C OPERATI; FRANKLIN A, 2006, ARCH PHYS MED REHAB, V87, pE30; GAJEWSKI G, 2006, J AM ACAD ORTHOP S S, V14, pS183; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Gunawardena NS, 2006, MIL MED, V171, P283, DOI 10.7205/MILMED.171.4.283; Gunderson EKE, 2005, MIL MED, V170, P172; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hospenthal DR, 2008, J TRAUMA, V64, pS211, DOI 10.1097/TA.0b013e318163c421; Ketz Ann Kobiela, 2008, Crit Care Nurs Clin North Am, V20, P51, DOI 10.1016/j.ccell.2007.10.006; KISBAUGH D, 1995, MIL MED, V160, P82; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Lin DL, 2004, J ORTHOP TRAUMA, V18, pS48, DOI 10.1097/00005131-200409001-00008; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; MacKenzie EJ, 2005, J BONE JOINT SURG AM, V87A, P1801, DOI 10.2106/JBJS.E.00032; Masini BD, 2009, J ORTHOP TRAUMA, V23, P261, DOI 10.1097/BOT.0b013e31819dfa04; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; Murray CK, 2008, J TRAUMA, V64, pS239, DOI 10.1097/TA.0b013e318163cd14; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pasquina PF, 2006, ARCH PHYS MED REHAB, V87, pS34, DOI 10.1016/j.apmr.2005.11.026; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS188; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Rybarczyk B, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P29, DOI 10.1037/10361-002; Smurr LM, 2008, J HAND THER, V21, P160, DOI 10.1197/j.jht.2007.09.006; Stansbury LG, 2008, J ORTHOP TRAUMA, V22, P43, DOI 10.1097/BOT.0b013e31815b35aa; Starr AJ, 2004, J BONE JOINT SURG AM, V86A, P1115, DOI 10.2106/00004623-200406000-00001; Toomey R, 2008, AM J EPIDEMIOL, V167, P1277, DOI 10.1093/aje/kwn083; Yun HC, 2008, J TRAUMA, V64, pS163, DOI 10.1097/TA.0b013e318160868c; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	40	41	42	0	12	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAR	2010	175	3					147	154		10.7205/MILMED-D-09-00120			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582GT	WOS:000276585400005	20358702	Bronze			2022-02-06	
J	Graham, JE; Radice-Neumann, DM; Reistetter, TA; Hammond, FM; Dijkers, M; Granger, CV				Graham, James E.; Radice-Neumann, Dawn M.; Reistetter, Timothy A.; Hammond, Flora M.; Dijkers, Marcel; Granger, Carl V.			Influence of Sex and Age on Inpatient Rehabilitation Outcomes Among Older Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Aged; Brain injuries; Rehabilitation	ETHNIC-DIFFERENCES; IMPACT; EPIDEMIOLOGY; GENDER; SYSTEM	Graham JE, Radice-Neumann DM, Reistetter TA, Hammond FM, Dijkers M, Granger CV. Influence of sex and age on inpatient rehabilitation outcomes among older adults with traumatic brain injury. Arch Phys Med Rehabil 2010;91:43-50. Objective: To assess the influence of sex and age on inpatient rehabilitation outcomes in a large national sample of older adults with traumatic brain injury (TBI). Design: Prospective case series. Setting: Eight hundred forty-eight inpatient rehabilitation facilities that subscribe to the Uniform Data System for Medical Rehabilitation. Participants: Patients (n=18,413) age 65 years and older admitted for inpatient rehabilitation after TBI from 2005 through 2007. Interventions: None. Main Outcome Measures: Rehabilitation length of stay, discharge FIM motor and cognitive ratings, discharge setting, and scheduled home health services at discharge. Results: Mean age +/- SD of the sample was 79 7 years, and 47% were women. In multivariable models, higher age was associated with shorter lengths of stay (P<.001), lower discharge FIM motor and cognitive ratings (P<.001), and greater odds of home health services at discharge (P<.001). Women demonstrated shorter lengths of stay (P=.006) and greater odds of being scheduled for home health services at discharge (P<.001) than men. The sex-by-age interaction term was not significant in any outcome model. Sex differences and trends were consistent across the entire age range of the sample. Conclusions: Sex and age patterns in rehabilitation outcomes among older adults with TBI varied by outcome. The current findings related to rehabilitation length of stay may be helpful for facility-level resource planning. Additional studies are warranted to identify the factors associated with returning to home and to assess the long-term benefits of combined inpatient rehabilitation and home health services for older adults with TBI.	[Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Radice-Neumann, Dawn M.; Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Reistetter, Timothy A.] E Carolina Univ, Dept Occupat Therapy, Greenville, NC USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Granger, Carl V.] SUNY Buffalo, Dept Rehabil Med, Buffalo, NY 14260 USA		Graham, JE (corresponding author), Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	jegraham@utmb.edu	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research [H133G080163]; National Institutes of Health, National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12-H0055929]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055929] Funding Source: NIH RePORTER	Supported in part by the National Institute on Disability and Rehabilitation Research (grant no. H133G080163) and the National Institutes of Health, National Institute for Child Health and Human Development and National Institute for Neurological Disorders and Stroke (grant no. K12-H0055929).	Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kraemer HC, 2004, INT J METH PSYCH RES, V13, P141, DOI 10.1002/mpr.170; KRAUS IF, 2000, NEUROSURG FOCUS, V8, pE5; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lum TY, 2005, J GERONTOL SOC WORK, V45, P3, DOI 10.1300/J083v45n04_02; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scharlach AE, 2006, J GERONTOL SOC WORK, V47, P133, DOI 10.1300/J083v47n01_09; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tieves Kelly S, 2005, WMJ, V104, P22; *UB FDN ACT, 2004, IRF PAI TRAIN MAN; *UDSMR, 2009, UN DAT SYST MED REH; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	34	41	41	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2010	91	1					43	50		10.1016/j.apmr.2009.09.017			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	592YG	WOS:000277417300007	20103395	Green Accepted			2022-02-06	
S	McAllister, TW; Stein, MB		Barchas, JD; Difede, J		McAllister, Thomas W.; Stein, Murray B.			Effects of psychological and biomechanical trauma on brain and behavior	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	traumatic brain injury (TBI); posttraumatic stress disorder (PTSD); psychological trauma; biomechanical trauma; behavior	POSTTRAUMATIC-STRESS-DISORDER; INJURY-INDUCED NEUROTRAUMA; HEAD-INJURY; BLAST INJURY; COGNITIVE REHABILITATION; POSTCONCUSSIVE SYMPTOMS; CEREBRAL AUTOREGULATION; PSYCHIATRIC SEQUELAE; MAJOR DEPRESSION; COMBAT VETERANS	The current conflicts in Iraq and Afghanistan have resulted in a large cohort of military personnel exposed to combat-related psychological trauma as well as biomechanical trauma, including proximity to blast events. Historically, the long-term effects of both types of trauma have been viewed as having different neural substrates, with some controversy over the proper attribution of such symptoms evident after each of the major conflicts of the last century. Recently, great effort has been directed toward distinguishing which neuropsychiatric sequelae are due to which type of trauma. Of interest, however, is that the chronic effects of exposure to either process are associated with a significant overlap in clinical symptoms. Furthermore, similar brain regions are vulnerable to the effects of either psychological or biomechanical trauma, raising the possibility that shared mechanisms may underlie the clinically observed overlap in symptom profile. This paper reviews the literature on the neural substrate of biomechanical and psychological injury and discusses the implications for evaluation and treatment of the neuropsychiatric sequelae of these processes.	[McAllister, Thomas W.] Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH 03756 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA		McAllister, TW (corresponding author), Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176, 1R01HD047242, 1R01HD48638]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1NS055020]; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; DoD/CDMRPUnited States Department of Defense [PT075446, W81XWH08-2-0159]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH64122]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638, R01HD047242, R01HD048176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH064122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	Supported in part by grants NICHD R01 HD048176, 1R01HD047242, and 1R01HD48638; NINDS 1RO1NS055020; CDC R01/CE001254; DoD/CDMRP PT075446; NIMH K24MH64122; DoD/CDMRP W81XWH08-2-0159.	Alavi A, 1996, J NUCL MED, V37, P1170; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; ARVIGO F, 1985, SURG NEUROL, V24, P211, DOI 10.1016/0090-3019(85)90187-9; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bremner J Douglas, 2007, Expert Rev Neurother, V7, P393, DOI 10.1586/14737175.7.4.393; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; CHEN YR, 2009, J MANAGE, V26, P1; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; COSETTI M, TXB TRAUMAT IN PRESS; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; CRAMER F, 1947, J NERV MENT DIS, V106, P602; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; DEBELLIS MD, 1994, J CLIN ENDOCR METAB, V78, P249, DOI 10.1210/jc.78.2.249; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; FRIEDMAN MJ, 1994, PSYCHIAT CLIN N AM, V17, P265; FRIEDMAN MJ, 1994, TOXICOL IND HEALTH, V10, P449; FRIEDMAN MJ, 2001, P 17 ANN M INT SOC T; Friedman MJ, 2007, HDB PTSD SCI PRACTIC, P376; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Heim C, 2001, AM J PSYCHIAT, V158, P575, DOI 10.1176/appi.ajp.158.4.575; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Institute of Medicine, 2009, GULF WAR HLTH, V7; Institute of Medicine Committee on Treatment of Posttraumatic Stress Disorder, 2008, TREATM POSTTR STRESS; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KAPOOR N, TXB TRAUMAT IN PRESS; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCEWEN BS, 1992, BIOL PSYCHIAT, V31, P177, DOI 10.1016/0006-3223(92)90204-D; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Neumeister A, 2005, BIOL PSYCHIAT, V57, P935, DOI 10.1016/j.biopsych.2005.01.016; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Rasmusson A.M., 2002, GENDER PTSD, P43; Rasmusson AM, 2001, BIOL PSYCHIAT, V50, P965, DOI 10.1016/S0006-3223(01)01264-1; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simmons AN, 2008, BIOL PSYCHIAT, V64, P681, DOI 10.1016/j.biopsych.2008.05.027; Southwick S. M., 2007, HDB PTSD SCI PRACTIC, P166; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vermetten E, 2002, DEPRESS ANXIETY, V16, P14, DOI 10.1002/da.10017; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27	111	41	42	2	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						46	57		10.1111/j.1749-6632.2010.05720.x			12	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000007	20955325	Green Accepted			2022-02-06	
J	McCauley, SR; Wilde, EA; Merkley, TL; Schnelle, KP; Bigler, ED; Hunter, JV; Chu, ZL; Vasquez, AC; Levin, HS				McCauley, Stephen R.; Wilde, Elisabeth A.; Merkley, Tricia L.; Schnelle, Kathleen P.; Bigler, Erin D.; Hunter, Jill V.; Chu, Zili; Vasquez, Ana C.; Levin, Harvey S.			Patterns of Cortical Thinning in Relation to Event-Based Prospective Memory Performance Three Months after Moderate to Severe Traumatic Brain Injury in Children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							SURFACE-BASED ANALYSIS; CEREBRAL-CORTEX; GEOMETRICALLY ACCURATE; PREFRONTAL CORTEX; HEAD-INJURY; MRI; THICKNESS; REGIONS; SEGMENTATION; IMPAIRMENTS	While event-based prospective memory (EB-PM) tasks are a familiar part of daily life for children, currently no data exists concerning the relation between EB-PM performance and brain volumetrics after traumatic brain injury (TBI). This study investigated EB-PM in children (7 to 17 years) with moderate to severe TBI or orthopedic injuries. Participants performed an EB-PM task and concurrently underwent neuroimaging at three months postinjury. Surface reconstruction and cortical thickness analysis were performed using FreeSurfer software. Cortical thickness was significantly correlated with EB-PM (adjusting for age). Significant thinning in the left (dorsolateral and inferior prefrontal cortex, anterior and posterior cingulate, temporal lobe, fusiform, and parahippocampal gyri), and right hemispheres (dorsolateral, inferior, and medial prefrontal cortex, cingulate, and temporal lobe) correlated positively and significantly with EB-PM performance; findings are comparable to those of functional neuroimaging and lesion studies of EB-PM.	[McCauley, Stephen R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Hematol Oncol Sect, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston Med Sch, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Hematol Oncol Sect, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	mccauley@bcm.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Center for Medical Rehabilitation Research [K23-HD40896]; National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD040896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was presented (in part) at the 7th annual meeting of the North American Brain Injury Society, Austin, Texas, October 2009 and was supported by National Center for Medical Rehabilitation Research grant K23-HD40896 ("Prospective memory in normal and head-injured children," McCauley, PI) and National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Medical Rehabilitation Research or the National Institutes of Health.	Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Athinoula A., 2005, FREESURFER; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cheng HD, 2008, BRAIN INJURY, V22, P697, DOI 10.1080/02699050802263035; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DAUM I, 1994, INT J NEUROSCI, V77, P187, DOI 10.3109/00207459408986030; Daum I, 2000, BEHAV NEUROL, V12, P161, DOI 10.1155/2000/327304; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Eschen A, 2007, INT J PSYCHOPHYSIOL, V64, P259, DOI 10.1016/j.ijpsycho.2006.09.005; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; HAUSER RM, 1997, SOCIOECONOMIC INDEXE; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Louda J., 2007, Z NEUROPSYCHOL, V18, P91, DOI [10.1080/09602010600831004, DOI 10.1080/09602010600831004]; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McDaniel M.A., 1996, PROSPECT MEM THEORY, P115; MEACHAM JA, 1976, 1284 MS; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Neisser U., 1982, MEMORY OBSERVED REME, P327; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Okuda J, 2007, INT J PSYCHOPHYSIOL, V64, P233, DOI 10.1016/j.ijpsycho.2006.09.009; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; TEASDALE G, 1974, LANCET, V2, P81; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; [No title captured]	69	41	41	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2010	35	3					318	332	PII 921878856	10.1080/87565641003696866			15	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	594EX	WOS:000277518100006	20446135	Green Accepted			2022-02-06	
J	Shorland, J; Douglas, JM				Shorland, Joanna; Douglas, Jacinta M.			Understanding the role of communication in maintaining and forming friendships following traumatic brain injury	BRAIN INJURY			English	Article						Communication; friendship; conversational skills; social participation; brain injury	FACIAL EXPRESSION; EMOTION RECOGNITION; DISCOURSE; DEFICITS; PEOPLE; SELF; INTEGRATION; COMPETENCE; ABILITIES; INSIGHTS	Research design: A qualitative approach based on Grounded Theory. Methods and procedures: Purposive sampling of two participants living in the community at a minimum of 2 years post-severe TBI was utilized. Data was collected via in-depth semi-structured interviews. Transcripts were analysed for categories and themes. Outcomes and results: Three major themes were evident: (1) The experience of friendship following TBI, (2) Changes to conversational skill and (3) Opening up to others. Communication change was important in the experience of friendships in so much as difficulties with conversational skill impacted on participation levels and self-disclosure. Participants identified aspects of communication associated with difficulties when interacting with friends and peers. Conclusions: Participants' stories illustrate the need to address post-TBI communication difficulties within social contexts. Further research addressing communication difficulties that impact on friendships specific to gender, age and time post-injury is warranted.	[Shorland, Joanna; Douglas, Jacinta M.] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Shorland, Joanna/0000-0001-6761-0346; Douglas, Jacinta/0000-0003-0940-6624			Axford R., 2004, RES METHODS NURSING, P210; Bluff R., 2005, QUALITATIVE RES HLTH, P147; BROWNE J, 2004, RES METHODS NURSING, P624; Burleson B.R., 1996, COMMUN REP, V9, P127, DOI [https://doi.org/10.1080/08934219609367645, DOI 10.1080/08934219609367645]; Burleson BR., 1992, S J COMMUN, V57, P260, DOI DOI 10.1080/10417949209372873; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho C. A., 1999, BRAIN DAM B; Crisp R., 1993, DISABIL HANDICAP SOC, V8, P393, DOI DOI 10.1080/02674649366780371; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; DOUGLAS JM, 2010, J SPEECH LA IN PRESS, V53; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Glaser B., 1967, DISCOVERY GROUNDED T; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Kinsella G, 1989, Int Disabil Stud, V11, P9; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kraus J, 2000, HEAD INJURY, P1; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; MAYS N, 2000, QUALITATIVE RES HLTH, P89; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Minichiello V., 2004, RES METHODS NURSING, V2nd; Morse J.M., 2002, READ ME 1 USERS GUID; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nussbaum JF., 1994, INTERPERSONAL COMMUN, P209; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paterson J., 2002, REHABIL NURS, V27, P13, DOI DOI 10.1002/J.2048-7940.2002.TB01973.X; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; Strauss A., 1990, BASICS QUALITATIVE R; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI [10.1375/brim.7.3.246, DOI 10.1375/BRIM.7.3.246]; [No title captured], DOI DOI 10.1375/BRIM.7.2.107; [No title captured]	56	41	42	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	4					569	580		10.3109/02699051003610441			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300001	20235759				2022-02-06	
J	Adamides, AA; Cooper, DJ; Rosenfeldt, FL; Bailey, MJ; Pratt, N; Tippett, N; Vallance, S; Rosenfeld, JV				Adamides, A. A.; Cooper, D. J.; Rosenfeldt, F. L.; Bailey, M. J.; Pratt, N.; Tippett, N.; Vallance, S.; Rosenfeld, J. V.			Focal cerebral oxygenation and neurological outcome with or without brain tissue oxygen-guided therapy in patients with traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Brain; Oxygen; Traumatic brain injury	SEVERE HEAD-INJURY; PERFUSION-PRESSURE; HYPERVENTILATION; REACTIVITY	In patients with severe traumatic brain injury (TBI), the depth and duration of cerebral hypoxia are independent predictors of outcome. This study aimed to evaluate the efficacy of brain oxygen-guided therapy in improving cerebral oxygenation and neurological outcome in severe TBI patients. Thirty TBI patients had brain oxygen monitors placed contralateral to the side of mass lesions, or to the non-dominant side if injury was diffuse. The first 10 patients (Group 1, observational) had brain tissue oxygen (PbrO(2)) monitored, but not treated. The next 20 patients (Group 2, interventional) were treated according to brain tissue oxygen-guided algorithms aiming to improve cerebral oxygen availability. The 6-month neurological outcome of Group 2 patients was compared with that of Group 1 patients and with contemporary control patients (Group 3) treated without the use of brain oxygen monitoring. The mean duration of brain hypoxic episodes (PbrO(2) < 15 mmHg) was 106 minutes in Group 1, and 34 minutes in Group 2 (p=0.01). Brain tissue oxygen was < 15 mmHg for 10% of monitoring time in Group 1 and 2.8% in Group 2 (p=0.12). The peak incidence of cerebral hypoxic events in both groups occurred during post-injury day 5. The mean Injury Severity Score (ISS) of patients experiencing cerebral hypoxia was higher than that of patients without cerebral hypoxic episodes (33.7 vs 24.2, p=0.04). There was no statistically significant difference in neurological outcome between those patients treated with and those without brain oxygen-guided therapy. In TBI patients, brain tissue oxygen-guided therapy is associated with decreased duration of episodes of cerebral hypoxia. Larger studies are indicated to determine the effects of this therapy on neurological outcome.	[Adamides, A. A.; Rosenfeld, J. V.] Alfred Hosp, Dept Neurosurg, Prahran, Vic 3181, Australia; [Cooper, D. J.; Pratt, N.; Tippett, N.; Vallance, S.] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Pratt, N.; Tippett, N.] Alfred Hosp, Dept Trauma Surg, Melbourne, Vic, Australia; [Adamides, A. A.; Rosenfeldt, F. L.; Rosenfeld, J. V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Cooper, D. J.; Bailey, M. J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Adamides, A. A.; Cooper, D. J.; Pratt, N.; Tippett, N.; Vallance, S.] Natl Trauma Res Inst, Melbourne, Vic, Australia		Rosenfeld, JV (corresponding author), Alfred Hosp, Dept Neurosurg, POB 315, Prahran, Vic 3181, Australia.	j.rosenfeld@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012	Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401	Victorian Trauma Foundation	The study was funded by a Victorian Trauma Foundation best practice grant. We acknowledge the efforts of the neurosurgical and ICU staff. We are grateful to Philip M. Lewis, John Iacono, Christina Lowe and Philippa Marks for efficient and reliable technical support and to Rachael Nevill for assistance with data collection.	Andrews Peter J D, 2003, Curr Opin Crit Care, V9, P83, DOI 10.1097/00075198-200304000-00001; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, P87, DOI DOI 10.1089/NEU.2006.0058; Brain Trauma Foundation: American association of Neurological surgeons, 2007, J NEUROTRAUMA S1, V24, pS59; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston AJ, 2003, BRIT J ANAESTH, V90, P774, DOI 10.1093/bja/aeg104; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Pagano A, 2003, ANN NY ACAD SCI, V1010, P405, DOI 10.1196/annals.1299.074; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	19	41	43	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2009	151	11					1399	1409		10.1007/s00701-009-0398-y			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	514NQ	WOS:000271402000008	19727549				2022-02-06	
J	Johnstone, B; Yoon, DP				Johnstone, Brick; Yoon, Dong Pil			Relationships Between the Brief Multidimensional Measure of Religiousness/Spirituality and Health Outcomes for a Heterogeneous Rehabilitation Population	REHABILITATION PSYCHOLOGY			English	Article						religion; spirituality; rehabilitation; traumatic brain injury; spinal cord injury; stroke; Brief Multidimensional Measure of Religiousness/Spirituality	QUALITY-OF-LIFE; MEDICAL REHABILITATION; RELIGIOUS SERVICES; SPIRITUALITY; PREDICTORS; ATTENDANCE; RECOVERY; STROKE; INTERVENTION; INDIVIDUALS	Purpose: To determine relationships between the Brief Multidimensional Measure of Religiousness/Spirituality (BMMRS; i.e., positive/negative spirituality, forgiveness, religious practices, positive/negative congregational support) and physical and mental health (Medical Outcomes Scale-Short Form 36; SF-36) for individuals with chronic disabilities. Research Method. A cross-sectional analysis of 118 individuals evaluated in outpatient settings, including 61 with traumatic brain injury (TBI), 32 with cerebral vascular accidents (CVA), and 25 with spinal cord injury (SCI). Results: Three of 6 BMMRS factor scores (i.e., positive spiritual experience, forgiveness, negative spiritual experience) were significantly correlated with the SF-36 General Health Perception (GHP) scale, and only I of 6 BMMRS factor scores (i.e., negative spiritual experience) was significantly and negatively correlated with the SF-36 General Mental Health (GMH) scale. BMMRS scales did not significantly predict either physical or mental health in hierarchical multiple regressions. Conclusions: Positive spiritual experiences and willingness to forgive are related to better physical health, while negative spiritual experiences are related to worse physical and mental health for individuals with chronic disabilities. Future research using the BMMRS will benefit from using a 6-factor model that evaluates positive/negative spiritual experiences, religious practices, and positive/negative congregationally support. Interventions to accentuate positive spiritual beliefs (e.g., forgiveness protocols, etc.) and reduce negative spiritual beliefs for individuals with chronic disabilities are suggested.	[Johnstone, Brick] Univ Missouri, Dept Hlth Psychol, Ctr Relig & Profess, Columbia, MO 65212 USA		Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Ctr Relig & Profess, DC116-88, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Ai AL, 1998, GERONTOLOGIST, V38, P591, DOI 10.1093/geront/38.5.591; Avants SK, 2001, J PSYCHOACTIVE DRUGS, V33, P39, DOI 10.1080/02791072.2001.10400467; Baskin TW, 2004, J COUNS DEV, V82, P79, DOI 10.1002/j.1556-6678.2004.tb00288.x; Berges IM, 2007, EXP AGING RES, V33, P1, DOI 10.1080/03610730601005893; Carson JW, 2005, J PAIN, V6, P84, DOI 10.1016/j.jpain.2004.10.012; COLANTONIO A, 1993, J GERONTOL, V48, pS261, DOI 10.1093/geronj/48.5.S261; COLANTONIO A, 1992, AM J EPIDEMIOL, V136, P884, DOI 10.1093/aje/136.7.884; Cooper-Effa M, 2001, J Am Board Fam Pract, V14, P116; Fetzer Institute/National Institute on Aging Working Group, 1999, MULT MEAS REL SPIR U; Fitchett G, 1999, REHABIL PSYCHOL, V44, P333, DOI 10.1037//0090-5550.44.4.333; Forchheimer M, 2004, AM J PHYS MED REHAB, V83, P390, DOI 10.1097/01.PHM.0000124441.78275.C9; Franska M, 2008, EUR J MASS SPECTROM, V14, P81, DOI 10.1255/ejms.914; Giaquinto S, 2007, STROKE, V38, P993, DOI 10.1161/01.STR.0000257996.26950.59; Glass B, 2007, J RELIG DISABILITY H, V11, P65, DOI DOI 10.1300/J095V11N03_06; Haley KC, 2001, J RELIG HEALTH, V40, P305, DOI 10.1023/A:1012561909054; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Hummer RA, 1999, DEMOGRAPHY, V36, P273, DOI 10.2307/2648114; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Johnstone B, 2007, DISABIL REHABIL, V29, P1153, DOI 10.1080/09638280600955693; Johnstone B, 2009, J RELIG HEALTH, V48, P146, DOI 10.1007/s10943-008-9179-9; Johnstone B, 2008, J CLIN PSYCHOL MED S, V15, P308, DOI 10.1007/s10880-008-9128-5; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kim J, 2000, REHABIL PSYCHOL, V45, P365, DOI 10.1037/0090-5550.45.4.365; Koenig HaroldG., 2001, HDB RELIG HLTH; Matheis EN, 2006, REHABIL PSYCHOL, V51, P265, DOI 10.1037/0090-5550.51.3.265; Matthees BJ, 2001, HEART LUNG, V30, P258, DOI 10.1067/mhl.2001.116135; McColl MA, 2000, DISABIL REHABIL, V22, P555, DOI 10.1080/096382800416805; McCullough ME, 2001, CURR DIR PSYCHOL SCI, V10, P194, DOI 10.1111/1467-8721.00147; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; Oman D, 2002, INT J PSYCHIAT MED, V32, P69, DOI 10.2190/RJY7-CRR1-HCW5-XVEG; PARGAMENT KI, 1994, J SCI STUD RELIG, V33, P347, DOI 10.2307/1386494; Pargament KI, 1995, J SOC ISSUES, V51, P13, DOI 10.1111/j.1540-4560.1995.tb01321.x; PARGAMENT KI, 1990, AM J COMMUN PSYCHOL, V18, P793, DOI 10.1007/BF00938065; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Rippentrop AE, 2005, PAIN, V116, P311, DOI 10.1016/j.pain.2005.05.008; Samuel-Hodge CD, 2000, DIABETES CARE, V23, P928, DOI 10.2337/diacare.23.7.928; Schnoll RA, 2000, CANCER PRACT, V8, P298, DOI 10.1046/j.1523-5394.2000.86006.x; Seybold KS, 2001, CURR DIR PSYCHOL SCI, V10, P21, DOI 10.1111/1467-8721.00106; Shatenstein B, 1998, NUTRITION, V14, P223, DOI 10.1016/S0899-9007(97)00425-5; STERN RC, 1992, J ADOLESCENT HEALTH, V13, P612, DOI 10.1016/1054-139X(92)90376-M; Strawbridge WJ, 2001, ANN BEHAV MED, V23, P68, DOI 10.1207/S15324796ABM2301_10; Tate DG, 2002, AM J PHYS MED REHAB, V81, P400, DOI 10.1097/00002060-200206000-00002; Tix AP, 1998, J CONSULT CLIN PSYCH, V66, P411, DOI 10.1037/0022-006X.66.2.411; UnderwoodGordon L, 1997, AM J PHYS MED REHAB, V76, P255, DOI 10.1097/00002060-199705000-00021; Ware J.E., 1993, SF 36 HLTH SURVEY MA	46	41	42	0	15	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					422	431		10.1037/a0017758			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Psychology; Rehabilitation	526YF	WOS:000272331600009	19929124				2022-02-06	
J	Saggar, V; Mittal, RS; Vyas, MC				Saggar, Vineet; Mittal, Radhey S.; Vyas, M. C.			Hemostatic Abnormalities in Patients with Closed Head Injuries and Their Role in Predicting Early Mortality	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; DIC; hemostatic abnormalities; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA PATIENTS; COAGULOPATHY	Abnormalities of blood coagulation are frequently found in patients following traumatic brain injury. Exposure to thromboplastin, which is abundant in brain, plays an important role in initiating coagulopathy. Eighty patients of moderate-to-severe head injury were screened for platelet count, prothombin time (PT), activated partial thromboplastin time (a-PPTK), fibrinogen degradation product levels (FDP), D-dimer levels, and disseminated intravascular coagulation scores (DIC), calculated within the first 24 hours of injury. Increased consumptive coagulopathy at admission, as reflected by high DIC scores, predicted mortality in both moderate and severe head injury patients with a high degree of accuracy (p<0.001). Similarly, increased PT, FDP, and D-dimer values correlated with higher mortality in both groups, but platelet counts and a-PPTK values correlated with mortality only in the severe head injury group. From this study we conclude that hemostatic abnormalities are independent predictors of early mortality in moderate-to-severe head injury patients.	[Saggar, Vineet; Mittal, Radhey S.] SMS Med Coll & Hosp, Dept Neurosurg, Jaipur, Rajasthan, India; [Vyas, M. C.] Cent Bur Hlth Intelligence, FSU, Jaipur, Rajasthan, India		Saggar, V (corresponding author), SMS Med Coll & Hosp, Dept Neurosurg, Residence Room 208 RD Hostel, Jaipur, Rajasthan, India.	memymyselfus@yahoo.co.in					Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; FARINGER PD, 1993, J TRAUMA, V34, P481, DOI 10.1097/00005373-199304000-00002; Gando S, 1999, ANN SURG, V229, P121, DOI 10.1097/00000658-199901000-00016; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; HOOTS WK, 1996, NEUROTRAUMA, P673; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KERNEY TJ, 1992, J TRAUMA, V32, P608; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567	14	41	44	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1665	1668		10.1089/neu.2008.0799			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200005	19697972				2022-02-06	
J	Kraus, J; Hsu, P; Schaffer, K; Vaca, F; Ayers, K; Kennedy, F; Afifi, AA				Kraus, Jess; Hsu, Paul; Schaffer, Kathryn; Vaca, Federico; Ayers, Kathl; Kennedy, Frank; Afifi, Abdelmonem A.			Preinjury Factors and 3-Month Outcomes Following Emergency Department Diagnosis of Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cohort study; mild traumatic brain injury; outcomes assessment; Pittsburgh Sleep Quality Index; Rivermead Post-Concussion Symptoms Questionnaire	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; SLEEP QUALITY; QUESTIONNAIRE; RECOVERY; INSOMNIA; VALIDITY; SEQUELAE	Objective: To investigate the sequelae of mild traumatic brain injury (MTBI) by comparing selected outcomes of emergency department-diagnosed patients with mild head injuries to those with non-head injuries. Setting: Five emergency departments in southern California. Participants: Two cohorts, one with MTBI (n = 689 at initial assessment) and another with non-head injuries (n = 1318). Main Measures: Rivermead Post-Concussion Symptoms Questionnaire and Pittsburgh Sleep Quality Index at 3 months postinjury. Results: Postconcussion symptom rates and summary Rivermead Post-Concussion Symptoms Questionnaire scores were significantly higher for persons with MTBI than for the comparison cohort. Women reported significantly more symptoms than men. Complaints about sleep quality overall (and also sleep latency and daytime dysfunction subcomponents) were significantly more frequent among those with MTBI. Conclusion: Patients with MTBI have significantly more negative outcomes than patients in the comparison cohort and should be clinically managed with these prevalent outcomes in mind. Further study of follow-up medical management and the development of treatment guidelines for this group of patients are both warranted.	[Kraus, Jess; Hsu, Paul; Schaffer, Kathryn; Afifi, Abdelmonem A.] Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA; [Vaca, Federico] Univ Calif Irvine, Ctr Trauma & Injury Prevent Res, Dept Emergency Med, Irvine, CA USA; [Ayers, Kathl; Kennedy, Frank] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA		Kraus, J (corresponding author), Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA.	jkraus3637@adelphia.net		Hsu, Paul/0000-0002-6153-364X; SCHAFFER, KATHRYN/0000-0002-3550-1679	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR922432]	This project was supported by the Centers for Disease Control and Prevention (grant #R49/CCR922432).	Afifi A., 2004, COMPUTER AIDED MULTI, V4th edn). Chapman and Hall CRC.; Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CASSIDY JD, 2004, J REHABIL MED S, V43, P126; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Department of Health and Human Services, 1989, INT CLASS DIS 9 REV; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hosmer D. W., 2001, APPL LOGISTIC REGRES, VSecond; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; *SAS I INC, 2003, VERS 9 1 3 SP4 COMP; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006	44	41	42	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					344	354		10.1097/HTR.0b013e3181ae35fd			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300005	19858968				2022-02-06	
J	Lima, FD; Oliveira, MS; Furian, AF; Souza, MA; Rambo, LM; Ribeiro, LR; Silva, LFA; Retamoso, LT; Hoffmann, MS; Magni, DV; Pereira, L; Fighera, MR; Mello, CF; Royes, LFF				Lima, Frederico Diniz; Oliveira, Mauro Schneider; Furian, Ana Flavia; Souza, Mauren Assis; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies; Hoffmann, Mauricio Scopel; Magni, Danieli Valnes; Pereira, Leticia; Fighera, Michele Rechia; Mello, Carlos Fernando; Freire Royes, Luiz Fernando			Adaptation to oxidative challenge induced by chronic physical exercise prevents Na+,K+-ATPase activity inhibition after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Na+,K+-ATPase; Oxidative damage; Physical exercise	NA+-K+-ATPASE; LATERAL FLUID PERCUSSION; INDUCED ENDOCYTOSIS; EPITHELIAL-CELLS; FREE-RADICALS; RAT-BRAIN; STRESS; LACTATE; METABOLISM; HIPPOCAMPAL	Physical exercise is likely to alter brain function and to afford neuroprotection in several neurological diseases. Although the favorable effects of physical exercise on traumatic brain injury (TBI) patients is well known, little information is available regarding the role of free radicals in the improvement induced by physical exercise in an experimental model of TBI induced by fluid percussion injury (FPI). Thus, we investigated whether 6 weeks of swimming training protects against oxidative damage (measured by protein carbonylation and thiobarbituric acid-reactive substances-TBARS) and neurochemical alterations represented by immunodetection of a subunit and activity of Na+,K+-ATPase after FPI in cerebral cortex of rats. Statistical analysis revealed that physical training protected against FPI-induced TBARS and protein carbonylation increase. In addition, physical training was effective against Na+,K+-ATPase enzyme activity inhibition and alpha(1) subunit level decrease after FPI. Pearson's correlation analysis revealed that the decrease in levels of catalytic alpha(1) subunit of Na+,K+-ATPase induced FPI correlated with TBARS and protein carbonylation content increase. Furthermore, the effective protection exerted by physical training against FPI-induced free radical correlated with the immunocontent of the catalytic alpha(1) subunit maintenance. These data suggest that TBI-induced reactive oxygen species (ROS) generation decreases Na+,K+-ATPase activity by decreasing the total number of enzyme molecules, and that physical exercise protects against this effect. Therefore, the effective protection of selected targets, such as Na+,K+-ATPase induced by physical training, supports the idea that physical training may exert prophylactic effects on neuronal cell dysfunction and damage associated with TBI. Published by Elsevier B.V.	[Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies] Univ Fed Santa Maria, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Lima, Frederico Diniz; Oliveira, Mauro Schneider; Furian, Ana Flavia; Souza, Mauren Assis; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies; Hoffmann, Mauricio Scopel; Pereira, Leticia; Fighera, Michele Rechia; Mello, Carlos Fernando; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Fisiol, Ctr Ciencias Saude, Lab Neurotoxicidade & Psicofarmacol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia; Fighera, Michele Rechia] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil; [Magni, Danieli Valnes; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Quim, Lab Neurotoxicidade, Ctr Ciencias Nat & Exatas, BR-97105900 Santa Maria, RS, Brazil; [Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Pediat, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil		Royes, LFF (corresponding author), Univ Fed Santa Maria, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Souza, Mauren/A-7990-2015; Rambo, Leonardo/F-8195-2012; Lima, Frederico Diniz/P-8479-2015; Mello, Carlos/C-7188-2013; Oliveira, Mauro Schneider/G-3437-2012; Hoffmann, Mauricio/AAM-9899-2020; Fighera, Michele R/J-9576-2014	Lima, Frederico Diniz/0000-0002-3298-2833; Mello, Carlos/0000-0002-1326-1045; Oliveira, Mauro Schneider/0000-0002-5381-1208; Hoffmann, Mauricio/0000-0003-4232-3169; Rambo, Leonardo/0000-0002-4769-3663; Fighera, Michele/0000-0002-3111-7530; Ribeiro, Leandro/0000-0002-8442-4075; Almeida Silva, Luiz Fernando/0000-0002-7621-4836	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [500120/2003-0]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [80-23]	Work supported by CNPq (grant: 500120/2003-0). C.F. Mello and A.F. Furian are the recipients of CNPq fellowships. M.S. Oliveira is the recipient of a CAPES fellowship. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. in addition, we would like to state that all authors have seen and approved the study and that no part of the work has been published or is under consideration for publication elsewhere. Moreover, the present study was supported by government funding and has no financial or other relationship that might lead to a conflict of interest. We also would like to declare that all experiments were carried out according to the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996, and that the University Ethics Committee approved the respective protocols.	Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arida RM, 1999, EPILEPSY RES, V37, P45, DOI 10.1016/S0920-1211(99)00032-7; Banjac A, 2001, PHYSIOL RES, V50, P411; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BOHANNON RW, 1993, CURR OPIN NEUROL, V6, P765, DOI 10.1097/00019052-199310000-00015; Boveris A, 2008, IUBMB LIFE, V60, P308, DOI 10.1002/iub.46; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho JF, 2005, COMP BIOCHEM PHYS A, V140, P409, DOI 10.1016/j.cbpb.2004.12.002; Chen ZP, 2006, AM J RESP CELL MOL, V35, P127, DOI 10.1165/rcmb.2006-0044OC; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Daggan RN, 2000, MED SCI SPORT EXER, V32, P2024, DOI 10.1097/00005768-200012000-00009; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Dencher NA, 2007, ANN NY ACAD SCI, V1100, P291, DOI 10.1196/annals.1395.030; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; Endres M, 2003, ANN NEUROL, V54, P582, DOI 10.1002/ana.10722; Erickson KI, 2009, BRIT J SPORT MED, V43, P22, DOI 10.1136/bjsm.2008.052498; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORDYCE DE, 1991, BEHAV BRAIN RES, V46, P123, DOI 10.1016/S0166-4328(05)80105-6; Gladden LB, 2000, MED SCI SPORT EXER, V32, P764, DOI 10.1097/00005768-200004000-00008; Gobatto CA, 2001, COMP BIOCHEM PHYS A, V130, P21, DOI 10.1016/S1095-6433(01)00362-2; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jamme I, 1995, NEUROREPORT, V7, P333; Jones AM, 2000, SPORTS MED, V29, P373, DOI 10.2165/00007256-200029060-00001; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; LEES GJ, 1990, NEUROSCI LETT, V120, P159, DOI 10.1016/0304-3940(90)90027-7; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Marquezi ML, 2003, INT J SPORT NUTR EXE, V13, P65, DOI 10.1123/ijsnem.13.1.65; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Packer L, 2008, FREE RADICAL BIO MED, V44, P123, DOI 10.1016/j.freeradbiomed.2007.05.031; Packer L, 2007, FREE RADICAL RES, V41, P951, DOI 10.1080/10715760701490975; Pari L, 2007, TOXICOLOGY, V234, P44, DOI 10.1016/j.tox.2007.01.021; Potts Mathew B, 2006, NeuroRx, V3, P143; Prada FJA, 2004, REV BRAS CIENCIA MOV, V12, P29; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith AD, 2003, EXP NEUROL, V184, P31, DOI 10.1016/j.expneurol.2003.08.017; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tillerson JL, 2003, NEUROSCIENCE, V119, P899, DOI 10.1016/S0306-4522(03)00096-4; Toldy A, 2005, BRAIN RES BULL, V65, P487, DOI 10.1016/j.brainresbull.2005.02.028; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Voltarelli FA, 2002, BRAZ J MED BIOL RES, V35, P1389, DOI 10.1590/S0100-879X2002001100018; Wang RY, 2001, BRAIN RES, V922, P140, DOI 10.1016/S0006-8993(01)03154-7; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362; Yilmaz G, 2007, TOHOKU J EXP MED, V211, P23, DOI 10.1620/tjem.211.23	69	41	41	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 7	2009	1279						147	155		10.1016/j.brainres.2009.04.052			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466PI	WOS:000267674100016	19422810				2022-02-06	
J	Davis, LC; Sander, AM; Struchen, MA; Sherer, M; Nakase-Richardson, R; Malec, JF				Davis, Lynne C.; Sander, Angelle M.; Struchen, Margaret A.; Sherer, Mark; Nakase-Richardson, Risa; Malec, James F.			Medical and Psychosocial Predictors of Caregiver Distress and Perceived Burden Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregivers; caregiver distress; traumatic brain injury	DISABILITY RATING-SCALE; BLUNT HEAD-INJURY; DEPRESSIVE SYMPTOMS; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; FAMILY CAREGIVERS; ELDERLY-PATIENTS; RELATIVES; ADJUSTMENT; RECOVERY	Objective: To determine whether caregivers' medical and psychiatric histories, coping style, and social support predict global distress and perceived burden. Design: Correlational, cohort study. Participants: A total of 114 caregivers of persons with moderate to severe traumatic brain injury, assessed 1 year postinjury. Measures: Ratings of caregivers' medical and psychiatric history; Disability Rating Scale; Ways of Coping Questionnaire; Multidimensional Scale of Perceived Social Support; Brief Symptom Inventory; and Modified Caregiver Appraisal Scale. Results: Caregivers' medical and psychiatric histories predicted global distress, after accounting for education, sex, income, and relationship, as well as disability of the person with injury. Increased use of escape-avoidance as a coping strategy was related to increased distress. Perceived burden was predicted by disability in the person with injury, use of escape-avoidance, and perceived social support. Conclusions: Caregivers' preinjury functioning is more predictive of global distress, whereas the functioning of the person with injury is more predictive of injury-related burden. Caregivers' medical and psychiatric histories are important considerations when targeting interventions; global stress management strategies may be as important as assisting with injury-related issues.	[Davis, Lynne C.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Davis, Lynne C.; Sander, Angelle M.; Struchen, Margaret A.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Nakase-Richardson, Risa] Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA		Davis, LC (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	lynne.davis@memorialhermann.org			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133A980058, H133A70015, H133A980035, H133A980036, H133B031117, H133A070043]	This work was supported in part 4 grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133A980058, H133A70015, H133A980035, H133A980036, H133B031117, H133A070043).	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; DAHLSTROM WG, 1969, MMPI RES DEV CLIN AP; De Jonge P, 2006, PSYCHOSOMATICS, V47, P33, DOI 10.1176/appi.psy.47.1.33; de Jonge P, 2004, AM J GERIAT PSYCHIAT, V12, P57, DOI 10.1176/appi.ajgp.12.1.57; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1984, STRESS; Folkman S., 1988, MANUAL WAYS COPING Q; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D., 1972, DETECTION PSYCHIAT I; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1975, LANCET, V1, P480; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Minnes P, 2000, BRAIN INJURY, V14, P737; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ranchor AV, 2002, QUAL LIFE RES, V11, P101, DOI 10.1023/A:1015053623843; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SANDER AM, 2006, BRAIN INJURY MED; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; United States Department of Health and Human Services, 2001, MENT HLTH REP SURG G; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	60	41	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					145	154		10.1097/HTR.0b013e3181a0b291			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800001	19461362				2022-02-06	
J	Petridis, AK; Dorner, L; Doukas, A; Eifrig, S; Barth, H; Mehdorn, M				Petridis, A. K.; Doerner, L.; Doukas, A.; Eifrig, S.; Barth, H.; Mehdorn, M.			Acute Subdural Hematoma in the Elderly; Clinical and CT Factors Influencing the Surgical Treatment Decision	CENTRAL EUROPEAN NEUROSURGERY			English	Article						acute subdural hematoma; Glasgow Coma Scale; Glasgow Outcome Score; midline shift	PROGNOSTIC-FACTORS; OUTCOME PREDICTION; BRAIN-DAMAGE; HEMORRHAGE; INJURY; MODEL; RAT	Objective: Acute subdural hematomas (aSDH) are severe traumatic brain injuries. Older patients have a higher mortality rate. In the present study the computed tomography (CT) and neurological deficits caused by aSDH were used as prognostic factors to define the outcome and surgical treatment indication in older patients. Methods: The affect of the Glasgow Coma Scale (GCS) score on initial presentation, pupil abnormalities, parenchymal lesions, SDH-thickness, midline shift and intracranial pressure (ICP) in the outcome of older patients (>= 65 years old) admitted to our hospital between 1993 and 2006 with aSDH was evaluated. The outcome was assessed with the Glasgow Outcome Scale (GOS). The data were collected retrospectively. Statistical analysis was performed with Chi-square test and ANOVA. Results: Older patients have a high mortality after aSDH. A low GCS score (3-8), pupil abnormalities, the presence of contusions and subarachnoid bleeding, midline shift > aSDH thickness as well as a highly elevated ICP > 40 mmHg are unfavorable factors in the prognosis of aSDH. Conclusion: Patients with a GCS of 13-15 can be observed clinically (the expected outcome is very good). Comatose patients (GCS 3-8) with bilateral dilatation of the pupils should not be operated (very high mortality rate). if the GCS score is < 13 and both pupils or only one are reactive to light and the midline shift < 10 mm, surgery is indicated. If the midline shift is > 10 mm and aSDH thickness > midline shift, surgery is also indicated. If in the same patient group midline shift > SDH thickness and ICP > 40 mmHg, surgery is not indicated.	[Petridis, A. K.; Doerner, L.; Doukas, A.; Eifrig, S.; Barth, H.; Mehdorn, M.] UKSH, Dept Neurosurg, D-24106 Kiel, Germany		Petridis, AK (corresponding author), UKSH, Dept Neurosurg, Campus Kiel,Schittenhelmstr 10, D-24106 Kiel, Germany.	opticdisc@aol.com	Mehdorn, Maximilian/D-2495-2010				Alessandri B, 2006, BRAIN RES, V1111, P196, DOI 10.1016/j.brainres.2006.06.105; D'Amato L, 2007, J Neurosurg Sci, V51, P107; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Domenicucci M, 1998, NEUROSURGERY, V42, P51, DOI 10.1097/00006123-199801000-00010; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KURODA Y, 1992, NEUROSURGERY, V30, P687; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	19	41	41	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	1868-4904	1868-4912		CENT EUR NEUROSURG	Cent. Eur. Neurosurg.	MAY	2009	70	2					73	78		10.1055/s-0029-1224096			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	449MG	WOS:000266334100003	19711259				2022-02-06	
J	Crawford, F; Wood, M; Ferguson, S; Mathura, V; Gupta, P; Humphrey, J; Mouzon, B; Laporte, V; Margenthaler, E; O'Steen, B; Hayes, R; Roses, A; Mullan, M				Crawford, F.; Wood, M.; Ferguson, S.; Mathura, V.; Gupta, P.; Humphrey, J.; Mouzon, B.; Laporte, V.; Margenthaler, E.; O'Steen, B.; Hayes, R.; Roses, A.; Mullan, M.			APOLIPOPROTEIN E-GENOTYPE DEPENDENT HIPPOCAMPAL AND CORTICAL RESPONSES TO TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						apolipoprotein E; traumatic brain injury; genomic; Ingenuity Pathway Analysis; microarray	CLOSED-HEAD INJURY; INTIMA-MEDIA THICKNESS; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ALZHEIMERS-DISEASE; ENVIRONMENTAL STIMULATION; MITOCHONDRIAL BIOGENESIS; ENHANCED NEUROGENESIS; NEURONS; EXPRESSION	The different alleles of the apolipoprotein E gene (APOE-gene, ApoE-protein) have been reported to influence recovery after traumatic brain injury (TBI) in both human patients and animal models, with the e4 allele typically conferring poorer prognosis for recovery. How the E4 allele, and consequently the ApoE4 isoform, affects recovery is unknown, but proposed mechanisms include neurogenesis, inflammatory response and amyloid processing or metabolism. Using the controlled cortical impact (CCI) model of brain injury and microarray technology we have characterized the genomic response to injury in the brains of APOE2, APOE3 and APOE4 transgenic mice and identified quantitatively and qualitatively significantly different profiles of gene expression in both the hippocampus and the cortex of the APOE3 mice compared to APOE4. The observed gene regulation predicts functional consequences including effects on inflammatory processes, cell growth and proliferation, and cellular signaling, and may suggest that the poor recovery post-TBI in APOE4 animals and human patients is less likely to result from a specific activation of neurodegenerative mechanisms than a loss of reparative capability. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Crawford, F.; Wood, M.; Ferguson, S.; Mathura, V.; Gupta, P.; Humphrey, J.; Mouzon, B.; Laporte, V.; Margenthaler, E.; Mullan, M.] Roskamp Inst, Sarasota, FL 34243 USA; [Crawford, F.; Wood, M.; Ferguson, S.; Humphrey, J.; Mouzon, B.; Mullan, M.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [O'Steen, B.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Hayes, R.] Banyan Biomarkers, Alachua, FL 32615 USA; [Roses, A.] Duke Univ, R David Thomas Execut Training Ctr, Durham, NC 27708 USA		Crawford, F (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	fcrawford@rfdn.org		Mullan, Michael/0000-0002-1473-7527	VA Merit awardUS Department of Veterans Affairs	This work was made possible by a VA Merit award to Dr. F. Crawford and the generosity of Robert and Diane Roskamp.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Belinson H, 2008, J NEUROSCI, V28, P4690, DOI 10.1523/JNEUROSCI.5633-07.2008; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brodbeck J, 2008, P NATL ACAD SCI USA, V105, P1343, DOI 10.1073/pnas.0709906104; Brown CM, 2007, ENDOCRINOLOGY, V148, P3383, DOI 10.1210/en.2006-1200; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Buttini M, 1999, J NEUROSCI, V19, P4867; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chen SA, 2005, J ALZHEIMERS DIS, V7, P25; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; D Roses A, 2007, PHARMACOGENOMICS J, V7, P10, DOI 10.1038/sj.tpj.6500397; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Debett S, 2006, STROKE, V37, P2917, DOI 10.1161/01.STR.0000249011.94055.00; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HAN SH, 1994, EXP NEUROL, V128, P13, DOI 10.1006/exnr.1994.1108; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; Hillen T, 2000, J INTERN MED, V247, P679, DOI 10.1046/j.1365-2796.2000.00681.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ilveskoski E, 1999, CIRCULATION, V100, P608, DOI 10.1161/01.CIR.100.6.608; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kohara K, 2002, HYPERTENS RES, V25, P31, DOI 10.1291/hypres.25.31; Lessner SM, 2002, AM J PATHOL, V160, P2145, DOI 10.1016/S0002-9440(10)61163-7; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Levi O, 2007, J NEUROCHEM, V103, P1031, DOI 10.1111/j.1471-4159.2007.04810.x; Levi O, 2007, J NEUROCHEM, V100, P202, DOI 10.1111/j.1471-4159.2006.04189.x; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-10; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Morris DC, 2007, NEUROSCI LETT, V418, P170, DOI 10.1016/j.neulet.2007.03.039; Muller W, 1998, BRAIN PATHOL, V8, P641; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Ramos EM, 2006, ARCH NEUROL-CHICAGO, V63, P1165, DOI 10.1001/archneur.63.8.1165; Rasbach KA, 2007, J BIOL CHEM, V282, P2355, DOI 10.1074/jbc.M608009200; Reynolds IJ, 2004, J BIOENERG BIOMEMBR, V36, P283, DOI 10.1023/B:JOBB.0000041754.78313.c2; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Roses AD, 1998, NEUROBIOL AGING, V19, pS53, DOI 10.1016/S0197-4580(98)00030-X; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sasaki T, 2006, J NEUROSCI RES, V84, P1187, DOI 10.1002/jnr.21036; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Strum JC, 2007, J ALZHEIMERS DIS, V11, P45; Sun YL, 1998, J NEUROSCI, V18, P3261; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsoi LM, 2007, ARCH BIOCHEM BIOPHYS, V460, P33, DOI 10.1016/j.abb.2007.01.019; Tziakas DN, 2006, J AM COLL CARDIOL, V48, P2471, DOI 10.1016/j.jacc.2006.08.032; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.0.CO;2-G; Westrick RJ, 2001, CIRCULATION, V103, P3044, DOI 10.1161/hc2501.092492; Williams KR, 1997, NEUROBIOL DIS, V4, P58, DOI 10.1006/nbdi.1997.0131; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YIN W, 2008, STROKE          0821	69	41	43	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 10	2009	159	4					1349	1362		10.1016/j.neuroscience.2009.01.033			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	432JR	WOS:000265129800017	19409232				2022-02-06	
J	Adamo, MA; Drazin, D; Waldman, JB				Adamo, Matthew A.; Drazin, Doniel; Waldman, John B.			Decompressive craniectomy and postoperative complication management in infants and toddlers with severe traumatic brain injuries Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Joint Section on Disorders of the Spine and Peripheral Nerves	MAR 01, 2008	Orlando, FL	Amer Assoc Neurol Surg		complication; decompressive craniectomy; head trauma; outcome; traumatic brain injury	HEAD-INJURY; CHILDREN; HYPOTHERMIA	Object. Infants with severe traumatic brain injury represent a therapeutic challenge. The internal absence of open space within the infant cranial vault makes volume increases poorly tolerated. This report presents 7 cases of decompressive craniectomy in infants with cerebral edema. Methods. The authors reviewed the medical charts of infants with brain injuries who presented to Albany Medical Center Hospital between January 2004 and July 2007. Variables that were examined included patient age, physical examination results at admission, positive imaging findings, surgery performed, complications, requirement of permanent CSF diversion, and physical examination results at discharge and outpatient follow-up using the King's Outcome Scale for Childhood Head Injury. Seven infants met the inclusion criteria for the study. Six infants experienced nonaccidental trauma, and I had a large infarction of the middle cerebral artery territory secondary to a carotid dissection. At admission, all patients were minimally responsive, 4 had equal and minimally reactive pupils, 3 had anisocoria with the enlarged pupil on the same side as the brain lesion, and all had right-sided hemiparesis. Six patients received a left hemicraniectomy, whereas I received a left frontal craniectomy. In all cases, bone was cultured and stored at the bone bank. Results. Postoperatively, 3 patients who developed draining CSF fistulas needed insertions of external ventricular drains, with incisions oversewn using nylon sutures and a liquid bonding agent. After prolonged CSF drainage and wound care, these patients all developed epidural and subdural empyemas necessitating surgical drainage and debridement. Methicillin-resistant Staphylococcus aureus was found in 2 patients and Enterococcus in the third. All patients developed hydrocephalus necessitating the insertion of a ventriculoperitoneal shunt, and all had bone replaced within 1-6 months from the time of the original operation. Two patients required reoperation due to bone resorption. At outpatient follow-up visits, all had scores of 3 or 4 on the King's Outcome Scale for Childhood Head Injury. Each patient was awake, interactive, and could sit, as well as either crawl or walk with assistance. All had persistent, improving right-sided hemiparesis and spasticity. Conclusions. Despite poor initial examination results, infants with severe traumatic brain injury can safely undergo decompressive craniectomy with reasonable neurological recovery. Postoperative complications must be anticipated and treated appropriately. Due to the high rate of CSF fistulas encountered in this study, it appears reasonable to recommend both the suturing in of a dural augmentation graft and the placement of either a subdural drain or a ventriculostomy catheter to relieve pressure on the healing surgical incision. Also, one might want to consider using a T-shaped incision as opposed to the traditional reverse question mark-shaped incision because wound healing may be compromised due to the potential interruption of the circulation to the posterior and inferior limb with this latter incision. (DOI: 10.3171/2008.12.PEDS08310)	[Adamo, Matthew A.] UPMC, Childrens Hosp, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Drazin, Doniel; Waldman, John B.] Albany Med Ctr, Div Neurosurg, Albany, NY USA		Adamo, MA (corresponding author), UPMC, Childrens Hosp, Dept Neurosurg, 3705 5th Ave,3rd Floor,Purple Bldg, Pittsburgh, PA 15213 USA.	matthew.a.adamo@gmail.com					Calvert S, 2008, DEV MED CHILD NEUROL, V50, P426, DOI 10.1111/j.1469-8749.2008.02061.x; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Miyake H, 2002, CHILD NERV SYST, V18, P500, DOI 10.1007/s00381-002-0596-x; Ok SH, 2005, ACTA ANAESTH SCAND, V49, P883, DOI 10.1111/j.1399-6576.2005.00728.x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010	13	41	44	1	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2009	3	4					334	339		10.3171/2008.12.PEDS08310			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pediatrics; Surgery	424UT	WOS:000264594500018	19338415				2022-02-06	
J	James, ML; Sullivan, PM; Lascola, CD; Vitek, MP; Laskowitz, DT				James, Michael L.; Sullivan, Patrick M.; Lascola, Christopher D.; Vitek, Michael P.; Laskowitz, Daniel T.			Pharmacogenomic Effects of Apolipoprotein E on Intracerebral Hemorrhage	STROKE			English	Article						apolipoprotein E; gene therapy; inflammation; intracerebral hemorrhage; mouse	NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN-INJURY; APOE GENOTYPE; SUBARACHNOID HEMORRHAGE; TARGETED REPLACEMENT; MIMETIC PEPTIDES; E GENE; EXPRESSION; EDEMA; INFLAMMATION	Background and Purpose-The purpose of the study was to evaluate the effect of APOE genotype and the feasibility of administering an apolipoprotein E-mimetic therapeutic to modify outcomes in a murine model of intracerebral hemorrhage. Methods-Intracerebral hemorrhage was induced via stereotactic injection of 0.1 U Clostridial collagenase into the left basal ganglia of wild-type and apolipoprotein-E targeted-replacement mice, consisting of either homozygous 3/3 or 4/4 genotypes. Animals were randomized to receive either vehicle or apolipoprotein E-mimetic peptide. Outcomes included functional neurological tests (21-point neuroseverity score and Rotorod latency) over the initial 7 days after injury, radiographic and histological hemorrhage size at 3 and 7 days, brain water content for cerebral edema at 24 hours, and quantitative polymerase chain reaction for inflammatory markers at 6, 24, and 48 hours. Results-Apolipoprotein-E targeted-replacement mice consisting of homozygous 3/3 demonstrated superior neuroseverity scores and Rotorod latencies over the first 3 days after intracerebral hemorrhage, decreased cerebral edema at 24 hours, and reduced upregulation of IL-6 and endothelial nitric oxide synthase at 6 hours when compared to their apolipoprotein-E targeted-replacement mice consisting of homozygous 4/4 counterparts. After intravenous administration of 1 mg/kg apolipoprotein E-mimetic peptide, both wild-type and apolipoprotein-E targeted-replacement mice consisting of homozygous 4/4 exhibited improved functional outcomes over 7 days after intracerebral hemorrhage, less edema at 24 hours, and reduced upregulation of IL-6 and endothelial nitric oxide synthase when compared to mice that did not receive the peptide. Conclusions-Our data indicate that APOE genotype influences neurological outcome after intracerebral hemorrhage in a murine model. In particular APOE4 is associated with poor functional outcome and increased cerebral edema. Additionally, this outcome can be modified by the addition of an apolipoprotein E mimetic-peptide, COG1410. (Stroke. 2009;40:632-639.)	[James, Michael L.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [James, Michael L.; Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Sullivan, Patrick M.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC 27710 USA; [Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [James, Michael L.] Duke Univ, Med Ctr, Dept Surg Neurosurg, Durham, NC 27710 USA; [Lascola, Christopher D.] Duke Univ, Med Ctr, Dept Radiol Neuroradiol, Durham, NC 27710 USA; [James, Michael L.; Lascola, Christopher D.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Lab, Durham, NC 27710 USA; [Vitek, Michael P.] Cognosci Inc, Morrisville, NC USA		James, ML (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	james040@mc.duke.edu	James, Michael L./AAJ-5592-2020; Lascola, Christopher D/B-9126-2017; tao, li/G-7956-2011	James, Michael L./0000-0002-8715-5210; Lascola, Christopher D/0000-0002-8031-782X; Vitek, Michael/0000-0001-8140-8048	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1 RR024128-01, 2R44 AG 020473]; Institute for the Study of Aging; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER	This study was possible through funding by NIH 1UL1 RR024128-01 (D. T. L.), 2R44 AG 020473 (M. P. V.), and grants from The Institute for the Study of Aging.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Colton CA, 2001, BBA-MOL BASIS DIS, V1535, P134, DOI 10.1016/S0925-4439(00)00092-2; Duan RS, 2006, EXP NEUROL, V202, P373, DOI 10.1016/j.expneurol.2006.06.013; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Grunenfelder J, 2004, J THORAC CARDIOV SUR, V128, P92, DOI 10.1016/j.jtcvs.2004.02.022; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; James ML, 2007, NEUROCRIT CARE; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Martinez-Gonzalez NA, 2006, J NEUROL NEUROSUR PS, V77, P1329, DOI 10.1136/jnnp.2006.097543; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Moretti EW, 2005, CRIT CARE MED, V33, P2521, DOI 10.1097/01.CCM.0000186368.96146.FB; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tzourio C, 2008, NEUROLOGY, V70, P1322, DOI 10.1212/01.wnl.0000308819.43401.87; Woo D, 2005, STROKE, V36, P1874, DOI 10.1161/01.STR.0000177891.15082.b9; Xue Mengzhou, 2003, J Stroke Cerebrovasc Dis, V12, P152, DOI 10.1016/S1052-3057(03)00036-3; Zhang XJ, 2006, NEUROL INDIA, V54, P402	32	41	43	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2009	40	2					632	639		10.1161/STROKEAHA.108.530402			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	399FD	WOS:000262784900046	19109539	Green Accepted, Bronze			2022-02-06	
J	Reed, TT; Owen, J; Pierce, WM; Sebastian, A; Sullivan, PG; Butterfield, DA				Reed, Tanea T.; Owen, Joshua; Pierce, William M.; Sebastian, Andrea; Sullivan, Patrick G.; Butterfield, D. Allan			Proteomic Identification of Nitrated Brain Proteins in Traumatic Brain-Injured Rats Treated Postinjury With Gamma-Glutamylcysteine Ethyl Ester: Insights Into the Role of Elevation of Glutathione as a Potential Therapeutic Strategy for Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						oxidative stress; brain; antioxidant	ALZHEIMERS-DISEASE BRAIN; MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVELY MODIFIED PROTEINS; MILD COGNITIVE IMPAIRMENT; LIPID-PEROXIDATION; TRANSGENIC MICE; NITRIC-OXIDE; PEROXYNITRITE; STRESS; CALPAIN	Traumatic brain injury (TBI) occurs suddenly and has damaging effects to the brain that are dependent on the severity of insult. Symptoms can be mild, moderate, or severe. Oxidative damage is associated with traumatic brain injury through reactive oxygen/nitrogen species production. One such species, peroxynitrite, is elevated in TBI brain tissue (Orihara et al. [2001] Forensic Sci. Int. 123:142-149; Deng et al. [2007] Exp. Neurol. 205:154-165). Peroxynitrite can react with carbon dioxide and decompose to produce NO2 and carbonate radicals, which in turn can lead to 3-nitrotyrosine, an index of protein nitration. Gamma-glutamylcysteine ethyl ester (GCEE) is an ethyl ester moiety of gamma-glutamylcysteine, an agent that up-regulates glutathione (GSH) production in brain (Drake et al. (2002] J. Neurosci. Res. 68:776-784). Many preclinical studies of TBI have employed pretreatment of animals with proposed beneficial agents prior to the injury itself. However, in the real world of TBI, treatment begins postinjury. Hence, insights into agents that improve outcome following injury are desperately needed. This study is one of the first to investigate a potential GSH-based therapy for TBI postinjury. Protein carbonyls, an index of protein oxidation, were significantly elevated in brain of animals subjected to TBI. However, if, after TBI, GCEE was administered i.p., protein carbonyl levels were significantly reduced. Similarly, 3-nitrotyrosine levels were elevated in brain following TBI but significantly decreased following TBI if GCEE was administered i.p. Redox proteomics analysis showed that several brain proteins were nitrated after TBI. However, if GCEE was given i.p. following TBI, many of these proteins were protected from nitration. The results are	[Butterfield, D. Allan] Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA; [Pierce, William M.] Univ Louisville, Dept Pharmacol, Louisville, KY 40292 USA; [Sebastian, Andrea; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA		Butterfield, DA (corresponding author), Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA.	dabens@uky.edu		Reed, Tanea/0000-0003-2642-3100	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-10836]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER	Contract grant sponsor NIH: Contract grant number: AG-10836 (to D.A.B.).	Alvarez B, 2004, FREE RADICAL BIO MED, V37, P813, DOI 10.1016/j.freeradbiomed.2004.06.006; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5; Bedell EA, 2002, CRIT CARE MED, V30, P710, DOI 10.1097/00003246-200203000-00041; Botti H, 2005, IUBMB LIFE, V57, P407, DOI 10.1080/15216540500137701; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Boyd-Kimball D, 2005, BRAIN RES, V1044, P206, DOI 10.1016/j.brainres.2005.02.086; Boyd-Kimball D, 2005, NEUROSCIENCE, V132, P313, DOI 10.1016/j.neuroscience.2004.12.022; Boyd-Kimball D, 2005, J NEUROSCI RES, V79, P700, DOI 10.1002/jnr.20394; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Butterfield DA, 2006, ANTIOXID REDOX SIGN, V8, P1971, DOI 10.1089/ars.2006.8.1971; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Castegna A, 2004, J NEUROCHEM, V88, P1540, DOI 10.1046/j.1471-4159.2003.02288.x; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Cooper AJL, 1997, BIOL CHEM, V378, P793; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Drake J, 2002, J NEUROSCI RES, V68, P776, DOI 10.1002/jnr.10266; Ekegren T, 2006, J PROTEOME RES, V5, P2364, DOI 10.1021/pr060237f; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Ginsberg MD, 2002, CRIT CARE MED, V30, P935, DOI 10.1097/00003246-200204000-00040; Gorska D, 2000, Neurol Neurochir Pol, V34, P573; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Jackson RM, 1998, FREE RADICAL BIO MED, V25, P463, DOI 10.1016/S0891-5849(98)00101-4; Joshi G, 2007, J NEUROSCI RES, V85, P497, DOI 10.1002/jnr.21158; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Mostert JP, 2008, CNS NEUROSCI THER, V14, P153, DOI 10.1111/j.1527-3458.2008.00040.x; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Onofri F, 2007, J BIOL CHEM, V282, P15754, DOI 10.1074/jbc.M701051200; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Perluigi M, 2005, FREE RADICAL BIO MED, V38, P960, DOI 10.1016/j.freeradbiomed.2004.12.021; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Poon HF, 2005, J NEUROCHEM, V94, P380, DOI 10.1111/j.1471-4159.2005.03215.x; Poon HF, 2005, NEUROBIOL DIS, V18, P492, DOI 10.1016/j.nbd.2004.12.009; Poon HF, 2004, NEUROSCIENCE, V126, P915, DOI 10.1016/j.neuroscience.2004.04.046; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Reed T, 2008, NEUROBIOL DIS, V30, P107, DOI 10.1016/j.nbd.2007.12.007; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sultana R, 2006, NEUROBIOL DIS, V22, P76, DOI 10.1016/j.nbd.2005.10.004; Sultana R, 2007, J CELL MOL MED, V11, P839, DOI 10.1111/j.1582-4934.2007.00065.x; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Tangpong J, 2007, J NEUROCHEM, V100, P191, DOI 10.1111/j.1471-4159.2006.04179.x; Thongboonkerd V, 2002, J BIOL CHEM, V277, P16599, DOI 10.1074/jbc.M200746200; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Wendt S, 2003, J BIOL CHEM, V278, P1125, DOI 10.1074/jbc.M208572200; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4	74	41	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 1	2009	87	2					408	417		10.1002/jnr.21872			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	403JQ	WOS:000263079300012	18803298				2022-02-06	
J	Sarnowska, A; Braun, H; Sauerzweig, S; Reymann, KG				Sarnowska, Anna; Braun, Holger; Sauerzweig, Steven; Reymann, Klaus G.			The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue	EXPERIMENTAL NEUROLOGY			English	Article						Neuroprotection; Transplantation; Bone marrow stem cells; Stem cell therapy; Hippocampal slice culture; Serum deprivation; Oxygen-glucose deprivation; Cortical primary culture	TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR PRODUCTION; STROMAL CELLS; IN-VITRO; INDUCED NEUROGENESIS; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; RAT HIPPOCAMPUS; CULTURES; EXPRESSION	Bone marrow stem cells (BMSCs) are able to confer beneficial effects after transplantation into animals with ischemic brain injuries. This effect is probably mainly caused by the release of trophic factors, though the possibility of dead neural cells being replaced by BMSCs cannot be excluded. The aim of this study was to determine whether the neuroprotective effects in question are dependent on direct cell-cell contacts between BMSCs and injured tissue. We therefore investigated that interplay in an in vitro model of hippocampal organotypic slice Cultures (OHCs), in order to avoid the interference due to immunological rejection processes following transplantation in vivo. To perform ischemic injury in vitro, OHCs were made subject to oxygen-glucose deprivation (OGD). The possible direct or indirect neuroprotective effects induced by BMSCs were evaluated 24 h after injury by reference to two experimental paradigms using ischemic injured hippocampal slices: (i) cell transplantation on the top of OGD-treated OHC (ii) co-cultivation of cell culture with OHC space separated for 24 h. In both paradigms, the BMSC treatment induced comparable and significant neuroprotection in OGD-injured OHCs. This effect increased after treatment with serum-deprived BMSCs, enriched with cells expressing nestin and GFAR Comparing cell transplantation and cell co-cultivation with injured tissue, we concluded that the neuroprotective effect of BMSCs evoked shortly after ischemia (24 h) does not depend on cell-cell contacts. Additionally OGD-treated OHC was found to stimulate co-cultured BMSCs into expressing higher levels of bFGF and NGF. Finally, ischemic hippocampal slices increased the expression of nestin and GFAP in co-cultivated BMSCs, as well as changing their morphology. (c) 2008 Elsevier Inc. All rights reserved.	[Sarnowska, Anna; Reymann, Klaus G.] FAN GmbH, Res Inst Appl Neurosci, D-39120 Magdeburg, Germany; [Braun, Holger; Sauerzweig, Steven; Reymann, Klaus G.] Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany; [Sarnowska, Anna] Polish Acad Sci, Med Res Inst, NeuroRepair Dept, Warsaw, Poland		Sarnowska, A (corresponding author), FAN GmbH, Res Inst Appl Neurosci, Leipziger Str 44, D-39120 Magdeburg, Germany.	a_sarnowska@tlen.pl			Marie Curie development host fellowshipEuropean Commission [MCFH-2001-00639]	Our work was supported by the Marie Curie development host fellowship program (MCFH-2001-00639).	Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bonthius DJ, 2003, DEV BRAIN RES, V140, P15, DOI 10.1016/S0165-3806(02)00549-7; Braun H, 2006, J NEUROSCI METH, V157, P32, DOI 10.1016/j.jneumeth.2006.03.019; Buhnemann C, 2006, BRAIN, V129, P3238, DOI 10.1093/brain/awl261; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Dempsey RJ, 2007, NEUROSURG CLIN N AM, V18, P183, DOI 10.1016/j.nec.2006.10.011; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dluzniewska J, 2005, FASEB J, V19, P1896, DOI 10.1096/fj.05-3786fje; Golbs A, 2007, J NEUROSCI METH, V161, P234, DOI 10.1016/j.jneumeth.2006.11.011; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnson-Farley NN, 2007, BRAIN RES, V1154, P40, DOI 10.1016/j.brainres.2007.04.026; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Lei ZG, 2006, NEUROSCI LETT, V407, P224, DOI 10.1016/j.neulet.2006.06.019; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Liu YB, 2006, J SURG RES, V136, P336, DOI 10.1016/j.jss.2006.07.037; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Nighoghossian N, 2007, STROKE, V38, P303, DOI 10.1161/01.STR.0000254548.30258.f2; Ortiz-Gonzalez XR, 2004, CURR NEUROVASC RES, V1, P207, DOI 10.2174/1567202043362342; Pforte C, 2005, NEUROSCIENCE, V136, P1133, DOI 10.1016/j.neuroscience.2005.08.043; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sauerzweig S, 2009, EXP CELL RES, V315, P50, DOI 10.1016/j.yexcr.2008.10.007; Schulman A, 2005, STEM CELL REV, V1, P291, DOI 10.1385/SCR:1:4:291; Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tabakman R, 2005, ANN NY ACAD SCI, V1053, P84, DOI 10.1196/annals.1344.008; Zaman V, 2003, EXP NEUROL, V183, P11, DOI 10.1016/S0014-4886(03)00167-5; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061	44	41	46	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2009	215	2					317	327		10.1016/j.expneurol.2008.10.023			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	400TG	WOS:000262890900014	19063882				2022-02-06	
J	Silverberg, ND; Millis, SR				Silverberg, Noah D.; Millis, Scott R.			Impairment versus deficiency in neuropsychological assessment: Implications for ecological validity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychological tests; Psychometrics; Activities of daily living; Work; Brain injury; Chronic; Cognition disorders	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; CLINICAL-NEUROPSYCHOLOGY; RATING-SCALE; TEST-SCORES; ABILITY; SENSITIVITY; POPULATION; INSTRUMENTS; DISABILITY	Neuropsychological test interpretation has relied on pre- and postmorbid comparisons, as exemplified by the use of demographically adjusted normative data. We argue that, when the assessment goal is to predict real-world functioning, this interpretive method Should be Supplemented by "absolute" scores. Such scores are derived from comparisons with the general healthy adult population (i.e., demographically unadjusted normative data) and reflect examinees' current ability, that is, the interaction between premorbid and injury/disease-related factors. In support of this view, we found that Substantial discrepancies between demographically adjusted and absolute scores were common in a traumatic brain injury sample, especially in participants with certain demographic profiles. Absolute scores predicted selected measures of functional Outcome better than demographically adjusted scores and also classified participants' functional status more accurately, to the extent that these scores diverged. In conclusion, the ecological validity of neuropsychological tests may be improved by the consideration of absolute scores. (JINS, 2009, 15, 94-102.)	[Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA		Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca			US Department of Education-National Institute of Disability Research and RehabilitationUS Department of Education; Traumatic Brain Injury Model Systems Project [H133A020515-04]	The authors thank Robert Kotasek and Dr. Robin Hanks for their assistance in preparing the dataset. This Study was supported by a grant from the US Department of Education-National Institute of Disability Research and Rehabilitation - The Traumatic Brain Injury Model Systems Project (H133A020515-04). There were no other funding sources and no perceived conflicts of interest.	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Crowe SF, 2004, ARCH CLIN NEUROPSYCH, V19, P673, DOI 10.1016/j.acn.2003.09.002; DELIS DC, 2000, CALIFORNIA VERBAL LE; DIJKERS M, 2007, BRAIN INJURY MED PRI; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Guilmette TJ, 2008, CLIN NEUROPSYCHOL, V22, P122, DOI 10.1080/13854040601064559; Hallam B. J., 2007, AM J ALZHEIMERS DIS, V22, P456; Hammersley M, 2004, STUD EDUC ETHNOG, V9, P25; Hardin JW, 2007, GEN LINEAR MODEL EXT; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 2004, COMPREHENSIVE NORMS; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Ivnik RJ, 2005, CLIN NEUROPSYCHOL, V19, P159, DOI 10.1080/13854040590945247; Lange RT, 2006, CLIN NEUROPSYCHOL, V20, P382, DOI 10.1080/13854040590967586; Lange RT, 2005, CLIN NEUROPSYCHOL, V19, P73, DOI 10.1080/13854040490888549; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEWIS R, 1979, MANNAL REPEATABLE CO; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Manly JJ, 2007, ARCH CLIN NEUROPSYCH, V22, P319, DOI 10.1016/j.acn.2007.01.006; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; Reitan RM, 2005, APPL NEUROPSYCHOL, V12, P181, DOI 10.1207/s15324826an1204_1; Reitan RM, 1985, HALSTEADREITAN NEURO; SBORDONE RJ, 1999, FORENSIC NEUROPSYCHO; Schretlen DJ, 2005, J INT NEUROPSYCH SOC, V11, P784, DOI 10.1017/S1355617705050939; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Steinberg B, 2005, CLIN NEUROPSYCHOL, V19, P277, DOI 10.1080/13854040590948992; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; TESTA A, 2007, 35 ANN M INT NEUR SO; Tuokko H, 2003, AGING MENT HEALTH, V7, P259, DOI 10.1080/1360786031000120750; Tuokko H, 1996, J CLIN EXP NEUROPSYC, V18, P479, DOI 10.1080/01688639608405871; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WHITENECK GG, 1997, ASSESSING MED REHABI; Williams JM, 1997, ARCH CLIN NEUROPSYCH, V12, P745, DOI 10.1016/S0887-6177(97)00048-6; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yantz CL, 2006, ARCH CLIN NEUROPSYCH, V21, P809, DOI 10.1016/j.acn.2006.09.001	47	41	41	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					94	102		10.1017/S1355617708090139			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300010	19128532				2022-02-06	
J	Finnerup, NB				Finnerup, Nanna B.			A review of central neuropathic pain states	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						central pain; multiple sclerosis; Parkinson's disease; poststroke pain; spinal cord injury; traumatic brain injury	SPINAL-CORD-INJURY; DOUBLE-BLIND; LAMOTRIGINE; VALIDATION; MODULATION; MICROGLIA; LEVODOPA; TRIAL	Purpose of review Central neuropathic pain is an important and disabling but often neglected problem following central nervous system lesions. The present review highlights recent advances in the understanding of the underlying mechanisms and in the diagnosis and treatment of central pain. Recent findings Within the past year, the field of central pain has moved toward a more integrative understanding of central pain. The involvement of nonneuronal cells and interaction between multiple areas of the central nervous system has been recognized as important in the underlying mechanisms. The interest for conditions other than spinal cord injury, multiple sclerosis, and stroke has increased, and continued discussions on clear clinical diagnostic criteria are needed. The treatment of central pain is still a great challenge, but recent evidence points to tricyclic antidepressants, gabapentin and pregabalin, and selective serotonin-noradrenaline reuptake inhibitors as first-line drugs in central pain. An increased understanding of the psychosocial aspects of central pain also has implications for the treatment. Summary Increased insight into the mechanisms of central pain will hopefully lead to increased efforts to study mechanism-based treatment of central pain.	[Finnerup, Nanna B.] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus C, Denmark; [Finnerup, Nanna B.] Viborg Hosp, Spinal Cord Unit, Viborg, Denmark		Finnerup, NB (corresponding author), Aarhus Univ Hosp, Danish Pain Res Ctr, Norrebrogade 44,Bldg 1A, DK-8000 Aarhus C, Denmark.	finnerup@ki.au.dk	Finnerup, Nanna Brix/ABA-8219-2020	Finnerup, Nanna Brix/0000-0001-5541-0240	Ludvig and Sara Elsass Foundation	The present work was supported by a grant from Ludvig and Sara Elsass Foundation.	Bennett MI, 2007, PAIN, V127, P199, DOI 10.1016/j.pain.2006.10.034; BOIVIE J, 2006, TXB PAIN, P1057; Boord P, 2008, SPINAL CORD, V46, P118, DOI 10.1038/sj.sc.3102077; Breuer B, 2007, CLIN THER, V29, P2022, DOI 10.1016/j.clinthera.2007.09.023; Bryce TN, 2007, J SPINAL CORD MED, V30, P421, DOI 10.1080/10790268.2007.11753405; Budh CN, 2007, CLIN REHABIL, V21, P89, DOI 10.1177/0269215506070313; Canavero S, 2007, ACTA NEUROCHIR SUPPL, V97, P27; Defrin R, 2007, ARCH PHYS MED REHAB, V88, P1574, DOI 10.1016/j.apmr.2007.07.025; Djaldetti R, 2007, CLIN NEUROPHARMACOL, V30, P201, DOI 10.1097/WNF.0B013E3180340319; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Ertas M, 1998, PAIN, V75, P257, DOI 10.1016/S0304-3959(98)00003-7; Finnerup NB, 2007, EXP NEUROL, V207, P139, DOI 10.1016/j.expneurol.2007.06.001; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332; Gerdelat-Mas A, 2007, J NEUROL NEUROSUR PS, V78, P1140, DOI 10.1136/jnnp.2007.120212; Kim JH, 2007, J NEUROSCI, V27, P4995, DOI 10.1523/JNEUROSCI.0716-07.2007; Knerlich-Lukoschus F, 2008, J NEUROTRAUM, V25, P427, DOI 10.1089/neu.2007.0431; Merskey H, 1994, CLASSIFICATION CHRON; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; PERTOVAARA A, 2007, PAIN; Rintala DH, 2007, ARCH PHYS MED REHAB, V88, P1547, DOI 10.1016/j.apmr.2007.07.038; Rog DJ, 2007, CLIN J PAIN, V23, P473, DOI 10.1097/AJP.0b013e31805d0c5d; Schestatsky P, 2007, NEUROLOGY, V69, P2162, DOI 10.1212/01.wnl.0000295669.12443.d3; Silver M, 2007, J PAIN SYMPTOM MANAG, V34, P446, DOI 10.1016/j.jpainsymman.2006.12.015; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Veldhuijzen Dieuwke S, 2007, Curr Pain Headache Rep, V11, P183, DOI 10.1007/s11916-007-0189-1; Vinik AI, 2007, PAIN, V128, P169, DOI 10.1016/j.pain.2006.09.040; Vranken JH, 2008, PAIN, V136, P150, DOI 10.1016/j.pain.2007.06.033; Widerstrom-Noga EG, 2007, ARCH PHYS MED REHAB, V88, P1628, DOI 10.1016/j.apmr.2007.09.013; Yezierski RP, 2006, HAND CLINIC, V81, P293, DOI 10.1016/S0072-9752(06)80025-4; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	33	41	47	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2008	21	5					586	589		10.1097/ACO.0b013e32830a4c11			4	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	398ER	WOS:000262715900010	18784483				2022-02-06	
J	Deshpande, LS; Sun, DA; Sombati, S; Baranova, A; Wilson, MS; Attkisson, E; Hamm, RJ; DeLorenzo, RJ				Deshpande, Laxmikant S.; Sun, David A.; Sombati, Sompong; Baranova, Anya; Wilson, Margaret S.; Attkisson, Elisa; Hamm, Robert J.; DeLorenzo, Robert J.			Alterations in neuronal calcium levels are associated with cognitive deficits after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						calcium dynamics; Fura-2; acute isolation of hippocampal neurons; morris water maze; neuronal death; Sprague-Dawley rats	GENE-EXPRESSION; CELL-DEATH; HOMEOSTATIC MECHANISMS; HIPPOCAMPAL-NEURONS; MEMORY IMPAIRMENT; HEAD-INJURY; AGED RATS; AREA CA1; CONCUSSION; NIMODIPINE	Traumatic brain injury (TBI) survivors often suffer from a post-traumatic syndrome with deficits in learning and memory. Calcium (Ca2+) has been implicated in the pathophysiology of TBI-induced neuronal death. However, the role of long-term changes in neuronal Call function in surviving neurons and the potential impact on TBI-induced cognitive impairments are less understood. Here we evaluated neuronal death and basal free intracellular Ca2+ ([Ca2+](i)) in acutely isolated rat CA3 hippocampal neurons using the Ca2+ indicator, Fura-2, at seven and thirty days after moderate central fluid percussion injury. In moderate TBI, cognitive deficits as evaluated by the Morris Water Maze (MWM), occur after injury but resolve after several weeks. Using MWM paradigm we compared alterations in [Ca2+](i) and cognitive deficits. Moderate TBI did not cause significant hippocampal neuronal death. However, basal [Ca2+](i) was significantly elevated when measured seven days post-TBI. At the same time, these animals exhibited significant cognitive impairment (F-2,F-25 = 3.43, p < 0.05). When measured 30 days post-TBI, both basal [Ca2+](i) and cognitive functions had returned to normal. Pretreatment with MK-801 blocked this elevation in [Ca2+](i) and also prevented MWM deficits. These studies provide evidence for a link between elevated [Ca2+](i) and altered cognition. Since no significant neuronal death was observed, the alterations in Ca2+ homeostasis in the traumatized, but surviving neurons may play a role in the pathophysiology of cognitive deficits that manifest in the acute setting after TBI and represent a novel target for therapeutic intervention following TBI. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Deshpande, Laxmikant S.; Sombati, Sompong; Attkisson, Elisa; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Sch Med, Dept Neurol, Richmond, VA 23298 USA; [DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Baranova, Anya; Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA; [Sun, David A.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Wilson, Margaret S.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA		DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Neurol, POB 980599, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu	Deshpande, Laxmikant S./B-7679-2013	Deshpande, Laxmikant S./0000-0003-1491-1561	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052529-04, R01 NS052529, U01 NS 058213, R01 NS051505-04, R01 NS051505, R01 NS 052529, U01 NS058213, R01 NS 051505, U01 NS058213-04, U01 NS058213-03, R01 NS051505-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS058213, R01NS051505, R01NS052529] Funding Source: NIH RePORTER		CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Delorenzo RJ, 1999, NEUROSCIENTIST, V5, P86, DOI 10.1177/107385849900500213; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hong Jun, 2002, Chin J Traumatol, V5, P36; LEVERE TE, 1992, NEUROBIOL AGING, V13, P63, DOI 10.1016/0197-4580(92)90010-U; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101; Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tonkikh A, 2006, EXP NEUROL, V197, P291, DOI 10.1016/j.expneurol.2005.06.014; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Veng LM, 2003, MOL BRAIN RES, V110, P193, DOI 10.1016/S0169-328X(02)00643-5; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	36	41	41	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 15	2008	441	1					115	119		10.1016/j.neulet.2008.05.113			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	333TD	WOS:000258174400024	18583041	Green Accepted			2022-02-06	
J	Glang, A; Ylvisaker, M; Stein, M; Ehlhardt, L; Todis, B; Tyler, J				Glang, Ann; Ylvisaker, Mark; Stein, Marcy; Ehlhardt, Laurie; Todis, Bonnie; Tyler, Janet			Validated instructional practices: Application to students with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive strategy intervention; Direct Instruction; education; instructional methodologies; interventions	COGNITIVE REHABILITATION; YOUNG-CHILDREN; SHORT-TERM; LEARNING-DISABILITIES; BEHAVIORAL SUPPORTS; EXECUTIVE FUNCTIONS; HEAD-INJURY; MEMORY; METAANALYSIS; TBI	Objective: There is a lack of empirical evidence of effectiveness for instructional interventions for children with traumatic brain injury (TBI). This article addresses this issue by providing an in-depth examination of instructional methodologies validated with other populations of students (with and without disability) and their potential for teaching children with TBI. Design: Literature review. Conclusions: Two instructional approaches-Direct Instruction and cognitive strategy intervention-have significant evidence supporting their use with many populations of children, with and without disabilities, and address many of the common needs and learning characteristics of students with TBI, thus showing particular promise for these students. Given the efficacy of these 2 approaches with students with similar learning and behavioral characteristics, the authors recommend establishing and funding a systematic research agenda to test their effectiveness with students with TBI.	[Glang, Ann; Ehlhardt, Laurie; Todis, Bonnie] Western Oregon Univ, Teaching Res Inst, Eugene, OR 97401 USA; [Glang, Ann] Oregon Ctr Appl Sci, Eugene, OR USA; [Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [Stein, Marcy] Univ Washington, Tacoma, WA USA; [Tyler, Janet] Univ Kansas, Med Ctr, Kansas Instruct Support Network, Kansas City, KS 66103 USA		Glang, A (corresponding author), Western Oregon Univ, Teaching Res Inst, 99 W 10th Ave,Suite370, Eugene, OR 97401 USA.	glanga@wou.edu					Adams G. L., 1996, RES DIRECT INSTRUCTI; Arroyos-Jurado E., 2006, EXCEPTIONALITY, V14, P125, DOI [10.1207/s15327035ex1403_2, DOI 10.1207/S15327035EX1403_2]; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baker S., 2002, LEARNING DISABILITIE, V17, P65, DOI DOI 10.1111/1540-5826.00032; BECKER WC, 1982, AM EDUC RES J, V19, P75, DOI 10.3102/00028312019001075; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; BULGREN C, 2006, TEACHING ADOLESCENTS, P79; Burgess PW, 1996, MEMORY, V4, P359, DOI 10.1080/096582196388906; Camine D., 1990, DIRECT INSTRUCTION R; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CARNINE D, 1980, J EDUC RES, V74, P106, DOI 10.1080/00220671.1980.10885292; Carnine D., 1990, DIRECT INSTRUCTION R; Carnine D. W., 2006, DESIGNING EFFECTIVE; CARNINE DW, 1982, J READING BEHAV, V14, P335, DOI 10.1080/10862968209547459; CARNINE DW, 1976, J APPL BEHAV ANAL, V9, P199, DOI 10.1901/jaba.1976.9-199; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COLVIN G, 1988, EDUC TREAT CHILD, V11, P341; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; ENGELMANN S, 1981, CORRECTIVE MATH; ENGLERT CS, 1984, REM SPEC EDUC, V5, P38, DOI DOI 10.1177/074193258400500208; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Feeney T, 2006, BRAIN INJURY, V20, P629, DOI 10.1080/02699050600744194; Feeney TJ, 2008, J POSIT BEHAV INTERV, V10, P115, DOI 10.1177/1098300707312540; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Gersten R. M., 1982, EDUC EVAL POLICY AN, V4, P67; GERSTEN RM, 1982, ANAL INTERVEN DEVEL, V2, P305, DOI 10.1016/0270-4684(82)90026-X; GERSTEN RM, 1984, EDUC EVAL POLICY AN, V6, P109, DOI DOI 10.3102/01623737006002109; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GRAFMAN J, 2000, PRINCIPLES FRONTAL L, P292; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Graham S., 2003, HDB LEARNING DISABIL, P323; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harris KR., 1996, MAKING WRITING PROCE; HORNER RH, 1987, RES DEV DISABIL, V8, P229, DOI 10.1016/0891-4222(87)90006-0; Horner RH., 1986, ED LEARNERS SEVERE H, P289; HORNER RH, 1986, J ASSOC PERS SEVERE, V4, P300; Kameenui E. J., 1990, DESIGNING INSTRUCTIO; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Koegel, 1988, GENERALIZATION MAINT, P99; KRYZANOWSKI J, 1980, J READING BEHAV, V12, P225, DOI 10.1080/10862968009547373; KULIK CLC, 1990, REV EDUC RES, V60, P265, DOI 10.2307/1170612; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; MADIGAN KA, 1997, EFFECTIVE ASSESSMENT; MARCHANDMARTELL.NE, 2006, J DIRECT INSTRUCTION, V6, P49; Martella R.C., 2004, INTRO DIRECT INSTRUC, P28, DOI DOI 10.1080/10573560490264125; Mozzoni MP, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199602000-00003; National Reading Panel, 2000, TEACH CHILDR READ EV; Nesbit JC, 2006, REV EDUC RES, V76, P413, DOI 10.3102/00346543076003413; Parsons J. L., 2004, J DIRECT INSTRUCTION, V4, P95; Perkins DN, 1997, AM PSYCHOL, V52, P1125; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; ROSENSHINE B, 1986, HDB RES TEACHING, P376; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schwartz M. F., 1993, J HEAD TRAUMA REHAB, V8, P59, DOI [10.1097/00001199-199303000-00007, DOI 10.1097/00001199-199303000-00007]; Shippen ME, 2005, REM SPEC EDUC, V26, P175, DOI 10.1177/07419325050260030501; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; STEBBINS LB, 1977, ED EXPT PLANNED VA A, V4; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Swanson HL, 2001, FOCUS EXCEPT CHILD, V34, P1; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.3102/00346543068003277; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Thiemann KS, 2004, J SPEECH LANG HEAR R, V47, P126, DOI 10.1044/1092-4388(2004/012); Todis B., 1997, STUDENTS ACQUIRED BR, P33; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; Walker B., 2006, J DIRECT INSTRUCTION, V6, P35; WALKER HM, 1983, ANAL INTERVEN DEVEL, V3, P105, DOI 10.1016/0270-4684(83)90029-0; WATKINS CL, 1997, PROJECT FOLLOW CASE; WEEKS M, 1981, J APPL BEHAV ANAL, V14, P449, DOI 10.1901/jaba.1981.14-449; White, 1982, EDUC TREAT CHILD, V5, P93; White, 1988, EDUC TREAT CHILD, V11, P364, DOI [DOI 10.1177/1053451298033004O1, 10.1177/105345129803300401]; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO., 2006, EXCEPTIONALITY, V14, P141, DOI DOI 10.1207/S15327035EX1403_; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181; [No title captured]	90	41	41	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					243	251		10.1097/01.HTR.0000327256.46504.9f			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900006	18650768				2022-02-06	
J	Casey, PA; Mckenna, MC; Fiskum, G; Saraswati, M; Robertson, CL				Casey, Paula A.; Mckenna, Mary C.; Fiskum, Gary; Saraswati, Manda; Robertson, Courtney L.			Early and sustained alterations in cerebral metabolism after traumatic brain injury in immature rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetyl aspartate; development; lactate; mitochondria; NMR spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; CLOSED-HEAD INJURY; L-ASPARTIC ACID; ENERGY-METABOLISM; NERVOUS-SYSTEM; IN-VIVO; MITOCHONDRIAL DYSFUNCTION; H-1-NMR SPECTROSCOPY; OUTCOME PREDICTION	Although studies have shown alterations in cerebral metabolism after traumatic brain injury (TBI), clinical data in the developing brain is limited. We hypothesized that post-traumatic metabolic changes occur early (< 24 h) and persist for up to 1 week. Immature rats underwent TBI to the left parietal cortex. Brains were removed at 4 h, 24 h, and 7 days after injury, and separated into ipsilateral (injured) and contralateral (control) hemispheres. Proton nuclear magnetic resonance (NMR) spectra were obtained, and spectra were analyzed for N-acetyl-aspartate (NAA), lactate (Lac), creatine (Cr), choline, and alanine, with metabolite ratios determined (NAA/Cr, Lac/Cr). There were no metabolic differences at any time in sham controls between cerebral hemispheres. At 4 and 24 h, there was an increase in Lac/Cr, reflecting increased glycolysis and/or decreased oxidative metabolism. At 24 h and 7 days, there was a decrease in NAA/Cr, indicating loss of neuronal integrity. The NAA/Lac ratio was decreased (similar to 15-20%) at all times (4 h, 24 h, 7 days) in the injured hemisphere of TBI rats. In conclusion, metabolic derangements begin early (< 24 h) after TBI in the immature rat and are sustained for up to 7 days. Evaluation of early metabolic alterations after TBI could identify novel targets for neuroprotection in the developing brain.	[Casey, Paula A.; Mckenna, Mary C.; Saraswati, Manda; Robertson, Courtney L.] Univ Maryland, Dept Pediat, Sch Med, Baltimore, MD 21201 USA; [Fiskum, Gary; Robertson, Courtney L.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA		Robertson, CL (corresponding author), Univ Maryland, Dept Pediat, Sch Med, 22 S Greene St,N5E13, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 16596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 42805] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1399; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates T E, 1989, NMR Biomed, V2, P225, DOI 10.1002/nbm.1940020509; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1990, NEUROCHEM RES, V15, P1009, DOI 10.1007/BF00965747; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; DAVIES SEC, 1995, J NEUROCHEM, V64, P742; Dienel GA, 2003, NEUROCHEM INT, V43, P339, DOI 10.1016/S0197-0186(03)00021-4; Federico F, 1997, J NEUROL NEUROSUR PS, V62, P239, DOI 10.1136/jnnp.62.3.239; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Godbolt AK, 2006, NEUROLOGY, V66, P718, DOI 10.1212/01.wnl.0000201237.05869.df; Harris NG, 1997, J NEUROCHEM, V68, P305; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hazany S, 2007, NEURORADIOLOGY, V49, P121, DOI 10.1007/s00234-006-0167-z; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; LOPEZVILLEGAS D, 1995, MAGNET RESON MED, V34, P32, DOI 10.1002/mrm.1910340107; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Malik GK, 2002, EUR J RADIOL, V43, P6, DOI 10.1016/S0720-048X(01)00435-1; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McKenna M. C., 2006, BASIC NEUROCHEMISTRY, P531; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; MEIJER AJ, 1974, BIOCHIM BIOPHYS ACTA, V346, P213, DOI 10.1016/0304-4173(74)90001-9; O'Brien J, 2007, NEUROCHEM RES, V32, P597, DOI 10.1007/s11064-006-9132-9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; Richards EM, 2007, STROKE, V38, P1578, DOI 10.1161/STROKEAHA.106.473967; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Satrustegui J, 2007, J NEUROSCI RES, V85, P3359, DOI 10.1002/jnr.21299; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Serres S, 2004, J BIOL CHEM, V279, P47881, DOI 10.1074/jbc.M409429200; Shu SK, 1997, PEDIATR NEUROL, V17, P309, DOI 10.1016/S0887-8994(97)00140-9; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; TALLAN HH, 1956, J BIOL CHEM, V219, P257; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	73	41	41	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					603	614		10.1089/neu.2007.0481			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900004	18454682	Green Published, Green Submitted			2022-02-06	
J	Taussky, P; Widmer, HR; Takala, J; Fandino, J				Taussky, Philipp; Widmer, Hqns Rudolf; Takala, Jukka; Fandino, Javier			Outcome after acute traumatic subdural and epidural haematoma in Switzerland: a single-centre experience	SWISS MEDICAL WEEKLY			English	Article						traumatic brain injury; epidural haematoma; subdural haematoma	HEAD-INJURY; COMATOSE PATIENTS; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; EXTRADURAL HEMATOMA; BRAIN-INJURY; MORTALITY; REHABILITATION; CRANIOTOMY; PROGNOSIS	Background: Acute epidural and subdural haematomas remain among the most common causes of mortality and disability resulting from traumatic brain injury. In the last three decades improvements in rescue, neuromonitoring and intensive care have led to better outcomes. The purpose of this study was to evaluate the impact of these strategies on outcome in patients treated in a single institution in Switzerland. Methods: A total of 76 consecutive patients who underwent emergency craniotomy for acute traumatic epidural and subdural haematoma at University Hospital Bern between January 2000 and December 2003 were included in this study Results: Thirty-seven patients presented with an epidural haematoma and 46 with a subdural haematoma. In seven patients both haematomas could be documented. The median age was 54 years (IQR 28). The median initial GCS score was 7 (IQR 6). The median time from primary injury to surgery was 3 hours (IQR 2.5 hours). The median stay in the ICU was 3 days (IQR: 3 days). The outcome was favourable (GOS 4 and 5) in 43 patients (57%). Thirteen patients (17%) remained severely or moderately disabled (GOS 3). Finally, a total of 21 patients (28%) died or remained in a persistent vegetative state (GOS 1 and 2). Mortality was 41% for acute subdural haematoma (19/46) and 3% (1/37) for patients with epidural haematoma. Only age, GCS at admission and pupil abnormalities seemed to be associated with outcome. Time to surgery was not. Conclusion: In patients admitted with acute traumatic epidural and subdural haematomas that are treated within a median of 3 hours after primary injury, factors such as age, initial GCS and pupil abnormalities still appear to be the most important factors correlating with outcome.	[Taussky, Philipp; Widmer, Hqns Rudolf; Fandino, Javier] Univ Hosp Bern, Dept Neurosurg, CH-3010 Bern, Switzerland; [Takala, Jukka; Fandino, Javier] Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland		Fandino, J (corresponding author), Kantonsspital Aarau, Dept Neurosurg, Tellstr, CH-5001 Aarau, Switzerland.	javier.fandino@ksa.ch	Widmer, Hans Rudolf/O-5172-2017	Widmer, Hans Rudolf/0000-0003-3378-8765			Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; EDDY VA, 1995, AM SURGEON, V61, P24; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; MARSHALL LF, 2004, YOUMANS NEUROLOGICAL, P5019; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Prabhu SS, 2004, YOUMANS NEUROLOGICAL, P5145; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uzan M, 1998, J Neurosurg Sci, V42, P89; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	31	41	42	0	2	E M H SWISS MEDICAL PUBLISHERS LTD	MUTTENZ	FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	MAY 3	2008	138	19-20					281	285					5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305TO	WOS:000256200900002	18491241				2022-02-06	
J	Brewer, BR; Klatzky, R; Matsuoka, Y				Brewer, Bambi Roberts; Klatzky, Roberta; Matsuoka, Yoky			Visual feedback distortion in a robotic environment for hand rehabilitation	BRAIN RESEARCH BULLETIN			English	Article						visual distortion; visual feedback; hand rehabilitation; robotic rehabilitation	RESEARCH ARM TEST; MANUAL DISCRIMINATION; FORCE CONTROL; STROKE; WEIGHT; RELIABILITY; INTENSITY; GRASP; TOUCH; SPAN	Robotic therapy offers a means of enhancing rehabilitation for individuals with chronic stroke or traumatic brain injury. The present research targets members of this population who demonstrate learned nonuse, a tendency to use affected limbs below the level of the individual's true capability. These individuals may not strive for difficult goals in therapy, which ultimately hampers their progress and the outcome of rehabilitation. Our research uses a paradigm called visual feedback distortion in which the visual feedback corresponding to force or distance is gradually changed by an imperceptible amount to encourage improved performance. Our first set of experiments was designed to assess the limits of imperceptible distortion for visual feedback concerning the force exerted or the distance moved by the index finger. A second set of experiments used these limits to gradually distort visual feedback in order to manipulate a subject's force or distance response. Based on this work, we designed a paradigm applying visual feedback distortion to the rehabilitation of individuals with chronic stroke and traumatic brain injury. Initial tests are reported for two subjects who participated in a six-week rehabilitation protocol. Each patient followed visual feedback distortion to levels of performance above that predicted by her performance during an initial assessment. Both patients showed functional improvements after participating in the study. Visual feedback distortion may provide a way to help a patient move beyond his or her self-assessed "best" performance, improving the outcome of robotic rehabilitation. (c) 2008 Elsevier Inc. All rights reserved.	[Brewer, Bambi Roberts; Klatzky, Roberta; Matsuoka, Yoky] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA		Brewer, BR (corresponding author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.	bbrewer@pitt.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020502] Funding Source: Medline		Atkinson JW, 1964, INTRO MOTIVATION; BANDURA A, 1986, ORGAN BEHAV HUM DEC, V38, P92, DOI 10.1016/0749-5978(86)90028-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERLINER JE, 1973, J ACOUST SOC AM, V53, P1270, DOI 10.1121/1.1913465; Boian R, 2002, STUD HEALTH TECHNOL, V85, P64; Brewer BR, 2006, P IEEE, V94, P1739, DOI 10.1109/JPROC.2006.880715; Brewer BR, 2005, IEEE T NEUR SYS REH, V13, P1, DOI 10.1109/TNSRE.2005.843443; BREWER BR, 2006, 5 INT WORKSH VIRT RE; BRODIE EE, 1984, PERCEPT PSYCHOPHYS, V36, P477, DOI 10.3758/BF03207502; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; COLE KJ, 1991, J MOTOR BEHAV, V23, P251, DOI 10.1080/00222895.1991.9942036; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P29, DOI 10.3758/BF03208071; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fitzgibbons PJ, 2001, J ACOUST SOC AM, V109, P2955, DOI 10.1121/1.1371760; Gescheider G.A, 1976, PSYCHOPHYSICS METHOD; Hermsdorfer J, 2003, CLIN NEUROPHYSIOL, V114, P915, DOI 10.1016/S1388-2457(03)00042-7; JARIC S, 1994, EXP BRAIN RES, V100, P353; JONES LA, 1989, PERCEPTION, V18, P681, DOI 10.1068/p180681; Kim JS, 1996, STROKE, V27, P677, DOI 10.1161/01.STR.27.4.677; Kopp B, 1997, ARCH PHYS MED REHAB, V78, P615, DOI 10.1016/S0003-9993(97)90427-5; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Krebs HI, 2000, J REHABIL RES DEV, V37, P639; PANG XD, 1991, PERCEPT PSYCHOPHYS, V49, P531, DOI 10.3758/BF03212187; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; RAJ DV, 1985, BRAIN, V108, P95, DOI 10.1093/brain/108.1.95; ROCK I, 1964, SCIENCE, V143, P594, DOI 10.1126/science.143.3606.594; ROSS HE, 1987, Q J EXP PSYCHOL-A, V39, P77, DOI 10.1080/02724988743000042; SHIMOKATA H, 1995, GERONTOLOGY, V41, P267; Shinomori K, 2001, J OPT SOC AM A, V18, P310, DOI 10.1364/JOSAA.18.000310; SRINIVASAN MA, 1996, ASME DYN SYST CONTR, P555; STEVENS JC, 1995, SOMATOSENS MOT RES, V12, P29, DOI 10.3109/08990229509063140; TAN HZ, 1989, J ACOUST SOC AM, V86, P981, DOI 10.1121/1.398733; TAN HZ, 1995, PERCEPT PSYCHOPHYS, V57, P495, DOI 10.3758/BF03213075; TAUB E, 1994, PL S BEHAV, P185; TAUB E, ARM MOTOR ABILITY TE; van der Lee JH, 2001, J REHABIL MED, V33, P110; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; VANDEWEGHE M, 2006, IEEE S HAPT INT VIRT; WELCH RB, 1980, PSYCHOL BULL, V88, P638, DOI 10.1037/0033-2909.88.3.638	39	41	41	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	APR 15	2008	75	6					804	813		10.1016/j.brainresbull.2008.01.006			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	297MT	WOS:000255621500012	18394527				2022-02-06	
J	Fournier, NM; Calverley, KL; Wagner, JP; Poock, JL; Crossley, M				Fournier, N. M.; Calverley, K. L.; Wagner, J. P.; Poock, J. L.; Crossley, M.			Impaired social cognition 30 years after hemispherectomy for intractable epilepsy: The importance of the right hemisphere in complex social functioning	EPILEPSY & BEHAVIOR			English	Article						social cognition; hemispherectomy; the Awareness of Social Inferences Test; theory of mind; sarcasm; emotional expressions	TEMPORAL-LOBE EPILEPSY; INTERICTAL GLUCOSE HYPOMETABOLISM; TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSIONS; EMOTION RECOGNITION; ECOLOGICAL VALIDITY; NEGATIVE EMOTIONS; ASPERGER-SYNDROME; PERCEPTION; MIND	Clinical research with individuals following hemispherectomy typically quantifies the success of surgical outcomes by focusing primarily on the achievement of seizure control and the preservation of general brain functions, such as movement, sensation, language, and memory. In addition to these outcomes, careful study of individuals following hemispherectomy also has the potential to contribute to our understanding of functional brain asymmetries involving other complex cognitive behaviors. In this study, we report preliminary evidence for the lateralization of social perception. We administered a series of neuropsychological tests that were developed to assess emotional recognition and the formation of social inferences and advanced social cognitive judgments, as they occur in everyday situations, to two adult participants who underwent complete anatomic left- or right-sided hemispherectomy. Our results show that despite a 30-year postsurgical period of recovery and consistent and high levels of family support and social engagement, distinct cognitive profiles are still evident between our right- and left-sided participants. In particular, participant S.M., who underwent an anatomic right hemispherectomy, showed the most severe impairments in identifying negative emotional expressions and conversational exchanges involving lies and sarcasm and in "mentalizing" the intent of others. In contrast, participant J.H., who underwent an anatomic left hemispherectomy was highly skilled interpersonally, despite evident language-related limitations, and showed only mild difficulties when asked to identify emotional expressions involving disgust and anger. These results suggest that the right hemisphere plays a particularly important role in social cognitive functioning and reasoning. Further examination of the extent of social perceptual difficulties prior to and following surgical intervention for epilepsy may guide the development of effective social skills training programs that can improve quality of life beyond seizure control. (C) 2007 Elsevier Inc. All rights reserved.	[Fournier, N. M.; Calverley, K. L.; Wagner, J. P.; Poock, J. L.; Crossley, M.] Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 5A5, Canada		Fournier, NM (corresponding author), Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 5A5, Canada.	nm.fournier@usask.ca	Fournier, Neil/AAI-8928-2020				Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; Arnold S, 1996, NEUROLOGY, V46, P1422, DOI 10.1212/WNL.46.5.1422; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Barr DJ, 2003, PSYCHON B REV, V10, P462, DOI 10.3758/BF03196507; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOROD JC, 1988, NEUROPSYCHOLOGIA, V26, P759, DOI 10.1016/0028-3932(88)90013-9; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Burneo JG, 2005, CAN MED ASSOC J, V172, P1175, DOI 10.1503/cmaj.045118; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Devinsky O, 2004, EPILEPSIA, V45, P34, DOI 10.1111/j.0013-9580.2004.452003.x; Devlin AM, 2003, BRAIN, V126, P556, DOI 10.1093/brain/awg052; DODRILL CB, 1984, EPILEPSIA, V25, P168, DOI 10.1111/j.1528-1157.1984.tb04173.x; EKMAN P, 1993, AM PSYCHOL, V48, P384, DOI 10.1037/0003-066X.48.4.384; EKMAN P, 2007, DARWIN FACIAL EXPRES, P169; ENGLE J, 1993, SURG TREATMENT EPILE, P609; Farrant A, 2005, EPILEPSY BEHAV, V7, P506, DOI 10.1016/j.yebeh.2005.07.018; FISKE ST, 1993, ANNU REV PSYCHOL, V44, P155, DOI 10.1146/annurev.ps.44.020193.001103; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frith CD, 2006, BRAIN RES, V1079, P36, DOI 10.1016/j.brainres.2005.12.126; Ganis G, 2003, CEREB CORTEX, V13, P830, DOI 10.1093/cercor/13.8.830; GOODGLASS H, 1983, ASSESSMENT APHASIAS; GOTT P S, 1973, Cortex, V9, P266; Heaton R.K., 1981, WISCONSIN CARD SORTI; JENSEN I, 1976, ACTA NEUROL SCAND, V54, P22, DOI 10.1111/j.1600-0404.1976.tb07618.x; Jokeit H, 1997, BRAIN, V120, P2283, DOI 10.1093/brain/120.12.2283; Keenan JP, 2005, CORTEX, V41, P695, DOI 10.1016/S0010-9452(08)70286-7; KELLY FD, 1973, PSYCHOL REP, V32, P1223, DOI 10.2466/pr0.1973.32.3c.1223; Killgore WDS, 2001, NEUROREPORT, V12, P2543, DOI 10.1097/00001756-200108080-00050; Kirsch HE, 2006, EPILEPSY BEHAV, V8, P71, DOI 10.1016/j.yebeh.2005.09.002; KOLB B, 2003, FUNDAMENTALS HUMAN N; LANTING S, 2006, P 7 NAT C CAN RUR HL; Lassonde M, 2006, EPILEPSIA, V47, P9, DOI 10.1111/j.1528-1167.2006.00680.x; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; Liegeois F, 2004, BRAIN, V127, P1229, DOI 10.1093/brain/awh159; Malcolm SR, 2005, LATERALITY, V10, P103, DOI 10.1080/13576500442000274; Mandal MK, 2004, BEHAV NEUROL, V15, P23, DOI 10.1155/2004/786529; MANDAL MK, 1991, CORTEX, V27, P247, DOI 10.1016/S0010-9452(13)80129-3; Mariotti P, 1998, NEUROPSYCHOLOGIA, V36, P1303, DOI 10.1016/S0028-3932(98)00031-1; McClelland S, 2006, EPILEPSIA, V47, P1337, DOI 10.1111/j.1528-1167.2006.00557.x; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; Mitchell RLC, 2005, BRAIN, V128, P963, DOI 10.1093/brain/awh466; Mohamed FB, 2006, RADIOLOGY, V238, P679, DOI 10.1148/radiol.2382050237; Noesselt T, 2005, CURR BIOL, V15, P424, DOI 10.1016/j.cub.2004.12.075; Pell MD, 2006, PROG BRAIN RES, V156, P303, DOI 10.1016/S0079-6123(06)56017-0; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Pourtois G, 2005, CORTEX, V41, P49, DOI 10.1016/S0010-9452(08)70177-1; Pulsifer MB, 2004, EPILEPSIA, V45, P243, DOI 10.1111/j.0013-9580.2004.15303.x; Rasmussen T, 1977, Ann N Y Acad Sci, V299, P355, DOI 10.1111/j.1749-6632.1977.tb41921.x; Reitan RM, 1992, TRAIL MAKING TEST MA; Ross ED, 2007, PERCEPT MOTOR SKILL, V104, P155, DOI 10.2466/PMS-104.1.155-165; Schacher M, 2006, EPILEPSIA, V47, P2141, DOI 10.1111/j.1528-1167.2006.00857.x; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Spence SA, 2001, NEUROREPORT, V12, P2849, DOI 10.1097/00001756-200109170-00019; Stein MB, 2007, AM J PSYCHIAT, V164, P318, DOI 10.1176/appi.ajp.164.2.318; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; STONE VE, 2005, SOCIAL NEUROSCIENCE, P103; STRAUSS E, 1990, NEUROPSYCHOLOGIA, V28, P1221, DOI 10.1016/0028-3932(90)90057-U; Teuber H. L., 1974, NEUROSCIENCES 3 STUD, P71; Tharin S, 2007, NEUROSURGERY, V60, P185, DOI 10.1227/01.0000255386.95464.52; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Trevathan E, 2003, NEUROLOGY, V61, P432, DOI 10.1212/WNL.61.4.432; Trimble MR, 1991, PSYCHOSES EPILEPSY; Uddin LQ, 2005, NEUROIMAGE, V25, P926, DOI 10.1016/j.neuroimage.2004.12.018; Vargha-Khadem F, 1994, J Child Neurol, V9 Suppl 2, P67; VARGHAKHADEM F, 1992, ADV EXP MED BIOL, V325, P137; VERITY CM, 1982, NEUROLOGY, V32, P629, DOI 10.1212/WNL.32.6.629; Vining EPG, 1997, PEDIATRICS, V100, P163, DOI 10.1542/peds.100.2.163; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Warrington E. K., 1991, VISUAL OBJECT SPACE; Wechsler D., 2007, WECHSLER ADULT INTEL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wicker B, 2003, BRAIN RES REV, V43, P224, DOI 10.1016/j.brainresrev.2003.08.003	80	41	41	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	APR	2008	12	3					460	471		10.1016/j.yebeh.2007.12.009			12	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	282FU	WOS:000254553900015	18222112				2022-02-06	
J	Brichtova, E; Kozak, L				Brichtova, Eva; Kozak, Libor			Apolipoprotein E genotype and traumatic brain injury in children - association with neurological outcome	CHILDS NERVOUS SYSTEM			English	Article						brain injuries; child; Apolipoprotein E4; association; Glasgow Coma Scale; Glasgow Outcome Scale	WITHIN-PERSON COMPARISONS; MILD HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL FUNCTION; APOE-EPSILON-4 ALLELE; APOE INFLUENCES; E POLYMORPHISM; EPSILON-4; RECOVERY	Objective To determine whether the presence of Apolipoprotein E epsilon 4 genotype (ApoE epsilon 4) is associated with outcomes of traumatic brain injury in children. Materials and methods The ApoE genotype was examined in the group of 70 pediatric patients who suffered from traumatic brain injury. The group consists of 48 boys and 22 girls, and the most frequent was the E3 isoform of ApoE. Polymerase chain reaction/restriction fragment length polymorphism method was used for the ApoE genotype assessment. The severity of trauma was assessed by Glasgow Coma Scale and graded into three categories. The presence of focal neurology signs, comparing the admission and dimission status, and duration of hospital care were observed. The neurological outcome after 1 year was assessed by Glasgow Outcome Scale. Trauma severity was compared with the neurological outcome, according to different ApoE genotypes. For statistical processing, t test, nonparametric Wilcoxon test, Fisher, and chi(2) tests were used. Conclusion Our results suggest the association between the ApoE genotype and outcome of traumatic brain injury in children. Patients with ApoE epsilon 4 genotype were more likely to have severe clinical symptomatology and unfavorable neurological outcome after traumatic brain injury compared to significantly better outcome with other ApoE genotype.	[Brichtova, Eva] Brno Fac Hosp, Clin Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Kozak, Libor] Brno Fac Hosp, Mol Biol & Gene Therapy Ctr, Brno, Czech Republic		Brichtova, E (corresponding author), Brno Fac Hosp, Clin Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic.	brichtovae@seznam.cz					Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Collie A, 2004, NEUROLOGY, V63, P2460, DOI 10.1212/WNL.63.12.2460; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; Krupa Mariusz, 2003, Neurol Neurochir Pol, V37, P1223; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lucotte G, 1997, HUM BIOL, V69, P253; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JA, 1996, ANN NY ACAD SCI, V17, P271; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Seliger G, 1997, NEUROLOGY, V48, P28001; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138	28	41	42	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2008	24	3					349	356		10.1007/s00381-007-0459-6			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	258RV	WOS:000252888100011	17932679				2022-02-06	
J	Poomthavorn, P; Maixner, W; Zacharin, M				Poomthavorn, P.; Maixner, W.; Zacharin, M.			Pituitary function in paediatric survivors of severe traumatic brain injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							GROWTH-HORMONE DEFICIENCY; HEAD TRAUMA; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PRACTICAL SCALE; HYPOPITUITARISM; CHILDHOOD; CHILDREN	Background: Traumatic brain injury (TBI)-mediated hypopituitarism is an increasingly recognised problem. Paediatric survivors of TBI may be vulnerable to the possible effects of pituitary deficits as pituitary hormones control normal growth and development. Research concerning pituitary dysfunction following childhood TBI is limited. Aim To identify pituitary dysfunction in paediatric survivors of severe TBI. Methods: Of 1020 children who sustained a TBI and were admitted to the Royal Children's Hospital, Melbourne, Australia over 10 years, 117 were identified as survivors of severe TBI. 54 patients (31 males) were enrolled and administered questionnaires regarding quality of life and possible endocrine dysfunction. Where indicated, hormone testing was performed. Results: 29 of the 54 patients underwent hormonal investigations, while 21 who had satisfactory questionnaires did not (four patients had already been diagnosed with pituitary deficiencies). In those 29 patients, TBI occurred at ages ranging from 0.25 to 16.80 years (median 9.7 years). Time from TBI to study ranged from 0.9 to 8.5 years (median 4.5 years). Of the 54 patients, nine had pituitary dysfunction, of whom four had multiple pituitary hormone deficiencies. Conclusions: Our study that confirms that paediatric survivors of severe TBI may develop pituitary dysfunction. Pituitary function should therefore be determined in these patients.	[Poomthavorn, P.; Zacharin, M.] Royal Childrens Hosp, Dept Endocrinol & Diabet, Parkville, Vic 3052, Australia; [Poomthavorn, P.] Ramathibodi Hosp, Fac Med, Dept Pediat, Div Endocrinol & Metab, Bangkok, Thailand; [Maixner, W.] Royal Childrens Hosp, Dept Neurosurg, Melbourne, Vic, Australia		Zacharin, M (corresponding author), Royal Childrens Hosp, Dept Endocrinol & Diabet, Flemington Rd, Parkville, Vic 3052, Australia.	margaret.zacharin@rch.org.au					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Dogru O, 2005, NEUROENDOCRINOL LETT, V26, P311; EICHLER I, 1988, J ENDOCRINOL INVEST, V11, P409, DOI 10.1007/BF03349069; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; Landgraf JM, 1996, CHILD HLTH QUESTIONN; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lim H S, 1990, Ann Acad Med Singap, V19, P851; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Poomthavorn P, 2007, EUR J PEDIATR, V166, P1163, DOI 10.1007/s00431-006-0406-7; SHAH A, 1992, BRIT MED J, V304, P173, DOI 10.1136/bmj.304.6820.173; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; YAMANAKA C, 1993, EUR J PEDIATR, V152, P99, DOI 10.1007/BF02072482	32	41	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	FEB	2008	93	2					133	137		10.1136/adc.2007.121137			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	253GX	WOS:000252507800010	17986604				2022-02-06	
J	Struchen, MA; Pappadis, MR; Mazzei, DK; Clark, AN; Davis, LC; Sander, AM				Struchen, Margaret A.; Pappadis, Monique R.; Mazzei, Diana K.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.			Perceptions of communication abilities for persons with traumatic brain injury: Validity of the La Trobe Communication Questionnaire	BRAIN INJURY			English	Article						Traumatic brain injury; communication; assessment	HEAD-INJURY; SEQUELAE	Primary objective: To further evaluate the construct validity of the La Trobe Communication Questionnaire (LCQ) and to investigate the extent to which self-ratings of adults with traumatic brain injury compared to ratings made by close others and self-ratings made by non-injured matched controls. Research design: Prospective cohort study. Methods and procedures: Two hundred and seventy-six adults with TBI (121 of which are 1-year post-injury and previously enrolled in TBI Model Systems and 155 of which were consecutively admitted to a Level 1 trauma centre and were at least 6-months post-injury) completed the La Trobe Communication Questionnaire. In addition, for the TBI Model systems sample, 88 friends/family members and 80 non-injured matched controls participated. Main outcomes and results: Principle components analysis with varimax rotation yielded four factors: Initiation/Conversational Flow, Disinhibition/Impulsivity, Conversational Effectiveness and Partner Sensitivity, which were found to have adequate internal consistency. Adequate discriminative validity was obtained in comparing adults with TBI to non-injured matched controls, while no significant differences were found between self-ratings of communication abilities by adults with TBI and those made by close others. Conclusions: Additional support for the LCQ as a useful measure of perceived social communication abilities was obtained. Confirmatory factor analysis with a larger sample of adults with TBI will be a useful step in further development of this tool.	[Struchen, Margaret A.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Pappadis, Monique R.; Mazzei, Diana K.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.] Mem Hermann TIRR, Houston, TX USA; [Pappadis, Monique R.] Univ Houston, Houston, TX USA		Struchen, MA (corresponding author), Brain Injury Res Ctr, 2323 Shepherd,Suite 907, Houston, TX USA.	struchen@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133G010152, H133B031117]	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education ( Grant #: H133G010152 and H133B031117). Appreciation is also extended to Laura Rosas, MA, and Patricia Terrell Smith, MA, for their assistance with data collection and to the Harris County Hospital District.	BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; BOAKE C, 1991, COGNITIVE REHABILITA, P181; Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Damico J. S., 1985, COMMUNICATION SKILLS, P165; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Hartley L. L, 1995, COGNITIVE COMMUNICAT; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MARSH NV, 1999, BRAIN DAM B, P175; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SNOW P, 2000, BRAIN IMPAIR, V1, P57; Stein S. C., 1996, NEUROTRAUMA, P31; Struchen MA, 2003, J INT NEUROPSYCH SOC, V9, P255; [No title captured]	30	41	41	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					940	951	PII 905461235	10.1080/02699050802425410			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900005	19005886				2022-02-06	
J	Stone, TW; Forrest, CM; Mackay, GM; Stoy, N; Darlington, LG				Stone, T. W.; Forrest, C. M.; Mackay, G. M.; Stoy, N.; Darlington, L. G.			Tryptophan, adenosine, neurodegeneration and neuroprotection	METABOLIC BRAIN DISEASE			English	Article; Proceedings Paper	4th International Hannover Conference on Hepatic Encephalopathy	JUN, 2006	Radebeul, GERMANY	Solvay Pharmaceut		glutamate; NMDA; ischaemia; neurodegeneration; neuroprotection	QUINOLINIC ACID ACCUMULATION; PERIPHERAL-BLOOD MONOCYTES/MACROPHAGES; EXPERIMENTAL HEPATIC-ENCEPHALOPATHY; CEREBRAL CORTICAL SLICES; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; KYNURENIC ACID; CEREBROSPINAL-FLUID; RAT HIPPOCAMPUS; SPINAL-CORD	This review summarises the potential contributions of two groups of compounds to cerebral dysfunction and damage in metabolic disease. The kynurenines are oxidised metabolites of tryptophan, the kynurenine pathway being the major route for tryptophan catabolism in most tissues. The pathway includes quinolinic acid - an agonist at N-methyl-D-aspartate (NMDA) receptors, kynurenic acid - an antagonist at glutamate and nicotinic receptors, and other redox active compounds that are able to generate free radicals under many physiological and pathological conditions. The pathway is activated in immune-competent cells, including glia in the central nervous system, and may contribute substantially to delayed neuronal damage following an infarct or metabolic insult. Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors. The extent of brain injury is critically dependent on the balance between the two opposing forces of kynurenines and purines.	Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland; Epsom Gen Hosp, Epsom KT18 7EG, Surrey, England		Stone, TW (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	t.w.stone@bio.gla.ac.uk	Stone, Trevor/M-7904-2015	Stone, Trevor/0000-0002-5532-0031			Albrecht J, 2005, METAB BRAIN DIS, V20, P253, DOI 10.1007/s11011-005-7904-6; ANDINE P, 1990, BRIT J PHARMACOL, V100, P814, DOI 10.1111/j.1476-5381.1990.tb14097.x; ARVIN B, 1989, BRIT J PHARMACOL, V98, P225, DOI 10.1111/j.1476-5381.1989.tb16886.x; Baratte S, 1998, MOL BRAIN RES, V59, P50, DOI 10.1016/S0169-328X(98)00136-3; BARTRUP JT, 1990, BRAIN RES, V530, P330, DOI 10.1016/0006-8993(90)91305-Z; BASILE AS, 1995, GASTROENTEROLOGY, V108, P818, DOI 10.1016/0016-5085(95)90456-5; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; Behan WMH, 2002, BRIT J PHARMACOL, V135, P1435, DOI 10.1038/sj.bjp.0704613; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BERGQVIST PBF, 1995, J NEUROCHEM, V65, P2235; Bergqvist PBF, 1996, NEUROPSYCHOPHARMACOL, V15, P382, DOI 10.1016/0893-133X(95)00256-D; BIRCH PJ, 1988, EUR J PHARMACOL, V154, P85, DOI 10.1016/0014-2999(88)90367-6; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BLIGHT AR, 1993, BRAIN RES, V632, P314, DOI 10.1016/0006-8993(93)91167-Q; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; CONNICK JH, 1989, NEUROSCI LETT, V101, P191, DOI 10.1016/0304-3940(89)90529-6; DAVAL JL, 1989, BRAIN RES, V491, P212, DOI 10.1016/0006-8993(89)90058-9; DEMENDONCA A, 1995, NEUROREPORT, V6, P1097, DOI 10.1097/00001756-199505300-00006; DYKENS JA, 1987, BIOCHEM PHARMACOL, V36, P211, DOI 10.1016/0006-2952(87)90691-5; DYKENS JA, 1989, BIOCHEM PHARMACOL, V38, P1555, DOI 10.1016/0006-2952(89)90301-8; EASTMAN CL, 1989, BRAIN RES, V495, P225, DOI 10.1016/0006-8993(89)90216-3; EASTMAN CL, 1990, NEUROCHEM RES, V15, P1101, DOI 10.1007/BF01101711; ESPEY MG, 1995, J LEUKOCYTE BIOL, V57, P199, DOI 10.1002/jlb.57.2.199; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; GALARRAGA E, 1990, BRAIN RES, V512, P269, DOI 10.1016/0006-8993(90)90636-P; Gao NF, 2002, MATER LETT, V55, P61, DOI 10.1016/S0167-577X(01)00620-6; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HERON A, 1994, BRAIN RES, V641, P217, DOI 10.1016/0006-8993(94)90149-X; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1990, J CEREBR BLOOD F MET, V10, P660, DOI 10.1038/jcbfm.1990.119; HEYES MP, 1989, BRAIN RES, V491, P173, DOI 10.1016/0006-8993(89)90101-7; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; Holt DE, 2002, AM J VET RES, V63, P1167, DOI 10.2460/ajvr.2002.63.1167; Hosseinzadeh H, 1998, J NEURAL TRANSM, V105, P161, DOI 10.1007/s007020050045; Jalan R, 2003, INT J BIOCHEM CELL B, V35, P1175, DOI 10.1016/S1357-2725(02)00396-5; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kerr SJ, 1995, J NEUROVIROL, V1, P375, DOI 10.3109/13550289509111027; Kerr SJ, 1998, AIDS, V12, P355, DOI 10.1097/00002030-199804000-00003; KHASPEKOV L, 1989, J NEUROSCI RES, V22, P150, DOI 10.1002/jnr.490220207; KIM JP, 1987, NEUROSCIENCE, V23, P423, DOI 10.1016/0306-4522(87)90066-2; Kitano T, 2004, NEUROCHEM INT, V44, P83, DOI 10.1016/S0197-0186(03)00124-4; Klejman A, 2005, NEUROCHEM INT, V47, P51, DOI 10.1016/j.neuint.2005.04.006; Kocki T, 2002, J NEUROSCI RES, V68, P622, DOI 10.1002/jnr.10243; Kosenko E, 2004, J NEUROCHEM, V89, P1101, DOI 10.1111/j.1471-4159.2004.02426.x; Kosenko E, 2003, NEUROCHEM INT, V43, P493, DOI 10.1016/S0197-0186(03)00039-1; Latini S, 1999, BRIT J PHARMACOL, V127, P729, DOI 10.1038/sj.bjp.0702591; LAU YS, 1993, J NEUROCHEM, V60, P768, DOI 10.1111/j.1471-4159.1993.tb03215.x; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; MACGREGOR DG, 1993, BRIT J PHARMACOL, V110, P470, DOI 10.1111/j.1476-5381.1993.tb13834.x; MACGREGOR DG, 1993, BRIT J PHARMACOL, V109, P316, DOI 10.1111/j.1476-5381.1993.tb13572.x; MacGregor DG, 1996, BRAIN RES, V725, P115, DOI 10.1016/S0006-8993(96)00342-3; Matsusue E, 2005, AM J NEURORADIOL, V26, P347; MICHAELIS ML, 1979, LIFE SCI, V24, P2083, DOI 10.1016/0024-3205(79)90082-1; Moffett JR, 1997, EXP NEUROL, V144, P287, DOI 10.1006/exnr.1996.6365; MOFFETT JR, 1994, CELL TISSUE RES, V278, P461; MOFFETT JR, 1993, BRAIN RES, V623, P337, DOI 10.1016/0006-8993(93)91450-7; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; MORONI F, 1986, J NEUROCHEM, V47, P1667, DOI 10.1111/j.1471-4159.1986.tb13071.x; MORONI F, 1986, J NEUROCHEM, V46, P869, DOI 10.1111/j.1471-4159.1986.tb13052.x; Nakagami Y, 1996, JPN J PHARMACOL, V71, P183, DOI 10.1254/jjp.71.183; Nakai M, 1999, MOL BRAIN RES, V64, P59, DOI 10.1016/S0169-328X(98)00310-6; Nakao N, 1997, NEUROSCIENCE, V76, P749, DOI 10.1016/S0306-4522(96)00223-0; Namboodiri AMA, 1996, J NEUROVIROL, V2, P433, DOI 10.3109/13550289609146910; Nikbakht MR, 2001, EUR J PHARMACOL, V427, P13, DOI 10.1016/S0014-2999(01)01171-2; Norenberg W, 1997, BRIT J PHARMACOL, V122, P71, DOI 10.1038/sj.bjp.0701347; O'Kane EM, 1998, EUR J PHARMACOL, V362, P17, DOI 10.1016/S0014-2999(98)00730-4; Okuda S, 1998, J NEUROCHEM, V70, P299; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Ongini E, 2001, DRUG DEVELOP RES, V52, P379, DOI 10.1002/ddr.1137; PEARSON SJ, 1991, J CHROMATOGR-BIOMED, V565, P436, DOI 10.1016/0378-4347(91)80406-3; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; PEARSON SJ, 1995, J NEURAL TRANSM-GEN, V102, P67, DOI 10.1007/BF01276566; Pemberton LA, 1997, J INTERF CYTOK RES, V17, P589, DOI 10.1089/jir.1997.17.589; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; Rao KVR, 2005, NEUROCHEM RES, V30, P1311, DOI 10.1007/s11064-005-8803-2; Rao KVR, 2005, NEUROCHEM INT, V47, P31, DOI 10.1016/j.neuint.2005.04.004; REGENOLD JT, 1990, N-S ARCH PHARMACOL, V341, P225; Reinhard JF, 1998, NEUROCHEM RES, V23, P661, DOI 10.1023/A:1022438822023; REYNOLDS GP, 1989, LANCET, V2, P979; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; ROBINSON MB, 1992, PEDIATR RES, V32, P483, DOI 10.1203/00006450-199210000-00021; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1994, NEUROSCI LETT, V178, P211, DOI 10.1016/0304-3940(94)90761-7; Saran T, 2004, J NEUROSCI RES, V75, P436, DOI 10.1002/jnr.10862; Saran T, 1998, BRAIN RES, V787, P348, DOI 10.1016/S0006-8993(98)00031-6; SARDAR AM, 1995, J NEUROCHEM, V64, P932; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; Shahraki A, 2004, EUR J NEUROSCI, V20, P719, DOI 10.1111/j.1460-9568.2004.03502.x; SHEADOWN MJ, 1996, DRUG DEVELOP RES, V38, P108; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; SPIGNOLI G, 1984, EUR J PHARMACOL, V97, P341, DOI 10.1016/0014-2999(84)90475-8; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Stone TW, 2000, TRENDS PHARMACOL SCI, V21, P149, DOI 10.1016/S0165-6147(00)01451-6; Stone TW, 2000, EUR J MED CHEM, V35, P179, DOI 10.1016/S0223-5234(00)00121-5; Sung V, 1997, CELL TISSUE RES, V290, P633, DOI 10.1007/s004410050969; TOMINAGA K, 1992, NEUROSCIENCE, V30, P451; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V369, P313, DOI 10.1016/S0014-2999(99)00073-4; VONLUBITZ DKEJ, 1989, NEUROSCIENCE, V30, P451, DOI 10.1016/0306-4522(89)90265-0; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WINN HR, 1979, CIRC RES, V45, P486, DOI 10.1161/01.RES.45.4.486; YAMAMOTO H, 1994, PEDIATR NEUROL, V10, P9, DOI 10.1016/0887-8994(94)90060-4	120	41	42	1	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490			METAB BRAIN DIS	Metab. Brain Dis.	DEC	2007	22	3-4					337	352		10.1007/s11011-007-9064-3			16	Endocrinology & Metabolism; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	223OD	WOS:000250379500012	17712616				2022-02-06	
J	Wang, YF; Luo, WB; Reiser, G				Wang, Yingfei; Luo, Weibo; Reiser, Georg			Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cytokine-induced neutrophil chemoattractant; growth-regulated oncogene; neuroprotection; rat astrocytes; signal transduction; thrombin	TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; RAT ASTROCYTES; GLIAL-CELLS; THROMBIN; PROTEINASE; NEURONS; DISEASE; GDNF; NEURODEGENERATION	Activation of protease-activated receptors (PARs) is known to exert neuroprotection when low concentrations of the agonist protease thrombin are applied. However, the mechanism of protection is still unclear. Here, we showed that activation of multiple PARs, including PAR-1, PAR-2 and PAR-4, was able to elevate the release of the chemokine cytokine-induced neutrophil chemoattractant (CINC)-3 from rat astrocytes, in addition to evoking CINC-1 secretion. Different molecular mechanisms were identified as being involved in the secretion of CINC-1 and CINC-3, upon activation of different PARs. Importantly, we found that both CINC-1 and CINC-3 could signal to rat cortical neurons. Both chemokines acted via CXCR2 to prevent C-2-ceramide-induced cytochrome c release from mitochondria. Consequently CINC-1 and CINC-3 protected neurons from apoptosis. We further revealed that conditioned media obtained from PAR-activated astrocytes similarly protected cortical neurons against C-2-ceramide-induced cell death. The neuroprotection was considerably suppressed by a CXCR2 antagonist. CXCR2 is the cognate receptor for CINC. Therefore, our findings demonstrate that PAR-activated astrocytes are able to protect neurons against neurodegeneration and cell death via regulation of the secretion of chemokines CINC-1 and CINC-3. These data indicate a previously unknown mechanism for astrocyte-mediated neuroprotection achieved by PAR activation.	Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany		Reiser, G (corresponding author), Univ Magdeburg, Fak Med, Inst Neurobiochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@med.ovgu.de		wang, yingfei/0000-0002-8723-252X; Luo, Weibo/0000-0002-1992-0320			Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; ENGELE J, 1991, J NEUROSCI RES, V30, P359, DOI 10.1002/jnr.490300212; Ishida Y, 2006, J NEUROPATH EXP NEUR, V65, P66, DOI 10.1097/01.jnen.0000195941.48033.eb; Kalehua AN, 2004, EXP CELL RES, V297, P197, DOI 10.1016/j.yexcr.2004.02.031; Limatola C, 2000, P NATL ACAD SCI USA, V97, P6197, DOI 10.1073/pnas.090105997; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; Luo WB, 2006, J BIOL CHEM, V281, P7927, DOI 10.1074/jbc.M510784200; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Nishina K, 2005, AM J RESP CELL MOL, V33, P505, DOI 10.1165/rcmb.2005-0113OC; Park KW, 2001, NEUROSCI RES, V40, P315, DOI 10.1016/S0168-0102(01)00242-5; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Sawada K, 2000, J NEUROCHEM, V74, P1731, DOI 10.1046/j.1471-4159.2000.0741731.x; Shibata F, 2000, CYTOKINE, V12, P1368, DOI 10.1006/cyto.2000.0739; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Walton KM, 1999, MOL NEUROBIOL, V19, P43, DOI 10.1007/BF02741377; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Wang YF, 2007, J NEUROCHEM, V103, P814, DOI 10.1111/j.1471-4159.2007.04803.x; Wang YF, 2007, BIOCHEM J, V401, P65, DOI 10.1042/BJ20060732; Wang YF, 2006, J NEUROCHEM, V99, P759, DOI 10.1111/j.1471-4159.2006.04105.x; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; Watson K, 2005, MOL PHARMACOL, V67, P757, DOI 10.1124/mol.104.004812; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318	33	41	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2007	26	11					3159	3168		10.1111/j.1460-9568.2007.05938.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	232NK	WOS:000251026200016	18005059				2022-02-06	
J	Alyagari, V; Diringer, MN				Alyagari, Venkatesh; Diringer, Michael N.			Fever control and its impact on outcomes: What is the evidence?	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						fever; non-narcotic analgesics; cerebrovascular accident; traumatic brain injury; intensive care	INTENSIVE-CARE-UNIT; ACUTE ISCHEMIC-STROKE; ELEVATED BODY-TEMPERATURE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; LENGTH-OF-STAY; CLINICAL-TRIAL; CARDIAC-ARREST; EARLY HYPERTHERMIA; FEBRILE CHILDREN	Fever is common in a variety of neurological disorders. There is abundant experimental evidence suggesting that fever leads to, or exacerbates, neuronal injury in conditions such as cerebral ischemia and traumatic brain injury. However, conclusive evidence linking control of fever to improved outcomes is lacking. It has been difficult to design studies looking at the impact of fever control on outcome, in part because traditional methods of fever control are ineffective. Recently, several new devices to control temperature have become available. These devices appear to be more effective than conventional means and might allow us to design studies that definitively answer the question: "Does controlling fever improve outcome?" (C) 2007 Elsevier B.V. All rights reserved.	Univ Illinois, Dept Neurol & Rehabil, NPI, Chicago, IL 60062 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA		Alyagari, V (corresponding author), Univ Illinois, Dept Neurol & Rehabil, NPI, 912 S Wood St,855 N,M-C 796, Chicago, IL 60062 USA.	aiyagari@uic.edu; diringerm@neuro.wusti.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Aiyagari, Venkatesh/0000-0001-8139-3819			Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Ahkee S, 1997, SOUTHERN MED J, V90, P296, DOI 10.1097/00007611-199703000-00006; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BEISEL WR, 1974, JAMA-J AM MED ASSOC, V228, P581, DOI 10.1001/jama.228.5.581; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Cormio M, 2000, INTENS CARE MED, V26, P552, DOI 10.1007/s001340051203; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Dippel DWJ, 2003, BMC CARDIOVASC DISOR, V3, DOI 10.1186/1471-2261-3-2; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; DORAN TF, 1989, J PEDIATR-US, V114, P1045, DOI 10.1016/S0022-3476(89)80461-5; FRIEDMAN PL, 1981, NEW ENGL J MED, V305, P1171, DOI 10.1056/NEJM198111123052002; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; Hacke W, 2000, CEREBROVASC DIS, V10, P22, DOI 10.1159/000047578; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; Koennecke HC, 2001, NEUROLOGY, V57, P2301, DOI 10.1212/WNL.57.12.2301; Kuikka A, 1998, EUR J CLIN MICROBIOL, V17, P701, DOI 10.1007/s100960050164; Kuikka A, 1997, EUR J CLIN MICROBIOL, V16, P125, DOI 10.1007/BF01709471; Mackowiak PA, 2000, ARCH INTERN MED, V160, P2680; MAHAR AF, 1994, CLIN PEDIATR, V33, P227, DOI 10.1177/000992289403300407; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; Plaisance KI, 2000, ARCH INTERN MED, V160, P449, DOI 10.1001/archinte.160.4.449; Polderman KH, 2004, CRIT CARE MED, V32, P2558, DOI 10.1097/01.CCM.0000148087.41418.0A; RAIZNER AE, 1980, CIRCULATION, V62, P925, DOI 10.1161/01.CIR.62.5.925; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; SCHNAIDERMAN D, 1993, EUR J PEDIATR, V152, P747, DOI 10.1007/BF01953992; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Sulter G, 2004, CEREBROVASC DIS, V17, P118, DOI 10.1159/000075779; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; UHARI M, 1995, J PEDIATR-US, V126, P991, DOI 10.1016/S0022-3476(95)70231-8; van Breda EJ, 2004, CEREBROVASC DIS, V18, P350, DOI 10.1159/000081813; van Stuijvenberg M, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e51; ZAREMBA J, 2004, INT MED J EXPT CLIN, V10, pRA148; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	61	41	42	2	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					39	46		10.1016/j.jns.2007.04.030			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	216JO	WOS:000249874500005	17537459				2022-02-06	
J	Song, SJ; Song, SJ; Zhang, HL; Cuevas, J; Sanchez-Ramos, J				Song, Shijie; Song, Shuojing; Zhang, Hongling; Cuevas, Javier; Sanchez-Ramos, Juan			Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells	STEM CELLS AND DEVELOPMENT			English	Article							MAMMALIAN SUBSTANTIA-NIGRA; STROMAL CELLS; NEUROECTODERMAL DIFFERENTIATION; PROGENITOR CELLS; IN-VITRO; NEUROGENESIS; FUSION; MICE; PROLIFERATION; INDUCTION	Bone marrow-derived stem/progenitor cells have been shown by independent investigators to give rise to neural-like cells (neurons and glia) both in vitro and in vivo. The objective of the present study was to determine whether nestin-enriched cells derived from bone marrow can differentiate into cells with the same morphological and functional characteristics as neurons derived from adult brain neurogenic zones. Cell culture methods were used for generation of adult bone marrow and brain stem/progenitor cells and for studying their differentiation into neural-like cells. The proportion of cells expressing neuronal markers was greater in cultures derived from adult hippocampal neural stem cells than in the bone marrow-derived cells, but the electrophysiological and functional characteristics of the cells were similar. Action potentials with electrical characteristics corresponding to those exhibited by adult neural stem cell-derived neurons were recorded from approximately 2.5% of patched neuron-like cells differentiated from bone marrow cells. The active uptake of tritium-labeled neurotransmitters gamma-aminobutyric acid ([H-3] GABA) and dopamine ([H-3] DA) was measured in both sets of cultures. [H-3] GABA uptake, but not [H-3] DA, was significantly increased in differentiated neurons in both neural stem cell cultures and bone marrow-derived cultures. [H-3] GABA uptake was greater in differentiated neurons derived from brain neural stem cells. In summary, both the nestin-expressing bone marrow and the adult brain neural stem/progenitors developed into cells with morphological, immunocytochemical, and functional characteristics of neurons. Even though a smaller proportion of neuron-like cells was generated from bone marrow-derived progenitors than from brain-derived neural stem cells, these cells may be useful in the cellular therapy of neurodegenerative diseases and traumatic brain and spinal cord injury.	Univ S Florida, Dept Neurol, MDC 55, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; MIT, Sch Engn, Cambridge, MA 02139 USA; James Haley VA Hosp, Tampa, FL 33612 USA		Sanchez-Ramos, J (corresponding author), Univ S Florida, Dept Neurol, MDC 55, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	jsramos@health.usf.edu	Cuevas, Javier/I-4941-2012; Sanchez-Ramos, Juan/O-7870-2014; Mordwinkin, Nicholas M/A-4347-2010; Sanchez-Ramos, Juan/A-1188-2009	Sanchez-Ramos, Juan/0000-0002-3391-7857			Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251; D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Egusa H, 2005, J BIOL CHEM, V280, P23691, DOI 10.1074/jbc.M413796200; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frielingsdorf H, 2004, P NATL ACAD SCI USA, V101, P10177, DOI 10.1073/pnas.0401229101; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SANCHEZRAMOS JR, 1992, J NEUROCHEM, V58, P328, DOI 10.1111/j.1471-4159.1992.tb09314.x; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; SONG S, 2002, PROTOCOLS NEURAL STE, P79; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, CYTOTHERAPY, V6, P372, DOI 10.1080/14653240410004943; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	50	41	44	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	OCT	2007	16	5					747	756		10.1089/scd.2007.0027			10	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	235XF	WOS:000251266900006	17999596				2022-02-06	
J	Collins, JM; Despa, F; Lee, RC				Collins, John M.; Despa, Florin; Lee, Raphael C.			Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188	BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES			English	Article						electroporation; poloxamer 188; skeletal muscle; action potential; MRI	T-2 RELAXATION DECAY; PURIFIED POLOXAMER-188; ACTIVE AGENT; RAT; PHARMACOKINETICS; KINETICS; INJURY; MODEL	A critical requirement for cell survival after trauma is sealing of breaks in the cell membrane [M. Bier, S.M. Hammer, D.J. Canaday, RC Lee, Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells, Bioelectromagnetics 20 (1999) 194-201; R.C. Lee, D.C. Gaylor, D. Bhatt, D.A. Israel, Role of cell membrane rupture in the pathogenesis of electrical trauma, J. Surg. Res. 44 (1988) 709-719; R.C. Lee, J.F. Burke, E.G. Cravalho (Eds.), Electrical Trauma: The Pathophysiology, Manifestations, and Clinical Management, Cambridge University Press, 1992; B.I. Tropea, R.C. Lee, Thermal injury kinetics in electrical trauma, J. Biomech. Engr. 114 (1992) 241-250; F. Despa, D.P. Orgill, J. Newalder, R.C Lee, The relative thermal stability of tissue macromolecules and cellular structure in burn injury, Burns 31 (2005) 568-577; T.A. Block, J.N. Aarsvold, K.L. Matthews II, R.A. Mintzer, L.P. River, M. Capelli-Schellpfeffer, R.L. Wollman, S. Tripathi, C.T. Chen, R.C. Lee, The 1995 Lindberg Award. Nonthermally mediated muscle injury and necrosis in electrical trauma, J. Burn Care and Rehabil. 16 (1995) 581-588; K. Miyake, P.L. McNeil, Mechanical injury and repair of cells, Crit. Care Med. 31 (2003) S496-S501; R.C. Lee, L.P. River, F.S. Pan, R.L. Wollmann, Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo, Proc. Natl. Acad. Sci. 89 (1992) 4524-4528; J.D. Marks, C.Y. Pan, T. Bushell, W. Cromie, R.C. Lee, Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection, FASEB J. 15 (2001) 11071109; B. Greenebaum, K. Blossfield, J. Hannig, C.S. Carrillo, M.A. Beckett, R.R. Weichselbaum, R.C. Lee, Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation, Burns 30 (2004) 539-547; G. Serbest, J. Horwitz, K. Barbee, The effect of poloxamer-188 on neuronal cell recovery from mechanical injury, J. Neurotrauma 22 (2005) 119-132]. The triblock copolymer surfactant Poloxamer 188 (P 188) is known to increase the cell survival after membrane electroporation [R.C. Lee, L.P. River, F.S. Pan, R.L. Wollmann, Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo, Proc. Natl. Acad. Sci. 89 (1992) 4524-4528; Z. Ababneh, H. Beloeil, C.B. Berde, G. Gambarota, S.E. Maier, R.V Mulkern, Biexponential parametrization of T2 and diffusion decay curves in a rat muscle edema model: Decay curve components and water compartments, Magn. Reson. Med. 54 (2005) 524-53 1]. Here, we use a rat hind-limb model of electroporation injury to determine if the intravenous administration of PI 88 improves the recovery of the muscle function. Rat hind-limbs received a sequence of either 0, 3, 6, 9, or 12 electrical current pulses (2 A, 4 ms duration, 10 s duty cycle). Magnetic resonance imaging (MRI) analysis, muscle water content and compound muscle action potential (CMAP) amplitudes were compared. Electroporation injury manifested edema formation and depression of the CMAP amplitudes. P 188 (one bolus of 1 mg/mI of blood) was administrated 30 or 60 min after injury. Animals receiving P 188 exhibited reduced tissue edema (p < 0.05) and increased CMAP amplitudes (p < 0.03). By comparison, treatment with 10 kDa neutral dextran, which produces similar serum osmotic effects as P 188, had no effect on post-electroporation recovery. Noteworthy, the present results suggest that a single intravenous dose of P 188 is effective to restore the structural integrity of damaged tissues with intact circulation. (c) 2007 Elsevier B.V. All rights reserved.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA		Lee, RC (corresponding author), Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA.	r-lee@uchicago.edu		Lee, Raphael C./0000-0002-6628-1867	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061101, R01GM064757] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM61101, R01-GM64757-04, R01 GM061101, R01 GM064757] Funding Source: Medline		Ababneh Z, 2005, MAGNET RESON MED, V54, P524, DOI 10.1002/mrm.20610; Abramov GS, 1996, BURNS, V22, P602, DOI 10.1016/S0305-4179(96)00055-1; BARRATT TM, 1969, J CLIN INVEST, V48, P56, DOI 10.1172/JCI105974; Baskaran H, 2001, J SURG RES, V101, P56, DOI 10.1006/jsre.2001.6262; Bertram HC, 2001, J AGR FOOD CHEM, V49, P3092, DOI 10.1021/jf001402t; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; Block Thomas A., 1995, Journal of Burn Care and Rehabilitation, V16, P581, DOI 10.1097/00004630-199511000-00004; Clausen T, 2005, ANN NY ACAD SCI, V1066, P286, DOI 10.1196/annals.1363.021; Despa F, 2005, BURNS, V31, P568, DOI 10.1016/j.burns.2005.01.015; Firestone MA, 2003, BIOMACROMOLECULES, V4, P1539, DOI 10.1021/bm034134r; FLECKENSTEIN JL, 1996, ENCY NUCL MAGNETIC R, P4430; Foley JM, 1999, J APPL PHYSIOL, V87, P2311, DOI 10.1152/jappl.1999.87.6.2311; Gambarota G, 2001, MAGNET RESON MED, V46, P592, DOI 10.1002/mrm.1232; Gissel H, 2005, ANN NY ACAD SCI, V1066, P272, DOI 10.1196/annals.1363.024; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Grindel JM, 2002, BIOPHARM DRUG DISPOS, V23, P87, DOI 10.1002/bdd.297; Grindel JM, 2002, J PHARM SCI-US, V91, P1936, DOI 10.1002/jps.10190; HAACKE EM, 2005, MAGNETIC RESONANCE I; Jewell RC, 1997, J PHARM SCI, V86, P808, DOI 10.1021/js960491e; Lee R.C., 1992, ELECT TRAUMA PATHOPH; LEE RC, 1988, J SURG RES, V44, P709, DOI 10.1016/0022-4804(88)90105-9; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; Matthews KL, 2006, BURNS, V32, P755, DOI 10.1016/j.burns.2006.01.011; Merletti R, 1999, IEEE T BIO-MED ENG, V46, P810, DOI 10.1109/10.771190; Miyake K, 2003, CRIT CARE MED, V31, pS496, DOI 10.1097/01.CCM.0000081432.72812.16; OKeefe JH, 1996, AM J CARDIOL, V78, P747, DOI 10.1016/S0002-9149(96)00414-6; Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099; Saab G, 1999, MAGNET RESON MED, V42, P150, DOI 10.1002/(SICI)1522-2594(199907)42:1<150::AID-MRM20>3.0.CO;2-5; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; TROPEA BI, 1992, J BIOMECH ENG-T ASME, V114, P241, DOI 10.1115/1.2891378; Wu GH, 2005, BIOPHYS J, V89, P3159, DOI 10.1529/biophysj.104.052290; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	34	41	41	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2736	1879-2642		BBA-BIOMEMBRANES	Biochim. Biophys. Acta-Biomembr.	MAY	2007	1768	5					1238	1246		10.1016/j.bbamem.2007.01.012			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	162MF	WOS:000246091000024	17382288	Bronze, Green Accepted			2022-02-06	
J	Goldenberg, G; Hartmann-Schmid, K; Surer, F; Daumuller, M; Hermsdorfer, J				Goldenberg, Georg; Hartmann-Schmid, Karoline; Suerer, Fatma; Daumueller, Meike; Hermsdoerfer, Joachim			The impact of dysexecutive syndrome on use of tools and technical devices	CORTEX			English	Article						apraxia; tool-use; dysexecutive syndrome; working memory; activities of daily living	CLOSED-HEAD-INJURY; NATURALISTIC ACTION; IDEATIONAL APRAXIA; ACTION IMPAIRMENT; BRAIN; KNOWLEDGE; DEFICIT; LONDON; STROKE; DAMAGE	We present two studies aimed at elucidating why patients with dysexecutive syndrome encounter difficulties with the use of tools and technical devices. Two different groups of patients with dysexecutive syndrome took part in them. Their results were compared with those of two groups of normal controls and in the first study also with those of patients with posterior left or right brain lesions. The first study contrasted single step with multi-step actions and explored the role of novelty and consecutive demands on problem solving. Dysexecutive patients encountered problems only with the multistep actions. The rank order of strength of impairment corresponded to the presumed rank order of demands on problem solving, but the analysis of individual results demonstrated high variability of this pattern which moreover could not be fully replicated when the same tests were applied in the second study. The second study pursued the hypothesis that maintenance of goals and constraints in working memory is the crucial factor for difficulties of dysexecutive patients. Support for this hypothesis was less ambiguous, but as this study did not include patients with posterior lesions it remains open whether this factor is specific for dysexecutive syndrome and prefrontal brain damage or applies to brain damage regardless of its location.	Bogenhausen Hosp, Neuropsychol Dept, D-81925 Munich, Germany		Goldenberg, G (corresponding author), Bogenhausen Hosp, Neuropsychol Dept, Englschaulkingerstr 77, D-81925 Munich, Germany.	Georg.Goldenberg@extem.lrz-muenchen.de					Baddeley A.D., 1986, WORKING MEMORY; Berg WK, 2002, J CLIN EXP NEUROPSYC, V24, P586, DOI 10.1076/jcen.24.5.586.1006; Buxbaum LJ, 1998, COGNITIVE NEUROPSYCH, V15, P617, DOI 10.1080/026432998381032; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goldenberg G, 1998, NEUROPSYCHOLOGIA, V36, P581, DOI 10.1016/S0028-3932(97)00165-6; Goldenberg G, 2003, NEUROPSYCHOLOGIA, V41, P1565, DOI 10.1016/S0028-3932(03)00120-9; Goldenberg G, 2002, NEUROPSYCHOLOGIE ALL; Hartmann K, 2005, NEUROPSYCHOLOGIA, V43, P625, DOI 10.1016/j.neuropsychologia.2004.07.015; Hodges JR, 1999, P NATL ACAD SCI USA, V96, P9444, DOI 10.1073/pnas.96.16.9444; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Morlaas J., 1928, CONTRIBUTION ETUDE A; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PICK A, 1905, STUDIENT MOTORISCHEN; POECK K, 1982, ARCH ITAL BIOL, V120, P361; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rumiati RI, 2001, COGN NEUROPSYCHOL, V18, P617, DOI 10.1080/02643290126375; Schwartz M. F., 2002, NATURALISTIC ACTION; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Spatt J, 2002, J NEUROL, V249, P601, DOI 10.1007/s004150200070; Sunderland A, 2000, NEUROPSYCHOLOGIA, V38, P923, DOI 10.1016/S0028-3932(00)00021-X; Sunderland A, 1999, STROKE, V30, P949, DOI 10.1161/01.STR.30.5.949; Unterrainer JM, 2004, J CLIN EXP NEUROPSYC, V26, P846, DOI 10.1080/13803390490509574; Zhang JJ, 1997, COGNITIVE SCI, V21, P179	31	41	41	0	1	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	APR	2007	43	3					424	435		10.1016/S0010-9452(08)70467-2			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	169QI	WOS:000246606300014	17533765				2022-02-06	
J	Hebb, MO; McArthur, DL; Alger, J; Etchepare, M; Glenn, TC; Bergsneider, M; Martin, N; Vespa, PM				Hebb, Matthew O.; McArthur, David L.; Alger, Jeffry; Etchepare, Maria; Glenn, Thomas C.; Bergsneider, Marvin; Martin, Neil; Vespa, Paul M.			Impaired percent alpha variability on continuous electroencephalography is associated with thalamic injury and predicts poor long-term outcome after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; electrophysiology; outcome measures; recovery; secondary insult	SEVERE HEAD-INJURY; CEREBRAL-CORTEX; METABOLIC-RATE; EEG FREQUENCY; CLASSIFICATION; RHYTHMS; STEM; MECHANISMS; PROGNOSIS; COMA	Continuous electroencephalography (cEEG) is potentially useful in determining prognosis in patients with traumatic brain injuries (TBI). The objective of this prospective, observational cohort study was to determine if the percent alpha variability (PAV) on cEEG was predictive of outcome following TBI. Injury characteristics were indexed to assess whether lesions in specific cerebral loci were correlated with PAV and patient recovery. Fifty-three TBI patients were studied using cEEG recording and serial neuroimaging. Clinical recovery was assessed at regular intervals in hospital and following discharge. The principal outcome measures included the mean 3-day PAV score, the 7-day PAV pattern, delineation of the anatomical sites of brain injury, and the 6-month clinical outcome, as measured by the Glasgow Outcome Scale (GOS). Significant univariate (p = 0.030) and multivariate (p = 0.008) relations were identified between PAV and GOS scores. PAV offered good discrimination between favorable and unfavorable 6-month outcomes (AUC 0.76) and, with a cut-point of 0.20, had a sensitivity of 87% and negative predictive value of 82%. Multivariate modeling revealed that injuries of the thalamus (p = 0.009) and basal ganglia (p = 0.016), and the presence of diffuse edema (p = 0.009), were the key anatomical predictors of PAV. Brainstem injuries (p = 0.020) and indicators of diffuse cerebral trauma, such as deep white matter shearing (p = 0.036) and multiple subcortical lesions (p = 0.033), were the principal determinants of 6-month recovery. Inclusion of PAV enhanced the accuracy of prediction models that encompassed a selective combination of clinical and anatomical variables (adjusted R-2 = 0.458, p < 0.001). The two main results of this study are (1) PAV is a sensitive predictor of 6-month clinical outcomes following TBI, and (2) injury to the thalamus is related to impaired PAV. PAV appears best utilized as a functional adjunct to traditional clinical and anatomical predictors.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Dalhousie Univ, Brain Repair Ctr, Div Neurosurg, Halifax, NS, Canada		Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, CHS 18-218,10833 LeConte Ave, Los Angeles, CA 90095 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131			BALDYMOULINIER M, 1968, EXP BRAIN RES, V5, P55; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; Danos P, 2001, NEUROPSYCHOBIOLOGY, V43, P265, DOI 10.1159/000054901; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Goldman RI, 2002, NEUROREPORT, V13, P2487, DOI 10.1097/00001756-200212200-00022; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hughes SW, 2005, NEUROSCIENTIST, V11, P357, DOI 10.1177/1073858405277450; INGVAR DH, 1976, ELECTROEN CLIN NEURO, V41, P268, DOI 10.1016/0013-4694(76)90119-X; IRAGUI VJ, 1983, J NEUROL NEUROSUR PS, V46, P632, DOI 10.1136/jnnp.46.7.632; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 2000, FEUROSURG FOCUS, V8, P1; Larson CL, 1998, PSYCHOPHYSIOLOGY, V35, P162, DOI 10.1017/S0048577298001620; Lindgren KA, 1999, BIOL PSYCHIAT, V45, P943, DOI 10.1016/S0006-3223(98)00350-3; Littell R.C., 1996, SAS SYSTEM MIXED MOD; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LOPESDASILVA FH, 1973, ELECTROEN CLIN NEURO, V35, P627, DOI 10.1016/0013-4694(73)90216-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORISON RS, 1945, J NEUROPHYSIOL, V8, P309; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Niedermeyer E, 1997, INT J PSYCHOPHYSIOL, V26, P31, DOI 10.1016/S0167-8760(97)00754-X; Nuwer M R, 1994, Neurosurg Clin N Am, V5, P647; OHMOTO T, 1978, APPL NEUROPHYSIOL, V41, P188; R Core Team, 2019, R LANG ENV STAT COMP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schreckenberger M, 2004, NEUROIMAGE, V22, P637, DOI 10.1016/j.neuroimage.2004.01.047; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SING T, 2004, ROCR R PACKAGE VISUA; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Steriade M, 1997, CEREB CORTEX, V7, P583, DOI 10.1093/cercor/7.6.583; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; WESTMORELAND BF, 1975, ARCH NEUROL-CHICAGO, V32, P713, DOI 10.1001/archneur.1975.00490530035001; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Yazawa S, 2001, INTERNAL MED, V40, P443, DOI 10.2169/internalmedicine.40.443; [No title captured]	53	41	43	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					579	590		10.1089/neu.2006.0146			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000001	17439342				2022-02-06	
J	Cardoso, EDS; Romero, MG; Chan, F; Dutta, A; Rahimi, M				da Silva Cardoso, Elizabeth; Romero, Maria G.; Chan, Fong; Dutta, Alo; Rahimi, Maryam			Disparities in vocational rehabilitation services and outcomes for Hispanic clients with traumatic brain injury: Do they exist?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; Hispanic; traumatic brain injury; vocational rehabilitation services	EMPLOYMENT; INDIVIDUALS; WORK; LIFE	Objective: Examine disparities in vocational rehabilitation (VR) services for Hispanic clients with traumatic brain injury. Design: Logistic regression analysis of secondary data. Participants: Five thousand eight hundred thirtyone European American and Hispanic clients. Main Outcome Measures: Type of services and employment status. Results: European Americans were 1.27 times more likely to obtain employment than were Hispanics. Hispanics with work disincentives had lower odds of returning to work and had more unmet basic needs (eg, food, shelter, and transportation) that need to be addressed in the rehabilitation process. job placement and on-the-job support services were found to significantly improve employment outcomes. However, on-the-job support services were more likely to be provided to European Americans than to Hispanics.	CUNY Hunter Coll, Dept Educ Fdn & Counseling, New York, NY 10021 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; So Univ, Dept Rehabil & Disabil Studies, Baton Rouge, LA USA; Univ Maryland Eastern Shore, Dept Rehabil Studies, Princess Anne, MD 21853 USA		Cardoso, EDS (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling, 695 Pk Ave,W1017, New York, NY 10021 USA.	ecardoso@huntencury.edu					Burnett DM, 2000, BRAIN INJURY, V14, P713; Capella ME, 2002, REHABIL COUNS BULL, V45, P143, DOI 10.1177/003435520204500303; Cardoso ED, 2006, REHABIL PSYCHOL, V51, P175, DOI 10.1037/0090-5550.51.2.175; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; Gamble D, 2003, J REHABIL, V69, P31; Gamble D., 2002, J APPL REHABILITATIO, V33, P41, DOI DOI 10.1891/0047-2220.33.3.41; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; Hennessey JC, 1997, SOC SECUR BULL, V60, P3; Ingraham K., 1992, J APPL REHABILITATIO, V23, P18; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Mngadi S, 1992, J APPL REHABILITATIO, V23, P12, DOI 10.1891/0047-2220.23.2.12; Sherer M, 1999, BRAIN INJURY, V13, P973; *SPSS, 2005, SPSS STAT PACK SOC S; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wilson KB, 2005, J COUNS DEV, V83, P86, DOI 10.1002/j.1556-6678.2005.tb00583.x	18	41	41	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					85	94		10.1097/01.HTR.0000265096.44683.6b			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500003	17414310				2022-02-06	
J	Cheung, PSY; Lam, JMY; Yeung, JHH; Graham, CA; Rainer, TH				Cheung, Phoebe S. Y.; Lam, Jenny M. Y.; Yeung, Janice H. H.; Graham, Colin A.; Rainer, Timothy H.			Outcome of traumatic extradural haematoma in Hong Kong	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						extradural haematoma; head injury; major trauma; emergency department; neurosurgery; mortality; outcome; pupils; Glasgow Coma Score	PRACTICAL SCALE; CRANIOTOMY; ADULT	Aim: Traumatic extradural haematoma (EDH) is a neurosurgical emergency and timely surgical intervention for significant EDH is the gold standard. This study aims to determine the incidence and mortality of consecutive patients with traumatic EDH admitted to the Emergency Department (ED) of Prince of Wales Hospital (PWH), a University Hospital Trauma Centre in Hong Kong. Patients and methods: Retrospective analysis of prospectively collected data for all consecutive trauma cases admitted through the ED during 2001-2004. EDH was diagnosed by CT in all cases. Both primary and delayed onset EDH were included, as were patients with combined EDH and other intracranial lesions (e.g. subdural haematoma). Age, sex, cause of injury, associated intracranial lesions, skull fracture, Glasgow Coma Scale, pupil reactivity, treatment, length of stay and clinical outcome were determined. Results: Two thousand and two hundred and eight patients were in the trauma registry for 2001-2004. Total 1080 head injured patients; 89 patients had traumatic EDH, mean of 1.9 patients per month. Seventy (79%) patients were mate, with a mean age of 37.7 years. Fifty (56%) patients were from road traffic crashes, 27 (30%) sustained falls, 10 (11%) had direct head trauma. On admission, 62 (70%) patients were GCS 13-15, 9 (10%) GCS 9-12 and 18 (20%) GCS 3-8. Sixty-six (74%) patients had a skull fracture. Thirty (34%) patients underwent neurosurgical operation. Overall, nine patients (10%) died; eight patients were GCS<8; five had bilateral fixed and dilated pupils; one had a single fixed and dilated pupil. Four patients died after neurosurgical operation, three of whom had fixed dilated pupils and were GCS 3 prior to surgery. Median length of hospital stay for survivors was 10.4 days. Conclusion: Survival from traumatic EDH was 90% (80/89) and 91% (73/80) of survivors had a Glasgow Outcome Score of 4 or 5 (good or moderate). The combination of bilateral fixed dilated pupils and GCS 3 suggests severe primary brain injury. Emergency evacuation of intracranial haematomas is unlikely to improve the outcome for these patients. Even in an urban environment with short prehospital times and rapid access to neurosurgery, outcome in patients who are GCS 3 following EDH is likely to be poor. (C) 2006 Elsevier Ltd. All rights reserved.	Prince Wales Hosp, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Accid & Emergency Med Acad Unit, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China		Graham, CA (corresponding author), Prince Wales Hosp, Trauma & Emergency Ctr, Shatin, Hong Kong, Peoples R China.	cagraham@cuhk.edu.hk	Graham, Colin A/B-4535-2013; Rainer, Timothy H/I-2591-2013	Graham, Colin A/0000-0002-4381-7470; Rainer, Timothy H/0000-0003-3355-3237			BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hutchinson J., 1867, LOND HOSP REP, V4, P51; Jacobson WHA, 1886, GUYS HOSP REP, V43, P147; JENNETT B, 1975, LANCET, V1, P480; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; LEUNG GKK, 2001, ASIAN J SURG, V24, P305; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; PATERNITI S, 1994, ACTA NEUROCHIR, V131, P207, DOI 10.1007/BF01808614; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; TEASDALE G, 1974, LANCET, V2, P81	13	41	43	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JAN	2007	38	1					76	80		10.1016/j.injury.2006.08.059			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	130XA	WOS:000243831100012	17097656				2022-02-06	
J	Sorani, MD; Hempbill, JC; Morabito, D; Rosenthal, G; Manley, GT				Sorani, Marco D.; Hempbill, J. Claude, III; Morabito, Diane; Rosenthal, Guy; Manley, Geoffrey T.			New approaches to physiological informatics in neurocritical care	NEUROCRITICAL CARE			English	Article						traumatic brain injury; intensive care; physiological monitoring; intracranial pressure; hierarchical clustering.	TRAUMATIC BRAIN-INJURY; MULTICENTER ANALYSIS; INTENSIVE-CARE; BIOINFORMATICS; PREDICTION; REGRESSION; VARIABLES; RECOVERY; PRESSURE; DATABASE	Introduction: A fundamental purpose of neurocritical care is the management of secondary brain injury. This is often accomplished by monitoring and managing individual patient parameters including physiological vital signs. Yet, the ability to record physiological data exceeds our ability to fully integrate it into patient care. We propose that advances in monitoring must be accompanied by advances in methods of high-frequency, multivariate data analysis that integrate the multiple processes occurring in critically ill patients. Methods: We describe initial work in the emerging field of physiological informatics in critical care medicine. We analyzed data on 23 patients with brain injury from our Neurotrauma and Critical Care Database, which contains more than 20 physiological parameters recorded automatically at one-minute intervals via bedside monitors connected to standard personal computers. We performed exploratory data analysis, studied two patient cases in detail, and implemented a data-driven classification approach using hierarchical clustering. Results: In this study, we present challenges and opportunities for high-frequency multimodal monitoring to quantitatively detect secondary brain insults, and develop clustering methodology to construct multivariate physiological data "profiles" to classify patients for diagnosis and treatment. Conclusions: Recording of many physiological variables across multiple patients is feasible and can lead to new clinical insights. Computational and analytical methods previously used primarily for basic science may have clinical relevance and can potentially be adapted to provide physicians with improved ability to integrate complex information for decision making in neurocritical care.	Univ Calif San Francisco, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; San Francisco Injury Ctr, San Francisco, CA USA		Manley, GT (corresponding author), Univ Calif San Francisco, 1001 Potrero Ave Rm 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Demchuk, Andrew M/E-1103-2012; Hemphill, Claude/AAY-5630-2021	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050173, 5F31NS049691] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Burnett DM, 2000, BRAIN INJURY, V14, P713; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; Herskovits EH, 2003, NEUROIMAGE, V19, P1664, DOI 10.1016/S1053-8119(03)00231-3; Jones PA, 2003, PHYSIOL MEAS, V24, P201, DOI 10.1088/0967-3334/24/1/315; Kapetanovic IM, 2004, ANN NY ACAD SCI, V1020, P10, DOI 10.1196/annals.1310.003; Kentala E, 2000, ANN OTO RHINOL LARYN, V109, P170, DOI 10.1177/000348940010900211; Kett-White R, 2002, ADV TECH STAND NEUR, V27, P87; Kim JH, 2002, GENET MED, V4, p62S, DOI 10.1097/00125817-200211001-00013; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764	20	41	41	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	7	1					45	52		10.1007/s12028-007-0043-7			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	200EN	WOS:000248746800009	17565451				2022-02-06	
J	Sundstrom, T; Sollid, S; Wentzel-Larsen, T; Wester, K				Sundstrom, Terje; Sollid, Snorre; Wentzel-Larsen, Tore; Wester, Knut			Head injury mortality in the Nordic countries	JOURNAL OF NEUROTRAUMA			English	Article						death; neurosurgery; Nordic countries; trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MANAGEMENT; EPIDEMIOLOGY; GUIDELINES; DEATH; ADULTS; DISABILITY; SEVERITY; PEOPLE; TRENDS	Traumatic brain injury (TBI) is a major cause of morbidity and mortality in Western countries. Effective management planning for these patients requires knowledge of TBI epidemiology. The purpose of this study was to describe and analyze the development of TBI mortality in the Nordic countries during the period 1987-2001. Data on TBI deaths were retrieved from the national official statistical agencies according to specified diagnostic codes. We also collected data on the number of operations for acute TBI in the year 2000 from all Nordic hospitals admitting trauma patients. Finland had about twice as high a TBI mortality rate as the other countries. Similarly, the Finnish incidence of acute TBI operations was nearly twice that of the other countries. The median TBI death rate for Finland was 21.2 per 100,000 per year, and for Denmark, Norway, and Sweden 11.5, 10.4, and 9.5, respectively. There were more male than female deaths in all countries. The mortality rate from extracranial injuries was relatively equal between the countries. We observed a sizeable reduction in TBI mortality rates for all countries, except in Finland. Younger age groups had the most pronounced decrease in TBI mortality rates. The oldest age group had the least favorable development of TBI mortality rates, and the mean age of TBI casualties increased substantially during the study period. This study demonstrates considerable differences in and between the Nordic countries regarding TBI mortality. Preventive measures and implementation of regional guidelines are needed to assure a positive development in the future.	Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway; Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; Univ Hosp N Norway, Dept Neurosurg, Tromso, Norway		Wester, K (corresponding author), Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway.	kgwe@helse-bergen.no		Sundstrom, Terje/0000-0002-6503-7141			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; AKEDOYA N, 2002, MMWR SURVEILL SUMM, V51, P1; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cipriani Francesco, 2001, Subst Abus, V22, P55, DOI 10.1023/A:1026423926192; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; *EUROSTAT, 2002, HLTH STAT ATL MOR EU; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jansson B, 1997, J CLIN EPIDEMIOL, V50, P367, DOI 10.1016/S0895-4356(96)00426-X; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Kristiansen I S, 2000, Tidsskr Nor Laegeforen, V120, P2023; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Lunetta P, 2001, ALCOHOL CLIN EXP RES, V25, P1654; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Melinder KA, 1998, SCAND J SOC MED, V26, P190, DOI 10.1177/14034948980260030901; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NOMESCO, 2003, HLTH STAT NORD COUNT; Paljarvi T, 2005, ADDICTION, V100, P1851, DOI 10.1111/j.1360-0443.2005.01258.x; Piek J, 1998, INTENS CARE MED, V24, P1221, DOI 10.1007/s001340050748; Rasanen P, 2002, J AFFECT DISORDERS, V71, P51, DOI 10.1016/S0165-0327(01)00411-6; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *STAT NORW, 2003, STAT YB NORW 2003 AR; *STAT SWED, 2004, PERS KILL SEV SLIGHT; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; THEELE DS, 2000, TIDDSKR NOR LAEGEFOR, V120, P2018; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; *WHO, 2006, PERC URB POP BOTH SE; *WHO, 2006, SDR HOM INT INJ ALL; *WHO, 2006, PUR ALC CONS LITR CA; *WHO, 2006, SDR SUIC SELF INFL I	49	41	42	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					147	153		10.1089/neu.2006.0099			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100014	17263678				2022-02-06	
J	Vergouwen, MDI; Vermeulen, M; Roos, YBWEM				Vergouwen, Mervyn D. I.; Vermeulen, Marinus; Roos, Yvo B. W. E. M.			Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review	LANCET NEUROLOGY			English	Article							HEAD-INJURY; TRIAL	Background Despite several randomised controlled trials, there is still much debate whether nimodipine improves outcome in patients with traumatic subarachnoid haemorrhage. A 2003 Cochrane review reported improved outcome with nimodipine in these patients; however, because the results of Head Injury Trial (HIT) 4 were only partly presented there is still discussion whether patients with traumatic subarachnoid haemorrhage should be treated with this drug. Here, we present data from all head-injury trials, including previously unpublished results from HIT 4. Methods We systematically searched PubMed and EMBASE databases using the following combinations of variables "nimodipine" or "calcium antagonist" with "traumatic subarachnoid haemorrhage", "head injury", "head trauma", "brain injury", or "brain trauma". Bayer AG and all principal investigators or corresponding authors of the identified studies were contacted for additional information. Findings Five manuscripts were identified, describing the results of four trials. We obtained additional data from HIT 1, 2, and 4. In total, 1074 patients with traumatic subarachnoid haemorrhage were included. The occurrence of poor outcome was similar in patients treated with nimodipine (39%) and those treated with placebo (40%); odds ratio was 0.88 (95% CI 0.51-1.54). Mortality rates did not differ between nimodipine (26%) and placebo (27%) treated patients (odds ratio 0.95; 95% CI 0.71-1.26). Interpretation Our results do not lend support to the finding of a beneficial effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage as reported in an earlier Cochrane review.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands		Vergouwen, MDI (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.d.vergouwen@amc.uva.nl	Roos, Yvo BWEM/B-9843-2013				BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENNETT B, 1975, LANCET, V2, P480; KOSTRON H, 1984, Neurological Research, V6, P29; Langham J, 2003, COCHRANE DB SYST REV; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Pillai SV, 2003, NEUROL INDIA, V51, P361; RINKEL GJ, 2005, COCHRANE DB SYST REV, V1; Roos YBWEM, 2001, STROKE, V32, P1860, DOI 10.1161/01.STR.32.8.1860; STEIGER HJ, 1994, NEUROSURGERY, V34, P79	13	41	45	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					1029	1032		10.1016/S1474-4422(06)70582-8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	WOS:000242266100032	17110283				2022-02-06	
J	Sadowski-Cron, C; Schneider, J; Senn, P; Radanov, BP; Ballinari, P; Zimmermann, H				Sadowski-Cron, Charlotte; Schneider, Joerg; Senn, Pascal; Radanov, Bogdan P.; Ballinari, Pietro; Zimmermann, Heinz			Patients with mild traumatic brain injury: Immediate and long-term outcome compared to intra-cranial injuries on CT scan	BRAIN INJURY			English	Article						mild traumatic brain injury; intra-cranial injury; neurocognitive tests at admission; subjective complaints after 1 year; costs	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; ADULTS; MANAGEMENT; DIAGNOSIS; SEQUELAE; CLASSIFICATION; METAANALYSIS; DISABILITY; UTILITY	Background: Mild traumatic brain injury ( MTBI) defined as Glasgow Coma Scale ( GCS) 14 or 15 has shown contradictory short- and long- term outcomes. The objective of this study was to correlate intra- cranial injuries ( ICI) on CT scan to neurocognitive tests at admission and to complaints after 1 year. Methods: Two hundred and five patients with MTBI underwent a CT scan and were examined with neurocognitive tests. After 1 year complaints were assessed by phone interviews. Results: The neurocognitive tests in 51% of the patients showed significant deficits; there was no difference for patients with GCS 14 - 15, nor was there a difference between patients with ICI to patients without. After 1 year patients with ICI had significantly more complaints than patients without ICI, the most frequent complaint was headache and memory deficits. Conclusions: No correlation was found between GCS or ICI and the neurocognitive tests upon admission. After 1 year, patients with ICI have significantly more complaints than patients without ICI. No cost savings resulted by doing immediate CT scan on all.	Univ Bern, Inselspital, Dept Accid & Emergency Med, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland		Zimmermann, H (corresponding author), Inselspital Bern, Dept Emergency Med, CH-3010 Bern, Switzerland.	heinz.zimmermann@insel.ch		Senn, Pascal/0000-0002-4619-3341			af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; AFGEIJERSTAM JL, 2003, ACTA NEUROCHIR WIEN, V145, P850; American College of Surgeons, 2004, ATLS ADV TRAUM LIF S, V7th ed; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; *C NEUR SURG INC, 1966, CLIN NEUROSURG, V14, P424; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; Eng J, 2003, NEUROIMAG CLIN N AM, V13, P273, DOI 10.1016/S1052-5149(03)00015-7; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; IMHOF HG, 1992, HELV CHIR ACTA, V58, P667; Jacobs A, 1996, J NUCL MED, V37, P1605; JERET JS, 1993, J TRAUMA, V35, P490, DOI 10.1097/00005373-199309000-00030; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK M, 1995, NEUROSYCHOLOGICAL AS; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV B, 1986, FORTSCHR NEUROL PSYC, V54, P375, DOI 10.1055/s-2007-1001942; RADANOV BP, 1992, LANCET, V339, P749, DOI 10.1016/0140-6736(92)90654-L; Regard M., 1981, COGNITIVE RIGIDITY F; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	43	41	41	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1131	1137		10.1080/02699050600832569			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600003	17123929				2022-02-06	
J	Nekludov, M; Bellander, BM; Mure, M				Nekludov, M.; Bellander, B. -M.; Mure, M.			Oxygenation and cerebral perfusion pressure improved in the prone position	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						intracranial pressure; cerebral perfusion pressure; prone position; traumatic brain injury; acute respiratory failure	INTRACRANIAL-PRESSURE; BLOOD-FLOW; MICRODIALYSIS; HEMODYNAMICS; POSTURE; SUPINE	Background: Treatment of patients in the prone position is a well-established method to improve oxygenation in general intensive care unit (ICU) practice. This method is rarely used in a neurosurgical ICU, considering the risk of intracranial hypertension. The aim of this study was to analyse the effect of prone position on intracranial pressure (ICP), cerebral perfusion pressure (CPP) and systemic oxygenation in patients with reduced intracranial compliance. We hypothesize that the beneficial effects of prone position can outweigh the hazardous effects on the intracranial pressure. Methods: Eight patients with traumatic brain injury or subarachnoid hemorrhage (SAH) were studied in the supine and prone posture. Hemodynamics, arterial oxygenation, respiratory mechanics, ICP and CPP were continuously measured. Results: A significant improvement in PaO2 was observed in the prone position, from 12.6 +/- 1.4 kPa to 15.7 +/- 3.2 kPa (P = 0.02). Both intracranial pressure and mean arterial pressure increased in the prone position, from 12 +/- 6 to 15 +/- 4 mmHg (P = 0.03) and from 78 +/- 8 to 88 +/- 8 mmHg (P = 0.005), respectively. Arterial pressure increased to a greater extent than ICP, resulting in improved CPP, from 66 +/- 7 to 73 +/- 8 mmHg (P = 0.03) in the prone position. Conclusions: The prone position can be used to improve the oxygenation as well as CPP in patients with traumatic brain injury or SAH. However, this method results in raised ICP, and should be used cautiously in patients with reduced intracranial compliance.	Karolinska Univ Hosp & Inst, Dept Anesthesiol & Intens Care, Stockholm, Sweden; Karolinska Univ Hosp & Inst, Dept Neurosurg, Stockholm, Sweden		Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se		Nekludov, Michael/0000-0001-9916-7086			Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FORTUNE JB, 1995, J TRAUMA, V39, P463; Hering R, 2001, ANESTH ANALG, V92, P1226, DOI 10.1097/00000539-200105000-00027; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LEE ST, 1989, HEART LUNG, V18, P411; Mure M, 2001, ACTA ANAESTH SCAND, V45, P150, DOI 10.1034/j.1399-6576.2001.450204.x; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Pelosi P, 2002, EUR RESPIR J, V20, P1017, DOI 10.1183/09031936.02.00401702; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Venet C, 2001, INTENS CARE MED, V27, P1352, DOI 10.1007/s001340101023; Walther SM, 1999, CRIT CARE MED, V27, P37, DOI 10.1097/00003246-199901000-00024; Wang J, 2002, ACTA ANAESTH SCAND, V46, P1094, DOI 10.1034/j.1399-6576.2002.460907.x; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	21	41	42	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					932	936		10.1111/j.1399-6576.2006.01099.x			5	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	076EF	WOS:000239939100004	16923086				2022-02-06	
J	Cutler, SM; VanLandingham, JW; Stein, DG				Cutler, Sarah M.; VanLandingham, Jacob W.; Stein, Donald G.			Tapered progesterone withdrawal promotes long-term recovery following brain trauma	EXPERIMENTAL NEUROLOGY			English	Article							CEREBRAL-ARTERY OCCLUSION; NEUROACTIVE STEROIDS; NEUROTROPHIC FACTOR; INFLAMMATORY RESPONSE; GABA(A) RECEPTOR; SPINAL-CORD; INJURY; RATS; EXPRESSION; NEUROSTEROIDS	We previously demonstrated that after traumatic brain injury (TBI), acute progesterone withdrawal (AW) causes an increase in anxiety behaviors and cerebro-cellular inflammation compared to tapered progesterone withdrawal (TW). Our current study investigates the behavioral and cellular effects of AW two weeks after termination of treatments to determine the longer-term influence of withdrawal after injury. Adult, male Sprague-Dawley rats received either bilateral frontal cortex contusion (L) or sham (S) surgery. Rats were injected at I and 6 h post-injury, then every 24 h for six days. Vehicle (V)-treated rats Were given 9 injections of 22.5% cyclodextrin, whereas AW rats received 9 injections of 16 mg/kg progesterone and TW rats received 7 injections of P at 16 mg/kg, followed by one at 8 mg/kg and one at 4 mg/kg. On day 8, sensory neglect and locomotor activity tests were initiated. Animals were killed 22 days post-TBI and the brains prepared for either molecular or histological analysis. Western blotting revealed increased brain-derived neurotrophic factor (BDNF) and heat shock protein 70 (HSP70) in TW vs. AW animals. P53 was increased in VL animals, whereas all progesterone-treated groups were equivalent to shams. TW animals had markedly decreased sensory neglect compared to AW animals and increased center time in locomotor activity assays. In addition, lesion reconstruction revealed a decreased lesion size for TWL over AWL over VL animals. Glial fibrillary acidic protein (GFAP) immunofluorescent staining followed this pattern as well. In conclusion, after TBI, AW affects select behaviors and molecular markers in the chronic recovery period. (c) 2006 Elsevier Inc. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA USA		Cutler, SM (corresponding author), 1365B Clifton Rd,Emory Clin Suite 5100,Room 5301, Atlanta, GA 30322 USA.	scutler@emory.edu	Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS540825, 1R01NS538664] Funding Source: Medline		Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; AKWA Y, 1991, J STEROID BIOCHEM, V40, P71, DOI 10.1016/0960-0760(91)90169-6; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burleson MH, 1998, PSYCHOSOM MED, V60, P17, DOI 10.1097/00006842-199801000-00004; CDC, 2004, TRAUM BRAIN INJ US, P1; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chuang De-Maw, 2004, Critical Reviews in Neurobiology, V16, P83, DOI 10.1615/CritRevNeurobiol.v16.i12.90; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; de Leme RJ, 2001, ARQ NEURO-PSIQUIAT, V59, P483; DELCERRO S, 1995, GLIA, V14, P65; DelCerro S, 1996, GLIA, V18, P293, DOI 10.1002/(SICI)1098-1136(199612)18:4<293::AID-GLIA4>3.0.CO;2-Z; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Foldvary-Schaefer Nancy, 2004, Cleve Clin J Med, V71 Suppl 2, pS11; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gulinello M, 2003, EUR J NEUROSCI, V17, P641, DOI 10.1046/j.1460-9568.2003.02479.x; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Horvath KM, 2000, EUR J PHARMACOL, V405, P33, DOI 10.1016/S0014-2999(00)00539-2; Kempermann G, 2000, Prog Brain Res, V127, P35; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Legrand A, 1998, BRAIN RES, V802, P125, DOI 10.1016/S0006-8993(98)00580-0; Lukasiuk K, 2000, J NEUROCHEM, V74, P2445, DOI 10.1046/j.1471-4159.2000.0742445.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Rupprecht R, 2001, BRAIN RES REV, V37, P59, DOI 10.1016/S0165-0173(01)00123-0; Rupprecht R, 2001, INT REV NEUROBIOL, V46, P461; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 2002, STEROIDS, V67, P519, DOI 10.1016/S0039-128X(01)00170-2; vandenPol AN, 1996, NEUROSCIENCE, V74, P653, DOI 10.1016/0306-4522(96)00153-4; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001	48	41	41	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2006	200	2					378	385		10.1016/j.expneurol.2006.02.137			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	072BH	WOS:000239647100011	16797538				2022-02-06	
J	Worthington, AD; Matthews, S; Melia, Y; Oddy, M				Worthington, Andrew D.; Matthews, Sarah; Melia, Yvonne; Oddy, Michael			Cost-benefits associated with social outcome from neurobehavioural rehabilitation	BRAIN INJURY			English	Article						rehabilitation; social outcome; cost-benefits	TRAUMATIC BRAIN-INJURY; SUPERVISION RATING-SCALE; CLOSED HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; HEALTH; ADULTS; DISABILITY; PROGRAM; RETURN; WORK	Primary objective: To carry out a clinical and cost-outcome evaluation of a neurobehavioural post-acute rehabilitation programme in the UK. Research design: The study was a multi-centre prospective cohort study of adults with acquired brain injury admitted for residential rehabilitation. Comprehensive data were collected on type of residence, amount and type of care, functional independence, engagement in constructive occupation and participation in social roles. Procedures: Data were gathered on admission relating to individuals' levels of care and functioning, both pre-morbidly and at the time of admission (pre-rehabilitation). Additional information about functioning was collected upon discharge (post-rehabilitation). Follow-up data was collated in person, by telephone or by post after an average of 18 months by a researcher who was blind to the rehabilitation outcomes. The data were analysed in terms of clinical outcomes and support costs. Savings in costs of care or support were calculated on the basis of difference between pre-rehabilitation and follow-up support costs minus the costs of rehabilitation. Results: Significant gains were evident at discharge and follow-up in virtually all indices of social outcome. Improvements were recorded in type of accommodation, levels of care, functional ability, productive occupation and performance of social roles. Patients admitted within 1 year of injury made the most progress, but improvements were made regardless of time since injury. Patients continued to benefit from rehabilitation well beyond the period when most natural recovery would take place. Economic calculations suggested that the initial costs of rehabilitation are generally offset by savings in care costs within 2 years. Sensitivity analysis on estimated savings in care costs yielded projected lifetime savings of between,1.1-0.8 pound M for persons admitted for rehabilitation within 12 months of injury, 0.7- pound 0.5 pound M within 2 years of injury and, 0.5-0.36M pound for admissions after 2 years. Conclusions: Specialist rehabilitation for neurobehavioural disability produces comprehensive and sustainable improvements in the life of individuals with brain injury. The initial costs associated with neurobehavioural rehabilitation are offset by savings in costs of support in the medium and longer term.	Brain Injury Rehabil Trust, Birmingham, W Midlands, England; Disabil Trust, Burgess Hill, W Sussex, England		Worthington, AD (corresponding author), W Heath House,54 Ivy House Rd, Birmingham B38 8JW, W Midlands, England.	aworthington@birt.co.uk		Melia, Yvonne/0000-0003-4430-9379			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BERG J, 2004, EUROPEAN J HLTH E S1, V6, pS84; Black N, 1996, BRIT MED J, V312, P1215; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cervelli L, 1997, ARCH PHYS MED REHAB, V78, pS36, DOI 10.1016/S0003-9993(97)90154-4; Chantler C, 2004, INT J TECHNOL ASSESS, V20, P87, DOI 10.1017/S0266462304000844; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Drummond MF, 2015, METHODS EC EVALUATIO; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Gold M., 1996, COST EFFECTIVENESS H; Greiner KA, 2004, SOC SCI MED, V59, P2303, DOI 10.1016/j.socscimed.2004.03.023; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Lannoo E, 2004, BRAIN INJURY, V18, P203, DOI 10.1080/02699050310001596905; LERI JE, 1995, BRAIN INJURY, V9, P533, DOI 10.3109/02699059509008212; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MCKENNA M, 1992, IS REHABILITATION CO; McMillan TM, 2004, CLIN REHABIL, V18, P132, DOI 10.1191/0269215504cr712oa; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Murrey GJ, 2004, BRAIN INJURY, V18, P519, DOI 10.1080/02699050310001646125; *NIH, 1999, JAMA-J AM MED ASSOC, V8, P974; Normand C, 1998, J PUBLIC HEALTH MED, V20, P129, DOI 10.1093/oxfordjournals.pubmed.a024730; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; *OFF NAT STAT, 2005, SOC TRENDS OFF NATL, V35; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Pollock C., 1993, CLIN REHABIL, V7, P63, DOI [DOI 10.1177/026921559300700109, 10.1177/026921559300700109]; Polverejan E, 2003, HEALTH ECON, V12, P935, DOI 10.1002/hec.774; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Reed K, 1999, ARCH CLIN NEUROPSYCH, V14, P795; ROBERTSON IH, 1994, NEUROPSYCHOLOGIA, V32, P1, DOI 10.1016/0028-3932(94)90064-7; *ROYAL COLL NURS, 2005, AG CHANG GUID NEW PA; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; SMITH D, 2000, TECHNICAL PAPER SERI, V19; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WAX W, 1991, J NEUROSURG, V48, P673; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Whyte J, 2002, ARCH PHYS MED REHAB, V83, P1320, DOI 10.1053/apmr.2002.34807; Wood RL, 1999, NEUROPSYCHOL REHABIL, V9, P505, DOI 10.1080/096020199389554; Wood RL, 2001, BRAIN DAM B, P133; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; WORTHINGTON A, 2005, EFFECTIVENESS REHABI, P257; Worthington AD, 2006, CLIN REHABIL, V20, P79, DOI 10.1191/0269215506cr881oa	63	41	41	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2006	20	9					947	957		10.1080/02699050600888314			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100007	17062426				2022-02-06	
J	Chung, CY; Chen, CL; Cheng, PT; See, LC; Tang, SFT; Wong, AMK				Chung, Chia-Ying; Chen, Chia-Ling; Cheng, Pao-Tsai; See, Lai-Chu; Tang, Simon Fuk-Tan; Wong, Alice May-Kuen			Critical score of Glasgow Coma Scale for pediatric traumatic brain injury	PEDIATRIC NEUROLOGY			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; EARLY PREDICTION; OUTCOME PREDICTION; PRACTICAL SCALE; DATA-BANK; CHILDREN; CT; CHILDHOOD	The aim of this study is to determine the predictive critical value of the Glasgow Coma Scale for use as a determinant of outcome for children with traumatic brain injuries. A total of 309 children, aged 2-10 years, were enrolled in this study. Each subject underwent the following assessments: Glasgow Coma Scale; clinical data, brain computed tomography; and Glasgow Outcome Scale assessments. The receiver operating characteristic curve indicated that a critical point of the Glasgow Coma Scale set at 5 was most strongly correlated with outcome of pediatric traumatic brain injury. Subarachnoid hemorrhage with brain swelling and edema, subdural, intracerebral hemorrhage, and basal ganglion lesions were associated with severe injury and poor outcome (P < 0.05). However, cortical lesions did not affect injury severity and outcome. In injuries associated with traumatic brain injuries, only chest trauma had a tendency to be associated with poor outcome (P < 0.05). Of the factors analyzed, the score of the Glasgow Coma Scale was the most effective predictor for outcome in pediatric traumatic brain injury. Furthermore, the predictive critical score of the Glasgow Coma Scale should be set at 5 for pediatric traumatic brain injury. The computed tomographic findings also were important in determining injury severity and predicting outcome. (c) 2006 by Elsevier Inc. All rights reserved.	Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan		Chen, CL (corresponding author), Chang Gung Mem Hosp, Dept Phys Med & Rehabil, 5,Fuhsing St, Taoyuan, Taiwan.	clingchen@gmail.com	Wong, Alice M. K./ABI-1000-2020	Wong, Alice M. K./0000-0003-3586-1292; See, Lai-Chu/0000-0002-1379-8969			Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; CARDIA E, 1990, CHILD NERV SYST, V6, P23, DOI 10.1007/BF00262261; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; Cusmano F, 1985, Acta Neurol (Napoli), V7, P14; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GIBSON RM, 1989, LANCET, V2, P369; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Hofer T, 1993, J Neurosci Nurs, V25, P218; JENNETT B, 1975, LANCET, V1, P480; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MURRAY RR, 1984, AM J NEURORADIOL, V5, P177; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; TEASDALE G, 1974, LANCET, V2, P81; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Yaryura-Tobias JA, 2003, J CLIN PSYCHIAT, V64, P1495, DOI 10.4088/JCP.v64n1214; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	45	41	42	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2006	34	5					379	387		10.1016/j.pediatrneurol.2005.10.012			9	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	043XR	WOS:000237636700008	16647999				2022-02-06	
J	Gordon, KE; Dooley, JM; Wood, EP				Gordon, Kevin E.; Dooley, Joseph M.; Wood, Ellen P.			Descriptive epidemiology of concussion	PEDIATRIC NEUROLOGY			English	Article							BRAIN; INJURIES; SPORTS	To describe the epidemiology of reported concussion derived from a large, nationally representative health survey, the microdata flies of the Canadian National Population Health Survey (1996-1997) were analyzed. Respondents reported whether they had "any injuries that were serious enough to limit their normal activities" in the preceding 12 months and the nature of the most serious injury. A total of 99.8% of 81,804 eligible respondents, representing 28,606,100 Canadians, reported their injury experience within the preceding year, with 89 reporting a concussion. The annual prevalence of Canadians reporting a concussion as their most serious injury was 110 per 100,000 population (95% confidence interval: 80, 140). Those reporting concussion were more likely to be younger (P < 0.001) and male (P = 0.02). Males were significantly overrepresented in the 16-34 year-old group (P = 0.004). More than 54% of all concussions were sport-related (95% confidence interval: 39%, 67%), occurring at a place for recreation or sport, with sport having a role in > 85% of concussions in the 16-34 year-old group. This study presents annual prevalence estimates of reported concussion, derived from a sizeable, nationally representative population survey. (c) 2006 by Elsevier Inc. All rights reserved.	IWK Hlth Ctr, Dept Pediat, Halifax, NS B3K 6R8, Canada; Dalhousie Univ, Div Pediat Neurol, Dept Pediat, Halifax, NS B3H 3J5, Canada		Gordon, KE (corresponding author), IWK Hlth Ctr, Dept Pediat, 5850 Univ Ave, Halifax, NS B3K 6R8, Canada.	KEGOR@DAL.CA					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; *SPSS INC, 1998, SYSTAT; *STAT CAN, 1998, NAT POP HLTH SURV NP; *STAT CAN, 1998, NAT POP HLTH SURV 19; Tambay J L, 1995, Health Rep, V7, P29; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017	16	41	42	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2006	34	5					376	378		10.1016/j.pediatrneurol.2005.09.007			3	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	043XR	WOS:000237636700007	16647998				2022-02-06	
J	Rapoport, MJ; Herrmann, N; Shammi, P; Kiss, A; Phillips, A; Feinstein, A				Rapoport, MJ; Herrmann, N; Shammi, P; Kiss, A; Phillips, A; Feinstein, A			Outcome after traumatic brain injury sustained in older adulthood: A one-year longitudinal study	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article; Proceedings Paper	11th Congress of the International-Psychogeriatric-Association	AUG 17-22, 2003	Chicago, IL	Int Psychogeriatr Assoc		traumatic brain injury; cognition; major depression	CLOSED-HEAD INJURY; NEUROBEHAVIORAL CONSEQUENCES; ALZHEIMERS-DISEASE; RISK-FACTOR; MILD; QUESTIONNAIRE; SYMPTOMS; DEPRESSION	Objective: The objective of this study was to explore the effects of traumatic brain injury (TBI) on cognition and functioning in older adults in a one-year longitudinal study. Methods: Participants with mild-to-moderate TBI were compared with an age-, gender-, and education-matched healthy comparison group on aspects of cognition. Neuropsychologic tests were administered at one year. Self-reported measures of functioning were completed at baseline, six months, and one year. Informants rated instrumental functioning at one year. Results: Sixty-nine subjects aged 50 years and over (mean: 67 years; standard deviation: 7.9) and a comparison group of 79 participants were assessed. Patients with TBI had poorer processing speed, verbal memory, language, and executive function; they self-reported more psychologic distress, psychosocial dysfunction, and postconcussive symptoms; and they were rated as more impaired in functioning than the comparison group. TBI of moderate severity accounted for most of the between-group differences. Conclusion: TBI, particularly of moderate severity, led to poorer cognitive and psychosocial functioning one year postinjury among older adults. The clinical significance of this may become more evident with time in this vulnerable population.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci, Toronto, ON, Canada		Rapoport, MJ (corresponding author), FRCPC, FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020				AharonPeretz J, 1997, BRAIN INJURY, V11, P871; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 1989, CALIFORNIA VERBAL LE; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; First M.B., 1996, STRUCTURED CLIN INTE; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lavretsky H, 2002, AM J GERIAT PSYCHIAT, V10, P239, DOI 10.1176/appi.ajgp.10.3.239; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mattis S., 1976, GERIATRIC PSYCHIAT H, P77; MAZZUCCHI A, 1992, J NEUROL, V239, P256; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MCCULLAGH S, 2004, NEUROPSYCHIAT TBI; MCCULLAGH S, 2002, J NEUROPSYCH CLIN N, V14, P116; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; *PSYCH CORP, 1997, WECHSL ADULT INT SCA; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tabert MH, 2002, NEUROLOGY, V58, P758, DOI 10.1212/WNL.58.5.758	40	41	44	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	MAY	2006	14	5					456	465		10.1097/01.JGP.0000199339.79689.8a			10	Geriatrics & Gerontology; Gerontology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Geriatrics & Gerontology; Psychiatry	038RC	WOS:000237239700009	16670250				2022-02-06	
J	Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D				Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D			Functional outcome in TBI II: Verbal memory and information processing speed mediators	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; HIV-1 INFECTION; SCHIZOPHRENIA; MODERATE; SCALE; DISABILITIES; IMPAIRMENT; PREVALENCE; PREDICTORS	Following traumatic brain injury (TBI), patients often report memory difficulties, as well as reduced information processing speed. However, it remains unclear the extent to which these deficits contribute to functional impairment. In the present study, we compared the relative contribution of verbal memory and information processing speed to functional impairment at 12-month post-injury, in 87 patients with moderate-to-severe TBI. Employing structural equation modeling, we found that information processing speed, but not verbal memory functions, significantly mediated the relationship between TBI severity and post-TBI adaptive functioning. These findings suggest that despite the pervasive memory complaints among patients with TBI, it is the impact of neurotrauma on frontal systems that appears to be primarily responsible for patients' difficulties in social and occupational functioning.	Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Daniel Freeman Mem Hosp, Inglewood, CA USA; Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Child Psychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA		Rassovsky, Y (corresponding author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.	yurir@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Rassovsky, Yuri/0000-0002-6362-9944			Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENTLER PM, 1996, EQS STRUCTURAL EQUAT; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Brekke JS, 1997, SCHIZOPHRENIA BULL, V23, P19, DOI 10.1093/schbul/23.1.19; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DELIA LF, 1996, COLOR TRAILS TEST AD; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Goodkin K, 2001, PSYCHIAT ANN, V31, P37, DOI 10.3928/0048-5713-20010101-09; Green MF, 1999, SCHIZOPHRENIA BULL, V25, P309, DOI 10.1093/oxfordjournals.schbul.a033380; Green MF, 1996, AM J PSYCHIAT, V153, P321; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; KlOve H, 1963, MED CLIN N AM; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS., 1982, NEUROBEHAVIORAL CONS; Light R, 1987, J HEAD TRAUMA REHAB, V2, P11, DOI DOI 10.1097/00001199-198703000-00005; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1984, CLOSED HEAD INJURY; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 2003, NEUROREHABILITATION, V18, P47; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; RASSOVSKY Y, IN PRESS J CLIN EXPT; Rey A., 1964, EXAMEN CLIN PSYCHOL; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Smith A., 1982, SYMBOL DIGIT MODALIT; *STAT U NEW YORK, 1993, AD FUNCT IND MEAS VE; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Ullman JB., 2001, USING MULTIVARIATE S, V4, P653; Vogenthaler D R, 1987, Brain Inj, V1, P113; Wilkie FL, 1998, J NEUROPSYCH CLIN N, V10, P125, DOI 10.1176/jnp.10.2.125	43	41	41	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2006	28	4					581	591		10.1080/13803390500434474			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	033MX	WOS:000236853600009	16624785				2022-02-06	
J	Zhang, L; Zhang, WP; Hu, H; Wang, ML; Sheng, WW; Yao, HT; Ding, W; Chen, Z; Wei, EQ				Zhang, L; Zhang, WP; Hu, H; Wang, ML; Sheng, WW; Yao, HT; Ding, W; Chen, Z; Wei, EQ			Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma	NEUROPATHOLOGY			English	Article						astrocytoma; 5-lipoxygenase; traumatic brain injury	ARACHIDONATE 5-LIPOXYGENASE; NORDIHYDROGUAIARETIC ACID; ACTIVATING PROTEIN; NUCLEAR-ENVELOPE; LEUKOTRIENE C-4; CELL-DEATH; LOCALIZATION; BIOSYNTHESIS; INHIBITION; ISCHEMIA	5-Lipoxygenase (5-LOX) is a key enzyme in the metabolism of arachidonic acid to leukotrienes. The levels of leukotrienes increase after brain injury and when tumors are present. It has been reported that 5-LOX is widely expressed in the brain and that 5-LOX inhibition provides neuroprotection. However, there is still no information available for the expression patterns of 5-LOX in human brain following trauma or with astrocytomas. We investigated its expression patterns by immunohistochemistry. We found that 5-LOX is normally expressed in neurons and glial cells. In neurons, it was expressed in two patterns: in the cytosol and nucleus or only in the cytosol. In traumatic brain injury, 5-LOX expression increased in glial cells and neutrophils. Double-labeling immunohistochemistry showed that part of the 5-LOX-positive glial cells were GFAP positive. No 5-LOX expression was found in brain microvessel endothelia, except in the regenerated endothelia of a patient 8 days following brain trauma. Furthermore, 5-LOX expression increased and showed a granular pattern in high-grade (grade III/IV) astrocytoma. These results indicate that 5-LOX has multiple expression patterns, and can be induced by brain injury, which implies that 5-LOX might have pathophysiological roles in the human brain.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 2, Sch Med, Hangzhou 310031, Peoples R China; Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Sch Med, Hangzhou 310031, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Arai K, 2001, BRAIN RES, V904, P167, DOI 10.1016/S0006-8993(01)02491-X; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1999, J IMMUNOL, V162, P1669; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Cowburn AS, 1999, J IMMUNOL, V163, P456; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghosh J, 2003, BIOCHEM BIOPH RES CO, V307, P342, DOI 10.1016/S0006-291X(03)01201-4; Golubic M, 2003, ADV EXP MED BIOL, V525, P205; Hashizume K, 2002, J NEUROPATH EXP NEUR, V61, P725, DOI 10.1093/jnen/61.8.725; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lebeau A, 2001, NEUROREPORT, V12, P2199, DOI 10.1097/00001756-200107200-00031; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; NAMURA Y, 1994, ACTA NEUROCHIR, P296; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PALMER MR, 1980, NEUROSCI LETT, V18, P173, DOI 10.1016/0304-3940(80)90322-5; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Seufferlein T, 2002, BRIT J CANCER, V86, P1188, DOI 10.1038/sj/bjc/6600186; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; SIMMET T, 1990, J NEUROCHEM, V54, P2091, DOI 10.1111/j.1471-4159.1990.tb04915.x; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; TEASDALE G, 1974, LANCET, V2, P81; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Unterberg A, 1990, Adv Neurol, V52, P211; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Uz T, 2001, EUR J PHARMACOL, V418, P15, DOI 10.1016/S0014-2999(01)00924-4; Walker JL, 2002, AM J PHYSIOL-HEART C, V282, pH585, DOI 10.1152/ajpheart.00003.2001; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Ye YN, 2004, TOXICOLOGY, V203, P179, DOI 10.1016/j.tox.2004.06.004	36	41	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	APR	2006	26	2					99	106		10.1111/j.1440-1789.2006.00658.x			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	029GL	WOS:000236548800001	16708542				2022-02-06	
J	Park, E; McKnight, S; Ai, JL; Baker, AJ				Park, Eugene; McKnight, Sarah; Ai, Jinglu; Baker, Andrew J.			Purkinje cell vulnerability to mild and severe forebrain head trauma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; cerebellum; fluid percussion injury (FPI); Purkinje cell; traumatic brain injury; TUNEL	CONTROLLED CORTICAL IMPACT; EXPERIMENTAL BRAIN-INJURY; LATERAL FLUID-PERCUSSION; EXTRACELLULAR POTASSIUM; NEURONAL APOPTOSIS; COGNITIVE DEFICITS; MOTOR COORDINATION; AMPA NEUROTOXICITY; CEREBELLAR DAMAGE; GLUTAMATE UPTAKE	Pathophysiological changes in the cortex, thalamus, and hippocampus have been implicated as contributors to motor and cognitive deficits in a number of animal models of traumatic brain injury (TBI). Indirect cerebellar injury may contribute to TBI pathophysiology because impairment of motor function and coordination are common consequences of TBI, but are also domains associated with cerebellar function. However, there is a lack of direct evidence to support this claim. Hence, in this study, a dose-response relationship of the cerebellum's susceptibility was determined at four grades of fluid percussion injury (1.5, 2.0, 2.5, and 3.0 atm) applied in the right lateral cerebral cortex of adult male Sprague-Dawley rats. Evidence suggests primary and secondary injury mechanisms resulting in selective cerebellar Purkinje neuron (PN) loss, whereas intemeurons of the molecular layer were spared. The posterior region of the cerebellar vermis displayed significant PN loss (p = 0.001) at 1 day postinjury, whereas the gyrus of the horizontal fissure and gyrus of lobules III and IV exhibited delayed PN loss at higher levels of injury severity. Interestingly, neither terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) or cleaved caspase-3 colocalized with PNs at any time point or injury severity. Expression of calbindin-28k increased in regions of greatest PN loss, suggesting that the surviving PNs possess higher calcium-buffering capacities, which may account for their survival.	St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada		Baker, AJ (corresponding author), Cara Phelan Ctr Trauma Res, 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barski JJ, 2003, J NEUROSCI, V23, P3469; Bastianelli E, 2003, CEREBELLUM, V2, P242, DOI 10.1080/14734220310022289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; BRORSON JR, 1994, J NEUROSCI, V14, P187; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GARTHWAITE G, 1991, EUR J NEUROSCI, V3, P715, DOI 10.1111/j.1460-9568.1991.tb01668.x; GARTHWAITE G, 1991, EUR J NEUROSCI, V3, P729, DOI 10.1111/j.1460-9568.1991.tb01669.x; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hattori N, 2003, J NUCL MED, V44, P1709; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Joyal CC, 1996, BRAIN RES, V739, P1, DOI 10.1016/S0006-8993(96)00333-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; Leggio MG, 2000, P NATL ACAD SCI USA, V97, P2320, DOI 10.1073/pnas.040554297; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RINK A, 1995, AM J PATHOL, V147, P1575; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Strahlendorf JC, 1996, BRAIN RES, V729, P197, DOI 10.1016/0006-8993(96)00367-8; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	61	41	41	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2006	65	3					226	234		10.1097/01.jnen.0000202888.29705.93			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	050EQ	WOS:000238070700004	16651884				2022-02-06	
J	Staszewski, RD; Yamamoto, BK				Staszewski, RD; Yamamoto, BK			Methamphetamine-induced spectrin proteolysis in the rat striatum	JOURNAL OF NEUROCHEMISTRY			English	Article						calpain; excitotoxicity; glutamate; methamphetamine; spectrin	INDUCED DOPAMINERGIC NEUROTOXICITY; TRANSIENT FOREBRAIN ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; GLUTAMATE RECEPTORS; GLOBAL-ISCHEMIA; EXTRACELLULAR CONCENTRATIONS; SEPTOHIPPOCAMPAL CULTURES	Methamphetamine (METH) is a widely abused psychostimulant. Multiple high doses of METH cause long-term toxicity to dopamine (DA) and serotonin (5-HT) nerve terminals in the brain, as evidenced by decreases in DA and 5-HT content, decreases in tyrosine and tryptophan hydroxylase activities, decreases in DA and 5-HT re-uptake sites, and nerve terminal degeneration. Multiple high doses of METH are known to elicit a rapid increase in DA release and hyperthermia. Although METH also produces a delayed and sustained rise in glutamate, no studies have shown whether METH produces structural evidence of excitotoxicity in striatum, or identified the receptors that mediate this toxicity directly, independent of alterations in METH-induced hyperthermia. These experiments investigated whether METH can cause excitotoxicity as evidenced by cytoskeletal protein breakdown in a glutamate receptor-dependent manner. METH increased calpain-mediated spectrin proteolysis in the rat striatum 5 and 7 days after METH administration without affecting caspase 3-dependent spectrin breakdown. This effect was completely blocked with the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, GYKI 52466, but not the NMDA receptor antagonist, MK-801. However, AMPA or NMDA receptor antagonism did not attenuate the METH-induced depletions of the dopamine transporter (DAT). Independent mechanisms involved in mediating spectrin proteolysis and DAT protein loss are discussed.	Boston Univ, Sch Med, Dept Pharmacol, Neurochem Lab, Boston, MA 02118 USA		Yamamoto, BK (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, Neurochem Lab, Boston, MA 02118 USA.	bkyam@bu.edu	Yamamoto, Bryan/Z-1050-2019		NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007606] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07606] Funding Source: Medline		ABEKAWA T, 1994, BRAIN RES, V643, P276, DOI 10.1016/0006-8993(94)90033-7; Abellan MT, 2000, EUR NEUROPSYCHOPHARM, V10, P455, DOI 10.1016/S0924-977X(00)00118-8; Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104; ALI SF, 1994, BRAIN RES, V658, P33, DOI 10.1016/S0006-8993(09)90007-5; ARVIN B, 1994, J NEUROCHEM, V62, P1458; BAKHIT C, 1981, NEUROPHARMACOLOGY, V20, P1135, DOI 10.1016/0028-3908(81)90053-8; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Battaglia G, 2002, J NEUROSCI, V22, P2135, DOI 10.1523/JNEUROSCI.22-06-02135.2002; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Betarbet R, 1999, EXP NEUROL, V159, P401, DOI 10.1006/exnr.1999.7154; Block F, 1996, J NEUROL SCI, V139, P167; BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Burrows Kristan B., 2003, P211; Chapman DE, 2001, J PHARMACOL EXP THER, V296, P520; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Fan XD, 1999, BRAIN RES, V850, P79, DOI 10.1016/S0006-8993(99)02106-X; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V283, P281; GIBB JW, 1979, N-S ARCH PHARMACOL, V310, P185, DOI 10.1007/BF00500283; Golembiowska K, 2003, NEUROPHARMACOLOGY, V45, P484, DOI 10.1016/S0028-3908(03)00209-0; GREEN AR, 1992, NEUROPHARMACOLOGY, V31, P315, DOI 10.1016/0028-3908(92)90062-T; Harold C, 2000, EUR J PHARMACOL, V400, P99, DOI 10.1016/S0014-2999(00)00392-7; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Hernandez LF, 2003, NEUROCHEM RES, V28, P1819, DOI 10.1023/A:1026115607216; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOTCHKISS AJ, 1979, LIFE SCI, V25, P1373, DOI 10.1016/0024-3205(79)90414-4; Itzhak Y, 2000, NEUROREPORT, V11, P2943, DOI 10.1097/00001756-200009110-00022; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; KEEFE KA, 1993, J NEURAL TRANSM-GEN, V91, P223, DOI 10.1007/BF01245233; Kitagawa K, 1999, J NEUROSCI RES, V55, P643, DOI 10.1002/(SICI)1097-4547(19990301)55:5<643::AID-JNR11>3.0.CO;2-V; Lai SK, 2003, NEUROCHEM INT, V43, P639, DOI 10.1016/S0197-0186(03)00080-9; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEPEILLET E, 1992, BRAIN RES, V571, P115; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J; ODELL SJ, 1991, BRAIN RES, V564, P256, DOI 10.1016/0006-8993(91)91461-9; OHTA K, 1994, NEUROSCI RES, V21, P83, DOI 10.1016/0168-0102(94)90071-X; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; Sakai K, 1997, NEUROCHEM INT, V30, P329, DOI 10.1016/S0197-0186(96)00047-2; SCHMIDT CJ, 1985, NEUROCHEM RES, V10, P637, DOI 10.1007/BF00964403; Segovia G, 1997, J NEUROCHEM, V69, P1476; SEIDEN LS, 1988, ANN NY ACAD SCI, V537, P161, DOI 10.1111/j.1749-6632.1988.tb42104.x; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SONSALLA PK, 1991, J PHARMACOL EXP THER, V256, P506; Stephans S, 1996, NEUROSCIENCE, V72, P593, DOI 10.1016/0306-4522(95)00587-0; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; WAGNER GC, 1985, RES COMMUN CHEM PATH, V47, P221; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yamamoto BK, 1998, J PHARMACOL EXP THER, V287, P107; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	65	41	42	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2006	96	5					1267	1276		10.1111/j.1471-4159.2005.03618.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	012IR	WOS:000235332600005	16417574	Bronze			2022-02-06	
J	Catalano, D; Pereira, AP; Wu, MY; Ho, H; Chan, F				Catalano, Denise; Pereira, Ana Paula; Wu, Ming-Yi; Ho, Hanson; Chan, Fong			Service patterns related to successful employment outcomes of persons with traumatic brain injury in vocational rehabilitation	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			Traumatic Brain Injury (TBI); state-federal vocational rehabilitation services; employment outcomes; job placement; work disincentives; CHAID analysis	SPINAL-CORD-INJURY; SUBSTANCE-ABUSE; PREDICTION; WORK; CONSEQUENCES; INDIVIDUALS; VARIABLES; ALCOHOL; CLIENTS; SAMPLE	This study analyzed the Rehabilitation Services Administration (RSA) case service report (RSA-911) data for fiscal year 2004 to examine effects of demographic characteristics, work disincentives, and vocational rehabilitation services patterns on employment outcomes of persons with traumatic brain injuries (TBI). The results indicated that European Americans (53%) had appreciably higher competitive employment rates than Native American (50%), Asian Americans (44%), African Americans (42%), and Hispanic/Latino Americans (41%). Clients without co-occurring psychiatric disabilities had a higher employment rate (51%) than those with psychiatric disabilities (45%). Clients without work disincentives showed better employment outcomes (58%) than those with disincentives (45%). An important finding from this analysis was the central role of job search assistance, job placement assistance, and on-the-job support services for persons with TBI in predicting employment outcomes. A data mining technique, the exhaustive CHAID analysis, was used to examine the interaction effects of race, gender, work disincentives and service variables on employment outcomes. The results indicated that the TBI clients in this study could be segmented into 29 homogeneous subgroups with employment rates ranging from a low of 11% to a high of 82%, and these differences can be explained by differences in work disincentives, race, and rehabilitation service patterns.	Univ N Texas, Dept Rehabil Social Work & Addict, Denton, TX 76203 USA; Univ Fed Parana, Dept Psychol, BR-80060000 Curitiba, Parana, Brazil; Natl Kaohsiung Normal Univ, Grad Inst Rehabil Counseling, Kaohsiung, Taiwan; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA		Catalano, D (corresponding author), Univ N Texas, Dept Rehabil Social Work & Addict, Denton, TX 76203 USA.	Catalano@pacs.unt.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A031705] Funding Source: Medline		Basford JR, 2002, ARCH PHYS MED REHAB, V83, P517, DOI 10.1053/apmr.2002.30922; BOLTON B, 1972, PREDICTING CLIENT OU; Bolton B. F., 2002, REHABILITATION COUNS, V44, P10; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P399, DOI 10.1037/10361-019; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BYRD EK, 1978, REHABIL COUNS BULL, V21, P350; CARDOSO E, IN PRESS REHABILITAT; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; *CDC, 2005, FACTS TRAUM BRAIN IN; Chan F., 2005, J APPL REHABILITATIO, V36, P3; Chan Fong, 2005, Work, V25, P77; CHRONISTER JA, 2005, CASE MANAGEMENT REHA, V2, P369; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CUNNINGHAM JM, 2005, CASE MANAGEMENT REHA, V2, P91; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIXON TM, 1999, MED ASPECTS DISABILI, P98; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Forthofer MS, 2000, AM J HEALTH BEHAV, V24, P36, DOI 10.5993/AJHB.24.1.6; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gamble D, 2003, J REHABIL, V69, P31; Gamble D., 2002, J APPL REHABILITATIO, V33, P41, DOI DOI 10.1891/0047-2220.33.3.41; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Habeck RV, 1997, PHYS MED REHAB CLIN, V8, P263; HANLEYMAXWELL C, 1992, REHABILITATION COUNS, P135; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hennessey JC, 1997, SOC SECUR BULL, V60, P3; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; HOUTENVILLE AJ, DISABILITY STAT US; Ingraham K., 1992, J APPL REHABILITATIO, V23, P18; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; MA TC, 2000, THESIS U IOWA; Marini I., 1999, J REHABILITATION ADM, V23, P31; NONG, 2003, HDB DATA MINING; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Radnitz CL, 1996, J NERV MENT DIS, V184, P431, DOI 10.1097/00005053-199607000-00006; ROSENTHAL DA, IN PRESS J REHABILIT; Sherer M, 1999, BRAIN INJURY, V13, P973; SHUTTER LA, 1998, TRAUMA Q, V14, P61; Simpson A, 2002, BRAIN INJURY, V16, P1075, DOI 10.1080/02699050210155249; Skeel RL, 2003, REHABIL PSYCHOL, V48, P145, DOI 10.1037/0090-5550.48.3.145; Sohlberg M., 2001, COGNITIVE REHABILITA; *SPSS, 1998, ANSWERTREE 2 0 US GU; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ FACT; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; WALLACE MD, 1982, INT STUD QUART, V26, P37, DOI 10.2307/2600598; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	60	41	41	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					279	293					15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700003	17361045				2022-02-06	
J	Empey, PE; McNamara, PJ; Young, B; Rosbolt, MB; Hatton, J				Empey, PE; McNamara, PJ; Young, B; Rosbolt, MB; Hatton, J			Cyclosporin A disposition following acute traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; dosing; human; neuroprotection; pharmacokinetics; traumatic brain injury	SEVERE HEAD-INJURY; ACUTE-PHASE RESPONSE; AMINO-ACID RELEASE; AXONAL DAMAGE; INTERLEUKIN-6; KINETICS; FLUID; PHARMACOKINETICS; TRANSPLANTATION; METABOLISM	Although the precise mechanism of action remains to be defined, Cyclosporin A (CsA) has demonstrated potential for neuroprotection in animal models. Predictive dosing strategies for CsA in acute traumatic brain injured (TBI) patients must account for the influence of the acute phase response on drug disposition. To characterize CsA pharmacokinetic parameters early following acute TBI, serial blood samples from patients enrolled into a Phase II dose-escalation trial were analyzed. Within eight hours of injury, thirty patients admitted with acute severe TBI were prospectively randomized into three cohorts (n = 8 CsA; n = 2 placebo per cohort) in this dose-escalation trial. Patients received one of three doses (I = 0.625 mg/kg/dose; II = 1.25 mg/kg/dose; III = 2.5 mg/kg/dose) or placebo intravenously every 12 h for 72 h. Serial blood collection began prior to dose I and continued for 72 h following the completion of six doses. Whole blood concentrations were determined by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. Pharmacokinetic parameters were determined for each patient by fitting the concentration-time profile to a two-compartmental model with first order elimination. Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*mu g/L, 398 mu g/L; II = 18300 h*mu g/L, 645 mu g/L; III = 32500 h*mu g/L, 1300 /mu g/L). Whole blood clearance, steady state volume of distribution, and beta half-life were independent of dose and higher than published reports from other populations: 0.420 L/h/kg, 5.91 L/kg, and 17.3 h, respectively. These, data show patients with acute severe TBI demonstrate a more rapid clearance and a larger distribution volume of CsA. Pharmacokinetic parameters derived from this study will guide dosing strategies for future prospective clinical trials evaluating CsA therapy following acute TBI.	Univ Kentucky, Coll Pharm, Dept Pharm & Neurosurg, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Pharmaceut Sci, Lexington, KY USA; Univ Kentucky, Coll Med, Div Neurosurg, Lexington, KY USA		Hatton, J (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharm & Neurosurg, Spinal Cord & Brain Injury Res Ctr, B357 Biol Basic Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	jhatt1@email.uky.edu	Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041239] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR02602] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS41239-01, 5R01NS041239] Funding Source: Medline		Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; AWEEKA FT, 1994, J CLIN PHARMACOL, V34, P60, DOI 10.1002/j.1552-4604.1994.tb03967.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURCKART GJ, 1986, J CLIN PHARMACOL, V26, P647, DOI 10.1002/j.1552-4604.1986.tb02966.x; CHEN SZ, 1994, REAL-TIME SYST, V6, P55, DOI 10.1007/BF01245299; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Doppenberg EMR, 1999, ACT NEUR S, V75, P31; EDWARDS DJ, 1982, CLIN PHARMACOL THER, V31, P62, DOI 10.1038/clpt.1982.10; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; FOLLATH F, 1983, CLIN PHARMACOL THER, V34, P638, DOI 10.1038/clpt.1983.226; GUPTA SK, 1990, J CLIN PHARMACOL, V30, P643, DOI 10.1002/j.1552-4604.1990.tb01868.x; Hatton J, 2004, J NEUROSURG, V100, P784; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Koura SS, 1998, ACT NEUR S, V71, P244; KRONBACH T, 1988, CLIN PHARMACOL THER, V43, P630, DOI 10.1038/clpt.1988.87; LEGG B, 1987, J PHARM PHARMACOL, V39, P599, DOI 10.1111/j.2042-7158.1987.tb03436.x; LEMAIRE M, 1982, J PHARM PHARMACOL, V34, P715, DOI 10.1111/j.2042-7158.1982.tb06206.x; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PTACHCINSKI RJ, 1985, CLIN PHARMACOL THER, V38, P296, DOI 10.1038/clpt.1985.174; PTACHCINSKI RJ, 1987, J CLIN PHARMACOL, V27, P243, DOI 10.1002/j.1552-4604.1987.tb02193.x; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; [The American Association of Neurological Surgeons The Brain Trauma Foundation], 2000, J NEUROTRAUM, V17, P463; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Yamamoto T, 1999, ACT NEUR S, V75, P17	39	41	41	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					109	116		10.1089/neu.2006.23.109			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100009	16430377				2022-02-06	
J	Tamietto, M; Torrini, G; Adenzato, M; Pietrapiana, P; Rago, R; Perino, C				Tamietto, M; Torrini, G; Adenzato, M; Pietrapiana, P; Rago, R; Perino, C			To drive or not to drive (after TBI)? A review of the literature and its implications for rehabilitation and future research	NEUROREHABILITATION			English	Article						TBI; brain injury; driving safety; rehabilitation	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INDIVIDUAL-DIFFERENCES; CEREBRAL-DAMAGE; RELATIVES VIEW; SELF-AWARENESS; PERFORMANCE; PERSONALITY; PREDICTORS; FITNESS	Development of reliable procedures to assess fitness to safe driving after traumatic brain injury ( TBI) is a crucial step in rehabilitation. However, prior studies are highly inconsistent in the choice of measures recommended for predicting driving fitness from different pre-driving measures. In the present paper the relevant literature is reviewed with the aim of shedding light on the reasons for these inconsistencies. The discrepant results reflect investigative choices which differ in five aspects: ( 1) the type of predictors used as pre-driving screening; ( 2) the type of measures considered as the criterion for the determination of fitness to drive after TBI; ( 3) the severity of the TBI in the sample of patients studied; ( 4) the extent of the neural structures damaged by TBI and the overlap of these areas with those involved in driving tasks; ( 5) the length of the follow-up considered. The strengths and weaknesses of the different methods and measures are discussed with their implications for future research and clinical rehabilitation. Encouraging findings come from recent studies that combined together medical, psychosocial, and personality measures, thereby improving the explanatory power of the predictors used. The use of post-injury driving fitness measures with great ecological and external validity seems equally promising in assessing actual driving in the real world.	Univ Turin, Dept Psychol, Turin, Italy; Univ Turin, Ctr Cognit Sci, Turin, Italy; Ausiliatrice Hosp, Fdn Carlo Gnocchi, ONLUS, Turin, Italy		Tamietto, M (corresponding author), Univ Turin, Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	tamietto@psych.unito.it	Adenzato, Mauro/I-5127-2012	Adenzato, Mauro/0000-0002-6997-9283; Tamietto, Marco/0000-0002-8815-8499			Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; Bogg T, 2004, PSYCHOL BULL, V130, P887, DOI 10.1037/0033-2909.130.6.887; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROWER W, 1992, 2 INT C OBJ EV ERH M; Calhoun VD, 2002, HUM BRAIN MAPP, V16, P158, DOI 10.1002/hbm.10032; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; DEBELLEIX X, 2001, EUROPA MEDICOPHYSICA, V37, P201; Dimarco F, 2001, EURA MEDICOPHYS, V37, P215; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Evans L., 1991, TRAFFIC SAFETY DRIVE; Farmer J, 2000, BRAIN INJURY, V14, P109, DOI 10.1080/026990500120772; Finset A, 2000, BRAIN INJURY, V14, P887; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORMISANO R, 2001, EUROPA MEDICOPHYSICA, V37, P257; FOX G, 1993, ASTB C TOK SEPT 1 11; Fox G K, 1992, Disabil Rehabil, V14, P140; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOLDBERG LR, 1993, AM PSYCHOL, V48, P26, DOI 10.1037/0003-066X.48.1.26; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Hartje W, 1991, NEUROPSYCHOL REHABIL, V3, P161; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; HOFMEIJER AMJ, 2002, EUROPA MEDICOPHYSICA, V38, P29; HUNT L, 1993, J AM GERIATR SOC, V71, P177; John, 1999, HDB PERSONALITY THEO, P102; JONES MH, 1978, 783 U SO CAL; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Kapust L R, 1992, J Geriatr Psychiatry Neurol, V5, P210; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kosslyn SM, 1999, PHILOS T ROY SOC B, V354, P1283, DOI 10.1098/rstb.1999.0479; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; MICHON JA, 1989, ACCIDENT ANAL PREV, V21, P341, DOI 10.1016/0001-4575(89)90025-0; MIHAL WL, 1976, J APPL PSYCHOL, V61, P229, DOI 10.1037/0021-9010.61.2.229; Nouri F M, 1987, Int Disabil Stud, V9, P110; Novack TA, 2000, BRAIN INJURY, V14, P987; O'Shanick G J, 1989, Psychiatr Med, V7, P1; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; PERINO, 1997, GIORNALE ITALIANO RI, V1, P53; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS SAN F; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; SCHWEITZER JR, 1994, ERGONOMICS REHABILIT, P85; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Uchiyama Y, 2003, NEUROSCI LETT, V352, P199, DOI 10.1016/j.neulet.2003.08.072; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN A, 1987, ARCH PHYS MED REHAB, V68, P607; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; WALLER PF, 1988, TRANSPORTATION AGING, V2, P72; Walter H, 2001, NEUROREPORT, V12, P1763, DOI 10.1097/00001756-200106130-00049; Wilson T, 1983, Int Rehabil Med, V5, P170; [No title captured]	83	41	43	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2006	21	1					81	92					12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	045KY	WOS:000237742200011	16720941				2022-02-06	
J	Kissick, J; Johnston, KM				Kissick, J; Johnston, KM			Return to play after concussion - Principles and practice	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; return to play; rehabilitation	SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; HEAD-INJURY; MANAGEMENT; EXERCISE; STATEMENT; SCIENCE	Objective: The sport medicine team is increasingly being asked to manage concussed athletes and to provide written clearance for return to play postconcussion, making it critical to have a good understanding of concussion recognition, assessment, and management. Data Sources/Synthesis: A handy way to think of concussion management is the four Rs: recognition, response, rehabilitation, and return. Results: Athletes, coaches, parents, therapists, and physicians need a thorough understanding of concussion signs and symptoms. An athlete suspected of having sustained a concussion should be removed from the game or practice and assessed by a member of the sideline medical team. All athletes who sustain a concussion should be evaluated by a medical doctor. Rehabilitation has similarities to but also differs from the traditional orthopedic model in that the first step is rest, both physical and cognitive. Once asymptomatic at rest, a step-wise return to activity is undertaken. Conclusions: This protocol has been adapted for various sports. It may be used for children, although it is prudent to be more conservative and to progress more slowly than in an older age group.	Ottawa Sport Med Ctr, Ottawa, ON, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Kinesiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Phys Educ, Montreal, PQ H3A 2T5, Canada		Kissick, J (corresponding author), 39 Goulding Cr, Ottawa, ON K2K 2N9, Canada.	jkissick@sympatico.ca					Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Braham RA, 2004, BRIT J SPORT MED, V38, P426, DOI 10.1136/bjsm.2002.004051; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haykowsky MJ, 2003, MED SCI SPORT EXER, V35, P65, DOI 10.1097/00005768-200301000-00011; Horton A., 2002, MED SCI SPORTS EXERC, V34, P99; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, 2004, THINK 1 SPORT SMART; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P190, DOI 10.1097/00042752-200107000-00010; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Podlog L, 2004, CLIN J SPORT MED, V14, P257, DOI 10.1097/00042752-200409000-00001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304	37	41	41	2	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2005	15	6					426	431		10.1097/01.jsm.0000186683.59158.8b			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	012BL	WOS:000235313100007	16278546				2022-02-06	
J	Iwata, A; Browne, KD; Chen, XH; Yuguchi, T; Smith, DH				Iwata, A; Browne, KD; Chen, XH; Yuguchi, T; Smith, DH			Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; apolipoprotein E; apolipoprotein J; GFAP; amyloid-beta	ALZHEIMERS AMYLOID-BETA; APOLIPOPROTEIN-E POLYMORPHISM; LIPOPROTEIN RECEPTOR GENE; FIBRILLARY ACIDIC PROTEIN; LONG-TERM ACCUMULATION; FLUID-PERCUSSION MODEL; IN-SITU HYBRIDIZATION; E MESSENGER-RNA; HEAD-INJURY; NEURON DEATH	Apolipoproteins play an important role in cell repair and have been found to increase shortly after traumatic brain injury (TBI). In addition, apolipoproteins reduce amyloid-beta (A beta) accumulation in models of Alzheimer's disease. Considering that TBI induces progressive neurodegeneration including A beta accumulation, we explored potential long-term changes in the gene and protein expression of apolipoproteins E and J (ApoE and J) over 6 months after injury. Anesthetized male Sprague-Dawley rats were subjected to parasagittal fluid-percussion brain injury and their brains were evaluated at 2, 4, 7, 14 days, and 1 and 6 months after TBI, In situ hybridization, Western blot, and immunohistochemical analysis demonstrated that although there was a prolonged upregulation in both the gene expression and protein concentration of ApoE and J after injury, these responses were uncoupled. Upregulation of ApoE and J mRNA expression lasted from 4 days to 1 month after injury. In contrast, a biphasic increase in protein concentration and number of immunoreactive cells for ApoE and ApoJ was observed, initially peaking at 2 days (i.e., before increased mRNA expression), returning to baseline by 2 weeks and then gradually increasing through 6 months postinjury. In addition, ApoE and J were found to colocalize with A beta accumulation in neurons and astrocytes at 1-6 months after injury. Collectively, these data suggest that ApoE and J play a role in the acute sequelae of brain trauma and reemerge long after the initial insult, potentially to modulate progressive neurodegenerative changes. (C) 2005 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Yukioka Hosp, Dept Neurosurg, Osaka, Japan		Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BISHOP RW, 1992, J LIPID RES, V33, P549; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FRITZ IB, 1992, CLIN EXP IMMUNOL, V88, P375; FRITZ IB, 1993, TRENDS PHARMACOL SCI, V14, P355, DOI 10.1016/0165-6147(93)90093-Y; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Giannakopoulos P, 1998, ACTA NEUROPATHOL, V95, P387, DOI 10.1007/s004010050815; Ginsberg MD, 1996, J NEUROSCI METH, V68, P225; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; MaatSchieman MLC, 1996, BRAIN PATHOL, V6, P115, DOI 10.1111/j.1750-3639.1996.tb00794.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martin RL, 1997, BELL LABS TECH J, V2, P3, DOI 10.1002/bltj.2027; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCGEER PL, 1992, BRAIN RES, V579, P337, DOI 10.1016/0006-8993(92)90071-G; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nishio M, 2003, NEUROL RES, V25, P390, DOI 10.1179/016164103101201544; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROSENBERG ME, 1993, J LAB CLIN MED, V121, P205; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seitz A, 2003, J NEUROSCI RES, V71, P417, DOI 10.1002/jnr.10482; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; Walton M, 1996, MOL BRAIN RES, V39, P137, DOI 10.1016/0169-328X(96)00019-8; Wiggins AK, 2003, MOL BRAIN RES, V114, P20, DOI 10.1016/S0169-328X(03)00124-4; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zlokovic BV, 1996, LIFE SCI, V59, P1483, DOI 10.1016/0024-3205(96)00310-4; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825	78	41	45	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT 1	2005	82	1					103	114		10.1002/jnr.20607			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	972CK	WOS:000232431300011	16118797				2022-02-06	
J	Lima, EF; Riet-Correa, F; de Castro, RS; Gomes, AAB; Lima, FDS				Lima, EF; Riet-Correa, F; de Castro, RS; Gomes, AAB; Lima, FDS			Clinical signs, distribution of the lesions in the central nervous system and epidemiology of rabies in northeastern Brazil.	PESQUISA VETERINARIA BRASILEIRA			Portuguese	Article						rabies; cattle; sheep; goats; horses; pathology; clinical signs; economical impact	SEMIARID REGION; DIAGNOSIS; CATTLE; FEATURES; STRAINS; STATE	Twenty four outbreaks of rabies in cattle, 4 in horses, 2 in sheep, and 2 in goats are reported in northeastern Brazil. All outbreaks occurred in the state of Paraiba, except one in horses that occurred in the state of Rio Grande do Norte. All outbreaks, except one in sheep, were probably transmitted by vampire-bats, but the transmission by foxes (Dusicyon vetulus) is also possible. Clinical signs were characteristic for distribution of the lesions in the central nervous system (CNS). In cattle, signs were mainly of the paralytic form of rabies, caused by lesions on the spinal cord, brain stem and cerebellum; but some animals showed also depression, excitation and other signs due to cerebral lesions. In 3 out of 5 horses, the main clinical signs were due to lesions in the cerebrum, and 2 had the paralytic form. From 4 sheep and 2 goats affected, 4 showed clinical signs of the paralytic form; but in I goat and I sheep the main clinical signs were caused by cerebral lesions. All affected animals, except I goat, had a clinical manifestation period of 2-8 days. The only gross lesions were distention of the urinary bladder in 4 cattle and distention of the rectum in 2 others. Two horses had skin lesions due to traumatic injury. Histologic lesions were diffuse non-suppurative encephalomyelitis and meningitis. In the horses, and in one goat with a clinical manifestation period of 35 days, the lesions were more severe, with neuronal necrosis, neuronophagia, and presence of axonal spheroids. Negri bodies were found in 87% (20/23) of the cattle cases examined histologically. In small ruminants, Negri bodies were found in 83% (5/6) of the cases. In sheep, goats and cattle, Negri bodies were more frequent in the cerebellum, but they were found also in brain stem, spinal cord and cerebrum. In horses, Negri bodies were found in small amounts only in the cortex of one animal, and in the cortex and hippocampus of another. Histologic lesions and Negri bodies in the trigeminal ganglia were less frequent than in the CNS. These results show that in rabies of herbivores, clinical signs and distribution of lesions in the CNS are variable, so that for the diagnosis and adequate clinical evaluation, the histologic study of different areas of the CNS are necessary. This also suggests that when the fluorescent antibody test and mouse inoculation test are negative, they should be repeated with samples from different areas of the brain and spinal cord. Frequency data of diseases from 4 diagnostic laboratories were used to estimate cattle deaths due to rabies in 3 Brazilian states. In Paraiba, with a population of 918,262 cattle, the annual death rate is estimated in 8,609 heads. In Mato Grosso do Sul, with a population of 23 millions cattle, deaths caused by rabies are estimated in 149,500 heads, and in Rio Grande do Sul, with a cattle population of 13 millions, cattle deaths due to rabies are estimated in 13,000 to 16,250 heads. If these data are used to estimate cattle losses in Brazil, with a cattle population of 195 millions, it can be estimated that 842,688 deaths are caused annually by rabies.	UFCG, Curso Med Vet, Ctr Saude & Tecnol Rural, BR-58700000 Patos de Minas, PB, Brazil; Univ Fed Rural Pernambuco, Curso Med Vet, BR-52171900 Recife, PE, Brazil		Lima, EF (corresponding author), UFCG, Curso Med Vet, Ctr Saude & Tecnol Rural, Campus Patos, BR-58700000 Patos de Minas, PB, Brazil.	riet@cstr.ufcg.br					ACHA PN, 1986, ZOONOSIS ENFERMEDADE, P502; ARAUJO FAA, 2002, THESIS U FEDERAL MIN; Bacon PJ., 1985, POPULATION DYNAMICS; BARROS CSL, 2003, COMUNICACAO PESSOAL; BARROS JS, 1989, ZOON REV INT, V1, P9; Batista-Morais N, 2000, MEM I OSWALDO CRUZ, V95, P609, DOI 10.1590/S0074-02762000000500003; Bingham J, 2002, J VIROL METHODS, V101, P85, DOI 10.1016/S0166-0934(01)00423-2; BRAUND KG, 1987, VET NEUROLOGY, P266; CARLTON WW, 1998, PATOLOGIA VET ESPECI; COELHO HE, 2002, PATOLOGIA VET; de Lahunta, 1995, VET NEUROPATHOLOGY; Dean D. J., 1996, P88; Fernandes C.G., 2001, DOENCAS RUMINANTES E, V1, P149; Germano P. M. L., 1977, Revista da Faculdade de Medicina Veterinaria e Zootecnia da Universidade de Sao Paulo, V14, P133; GERMANO P M L, 1990, Boletin de la Oficina Sanitaria Panamericana, V108, P39; GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996; GOMES AAB, 2004, THESIS U SAO PAULO; HAYASHI Y, 1984, ARQ BIOL TECNOL, V27, P27; Heinemann MB, 2002, EPIDEMIOL INFECT, V128, P503, DOI 10.1017/S095026880200688X; Hudson LC, 1996, J VET MED B, V43, P85, DOI 10.1111/j.1439-0450.1996.tb00292.x; JONES TC, 2000, PATOLOGIA VET; Jubb KVF, 1993, PATHOLOGY DOMESTIC A, P267; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; Koprowski H., 1996, P80; Langohr Ingeborg Maria, 2003, Cienc. Rural, V33, P125, DOI 10.1590/S0103-84782003000100020; LEMOS RRA, 2005, THESIS U ESTADUAL PA; Lima EF, 2005, PESQUI VET BRASIL, V25, P9, DOI 10.1590/S0100-736X2005000100003; MARCRUZ R, 1977, REV FAC MED VET ZOOT, V14, P123; MONTANO JA, 1987, ARQ BIOL TECNOL, V30, P367; MORI AE, 2004, SERIE QUALIFICACAO R, V2, P63; Nobre VMD, 2004, PESQUI VET BRASIL, V24, P132, DOI 10.1590/S0100-736X2004000300004; *ORG PAN AM SAL RI, 2001, ORG PAN AM SAL B, V33; Peixoto ZMP, 2000, BRAZ J MICROBIOL, V31, P72; RADOSTITS OM, 2002, CLIN VET TRATADO DOE; *RED INT INF SAUD, 2002, IND BAS SAUD BRAS CO, P150; Riet-Correa F, 2002, PESQUISA VET BRASIL, V22, P161, DOI 10.1590/S0100-736X2002000400006; RIET-CORREA F., 2003, SEMIARIDO FOCO, V1, P2; RIETCORREA F, 1999, RELATORIO ATIVIDADES; RIETCORREA F, 1983, RELATORIO ATIVIDADES; Rodrigues da Silva Andrea De Cassia, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P95, DOI 10.1590/S0036-46652000000200006; Rondon E. S., 1995, Revista Brasileira de Medicina Veterinaria, V17, P253; Sanches AWD, 2000, PESQUISA VET BRASIL, V20, P113, DOI 10.1590/S0100-736X2000000300005; Silva JA, 2001, ARQ BRAS MED VET ZOO, V53, P263; SILVA RA, 1974, PESQ AGROP BRAS SER, V9, P29; SWANEPOEL R, 1994, INFECT DIS LIVESTOCK, V1, P392; Tierkel E. S., 1975, The natural history of rabies,, P123; ZIMMER K, 1990, J VET MED B, V37, P392, DOI 10.1111/j.1439-0450.1990.tb01074.x	47	41	48	0	7	REVISTA PESQUISA VETERINARIA BRASILEIRA	RIO JANEIRO	EMBRAPA-SAUDE ANIMAL, KM47 SEROPEDICA, 23851-970 RIO JANEIRO, BRAZIL	0100-736X	1678-5150		PESQUI VET BRASIL	Pesqui. Vet. Bras.	OCT-DEC	2005	25	4					250	264		10.1590/S0100-736X2005000400011			15	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	010ZB	WOS:000235236300011		gold			2022-02-06	
J	Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME				Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME			The high-level mobility assessment tool (HiMAT) for traumatic brain injury. Part 1: Item generation	BRAIN INJURY			English	Article						brain injuries; rehabilitation; circuit disorders; neurologic; outcome assessment	FUNCTIONAL MOBILITY; OUTCOME MEASURE; BALANCE; MOTOR; REHABILITATION; STROKE; RECOVERY; PROFILE; ADULTS; IDENTIFICATION	Primary objective: To generate a comprehensive list of items for a scale suitable for assessing high-level mobility in people with traumatic brain injury (TBI). Research design: High-level mobility items were generated following a critical evaluation of existing adult and paediatric mobility scales and by surveying expert clinicians for opinions about items appropriate for inclusion on a high-level mobility scale. Main outcomes and results: The critical evaluation identified 18 different items from 31 mobility scales. These included nine walking items in addition to higher level activities such as stair use, running, jumping and hopping. Expert clinicians generated 157 items that were collated and condensed to 88 items for ranking on a questionnaire. Fifteen items on the questionnaire were rated as very important by 80% of the expert clinicians. These included walking forwards, walking on slopes and different surfaces, changing direction, walking long distances and stair use. Running items included forwards, backwards, on slopes and over different surfaces, changing direction, stopping and starting as well as running long distances. Balancing in single limb stance was also included. Conclusion: The final list comprised walking, running, hopping, skipping, jumping and balance items. This initial version of the HiMAT has face and content validity although requires further testing to investigate whether it is uni-dimensional and valid for people with TBI.	Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Bundoora, Vic, Australia		Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473			Badke Mary Beth, 1993, Physiotherapy Canada, V45, P15; Baer HR, 2001, STROKE, V32, P973, DOI 10.1161/01.STR.32.4.973; Bayley N., 1969, MANUAL BAYLEY SCALES; BERG K, 1989, Physiotherapy Canada, V41, P304; Bobath B., 1990, ADULT HEMIPLEGIA EVA; Burdon B., 1993, AUSTR DEV SCREENING; Carr J.H., 1982, MOTOR RELEARNING PRO; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Collen F M, 1991, Int Disabil Stud, V13, P50; DUNCAN P, 1995, DUKE MOBILITY SKILLS; ENZIN NK, 1994, HDB QUALITATIVE RES; Folio MR, 1983, PEABODY DEV MOTOR SC; GOLDIE PA, 1994, ARCH PHYS MED REHAB, V75, P969; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; Granger CV, 1983, GUIDE USE UNIFORM DA; Guttman L, 1944, AM SOCIOL REV, V9, P139, DOI 10.2307/2086306; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Holder-Powell HM, 2000, ARCH PHYS MED REHAB, V81, P265, DOI 10.1053/apmr.2000.0810265; JOHANSSON G, 1991, Physiotherapy Theory and Practice, V7, P121, DOI 10.3109/09593989109106962; JONES J, 1996, QUALITATIVE RES HLTH; KORNERBITENSKY N, 1989, ARCH PHYS MED REHAB, V70, P95; Lincoln N, 1979, Physiotherapy, V65, P48; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin J., 1988, PREVALENCE DISABILIT; McGuine TA, 2000, CLIN J SPORT MED, V10, P239, DOI 10.1097/00042752-200010000-00003; Means KM, 1996, J REHABIL RES DEV, V33, P413; Miller L. J., 1994, TIME TODDLER INFANT; Minichiello V., 1995, IN DEPTH INTERVIEWIN; MOORE M, 1994, GROUP TECHNIQUES IDE; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Novacheck TF, 2000, J PEDIATR ORTHOPED, V20, P75, DOI 10.1097/00004694-200001000-00017; O'Connell M, 1998, GAIT POSTURE, V8, P136, DOI 10.1016/S0966-6362(98)00023-X; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OREST MR, 2000, PHYSIOTHERAPY CANADA, V52, P131; Patla AE, 1999, J AGING PHYS ACTIV, V7, P7, DOI 10.1123/japa.7.1.7; PILON M, 1995, BRAIN INJURY, V9, P365, DOI 10.3109/02699059509005776; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Quinn B, 2000, BRAIN INJURY, V14, P1063; RANKENBURG, 1975, REVISED DENVER DEV S; Russell, 1993, GROSS MOTOR FUNCTION; SEABY L, 1989, Physiotherapy Canada, V41, P264; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; SWAINE BR, 1994, BRAIN INJURY, V8, P323, DOI 10.3109/02699059409150983; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; Vitale AE, 1996, BRAIN INJURY, V10, P367, DOI 10.1080/026990596124377; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams G, 2001, BRAIN INJURY, V15, P831; World Health Organization, 2001, ICF INT CLASS FUNCT; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; [No title captured]; [No title captured]	56	41	41	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					925	932		10.1080/02699050500058687			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500007	16243748				2022-02-06	
J	Striedinger, K; Petrasch-Parwez, E; Zoidl, G; Napirei, M; Meier, C; Eysel, UT; Dermietzel, R				Striedinger, K; Petrasch-Parwez, E; Zoidl, G; Napirei, M; Meier, C; Eysel, UT; Dermietzel, R			Loss of connexin36 increases retinal cell vulnerability to secondary cell loss	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						gap junction; infrared laser photocoagulation; mouse; neuronal survival	GAP JUNCTIONAL COMMUNICATION; MOUSE RETINA; NEURONAL CONNEXIN36; EFFECTIVE REDUCTION; MAMMALIAN RETINA; GENE CONNEXIN36; NERVOUS-SYSTEM; RODENT MODEL; ATP RELEASE; TUNEL ASSAY	Accruing evidence indicates that gap junctions are involved in neuronal survival after brain injury. The present study was aimed at clarifying the contribution of the neuronal gap-junction protein connexin36 (Cx36) to secondary cell loss after injury in the mouse retina. A focal retinal lesion was induced by infrared laser photocoagulation. Remarkably, this model allowed spatial and temporal definition of the lesion with high reproducibility. Moreover, Cx36 is abundantly expressed in the retina and plays an essential role in the visual transmission process. Taking advantage of these features, cell death was assessed using TUNEL assay and light and electron microscopy, and the extent of Cx36 expression was studied by immunohistochemistry, Western blot, in situ hybridization and real-time RT-PCR. Secondary cell loss was most prominent between 24 and 48 h after lesioning. This peak was accompanied by an increase in Cx36 expression. When cultured explanted retinas were subjected to gap-junction blockers a significant increase in the extent of secondary cell loss after laser photocoagulation became evident. Using the same experimental paradigm we compared the incidence of cell death in wild-type and Cx36(-/-) mice. A significant increase in total number of TUNEL-positive cells occurred in the Cx36(-/-) mice compared to controls. From these data we conclude that Cx36 contributes to the survival and resistance against damage of retinal cells and thus constitutes a protective factor after traumatic injury of the retina.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany; Ruhr Univ Bochum, Dept Anat & Embryol, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Neurophysiol, D-4630 Bochum, Germany; Ruhr Univ Bochum, Int Grad Sch Neurosci, D-4630 Bochum, Germany		Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ Str 150,MA 6-159, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de		Eysel, Ulf/0000-0001-6087-957X			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; Berger JW, 1997, LASER SURG MED, V20, P409, DOI 10.1002/(SICI)1096-9101(1997)20:4<409::AID-LSM6>3.0.CO;2-U; Blanc EM, 1998, J NEUROCHEM, V70, P958; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cusato K, 2003, J NEUROSCI, V23, P6413; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Dermietzel R, 1998, BRAIN RES REV, V26, P176, DOI 10.1016/S0165-0173(97)00031-3; Dowling J.E., 1987, RETINA APPROACHABLE; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; FAWCETT J, 2001, BRAIN DAMAGE BRAIN; Feigenspan A, 2004, J NEUROSCI, V24, P3325, DOI 10.1523/JNEUROSCI.5598-03.2004; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Gillen C, 1996, EUR J NEUROSCI, V8, P405, DOI 10.1111/j.1460-9568.1996.tb01223.x; Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; Guldenagel M, 2000, J COMP NEUROL, V425, P193; Jerome KR, 2000, PATHOLOGY, V32, P186; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MALCHOW RP, 1994, J GEN PHYSIOL, V104, P1039, DOI 10.1085/jgp.104.6.1039; Meier C, 2002, HISTOCHEM CELL BIOL, V117, P461, DOI 10.1007/s00418-002-0417-z; Mills SL, 2001, J COMP NEUROL, V436, P336; Naus CCG, 2001, CELL COMMUN ADHES, V8, P325, DOI 10.3109/15419060109080747; Ogilvie JM, 1999, J NEUROSCI METH, V87, P57; Oguro K, 2001, J NEUROSCI, V21, P7534, DOI 10.1523/JNEUROSCI.21-19-07534.2001; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Petrasch-Parwez E, 2004, J COMP NEUROL, V479, P181, DOI 10.1002/cne.20327; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Rozental R, 2001, METH MOL B, V154, P447; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Sohl G, 2000, BRAIN RES REV, V32, P138, DOI 10.1016/S0165-0173(99)00074-0; Srinivas M, 2001, P NATL ACAD SCI USA, V98, P10942, DOI 10.1073/pnas.191206198; Vaney DI, 1998, J NEUROSCI, V18, P10594; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; WHEELER CB, 1976, PHYS MED BIOL, V21, P616, DOI 10.1088/0031-9155/21/4/012; Xia YQ, 2003, VISUAL NEUROSCI, V20, P429, DOI 10.1017/S0952523803204089; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284	53	41	42	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2005	22	3					605	616		10.1111/j.1460-9568.2005.04228.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	954IE	WOS:000231147700007	16101742				2022-02-06	
J	Du, R; Meeker, M; Bacchetti, P; Larson, MD; Holland, MC; Manley, GT				Du, R; Meeker, M; Bacchetti, P; Larson, MD; Holland, MC; Manley, GT			Evaluation of the portable infrared pupillometer	NEUROSURGERY			English	Article						pupillometer; pupillary examination; traumatic brain injury	SEVERE HEAD-INJURY; PROGNOSIS		Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave 4M39, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Du, Rose/AAJ-2873-2020; Du, Rose/I-5402-2012	Du, Rose/0000-0003-2641-6496	ODCDC CDC HHS [R49/CCR903697] Funding Source: Medline		CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; LARSON MD, 1995, ARCH NEUROL-CHICAGO, V52, P369, DOI 10.1001/archneur.1995.00540280051018; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; VANDENBERGE JH, 1979, J NEUROL NEUROSUR PS, V42, P1163, DOI 10.1136/jnnp.42.12.1163	9	41	42	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2005	57	1					198	202		10.1227/01.NEU.0000163425.79170.CB			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	942ZQ	WOS:000230321800051	15987563				2022-02-06	
J	Pentland, B; Hutton, LS; Jones, PA				Pentland, B; Hutton, LS; Jones, PA			Late mortality after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SUICIDE; POPULATION; DISABILITY; ALCOHOL	Objectives: To investigate mortality trends in a cohort of people admitted to a regional head injury unit with all severities of injury in the calendar year 1981. Methods: A computerised database with details of 1919 admissions was compared with deaths registered by the NHS Central Register, Scotland for the years 1981 to mid-2002. Death certificate information for matches was analysed. Results: The 1919 admissions referred to 1871 individuals, comprising 93 severe, 205 moderate, and 1573 minor injuries according to Glasgow coma scale criteria. There were 57 deaths (42 severe head injuries, eight moderate, seven minor) during the initial admission, and 340 (six severe, 33 moderate, 301 minor) in the subsequent years. Substance abuse, principally alcohol, was a factor in 37 deaths, suicide accounted for 20, and accidents for 25. The great majority of these latter deaths were in people under the age of 70 years. Conclusion: Premature deaths after predominantly minor head injury are commonly alcohol related or the result of suicide or accidents.	Astley Ainslie Hosp, Scottish Brain Injury Rehabil Serv, Edinburgh EH9 2HL, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH8 9YL, Midlothian, Scotland		Pentland, B (corresponding author), Astley Ainslie Hosp, Scottish Brain Injury Rehabil Serv, Edinburgh EH9 2HL, Midlothian, Scotland.	Brian.Pentland@lpct.scot.nhs.uk					ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Baguley I, 2000, BRAIN INJURY, V14, P505; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Corrigan J. D., 1999, REHABILITATION ADULT; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; GOLDACRE MJ, 1996, OXFORD TXB MED, P39; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1998, EPIDEMIOLOGY NEUROLO, P75; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kraus J. F., 1999, REHABILITATION ADULT, P3; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MILLER JD, 1985, LANCET, V1, P1141; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RUSSELL WR, 1951, J NEUROL NEUROSUR PS, V14, P35, DOI 10.1136/jnnp.14.1.35; Scottish Executive, 2002, CHOOS LIF NAT STRAT; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VAUHKONEN K, 1959, ACTA PSYCHIAT NEUR S, V137, P90; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001	35	41	41	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2005	76	3					395	400		10.1136/jnnp.2004.037861			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	901TM	WOS:000227304800022	15716535	Bronze, Green Published			2022-02-06	
J	af Geijerstam, JL; Britton, M				af Geijerstam, JL; Britton, M			Mild head injury: reliability of early computed tomographic findings in triage for admission	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; DELAYED EPIDURAL HEMATOMA; EXTRADURAL HEMATOMAS; SUBDURAL-HEMATOMA; EMERGENCY-DEPARTMENT; NEUROLOGIC EXAMINATION; PEDIATRIC-PATIENTS; CT SCANS; MANAGEMENT; MORTALITY	Objective: To search the literature for case reports on adverse outcomes in patients with mild head injury where acute computed tomography (CT) findings had been normal. Methods: Mild head injury was defined as head trauma involving amnesia or loss of consciousness, but where neurological findings are normal on arrival at hospital (GCS 15). The scientific literature was systematically searched for case reports where an early CT was normal and the patient deteriorated within two days. In these cases, early discharge despite a normal CT head scan would have been hazardous. Results: Two prospective studies were found that investigated the safety of early CT in 3300 patients with mild head injury, as were 39 reports on adverse outcomes describing 821 patients. In addition, 52 studies containing over 62 000 patients with mild head injury were reviewed. In total, only three cases were deemed to have experienced an early adverse outcome despite a normal CT and GCS 15 on initial presentation. In another eight cases with incomplete descriptions, the interpretation was doubtful. Many reports of complications were not relevant to our question and excluded. These reports included cases with more severe head injury/not GCS 15 at presentation, complications that occurred after more than two days, or initial CT findings that were not fully normal. Conclusion: Very few cases were found where an early adverse event occurred after normal acute CT in patients with mild head injury. The strongest scientific evidence available at this time shows that a CT strategy is a safe way to triage patients for admission.	Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden; Swedish Council Technol Assessment Hlth Care SBU, Stockholm, Sweden		af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@medks.ki.se					af Geijerstam JL, 2000, EUR J SURG, V166, P526; ALFARO D, 1995, ANN EMERG MED, V25, P169, DOI 10.1016/S0196-0644(95)70319-5; Arendts Glenn, 2003, Australas Radiol, V47, P368, DOI 10.1046/j.1440-1673.2003.01204.x; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; Atkinson JLD, 2003, J MAGN RESON IMAGING, V17, P484, DOI 10.1002/jmri.10275; Bor-Seng-Shu E, 1997, CHILD NERV SYST, V13, P605, DOI 10.1007/s003810050151; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BRUNETTI J, 1979, NEURORADIOLOGY, V18, P43, DOI 10.1007/BF00346211; CERVANTES LA, 1983, J NEUROSURG, V59, P351, DOI 10.3171/jns.1983.59.2.0351; Chang JH, 2002, CHILD NERV SYST, V18, P712, DOI 10.1007/s00381-002-0664-2; CIQUINI JO, 1992, ARQ NEURO-PSIQUIAT, V50, P361; Cook L S, 1994, Acad Emerg Med, V1, P227; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DAVIES KG, 1990, BRIT J CLIN PRACT, V44, P420; DAVIES RL, 1995, PEDIATRICS, V95, P345; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DIROCCO A, 1991, NEURORADIOLOGY, V33, P253, DOI 10.1007/BF00588229; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Egger M, 2003, Health Technol Assess, V7, P1; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANKHAUSER H, 1983, NEUROCHIRURGIE, V29, P255; FANKHAUSER H, 1982, ACTA NEUROCHIR, V60, P29, DOI 10.1007/BF01401747; Ferrera PC, 1997, AM J EMERG MED, V15, P76, DOI 10.1016/S0735-6757(97)90055-3; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FUKAMACHI A, 1984, COMPUT RADIOL, V8, P197, DOI 10.1016/0730-4862(84)90123-9; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Hemphill RR, 1999, ACAD EMERG MED, V6, P957, DOI 10.1111/j.1553-2712.1999.tb01248.x; Inamasu J, 2001, AM J EMERG MED, V19, P324, DOI 10.1053/ajem.2001.24480; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; KESKIL IS, 1995, CHILD NERV SYST, V11, P467, DOI 10.1007/BF00334967; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lal NR, 2000, AM J NEURORADIOL, V21, P124; LEE ST, 1991, ACTA NEUROCHIR, V113, P121, DOI 10.1007/BF01403196; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Mandavia DP, 2001, PEDIATR EMERG CARE, V17, P193, DOI 10.1097/00006565-200106000-00011; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Newman TB, 2003, BRIT MED J, V327, P1424, DOI 10.1136/bmj.327.7429.1424; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; POON WS, 1992, NEUROSURGERY, V30, P681; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; RIVARA F, 1987, PEDIATRICS, V80, P579; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; Shu EBS, 2000, PEDIATR NEUROSURG, V32, P176, DOI 10.1159/000028930; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; *SWED COUNC TECHN, 2000, 153 SBU SWED COUNC T; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	74	41	42	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	FEB 1	2005	22	2					103	107		10.1136/emj.2004.015396			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	892DQ	WOS:000226630400007	15662058	Bronze, Green Published			2022-02-06	
J	Wagner, AK; Fabio, A; Puccio, AM; Hirschberg, R; Li, W; Zafonte, RD; Marion, DW				Wagner, AK; Fabio, A; Puccio, AM; Hirschberg, R; Li, W; Zafonte, RD; Marion, DW			Gender associations with cerebrospinal fluid glutamate and lactate/pyruvate levels after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	20th National Neurotrauma-Society	OCT 27-NOV 01, 2002	Tampa, FL	Neurotrauma Soc		gender; glutamate; hypothermia; lactate; traumatic brain injury	SEVERE HEAD-INJURY; EXCITATORY AMINO-ACIDS; THERAPEUTIC HYPOTHERMIA; EXTRACELLULAR GLUTAMATE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; BASE-BALANCE; ESTROGEN; LACTATE	Objective: Female sex hormones appear to be neuroprotective after traumatic brain injury by attenuating multiple mechanisms of secondary insult, including excitotoxicity and ischemia. The purpose of this study was to evaluate associations between gender and cerebrospinal fluid glutamate and lactate/pyruvate production and the role of hypothermia with gender in attenuating these markers. Design: Prospectively collected data were analyzed for adult patients with severe traumatic brain injury. Gender comparisons for cerebrospinal fluid glutamate and lactate/pyruvate production were determined using ventricular samples obtained over the first 48 hrs postinjury. Setting: University-based level I trauma center. Patients: There were 123 patients, male n = 93 and female n 30 (n = 686 cerebrospinal fluid samples), with severe traumatic brain injury (Glasgow Coma Scale score less than or equal to 8). Interventions: A portion of these patients were part of a randomized controlled trial evaluating the effect of (48 hrs) therapeutic hypothermia after severe traumatic brain injury. The remainder received hypothermia (24 hrs) if they met clinical care criteria. Patients were cooled to 32-33degreesC (within similar to8 hrs) for either 24 or 48 hrs and then were rewarmed or remained normothermic. Measurements and Main Results: Regression analyses using generalized estimating equations for repeated measures showed significant increases in cerebrospinal fluid glutamate production for males compared with females (p = .0023) and a significant interaction between glutamate concentration, gender, and time (p = .0035) by 24 hrs postinjury. Females had lower lactate/pyruvate ratios than males (p = .0006), and there was a significant interaction between lactate/pyruvate, gender, and time (p = .0045) throughout the first 48 hrs postinjury. Hypothermia attenuated glutamate levels, particularly for males, over the time course studied. Conclusions: These data suggest significant gender differences with glutamate and lactate/pyruvate production after severe traumatic brain injury. Gender- and hormone-mediated differences in central nervous system pathophysiology should be considered with clinical trials in traumatic brain injury.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA; Harvard Univ, Spaulding Rehabil Inst, Cambridge, MA 02138 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021	Fabio, Anthony/0000-0002-6808-4939	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133P970013-00] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; ELOVIC E, 1996, MED REHABILITATION T, P11; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FUJISHIMA M, 1975, STROKE, V6, P707, DOI 10.1161/01.STR.6.6.707; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gopinath SP, 2000, ACT NEUR S, V76, P437; GRANHOLM L, 1969, SCAND J CLIN LAB INV, V23, P361, DOI 10.3109/00365516909081702; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; LEVINTHAL R, 1977, SURG NEUROL, V7, P269; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Love S, 1999, BRAIN PATHOL, V9, P119; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shiogai T, 1999, ACT NEUR S, V75, P49; Siesj? BK., 1978, BRAIN ENERGY METABOL; SIESJO BK, 1970, ACTA PHYSIOL SCAND, V79, P114, DOI 10.1111/j.1748-1716.1970.tb04707.x; SIESJO BK, 1970, ACTA NEUROL SCAND, V46, P187, DOI 10.1111/j.1600-0404.1970.tb05615.x; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yang CS, 1996, FREE RADICAL BIO MED, V20, P245, DOI 10.1016/0891-5849(95)02042-X; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Zhang H, 2003, J CHROMATOGR B, V784, P131, DOI 10.1016/S1570-0232(02)00788-2; Zhang H, 2001, CLIN CHEM, V47, P1458; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	62	41	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2005	33	2					407	413		10.1097/01.CCM.0000153931.23488.DD			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	898LE	WOS:000227077500017	15699846				2022-02-06	
J	Willoughby, KA; Kleindienst, A; Muller, C; Chen, T; Muir, JK; Ellis, EF				Willoughby, KA; Kleindienst, A; Muller, C; Chen, T; Muir, JK; Ellis, EF			S100B protein is released by in vitro trauma and reduces delayed neuronal injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cell culture; in vitro models; neurons; neuroprotection; S100B protein; traumatic brain injury	STRETCH-INDUCED INJURY; METABOTROPIC GLUTAMATE RECEPTORS; BRAIN-DAMAGE; CORTICAL-NEURONS; CALCIUM; S100-BETA; S-100B; ANTAGONISM; ACTIVATION; MARKERS	S100B protein in brain is produced primarily by astrocytes, has been used as a marker for brain injury and has also been shown to be neurotrophic and neuroprotective. Using a well characterized in vitro model of brain cell trauma, we examined the potential role of exogenous S100B in preventing delayed neuronal injury. Neuronal plus glial cultures were grown on a deformable Silastic membrane and then subjected to strain (stretch) injury produced by a 50 ms displacement of the membrane. We have previously shown that this injury causes an immediate, but transient, nuclear uptake of the fluorescent dye propidium iodide by astrocytes and a 24-48 h delayed uptake by neurons. Strain injury caused immediate release of S100-beta with further release by 24 and 48 h. Adding 10 or 100 nm S100B to injured cultures at 15 s, 6 h or 24 h after injury reduced delayed neuronal injury measured at 48 h. Exogenous S100B was present in the cultures through 48 h. These studies directly demonstrate the release and neuroprotective role of S100B after traumatic injury and that, unlike most receptor antagonists used for the treatment of trauma, S100B is neuroprotective when given at later, more therapeutically relevant time points.	Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Neurosurg, Richmond, VA USA; Humboldt Univ, Charite, Inst Lab Med & Pathobiochem, Berlin, Germany		Ellis, EF (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	eellis@mail2.vcu.edu	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS 07288] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 57869] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; AHMED SM, 1998, J NEUROTRAUM, V15, P854; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hu JR, 1997, J NEUROCHEM, V69, P2294; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Missler U, 2000, CLIN CHEM, V46, P993; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MUIR JK, 2002, J NEUROTRAUM, V19, P1361; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; RZIGALINSKI BA, 1999, J NEUROTRAUM, V16, P962; Schreiber D., 1995, P 1995 INT RES C BIO, P233; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082	40	41	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2004	91	6					1284	1291		10.1111/j.1471-4159.2004.02812.x			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	884VX	WOS:000226115900004	15584905	Bronze			2022-02-06	
J	Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Hovda, DA; Bergsneider, M				Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Hovda, DA; Bergsneider, M			Subcortical white matter metabolic chances remote from focal hemorrhagic lesions suggest diffuse injury after human traumatic brain injury	NEUROSURGERY			English	Article						diffuse axonal injury; hyperglycolysis; oxidative metabolism; reactive gliosis	CEREBRAL BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE SPECTROSCOPY; AXONAL INJURY; HEAD-INJURY; GLUCOSE-UTILIZATION; OXYGEN UTILIZATION; PRACTICAL SCALE; CYCLOSPORINE-A; NORMAL VALUES	OBJECTIVE: We used positron emission tomographic studies to prospectively examine the relationship between glucose and oxidative metabolism in the subcortical white matter (WM) acutely after traumatic brain injury (TBI). The objective was to determine the nature, extent, and degree of metabolic abnormalities in subcortical brain regions remote from hemorrhagic lesions. METHODS: Sixteen normal volunteers and 10 TBI patients (Glasgow Coma Scale score, 4-10; age, 17-64 yr; 6 with focal and 4 with diffuse injury) were studied. Each subject underwent dynamic positron emission tomographic studies using [O-15]CO, O-15(2), [O-15]H2O, and fluorodeoxyglucose plus a magnetic resonance imaging scan acutely after TBI. Parametric images of the metabolic rate of oxygen and metabolic rate of glucose were generated, and a molar oxygen-to-glucose utilization ratio was calculated. Data from gray matter and WM remote from hemorrhagic lesions, plus whole brain, were analyzed. RESULTS: There was a significant reduction in the subcortical WM oxygen-to-glucose utilization ratio after TBI compared with normal values (3.99 +/- 0.77 versus 5.37 +/- 1.00; P < 0.01), whereas the mean cortical gray matter and whole-brain values remained unchanged. WM metabolic changes, which were diffuse throughout the hemispheres, were characterized by a reduction in the metabolic rate of oxygen without a concomitant drop in the metabolic rate of glucose. CONCLUSION: The extent and degree of subcortical WM metabolic abnormalities after moderate and severe TBI suggest that diffuse WM injury is a general phenomenon after such injuries. This pervasive finding may indicate that the concept of focal traumatic injury, although valid from a computed tomographic imaging standpoint, may be misleading when considering metabolic derangements associated with TBI.	Univ Calif Los Angeles, Daivd Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, DOE Ctr Mol Med, Los Angeles, CA 90095 USA		Bergsneider, M (corresponding author), Univ Calif Los Angeles, Daivd Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, 10833 Leconte Ave,Room 74-134 CHS,Mail Code 95690, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012	Glenn, Thomas/0000-0003-4273-3408	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [Z01DE000387] Funding Source: NIH RePORTER; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE-FC03-02ER63420, DE-FC0387-ER60615] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brix G, 1997, J NUCL MED, V38, P1614; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byas-Smith Michael, 2002, Mol Imaging Biol, V4, P139, DOI 10.1016/S1536-1632(01)00006-3; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; DASTUR DK, 1963, USPHS PUBLICATION, V986, P59; Despopoulos A., 1991, COLOR ATLAS PHYSL; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GJEDDE A, 1982, BRAIN RES REV, V4, P237, DOI 10.1016/0165-0173(82)90018-2; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HATTORI N, IN PRESS J NUCL MED; HUANG SC, 1983, J CEREBR BLOOD F MET, V3, P141, DOI 10.1038/jcbfm.1983.21; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Liu YY, 2001, NEUROREPORT, V12, P3239, DOI 10.1097/00001756-200110290-00019; MINTUN MA, 1984, J NUCL MED, V25, P177; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NAKAI H, 1987, STROKE, V18, P158, DOI 10.1161/01.STR.18.1.158; Nakao Y, 2001, P NATL ACAD SCI USA, V98, P7593, DOI 10.1073/pnas.121179898; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oehler R, 2000, BLOOD, V95, P1086, DOI 10.1182/blood.V95.3.1086.003k09_1086_1092; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PHELPS ME, 1979, J NUCL MED, V20, P328; Povlishock JT, 1999, ACT NEUR S, V73, P15; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; Sanchez-Abarca LI, 2001, GLIA, V36, P321, DOI 10.1002/glia.1119; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Soares HD, 1995, J NEUROSCI, V15, P8223; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEWART L, 1994, ACTA NEUROCHIR, P544; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; WU HM, 2003, MOL IMAGING BIOL, V4, P1; WU HM, 2002, BRAIN IMAGING USING, P147; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	58	41	44	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1306	1317		10.1227/01.NEU.0000143028.08719.42			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000009	15574212				2022-02-06	
J	Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Lu, M; Chopp, M				Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Lu, M; Chopp, M			Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hematoma; atorvastatin; rat	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; SYNAPTOGENESIS; ANGIOGENESIS; MECHANISMS; ISCHEMIA; PROTECTS; STATINS; EDEMA; CELLS	Object. Atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects such as improving thrombogenic profile, promoting angiogenesis, and reducing inflammatory responses and has shown promise in enhancing neurological functional improvement and promoting neuroplasticity in animal models of traumatic brain injury (TBI), stroke, and intracranial hemorrhage. The authors tested the effect of atorvastatin on intracranial hematoma after TBI. Methods. Mate Wistar rats were subjected to controlled cortical impact, and atorvastatin (1 mg/kg) was orally administered 1 day after TBI and daily for 7 days thereafter. Rats were killed at 1, 8, and 15 days post-TBI. The temporal profile of intraparenchymal hematoma was measured on brain tissue sections by using a MicroComputer Imaging Device and light microscopy. Conclusions. Data in this study showed that intraparenchymal and intraventricular hemorrhages are present 1 day after TBI and are absorbed at 15 days after TBI. Furthermore, atorvastatin reduces the volume of intracranial hematoma 8 days after TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Biostat, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bhasin RR, 2002, ACTA NEUROCHIR SUPPL, V81, P249; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Dalla Nora E, 2003, J ENDOCRINOL INVEST, V26, P73, DOI 10.1007/BF03345126; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Gong C, 2001, NEUROSURGERY, V48, P875, DOI 10.1097/00006123-200104000-00037; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Gryglewski RJ, 2001, ANN NY ACAD SCI, V947, P229; Honjo M, 2002, ARCH OPHTHALMOL-CHIC, V120, P1707; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mason JC, 2002, CIRC RES, V91, P696, DOI 10.1161/01.RES.0000038151.57577.19; Mital S, 2000, AM J PHYSIOL-HEART C, V279, pH2649, DOI 10.1152/ajpheart.2000.279.6.H2649; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820	30	41	41	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2004	101	5					822	825		10.3171/jns.2004.101.5.0822			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	873UL	WOS:000225306500014	15540921				2022-02-06	
J	Olson, EE; Lyuboslavsky, T; Traynelis, SF; McKeon, RJ				Olson, EE; Lyuboslavsky, T; Traynelis, SF; McKeon, RJ			PAR-1 deficiency protects against neuronal damage and neurologic deficits after unilateral cerebral hypoxia/ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						protease activated receptors; serine protease; cerebral ischemia; neuronal death	PROTHROMBIN-MESSENGER-RNA; THROMBIN-RECEPTOR ACTIVATION; TISSUE-PLASMINOGEN ACTIVATOR; NIGRAL DOPAMINERGIC-NEURONS; SIGNALING PATHWAYS; PROTEASE THROMBIN; NERVOUS-SYSTEM; BRAIN-DAMAGE; CELL-DEATH; RAT-BRAIN	Cardiovascular and neurologic surgeries often involve a temporary reduction in cerebral blood flow. In these conditions, as well as during cerebral ischemia and traumatic brain injury, the temporary loss of oxygen and glucose initiates a cascade of cellular events that culminate in neuronal death and damage. Understanding the mechanisms that contribute to neuronal death after hypoxia/ischemia is critically important for treatment of such brain injury. Here, we use a model of combined cerebral hypoxia/ischemia (H/I) to examine the role of protease-activated receptor-1 (PAR-1) in hypoxic/ischemic neuronal damage. Our data show that PAR-1-deficient mice have smaller lesion volumes than wild-type controls after 45 minutes of H/I. The results of the genetic block of PAR-I were corroborated using a PAR-1 antagonist, which decreased infarct volume in wild-type C57B16 mice. Examination of cellular responses to H/I reveals that PAR-1 -/- animals have less cellular death and diminished glial fibrillary acidic protein expression. Additionally, PAR-1 -/- mice exhibit less motor behavior impairment in rotorod and inverted wire-hang tests. These data suggest that PAR-1 contributes to hypoxic/ischemic brain injury and are consistent with other studies that implicate serine proteases and their receptors in neuropathology after cerebral insults.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA		McKeon, RJ (corresponding author), Emory Univ, Dept Cell Biol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	mckeon@cellbio.emory.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 35986, NS 39419, NS42717] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039419, R29NS035986, R01NS042717] Funding Source: NIH RePORTER		Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Busch E, 1997, ACT NEUR S, V70, P206; Carreno-Muller E, 2003, J NEUROCHEM, V84, P1201, DOI 10.1046/j.1471-4159.2003.01634.x; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Choi SH, 2003, J NEUROSCI, V23, P5877; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Debeir T, 1996, BRAIN RES, V708, P159, DOI 10.1016/0006-8993(95)01237-0; Derian CK, 2003, J PHARMACOL EXP THER, V304, P855, DOI 10.1124/jpet.102.042663; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1997, J NEUROSCI, V17, P5316; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P404, DOI 10.1097/00004647-200204000-00004; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kessler C, 1997, ANAESTHESIA, V52, P433, DOI 10.1111/j.1365-2044.1997.113-az0107.x; Khanna G, 2000, NEW J PHYS, V2, P31, DOI 10.1088/1367-2630/2/1/303; Kim YD, 2002, BRAIN RES BULL, V58, P491, DOI 10.1016/S0361-9230(02)00823-7; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Masada T, 2000, BRAIN RES, V867, P173, DOI 10.1016/S0006-8993(00)02302-7; Motohashi O, 1997, J NEUROTRAUM, V14, P747, DOI 10.1089/neu.1997.14.747; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; O'Donnell SL, 2002, GLIA, V39, P85, DOI 10.1002/glia.10081; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; SAMSON D, 1994, NEUROSURGERY, V34, P22; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Turgeon VL, 1999, J NEUROPATH EXP NEUR, V58, P499, DOI 10.1097/00005072-199905000-00009; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; Vannucci SJ, 2001, J CEREBR BLOOD F MET, V21, P52, DOI 10.1097/00004647-200101000-00007; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x	41	41	42	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2004	24	9					964	971		10.1097/01.WCB.0000128266.87474.BF			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	853CO	WOS:000223804100002	15356417	Bronze			2022-02-06	
J	de boussard, CN; Fredman, P; Lundin, A; Andersson, K; Edman, G; Borg, J				de boussard, CN; Fredman, P; Lundin, A; Andersson, K; Edman, G; Borg, J			S100 in mild traumatic brain injury	BRAIN INJURY			English	Article							NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; CALCIUM-BINDING PROTEINS; MINOR HEAD TRAUMA; S-100 PROTEIN; COMPUTED-TOMOGRAPHY; SERUM-LEVELS; OUTCOME PREDICTION; DAMAGE; FAMILY	Primary objectives : To examine the diagnostic value of S100 in mild traumatic brain injury (MTBI). Research design : Prospective cohort study. Methods and procedures : S100B, S100A1B and S100BB concentrations were examined in sera from patients with MTBI with an arrival Glasgow Coma Scale score of 15 or 14, patients with orthopaedic injuries and non-injured subjects. Main outcome and results : Mean values and proportions of subjects above cut-off limits for S100B and S100A1B were significantly higher in each trauma group than in non-injured controls, but only for S100A1B when patients with MTBI were compared with controls with orthopaedic injuries. Using a 97.5 percentile cut-off limit, the sensitivity of S100A1B for MTBI vs orthopaedic injury was 61% (95% confidence interval (CI) 49-73%), specificity 77% (95% CI 62-93%). The area under the ROC curve did not approach 0.9 for any cut off limit. Conclusions : Diagnostic validity of S100 in acute MTBI was not demonstrated. S100A1B has merits for long-term prognostic studies.	Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden; Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Sect Expt Neurosci, SU Molndal, Sweden; Danderyd Hosp, Karolinska Inst, Dept Psychiat, R&D Unit, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden		de boussard, CN (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden.	catharina.nygren@reh.ds.sll.se		Borg, Jorgen/0000-0002-2372-7478			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blockzjil A, 1998, TUMOR BIOL, V19, P46, DOI 10.1159/000056504; BRITTON M, 2000, 2000 SBU; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Johnsson P, 2000, SCAND CARDIOVASC J, V34, P548, DOI 10.1080/140174300750064459; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; NYBERG L, 1996, 24 M INT SOC ONC BIO; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stigbrand T, 2000, INT J BIOL MARKER, V15, P33, DOI 10.1177/172460080001500106; Teasdale TW, 1997, BRIT MED J, V315, P569; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	48	41	41	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					671	683		10.1080/02699050310001646215			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700004	15204328				2022-02-06	
J	Campbell, CGN; Kuehn, SM; Richards, PMP; Ventureyra, E; Hutchison, JS				Campbell, CGN; Kuehn, SM; Richards, PMP; Ventureyra, E; Hutchison, JS			Medical and cognitive outcome in children with traumatic brain injury	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SEVERE HEAD-INJURY; ADOLESCENTS; SURVIVAL; SEQUELAE; COHORT	Background: Head injury is an important cause of morbidity and mortality in pediatrics. Comprehensive studies on outcome are scarce despite significant clinical concern that multiple areas of functioning may be impaired following moderate to severe head injury. The literature suggests that sequelae include not only medical problems but also impairments in cognitive functioning. Methods: A retrospective medical and psychology chart review of patients, age 1-18 years, admitted to the Children's Hospital of Eastern Ontario with moderate (Glasgow Coma Scale [GCS] 9-12) or severe head injury (GCS :5 8) from November 1, 1993 until December 31, 1998 was conducted. Correlations were performed between medical variables (i.e., GCS, Pediatric Risk of Mortality [PRISM] III score, duration of ICU and hospital stay) and measures of intelligence and memory functioning. Results: Eighty-three children age I to 18 were included. Seventy percent of the children were classified as having a severe head injury. There was a mortality rate of thirteen percent. Younger age at injury, lower GCS, and higher PRISM III scores predicted higher mortality. Medical complications were documented systematically. Forty-four patients underwent at least one cognitive assessment and 17 of these children had intelligence testing at three points in time: baseline (< four months), early recovery (five to 15 months) and follow-up (16 to 38 months). The mean intelligence and memory scores fell within the average range at the latest point in follow-up. For those children who underwent three serial assessments, the mean verbal and performance IQ fell within the low average range at baseline improving significantly to fall within the average range by early recovery. Continued improvements were apparent in verbal memory beyond early recovery, with the mean obtained at follow-up falling within 1 SD of the normative mean. Despite the return to normal ranges for the group means the proportion of scores falling below 1.5 standard deviations from the mean was greater than population norms for verbal IQ, performance IQ and verbal memory. Lower GCS scores and longer duration of stay in ICU or hospital were predictive of lower nonverbal intelligence. Lower GCS was also predictive of lower visual memory scores. Conclusions: This study describes a population of Canadian children who suffered moderate or severe traumatic brain injury. Initial GCS was the best predictor of mortality and cognitive outcome. These children demonstrated a temporal improvement in intelligence and memory functioning, with their mean performance on these cognitive measures failing within the average range at 16 to 38 months postinjury, although there was considerable variability in the outcomes between individuals.	Univ Toronto, Hosp Sick Children, Dept Crit Care, Fac Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Fac Med, Toronto, ON M5G 1X8, Canada; Carleton Univ, Fac Psychol, Ottawa, ON K1S 5B6, Canada; Univ Ottawa, Fac Med, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Dept Mental Hlth, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Div Neurosurg, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Div Neurol, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Discipline Psychol, Ottawa, ON K1H 8L1, Canada		Hutchison, JS (corresponding author), Univ Toronto, Hosp Sick Children, Dept Crit Care, Fac Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.						Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BEHRMAN RE, 1996, NELSON TXB PEDIAT, P1; BROWN S, 1994, J NEUROPSYCHIATRY CL, V16, P15; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; Davis RJ, 1992, TXB PEDIAT INTENSIVE, P805; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; EWINGCOBBS L, 1990, NEUROSURGERY, V26, P638; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Helfaer Mark A., 1993, Current Opinion in Pediatrics, V5, P303; HUN SS, 1997, CHILD NERV SYST, V13, P82; JOHNSON DA, 1992, BRIT J EDUC PSYCHOL, V62, P404, DOI 10.1111/j.2044-8279.1992.tb01033.x; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; Semple PL, 1998, S AFR MED J, V88, P440; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D., 1997, WECHSLER INTELLIGENC; WECHSLER D, 1974, INTELLIGENCE SCALE C; Wechsler D., 1981, ADULT INTELLIGENCE S; YLVISAKER M, 1990, REHABILITATION ADULT	41	41	45	0	3	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2004	31	2					213	219		10.1017/S0317167100053853			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	820IY	WOS:000221383600014	15198446	Bronze			2022-02-06	
J	Tam, SF; Man, WK				Tam, SF; Man, WK			Evaluating computer-assisted memory retraining programmes for people with post-head injury amnesia	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; SELF-EFFICACY; COGNITIVE REHABILITATION; FEEDBACK; INDIVIDUALS; OUTCOMES	Objective : The present study was designed to perform theory-driven empirical work that might contribute to a better understanding of computer-assisted training effects adopting theoretically different memory retraining strategies for people who had amnesia as a result of a brain injury. Research design : A pre-test and post-test control group quasi-experimental design was adopted to test the differences in effectiveness of four different computer-assisted memory training strategies, which were hypothesized to improve different memory skills of persons with brain injury. Method and procedures : Twenty-six persons with brain injury were randomly assigned to four age- and gender-matched memory training groups (self-paced, feedback, personalized, visual presentation) and they were trained using the related computer software, evaluated by the Rivermead Behavioural Memory Test (RBMT), self-efficacy scale and built-up computer performance records. Main outcomes and results : All the four memory training methods showed positive among the persons with brain injury as compared with a control group, although there was no statistically significant difference among the four training methods. However, clinical improvement was found in all four methods and the Feedback group showed significant improvement in self efficacy, in comparison with the other groups. Conclusion : This attempt to develop and evaluate different computer applications for memory retraining was made and the effectiveness of applying customized computer technology in memory rehabilitation was critically evaluated. Results of the present study showed that the unique customized therapeutic characteristics of computer-assisted memory retraining (e.g. self-paced practice, performance feedback, salient visual presentation and personalized training contents) are positive attributes of memory skill retraining outcomes.	Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China		Tam, SF (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.	rsalan@polyu.edu.hk					ARMSTRONG C, 1989, COGNITIVE REHABILITA, V1, P10; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BANDURA A, 1982, J PERS SOC PSYCHOL, V43, P5, DOI 10.1037/0022-3514.43.1.5; Bandura A., 1992, 6 THEORIES CHILD DEV, P1; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bellus SB, 1998, BRAIN INJURY, V12, P139, DOI 10.1080/026990598122764; Bracy O.D., 1999, COGN TECHNOL, V4, P19; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; BURDA PC, 1994, COMPUT HUM BEHAV, V10, P359, DOI 10.1016/0747-5632(94)90061-2; CERVONE D, 1986, J PERS SOC PSYCHOL, V50, P492, DOI 10.1037/0022-3514.50.3.492; Chen SHA, 1997, BRAIN INJURY, V11, P197; CLARK SC, 1997, DISS ABSTR INT, V58, P2177; Collins J. L., 1982, PAPER PRESENTED ANN; DANIELS J, 2001, COUNS EDUC SUPERV, V41, P120, DOI DOI 10.1002/J.1556-6978.2001.TB01276.X; Escarti A, 1999, J APPL SPORT PSYCHOL, V11, P83, DOI 10.1080/10413209908402952; GILES GM, 1989, ARCH PHYS MED REHAB, V70, P156; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GREEN RC, 1994, ARCH NEUROL-CHICAGO, V51, P779, DOI 10.1001/archneur.1994.00540200055017; Johnson P, 1994, J COGNITIVE REHABILI, V12, P10; JOHNSON R, 1985, OCCUPATIONAL THERAPY, V48, P46; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; Man D.W.K., 2001, CLIN GERONTOLOGIST, V24, P27; MCGUIRE BE, 1990, IRISH J PSYCHOL, V11, P299, DOI 10.1080/03033910.1990.10557810; Miyake M, 2002, PSYCHOL REP, V90, P301, DOI 10.2466/pr0.2002.90.1.301; *NEUR WORK GROUP, 1998, HONG KONG J OCCUPATI, V9, P18; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SCHUNK DH, 1985, J EARLY ADOLESC, V5, P247, DOI DOI 10.1177/0272431685052008; SMART S, 1998, CLIN REHABIL, V2, P61; Tam SF, 1996, J PSYCHOL, V130, P51, DOI 10.1080/00223980.1996.9914987; TAM SF, 1982, P BME 92 BIOM ENG S, P53; Wilson B., 1992, CLIN MANAGEMENT MEMO, P120; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; YLVISAKER M, 1998, REHABILITATION TRAUM, P303; Zhang AQ, 2002, SOC BEHAV PERSONAL, V30, P281, DOI 10.2224/sbp.2002.30.3.281	37	41	43	2	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					461	470		10.1080/02699050310001646099			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600005	15195794				2022-02-06	
J	Krotz, M; Linsenmaier, U; Kanz, KG; Pfeifer, KJ; Mutschler, W; Reiser, M				Krotz, M; Linsenmaier, U; Kanz, KG; Pfeifer, KJ; Mutschler, W; Reiser, M			Evaluation of minimally invasive percutaneous CT-controlled ventriculostomy in patients with severe head trauma	EUROPEAN RADIOLOGY			English	Article						intracranial pressure; computed tomography; CT-controlled ventriculostomy; ventricular catheters; traumatic brain injury; craniocerebral trauma; multiple trauma	INTRA-CRANICAL PRESSURE; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; FIBEROPTIC DEVICE; INJURED PATIENTS; TISSUE PRESSURE; MANAGEMENT; INFECTIONS; DURATION	Evaluation of percutaneous CT-controlled ventriculostomy (PCV) in patients with severe traumatic brain injury to measure intracranial pressure as a component of early clinical care. A consecutive series of 52 interventions with PCV was prospectively analyzed with regard to technical success, procedural time, time from the initial cranial computed tomography (CCT) until procedure and transfer to the intensive care unit (ICU). Additionally, the data was compared with a retrospective control group of 12 patients with 13 procedures of conventional burr-hole ventriculostomy (OP-ICP). The PCV was successful in all cases (52 of 52; 95% CI 94-100%). In 1 case a minor hemorrhage into the ipsilateral lateral ventricle was observed on CT scans due to an initially unsuccessful puncture (95% CI 0-6%). No infections occurred (95% CI 0-6%). In the control group with OP-ICP one catheter infection and one unsuccessful catheter placement occurred (each 8%, 95% CI 0-20%). The PCV led to a significant decrease of procedure time from 45+/-11 min (OP-ICP) to 20+/-12 min (PCV). The interval from the initial CCT until procedure (PCV 28+/-11 min, OP-ICP 78+/-33 min) and transfer to the ICU (PCV 69+/-34 min, OP-ICP 138+/-34 min) could also be significantly reduced (each with p<0.05, Mann-Whitney U-test). Percutaneous CT-controlled ventriculostomy is a safe and efficient method for ICP catheter placement during initial trauma room management. It significantly reduces the time of initial trauma room treatment.	Univ Munich, Klinikum Innenstadt, Dept Clin Radiol, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Dept Surg, D-80336 Munich, Germany		Krotz, M (corresponding author), Univ Munich, Klinikum Innenstadt, Dept Clin Radiol, Nussbaumstr 20, D-80336 Munich, Germany.	mkroetz@gmx.net					BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; Kroetz MM, 2000, RADIOLOGY, V217, P184; Linsenmaier U, 2002, EUR RADIOL, V12, P1728, DOI 10.1007/s00330-001-1225-x; LINSENMAIER U, 2001, ROFO FORTSCHR RONTG, V173, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nast-Kolb D, 1999, UNFALLCHIRURG, V102, P338, DOI 10.1007/s001130050415; NASTKOLB D, 1997, ARCH CHIR S, V114, P330; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PIEK J, 1990, INTENS CARE MED, V16, P184, DOI 10.1007/BF01724800; Prabhu VC, 1999, SURG NEUROL, V52, P226, DOI 10.1016/S0090-3019(99)00084-1; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Ruchholtz S, 1998, J TRAUMA, V45, P505, DOI 10.1097/00005373-199809000-00013; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; SAUL TG, 1982, AM SURGEON, V48, P477; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603	31	41	43	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	FEB	2004	14	2					227	233		10.1007/s00330-003-2134-y			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	767VD	WOS:000188493800008	14605843				2022-02-06	
J	Lambert, JC; Coyle, N; Lendon, C				Lambert, JC; Coyle, N; Lendon, C			The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease	JOURNAL OF MEDICAL GENETICS			English	Article							APOE PROMOTER POLYMORPHISMS; ALPHA GENE POLYMORPHISMS; TRAUMATIC BRAIN INJURY; REPLACEMENT THERAPY; TRANSGENIC MICE; RECEPTOR-ALPHA; HEAD-INJURY; POSTMENOPAUSAL WOMEN; MESSENGER-RNA; OLDER WOMEN	Background: The epsilon4 allele of the apolipoprotein E ( APOE) gene is a major genetic risk factor for Alzheimer's disease but appears to be associated with greater risk in women than in men. Some studies suggest that the level of APOE may of its own modulate the risk for Alzheimer's disease. Sex differences and an apparent benefit of oestrogen therapy suggest a role for oestrogen. APOE expression is influenced by oestrogen and oestrogen therapy may not benefit women bearing an APOE epsilon4 allele. These findings suggest an interaction between oestrogen and APOE in the Alzheimer's disease process. Aim: To explore the hypothesis that APOE expression is regulated by a genomic mechanism and is modified by the polymorphisms in APOE associated with risk for Alzheimer's disease. Methods: In vitro binding studies were undertaken between oestrogen receptors and fragments of the human APOE gene. APOE gene expression was studied to investigate a possible functional interaction. Results: APOE epsilon2/epsilon3/epsilon4 coding and - 219 G/T promoter polymorphisms influenced binding to the oestrogen receptor and altered transcriptional activity in response to oestrogen. Conclusions: An allele dependent modulation of oestrogen induced regulation of APOE might be involved in the increased risk for Alzheimer's disease in women bearing an epsilon4 allele.	Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England		Lendon, C (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.	c.l.lendon@bham.ac.uk	lambert, jean-charles/F-8787-2013; Lambert, jean-charles/A-9553-2014	lambert, jean-charles/0000-0003-0829-7817; Lambert, jean-charles/0000-0003-0829-7817			Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Baum L, 2000, MICROSC RES TECHNIQ, V50, P278, DOI 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T; Behl C, 2002, PROG BRAIN RES, V138, P135, DOI 10.1016/S0079-6123(02)38075-0; Berr C, 2001, NEUROBIOL AGING, V22, P227, DOI 10.1016/S0197-4580(00)00227-X; Brandi ML, 1999, BIOCHEM BIOPH RES CO, V265, P335, DOI 10.1006/bbrc.1999.1665; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Bretsky PM, 1999, ALZ DIS ASSOC DIS, V13, P216, DOI 10.1097/00002093-199910000-00007; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; COEZY E, 1982, CANCER RES, V42, P317; Costa MM, 1999, BIOL PSYCHIAT, V46, P182, DOI 10.1016/S0006-3223(98)00355-2; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geerlings MI, 2001, JAMA-J AM MED ASSOC, V285, P1475, DOI 10.1001/jama.285.11.1475; Growdon WB, 1999, NEUROSCI LETT, V272, P83, DOI 10.1016/S0304-3940(99)00557-1; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.3.CO;2-#; Houlden H, 1998, AM J MED GENET, V81, P117, DOI 10.1002/(SICI)1096-8628(19980207)81:1<117::AID-AJMG19>3.0.CO;2-M; Inestrosa NC, 1998, MOL NEUROBIOL, V17, P73, DOI 10.1007/BF02802025; Isoe K, 1997, ALZHEIMERS RES, V3, P195; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lambert JC, 2001, NEUROSCI LETT, V306, P193, DOI 10.1016/S0304-3940(01)01806-7; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Lendon CL, 1997, HUM MUTAT, V10, P186; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; LESLIE KK, 1994, J SOC GYNECOL INVEST, V1, P238, DOI 10.1177/107155769400100311; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Maruyama H, 2000, ARCH NEUROL-CHICAGO, V57, P236, DOI 10.1001/archneur.57.2.236; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Payami H, 1996, AM J HUM GENET, V58, P803; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Seshadri S, 2001, ARCH NEUROL-CHICAGO, V58, P435, DOI 10.1001/archneur.58.3.435; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Srivastava RAK, 1997, J BIOL CHEM, V272, P33360, DOI 10.1074/jbc.272.52.33360; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, J NEUROSCI, V18, P3180; Sun YL, 1998, J NEUROSCI, V18, P3261; Szklo M, 1996, AM J EPIDEMIOL, V144, P1048; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1997, J NEUROSCI, V17, P5678; Town T, 1998, NEUROSCI LETT, V252, P95, DOI 10.1016/S0304-3940(98)00567-9; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang JC, 2000, NEUROLOGY, V55, P1644, DOI 10.1212/WNL.55.11.1644; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2	82	41	43	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-2593	1468-6244		J MED GENET	J. Med. Genet.	FEB 1	2004	41	2					104	112		10.1136/jmg.2003.005033			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	769VE	WOS:000188669800005	14757857	Bronze, Green Published			2022-02-06	
J	Colletti, V; Carner, M; Miorelli, V; Colletti, L; Guida, M; Fiorino, F				Colletti, V; Carner, M; Miorelli, V; Colletti, L; Guida, M; Fiorino, F			Auditory brainstem implant in posttraumatic cochlear nerve avulsion	AUDIOLOGY AND NEURO-OTOLOGY			English	Article; Proceedings Paper	Conference on Candidacy for Implantable Hearing Devices	JUN 27-29, 2002	Utrecht, NETHERLANDS			auditory brainstem implant; profound hearing loss; head injury	SENSORINEURAL HEARING-LOSS; TEMPORAL BONE-FRACTURE; ELECTRICAL-STIMULATION; ROUND-WINDOW; CANDIDATES; EXPERIENCE; SURVIVAL	Patients aged over 12 years with neurofibromatosis type 2 are considered candidates for an auditory brainstem implant (ABI). This study extends the indication criteria of ABI to subjects with profound hearing loss due to damaged cochleas and/or cochlear nerves (CNs) following head injuries. In our department, over the period from April 1997 to November 2002, 32 patients, 23 adults and 9 children, were fitted with ABIs. Their ages ranged from 14 months to 70 years. These patients were suffering from a variety of tumor (13 subjects) and nontumor CN or cochlear diseases (19 subjects). Six patients, 5 adults and 1 child, had profound hearing loss following head injury. Their mean age was 25 years (range: 16-48 years). Five were male and 1 female. The retrosigmoid approach was used in all 6 patients. The electrode array was inserted into the lateral recess of the fourth ventricle and correct electrode positioning was monitored with the aid of electrically evoked auditory brainstem responses and neural response telemetry. Correct implantation was achieved in all patients. No complications were observed due to implantation surgery or related to ABI activation and stimulation of the cochlear nuclei. At activation, an average of 9.8 electrodes (range 5-13) were switched on without side effects. One to 6 electrodes were activated in the following sessions after time periods ranging from 2 to 16 months. All patients achieved auditory-alone-mode closed-set word recognition scores ranging from 40 to 100%; 3 had auditory-alone-mode open-set sentence recognition scores of 60 100%; 2 of these even had speech-tracking performance scores of 38 and 43 words, respectively, showing an ability to engage in normal conversation and converse over the phone. The present study demonstrates that the ABI is a useful rehabilitation instrument in subjects with damaged cochleas and/or CN avulsion following head injury who are unamenable or poorly responsive to auditory rehabilitation using cochlear implants. Copyright (C) 2004 S. Karger AG, Basel.	Univ Verona, ENT Dept, IT-37100 Verona, Italy		Colletti, V (corresponding author), Univ Verona, ENT Dept, Ple LA Scuro 10, IT-37100 Verona, Italy.	vittoriocolletti@yahoo.com		COLLETTI, Liliana/0000-0001-8089-5681			Brown CJ, 1998, AM J OTOL, V19, P320; Camilleri AE, 1999, J LARYNGOL OTOL, V113, P454, DOI 10.1017/S0022215100144202; COHEN NL, 1988, ANN OTOL RHINOL LA S, V135, P8; COLIGADO EJ, 1993, ARCH PHYS MED REHAB, V74, P653, DOI 10.1016/0003-9993(93)90166-8; Colletti V, 2002, OTOLARYNG HEAD NECK, V127, P84, DOI 10.1067/mhn.2002.126723; Colletti V, 2001, INT J PEDIATR OTORHI, V60, P99, DOI 10.1016/S0165-5876(01)00465-7; COLLETTI V, IN PRESS OTOL NEUROT; DESAUVAGE RC, 1983, J ACOUST SOC AM, V73, P616, DOI 10.1121/1.388872; FIFER RC, 1991, AM J OTOL, V12, P350; GANTZ BJ, 1993, ADV OTO-RHINO-LARYNG, V48, P153; GRAY RF, 1990, CLIN OTOLARYNGOL, V15, P29, DOI 10.1111/j.1365-2273.1990.tb00428.x; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; *ISTAT, 2000, STAT INC STRAD ANN 2; KILENY PR, 1992, EAR HEARING, V13, P294, DOI 10.1097/00003446-199210000-00006; KILENY PR, 1987, ARCH OTOLARYNGOL, V113, P1072; KOCKHAR MS, 1990, ENT-EAR NOSE THROAT, V69, P537; KOEFOEDNIELSEN B, 1982, ORL J OTO-RHINO-LARY, V44, P206, DOI 10.1159/000275594; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; Mason SM, 1997, AM J OTOL, V18, P466; MECKLENBURG DJ, 1997, MANUAL AUDITORY REHA; Moore A, 1999, J LARYNGOL OTOL, V113, P34, DOI 10.1017/S0022215100146079; MORGAN WE, 1994, LARYNGOSCOPE, V104, P426; Nikolopoulos TP, 2000, EAR HEARING, V21, P236, DOI 10.1097/00003446-200006000-00007; SEKIYA T, 1988, ACTA NEUROCHIR, V90, P45, DOI 10.1007/BF01541266; SMITH L, 1983, ANN OTO RHINOL LARYN, V92, P19, DOI 10.1177/000348948309200105	26	41	46	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-3030			AUDIOL NEURO-OTOL	Audiol. Neuro-Otol.		2004	9	4					247	255		10.1159/000078394			9	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	830CH	WOS:000222098700008	15205552				2022-02-06	
J	Rogatsky, GG; Sonn, J; Kamenir, Y; Zarchin, N; Mayevsky, A				Rogatsky, GG; Sonn, J; Kamenir, Y; Zarchin, N; Mayevsky, A			Relationship between intracranial pressure and cortical spreading depression following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cortical spreading depression; head injury; intracranial pressure; post-traumatic hypoxic insult	COMPRESSION CONTUSION TRAUMA; CEREBRAL BLOOD-FLOW; AMINO-ACID RELEASE; SEVERE HEAD-INJURY; CALCIUM TRANSIENTS; ENERGY-METABOLISM; ISCHEMIA; DAMAGE; MODEL; OXYGENATION	Traumatic brain injury (TBI) is known to be accompanied by an increase in intracranial pressure (ICP) and in some cases, by spontaneous generation of cortical spreading depression (CSD) cycles. However, the role of CSD in the pathophysiology of cerebral contusion is still unknown. A multi-parametric monitoring assembly was placed on the right hemisphere of the rat brain to evaluate ICP, DC potential, extracellular K+, cerebral blood flow (CBF), and electrocorticogram in 27 rats during 5 h. Fluid percussion brain injury (FPBI) with the magnitude of the impact 2.9, 3.3, 4.1, and 5.0 atmospheres was induced to the left parietal cortex in animal groups A, B, C, and D, respectively. A slow increase in ICP was evident, and was pronounced in group C and especially in group D, where four of nine animals died during the monitoring. At the end of the 5 h experiment, the mean ICP levels were 6.75 +/- 2.87, 8.40 +/- 2.70, 12.75 +/- 4.03, 29.56 +/- 9.25, and the mean total number of CSD cycles was 2.00 +/- 1.41, 4.29 +/- 4.23, 11.71 +/- 13.29, and 20.11 +/- 19.26 in groups A, B, C, and D, respectively. The maximal level of intensity of CSD cycle generation after FPBI was obtained in group D, where almost constant activity was maintained until the end of the experiment. A significant coefficient of correlation between ICP level and total number of CSD cycles was found for all ICP measurements (r = 0.47-0.63, p < 0.05, n = 27), however more significant (p < 0.001) was the coefficient during the period of monitoring between 2 and 4 h after FPBI. Our results suggest that numerous repeating CSD cycles are typical phenomena in moderate and especially severe forms of FPBI. The rising number of CSD cycles under condition of an ICP level greater than or equal to20 mm Hg may demonstrate, with high probability, the unfavorable development of TBI, caused by growing secondary hypoxic insult.	Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel		Mayevsky, A (corresponding author), Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel.	mayevsa@mail.biu.ac.il					BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bardt TF, 1998, ACT NEUR S, V71, P153; BENVENISTE H, 1988, ACTA NEUROL SCAND, V78, P529, DOI 10.1111/j.1600-0404.1988.tb03697.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 1997, ACT NEUR S, V70, P123; GIDO G, 1994, EXP BRAIN RES, V97, P397; Gido G, 1994, Neurobiol Dis, V1, P31, DOI 10.1006/nbdi.1994.0005; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; Koura SS, 1998, ACT NEUR S, V71, P244; KUBOTA M, 1989, Neurosurgical Review, V12, P393, DOI 10.1007/BF01790681; Lang E W, 1995, New Horiz, V3, P400; LAURITZEN M, 1987, ACTA NEUROL SCAND, V76, P9; Manor T, 2003, ADV EXP MED BIOL, V510, P409; Marmarou A, 1990, Adv Neurol, V52, P233; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Mayevsky A, 1998, ACT NEUR S, V71, P78; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MAYEVSKY A, 1992, ADV EXP MED BIOL, V317, P707; MAYEVSKY A, 1995, J APPL PHYSIOL, V78, P1188, DOI 10.1152/jappl.1995.78.3.1188; Mayevsky A, 1999, ACT NEUR S, V75, P63; Mayevsky A, 1999, ADV EXP MED BIOL, V471, P133; Mayevsky A., 1993, MIGRAINE BASIC MECH, P379; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NORUSIS M. J, 1999, GUIDE DATA ANAL; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Otsuka H, 2000, EXP NEUROL, V162, P201, DOI 10.1006/exnr.1999.7326; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Sonn J, 2000, BRAIN RES, V882, P212, DOI 10.1016/S0006-8993(00)02827-4; Stocchetti N, 1991, Minerva Anestesiol, V57, P327; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Thomas S, 2000, ACTA NEUROCHIR SUPPL, V76, P203; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	57	41	41	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1315	1325		10.1089/089771503322686111			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700004	14748980				2022-02-06	
J	Duhaime, AC; Hunter, JV; Grate, LL; Kim, A; Golden, J; Demidenko, E; Harris, C				Duhaime, AC; Hunter, JV; Grate, LL; Kim, A; Golden, J; Demidenko, E; Harris, C			Magnetic resonance imaging studies of age-dependent responses to scaled focal brain injury in the piglet	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; magnetic resonance imaging; contusion; infant; pig	CENTRAL-NERVOUS-SYSTEM; CEREBRAL BLOOD-FLOW; HEAD-INJURY; DEVELOPMENTAL-CHANGES; CORTICAL IMPACT; MINIATURE SWINE; CHILDREN; PRESSURE; EDEMA; METABOLISM	Object. Whether the brain differs in its response to traumatic injury as a function of age remains unclear. To further investigate the age-dependent response of the brain to mechanical trauma, a cortical contusion model scaled for brain growth during maturation was used to study the evolution of injury over time as demonstrated on serial magnetic resonance (MR) imaging studies in piglets of different ages. Methods. Sixteen Yorkshire piglets received scaled cortical contusions. Animals were either 5 days (six animals), I month (five animals), or 4 months (five animals) of age at injury. These ages correspond developmentally to human infants, toddlers, and early adolescents, respectively. Serial MR imaging examinations, including fluid-attenuated inversion-recovery and T-1-, T-2-, and diffusion-weighted sequences were performed at 24 hours, I week, and I month after injury. Lesions were quantified and expressed as a ratio of the lesion volume divided by the volume of the uninjured hemisphere for each animal and each MR sequencing. Differences in relative lesion volume among the varied ages at a single time point and in lesion volume over time at each age were compared. In addition, the relationship between age and evolution of injury were analyzed using a two-compartment mathematical model. Histological features were examined at I month postinjury. Despite comparable injury inputs, the youngest animals had lesions whose volumes peaked earlier and resolved more quickly than those in older animals. The intermediate-age piglets (toddler) had the most pronounced swelling of any age group, and the oldest piglets (adolescent) had the latest peak in lesion volume. Conclusions. Scaled cortical contusions in piglets demonstrated age-dependent differences in injury response, both in magnitude and time course. These observations may shed light on development-related trauma response in the gyrencephalic brain.	Dartmouth Hitchcock Med Ctr, Dept Neurosurg, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biostat & Epidemiol, Lebanon, NH USA; Baylor Coll Med, Texas Childrens Hosp, Dept Neuroradiol, Houston, TX 77030 USA; Childrens Hosp Philadelphia, Dept Neuropathol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Duhaime, AC (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Neurosurg, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS37132] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS037132] Funding Source: NIH RePORTER		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; GREENBERG RS, 1994, CRIT CARE MED, V22, P384, DOI 10.1097/00003246-199403000-00006; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; JAKOBSSON KE, 1995, NEUROL RES, V17, P217, DOI 10.1080/01616412.1995.11740315; Kobayashi Ayame, 1996, No To Hattatsu, V28, P501; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Prough DS, 1999, J NEUROSURG ANESTH, V11, P102, DOI 10.1097/00008506-199904000-00006; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; THOMAS JM, 1971, GROWTH, V35, P259; TROUPP H, 1971, ACTA NEUROCHIR, V24, P89, DOI 10.1007/BF01403314; Wild C., 1989, NONLINEAR REGRESSION; WOOTTON R, 1982, BIOL NEONATE, V41, P209; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	27	41	41	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2003	99	3					542	548		10.3171/jns.2003.99.3.0542			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	715JZ	WOS:000184969500016	12959443				2022-02-06	
J	Ip, EY; Zanier, ER; Moore, AH; Lee, SM; Hovda, DA				Ip, EY; Zanier, ER; Moore, AH; Lee, SM; Hovda, DA			Metabolic, neurochemical, and histologic responses to vibrissa motor cortex stimulation after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortex; fluid percussion injury; fluorodeoxyglucose autoradiography; microdialysis; stimulation; vibrissa	LONG-TERM POTENTIATION; CEREBRAL GLUCOSE-UTILIZATION; FLUID-PERCUSSION INJURY; BLOOD-FLOW; EVOKED-POTENTIALS; HEAD-INJURY; RAT; ISCHEMIA; ACTIVATION; DEPRESSION	During the prolonged metabolic depression after traumatic brain injury (TBI), neurons are less able to respond metabolically to peripheral stimulation. Because this decreased responsiveness has been attributed to circuit dysfunction, the present study examined the metabolic, neurochemical, and histologic responses to direct cortical stimulation after lateral fluid percussion injury (LFPI). This study addressed three specific hypotheses: that neurons, if activated after LFPI, will increase their utilization of glucose even during a period of posttraumatic metabolic depression; that this secondary activation results in an increase in the production of lactate and a depletion of extracellular glucose; and that because cells are known to be in a state of energy crisis after traumatic brain injury, additional energy demands resulting from activation can result in their death. The results indicate that stimulating to levels eliciting a vibrissa twitch resulted in an increase in the cerebral metabolic rate for glucose (CMRglc; mumol. 100 g(-1).min(-1)) of 34% to 61% in the sham-operated, 1-hour LFPI, and 7-day LFPI groups. However, in the 1-day LFPI group, stimulation induced a 161 % increase in CMRglc and a 35% decrease in metabolic activation volume. Extracellular lactate concentrations during stimulation significantly increased from 23% in the sham-injured group to 55% to 63% in the 1-day and 7-day LFPI groups. Extracellular glucose concentrations during stimulation remained unchanged in the sham-injured and 7-day LFPI groups, but decreased 17% in the 1-day LFPI group. The extent of cortical degeneration around the stimulating electrode in the 1-day LFPI group nearly doubled when compared with controls. These results indicate that at I day after LFPI, the cortex can respond to stimulation with an increase in anaerobic glycolysis; however, this metabolic response to levels eliciting a vibrissa response via direct cortical stimulation appears to constitute a secondary injury in the TBI brain.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Neurosci Interdept PhD Program, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA USA; Univ Rochester, Dept Neurobiol & Anat M&D, Rochester, NY USA; Osped Maggiore, Policlin IRRCS, Dept Anesthesia & Crit Care Med, Milan, Italy		Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu	Zanier, Elisa/AAA-8095-2020	Zanier, Elisa/0000-0002-3011-8718	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline		Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang XB, 1999, NEUROL MED-CHIR, V39, P649, DOI 10.2176/nmc.39.649; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schiene K, 1999, J NEUROL SCI, V162, P6, DOI 10.1016/S0022-510X(98)00292-5; SHARP FR, 1982, J COMP NEUROL, V208, P255, DOI 10.1002/cne.902080305; SHAW NA, 1986, J NEUROL SCI, V74, P257, DOI 10.1016/0022-510X(86)90111-5; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	44	41	41	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2003	23	8					900	910		10.1097/01.WCB.0000076702.71231.F2			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	709BJ	WOS:000184604600003	12902834	Bronze			2022-02-06	
J	Khan-Bourne, N; Brown, RG				Khan-Bourne, N; Brown, RG			Cognitive behaviour therapy for the treatment of depression in individuals with brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; MULTIPLE-SCLEROSIS; COPING STRATEGIES; MOOD DISORDERS; REHABILITATION; LONG; COMORBIDITY; PREVALENCE; POSTSTROKE	This article focuses on depression and its psychological management following brain injury or stroke in the adult population. The presentation of depression in the context of brain injury is discussed and a summary of the psychosocial aetiological factors for the development of depression in this context is provided. The links between depression and neuropsychological functioning are explored and the significant impact of depression on neurorehabilitation outcome highlights the need for the development of effective interventions in this area. Cognitive behaviour therapy (CBT) is presented as a potentially suitable treatment: The model is described with ideas for the clinician on how to adapt the delivery of CBT for clients with neuropsychological impairment. To date, there have been a very small number of studies evaluating CBT for the treatment of depression in brain injury, however their results have been promising. It is concluded that further research is necessary.	Kings Coll London, Dept Psychol, Inst Psychiat, London SE5 8AF, England; Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, S London, England; Maudsley NHS Trust, London, England		Brown, RG (corresponding author), Kings Coll London, Dept Psychol, Inst Psychiat, PO77,De Crespigny Pk, London SE5 8AF, England.		Brown, Richard G/A-9599-2010	Brown, Richard G/0000-0001-9021-0172			Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Alford, 1999, SCI FDN COGNITIVE TH; Angst J, 1996, BRIT J PSYCHIAT, V168, P31, DOI 10.1192/S0007125000298383; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asvall J. E., 2001, DEPRESSION SOCIAL EC; BECK AT, 1970, BEHAV THER, V1, P184, DOI 10.1016/S0005-7894(70)80030-2; Bellus SB, 1998, BRAIN INJURY, V12, P139, DOI 10.1080/026990598122764; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bowen A, 1999, BRAIN INJURY, V13, P547; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; BROWN RG, 1994, PSYCHOL MED, V24, P829, DOI 10.1017/S0033291700028932; BURGHLEIGH SA, 1998, AM J OCCUPATIONAL TH, V52, P45; Chisholm D, 2001, DEPRESSION SOCIAL EC; Coyne JC, 1999, J CONSULT CLIN PSYCH, V67, P76, DOI 10.1037/0022-006X.67.1.76; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DAVIS GR, 1984, J CLIN PSYCHOL, V40, P930, DOI 10.1002/1097-4679(198407)40:4<930::AID-JCLP2270400410>3.0.CO;2-Q; Drummond A, 1996, BR J OCCUP THER, V59, P330; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fennell M., 1999, OVERCOMING LOW SELF; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GUTH PE, 2000, DISS ABSTR INT B, V61, P1803; Hawton K., 1989, COGNITIVE BEHAV TREA; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOUSE A, 1992, OX MED PUBL, P51; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P295, DOI 10.1037/0022-006X.64.2.295; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LARCOMBE NA, 1984, BRIT J PSYCHIAT, V145, P366, DOI 10.1192/bjp.145.4.366; LEUNG M, 1997, CLIN PSYCHOL, V10, P2002; Lewinsohn P.M., 1974, PSYCHOL DEPRESSION C; Lincoln NB, 1997, CLIN REHABIL, V11, P114, DOI 10.1177/026921559701100204; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Lishman W. A., 1987, ORGANIC PSYCHIAT; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Marin RS, 1997, PSYCHIAT ANN, V27, P30, DOI 10.3928/0048-5713-19970101-08; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; Mohr DC, 2001, J CONSULT CLIN PSYCH, V69, P942, DOI 10.1037//0022-006X.69.6.942; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ohayon MM, 1999, BIOL PSYCHIAT, V45, P300, DOI 10.1016/S0006-3223(98)00011-0; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PERSONS J, 1997, HDB PSYCHOTHERAPY CA; PICCINELLI M, 1994, BRIT J PSYCHIAT, V164, P297, DOI 10.1192/bjp.164.3.297; Pohjasvaara T, 2001, EUR J NEUROL, V8, P315, DOI 10.1046/j.1468-1331.2001.00182.x; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Reischies FM, 2000, EUR ARCH PSY CLIN N, V250, P186, DOI 10.1007/s004060070023; ROSENTHAL TL, 1971, COND REFLEX, V6, P22; Sandin K, 1994, ARCH PHYS MED REHAB, V75, P52; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schlund MW, 1999, BRAIN INJURY, V13, P889; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; Wallace CA, 2000, BRAIN INJURY, V14, P549; WALLACE CA, 2000, DISS ABSTR INT B, V60, P4257; Watkins E, 2002, J NEUROL NEUROSUR PS, V72, P400, DOI 10.1136/jnnp.72.3.400; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wood R, 2000, NEUROBEHAVIOURAL DIS	65	41	42	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		89	107		10.1080/09602010244000318			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500006	21854329				2022-02-06	
J	Cherian, L; Robertson, CS				Cherian, L; Robertson, CS			L-arginine and free radical scavengers increase cerebral blood flow and brain tissue nitric oxide concentrations after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						D-arginine; L-arginine; cortical impact injury; hypotension; intracranial hypertension; nitric oxide; superoxide dismutase; traumatic brain injury	SUPEROXIDE GENERATION; SYNTHASE; INHIBITION	To examine the mechanism of the increase in cerebral blood flow induced by L-arginine administration after traumatic brain injury, the cerebral hemodynamic effects Of L-arginine, D-arginine, and the free radical scavengers superoxide dismutase (SOD) and catalase were compared in the controlled cortical impact injury model in rats. Animals were anesthetized with isoflurane. Measured parameters included mean blood pressure, intracranial pressure, cerebral blood flow using laser Doppler flowmetry (LDF) and brain tissue nitric oxide (NO) concentrations using an NO electrode. L-arginine, but not D-arginine, administration resulted in a significant increase in tissue NO concentrations and an improvement in LDF at the impact site, compared to control animals given saline. Administration of SOD alone and in combination with catalase resulted in a significant increase in brain tissue NO concentrations. However, LDF was consistently improved only when both SOD and catalase were given. These studies support the theory that L-arginine administration improves post-traumatic cerebral blood flow by increasing NO production. Free radical production after trauma may also contribute to the reduction in CBF by inactivating NO.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	lcherian@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	25	41	43	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					77	85		10.1089/08977150360517209			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200007	12614590				2022-02-06	
J	Beukelman, DR; Fager, S; Ullman, C; Hanson, E; Logemann, J				Beukelman, DR; Fager, S; Ullman, C; Hanson, E; Logemann, J			The impact of speech supplementation and clear speech on the intelligibility and speaking rate of people with traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article; Proceedings Paper	Conference on Motor Speech	MAR 14-17, 2002	WILLIAMSBURG, VA				LINGUISTIC CUES	The purpose of this study was to investigate the differences in speech intelligibility and speaking rate for (a) habitual speech, (b) clear speech, (c) alphabet-supplemented speech, and (d) topic-supplemented speech. Eight people with severe dysarthria following traumatic brain injury participated in this project. Speakers were video recorded as they produced ten sentences under each of the four conditions. Five listeners transcribed each of the speech samples. The alphabet-supplemented speech intervention yielded significantly larger higher observed intelligibility scores than habitual speech, clear speech, topic-supplemented speech, or alphabet-supplemented habitual speech.	Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, Lincoln, NE USA; Amer Speech Language Hearing Assoc, Commun Sci & Disorders Clin Trials Res Grp, Rockville, MD USA		Beukelman, DR (corresponding author), Univ Nebraska, Barkley Mem Ctr 202, Lincoln, NE 68583 USA.	dbeukelman1@unl.edu					Ball LJ, 2001, J NEUROL SCI, V191, P43, DOI 10.1016/S0022-510X(01)00623-2; BEUKELMAN DR, 1977, J SPEECH HEAR DISORD, V42, P265, DOI 10.1044/jshd.4202.265; BEUKELMAN DR, 1979, J COMMUN DISORD, V12, P189, DOI 10.1016/0021-9924(79)90040-6; CROW E, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P99; DONGILLI P, 1994, MOTOR SPEECH DISORDE, P175; DOWDEN P, 1997, AUGMENTATIVE ALTERNA, V13; GIOLAS TG, 1963, J SPEECH HEAR RES, V6, P349, DOI 10.1044/jshr.0604.349; HAMMEN VL, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P43; Hammen VL, 1996, DISORDERS MOTOR SPEE, P67; Hustad KC, 2002, J SPEECH LANG HEAR R, V45, P545, DOI 10.1044/1092-4388(2002/043); Hustad KC, 2001, J SPEECH LANG HEAR R, V44, P497, DOI 10.1044/1092-4388(2001/039); LINDBLOM B, 1990, AAC (Augmentative and Alternative Communication), V6, P220, DOI 10.1080/07434619012331275504; MCHENRY MA, 1994, J MED SPEECH-LANG PA, V2, P59; MURDOCH BE, 1999, BRAIN DAM B, P211; NETSELL R, 1979, ARCH PHYS MED REHAB, V60, P502; NETSELL R, 1992, SPECIAL INTEREST DIV, V2, P1; NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469; PINCHEY M, 1989, J SPEECH HEAR RES, V32, P600; PINCHEY M, 1986, J SPEECH HEAR RES, V29, P434; Yorkston K, 1991, COMMUNICATION DISORD, P251; YORKSTON K, 2000, AUGMENTATIVE ALTERNA	21	41	41	0	11	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	DEC	2002	10	4					237	242					6	Audiology & Speech-Language Pathology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Neurosciences & Neurology	659LW	WOS:000181779000005					2022-02-06	
J	Lew, HL; Lee, E; Date, ES; Zeiner, H				Lew, HL; Lee, E; Date, ES; Zeiner, H			Influence of medical comorbidities and complications on FIM (TM) change and length of stay during inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						medical comorbidities; medical complications; length of stay; FIM efficiency; inpatient rehabilitation; physician; physiatrist	STROKE REHABILITATION	Objective: This study was performed to evaluate the influence of medical problems on functional outcome measures of patients admitted for comprehensive inpatient rehabilitation. Design: In this retrospective database review of patients, demographic information, length of stay, FIM scores at admission and discharge, and FIM efficiency were collected and analyzed. Preexisting comorbidities and acute medical complications of all patients were identified, tabulated, and analyzed. Results: A total of 175 patients were categorized into three major groups. In the postorthopedic surgery group, the presence of preexisting medical comorbidities did not significantly affect admission or discharge FIM scores. In contrast, traumatic brain injury patients with preexisting medical comorbidities had a tendency to be admitted and discharged with lower FIM scores. However, traumatic brain injury patients with acute medical complications still made reasonable functional improvement during their extended stay, so that their FIM efficiency was adequately maintained. In the cerebrovascular accident group, almost all patients had preexisting medical issues. Conclusions: The rehabilitation population is diverse, and functional outcome measures for distinct disease entities may be differentially affected by factors such as preexisting medical comorbidities and acute medical complications. Except for life-threatening medical emergencies, rehabilitation patients may benefit by staying on the acute rehabilitation unit, where both medical management and a comprehensive rehabilitation program are provided with continuity.	VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA USA		Lew, HL (corresponding author), PM&R Serv, Comprehens Rehabil Ctr, VAPAHCS, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.						[Anonymous], 1993, GUIDE UNIFORM DATA S; CHAMIE M, 1995, DISABIL REHABIL, V17, P323, DOI 10.3109/09638289509166718; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; DROMERICK A, 1994, STROKE, V25, P358, DOI 10.1161/01.STR.25.2.358; GRANGER CV, 1996, PHYSICAL MED REHABIL, P247; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; JEFFERY DR, 1995, CURR OPIN NEUROL, V8, P62, DOI 10.1097/00019052-199502000-00010; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Paolucci S, 2000, ARCH PHYS MED REHAB, V81, P695, DOI 10.1053/apmr.2000.5583; Pinto AN, 1998, CEREBROVASC DIS, V8, P204, DOI 10.1159/000015852; ROTH EJ, 1988, STROKE, V19, P42, DOI 10.1161/01.STR.19.1.42; SIEGLER EL, 1994, ARCH INTERN MED, V154, P2185, DOI 10.1001/archinte.154.19.2185; Wright RE, 1996, ARCH PHYS MED REHAB, V77, P1049, DOI 10.1016/S0003-9993(96)90067-2	14	41	41	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2002	81	11					830	837		10.1097/00002060-200211000-00005			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	607FP	WOS:000178781700005	12394994				2022-02-06	
J	Sellal, FO; Manning, L; Seegmuller, C; Scheiber, C; Schoenfelder, F				Sellal, FO; Manning, L; Seegmuller, C; Scheiber, C; Schoenfelder, F			Pure retrograde amnesia following a mild head trauma: A neuropsychological and metabolic study	CORTEX			English	Article						retrograde amnesia; recovery; SPECT; procedural memory	TRANSIENT GLOBAL AMNESIA; LONG-TERM-MEMORY; ELECTROCONVULSIVE-THERAPY; ATTRIBUTION; CAUSALITY; ACCOUNT; DISEASE	After a minor closed head injury, a 33-year-old man acquired extensive retrograde amnesia (RA) covering the previous ten years and concerning autobiographical, semantic and procedural memories. The patient's learning abilities remained excellent and he recovered considerable information from his wife, the media and personal documents. This relearned information did not, however, provide a sense of personal experience in the first weeks. CT and MRI failed to show brain damage, but EEG and SPECT examination showed a marked right temporal dysfunction. After three months the patient had almost completely recovered from RA. Interestingly, a parallel recovery was observed in the second SPECT obtained at this period. There was clearly a blockade of retrieval, while the stored engrams were probably intact. The mechanisms underlying such a functional amnesia are discussed in the light of previous reports of amnesia without brain lesions.	Hop Univ Strasbourg, Serv Neurol Neuropsychol & Explorat Fonctionnelle, F-67091 Strasbourg, France; Univ Strasbourg 1, UMR 7521, Lab Neurosci Comportementales & Cognit, F-67083 Strasbourg, France; Hop Univ Strasbourg, Inst Biol Phys, F-67091 Strasbourg, France		Sellal, FO (corresponding author), Hop Univ Strasbourg, Serv Neurol Neuropsychol & Explorat Fonctionnelle, 1 Pl Hop, F-67091 Strasbourg, France.			Manning, Liliann/0000-0001-5027-8551			DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DeRenzi E, 1997, NEUROPSYCHOLOGIA, V35, P781, DOI 10.1016/S0028-3932(97)00018-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; Evans JJ, 1996, NEUROCASE, V2, P1; FINCK G, 1996, J NEUROSCI, V16, P4275; Fujii T, 1999, CORTEX, V35, P599, DOI 10.1016/S0010-9452(08)70822-0; GLOOR P, 1990, BRAIN, V113, P1673, DOI 10.1093/brain/113.6.1673; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; HAAS DC, 1990, TRANSIENT GLOBAL AMN, P79; HODGES JR, 1989, BRAIN, V112, P595, DOI 10.1093/brain/112.3.595; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Kapur N, 2000, COGN NEUROPSYCHOL, V17, P623, DOI 10.1080/026432900750002181; Kapur N, 1997, MEMORY, V5, P115, DOI 10.1080/741941152; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; KRITCHEVSKY M, 1989, NEUROLOGY, V39, P213, DOI 10.1212/WNL.39.2.213; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Markowitsch HJ, 1996, NEUROCASE, V2, P357; Markowitsch HJ, 1997, PSYCHIAT RES-NEUROIM, V74, P119, DOI 10.1016/S0925-4927(97)03041-2; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; McClelland J. L., 1986, PARALLEL DISTRIBUTED; Ribot, 1881, MALADIES MEMOIRE; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SCHACTER DL, 1982, NEUROPSYCHOLOGIA, V20, P523, DOI 10.1016/0028-3932(82)90026-4; SCHACTER DL, 1989, HDB NEUROPSYCHOLOGY, V3, P209; SELTZER B, 1974, NEUROLOGY, V24, P527, DOI 10.1212/WNL.24.6.527; Spinnler H, 1996, BRAIN, V119, P1403, DOI 10.1093/brain/119.4.1403; SQUIRE LR, 1975, SCIENCE, V187, P77, DOI 10.1126/science.1109228; SQUIRE LR, 1981, ARCH GEN PSYCHIAT, V38, P89; STUSS D, 1988, BRAIN COGNITION, V7, P21; Thomas-Anterion C., 1994, Annales de Readaptation et de Medecine Physique, V37, P381; Wechsler D., 1991, ECHELLE CLIN MEMOIRE	37	41	44	0	8	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	SEP	2002	38	4					499	509		10.1016/S0010-9452(08)70019-4			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RE	WOS:000179716000005	12465665				2022-02-06	
J	McCarthy, ML; Serpi, T; Kufera, JA; Demeter, LA; Paidas, C				McCarthy, ML; Serpi, T; Kufera, JA; Demeter, LA; Paidas, C			Factors influencing admission among children with a traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article						admission; emergency department; pediatric; traumatic brain injury; children	CLOSED HEAD-INJURY; UNITED-STATES; HOSPITAL ADMISSION; INSURANCE STATUS; MYOCARDIAL-INFARCTION; INTELLECTUAL ABILITY; HEALTH-INSURANCE; SEVERITY SCORE; CARE; EMERGENCY	Objectives: To describe the epidemiology of traumatic brain injury (TBI) among children in Maryland and to examine factors that influence hospital admission. Methods: Statewide mortality, hospital discharge, and ambulatory care data were used to identify all TBI-related emergency department (ED) visits, hospitalizations, and deaths that occurred in 1998 to children aged 0-19 years according to the Centers for Disease Control and Prevention's standard case definition and protocol. Inpatient admission was modeled as a function of patient, injury, and hospital characteristics. Results: The overall incidence of pediatric TBI (i.e., ED visits, hospitalizations, and deaths) in 1998 was 670/100,000. After controlling for injury severity and other factors, uninsured children were 40% less likely to be hospitalized (95% CI = 0.43 to 0.82) and children with Medicaid were 90% more likely to be hospitalized (95% CI = 1.42 to 2.54) than were those with private insurance. The presence of a major associated injury significantly influenced the likelihood of hospitalization, especially among children with a minor (OR = 8.8) to moderate (OR = 11.6) TBI. Children who presented to a trauma center hospital were significantly more likely to be hospitalized than children treated at a non-trauma center hospital, although this varied depending on income (OR = 1.8 for high versus low) and hospital volume (OR = 2.6 for a small hospital and OR = 29.0 for a large hospital). Conclusions: After adjusting for TBI severity and the presence of associated injuries, significant differences in hospitalization rates may exist among different patient subgroups and hospitals for children who sustain TBIs. Key words: admission; emergency department pediatric; traumatic brain injury; children.	Johns Hopkins Univ, Dept Emergency Med, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Sch Med, Baltimore, MD 21205 USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA; Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD USA		McCarthy, ML (corresponding author), Johns Hopkins Univ, Dept Emergency Med, Sch Med, Suite 6-102,1830 E Monument St, Baltimore, MD 21205 USA.				ODCDC CDC HHS [U17/CCU314059-03] Funding Source: Medline		*ASS ADV AUT MED, 1974, INJ SEV SCOR DEV POT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Best A E, 1999, J Med Syst, V23, P175, DOI 10.1023/A:1020515419714; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; Byck GR, 2000, PEDIATRICS, V106, P14, DOI 10.1542/peds.106.1.14; CASEY R, 1986, PEDIATRICS, V78, P497; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; COOPER A, 1992, J PEDIATR SURG, V27, P149, DOI 10.1016/0022-3468(92)90303-O; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; DUNN KA, 1999, REPORT CONSENSUS DEV, P1; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; GREEN LA, 1994, MED CARE, V32, P1086, DOI 10.1097/00005650-199411000-00002; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Halm EA, 2000, ARCH INTERN MED, V160, P98, DOI 10.1001/archinte.160.1.98; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kerr E A, 1993, J Health Care Poor Underserved, V4, P133; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Krug SE, 1997, PEDIATR EMERG CARE, V13, P87, DOI 10.1097/00006565-199704000-00001; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MacKenzie E J, 1989, Md Med J, V38, P725; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; McBean A M, 1994, Health Care Financ Rev, V15, P77; McCarthy ML, 2001, ACCIDENT ANAL PREV, V33, P821, DOI 10.1016/S0001-4575(00)00096-8; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; PEARSON SD, 1994, HEALTH SERV RES, V29, P59; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P25; Poole GV, 1996, J TRAUMA, V40, P951, DOI 10.1097/00005373-199606000-00014; RUNYAN CW, 1985, AM J PUBLIC HEALTH, V75, P1429, DOI 10.2105/AJPH.75.12.1429; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Thomas SHL, 1996, HUM EXP TOXICOL, V15, P915, DOI 10.1177/096032719601501109; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Weinick RM, 1998, HEALTH AFFAIR, V17, P127, DOI 10.1377/hlthaff.17.2.127; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1995, TRAUMATIC HEAD INJUR	56	41	41	0	7	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL	2002	9	7					684	693					10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	569VN	WOS:000176623200004	12093708				2022-02-06	
J	Albert, SM; Im, A; Brenner, L; Smith, M; Waxman, R				Albert, SM; Im, A; Brenner, L; Smith, M; Waxman, R			Effect of a social work liaison program on family caregivers to people with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; caregiver burden; caregiving; mental health; social work	SEVERE HEAD-INJURY; RELATIVES; NEEDS; SUPPORT; MEMBER; IMPACT	Objective: We assessed the effect of a social work liaison program on caregiver outcomes for families caring for people with brain injury. Design: All telephone calls received by the team were entered into a standardized log form to record topics raised by caregivers. Main Outcome Measures: We compared the experience of this cohort of traumatic brain injury (TBI) caregivers with the experience of an earlier cohort by use of standard measures of caregiver mental health. Because patients in the cohort had mixed etiologies, we also examined the experience of caregivers according to type of brain injury, comparing cerebrovascular accident with TBI patients. Results: The social work liaison program offered benefit to caregivers on burden, satisfaction, and mastery outcomes. Conclusions: This research suggests that a relatively low-cost, nonintensive intervention may offer substantial benefit to families caring for people with brain injury.	Columbia Univ, Gertrude H Sergievsky Ctr, Dept Sociomed Sci, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA; Peninsula Hosp Ctr, Traumat Brain Injury Unit, Psychol Serv, Far Rockaway, NY USA		Albert, SM (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Dept Sociomed Sci, PH-19,630 W 168th St, New York, NY 10032 USA.	sma10@columbia.edu		Albert, Steven/0000-0001-6786-9956			BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Frosch S, 1997, BRAIN INJURY, V11, P891; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; ROSENTHAL M, 1995, NEUROPSYCHOLOGY HDB, V2, P73; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith LM, 1995, FAMILY SUPPORT PROGR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; WANTANABE Y, 2001, DISABILITY, V9, P370	30	41	41	2	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					175	189		10.1097/00001199-200204000-00007			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500007	11909513				2022-02-06	
J	Pfenninger, J; Santi, A				Pfenninger, J; Santi, A			Severe traumatic brain injury in children are the results improving?	SWISS MEDICAL WEEKLY			English	Article						head injury; miltiple injury; computerized tomography; consukption coagulopathy; intracranial pressure	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; INSULTS; CARE	Questions under study: Traumatic brain injury (TBI) remains an important cause of mortality and morbidity in children. Medical management is constantly being refined, and thus results should improve. The aim of the present study was to analyse our data of recent years and to compare them with previous series (1978-83 and 1988-92). Patients and methods: The data of 51 children (1 month to 16 years old) with severe blunt TBI treated in our unit from 1994 to 1998 were analyzed retrospectively. Severe TBI was defined by immediate loss of consciousness and an admission Glasgow coma scale (GCS) <8. Outcome,,vas classified by using the Glasgow outcome scale (GOS) 6 to 12 months after injury. Results: 35 patients (69%) showed a good outcome (GOS 4 and 5), 14 died (GOS 1), one survived in a permanent vegetative state (GOS 2), and another was severely disabled (GOS 3) (GOS 1-3 = bad outcome, 31%). Bad outcome was associated with low GCS (i.e. 3 and 4), fixed and dilated pupils at admission, invisible basal cisterns on first computerized tomography, and presence of coagulopathy. Moderate to severe intracranial hypertension was also significantly related to bad outcome in the 26 patients with intracranial pressure monitoring. Compared to our first series severity of TBI was unchanged, and the incidence of multiple injury and consumption coagulopathy was less frequent. Intubation rate prior to admission to the centre increased from 3 5% to 94%. Intensive care measures (duration of mechanical ventilation, use of hypothermia, mannitol, thiopentone etc.) were less aggressive. The rate of good outcome remained unchanged (69% vs. 60%). Conclusions: Despite changing management policies, results were comparable with those of our former series. This fact underlines the importance of primary injury and the secondary role of intensive care management on final outcome.	Univ Bern, Inselspital, Univ Childrens Hosp, Pediat Intens Care Unit, CH-3010 Bern, Switzerland		Pfenninger, J (corresponding author), Univ Bern, Inselspital, Univ Kinderklin, Abt Padiatr Intens Behandlung, CH-3010 Bern, Switzerland.						BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1997, YB INTENSIVE CARE EM, P749; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; DYKES EH, 1989, J TRAUMA, V29, P724, DOI 10.1097/00005373-198906000-00004; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; JENNETT B, 1995, LANCET, V345, P480; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; PFENNINGER J, 1993, INTENS CARE MED, V19, P243, DOI 10.1007/BF01690543; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; PFENNINGER J, 1982, EUR J PEDIATR SURG, V37, P53; PFENNINGER J, 1997, YB INTENSIVE CARE EM, P766; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; SOUTER M, 1996, INTENSIVE CARE WORLD, V13, P32; Suominen P, 2000, Eur J Emerg Med, V7, P3; THOMAS D G T, 1978, Lancet, V1, P113; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; VOS LJM, 1972, EUR J PEDIAT SURG S, V11, P334; Zornow M H, 1995, New Horiz, V3, P488	23	41	43	0	2	E M H SWISS MEDICAL PUBLISHERS LTD	BASEL	STEINENTORSTRASSE 13, CH-4-10 BASEL, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	MAR 9	2002	132	9-10					116	120					7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	560RJ	WOS:000176094800002	12045999				2022-02-06	
J	Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG				Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG			Expression of c-Fos and c-Myc and deposition of beta-APP in neurons in the adult rat brain as a result of exposure to short-lasting impulse noise	JOURNAL OF NEUROTRAUMA			English	Article						acoustic energy; degeneration; pressure waves; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; IMMEDIATE-EARLY GENES; FATAL HEAD-INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNA; JUN; NEUROTOXICITY; ACCUMULATION; EVOLUTION; APOPTOSIS	There is increasing evidence that impulse noise causes brain damage, but little is known about the mechanisms and extent of the response. Here, rat brains were investigated immunohistochemically for the expression of c-Fos, c-Myc, and beta-APP during the first 3 weeks postexposure to impulse noise of 198 or 202 dB. The expression of c-Fos and c-Myc increased at 2 h after exposure in neurons of the cerebral cortex, thalamus, and hippocampus; and this c-Fos immunoreactivity remained elevated for the entire observation period. The c-Myc immunoreactivity peaked at 18 h in both neurons and astrocytes but returned to control levels at 7 days. Abnormal deposition of beta-APP was evident within 6 h in the same brain regions. The beta-APP immunoreactivity was most prominent at 18 h and remained increased over the 21-day period assessed. The observed effects were similar to those described in humans following traumatic brain injury and in Alzheimer's disease. We conclude that impulse noise influences the brain in a fashion similar to that in cases with progressive CNS degeneration.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; China Med Univ, Inst Brain Res, Shenyang, Peoples R China; Zunyi Med Coll, Dept Pharmacol, Zunyi, Peoples R China		Saljo, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se					Aubry S, 2000, DNA CELL BIOL, V19, P353, DOI 10.1089/10445490050043326; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CLEMEDSON CARL-JOHAN, 1955, JOUR AVIATION MED, V26, P373; Cunningham K, 2000, J ACCID EMERG MED, V17, P139; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; Dancer A, 1998, SCAND AUDIOL, V27, P123; Duma SM, 1996, J TRAUMA, V41, P114, DOI 10.1097/00005373-199607000-00018; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Estus S, 1997, J NEUROSCI, V17, P7736; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; Gass P, 1995, PROG NEUROBIOL, V47, P257, DOI 10.1016/0301-0082(95)00022-4; Gillardon F, 1996, BRAIN RES, V706, P169, DOI 10.1016/0006-8993(95)01332-6; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Griffin WST, 1998, BRAIN PATHOL, V8, P65; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; HUGHES P, 1995, PHARMACOL REV, V47, P133; *ISO, 1992, AC QUANT UN; Lodish HA., 1999, MOL CELL BIOL, V4th edition; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McFeely WJ, 1999, OTOLARYNG HEAD NECK, V121, P367, DOI 10.1016/S0194-5998(99)70222-6; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Price GR, 1999, J ACOUST SOC AM, V106, P2629, DOI 10.1121/1.428092; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; SALJO A, 2002, IN PRESS J NEUROTRAU; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; Saunders JE, 1998, OTOLARYNG HEAD NECK, V118, P228, DOI 10.1016/S0194-5998(98)80021-1; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Van den Heuvel C, 2000, J CLIN NEUROSCI, V7, P140; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; Whitfield PC, 2000, NEUROL RES, V22, P138, DOI 10.1080/01616412.2000.11741050; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	47	41	44	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					379	385		10.1089/089771502753594945			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900009	11939505				2022-02-06	
J	Cocchini, G; Beschin, N; Della Sala, S				Cocchini, G; Beschin, N; Della Sala, S			Chronic anosognosia: a case report and theoretical account	NEUROPSYCHOLOGIA			English	Article						anosognosia; hemiplegia; neglect; amnesia; executive functions	VESTIBULAR STIMULATION; UNILATERAL NEGLECT; PERSONAL NEGLECT; HEMIPLEGIA; HYPOTHESIS; AWARENESS; UNAWARENESS; REMISSION; HEMISPHERE; LESIONS	Unawareness of motor disorders (anosognosia) has often been reported after brain lesions, and it has been considered a temporary condition common in the acute and post-acute phases. The presence of anosognosia in a chronic phase (i.e. lasting more than few weeks) is a rare occurrence, thought to be the result of reasoning deficits which prevent patients from performing an adequate check of reality. Although this assumption is widely shared amongst researchers, only a few studies have actually addressed this issue. We report on the case of a patient (NS) who was still showing anosognosia for hemiplegia I year after a traumatic brain-head injury, while his reasoning abilities were well preserved. By means of a series of tests and experiments, we evaluated the main theoretical approaches. NS's long-lasting anosognosia is discussed in terms of a combination of clinical manifestations, whereby personal neglect and motor-sensory information play a key role in preventing awareness, whereas memory difficulties in updating pre-existing personal schema may be crucial in maintaining NS's anosognosic status. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ E London, Sch Psychol, London E15 4LZ, England; Gallarate Hosp, Unit Rehabil Somma Lombardo, Varese, Italy; Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Aberdeen, Scotland		Cocchini, G (corresponding author), Univ E London, Sch Psychol, London E15 4LZ, England.			Cocchini, Gianna/0000-0002-4789-9661			Adair JC, 1997, J NEUROL NEUROSUR PS, V63, P798, DOI 10.1136/jnnp.63.6.798; Adair JC, 1995, NEUROLOGY, V45, P2195, DOI 10.1212/WNL.45.12.2195; Azouvi P, 1996, NEUROPSYCHOL REHABIL, V6, P133, DOI 10.1080/713755501; Babinski J, 1914, REV NEUROL, V27, P845; Bakchine S, 1997, J NEUROL NEUROSUR PS, V63, P686, DOI 10.1136/jnnp.63.5.686; BARAT L, 1912, J PSYCHOL NORMALE PA, P163; BEAUMONT JG, 1996, BLACKWELL DICT NEURO, P80; Berti A, 1996, J Int Neuropsychol Soc, V2, P426; BERTI A, 1998, COGNITIVE NEUROPSYCH, V3, P21, DOI DOI 10.1080/135468098396233; Beschin N, 1997, CORTEX, V33, P379, DOI 10.1016/S0010-9452(08)70013-3; BISIACH E, 1990, QUANT AN B, V9, P3; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Bisiach E, 1995, HIGHER BRAIN FUNCTIO, V15, P113; Bisiach E., 1991, AWARENESS DEFICIT BR, P17; CAPPA S, 1987, NEUROPSYCHOLOGIA, V25, P775, DOI 10.1016/0028-3932(87)90115-1; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; CARPENTER K, 1995, BRAIN, V118, P243, DOI 10.1093/brain/118.1.243; Cocchini G, 2001, NEUROPSYCHOL REHABIL, V11, P17, DOI 10.1080/09602010042000132; Critchley M, 1953, PARIETAL LOBE; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DYWAN CA, 1995, J CLIN EXP NEUROPSYC, V17, P431, DOI 10.1080/01688639508405134; Ellis S, 1997, STROKE, V28, P67, DOI 10.1161/01.STR.28.1.67; Feinberg T.E., 1997, BEHAV NEUROLOGY NEUR, P369; Feinberg TE, 2000, J NEUROL NEUROSUR PS, V68, P511, DOI 10.1136/jnnp.68.4.511; GILLIATT RW, 1952, J NEUROL NEUROSUR PS, V15, P264, DOI 10.1136/jnnp.15.4.264; GILMORE RL, 1992, NEUROLOGY, V42, P925, DOI 10.1212/WNL.42.4.925; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; GOLDBERG E, 1991, AWARENESS DEFICIT BR, P152; Heilman K.M., 1991, AWARENESS DEFICIT BR, P53; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; Johnson MK., 1991, REALITY MONITORING E, P176; KAPLAN RF, 1993, J CLIN EXP NEUROPSYC, V15, P383; Knight Robert T., 1995, P1357; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LEVINE DN, 1991, NEUROLOGY, V41, P1770, DOI 10.1212/WNL.41.11.1770; Liebson E, 2000, J NEUROL NEUROSUR PS, V68, P107, DOI 10.1136/jnnp.68.1.107; Mattioli F., 1992, NEUROPSYCHOL REHABIL, V2, P169, DOI [10.1080/09602019208401406, DOI 10.1080/09602019208401406]; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; NATHANSON M, 1952, AMA ARCH NEUROL PSY, V68, P380, DOI 10.1001/archneurpsyc.1952.02320210090010; NOVELLI C, 1986, ARCH NEUROLOGIA PSIC, V47, P278; Ramachandran VS, 2000, MEMORY, BRAIN, AND BELIEF, P87; Ramachandran VS, 1998, PHANTOMS BRAIN PROBI, P127; Rode G, 1998, CORTEX, V34, P253; RODE G, 1992, CORTEX, V28, P203, DOI 10.1016/S0010-9452(13)80048-2; RUBENS AB, 1985, NEUROLOGY, V35, P1019, DOI 10.1212/WNL.35.7.1019; SANDIFER PH, 1946, BRAIN, V69, P122, DOI 10.1093/brain/69.2.122; SCHACTER DL, 1991, AWARENESS DEFICIT BR, P127; Spinnler H, 1987, ITAL J NEUROL SCI S8, V6, P1; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STONE SP, 1993, AGE AGEING, V22, P46, DOI 10.1093/ageing/22.1.46; Tei H, 2000, J NEUROL NEUROSUR PS, V69, P274, DOI 10.1136/jnnp.69.2.274; TERZIAN H, 1964, Acta Neurochir (Wien), V12, P230, DOI 10.1007/BF01402095; UYSAL S, 1993, J CLIN EXP NEUROPSYC, V15, P24; VALLAR G, 1990, CORTEX, V26, P123, DOI 10.1016/S0010-9452(13)80078-0; WADA J, 1949, MED BIOL TOKYO, V14, P221; Wechsler D., 1992, WAIS SCALA INTELLIGE; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO	57	41	41	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	12					2030	2038	PII S0028-3932(02)00054-4	10.1016/S0028-3932(02)00054-4			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	601AJ	WOS:000178423700018	12208000				2022-02-06	
J	Vink, R; Nimmo, AJ; Cernak, I				Vink, R; Nimmo, AJ; Cernak, I			An overview of new and novel pharmacotherapies for use in traumatic brain injury	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the Australasian-Society-of-Clinical-and-Experimental-Pharmacologists-and-Toxicologists	DEC 03-06, 2000	NEWCASTLE, AUSTRALIA	Australasian Soc Clin & Exptl Pharmacologists & Toxicologists		apoptosis; brain injury; gender; neurotrauma; tachykinin; therapy	FREE MAGNESIUM CONCENTRATION; CYCLOSPORINE-A; PHARMACOLOGICAL STRATEGIES; PERMEABILITY TRANSITION; RECEPTOR ANTAGONIST; CORTICAL DAMAGE; CNS TRAUMA; RATS; MITOCHONDRIA; ESTROGEN	1. Although a number of interventional pharmacotherapies have undergone clinical trial in traumatic brain injury (TBI), none has shown considerable promise. The present short review will examine some of the more novel compounds that have been proposed recently as potential therapeutic agents for use in TBI. 2. Previous experimental studies have demonstrated that brain intracellular free magnesium significantly declines following TBI and that the administration of magnesium salts attenuates the post-traumatic neurological deficits. More recent studies have established that magnesium salts administered after trauma enter the brain intracellular space and reduce the size of the lesion volume. Such protection could be afforded through attenuation of both necrotic and apoptotic cell death. Magnesium salts are currently on clinical trial in TBI. 3. Cyclosporine A is known to inhibit opening of the mitochondrial permeability transition pore. Administration of cyclosporine A after TBI has been shown to attenuate axonal injury and decrease the resultant lesion volume. Therefore, inhibitors of mitochondrial transition pore opening and resultant attenuation of apoptosis show some promise as neuroprotective agents. 4. Recent evidence has shown that substance P antagonists may decrease lesion volume and improve neurological outcome after ischaemia. Similar findings have recently been reported in TBI. The fact that substance P antagonists are known to reduce neurogenic inflammation, oedema formation and are clinically being trialed as both antidepressants and antinociceptive agents suggests that these agents warrant further investigation as therapeutic agents following TBI. 5. There are numerous contradictions in the literature regarding the potential neuroprotective effects of the hormones oestrogen and progesterone. Recent studies suggest that both hormones are protective in TBI and further studies are required to ascertain the mechanisms associated with this protection and any potential for clinical application.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		Vink, Robert/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BIBAN C, 1995, BIOCHEM PHARMACOL, V50, P497, DOI 10.1016/0006-2952(95)00165-V; Birch N.J., 1993, MAGNESIUM CELL; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Ema M, 1998, ALCOHOL, V15, P95, DOI 10.1016/S0741-8329(97)00102-X; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GITTER BD, 1995, EUR J PHARM-MOLEC PH, V289, P439, DOI 10.1016/0922-4106(95)90152-3; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; SZABO I, 1991, J BIOL CHEM, V266, P3376; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 2000, REST NEUROL NEUROSCI, V16, P164; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006; ZHANG C, 1998, J NEUROTRAUM, V15, P904	33	41	48	0	3	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0305-1870			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	NOV	2001	28	11					919	921		10.1046/j.1440-1681.2001.03548.x			3	Pharmacology & Pharmacy; Physiology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	548PA	WOS:000175396000013	11703396				2022-02-06	
J	Kelly, JP				Kelly, JP			Loss of consciousness: Pathophysiology and implications in grading and safe return to play	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild traumatic brain injury; sport concussion guidelines	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CONCUSSION; MILD; GUIDELINES; PREDICTION; MANAGEMENT; SEQUELAE; LESIONS; SPORTS	Objective: To provide historical background and current concepts regarding the importance of loss of consciousness (LOC) in the evaluation of concussion and athletes. Data Sources: A MEDLINE search identified scientific and clinical articles on sport concussion management published from 1966 to present. Discussions were held with authors of selected reports. Recent research findings reported at national meetings were reviewed. Data Synthesis: The relative importance of LOC in the evaluation of concussion was reviewed in light of scientific and clinical evidence in the literature. Comments made by authors of concussion grading scales were considered in the development of expert consensus statements. Conclusions/Recommendations: The observation of LOC at the time of concussion must be viewed as reflecting a potentially worrisome traumatic brain injury. LOC is followed by more severe acute mental status abnormalities and carries a greater risk of intracranial pathology than concussion without LOC. Prolonged LOC represents a neurologic emergency, which may require neurosurgical intervention. Lingering symptoms of concussion, even without LOC, should be monitored closely and managed according to established guidelines for safe return to play.	Chicago Neurol Inst, Chicago, IL 60611 USA		Kelly, JP (corresponding author), Chicago Neurol Inst, 233 E Erie St,Suite 704, Chicago, IL 60611 USA.	jpk070@northwestern.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Gennarelli TA, 1993, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; Kelly JP, 2000, NEUROLOGY, V54, pA243; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McIntosh TK, 1996, LAB INVEST, V74, P315; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Plum F, 1982, DIAGNOSIS STUPOR COM, V3rd, P3; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WOLJTYS EM, 1999, AM J SPORTS MED, V27, P676; YARNELL PR, 1970, LANCET, V1, P863; 1987, NEW LEXICON WEBSTERS, P1072	41	41	41	0	2	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					249	252					4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	557NC	WOS:000175913800006	12937492				2022-02-06	
J	Greenwald, BD; Cifu, DX; Marwitz, JH; Enders, LJ; Brown, AW; Englander, JS; Zafonte, RD				Greenwald, BD; Cifu, DX; Marwitz, JH; Enders, LJ; Brown, AW; Englander, JS; Zafonte, RD			Factors associated with balance deficits on admission to rehabilitation after traumatic brain injury: A multicenter analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; adult; ambulation; balance; brain injuries; equilibrium; Glasgow Coma Score; human; medical complication; rehabilitation	ACUTE STROKE; HEAD-INJURY; INPATIENT REHABILITATION; BODY SWAY; LENGTH; STAY; OUTCOMES; PERFORMANCE; PREDICTORS; DISABILITY	Objective: To evaluate how demographics, measures of injury severity, and acute care complications relate to sitting and standing balance in patients with traumatic brain injury (TBI). Design: Multicenter analysis of consecutive admissions to designated TBI Model Systems of Care (TBIMS). Setting: Ten National Institute for Disability and Rehabilitation Research TBI Model System centers for coordinated acute and rehabilitation care. Participants: 908 adults with TBI were included in the study. Main Outcome Measures: Sitting and standing balance were assessed within 72 hours of admission to inpatient rehabilitation. Results: Age less than 50 years had a significant association with normal sitting and standing balance (P = .001 and .05, respectively). Measures of severity of traumatic brain injury, including admission Glasgow Coma Score, length of posttraumatic amnesia ( PTA), Length of coma, and acute care length of stay were each significantly related to impaired sitting and standing balance ratings (P < .01). Initial abnormalities in pupillary response had a significant relationship with impairment of sitting (P = .009) but not standing balance. Incidence of respiratory failure, pneumonia, soft tissue infections, and urinary tract infections were all related to impaired sitting balance (P < .01). Presence of intracranial hemorrhages did not have a significant relationship with either sitting or standing balance. Intracranial compression had a significant relationship with standing (P = .05) but not sitting balance. A discriminant function analysis, which included neuroradiological findings, injury severity, and medical complications, could not accurately predict impaired balance ratings. Conclusions: This study demonstrated that rehabilitation admission balance ratings have a significant relationship with age, multiple measures of severity, and acute care medical complications after TBI. Prospective studies are indicated to evaluate the role balance at rehabilitation admission plays in the functional prognosis of patients with TBI.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA		Greenwald, BD (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, 150 Bergen St,UH B261, Newark, NJ 07103 USA.			Cifu, David/0000-0003-1600-9387; Brown, Allen W./0000-0001-7228-3351			ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Bohannon RW, 1997, INT J REHABIL RES, V20, P107, DOI 10.1097/00004356-199703000-00011; BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Feigin L, 1996, GERONTOLOGY, V42, P348, DOI 10.1159/000213814; Fidell, 1989, USING MULTIVARIATE S; Franchignoni FP, 1997, STROKE, V28, P1382, DOI 10.1161/01.STR.28.7.1382; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HAMRIN E, 1982, UPSALA J MED SCI, V87, P11, DOI 10.3109/03009738209178405; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Hillier SL, 1997, BRAIN INJURY, V11, P661; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; KOLLEGGER H, 1992, EUR NEUROL, V32, P253, DOI 10.1159/000116836; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Lee MY, 1997, AM J PHYS MED REHAB, V76, P401, DOI 10.1097/00002060-199709000-00011; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Levin HS., 1982, NEUROBEHAVIORAL CONS; LOEWEN SC, 1990, STROKE, V21, P78, DOI 10.1161/01.STR.21.1.78; MAYO NE, 1991, AM J PHYS MED REHAB, V70, P118, DOI 10.1097/00002060-199106000-00002; Miyai I, 1997, NEUROLOGY, V48, P95, DOI 10.1212/WNL.48.1.95; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SINCLAIR A J, 1990, Comprehensive Therapy, V16, P44; Smith MT, 1999, ARCH PHYS MED REHAB, V80, P442, DOI 10.1016/S0003-9993(99)90283-6; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wee JYM, 1999, ARCH PHYS MED REHAB, V80, P448, DOI 10.1016/S0003-9993(99)90284-8; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	41	41	42	1	3	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					238	252		10.1097/00001199-200106000-00003			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600003	11346446				2022-02-06	
J	Lewen, A; Skoglosa, Y; Clausen, F; Marklund, N; Chan, PH; Lindholm, D; Hillered, L				Lewen, A; Skoglosa, Y; Clausen, F; Marklund, N; Chan, PH; Lindholm, D; Hillered, L			Paradoxical increase in neuronal DNA fragmentation after neuroprotective free radical scavenger treatment in experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cell death; apoptosis; necrosis; behavior; Outcome; caspases	TERT-BUTYL NITRONE; APOPTOTIC CELL-DEATH; RAT-BRAIN; DELAYED TREATMENT; CONTUSION TRAUMA; NECROSIS; PBN; DYSFUNCTION; ACTIVATION; DEFICITS	The mechanisms and role of nerve cell death after traumatic brain injury (TBI) are not fully understood. The authors investigated the effect of pretreatment with the oxygen free radical spin trap alpha -phenyl-N-tert-butyl-nitrone (PBN) on the number of neurons undergoing apoptosis after TBI in rats. Apoptotic cells were identified by the TUNEL method combined with the nuclear stain, Hoechst 33258, and immunohistochemistry for the active form of caspase-3. Numerous neurons became positive for activated caspase-3 and TUNEL in the cortex at 24 hours after injury, suggesting ongoing biochemical apoptosis. In PBN-treated rats, a significantly greater number of cells were found to be TUNEL positive at 24 hours compared with controls. However, PEN treatment resulted in a reduced cortical lesion volume and improved behavioral outcome two weeks after injury. The authors conclude that a treatment producing an increase in DNA fragmentation in the early phase may be compatible with an overall beneficial effect on outcome after TBI. This should be considered in the screening process for future neuroprotective remedies.	Univ Uppsala Hosp, Div Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Sci Clin Chem, SE-75185 Uppsala, Sweden; Ctr Biomed, Div Neurobiol, Dept Neurosci, Uppsala, Sweden; Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Neurosci, Palo Alto, CA 94304 USA		Hillered, L (corresponding author), Univ Uppsala Hosp, Div Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013; Lindholm, Dan/B-3777-2014	Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; Chan P.H, 1988, CELLULAR ANTIOXIDANT, VVolume 3, P89; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Folbergrova J, 1999, NEUROSCI LETT, V266, P121, DOI 10.1016/S0304-3940(99)00279-7; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock J T, 1992, Hum Cell, V5, P345; RINK A, 1995, AM J PATHOL, V147, P1575; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	39	41	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2001	21	4					344	350		10.1097/00004647-200104000-00003			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	421PT	WOS:000168073300003	11323520	Bronze			2022-02-06	
J	Lin, B; Ginsberg, MD; Zhao, WH; Alonso, OF; Belayev, L; Busto, R				Lin, B; Ginsberg, MD; Zhao, WH; Alonso, OF; Belayev, L; Busto, R			Quantitative analysis of microvascular alterations in traumatic brain injury by endothelial barrier antigen immunohistochemistry	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; edema; endothelium; fluid-percussion brain injury; image-analysis; microvasculature; rat	EXCITATORY AMINO-ACIDS; REDUCES HISTOPATHOLOGICAL DAMAGE; SPINAL-CORD; CEREBRAL CONTUSION; RATS; EXPRESSION; IMMUNOREACTIVITY; ALBUMIN; EDEMA; ANGIOGENESIS	Endothelial barrier antigen (EBA) is a protein triplet located in the plasma membrane of microvascular endothelium and selectively expressed in the normal nervous system. In this study, microvascular alterations following traumatic brain injury were studied using EBA immunohistochemistry. Anesthetized, physiologically regulated, normothermic Sprague-Dawley rats received moderate (1.5-2.0 atm) parieto-occipital parasagittal fluid-percussion traumatic brain injury (TBI). Control rats were subjected to similar anesthesia and physiological monitoring. Seven days after operative procedures, brains were perfusion-fixed, and coronal sections were reacted for EBA immunohistochemistry using a monoclonal antibody to rat EBA. Selected sections were reacted for isolectin B-4 histochemistry. Computerized image analysis was used to compute numbers of EBA-immunopositive vascular profiles and mean vascular profile areas. In control brains, virtually all brain microvessels were clearly and positively immunostained, acid antibody binding was specific for blood vessels. In rats with TBI, EBA immunoreactivity was greatly reduced in the zone of cortical contusion. Within the core contusion, fractional areas occupied by vascular profiles were markedly reduced (on average, by 57%), vascular profile counts were diminished, and lectin histochemistry revealed a robust inflammatory response with abundant macrophages. Taken together, these findings were thought to indicate frank microvascular destruction. At adjacent peri-contusional sites, the intensity of EBA immunostaining was also diminished; and vascular profile counts were reduced at adjacent cortical sites and homologous contralateral sites. The latter findings were interpreted as sublethal microvascular alterations possibly related to cerebral edema. The present results confirm that EBA is a specific immunohistochemical marker of normal central nervous system microvessels; that it is suitable for use in formaldehyde-fixed material; and that it is useful in quantitatively assessing microvascular alterations observed at contusional, peri-contusional and more remote sites following traumatic brain injury.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, Miami, FL 33101 USA		Lin, B (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.			Lin, Binshan/0000-0002-8481-302X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [05820] Funding Source: Medline		BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barzo P, 1997, ACT NEUR S, V70, P119; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; Hartl R, 1997, ACT NEUR S, V70, P240; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Kadota E, 1997, ACT NEUR S, V70, P141; KRUM JM, 1991, EXP NEUROL, V111, P152, DOI 10.1016/0014-4886(91)90002-T; Krum JM, 1997, EXP NEUROL, V146, P33, DOI 10.1006/exnr.1997.6528; Lin BW, 1998, ACTA NEUROPATHOL, V95, P511, DOI 10.1007/s004010050832; Lin BW, 2000, BRAIN RES, V865, P237, DOI 10.1016/S0006-8993(00)02228-9; Maeda T, 1997, ACT NEUR S, V70, P102; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Nishigaya K, 2000, ACTA NEUROPATHOL, V99, P231, DOI 10.1007/PL00007432; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Perdiki M, 1998, ACTA NEUROPATHOL, V96, P8, DOI 10.1007/s004010050854; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; ROSENSTEIN JM, 1992, DEV BRAIN RES, V66, P47, DOI 10.1016/0165-3806(92)90138-M; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; STERNBERGER NH, 1989, RES IMMUNOL, V140, P187, DOI 10.1016/0923-2494(89)90084-9; STERNBERGER NH, 1987, P NATL ACAD SCI USA, V84, P8169, DOI 10.1073/pnas.84.22.8169; STERNBERGER NH, 1989, J NEUROIMMUNOL, V21, P241, DOI 10.1016/0165-5728(89)90180-X; Strasser A, 1997, ACT NEUR S, V70, P8; Unterberg AW, 1997, ACT NEUR S, V70, P106; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang RL, 1998, BRAIN RES, V785, P207, DOI 10.1016/S0006-8993(97)01343-7; Zilles K, 1985, CORTEX RAT	37	41	45	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					389	397		10.1089/089771501750170958			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000003	11336440				2022-02-06	
J	Lu, J; Moochhala, S; Kaur, C; Ling, EA				Lu, J; Moochhala, S; Kaur, C; Ling, EA			Cellular inflammatory response associated with breakdown of the blood-brain barrier after closed head injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; closed head injury; IgG; MHC class II antigen; microglia; NOS; rat; RhIc	NITRIC-OXIDE SYNTHASE; COMPLEX ANTIGEN EXPRESSION; AMEBOID MICROGLIAL CELLS; CENTRAL-NERVOUS-SYSTEM; CLASS-II EXPRESSION; INTRACEREBRAL INJECTION; LATERAL VENTRICLES; ENDOTHELIAL-CELLS; EPIPLEXUS CELLS; SPINAL-CORD	This study reports a widespread microglial response characterized by an upregulation of surface antigens, such as complement type 3 receptors (CR3) and major histocompatibility complex (MHC) class II antigens on these cells following closed head injury. Increased expression of CR3 (OX-42) and MHC class II antigens (OX-6) was observed in rats killed at 1, 3, and 5 days after injury. Intense OX-42 immunoreactivity was observed in microglial cells throughout the brain with a smaller number of them being OX-6 positive. In addition to microglial reaction, astrocytic activation reflected in cellular hypertrophy and increased immunoreactivity for glial fibrillary acidic protein (GFAP) was observed at 5 days after head injury. Together with the above, a diffuse perivascular and intraneuronal immunostaining for immunoglobulin G (IgG) was observed primarily in the cerebral cortex. This was accompanied by an enhanced expression of both endothelial nitric oxide synthase (eNOS) in blood vessels and inducible nitric oxide synthase (iNOS) in brain macrophages. In rats subjected to closed head injury followed by a single intraperitoneal (i.p.) injection of rhodamine isothiocyanate (RhIc), seepage of the fluorescent dye into the neuropil was observed. This had resulted in the labelling of the cortical neurons dearly demonstrating a breakdown of the blood-brain barrier (BBB). In the latter, it is conceivable that the ensuing leakage of plasma immunoglobulins and other serum-derived materials could induce the expression of MHC class II antigens on microglia. The mechanism causing the BBB dysfunction is not clear, although present results suggest that excessive release of nitric oxide (NO) may be a contributory factor. The widespread activation of microglia in rats after head injury suggests their involvement in increased endocytosis and immunological responses.	Def Sci & Technol Agcy, Def Med Res Inst, Singapore 109681, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117548, Singapore		Moochhala, S (corresponding author), Def Sci & Technol Agcy, Def Med Res Inst, Def Technol Tower B,20-04 Depot Rd, Singapore 109681, Singapore.	nmiv19@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			ABRAHAMSON DR, 1983, LAB INVEST, V48, P162; AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; DEGROOT CJA, 1991, INT J NEUROSCI, V59, P53, DOI 10.3109/00207459108985449; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engel S, 1996, ACT NEUR S, V66, P87; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FREI K, 1994, J IMMUNOL, V152, P2720; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; Giovannoni G, 1998, MULT SCLER J, V4, P212, DOI 10.1177/135245859800400323; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; HOWARDJONES N, 1985, WHO CHRON, V39, P51; Htain WW, 1997, NEUROSCI LETT, V223, P53; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KAUR C, 1992, J ANAT, V180, P333; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lehrmann E, 1997, J COMP NEUROL, V386, P461; LU J, 1993, J ANAT, V183, P405; LU J, 1995, BRAIN RES, V699, P275, DOI 10.1016/0006-8993(95)00919-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYHAN WG, 1995, BRAIN RES, V686, P99, DOI 10.1016/0006-8993(95)00460-8; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MORIOKA T, 1992, ACTA NEUROPATHOL, V83, P149, DOI 10.1007/BF00308474; MORIOKA T, 1991, J NEUROIMMUNOL, V35, P21, DOI 10.1016/0165-5728(91)90158-4; Nakano S, 1996, CANCER RES, V56, P4027; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Nottet HSLM, 1999, J NEUROVIROL, V5, P659, DOI 10.3109/13550289909021294; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RAIVICH G, 1994, NEUROPATH APPL NEURO, V20, P209; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; STEINIGER B, 1988, J NEUROIMMUNOL, V19, P111, DOI 10.1016/0165-5728(88)90040-9; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; WEINSTEIN DL, 1990, J NEUROSCI RES, V26, P55, DOI 10.1002/jnr.490260107; XU J, 1994, J ANAT, V184, P285; XU J, 1993, J ANAT, V182, P55; Yamanaka K, 1998, NEUROSCI RES, V31, P347, DOI 10.1016/S0168-0102(98)00052-2; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	50	41	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					399	408		10.1089/089771501750170976			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000004	11336441				2022-02-06	
J	Prins, ML; Hovda, DA				Prins, ML; Hovda, DA			Mapping cerebral glucose metabolism during spatial learning: Interactions of development and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; brain injury; 2-deoxy-glucose; development; fluid percussion; Morris water maze	FLUID-PERCUSSION MODEL; MORRIS WATER-MAZE; RAT-BRAIN; POSTNATAL-DEVELOPMENT; PARIETAL CORTEX; MEMORY; MOTOR; HIPPOCAMPUS; TASK; IMMATURE	Previous studies have demonstrated that, compared to adults, postnatal clay 17 (P17) and P28 rats show remarkable cognitive recovery in the Morris water maze (MWM) following fluid percussion injury (FPI). This observed age-at-trauma effect could result from either younger animals solving the MWM task using noninjured neural circuitry or an inability of adult and P28 brains to activate appropriate neural networks due to trauma-induced neurological dysfunction. To address these possibilities, we compared "activated" brain regions during normal MWM acquisition and following FP injury. To generate "activated" images of the brain while animals were performing the MWM task, qualitative [C-14]2-deoxy-D-glucose was conducted on days 2, 5, and 14 during training in sham and injured adult, P28, and P17 rats. When maturational changes in cerebral glucose metabolism are taken into account, the results suggests similar activity changes in the cerebral cortex and lacunosum moleculare of CA1 during acquisition in all age groups, suggesting that the developmental rates of MWM learning do not correspond to different patterns of activated cerebral metabolism. Injured P17s, showing no latency deficits, revealed activated cerebral metabolic patterns similar to noninjured P17 animals. In P28 and adult cases, animals exhibited cognitive deficits and their metabolic studies indicated that the cortical-hippocampal pattern of activation was disrupted by marked injury-induced metabolic depression, which primarily affected the ipsilateral hemisphere and lasted for as long as 14 days in adult animals.	Dept Neurobiol, Los Angeles, CA USA; Dept Surg, Los Angeles, CA USA; Dept Mol & Med Pharmacol, Los Angeles, CA USA		Prins, ML (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Dept Anat, Sanger Hall,1101 E Marshall St,Box 980709, Richmond, VA 23298 USA.	mlprins@hsc.vcu.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bontempi B, 1996, EUR J NEUROSCI, V8, P2348, DOI 10.1111/j.1460-9568.1996.tb01198.x; Dalezios Y, 1996, NEUROSCIENCE, V72, P325, DOI 10.1016/0306-4522(95)00516-1; DAUTH GW, 1985, ANN NEUROL, V17, P431, DOI 10.1002/ana.410170503; DESTRADE C, 1992, NATO ADV SCI I D-BEH, V68, P389; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBRAHIMIGAILLARD A, 1994, SOMATOSENS MOT RES, V11, P229, DOI 10.3109/08990229409051391; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRIEDMAN HR, 1994, J NEUROSCI, V14, P2775; GALEA LAM, 1994, BEHAV BRAIN RES, V60, P43, DOI 10.1016/0166-4328(94)90061-2; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; GONZALEZLIMA F, 1993, PHYSIOL BEHAV, V54, P605, DOI 10.1016/0031-9384(93)90256-F; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAIER RJ, 1992, BRAIN RES, V570, P134, DOI 10.1016/0006-8993(92)90573-R; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hovda D.A., 1996, NEUROTRAUMA, P1459; INAO S, 1990, J NEUROTRAUM, V7, P100; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LEE SM, 1993, SOC NEUR ABSTR, V3, P1882; LISBERGER SG, 1988, SCIENCE, V242, P728, DOI 10.1126/science.3055293; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTINEZ JL, 1982, J COMP PHYSIOL PSYCH, V96, P721, DOI 10.1037/h0077922; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEIBACH RC, 1980, BRAIN RES, V195, P167, DOI 10.1016/0006-8993(80)90874-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; NEHLIG A, 1988, J NEUROSCI, V8, P2321; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; SARTER M, 1989, BEHAV NEUROSCI, V103, P1217; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	50	41	41	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2001	18	1					31	46		10.1089/089771501750055758			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	390EU	WOS:000166283400004	11200248				2022-02-06	
J	Zhang, J; Lautar, S; Huang, S; Ramsey, C; Cheung, A; Li, JH				Zhang, J; Lautar, S; Huang, S; Ramsey, C; Cheung, A; Li, JH			GPI 6150 prevents H2O2 cytotoxicity by inhibiting poly(ADP-ribose) polymerase	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						reactive oxygen species damage; NAD(+) depletion; small molecule PARP inhibitor; specificity of GPI 6150	ADP-RIBOSE SYNTHETASE; ISCHEMIA-REPERFUSION INJURY; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; DNA DAMAGE; CELLS; 3-AMINOBENZAMIDE; PROTECTION; MICE; DYSFUNCTION	GPI 6150 (1,11b-dihydro-[2H]benzopyrano[4,3,2-de]isoquinolin-3-one) is a novel inhibitor of poly(ADP-ribose) polymerase (PARP). It has demonstrated efficacy in rodent models of focal cerebral ischemia, traumatic brain injury, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine damage to dopaminergic neurons, regional myocardial ischemia, streptozotocin-induced diabetes, septic shock, and arthritis. Here we report the structure of GPI 6150, its enzymatic characteristics, and biochemical property in cytoprotection. As a competitive PARP inhibitor (K-i = 60 nM), GPI 6150 protected the P388D1 cells against hydrogen peroxide cytotoxicity, by preventing PARP activation and the depletion of NAD(+), the substrate for PARP. To address the concerns of potential side effects of PARP inhibition, we tested GPI 6150 and found it had no effect on the repair and expression of a plasmid DNA damaged by N-methyl-N'-nitro-N-nitrosoguanidine. Neither did it affect dehydrogenases with NAD co-enzyme. GPI 6150 was much less potent to inhibit mono-ADP-ribosyltransferase. There was no selectivity for GPI 6150 between PARP isozymes. These attributes render GPI 6150 a useful tool to probe the functions of PARP. (C) 2000 Academic Press.	Guilford Pharmaceut Inc, Baltimore, MD 21224 USA		Zhang, J (corresponding author), Guilford Pharmaceut Inc, 6611 Tributary St, Baltimore, MD 21224 USA.	zhang_j@guilfordpharm.com					Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ayoub I. A., 1998, Society for Neuroscience Abstracts, V24, P214; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Chatterjee PK, 2000, FASEB J, V14, P641, DOI 10.1096/fasebj.14.5.641; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Grupp IL, 1999, J MOL CELL CARDIOL, V31, P297, DOI 10.1006/jmcc.1998.0864; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Koyama Y, 1999, GENE, V226, P339, DOI 10.1016/S0378-1119(98)00529-0; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Lee HC, 2000, CHEM IMMUNOL, V75, P39; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LU XCM, 2000, SOC NEUR ABSTR, V26, P1026; McDonald MC, 2000, BRIT J PHARMACOL, V130, P843, DOI 10.1038/sj.bjp.0703391; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SIMBULANROSENTH.CM, 2000, IN PRESS NUCL ACIDS; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sun AY, 1998, ACTA PHARMACOL SIN, V19, P104; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Walles T, 1998, CIRCULATION, V98, P260; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Zhang J, 2000, PHARM TOXIC, P279; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J., 1998, Society for Neuroscience Abstracts, V24, P1226; Zhang J., 1999, Acta Physiologica Scandinavica, V167, P90; ZHANG J, 1999, EMERGING DRUGS PROSP, V4, P209; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	54	41	43	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	NOV 30	2000	278	3					590	598		10.1006/bbrc.2000.3816			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	380KW	WOS:000165701900015	11095954				2022-02-06	
J	O'Neill, MJ; Murray, TK; McCarty, DR; Hicks, CA; Dell, CP; Patrick, KE; Ward, MA; Osborne, DJ; Wiernicki, TR; Roman, CR; Lodge, D; Fleisch, JH; Singh, J				O'Neill, MJ; Murray, TK; McCarty, DR; Hicks, CA; Dell, CP; Patrick, KE; Ward, MA; Osborne, DJ; Wiernicki, TR; Roman, CR; Lodge, D; Fleisch, JH; Singh, J			ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia	BRAIN RESEARCH			English	Article						cerebral ischemia; ARL 17477; nitric oxide; mongolian gerbil; rat; neuroprotection	ARGININE METHYL-ESTER; TRAUMATIC BRAIN INJURY; ARTERY OCCLUSION; 1-(2-TRIFLUOROMETHYLPHENYL) IMIDAZOLE; RECEPTOR ANTAGONIST; 7-NITRO INDAZOLE; INFARCT VOLUME; NOS INHIBITOR; ISCHEMIA; RAT	In the present studies, we have evaluated the effects of N-[4-(2-{[( 3-Chlorophenyl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide dihydrochloride (ARL 17477) on recombinant human neuronal NOS (nNOS) and endothelial NOS (eNOS). We then carried out pharmacokinetic studies and measured cortical nitric oxide synthase (NOS) inhibition to determine that the compound crossed the blood brain barrier. Finally, the compound was evaluated in a model of global ischaemia in the gerbil and two models of transient focal ischaemia in the rat. The IC50 values for ARL 17477 on human recombinant human nNOS and eNOS were 1 and 17 mu M, respectively. ARL 17477 (50 mg/kg i.p.) produced a significant reduction in the ischaemia-induced hippocampal damage following global ischaemia when administered immediately post-occlusion, but failed to protect when administration was delayed until 30 min post-occlusion. In the endothelin-l model of focal ischaemia, ARL 17477 (1 mg/kg i.v.) significantly attenuated the infarct volume when administered at either 0, 1 or 2 h post-endothelin-1 (P<0.05). In the intraluminal suture model, ARL 17477 at both 1 and 3 mg/kg i.v. failed to reduce the infarct volume measured at 1, 3 or 7 days post-occlusion. These results demonstrate that ARL 17477 protects against global ischaemia in gerbils and provides some reduction in infarct volume following transient middle cerebral artery occlusion in rats, indicating that nNOS inhibition may be a useful treatment of ischaemic conditions. (C) 2000 Elsevier Science B.V. All rights reserved.	Eli Lilly & Co Ltd, Lilly Res Ctr, Windlesham GU20 6PH, Surrey, England; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA		O'Neill, MJ (corresponding author), Eli Lilly & Co Ltd, Lilly Res Ctr, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England.	oneill_michael_j@lilly.com					BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; BUISSON A, 1993, J NEUROCHEM, V61, P690; CALDWELL M, 1994, EUR J PHARMACOL, V260, P191, DOI 10.1016/0014-2999(94)90337-9; CALDWELL M, 1995, EUR J PHARMACOL, V285, P203, DOI 10.1016/0014-2999(95)00502-C; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; CHABRIER PE, 1999, P NATL ACAD SCI USA, V14, P10557; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; Coert BA, 1999, J NEUROSURG, V90, P332, DOI 10.3171/jns.1999.90.2.0332; DAWSON DA, 1994, BRIT J PHARMACOL, V113, P247, DOI 10.1111/j.1476-5381.1994.tb16201.x; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; Dawson VL, 1996, J NEUROSCI, V16, P2479; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GENTILE RJ, 1995, Patent No. 05363; Green IC, 1999, DRUG DISCOV TODAY, V4, P47, DOI 10.1016/S1359-6446(98)01296-3; HANDY RLC, 1995, BRIT J PHARMACOL, V116, P2349, DOI 10.1111/j.1476-5381.1995.tb15078.x; Harukuni I, 1999, CRIT CARE MED, V27, P2508, DOI 10.1097/00003246-199911000-00030; Hicks CA, 1999, EUR J PHARMACOL, V381, P113, DOI 10.1016/S0014-2999(99)00543-9; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Lei BP, 1999, STROKE, V30, P669, DOI 10.1161/01.STR.30.3.669; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore PK, 1997, TRENDS PHARMACOL SCI, V18, P204, DOI 10.1016/S0165-6147(97)01064-X; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; O'Neill MJ, 2000, NEUROPHARMACOLOGY, V39, P1575, DOI 10.1016/S0028-3908(99)00250-6; Olesen SP, 1997, ACTA NEUROL SCAND, V95, P219, DOI 10.1111/j.1600-0404.1997.tb00102.x; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; ONeill MJ, 1997, BRAIN RES, V760, P170, DOI 10.1016/S0006-8993(97)00293-X; Panahian N, 1996, NEUROSCIENCE, V72, P343, DOI 10.1016/0306-4522(95)00563-3; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; Schmid-Elsaesser R, 1999, BRAIN RES, V816, P471, DOI 10.1016/S0006-8993(98)01197-4; Schulz JB, 1996, J NEUROCHEM, V67, P430; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHARKEY J, 1994, J AUTONOM NERV SYST, V49, pS177; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Spinnewyn B, 1999, J CEREBR BLOOD F MET, V19, P139, DOI 10.1097/00004647-199902000-00004; Togashi H, 1998, NEUROSCI LETT, V240, P53, DOI 10.1016/S0304-3940(97)00918-X; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	51	41	52	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 21	2000	871	2					234	244		10.1016/S0006-8993(00)02471-9			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	337TG	WOS:000088377300008	10899290				2022-02-06	
J	Kluger, G; Kochs, A; Holthausen, H				Kluger, G; Kochs, A; Holthausen, H			Heterotopic ossification in childhood and adolescence	JOURNAL OF CHILD NEUROLOGY			English	Article							PARA-ARTICULAR OSSIFICATIONS; SPINAL-CORD INJURY; NEW-BONE FORMATION; LONG-TERM COMA; MYOSITIS-OSSIFICANS; CLINICAL-FEATURES; PROGRESSIVA; CHILDREN; THERAPY; HISTORY	Heterotopic ossification, or myositis ossificans, denotes true bone in an abnormal place. The pathogenic mechanism is still unclear A total of 643 patients (mean age, 9.1 years) admitted for neuropediatric rehabilitation were analyzed retrospectively with respect to the existence of neurogenic heterotopic ossification. The purpose of this study was to obtain information about incidence, etiology, clinical aspect, and consequences for diagnosis and therapy of this condition in childhood and adolescence. Heterotopic ossification was diagnosed in 32 patients (mean age, 14.8 years) with average time of onset of 4 months after traumatic brain injury, near drowning, strangulation, cerebral hemorrhage, hydrocephalus, or spinal cord injury. The sex ratio was not significant. In contrast to what has been found in adult studies, serum alkaline phosphatase was not elevated during heterotopic ossification formation. A persistent vegetative state for longer than 30 days proved to be a significant risk factor for heterotopic ossification. The incidence of neurogenic heterotopic ossification in children seems to be lower than in adults. A genetic predisposition to heterotopic ossification is suspected but not proven. As a prophylactic regimen against heterotopic ossification we use salicylates for those patients in a coma or persistent vegetative state with warm and painful swelling of a joint and consider continuous intrathecal baclofen infusion and botulinum toxin injection for those patients with severe spasticity. We prefer to wait at least 1 year after trauma before excision of heterotopic ossification.	Behandlungszentrum Vogtareuth, Neuropediat Dept, Neuropadiat Abt, D-83569 Vogtareuth, Germany; CHU Montpellier, Serv Orthoped & Traumatol Pediat, Hop Lapeyronie, Montpellier, France		Kluger, G (corresponding author), Behandlungszentrum Vogtareuth, Neuropediat Dept, Neuropadiat Abt, Krankenhausstr 20, D-83569 Vogtareuth, Germany.						AHRENGART L, 1993, CLIN ORTHOP RELAT R, P153; AN HS, 1987, CLIN ORTHOP RELAT R, P291; AYERS DC, 1991, CLIN ORTHOP RELAT R, P87; BANOVAC K, 1993, PARAPLEGIA, V31, P660, DOI 10.1038/sc.1993.106; BOS CFA, 1993, J BONE JOINT SURG, V5, P1940; BRESSLER L, 1987, AM J ROENTGENOL, V48, P931; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301-620X.64B1.7068725; CONNOR JM, 1983, SOFT TISSUE OSSIFICA; CUSHNER FD, 1995, ORTHOPEDICS, V18, P287; Delatycki M, 1998, CLIN ORTHOP RELAT R, P15; DICKERSON RC, 1971, CLIN ORTHOP RELAT R, P42, DOI 10.1097/00003086-197109000-00006; EKELUND A, 1991, CLIN ORTHOP RELAT R, P102; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; FINERMAN GAM, 1981, METAB BONE DIS RELAT, V3, P337, DOI 10.1016/0221-8747(81)90050-3; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1989, CLIN ORTHOP RELAT R, P303; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1989, CLIN ORTHOPAEDICS, V242, P16; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; HERNANDEZ AM, 1978, PARAPLEGIA, V16, P272, DOI 10.1038/sc.1978.52; HOFFER MM, 1978, J TRAUMA, V18, P667, DOI 10.1097/00005373-197809000-00009; Hung JCC, 1997, DEV MED CHILD NEUROL, V39, P775; JACOBS P, 1962, ARCH DIS CHILD, V37, P90, DOI 10.1136/adc.37.191.90; Kaplan FS, 1998, CLIN ORTHOP RELAT R, P134; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LORBER J, 1953, ARCH DIS CHILD, V28, P98, DOI 10.1136/adc.28.138.98; LORBER J, 1963, ARCH DIS CHILD, V28, P98; MAJOR P, 1980, RADIOLOGY, V136, P797, DOI 10.1148/radiology.136.3.6773108; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P14; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; *MULT SOC TASK FOR, 1994, CLIN ORTHOPAEDICS, V330, P1499; OGILVIEHARRIS DJ, 1980, J BONE JOINT SURG AM, V62, P1274, DOI 10.2106/00004623-198062080-00006; ORZEL JA, 1985, J NUCL MED, V26, P125; Ritter M, 1979, J BONE JOINT SURG, V61, P113; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; ROGERS JG, 1979, J BONE JOINT SURG AM, V61, P909, DOI 10.2106/00004623-197961060-00019; ROSER B, 1989, ACTA ORTHOP SCAND, V60, P457; ROSSIER AB, 1973, PARAPLEGIA, V11, P36; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; Smith R, 1998, CLIN ORTHOP RELAT R, P7; SMITH R, 1976, J BONE JOINT SURG BR, V58, P48, DOI 10.1302/0301-620X.58B1.818090; SMITH R, 1998, J BONE JOINT SURG, V346, P7; SODEMANN B, 1988, CLIN ORTHOPAEDICS, V237, P159; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; URIST MR, 1978, ARCH PATHOL LAB MED, V102, P312; Valentin P, 1969, Rev Chir Orthop Reparatrice Appar Mot, V55, P351; WILKES LL, 1975, CLIN ORTHOP RELAT R, V118, P151; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26	52	41	42	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON, ONTARIO L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	JUN	2000	15	6					406	413		10.1177/088307380001500610			16	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	321QG	WOS:000087465700011	10868785				2022-02-06	
J	Zoccolotti, P; Matano, A; Deloche, G; Cantagallo, A; Passadori, A; Leclercq, M; Braga, L; Cremel, N; Pittau, P; Renom, M; Rousseaux, M; Truche, A; Fimm, B; Zimmermann, P				Zoccolotti, P; Matano, A; Deloche, G; Cantagallo, A; Passadori, A; Leclercq, M; Braga, L; Cremel, N; Pittau, P; Renom, M; Rousseaux, M; Truche, A; Fimm, B; Zimmermann, P			Patterns of attentional impairment following closed head injury: A collaborative European study	CORTEX			English	Article						head injury; attention; selective attention; divided attention; alertness; vigilance	SUSTAINED ATTENTION; REACTION-TIME; DEFICITS; PERFORMANCE	A comprehensive assessment of both selective (focused attention, divided attention) and intensive (alertness and vigilance) attentional processes was performed on 106 patients with closed head injury using a computerised battery for the evaluation of attention. All patients were tested at least five months after their accident. A high percentage of patients were pathological in tests mapping the selective components of attention while only a minority were impaired on tests mapping the intensive components of attention. Three different subgroups of patients with consistent performance patterns were evidenced. The psychometric characteristics of the battery and its possible clinical usefulness are discussed.	Osped S Lucia, IRCCS, Rome, Italy; Univ Reims, CIRLEP, Reims, France; Unita Operat Med Riabilitat, Ferrara, Italy; Ctr Readaptat Mulhouse, Mulhouse, France; Ctr Neurol William Lennox, Ottignies, Belgium; Sarah Hosp, Brasilia, DF, Brazil; USL Grossetana, Div Neurol, Grossetana, Italy; Hosp Santa Creu & Sant Pau, EPL, Barcelona, Spain; Serv Reeducat & Convalescence Neurol, Lille, France; Ctr Reeduc & Etud Activ Mnes, Tassin La Demi Lune, France; Neurol Clin, Aachen, Germany; Univ Freiburg, Inst Physiol, D-7800 Freiburg, Germany		Zoccolotti, P (corresponding author), IRCCS S Lucia, Ctr Ric, Via Ardeatina 306, I-00179 Rome, Italy.	zoccolotti@axrma.uniroma1.it	Zoccolotti, Pierluigi/H-4437-2019; Braga, Lucia/AAQ-1030-2020	Zoccolotti, Pierluigi/0000-0002-6351-2455; Renom, Marta/0000-0002-2490-494X			ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DOMHOLDT E, 1993, PHYSICAL THERAPY RES; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Miller E, 1970, Cortex, V6, P121; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; ODDY M, 1978, J NEUROL NEUROSUR PS, V48, P21; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WHITE J, 1992, NEUROPSYCHOLOGIA, V35, P313; Zimmermann P., 1992, TESTBATTERIE AUFMERK	25	41	42	0	3	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2000	36	1					93	107		10.1016/S0010-9452(08)70839-6			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	291MN	WOS:000085740800008	10728900				2022-02-06	
J	Hofman, PAM; Kemerink, GJ; Jolles, J; Wilmink, JT				Hofman, PAM; Kemerink, GJ; Jolles, J; Wilmink, JT			Quantitative analysis of magnetization transfer images of the brain: Effect of closed head injury, age and sex on white matter	MAGNETIC RESONANCE IN MEDICINE			English	Article						magnetization transfer; quantitative imaging; normal aging; MRI	MULTIPLE-SCLEROSIS LESIONS; HISTOPATHOLOGIC CORRELATION; MICROSCOPIC DISEASE; TRANSFER RATIO; ECHO IMAGES; MR; DECADES; BURDEN; LIFE; T1	Magnetization transfer (MT) imaging has an application in quantitative assessment of cerebral white matter. Previously published postprocessing methods have inherent problems, and therefore a new analysis technique is presented. This technique was found to be more sensitive for white matter changes in patients with a postconcussional syndrome, compared to other methods previously described. Because of the potential application of this technique in longitudinal and group studies, age and sex dependence of the MT ratio (MTR) of white matter were studied. In a group of 51 healthy subjects, a decrease in the mean MTR as well as an increasing distribution width of the MTR was found with increasing age. The mean MTR in males was higher than in females. These results stress the need to take age and sex into account when interpreting MTR data. Magn Reson Med 42:803-806, 1999. (C) 1999 Wiley-Liss, Inc.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Psychiat & Neuropsychiat, NL-6200 AZ Maastricht, Netherlands		Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.	pho@rdia.azm.nl					AGARTZ I, 1991, RADIOLOGY, V181, P537, DOI 10.1148/radiology.181.2.1924801; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; BREGER RK, 1991, RADIOLOGY, V181, P545, DOI 10.1148/radiology.181.2.1924802; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FRANCES CA, 1994, DIAGNOSTIC STAT MANU; HIEHLE JF, 1995, AM J NEURORADIOL, V16, P69; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; MEHTA RC, 1995, AM J NEURORADIOL, V16, P2085; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; REISS AL, 1996, BRAINIMAGE; Silver NC, 1997, J NEUROL NEUROSUR PS, V62, P223, DOI 10.1136/jnnp.62.3.223; TEASDALE G, 1974, LANCET, V2, P81; TOMIAK MM, 1994, AM J NEURORADIOL, V15, P1569; vanBuchem MA, 1997, AM J NEURORADIOL, V18, P1287; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; WONG KT, 1995, AM J NEURORADIOL, V16, P253	21	41	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	OCT	1999	42	4					803	806		10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6			4	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	242MG	WOS:000082944400024	10502771				2022-02-06	
J	Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ				Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ			Traumatic injury to rat brain upregulates neuronal nitric oxide synthase expression and L-[H-3]nitroarginine binding	JOURNAL OF NEUROTRAUMA			English	Article						mRNA; nitric oxide; neuronal nitric oxide synthase, L-nitroarginine; RT-PCR; traumatic brain injury; Western blotting	CORTICAL IMPACT INJURY; TRANSIENT FOCAL ISCHEMIA; NITROARGININE BINDING; NMDA RECEPTORS; MUTANT MICE; MITOCHONDRIAL; SYNAPTOSOMES; PHARMACOLOGY; MECHANISMS; INHIBITION	Overstimulation of N-methyl-D-aspartate (NMDA) receptors is felt to precipitate the neuronal damage following traumatic brain injury (TBI). NMDA receptor-mediated, glutamate-induced excitotoxicity is thought to be mediated via nitric oxide (NO) formed by neuronal nitric oxide synthase (nNOS), The present study examined the mRNA and protein levels of nNOS in the ipsilateral and contralateral cortex of rats as a function of time (5 minutes to 1 week) after controlled cortical impact (CCI) brain injury, Sham-operated rats served as controls. TBI resulted in a significant increase in the levels of nNOS mRNA (1.5- to 2.8-fold, p <.05) between 2 and 4 hours after the injury, There was also a significant increase in the levels of nNOS protein (by 55% to 90%,p <.05) and binding densities of the nNOS-specific ligand L-[H-3]nitroarginine (L-[H-3]NOARG) (by 35% to 59%,p <.05) between 2 and 12 hours after the injury, Increased nNOS expression and function may contribute to the concomitant excitotoxic neuronal death after TBI.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; William S Middleton Mem Vet Adm Hosp, Madison, WI USA		Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.		Dogan, Aclan/AAF-8305-2019				Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Araki T, 1998, EUR J PHARMACOL, V354, P153, DOI 10.1016/S0014-2999(98)00457-9; Ayata C, 1997, J NEUROSCI, V17, P6908; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beckman JS, 1996, ADV NEUROL, V71, P339; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689; CHOI DW, 1997, PRIMER CEREBROVASCUL, P187; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Felley-Bosco E, 1998, CANCER METAST REV, V17, P25, DOI 10.1023/A:1005948420548; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GORMAN LK, 1996, SOC NEUR ABST, V26; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Hara H, 1997, J CEREBR BLOOD F MET, V17, P515, DOI 10.1097/00004647-199705000-00005; Hara H, 1996, NEUROSCIENCE, V75, P881, DOI 10.1016/0306-4522(96)00313-2; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McNaught KSP, 1998, J NEUROCHEM, V70, P1541; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUSSEAU DD, 1999, NEUROMETH, V34, P167; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rao VLR, 1996, NEUROCHEM RES, V21, P355; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Rao VLR, 1997, BRAIN RES, V765, P169, DOI 10.1016/S0006-8993(97)00652-5; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 1996, J NEUROCHEM, V66, P701; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; Rao VLR, 1996, J NEUROCHEM, V67, P1275; RINK A, 1995, AM J PATHOL, V147, P1575; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SCHMIDT K, 1995, J NEUROCHEM, V64, P1469; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIESJO BK, 1997, PRIMER CEREBROVASCUL, P172; Smith D H, 1995, New Horiz, V3, P562; Sriram K, 1998, J NEUROSCI, V18, P10287; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TROTTI D, 1996, J BIOL CHEM, V271, P5967; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	72	41	44	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					865	877		10.1089/neu.1999.16.865			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900002	10547096				2022-02-06	
J	Tate, PS; Freed, DM; Bombardier, CH; Harter, SL; Brinkman, S				Tate, PS; Freed, DM; Bombardier, CH; Harter, SL; Brinkman, S			Traumatic brain injury: influence of blood alcohol level on post-acute cognitive function	BRAIN INJURY			English	Article							SUBSTANCE-ABUSE; HEAD-INJURY; INTOXICATION; REHABILITATION; ETHANOL	Alcohol intoxication frequently contributes to the occurrence of traumatic brain injury. Few studies, however, have examined whether acute pre-injury alcohol intoxication or premorbid history of alcohol abuse exacerbate cognitive impairments that commonly result from traumatic brain injury. This study examined the influence of blood alcohol level at time of hospital admission on cognitive functioning during the pose-acute stage of recovery from traumatic brain injury. After controlling for pre-injury history of alcohol abuse, hospital admission blood alcohol level was predictive of poorer delayed verbal memory, greater decrement in verbal memory over time, and poorer visuospatial functioning. Moreover, there were non-significant trends for higher blood alcohol levels to predict poorer performance on measures of immediate verbal memory and perseveration.	Texas Tech Univ, Dept Psychol, Lubbock, TX 79409 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Neuropsychiat, Lubbock, TX 79409 USA; Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; Neuropsychol Clin, Abilene, TX USA		Tate, PS (corresponding author), 1416 McMillan Ave,Suite A-3, Summer, WA 98390 USA.		Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR011714] Funding Source: Medline		Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CALLAHAN D, 1968, Q J STUD ALCOHOL, V29, P130; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1983, APPL MULTIPLE REGRES; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Golden CJ, 1978, STROOP COLOR WORD TE; Heaton RK, 1993, WISCONSIN CARD SORT; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kraus Jess F., 1994, P3; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEMKUHL LD, 1993, J HEAD TRAUMA REHAB, V8, P88; LEONARD BE, 1995, NEUROCHEM INT, V26, P343, DOI 10.1016/0197-0186(94)00141-G; LEZAK MD, 1995, NEURSYCHOLOGICAL ASS; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MARZAUX JM, 1997, ARCH PHYSICAL MED RE, V78, P1316; NACHSHON K, 1998, C NEUR SURG SEATL WA; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PARSONS OA, 1993, NEUROL CLIN, V11, P205, DOI 10.1016/S0733-8619(18)30178-6; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL R, 1992, NEUROSURGERY, V11, P344; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; SABHESAN S, 1987, Indian Journal of Psychological Medicine, V10, P61; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Tabachnick B. G., 1989, USING MULTIVARIATE S; WALLENBURG HCS, 1986, LANCET, V1, P1; Wechsler D, 1987, MANUAL WECHSLER MEMO; Wechsler D, 1981, WECHSLER ADULT INTEL; WEINSTEIN DD, 1995, AM J ADDICTION, V4, P285; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zauner A, 1998, NEUROL RES, V20, pS85; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	64	41	41	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					767	784					18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800003	10576461				2022-02-06	
J	Morita-Fujimura, Y; Fujimura, M; Kawase, M; Chen, SF; Chan, PH				Morita-Fujimura, Y; Fujimura, M; Kawase, M; Chen, SF; Chan, PH			Release of mitochondrial cytochrome c and DNA fragmentation after cold injury-induced brain trauma in mice: possible role in neuronal apoptosis	NEUROSCIENCE LETTERS			English	Article						cold injury; cytochrome c; traumatic brain injury; apoptosis; mitochondrial injury; caspase	CUZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; ACTIVATION; EDEMA; INHIBITION; INDUCTION; CASPASE-3; DAMAGE; ENZYME	Recent studies have shown that release of mitochondrial cytochrome c is a critical step in the apoptosis process. In this study, we examined the subcellular distribution of the cytochrome c protein after cold injury (Cl), in which apoptosis is assumed to participate. Western blotting and immunohistochemistry showed cytosolic cytochrome c as early as 1 h after Cl, and correspondingly, there was a reduction in mitochondrial cytochrome c after injury. Neuronal distribution of cytosolic cytochrome c was shown by double staining with a neuronal nuclear marker by immunohistochemistry. A significant amount of DNA laddering was detected 4 h after Cl, and increased in a time-dependent manner. These data suggest that early cytochrome c release from mitochondria may contribute to apoptosis induction after traumatic brain injury. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.	Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Neurosci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol Surg, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA		Chan, PH (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA.		fujimura, yuiko/M-7393-2013; Morita-fujimura, Yuiko/N-4804-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036147, R01NS025372, P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543, NS36147, NS25372] Funding Source: Medline		BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, J NEUROSCI, V17, P4180; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MORITAFUJIMURA Y, 1999, IN PRESS J CEREB BLO; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Namura S, 1998, J NEUROSCI, V18, P3659; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	21	41	44	1	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 4	1999	267	3					201	205		10.1016/S0304-3940(99)00327-4			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	202LK	WOS:000080653600014	10381011				2022-02-06	
J	Pieter, W; Zemper, ED				Pieter, W; Zemper, ED			Head and neck injuries in young taekwondo athletes	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						taekwondo; head injuries; neck injuries; athletic injuries	TRAUMATIC BRAIN INJURY; SPINAL-INJURIES; CHAMPIONSHIPS; PLAYERS	Background. To investigate the location, type, situation and mechanism of head and neck injuries in young taekwondo athletes. Methods. Experimental design: Prospective. Setting: National and international taekwondo tournaments. Participants: 3,341 boys and 917 girls, aged 6 to 16 years. Measures: Injury rates per 1,000 athlete-exposures (A-E) for total number of head and neck injuries, location, type, situation, and mechanism of injury. Results. There was a significant difference between young male and female taekwondo athletes in total head and neck injury rate (p<0.001) with the boys (21.42/1,000 A-E) recording a higher rate than the girls (16.91/1,000 A-E). The head was the most often injured body part (6.10/1,000 A-E and 4.55/1,000 A-E for boys and girls, respectively). The contusion was the most often occurring injury type for both boys (8.41/1,000 A-E) and girls (7.80/1,000 A-E). The cerebral concussion ranked second in both boys (5.11/1,000 4-E) and girls (4.55/1,000 A-E). The unblocked attack was the major injury situation for both boys (19.78/1,000 A-E) and girls (14.96/1,000 A-E). As a consequence, the major injury mechanism was receiving a blow (20.93/1,000 A-E and 16.25/1,000 A-E for boys and girls, respectively). Only the buys (0.66/1,000 A-E) incurred the most serious head and neck injuries that resulted in greater than or equal to 21 days away from participation. Conclusions. The national and international taekwondo governing bodies should review their current injury prevention measures. Given the potentially debilitating nature of these injuries, inplications for any diagnostic capabilities on site should be carefully reviewed.	Univ N London, Sch Hlth & Sports Sci, London N7 8DB, England; ExRA, Eugene, OR USA		Pieter, W (corresponding author), Univ N London, Sch Hlth & Sports Sci, 166-220 Holloway Rd, London N7 8DB, England.						Caine D.J., 1996, EPIDEMIOLOGY SPORTS; CITTAPIETROLUNGO TJ, 1993, ARCH PHYS MED REHAB, V74, P905; Fauno P., 1992, SCAND J MED SCI SPOR, V3, P62, DOI DOI 10.1111/J.1600-0838.1993.TB00363.X; HUTCHINSON MR, 1995, MED SCI SPORT EXER, V27, P826; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P85, DOI 10.1080/00913847.1988.11709529; MANN DC, 1993, ORTHOPEDICS, V16, P159; Maroon J C, 1981, Phys Sportsmed, V9, P83, DOI 10.1080/00913847.1981.11711209; MATSUBAYASHI K, 1993, 1993 ADV BIOENGINEER, V26, P259; MCLATCHIE GR, 1994, ENCY SPORTS MED, V5, P609; MUELLER FO, 1986, PHYSICIAN SPORTSMED, V14, P139, DOI 10.1080/00913847.1986.11709202; NIEZGODA JA, 1990, ANN THORAC SURG, V50, P615, DOI 10.1016/0003-4975(90)90199-G; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1997, 2 ANN C EUR COLL SPO; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1995, BOHN STAFLEU LOGHUM, V3205, P1; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; SCHMIDT RJ, 1975, MED SCI SPORT EXER, V7, P59; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; SIM FH, 1988, PHYSICIAN SPORTSMED, V16, P92, DOI 10.1080/00913847.1988.11709456; SMITH DJ, 1988, INT OPHTHALMOL CLIN, V28, P242, DOI 10.1097/00004397-198802830-00016; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; STOREY MD, 1989, PHYSICIAN SPORTSMED, V17, P85; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; Zandbergen A, THESIS TWENTSE AKAD; Zemper E D, 1989, Br J Sports Med, V23, P161; ZEMPER ED, 1989, PHYSICIAN SPORTSMED, V17, P100, DOI 10.1080/00913847.1989.11709915; ZEMPER ED, 1993, PRIMARY CARE SPORTS, P63	29	41	42	0	9	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707			J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	JUN	1999	39	2					147	153					7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	208FH	WOS:000080979800011	10399424				2022-02-06	
J	Schmitter-Edgecombe, M				Schmitter-Edgecombe, M			Effects of divided attention on perceptual and conceptual memory tests: An analysis using a process-dissociation approach	MEMORY & COGNITION			English	Article							CLOSED-HEAD-INJURY; WORD-STEM COMPLETION; IMPLICIT MEMORY; EXPLICIT MEMORY; UNCONSCIOUS INFLUENCES; DRIVEN PROCESSES; PERFORMANCE; AMNESIA; TASKS; INDEPENDENCE	In two experiments, the nature of the relation between attention available at learning and subsequent automatic and controlled influences of memory was explored. Participants studied word lists in full and divided encoding conditions. Memory for the word lists was then tested with a perceptually driven task (stem completion) in Experiment 1 and with a conceptually driven task (category association) in Experiment 2. For recall cued with word stems, automatic influences of memory derived using the process-dissociation procedure remained invariant across a manipulation of attention that substantially reduced conscious recollection for the learning episode. In contrast, for recall cued with category names, dividing attention at learning significantly reduced the parameter estimates representing both controlled and automatic memory processes. These findings were similar to those obtained using indirect test instructions. The results suggest that, in contrast to perceptual priming, conceptual priming may be enhanced by semantic processing, and this effect is not an artifact of contamination from conscious retrieval processes.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA		Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu					BADDELEY AD, 1969, BRIT J PSYCHOL, V60, P51, DOI 10.1111/j.2044-8295.1969.tb01175.x; BARTZ WH, 1970, J EXP PSYCHOL, V84, P380, DOI 10.1037/h0029100; BASSILI JN, 1989, Q J EXP PSYCHOL-A, V41, P439, DOI 10.1080/14640748908402375; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; BENNET B, 1965, BRIT J PSYCHOL, V56, P413; BENTIN S, 1992, J EXP PSYCHOL LEARN, V18, P1270, DOI 10.1037/0278-7393.18.6.1270; BLAXTON TA, 1989, J EXP PSYCHOL LEARN, V15, P657, DOI 10.1037/0278-7393.15.4.657; BUCHNER A, 1995, J EXP PSYCHOL GEN, V124, P137, DOI 10.1037/0096-3445.124.2.137; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Cermak Laird S., 1993, P287; CERMAK LS, 1995, NEUROPSYCHOLOGY, V9, P281, DOI 10.1037/0894-4105.9.3.281; CERMAK LS, 1973, NEUROPSYCHOLOGIA, V11, P85, DOI 10.1016/0028-3932(73)90068-7; Cohen J., 1977, STAT ANAL BEHAV SCI; Cowan N, 1996, J EXP PSYCHOL GEN, V125, P195, DOI 10.1037/0096-3445.125.2.195; Craik F. I. M., 1982, AGING COGNITIVE PROC, P191, DOI [DOI 10.1007/978-1-4684-4178-9_11, 10.1007/978-1-4684-4178-9_11]; CRAIK FIM, 1983, PHILOS T R SOC B, V302, P155; CURRAN T, 1995, J EXP PSYCHOL LEARN, V21, P531, DOI 10.1037/0278-7393.21.3.531; Curran T, 1997, J EXP PSYCHOL LEARN, V23, P496, DOI 10.1037/0278-7393.23.2.496; Dodson CS, 1996, J EXP PSYCHOL GEN, V125, P181, DOI 10.1037/0096-3445.125.2.181; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAF P, 1994, EUR J COGN PSYCHOL, V6, P113, DOI 10.1080/09541449408520139; GREENE RL, 1986, Q J EXP PSYCHOL-A, V38, P663, DOI 10.1080/14640748608401619; HAIST F, 1991, PSYCHOBIOLOGY, V19, P275; HAMANN SB, 1990, J EXP PSYCHOL LEARN, V16, P970, DOI 10.1037/0278-7393.16.6.970; Hamann SB, 1996, J EXP PSYCHOL LEARN, V22, P933; Hay JF, 1996, J EXP PSYCHOL LEARN, V22, P1323, DOI 10.1037/0278-7393.22.6.1323; Hintzman DL, 1997, J EXP PSYCHOL LEARN, V23, P511, DOI 10.1037/0278-7393.23.2.511; Hunt K. P., 1971, PSYCHONOMIC MONOGR S, V4, P97; ISINGRINI M, 1995, MEM COGNITION, V23, P462, DOI 10.3758/BF03197247; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P505, DOI 10.1037/0278-7393.23.2.505; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; Jacoby LL, 1998, J EXP PSYCHOL LEARN, V24, P3, DOI 10.1037/0278-7393.24.1.3; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jacoby LL, 1997, CARN S COGN, P13; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P484, DOI 10.1037/0278-7393.23.2.484; JOORDENS S, 1993, J EXP PSYCHOL GEN, V122, P462, DOI 10.1037/0096-3445.122.4.462; Keane MM, 1997, NEUROPSYCHOLOGY, V11, P59, DOI 10.1037/0894-4105.11.1.59; KOMATSU S, 1995, EUR J COGN PSYCHOL, V7, P19, DOI 10.1080/09541449508520155; KORIAT A, 1976, ACTA PSYCHOL, V40, P57, DOI 10.1016/0001-6918(76)90044-5; Kuera H., 1967, COMPUTATIONAL ANAL P; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; Mecklenbrauker S, 1996, SWISS J PSYCHOL, V55, P34; Mulligan NW, 1997, J EXP PSYCHOL LEARN, V23, P280, DOI 10.1037/0278-7393.23.2.280; Mulligan NW, 1998, J EXP PSYCHOL LEARN, V24, P27, DOI 10.1037/0278-7393.24.1.27; Mulligan NW, 1996, MEM COGNITION, V24, P453, DOI 10.3758/BF03200934; Mulligan NW, 1997, MEM COGNITION, V25, P11, DOI 10.3758/BF03197281; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; Parkin A. J., 1990, EUROPEAN J COGNITIVE, V2, P71, DOI [DOI 10.1080/09541449008406198, 10.1080/09541449008406198]; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PERRUCHET P, 1989, MEM COGNITION, V17, P77, DOI 10.3758/BF03199559; RAPPOLD VA, 1991, J EXP PSYCHOL LEARN, V17, P103, DOI 10.1037/0278-7393.17.1.103; Reingold EM, 1996, J EXP PSYCHOL LEARN, V22, P397; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; ROEDIGER HL, 1992, J EXP PSYCHOL LEARN, V18, P1251, DOI 10.1037/0278-7393.18.6.1251; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROEDIGER HL, 1989, VARIATIONS MEMORY CO, P00003; ROTHKEGEL R, 1998, APPLETREE STAT INFER; SCHACTER DL, 1992, J COGNITIVE NEUROSCI, V4, P244, DOI 10.1162/jocn.1992.4.3.244; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schmidt S, 1996, AGRO FOOD IND HI TEC, V7, P2; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; TOTH JP, 1994, J EXP PSYCHOL LEARN, V20, P290, DOI 10.1037/0278-7393.20.2.290; TOTH JP, 1995, EUR J COGN PSYCHOL, V7, P113, DOI 10.1080/09541449508403095; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Wagner AD, 1997, J EXP PSYCHOL LEARN, V23, P305, DOI 10.1037/0278-7393.23.2.305; Wechsler D, 1981, WECHSLER ADULT INTEL; Wolters G, 1997, MEM COGNITION, V25, P764, DOI 10.3758/BF03211319; Yonelinas AP, 1996, CONSCIOUS COGN, V5, P131, DOI 10.1006/ccog.1996.0008	82	41	45	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-502X	1532-5946		MEM COGNITION	Mem. Cogn.	MAY	1999	27	3					512	525		10.3758/BF03211545			14	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	199KC	WOS:000080479200011	10355240	Bronze			2022-02-06	
J	Markowitsch, HJ; Calabrese, P; Neufeld, H; Gehlen, W; Durwen, HF				Markowitsch, HJ; Calabrese, P; Neufeld, H; Gehlen, W; Durwen, HF			Retrograde amnesia for world knowledge and preserved memory for autobiographic events. A case report	CORTEX			English	Article						traumatic brain injury; retrograde amnesia; general knowledge; episodic memory	EPISODIC MEMORY; FUNCTIONAL NEUROANATOMY; TEMPORAL POLE; BRAIN-REGIONS; RETRIEVAL; CORTEX; ORGANIZATION	A patient (PC) with severe and chronic retrograde amnesia for world knowledge (tested with famous events and famous faces), but unimpaired autobiographical memory is described. The 64-year-old man had traumatic brain injury four years prior to the present evaluation. Current brain imaging showed principally damage involving the infero-lateral prefrontal and the lateral temporal regions of the left-hemisphere. PC was of average intelligence, had no depression and only minor language problems, but manifested some additional anterograde memory deficits and performed subaverage in various frontal lobe-sensitive tests. Patient PC represents one of the very few cases with a preserved retrograde episodic and an impaired retrograde knowledge system, showing a dissociation between preserved retrieval of autobiographical events and amnesia for nonpersonal famous events. It is hypothesized that the sparing of autobiographical memories can be linked to the integrity of the right frontal and temporo-polar cortices.	Univ Bielefeld, D-33501 Bielefeld, Germany; Univ Clin Bochum, Dept Neurol, Bochum, Germany		Markowitsch, HJ (corresponding author), Univ Bielefeld, POB 100131, D-33501 Bielefeld, Germany.		Calabrese, Pasquale/AAL-5291-2020				ARNOLD SE, 1994, ARCH NEUROL-CHICAGO, V51, P145, DOI 10.1001/archneur.1994.00540140051014; Baddeley A. D., 1990, AUTOBIOGRAPHICAL MEM; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; CRONINGOLOMB A, 1986, NEUROPSYCHOLOGIA, V24, P881, DOI 10.1016/0028-3932(86)90088-6; DAHL G, 1986, REDUZIERTER WECHSLER; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DONALD MW, 1977, INT ENCY PSYCHIAT PS, V2, P455; EBNER A, 1987, ZUGANG VERSTANDNIS H; Fink GR, 1996, J NEUROSCI, V16, P4275; Fletcher PC, 1997, TRENDS NEUROSCI, V20, P213, DOI 10.1016/S0166-2236(96)01013-2; FRANZEN EA, 1973, NEUROPSYCHOLOGIA, V11, P141, DOI 10.1016/0028-3932(73)90002-X; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; HAUTZINGER M, 1991, NERVENARZT, V62, P689; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Kopelman M D, 1994, Memory, V2, P211, DOI 10.1080/09658219408258945; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Leplow B, 1997, DIAGNOSTICA, V43, P193; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Markowitsch H J, 1997, Cogn Neuropsychiatry, V2, P135, DOI 10.1080/135468097396379; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P627, DOI 10.1080/01688639308402586; MARKOWITSCH HJ, 1985, J COMP NEUROL, V242, P425, DOI 10.1002/cne.902420310; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; Markowitsch HJ, 1997, TRENDS NEUROSCI, V20, P557; MARKOWITSCH J, 1995, COGNITIVE NEUROSCIEN, P665; MILNER B, 1985, HUM NEUROBIOL, V4, P137; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Orgass B., 1982, TOKEN TEST DTSCH BEA; RYAN C, 1979, ALCOHOL INTOXICATION, P109; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SPREEN E, 1991, COMPENDIUM NEUROPSYC; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Tulving E., 1983, ELEMENTS EPISODIC ME; Tulving Endel, 1995, P839; Warrington E, 1984, RECOGNITION MEMORY T, V1; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; Zimmermann P., 1993, TESTBATTERIE AUFMERK	43	41	41	0	4	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	APR	1999	35	2					243	252		10.1016/S0010-9452(08)70797-4			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	198AC	WOS:000080398700007	10369096				2022-02-06	
J	Rivara, FP				Rivara, FP			Pediatric injury control in 1999: Where do we go from here?	PEDIATRICS			English	Article							TRAUMATIC BRAIN INJURY; FUNCTIONAL INDEPENDENCE MEASURE; UNITED-STATES; POSTTRAUMATIC SEIZURES; BURN PREVENTION; HEAD-INJURY; CHILDREN; REHABILITATION; PREDICTORS; DEATHS		Univ Washington, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		Rivara, FP (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359960, Seattle, WA 98104 USA.						AITKEN M, IN PRESS ARCH PHYS M; Asher K N, 1995, Inj Prev, V1, P228, DOI 10.1136/ip.1.4.228; BERNARD AR, 1994, STUDY LOUISIANAS REC; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DESAI M H, 1991, Journal of Burn Care and Rehabilitation, V12, P482, DOI 10.1097/00004630-199109000-00016; DIEKEMA DS, 1993, PEDIATRICS, V91, P612; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Ellis AA, 1997, PUBLIC HEALTH REP, V112, P73; ERBAUGH SJ, 1986, PERCEPT MOTOR SKILL, V62, P439, DOI 10.2466/pms.1986.62.2.439; ERDMANN TC, 1991, PEDIATRICS, V88, P572; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FELDMAN KW, 1978, PEDIATRICS, V62, P1; Gean A D, 1995, New Horiz, V3, P549; Graham JD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e3; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; HEIMBACH D, 1992, WORLD J SURG, V16, P10, DOI 10.1007/BF02067108; HERRSTEDT L, 1992, ACCIDENT ANAL PREV, V24, P3, DOI 10.1016/0001-4575(92)90067-S; *I MED, 1998, INJ CONTR; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JOHNSTON C, 1994, PEDIATRICS, V93, P960; Jonsson C E, 1997, Acta Chir Plast, V39, P3; Kann L, 1995, MMWR CDC Surveill Summ, V44, P1; Kellermann AL, 1996, NEW ENGL J MED, V335, P1438, DOI 10.1056/NEJM199611073351906; KLEINBERGER M, 1997, 41 ANN M ASS ADV AUT; Landgraf JM, 1996, CHILD HLTH QUESTIONN; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MCLOUGHLIN E, 1982, AM J PUBLIC HEALTH, V72, P241, DOI 10.2105/AJPH.72.3.241; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Morrow SE, 1996, J PEDIATR SURG, V31, P329, DOI 10.1016/S0022-3468(96)90732-0; *NAT CTR STAT AN, 1986, 806 DOT HS NAT CTR S; *NAT CTR STAT AN, 1997, 808 DOT HS NAT CTR S; *NAT HIGHW TRAFF S, 1997, TRAFF SAF FACTS 1996; *NAT RES COUNC, 1985, INJ AM; *NAT TRANSP SAF BO, 1996, SAF STUD PERF US CHI, V1; National Center for Health Statistics, 1997, HLTH PEOPL 2000 REV; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; PARTYKA SC, 1984, RESTRAINT USE FATALI; QUAN L, 1992, PEDIATRICS, V90, P909; Quan L, 1998, Inj Prev, V4, P203; Rauchschwalbe R, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e1; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; Rivara FP, 1996, PEDIATRICS, V97, P791; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, REV PREVENTION STRAT; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; Roberts I, 1996, BRIT MED J, V312, P29, DOI 10.1136/bmj.312.7022.29; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P209; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; SAFFLE JR, 1993, AM J SURG, V166, P581, DOI 10.1016/S0002-9610(05)80661-0; Schieber R A, 1996, Inj Prev, V2, P228, DOI 10.1136/ip.2.3.228; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Scholer SJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e12; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; *SOC AUT ENG, 1997, CHILD OCC PROT 2 S P; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spack L, 1997, PEDIATR EMERG CARE, V13, P98, DOI 10.1097/00006565-199704000-00004; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STARFIELD B, 1995, MED CARE, V33, P553, DOI 10.1097/00005650-199505000-00008; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON DC, 1998, COCHRANE LIB; Treser CD, 1997, J PUBLIC HEALTH POL, V18, P346, DOI 10.2307/3343315; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WILLIAMS AF, 1979, AM J PUBLIC HEALTH, V69, P455, DOI 10.2105/AJPH.69.5.455; WINTEMUTE GJ, 1990, AM J DIS CHILD, V144, P663, DOI 10.1001/archpedi.1990.02150300061018; Ytterstad B, 1998, Inj Prev, V4, P176; Zeitlin REK, 1998, BURNS, V24, P3, DOI 10.1016/S0305-4179(97)00052-1; Zuckerman GB, 1998, ARCH PEDIAT ADOL MED, V152, P134; 1993, MMWR, V42, P681	75	41	42	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	1999	103	4		S			883	888					6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	183YW	WOS:000079583400008	10103326				2022-02-06	
J	Farooque, M; Isaksson, J; Olsson, Y				Farooque, M; Isaksson, J; Olsson, Y			Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice	NEUROREPORT			English	Article						ICAM-1; knockout mice; mice; P-selectin; spinal cord injury	CEREBRAL-ARTERY OCCLUSION; INTERCELLULAR-ADHESION MOLECULE-1; SYSTEM ISCHEMIC-INJURY; BRAIN INJURY; NEUTROPHILS; RAT; PATHOGENESIS; ANTIBODY; STROKE; REDUCTION	TRAUMATIC spinal cord injury is followed by infiltration of leukocytes, influenced by endothelial adhesion molecules such as ICAM-1 and P-selectin. In order to evaluate the pathogenetical role of these molecules, wild-type mice and mice lacking ICAM-1 and P-selectin were subjected to an experimental spinal cord compression of two degrees of severity. Hind limb motor function decreased after injury in all animals but the groups of injured ICAM-1/P-selectin knockout animals had a better functional outcome during the entire observation period of 14 days. This difference was statistically significant on day 1. Our results indicate that adhesion molecules influence the functional outcome after spinal cord injury in a negative way and may be a target for future therapy of neurotrauma. (C) 1999 Lippincott Williams & Wilkins.	Univ Uppsala Hosp, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden		Farooque, M (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden.						BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; FAROOQUE M, UNPUB; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; ISAKSSON J, IN PRESS J NEUROTRAU; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, BRAIN RES, V799, P264, DOI 10.1016/S0006-8993(98)00459-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	21	41	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JAN 18	1999	10	1					131	134		10.1097/00001756-199901180-00024			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	179TW	WOS:000079346100027	10094148				2022-02-06	
J	Catroppa, C; Anderson, V; Stargatt, R				Catroppa, C; Anderson, V; Stargatt, R			A prospective analysis of the recovery of attention following pediatric head injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injury; children; attention; recovery	CHILDREN; DEFICITS	Little is known about specific attentional sequelae following a closed head injury, their pattern of recovery or their interaction with ongoing development. The present study examined attentional abilities in a group of children who had sustained a mild, moderate, or severe head injury. Results showed that the severe head injury group exhibited greater deficits on a number of attentional measures at acute and 6 months postinjury phases, in comparison to children in the mild and moderate head injury groups. Specifically, deficits were most evident on timed tasks where speed of processing was an integral component. Difficulties persisted to at least 6 months postinjury and so may lead to cumulative deficits over time.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.		Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, IN PRESS NEUROPSYCHO; BROUWER WH, 1988, ROAD USER BEHAV THEO, P296; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kraus JF, 1987, HEAD INJURY, V2, P1; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Talland G.A., 1965, DERANGED MEMORY; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WALSH KW, 1978, NEUORPSYCHOLOGY CLIN; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603; [No title captured]; [No title captured]	32	41	41	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	1999	5	1					48	57		10.1017/S1355617799511077			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	162BR	WOS:000078325800007	9989024				2022-02-06	
J	Doornhein, K; de Haan, EHF				Doornhein, K; de Haan, EHF			Cognitive training for memory deficits in stroke patients	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								This study was set up to evaluate the efficacy of a memory training programme in a group of stroke patients. Berg, Koning-Haanstra, and Deelman (1991) developed a training procedure which successfully improved the memory performance of a group of closed head injury patients. The training programme consists of six simple memory strategies, which are applied to daily memory problems that are selected with the patient. Two groups of stroke patients with demonstrable memory deficits were randomly assigned to the training programme or a non-specific training programme involving repetitive practice on memory tasks. After a four week training period retesting showed a significant improvement of the trained memory skills, but there was no improvement on control memory tasks. Subjective ratings of everyday memory functioning did not differ between the two groups.	Univ Utrecht, Psychol Lab, NL-3584 CS Utrecht, Netherlands					de Haan, Edward/0000-0003-0312-3674			Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; BERG IJ, 1993, MEMORY REHABILITATIO; De Renzi E., 1982, DISORDERS SPACE EXPL; DEHAAN RJ, 1995, STROKE, V26, P402, DOI 10.1161/01.STR.26.3.402; GLISKEY EL, 1994, COGNITIVE NEUROPSYCH, P528; MEYBOOMDEJONG B, 1995, ZORG BEROERTE; NEWCOMBE F, 1987, NEUROPSYCHOLOGIA, V25, P149, DOI 10.1016/0028-3932(87)90127-8; NEWCOMBE F, 1985, J CLIN EXP NEUROPSYC, V7, P663, DOI 10.1080/01688638508401290; Reinink ER, 1987, 8727 U GRON DEP NEUR; SAAN RJ, 1986, VIJFTIEN WOORDEN TES; SCOGIN F, 1988, PSYCHOL AGING, V3, P334, DOI 10.1037/0882-7974.3.4.334; Stewart FM, 1996, BRIT J CLIN PSYCHOL, V35, P369, DOI 10.1111/j.2044-8260.1996.tb01191.x; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; van Crevel H, 1991, Ned Tijdschr Geneeskd, V135, P2280; VENEMA JW, 1989, 8938 U GRON DEP NEUR; Verhage F, 1964, INTELLIGENTIE LEEFTI; Wade D T, 1986, Int Rehabil Med, V8, P60; WILSON B, 1982, CORTEX, V18, P580; WILSON BA, 1992, CLIN MANAGEMENT MEMO	19	41	42	1	13	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	1998	8	4					393	400		10.1080/713755579			8	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	133JR	WOS:000076683900002					2022-02-06	
J	Suchanek, B; Struppeck, H; Fahrig, T				Suchanek, B; Struppeck, H; Fahrig, T			The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						BAY x 3702; staurosporine; 5-HT1A receptor; apoptosis	PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; RAT-BRAIN; ALZHEIMERS-DISEASE; DNA FRAGMENTATION; INDUCTION; NEURONS; ANTAGONIST; WAY-100635; INHIBITORS	The 5-HT1A receptor agonist (-)-(R)-2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one1,1-dioxide monohydrochloride (BAY x 3702) was recently shown to have pronounced neuroprotective effects in rat models of cerebral ischemia and traumatic brain injury. In the present study we investigated the neuroprotective effects of BAY x 3702 in primary cultures of hippocampal and cortical neurons. Cell death was induced by 25 nM of the apoptosis inducing agent staurosporine and analyzed 24 h later by release of lactate dehydrogenase, formation of apoptotic bodies and DNA fragmentation. A significant neuroprotection was seen after pretreatment of the affected neurons with 50 pM to 1 mu M BAY x 3702. The effects of BAY x 3702 were completely blocked by the selective 5-HT1A receptor antagonist N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride) (WAY-100635). These results indicate that low concentrations of BAY x 3702 protect cortical as well as hippocampal neurons from apoptotic cell death via a 5-HT1A receptor mediated pathway. (C) 1998 Elsevier Science B.V. All rights reserved.	Bayer, CNS Res, Pharma Forschungszentrum, D-42096 Wuppertal, Germany		Suchanek, B (corresponding author), Bayer, CNS Res, Pharma Forschungszentrum, Aprather Weg, D-42096 Wuppertal, Germany.						Ahlemeyer B, 1997, BRAIN RES, V777, P179; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; BANERJEE P, 1996, SOC NEUR ABSTR; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIELENBERG GW, 1990, EUR J PHARMACOL, V183, P1953, DOI 10.1016/0014-2999(90)92302-Y; BODEGREUEL KM, 1990, STROKE, V21, P164; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; CHALMERS DT, 1991, BRAIN RES, V561, P51, DOI 10.1016/0006-8993(91)90748-K; CHOI DW, 1987, J NEUROSCI, V7, P357; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; CONTRERAS PC, 1992, LIFE SCI, V51, P1145, DOI 10.1016/0024-3205(92)90516-R; DAVIES MF, 1987, BRAIN RES, V423, P347, DOI 10.1016/0006-8993(87)90861-4; De Vry Jean, 1997, Drugs of the Future, V22, P341; DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1; DEVRY J, 1998, IN PRESS J PHARM EXP; DOWSON G, 1997, J NEUROCHEM, V68, P2363; FORSTER EA, 1995, EUR J PHARMACOL, V281, P81, DOI 10.1016/0014-2999(95)00234-C; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; HORVATH E, 1997, J NEUROTRAUMA, V14; HORVATH E, 1997, SOC NEUR ABSTR; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JARVIS WD, 1994, CANCER RES, V54, P1707; KHAWAJA X, 1995, J NEUROCHEM, V64, P2716; KRUMAN I, 1997, SOC NEUR ABSTR; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Nicotera P, 1997, CELL DEATH DIFFER, V4, P435, DOI 10.1038/sj.cdd.4400265; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Posmantur R, 1997, J NEUROCHEM, V68, P2328; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RINK A, 1995, AM J PATHOL, V147, P1575; Singh JK, 1996, J NEUROCHEM, V66, P2361; TAMARAT K, 1991, J PHYS IV, V1, P347, DOI 10.1051/jp4:1991452; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x	37	41	41	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 14	1998	355	1					95	101		10.1016/S0014-2999(98)00469-5			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	113VT	WOS:000075575100012	9754943				2022-02-06	
J	Max, JE; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ				Max, JE; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ			Oppositional defiant disorder symptomatology after traumatic brain injury: A prospective study	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							CHILDREN; RELIABILITY; SCALE	Our goal was to prospectively study the course of oppositional defiant disorder (ODD) symptomatology in children and adolescents in the first 2 years after traumatic brain injury (TBI). Fifty children aged 6 to 14, hospitalized after TBI, were assessed soon after TBI regarding injury severity; preinjury psychiatric, socioeconomic, family functioning, and family psychiatric history status; and neuroimaging was analyzed. ODD symptomatology in the first year after TBI was related to preinjury family function, social class, and preinjury ODD symptomatology. Increased severity of TBI predicted ODD symptomatology 2 years after injury. Change (from before TBI) in ODD symptomatology at 6, 12, and 24 months after TBI was influenced by socioeconomic status. Only at 2 years after injury was severity of injury a predictor of change in ODD symptomatology. The influence of psychosocial factors appears greater than severity of injury in accounting for ODD symptomatology and change in such symptomatology in the first but not the second year after TBI in children and adolescents. This appears related to persistence of new ODD symptomatology after more serious TBL.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Cedar Ctr, Cedar Rapids, IA USA; Yasugi Daiichi Hosp, Shimane, Japan; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH40856, MH31593] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH043271, P30MH043271, R37MH031593, R01MH031593, R01MH040856] Funding Source: NIH RePORTER		ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BLACK P, 1971, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EARLS F, 1994, CHILD ADOLESCENT PSY, P308; GOODMAN R, 1994, CHILD ADOLESCENT PSY, P172; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, BRAIN INJURY, V12, P41; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; TEASDALE G, 1974, LANCET, V2, P81	21	41	41	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1998	186	6					325	332		10.1097/00005053-199806000-00001			8	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	ZV640	WOS:000074326100001	9653415				2022-02-06	
J	Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS				Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS			Traumatic brain injury in children and adolescents: Psychiatric disorders at one year	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; RELIABILITY; DEPRESSION	Factors predictive of psychiatric outcome in the second 6 months following traumatic brain injury (TBI) in 43 children and adolescents were assessed prospectively. The outcome measure was the presence of a psychiatric disorder not present before the injury ("novel"). Out of six models tested, four were predictive of novel psychiatric disorder: preinjury family function, family psychiatric history, socioeconomic class/intellectual function, and behavior/adaptive function. Post hoc analyses suggested that preinjury family functioning measured by a structured interview was a significant predictive variable. Severity of injury, when reclassified as severe versus mild/moderate TBI, significantly predicted novel psychiatric disorders. These data suggest that some children, identifiable through clinical assessment, are at increased risk for psychiatric disorders following TBI.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Ciccetti D., 1984, VINELAND ADAPTIVE BE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Garmezy N, 1994, CHILD ADOLESCENT PSY, P191; HIERONYMUS AN, 1991, TESTS BASIC SKILLS F; HOLLINGSHEAD AB, 1975, 4 FATOR INDEX SOCIAL; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; *SPSS INC, 1993, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P281	20	41	41	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1998	10	3					290	297		10.1176/jnp.10.3.290			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	106GJ	WOS:000075121300004	9706536				2022-02-06	
J	van der Sluis, CK; Eisma, WH; Groothoff, JW; ten Duis, HJ				van der Sluis, CK; Eisma, WH; Groothoff, JW; ten Duis, HJ			Long-term physical, psychological and social consequences of severe injuries	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							TRAUMATIC BRAIN INJURY; HEAD-INJURY; FOLLOW-UP; RETURN; IMPAIRMENT; WORK; RECOVERY; SCALES; CARE	This 6 year follow-up study was designed to evaluate the long-term physical, psychological and social outcomes of severely injured patients (Injury Severity Score of greater than or equal to 16). Patients were treated at the University Hospital Groningen, the Netherlands, between January 1989 and December 1989. Outcomes were assessed using a postal questionnaire. After injury, the 55 respondents had predominantly complaints of the extremities, the spine and the head. Psychological complaints were present in 84 per cent of patients and mainly concerned Jr?fatigue, slowness and memory impairments. Despite these physical and psychological complaints, 74 per cent of patients were able to return to work and the majory succeeded in complying with job requirements. Injuries of the extremities and the spine were risk factors Jot failing to return to work. Social consequences were also reflected in broken marriages (6/22) and changes of leisure activities (45 per cent). Oil the basis of the impairments and disabilities revealed, we conclude that further improvement of the long-tern? outcomes of severely injured patients may be achieved by advancements in the treatment of injuries to the head, spine oi extremities, comprehensive psychological support and vocational rehabilitation. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Groningen Hosp, Dept Rehabil, NL-9700 RB Groningen, Netherlands		van der Sluis, CK (corresponding author), Univ Groningen Hosp, Dept Rehabil, POB 30001, NL-9700 RB Groningen, Netherlands.						*AM ASS AUT MED, 1985, ABBR INJ SCAL 1985 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; GORIS RJA, 1983, WORLD J SURG, V7, P12, DOI 10.1007/BF01655907; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; KIVIOJA AH, 1990, J TRAUMA, V30, P480, DOI 10.1097/00005373-199030040-00020; LARSSON TJ, 1995, SCAND J SOC MED, V23, P121, DOI 10.1177/140349489502300207; LAUWERS LF, 1986, INTENS CARE MED, V12, P296; LYLE DM, 1991, INT DISABILITY STUDI, V12, P113; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RIIPINEN M, 1994, SCAND J REHABIL MED, V26, P103; SCOTT J, 1979, ANN RHEUM DIS, V38, P560, DOI 10.1136/ard.38.6.560; SLUIS CK, 1995, J TRAUMA INJURY INFE, V38, P681; *STAT NETH, 1995, VAD HLTH STAT NETH 1; TATE DG, 1992, AM J PHYS MED REHAB, V71, P92, DOI 10.1097/00002060-199204000-00006; World Health Organization, 1980, INT CLASS IMP DIS HA	26	41	41	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	1998	29	4					281	285		10.1016/S0020-1383(97)00199-X			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	ZW532	WOS:000074420400007	9743748	Green Published			2022-02-06	
J	Gilkey, SJ; Ramadan, NM; Aurora, TK; Welch, KMA				Gilkey, SJ; Ramadan, NM; Aurora, TK; Welch, KMA			Cerebral blood flow in chronic posttraumatic headache	HEADACHE			English	Article						headache; closed head injury; cerebral blood flow	TRAUMATIC BRAIN INJURY; MANAGEMENT	Background and Purpose.-Headache is the most common neurologic symptom following minor closed head injury. There is often a lack of objective evidence supporting an organic basis of cerebral pathology in these cases. This pilot study considers the possibility of alterations in cerebral blood flow, indicating evidence of an organic disorder in posttraumatic headache. Methods.-Regional cerebral blood flow studies of 35 patients with chronic posttraumatic headache (PTH) (International Headache Society criteria), identified retrospectively from our cerebral blood flow data base, were compared with those of 49 nonheadache controls and 92 migraineurs (Ad Hoc Committee criteria). Regional cerebral blood flow (initial slope index method) was measured using the xenon Xe 133 inhalation technique. Results.-Compared to migraineurs and controls, and after adjusting for differences (analysis of covariance) in baseline variables such as blood pressure, hematocrit and Pco(2),, patients with PTH had: (1)significantly lower mean initial slope indices (P<0.001, P=0.002, respectively); (2) regional interhemispheric flow differences (rIFD), with higher distribution of regional asymmetrical probe pairs (rIFD greater than or equal to 7%: P[PTH versus control]=0.006, P[PTH versus migraine]=0.016; rIFD greater than or equal to 10%: P[PTH versus control]=0.011, P[PTH versus migraine]=0.003); and (3) more hemispheric asymmetries (P[PTH versus control]=0.023. P[PTH versus migraine]=0.57). Lower mean initial slope indices and hemispheric asymmetry (mean interhemispheric flow difference greater than or equal to 3.2%) predicted PTH over control (P=0.023 and 0.002, respectively). Lower mean initial slope indices predicted PTH over migraine (P=0.002). Conclusions.-Patients with PTH have reduced regional cerebral blood flow, and regional and hemispheric asymmetries. These cerebral hemodynamic alterations support an organic basis to chronic posttraumatic headache.	HENRY FORD HOSP & HLTH SCI CTR, DEPT NEUROL, HEADACHE CTR, DETROIT, MI USA								Ad Hoc Committee on Classification of Headache of the National Institute of Neurological Diseases and Blindness, 1962, ARCH NEUROL-CHICAGO, V6, P173, DOI DOI 10.1001/ARCHNEUR.1962.00450210001001; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; APPENZELLER O, 1987, WOLFFS HEADACHE OTHE, P289; Bailey B. N., 1989, TXB HEAD INJURY, P308; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARTLIDGE NEF, 1981, INJURY, P95; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Haas David C., 1993, P629; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; LANGFITT TW, 1982, CLIN NEUR, V29, P353; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Northfield DWC, 1938, BRAIN, V61, P133, DOI 10.1093/brain/61.2.133; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1975, HEAD INJURIES, P11; Pickering GW, 1933, CLIN SCI, V1, P77; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAMADAN NM, 1994, STROKE, V25, P1219, DOI 10.1161/01.STR.25.6.1219; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; TAYLOR AR, 1966, LANCET, V2, P178; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67	27	41	43	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	OCT	1997	37	9					583	587		10.1046/j.1526-4610.1997.3709583.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YF401	WOS:A1997YF40100009	9385758				2022-02-06	
J	Masson, F; Vecsey, J; Salmi, LR; Dartigues, JF; Erny, P; Maurette, P				Masson, F; Vecsey, J; Salmi, LR; Dartigues, JF; Erny, P; Maurette, P			Disability and handicap 5 years after a head injury: A population-based study	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						epidemiology; head injury; long-term outcome; incidence; disability; handicap	TRAUMATIC BRAIN INJURY; IMPAIRMENT; RECOVERY; COMA; MORTALITY; RELATIVES; SEVERITY; COUNTY	A population-based cohort of 407 head trauma patients has been studied since 1986 to estimate the prevalence of long-term disabilities and handicaps by means of a structured questionnaire. Five years later, 64 patients were deceased and 36 were lost to follow-up. Prevalence of subjective and behavioral complaints was high whatever the initial head trauma severity. Lethality in severe head injuries was 56%, and half of the survivors remained disabled. In minor and moderate head injured patients, most disabilities were related to extracranial injuries. Taking all disabilities into consideration, each Bear 24 per 100,000 patients of such a population are likely to suffer from at least one long-lasting disability, including 10 per 100,000 whose disabilities are due to extracranial injuries. Head injuries induce long lasting handicap in 9 per 100,000 habitants which is severe in 2 per 100,000. These figures point to the need of reinforcing preventive actions and long-term care of these patients. (C) 1997 Elsevier Science Inc.	HOP PELLEGRIN, DEPT ANESTHESIE REANIMAT 1, F-33076 BORDEAUX, FRANCE; HOP PELLEGRIN, SERV READAPTAT FONCT, F-33076 BORDEAUX, FRANCE; UNIV BORDEAUX 2, INSERM U330, DEPT EPIDEMIOL & INFORMAT MED, F-33076 BORDEAUX, FRANCE				DARTIGUES, Jean Francois/T-4513-2019; Salmi, Louis-Rachid/T-1982-2019				ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annoni J M, 1992, Disabil Rehabil, V14, P23; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; COLLE MB, 1990, MORTALITE CAUSES DEC; *COMM INJ SCAL, 1980, ABBR INJ SCAL AIS 19; Commission for Racial Equality, 1985, INJ AM CONT PUBL HLT, P1; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; HOOK O, 1988, SCAND J REHABIL MED, P65; JENNETT B, 1975, LANCET, V1, P480; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MAURETTE P, 1992, J TRAUMA, V33, P728, DOI 10.1097/00005373-199211000-00023; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SLEET DA, 1987, J TRAUMA, V27, P695, DOI 10.1097/00005373-198707000-00001; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; TRUELLE JL, 1992, SCAND J REHABIL MED, P115; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; World Health Organization, 1980, INT CLASS IMP DIS HA	38	41	41	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	1997	50	5					595	601		10.1016/S0895-4356(97)00012-7			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	XD004	WOS:A1997XD00400011	9180652				2022-02-06	
J	Freed, S; Hellerstein, LF				Freed, S; Hellerstein, LF			Visual electrodiagnostic findings in mild traumatic brain injury	BRAIN INJURY			English	Article							PATTERN REVERSAL; HEAD TRAUMA; WHIPLASH	Patients with traumatic brain injury (TBI) frequently exhibit varied forms of visual system dysfunction including: binocular, oculomotor, accommodative, refractive error shift, visual field loss, and visual perceptual deficits. A 5-year collaborative study between optometry and ophthalmology was initiated to follow documented mild TBI patients utilizing diagnostic methods to assess the quantity and quality of visual system deficits and recovery. A group of patients with mild TBI receiving optometric rehabilitation were compared with a group of age-matched, gender-matched, and headsize-matched TBI patients not receiving such treatment. Eighteen patients diagnosed with mild TBI underwent a treatment regimen of optometric rehabilitation (group I); 32 patients diagnosed with mild TBI did not receive optometric rehabilitation (group II). Pattern visually evoked cortical potential (VECP) testing and electroretinography (ERG) evaluation were utilized initially, repeated 6-12 months later and then 12-18 months after baseline. All TBI patients' VECP and ERG results were compared to age-matched headsize-matched controls. Once the ERG had been used to exclude retinal involvement, identification of visual pathway dysfunction was possible with the VECP. Full-field ERG results in all groups were not remarkable and not sensitive for patients with mild TBI. Initial testing results revealed that 72% of those TBI patients in group I demonstrated VECP waveform abnormalities and 81% of those patients in group II showed waveform dysfunction. In the testing performed 12-18 months later, 38% of group I TBI patients, after receiving a treatment regimen of optometric rehabilitation, showed VECP waveform abnormalities; 78% of group II TBI patients demonstrated waveform abnormalities. VECP evaluation in patients with mild TBI can provide a useful and reliable tool for objective assessment of visual system deficit and recovery. Significant differences in visual system recovery were shown when comparing group I and group II.	COLORADO EYE CTR OPHTHALMOL,PHYSIOL LAB,DENVER,CO; HOMESTEAD PK VIS CLIN PC,ENGLEWOOD,CO								Aksionoff E B, 1992, J Am Optom Assoc, V63, P554; *AM OPT ASS, 1991, DEF OPT VIS THER; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; BECK RW, 1985, AM ORTHOPTICS J, V35, P103; BERNE SA, J OPTOMETRY VISUAL D, V21, P13; BLUMHARDT LD, 1977, BRIT J OPHTHALMOL, V61, P454, DOI 10.1136/bjo.61.7.454; BURKE JP, 1992, GRAEF ARCH CLIN EXP, V230, P335, DOI 10.1007/BF00165941; Cohen A H, 1992, J Am Optom Assoc, V63, P530; COPENHAVER RM, 1964, INVEST OPHTH VISUAL, V3, P665; CREWS SJ, 1978, DOC OPHTHALMOL, V15, P13; FOWLER MS, 1991, BR ORTHOPTIC J, V48, P2; FRACO RF, 1989, BRIT J OPTOMETRY, V46, P40; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GIANUTSOS R, 1988, J VISION REHABILITAT, V2, P37; Hall A. V., 1982, CLIN APPLICATIONS EV, P1; HALLIDAY AM, 1980, EVOKED POTENTIAL, P282; HARDING GFA, 1991, PRINCIPLES PRACTICE, P35; Harrison RJ., 1987, BINO VIS, V2, P93; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HELLERSTEIN LF, 1994, J BEHAV OPTOMETRY, V5, P143; JEFFREYS DA, 1972, EXP BRAIN RES, V16, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KAY T, 1986, MINOR HEAD INJURY IN, P1; MARMOR MF, 1991, PRINCIPLES PRACTICE, P283; MAZOW ML, 1982, AM ORTHOPT J, V32, P31; NEETENS A, 1983, NEURO-OPHTHALMOLOGY, V3, P43, DOI 10.3109/01658108309009717; *NEUR REH ASS, 1992, DEF NEUR REH; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; PADULA WV, 1992, J OPTOM VIS DEV, V23, P4; PRATTJOHNSON JA, 1973, BRIT J OPHTHALMOL, V57, P347, DOI 10.1136/bjo.57.5.347; ROBINSON K, 1984, J NEUROL SCI, V64, P225, DOI 10.1016/0022-510X(84)90172-2; ROSENTHAL M, 1990, REHABILITATION ADULT, P351; RUBENSTEIN MP, 1980, INVESTIGATIVE OPHTHL, V19, P318; RUBENSTEIN MP, 1986, EXCERPTA MED INT C S, P464; SABETES NR, 1991, J CLIN NEUROOPHTHLAM, V11, P273; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; Tierney D W, 1988, J Am Optom Assoc, V59, P614; TOYANAGA N, 1986, DOC OPHTHALMOL, V63, P23; TYLER CW, 1981, VISION RES, V21, P607, DOI 10.1016/0042-6989(81)90109-7; Vogel M S, 1992, J Am Optom Assoc, V63, P542; WIESINGER H, 1962, Va Med Mon (1918), V89, P165; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	42	41	41	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1997	11	1					25	36		10.1080/026990597123782			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300003	9012549				2022-02-06	
J	Eldadah, BA; Yakovlev, AG; Faden, AI				Eldadah, BA; Yakovlev, AG; Faden, AI			A new approach for the electrophoretic detection of apoptosis	NUCLEIC ACIDS RESEARCH			English	Article							TRAUMATIC BRAIN INJURY; CEREBELLAR GRANULE NEURONS; CELL-DEATH; DNA FRAGMENTATION; RAT; ACTIVATION	Apoptotic cell death is often characterized by internucleosomal cleavage of genomic DNA, which exhibits a distinctive ladder upon electrophoresis. However, techniques used for the isolation and detection of DNA to demonstrate laddering may not be sufficiently sensitive, particularly when cleaved DNA is present at modest levels. We propose a new approach for isolating total cellular DNP, using a silica-based resin that improves the resolution of DNA laddering. In addition, we introduce a rapid DNA labeling method that can increase the sensitivity of detecting DNA laddering, Each of these methods can be used for DNA from cell cultures or tissues.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,GEORGETOWN INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007								Atabay C, 1996, J NEUROSCI RES, V43, P465; Beilharz Erica J., 1995, Molecular Brain Research, V29, P1, DOI 10.1016/0169-328X(94)00217-3; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; RINK A, 1995, AM J PATHOL, V147, P1575; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; WONG P, 1994, BIOCHEM CELL BIOL, V72, P649, DOI 10.1139/o94-085; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAKOVLEV AG, 1996, J NEUROTRAUM, V12, P767; YAN GM, 1995, J NEUROCHEM, V65, P2425	17	41	41	0	1	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0305-1048			NUCLEIC ACIDS RES	Nucleic Acids Res.	OCT 15	1996	24	20					4092	4093		10.1093/nar/24.20.4092			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP702	WOS:A1996VP70200031	8918817	Bronze, Green Published			2022-02-06	
J	Dywan, J; Segalowitz, SJ				Dywan, J; Segalowitz, SJ			Self- and family ratings of adaptive behavior after traumatic brain injury: Psychometric scores and frontally generated ERPs	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adaptive functioning; attention; Brock Adaptive Functioning Questionnaire; contingent negative variation; frontal lobe; sequelae; traumatic brain injury	HEAD-INJURY; PREFRONTAL CORTEX; PATIENT; LOBE; MONKEYS; TESTS; LIFE; CNV	Reported hem are self- and family ratings on five scales reflecting planning, initiation, attention/memory, arousal/inhibition, and social monitoring among survivors of traumatic brain injury (TBI). The contingent negative variation, a frontally generated electrophysiological response elicited during a simple attentional task, was strongly predictive of planning and initiation as described in everyday life. Most traditional psychometric measures were relatively poor predictors of adaptive behavior ratings. Results are consistent with hypothesized dissociations in executive functions and they support the growing appreciation that self- and family reports of adaptation in everyday life are essential in evaluating the behavioral sequelae of TBI.			Dywan, J (corresponding author), BROCK UNIV, DEPT PSYCHOL, ST CATHARINES, ON L2S 3A1, CANADA.						Benson D.F., 1986, FRONTAL LOBES; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROUWER W, 1990, TENNET MONTR PQ OCT; CASSIDY JW, 1994, NEUROPSYCHIATRY TRAU; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, V3; CHELUNE GJ, 1986, NEUROPSYCHOLOGY HDB; Cohen J., 1983, APPL MULTIPLE REGRES, V2nd ed.; Cummings J, 1985, CLIN NEUROPSYCHIATRY; Damasio A.R, 1991, FRONTAL LOBE FUNCTIO; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMASIO AR, 1994, DESCARTESERROR; Delis DC, 1987, CALIFORNIA VERBAL LE; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DYWAN J, 1993, BRAIN COGNITION, V21, P20, DOI 10.1006/brcg.1993.1002; DYWAN J, 1994, PSYCHOL AGING, V9, P568, DOI 10.1037/0882-7974.9.4.568; DYWAN J, 1995, INT NEUR SOC SEATT F; DYWAN J, 1992, MEMORY SOURCE MONITO; ENTON A, 1983, CONTRIBUTIONS NEUROP; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FUSTER JM, 1990, ANN NY ACAD SCI, V608, P318, DOI 10.1111/j.1749-6632.1990.tb48901.x; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GRAFMAN J, 1994, HDB NEUROPSYCHOLOGY, V9; HALL RE, 1977, J NEUROSURG, V46, P638, DOI 10.3171/jns.1977.46.5.0638; Hamster K., 1983, MULTILINGUAL APHASIA; HAYES RI, 1989, MILD HEAD INJURY; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; POSNER MI, 1988, CLIN NEUROPSYCHOL BR; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUCHKIN DS, 1986, ELECTROEN CLIN NEURO, V63, P445, DOI 10.1016/0013-4694(86)90127-6; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SEGALOWITZ SJ, 1992, DEV NEUROPSYCHOL, V8, P279, DOI 10.1080/87565649209540528; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SIEGEL LS, 1994, INT J BEHAV DEV, V17, P109, DOI 10.1177/016502549401700107; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Stuss D., 1991, AWARENESS DEFICIT BR, P63; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TRANEL D, 1994, NEUROPSYCHOLOGICAL A; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1974, WECHSLER INTELLIGENC; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILSON BA, 1995, INT NEUR SOC SEATT F; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; YAMAMOTO T, 1986, JAPANESE J EEG EMG, V14, P103	64	41	41	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					79	95		10.1097/00001199-199604000-00008			17	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400008					2022-02-06	
J	Mateer, CA; Mapou, RL				Mateer, CA; Mapou, RL			Understanding, evaluating, and managing attention disorders following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention; evaluation; neuropsychology; treatment	CLOSED-HEAD-INJURY; DEFICITS; PERFORMANCE; MARKERS; PROGRAM; DAMAGE	Disorders of attention are among the most frequently reported problems following traumatic brain injury (TBI). However, considerable disagreement exists regarding the most appropriate definitions and conceptualizations of attention. This article addresses several issues related to attentional disorders following TBI. First, we summarize the types of attentional impairments observed in TBI. Next, we describe several multicomponent models of attention. We discuss the merits and applicability of each model and suggest psychometric approaches to the assessment of attention based on these models. Finally, we summarize controversies and relevant research findings with regard to the rehabilitation of individuals with attentional disorders.	CTR NEUROREHABIL,BETHESDA,MD; GEORGETOWN UNIV,SCH MED,DEPT NEUROL PSYCHOL,WASHINGTON,DC		Mateer, CA (corresponding author), UNIV VICTORIA,DEPT PSYCHOL,POB 3050,VICTORIA,BC V8W 3P5,CANADA.		Mapou, Robert/AAC-9897-2021				AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Baribeau J, 1989, J NEUROL REHABIL, V3, P71; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R; BOHNEN NI, 1991, MILD HEAD INJURY POS; BROOKS N, 1984, CLOSED HEAD INJURY P; BUTTERS N, 1993, NEUROPSYCHOLOGY, V7, P3; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; DELAND N, 1992, BAYCR C ATT THEOR CL; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Diller L, 1974, REHABILITATION MONOG, V50; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; FORD JM, 1994, ELECTROEN CLIN NEURO, V90, P214, DOI 10.1016/0013-4694(94)90093-0; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1991, NEUROPSYCHOLOGY, V5, P235; Harris J E, 1981, Int Rehabil Med, V3, P206; Heaton RK, 1991, COMPREHENSIVE NORMS; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1994, NEUROPSYCHOLOGICAL A; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Mapou R. L., 1995, CLIN NEUROPSYCHOLOGI; Mateer C.A., 1990, COGNITIVE REHABILITA; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MATEER CA, 1995, WORKSH W REED ARM ME; MATEER CA, 1988, NEUROPSYCHOLOGICAL S; MATEER CA, 1992, REHABILITATION POST; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MIRSKY AF, 1995, CLIN NEUROPSYCHOLOGI; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POWELL GE, 1981, BRAIN FUNCTION THERA; RASKIN E, 1993, M AM COLL REH MED DE; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUSSELL EW, 1992, J CLIN PSYCHOL, V48, P530, DOI 10.1002/1097-4679(199207)48:4<530::AID-JCLP2270480415>3.0.CO;2-B; SCHMIDT M, 1994, ARCH CLIN NEUROPSYCH, V9, P383, DOI 10.1016/0887-6177(94)90002-7; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P531, DOI 10.1080/01688639408402664; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1993, ATTENTION PROCESS TR, V2; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STURM W, 1983, ARCH PSYCHIAT NERVEN, V233, P9, DOI 10.1007/BF00540034; STURM W, 1993, DEV ASSESSMENT REHAB; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI [DOI 10.1080/13854048708520046, 10.1080/13854048708520046]; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P1094; Wood R L, 1987, Int Disabil Stud, V9, P149; ZUBIN J, 1975, EXPT APPROACHES PSYC	71	41	44	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					1	16					16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400002					2022-02-06	
J	Porter, M; OBrien, M				Porter, M; OBrien, M			Incidence and severity of injuries resulting from amateur boxing in Ireland	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						injury incidence; amateur boxing; competition; training; cerebral injuries		Objective: To determine the incidence, pattern, and severity of injuries resulting from participation in amateur boxing. Design: A prospective 5-month survey of injuries which occurred during competitive amateur boxing and training. Setting: Amateur boxing competitions held in Dublin between November 1992 and March 1993, and the six largest amateur boxing clubs in Dublin. Participants: All the competitors in the tournaments and the >16 year old members of the boxing clubs. Interventions: Participation in competitive amateur bouts and/or boxing training. Main outcome measures: Incidence, pattern, and severity of injuries sustained in competition and training. Results: The incidence of injuries in competition was 0.92 injuries per man-hour of play (or 0.7 injuries per boxer per year), while the incidence in training was 0.69 injuries per boxer per year. Cerebral injuries were reported only in competition, most of these being mild concussion. Hand, wrist and facial injuries were related to direct impact and occurred more frequently in competition than training, while injuries to other body parts were predominantly chronic and training-associated. Shoulder and knee injuries were the most debilitating injuries seen. Conclusions: The yearly risk of injury resulting from participation in amateur boxing is relatively low when compared with other sports, Cerebral injuries, which occur almost exclusively in competition, are predominantly mild concussions.	TRINITY COLL DUBLIN,DEPT ANAT,DUBLIN,IRELAND		Porter, M (corresponding author), AUSTRALIAN INST SPORT,DEPT SPORTS MED,POB 176,BELCONNEN,ACT 2616,AUSTRALIA.						ENZENAUER RW, 1980, JAMA-J AM MED ASSOC, V261, P1463; ESTWANIK J, 1984, PHYSICIAN SPORTSMED, V12, P23; JORDAN B, 1990, PHYSICIAN SPORTSMED, V8, P81; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; SCHMIDTOLSEN S, 1990, AM J SPORT MED, V18, P98, DOI 10.1177/036354659001800117; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; WATSON AWA, 1993, INCIDENCE NATURE SPO; WELCH MJ, 1986, PHYSICIAN SPORTSMED, V14, P81, DOI 10.1080/00913847.1986.11709169; WELCH MJ, 1982, PHYSICIAN SPORTSMED, V10, P43	9	41	43	1	8	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	APR	1996	6	2					97	101		10.1097/00042752-199604000-00006			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	UC180	WOS:A1996UC18000006	8673583				2022-02-06	
J	Mattioli, F; Grassi, F; Perani, D; Cappa, SF; Miozzo, A; Fazio, F				Mattioli, F; Grassi, F; Perani, D; Cappa, SF; Miozzo, A; Fazio, F			Persistent post-traumatic retrograde amnesia: A neuropsychological and (18F)FDG PET study	CORTEX			English	Article							MAGNETIC-RESONANCE; MEMORY; HIPPOCAMPUS; IMPAIRMENT; ACTIVATION; DEFICIT; HUMANS; BRAIN	We report the case of a 48-year old woman who, after a severe closed head injury, developed a severe and persistent disruption of retrograde memory, associated with a mild impairment of learning abilities. The patient's dense amnesia spared only the childhood period and included both explicit memory (autobiographical and semantic) and procedural skills. Because of her partially spared learning ability and intact language, intensive training by family members resulted in the reacquisition and retention of many autobiographical events and of some skills she had lost after the accident. Brain CT scan and MRI were normal; a PET study with (18F)FDG revealed a significant bilateral reduction of metabolism in the hippocampus and anterior cingulate cortex, suggesting a role for these structures in memory for past events.	UNIV BRESCIA,NEUROL CLIN,I-25125 BRESCIA,ITALY; UNIV MILAN,IST SCI SAN RAFFAELE,MILAN,ITALY; UNIV MILAN,IST NEUROSCI & BIOIMMAGINI,CNR,MILAN,ITALY; UNIV MILAN,DIPARTIMENTO MED NUCL,MILAN,ITALY				Perani, Daniela/AAN-3221-2020; Cappa, Stefano/B-1874-2014	Cappa, Stefano/0000-0003-1003-3925			ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; ANDREWS E, 1982, CORTEX, V18, P441, DOI 10.1016/S0010-9452(82)80041-5; BETTINARDI V, 1991, J COMPUT ASSIST TOMO, V15, P886, DOI 10.1097/00004728-199109000-00034; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; Costa M, 1989, ARCH PSICOLOGIA NEUR, V50, P735; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; FAZIO F, 1992, J CEREBR BLOOD F MET, V12, P353, DOI 10.1038/jcbfm.1992.52; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KAPUR N, 1988, MEMORY DISORDERS CLI; Kopelman M.D., 1993, HDB NEUROPSYCHOLOGY, P215; KOPELMAN MD, 1991, BRAIN, V114, P117; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MARIANI C, 1991, J NEUROL, V238, P395, DOI 10.1007/BF00319859; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; MAYES AR, 1991, CURR OPIN NEUROL NEU, V4, P115; PERANI D, 1993, BRAIN, V116, P903, DOI 10.1093/brain/116.4.903; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; SCHACTER DL, 1989, HDB NEUROPSYCHOLOGY, V3, P209; SCHACTER DL, 1989, FDN COGNITIVE SCI; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI DOI 10.1017/CBO9780511665547.003; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spinnler H., 1987, ITAL J NEUROL SCI, VS8, P6; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Talairach J., 1988, COPLANAR STEREOTAXIC; Tulving E., 1972, ORG MEMORY; VONCRAMON DY, 1985, BRAIN, V108, P993, DOI 10.1093/brain/108.4.993; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	35	41	41	0	2	MASSON DIVISIONE PERIODICI	MILAN	VIA STATUTO 2/4, 20121 MILAN, ITALY	0010-9452			CORTEX	Cortex	MAR	1996	32	1					121	129		10.1016/S0010-9452(96)80021-9			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	UB975	WOS:A1996UB97500008	8697743				2022-02-06	
J	Meythaler, JM; DeVivo, MJ; Hayne, JB				Meythaler, JM; DeVivo, MJ; Hayne, JB			Cost-effectiveness of routine screening for proximal deep venous thrombosis in acquired brain injury patients admitted to rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TOTAL HIP-REPLACEMENT; VEIN-THROMBOSIS; COMPRESSION ULTRASONOGRAPHY; IMPEDANCE PLETHYSMOGRAPHY; PNEUMATIC COMPRESSION; COLORECTAL-CANCER; THROMBOEMBOLISM; PREVENTION; SURGERY; PROPHYLAXIS	Objective: Determine the prevalence of proximal deep venous thrombosis (DVT) among acquired brain injury patients on admission to rehabilitation and assess cost-effectiveness of routine ultrasound screening for proximal DVT in those patients. Design: Prospective study, sequential case series. Setting: University tertiary care rehabilitation center. Data Set: One hundred sixteen traumatic brain injury patients (TBI) and 48 nontraumatic brain injury patients were admitted to our brain injury (BI) unit over a 21-month period and screened for a DVT on admission to rehabilitation utilizing real time, spectral Doppler, and color Doppler ultrasound, Patients with a previous clinically recognized and treated DVT were excluded. No patients had been treated with prophylactic anticoagulation or intermittent anticoagulation since their BI and all patients were within 4 months of the original injury, Results: Fourteen patients in total (8.5%) were found to have a DVT in the thigh or popliteal area, 9 of the 116 patients in the TBI group (7.8%), and 5 of the 48 patients in the nontraumatic BI group (10.4%). Statistically, there was no significant difference in the total number of detected proximal lower extremity DVTs between the TBI and the nontraumatic BI groups (Fisher's exact test). In the TBI group 22 patients had associated lower extremity or pelvic fractures, but this factor appeared not to be significant, because only 1 of the 22 patients was discovered to have a DVT. The average admission Glascow Coma Score (GCS) of the TBI group was 8.6 but there was no correlation with the GCS and the prevalence of DVT. The additional cost of screening for and treating the additional DVTs utilizing color Doppler ultrasound is conservatively estimated to be $674.84 per patient admitted to the BI rehabilitation unit. It can be estimated the cost of saving one life is $129,527.83. Conclusion: DVT screening in this patient population appears to be more cost-effective than mass screening programs for either breast cancer or colorectal cancer. The cost per year of life saved, estimated at only $2,977.65 ($129,527.83/43.5 years) for DVT screening for brain injury patients on admission to rehabilitation, is lower than those costs proposed for comparable programs with significant social support. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation			Meythaler, JM (corresponding author), UNIV ALABAMA,CTR SPAIN REHABIL,SCH MED,DEPT REHABIL MED,1717 6TH AVE S,,BIRMINGHAM,AL 35233, USA.						BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; BRANDSTATER ME, 1992, ARCH PHYS MED REHAB, V73, pS379; BURKE AM, 1979, SURG GYNECOL OBSTET, V148, P9; BYERS T, 1992, CANCER, V70, P1288, DOI 10.1002/1097-0142(19920901)70:3+<1288::AID-CNCR2820701515>3.0.CO;2-1; COON WW, 1984, CLIN CHEST MED, V5, P391; FERREE BA, 1993, SPINE, V18, P315, DOI 10.1097/00007632-199303000-00001; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GELMERS HJ, 1980, ACTA NEUROL SCAND, V61, P517; GITEL SN, 1979, J BONE JOINT SURG AM, V61, P653, DOI 10.2106/00004623-197961050-00002; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; GREENFIELD LJ, 1988, SURGERY, V104, P706; GRUMBACH K, 1994, JAMA-J AM MED ASSOC, V272, P1458, DOI 10.1001/jama.272.18.1458; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KONTOS HA, CECIL TXB MED, P355; LACHMANN EA, 1992, ARCH PHYS MED REHAB, V73, P482; Lamb G C, 1993, J Am Paraplegia Soc, V16, P153; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; OUDKERK M, 1993, ARCH INTERN MED, V153, P947, DOI 10.1001/archinte.153.8.947; PEDERSEN OM, 1991, ARCH INTERN MED, V151, P2217, DOI 10.1001/archinte.151.11.2217; ROSBERG B, 1981, ANN CLIN RES, V13, P84; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SASAHARA AA, 1979, AM J CARDIOL, V43, P1214, DOI 10.1016/0002-9149(79)90156-5; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1969, THROMBOSIS, P29; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; STEINBERG DP, 1993, ARCH PHYS MED REHAB, V64, P1243; TEASDALE G, 1974, LANCET, V2, P81; VERSTRAETE M, 1993, NEW ENGL J MED, V329, P1418, DOI 10.1056/NEJM199311043291911; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921; 1994, VITAL STATISTICS U A, V2; 1986, JAMA-J AM MED ASSOC, V256, P744	38	41	41	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					1	5		10.1016/S0003-9993(96)90210-5			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200001	8554463				2022-02-06	
J	SCHLAGETER, K; GRAY, B; HALL, K; SHAW, R; SAMMET, R				SCHLAGETER, K; GRAY, B; HALL, K; SHAW, R; SAMMET, R			INCIDENCE AND TREATMENT OF VISUAL DYSFUNCTION IN TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article								The incidence of visual dysfunction and effectiveness of visual exercises in acute traumatically brain injured inpatients in a rehabilitation programme were studied. Vision evaluation norms were established on 23 hospital staff. The evaluation was then administered to 51 inpatients within days after admission. An additional 21 patients were unable to participate, usually due to decreased cognition or agitation. Thirty of 51 (59%) scored impaired in one or more of the following: pursuits, saccades, ocular posturing, stereopsis, extra-ocular movements, and near/far eso-exotropia. For patients having dysfunction in pursuits or saccades, a 2-week baseline was followed by vision exercises. During the baseline interval patients were evaluated by an optometrist to verify therapists' findings. Six patients who participated in several weeks of treatment were evaluated at 2-week intervals by an independent rater. Progress is graphically illustrated. Conclusions were that the suitability of an inpatient vision programme, from our experience, is questionable. However, an initial evaluation proved valuable for informing staff of patients' visual status and for referral to an optometrist/ophthalmologist for further treatment.	SANTA CLARA VALLEY MED CTR,751 S BASCOM AVE,SAN JOSE,CA 95128								BECKER J, 1987, ARCH PHYSICAL M 1001; BERNE SA, 1990, J OPTOM VIS DEV, V21, P13; BOUSKA MJ, 1988, OCCUPATIONAL THERAPY, V69, P573; Cohen A H, 1978, J Am Optom Assoc, V49, P831; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; ELSTON JS, 1984, BRIT J OPHTHALMOL, V68, P538, DOI 10.1136/bjo.68.8.538; HALL KM, 1992, NEUROREHABILITATION, V2, P97; Harrison RJ., 1987, BINO VIS, V2, P93; KADET TS, 1987, 6TH NAT HEAD INJ F A; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; MITCHELL R, 1983, AUST ORTHOP J, V20, P31; NEGER RE, 1989, J HEAD TRAUMA REHAB, V4, P27; PADULA WV, 1988, POSTTRAUMA VISION SY, P167; PADULA WV, 1988, N ENGL J OPTOM   DEC, P16; Roca P D, 1972, Ann Ophthalmol, V4, P63; Tierney D W, 1988, J Am Optom Assoc, V59, P614; UZZELL BP, 1988, ARCH NEUROL-CHICAGO, V45, P420, DOI 10.1001/archneur.1988.00520280066017	18	41	41	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP-OCT	1993	7	5					439	448		10.3109/02699059309029687			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	MA172	WOS:A1993MA17200007	8401486				2022-02-06	
J	GORMAN, LK; SHOOK, BL; BECKER, DP				GORMAN, LK; SHOOK, BL; BECKER, DP			TRAUMATIC BRAIN INJURY PRODUCES IMPAIRMENTS IN LONG-TERM AND RECENT MEMORY	BRAIN RESEARCH			English	Article						LONG-TERM MEMORY; RECENT MEMORY; TRAUMATIC BRAIN INJURY; POSTTRAUMATIC AMNESIA; ANTEROGRADE AMNESIA; RETROGRADE AMNESIA	FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; RAT	Traumatic brain injury (TBI) in humans typically produces neurological suppression and a longer lasting impairment of memory clinically defined as post-traumatic amnesia. An animal model that reliably reproduces the physiological changes associated with TBI was used to assess the memory deficits following brain injury. Prior to TBI, rats were trained to perform one of four tasks that assessed either motor performance, long-term or recent memory. Rats were randomly assigned to one of three groups (anesthesia only, sham operation or fluid percussion). Following fluid percussion, used to produce TBI, rats were tested for 6 test sessions. The first session occurred 1-2 min after the experimental manipulation. The next 5 sessions followed the training schedule maintained prior to experimental manipulation. Differences in long-term memory occurred only in the first post-operative test session. Differences in recent memory performance were found across all 6 test sessions. The memory deficits were clearly dissociated from motor deficits. The similar memory deficits observed following human head injury and the experimentally produced TBI injury demonstrate that fluid percussion is a useful approach to examine underlying neurobiological mechanisms involved in head injury and possible clinical interventions.	UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV NEUROSURG,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024								BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNETT SB, 1985, PSYCHOPHARMACOLOGY, V87, P357, DOI 10.1007/BF00432721; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; GENARELLI TA, 1985, CENTRAL NERVOUS SYST, P391; GENARELLI TA, 1982, ANN NEUROL, V12, P564; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; OLTON DS, 1977, SCI AM, V236, P82, DOI 10.1038/scientificamerican0677-82; OLTON DS, 1979, NEUROBIOLOGY HIPPOCA, P355; OLTON DS, 1979, BEH BRIAN SCI, V2, P353; OMMAYA A K, 1971, International Journal of Neuroscience, V1, P371, DOI 10.3109/00207457109146986; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; ROSENER MJ, 1983, INTRACRANIAL PRESSUR, P301; Russell WR, 1935, LANCET, V2, P762; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Squire L. R., 1984, NEUROBIOLOGY LEARNIN, P3; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WILKINS RH, 1985, NEUROSURGERY, P34; [No title captured]	30	41	43	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	1993	614	1-2					29	36		10.1016/0006-8993(93)91014-J			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LJ044	WOS:A1993LJ04400005	8348320				2022-02-06	
J	SUNDERLAND, PM; HEILBRUN, MP				SUNDERLAND, PM; HEILBRUN, MP			ESTIMATING ENERGY-EXPENDITURE IN TRAUMATIC BRAIN INJURY - COMPARISON OF INDIRECT CALORIMETRY WITH PREDICTIVE FORMULAS	NEUROSURGERY			English	Article						ENTERAL NUTRITION; INDIRECT CALORIMETRY; MEASURED ENERGY EXPENDITURE; NUTRITIONAL REQUIREMENTS; PARENTERAL NUTRITION; PREDICTED ENERGY EXPENDITURE; TRAUMATIC BRAIN INJURY	TOTAL PARENTERAL-NUTRITION; SEVERE HEAD-INJURY; METABOLIC RESPONSE; GAS-EXCHANGE; PATIENT; COMA	A HIGH DEGREE of variability in energy expenditure has characterized the metabolic response to traumatic brain injury. A goal of parenteral or enteral repletion in this population is the precise estimation of caloric requirement to avoid complications associated with overfeeding and underfeeding. The first aim of this study was to evaluate three predictive formulas for comparison to measured energy expenditure (MEE) derived from indirect calorimetry in patients with traumatic brain injury. A total of 385 measurements were obtained in 102 patients and were compared concurrently with these predictive formulas. The best predictive method in this phase (bivariate regression) yielded r = 0.39 and P < 0.001 (231 repeated measures). This best prediction, when compared with MEE, however, was able to capture values within 75 to 125% of MEE in only 56% of measurements. The two remaining formulas yielded r = 0.38 (P < 0.001) and r = 0.23 (P < 0.001) in 386 and 267 repeated measures, respectively. The second aim of this study was to evaluate the ability of additional nutritional markers to improve predictive ability. Regression analyses were performed on nutritional markers including indices of severity of injury, concurrent drug therapy, vital signs, neurological status, gluconeogenesis, protein synthesis/excretion, and immune response. The statistical results of the analysis on these multiple nutritional markers showed only heart rate, temperature, and number of days elapsed after injury to be significant predictors of MEE by indirect calorimetry in multiple regression analyses (R = 0.32; P < 0.001). These data suggest clinically significant discrepancies between MEE and these predictive formulas. Further regression analyses with additional variables did not result in substantially improved prediction. The ability to decipher the meaning of specific metabolic indicators and to make reasonable clinical decisions as to specific caloric supplementation may be tenuous when estimating energy expenditure with predictive formulas. The routine use of indirect calorimetry to guide caloric supplementation in patients with traumatic brain injury is warranted.			SUNDERLAND, PM (corresponding author), UNIV UTAH,SCH MED,DIV NEUROSURG,RM 3B409,50 N MED DRIVE,SALT LAKE CITY,UT 84132, USA.						BLACKBURN GL, 1989, NUTRITIONAL MED CASE, P2175; CAMPBELL SM, 1988, JPEN-PARENTER ENTER, V12, P610, DOI 10.1177/0148607188012006610; CERRA FB, 1982, CATABOLIC PHASE, P29; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; FLEMING CR, 1988, NUTR METAB, P752; HAUSMANN D, 1985, INTENS CARE MED, V11, P80; JEEJEEBHOY KN, 1988, NUTR METAB, P60; KINNEY JM, 1988, NUTR METAB, P656; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Konstantinidis N. N., 1984, NUTR SUPPORT SERV, V4, P41; MAKK LJK, 1990, CRIT CARE MED, V18, P1320, DOI 10.1097/00003246-199012000-00003; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; NORUSIS MJ, 1988, STATISTICAL PACKAGE; Ott L, 1990, Nutr Clin Pract, V5, P68, DOI 10.1177/011542659000500268; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; SAX HC, 1988, JPEN-PARENTER ENTER, V12, P615, DOI 10.1177/0148607188012006615; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TWYMAN DL, 1989, NUTRITIONAL MED CASE, P10; WESTENSKOW DR, 1984, CRIT CARE MED, V12, P183, DOI 10.1097/00003246-198403000-00006; WESTENSKOW DR, 1988, JPEN-PARENTER ENTER, V12, P20, DOI 10.1177/014860718801200120; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; 1989, STATISTICS GUIDE SPS, pB20; [No title captured]	32	41	41	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1992	31	2					246	253		10.1227/00006123-199208000-00009			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	JJ520	WOS:A1992JJ52000009	1513430				2022-02-06	
J	HEINZE, HJ; MUNTE, TF; GOBIET, W; NIEMANN, H; RUFF, RM				HEINZE, HJ; MUNTE, TF; GOBIET, W; NIEMANN, H; RUFF, RM			PARALLEL AND SERIAL VISUAL-SEARCH AFTER CLOSED HEAD-INJURY - ELECTROPHYSIOLOGICAL EVIDENCE FOR PERCEPTUAL DYSFUNCTIONS	NEUROPSYCHOLOGIA			English	Article							EVENT-RELATED POTENTIALS; BILATERAL STIMULUS ARRAYS; INDEX FOCUSED ATTENTION; MILD	Event-related potentials (ERPs) were recorded from closed head injury (CHI) patients at least 2 years postinjury and from controls in order to assess their parallel and serial processing abilities during visual search. In Experiment 1, stimuli consisted of arrays of eight triangles; half of the arrays contained a target item. In the "feature-present" condition, the target item was a triangle with an additional horizontal line that could be detected automatically and in parallel, while in the "feature-absent" condition all items except for the target triangle had an additional horizontal line, thus requiring a serial search. In Experiment 2, stimuli consisted of eight solid bars (50%), seven solid bars and a vertical open bar (25%), and seven solid bars and a horizontal open bar (25%): the array containing the horizontal bar served as a target. By recording ERPs to the arrays containing vertical open bars, which were similar to the target items, parallel processing of "pop-out" stimuli could be studied in the absence of any overt response. ERP data were compared with the results of neuropsychological and neuroimaging (MRI, CAT) examination. Patient exhibited a decreased behavioral performance both in the parallel and in the serial processing mode. Furthermore, abnormalities of early and intermediate ERP components (P1, N1, P2, N2) were found, whereas the late component (P3) was less affected by CHI. The results were interpreted as an index of CHI-induced dysfunctions in perceptual processes such as simple feature registration and early target discrimination. It was suggested that these dysfunctions contribute to impairments of parallel as well as serial processes in visual search.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; NEUROL KLIN HESS OLDENDORF,OLDENDORF,GERMANY; EPILEPSIEZENTRUM BETHEL,BETHEL,GERMANY		HEINZE, HJ (corresponding author), MED SCH HANNOVER,DEPT NEUROL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY.		Munte, Thomas/C-2077-2014				ABT K, 1987, METHOD INFORM MED, V26, P77; ABT K, 1983, NEUROPSYCHOBIOLOGY, V9, P47, DOI 10.1159/000117937; BENYISHAI Y, 1987, NEUROPSYCHOLOGICAL R; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CAMPBELL K, 1986, EEG S, V38; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Donchin E., 1986, PSYCHOPHYSIOL SYST P, P244; Duncan J., 1985, ATTENTION PERFORMANC, P85; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HARTER MR, 1984, VARIETIES ATTENTION, P292; HEINZE HJ, 1990, ELECTROEN CLIN NEURO, V75, P511, DOI 10.1016/0013-4694(90)90138-A; HILLYARD SA, 1990, MACHINERY OF THE MIND, P186; JULESZ B, 1984, DYNAMIC ASPECTS NEOC, P120; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LUCK S J, 1988, Society for Neuroscience Abstracts, V14, P1013; LUCK SJ, 1990, PERCEPT PSYCHOPHYS, V48, P603, DOI 10.3758/BF03211606; LUCK SJ, 1990, ELECTROEN CLIN NEURO, V75, P528, DOI 10.1016/0013-4694(90)90139-B; Marr D., 1982, VISION COMPUTATIONAL, P428; MCCALLUM WC, 1973, ELECTROEN CLIN NEURO, V35, P449, DOI 10.1016/0013-4694(73)90020-5; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; Plum F., 1987, HDB PHYSL 1 NERVOUS, V5, P519; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; RUFF RM, 1986, SAN DIEGO NEUROPSYCH; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schneider W., 1984, VARIETIES ATTENTION, P1; Tewes U., 1991, HAMBURG WECHSLER INT, V2nd; TREISMAN A, 1985, J EXP PSYCHOL GEN, V114, P285, DOI 10.1037/0096-3445.114.3.285; TREISMAN A, 1985, COMPUT VISION GRAPH, V31, P156, DOI 10.1016/S0734-189X(85)80004-9; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Trites R. L., 1977, NEUROPSYCHOLOGICAL T; ULLMAN S, 1984, COGNITION, V18, P97, DOI 10.1016/0010-0277(84)90023-4; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZOMEREN AHV, 1987, NEUROBEHAVIORAL RECO, P398	40	41	41	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUN	1992	30	6					495	514		10.1016/0028-3932(92)90054-P			20	Behavioral Sciences; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	JC958	WOS:A1992JC95800001	1641115				2022-02-06	
J	RUDY, EB; TURNER, BS; BAUN, M; STONE, KS; BRUCIA, J				RUDY, EB; TURNER, BS; BAUN, M; STONE, KS; BRUCIA, J			ENDOTRACHEAL SUCTIONING IN ADULTS WITH HEAD-INJURY	HEART & LUNG			English	Article								The purpose of this study was to determine the method of endotracheal suctioning (ETS) that resulted in the least compromise to the cerebrovascular status of adult patients with severe head injuries. A two-group (two vs three ETS), two-protocol (100% tidal volume [VT] vs 135% VT) design was used. The dependent variables were mean intracranial pressure (MICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), heart rate (HR), and oxygen saturation (SaO2). By random assignment, 14 subjects were in the two-ETS group and 16 subjects were in the three-ETS group. Intracranial pressure response to ETS in these patients with head injury can be characterized as falling into three patterns: (1) a rise in baseline beginning with ETS and continuing throughout the ETS sequences; (2) intracranial pressure spiking during the suctioning component of the protocol; (3) a combination of both a rising baseline and spiking. There was a significant (p less-than-or-equal-to 0.001) increase from baseline for both two- and three-ETS groups with both hyperoxygenation protocols (100% VT VS 135% VT) for MICP, MAP, HR, and CPP. No significant difference was found for Sao2 for either of the protocols regardless of number of suction passes. No significant differences were found between two- and three-ETS groups for any of the dependent variables. All groups, however, regardless of number of suction passes, demonstrated a cumulative increase in MICP. MAP, and CPP with each consecutive suction sequence. We conclude that patients with severe closed head injury (Glasgow Coma Scale score less-than-or-equal-to 8), particularly those who respond with a spiking intracranial pressure Pattern, are at risk for periods of cerebral hypertension during an ETS procedure. In some patients the response to ETS is cumulative, making multiple suction passes particularly dangerous. Preoxygenation of patients with 100% oxygen is not adequate to prevent extreme rises in MICP. It is recommended that the number of suction passes be limited to two per procedure, combined with an adequate preoxygenation routine.			RUDY, EB (corresponding author), CASE WESTERN RESERVE UNIV,SCH NURSING,1900 EUCLID AVE,CLEVELAND,OH 44106, USA.				NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR01525] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR001525] Funding Source: NIH RePORTER			0	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung	NOV	1991	20	6					667	674					8	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Nursing; Respiratory System	GU138	WOS:A1991GU13800010	1960071				2022-02-06	
J	Goldman, H; Hodgson, V; Morehead, M; Hazlett, J; Murphy, S				Goldman, Harold; Hodgson, Voigt; Morehead, Marilyn; Hazlett, James; Murphy, Sharon			Cerebrovascular Changes in a Rat Model of Moderate Closed-Head Injury	JOURNAL OF NEUROTRAUMA			English	Article								We have developed and tested a rat (Wistar) model of moderate concussion. Concussion is produced by controlled and repeatable mechanical fixed, closed-head injury. Moderate concussion in this model is characterized by 4 to 10 minutes of unconsciousness, absence of skull fractures or brain contusions, and few, if any, acute neurologic symptoms. By 2 hours postinjury, the subsequent trauma is further characterized by regional and global increases in cerebrovascular permeability and decreases in cerebral blood flow. Such changes are accompanied by brain swelling and two phases of elevated intracranial pressure; one lasting about 5 hours with a peak of aboui 10 mmHg, the other lasting more than 3 days postinjury with a peak of about 30 mmHg. Regional neurohistologic damage detected between 3 and 4 days postinjury correlates for the most part with earlier changes in regional permeability and blood flow. Significant morphologic changes which are characterized by patchy neuronal degeneration can be found in numerous forebrain locations, particularly in the frontal (coup) and entorhinal (contre coup) cortices. These observations have important parallels in human head trauma and suggest that this reliable physiological model may be a useful, relatively simple and inexpensive tool for investigating the mechanisms and therapeutics of head trauma.	[Goldman, Harold; Morehead, Marilyn; Murphy, Sharon] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Hodgson, Voigt] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; [Hazlett, James] Wayne State Univ, Sch Med, Dept Anat, Detroit, MI 48201 USA		Goldman, H (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NIDRR [G0087C2022]; Southeastern Michigan Traumatic Brain Injury System; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [CCR49-502351]; Wayne State University Injury Prevention Research Cente; Michigan Automobile Association	This work was supported by NIDRR Grant G0087C2022 to the Southeastern Michigan Traumatic Brain Injury System, by CDC Grant CCR49-502351 to the Wayne State University Injury Prevention Research Center, and a grant from the Michigan Automobile Association.	BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BEAN JW, 1969, J APPL PHYSIOL, V37, P807; BECKMAN DL, 1970, J APPL PHYSIOL, V29, P631, DOI 10.1152/jappl.1970.29.5.631; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P215, DOI 10.1038/jcbfm.1983.29; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1988, J NEUROTRAUM, V5, P99; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENNARELLI TA, 1982, BRAIN RES, V211, P564; GOLDMAN H, 1973, AM J PHYSIOL, V224, P122, DOI 10.1152/ajplegacy.1973.224.1.122; GURDJIAN ES, 1954, NEUROLOGY, V4, P882; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lindgren S., 1965, BIOPHYSIK, V2, P20; MCHEDLISHVILI G, 1987, STROKE MICROCIRCULAT, P63; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OHNO K, 1979, SURG NEUROL, V12, P323; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; RAPOPORT SI, 1980, AM J PHYSIOL, V238, pR421, DOI 10.1152/ajpregu.1980.238.5.R421; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SAPIRSTEIN LA, 1958, AM J PHYSIOL, V193, P161, DOI 10.1152/ajplegacy.1958.193.1.161; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAW NA, 1985, PHYSIOL BEHAV, V35, P637, DOI 10.1016/0031-9384(85)90154-4; SIESJO BK, 1990, NEWS PHYSIOL SCI, V5, P120; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	31	41	42	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1991	8	2					129	144		10.1089/neu.1991.8.129			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V07US	WOS:000207286700004	1870136				2022-02-06	
J	STUSS, DT; STETHEM, LL; PICTON, TW; LEECH, EE; PELCHAT, G				STUSS, DT; STETHEM, LL; PICTON, TW; LEECH, EE; PELCHAT, G			TRAUMATIC BRAIN INJURY, AGING AND REACTION-TIME	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article									UNIV OTTAWA,SCH MED NEUROL,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,SCH PSYCHOL,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,HUMAN NEUROSCI RES UNIT,OTTAWA K1N 6N5,ONTARIO,CANADA; OTTAWA GEN HOSP,OTTAWA K1H 8L6,ONTARIO,CANADA								Albert M., 1980, NEW DIRECTIONS MEMOR, P403; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ANDERS TR, 1973, DEV PSYCHOL, V9, P411, DOI 10.1037/h0034930; Benson D.F., 1986, FRONTAL LOBES; BENTON AL, 1958, J ABNORMAL SOCIAL PS, V54, P109; BIRREN JE, 1980, PSYCHOL ISSUES, P293; BLACKBURN H L, 1955, Confin Neurol, V15, P327; Cerella J., 1980, PSYCHOL ISSUES, P332; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHOWN SM, 1961, J GERONTOL, V16, P353, DOI 10.1093/geronj/16.4.353; CLIFTON GL, 1980, J NEUROSURG, V52, P619; COHEN G, 1983, J GERONTOL, V38, P447, DOI 10.1093/geronj/38.4.447; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; Cummings J. L., 1983, DEMENTIA CLIN APPROA; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; DUARA R, 1984, ANN NEUROL, V16, P702, DOI 10.1002/ana.410160613; Dupui P, 1984, Monogr Neural Sci, V11, P131; Fuster JM., 1980, PREFRONTAL CORTEX; GAYLORD SA, 1975, J GERONTOL, V30, P674; GRIEW S, 1958, GERONTOLOGY, V2, P284, DOI 10.1159/000210764; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; HOWELL SC, 1972, PERCEPT MOTOR SKILL, V34, P732, DOI 10.2466/pms.1972.34.3.732; Kemper T.N., 1984, CLIN NEUROLOGY AGING, P9; KINSBOURNE M, 1974, INT J AGING HUM DEV, V5, P41, DOI 10.2190/N46C-2A38-2AQV-26TU; KLAYMAN J, 1987, PSYCHOL REV, V94, P211, DOI 10.1037/0033-295X.94.2.211; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luria A.R., 1973, WORKING BRAIN; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDEN DJ, 1983, DEV PSYCHOL, V19, P499, DOI 10.1037/0012-1649.19.4.499; Miller E, 1970, Cortex, V6, P121; MISTLERLACHMAN JL, 1977, J GERONTOL, V32, P68, DOI 10.1093/geronj/32.1.68; MOSCOVITCH M, 1983, CAN J PSYCHOL, V37, P331, DOI 10.1037/h0080743; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RABBITT P, 1965, J GERONTOL, V20, P233, DOI 10.1093/geronj/20.2.233; RABBITT PMA, 1968, HUM AGING BEHAV, P75; Salthouse TimothyA., 1985, HDB PSYCHOL AGING, V2nd ed., P400; Schaie K. W., 1980, HDB MENTAL HLTH AGIN, P262; Schiae KW, 1977, HDB PSYCHOL AGING; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Welford A. T, 1980, HDB MENTAL HLTH AGIN, P192; WETHERICK NE, 1965, GERONTOLOGIA, V77, P89; WRIGHT LL, 1979, J GERONTOL, V34, P704, DOI 10.1093/geronj/34.5.704; [No title captured]	56	41	41	0	4	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	1989	16	2					161	167		10.1017/S0317167100028833			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	U6083	WOS:A1989U608300002	2731082	Bronze			2022-02-06	
J	SHOHAMI, E; SHAPIRA, Y; COTEV, S				SHOHAMI, E; SHAPIRA, Y; COTEV, S			EXPERIMENTAL CLOSED HEAD-INJURY IN RATS - PROSTAGLANDIN PRODUCTION IN A NONINJURED ZONE	NEUROSURGERY			English	Article									HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT ANESTHESIOL,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INTENS CARE UNIT,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,TRAUMA RES CTR,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH HOSP,IL-91010 JERUSALEM,ISRAEL		SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHARMACOL,IL-91010 JERUSALEM,ISRAEL.						ABDELHALIM MS, 1980, PROSTAGLANDINS, V19, P249, DOI 10.1016/0090-6980(80)90023-4; AMES A, 1968, AM J PATHOL, V52, P437; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; ELLIS EF, 1979, AM J PHYSIOL, V237, pH381, DOI 10.1152/ajpheart.1979.237.3.H381; FORSTERMANN U, 1982, BRAIN RES, V240, P303, DOI 10.1016/0006-8993(82)90225-6; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GERRITSEN ME, 1981, PROSTAGLANDINS, V22, P553, DOI 10.1016/0090-6980(81)90065-4; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRYGLEWSKI RJ, 1982, PHARMACOL RES COMMUN, V14, P879, DOI 10.1016/S0031-6989(82)80012-X; HALLENBECK JM, 1979, STROKE, V10, P629, DOI 10.1161/01.STR.10.6.629; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOSSMANN KA, 1974, BRAIN RES, V81, P59, DOI 10.1016/0006-8993(74)90478-8; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P183, DOI 10.1038/jcbfm.1983.25; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P170, DOI 10.1038/jcbfm.1983.24; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; LEFER AM, 1980, PHARMACOLOGY, V21, P206, DOI 10.1159/000137434; LEFER AM, 1978, SCIENCE, V200, P52, DOI 10.1126/science.345441; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA Y, 1986, N-S ARCH PHARMACOL, V334, P282, DOI 10.1007/BF00508783; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NIKOLOV R, 1982, METHOD FIND EXP CLIN, V4, P211; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; ROSEN R, 1981, EUR J PHARMACOL, V69, P489, DOI 10.1016/0014-2999(81)90454-4; SEREGI A, 1985, BRAIN RES, V337, P171, DOI 10.1016/0006-8993(85)91626-9; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; [No title captured]	37	41	42	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1988	22	5					859	863		10.1227/00006123-198805000-00007			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	N2659	WOS:A1988N265900009	3164097				2022-02-06	
J	WILLIAMS, JM; GOMES, F; DRUDGE, OW; KESSLER, M				WILLIAMS, JM; GOMES, F; DRUDGE, OW; KESSLER, M			PREDICTING OUTCOME FROM CLOSED HEAD-INJURY BY EARLY ASSESSMENT OF TRAUMA SEVERITY	JOURNAL OF NEUROSURGERY			English	Article									UNIV VERMONT,DEPT SURG,DIV NEUROSURG,BURLINGTON,VT 05405; UNIV VERMONT,DEPT PSYCHOL,BURLINGTON,VT 05405		WILLIAMS, JM (corresponding author), MEMPHIS STATE UNIV,DEPT PSYCHOL,MEMPHIS,TN 38152, USA.						BENTON A, 1979, CENTRAL NERVOUS SYST, P220; Boll TJ, 1981, HDB CLIN NEUROPSYCHO, P577; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Fleischer A S, 1976, Surg Neurol, V6, P31; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Levin HS., 1982, NEUROBEHAVIORAL CONS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MILLER E, 1979, BRIT J SOC CLIN PSYC, V18, P87, DOI 10.1111/j.2044-8260.1979.tb00310.x; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NUNNALLY J, 1978, PSYCHOMETRIC THEORY, P138; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; TEASDALE G, 1974, LANCET, V2, P81; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; 1971, CLIN EXAMINATIONS NE, P202; [No title captured]	26	41	41	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1984	61	3					581	585		10.3171/jns.1984.61.3.0581			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TG601	WOS:A1984TG60100022	6747697				2022-02-06	
J	Sheth, KN; Mazurek, MH; Yuen, MM; Cahn, BA; Shah, JT; Ward, A; Kim, JA; Gilmore, EJ; Falcone, GJ; Petersen, N; Gobeske, KT; Kaddouh, F; Hwang, DY; Schindler, J; Sansing, L; Matouk, C; Rothberg, J; Sze, G; Siner, J; Rosen, MS; Spudich, S; Kimberly, WT				Sheth, Kevin N.; Mazurek, Mercy H.; Yuen, Matthew M.; Cahn, Bradley A.; Shah, Jill T.; Ward, Adrienne; Kim, Jennifer A.; Gilmore, Emily J.; Falcone, Guido J.; Petersen, Nils; Gobeske, Kevin T.; Kaddouh, Firas; Hwang, David Y.; Schindler, Joseph; Sansing, Lauren; Matouk, Charles; Rothberg, Jonathan; Sze, Gordon; Siner, Jonathan; Rosen, Matthew S.; Spudich, Serena; Kimberly, W. Taylor			Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	JAMA NEUROLOGY			English	Article								Question Can brain injury in patients who are critically ill be assessed using a novel portable, low-field magnetic resonance imaging (MRI) device at the bedside in an intensive care setting? Findings In this cohort study of a series of 50 patients imaged with a portable, bedside MRI device, including patients with ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, traumatic brain injury, brain tumor, and COVID-19 and altered mental status, abnormal neuroimaging findings were detected in 29 of 30 patients without COVID-19 (97%); 8 of 20 patients with COVID-19 (40%) demonstrated abnormalities. There were no adverse events or complications. Meaning This study demonstrates the capability of low-field, portable MRI to obtain neuroimaging at the bedside in intensive care settings. This cohort study describes the outcomes of assessments of brain injury in patients with critical illness in intensive care units using a portable low-field magnetic resonance image device at the bedside, rather than a conventional imaging suite. Importance Neuroimaging is a key step in the clinical evaluation of brain injury. Conventional magnetic resonance imaging (MRI) systems operate at high-strength magnetic fields (1.5-3 T) that require strict, access-controlled environments. Limited access to timely neuroimaging remains a key structural barrier to effectively monitor the occurrence and progression of neurological injury in intensive care settings. Recent advances in low-field MRI technology have allowed for the acquisition of clinically meaningful imaging outside of radiology suites and in the presence of ferromagnetic materials at the bedside. Objective To perform an assessment of brain injury in critically ill patients in intensive care unit settings, using a portable, low-field MRI device at the bedside. Design, Setting, and Participants This was a prospective, single-center cohort study of 50 patients admitted to the neuroscience or coronavirus disease 2019 (COVID-19) intensive care units at Yale New Haven Hospital in New Haven, Connecticut, from October 30, 2019, to May 20, 2020. Patients were eligible if they presented with neurological injury or alteration, no contraindications for conventional MRI, and a body habitus not exceeding the scanner's 30-cm vertical opening. Diagnosis of COVID-19 was determined by positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction nasopharyngeal swab result. Exposures Portable MRI in an intensive care unit room. Main Outcomes and Measures Demographic, clinical, radiological, and treatment data were collected and analyzed. Brain imaging findings are described. Results Point-of-care MRI examinations were performed on 50 patients (16 women [32%]; mean [SD] age, 59 [12] years [range, 20-89 years]). Patients presented with ischemic stroke (n = 9), hemorrhagic stroke (n = 12), subarachnoid hemorrhage (n = 2), traumatic brain injury (n = 3), brain tumor (n = 4), and COVID-19 with altered mental status (n = 20). Examinations were acquired at a median of 5 (range, 0-37) days after intensive care unit admission. Diagnostic-grade T1-weighted, T2-weighted, T2 fluid-attenuated inversion recovery, and diffusion-weighted imaging sequences were obtained for 37, 48, 45, and 32 patients, respectively. Neuroimaging findings were detected in 29 of 30 patients who did not have COVID-19 (97%), and 8 of 20 patients with COVID-19 (40%) demonstrated abnormalities. There were no adverse events or complications during deployment of the portable MRI or scanning in an intensive care unit room. Conclusions and Relevance This single-center series of patients with critical illness in an intensive care setting demonstrated the feasibility of low-field, portable MRI. These findings demonstrate the potential role of portable MRI to obtain neuroimaging in complex clinical care settings.	[Sheth, Kevin N.; Mazurek, Mercy H.; Yuen, Matthew M.; Cahn, Bradley A.; Shah, Jill T.; Kim, Jennifer A.; Gilmore, Emily J.; Falcone, Guido J.; Petersen, Nils; Gobeske, Kevin T.; Kaddouh, Firas; Hwang, David Y.; Schindler, Joseph; Sansing, Lauren] Yale Univ, Sch Med, Dept Neurol, 15 York St,LLCI Room 1003C,Box 208018, New Haven, CT 06520 USA; [Ward, Adrienne] Yale New Haven Med Ctr, Neurosci Intens Care Unit, 20 York St, New Haven, CT 06504 USA; [Matouk, Charles] Yale Sch Med, Dept Neurosurg, New Haven, CT USA; [Rothberg, Jonathan] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Rothberg, Jonathan] Hyperfine Res Inc, Guilford, CT USA; [Sze, Gordon] Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06510 USA; [Siner, Jonathan] Yale Univ, Sch Med, Dept Med, Div Pulmonol & Sleep Med, New Haven, CT 06510 USA; [Rosen, Matthew S.] Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Spudich, Serena] Yale Univ, Sch Med, Dept Neurol, Div Neurol Infect & Global Neurol, New Haven, CT 06510 USA; [Kimberly, W. Taylor] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care, 55 Fruit St,Lunder 644,Mailcode WACC 8-835, Boston, MA 02114 USA		Sheth, KN (corresponding author), Yale Univ, Sch Med, Dept Neurol, 15 York St,LLCI Room 1003C,Box 208018, New Haven, CT 06520 USA.; Kimberly, WT (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care, 55 Fruit St,Lunder 644,Mailcode WACC 8-835, Boston, MA 02114 USA.	kevin.sheth@yale.edu; wtkimberly@mgh.harvard.edu	Hwang, David/ABG-6957-2020	Hwang, David/0000-0002-2150-4289; Yuen, Matthew/0000-0003-2431-8534; Cahn, Bradley/0000-0003-1553-4446; Kaddouh, Firas/0000-0001-9531-4560; Mazurek, Mercy/0000-0002-4655-4266; Shah, Jill/0000-0002-9248-0368; Rosen, Matthew/0000-0002-7194-002X	American Heart AssociationAmerican Heart Association [18TPA34170180, 17CSA33550004, 17CSA3355004]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U24NS107136, U24NS107215, R01NR018335, U01NS106513]; Hyperfine Research Inc research grant	This study was supported by funding from the American Heart Association (Collaborative Science Award 17CSA3355004 [Drs Sheth, Kimberly, and Rosen]). The prototype device that was developed, deployed, and provided to Yale University was born out of an academic-industry collaboration in which the American Health Association grant supported the academic investigators. Dr Sheth is supported by the National Institutes of Health (grants U24NS107136, U24NS107215, R01NR018335, and U01NS106513) and the American Heart Association (grants 18TPA34170180 and 17CSA33550004) and a Hyperfine Research Inc research grant.	Agrawal S, 2010, EUR J TRAUMA EMERG S, V36, P346, DOI 10.1007/s00068-009-9127-8; Brenner DJ, 2010, JAMA-J AM MED ASSOC, V304, P208, DOI 10.1001/jama.2010.973; Hanidziar D, 2020, ANESTH ANALG, V131, pE40, DOI 10.1213/ANE.0000000000004887; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Hricak H, 2011, RADIOLOGY, V258, P889, DOI 10.1148/radiol.10101157; Kandemirli SG, 2020, RADIOLOGY, V297, pE232, DOI 10.1148/radiol.2020201697; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Peace K, 2011, J NEUROSURG, V114, P1479, DOI 10.3171/2010.11.JNS091148; Peace K, 2010, J NEUROSCI NURS, V42, P109, DOI 10.1097/JNN.0b013e3181ce5c5b; Sarracanie M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15177; US Food and Drug Administration, 2020, ENF POL IM SYST COR; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5	12	40	40	6	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JAN	2021	78	1					41	47		10.1001/jamaneurol.2020.3263		SEP 2020	7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PW4YF	WOS:000572383900004	32897296	Green Published			2022-02-06	
J	O'Keeffe, E; Kelly, E; Liu, YZ; Giordano, C; Wallace, E; Hynes, M; Tiernan, S; Meagher, A; Greene, C; Hughes, S; Burke, T; Kealy, J; Doyle, N; Hay, A; Farrell, M; Grant, GA; Friedman, A; Veksler, R; Molloy, MG; Meaney, JF; Pender, N; Camarillo, D; Doherty, CP; Campbell, M				O'Keeffe, Eoin; Kelly, Eoin; Liu, Yuzhe; Giordano, Chiara; Wallace, Eugene; Hynes, Mark; Tiernan, Stephen; Meagher, Aidan; Greene, Chris; Hughes, Stephanie; Burke, Tom; Kealy, John; Doyle, Niamh; Hay, Alison; Farrell, Michael; Grant, Gerald A.; Friedman, Alon; Veksler, Ronel; Molloy, Michael G.; Meaney, James F.; Pender, Niall; Camarillo, David; Doherty, Colin P.; Campbell, Matthew			Dynamic Blood-Brain Barrier Regulation in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; blood-brain barrier dysfunction; MRI	ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; CONCUSSION; DISRUPTION; ENCEPHALOPATHY; DYSFUNCTION; PATHOLOGY; HEALTH; YOUTH	Whereas the diagnosis of moderate and severe traumatic brain injury (TBI) is readily visible on current medical imaging paradigms (magnetic resonance imaging [MRI] and computed tomography [CT] scanning), a far greater challenge is associated with the diagnosis and subsequent management of mild TBI (mTBI), especially concussion which, by definition, is characterized by a normal CT. To investigate whether the integrity of the blood-brain barrier (BBB) is altered in a high-risk population for concussions, we studied professional mixed martial arts (MMA) fighters and adolescent rugby players. Additionally, we performed the linear regression between the BBB disruption defined by increased gadolinium contrast extravasation on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on MRI and multiple biomechanical parameters indicating the severity of impacts recorded using instrumented mouthguards in professional MMA fighters. MMA fighters were examined pre-fight for a baseline and again within 120 h post-competitive fight, whereas rugby players were examined pre-season and again post-season or post-match in a subset of cases. DCE-MRI, serological analysis of BBB biomarkers, and an analysis of instrumented mouthguard data, was performed. Here, we provide pilot data that demonstrate disruption of the BBB in both professional MMA fighters and rugby players, dependent on the level of exposure. Our data suggest that biomechanical forces in professional MMA and adolescent rugby can lead to BBB disruption. These changes on imaging may serve as a biomarker of exposure of the brain to repetitive subconcussive forces and mTBI.	[O'Keeffe, Eoin; Greene, Chris; Kealy, John; Campbell, Matthew] Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland; [Kelly, Eoin; Wallace, Eugene; Hay, Alison; Doherty, Colin P.] St James Hosp, Hlth Care Ctr, Dept Neurol, Hosp 5, Dublin, Ireland; [Liu, Yuzhe; Giordano, Chiara; Camarillo, David] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Hynes, Mark] Personal Hlth, Dublin, Ireland; [Tiernan, Stephen; Meagher, Aidan] Technol Univ Dublin, Dept Mech Engn, Dublin, Ireland; [Tiernan, Stephen; Hughes, Stephanie; Doyle, Niamh; Pender, Niall] Beaumont Hosp, Dept Psychol, Dublin, Ireland; [Burke, Tom; Doherty, Colin P.] Trinity Coll Dublin, Acad Unit Neurol, Inst Biomed Sci, Dublin, Ireland; [Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA USA; [Friedman, Alon; Veksler, Ronel] Ben Gur Univ Negev, Zlotowski Ctr Neurosci, Dept Cognit & Brain Sci, Beer Sheva, Israel; [Friedman, Alon] Dalhousie Univ, Dept Med Neurosci, Halifax, NS, Canada; [Molloy, Michael G.] Univ Coll Cork, Dept Med, Cork, Ireland; [Meaney, James F.] St James Hosp, Dept Radiol, Dublin, Ireland; [Meaney, James F.] St James Hosp, CAMI, Dublin, Ireland		Campbell, M (corresponding author), Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland.	Matthew.Campbell@tcd.ie	Burke, Tom/AAH-8963-2020; Kealy, John/A-6515-2010	Burke, Tom/0000-0002-6563-1597; Kealy, John/0000-0002-0503-4379; Doherty, Colin/0000-0002-8869-8567; , Alon/0000-0003-4780-8456; Tiernan, Stephen/0000-0002-0658-7557; Meaney, James FM/0000-0003-1596-4972; Greene, Chris/0000-0003-4192-9433	Science Foundation Ireland (SFI)Science Foundation Ireland [12/YI/B2614, 11/PI/1080]; Health Research Board of Ireland (HRB); BrightFocus FoundationBrightFocus Foundation; St James' Hospital Foundation; Ellen Mayston Bates Bequest at the Trinity Foundation; SFIScience Foundation Ireland [16/RC/3948]; European Regional Development fundEuropean Commission; Canada Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This work was supported by grants from Science Foundation Ireland (SFI; 12/YI/B2614 and 11/PI/1080), The Health Research Board of Ireland (HRB), the BrightFocus Foundation, and the St James' Hospital Foundation with support to E.K. from the Ellen Mayston Bates Bequest at the Trinity Foundation. The Campbell lab at TCD is also supported by an SFI Centres grant supported, in part, by a research grant from SFI under grant number 16/RC/3948 and co-funded under the European Regional Development fund by FutureNeuro industry partners. Work in the laboratory of A.F. is supported by the Canada Institute for Health Research (CIHR; to A.F.).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Doherty CP, 2019, CLIN NEUROPATHOL, V38, P14, DOI 10.5414/NP301131; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Greene C, 2018, MOL PSYCHIATR, V23, P2156, DOI 10.1038/mp.2017.156; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Iacono D, 2017, PHYS MED REH CLIN N, V28, P301, DOI 10.1016/j.pmr.2016.12.007; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Koerte IK, 2017, J NEUROTRAUM, V34, P2389, DOI 10.1089/neu.2016.4960; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lynall RC, 2017, J NEUROTRAUM, V34, P2684, DOI 10.1089/neu.2017.5032; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Pardridge William M, 2005, NeuroRx, V2, P1, DOI 10.1602/neurorx.2.1.1; Prasad P, 2008, STAPP CAR C, V52, P187; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Veksler R, 2014, ARCH MED RES, V45, P646, DOI 10.1016/j.arcmed.2014.11.016; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	39	40	41	5	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2020	37	2					347	356		10.1089/neu.2019.6483		NOV 2019	10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	JZ2YM	WOS:000495443500001	31702476	Green Submitted			2022-02-06	
J	Li, D; Huang, S; Yin, ZY; Zhu, JL; Ge, XT; Han, ZL; Tan, J; Zhang, SS; Zhao, J; Chen, FL; Wang, HC; Lei, P				Li, Dai; Huang, Shan; Yin, Zhenyu; Zhu, Jialin; Ge, Xintong; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Chen, Fanglian; Wang, Haichen; Lei, Ping			Increases in miR-124-3p in Microglial Exosomes Confer Neuroprotective Effects by Targeting FIP200-Mediated Neuronal Autophagy Following Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Exosomes; Autophagy; miRNA; Microglia	NEGATIVELY REGULATE AUTOPHAGY; MESENCHYMAL STROMAL CELLS; EXTRACELLULAR VESICLES; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; DOWN-REGULATION; IN-VITRO; APOPTOSIS; PATHWAY; CANCER	In our recent study, we observed consistent increases in miR-124-3p levels in exosomes derived from cultured BV2 microglia which was treated with repetitive traumatic brain injury (rTBI) mouse model brain extracts. To clarify the mechanisms underlying increases in microglia-derived exosomal miR-124-3p and their role in regulating neuronal autophagy after TBI, we investigated the impact of exosomal miR-124-3p on neuronal autophagy in scratch-injured HT22 neurons and rTBI mice. We harvested injured brain extracts from rTBI mice at 3 to 21days post injury (DPI) for the treatment of cultured BV2 microglia in vitro. We observed significant induction of autophagy following TBI in vitro, and that inhibition of activated neuronal autophagy could protect against trauma-induced injury. Our results indicated that co-culture of injured HT22 neurons with miR-124-3p overexpressing BV2 microglia exerted a protective effect by inhibiting neuronal autophagy in scratch-injured neurons. Further research revealed that these effects were achieved mainly via upregulation of exosomal miR-124-3p, and that Focal adhesion kinase family-interacting protein of 200kDa (FIP200) plays a key role in trauma-induced autophagy. Injection of exosomes into the vena caudalis in in vivo experiments revealed that exosomal miR-124-3p was associated with decreases in the modified neurological severity score (mNSS) and improvements in Morris water maze (MWM) test results in rTBI mice. Altogether, our results indicate that increased miR-124-3p in microglial exosomes following TBI may inhibit neuronal autophagy and protect against nerve injury via their transfer into neurons. Thus, treatment with microglial exosomes enriched with miR-124-3p may represent a novel therapeutic strategy for the treatment of nerve injury after TBI.	[Li, Dai; Huang, Shan; Yin, Zhenyu; Ge, Xintong; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neuro Trauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Li, Dai; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China; [Ge, Xintong] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Zhu, Jialin] Tianjin Med Univ Canc Inst & Hosp, Dept Ultrasound Diag & Treatment, Tianjin 300060, Peoples R China; [Wang, Haichen] Duke Univ, Dept Neurol, Med Ctr, Durham, NC 27710 USA; [Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Lab Neurotrauma & Neurodegenerat Disorders, Anshan Rd, Tianjin 300054, Peoples R China		Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neuro Trauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Lab Neurotrauma & Neurodegenerat Disorders, Anshan Rd, Tianjin 300054, Peoples R China.	luke88956@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772060, 81471252]; Tianjin Science FoundationNatural Science Foundation of Tianjin [16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090]; Tianjin Medical University General Hospital Youth Cultivation Foundation [ZYYFY2016001, ZYYFY2014025]	This research was supported by Grants from the National Natural Science Foundation of China (Grant Nos. 81772060, 81471252), Tianjin Science Foundation (Grant Nos. 16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090), Tianjin Medical University General Hospital Youth Cultivation Foundation (Grant Nos. ZYYFY2016001, ZYYFY2014025). The authors appreciate Li Liu, Weiyun Cui and Lei Zhou from Tianjin Neurological Institute for their technical support.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; An FM, 2017, ONCOTARGET, V8, P114065, DOI 10.18632/oncotarget.23119; Antonucci F, 2012, EMBO J, V31, P1231, DOI 10.1038/emboj.2011.489; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Au AK, 2017, NEUROCRIT CARE, V26, P348, DOI 10.1007/s12028-016-0351-x; Ban BK, 2013, MOL CELL BIOL, V33, P3907, DOI 10.1128/MCB.00627-13; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Dong RF, 2018, J CELL BIOCHEM, V119, P269, DOI 10.1002/jcb.26170; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266; Gabrielli M, 2015, EMBO REP, V16, P213, DOI 10.15252/embr.201439668; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2018, J NEUROSCI METH, V308, P162, DOI 10.1016/j.jneumeth.2018.07.021; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gong X, 2016, AM J TRANSL RES, V8, P2127; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Huang S, 2018, FASEB J, V32, P2315, DOI 10.1096/fj.201700673RERR; Jiang, 2012, J NEUROTRAUM, DOI DOI 10.1089/NEU.2011.2134; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jiang M, 2018, CELL PHYSIOL BIOCHEM, V47, P864, DOI [10.1159/000490078and, 10.1159/000490078]; Johnson WD, 2017, LANCET NEUROL, V16, P949, DOI 10.1016/S1474-4422(17)30362-9; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351; Kramer-Albers EM, 2016, CURR OPIN NEUROBIOL, V39, P101, DOI 10.1016/j.conb.2016.04.016; Legakis JE, 2007, AUTOPHAGY, V3, P422, DOI 10.4161/auto.4129; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044; Liao WT, 2014, J PATHOL, V232, P415, DOI 10.1002/path.4309; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Martinez B, 2017, NEURAL REGEN RES, V12, P1749, DOI 10.4103/1673-5374.219025; Mehta AK, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6291; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Menghini R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.556; Osier N, 2018, MOL NEUROBIOL, V55, P9280, DOI 10.1007/s12035-018-1054-4; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Paolicelli RC, 2019, NEUROSCIENCE, V405, P148, DOI 10.1016/j.neuroscience.2018.04.003; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Taj SH, 2016, BIOMATERIALS, V91, P151, DOI 10.1016/j.biomaterials.2016.03.025; Tamboli IY, 2010, J BIOL CHEM, V285, P37405, DOI 10.1074/jbc.M110.149468; Thompson AG, 2016, NAT REV NEUROL, V12, P346, DOI 10.1038/nrneurol.2016.68; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Vuokila N, 2018, CELL MOL LIFE SCI, V75, P4557, DOI 10.1007/s00018-018-2911-z; Wang DY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0019629, 10.1371/journal.pone.0019835]; Wang F, 2013, STEM CELL RES, V11, P657, DOI 10.1016/j.scr.2013.04.005; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zheng TT, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00012; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	75	40	43	0	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	AUG	2019	44	8					1903	1923		10.1007/s11064-019-02825-1			21	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	IL9EY	WOS:000477589200012	31190315				2022-02-06	
J	Broglio, SP; Kontos, AP; Levin, H; Schneider, K; Wilde, EA; Cantu, RC; Feddermann-Demont, N; Fuller, GW; Gagnon, I; Gioia, GA; Giza, C; Griesbach, GS; Leddy, JJ; Lipton, ML; Mayer, AR; McAllister, TW; McCrea, M; McKenzie, LB; Putukian, M; Signoretti, S; Suskauer, SJ; Tamburro, R; Turner, M; Yeates, KO; Zemek, R; Ala'i, S; Esterlitz, J; Gay, K; Bellgowan, PSF; Joseph, K				Broglio, Steven P.; Kontos, Anthony P.; Levin, Harvey; Schneider, Kathryn; Wilde, Elisabeth A.; Cantu, Robert C.; Feddermann-Demont, Nina; Fuller, Gordon W.; Gagnon, Isabelle; Gioia, Gerard A.; Giza, Christopher; Griesbach, Grace S.; Leddy, John J.; Lipton, Michael L.; Mayer, Andrew R.; McAllister, Thomas W.; McCrea, Michael; McKenzie, Lara B.; Putukian, Margot; Signoretti, Stefano; Suskauer, Stacy J.; Tamburro, Robert; Turner, Michael; Yeates, Keith O.; Zemek, Roger; Ala'i, Sherita; Esterlitz, Joy; Gay, Katelyn; Bellgowan, Patrick S. F.; Joseph, Kristen		Sport-Related Concussion CDE	National Institute of Neurological Disorders and Stroke and Department of Defense Sport-Related Concussion Common Data Elements Version 1.0 Recommendations	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; clinical outcomes; clinical research; common data elements; data sets; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL HEALTH; OUTCOME MEASURES; WORKING GROUP; DEMOGRAPHICS; BIOSPECIMENS	Through a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, and Department of Defense, the development of Sport-Related Concussion (SRC) Common Data Elements (CDEs) was initiated. The aim of this collaboration was to increase the efficiency and effectiveness of clinical research studies and clinical treatment outcomes, increase data quality, facilitate data sharing across studies, reduce study start-up time, more effectively aggregate information into metadata results, and educate new clinical investigators. The SRC CDE Working Group consisted of 32 worldwide experts in concussion from varied fields of related expertise divided into three Subgroups: Acute (<72h post-concussion), Subacute (3 days-3 months post-concussion) and Persistent/Chronic (>3 months post-concussion). To develop CDEs, the Subgroups reviewed various domains, then selected from, refined, and added to existing CDEs, case report forms and field-tested data elements from national registries and funded research studies. Recommendations were posted to the NINDS CDE Website for Public Review from February 2017 to April 2017. Following an internal Working Group review of recommendations, along with consideration of comments received from the Public Review period, the first iteration (Version 1.0) of the NINDS SRC CDEs was completed in June 2017. The recommendations include Core and Supplemental-Highly Recommended CDEs for cognitive data elements and symptom checklists, as well as other outcomes and end-points (e.g., vestibular, oculomotor, balance, anxiety, depression), and sample case report forms (e.g., injury reporting, demographics, concussion history) for domains typically included in clinical research studies. The NINDS SRC CDEs and supporting documents are publicly available on the NINDS CDE website www.commondataelements.ninds.nih.gov. Widespread use of CDEs by researchers and clinicians will facilitate consistent SRC clinical research and trial design, data sharing, and metadata retrospective analysis.	[Broglio, Steven P.] Univ Michigan, Ann Arbor, MI 48109 USA; [Kontos, Anthony P.] Univ Pittsburgh, Pittsburgh, PA USA; [Levin, Harvey; Wilde, Elisabeth A.] Baylor Coll Med, Houston, TX 77030 USA; [Levin, Harvey; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Schneider, Kathryn; Yeates, Keith O.] Univ Calgary, Calgary, AB, Canada; [Wilde, Elisabeth A.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Cantu, Robert C.] Emerson Hosp, Concuss Ctr, Concord, MA USA; [Feddermann-Demont, Nina] Univ Zurich, Swiss Concuss Ctr, Zurich, Switzerland; [Fuller, Gordon W.] Univ Sheffield, Sheffield, S Yorkshire, England; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Hlth Ctr, Montreal, PQ, Canada; [Gioia, Gerard A.] Childrens Natl Hlth Syst, Washington, DC USA; [Giza, Christopher] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Steve Tisch BrainSPORT Program, Los Angeles, CA USA; [Griesbach, Grace S.] Ctr Neuro Skills, Encino, CA USA; [Leddy, John J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA; [Lipton, Michael L.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Lipton, Michael L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Mayer, Andrew R.] Univ New Mexico, Mind Res Network, Albuquerque, NM 87131 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [McCrea, Michael] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [McKenzie, Lara B.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Signoretti, Stefano] San Camillo Forlanini Hosp, Rome, Italy; [Suskauer, Stacy J.; Tamburro, Robert] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA; [Tamburro, Robert] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA; [Turner, Michael] Int Concuss & Head Injury Res Fdn, London, England; [Zemek, Roger] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada; [Ala'i, Sherita; Esterlitz, Joy; Gay, Katelyn; Joseph, Kristen] Emmes Corp, Rockville, MD USA; [Bellgowan, Patrick S. F.] NINDS, Bethesda, MD USA		Broglio, SP (corresponding author), Univ Michigan, NeuroTrauma Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Signoretti, stefano/AAL-5631-2020; Yeates, Keith/AAJ-4223-2020	Signoretti, stefano/0000-0002-8086-1622; Gagnon, Isabelle/0000-0003-2043-1644; McKenzie, Lara/0000-0003-2889-0001; Fuller, Gordon Ward/0000-0001-8532-3500; Yeates, Keith/0000-0001-7680-2892; TURNER, Michael/0000-0003-2323-2456; Schneider, Kathryn/0000-0002-5951-5899	U.S Army Medical Research and Materiel Command's Combat Casualty Care Research Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHSN271201700064C, HHSN271201200034C]	The funding source for this project is the U.S Army Medical Research and Materiel Command's Combat Casualty Care Research Program and NIH contracts HHSN271201700064C and HHSN271201200034C. The views expressed here are those of the authors and do not represent those of the National Institutes of Health (NIH), the National Institute of Neurological Disorders and Stroke (NINDS) or the U.S. government. The development of the NINDS SRC CDEs was made possible thanks to the great investment of time and effort of Working Group members and the members of the NINDS CDE Project team participating from 2016 to present. In addition, we are grateful for the input provided during the public review period.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ COMM; National Institute of Neurological Disorders and Stroke, SPORTS REL CONC COMM; National Institute of Neurological Disorders and Stroke, 2017, GLOSSARYNINDS COMM D; National Institute on Neurological Disorders and Stroke, NINDS COMM DAT EL; National Institutes of Health U. S . Army Medical Research and Materiel Commang Combat Casualty Care Research Program National Institutes of Health Center for Information Technology National Institute of Neurological Disorders and Stroke, 2017, FED INT TRAUM BRAIN; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	24	40	40	2	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2018	35	23					2776	2783		10.1089/neu.2018.5643		JUL 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HB1WO	WOS:000439648200001	29717643	Green Published, Green Accepted			2022-02-06	
J	Lawrence, DW; Richards, D; Comper, P; Hutchison, MG				Lawrence, David Wyndham; Richards, Doug; Comper, Paul; Hutchison, Michael G.			Earlier time to aerobic exercise is associated with faster recovery following acute sport concussion	PLOS ONE			English	Article							PROPENSITY SCORE METHODS; REST; SYMPTOMS; METAANALYSIS; OUTCOMES; CHILDREN; ADULTS	Objective To determine whether earlier time to initiation of aerobic exercise following acute concussion is associated with time to full return to (1) sport and (2) school or work. Methods A retrospective stratified propensity score survival analysis of acute (<= 14 days) concussion was used to determine whether time (days) to initiation of aerobic exercise post-concussion was associated with, both, time (days) to full return to (1) sport and (2) school or work. Results A total of 253 acute concussions [median (IQR) age, 17.0 (15.0-20.0) years; 148 (58.5%) males] were included in this study. Multivariate Cox regression models identified that earlier time to aerobic exercise was associated with faster return to sport and school/work adjusting for other covariates, including quintile propensity strata. For each successive day in delay to initiation of aerobic exercise, individuals had a less favourable recovery trajectory. Initiating aerobic exercise at 3 and 7 days following injury was associated with a respective 36.5% (HR, 0.63; 95% CI, 0.53-0.76) and 73.2% (HR, 0.27; 95% CI, 0.16-0.45) reduced probability of faster full return to sport compared to within 1 day; and a respective 45.9% (HR, 0.54; 95% CI, 0.44-0.66) and 83.1% (HR, 0.17; 95% CI, 0.10-0.30) reduced probability of faster full return to school/work. Additionally, concussion history, symptom severity, LOC deleteriously influenced concussion recovery. Conclusion Earlier initiation of aerobic exercise was associated with faster full return to sport and school or work. This study provides greater insight into the benefits and safety of aerobic exercise within the first week of the injury.	[Lawrence, David Wyndham; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Lawrence, David Wyndham; Comper, Paul] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Lawrence, David Wyndham] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada		Lawrence, DW (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.; Lawrence, DW (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada.; Lawrence, DW (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	dw.lawrence@mail.utoronto.ca					Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328; Austin PC, 2014, STAT MED, V33, P1242, DOI 10.1002/sim.5984; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bidonde J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012700; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Dobney DM, 2017, BRAIN INJURY, V31, P1753, DOI 10.1080/02699052.2017.1346294; Edmonds M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003200.PUB2; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Hsu CL, 2018, BRIT J SPORT MED, V52, P184, DOI 10.1136/bjsports-2016-096846; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lal A, 2018, AM J SPORT MED, V46, P743, DOI 10.1177/0363546517706137; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P., 2017, 5 INT C CONC SPORT H; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; Moor HM, 2015, INT J SPORTS PHYS TH, V10, P225; Pang MYC, 2013, CEREBROVASC DIS, V35, P7, DOI 10.1159/000346075; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Winters-Stone KM, 2014, BRIT J SPORT MED, V48, P987, DOI 10.1136/bjsports-2012-091732; Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392	34	40	41	7	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2018	13	4							e0196062	10.1371/journal.pone.0196062			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD1VU	WOS:000430290200076	29668716	Green Published, gold, Green Submitted			2022-02-06	
J	Mettang, M; Reichel, SN; Lattke, M; Palmer, A; Abaei, A; Rasche, V; Huber-Lang, M; Baumann, B; Wirth, T				Mettang, Melanie; Reichel, Stephanie Nadine; Lattke, Michael; Palmer, Annette; Abaei, Alireza; Rasche, Volker; Huber-Lang, Markus; Baumann, Bernd; Wirth, Thomas			IKK2/NF-kappa B signaling protects neurons after traumatic brain injury	FASEB JOURNAL			English	Article						neuroinflammation; apoptosis neurological outcome; neurodegeneration; conditional mouse model	NF-KAPPA-B; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; REDUCES INFLAMMATION; FUNCTIONAL RECOVERY; ACTIVATION; EXPRESSION; EPIDEMIOLOGY; MICE	Traumatic brain injury (TBI) is the leading cause of death in young adults. After the initial injury, a poorly understood secondary phase, including a strong inflammatory response determines the final outcome of TBI. The inhibitor of NF-kappa B kinase (IKK)/NF-kappa B signaling system is the key regulator of inflammation and also critically involved in regulation of neuronal survival and synaptic plasticity. We addressed the neuron-specific function of IKK2/NF-kappa B signaling pathway in TBI using an experimental model of closed-head injury (CHI) in combination with mouse models allowing conditional regulation of IKK/NF-kappa B signaling in excitatory forebrain neurons. We found that repression of IKK2/NF-kappa B signaling in neurons increases the acute posttraumatic mortality rate, worsens the neurological outcome, and promotes neuronal cell death by apoptosis, thus resulting in enhanced proinflammatory gene expression. As a potential mechanism, we identified elevated levels of the proapoptotic mediators Bax and Bad and enhanced expression of stress response genes. This phenotype is also observed when neuronal IKK/NF-kappa B activity is inhibited just before CHI. In contrast, neuron-specific activation of IKK/NF-kappa B signaling does not alter the TBI outcome. Thus, this study demonstrates that physiological neuronal IKK/NF-kappa B signaling is necessary and sufficient to protect neurons from trauma consequences.	[Mettang, Melanie; Reichel, Stephanie Nadine; Lattke, Michael; Baumann, Bernd; Wirth, Thomas] Ulm Univ, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany; [Abaei, Alireza; Rasche, Volker] Ulm Univ, Core Facil Small Anim Magnet Resonance Imaging, Ulm, Germany; [Lattke, Michael] Francis Crick Inst, Neural Stem Cell Biol Lab, London, England; [Palmer, Annette; Huber-Lang, Markus] Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany		Wirth, T (corresponding author), Ulm Univ, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.	thomas.wirth@uni-ulm.de	Rasche, Volker/P-6523-2016; Lattke, Michael/AAE-5079-2020; Huber-Lang, Markus/AAJ-2209-2020; Wirth, Thomas/X-7172-2019	Rasche, Volker/0000-0001-8844-3583; Lattke, Michael/0000-0001-5533-8592; 	German research foundationGerman Research Foundation (DFG) [CRC1149]	The authors thank Petra Weihrich, Melanie Gerstenlauer, Annika Gnann, Ute Leschik (all from the Institute of Physiological Chemistry, Ulm University), and Sonja Braumuller (Institute of Clinical and Experimental Trauma-Immunology, University Hospital Ulm) for excellent technical assistance. This work was supported by the German research foundation (CRC1149/Project A03 to T.W. and CRC1149/Project Z03). Melanie Mettang and Stephanie N. Reichel are members of the International Graduate School in Molecular Medicine Ulm (IGradU). The authors declare no conflicts of interest.	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Acarin L, 1998, NEUROREPORT, V9, P2869, DOI 10.1097/00001756-199808240-00035; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Braunstein KE, 2010, HUM MOL GENET, V19, P4385, DOI 10.1093/hmg/ddq361; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Duckworth EAM, 2006, BRAIN RES, V1088, P167, DOI 10.1016/j.brainres.2006.02.103; Engelmann C, 2014, NEURAL REGEN RES, V9, P707, DOI 10.4103/1673-5374.131572; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kaltschmidt B., 2015, BRAIN FRONT MOL NEUR, V8, P69, DOI DOI 10.3389/FNM0L.2015.00069; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kirkley KS, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0871-0; Lagraoui M, 2017, BRAIN BEHAV IMMUN, V61, P96, DOI 10.1016/j.bbi.2016.12.005; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lattke M, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0157-0; Lattke M, 2012, J NEUROSCI, V32, P11511, DOI 10.1523/JNEUROSCI.0182-12.2012; Ledoux AC, 2014, BIOCHEM SOC T, V42, P76, DOI 10.1042/BST20130156; Lian H, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-47; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maqbool A, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-40; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Memet S, 2006, BIOCHEM PHARMACOL, V72, P1180, DOI 10.1016/j.bcp.2006.09.003; Menon DK, 2017, HAND CLINIC, V140, P239, DOI 10.1016/B978-0-444-63600-3.00014-3; Mincheva-Tasheva S, 2013, NEUROSCIENTIST, V19, P175, DOI 10.1177/1073858412444007; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; Pennypacker KR, 2000, ACTA NEUROBIOL EXP, V60, P515; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pizzi M, 2006, EUR J PHARMACOL, V545, P22, DOI 10.1016/j.ejphar.2006.06.027; Qin ZH, 2007, ACTA PHARMACOL SIN, V28, P1859, DOI 10.1111/j.1745-7254.2007.00741.x; Quillinan Nidia, 2016, Anesthesiol Clin, V34, P453, DOI 10.1016/j.anclin.2016.04.011; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Schmeisser MJ, 2012, J NEUROSCI, V32, P5688, DOI 10.1523/JNEUROSCI.0111-12.2012; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt-Strassburger U, 2012, FASEB J, V26, P4990, DOI 10.1096/fj.12-208587; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Villasana LE, 2014, EXP NEUROL, V261, P156, DOI 10.1016/j.expneurol.2014.05.016; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang DB, 2014, BBA-MOL BASIS DIS, V1842, P1186, DOI 10.1016/j.bbadis.2013.12.015; Widera D, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.4.041804; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yang Li, 2007, Neurosci Bull, V23, P307, DOI 10.1007/s12264-007-0046-6; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008	77	40	42	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2018	32	4					1916	1932		10.1096/fj.201700826R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB4SP	WOS:000429051400015	29187362	Green Published			2022-02-06	
J	Alali, AS; Mukherjee, K; McCredie, VA; Golan, E; Shah, PS; Bardes, JM; Hamblin, SE; Haut, ER; Jackson, JC; Khwaja, K; Patel, NJ; Raj, SR; Wilson, LD; Nathens, AB; Patel, MB				Alali, Aziz S.; Mukherjee, Kaushik; McCredie, Victoria A.; Golan, Eyal; Shah, Prakesh S.; Bardes, James M.; Hamblin, Susan E.; Haut, Elliott R.; Jackson, James C.; Khwaja, Kosar; Patel, Nimitt J.; Raj, Satish R.; Wilson, Laura D.; Nathens, Avery B.; Patel, Mayur B.			Beta-blockers and Traumatic Brain Injury A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline	ANNALS OF SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		beta-blocker; cardiovascular; Eastern Association for the Surgery of Trauma; mortality; traumatic brain injury	HEAD-INJURY; CRASH TRIAL; DECOMPRESSIVE CRANIECTOMY; CEREBRAL PERFUSION; IMPROVED SURVIVAL; EARLY PROPRANOLOL; IMPROVE SURVIVAL; BLOCKADE; OUTCOMES; METOPROLOL	Objective: To determine if beta-(beta)-blockers improve outcomes after acute traumatic brain injury (TBI). Background: There have been no new inpatient pharmacologic therapies to improve TBI outcomes in a half-century. Treatment of TBI patients with beta-blockers offers a potentially beneficial approach. Methods: Using MEDLINE, EMBASE, and CENTRAL databases, eligible articles for our systematic review and meta-analysis (PROSPERO CRD42016048547) included adult (age >= 16 years) blunt trauma patients admitted with TBI. The exposure of interest was beta-blocker administration initiated during the hospitalization. Outcomes were mortality, functional measures, quality of life, cardiopulmonary morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure). Data were analyzed using a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI) and statistical heterogeneity (I-2). Results: Data were extracted from 9 included studies encompassing 2005 unique TBI patients with beta-blocker treatment and 6240 unique controls. Exposure to beta-blockers after TBI was associated with a reduction of inhospital mortality (pooled OR 0.39, 95% CI: 0.27-0.56; I-2 = 65%, P < 0.00001). None of the included studies examined functional outcome or quality of life measures, and cardiopulmonary adverse events were rarely reported. No clear evidence of reporting bias was identified. Conclusions: In adults with acute TBI, observational studies reveal a significant mortality advantage with beta-blockers; however, quality of evidence is very low. We conditionally recommend the use of in-hospital beta-blockers. However, we recommend further high-quality trials to answer questions about the mechanisms of action, effectiveness on subgroups, dose-response, length of therapy, functional outcome, and quality of life after beta-blocker use for TBI.	[Alali, Aziz S.; McCredie, Victoria A.; Golan, Eyal] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Mukherjee, Kaushik] Loma Linda Univ, Med Ctr, Dept Surg, Div Acute Care Surg, Loma Linda, CA 92350 USA; [Mukherjee, Kaushik; Bardes, James M.; Haut, Elliott R.; Khwaja, Kosar; Patel, Nimitt J.; Patel, Mayur B.] Eastern Assoc Surg Trauma, Chicago, IL USA; [McCredie, Victoria A.; Golan, Eyal] Univ Hlth Network, Dept Crit Care, Toronto, ON, Canada; [Golan, Eyal] Mackenzie Hlth, Div Crit Care, Toronto, ON, Canada; [Golan, Eyal] Mackenzie Hlth, Dept Med, Toronto, ON, Canada; [Shah, Prakesh S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Bardes, James M.] West Virginia Univ, Dept Surg, Morgantown, WV 26506 USA; [Bardes, James M.] USC LAC, Dept Surg, Los Angeles, CA USA; [Hamblin, Susan E.] Vanderbilt Univ, Med Ctr, Dept Pharmaceut Serv, 221 Kirkland Hall, Nashville, TN 37235 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; [Jackson, James C.] Vanderbilt Univ, Med Ctr, Div Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Jackson, James C.] Vanderbilt Univ, Med Ctr, Dept Med, Ctr Hlth Serv Res, 221 Kirkland Hall, Nashville, TN 37235 USA; [Jackson, James C.] Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Res Serv, Nashville, TN USA; [Khwaja, Kosar] McGill Univ, Hlth Ctr, Dept Surg, Montreal, PQ, Canada; [Khwaja, Kosar] McGill Univ, Hlth Ctr, Dept Crit Care Med, Montreal, PQ, Canada; [Patel, Nimitt J.] Metrohlth Med Ctr, Dept Surg, Div Trauma Crit Care & Burns, Cleveland, OH 44109 USA; [Raj, Satish R.] Univ Calgary, Libin Cardiovasc Inst, Dept Cardiac Sci, Calgary, AB, Canada; [Wilson, Laura D.] Univ Tulsa, Oxley Coll Hlth Sci, Dept Commun Sci & Disorders, Tulsa, OK 74104 USA; [Wilson, Laura D.] Vanderbilt Univ, Sch Med, Dept Hearing & Speech Sci, Nashville, TN 37212 USA; [Nathens, Avery B.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Nathens, Avery B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Patel, Mayur B.] Vanderbilt Univ, Vanderbilt Brain Inst,Dept Surg, Vanderbilt Ctr Hlth Serv Res,Sect Surg Sci, Med Ctr,Div Trauma Emergency Gen Surg & Crit Care, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Vanderbilt Brain Inst,Sect Surg Sci,Dept Neurosur, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] Vanderbilt Univ, Vanderbilt Brain Inst,Sect Surg Sci, Vanderbilt Ctr Hlth Serv Res, Med Ctr,Dept Hearing & Speech Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville VA Med Ctr, Gen Surg Sect,Surg Serv, Nashville, TN USA		Patel, MB (corresponding author), 1211 21st Ave South,404 Med Arts Bldg, Nashville, TN 37212 USA.	mayur.b.patel@vanderbilt.edu	Shah, Prakesh S/I-8098-2013; Haut, Elliott R./J-3948-2019; Shah, Prakesh/AAA-9884-2020	Haut, Elliott/0000-0001-7075-771X; Bardes, James/0000-0002-9361-6263	Vanderbilt Institute for Clinical and Translational Research via CTSA grant [VR1584, VR5351, VR9276, VR12073, UL1TR000011]; EAST Trauma Foundation Research Scholarship; PfizerPfizer; AHRQ grant of a PCORI contractPatient-Centered Outcomes Research Institute - PCORI [R01HS024547, CE-12-11-4489]; VHA/Vizient IMPERATIV Advantage Performance Improvement Collaborative; Illinois Surgical Quality Improvement Collaborative; National Academies of Medicine; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS024547] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445, UL1TR002243] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	Dr MBP has been or is supported by the Vanderbilt Institute for Clinical and Translational Research awards (VR1584, VR5351, VR9276, VR12073) via CTSA grant UL1TR000011 (NCRR/NCATS/NIH), a 2013 EAST Trauma Foundation Research Scholarship, and speaker fees from Pfizer. Drs ERH and MBP have served on the EAST Guidelines Section and Board of Directors. Dr ERH is the primary investigator of a AHRQ grant (R01HS024547) of a PCORI contract (CE-12-11-4489). Dr ERH receives book royalties from Lippincott, Williams, Wilkins ("Avoiding Common ICU Errors''), consultant and speaker fees from VHA/Vizient IMPERATIV Advantage Performance Improvement Collaborative, and consultant and speaker fees for the Illinois Surgical Quality Improvement Collaborative. Dr ERH was the paid author of a paper commissioned by the National Academies of Medicine.	Alali AS, 2014, NEUROCRIT CARE, V20, P514, DOI 10.1007/s12028-013-9903-5; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Alderson P, 1999, BRIT MED J, V319, P1068, DOI 10.1136/bmj.319.7216.1068a; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2009, J Am Coll Cardiol, V54, P2102, DOI 10.1016/j.jacc.2009.07.004; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bukur M, 2012, AM J SURG, V204, P697, DOI 10.1016/j.amjsurg.2012.02.007; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coppola S, 2015, ANN UPDATE INTENSIVE, P139; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Evans David C, 2014, J Emerg Trauma Shock, V7, P305, DOI 10.4103/0974-2700.142766; Friedman A, 2014, EXPERT REV NEUROTHER, V14, P1365, DOI 10.1586/14737175.2014.972945; FUCHS HJ, 1980, DEUT MED WOCHENSCHR, V105, P1531, DOI 10.1055/s-2008-1070906; Grande P O, 1994, Nord Med, V109, P157; Gregson B, 1999, BRIT MED J, V319, P578, DOI 10.1136/bmj.319.7209.578; Griffin GD, 2015, MED HYPOTHESES, V85, P224, DOI 10.1016/j.mehy.2015.05.005; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hadjizacharia P, 2011, AM SURGEON, V77, P634; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Henden PL, 2014, J NEUROSURG ANESTH, V26, P50, DOI 10.1097/ANA.0b013e3182a47b62; Hendrick LE, 2016, AM SURGEON, V82, P575; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kerwin AJ, 2012, J TRAUMA ACUTE CARE, V73, pS283, DOI 10.1097/TA.0b013e31827013e9; Ko A, 2016, J TRAUMA ACUTE CARE, V80, P637, DOI 10.1097/TA.0000000000000959; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Koskinen LOD, 2014, NEUROSCIENCE, V283, P245, DOI 10.1016/j.neuroscience.2014.06.039; Lewis PR, 2016, J TRAUMA ACUTE CARE, V80, P643, DOI 10.1097/TA.0000000000000957; Ley EJ, 2010, J SURG RES, V163, P142, DOI 10.1016/j.jss.2010.04.046; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Mohseni S, 2015, WORLD J SURG, V39, P2076, DOI 10.1007/s00268-015-3039-z; Mohseni S, 2014, J TRAUMA ACUTE CARE, V76, P804, DOI 10.1097/TA.0000000000000139; Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477; Murry JS, 2016, J SURG RES, V200, P221, DOI 10.1016/j.jss.2015.06.045; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 2014, INTENS CARE MED, V24, P446; Neideen T, 2008, J TRAUMA, V65, P1016, DOI 10.1097/TA.0b013e3181897eac; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Radosevich JJ, 2013, BRAIN INJURY, V27, P1492, DOI 10.3109/02699052.2013.823658; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Shoup JP, 2014, J NEUROL SCI, V336, P127, DOI 10.1016/j.jns.2013.10.022; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Song D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/873590; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stein D., 2016, OPINION WHY MOST TBI; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; van den Bergh WM, 2016, NETH J CRIT CARE, V24, P6; Velayutham PK, 2013, J SURG RES, V179, P125, DOI 10.1016/j.jss.2012.09.005; Webb A, GREATER TRANSMISSION; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Zangbar B, 2016, J SURG RES, V200, P586, DOI 10.1016/j.jss.2015.08.020	73	40	40	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	DEC	2017	266	6					952	961		10.1097/SLA.0000000000002286			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	FR4FZ	WOS:000419022400108	28525411	Green Accepted			2022-02-06	
J	Asken, BM; Snyder, AR; Clugston, JR; Gaynor, LS; Sullan, MJ; Bauer, RM				Asken, Breton M.; Snyder, Aliyah R.; Clugston, James R.; Gaynor, Leslie S.; Sullan, Molly J.; Bauer, Russell M.			Concussion-Like Symptom Reporting in Non-Concussed Collegiate Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						SCAT3; Post-Concussion Scale; Post-concussion syndrome; College; Brain injury; Athlete	SPORTS-RELATED CONCUSSION; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; HIGH-SCHOOL; BASE-LINE; NEUROCOGNITIVE PERFORMANCE; EXPECTATION; PREDICTORS; DEPRESSION; RECOVERY	Objective: Non-concussed individuals may report a variety of concussion-like symptoms even in the absence of a diagnosed brain injury. Previous studies described concussion-like symptom reporting in adolescent athletes. This study provides complementary data on concussion-like symptoms in collegiate athletes. Methods: We analyzed baseline symptom scales from 738 collegiate athletes (452 men and 286 women) who completed either the Sport Concussion Assessment Tool, 3 Symptom Evaluation (S3SE; n = 377) or the Post-Concussion Scale (PCS; n = 361) and determined if subjects met criteria for diagnosis of International Classification of Diseases 10th Revision (ICD-10) postconcussional syndrome. Symptoms were grouped as somatic, cognitive, emotional, or sleep-related. We analyzed associations with medical history factors using chi-square analyses, and examined recovery time of a subset of concussed athletes based on baseline symptomatology (n = 117) with independent samples t-test. Results: Across all athletes, 120 (16.3%) reported baseline symptoms meeting criteria for ICD-10 postconcussional syndrome. Women were 1.7 times more likely to meet these criteria (21.7% vs. 12.8%, p = .002). Athletes completing the S3SE were 1.5 times more likely to meet criteria than those completing the PCS (p = .011). Previously diagnosed psychiatric disorder was significantly associated with emotional domain symptom reporting, and attention deficit-hyperactivity disorder diagnosis was associated with cognitive domain symptom reporting. On average, athletes meeting ICD-10 postconcussional syndrome criteria at baseline experienced longer recovery from concussion (t[115] = 2.35, p = .020). Conclusions: Non-concussed collegiate athletes report concussion-like symptoms at a clinically significant rate. Pre-injury medical history and reporting rates of concussion-like symptoms may explain variance in post-concussion symptom expression. Measured incidence of baseline postconcussional syndrome may, in part, depend on the symptom report measure that is used.	[Asken, Breton M.; Snyder, Aliyah R.; Gaynor, Leslie S.; Sullan, Molly J.; Bauer, Russell M.] Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Univ Athlet Assoc, Gainesville, FL 32610 USA		Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA.	basken8@phhp.ufl.edu	Snyder, Aliyah/AAT-6250-2020	Asken, Breton/0000-0001-8419-142X; Clugston, James/0000-0002-2103-1039; Snyder, Aliyah/0000-0003-1185-7424	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; U.S. Army Medical Research Acquisition Activity, Chandler Street, Ford Detrick MD; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	Data collection for this project was supported, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense (DHP funds).	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Blom G, 1958, STAT ESTIMATES TRANS; Brooks A, 2014, BR J SPORTS MED, V48, P573, DOI DOI 10.1136/BJSPORTS-2014-093494.38; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merritt VC, 2015, DEV NEUROPSYCHOL, V40, P45, DOI 10.1080/87565641.2014.979928; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Putukian M, 2003, CLIN SPORT MED, V22, P617, DOI 10.1016/S0278-5919(02)00100-X; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; SCAT3, 2013, BRIT J SPORT MED, V47, P259; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spielberger CD., 1983, STATE TRAIT ANXIETY; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265	44	40	40	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2017	32	8					963	971		10.1093/arclin/acx018			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	FN7AS	WOS:000416170000005	28334382	Bronze			2022-02-06	
J	Churchill, NW; Caverzasi, E; Graham, SJ; Hutchison, MG; Schweizer, TA				Churchill, Nathan W.; Caverzasi, Eduardo; Graham, Simon J.; Hutchison, Michael G.; Schweizer, Tom A.			White matter microstructure in athletes with a history of concussion: Comparing diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI)	HUMAN BRAIN MAPPING			English	Article						concussion; white matter; diffusion tensor imaging; NODDI	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; RECURRENT CONCUSSION; AXONAL INJURY; RECOVERY; STATE	Sport concussion is associated with disturbances in brain function in the absence of gross anatomical lesions, and may have long-term health consequences. Diffusion-weighted magnetic resonance imaging (MRI) methods provide a powerful tool for investigating alterations in white matter microstructure reflecting the long-term effects of concussion. In a previous study, diffusion tensor imaging (DTI) showed that athletes with a history of concussion had elevated fractional anisotropy (FA) and reduced mean diffusivity (MD) parameters. To better understand these effects, this study compared DTI results to neurite orientation dispersion and density imaging (NODDI), which was used to estimate the intracellular volume fraction (V-IC) and orientation dispersion index (ODI). Sixty-eight (68) varsity athletes were recruited, including 37 without a history of concussion and 31 with concussion >6 months prior to imaging. Univariate analyses showed elevated FA and decreased MD for concussed athletes, along with increased V-IC and reduced ODI, indicating greater neurite density and coherence of neurite orientation within white matter. Multivariate analyses also showed that for athletes with a history of concussion, white matter regions with increased FA had increased V-IC and decreased ODI, with greater effects among athletes who were imaged a longer time since their last concussion. These findings enhance our understanding of the relationship between the biophysics of water diffusion and concussion neurobiology for young, healthy adults. Hum Brain Mapp 38:4201-4211, 2017. (c) 2017 Wiley Periodicals, Inc.	[Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Churchill, Nathan W.; Schweizer, Tom A.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Caverzasi, Eduardo] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Caverzasi, Eduardo] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Graham, Simon J.] Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Div Neurosurg, Fac Med, Toronto, ON, Canada		Churchill, NW (corresponding author), 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com	Caverzasi, Eduardo/P-1707-2019	Caverzasi, Eduardo/0000-0002-0350-0460	Siemens Canada, Ltd.; Canadian Institutes of Military and Veterans Health (CIMVHR); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	Contract grant sponsors: Siemens Canada, Ltd., Canadian Institutes of Military and Veterans Health (CIMVHR), and Canadian Institutes of Health Research (CIHR)	Adluru G, 2014, IEEE ENG MED BIO, P742, DOI 10.1109/EMBC.2014.6943697; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bro R., 1996, J CHEMOMETRICS, V10; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Caverzasi E, 2016, J NEUROIMAG; Chang YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123656; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Churchill N, 2016, J NEUROTRAUMA; Colgan N, 2016, NEUROIMAGE, V125, P739, DOI 10.1016/j.neuroimage.2015.10.043; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Mayer AR, 2016, BRAIN IMAGING BEHAV, P1; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe V, 2007, BR J NEUROSURG; Owen JP, 2014, J NEUROSCI, V34, P6214, DOI 10.1523/JNEUROSCI.4495-13.2014; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Tremblay S, 2014, BRAIN; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	44	40	43	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	AUG	2017	38	8					4201	4211		10.1002/hbm.23658			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ8GV	WOS:000404963900030	28556431	Bronze, Green Published			2022-02-06	
J	Lin, C; Chao, HL; Li, Z; Xu, XP; Liu, YL; Bao, ZY; Hou, LJ; Liu, Y; Wang, XM; You, YP; Liu, N; Ji, J				Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Bao, Zhongyuan; Hou, Lijun; Liu, Yan; Wang, Xiaoming; You, Yongping; Liu, Ning; Ji, Jing			Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Inflammation; NLRP3; omega-3 FAs	INTRACEREBRAL HEMORRHAGE; INSULIN-SECRETION; CLINICAL-TRIALS; FATTY-ACIDS; ER STRESS; SUPPLEMENTATION; TARGET; CELLS; MODEL; GPR40	Omega-3 fatty acids (omega-3 FAS) attenuate inflammation and improve neurological outcome in response to traumatic brain injury (TBI), but the specific anti-inflammatory mechanisms remain to be elucidated. Here we found that NLRP3 inflammasome and subsequent pro-inflammatory cytokines were activated in human brains after TBI. Rats treated with omega-3 FM had significantly less TBI-induced caspase-1 cleavage and IL-1 beta secretion than those with vehicle. G protein-coupled receptor 40 (GPR40) was observed to be involved in this anti-inflammation. GW1100, a GPR40 inhibitor, eliminated the anti-inflammatory effect of omega-3 FAs after TBI. beta-Arrestin-2 (ARRB2), a downstream scaffold protein of GPR40, was activated to inhibit inflammation via directly binding with NLRP3 in the omega-3 FAs treatment group. Interestingly, we also observed that omega-3 FAs prevented NLRP3 mitochondrial localization, which was reversed by GW1100. Furthermore, omega-3 FAs markedly ameliorated neuronal death and behavioral deficits after TBI, while GW1100 significantly suppressed this effect. Collectively, these data indicate that the GPR40-mediated pathway is involved in the inhibitory effects of omega-3 FAs on TBI-induced inflammation and ARRB2 is activated to interact with NLRP3. (C) 2017 Published by Elsevier Inc.	[Lin, Chao; Chao, Honglu; Li, Zheng; Xu, Xiupeng; Liu, Yinlong; Bao, Zhongyuan; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Hou, Lijun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Liu, Yan] Nanjing Med Univ, Sch Pharm, Inst Stem Cell & Neural Regenerat, Nanjing, Jiangsu, Peoples R China; [Wang, Xiaoming] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China		Liu, N; Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	liuning_0853@163.com; jijing@njmu.edu.cn			Jiangsu Innovation Project, China Scholarship Council [201508320270]; Provincial Initiative Program for Excellency Disciplines [20142101]; Jiangsu Province's Key Discipline of Medicine [XK201117]; Jiangsu Province; Outstanding Youth of Jiangsu Province [BK20160047, BK20160044]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998, 31570881]; Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD)	`This study was supported by Jiangsu Innovation Project, China Scholarship Council (201508320270), the Provincial Initiative Program for Excellency Disciplines (20142101, Chao Lin), Jiangsu Province's Key Discipline of Medicine (XK201117), Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD), Outstanding Youth of Jiangsu Province (BK20160047 and BK20160044), and National Natural Science Foundation of China (81471269, 81300998, and 31570881)	Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hashimoto M, 2002, J NEUROCHEM, V81, P1084, DOI 10.1046/j.1471-4159.2002.00905.x; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jones ML, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103754; Khan M.Z., 2015, NEUROPHARMACOLOGY; Kumar Parvathy R, 2014, J Tradit Complement Med, V4, P89, DOI 10.4103/2225-4110.130374; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lewis M, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.014; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lin C., 2016, J PINEAL RES; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Lin C, 2013, J NEUROSURG, V118, P364, DOI 10.3171/2012.9.JNS12702; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Nakamoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081563; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Potts Mathew B, 2006, NeuroRx, V3, P143; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Stonehouse W, 2014, NUTRIENTS, V6, P2730, DOI 10.3390/nu6072730; Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang WJ, 2013, ECOSPHERE, V4, DOI 10.1890/ES13-00040.1; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xi G, 2002, ACT NEUR S, V81, P253; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	39	40	43	2	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						115	122		10.1016/j.expneurol.2017.01.005			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EM5QR	WOS:000395368000011	28077335				2022-02-06	
J	Robinson, S; Berglass, JB; Denson, JL; Berkner, J; Anstine, CV; Winer, JL; Maxwell, JR; Qiu, JH; Yang, YR; Sillerud, LO; Meehan, WP; Mannix, R; Jantzie, LL				Robinson, Shenandoah; Berglass, Jacqueline B.; Denson, Jesse L.; Berkner, Justin; Anstine, Christopher V.; Winer, Jesse L.; Maxwell, Jessie R.; Qiu, Jianhua; Yang, Yirong; Sillerud, Laurel O.; Meehan, William P., III; Mannix, Rebekah; Jantzie, Lauren L.			Microstructural and Microglial Changes After Repetitive Mild Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						DTI; microhemorrhage; inflammation; SWI; axial diffusion; RRID:AB_2314667; RRID:AB_323909; RRID:AB_2144905	TUMOR-NECROSIS-FACTOR; DIFFUSE AXONAL INJURY; WHITE-MATTER; CEREBRAL MICROBLEEDS; MOUSE MODEL; SPINAL-CORD; TENSOR; RECEPTOR; TRACTOGRAPHY; VALIDATION	Traumatic brain injury (TBI) is a major public health issue, with recently increased awareness of the potential long-term sequelae of repetitive injury. Although TBI is common, objective diagnostic tools with sound neurobiological predictors of outcome are lacking. Indeed, such tools could help to identify those at risk for more severe outcomes after repetitive injury and improve understanding of biological underpinnings to provide important mechanistic insights. We tested the hypothesis that acute and subacute pathological injury, including the microgliosis that results from repeated mild closed head injury (rmCHI), is reflected in susceptibility-weighted magnetic resonance imaging and diffusion-tensor imaging microstructural abnormalities. Using a combination of high-resolution magnetic resonance imaging, stereology, and quantitative PCR, we studied the pathophysiology of male mice that sustained seven consecutive mild traumatic brain injuries over 9 days in acute (24 hr) and subacute (1 week) time periods. rmCHI induced focal cortical microhemorrhages and impaired axial diffusivity at 1 week postinjury. These microstructural abnormalities were associated with a significant increase in microglia. Notably, microgliosis was accompanied by a change in inflammatory microenvironment defined by robust spatiotemporal alterations in tumor necrosis factor-a receptor mRNA. Together these data contribute novel insight into the fundamental biological processes associated with repeated mild brain injury concomitant with subacute imaging abnormalities in a clinically relevant animal model of repeated mild TBI. These findings suggest new diagnostic techniques that can be used as biomarkers to guide the use of future protective or reparative interventions. (C) 2016 Wiley Periodicals, Inc.	[Robinson, Shenandoah; Winer, Jesse L.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurosurg, Kirby Ctr Neurobiol, Boston, MA USA; [Robinson, Shenandoah; Winer, Jesse L.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Kirby Ctr Neurobiol, Boston, MA USA; [Robinson, Shenandoah] Johns Hopkins Univ, Pediat Neurosurg, Baltimore, MD USA; [Berglass, Jacqueline B.; Berkner, Justin; Qiu, Jianhua; Meehan, William P., III; Mannix, Rebekah] Harvard Med Sch, Boston Childrens Hosp, Dept Emergency Med, Boston, MA USA; [Anstine, Christopher V.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA; [Anstine, Christopher V.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Yang, Yirong; Sillerud, Laurel O.; Meehan, William P., III] Univ New Mexico, Dept Neurol, BRaIN, Albuquerque, NM 87131 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Jantzie, LL (corresponding author), Dept Pediat, MSC10 5590,1 Univ New Mexico, Albuquerque, NM 87131 USA.	ljantzie@salud.unm.edu	Mannix, Rebekah/AAD-8702-2020; Maxwell, Jessie R./N-1890-2019	Maxwell, Jessie R./0000-0001-8990-7239	Centers for Biomedical Research Excellence [Jantzie/CoBRE P30GM103400]; National Hockey League Alumni Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	Contract grant sponsor: Centers for Biomedical Research Excellence; Contract grant number: Jantzie/CoBRE P30GM103400/Pi:Liu; Contract grant sponsor: National Hockey League Alumni Association	Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Bruce ED, 2015, MOL CELL NEUROSCI, V66, P103, DOI 10.1016/j.mcn.2015.03.017; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Erickson MA, 2011, BRAIN BEHAV IMMUN, V25, P1637, DOI 10.1016/j.bbi.2011.06.006; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fox RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1179, DOI 10.1001/archneur.65.9.1179; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Jantzie LL, 2014, MOL CELL NEUROSCI, V61, P152, DOI 10.1016/j.mcn.2014.06.009; Jantzie LL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-131; Kallakuri S, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.166354; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu SF, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3552; Liu S, 2014, J HISTOCHEM CYTOCHEM, V62, P767, DOI 10.1369/0022155414546692; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mori Y, 2014, INT IMMUNOL, V26, P93, DOI 10.1093/intimm/dxt044; Mouton, 2014, NEUROSTEREOLOGY UNBI; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Naude PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742-4658.2011.08017.x; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Owen JP, 2013, NEUROIMAGE-CLIN, V2, P844, DOI 10.1016/j.nicl.2013.06.009; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robinson S, 2016, J NEUROSURG-PEDIATR, V17, P739, DOI 10.3171/2015.10.PEDS15554; Toth A, 2016, NEUROSCI LETT, V617, P207, DOI 10.1016/j.neulet.2016.02.028; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229	49	40	40	0	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2017	95	4					1025	1035		10.1002/jnr.23848			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EJ8DP	WOS:000393455500008	27452502	Green Accepted			2022-02-06	
J	Ji, XR; Peng, DY; Zhang, YL; Zhang, J; Wang, YN; Gao, Y; Lu, N; Tang, PF				Ji, Xinran; Peng, Dayong; Zhang, Yiling; Zhang, Jun; Wang, Yuning; Gao, Yuan; Lu, Ning; Tang, Peifu			Astaxanthin improves cognitive performance in mice following mild traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Astaxanthin; NSS; Rotarod test; Y-maze; Object recognition test; Growth-associated protein; Synaptic protein	CLOSED-HEAD INJURY; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; OXIDATIVE STRESS; IN-VITRO; RATS; PATHOPHYSIOLOGY; DEFICITS; PATHWAY; MOTOR; NEUROINFLAMMATION	Background: Traumatic brain injury (TBI) produces lasting neurological deficits that plague patients and physicians. To date, there is no effective method to combat the source of this problem. Here, we utilized a mild, closed head TBI model to determine the modulatory effects of a natural dietary compound, astaxanthin (AST). AST is centrally active following oral administration and is neuroprotective in experimental brain ischemia/stroke and subarachnoid hemorrhage (SAH) models. We examined the effects of oral AST on the long-term neurological functional recovery and histological outcomes following moderate TBI in a mice model. Methods: Male adult ICR mice were divided into 3 groups: (1) Sham + olive oil vehicle treated, (2) TBI + olive oil vehicle treated, and (3) TBI + AST. The olive oil vehicle or AST were administered via oral gavage at scheduled time points. Closed head brain injury was applied using M.A. Flierl weight-drop method. NSS, Rotarod, ORT, and Y-maze were performed to test the behavioral or neurological outcome. The brain sections from the mice were stained with H&E and cresyl-violet to test the injured lesion volume and neuronal loss. Western blot analysis was performed to investigate the mechanisms of neuronal cell survival and neurological function improvement. Results: AST administration improved the sensorimotor performance on the Neurological Severity Score (NSS) and rotarod test and enhanced cognitive function recovery in the object recognition test (ORT) and Y-maze test. Moreover, AST treatment reduced the lesion size and neuronal loss in the cortex compared with the vehicle-treated TBI group. AST also restored the levels of brain-derived neurotropic factor (BDNF), growth-associated protein-43 (GAP-43), synapsin, and synaptophysin (SYP) in the cerebral cortex, which indicates the promotion of neuronal survival and plasticity. Conclusion: To the best of our knowledge, this is the first study to demonstrate the protective role and the underlining mechanism of AST in TBI. Based on these neuroprotective actions and considering its long-standing clinical use, AST should be considered for the clinical treatment of TBI. (C) 2017 Elsevier B.V. All rights reserved.	[Ji, Xinran; Zhang, Yiling; Zhang, Jun; Wang, Yuning; Gao, Yuan; Lu, Ning; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed Surg, 28 Fuxing Rd, Beijing 100000, Peoples R China; [Peng, Dayong] Shandong Univ, Shandong Qianfoshan Hosp, Dept Orthoped, Jing Shi Rd, Jinan 250014, Shandong, Peoples R China		Lu, N; Tang, PF (corresponding author), Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed Surg, 28 Fuxing Rd, Beijing 100000, Peoples R China.	luning301@126.com; tangpeifu301@126.com					Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chew BP, 2004, J NUTR, V134, p257S, DOI 10.1093/jn/134.1.257S; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kidd PM, 2009, ALTERN MED REV, V14, P14; Kuzelova K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Lin TY, 2010, J AGR FOOD CHEM, V58, P8271, DOI 10.1021/jf101689t; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Parchani A, 2014, WORLD NEUROSURG, V82, pE639, DOI 10.1016/j.wneu.2014.06.022; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Tripathi DN, 2010, MUTAT RES-GEN TOX EN, V696, P69, DOI 10.1016/j.mrgentox.2009.12.014; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang HQ, 2010, BRAIN RES, V1360, P159, DOI 10.1016/j.brainres.2010.08.100; Wang MR, 2013, FOOD CHEM TOXICOL, V56, P450, DOI 10.1016/j.fct.2013.03.004; Weng SM, 2011, NEUROSCIENCE, V180, P314, DOI 10.1016/j.neuroscience.2011.01.061; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	45	40	41	1	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 15	2017	1659						88	95		10.1016/j.brainres.2016.12.031			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EM8ZH	WOS:000395600000010	28048972				2022-02-06	
J	Li, X; Tan, J; Xiao, ZF; Zhao, YN; Han, SF; Liu, DY; Yin, W; Li, J; Li, J; Wanggou, SY; Chen, B; Ren, CP; Jiang, XJ; Dai, JW				Li, Xing; Tan, Jun; Xiao, Zhifeng; Zhao, Yannan; Han, Sufang; Liu, Dingyang; Yin, Wen; Li, Jing; Li, Juan; Wanggou, Siyi; Chen, Bing; Ren, Caiping; Jiang, Xingjun; Dai, Jianwu			Transplantation of hUC-MSCs seeded collagen scaffolds reduces scar formation and promotes functional recovery in canines with chronic spinal cord injury	SCIENTIFIC REPORTS			English	Article							MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; AXONAL REGENERATION; REPARATIVE RESPONSE; NERVE REGENERATION; RAT; TRANSECTION; FACILITATE; STRATEGIES; IMPROVE	Spinal cord injury (SCI) can lead to locomotor deficits, and the repair of chronic SCI is considered one of the most challenging clinical problems. Although extensive studies have evaluated treatments for acute SCI in small animals, comparatively fewer studies have been conducted on large-animal SCI in the chronic phase, which is more clinically relevant. Here, we used a collagen-based biomaterial, named the NeuroRegen scaffold, loaded with human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in a canine chronic SCI model. To generate chronic SCI, the T8 spinal cord segment was removed by complete transection of the spinal cord. Two months later, glial scar tissue was removed and a NeuroRegen scaffold was transplanted into the lesion area. Functionalized NeuroRegen scaffold implantation promoted both locomotor recovery and endogenous neurogenesis in the lesion area. Moreover, some newly generated neurons successfully matured into 5-HT-positive neurons at 1 year post-injury. In addition, many regenerated axon fibers in the lesion area exhibited remyelination and synapse formation at 1 year post-injury in the functionalized NeuroRegen scaffold group. In conclusion, the NeuroRegen scaffold functionalized with hUC-MSCs is a promising potential therapeutic approach to chronic SCI that promotes neuronal regeneration, reduces glial scar formation, and ultimately improves locomotor recovery.	[Li, Xing; Xiao, Zhifeng; Zhao, Yannan; Han, Sufang; Li, Jing; Chen, Bing; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China; [Tan, Jun; Liu, Dingyang; Yin, Wen; Li, Juan; Wanggou, Siyi; Jiang, Xingjun] Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Ren, Caiping] Cent S Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha 410008, Hunan, Peoples R China		Dai, JW (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China.; Jiang, XJ (corresponding author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	jiangxingjun@sina.com; jwdai@genetics.ac.cn			Strategic Priority Research Program of the Chinese Academy of SciencesChinese Academy of Sciences [XDA01030000]; Program of the Chinese Academy of SciencesChinese Academy of Sciences [ZDRW-ZS-2016-2]	This work was supported by the "Strategic Priority Research Program of the Chinese Academy of Sciences" (grant no. XDA01030000), the Key Research Program of the Chinese Academy of Sciences (grant no. ZDRW-ZS-2016-2).	Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Ceballos D, 1999, EXP NEUROL, V158, P290, DOI 10.1006/exnr.1999.7111; Cholas R, 2012, TISSUE ENG PT A, V18, P2158, DOI [10.1089/ten.tea.2011.0577, 10.1089/ten.TEA.2011.0577]; Cholas RH, 2012, BIOMATERIALS, V33, P2050, DOI 10.1016/j.biomaterials.2011.11.028; Crespo D, 2007, EXP NEUROL, V206, P159, DOI 10.1016/j.expneurol.2007.05.001; Dasari Venkata Ramesh, 2014, World J Stem Cells, V6, P120, DOI 10.4252/wjsc.v6.i2.120; De Miguel MP, 2012, CURR MOL MED, V12, P574; Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841; English K, 2010, CELL STEM CELL, V7, P431, DOI 10.1016/j.stem.2010.09.009; Fan JA, 2010, J NEUROTRAUM, V27, P1671, DOI 10.1089/neu.2010.1281; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Hamilton LK, 2009, NEUROSCIENCE, V164, P1044, DOI 10.1016/j.neuroscience.2009.09.006; Han QQ, 2009, TISSUE ENG PT A, V15, P2927, DOI [10.1089/ten.tea.2008.0506, 10.1089/ten.TEA.2008.0506]; Han QQ, 2010, BIOMATERIALS, V31, P9212, DOI 10.1016/j.biomaterials.2010.08.040; Han S, 2014, SPINAL CORD, V52, P867, DOI 10.1038/sc.2014.173; Han SF, 2016, J BIOMED MATER RES A, V104, P1759, DOI 10.1002/jbm.a.35708; Han SF, 2015, BIOMATERIALS, V41, P89, DOI 10.1016/j.biomaterials.2014.11.031; Harness ET, 2008, SPINAL CORD, V46, P733, DOI 10.1038/sc.2008.56; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Jeffery ND, 2005, J NEUROTRAUM, V22, P1282, DOI 10.1089/neu.2005.22.1282; Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027; Kadoya K, 2009, NEURON, V64, P165, DOI 10.1016/j.neuron.2009.09.016; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Labrador RO, 1998, EXP NEUROL, V149, P243, DOI 10.1006/exnr.1997.6650; Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; Lee JH, 2011, J NEUROL SCI, V300, P86, DOI 10.1016/j.jns.2010.09.025; Lin H, 2006, J BIOMED MATER RES A, V79A, P591, DOI 10.1002/jbm.a.30862; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Olby NJ, 2001, AM J VET RES, V62, P1624, DOI 10.2460/ajvr.2001.62.1624; Oliveri RS, 2014, NEUROBIOL DIS, V62, P338, DOI 10.1016/j.nbd.2013.10.014; Pearse DD, 2006, J NEUROTRAUM, V23, P438, DOI 10.1089/neu.2006.23.437; Qin Y, 2015, J NEUROSCI RES, V93, P391, DOI 10.1002/jnr.23480; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Rocha LB, 2002, BIOMATERIALS, V23, P449, DOI 10.1016/S0142-9612(01)00126-0; Sabelstrom H, 2014, EXP NEUROL, V260, P44, DOI 10.1016/j.expneurol.2013.01.026; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Torbet J, 2007, BIOMATERIALS, V28, P4268, DOI 10.1016/j.biomaterials.2007.05.024; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; van Velthoven CTJ, 2012, PEDIATR RES, V71, P474, DOI 10.1038/pr.2011.64; Yang ZY, 2015, P NATL ACAD SCI USA, V112, P13354, DOI 10.1073/pnas.1510194112	49	40	44	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 6	2017	7								43559	10.1038/srep43559			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EM6OE	WOS:000395431200001	28262732	Green Published, gold			2022-02-06	
J	Rizoli, SB; Jaja, BNR; Di Battista, AP; Rhind, SG; Neto, AC; da Costa, L; Inaba, K; da Luz, LT; Nascimento, B; Perez, A; Baker, AJ; Manoel, ALD				Rizoli, Sandro B.; Jaja, Blessing N. R.; Di Battista, Alex P.; Rhind, Shawn G.; Neto, Antonio Capone; da Costa, Leodante; Inaba, Kenji; da Luz, Luis Teodoro; Nascimento, Bartolomeu; Perez, Adic; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira			Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study	CRITICAL CARE			English	Article						Traumatic brain injury; Catecholamines; Epinephrine; Norepinephrine; Functional outcome	CARDIAC SEQUELAE; EPIDEMIOLOGY; EPINEPHRINE; THERAPY; EDEMA	Background: Elevated catecholamine levels might be associated with unfavorable outcome after traumatic brain injury (TBI). We investigated the association between catecholamine levels in the first 24 h post-trauma and functional outcome in patients with isolated moderate-to-severe TBI. Methods: A cohort of 174 patients who sustained isolated blunt TBI was prospectively enrolled from three Level-1 Trauma Centers. Epinephrine (Epi) and norepinephrine (NE) concentrations were measured at admission (baseline), 6, 12 and 24 h post-injury. Outcome was assessed at 6 months by the extended Glasgow Outcome Scale (GOSE) score. Fractional polynomial plots and logistic regression models (fixed and random effects) were used to study the association between catecholamine levels and outcome. Effect size was reported as the odds ratio (OR) associated with one logarithmic change in catecholamine level. Results: At 6 months, 109 patients (62.6%) had an unfavorable outcome (GOSE 5-8 vs. 1-4), including 51 deaths (29.3%). Higher admission levels of Epi were associated with a higher risk of unfavorable outcome (OR, 2.04, 95% CI: 1.31-3.18, p = 0.002) and mortality (OR, 2.86, 95% CI: 1.62-5.01, p = 0.001). Higher admission levels of NE were associated with higher risk of unfavorable outcome (OR, 1.59, 95% CI: 1.07-2.35, p = 0.022) but not mortality (OR, 1. 45, 95% CI: 0.98-2.17, p = 0.07). There was no relationship between the changes in Epi levels over time and mortality or unfavorable outcome. Changes in NE levels with time were statistically associated with a higher risk of mortality, but the changes had no relation to unfavorable outcome. Conclusions: Elevated circulating catecholamines, especially Epi levels on hospital admission, are independently associated with functional outcome and mortality after isolated moderate-to-severe TBI.	[Rizoli, Sandro B.; Perez, Adic; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Jaja, Blessing N. R.; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Rizoli, Sandro B.; Di Battista, Alex P.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rhind, Shawn G.] Toronto Res Ctr, DRDC, Toronto, ON, Canada; [Neto, Antonio Capone] Hosp Israelita Albert Einstein, Ave Albert Einstein,627-701 Morumbi, BR-05652900 Sao Paulo, SP, Brazil; [da Costa, Leodante; da Luz, Luis Teodoro; Nascimento, Bartolomeu; Perez, Adic] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Inaba, Kenji] Univ Southern Calif, IPT, 2051 Marengo St,C5L100, Los Angeles, CA 90033 USA; [Jaja, Blessing N. R.; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Li Ka Shing Knowledge Inst, Neurosci Res Program, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada		Manoel, ALD (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Manoel, ALD (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Manoel, ALD (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Neurosci Res Program, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada.	airtonleo.manoel@gmail.com	de Oliveira Manoel, Airton Leonardo/C-4724-2018; INABA, KENJI/AAC-8532-2020	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Di Battista, Alex/0000-0002-3325-6833; Rhind, Shawn/0000-0003-2300-0620	Physician's Services Incorporation Foundation	This study was funded by a Research Grant awarded to Dr. Sandro Rizoli by the Physician's Services Incorporation Foundation.	Alali AS, 2014, NEUROCRIT CARE, V20, P514, DOI 10.1007/s12028-013-9903-5; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Di Battista AP, 2016, SHOCK, V46, P96, DOI 10.1097/SHK.0000000000000642; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Diaz EC, 2015, BURNS, V41, P649, DOI 10.1016/j.burns.2014.10.010; Dunser MW, 2009, CRIT CARE, V13, DOI 10.1186/cc8167; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LARREMORE T, 1983, BRIT HEART J, V49, P101; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Ristagno G, 2007, CRIT CARE MED, V35, P2145, DOI 10.1097/01.CCM.0000280427.76175.D2; Ristagno G, 2009, CRIT CARE MED, V37, P1408, DOI 10.1097/CCM.0b013e31819cedc9; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Simon RJ, 2004, J TRAUMA, V56, P269; TEASDALE G, 1974, LANCET, V2, P81; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1371/journal.pmed.0040297, 10.1371/journal.pmed.0040296, 10.1157/13119325, 10.1016/S0140-6736(07)61602-X]; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	35	40	41	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1364-8535	1466-609X		CRIT CARE	Crit. Care	FEB 23	2017	21								37	10.1186/s13054-017-1620-6			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM5HD	WOS:000395341700001	28228155	gold, Green Published			2022-02-06	
J	Akin, FW; Murnane, OD; Hall, CD; Riska, KM				Akin, Faith W.; Murnane, Owen D.; Hall, Courtney D.; Riska, Kristal M.			Vestibular consequences of mild traumatic brain injury and blast exposure: a review	BRAIN INJURY			English	Article						Mild brain injury; concussion; balance	PAROXYSMAL POSITIONAL VERTIGO; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; POSTURAL STABILITY; BALANCE DISORDERS; NOISE EXPOSURE; REHABILITATION; DIZZINESS; DYSFUNCTION; IMPAIRMENT	The purpose of this article is to review relevant literature on the effect of mild traumatic brain injury (mTBI) and blast injury on the vestibular system. Dizziness and imbalance are common sequelpe associated with mTBI; and in some individuals, these symptoms may last for six months or longer. In war-related injuries, mTBI is often associated with blast exposure. The causes of dizziness Or imbalance following mTBI and blast injuries have been linked to white matter abnormalities, diffuse axonal injury in the brain, and central and peripheral vestibular system damage. There is some evidence that the otolith organs may be more vulnerable to damage from blast exposure or mTBI than the horizontal semicircular canal's. In addition benign paroxysmal positional vertigo (BPPV) is a common vestibular disorder following head injury that is treated effectively with canalith repositioning therapy. Treatment for (non-BPPV) mTBI-related vestibular dysfunction has focused on the use of vestibular, rehabilitation (VR) augmented with additional rehabilitation methods and Medication: New treatment approaches may be necessary for effective otolith organ pathway recovery in addition to traditional VR for horizontal semicircular canal (vestibulo-ocular reflex) recovery.	[Akin, Faith W.; Murnane, Owen D.; Riska, Kristal M.] James H Quillen VA Med Ctr Mt Home, Vestibular Lab, Mountain Home, TN USA; [Akin, Faith W.; Murnane, Owen D.; Riska, Kristal M.] East Tennessee State Univ, Dept Audiol & Speech Language Pathol, Johnson City, TN 37614 USA; [Hall, Courtney D.] James H Quillen VA Med Ctr, Gait & Balance Lab, Mountain Home, TN USA; [Hall, Courtney D.] East Tennessee State Univ, Dept Phys Therapy, Johnson City, TN 37614 USA		Akin, FW (corresponding author), James H Quillen VA Med Ctr, Vestibular & Balance Lab, Mountain Home, TN 37684 USA.	Faith.Akin@va.gov					Ahn SK, 2011, J TRAUMA, V70, P442, DOI 10.1097/TA.0b013e3181d0c3d9; Akin FW, 2012, EAR HEARING, V33, P458, DOI 10.1097/AUD.0b013e3182498c5f; Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; [Anonymous], 2016, VADOD CLIN PRACT GUI; Balaban C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162168; Baldassarre M, 2015, PM&R, V7, P845, DOI 10.1016/j.pmrj.2015.03.003; BARBER H O, 1964, Laryngoscope, V74, P891; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Basta D, 2005, HUM MOVEMENT SCI, V24, P268, DOI 10.1016/j.humov.2005.04.002; Basta D, 2008, GAIT POSTURE, V28, P397, DOI 10.1016/j.gaitpost.2008.01.006; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chandrasekhar SS, 2013, NEUROREHABILITATION, V32, P445, DOI 10.3233/NRE-130867; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; Curthoys IS, 2007, VESTIBULAR REHABILIT; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Ettenhofer ML, 2016, J NEUROPSYCH CLIN N, V28, P223, DOI 10.1176/appi.neuropsych.15100243; Farrell L., 2014, ISRN REHABILITATION, V2, P1; Fife TD, 2008, NEUROLOGY, V70, P2067, DOI 10.1212/01.wnl.0000313378.77444.ac; Fife TD, 2000, NEUROLOGY, V55, P1431, DOI 10.1212/WNL.55.10.1431; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; Gattu R, BRAIN INJ IN PRESS; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; HALL SF, 1979, J OTOLARYNGOL, V8, P151; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Hsu WC, 2008, ARCH OTOLARYNGOL, V134, P1099, DOI 10.1001/archotol.134.10.1099; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lachman J, 1955, ACTA MED ORIENT, V14, P44; Lee JD, 2011, EUR ARCH OTO-RHINO-L, V268, P1427, DOI 10.1007/s00405-010-1426-5; Leigh RJ, 2001, NEUROLOGY EYE MOVEME; Lynn S, 1995, OTOLARYNG HEAD NECK, V113, P712, DOI 10.1016/S0194-5998(95)70010-2; Marshall S, 2015, BRAIN INJURY, P1; McDonnell MN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub4; Murray KJ, 2010, J NEUROL PHYS THER, V34, P70, DOI 10.1097/NPT.0b013e3181dde5dd; Naguib MB, 2014, J CHIROPR MED, V13, P14, DOI 10.1016/j.jcm.2014.01.011; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Perez R, 2002, LARYNGOSCOPE, V112, P1110, DOI 10.1097/00005537-200206000-00032; Picciotti PM, 2016, INT J AUDIOL, V55, P279, DOI 10.3109/14992027.2016.1143981; PROCTOR B, 1956, Laryngoscope, V66, P16; RUBIN AM, 1995, AM J OTOL, V16, P216; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Schneider KJ, 2014, BRIT J SPORT MED, P1; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; Serrador JM, 2012, P 35 ANN ASS RES OT; Serrador JM, 2009, NEUROSCI LETT, V465, P10, DOI 10.1016/j.neulet.2009.08.057; Sessoms PH, 2015, MIL MED, V180, P143, DOI 10.7205/MILMED-D-14-00385; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Tuohimaa P, 1978, Acta Otolaryngol Suppl, V359, P3; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Wang YP, 2006, OTOL NEUROTOL, V27, P956, DOI 10.1097/01.mao.0000231590.57348.4b; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wu CC, 2009, INT J AUDIOL, V48, P655, DOI 10.1080/14992020903012481; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	75	40	41	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1188	1194		10.1080/02699052.2017.1288928			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600005	28981340	hybrid			2022-02-06	
J	Feng, Y; Gao, JL; Cui, Y; Li, MH; Li, R; Cui, CM; Cui, JZ				Feng, Yan; Gao, Junling; Cui, Ying; Li, Minghang; Li, Ran; Cui, Changmeng; Cui, Jianzhong			Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Toll-like receptor 4 (TLR4); Resatorvid (TAK-242); Traumatic brain injury (TBI); Autophagy; Neuroinflammation	TOLL-LIKE RECEPTORS; CELL-DEATH; CEREBRAL EDEMA; TAK-242; ANTAGONIST; INHIBITOR; INFLAMMATION; CONTRIBUTES; MECHANISM; DEFICITS	Accumulating evidence indicates that autophagy and inflammatory responses contributes to secondary brain injury after traumatic brain injury (TBI), and toll-like receptor 4 (TLR4) is considered to involvement of this cascade and plays an important role. The present study was designed to determine the hypothesis that administration of resatorvid (TAK-242), a TLR4 antagonist, might provide a neuroprotective effect by inhibit TLR4-mediated pathway in a TBI rat model. Rat subjected to controlled cortical impact injury were injected with TAK-242 (0.5 mg/kg, i.v. injected) 10 min prior to injury. The results demonstrated that TAK-242 treatment significantly attenuated TBI-induced neurons loss, brain edema, and neurobehavioral impairment in rats. Immunoblotting analysis showed that TAK-242 treatment reduced TBI-induced TLR4, Beclin 1, and LC3-II levels, and maintained p62 levels at 24 h. Double immunolabeling demonstrated that LC3 dots co-localized with the hippocampus pyramidal neurons, and TLR4 was localized with the hippocampus neurons and astrocytes. In addition, the expression of TLR4 downstream signaling molecules, including MyD88, TRIF, NF-kappa B, TNF-alpha, and IL-1 beta, was significantly downregulated in hippocampus tissue by Western blot analysis. In conclusion, our findings indicate that pre-injury treatment with TAK-242 could inhibit neuronal autophagy and neuroinflammation responses in the hippocampus in a rat model of TBI. The neuroprotective effects of TAK-242 may be related to modulation of the TLR4-MyD88/TRIF-NF-kappa B signaling pathway. Furthermore, the study also suggests that TAK-242, an attractive potential drug, may be a promising drug candidate for TBI.	[Feng, Yan; Cui, Changmeng; Cui, Jianzhong] Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China; [Feng, Yan] Hebei Med Univ, Dept Neurosurg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China; [Gao, Junling; Li, Minghang; Li, Ran] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan, Peoples R China; [Cui, Ying; Cui, Jianzhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China		Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.; Cui, JZ (corresponding author), Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China.	jzhcuidr2001@163.com		Gao, Junling/0000-0001-5267-5884	Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (Grant No. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Bursch W, 2000, J CELL SCI, V113, P1189; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40; Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Garate I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-8; Hanamsagar R, 2012, TRENDS IMMUNOL, V33, P333, DOI 10.1016/j.it.2012.03.001; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Hua F, 2015, J CEREBR BLOOD F MET, V35, P536, DOI 10.1038/jcbfm.2014.240; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li HY, 2012, CHINESE MED J-PEKING, V125, P1586, DOI 10.3760/cma.j.issn.0366-6999.2012.09.012; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Simao F, 2012, EUR J NEUROSCI, V36, P2899, DOI 10.1111/j.1460-9568.2012.08229.x; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Wu FX, 2010, INT J MED SCI, V7, P251; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	57	40	41	2	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2017	37	1					155	168		10.1007/s10571-016-0356-1			14	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	EI3QU	WOS:000392407200016	26961544				2022-02-06	
J	Bombardier, CH; Hoekstra, T; Dikmen, S; Fann, JR				Bombardier, Charles H.; Hoekstra, Trynke; Dikmen, Sureyya; Fann, Jesse R.			Depression Trajectories during the First Year after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						depression; prognosis; substance abuse; trajectories; traumatic brain injury	SCHEDULED TELEPHONE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; SUICIDAL IDEATION; AXIS-I; SYMPTOMS; SEVERITY; MODERATE; RESILIENCE	Major depression is prevalent after traumatic brain injury (TBI) and associated with poor outcomes. Little is known about the course of depression after TBI. Participants were 559 consecutively admitted patients with mild to severe TBI recruited from inpatient units at Harborview Medical Center, a Level I trauma center in Seattle, WA. Participants were assessed with the Patient Health Questionnaire-9 (PHQ-9) depression measure at months 1-6, 8, 10, and 12 post-injury. We used linear latent class growth mixture modeling (LCGMM) of PHQ-9 total scores to identify homogeneous subgroups with distinct longitudinal trajectories. A four-class LCGMM had good fit indices and clinical interpretability. Trajectory groups were: low depression (70.1%), delayed depression (13.2%), depression recovery (10.4%), and persistent depression (6.3%). Multinomial logistic regression analyses were used to distinguish trajectory classes based on baseline demographic, psychiatric history, and clinical variables. Relative to the low depression group, the other three groups were consistently more likely to have a pre-injury history of other mental health disorders or major depressive disorder, a positive toxicology screen for cocaine or amphetamines at the time of injury, and a history of alcohol dependence. They were less likely to be on Medicare versus commercial insurance. Trajectories based on LCGMM are an empirical and clinically meaningful way to characterize distinct courses of depression after TBI. When combined with baseline predictors, this line of research may improve our ability to predict prognosis and target groups who may benefit from treatment or secondary prevention efforts (e.g., proactive telephone counseling).	[Bombardier, Charles H.; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Hoekstra, Trynke] Vrije Univ Amsterdam, Med Ctr, Dept Hlth Sci, Fac Earth & Life Sci, Amsterdam, Netherlands; [Hoekstra, Trynke] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Bombardier, CH (corresponding author), Univ Washington, Dept Rehabil Med, Harborview Med Ctr, Box 359612,325 9th Ave, Seattle, WA 98104 USA.	chb@uw.edu	Hoekstra, Trynke/AAG-5901-2020; Bombardier, Charles H./AAZ-3260-2021	Hoekstra, Trynke/0000-0002-0535-0056; Bombardier, Charles H./0000-0003-4758-6283	National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health [R01HD39415]	This work was supported by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health grant R01HD39415 to Drs. Bombardier and Fann (co-principal investigators). Pfizer supplied masked sertraline and placebo for the controlled trial. The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the article.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Asparouhov T, 2014, STRUCT EQU MODELING, V21, P329, DOI 10.1080/10705511.2014.915181; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bonanno GA, 2011, ANNU REV CLIN PSYCHO, V7, P511, DOI 10.1146/annurev-clinpsy-032210-104526; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DOBSON KS, 1986, COGNITIVE THER RES, V10, P13, DOI 10.1007/BF01173379; Duncan T.E., 1999, INTRO LATENT VARIABL; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fava M, 2000, NEURON, V28, P335, DOI 10.1016/S0896-6273(00)00112-4; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoekstra T, 2013, APPL LATENT CLASS MO; Hoekstra T, 2011, LONGITUD LIFE COURSE, V2, P319; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Jakubovski E, 2014, J CLIN PSYCHIAT, V75, P738, DOI 10.4088/JCP.13m08727; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jung T, 2008, SOC PERSONAL PSYCHOL, V2, P302, DOI 10.1111/j.1751-9004.2007.00054.x; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEWINSOHN PM, 1973, J CONSULT CLIN PSYCH, V41, P261, DOI 10.1037/h0035142; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Muthen B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/j.1530-0277.2000.tb02070.x; Muthen B, 2006, INFANT CHILD DEV, V15, P623, DOI 10.1002/icd.482; Muthen L. K., 2012, MPLUS USERS GUIDE, V5th; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sigurdardottir S, 2014, BRAIN INJURY, V28, P1542, DOI 10.3109/02699052.2014.934285; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; van Leeuwen CM, 2011, ARCH PHYS MED REHAB, V92, P207, DOI 10.1016/j.apmr.2010.10.011; van Loo HM, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-156; Vermunt JK, 2010, POLIT ANAL, V18, P450, DOI 10.1093/pan/mpq025; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	71	40	40	0	48	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2115	2124		10.1089/neu.2015.4349			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800007	26979826	Green Published			2022-02-06	
J	Barth, C; Steele, CJ; Mueller, K; Rekkas, VP; Arelin, K; Pampel, A; Burmann, I; Kratzsch, J; Villringer, A; Sacher, J				Barth, Claudia; Steele, Christopher J.; Mueller, Karsten; Rekkas, Vivien P.; Arelin, Katrin; Pampel, Andre; Burmann, Inga; Kratzsch, Juergen; Villringer, Arno; Sacher, Julia			In-vivo Dynamics of the Human Hippocampus across the Menstrual Cycle	SCIENTIFIC REPORTS			English	Article							FUNCTIONAL CONNECTIVITY CHANGES; WHITE-MATTER MICROSTRUCTURE; TRAUMATIC BRAIN-INJURY; POSTMENOPAUSAL WOMEN; SEX-DIFFERENCES; DIFFUSION; VOLUME; DEPRESSION; MRI; HORMONES	Sex hormones fluctuate during the menstrual cycle. Evidence from animal studies suggests similar subtle fluctuations in hippocampal structure, predominantly linked to estrogen. Hippocampal abnormalities have been observed in several neuropsychiatric pathologies with prominent sexual dimorphism. Yet, the potential impact of subtle sex-hormonal fluctuations on human hippocampal structure in health is unclear. We tested the feasibility of longitudinal neuroimaging in conjunction with rigorous menstrual cycle monitoring to evaluate potential changes in hippocampal microstructure associated with physiological sex-hormonal changes. Thirty longitudinal diffusion weighted imaging scans of a single healthy female subject were acquired across two full menstrual cycles. We calculated hippocampal fractional anisotropy (FA), a measure sensitive to changes in microstructural integrity, and investigated potential correlations with estrogen. We observed a significant positive correlation between FA values and estrogen in the hippocampus bilaterally, revealing a peak in FA closely paralleling ovulation. This exploratory, single-subject study demonstrates the feasibility of a longitudinal DWI scanning protocol across the menstrual cycle and is the first to link subtle endogenous hormonal fluctuations to changes in FA in vivo. In light of recent attempts to neurally phenotype single humans, our findings highlight menstrual cycle monitoring in parallel with highly sampled individual neuroimaging data to address fundamental questions about the dynamics of plasticity in the adult brain.	[Barth, Claudia; Steele, Christopher J.; Mueller, Karsten; Arelin, Katrin; Pampel, Andre; Burmann, Inga; Villringer, Arno; Sacher, Julia] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany; [Steele, Christopher J.] McGill Univ, Douglas Mental Hlth Inst, Dept Psychiat, Cerebral Imaging Ctr, Montreal, PQ, Canada; [Rekkas, Vivien P.] Univ Toronto, CAMH Res Imaging Ctr, Toronto, ON, Canada; [Rekkas, Vivien P.] Univ Toronto, Campbell Family Mental Hlth Res Inst, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Rekkas, Vivien P.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Arelin, Katrin; Villringer, Arno; Sacher, Julia] Univ Leipzig, Clin Cognit Neurol, Leipzig, Germany; [Arelin, Katrin; Villringer, Arno] Univ Leipzig, Leipzig Res Ctr Civilizat Dis, Leipzig, Germany; [Kratzsch, Juergen] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany; [Villringer, Arno] Univ Leipzig, Integrated Res & Treatment Ctr Adipos Dis, Leipzig, Germany; [Villringer, Arno] Berlin Sch Mind & Brain, Mind & Brain Inst, Berlin, Germany		Barth, C; Sacher, J (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany.; Sacher, J (corresponding author), Univ Leipzig, Clin Cognit Neurol, Leipzig, Germany.	sacher@cbs.mpg.de; sacher@cbs.mpg.de	Sacher, Julia/M-7060-2016	Sacher, Julia/0000-0003-0944-0558; Villringer, Arno/0000-0003-2604-2404; Barth, Claudia/0000-0001-6544-0945; Steele, Christopher/0000-0003-1656-7928	Society in Science-The Branco Weiss Fellowship; Max Planck SocietyMax Planck Society	The study was supported by a research grant from the Society in Science-The Branco Weiss Fellowship to Dr. Julia Sacher and research funds from the Max Planck Society. We thank Dr. Pierre-Louis Bazin and Dr. Daniel Margulies for critical discussion.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arelin K, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00044; Barha CK, 2010, BBA-GEN SUBJECTS, V1800, P1056, DOI 10.1016/j.bbagen.2010.01.006; Barth C, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00037; BAUMAN JE, 1981, FERTIL STERIL, V36, P729; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Boccardi M, 2006, MENOPAUSE, V13, P584, DOI 10.1097/01.gme.0000196811.88505.10; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; COUTTS JRT, 1982, CLIN ENDOCRINOL, V17, P389, DOI 10.1111/j.1365-2265.1982.tb01604.x; Cox SR, 2015, PSYCHONEUROENDOCRINO, V62, P129, DOI 10.1016/j.psyneuen.2015.08.005; De Bondt T, 2013, EUR RADIOL, V23, P57, DOI 10.1007/s00330-012-2572-5; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Douaud G, 2007, BRAIN, V130, P2375, DOI 10.1093/brain/awm184; Duarte-Guterman P, 2015, HORM BEHAV, V74, P37, DOI 10.1016/j.yhbeh.2015.05.024; First MB, 2002, PSYCHOPATHOLOGY, V35, P67, DOI 10.1159/000065121; First MB, 1997, COMMUNICATION; Foy MR, 1999, J NEUROPHYSIOL, V81, P925, DOI 10.1152/jn.1999.81.2.925; Franke K, 2015, NEUROIMAGE, V115, P1, DOI 10.1016/j.neuroimage.2015.04.036; Freeman EW, 2014, JAMA PSYCHIAT, V71, P36, DOI 10.1001/jamapsychiatry.2013.2819; Freeman EW, 2006, ARCH GEN PSYCHIAT, V63, P375, DOI 10.1001/archpsyc.63.4.375; Galea LAM, 2008, CAN J EXP PSYCHOL, V62, P247, DOI 10.1037/a0014501; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Goto M, 2011, J MAGN RESON IMAGING, V33, P48, DOI 10.1002/jmri.22328; Hagemann G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014655; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Herting MM, 2012, CEREB CORTEX, V22, P1979, DOI 10.1093/cercor/bhr246; Hu SY, 2013, NEUROIMAGE, V74, P276, DOI 10.1016/j.neuroimage.2013.02.032; Ingalhalikar M, 2014, P NATL ACAD SCI USA, V111, P823, DOI 10.1073/pnas.1316909110; Kesler SR, 2004, NEUROPSYCHOLOGIA, V42, P1971, DOI 10.1016/j.neuropsychologia.2004.04.021; Kessler RC, 2003, J AFFECT DISORDERS, V74, P5, DOI 10.1016/S0165-0327(02)00426-3; Killgore WDS, 2013, SCI REP-UK, V3, DOI 10.1038/srep03457; Kranz GS, 2014, J NEUROSCI, V34, P15466, DOI 10.1523/JNEUROSCI.2488-14.2014; Laumann TO, 2015, NEURON, V87, P657, DOI 10.1016/j.neuron.2015.06.037; Lee SJ, 2001, ANNU REV PHARMACOL, V41, P569, DOI 10.1146/annurev.pharmtox.41.1.569; Lin M, 2016, MAGN RESON MED, V76, P290, DOI 10.1002/mrm.25816; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lisofsky N, 2015, NEUROIMAGE, V118, P154, DOI 10.1016/j.neuroimage.2015.06.012; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Munk-Olsen T, 2006, JAMA-J AM MED ASSOC, V296, P2582, DOI 10.1001/jama.296.21.2582; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Pawluski JL, 2009, FRONT NEUROENDOCRIN, V30, P343, DOI 10.1016/j.yfrne.2009.03.007; Peper JS, 2011, NEUROSCIENCE, V191, P28, DOI 10.1016/j.neuroscience.2011.02.014; Petersen N, 2014, NEUROIMAGE, V90, P24, DOI 10.1016/j.neuroimage.2013.12.016; Pletzer B, 2010, BRAIN RES, V1348, P55, DOI 10.1016/j.brainres.2010.06.019; Poldrack RA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9885; Protopopescu X, 2008, HIPPOCAMPUS, V18, P985, DOI 10.1002/hipo.20468; Qiu LR, 2013, NEUROIMAGE, V83, P593, DOI 10.1016/j.neuroimage.2013.06.074; Raffin E, 2013, FRONT NEUROL NEUROSC, V32, P26, DOI 10.1159/000348818; Sacher J, 2013, MAGN RESON IMAGING, V31, P366, DOI 10.1016/j.mri.2012.06.007; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Steele CJ, 2013, J NEUROSCI, V33, P1282, DOI 10.1523/JNEUROSCI.3578-12.2013; Steele CJ, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00289; Streitburger DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044195; Taubert M, 2012, NEUROSCIENTIST, V18, P320, DOI 10.1177/1073858411419048; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Wegienka G, 2005, J WOMENS HEALTH, V14, P248, DOI 10.1089/jwh.2005.14.248; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhou J, 2005, NEUROENDOCRINOLOGY, V81, P294, DOI 10.1159/000088448	68	40	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 7	2016	6								32833	10.1038/srep32833			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH8BZ	WOS:000391997900001	27713470	gold, Green Published			2022-02-06	
J	Raheja, A; Sinha, S; Samson, N; Bhoi, S; Subramanian, A; Sharma, P; Sharma, BS				Raheja, Amol; Sinha, Sumit; Samson, Neha; Bhoi, Sanjeev; Subramanian, Arulselvi; Sharma, Pushpa; Sharma, Bhawani Shankar			Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial	JOURNAL OF NEUROSURGERY			English	Article						glial fibrillary acidic protein; interleukin-6; progesterone; predictors of outcome; serum biomarkers; severe traumatic brain injury; trauma	NEURON-SPECIFIC ENOLASE; CRITICALLY-ILL; PROGESTERONE; INTERLEUKIN-6; PROTEIN; S100B; NEUROINFLAMMATION; MARKERS; IL-6	OBJECTIVE There has been increased interest in the potential importance of biochemical parameters as predictors of outcome in severe traumatic brain injury (sTBI). METHODS Of 107 patients with sTBI (age 18-65 years with a Glasgow Coma Scale score of 4-8 presenting within 8 hours after injury) who were randomized for a placebo-controlled Phase II trial of progesterone with or without hypothermia, the authors serially analyzed serum biomarkers (S100-B, glial fibrillary acidic protein [GFAP], neuron-specific enolase [NSE], tumor necrosis factor-alpha, interleukin-6 [IL-6], estrogen [Eg], and progesterone [Pg]). This analysis was performed using the sandwich enzyme-linked immunosorbent assay technique at admission and 7 days later for 86 patients, irrespective of assigned group. The long-term predictive values of serum biomarkers for dichotomized Glasgow Outcome Scale (GOS) score, functional independence measure, and survival status at 6 and 12 months were analyzed using an adjusted binary logistic regression model and receiver operating characteristic curve. RESULTS A favorable GOS score (4-5) at 1 year was predicted by higher admission IL-6 (above 108.36 pg/ml; area under the curve [AUC] 0.69, sensitivity 52%, and specificity 78.6%) and Day 7 Pg levels (above 3.15 ng/ml; AUC 0.79, sensitivity 70%, and specificity 92.9%). An unfavorable GOS score (1-3) at 1 year was predicted by higher Day 7 GFAP levels (above 9.50 ng/ml; AUC 0.82, sensitivity 78.6%, and specificity 82.4%). Survivors at 1 year had significantly higher Day 7 Pg levels (above 3.15 ng/ml; AUC 0.78, sensitivity 66.7%, and specificity 90.9%). Nonsurvivors at 1 year had significantly higher Day 7 GFAP serum levels (above 11.14 ng/ml; AUC 0.81, sensitivity 81.8%, and specificity 88.9%) and Day 7 IL-6 serum levels (above 71.26 pg/ml; AUC 0.87, sensitivity 81.8%, and specificity 87%). In multivariate logistic regression analysis, independent predictors of outcome at 1 year were serum levels of Day 7 Pg (favorable GOS OR 3.24, CI 1.5-7, p = 0.003; and favorable survival OR 2, CI 1.2-3.5, p = 0.01); admission IL-6 (favorable GOS OR 1.04, CI 1.00-1.08, p = 0.04); and Day 7 GFAP (unfavorable GOS OR 0.79, CI 0.65-0.95, p = 0.01; and unfavorable survival-OR 0.80, CI 0.66-0.96, p = 0.01). CONCLUSIONS Serial Pg, GFAP, and IL-6 monitoring could aid in prognosticating outcomes in patients with acute sTBI. A cause and effect relationship or a mere association of these biomarkers to outcome needs to be further studied for better understanding of the pathophysiology of sTBI and for choosing potential therapeutic targets.	[Raheja, Amol; Sinha, Sumit; Samson, Neha; Sharma, Bhawani Shankar] All India Inst Med Sci, Dept Neurosurg, New Delhi, India; [Bhoi, Sanjeev] All India Inst Med Sci, Dept Emergency Med, New Delhi, India; [Subramanian, Arulselvi] All India Inst Med Sci, Dept Lab Med, New Delhi, India; [Sharma, Pushpa] Uniformed Serv Univ Hlth Sci, Dept Anaesthesiol, Bethesda, MD 20814 USA		Sinha, S (corresponding author), All India Inst Med Sci, Dept Neurosurg & Gamma Knife, Neurosci Ctr, F25,Aiims Campus, New Delhi 110029, India.	sumitneuro@gmail.com	Subramanian, arulselvi/AAG-1670-2020; Sharma, Pushpa/AAY-8756-2020	Subramanian, arulselvi/0000-0001-7797-6683; 	Department of Biotechnology, Ministry of Science and Technology, India	This study was funded by the Department of Biotechnology, Ministry of Science and Technology, India.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; SCHAARSCHMIDT H, 1994, STROKE, V25, P558, DOI 10.1161/01.STR.25.3.558; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698	37	40	41	1	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2016	125	3					631	641		10.3171/2015.6.JNS15674			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DT8YS	WOS:000381782300014	26722854	Bronze			2022-02-06	
J	Sariaslan, A; Lichtenstein, P; Larsson, H; Fazel, S				Sariaslan, Amir; Lichtenstein, Paul; Larsson, Henrik; Fazel, Seena			Triggers for Violent Criminality in Patients With Psychotic Disorders	JAMA PSYCHIATRY			English	Article							OF-THE-LITERATURE; CASE-CROSSOVER; BIPOLAR DISORDER; RISK-ASSESSMENT; SELF-HARM; POPULATION; SUICIDE; SCHIZOPHRENIA; CRIME; AGGRESSION	IMPORTANCE Absolute and relative risks of violence are increased in patients with psychotic disorders, but the contribution of triggers for violent acts to these risks is uncertain. OBJECTIVE To examine whether a range of triggers for violent acts are associated with risks of violence in patients diagnosed with psychotic disorders and in individuals without a psychiatric diagnosis. DESIGN, SETTING, AND PARTICIPANTS Using a sample of all individuals born in Sweden between 1958 and 1988 (N = 3 123 724), we identified patients in the National Patient Register who were diagnosed with schizophrenia spectrum disorders (n = 34 903) and bipolar disorder (n = 29 692), as well as unaffected controls (n = 2 763 012). We then identified, within each subsample, persons who had experienced any of the following triggers for violent acts between January 1, 2001, and December 15, 2013: exposure to violence, parental bereavement, self-harm, traumatic brain injury, unintentional injuries, and substance intoxication. By using within-individual models, we conducted conditional logistic regression to compare the risk of the individual engaging in violent acts in the week following the exposure to a trigger with the risk during earlier periods of equivalent length. All time-invariant confounders (eg, genetic and early environmental influences) were controlled for by this research design and we further adjusted for time-varying sociodemographic factors. MAIN OUTCOMES AND MEASURES Adjusted odds ratios (aORs) of violent crime occurring in the week following the exposure to a trigger event compared with earlier periods. RESULTS Among the sample of 2 827 607 individuals (1 492 186 male and 1 335 421 female), all of the examined trigger events were associated with increased risk of violent crime in the week following exposure. The largest 1-week absolute risk of violent crime was observed following exposure to violence (70-177 violent crimes per 10 000 persons). For most triggers, the relative risks did not vary significantly by diagnosis, including unintentional injuries (aOR range, 3.5-4.8), self-harm (aOR range, 3.9-4.2), and substance intoxication (aOR range, 3.0-4.0). Differences by diagnosis included parental bereavement, which was significantly higher in patients with schizophrenia spectrum disorders (aOR, 5.0; 95% CI, 3.0-8.1) compared with controls (aOR, 1.7; 95% CI, 1.3-2.2). CONCLUSIONS AND RELEVANCE In addition to identifying risk factors for violence, clarifying the timing of the triggers may provide opportunities to improve risk assessment and management in individuals with psychotic disorders.	[Sariaslan, Amir; Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Lichtenstein, Paul; Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Larsson, Henrik] Univ Orebro, Dept Med Sci, Orebro, Sweden		Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365; Sariaslan, Amir/0000-0002-6151-3278	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Research CouncilSwedish Research CouncilEuropean Commission [2010-3184, 2011-2492, 2013-5867]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061817]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061817] Funding Source: NIH RePORTER	This study was supported by grant 095806 from the Wellcome Trust; the Swedish Council for Working Life and Social Research; grants 2010-3184, 2011-2492, and 2013-5867 from the Swedish Research Council; and grant HD061817 from the National Institute of Child Health and Human Development.	Caine ED, 2011, PUBLIC HLTH POPULATI; Caine ED, 2013, AM J PUBLIC HEALTH, V103, P822, DOI 10.2105/AJPH.2012.301078; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Douglas KS, 2005, PSYCHOL PUBLIC POL L, V11, P347, DOI 10.1037/1076-8971.11.3.347; Edmondson D, 2013, EUR HEART J, V34, P300, DOI 10.1093/eurheartj/ehs398; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; Elzerbi C, 2015, ADDICTION, V110, P1082, DOI 10.1111/add.12960; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Fazel S, 2010, ARCH GEN PSYCHIAT, V67, P931, DOI 10.1001/archgenpsychiatry.2010.97; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Frisell T, 2012, EPIDEMIOLOGY, V23, P713, DOI 10.1097/EDE.0b013e31825fa230; Gayer-Anderson C, 2013, EPIDEMIOL PSYCH SCI, V22, P131, DOI 10.1017/S2045796012000406; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Haggard-Grann U, 2006, ADDICTION, V101, P100, DOI 10.1111/j.1360-0443.2005.01293.x; Haggard-Grann U, 2006, SOC PSYCH PSYCH EPID, V41, P532, DOI 10.1007/s00127-006-0056-0; Hallden K., 2008, INT STANDARD CLASSIF; Hawton K, 2014, LANCET, V383, P1147, DOI 10.1016/S0140-6736(13)62118-2; Jennings WG, 2012, AGGRESS VIOLENT BEH, V17, P16, DOI 10.1016/j.avb.2011.09.003; Kuhlhorn E, 2007, SERIOUS VIOLENCE HOS; Large MM, 2011, SCHIZOPHR RES, V125, P209, DOI 10.1016/j.schres.2010.11.026; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Lundholm L, 2013, DRUG ALCOHOL DEPEN, V129, P110, DOI 10.1016/j.drugalcdep.2012.09.019; Malby, 2010, INT STAT CRIME JUSTI, P21; McGuire J, 2008, PHILOS T R SOC B, V363, P2577, DOI 10.1098/rstb.2008.0035; Merikangas KR, 2011, ARCH GEN PSYCHIAT, V68, P241, DOI 10.1001/archgenpsychiatry.2011.12; Mittleman MA, 2014, INT J EPIDEMIOL, V43, P1645, DOI 10.1093/ije/dyu081; Mittleman MA, 2011, CIRCULATION, V124, P346, DOI 10.1161/CIRCULATIONAHA.110.968776; National Institute for Health and Care Excellence, 2011, ALC US DIS DIAGN ASS; National Institute of Public Health, 2007, ALC STAT 2007; Nilsson A C, 1994, Lakartidningen, V91, P603; Nilsson AC., 1994, LAKARTIDNINGEN, V91, P603; O'Donnell O, 2015, J AFFECT DISORDERS, V175, P325, DOI 10.1016/j.jad.2014.12.051; Office for National Statistics, 2015, CRIM ENGL WAL YEAR E; Penn JV, 2003, J AM ACAD CHILD PSY, V42, P762, DOI 10.1097/01.CHI.0000046869.56865.46; Purtle J, 2015, ANN INTERN MED, V163, P715, DOI 10.7326/M15-0586; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Sariaslan A, MOL PSYCHIAT; Sariaslan A, 2015, SCHIZOPHRENIA BULL, V41, P494, DOI 10.1093/schbul/sbu105; Sariaslan A, 2014, BRIT J PSYCHIAT, V205, P286, DOI 10.1192/bjp.bp.113.136200; Sellgren C, 2011, ACTA PSYCHIAT SCAND, V124, P447, DOI 10.1111/j.1600-0447.2011.01747.x; Singh JP, 2011, SCHIZOPHRENIA BULL, V37, P899, DOI 10.1093/schbul/sbr093; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; The Swedish National Council for Crime Prevention, 2015, EXP CRIM 2014 RES NA; Troquete NAC, 2013, BRIT J PSYCHIAT, V202, P365, DOI 10.1192/bjp.bp.112.113043; WHO, GLOB HLTH OBS DAT RE; Wikstrom POH, 2006, PATHWAY CRIME, P61, DOI 10.1017/CBO9780511489341.004; Wilcox HC, 2010, J AM ACAD CHILD PSY, V49, P514, DOI 10.1016/j.jaac.2010.01.020; Witt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055942; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018	51	40	40	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	AUG	2016	73	8					796	803		10.1001/jamapsychiatry.2016.1349			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	DW9OX	WOS:000383991700009	27410165	Green Accepted, Bronze			2022-02-06	
J	Sykora, M; Czosnyka, M; Liu, XY; Donnelly, J; Nasr, N; Diedler, J; Okoroafor, F; Hutchinson, P; Menon, D; Smielewski, P				Sykora, Marek; Czosnyka, Marek; Liu, Xiuyun; Donnelly, Joseph; Nasr, Nathalie; Diedler, Jennifer; Okoroafor, Francois; Hutchinson, Peter; Menon, David; Smielewski, Peter			Autonomic Impairment in Severe Traumatic Brain Injury: A Multimodal Neuromonitoring Study	CRITICAL CARE MEDICINE			English	Article						autonomic; baroreflex; heart rate variability; intracranial pressure; outcome; traumatic brain injury	HEART-RATE-VARIABILITY; CEREBROVASCULAR PRESSURE REACTIVITY; CARDIOVASCULAR VARIABILITY; INTRACRANIAL HYPERTENSION; BAROREFLEX SENSITIVITY; POWER; FREQUENCY; CARE; TONE	Objectives: Autonomic impairment after acute traumatic brain injury has been associated independently with both increased morbidity and mortality. Links between autonomic impairment and increased intracranial pressure or impaired cerebral autoregulation have been described as well. However, relationships between autonomic impairment, intracranial pressure, impaired cerebral autoregulation, and outcome remain poorly explored. Using continuous measurements of heart rate variability and baroreflex sensitivity we aimed to test whether autonomic markers are associated with functional outcome and mortality independently of intracranial variables. Further, we aimed to evaluate the relationships between autonomic functions, intracranial pressure, and cerebral autoregulation. Design: Retrospective analysis of a prospective database. Setting: Neurocritical care unit in a university hospital. Subjects: Sedated patients with severe traumatic brain injury. Measurements and Main Results: Waveforms of intracranial pressure and arterial blood pressure, baseline Glasgow Coma Scale and 6 months Glasgow Outcome Scale were recorded. Baroreflex sensitivity was assessed every 10 seconds using a modified cross-correlational method. Frequency domain analyses of heart rate variability were performed automatically every 10 seconds from a moving 300 seconds of the monitoring time window. Mean values of baroreflex sensitivity, heart rate variability, intracranial pressure, arterial blood pressure, cerebral perfusion pressure, and impaired cerebral autoregulation over the entire monitoring period were calculated for each patient. Two hundred and sixty-two patients with a median age of 36 years entered the analysis. The median admission Glasgow Coma Scale was 6, the median Glasgow Outcome Scale was 3, and the mortality at 6 months was 23%. Baroreflex sensitivity (adjusted odds ratio, 0.9; p = 0.02) and relative power of a high frequency band of heart rate variability (adjusted odds ratio, 1.05; p < 0.001) were individually associated with mortality, independently of age, admission Glasgow Coma Scale, intracranial pressure, pressure reactivity index, or cerebral perfusion pressure. Baroreflex sensitivity showed no correlation with intracranial pressure or cerebral perfusion pressure; the correlation with pressure reactivity index was strong in older patients (age, > 60 yr). The relative power of high frequency correlated significantly with intracranial pressure and cerebral perfusion pressure, but not with pressure reactivity index. The relative power of low frequency correlated significantly with pressure reactivity index. Conclusions: Autonomic impairment, as measured by heart rate variability and baroreflex sensitivity, is significantly associated with increased mortality after traumatic brain injury. These effects, though partially interlinked, seem to be independent of age, trauma severity, intracranial pressure, or autoregulatory status, and thus represent a discrete phenomenon in the pathophysiology of traumatic brain injury. Continuous measurements of heart rate variability and baroreflex sensitivity in the neuromonitoring setting of severe traumatic brain injury may carry novel pathophysiological and predictive information.	[Sykora, Marek; Czosnyka, Marek; Liu, Xiuyun; Donnelly, Joseph; Nasr, Nathalie; Okoroafor, Francois; Hutchinson, Peter; Smielewski, Peter] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Sykora, Marek] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Nasr, Nathalie] CHU Toulouse, Dept Neurol, Unite Neurol Vasc, Toulouse, France; [Nasr, Nathalie] Univ Toulouse 3, INSERM U1048, I2MC Toulouse, Team 11, F-31062 Toulouse, France; [Diedler, Jennifer] Univ Tubingen, Dept Neurol & Neurosurg, Tubingen, Germany; [Menon, David] Univ Cambridge, Dept Anaesthesiol, Cambridge, England		Sykora, M (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.; Sykora, M (corresponding author), Heidelberg Univ, Dept Neurol, Heidelberg, Germany.	marek.sykora@med.uni-heidelberg.de	Donnelly, Joseph/E-9235-2018; Donnelly, Joseph/N-6803-2019; NASR, NATHALIE/K-3521-2019; Liu, Xiuyun/V-4427-2017	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Smielewski, Peter/0000-0001-5096-3938; Nasr, Nathalie/0000-0003-1660-8718	National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish; Department of HealthEuropean Commission [NIHR-RP-R3-12-013, 12/35/57] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025] Funding Source: UKRI		Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Billman GE, 2013, FRONT PHYSIOL, V4, DOI [10.3389/fphys.2013.00222, 10.3389/fphys.2013.00026]; Billman GE, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00086; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Camm AJ, 1996, CIRCULATION, V93, P1043; De Raedt S, 2015, J NEUROL SCI, V348, P24, DOI 10.1016/j.jns.2014.12.007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; GOLDSTEIN B, 1994, PEDIATR RES, V36, P358, DOI 10.1203/00006450-199409000-00016; Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259; Gunther A, 2012, ACTA NEUROL SCAND, V126, P189, DOI 10.1111/j.1600-0404.2011.01626.x; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; Hall S, 2014, BRIT J NEUROSURG, V28, P181, DOI 10.3109/02688697.2013.835373; JENNETT B, 1975, LANCET, V1, P480; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Kox M, 2012, J NEUROTRAUM, V29, P747, DOI 10.1089/neu.2011.2035; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; Mazzeo AT, 2011, ACTA ANAESTH SCAND, V55, P797, DOI 10.1111/j.1399-6576.2011.02466.x; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parati G, 2006, J APPL PHYSIOL, V101, P676, DOI 10.1152/japplphysiol.00446.2006; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sykora M, 2009, STROKE, V40, pE678, DOI 10.1161/STROKEAHA.109.565838; Team RDC, 2010, R LANG ENV STAT COMP; Westerhof BE, 2004, J HYPERTENS, V22, P1371, DOI 10.1097/01.hjh.0000125439.28861.ed; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	31	40	40	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2016	44	6					1173	1181		10.1097/CCM.0000000000001624			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DL9EK	WOS:000375944200046	26968025				2022-02-06	
J	Dash, PK; Hergenroeder, GW; Jeter, CB; Choi, HA; Kobori, N; Moore, AN				Dash, Pramod K.; Hergenroeder, Georgene W.; Jeter, Cameron B.; Choi, H. Alex; Kobori, Nobuhide; Moore, Anthony N.			Traumatic Brain Injury Alters Methionine Metabolism: Implications for Pathophysiology	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						concussion; epigenetic changes; metabolomics; protein methylation; S-adenosylmethionine; transsulfuration	S-ADENOSYLMETHIONINE; AMINO-ACIDS; PLASMA; METHYLATION; INCREASES; DISEASE; SYSTEM; MODEL	Methionine is an essential proteinogenic amino acid that is obtained from the diet. In addition to its requirement for protein biosynthesis, methionine is metabolized to generate metabolites that play key roles in a number of cellular functions. Metabolism of methionine via the transmethylation pathway generates S-adenosylmethionine (SAM) that serves as the principal methyl (CH3) donor for DNA and histone methyltransferases (MTs) to regulate epigenetic changes in gene expression. SAM is also required for methylation of other cellular proteins that serve various functions and phosphatidylcholine synthesis that participate in cellular signaling. Under conditions of oxidative stress, homocysteine (which is derived from SAM) enters the transsulfuration pathway to generate glutathione, an important cytoprotective molecule against oxidative damage. As both experimental and clinical studies have shown that traumatic brain injury (TBI) alters DNA and histone methylation and causes oxidative stress, we examined if TBI alters the plasma levels of methionine and its metabolites in human patients. Blood samples were collected from healthy volunteers (HV; n = 20) and patients with mild TBI (mTBI; GCS > 12; n = 20) or severe TBI (sTBI; GCS < 8; n = 20) within the first 24 h of injury. The levels of methionine and its metabolites in the plasma samples were analyzed by either liquid chromatography-mass spectrometry or gas chromatography-mass spectrometry (LC-MS or GC-MS). sTBI decreased the levels of methionine, SAM, betaine and 2-methylglycine as compared to HV, indicating a decrease in metabolism through the transmethylation cycle. In addition, precursors for the generation of glutathione, cysteine and glycine were also found to be decreased as were intermediate metabolites of the gamma-glutamyl cycle (gamma-glutamyl amino acids and 5-oxoproline). mTBI also decreased the levels of methionine, a-ketobutyrate, 2 hydroxybutyrate and glycine, albeit to lesser degrees than detected in the sTBI group. Taken together, these results suggest that decreased levels of methionine and its metabolic products are likely to alter cellular function in multiple organs at a systems level.	[Dash, Pramod K.; Kobori, Nobuhide; Moore, Anthony N.] UTHlth McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Dash, Pramod K.; Hergenroeder, Georgene W.; Choi, H. Alex] UTHlth McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX USA; [Jeter, Cameron B.] Univ Texas Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX USA		Dash, PK (corresponding author), UTHlth McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA.; Dash, PK (corresponding author), UTHlth McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX USA.	p.dash@uth.tmc.edu	Jeter, Cameron B./AAO-1797-2021	Jeter, Cameron B./0000-0001-5303-5897	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087149]; Mission Connect/TIRR Foundation; Gilson-Longenbaug Foundation	This study was supported by Grants from NIH (NS087149), Mission Connect/TIRR Foundation, and the Gilson-Longenbaug Foundation.	Akkaya H, 2014, J BIOCHEM MOL TOXIC, V28, P373, DOI 10.1002/jbt.21573; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1053/apmr.2000.0810176; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bistrian BR, 1998, CRIT CARE MED, V26, P1476, DOI 10.1097/00003246-199809000-00006; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Grillo MA, 2008, AMINO ACIDS, V34, P187, DOI 10.1007/s00726-007-0500-9; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; LAJTHA A, 1961, J NEUROCHEM, V7, P210, DOI 10.1111/j.1471-4159.1961.tb13505.x; Lamont LS, 2003, J APPL PHYSIOL, V95, P1259, DOI 10.1152/japplphysiol.01028.2002; Lardenoije R, 2015, PROG NEUROBIOL, V131, P21, DOI 10.1016/j.pneurobio.2015.05.002; Lee S, 2012, J ALZHEIMERS DIS, V28, P423, DOI 10.3233/JAD-2011-111025; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lu SC, 2009, HEPATOLOGY, V50, P462, DOI 10.1002/hep.22990; Montgomery SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107756; Nageli M, 2014, CRIT CARE, V18, DOI 10.1186/cc13962; ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248; OTT LG, 1988, DRUG INTEL CLIN PHAR, V22, P763, DOI 10.1177/106002808802201004; Papakostas GI, 2009, J CLIN PSYCHIAT, V70, P18, DOI 10.4088/JCP.8157su1c.04; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Povlishock J T, 1992, Hum Cell, V5, P345; Purohit V, 2007, AM J CLIN NUTR, V86, P14, DOI 10.1093/ajcn/86.1.14; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith CJ, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00240, 10.3389/fneur.2015.00073]; Vuille-Dit-Bille RN, 2012, AMINO ACIDS, V43, P1287, DOI 10.1007/s00726-011-1202-x; WENDEL A, 1980, FEBS LETT, V120, P209, DOI 10.1016/0014-5793(80)80299-7; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061	36	40	40	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	APR 29	2016	10								36	10.3389/fnsys.2016.00036			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DK7IV	WOS:000375099300001	27199685	gold, Green Published			2022-02-06	
J	Meissner, L; Gallozzi, M; Balbi, M; Schwarzmaier, S; Tiedt, S; Terpolilli, NA; Plesnila, N				Meissner, Lilja; Gallozzi, Micaela; Balbi, Matilde; Schwarzmaier, Susanne; Tiedt, Steffen; Terpolilli, Nicole A.; Plesnila, Nikolaus			Temporal Profile of MicroRNA Expression in Contused Cortex after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						mouse; traumatic brain injury; microarray; penumbra; miRNA; controlled cortical impact	DOWN-REGULATION; PROTECTS; DEATH; RNA; PATHOPHYSIOLOGY; EFFICACY; NEURONS; IMPACT; EFA6A; ARF6	MicroRNAs (miRNAs) were recently identified as important regulators of gene expression under a wide range of physiological and pathophysiological conditions. Thus, they may represent a novel class of molecular targets for the management of traumatic brain injury (TBI). In this study, we investigated the temporal profile of miRNA expression during the development of secondary brain damage after experimental TBI. For this purpose, we used a controlled cortical impact model in C57Bl/6 mice (n = 6) to induce a cortical contusion and analyzed miRNA expression in the traumatized cortex by microarray analysis during the development of secondary contusion expansion-i.e., at 1, 6, and 12 h after TBI. Of a total 780 mature miRNA sequences analyzed, 410 were detected in all experimental groups. Of these, 158 miRNAs were significantly upregulated or downregulated in TBI compared with sham-operated animals, and 52 miRNAs increased more than twofold. We validated the upregulation of five of the most differentially expressed miRNAs (miR-21*, miR-144, miR-184, miR-451, miR-2137) and the downregulation of four of the most differentially expressed miRNAs (miR-107, miR-137, miR-190, miR-541) by quantitative polymerase chain reaction (qPCR). miR-2137, the most differentially expressed miRNA after TBI, was further investigated by in situ hybridization and was found to be upregulated in neurons within the traumatic penumbra. This study gives a comprehensive picture of miRNA expression levels during secondary contusion expansion after TBI and may pave the way for the identification of novel targets for the management of brain trauma.	[Meissner, Lilja; Gallozzi, Micaela; Balbi, Matilde; Schwarzmaier, Susanne; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Meissner, Lilja; Balbi, Matilde; Tiedt, Steffen; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany; [Terpolilli, Nicole A.] Univ Munich, Inst Surg Res, Med Ctr, D-81377 Munich, Germany; [Plesnila, Nikolaus] Munich Cluster Syst Neurol SyNergy, Munich, Germany		Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Balbi, Matilde/ABC-2246-2021; Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019	Balbi, Matilde/0000-0003-4590-5447; Tiedt, Steffen/0000-0002-8817-8457			Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Behrman S, 2011, J CELL BIOL, V192, P919, DOI 10.1083/jcb.201010055; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Coolen M, 2009, CURR OPIN NEUROBIOL, V19, P461, DOI 10.1016/j.conb.2009.09.006; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Funk K, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-32; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv GW, 2014, J CELL BIOCHEM, V115, P93, DOI 10.1002/jcb.24636; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029; McKiernan RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035921; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ribaudo R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1011s04; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Roshan R, 2009, DRUG DISCOV TODAY, V14, P1123, DOI 10.1016/j.drudis.2009.09.009; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakagami H, 2004, EUR J NEUROSCI, V19, P863, DOI 10.1111/j.0953-816X.2004.03195.x; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Tang XQ, 2007, RNA, V13, P1803, DOI 10.1261/rna.498607; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Wang XH, 2012, CARDIOVASC RES, V94, P379, DOI 10.1093/cvr/cvs096; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110; Zhang K, 2014, ONCOTARGET, V5, P12916, DOI 10.18632/oncotarget.2682; Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	45	40	41	0	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					713	720		10.1089/neu.2015.4077			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900001	26426744				2022-02-06	
J	Federolf, PA				Federolf, Peter A.			A novel approach to study human posture control: "Principal movements" obtained from a principal component analysis of kinematic marker data	JOURNAL OF BIOMECHANICS			English	Article						Human movement; Motor control; Stability; Balance; Principal component analysis PCA; Principal movements; Center of pressure COP	CEREBRAL CONCUSSION; STANDING PERSONS; MUSCLE SYNERGIES; QUIET STANCE; STABILITY; PRESSURE; BALANCE; SWAY; GAIT; ADJUSTMENTS	Human upright posture is maintained by postural movements, which can be quantified by "principal movements" (PMs) obtained through a principal component analysis (PCA) of kinematic marker data. The current study expands the concept of "principal movements" in analogy to Newton's mechanics by defining "principal position" (PP), "principal velocity" (PV), and "principal acceleration" (PA) and demonstrates that a linear combination of PPs and PAs determines the center of pressure (COP) variance in upright standing. Twenty-one subjects equipped with 27-markers distributed over all body segments stood on a force plate while their postural movements were recorded using a standard motion tracking system. A PCA calculated on normalized and weighted posture vectors yielded the PPs and their time derivatives, the PVs and PAs. COP variance explained by the PPs and PAs was obtained through a regression analysis. The first 15 PMs quantified 99.3% of the postural variance and explained 99.60% 0.22% (mean +/- SD) of the anterior-posterior and 98.82 +/- 0.74% of the lateral COP variance in the 21 subjects. Calculation of the PMs thus provides a data-driven definition of variables that simultaneously quantify the state of the postural system (PPs and PVs) and the activity of the neuro-muscular controller (PM). Since the definition of PPs and PM is consistent with Newton's mechanics, these variables facilitate studying how mechanical variables, such as the COP motion, are governed by the postural control system. (C) 2016 Elsevier Ltd. All rights reserved.	[Federolf, Peter A.] Univ Innsbruck, Dept Sport Sci, Furstenweg 185, A-6020 Innsbruck, Austria; [Federolf, Peter A.] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Federolf, Peter A.] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway		Federolf, PA (corresponding author), Univ Innsbruck, Dept Sport Sci, Furstenweg 185, A-6020 Innsbruck, Austria.	Peter.Federolf@uibk.ac.at	Federolf, Peter/H-4481-2019	Federolf, Peter/0000-0002-0266-6813			Alexandrov A, 1998, EXP BRAIN RES, V118, P210, DOI 10.1007/s002210050274; Bonnet CT, 2012, HUM MOVEMENT SCI, V31, P1541, DOI 10.1016/j.humov.2012.05.001; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Corriveau H, 2004, ARCH PHYS MED REHAB, V85, P1095, DOI 10.1016/j.apmr.2003.09.023; Daffertshofer A, 2004, CLIN BIOMECH, V19, P415, DOI 10.1016/j.clinbiomech.2004.01.005; Danna-dos-Santos A, 2007, EXP BRAIN RES, V179, P533, DOI 10.1007/s00221-006-0812-0; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; Donker SF, 2008, EXP BRAIN RES, V184, P363, DOI 10.1007/s00221-007-1105-y; Eskofier BM, 2013, COMPUT METHOD BIOMEC, V16, P435, DOI 10.1080/10255842.2011.624515; Federolf P, 2014, SCAND J MED SCI SPOR, V24, P491, DOI 10.1111/j.1600-0838.2012.01455.x; Federolf PA, 2013, J BIOMECH, V46, P2173, DOI 10.1016/j.jbiomech.2013.06.032; Federolf P, 2013, J BIOMECH, V46, P2626, DOI 10.1016/j.jbiomech.2013.08.008; Federolf P, 2012, J BIOMECH, V45, P1127, DOI 10.1016/j.jbiomech.2012.02.008; Federolf PA, 2012, FOOTWEAR SCI, V4, P115, DOI 10.1080/19424280.2012.666270; Federolf PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078689; Freitas SMSF, 2006, J NEUROPHYSIOL, V95, P636, DOI 10.1152/jn.00482.2005; Hillman CH, 2004, BIOL PSYCHOL, V66, P51, DOI 10.1016/j.biopsycho.2003.07.005; Hodges PW, 2002, EXP BRAIN RES, V144, P293, DOI 10.1007/s00221-002-1040-x; Hsu WL, 2007, J NEUROPHYSIOL, V97, P3024, DOI 10.1152/jn.01142.2006; Klous M, 2011, J NEUROPHYSIOL, V105, P2275, DOI 10.1152/jn.00665.2010; Krishnamoorthy V, 2003, EXP BRAIN RES, V152, P281, DOI 10.1007/s00221-003-1574-6; Krishnamoorthy V, 2003, BIOL CYBERN, V89, P152, DOI 10.1007/s00422-003-0419-5; Lipsitz LA, 2002, J GERONTOL A-BIOL, V57, pB115, DOI 10.1093/gerona/57.3.B115; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53; Maurer C, 2012, GAIT POSTURE, V36, P40, DOI 10.1016/j.gaitpost.2011.12.023; Nigg BM, 2012, J BIOMECH, V45, P1692, DOI 10.1016/j.jbiomech.2012.03.027; Pinter IJ, 2008, J NEUROPHYSIOL, V100, P3197, DOI 10.1152/jn.01312.2007; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Rose J, 2002, DEV MED CHILD NEUROL, V44, P58, DOI 10.1017/S0012162201001669; RUBIN AM, 1995, AM J OTOL, V16, P216; Salavati M, 2009, GAIT POSTURE, V29, P460, DOI 10.1016/j.gaitpost.2008.11.016; Scharli AM, 2013, EXP BRAIN RES, V227, P523, DOI 10.1007/s00221-013-3528-y; Tricon V, 2007, NEUROSCI LETT, V415, P81, DOI 10.1016/j.neulet.2006.12.046; Troje NF, 2002, J VISION, V2, P371, DOI 10.1167/2.5.2; Vernazza S, 1996, NEUROSCI LETT, V206, P77, DOI 10.1016/S0304-3940(96)12464-2; Verrel J, 2009, PSYCHOL AGING, V24, P75, DOI 10.1037/a0014272; WINTER DA, 1993, NEUROSCI RES COMMUN, V12, P141; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334, DOI 10.1152/jn.1996.75.6.2334	40	40	41	2	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	FEB 8	2016	49	3					364	370		10.1016/j.jbiomech.2015.12.030			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	DF7PA	WOS:000371548700007	26768228	Green Accepted			2022-02-06	
J	Kizuka, Y; Nakano, M; Kitazume, S; Saito, T; Saido, TC; Taniguchi, N				Kizuka, Yasuhiko; Nakano, Miyako; Kitazume, Shinobu; Saito, Takashi; Saido, Takaomi C.; Taniguchi, Naoyuki			Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions	BIOCHEMICAL JOURNAL			English	Article						Alzheimer's disease; BACE1; bisecting GlcNAc; glycobiology; GnT-III; oxidative stress	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; ASPARAGINE-LINKED OLIGOSACCHARIDES; ALZHEIMERS BETA-SECRETASE; BRANCHED N-GLYCANS; MOUSE MODELS; DISEASE; THERAPEUTICS; CANCER; SENSITIVITY	beta-Site amyloid precursor protein-cleaving enzyme-1 (BACE1) is a protease essential for amyloid-beta (A beta) production in Alzheimer's disease (AD). BACE1 protein is known to be up-regulated by oxidative stress-inducing stimuli but the mechanism for this up-regulation still needs to be clarified. We have recently found that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc) by N-acetylglucosaminyltransferase-III (GnT-III, encoded by the Mgat3 gene) and that GnT-III deficiency reduces A beta-plaque formation in the brain by accelerating lysosomal degradation of BACE1. Therefore, we hypothesized that bisecting GlcNAc would stabilize BACE1 protein on oxidative stress. In the present study, we first show that A beta deposition in the mouse brain induces oxidative stress, together with an increase in levels of BACE1 and bisecting GlcNAc. Furthermore, prooxidant treatment induces expression of BACE1 protein in wild-type mouse embryonic fibroblasts (MEFs), whereas it reduces BACE1 protein in GnT-III (Mgat3) knock-out MEFs by accelerating lysosomal degradation of BACE1. We purified BACE1 from Neuro2A cells and performed LC/ESI/MS analysis for BACE1-derived glycopeptides and mapped bisecting GlcNAc-modified sites on BACE1. Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1. These mutations almost cancelled the enhanced BACE1 degradation seen in Mgat3(-/-) MEFs, indicating that bisecting GlcNAc on BACE1 indeed regulates its degradation. Finally, we show that traumatic brain injury-induced BACE1 up-regulation is significantly suppressed in the Mgat3(-/-) brain. These results highlight the role of bisecting GlcNAc in oxidative stress-induced BACE1 expression and offer a novel glycan-targeted strategy for suppressing A beta generation.	[Kizuka, Yasuhiko; Kitazume, Shinobu; Taniguchi, Naoyuki] RIKEN, Max Planck Joint Res Ctr Syst Chem Biol, Syst Glycobiol Res Grp, Dis Glyc Team,Global Res Cluster, 2-1 Hirosawa, Wako, Saitama 3510198, Japan; [Nakano, Miyako] Hiroshima Univ, Grad Sch Adv Sci Matter, 1-3-1 Kagamiyama, Higashihiroshima, Hiroshima 7398530, Japan; [Saito, Takashi; Saido, Takaomi C.] RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan		Kitazume, S; Taniguchi, N (corresponding author), RIKEN, Max Planck Joint Res Ctr Syst Chem Biol, Syst Glycobiol Res Grp, Dis Glyc Team,Global Res Cluster, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	shinobuk@riken.jp; dglycotani@riken.jp	Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Taniguchi, Naoyuki/A-7086-2016; Saito, Takashi/G-2563-2015; Taniguchi, Naoyuki/I-4182-2014	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; Kizuka, Yasuhiko/0000-0002-3181-9743	RIKEN; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26670148, 15K14481, 15H04700, 26110723, 26117522]	This work was supported by RIKEN (the Systems Glycobiology Research project to N.T., Special Postdoctoral Researchers Program to Y.K. and Incentive Research Grant to Y.K.) and by the Japan Society for the Promotion of Science (Grant-in-Aid for Challenging Exploratory Research to Y.K. [26670148] and to N.T. [15K14481], Grant-in-Aid for Scientific Research (B) to N.T. [15H04700], and Grant-in-Aid for Scientific Research on Innovative Areas to Y.K. [26110723] and S.K. [26117522]).	Abbott A, 2011, NATURE, V475, pS2, DOI 10.1038/475S2a; Abdul HM, 2006, J NEUROCHEM, V96, P1322, DOI 10.1111/j.1471-4159.2005.03647.x; Akasaka-Manya K, 2010, GLYCOBIOLOGY, V20, P99, DOI 10.1093/glycob/cwp152; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104; Guglielmotto M, 2009, J NEUROCHEM, V108, P1045, DOI 10.1111/j.1471-4159.2008.05858.x; Kandalepas PC, 2013, ACTA NEUROPATHOL, V126, P329, DOI 10.1007/s00401-013-1152-3; Kang EL, 2010, J BIOL CHEM, V285, P24108, DOI 10.1074/jbc.M109.092742; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kizuka Y, 2015, EMBO MOL MED, V7, P175, DOI 10.15252/emmm.201404438; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Kurimoto A, 2014, J BIOL CHEM, V289, P11704, DOI 10.1074/jbc.M113.502542; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Miyoshi E, 1997, INT J CANCER, V72, P1117; Mouton-Liger F, 2012, BBA-MOL BASIS DIS, V1822, P885, DOI 10.1016/j.bbadis.2012.01.009; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakano M, 2008, INT J CANCER, V122, P2301, DOI 10.1002/ijc.23364; Nakano M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009001; Nishima W, 2012, J PHYS CHEM B, V116, P8504, DOI 10.1021/jp212550z; O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Re S, 2011, BIOPHYS J, V101, pL44, DOI 10.1016/j.bpj.2011.10.019; Sadleir KR, 2012, J BIOL CHEM, V287, P7224, DOI 10.1074/jbc.M111.333914; Saito T, 2014, NAT NEUROSCI, V17, P661, DOI 10.1038/nn.3697; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Selkoe DJ, 2011, NAT MED, V17, P1060, DOI 10.1038/nm.2460; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tamagno E, 2008, J NEUROCHEM, V104, P683, DOI 10.1111/j.1471-4159.2007.05072.x; Tan JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051922; Taniguchi N, 2006, CURR OPIN STRUC BIOL, V16, P561, DOI 10.1016/j.sbi.2006.08.011; Taniguchi N, 2011, BMB REP, V44, P772, DOI 10.5483/BMBRep.2011.44.12.772; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; von Bernhardi R, 2012, ANTIOXID REDOX SIGN, V16, P974, DOI 10.1089/ars.2011.4082; Walker KR, 2012, J NEUROSCI, V32, P10423, DOI 10.1523/JNEUROSCI.5491-11.2012; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang XM, 2009, EUR J NEUROSCI, V30, P2271, DOI 10.1111/j.1460-9568.2009.07017.x; Zhao YY, 2008, FEBS J, V275, P1939, DOI 10.1111/j.1742-4658.2008.06346.x	43	40	40	0	17	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0264-6021	1470-8728		BIOCHEM J	Biochem. J.	JAN 1	2016	473		1				21	30		10.1042/BJ20150607			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DK2ZI	WOS:000374783900004	26467158				2022-02-06	
J	Silva, S; de Pasquale, F; Vuillaume, C; Riu, B; Loubinoux, I; Geeraerts, T; Seguin, T; Bounes, V; Fourcade, O; Demonet, JF; Peran, P				Silva, Stein; de Pasquale, Francesco; Vuillaume, Corine; Riu, Beatrice; Loubinoux, Isabelle; Geeraerts, Thomas; Seguin, Thierry; Bounes, Vincent; Fourcade, Olivier; Demonet, Jean-Francois; Peran, Patrice			Disruption of posteromedial large-scale neural communication predicts recovery from coma	NEUROLOGY			English	Article							DEFAULT MODE NETWORK; POSTERIOR PARIETAL CORTEX; FUNCTIONAL CONNECTIVITY; RHESUS-MONKEY; VEGETATIVE STATE; BRAIN-FUNCTION; CONSCIOUSNESS; CINGULATE; PARCELLATION; ARCHITECTURE	Objective: We hypothesize that the major consciousness deficit observed in coma is due to the breakdown of long-range neuronal communication supported by precuneus and posterior cingulate cortex (PCC), and that prognosis depends on a specific connectivity pattern in these networks. Methods: We compared 27 prospectively recruited comatose patients who had severe brain injury (Glasgow Coma Scale score <8; 14 traumatic and 13 anoxic cases) with 14 age-matched healthy participants. Standardized clinical assessment and fMRI were performed on average 4 +/- 2 days after withdrawal of sedation. Analysis of resting-state fMRI connectivity involved a hypothesis-driven, region of interest-based strategy. We assessed patient outcome after 3 months using the Coma Recovery Scale-Revised (CRS-R). Results: Patients who were comatose showed a significant disruption of functional connectivity of brain areas spontaneously synchronized with PCC, globally notwithstanding etiology. The functional connectivity strength between PCC and medial prefrontal cortex (mPFC) was significantly different between comatose patients who went on to recover and those who eventually scored an unfavorable outcome 3 months after brain injury (Kruskal-Wallis test, p < 0.001; linear regression between CRS-R and PCC-mPFC activity coupling at rest, Spearman r = 0.93, p < 0.003). Conclusion: In both etiology groups (traumatic and anoxic), changes in the connectivity of PCC-centered, spontaneously synchronized, large-scale networks account for the loss of external and internal self-centered awareness observed during coma. Sparing of functional connectivity between PCC and mPFC may predict patient outcome, and further studies are needed to substantiate this potential prognosis biomarker.	[Silva, Stein; Riu, Beatrice] Univ Teaching Hosp Purpan, Crit Care Unit, Pl Dr Baylac, F-31059 Toulouse 9, France; [Silva, Stein; Vuillaume, Corine; Riu, Beatrice; Geeraerts, Thomas; Seguin, Thierry; Fourcade, Olivier] Univ Teaching Hosp Purpan, Crit Care & Anaesthesiol Dept, F-31059 Toulouse 9, France; [Bounes, Vincent] Univ Teaching Hosp Purpan, SAMU 31, F-31059 Toulouse 9, France; [Silva, Stein; Vuillaume, Corine; Loubinoux, Isabelle; Peran, Patrice] CHU Purpan, INSERM U825, F-31059 Toulouse 9, France; [de Pasquale, Francesco] Santa Lucia Fdn, Dept Radiol, Rome, Italy; [de Pasquale, Francesco] Univ G DAnnunzio, ITAB, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Demonet, Jean-Francois] Dept Clin Neurosci CHUV, Leenaards Memory Ctr, Lausanne, Switzerland; [Demonet, Jean-Francois] Univ Lausanne, CH-1015 Lausanne, Switzerland		Silva, S (corresponding author), Univ Teaching Hosp Purpan, Crit Care Unit, Pl Dr Baylac, F-31059 Toulouse 9, France.	silva.s@chu-toulouse.fr	de Pasquale, Francesco/AAB-3440-2019; Peran, Patrice/N-7561-2015; Loubinoux, Isabelle/E-5537-2016	Peran, Patrice/0000-0001-7200-0139; Loubinoux, Isabelle/0000-0003-4461-0890; Demonet, Jean-Francois/0000-0003-0100-6175; DE PASQUALE, Francesco/0000-0003-1109-3305	Association des Traumatises du Crane et de la Face; Institut des Sciences du Cerveau de Toulouse; Institut National de la Sante et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm)	Funding was provided by the Association des Traumatises du Crane et de la Face, Institut des Sciences du Cerveau de Toulouse, and Institut National de la Sante et de la Recherche Medicale. The funding sources had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.	Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Andrews-Hanna JR, 2010, NEURON, V65, P550, DOI 10.1016/j.neuron.2010.02.005; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Boly M, 2009, PROG BRAIN RES, V177, P383, DOI 10.1016/S0079-6123(09)17727-0; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Dixon ML, 2014, NEUROPSYCHOLOGIA, V62, P321, DOI 10.1016/j.neuropsychologia.2014.05.024; FLETCHER PC, 1995, NEUROIMAGE, V2, P195, DOI 10.1006/nimg.1995.1025; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Palacios EM, 2013, J NEUROTRAUM, V30, P1991, DOI 10.1089/neu.2012.2836; PANDYA DN, 1982, J COMP NEUROL, V204, P196, DOI 10.1002/cne.902040208; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Soddu A, 2011, FUNCT NEUROL, V26, P37; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Vogt BA, 2005, J COMP NEUROL, V485, P218, DOI 10.1002/cne.20512; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	38	40	43	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 8	2015	85	23					2036	2044		10.1212/WNL.0000000000002196			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF8WV	WOS:000371642200011	26561296	Green Published, hybrid			2022-02-06	
J	Karumbaiah, L; Enam, SF; Brown, AC; Saxena, T; Betancur, MI; Barker, TH; Bellamkonda, RV				Karumbaiah, Lohitash; Enam, Syed Faaiz; Brown, Ashley C.; Saxena, Tarun; Betancur, Martha I.; Barker, Thomas H.; Bellamkonda, Ravi V.			Chondroitin Sulfate Glycosaminoglycan Hydrogels Create Endogenous Niches for Neural Stem Cells	BIOCONJUGATE CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; BINDING GROWTH-FACTORS; SPINAL-CORD; EXTRACELLULAR-MATRIX; HYALURONIC-ACID; HYBRID CHAINS; SELF-RENEWAL; MOLECULAR-INTERACTIONS; PROGENITOR CELLS; SYSTEM	Neural stem cells (NSCs) possess great potential for neural tissue repair after traumatic injuries to the central nervous system (CNS). However, poor survival and self-renewal of NSCs after injury severely limits its therapeutic potential. Sulfated chondroitin sulfate glycosaminoglycans (CS-GAGs) linked to CS proteoglycans (CSPGs) in the brain extracellular matrix (ECM) have the ability to bind and potentiate trophic factor efficacy, and promote NSC self-renewal in vivo. In this study, we investigated the potential of CS-GAG hydrogels composed of monosulfated CS-4 (CS-A), CS-6 (CS-C), and disulfated CS-4,6 (CS-E) CS-GAGs as NSC carriers, and their ability to create endogenous niches by enriching specific trophic factors to support NSC self-renewal. We demonstrate that CS-GAG hydrogel scaffolds showed minimal swelling and degradation over a period of 15 days in vitro, absorbing only 6.5 +/- 0.019% of their initial weight, and showing no significant loss of mass during this period. Trophic factors FGF-2, BDNF, and IL10 bound with high affinity to CS-GAGs, and were significantly (p <0.05) enriched in CS-GAG hydrogels when compared to unsulfated hyaluronic acid (HA) hydrogels. Dissociated rat subventricular zone (SVZ) NSCs when encapsulated in CS-GAG hydrogels demonstrated similar to 88.5 +/- 6.1% cell viability in vitro. Finally, rat neurospheres in CS-GAG hydrogels conditioned with the mitogen FGF-2 demonstrated significantly (p < 0.05) higher self-renewal when compared to neurospheres cultured in unconditioned hydrogels. Taken together, these findings demonstrate the ability of CS-GAG based hydrogels to regulate NSC self-renewal, and facilitate growth factor enrichment locally.	[Enam, Syed Faaiz; Saxena, Tarun; Barker, Thomas H.; Bellamkonda, Ravi V.] Emory Univ, Sch Med, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Karumbaiah, Lohitash; Betancur, Martha I.] Univ Georgia, Regenerat Biosci Ctr, Athens, GA 30602 USA; [Brown, Ashley C.] N Carolina State Univ, UNC Chapel Hill, Joint Dept Biomed Engn, Raleigh, NC 27695 USA		Bellamkonda, RV (corresponding author), Emory Univ, Sch Med, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	ravi@gatech.edu		Karumbaiah, Lohitash/0000-0001-7969-417X; Enam, Syed Faaiz/0000-0002-5320-6809	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 079739]; Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center; University of Georgia Athletic Association; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR00454]; National Institutes of Health (NIH/NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 P41 RR018502-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR018502] Funding Source: NIH RePORTER	This research was supported in part by NIH R01 079739 (RVB), seed grant funding from the Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center and The University of Georgia Athletic Association awarded to RVB and LK. This work is also supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR00454. The National Institutes of Health (NIH/NCRR)-funded grant entitled 'Integrated Technology Resource for Biomedical Glycomics' (grant no. 1 P41 RR018502-01) to the Complex Carbohydrate Research Center, The University of Georgia. We would also like to acknowledge Ms. Meghan Logun for technical assistance with SEM imaging, and Dr. Johannes Leisen for technical assistance with NMR.	Akita K, 2008, STEM CELLS, V26, P798, DOI 10.1634/stemcells.2007-0448; Austin JW, 2012, BIOMATERIALS, V33, P4555, DOI 10.1016/j.biomaterials.2012.03.022; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004; Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050; BERTOLOTTO A, 1990, J NEUROL SCI, V100, P113, DOI 10.1016/0022-510X(90)90021-E; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Cai SS, 2005, BIOMATERIALS, V26, P6054, DOI 10.1016/j.biomaterials.2005.03.012; Cave JW, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00016; Conovaloff A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056003; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; DAMON DH, 1988, J CELL PHYSIOL, V135, P293, DOI 10.1002/jcp.1041350217; Deepa SS, 2006, J BIOL CHEM, V281, P17789, DOI 10.1074/jbc.M600544200; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Donaghue IE, 2014, J CONTROL RELEASE, V190, P219, DOI 10.1016/j.jconrel.2014.05.040; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; Emerling DE, 1996, NEURON, V17, P1089, DOI 10.1016/S0896-6273(00)80242-1; Erceg S, 2009, STEM CELLS, V27, P78, DOI 10.1634/stemcells.2008-0543; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; Gerecht S, 2007, P NATL ACAD SCI USA, V104, P11298, DOI 10.1073/pnas.0703723104; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Ida M, 2006, J BIOL CHEM, V281, P5982, DOI 10.1074/jbc.M507130200; Jedrzejas MJ, 2005, PROTEINS, V61, P227, DOI 10.1002/prot.20592; Jeon O, 2009, BIOMATERIALS, V30, P2724, DOI 10.1016/j.biomaterials.2009.01.034; Johnson PJ, 2009, BIOTECHNOL BIOENG, V104, P1207, DOI 10.1002/bit.22476; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; Karumbaiah L, 2014, CURR MED CHEM, V21, P4257, DOI 10.2174/0929867321666140815124447; Karumbaiah L, 2011, GLIA, V59, P981, DOI 10.1002/glia.21170; Kazanis I, 2011, DEV NEUROBIOL, V71, P1006, DOI 10.1002/dneu.20970; KIANG WL, 1981, J BIOL CHEM, V256, P529; Kim BG, 2007, CELL TRANSPLANT, V16, P355, DOI 10.3727/000000007783464885; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LAMBERG SI, 1974, J INVEST DERMATOL, V63, P433, DOI 10.1111/1523-1747.ep12680346; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Lawrence R, 2008, NAT METHODS, V5, P291, DOI 10.1038/nmeth0408-291; Li Q, 2004, J BIOMED MATER RES A, V68A, P28, DOI 10.1002/jbm.a.20007; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602; Manzi A, 2001, Curr Protoc Mol Biol, VChapter 17, DOI 10.1002/0471142727.mb1709s32; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARGOLIS RU, 1967, BIOCHIM BIOPHYS ACTA, V141, P91, DOI 10.1016/0304-4165(67)90248-6; Marshall Gregory P. II, 2008, V438, P135, DOI 10.1007/978-1-59745-133-8_12; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Matsui T, 2012, STEM CELLS, V30, P1109, DOI 10.1002/stem.1091; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Mitsunaga C, 2006, J BIOL CHEM, V281, P18942, DOI 10.1074/jbc.M510870200; Mizumoto S, 2013, GLYCOCONJUGATE J, V30, P619, DOI 10.1007/s10719-012-9463-5; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2001, SEIKAGAKU, V73, P471; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park D, 2010, STEM CELLS, V28, P2162, DOI 10.1002/stem.541; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; Saxena T, 2012, J NEUROTRAUM, V29, P1747, DOI 10.1089/neu.2011.1818; Saxena T, 2009, J BIOMED MATER RES A, V90A, P1206, DOI 10.1002/jbm.a.32178; Schwartz NB, 2004, GLYCOCONJUGATE J, V21, P329, DOI 10.1023/B:GLYC.0000046278.34016.36; Seidlits SK, 2010, BIOMATERIALS, V31, P3930, DOI 10.1016/j.biomaterials.2010.01.125; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Sirko S, 2007, DEVELOPMENT, V134, P2727, DOI 10.1242/dev.02871; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Strehin I, 2010, BIOMATERIALS, V31, P2788, DOI 10.1016/j.biomaterials.2009.12.033; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Valmikinathan CM, 2012, SOFT MATTER, V8, P1964, DOI 10.1039/c1sm06629c; Varghese S, 2008, MATRIX BIOL, V27, P12, DOI 10.1016/j.matbio.2007.07.002; Vermonden T, 2008, BIOMACROMOLECULES, V9, P919, DOI 10.1021/bm7013075; Wang SC, 2007, INT J PHARM, V329, P103, DOI 10.1016/j.ijpharm.2006.08.041; Williams CG, 2005, BIOMATERIALS, V26, P1211, DOI 10.1016/j.biomaterials.2004.04.024; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhong J, 2010, NEUROREHAB NEURAL RE, V24, P636, DOI 10.1177/1545968310361958	98	40	41	3	52	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1043-1802			BIOCONJUGATE CHEM	Bioconjugate Chem.	DEC	2015	26	12					2336	2349		10.1021/acs.bioconjchem.5b00397			14	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	CZ1PI	WOS:000366877400007	26440046				2022-02-06	
J	Chandler, JA				Chandler, Jennifer A.			The use of neuroscientific evidence in Canadian criminal proceedings	JOURNAL OF LAW AND THE BIOSCIENCES			English	Article						Canadian criminal justice system; criminal law; law and neuroscience; brain damage; fetal alcohol spectrum disorder; FASD; traumatic brain injury		This article addresses the question of how neuroscientific evidence is currently used in the Canadian criminal justice system, with a view to identifying the main contexts in which this evidence is raised, as well as to discern the impact of this evidence on judgements of responsibility, dangerousness, and treatability. The most general Canadian legal database was searched for cases in the five-year period between 2008 and 2012 in which neuroscientific evidence related to the responsibility and recidivism risk of criminal offenders was considered. Canadian courts consider neuroscientific evidence of many types, particularly evidence of prenatal alcohol exposure, traumatic brain injury, and neuropsychological testing. The majority of the cases are sentencing decisions, which is useful given that it offers an opportunity to observe how judges wrestle with the tension that evidence of diminished capacity due to brain damage tends to reduce moral blameworthiness, while it also tends to increase perceptions of risk and dangerousness. This so-called double-edged sword of the biological explanation of criminal behavior was reflected in this study, and raises questions about whether and when the pursuit of such evidence is advisable from the defense perspective.	[Chandler, Jennifer A.] Univ Ottawa, Common Law, 57 Louis Pasteur St, Ottawa, ON K1N 6N5, Canada		Chandler, JA (corresponding author), Univ Ottawa, Common Law, 57 Louis Pasteur St, Ottawa, ON K1N 6N5, Canada.	chandler@uottawa.ca					Aspinwall LG, 2012, SCIENCE, V337, P846, DOI 10.1126/science.1219569; Boyce J., 2013, ADULT CRIMINAL COURT; Cashmore AR, 2010, P NATL ACAD SCI USA, V107, pE150, DOI 10.1073/pnas.1011107107; Cashmore AR, 2010, P NATL ACAD SCI USA, V107, P4499, DOI 10.1073/pnas.0915161107; Colantonio A, 2014, J CORRECT HEALTH CAR, V20, P271, DOI 10.1177/1078345814541529; Dauvergne Mia, 1992, YOUTH COURT STAT CAN; DENNO DW, 2015, BC L REV, V56, P493; Dolphin Myles, 2014, YUKON NEWS      1126; Goodenough OR, 2010, ANNU REV LAW SOC SCI, V6, P61, DOI 10.1146/annurev.lawsocsci.093008.131523; Greene Joshua, PHIL T ROYAL SOC B, V359, P1785; Greene Joshua, PHIL T ROYAL SOC B, V359, P1775; Health Canada, 2006, FETAL ALCOHOL SPECTR; Institute of Health Economics, 2013, CONS STAT LEG ISS FE, P22; Jones Owen D., 2012, INT NEUROLAW A COMP, P351; Jones Simon Verdun, 2012, CRIMINAL JUSTICE INC, V163, P177; Katz-Schiavone S., 2008, J CRIMINAL JUSTICE P, V15, P291; Katz-Schiavone Stacey, 2008, J CRIM JUST POP CULT, V15, P311; Morse Stephen J., 2010, LAW NEUROSCIENCE CUR, V13, P529; PENNEY STEVEN, 2011, CRIMINAL PROCEDURE C, P689; Public Safety Canada, 2012, 2012 CORR COND REL S; Puranik D.A., 2009, P 20 ALL IND FOR SCI, P815; Rigoni D, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00160; Roach K., 2009, U BRIT COLUMBIA LAW, V42, P1; Roach K., 2009, UBC LAW REV, V41, P68; SCHNEIDER RICHARD D., 2013, MENTAL DISORDER LAW, P132; Statistics Canada, 2013, AD CRIM COURT STAT C; Williams Huw, 2012, REPORT COMMISSIONED	27	40	40	1	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	2053-9711			J LAW BIOSCI	J. Law Biosci.	NOV	2015	2	3					550	579		10.1093/jlb/lsv026			30	Ethics; Law; Medical Ethics; Medicine, Legal	Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	DJ8XO	WOS:000374497800004	27774212	Green Submitted, Green Published, gold			2022-02-06	
J	Yao, XM; Uchida, K; Papadopoulos, MC; Zador, Z; Manley, GT; Verkman, AS				Yao, Xiaoming; Uchida, Kazuyoshi; Papadopoulos, Marios C.; Zador, Zsolt; Manley, Geoffrey T.; Verkman, Alan S.			Mildly Reduced Brain Swelling and Improved Neurological Outcome in Aquaporin-4 Knockout Mice following Controlled Cortical Impact Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						AQP4; brain edema; brain trauma; controlled cortical impact injury; cytotoxic edema	GLOBAL CEREBRAL-ISCHEMIA; AQP4 EXPRESSION; WATER CHANNELS; RECEPTOR ANTAGONIST; EDEMA; RATS; CONTUSION; BLOOD; BARRIER; ASTROCYTES	Brain edema following traumatic brain injury (TBI) is associated with considerable morbidity and mortality. Prior indirect evidence has suggested the involvement of astrocyte water channel aquaporin-4 (AQP4) in the pathogenesis of TBI. Here, focal TBI was produced in wild type (AQP4(+/+)) and knockout (AQP4(-/-)) mice by controlled cortical impact injury (CCI) following craniotomy with dura intact (parameters: velocity 4.5m/sec, depth 1.7mm, dwell time 150 msec). AQP4-deficient mice showed a small but significant reduction in injury volume in the first week after CCI, with a small improvement in neurological outcome. Mechanistic studies showed reduced intracranial pressure at 6h after CCI in AQP4(-/-) mice, compared with AQP4(+/+) control mice (11 vs. 19mm Hg), with reduced local brain water accumulation as assessed gravimetrically. Transmission electron microscopy showed reduced astrocyte foot-process area in AQP4(-/-) mice at 24h after CCI, with greater capillary lumen area. Blood-brain barrier disruption assessed by Evans blue dye extravasation was similar in AQP4(+/+) and AQP4(-/-) mice. We conclude that the mildly improved outcome in AQP4(-/-) mice following CCI results from reduced cytotoxic brain water accumulation, though concurrent cytotoxic and vasogenic mechanisms in TBI make the differences small compared to those seen in disorders where cytotoxic edema predominates.	[Yao, Xiaoming; Uchida, Kazuyoshi; Zador, Zsolt; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Yao, Xiaoming; Verkman, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Yao, Xiaoming; Verkman, Alan S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Papadopoulos, Marios C.] Univ London, Acad Neurosurg Unit, London, England		Yao, XM (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci East Tower,513 Parnassus Ave, San Francisco, CA 94143 USA.	xiaoming.yao@ucsf.edu		zador, zsolt/0000-0003-4297-616X; Papadopoulos, Marios/0000-0001-9174-4176; Zador, Zsolt/0000-0001-9767-3372	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK35124, EY13574, EB00415, DK72517, NS050173]; Guthy-Jackson Charitable Foundation; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK072517, R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2014-06-004] Funding Source: researchfish	This work was supported by grants DK35124, EY13574, EB00415, DK72517 and NS050173 from the National Institutes of Health and a grant from the Guthy-Jackson Charitable Foundation.	Akdemir G, 2014, NEUROSCI LETT, V574, P70, DOI 10.1016/j.neulet.2014.03.073; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Katada R, 2014, FASEB J, V28, P705, DOI 10.1096/fj.13-231274; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; Marmarou A, 2000, ACT NEUR S, V76, P349; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nielsen S, 1997, J NEUROSCI, V17, P171; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Portella G, 2000, ACT NEUR S, V76, P273; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	44	40	40	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1458	1464		10.1089/neu.2014.3675			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500004	25790314	Green Published			2022-02-06	
J	Bharath, RD; Munivenkatappa, A; Gohel, S; Panda, R; Saini, J; Rajeswaran, J; Shukla, D; Bhagavatula, ID; Biswal, BB				Bharath, Rose D.; Munivenkatappa, Ashok; Gohel, Suril; Panda, Rajanikant; Saini, Jitender; Rajeswaran, Jamuna; Shukla, Dhaval; Bhagavatula, Indira D.; Biswal, Bharat B.			Recovery of resting brain connectivity ensuing mild traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						mild traumatic brain injury; resting state functional connectivity; longitudinal study; time varying changes; brain plasticity; hyper connectivity	DIFFUSE AXONAL INJURY; HEAD-INJURY; FUNCTIONAL CONNECTIVITY; COGNITIVE IMPAIRMENT; WORKING-MEMORY; NETWORK; STATE; DEFICITS; TASK; FMRI	Brains reveal amplified plasticity as they recover from an injury. We aimed to define time dependent plasticity changes in patients recovering from mild traumatic brain injury (mTBI). Twenty-five subjects with mild head injury were longitudinally evaluated within 36 h, 3 and 6 months using resting state functional connectivity (RSFC). Region of interest (ROI) based connectivity differences over time within the patient group and in comparison with a healthy control group were analyzed at p < 0.005. We found 33 distinct ROI pairs that revealed significant changes in their connectivity strength with time. Within 3 months, the majority of the ROI pairs had decreased connectivity in mTBI population, which increased and became comparable to healthy controls at 6 months. Within this diffuse decreased connectivity in the first 3 months, there were also few regions with increased connections. This hyper connectivity involved the salience network and default mode network within 36 h, and lingual, inferior frontal and fronto-parietal networks at 3 months. Our findings in a fairly homogenous group of patients with mTBI evaluated during the 6 month window of recovery defines time varying brain connectivity changes as the brain recovers from an injury. A majority of these changes were seen in the frontal and parietal lobes between 3 and 6 months after injury. Hyper connectivity of several networks supported normal recovery in the first 6 months and it remains to be seen in future studies whether this can predict an early and efficient recovery of brain function.	[Bharath, Rose D.; Panda, Rajanikant] Natl Inst Mental Hlth & Neurosci, Adv Brain Imaging Facil, Cognit Neurosci Ctr, Bangalore 560029, Karnataka, India; [Bharath, Rose D.; Panda, Rajanikant; Saini, Jitender] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bangalore 560029, Karnataka, India; [Munivenkatappa, Ashok] Natl Inst Mental Hlth & Neurosci, Dept Clin Neurosci, Bangalore 560029, Karnataka, India; [Gohel, Suril; Biswal, Bharat B.] Univ Hts, New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ USA; [Rajeswaran, Jamuna] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Neuropsychol Unit, Bangalore 560029, Karnataka, India; [Biswal, Bharat B.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India		Bhagavatula, ID (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Hosur Rd, Bangalore 560029, Karnataka, India.	bidevidr@gmaii.com	Munivenkatappa, Ashok/ABA-5952-2021	Bharath, Rose Dawn/0000-0002-7464-4250; Panda, Rajanikant/0000-0002-0960-4340	Department of Science and Technology, IndiaDepartment of Science & Technology (India) [SR/CSI/44/2008(5)]; National Institute of Aging, a part of National Institute of Health, US (NIH) [R01AG032088]	This research work was funded by the Department of Science and Technology, India under the cognitive science initiative, Ref: SR/CSI/44/2008(5). BB and SG are supported by funding from National Institute of Aging, a part of National Institute of Health, US (NIH) [grant number R01AG032088 (BB)]. We thank all the patients who participated in the study for their time and patience especially during the follow up visits. We also acknowledge the staff and radiographers from the Department of Neuroimaging and Interventional Radiology for their technical support during data collection especially during odd hours.	Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; Bharath RD, 2015, AM J NEURORADIOL, V36, P1890, DOI 10.3174/ajnr.A4373; Bharath RD, 2015, EUR J NEUROL, V22, P796, DOI 10.1111/ene.12653; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Comeau WL, 2010, BEHAV BRAIN RES, V214, P91, DOI 10.1016/j.bbr.2010.04.033; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Giza CC, 2001, J ATHL TRAINING, V36, P228; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kolb B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00377; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Munivenkatappa A, 2014, J NEUROSURG SCI; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rao S. L., 2004, NIMHANS NEUROPSYCHOL; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Shanmukhi S, 2003, NEUROL INDIA, V51, P518; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stamelou M, 2012, BRAIN, V135, P1668, DOI 10.1093/brain/awr224; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Taylor PA, 2013, BRAIN CONNECT, V3, P523, DOI 10.1089/brain.2013.0154; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	43	40	40	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	SEP 22	2015	9								513	10.3389/fnhum.2015.00513			13	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	CT2RJ	WOS:000362650900002	26441610	gold, Green Published			2022-02-06	
J	Bigler, ED				Bigler, Erin D.			Neuroimaging as a biomarker in symptom validity and performance validity testing	BRAIN IMAGING AND BEHAVIOR			English	Article						Symptom validity testing; Performance validity testing; Effort; Neuroimaging; Cognitive neuroscience of effort	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; WHITE-MATTER INJURY; CONVERSION DISORDER; MULTIPLE-SCLEROSIS; COGNITIVE EFFORT; RESPONSE BIAS; PSYCHOLOGICAL-ASSESSMENT; PSYCHOSOCIAL RISK; ILLNESS BEHAVIOR	How neuropsychological assessment findings are deemed valid has been a topic of numerous articles but few have addressed any role that neuroimaging studies could provide. Within military and various clinical samples of individuals undergoing neuropsychological evaluations, high levels of failure on measures of symptom validity testing (SVT) and/or performance validity testing (PVT) have been reported. Where 'failure' is defined as a below cut-score performance on some pre-determined set-point on a SVT/PVT measure, are such failures always indicative of invalid test findings or are there other explanations, especially based on informative neuroimaging findings? This review starts with the premise that even though the SVT/PVT task is designed to be simple and easy to perform, it nonetheless requires intact frontoparietal attention, working memory and task engagement (motivation) networks. If there is damage or pathology within any aspect of these networks as demonstrated by neuroimaging findings, the patient may perform below the cut-point as a result of the underlying damage or pathophysiology. The argument is made that neuroimaging findings should be considered as to where SVT/PVT cut-points are established and there should be much greater flexibility in SVT/PVT measures based on other personal, demographic and neuroimaging information. Several case studies are used to demonstrate these points.	Brigham Young Univ, Dept Psychol & Neurosci Ctr, Provo, UT 84602 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol & Neurosci Ctr, 1001 Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Arnsten AFT, 2012, NEURON, V76, P223, DOI 10.1016/j.neuron.2012.08.038; Arnsten AFT, 2012, J AM ACAD CHILD PSY, V51, P356, DOI 10.1016/j.jaac.2012.01.008; Aronoff Gerald M, 2007, Pain Pract, V7, P178, DOI 10.1111/j.1533-2500.2007.00126.x; Astafiev SV, 2015, J NEUROTRAUM, V32, P1254, DOI 10.1089/neu.2014.3547; Aybek S, 2014, JAMA PSYCHIAT, V71, P52, DOI 10.1001/jamapsychiatry.2013.2842; Bass C, 2007, J ROY SOC MED, V100, P81, DOI 10.1258/jrsm.100.2.81; Bass C, 2014, LANCET, V383, P1422, DOI 10.1016/S0140-6736(13)62186-8; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; BENDEFELDT F, 1976, ARCH GEN PSYCHIAT, V33, P1250; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bigler E. D., 2015, USE SYMPTOM VALIDITY; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2014, NEUROLOGY, V83, P1226, DOI 10.1212/WNL.0000000000000848; Bigler ED, 2014, NEUROLOGY, V82, P1641, DOI 10.1212/WNL.0000000000000395; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Binder LM, 2014, CLIN NEUROPSYCHOL, V28, P1366, DOI 10.1080/13854046.2014.978383; Bol Y, 2010, CLIN REHABIL, V24, P854, DOI 10.1177/0269215510367540; Bracht T, 2015, J AFFECT DISORDERS, V170, P143, DOI 10.1016/j.jad.2014.08.031; Brancu M, 2014, PSYCHIAT RES, V217, P86, DOI 10.1016/j.psychres.2014.02.025; Braver TS, 2014, COGN AFFECT BEHAV NE, V14, P443, DOI 10.3758/s13415-014-0300-0; Browndyke JN, 2008, BRAIN INJURY, V22, P481, DOI 10.1080/02699050802084894; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chew LJ, 2013, DEV NEUROSCI-BASEL, V35, P102, DOI 10.1159/000346157; Clark A. L., 2015, WHITE MATTE IN PRESS; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Clery-Melin ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023178; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Dahm J, 2015, INJURY, V46, P142, DOI 10.1016/j.injury.2014.07.012; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Dobryakova E, 2013, J INT NEUROPSYCH SOC, V19, P849, DOI 10.1017/S1355617713000684; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Engelmann JB, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.004.2009; Engstrom M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00140; Esposito F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094222; Farah MJ, 2014, NAT REV NEUROSCI, V15, P123, DOI 10.1038/nrn3665; Ferrari R, 2001, MED HYPOTHESES, V57, P68, DOI 10.1054/mehy.2000.1167; Fervaha G, 2013, NEUROSCI BIOBEHAV R, V37, P2649, DOI 10.1016/j.neubiorev.2013.09.001; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01, https://doi.org/10.1300/J151v02n03_01]; Freedman D., 2015, USE NORMATIVE DATA M; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Gil R, 2010, REV NEUROL-FRANCE, V166, P699, DOI 10.1016/j.neurol.2010.01.002; Gombos VA, 2006, GENET SOC GEN PSYCH, V132, P197, DOI 10.3200/MONO.132.3.197-214; Gondi V, 2010, RADIOTHER ONCOL, V97, P370, DOI 10.1016/j.radonc.2010.09.013; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Groenewold NA, 2015, COGN AFFECT BEHAV NE, V15, P69, DOI 10.3758/s13415-014-0316-5; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Hammar A, 2003, J INT NEUROPSYCH SOC, V9, P954, DOI 10.1017/S1355617703960152; Hammar A, 2012, PSYCHIAT RES, V198, P420, DOI 10.1016/j.psychres.2011.11.020; Hampson NE, 2014, APPL NEUROPSYCH-ADUL, V21, P183, DOI 10.1080/09084282.2013.787425; Harrington ME, 2012, PROG NEUROBIOL, V99, P93, DOI 10.1016/j.pneurobio.2012.07.004; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Herman AB, 2013, J NEUROSCI, V33, P5439, DOI 10.1523/JNEUROSCI.1472-12.2013; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Hoover S, 2014, INT J PSYCHOPHYSIOL, V91, P139, DOI 10.1016/j.ijpsycho.2013.12.009; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Hughes DM, 2015, SOC COGN AFFECT NEUR, V10, P1015, DOI 10.1093/scan/nsu149; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Induruwa I, 2012, J NEUROL SCI, V323, P9, DOI 10.1016/j.jns.2012.08.007; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; Jobes DA, 2013, PSYCHIATRY, V76, P126, DOI 10.1521/psyc.2013.76.2.126; Johnstone T, 2007, J NEUROSCI, V27, P8877, DOI 10.1523/JNEUROSCI.2063-07.2007; Kamat R, 2014, J CLIN EXP NEUROPSYC, V36, P854, DOI 10.1080/13803395.2014.950636; Kanaan R, 2009, BRAIN, V132, P2889, DOI 10.1093/brain/awp060; Kawa L, 2015, J NEUROTRAUM, V32, P1190, DOI 10.1089/neu.2014.3669; KIMBLE GA, 1950, J EXP PSYCHOL, V40, P248, DOI 10.1037/h0056256; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kwan O, 2002, MED HYPOTHESES, V59, P129, DOI 10.1016/S0306-9877(02)00119-6; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larsen JD, 2010, BRAIN INJURY, V24, P89, DOI 10.3109/02699050903508218; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lester K, 2007, J BEHAV MED, V30, P177, DOI 10.1007/s10865-007-9095-6; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Liu XH, 2014, ACTA NEUROPSYCHIATR, V26, P195, DOI 10.1017/neu.2013.47; Lloyd DM, 2014, PSYCHOSOM MED, V76, P413, DOI 10.1097/PSY.0000000000000076; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Lui YW, 2014, NEUROLOGY, V83, P1235, DOI 10.1212/WNL.0000000000000834; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Matthews G, 2015, HUM FACTORS, V57, P125, DOI 10.1177/0018720814539505; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Nave KA, 2014, JAMA PSYCHIAT, V71, P582, DOI 10.1001/jamapsychiatry.2014.189; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Nicholson TR, 2014, J NEUROL NEUROSUR PS, V85, P227, DOI 10.1136/jnnp-2013-305012; Nicholson TRJ, 2011, J NEUROL NEUROSUR PS, V82, P1267, DOI 10.1136/jnnp.2008.171306; Nihonmatsu-Kikuchi N, 2013, J ALZHEIMERS DIS, V37, P611, DOI 10.3233/JAD-130752; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; O'Neil EB, 2015, J COGNITIVE NEUROSCI, V27, P1708, DOI 10.1162/jocn_a_00816; Ota M, 2015, PSYCHIAT CLIN NEUROS, V69, P360, DOI 10.1111/pcn.12255; Passarotti AM, 2012, BRAIN CONNECT, V2, P320, DOI 10.1089/brain.2012.0089; Patti F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120754; Pedersen H, 2014, ARCH CLIN NEUROPSYCH, V29; Perez DL, 2012, J NEUROPSYCH CLIN N, V24, P141, DOI 10.1176/appi.neuropsych.11050110; Pessoa L, 2010, FRONT HUM NEUROSCI, V4, DOI [10.3389/fnhum.2010.00172, 10.3389/fnins.2010.00017]; Ploetz DM, 2016, CHILD NEUROPSYCHOL, V22, P133, DOI 10.1080/09297049.2014.986446; Pogoda TK, 2016, J HEAD TRAUMA REHAB, V31, P191, DOI 10.1097/HTR.0000000000000092; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; REY A, 1964, LEXAMEN CLIN PSYCHOL; Rey A, 1958, LEXAMEN CLINIQUE PSY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Robinson MJF, 2014, J NEUROSCI, V34, P16567, DOI 10.1523/JNEUROSCI.2013-14.2014; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2012, J NEUROPSYCH CLIN N, V24, pE33, DOI 10.1176/appi.neuropsych.11020044; Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Sela I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046527; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Silvia PJ, 2014, MOTIV EMOTION, V38, P779, DOI 10.1007/s11031-014-9443-0; Skerrett TN, 2006, J PSYCHOSOM RES, V61, P587, DOI 10.1016/j.jpsychores.2006.04.018; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Starkstein SE, 2014, PSYCHIAT CLIN N AM, V37, P103, DOI 10.1016/j.psc.2013.10.002; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Storbeck J, 2015, COGNITION EMOTION, V29, P95, DOI 10.1080/02699931.2014.904222; Suchotzki K, 2015, HUM BRAIN MAPP, V36, P427, DOI 10.1002/hbm.22637; Suchy Y, 2012, CLIN NEUROPSYCHOL, V26, P1296, DOI 10.1080/13854046.2012.722230; Sweet JJ, 2013, BEHAV SCI LAW, V31, P756, DOI 10.1002/bsl.2088; Takarada Y, 2014, NEUROSCI RES, V89, P54, DOI 10.1016/j.neures.2014.09.005; Tanner JJ, 2015, CLIN NEUROPSYCHOL, V29, P272, DOI 10.1080/13854046.2015.1008047; Thomas P, 1999, EUR ARCH PSY CLIN N, V249, P79, DOI 10.1007/s004060050070; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; U. S. Armed Forces, 1998, MSMR, V20, P20; U. S. Armed Forces, 1998, MSMR, V20, P23; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; van Hooft EAJ, 2012, J APPL PSYCHOL, V97, P301, DOI 10.1037/a0025711; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wieser GL, 2013, GLIA, V61, P869, DOI 10.1002/glia.22480; Willis PF, 2011, MIL MED, V176, P1426, DOI 10.7205/MILMED-D-11-00168; Yang XH, 2014, PSYCHIAT RES, V220, P874, DOI 10.1016/j.psychres.2014.08.056; Yang Z, 2014, NEUROIMAGE, V99, P80, DOI 10.1016/j.neuroimage.2014.05.034; Young G, 2014, PSYCHOL INJ LAW, V7, P206, DOI 10.1007/s12207-014-9202-2; Zeineh MM, 2015, RADIOLOGY, V274, P517, DOI 10.1148/radiol.14141079; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zorrilla EP, 2013, NEUROSCI BIOBEHAV R, V37, P1932, DOI 10.1016/j.neubiorev.2012.11.019	156	40	40	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					421	444		10.1007/s11682-015-9409-1			24	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR8LQ	WOS:000361604300005	26100657				2022-02-06	
J	Patton, DA; McIntosh, AS; Kleiven, S				Patton, Declan A.; McIntosh, Andrew S.; Kleiven, Svein			The Biomechanical Determinants of Concussion: Finite Element Simulations to Investigate Tissue-Level Predictors of Injury During Sporting Impacts to the Unprotected Head	JOURNAL OF APPLIED BIOMECHANICS			English	Article						biomechanics; head injury; modeling; sport		Biomechanical studies of concussions have progressed from qualitative observations of head impacts to physical and numerical reconstructions, direct impact measurements, and finite element analyses. Supplementary to a previous study, which investigated maximum principal strain, the current study used a detailed finite element head model to simulate unhelmeted concussion and no-injury head impacts and evaluate the effectiveness of various tissue-level brain injury predictors: strain rate, product of strain and strain rate, cumulative strain damage measure, von Mises stress, and intracranial pressure. Von Mises stress was found to be the most effective predictor of concussion. It was also found that the thalamus and corpus callosum were brain regions with strong associations with concussion. Tentative tolerance limits for tissue-level predictors were proposed in an attempt to broaden the understanding of unhelmeted concussions. For the thalamus, tolerance limits were proposed for a 50% likelihood of concussion: 2.24 kPa, 24.0 s(-1), and 2.49 s(-1) for von Mises stress, strain rate, and the product of strain and strain rate, respectively. For the corpus callosum, tolerance limits were proposed for a 50% likelihood of concussion: 3.51 kPa, 25.1 s(-1), and 2.76 s(-1) for von Mises stress, strain rate, and the product of strain and strain rate, respectively.	[Patton, Declan A.] Univ New S Wales, Fac Sci, Kensington, NSW 2033, Australia; [Patton, Declan A.; McIntosh, Andrew S.] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Stockholm, Sweden		Patton, DA (corresponding author), Univ New S Wales, Fac Sci, POB 1, Kensington, NSW 2033, Australia.	declan@unswalumni.com					Anderson RWG, 1999, IRCOBI C SITG SPAIN; [Anonymous], 2009, PASW STAT; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; MILLER RT, 1998, 42 STAPP CAR CRASH C; Newman JA, 1999, IRCOBI C SITG SPAIN; Newman JA, 2000, IRCOBI C MONTP FRANC; Patton DA, 2013, J APPL BIOMECH, V29, P721, DOI 10.1123/jab.29.6.721; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Zhang L, 2008, IRCOBI C BERN SWITZ; Zhang L., 2003, P 2003 SUMM BIOENG C, P137; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310	30	40	40	0	19	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	AUG	2015	31	4					264	268		10.1123/jab.2014-0223			5	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	CO3YI	WOS:000359096800009	25781376				2022-02-06	
J	Hue, CD; Cho, FS; Cao, SQ; Bass, CR; Meaney, DF; Morrison, B				Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Bass, Cameron R.Dale; Meaney, David F.; Morrison, Barclay, III			Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						bEnd.3; blood-brain barrier; dexamethasone; primary blast injury; recovery	TRABECULAR MESHWORK; MODEL; PERMEABILITY; DISRUPTION; MECHANISMS; RESISTANCE; STEROIDS; TARGET	Owing to the frequent incidence of blast-induced traumatic brain injury (bTBI) in recent military conflicts, there is an urgent need to develop effective therapies for bTBI-related pathologies. Blood-brain barrier (BBB) breakdown has been reported to occur after primary blast exposure, making restoration of BBB function and integrity a promising therapeutic target. We tested the hypothesis that treatment with dexamethasone (DEX) after primary blast injury potentiates recovery of an in vitro BBB model consisting of mouse brain endothelial cells (bEnd.3). DEX treatment resulted in complete recovery of transendothelial electrical resistance and hydraulic conductivity 1 day after injury, compared with 3 days for vehicle-treated injured cultures. Administration of RU486 (mifepristone) inhibited effects of DEX, confirming that barrier restoration was mediated by glucocorticoid receptor signaling. Potentiated recovery with DEX treatment was accompanied by stronger zonula occludens (ZO)-1 tight junction immunostaining and expression, suggesting that increased ZO-1 expression was a structural correlate to BBB recovery after blast. Interestingly, augmented ZO-1 protein expression was associated with specific upregulation of the alpha(+) isoform but not the alpha(-) isoform. This is the first study to provide a mechanistic basis for potentiated functional recovery of an in vitro BBB model because of glucocorticoid treatment after primary blast injury.	[Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Bass, Cameron R.Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122; , Siqi/0000-0001-9779-4174	Multidisciplinary University Research Initiative from the Army Research Office [W911MF-10-1-0526]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE-07-07425]	This work was supported by a Multidisciplinary University Research Initiative from the Army Research Office (W911MF-10-1-0526), and a National Science Foundation Graduate Research Fellowship (CDH; DGE-07-07425).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alvarado JA, 2004, AM J PHYSIOL-CELL PH, V286, pC621, DOI 10.1152/ajpcell.00108.2003; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; Blecharz KG, 2010, MULT SCLER J, V16, P293, DOI 10.1177/1352458509358189; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Cucullo L, 2004, BRAIN RES, V997, P147, DOI 10.1016/j.brainres.2003.09.079; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Eigenmann DE, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-33; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2006, J PHYSIOL-LONDON, V573, P413, DOI 10.1113/jphysiol.2006.106385; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; KIMBERLY R P, 1991, Current Opinion in Rheumatology, V3, P373, DOI 10.1097/00002281-199106000-00008; Lamprecht MR, 2014, BRAIN RES, V1563, P131, DOI 10.1016/j.brainres.2014.03.037; Li GL, 2010, ANN BIOMED ENG, V38, P2499, DOI 10.1007/s10439-010-0023-5; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; MILLER DH, 1992, J NEUROL NEUROSUR PS, V55, P450, DOI 10.1136/jnnp.55.6.450; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Poungvarin N, 2004, STROKE, V35, P229, DOI 10.1161/01.STR.0000105931.81723.26; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Sheth B, 1997, DEVELOPMENT, V124, P2027; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330; WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhuo YH, 2010, MOL VIS, V16, P61	40	40	40	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2015	35	7					1191	1198		10.1038/jcbfm.2015.38			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CL7FI	WOS:000357137500018	25757751	Green Published, Bronze			2022-02-06	
J	van Zellem, L; Buysse, C; Madderom, M; Legerstee, JS; Aarsen, F; Tibboel, D; Utens, EM				van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Legerstee, Jeroen S.; Aarsen, Femke; Tibboel, Dick; Utens, Elisabeth M.			Long-term neuropsychological outcomes in children and adolescents after cardiac arrest	INTENSIVE CARE MEDICINE			English	Article						Heart arrest; Follow-up studies; Neuropsychology; Pediatric; Cognition	TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTION; EXECUTIVE FUNCTION; FOLLOW-UP; ENCEPHALOPATHY; RESUSCITATION; MULTICENTER; IMPAIRMENT; SURVIVORS; RECOVERY	Research into neuropsychological functioning of survivors of cardiac arrest (CA) in childhood is scarce. We sought to assess long-term neuropsychological functioning in children and adolescents surviving CA. Neuropsychological follow-up study involving all consecutive children surviving CA between January 2002 and December 2011. Intelligence (IQ), language, attention, memory, visual-spatial, and executive functioning were assessed with internationally validated, neuropsychological tests and questionnaires. Scores were compared with Dutch normative data. Of 107 eligible children, 47 who visited the outpatient clinic (median follow-up interval: 5.6 years) were analyzed. Fifty-five percent had an in-hospital CA, 86 % a non-shockable rhythm, and 49 % a respiratory-related etiology. CA survivors scored significantly worse on full-scale IQ (), verbal IQ (), performance IQ (), verbal comprehension index (), perceptual organization index (), and processing speed index (), than the norm population (mean IQ = 100). On neuropsychological tests, compared with norms, respectively adjusted for IQ, significantly worse scores were found on visual memory, significantly better on verbal memory (recognition), and comparable outcomes on visual-motor integration, attention, other measures of verbal memory, and executive functioning. On questionnaires, parents reported better executive functioning than the norm, but teachers reported more problems in planning/organizing skills. Long-term neuropsychological assessment of CA survivors showed significant weaknesses, but also relatively intact functioning. As deficits in IQ, memory and executive functioning have significant impact on the child, long-term follow-up and neuropsychological support of CA survivors is warranted.	[van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Aarsen, Femke; Tibboel, Dick] Erasmus MC Sophia Childrens Hosp, Intens Care, NL-3015 CN Rotterdam, Netherlands; [van Zellem, Lennart; Buysse, Corinne; Madderom, Marlous; Aarsen, Femke; Tibboel, Dick] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg, NL-3015 CN Rotterdam, Netherlands; [Madderom, Marlous; Legerstee, Jeroen S.; Aarsen, Femke; Utens, Elisabeth M.] Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, NL-3015 CN Rotterdam, Netherlands		Buysse, C (corresponding author), Erasmus MC Sophia Childrens Hosp, Intens Care, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	c.buysse@erasmusmc.nl					Aarsen FK, 2006, CANCER-AM CANCER SOC, V106, P396, DOI 10.1002/cncr.21612; Amicuzi I, 2005, BRAIN INJURY, V19, P371, DOI 10.1080/02699050400004286; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Antonelli M, 2012, INTENS CARE MED, V38, P542, DOI 10.1007/s00134-012-2508-1; Beery K.E., 2004, BEERY BUKTENICA DEV; Cassidy AR, 2015, J INT NEUROPSYCH SOC, V21, P34, DOI 10.1017/S1355617714001027; Chiang MC, 2009, J NEUROSCI, V29, P2212, DOI 10.1523/JNEUROSCI.4184-08.2009; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; Dunn L.M., 2005, PEABODY PICTURE VOCA; Gonzalez FF, 2006, ARCH DIS CHILD-FETAL, V91, pF454, DOI 10.1136/adc.2005.092445; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; Hendriksen J, 2009, WPPSI 3 NL WECHSLER; Kok TB, 2009, TIJDSCHRIFT NEUROPSY, V4, P42; Kort W., 2005, WISC 3 NL WECHSLER I; Lopez-Herce J, 2013, INTENS CARE MED, V39, P309, DOI 10.1007/s00134-012-2709-7; Madderom MJ, 2013, INTENS CARE MED, V39, P1584, DOI 10.1007/s00134-013-2973-1; Manly T., 1999, TEST EVERYDAY ATTENT; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Maryniak A, 2008, RESUSCITATION, V77, P46, DOI 10.1016/j.resuscitation.2007.10.024; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Michiels EA, 2013, PEDIATR CRIT CARE ME, V14, P755, DOI 10.1097/PCC.0b013e31829763e2; Middleton JA, 2001, ADV PSYCHIAT TREAT, V7, P257, DOI DOI 10.1192/APT.7.4.257; MORRIS RD, 1993, J LEARN DISABIL, V26, P46, DOI 10.1177/002221949302600105; Opic P, 2013, IMPACT CONGENITAL HE; Oualha M, 2013, INTENS CARE MED, V39, P1306, DOI 10.1007/s00134-013-2930-z; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schmand B, 2005, NORMEN STROOP KLEURW; Schmand B., 2012, NORMEN 15 WOORDENTES; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Smidts D, 2009, BRIEF EXECUTIEVE FUN; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suominen PK, 2014, RESUSCITATION, V85, P1059, DOI 10.1016/j.resuscitation.2014.03.307; Suominen PK, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-55; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; The Netherlands Institute for Social Research (Sociaal en Cultureel Planbureau), 2012, RANG NAAR SOC STAT P; Topjian AA, 2009, CURR OPIN CRIT CARE, V15, P203, DOI 10.1097/MCC.0b013e32832931e1; Vermunt LCAC, 2009, BRIT J CLIN PSYCHOL, V48, P195, DOI 10.1348/014466508X391094; Wechsler D., 2012, WECHSLER ADULT INTEL; Wernovsky G, 2006, CARDIOL YOUNG, V16, P92, DOI 10.1017/S1047951105002398	40	40	40	2	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1057	1066		10.1007/s00134-015-3789-y			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL2UO	WOS:000356801200010	25894622	Green Published, hybrid			2022-02-06	
J	Yaffe, K; Nettiksimmons, J; Yesavage, J; Byers, A				Yaffe, Kristine; Nettiksimmons, Jasmine; Yesavage, Jerome; Byers, Amy			Sleep Quality and Risk of Dementia Among Older Male Veterans	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Sleep; dementia; veterans	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DAYTIME SLEEPINESS; BEHAVIOR DISORDER; LEWY BODIES; MEMORY; DEPRIVATION; DISTURBANCE; IMPAIRMENT; SYMPTOMS	Objective: To determine whether a diagnosis of sleep disturbance is associated with dementia in older veterans. Methods: For this retrospective cohort study, we obtained medical record data from the Department of Veterans Affairs National Patient Care Database for 200,000 randomly selected veterans aged 55 years and older. Prevalent cases of dementia from the baseline period (2000-2003) were excluded, leaving an analytic sample of 179,738 male veterans. Follow-up took place from 2004 to 2011. The primary outcome was all-cause dementia, ascertained using International Classification of Disease, Ninth Revision codes. Sleep disturbance, the primary predictor, was also ascertained using these codes. Results: After adjusting for potential confounders, those with sleep disturbance had a 27% increased risk of dementia (hazard ratio: 1.27; 95% confidence interval: 1.20-1.34). Conclusion: Sleep disturbance was associated with increased risk of dementia among a large cohort of older, primarily male veterans.	[Yaffe, Kristine; Nettiksimmons, Jasmine; Byers, Amy] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; [Yaffe, Kristine; Byers, Amy] San Francisco Veteran Affairs Med Ctr, San Francisco, CA 94121 USA; [Yesavage, Jerome] Stanford Univ, Sch Med, Dept Psychiat Sci, Palo Alto, CA 94304 USA; [Yesavage, Jerome] Stanford Univ, Sch Med, Dept Behav Sci, Palo Alto, CA 94304 USA; [Yesavage, Jerome] Palo Alto Veteran Affairs Med Ctr, Palo Alto, CA USA		Yaffe, K (corresponding author), San Francisco Veteran Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.	Kristine.yaffe@ucsf.edu			Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers; Department of DefenseUnited States Department of Defense [W81XWH-11-2-0189]	This study was supported by The Sierra Pacific VISN Mental Illness Research, Education, and Clinical Centers and by a Department of Defense grant (W81XWH-11-2-0189), which was administered by the Northern California Institute for Research and Education.	Ballard C, 2013, DRUG AGING, V30, P603, DOI 10.1007/s40266-013-0092-x; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Blackwell T, 2006, J GERONTOL A-BIOL, V61, P405, DOI 10.1093/gerona/61.4.405; Bliwise Donald L, 2004, Clin Cornerstone, V6 Suppl 1A, pS16, DOI 10.1016/S1098-3597(04)90014-2; Bliwise DL, 2011, DEMENT GERIATR COGN, V31, P239, DOI 10.1159/000326238; Boeve BF, 2013, LANCET NEUROL, V12, P469, DOI 10.1016/S1474-4422(13)70054-1; Canchola AJ, 2003, COX REGRESSION USING; Chen PL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049113; Claassen DO, 2010, NEUROLOGY, V75, P494, DOI 10.1212/WNL.0b013e3181ec7fac; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; Elwood PC, 2011, J EPIDEMIOL COMMUN H, V65, P820, DOI 10.1136/jech.2009.100503; Faestel PM, 2013, J CLIN SLEEP MED, V9, P577, DOI 10.5664/jcsm.2754; Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010; Foley D, 2001, J AM GERIATR SOC, V49, P1628, DOI 10.1111/j.1532-5415.2001.49271.x; Havekes R, 2012, CELL SIGNAL, V24, P1251, DOI 10.1016/j.cellsig.2012.02.010; Hiestand DM, 2006, CHEST, V130, P780, DOI 10.1378/chest.130.3.780; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; Katz IR, 2012, AM J GERIAT PSYCHIAT, V20, P195, DOI 10.1097/JGP.0b013e3182435f00; Kinoshita LM, 2012, SLEEP BREATH, V16, P1201, DOI 10.1007/s11325-011-0632-8; Knutson KL, 2010, BEST PRACT RES CL EN, V24, P731, DOI 10.1016/j.beem.2010.07.001; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Ooms S, 2014, JAMA NEUROL, V71, P971, DOI 10.1001/jamaneurol.2014.1173; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Terzaghi M, 2013, MOVEMENT DISORD, V28, P1416, DOI 10.1002/mds.25523; VITIELLO MV, 1991, CAN J PSYCHOL, V45, P221, DOI 10.1037/h0084283; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu L, 2011, SLEEP, V34, P575, DOI 10.1093/sleep/34.5.575; Yaffe K, 2011, JAMA-J AM MED ASSOC, V306, P613, DOI 10.1001/jama.2011.1115; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	30	40	40	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	JUN	2015	23	6					651	654		10.1016/j.jagp.2015.02.008			4	Geriatrics & Gerontology; Gerontology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychiatry	CH9EF	WOS:000354338100013	25794635				2022-02-06	
J	Long, JA; Watts, LT; Chemello, J; Huang, SL; Shen, Q; Duong, TQ				Long, Justin Alexander; Watts, Lora Talley; Chemello, Jonathan; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.			Multiparametric and Longitudinal MRI Characterization of Mild Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; diffusion tensor imaging; immunohistochemistry; TBI; controlled cortical impact; quantitative magnetic resonance imaging	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; IMAGING FINDINGS; NEURONAL DEGENERATION; FLUORO-JADE; PERFUSION; EDEMA; DYNAMICS; HYPOXIA; MODELS	This study reports T-2 and diffusion-tensor magnetic resonance imaging (MRI) studies of a mild open-skull, controlled cortical impact injury in rats (n=6) from 3 h to up to 14 d after traumatic brain injury (TBI). Comparison was made with longitudinal behavioral measurements and end-point histology. The impact was applied over the left primary forelimb somatosensory cortex (S1FL). The major findings were: 1) In the S1FL, T-2 increased and fractional anisotropy (FA) decreased at 3 h after TBI and gradually returned toward normal by Day 14; 2) in the S1FL, the apparent diffusion coefficient (ADC) increased at 3 h, peaked on Day 2, and gradually returned toward normal at Day 14; 3) in the corpus callosum underneath the S1FL, FA decreased at 3 h to Day 2 but returned to normal at Day 7 and 14, whereas T-2 and ADC were normal throughout; 4) heterogeneous hyperintense and hypointense T-2 map intensities likely indicated the presence of hemorrhage but were not independently verified; 5) lesion volumes defined by abnormal T-2, ADC, and FA showed similar temporal patterns, peaking around Day 2 and returning toward normal on Day 14; 6) the temporal profiles of lesion volumes were consistent with behavioral scores assessed by forelimb placement and forelimb foot fault tests; and 7) at 14 d post-TBI, there was substantial tissue recovery by MRI, which could either reflect true tissue recovery or reabsorption of edema. Histology performed 14 d post-TBI, however, showed a small cavitation and significant neuronal degeneration surrounding the cavitation in S1FL. Thus, the observed improvement of behavioral scores likely involves both functional recovery and functional compensation.	[Long, Justin Alexander; Watts, Lora Talley; Chemello, Jonathan; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA		Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthamol, Radiol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	duongt@uthscsa.edu	Watts, Lora Talley/A-2724-2012; Duong, Tim/AAL-8357-2021; Shen, Qiang/B-8784-2008	Watts, Lora Talley/0000-0002-2337-1504; Duong, Tim/0000-0001-6403-2827; Shen, Qiang/0000-0002-4287-3403	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45879]; TL1 grant; Clinical Translational Science Awards (CTSA) [KL2 TR001118, UL1TR000149, TL1TR001119]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA054174] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001119, UL1TR001120, UL1TR000149, KL2TR001118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG019316] Funding Source: NIH RePORTER	The authors wish to thank Timothy Schallert and Theresa Jones of UT Austin for their assistance in the setup of the behavioral assays utilized in this study. This work was supported in part by NIH/NINDS R01 NS45879 (TQD), a TL1 grant (JAL) and KL2 TR001118 (LTW) via the Clinical Translational Science Awards (CTSA, parent grant UL1TR000149 and TL1TR001119). Images were generated in the Core Optical Imaging Facility which is supported by UTHSCSA, NIH/NCI P30CA54174 and NIH/NIA P01AG19316.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Danker JF, 2007, BRAIN RES, V1150, P217, DOI 10.1016/j.brainres.2007.02.082; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kubin MZ, 1999, EUR J IMMUNOL, V29, P3466, DOI 10.1002/(SICI)1521-4141(199911)29:11<3466::AID-IMMU3466>3.0.CO;2-9; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Liu ZHM, 2004, MAGN RESON MED, V52, P277, DOI 10.1002/mrm.20148; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmidt KF, 2004, J NEURO-ONCOL, V68, P207, DOI 10.1023/B:NEON.0000033364.43142.bf; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; van de Looij Y., 2012, N M R BIOMED, V25, P93; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739	40	40	40	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					598	607		10.1089/neu.2014.3563			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900010	25203249	Green Published			2022-02-06	
J	Kirkwood, G; Parekh, N; Ofori-Asenso, R; Pollock, AM				Kirkwood, Graham; Parekh, Nikesh; Ofori-Asenso, Richard; Pollock, Allyson M.			Concussion in youth rugby union and rugby league: a systematic review	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Rugby; Children; Adolescent; Sporting injuries	CHRONIC TRAUMATIC ENCEPHALOPATHY; EMERGENCY-DEPARTMENTS; RECURRENT CONCUSSION; CONSENSUS STATEMENT; DATA-COLLECTION; UNITED-STATES; INJURIES; PLAYERS; SPORT; EPIDEMIOLOGY	Background Children and adolescents who play rugby are at increased risk of concussion and its effects. Competitive rugby union and rugby league feature as major sports in the school sport curriculum in the UK. There is a need for a thorough understanding of the epidemiology of concussion in youth rugby, the mechanisms involved in injuries and predisposing risk factors. Data Sources The publication databases Pubmed, Embase and SportDISCUS were searched in April 2014 for primary research studies of child and adolescent rugby union and rugby league (under 20years) in English language with data on concussion injuries. The review was conducted within a larger all injury systematic review on rugby union and rugby league where key words used in the search included rugby, injury and concussion with child, adolescent, paediatric and youth. Results There were 25 studies retrieved with data on child or adolescent rugby and concussion, 20 were on rugby union, three on rugby league and in two the code of rugby was unspecified. There was significant heterogeneity in the definitions of injuries and of concussion. The incidence of child and adolescent match concussion ranged from 0.2 to 6.9 concussions per 1000 player-hours for rugby union and was 4.6 and 14.7 concussions per 1000 player-hours for rugby league, equivalent to a probability of between 0.3% and 11.4% for rugby union and of 7.7% and 22.7% for rugby league. Conclusions There is a significant risk of concussion in children and adolescents playing rugby union and rugby league evident from the studies included in this systematic review. There is a need for reliable data through routine monitoring and reporting in schools and clubs and in hospital emergency departments in order to inform prevention. Concussion protocols should be implemented and tested.	[Kirkwood, Graham; Ofori-Asenso, Richard; Pollock, Allyson M.] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, London E1 2AB, England; [Parekh, Nikesh] Lewisham & Greenwich NHS Trust, London, England		Pollock, AM (corresponding author), Queen Mary Univ London, Ctr Primary Care & Publ Hlth, Yvonne Carter Bldg,58 Turner St, London E1 2AB, England.	a.pollock@qmul.ac.uk		pollock, allyson/0000-0002-7388-3110	Barts Charity through the Centre for Trauma Sciences project	The authors thank Dr Andreas Freitag (AF) and Dr Sebastian Scharer (SS) for literature searching as part of a larger rugby injury study. The authors thank also the Barts Charity for funding for staff through the Centre for Trauma Sciences project.	American Academy of Neurology, POS POL DOC; [Anonymous], 2013, BBC NEWS; Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; England Professional Rugby Injury Surveillance Project Steering Group, ENGL PROF RUGB INJ S; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2011, CLIN J SPORT MED, V21, P356, DOI 10.1097/JSM.0b013e31821f5085; Gabbett TJ, 2008, J SCI MED SPORT, V11, P323, DOI 10.1016/j.jsams.2007.06.003; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Kaplan KM, 2008, BULL HOSP JT DIS, V66, P86; King D, 2006, NZ J SPORTS MED, V34, P21; King D, 2013, NZ J SPORTS MED, V40, P64; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; Lawton G, NEW SCI; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; NATHAN M, 1983, S AFR MED J, V64, P132; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; Parekh N, 2012, BRIT J SPORT MED, V46, P611, DOI 10.1136/bjsports-2011-090431; Raftery M, 2014, BRIT J SPORT MED, V48, P79, DOI 10.1136/bjsports-2013-093051; ROUX CE, 1987, S AFR MED J, V71, P307; Rugby Football Union (RFU), RET PLAY CONC; Rugby League International Federation, RANK; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Sparks J P, 1985, Br J Sports Med, V19, P71; Sparks J P, 1981, Br J Sports Med, V15, P30; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; SUGERMAN S, 1983, AUST J SPORTS MED EX, V15, P5; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Upton PAH, 1996, S AFR MED J, V86, P531; Watson AWS, 1997, NZ J SPORTS MED, V25, P22; Yard EE, 2006, J ATHL TRAINING, V41, P325; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	56	40	40	2	48	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					506	510		10.1136/bjsports-2014-093774			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CF4OI	WOS:000352529000006	25586912	Bronze			2022-02-06	
J	Barhon, LI; Batchelor, J; Meares, S; Chekaluk, E; Shores, EA				Barhon, Lucienne Isabel; Batchelor, Jennifer; Meares, Susanne; Chekaluk, Eugene; Shores, E. Arthur			A Comparison of the Degree of Effort Involved in the TOMM and the ACS Word Choice Test Using a Dual-Task Paradigm	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						symptom validity testing; tests; neuropsychology	MEMORY MALINGERING TOMM; SYMPTOM VALIDITY TEST; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; BRAIN-INJURY; HEAD-INJURY; COGNITIVELY INTACT; NORMATIVE DATA; SIMULATORS; IMPAIRMENT; BIAS	The aims of the current study were to: (a) examine the predictive validity and efficacy of the Advanced Clinical Solutions Word Choice Test (WCT) as a measure of effort relative to the Test of Memory Malingering (TOMM); (b) investigate whether performing a dual (distraction) task would undermine performance on either test; (c) assess the effect of coaching on the diagnostic accuracy of both the WCT and the TOMM; and (d) establish an optimal cut score for the WCT. The current study used a simulation design based on an analogue design in which normal participants were instructed to either apply full effort or simulate a brain injury on the tasks without being detected. Participants included 93 undergraduate university students who were randomly assigned to 1 of 4 conditions: (a) distraction, (b) uncoached traumatic brain injury (TBI) simulators, (c) coached TBI simulators, or (d) full effort. The results demonstrated that the WCT and the TOMM were effective in detecting simulated cognitive impairment. Both tests were resistant to the effects of distraction and were equally effective in detecting coached and uncoached simulators. A cut score of 42 on the WCT was found to provide optimal specificity and sensitivity on the test.	[Barhon, Lucienne Isabel; Batchelor, Jennifer; Meares, Susanne; Chekaluk, Eugene; Shores, E. Arthur] Macquarie Univ, Sydney, NSW 2109, Australia		Barhon, LI (corresponding author), Macquarie Univ, Balaclava Rd, Sydney, NSW 2109, Australia.	lucienne.barhon@students.mq.edu.au		Meares, Susanne/0000-0002-3859-9974; Batchelor, Jennifer/0000-0003-4438-4993; Shores, Edwin A/0000-0003-1553-5131			An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Bender S., 2008, CLIN ASSESSMENT MALI, P69; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Cochrane HJ, 1998, BRIT J CLIN PSYCHOL, V37, P31, DOI 10.1111/j.2044-8260.1998.tb01277.x; Craik F.I., 1982, COGNITIVE RES PSYCHO, P152; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Erdal K, 2004, ARCH CLIN NEUROPSYCH, V19, P73; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Kim M., 2010, ARCH CLIN NEUROPSYCH, V25, P410; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P3; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McCarter RJ, 2009, CLIN NEUROPSYCHOL, V23, P1050, DOI 10.1080/13854040802665790; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Paivio A., 1991, IMAGES MILD EVOLUTIO; Pearson, 2009, ADV CLIN SOLUTIONS W; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rogers R., 1997, CLIN ASSESSMENT MALI; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SHEPARD RN, 1967, J VERB LEARN VERB BE, V6, P156, DOI 10.1016/S0022-5371(67)80067-7; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T. N., 1996, TOMMTEST MEMORY MALI; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Warrington E, 1984, RECOGNITION MEMORY T, V1; Weinborn M, 2012, CLIN NEUROPSYCHOL, V26, P832, DOI 10.1080/13854046.2012.686630; Zapf, 2009, INT J FORENSIC MENT, V8, DOI [10.1080/14999011003635514, DOI 10.1080/14999011003635514, https://doi.org/10.1080/14999011003635514]	42	40	40	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					114	123		10.1080/23279095.2013.863775			10	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400006	25117219				2022-02-06	
J	Davenport, ND; Lim, KO; Sponheim, SR				Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.			White Matter Abnormalities Associated With Military PTSD in the Context of Blast TBI	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; diffusion magnetic resonance imaging; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSION-TENSOR; TRACT INTEGRITY; INDIVIDUAL-DIFFERENCES; TRAIT ANXIETY; AFGHANISTAN; CINGULUM; IRAQ; CONNECTIVITY	Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) are common among recent military veterans and involve substantial symptom overlap, making clinical distinction and effective intervention difficult. Emerging evidence of cerebral white matter abnormalities associated with mTBI may provide a biological measure to inform diagnosis and treatment, but the potentially confounding effects between PTSD and mTBI have largely gone unexamined. We collected diffusion imaging data from 133 recently-deployed American service members who developed PTSD and/or sustained mTBI, or had neither condition. Effects of PTSD and mTBI on traditional tensor-based measures of cerebral white matter integrity (fractional anisotropy [FA] and mean diffusivity [MD]) were compared in anatomical regions of interest and individual voxels throughout the brain. Generalized FA (GFA), which allows for multiple fiber orientations per voxel, was also included to improve sensitivity in white matter areas containing crossing or diverging axon bundles. PTSD was consistently associated with high GFA in select brain regions, greater likelihood of regions and voxels with abnormally low MD, and a greater number of voxels with abnormally high FA, while mTBI was associated with fewer high MD regions. Overall, PTSD was associated with more restricted diffusion (low MD) and greater anisotropy (high GFA) in regions of crossing/diverging fibers poorly characterized by a single tensor (FA), suggesting that interstitial fibers may be involved. Contrary to earlier results in a sample without PTSD, mTBI was not associated with anisotropy abnormalities, perhaps indicating the cooccurrence of PTSD and mTBI requires special consideration with regard to structural brain connectivity. Hum Brain Mapp 36:1053-1064, 2015.(c) 2014 Wiley Periodicals, Inc.	[Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA; [Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sponheim, Scott R.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA		Davenport, ND (corresponding author), VA Med Ctr B68 2, 1 Vet Dr, Minneapolis, MN 55417 USA.	nicholas.davenport@va.gov	Sponheim, Scott/J-3857-2017; Davenport, Nicholas/AAY-8057-2020; Lim, Kelvin/AAF-6833-2020	Sponheim, Scott/0000-0002-2782-0856; Davenport, Nicholas/0000-0002-3441-7256; Lim, Kelvin/0000-0002-2390-7268	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000622-01A1, 1IK2RX000709-01A3]; Veterans AffairsUS Department of Veterans Affairs [I01RX000622] Funding Source: NIH RePORTER	Contract grant sponsor: Congressionally Directed Medical Research Program; Contract grant number: PT074550 and W81XWH-08-2-0038; Contract grant sponsor: Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service; Contract grant number: 1I01RX000622-01A1 (S.R.S.) and 1IK2RX000709-01A3 (N.D.D.)	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Assemlal H-E, 2007, Proceedings 2007 IEEE International Conference on Image Processing, ICIP 2007, P133; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Christensen J, 2004, PSYCHIAT RES-NEUROIM, V130, P71, DOI 10.1016/j.pscychresns.2003.08.002; Clewett D, 2014, NEUROPSYCHOLOGY, V28, P631, DOI 10.1037/neu0000060; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Fried I, 1997, J NEUROPSYCH CLIN N, V9, P420; Fritzsche KH, 2010, NEUROIMAGE, V51, P242, DOI 10.1016/j.neuroimage.2010.02.007; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lochner C, 2012, J PSYCHIATR NEUROSCI, V37, P193, DOI 10.1503/jpn.110059; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Modi S, 2013, BEHAV BRAIN RES, V238, P188, DOI 10.1016/j.bbr.2012.10.007; Montag C, 2012, NEUROSCIENCE, V217, P77, DOI 10.1016/j.neuroscience.2012.05.017; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mori S, 2005, MRI ATLAS HUMAN WHIT; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Sekiguchi A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/180468; Sekiguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083967; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sullivan EV, 2006, NEUROSCI BIOBEHAV R, V30, P749, DOI 10.1016/j.neubiorev.2006.06.002; Sullivan EV, 2003, EUR J RADIOL, V45, P244, DOI 10.1016/S0720-048X(02)00313-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	57	40	40	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2015	36	3					1053	1064		10.1002/hbm.22685			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CB4QI	WOS:000349612500018	25387950	Green Published			2022-02-06	
J	Manoel, ALD; Neto, AC; Veigas, PV; Rizoli, S				de Oliveira Manoel, Airton Leonardo; Capone Neto, Antonio; Veigas, Precilla V.; Rizoli, Sandro			Traumatic Brain Injury Associated Coagulopathy	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Abbreviated injury scale score; Trauma-coagulopathy; DIC	SEVERE HEAD-INJURY; BASE DEFICIT; INTRAVASCULAR COAGULATION; PROGRESSIVE HEMORRHAGE; THROMBOCYTOPENIA; HYPOPERFUSION; RISK	The presence of coagulopathy is common after severe trauma. The aim of this study was to identify whether isolated severe traumatic brain injury (TBI) is an independent risk factor for coagulopathy. Prospective observational cohort of adult patients admitted to a Level I Trauma Center within 6 h of injury. Patients were categorized according to the abbreviated injury scale (AIS): Group 1-isolated severe TBI (AIS head a parts per thousand yen 3 + AIS non-head < 3); Group 2-severe multisystem trauma associated with severe TBI (AIS head a parts per thousand yen 3 + AIS non-head a parts per thousand yen 3); Group 3-severe multisystem trauma without TBI (AIS head < 3 + AIS non-head a parts per thousand yen 3). Primary outcome was the development of coagulopathy. Secondary outcome was in-hospital mortality. Three hundred and forty five patients were included (Group 1 = 48 patients, Group 2 = 137, and Group 3 = 160). Group 1 patients had the lowest incidence of coagulopathy and disseminated intravascular coagulopathy, and in general presented with better coagulation profile measured by either classic coagulation tests, thromboelastography or clotting factors. Isolated severe TBI was not an independent risk factor for the development of coagulopathy (OR 1.06; 0.35-3.22 CI, p = 0.92), however, isolated severe TBI patients who developed coagulopathy had higher mortality rates than isolated severe TBI patients without coagulopathy (66 vs. 16.6 %, p < 0.05). The presence of coagulopathy (OR 5.61; 2.65-11.86 CI, p < 0.0001) and isolated severe TBI (OR 11.51; 3.9-34.2 CI, p < 0.0001) were independent risk factors for in-hospital mortality. Isolated severe TBI is not an independent risk factor for the development of coagulopathy. However, severe TBI patients who develop coagulopathy have extremely high mortality rates.	[de Oliveira Manoel, Airton Leonardo; Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Trauma & Neurosurg Intens Care Unit, Toronto, ON M4N 3M5, Canada; [de Oliveira Manoel, Airton Leonardo] Univ Toronto, St Michaels Hosp, Dept Med Imaging, Toronto, ON M4N 3M5, Canada; [Capone Neto, Antonio] Hosp Israelita Albert Einstein, Adult Intens Care Unit, Sao Paulo, Brazil; [Veigas, Precilla V.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Rizoli, Sandro] Univ Toronto, St Michaels Hosp, Endowed Chair Trauma Res, Toronto, ON M4N 3M5, Canada		Manoel, ALD (corresponding author), Univ Toronto, St Michaels Hosp, Trauma & Neurosurg Intens Care Unit, 30 Bond St Donnelly Wing,Room 3-074B, Toronto, ON M4N 3M5, Canada.	airtonleo.manoel@gmail.com	de Oliveira Manoel, Airton Leonardo/C-4724-2018	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013	Canadian Institute of Health Research/NovoNordiskNovo NordiskCanadian Institutes of Health Research (CIHR); NovoNordiskNovo Nordisk	S.B.R. received a salary award from the Canadian Institute of Health Research/NovoNordisk, honoraria and speaking fees from NovoNordisk.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DAVIS JW, 1991, SURG GYNECOL OBSTET, V173, P473; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Frith D, 2010, SURG-J R COLL SURG E, V8, P159, DOI 10.1016/j.surge.2009.10.022; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schrieber M, 2007, J TRAUMA, V63, P1261; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	33	40	41	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2015	22	1					34	44		10.1007/s12028-014-0026-4			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CA3FH	WOS:000348791300006	25052157				2022-02-06	
J	Liu, XY; Czosnyka, M; Donnelly, J; Budohoski, KP; Varsos, GV; Nasr, N; Brady, KM; Reinhard, M; Hutchinson, PJ; Smielewski, P				Liu, Xiuyun; Czosnyka, Marek; Donnelly, Joseph; Budohoski, Karol P.; Varsos, Georgios V.; Nasr, Nathalie; Brady, Ken M.; Reinhard, Matthias; Hutchinson, Peter J.; Smielewski, Peter			Comparison of frequency and time domain methods of assessment of cerebral autoregulation in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral autoregulation index; mean flow index; transcranial doppler; transfer function analysis	TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-PRESSURE FLUCTUATIONS; HEAD-INJURY; DYNAMIC AUTOREGULATION; FLOW VELOCITY; INTRACRANIAL-PRESSURE; HUMANS; ARTERIAL; OSCILLATIONS; REACTIVITY	The impulse response (IR)-based autoregulation index (ARI) allows for continuous monitoring of cerebral autoregulation using spontaneous fluctuations of arterial blood pressure (ABP) and cerebral flow velocity (FV). We compared three methods of autoregulation assessment in 288 traumatic brain injury (TB!) patients managed in the Neurocritical Care Unit: (1) IR-based ARI; (2) transfer function (TF) phase, gain, and coherence; and (3) mean flow index (Mx). Autoregulation index was calculated using the TF estimation (Welch method) and classified according to the original Tiecks' model. Mx was calculated as a correlation coefficient between 10-second averages of ABP and FV using a moving 300-second data window. Transfer function phase, gain, and coherence were extracted in the very low frequency (VLF, 0 to 0.05 Hz) and low frequency (LF, 0.05 to 0.15 Hz) bandwidths. We studied the relationship between these parameters and also compared them with patients' Glasgow outcome score. The calculations were performed using both cerebral perfusion pressure (CPP; suffix 'c') as input and ABP (suffix 'a'). The result showed a significant relationship between ARI and Mx when using either ABP (r=-0.38, P < 0.001) or CPP (r=-0.404, P < 0.001) as input. Transfer function phase and coherence_a were significantly correlated with ARI_a and ARI_c (P < 0.05). Only ARI_a, ARI_c, Mx_a, Mx_c, and phase_c were significantly correlated with patients' outcome, with Mx_c showing the strongest association.	[Liu, Xiuyun; Czosnyka, Marek; Donnelly, Joseph; Budohoski, Karol P.; Varsos, Georgios V.; Nasr, Nathalie; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Nasr, Nathalie] Univ Toulouse 3, Hop Rangueil, INSERM U1048, Serv Neurol Vasc,Team 11,Toulouse I2MC, F-31062 Toulouse, France; [Brady, Ken M.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Reinhard, Matthias] Univ Freiburg, Univ Hosp, Dept Neurol, Freiburg, Germany		Liu, XY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	xl334@cam.ac.uk	Donnelly, Joseph/E-9235-2018; Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/N-6803-2019; NASR, NATHALIE/K-3521-2019	Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Nasr, Nathalie/0000-0003-1660-8718; Smielewski, Peter/0000-0001-5096-3938; Hutchinson, Peter/0000-0002-2796-1835	Department of HealthEuropean Commission [NIHR-RP-R3-12-013] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G0600986, G9439390] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0601025, G9439390] Funding Source: UKRI		AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Bendat J., 2010, RANDOM DATA ANAL MEA; Blaber AP, 1997, STROKE, V28, P1686, DOI 10.1161/01.STR.28.9.1686; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; DEBOER RW, 1985, MED BIOL ENG COMPUT, V23, P352, DOI 10.1007/BF02441589; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Mayer S, 1876, KAIS AKAD WISS SITZ, V74, P281; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Panerai RB, 1998, MED BIOL ENG COMPUT, V36, P315, DOI 10.1007/BF02522477; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	37	40	40	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2015	35	2					248	256		10.1038/jcbfm.2014.192			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CA2QS	WOS:000348753100012	25407266	Green Published, Bronze, Green Accepted			2022-02-06	
J	Wang, L; Wang, XN; Su, H; Han, ZY; Yu, HJ; Wang, D; Jiang, RC; Liu, ZL; Zhang, JN				Wang, Liang; Wang, Xiaonan; Su, Hua; Han, Zhenying; Yu, Huijie; Wang, Dong; Jiang, Rongcai; Liu, Zhenlin; Zhang, Jianning			Recombinant Human Erythropoietin Improves the Neurofunctional Recovery of Rats Following Traumatic Brain Injury via an Increase in Circulating Endothelial Progenitor Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						Traumatic brain injury; Erythropoietin; Endothelial progenitor cells; Angiogenesis	ISCHEMIA-REPERFUSION INJURY; FUNCTIONAL OUTCOMES; CEREBRAL-ISCHEMIA; NEOVASCULARIZATION; MICE; TRANSPLANTATION; PROTECTS; ANGIOGENESIS; MYOCARDIUM; STROKE	Previous studies show that circulating endothelial progenitor cells (EPCs) promote angiogenesis, which is a process associated with improved recovery in animal models of traumatic brain injury (TBI), and that recombinant human erythropoietin (rhEPO) plays a protective role following stroke. Thus, it was hypothesized that rhEPO would enhance recovery following brain injury in a rat model of TBI via an increase in the mobilization of EPCs and, subsequently, in angiogenesis. Flow cytometry assays using CD34- and CD133-specific antibodies were utilized to identify alterations in EPC levels, CD31 and CD34 antibody-stained brain tissue sections were used to quantify angiogenesis, and the Morris water maze (MWM) test and the modified Neurological Severity Score (mNSS) test were used to evaluate behavioral recovery. Compared with saline treatment, treatment with rhEPO significantly increased the number of circulating EPCs on days 1, 4, 7, and 14 (P < 0.05), improved spatial learning ability on days 24 and 25 (P < 0.05), and enhanced memory recovery on day 26 (P < 0.05). Moreover, rhEPO treatment decreased mNSS assessment scores on days 14, 21, and 25 (P < 0.05). There was a strong correlation between levels of circulating EPCs and CD34- and CD31-positive cells within the injured boundary zone (CD34(+) r = 0.910, P < 0.01; CD31(+) r = 0.894, P < 0.01) and the ipsilateral hippocampus (CD34(+) r = 0.841, P < 0.01; CD31(+) r = 0.835, P < 0.01). The present data demonstrate that rhEPO treatment improved functional outcomes in rats following TBI via an increase in the mobilization of EPCs and in subsequent angiogenesis.	[Wang, Liang; Liu, Zhenlin] Tianjin 5th Ctr Hosp, Dept Neurosurg, Tianjin 300450, Peoples R China; [Wang, Xiaonan] Nankai Hosp, Dept Neurosurg, Tianjin 300102, Peoples R China; [Su, Hua] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Cerebrovasc Res Ctr, San Francisco, CA 94110 USA; [Han, Zhenying; Yu, Huijie; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China		Liu, ZL (corresponding author), Tianjin 5th Ctr Hosp, Dept Neurosurg, 41 Zhejiang Rd, Tianjin 300450, Peoples R China.	wjzhenlin817@sina.com; jianningzhang@hotmail.com			Emerging Project Committee of Science and Technology of Tanggu District of Tianjin, China [2012XQ15-07]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100920, 81200907]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCQNJC6800]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL122774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027713] Funding Source: NIH RePORTER	We thank Li Liu, Weiyun Cui, Fanglian Chen, and Lei Zhang for their excellent technical support. The authors thank Voltaire Gungab for the editorial assistance. This work was supported by grants from the Emerging Project Committee of Science and Technology of Tanggu District of Tianjin (2012XQ15-07), China; the National Natural Science Foundation of China (grants 81100920 and 81200907); and Tianjin Research Program of Application Foundation and Advanced Technology (grants12JCQNJC6800).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Clarkson AN, 2007, BRAIN RES, V1171, P111, DOI 10.1016/j.brainres.2007.06.100; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gehling UM, 2000, BLOOD, V95, P3106; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Grisar JC, 2011, BIOMARK MED, V5, P731, DOI [10.2217/BMM.11.92, 10.2217/bmm.11.92]; Hirata A, 2006, J AM COLL CARDIOL, V48, P176, DOI 10.1016/j.jacc.2006.04.008; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Lipsic E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.fjc.0000140209.04675.c3; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Park KJ, 2014, J CEREBR BLOOD F MET, V34, P357, DOI 10.1038/jcbfm.2013.216; Potts Mathew B, 2006, NeuroRx, V3, P143; Resch T, 2012, STEM CELL REV REP, V8, P926, DOI 10.1007/s12015-011-9332-9; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Satoh K, 2006, CIRCULATION, V113, P1442, DOI 10.1161/CIRCULATIONAHA.105.583732; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tei K, 2008, STEM CELLS, V26, P819, DOI 10.1634/stemcells.2007-0671; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang L, 2004, NEUROREPORT, V15, P1225, DOI 10.1097/01.wnr.0000127636.15181.c1; Westenbrink BD, 2007, EUR HEART J, V28, P2018, DOI 10.1093/eurheartj/ehm177; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yip HK, 2011, CRIT CARE, V15, DOI 10.1186/cc10002; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	47	40	44	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	FEB	2015	6	1					50	59		10.1007/s12975-014-0362-x			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AZ3IT	WOS:000348121500007	25085436	Green Accepted, Green Submitted			2022-02-06	
J	Badaut, J; Ajao, DO; Sorensen, DW; Fukuda, AM; Pellerin, L				Badaut, J.; Ajao, D. O.; Sorensen, D. W.; Fukuda, A. M.; Pellerin, L.			CAVEOLIN EXPRESSION CHANGES IN THE NEUROVASCULAR UNIT AFTER JUVENILE TRAUMATIC BRAIN INJURY: SIGNS OF BLOOD-BRAIN BARRIER HEALING?	NEUROSCIENCE			English	Article						blood-brain barrier; endothelium; astrocyte; juvenile traumatic brain injury; caveolin	ENDOTHELIAL PERMEABILITY; NITRIC-OXIDE; TIGHT JUNCTIONS; P-GLYCOPROTEIN; NULL MICE; IN-VIVO; RATS; ASTROCYTES; OCCLUDIN; BREAKDOWN	Traumatic brain injury (TBI) is one of the major causes of death and disability in pediatrics, and results in a complex cascade of events including the disruption of the blood-brain barrier (BBB). A controlled-cortical impact on post-natal 17-day-old rats induced BBB disruption by IgG extravasation from 1 to 3 days after injury and returned to normal at day 7. In parallel, we characterized the expression of three caveolin isoforms, caveolin 1 (cav-1), caveolin 2 (cav-2) and caveolin 3 (cav-3). While cav-1 and cav-2 are expressed on endothelial cells, both cav-1 and cav-3 were found to be present on reactive astrocytes, in vivo and in vitro. Following TBI, cav-1 expression was increased in blood vessels at 1 and 7 days in the perilesional cortex. An increase of vascular cav-2 expression was observed 7 days after TBI. In contrast, astrocytic cav-3 expression decreased 3 and 7 days after TBI. Activation of endothelial nitric oxide synthase (eNOS) (via its phosphorylation) was detected 1 day after TBI and phospho-eNOS was detected both in association with blood vessels and with astrocytes. The molecular changes involving caveolins occurring in endothelial cells following juvenile-TBI might participate, independently of eNOS activation, to a mechanism of BBB repair while, they might subserve other undefined roles in astrocytes. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Badaut, J.] Univ Bordeaux, CNRS UMR5287, F-33076 Bordeaux, France; [Badaut, J.; Ajao, D. O.; Sorensen, D. W.; Fukuda, A. M.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA; [Badaut, J.; Sorensen, D. W.] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA; [Pellerin, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland		Badaut, J (corresponding author), Univ Bordeaux, CNRS UMR 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Jerome.badaut@u-bordeaux.fr	Pellerin, Luc/A-8912-2017; Fukuda, Andrew/ABD-1038-2021	Pellerin, Luc/0000-0002-1016-1970; Fukuda, Andrew/0000-0002-7927-6602	National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Dr Sean M. Wilson) and the Loma Linda University School of Medicine.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Cameron PL, 1997, J NEUROSCI, V17, P9520; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V252, P552, DOI 10.1006/bbrc.1998.9691; Faul M, 2010, TRAUMATIC BRAIN INJU; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Gonzalez MI, 2007, J BIOL CHEM, V282, P29855, DOI 10.1074/jbc.M704738200; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Jasmin JF, 2007, CIRC RES, V100, P721, DOI 10.1161/01.RES.0000260180.42709.29; Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x; Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833; Lajoie P, 2009, J CELL BIOL, V185, P381, DOI 10.1083/jcb.200811059; McCaffrey G, 2007, J NEUROCHEM, V103, P2540, DOI 10.1111/j.1471-4159.2007.04943.x; McCaffrey G, 2012, J NEUROCHEM, V122, P962, DOI 10.1111/j.1471-4159.2012.07831.x; McCaffrey G, 2009, J NEUROCHEM, V110, P58, DOI 10.1111/j.1471-4159.2009.06113.x; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006; Razani B, 2001, J BIOL CHEM, V276, P38121; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Shin T, 2005, J NEUROIMMUNOL, V165, P11, DOI 10.1016/j.jneuroim.2005.03.019; Shin T, 2007, BRAIN RES, V1141, P228, DOI 10.1016/j.brainres.2007.01.009; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siddiqui MR, 2011, J CELL BIOL, V193, P841, DOI 10.1083/jcb.201012129; Stamatovic SM, 2009, J BIOL CHEM, V284, P19053, DOI 10.1074/jbc.M109.000521; Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306-4522(02)00374-3; Wiencken AE, 1999, GLIA, V26, P280; Zschocke J, 2005, GLIA, V49, P275, DOI 10.1002/glia.20116	41	40	43	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 29	2015	285						215	226		10.1016/j.neuroscience.2014.10.035			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX7PE	WOS:000347106700018	25450954	Green Accepted, Green Published			2022-02-06	
J	Juengst, SB; Graham, KM; Pulantara, IW; McCue, M; Whyte, EM; Dicianno, BE; Parmanto, B; Arenth, PM; Skidmore, ERD; Wagner, AK				Juengst, Shannon B.; Graham, Kristin M.; Pulantara, I. Wayan; McCue, Michael; Whyte, Ellen M.; Dicianno, Brad E.; Parmanto, Bambang; Arenth, Patricia M.; Skidmore, Elizabeth R. D.; Wagner, Amy K.			Pilot feasibility of an mHealth system for conducting ecological momentary assessment of mood-related symptoms following traumatic brain injury	BRAIN INJURY			English	Article						Depression; mental health assessments; rehabilomics; telehealth tools; traumatic brain injury	NEGATIVE AFFECT; DEPRESSION; VALIDITY; ANXIETY; REHABILITATION; SMARTPHONE; PREDICTORS; DISORDER; ADULTS; RATES	Objective: This study assessed pilot feasibility and validity of a mobile health (mHealth) system for tracking mood-related symptoms after traumatic brain injury (TBI). Design: A prospective, repeated measures design was used to assess compliance with daily ecological momentary assessments (EMA) conducted via a smartphone application over an 8-week period. Methods: An mHealth system was developed specifically for individuals with TBI and utilized previously validated tools for depressive and anxiety symptoms (Patient Health Questionnaire-9, Generalized Anxiety Disorder-7). Feasibility was assessed in 20 community-dwelling adults with TBI via an assessment of compliance, satisfaction and usability of the smartphone applications. The authors also developed and implemented a clinical patient safety management mechanism for those endorsing suicidality. Results: Participants correctly completed 73.4% of all scheduled assessments, demonstrating good compliance. Daily assessments took <2 minutes to complete. Participants reported high satisfaction with smartphone applications (6.3 of 7) and found them easy to use (6.2 of 7). Comparison of assessments obtained via telephone-based interview and EMA demonstrated high correlations (r = 0.81-0.97), supporting the validity of conducting these assessments via smartphone application in this population. Conclusions: EMA conducted via smartphone demonstrates initial feasibility among adults with TBI and presents numerous opportunities for long-term monitoring of mood-related symptoms in real-world settings.	[Juengst, Shannon B.; Whyte, Ellen M.; Dicianno, Brad E.; Arenth, Patricia M.; Skidmore, Elizabeth R. D.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Graham, Kristin M.; McCue, Michael; Dicianno, Brad E.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15213 USA; [Pulantara, I. Wayan; Parmanto, Bambang] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Hlth Informat Management, Pittsburgh, PA 15213 USA; [Whyte, Ellen M.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Psychiat, Pittsburgh, PA 15213 USA; [Skidmore, Elizabeth R. D.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Phys Med & Rehabil, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019; Dicanno, Brad/AAC-5918-2019	Juengst, Shannon B/0000-0003-4709-545X; Dicanno, Brad/0000-0003-0738-0192; Pulantara, I Wayan/0000-0002-6532-3666	National Institute on Disability & Rehabilitation Research (NIDRR) [H133A120087]	The authors report no conflicts of interest. The National Institute on Disability & Rehabilitation Research (NIDRR) supported this work, under the grant 'Rehabilomics: Revolutionizing 21st Century TBI Care and Research, H133A120087'.	[Anonymous], 2010, TBI US REP TRAUM BRA; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ben-Zeev D, 2013, PSYCHIATR REHABIL J, V36, P289, DOI 10.1037/prj0000019; Boman IL, 2007, DISABIL REHABIL-ASSI, V2, P23, DOI 10.1080/17483100600856213; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Choi SW, 2014, PSYCHOL ASSESSMENT, V26, P513, DOI 10.1037/a0035768; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Culley C, 2010, NEUROPSYCHOL REHABIL, V20, P103, DOI 10.1080/09602010902906926; DAVIS FD, 1993, INT J MAN MACH STUD, V38, P475, DOI 10.1006/imms.1993.1022; De Joode EA, 2013, NEUROPSYCHOL REHABIL, V23, P133, DOI 10.1080/09602011.2012.726632; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donker T, 2013, J MED INTERNET RES, V15, P541; Dunbar MS, 2010, NICOTINE TOB RES, V12, P226, DOI 10.1093/ntr/ntp198; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Garcia C, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.2576; Garcia-Palacios A, 2014, EUR J PAIN, V18, P862, DOI 10.1002/j.1532-2149.2013.00425.x; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hoofien D, 2001, BRAIN INJURY, V15, P189; Husky M, 2014, PSYCHIAT RES, V220, P564, DOI 10.1016/j.psychres.2014.08.019; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Juengst SB, 2014, BRAIN BEHAV IMMUN, V41, P134, DOI 10.1016/j.bbi.2014.05.020; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Kim J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074979; Kirk GD, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/594671; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lella A, 2014, COMSCORE REPORTS APR; LEWIS JR, 1995, INT J HUM-COMPUT INT, V7, P57, DOI 10.1080/10447319509526110; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Obeid JS, 2013, J BIOMED INFORM, V46, P259, DOI 10.1016/j.jbi.2012.10.006; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Runyan JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071325; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Smyth J.M., 2003, J HAPPINESS STUD, V4, P35, DOI 10.1023/A:1023657221954; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Strong CAH, 2011, J INT NEUROPSYCH SOC, V17, P230, DOI 10.1017/S1355617710001451; TEASDALE G, 1974, LANCET, V2, P81; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Walz LC, 2014, J ANXIETY DISORD, V28, P925, DOI 10.1016/j.janxdis.2014.09.022; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	53	40	40	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	11					1351	1361		10.3109/02699052.2015.1045031			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CR4MF	WOS:000361306100010	26287756				2022-02-06	
J	Kostyun, RO; Hafeez, I				Kostyun, Regina O.; Hafeez, Imran			Protracted Recovery From a Concussion: A Focus on Gender and Treatment Interventions in an Adolescent Population	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; sex; adolescent; treatment intervention	SPORT-RELATED CONCUSSION; STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; VESTIBULAR REHABILITATION; SEX-DIFFERENCES; SYMPTOMS; DISORDERS; ANXIETY; DEPRESSION; MANAGEMENT	Background: Several studies have demonstrated that age and sex may influence concussion recovery time frames, with female athletes and adolescents being potentially more susceptible to a protracted recovery course. Currently, limited work has examined the influence sex may have on concussion management strategies and treatment interventions, especially for younger individuals suffering persistent concussion symptoms and cognitive dysfunctions. Hypothesis: Female athletes are prescribed more treatment interventions than male athletes during a protracted recovery from a concussion. Study Design: Descriptive epidemiology study. Methods: Data were retrospectively collected for adolescent athletes presenting to a sports medicine concussion clinic between September 2010 and September 2011. Results: A total of 266 adolescent athletes were evaluated and treated for concussion. Female athletes had a longer recovery course (P = 0.002) and required more treatment interventions (P < 0.001) for their symptoms and dysfunction. Female athletes were more likely to require academic accommodations (P < 0.001), vestibular therapy (P < 0.001), or medication (P < 0.001). Conclusion: Medical providers should be aware that during the recovery course, adolescent female athletes may require a management plan that will most likely include additional treatment interventions beyond the standard cognitive and physical rest.	[Kostyun, Regina O.; Hafeez, Imran] Connecticut Childrens Med Ctr, Elite Sports Med, 399 Farmington Ave, Farmington, CT 06032 USA		Kostyun, RO (corresponding author), Connecticut Childrens Med Ctr, Elite Sports Med, 399 Farmington Ave, Farmington, CT 06032 USA.	rkostyun@connecticutchildrens.org					Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barth JT, 2001, J ATHL TRAINING, V36, P253; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Broshek DK, 2014, J CHILD NEUROL, V29, P17, DOI 10.1177/0883073812464525; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dumont IP, 2012, J AM BOARD FAM MED, V25, P291, DOI 10.3122/jabfm.2012.03.110056; Fernandez-de-Las-Penas Cesar, 2007, Curr Pain Headache Rep, V11, P365, DOI 10.1007/s11916-007-0219-z; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grills AE, 2002, J CLIN CHILD ADOLESC, V31, P59, DOI 10.1207/153744202753441675; Grills-Taquechel AE, 2010, ANXIETY STRESS COPIN, V23, P493, DOI 10.1080/10615800903494127; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; MCGEE R, 1992, J AM ACAD CHILD PSY, V31, P50, DOI 10.1097/00004583-199201000-00009; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Missaghi Babak, 2004, J Can Chiropr Assoc, V48, P201; Morin AK, 2007, PHARMACOTHERAPY, V27, P89, DOI 10.1592/phco.27.1.89; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	42	40	40	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	JAN-FEB	2015	7	1					52	57		10.1177/1941738114555075			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	V20GY	WOS:000214876300006	25553213	Green Published			2022-02-06	
J	O'Leary, O; Nolan, Y				O'Leary, Olivia; Nolan, Yvonne			Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders	CNS DRUGS			English	Article							AMYLOID PROTEIN DEPOSITION; POSTMORTEM FRONTAL-CORTEX; EUTHYMIC BIPOLAR PATIENTS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; LITHIUM TREATMENT; BETA-CATENIN; TAU PHOSPHORYLATION; PREFRONTAL CORTEX; TRANSGENIC MODEL	The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) is involved in a broad range of cellular processes including cell proliferation, apoptosis and inflammation. It is now also increasingly acknowledged as having a role to play in cognitive-related processes such as neurogenesis, synaptic plasticity and neural cell survival. Cognitive impairment represents a major debilitating feature of many neurodegenerative and psychiatric disorders, including Alzheimer's disease, mood disorders, schizophrenia and fragile X syndrome, as well as being a result of traumatic brain injury or cranial irradiation. Accordingly, GSK-3 has been identified as an important therapeutic target for cognitive impairment, and recent preclinical studies have yielded important evidence demonstrating that GSK-3 inhibitors may be useful therapeutic interventions for restoring cognitive function in some of these brain disorders. The current review summarises the role of GSK-3 as a regulator of cognitive-dependent functions, examines current preclinical and clinical evidence of the potential of GSK-3 inhibitors as therapeutic agents for cognitive impairments in neuropsychiatric disorders, and offers some insight into the current obstacles that are impeding the clinical use of selective GSK-3 inhibitors in the treatment of cognitive impairment.	[O'Leary, Olivia; Nolan, Yvonne] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland		Nolan, Y (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Western Gateway Bldg,Room 3-83, Cork, Ireland.	y.nolan@ucc.ie		Nolan, Yvonne/0000-0003-2426-234X; O'Leary, Olivia/0000-0002-9171-2032	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/IA/1537]; University College Cork (UCC) Strategic Research Fund	Work in Olivia O'Leary's and Yvonne Nolan's laboratories is currently supported by a Grant from Science Foundation Ireland (12/IA/1537) and the University College Cork (UCC) Strategic Research Fund. No funding was specifically received for the preparation of this article. Olivia O'Leary and Yvonne Nolan declare that they have no conflict of interest.	Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Altshuler LL, 2004, BIOL PSYCHIAT, V56, P560, DOI 10.1016/j.biopsych.2004.08.002; Aplin AE, 1996, J NEUROCHEM, V67, P699; Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250; Beasley C, 2001, NEUROSCI LETT, V302, P117, DOI 10.1016/S0304-3940(01)01688-3; Beaulieu JM, 2008, P NATL ACAD SCI USA, V105, P1333, DOI 10.1073/pnas.0711496105; Beaulieu JM, 2012, J PSYCHIATR NEUROSCI, V37, P7, DOI 10.1503/jpn.110011; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Benedetti F, 2005, NEUROSCI LETT, V376, P51, DOI 10.1016/j.neulet.2004.11.022; Benedetti F, 2010, GENES BRAIN BEHAV, V9, P365, DOI 10.1111/j.1601-183X.2010.00566.x; Berry-Kravis E, 2008, J DEV BEHAV PEDIATR, V29, P293, DOI 10.1097/DBP.0b013e31817dc447; Bersudsky Y, 2008, BEHAV PHARMACOL, V19, P217, DOI 10.1097/FBP.0b013e3282feb099; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Blasi G, 2013, AM J PSYCHIAT, V170, P868, DOI 10.1176/appi.ajp.2012.12070908; Caccamo A, 2007, AM J PATHOL, V170, P1669, DOI 10.2353/ajpath.2007.061178; CALEV A, 1986, PSYCHOL MED, V16, P789, DOI 10.1017/S0033291700011806; Carvalho AF, 2007, J CLIN PHARM THER, V32, P415, DOI 10.1111/j.1365-2710.2007.00846.x; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chan MH, 2012, SCHIZOPHR RES, V136, P96, DOI 10.1016/j.schres.2012.01.024; Chen L, 2011, MOL PHARMACOL, V79, P974, DOI 10.1124/mol.111.071092; Chen LG, 2009, MOL PHARMACOL, V76, P1150, DOI 10.1124/mol.109.056994; Clark L, 2002, BRIT J PSYCHIAT, V180, P313, DOI 10.1192/bjp.180.4.313; Clifford DB, 2013, LANCET INFECT DIS, V13, P976, DOI 10.1016/S1473-3099(13)70269-X; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342; Cowen P, 2013, J PSYCHOPHARMACOL, V27, P575, DOI 10.1177/0269881113482531; Crews L, 2009, INT J MOL SCI, V10, P1045, DOI 10.3390/ijms10031045; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD-2012-120805; Dewachter I, 2009, NEUROBIOL DIS, V35, P193, DOI 10.1016/j.nbd.2009.04.003; Dias VV, 2012, ACTA PSYCHIAT SCAND, V126, P315, DOI 10.1111/j.1600-0447.2012.01910.x; Ding Y, 2010, NEUROBIOL DIS, V39, P156, DOI 10.1016/j.nbd.2010.03.022; Diniz BS, 2013, NEUROPSYCH DIS TREAT, V9, P493, DOI 10.2147/NDT.S33086; El-Badri SM, 2001, BIPOLAR DISORD, V3, P79, DOI 10.1034/j.1399-5618.2001.030206.x; Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Engel T, 2006, J NEUROSCI, V26, P5083, DOI 10.1523/JNEUROSCI.0604-06.2006; ENGELSMANN F, 1988, J CLIN PSYCHOPHARM, V8, P207; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Farr SA, 2014, FREE RADICAL BIO MED, V67, P387, DOI 10.1016/j.freeradbiomed.2013.11.014; Ferreira AS, 2014, EUR ARCH PSYCHIAT CL; Fiorentini A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014382; Forlenza OV, 2012, DRUG AGING, V29, P335, DOI 10.2165/11599180-000000000-00000; Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044; Franklin AV, 2014, BIOL PSYCHIAT, V75, P198, DOI 10.1016/j.biopsych.2013.08.003; Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Giese KP, 2009, IUBMB LIFE, V61, P516, DOI 10.1002/iub.187; Goldberg JF, 2009, BIPOLAR DISORD, V11, P123, DOI 10.1111/j.1399-5618.2009.00716.x; de Barreda EG, 2010, NEUROBIOL DIS, V37, P622, DOI 10.1016/j.nbd.2009.11.017; GOODE N, 1992, J BIOL CHEM, V267, P16878; Green HF, 2012, NEUROCHEM INT, V61, P666, DOI 10.1016/j.neuint.2012.07.003; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guo WX, 2012, HUM MOL GENET, V21, P681, DOI 10.1093/hmg/ddr501; Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606; Hendrie HC, 2014, AM J GERIAT PSYCHIAT, V22, P427, DOI 10.1016/j.jagp.2012.10.025; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Honig A, 1999, INT CLIN PSYCHOPHARM, V14, P167, DOI 10.1097/00004850-199905002-00003; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hulsken J, 2000, J CELL SCI, V113, P3545; Hurtado DE, 2012, J NEUROSCI, V32, P7392, DOI 10.1523/JNEUROSCI.0889-12.2012; Ikeda M, 2004, BIOL PSYCHIAT, V56, P698, DOI 10.1016/j.biopsych.2004.07.023; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; JOFFE RT, 1988, J CLIN PSYCHOPHARM, V8, P425; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jung HJ, 2011, NEUROSCI LETT, V487, P139, DOI 10.1016/j.neulet.2010.10.009; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kessing LV, 2010, BIPOLAR DISORD, V12, P87, DOI 10.1111/j.1399-5618.2009.00788.x; Khasraw M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-131; Kimura T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003540; King MR, 2013, J NEUROSCI RES, V91, P506, DOI 10.1002/jnr.23192; Kirschenbaum F, 2001, J BIOL CHEM, V276, P30701, DOI 10.1074/jbc.M102849200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1583, DOI 10.1007/s00702-004-0166-3; Kozlovsky N, 2000, AM J PSYCHIAT, V157, P831, DOI 10.1176/appi.ajp.157.5.831; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1093, DOI 10.1007/s00702-003-0127-0; Kozlovsky N, 2001, SCHIZOPHR RES, V52, P101, DOI 10.1016/S0920-9964(00)00174-2; Kunick C, 2004, BIOORG MED CHEM LETT, V14, P413, DOI 10.1016/j.bmcl.2003.10.062; Lachman HM, 2007, AM J MED GENET B, V144B, P259, DOI 10.1002/ajmg.b.30498; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee KY, 2006, NEUROSCI LETT, V395, P175, DOI 10.1016/j.neulet.2005.10.059; Lee SJ, 2006, NEUROSCI LETT, V409, P134, DOI 10.1016/j.neulet.2006.09.026; Leeds PR, 2014, ACS CHEM NEUROSCI; Lehmann SW, 2013, J AFFECT DISORDERS, V146, P151, DOI 10.1016/j.jad.2012.08.028; Lesort M, 1999, J NEURAL TRANSM, V106, P1217, DOI 10.1007/s007020050235; Letendre SL, 2006, AIDS, V20, P1885, DOI 10.1097/01.aids.0000244208.49123.1b; Leyhe T, 2009, J ALZHEIMERS DIS, V16, P649, DOI 10.3233/JAD-2009-1004; Li HL, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/241864; Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439; Li XH, 2010, BIPOLAR DISORD, V12, P741, DOI 10.1111/j.1399-5618.2010.00866.x; Li XH, 2007, INT J NEUROPSYCHOPH, V10, P7, DOI 10.1017/S1461145706006547; Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lin YF, 2013, J AFFECT DISORDERS, V147, P401, DOI 10.1016/j.jad.2012.08.025; Lipina TV, 2013, NEUROPHARMACOLOGY, V64, P205, DOI 10.1016/j.neuropharm.2012.06.032; Lopez-Jaramillo C, 2010, J CLIN PSYCHIAT, V71, P1055, DOI 10.4088/JCP.08m04673yel; Lovestone S, 2007, TRENDS NEUROSCI, V30, P142, DOI 10.1016/j.tins.2007.02.002; Ly PTT, 2013, J CLIN INVEST, V123, P224, DOI 10.1172/JCI64516; Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964; Malaterre J, 2012, STEM CELL TRANSL MED, V1, P469, DOI 10.5966/sctm.2011-0046; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Dominguez JM, 2012, J BIOL CHEM, V287, P893, DOI 10.1074/jbc.M111.306472; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Min WW, 2009, NEUROPHARMACOLOGY, V56, P463, DOI 10.1016/j.neuropharm.2008.09.017; Mines MA, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00035; Monleon S, 2008, EUR NEUROPSYCHOPHARM, V18, P235, DOI 10.1016/j.euroneuro.2007.07.001; Morales-Garcia JA, 2012, ACS CHEM NEUROSCI, V3, P963, DOI 10.1021/cn300110c; Mur M, 2008, ACTA PSYCHIAT SCAND, V118, P373, DOI 10.1111/j.1600-0447.2008.01245.x; Mur M, 2007, J CLIN PSYCHIAT, V68, P1078, DOI 10.4088/JCP.v68n0715; Nadri C, 2004, SCHIZOPHR RES, V71, P377, DOI 10.1016/j.schres.2004.02.020; Nadri C, 2002, PSYCHIAT RES, V112, P51, DOI 10.1016/S0165-1781(02)00191-9; Nishiguchi N, 2006, NEUROSCI LETT, V394, P243, DOI 10.1016/j.neulet.2005.10.042; Noh MY, 2013, BIOCHEM BIOPH RES CO, V435, P274, DOI 10.1016/j.bbrc.2013.04.065; Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104; Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; O'Leary OF, 2015, EUR J PHARMACOL, V753, P32, DOI 10.1016/j.ejphar.2014.07.046; Onishi T, 2011, J NEUROCHEM, V119, P1330, DOI 10.1111/j.1471-4159.2011.07532.x; Pachet AK, 2003, PSYCHOPHARMACOLOGY, V170, P225, DOI 10.1007/s00213-003-1592-x; Palomo V, 2011, J MED CHEM, V54, P8461, DOI 10.1021/jm200996g; Pandey GN, 2015, BIPOLAR DISORD, V17, P160, DOI 10.1111/bdi.12228; Park SW, 2011, NEUROSCI RES, V71, P335, DOI 10.1016/j.neures.2011.08.010; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43; Polter AM, 2012, CELL SIGNAL, V24, P265, DOI 10.1016/j.cellsig.2011.09.009; Pomara N, 2009, PSYCHOPHARMACOLOGY, V205, P169, DOI 10.1007/s00213-009-1510-y; Quiroz JA, 2010, NEUROPSYCHOBIOLOGY, V62, P50, DOI 10.1159/000314310; Rix LLR, 2014, ACS CHEM BIOL, V9, P353, DOI 10.1021/cb400660a; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Roh MS, 2007, EXP MOL MED, V39, P353, DOI 10.1038/emm.2007.39; Ronai Z, 2014, AM J MED GENET B, V165, P217, DOI 10.1002/ajmg.b.32223; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rybakowski JK, 2010, INT J NEUROPSYCHOPH, V13, P617, DOI 10.1017/S1461145710000404; Saitoh M, 2009, J MED CHEM, V52, P6270, DOI 10.1021/jm900647e; Saitoh M, 2009, BIOORGAN MED CHEM, V17, P2017, DOI 10.1016/j.bmc.2009.01.019; Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Savitz JB, 2008, BIPOLAR DISORD, V10, P479, DOI 10.1111/j.1399-5618.2008.00591.x; Schouws SNTM, 2010, J AFFECT DISORDERS, V125, P330, DOI 10.1016/j.jad.2009.12.004; Schwab SG, 2005, BIOL PSYCHIAT, V58, P446, DOI 10.1016/j.biopsych.2005.05.005; Senturk V, 2007, BIPOLAR DISORD, V9, P136, DOI 10.1111/j.1399-5618.2007.00481.x; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x; Sharma S, 2014, BIOCHEM BIOPH RES CO, V452, P1009, DOI 10.1016/j.bbrc.2014.09.034; SHAW ED, 1987, J ABNORM PSYCHOL, V96, P64, DOI 10.1037/0021-843X.96.1.64; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Silva T, 2014, AGEING RES REV, V15, P116, DOI 10.1016/j.arr.2014.03.008; Sproule BA, 2000, DRUG AGING, V16, P165, DOI 10.2165/00002512-200016030-00002; SQUIRE LR, 1980, AM J PSYCHIAT, V137, P1042; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stoudemire A, 1998, GEN HOSP PSYCHIAT, V20, P85, DOI 10.1016/S0163-8343(97)00129-1; Sudduth TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031993; Suganthi M, 2012, BIOL TRACE ELEM RES, V150, P477, DOI 10.1007/s12011-012-9510-x; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Sutton LP, 2011, NEUROSCIENCE, V199, P116, DOI 10.1016/j.neuroscience.2011.09.056; Szczepankiewicz A, 2006, NEUROPSYCHOBIOLOGY, V53, P51, DOI 10.1159/000090704; Tang H, 2013, MOL NEUROBIOL, V48, P404, DOI 10.1007/s12035-013-8414-x; Terao T, 2006, PROG NEURO-PSYCHOPH, V30, P1125, DOI 10.1016/j.pnpbp.2006.04.020; Thiselton DL, 2008, BIOL PSYCHIAT, V63, P449, DOI 10.1016/j.biopsych.2007.06.005; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thotala DK, 2008, CANCER RES, V68, P5859, DOI 10.1158/0008-5472.CAN-07-6327; Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72; Wang JS, 2008, WORLD J GASTROENTERO, V14, P3982, DOI 10.3748/wjg.14.3982; Wingo AP, 2009, J CLIN PSYCHIAT, V70, P1588, DOI 10.4088/JCP.08r04972; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Yazlovitskaya EM, 2006, CANCER RES, V66, P11179, DOI 10.1158/0008-5472.CAN-06-2740; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yuskaitis CJ, 2010, BIOCHEM PHARMACOL, V79, P632, DOI 10.1016/j.bcp.2009.09.023; Zerbi F, 1981, Bibl Psychiatr, P190; Zhang X, 2011, J ALZHEIMERS DIS, V24, P739, DOI 10.3233/JAD-2011-101875; Zhou WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043262; Zhu LQ, 2007, J NEUROSCI, V27, P12211, DOI 10.1523/JNEUROSCI.3321-07.2007; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	190	40	40	0	20	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs	JAN	2015	29	1					1	15		10.1007/s40263-014-0213-z			15	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AZ6OY	WOS:000348339900001	25380674				2022-02-06	
J	Olabarrieta-Landa, L; Rivera, D; Galarza-del-Angel, J; Garza, MT; Saracho, CP; Rodriguez, W; Chavez-Oliveros, M; Rabago, B; Leibach, G; Schebela, S; Martinez, C; Luna, M; Longoni, M; Ocampo-Barba, N; Rodriguez, G; Aliaga, A; Esenarro, L; de la Cadena, CG; Perrin, PB; Arango-Lasprilla, JC				Olabarrieta-Landa, L.; Rivera, D.; Galarza-del-Angel, J.; Garza, M. T.; Saracho, C. P.; Rodriguez, W.; Chavez-Oliveros, M.; Rabago, B.; Leibach, G.; Schebela, S.; Martinez, C.; Luna, M.; Longoni, M.; Ocampo-Barba, N.; Rodriguez, G.; Aliaga, A.; Esenarro, L.; Garcia de la Cadena, C.; Perrin, P. B.; Arango-Lasprilla, J. C.			Verbal Fluency Tests: Normative data for the Latin American Spanish speaking adult population	NEUROREHABILITATION			English	Article						Normative data; semantic verbal fluency test; phonological verbal fluency test; Latin America; executive functions	TRAUMATIC BRAIN-INJURY; WORD-ASSOCIATION TEST; CATEGORY FLUENCY; NEUROPSYCHOLOGICAL TESTS; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; NORMS; AGE; EDUCATION; PERFORMANCE	OBJECTIVE: To generate normative data for theVerbal Fluency Tests across 11 countries in Latin America, with country-specific adjustments for gender, age, and education, where appropriate. METHOD: The sample consisted of 3,977 healthy adults who were recruited from Argentina, Bolivia, Chile, Cuba, El Salvador, Guatemala, Honduras, Mexico, Paraguay, Peru, and, Puerto Rico. Each subject was administered the Verbal Fluency Test as part of a larger neuropsychological battery. A standardized five-step statistical procedure was used to generate the norms. RESULTS: The final multiple linear regression models for the letter F explained 8-30% of the variance, 7-32% for letter A, 8-32% for the letter S, and 16-43% for the animal category in Verbal Fluency Test scores. Although t-tests showed significant differences between men and women on the Verbal Fluency Test, they did not have an effect size larger than 0.3. As a result, gender-adjusted norms were not generated. CONCLUSIONS: This is the first normative multicenter study conducted in Latin America aiming to create norms for the Verbal Fluency Test; this study will have important outcomes for the future of neuropsychology in the region.	[Olabarrieta-Landa, L.; Rivera, D.; Arango-Lasprilla, J. C.] Univ Deusto, Fac Psychol & Educ, Bilbao, Spain; [Galarza-del-Angel, J.] Univ Autonoma Baja California, Mexicali 21100, Baja California, Mexico; [Garza, M. T.] Univ Autonoma Nuevo Leon, Fac Psicol, Monterrey, Mexico; [Saracho, C. P.] CETYS Univ, Mexicali, Baja California, Mexico; [Rodriguez, W.] Ponce Hlth Sci Univ, Ponce, Puerto Rico, Spain; [Chavez-Oliveros, M.] Inst Nacl Neurol & Neurocirugia MVS, Mexico City, DF, Mexico; [Rabago, B.] Inst Vocac Enrique Diaz Leon, Guadalajara, Mexico; [Leibach, G.; Perrin, P. B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Schebela, S.] Inst Prevenc Social, Asuncion, Paraguay; [Martinez, C.] Univ Nacl Autonoma Honduras, Dept Med Rehabilitac, Tegucigalpa, Honduras; [Luna, M.] Univ Dr Jose Matias Delgado, San Salvador, El Salvador; [Longoni, M.] Clin Rehabilitac Las Araucarias, Buenos Aires, DF, Argentina; [Ocampo-Barba, N.] Fdn Horizontes, Santa Cruz, Bolivia; [Rodriguez, G.] Univ Camaguey Ignacio Agramonte Loynaz, Camaguey, Cuba; [Aliaga, A.] Minist Justicia, Serv Med Legal, Santiago, Chile; [Esenarro, L.] Inst Neuropsicol & Demencias, Lima, Peru; [Garcia de la Cadena, C.] Univ Valle Guatemala, Dept Psicol, Guatemala City, Guatemala; [Arango-Lasprilla, J. C.] Ikerbasque, Basque Fdn Sci, E-48011 Bilbao, Spain		Arango-Lasprilla, JC (corresponding author), Univ Deusto, Basque Fdn Sci, Ikerbasque, Dept Psychol, Bilbao, Spain.	jcarango@deusto.es	Rivera, Diego/U-8872-2017; Rabago, Brenda/AAF-6231-2021; Oliveros, Mireya Chavez -/AAU-3898-2020; Galarza-del-Angel, Javier/AAS-4113-2021; Landa, Laiene Olabarrieta/V-6207-2017	Rivera, Diego/0000-0001-7477-1893; Oliveros, Mireya Chavez -/0000-0002-1064-2096; Landa, Laiene Olabarrieta/0000-0002-8305-8720; Galarza-del-Angel, Javier/0000-0001-5865-5198; Esenarro, Loida/0000-0002-9978-0072			Acevedo A, 2000, J INT NEUROPSYCH SOC, V6, P760, DOI 10.1017/S1355617700677032; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anhoque CF, 2013, ARQ NEURO-PSIQUIAT, V71, P74, DOI 10.1590/S0004-282X2013005000004; Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Benton A, 1989, CLIN NEUROPSYCHOL, V3, P375, DOI DOI 10.1080/13854048908401486; Brissart H, 2013, NEUROCASE, V19, P553, DOI 10.1080/13554794.2012.701644; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Costafreda SG, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-18; da Silva CG, 2004, J CLIN EXP NEUROPSYC, V26, P266, DOI 10.1076/jcen.26.2.266.28089; Delis DC., 2001, DELIS KAPLAN EXECUTI; Diaz-Asper CM, 2004, J INT NEUROPSYCH SOC, V10, P82; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Guardia-Olmos J, 2015, NEUROREHABILITATION, V37, P493, DOI 10.3233/NRE-151277; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; Heaton R. K., 2004, REVISED COMPREHENSIV; HELLER RB, 1993, PSYCHOL AGING, V8, P443, DOI 10.1037/0882-7974.8.3.443; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, J INT NEUROPSYCH SOC, V10, P608, DOI 10.1017/S1355617704104141; Henry Julie D, 2005, Cogn Neuropsychiatry, V10, P1, DOI 10.1080/13546800344000309; Indefrey P., 2000, NEW COGNITIVE NEUROS, P845; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Moreno-Martinez FJ, 2010, APHASIOLOGY, V24, P1389, DOI 10.1080/02687030903515370; Johnson-Selfridge M, 2001, SCHIZOPHRENIA BULL, V27, P305, DOI 10.1093/oxfordjournals.schbul.a006876; Khalil MS, 2010, J CLIN EXP NEUROPSYC, V32, P1028, DOI 10.1080/13803391003672305; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Loonstra A S, 2001, Appl Neuropsychol, V8, P161, DOI 10.1207/S15324826AN0803_5; Lucas JA, 1998, J CLIN EXP NEUROPSYC, V20, P194, DOI 10.1076/jcen.20.2.194.1173; MAHONEY F I, 1965, Md State Med J, V14, P61; March EG, 2006, J CLIN EXP NEUROPSYC, V28, P549, DOI 10.1080/13803390590949502; McGraw P, 2001, NEUROIMAG CLIN N AM, V11, P343; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; PASQUIER F, 1995, J NEUROL NEUROSUR PS, V58, P81, DOI 10.1136/jnnp.58.1.81; Price SE, 2012, NEUROPSYCHOLOGY, V26, P490, DOI 10.1037/a0028567; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Ravdin LD, 2003, CLIN NEUROPSYCHOL, V17, P195, DOI 10.1076/clin.17.2.195.16500; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Sauzeon H, 2004, BRAIN LANG, V89, P192, DOI 10.1016/S0093-934X(03)00367-5; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stricks L, 1998, J INT NEUROPSYCH SOC, V4, P311, DOI 10.1017/S1355617798003117; Tallberg IM, 2008, SCAND J PSYCHOL, V49, P479, DOI 10.1111/j.1467-9450.2008.00653.x; Till C, 2013, NEUROPSYCHOLOGY, V27, P210, DOI 10.1037/a0031665; Ting SKS, 2013, CLIN NEUROL NEUROSUR, V115, P1049, DOI 10.1016/j.clineuro.2012.10.030; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Van Breukelen GJP, 2005, PSYCHOL ASSESSMENT, V17, P336, DOI 10.1037/1040-3590.17.3.336; Van der Elst W, 2006, J INT NEUROPSYCH SOC, V12, P80, DOI 10.1017/S1355617706060115; Van Der Elst W, 2007, PSYCHOL MED, V37, P1335, DOI 10.1017/S0033291707000360; Weber N, 2012, J NEUROL NEUROSUR PS, V83, pA36, DOI 10.1136/jnnp-2012-303524.114; Wysokinski A, 2010, ARCH MED SCI, V6, P438, DOI 10.5114/aoms.2010.14268	55	40	43	1	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2015	37	4					515	561		10.3233/NRE-151279			47	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DA0XY	WOS:000367522100004	26639930	Bronze			2022-02-06	
J	Jeon, SB; Choi, HA; Badjatia, N; Schmidt, JM; Lantigua, H; Claassen, J; Connolly, ES; Mayer, SA; Lee, K				Jeon, Sang-Beom; Choi, H. Alex; Badjatia, Neeraj; Schmidt, J. Michael; Lantigua, Hector; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Lee, Kiwon			Hyperoxia may be related to delayed cerebral ischemia and poor outcome after subarachnoid haemorrhage	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; OXYGEN-THERAPY; OXIDATIVE STRESS; HEAD-INJURY; BLOOD-FLOW; VASOSPASM; STROKE; ASSOCIATION; REPERFUSION; MORTALITY	Objective To determine the association between exposure to hyperoxia and the risk of delayed cerebral ischaemia (DCI) after subarachnoid haemorrhage (SAH). Methods We analysed data from a single centre, prospective, observational cohort database. Patient inclusion criteria were age >= 18 years, aneurysmal SAH, endotracheal intubation with mechanical ventilation, and arterial partial pressure of oxygen (PaO2) measurements. Hyperoxia was defined as the highest quartile of an area under the curve of PaO2, until the development of DCI (PaO2 >= 173 mm Hg). Poor outcome was defined as modified Rankin Scale 4-6 at 3 months after SAH. Results Of 252 patients, there were no differences in baseline characteristics between the hyperoxia and control group. Ninety-seven (38.5%) patients developed DCI. The hyperoxia group had a higher incidence of DCI (p<0.001) and poor outcome (p=0.087). After adjusting for modified Fisher scale, rebleeding, global cerebral oedema, intracranial pressure crisis, pneumonia and sepsis, hyperoxia was independently associated with DCI (OR, 3.16; 95% CI 1.69 to 5.92; p<0.001). After adjusting for age, Hunt-Hess grade, aneurysm size, Acute Physiology and Chronic Health Evaluation II score, rebleeding, pneumonia and sepsis, hyperoxia was independently associated with poor outcome (OR, 2.30; 95% CI 1.03 to 5.12; p=0.042). Conclusions In SAH patients, exposure to hyperoxia was associated with DCI. Our findings suggest that exposure to excess oxygen after SAH may represent a modifiable factor for morbidity and mortality in this population.	[Jeon, Sang-Beom] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea; [Jeon, Sang-Beom; Choi, H. Alex; Lee, Kiwon] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX 77030 USA; [Jeon, Sang-Beom; Choi, H. Alex; Lee, Kiwon] Univ Texas Med Sch Houston, Dept Neurosurg, Houston, TX 77030 USA; [Jeon, Sang-Beom; Choi, H. Alex; Badjatia, Neeraj; Schmidt, J. Michael; Lantigua, Hector; Claassen, Jan; Mayer, Stephan A.; Lee, Kiwon] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; [Badjatia, Neeraj] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Connolly, E. Sander] Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA		Lee, K (corresponding author), Univ Texas Med Sch Houston, Dept Neurol, 6431 Fannin St,MSB 7-152, Houston, TX 77030 USA.	Kiwon.Lee@uth.tmc.edu	Jeon, Sang-Beom/AAD-6605-2022; Claassen, Jan/AAA-5451-2020; Badjatia, Neeraj/AAS-4855-2021	Jeon, Sang-Beom/0000-0003-0735-5499; Badjatia, Neeraj/0000-0003-1509-9034; Schmidt, J. Michael/0000-0001-8141-2944			BALENTINE JD, 1966, NEW ENGL J MED, V275, P1038, DOI 10.1056/NEJM196611102751903; Barazzone C, 1996, J CLIN INVEST, V98, P2666, DOI 10.1172/JCI119089; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Buonocore G, 2010, SEMIN FETAL NEONAT M, V15, P186, DOI 10.1016/j.siny.2010.04.003; Calzia E, 2010, CRIT CARE MED, V38, pS559, DOI 10.1097/CCM.0b013e3181f1fe70; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; GRIFFITH DE, 1992, CHEST, V101, P392, DOI 10.1378/chest.101.2.392; Hazelton JL, 2010, J NEUROTRAUM, V27, P753, DOI 10.1089/neu.2009.1186; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Ko SB, 2011, STROKE, V42, P3087, DOI 10.1161/STROKEAHA.111.623165; Leng LZ, 2011, ARCH NEUROL-CHICAGO, V68, P31, DOI 10.1001/archneurol.2010.226; Lord AS, 2012, NEUROLOGY, V78, P31, DOI 10.1212/WNL.0b013e31823ed0a4; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001; Pancioli AM, 2004, STROKE PATHOPHYSIOLO, P905; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rousseau A, 2005, ACTA PHYSIOL SCAND, V183, P231, DOI 10.1111/j.1365-201X.2005.01405.x; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2007, STROKE, V38, P2851, DOI 10.1161/STROKEAHA.107.487280; Singhal AB, 2006, INT J STROKE, V1, P191, DOI 10.1111/j.1747-4949.2006.00058.x; Starke RM, 2013, CURR NEUROVASC RES, V10, P247, DOI 10.2174/15672026113109990003; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Watson NA, 2000, EUR J ANAESTH, V17, P152, DOI 10.1046/j.1365-2346.2000.00640.x	33	40	44	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2014	85	12					1301	1307		10.1136/jnnp-2013-307314			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	AT9XF	WOS:000345276400005	24860138	Bronze			2022-02-06	
J	Marini, A; Zettin, M; Galetto, V				Marini, Andrea; Zettin, Marina; Galetto, Valentina			Cognitive correlates of narrative impairment in moderate traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						Moderate traumatic brain injury; Narrative analysis; Neurolinguistics; Neuropsychology; Language	CLOSED-HEAD-INJURY; DISCOURSE PRODUCTION; WORD RETRIEVAL; FOLLOW-UP; COMMUNICATION PARTNERS; EXECUTIVE FUNCTIONS; STORY NARRATIVES; MILD; ADULTS; LANGUAGE	Traumatic brain injuries (TBIs) are often associated with communicative deficits. The incoherent and impoverished language observed in non-aphasic individuals with severe TBI has been linked to a problem in the global organization of information at the text level. The present study aimed to analyze the features of narrative discourse impairment in a group of adults with moderate TBI (modTBI). 10 non-aphasic speakers with modTBI and 20 neurologically intact participants were recruited for the experiment. Their cognitive, linguistic and narrative skills were thoroughly assessed. The persons with modTBI exhibited normal phonological, lexical and grammatical skills. However, their narratives were characterized by lower levels of Lexical Informativeness and more errors of both Local and Global Coherence that, at times, made their narratives vague and ambiguous. Significant correlations were found between these narrative difficulties and the production of both perseverative and non-perseverative errors on the WCST. These disturbances confirm previous findings which suggest a deficit at the interface between cognitive and linguistic processing rather than a specific linguistic disturbance in these patients. (C) 2014 Elsevier Ltd. All rights reserved.	[Marini, Andrea] Univ Udine, Dipartimento Sci Umane, I-33100 Udine, Italy; [Marini, Andrea] IRCCS E Medea La Nostra Famiglia, San Vito Al Tagliamento, Pn, Italy; [Zettin, Marina; Galetto, Valentina] Ctr Puzzle, Turin, Italy; [Zettin, Marina; Galetto, Valentina] Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy		Marini, A (corresponding author), Univ Udine, Dipartimento Sci Umane, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	Marini, Andrea/A-1206-2012	Marini, Andrea/0000-0002-6058-3864	IRCCS "E. Medea"	Funding for this study was provided by IRCCS "E. Medea". The IRCCS "E. Medea" had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Adamovich B.L.B., 2005, APHASIA RELATED NEUR; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Ash S, 2006, NEUROLOGY, V66, P1405, DOI 10.1212/01.wnl.0000210435.72614.38; Barrow IM, 2003, J TRAUMA, V54, P888, DOI 10.1097/01.TA.0000057150.60668.7C; Barrow IM, 2006, BRAIN INJURY, V20, P845, DOI 10.1080/02699050600832445; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Body R., 1999, COMMUNICAITON DISORE; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Carlomagno S, 2011, BRAIN INJURY, V25, P1010, DOI 10.3109/02699052.2011.605097; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GILLIS R, 1996, TRAUMATIC BRAIN INJU; Goozee J V, 2001, Logoped Phoniatr Vocol, V26, P51; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Hough MS, 2008, APHASIOLOGY, V22, P644, DOI 10.1080/02687030701541024; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kertesz A., 1982, W APHASIA BATTERY; King KA, 2006, APHASIOLOGY, V20, P233, DOI 10.1080/02687030500473155; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; Linebarger MC, 2004, COGN NEUROPSYCHOL, V21, P267, DOI 10.1080/02643290342000537; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2011, APHASIOLOGY, V25, P1372, DOI 10.1080/02687038.2011.584690; Marini A, 2012, J COGNITIVE NEUROSCI, V24, P2211, DOI 10.1162/jocn_a_00283; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Raven, 1938, PROGR MATRICES PERCE; Reitan RM, 1992, TRAIL MAKING TEST; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sherratt S, 2007, APHASIOLOGY, V21, P375, DOI 10.1080/02687030600911435; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sim P, 2013, BRAIN INJURY, V27, P717, DOI 10.3109/02699052.2013.775485; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2001, LANGUAGE INTERVENTIO; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	61	40	41	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	NOV	2014	64						282	288		10.1016/j.neuropsychologia.2014.09.042			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	AU6TL	WOS:000345734500028	25281884				2022-02-06	
J	Schatz, P; Robertshaw, S				Schatz, Philip; Robertshaw, Stacey			Comparing Post-Concussive Neurocognitive Test Data to Normative Data Presents Risks for Under-Classifying "Above Average" Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; mTBI; Neuropsychological assessment; Baseline assessment	TEST-RETEST RELIABILITY; SPORT-RELATED CONCUSSION; COUNSELING PSYCHOMETRIC ISSUES; IMPACT TEST BATTERY; CONSTRUCT-VALIDITY; CLINICAL UTILITY; RELIABLE CHANGE; RECOVERY; PSYCHOTHERAPY; PERFORMANCE	We compared classification accuracy of post-concussion test data against baseline and normative data, accounting for baseline level of performance. Athletes (N = 250) completed baseline and post-concussion ImPACT assessments, within 7 days of concussion (verified by sports medicine professionals and self-reported symptoms). Athletes were classified as "below average," " average," or "above average" at baseline. Change from baseline was calculated using reliable change indices (RCIs) and regression-based measures (RBz), and comparison to normative data was achieved using z-scores. Normative comparisons identified fewer symptomatic, concussed athletes than RCIs and RBz. Both RCIs and RBz consistently identified "impairment" at 1 and 1.5 SD, regardless of baseline level, whereas normative comparisons identified 46-48% fewer athletes performing "above average" at baseline using a cut-off of 1 SD and 36-38% fewer using a cut-off of 1.5 SD. The use of normative comparisons may differentially classify concussed, symptomatic athletes who are outside the "average" range at baseline.	[Schatz, Philip; Robertshaw, Stacey] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	Dr P.S. has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation and the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications, Inc. However, these entities had no role in the conceptualization of the study, the collection or analysis of data, the writing of the article, or the decision to submit it for publication. Ms S.R. has no Conflict of Interest to declare.	Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Barth JT, 1989, MILD HEAD INJURY, P257; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Collins M. W., 1998, JOURNAL OF HEAD TRAU, V13, P9; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Heaton RK, 1991, COMPREHENSIVE NORMS; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HSU LM, 1995, J CONSULT CLIN PSYCH, V63, P141, DOI 10.1037/0022-006X.63.1.141; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kvalseth TO, 2003, PSYCHOL REP, V93, P1283, DOI 10.2466/PR0.93.7.1283-1290; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell M.R., 2011, IMPACT TECHNICAL MAN, V2013; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Rabinowitz AR, 2012, J INT NEUROPSYCH SOC, V18, P139, DOI 10.1017/S1355617711001275; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P., 2009, THE AMERICAN JOURNAL, V38, P47; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	43	40	40	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2014	29	7					625	632		10.1093/arclin/acu041			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AU9DA	WOS:000345890600003	25178629	Green Published, Bronze			2022-02-06	
J	Jean, A; Nyein, MK; Zheng, JQ; Moore, DF; Joannopoulos, JD; Radovitzky, R				Jean, Aurelie; Nyein, Michelle K.; Zheng, James Q.; Moore, David F.; Joannopoulos, John D.; Radovitzky, Raul			An animal-to-human scaling law for blast-induced traumatic brain injury risk assessment	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						interspecies scaling; injury risk criteria; transfer function; TBI	VIRTUAL TEST FACILITY; DYNAMIC-RESPONSE; HEAD; BIOMECHANICS; SIMULATION; MODEL; EXPOSURE; SHOCK; RATS; IRAQ	Despite recent efforts to understand blast effects on the human brain, there are still no widely accepted injury criteria for humans. Recent animal studies have resulted in important advances in the understanding of brain injury due to intense dynamic loads. However, the applicability of animal brain injury results to humans remains uncertain. Here, we use advanced computational models to derive a scaling law relating blast wave intensity to the mechanical response of brain tissue across species. Detailed simulations of blast effects on the brain are conducted for different mammals using image-based biofidelic models. The intensity of the stress waves computed for different external blast conditions is compared across species. It is found that mass scaling, which successfully estimates blast tolerance of the thorax, fails to capture the brain mechanical response to blast across mammals. Instead, we show that an appropriate scaling variable must account for the mass of protective tissues relative to the brain, as well as their acoustic impedance. Peak stresses transmitted to the brain tissue by the blast are then shown to be a power function of the scaling parameter for a range of blast conditions relevant to TBI. In particular, it is found that human brain vulnerability to blast is higher than for any other mammalian species, which is in distinct contrast to previously proposed scaling laws based on body or brain mass. An application of the scaling law to recent experiments on rabbits furnishes the first physics-based injury estimate for blast-induced TBI in humans.	[Jean, Aurelie; Nyein, Michelle K.; Moore, David F.; Joannopoulos, John D.; Radovitzky, Raul] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA; [Jean, Aurelie; Nyein, Michelle K.; Radovitzky, Raul] MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA; [Joannopoulos, John D.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Zheng, James Q.] US Army, Program Execut Off Soldier, Ft Belvoir, VA 22060 USA		Jean, A (corresponding author), MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA.	ajean@mit.edu; joannop@mit.edu	Joannopoulos, John D/E-6401-2013; Radovitzky, Raul A/A-5353-2009	Radovitzky, Raul A/0000-0001-6339-2708	US Army through the Institute for Soldier Nanotechnologies [DAAD-19-02-D-0002]	This work was supported by the US Army through the Institute for Soldier Nanotechnologies under Contract DAAD-19-02-D-0002.	ALBERIUS P, 1987, ARCH ORAL BIOL, V32, P637, DOI 10.1016/0003-9969(87)90037-9; ANSYS, 2012, ANSYS AC RES REL 15; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Belingardi G., 2005, P 19 INT TECHN C ENH, P1; Bochicchio GV, 2008, AM SURGEON, V74, P267; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CRILE GEORGE, 1940, OHIO JOUR SCI, V40, P219; Cummings J, 2002, J SUPERCOMPUT, V23, P39, DOI 10.1023/A:1015733102520; Deiterding R, 2006, ENG COMPUT-GERMANY, V22, P325, DOI 10.1007/s00366-006-0043-9; *DVBIC, 2010, TBI NUMB DEP DEF NUM; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Fang QQ, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P1142, DOI 10.1109/ISBI.2009.5193259; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gong SW, 2008, COMPUT STRUCT, V86, P758, DOI 10.1016/j.compstruc.2007.06.003; Hansen CD, 2005, VISUALIZATION HDB; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2012, TRAUMATIC BRAIN INJU, P1; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okhotsimskii DE, 1957, T MAT I STEKLOVA, V50, P1; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2010, J TRAUMA, V69, P368, DOI 10.1097/TA.0b013e3181e88122; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Wood GW, 2013, P INT RES COUNC BIOM, P549; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L, 2011, HFM 207 SURVEY BLAST, P33; Zhang LY, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00088; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2013, J MECH MED BIOL, V13, DOI 10.1142/S0219519413500656	55	40	41	0	20	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	OCT 28	2014	111	43					15310	15315		10.1073/pnas.1415743111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR6ZL	WOS:000343729500029	25267617	Green Published, Bronze			2022-02-06	
J	McGuine, TA; Hetzel, S; McCrea, M; Brooks, MA				McGuine, Timothy A.; Hetzel, Scott; McCrea, Michael; Brooks, M. Alison			Protective Equipment and Player Characteristics Associated With the Incidence of Sport-Related Concussion in High School Football Players A Multifactorial Prospective Study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						football helmet; concussion; high school	STATES HIGH-SCHOOL; IMPACT PERFORMANCE; RISK-FACTORS; EPIDEMIOLOGY; COLLEGIATE; SYMPTOMS; INJURIES; HELMETS	Background: The incidence of sport-related concussion (SRC) in high school football is well documented. However, limited prospective data are available regarding how player characteristics and protective equipment affect the incidence of SRC. Purpose: To determine whether the type of protective equipment (helmet and mouth guard) and player characteristics affect the incidence of SRC in high school football players. Design: Cohort study; Level of evidence, 2. Methods: Certified athletic trainers (ATs) at each high school recorded the type of helmet worn (brand, model, purchase year, and recondition status) by each player as well as information regarding players' demographics, type of mouth guard used, and history of SRC. The ATs also recorded the incidence and days lost from participation for each SRC. Incidence of SRC was compared for various helmets, type of mouth guard, history of SRC, and player demographics. Results: A total of 2081 players (grades 9-12) enrolled during the 2012 and/or 2013 football seasons (2287 player-seasons) and participated in 134,437 football (practice or competition) exposures. Of these players, 206 (9%) sustained a total of 211 SRCs (1.56/1000 exposures). There was no difference in the incidence of SRC (number of helmets, % SRC [95% CI]) for players wearing Riddell (1171, 9.1% [7.6%-11.0%]), Schutt (680, 8.7% [6.7%-11.1%]), or Xenith (436, 9.2% [6.7%-12.4%]) helmets. Helmet age and recondition status did not affect the incidence of SRC. The rate of SRC (hazard ratio [HR]) was higher in players who wore a custom mouth guard (HR = 1.69 [95% CI, 1.20-2.37], P < .001) than in players who wore a generic mouth guard. The rate of SRC was also higher (HR = 1.96 [95% CI, 1.40-2.73], P < .001) in players who had sustained an SRC within the previous 12 months (15.1% of the 259 players [95% CI, 11.0%-20.1%]) than in players without a previous SRC (8.2% of the 2028 players [95% CI, 7.1%-9.5%]). Conclusion: Incidence of SRC was similar regardless of the helmet brand (manufacturer) worn by high school football players. Players who had sustained an SRC within the previous 12 months were more likely to sustain an SRC than were players without a history of SRC. Sports medicine providers who work with high school football players need to realize that factors other than the type of protective equipment worn affect the risk of SRC in high school players.	[McGuine, Timothy A.; Hetzel, Scott; McCrea, Michael; Brooks, M. Alison] Univ Wisconsin, Madison, WI 53711 USA		McGuine, TA (corresponding author), Univ Wisconsin, Hlth Sports Med Ctr, 621 Sci Dr, Madison, WI 53711 USA.	tmcguine@uwhealth.org			University of Wisconsin Department of Orthopedics and Rehabilitation; UW Sports Medicine Classic Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055894] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: Funding for this study was provided by the University of Wisconsin Department of Orthopedics and Rehabilitation and UW Sports Medicine Classic Fund.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; [Anonymous], 2006, Current Sports Medicine Reports, V5, P268, DOI 10.1097/01.CSMR.0000306427.16414.1b; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Comstock D, 2012, EPIDEMIOLOGY PREVENT; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Demorest RA, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P177, DOI 10.1007/978-0-387-89545-1_13; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kelly JP, 1997, NEUROLOGY, V48, P581; Knowles S, 2012, EPIDEMIOLOGY, V20, P302; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Nation AD, 2011, CLIN PEDIATR, V50, P200, DOI 10.1177/0009922810388511; National Federation of State High School Associations, 2012, HIGH SCH ATHL PART S; Olson DE, 2011, CURR SPORT MED REP, V10, P290, DOI 10.1249/JSR.0b013e31822d4029; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wisconsin Interscholastioc Athletic Association, WIAA CONC POL	36	40	40	0	50	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2014	42	10					2470	2478		10.1177/0363546514541926			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	AQ4XQ	WOS:000342805000026	25060072	Green Accepted			2022-02-06	
J	Lee, LK; Monroe, D; Bachman, MC; Glass, TF; Mahajan, PV; Cooper, A; Stanley, RM; Miskin, M; Dayan, PS; Holmes, JF; Kuppermann, N				Lee, Lois K.; Monroe, David; Bachman, Michael C.; Glass, Todd F.; Mahajan, Prashant V.; Cooper, Arthur; Stanley, Rachel M.; Miskin, Michelle; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		TBI Working Grp PECARN	Isolated Loss of Consciousness in Children With Minor Blunt Head Trauma	JAMA PEDIATRICS			English	Article							CRANIAL COMPUTED-TOMOGRAPHY; SIGNIFICANT INTRACRANIAL INJURY; DECISION RULE; RADIATION-EXPOSURE; NEUROLOGIC EXAMINATION; BRAIN-INJURIES; RISK; PREDICT; SCANS; METAANALYSIS	IMPORTANCE A history of loss of consciousness (LOC) is frequently a driving factor for computed tomography use in the emergency department evaluation of children with blunt head trauma. Computed tomography carries a nonnegligible risk for lethal radiation-induced malignancy. The Pediatric Emergency Care Applied Research Network (PECARN) derived 2 age-specific prediction rules with 6 variables for clinically important traumatic brain injury (ciTBI), which included LOC as one of the risk factors. OBJECTIVE To determine the risk for ciTBIs in children with isolated LOC. DESIGN, SETTING, AND PARTICIPANTS This was a planned secondary analysis of a large prospective multicenter cohort study. The study included 42 412 children aged 0 to 18 years with blunt head trauma and Glasgow Coma Scale scores of 14 and 15 evaluated in 25 emergency departments from 2004-2006. EXPOSURE A history of LOC after minor blunt head trauma. MAIN OUTCOMES AND MEASURES The main outcome measures were ciTBIs (resulting in death, neurosurgery, intubation for >24 hours, or hospitalization for >= 2 nights) and a comparison of the rates of ciTBIs in children with no LOC, any LOC, and isolated LOC (ie, with no other PECARN ciTBI predictors). RESULTS A total of 42 412 children were enrolled in the parent study, with 40 693 remaining in the current analysis after exclusions. Of these, LOC occurred in 15.4%(6286 children). The prevalence of ciTBI with any history of LOC was 2.5% and for no history of LOC was 0.5% (difference, 2.0%; 95% CI, 1.7-2.5). The ciTBI rate in children with isolated LOC, with no other PECARN predictors, was 0.5%(95% CI, 0.2-0.8; 13 of 2780). When comparing children who have isolated LOC with those who have LOC and other PECARN predictors, the risk ratio for ciTBI in children younger than 2 years was 0.13 (95% CI, 0.005-0.72) and for children 2 years or older was 0.10 (95% CI, 0.06-0.19). CONCLUSIONS AND RELEVANCE Children with minor blunt head trauma presenting to the emergency department with isolated LOC are at very low risk for ciTBI and do not routinely require computed tomographic evaluation.	[Lee, Lois K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Monroe, David] Howard Cty Gen Hosp, Dept Emergency Med, Columbia, MD USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Emergency Med, Newark, NJ USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Pediat, Newark, NJ USA; [Glass, Todd F.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Mahajan, Prashant V.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Cooper, Arthur] Columbia Univ, Harlem Hosp, Med Ctr, Dept Surg, New York, NY USA; [Stanley, Rachel M.] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA; [Miskin, Michelle] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Emergency Med, New York, NY USA; [Kuppermann, Nathan] Univ Calif, Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Kuppermann, Nathan] Univ Calif, Davis Sch Med, Dept Pediat, Sacramento, CA USA		Lee, LK (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	lois.lee@childrens.harvard.edu		Holubkov, Richard/0000-0003-0431-3381; Tsung, James/0000-0002-4718-8325	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB) Division of Research, Education and Training (DRTE) [R40MC02461]; Emergency Medical Services for Children (EMSC) Program; HRSA/MCHB/EMSC Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]; EMSC program of the MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This study was supported by grant R40MC02461 from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB) Division of Research, Education and Training (DRTE) and the Emergency Medical Services for Children (EMSC) Program. The PECARN is supported by the HRSA/MCHB/EMSC Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. The PECARN is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685 from the EMSC program of the MCHB/HRSA.	ABIM Foundation American Academy of Pediatrics, 2013, CHOOS WIS 5 THINGS P; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Faul M, 2010, TRAUMATIC BRAIN INJU; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larson DB, 2011, RADIOLOGY, V258, P164, DOI 10.1148/radiol.10100640; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Munafo S, 2013, ACAD EMERG MED, V20, ps235; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shah P, 2012, ACAD EMERG MED, V19, ps156; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Smith-Bindman R, 2012, JAMA-J AM MED ASSOC, V307, P2400, DOI 10.1001/jama.2012.5960; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Walker G, PECARN PEDIAT HEAD I	44	40	42	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	SEP	2014	168	9					837	843		10.1001/jamapediatrics.2014.361			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AO8AS	WOS:000341575200012	25003654	Bronze			2022-02-06	
J	Minei, JP; Fabian, TC; Guffey, DM; Newgard, CD; Bulger, EM; Brasel, KJ; Sperry, JL; MacDonald, RD				Minei, Joseph P.; Fabian, Timothy C.; Guffey, Danielle M.; Newgard, Craig D.; Bulger, Eileen M.; Brasel, Karen J.; Sperry, Jason L.; MacDonald, Russell D.		Resuscitation Outcome Consortium I	Increased Trauma Center Volume Is Associated With Improved Survival After Severe Injury Results of a Resuscitation Outcomes Consortium Study	ANNALS OF SURGERY			English	Article						trauma center designation level; trauma center outcomes; trauma center survival; trauma center volume; trauma systems	STANDARD OPERATING PROCEDURES; SCALE COLLABORATIVE PROJECT; ORIENTED RESEARCH CORE; CLINICAL CARE; HOST RESPONSE; DATA-BANK; LEVEL-I; HYPERTONIC RESUSCITATION; CENTER DESIGNATION; PATIENT	Objective: To investigate the relationship between trauma center volume and outcome. Background: The Resuscitation Outcomes Consortium is a network of 11 centers and 60 hospitals conducting emergency care research. For many procedures, high-volume centers demonstrate superior outcomes versus low-volume centers. This remains controversial for trauma center outcomes. Methods: This study was a secondary analysis of prospectively collected data from the Resuscitation Outcomes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Scale score of 8 or less (traumatic brain injury) or systolic blood pressure of 90 or less and pulse of 110 or more (shock). Regression analyses evaluated associations between trauma volume and the following outcomes: 24-hour mortality, 28-day mortality, ventilator-free days, Multiple Organ Dysfunction Scale incidence, worst Multiple Organ Dysfunction Scale score, and poor 6-month Glasgow Outcome Scale-Extended score. Results: A total of 2070 patients were evaluated: 1251 in the traumatic brain injury cohort and 819 in the shock cohort. Overall, 24-hour and 28-day mortality was 16% and 25%, respectively. For every increase of 500 trauma center admissions, there was a 7% decreased odds of 24-hour and 28-day mortality for all patients. As trauma center volume increased, nonorgan dysfunction complications increased, ventilator-free days increased, and worst Multiple Organ Dysfunction Scale score decreased. The associations with higher trauma center volume were similar for the traumatic brain injury cohort, including better neurologic outcomes at 6 months, but not for the shock cohort. Conclusions: Increased trauma center volume was associated with increased survival, more ventilator-free days, and less severe organ failure. Trauma system planning and implementation should avoid unnecessary duplication of services.	[Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Guffey, Danielle M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Sperry, Jason L.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [MacDonald, Russell D.] Univ Toronto, Dept Med, Toronto, ON, Canada; [MacDonald, Russell D.] Ornge Transport Med, Mississauga, ON, Canada		Minei, JP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joseph.minei@utsouthwestern.edu		Guffey, Danielle/0000-0003-3721-614X	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077866, HL077867, HL077871, HL077872, HL077873, HL077881, HL077885, HL077887, HL077908]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077887, U01HL077866, U01HL077867, U01HL077871, U01HL077908, U01HL077872, U01HL077881, U01HL077863, U01HL077873, U01HL077885] Funding Source: NIH RePORTER	The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to 9 regional clinical centers and 1 Data Coordinating Center (5U01 HL077863-University of Washington Data Coordinating Center; HL077866-Medical College of Wisconsin; HL077867-University of Washington; HL077871-University of Pittsburgh; HL077872-St. Michael's Hospital; HL077873-Oregon Health and Science University; HL077881-University of Alabama at Birmingham; HL077885-Ottawa Hospital Research Institute; HL077887-University of Texas Southwestern Medical Center, Dallas; HL077908-University of California San Diego) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research & Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defense Research and Development Canada and the Heart, Stroke Foundation of Canada, and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the National Institutes of Health. The authors declare no conflicts of interest.	American College of Surgeons, 2006, RES OPT CAR INJ PAT; Arbabi S, 2005, J TRAUMA, V59, P815, DOI 10.1097/01.ta.0000188390.80199.37; Bennett KM, 2011, J SURG RES, V167, P19, DOI 10.1016/j.jss.2010.05.020; Bochicchio GV, 2008, SURG INFECT, V9, P415, DOI 10.1089/sur.2006.069; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bukur M, 2012, AM SURGEON, V78, P36; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Claridge JA, 2000, J TRAUMA, V48, P8, DOI 10.1097/00005373-200001000-00003; Clement RC, 2013, J NEUROSURG, V118, P687, DOI 10.3171/2012.10.JNS12682; Cole E, 2014, J TRAUMA ACUTE CARE, V76, P730, DOI 10.1097/TA.0b013e31829fdbd7; Cole E, 2013, J TRAUMA ACUTE CARE, V74, P51, DOI 10.1097/TA.0b013e3182788b0f; Croce MA, 2005, J TRAUMA, V59, P19, DOI 10.1097/01.TA.0000171459.21450.DC; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Cuschieri J, 2012, ANN SURG, V255, P993, DOI 10.1097/SLA.0b013e31824f1ebc; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Freeman Jenny, 2006, J Health Serv Res Policy, V11, P101, DOI 10.1258/135581906776318857; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Harbrecht BG, 2007, J TRAUMA, V63, P703, DOI 10.1097/TA.0b013e31811eadea; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marx WH, 2011, J TRAUMA, V71, P339, DOI 10.1097/TA.0b013e3182214055; Matsushima K, 2014, JAMA SURG, V149, P319, DOI 10.1001/jamasurg.2013.4834; Minei JP, 2012, CRIT CARE MED, V40, P1129, DOI 10.1097/CCM.0b013e3182376e9f; Minei JP, 2010, ANN SURG, V252, P149, DOI 10.1097/SLA.0b013e3181df0401; Nathens AB, 2005, J TRAUMA, V59, P764, DOI 10.1097/01.ta.0000177759.17704.35; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Pandya SR, 2011, J TRAUMA, V70, P1326, DOI 10.1097/TA.0b013e31820e327c; Pasquali SK, 2013, ANN THORAC SURG, V95, P197, DOI 10.1016/j.athoracsur.2012.08.074; Richardson JD, 1998, J TRAUMA, V44, P266, DOI 10.1097/00005373-199802000-00004; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sava J, 2003, J TRAUMA, V54, P829, DOI 10.1097/01.TA.0000063002.12062.21; Simon R, 2009, J TRAUMA, V67, P645, DOI 10.1097/TA.0b013e31818cae0c; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tepas JJ, 2013, J TRAUMA ACUTE CARE, V74, P143, DOI 10.1097/TA.0b013e3182788b5a; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; Yaghoubian A, 2008, AM SURGEON, V74, P930	40	40	40	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	SEP	2014	260	3					456	465		10.1097/SLA.0000000000000873			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AO2SJ	WOS:000341175600006	25115421	Green Accepted			2022-02-06	
J	Si, DW; Li, J; Liu, J; Wang, XY; Wei, ZF; Tian, QY; Wang, HT; Liu, G				Si, Daowen; Li, Juan; Liu, Jiang; Wang, Xiaoyin; Wei, Zifeng; Tian, Qingyou; Wang, Haitao; Liu, Gang			Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						progesterone; traumatic brain injury; blood-brain barrier; neurological function	SEX STEROID-HORMONES; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; ALLOPREGNANOLONE; EXPRESSION; EDEMA; CONTUSION; DAMAGE; CELLS; TRIAL	Inflammatory responses are associated with blood-brain barrier (BBB) dysfunction and neurological deficits following traumatic brain injury (TB!). The aim of the present study was to investigate the effects of progesterone on the expression of the inflammatory mediators prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF kappa B) and tumor necrosis factor-alpha (TNF-alpha) in the brain, BBB permeability, cerebral edema and neurological outcome, as well as to explore the mechanism of its neuroprotective effect. In this study, male rats were randomly divided into three groups: a sham-operated group (SHAM), a TBI group (TBI) and a progesterone treatment group (TBI-PROG). The TBI model was established using a modified Feeney's weight-dropping method. Brain samples were extracted 24 h following injury. The expression levels of COX-2 and NF-kappa B were examined using immunohistochemistry, whilst the expression levels of PGE2 and TNF-alpha were detected by enzyme-linked immuno-sorbent assay. BBB permeability was analyzed using Evans blue and cerebral edema was determined using the dry-wet method. The neurological outcome was evaluated using the modified neurological severity score test. The results revealed that progesterone treatment significantly reduced post-injury inflammatory response, brain edema and Evans blue dye extravasation, and improved neurological scores compared with those in the TBI group. In conclusion, the inhibition of inflammation may be an important mechanism by which progesterone protects the BBB and improves neurological outcome.	[Si, Daowen; Li, Juan; Liu, Jiang; Wei, Zifeng; Tian, Qingyou; Wang, Haitao] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Wang, Xiaoyin] Xinxiang Med Coll, Dept Biochem & Mol Biol, Xinxiang 453000, Henan, Peoples R China; [Liu, Gang] Hebei United Univ, Affiliated Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China		Liu, G (corresponding author), Hebei United Univ, Affiliated Hosp, Dept Neurosurg, 57 Jianshenan Rd, Tangshan 063000, Hebei, Peoples R China.	sidaowen@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201048]; Natural Science Foundation of Hebei Province, ChinaNatural Science Foundation of Hebei Province [H2012401009]	This study was supported by the National Natural Science Foundation of China (81201048) and the Natural Science Foundation of Hebei Province (H2012401009), China.	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Beaumont A, 2002, ACT NEUR S, V81, P217; Buccellati C, 1998, NEUROSCI LETT, V257, P123, DOI 10.1016/S0304-3940(98)00745-9; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Knoferl MW, 2001, SHOCK, V16, P479, DOI 10.1097/00024382-200116060-00013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; McIntosh TK, 1996, LAB INVEST, V74, P315; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; Wang XY, 2013, EXP THER MED, V6, P263, DOI 10.3892/etm.2013.1116; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	30	40	47	1	18	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	SEP	2014	8	3					1010	1014		10.3892/etm.2014.1840			5	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	AN8KZ	WOS:000340854400056	25120639	Green Published, Green Submitted, gold			2022-02-06	
J	Deer, TR; Mekhail, N; Petersen, E; Krames, E; Staats, P; Pope, J; Saweris, Y; Lad, SP; Diwan, S; Falowski, S; Feler, C; Slavin, K; Narouze, S; Merabet, L; Buvanendran, A; Fregni, F; Wellington, J; Levy, RM				Deer, Timothy R.; Mekhail, Nagy; Petersen, Erika; Krames, Elliot; Staats, Peter; Pope, Jason; Saweris, Youssef; Lad, Shivanand P.; Diwan, Sudhir; Falowski, Steven; Feler, Claudio; Slavin, Konstantin; Narouze, Samer; Merabet, Lotfi; Buvanendran, Asokumar; Fregni, Felipe; Wellington, Joshua; Levy, Robert M.			The Appropriate Use of Neurostimulation: Stimulation of the Intracranial and Extracranial Space and Head for Chronic Pain	NEUROMODULATION			English	Article						Cranial nerve stimulation; deep brain stimulation; migraine; motor cortex stimulation; neurostimulation; occipital nerve stimulation; peripheral nerve stimulation; trigeminal nerve stimulation; vagal nerve stimulation	OCCIPITAL NERVE-STIMULATION; MOTOR-CORTEX-STIMULATION; DEEP BRAIN-STIMULATION; SPINAL-CORD STIMULATION; CHRONIC CLUSTER HEADACHE; TERM-FOLLOW-UP; DORSAL-ROOT GANGLION; LOW-BACK-PAIN; SUBCUTANEOUS FIELD STIMULATION; CHRONIC NEUROPATHIC PAIN	Introduction: The International Neuromodulation Society (INS) has identified a need for evaluation and analysis of the practice of neurostimulation of the brain and extracranial nerves of the head to treat chronic pain. Methods: The INS board of directors chose an expert panel, the Neuromodulation Appropriateness Consensus Committee (NACC), to evaluate the peer-reviewed literature, current research, and clinical experience and to give guidance for the appropriate use of these methods. The literature searches involved key word searches in PubMed, EMBASE, and Google Scholar dated 1970-2013, which were graded and evaluated by the authors. Results: The NACC found that evidence supports extracranial stimulation for facial pain, migraine, and scalp pain but is limited for intracranial neuromodulation. High cervical spinal cord stimulation is an evolving option for facial pain. Intracranial neurostimulation may be an excellent option to treat diseases of the nervous system, such as tremor and Parkinson's disease, and in the future, potentially Alzheimer's disease and traumatic brain injury, but current use of intracranial stimulation for pain should be seen as investigational. Conclusions: The NACC concludes that extracranial nerve stimulation should be considered in the algorithmic treatment of migraine and other disorders of the head. We should strive to perfect targets outside the cranium when treating pain, if at all possible.	[Deer, Timothy R.; Pope, Jason] Ctr Pain Relief, Charleston, WV 25301 USA; [Mekhail, Nagy; Saweris, Youssef] Cleveland Clin, Evidence Based Pain Management Res & Educ, Cleveland, OH 44106 USA; [Petersen, Erika] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Krames, Elliot] Pacific Pain Treatment Ctr, San Francisco, CA USA; [Staats, Peter] Premier Pain Management Ctr, Shrewsbury, NJ USA; [Staats, Peter] Johns Hopkins Univ, Baltimore, MD USA; [Lad, Shivanand P.] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA; [Diwan, Sudhir] Lenox Hill Hosp, Manhattan Spine & Pain Med, New York, NY 10021 USA; [Falowski, Steven] St Lukes Neurosurg Associates, Bethlehem, PA USA; [Feler, Claudio] Univ Tennessee, Memphis, TN USA; [Feler, Claudio] Valley View Hosp, Glenwood Springs, CO USA; [Slavin, Konstantin] Univ Illinois, Chicago, IL USA; [Narouze, Samer] Summa Western Reserve Hosp, Cuyahoga Falls, OH USA; [Merabet, Lotfi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA; [Merabet, Lotfi] Harvard Univ, Schepens Eye Res Inst, Sch Med, Boston, MA USA; [Buvanendran, Asokumar] Rush Univ, Dept Anesthesia, Med Ctr, Chicago, IL 60612 USA; [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA; [Wellington, Joshua] Indiana Univ, Pain Med Ctr, Indianapolis, IN 46204 USA; [Levy, Robert M.] Univ Florida, Coll Med, Jacksonville, FL USA		Deer, TR (corresponding author), Ctr Pain Relief, 400 Court St,Ste 100, Charleston, WV 25301 USA.	doctdeer@aol.com	Slavin, Konstantin/H-3269-2019; merabet, lotfi/AAU-8259-2020; Merabet, Lotfi B./V-2735-2017	Slavin, Konstantin/0000-0002-7946-8639; merabet, lotfi/0000-0002-8094-9536; Merabet, Lotfi B./0000-0002-8094-9536; Petersen, Erika/0000-0002-8548-1450; Fregni, Felipe/0000-0001-9359-8643	International Neuromodulation Society; Medtronic Inc.Medtronic; St. Jude Medical Inc.St. Jude Medical; Boston Scientific Corp.Boston Scientific; Nevro Corp.; Spinal Modulation Inc.	This project was supported by the International Neuromodulation Society and was partially funded by a series of unrestricted educational grants from Medtronic Inc., St. Jude Medical Inc., Boston Scientific Corp., Nevro Corp., and Spinal Modulation Inc. No corporate entities had any direct input into the contents of this manuscript, or the conclusions of the collaborators.	Abejon D, 2009, NEUROMODULATION, V12, P1, DOI 10.1111/j.1525-1403.2009.00192.x; Acar F, 2008, STEREOT FUNCT NEUROS, V86, P106, DOI 10.1159/000113872; Aderjan D, 2010, PAIN, V151, P97, DOI 10.1016/j.pain.2010.06.024; Amin S, 2008, CEPHALALGIA, V28, P355, DOI 10.1111/j.1468-2982.2008.01535.x; Ansarinia M, 2010, HEADACHE, V50, P1164, DOI 10.1111/j.1526-4610.2010.01661.x; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; ANTHONY M, 1992, CLIN NEUROL NEUROSUR, V94, P297, DOI 10.1016/0303-8467(92)90177-5; Asensio-Samper Juan M, 2008, Pain Pract, V8, P120, DOI 10.1111/j.1533-2500.2007.00165.x; Bajbouj M, 2010, J CLIN PSYCHOPHARM, V30, P273, DOI 10.1097/JCP.0b013e3181db8831; BAROLAT G, 1993, J NEUROSURG, V78, P233, DOI 10.3171/jns.1993.78.2.0233; Barolat Giancarlo, 1993, Stereotactic and Functional Neurosurgery, V61, P60, DOI 10.1159/000100624; Bartsch T, 2009, CURR OPIN NEUROL, V22, P262, DOI 10.1097/WCO.0b013e32832ae61e; Beltrutti Diego, 2004, Pain Pract, V4, P204, DOI 10.1111/j.1533-2500.2004.04305.x; Bernard E J Jr, 1987, Br J Neurosurg, V1, P81, DOI 10.3109/02688698709034343; Beving H, 1996, BLOOD COAGUL FIBRIN, V7, P80, DOI 10.1097/00001721-199601000-00010; Bittar RG, 2005, J CLIN NEUROSCI, V12, P12, DOI 10.1016/j.jocn.2004.03.025; Boccard SGJ, 2013, NEUROSURGERY, V72, P221, DOI 10.1227/NEU.0b013e31827b97d6; Broggi G, 2009, NEUROL SCI, V30, pS75, DOI 10.1007/s10072-009-0082-2; Broggi G, 2010, NEUROL SCI, V31, P87, DOI 10.1007/s10072-010-0293-6; Brown JA, 2005, NEUROSURGERY, V56, P290, DOI 10.1227/01.neu.0000148905.75845.98; Bullard DE, 1997, STEREOT FUNCT NEUROS, V68, P168, DOI 10.1159/000099918; Burgher AH, 2012, NEUROMODULATION, V15, P100, DOI 10.1111/j.1525-1403.2011.00388.x; Burkey AR, 2010, PAIN MED, V11, P127, DOI 10.1111/j.1526-4637.2009.00764.x; Burns B, 2008, LANCET NEUROL, V7, P1001, DOI 10.1016/S1474-4422(08)70217-5; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Burns B, 2009, NEUROLOGY, V72, P341, DOI 10.1212/01.wnl.0000341279.17344.c9; Campbell CM, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-012-0307-6; Carroll D, 2000, PAIN, V84, P431, DOI 10.1016/S0304-3959(99)00245-6; Cecchini AP, 2009, NEUROL SCI, V30, pS101, DOI 10.1007/s10072-009-0073-3; Chiou RJ, 2013, BRAIN RES, V18, P756; Cianchetti C, 2012, CEPHALALGIA, V32, P778, DOI 10.1177/0333102412449930; Coffey RJ, 2001, PAIN MED, V2, P183, DOI 10.1046/j.1526-4637.2001.01029.x; CRUE BL, 1956, NEUROLOGY, V6, P196, DOI 10.1212/WNL.6.3.196; de Louw AJA, 2001, EUR J PAIN-LONDON, V5, P169; Deer T, 2008, PAIN MED, V9, pS82, DOI 10.1111/j.1526-4637.2008.00443.x; Deer Timothy R., 2011, ATLAS IMPLANTABLE TH; Deer TR, 2014, NEUROMODULA IN PRESS; Deshpande KK, 2011, PAIN PHYSICIAN, V14, P37; Dieckhofer A, 2006, CLIN NEUROPHYSIOL, V117, P2221, DOI 10.1016/j.clinph.2006.07.136; DIECKMANN G, 1982, APPL NEUROPHYSIOL, V45, P167; Doleys Daniel M, 2006, Neurosurg Focus, V21, pE1; Drummond PD, 2008, CEPHALALGIA, V28, P782, DOI 10.1111/j.1468-2982.2008.01575.x; Dunteman E, 2002, NEUROMODULATION, V5, P32, DOI 10.1046/j.1525-1403.2002._2006.x; Ebel H, 1996, ACTA NEUROCHIR, V138, P1300, DOI 10.1007/BF01411059; Eglen RM, 1999, TRENDS PHARMACOL SCI, V20, P337, DOI 10.1016/S0165-6147(99)01372-3; Erdine S., 2007, TECH REG ANEST PAIN, V11, P63; Fahy BG, 2010, J CLIN ANESTH, V22, P213, DOI 10.1016/j.jclinane.2009.10.002; Falco FJE, 2009, PAIN PHYSICIAN, V12, P965; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Ghaemi K, 2008, STEREOT FUNCT NEUROS, V86, P391, DOI 10.1159/000175802; Gharabaghi A, 2005, NEUROSURGERY, V57, P114, DOI 10.1227/01.NEU.0000164385.42652.9E; Goadsby P, 2013, AM AC NEUR 65 ANN M; Goadsby PJ, 2006, CEPHALALGIA, V26, P1168, DOI 10.1111/j.1468-2982.2006.01173.x; Goadsby PJ, 2008, HEADACHE, V48, P313, DOI 10.1111/j.1526-4610.2007.01022.x; Goadsby PJ, 2013, CEPHALALGIA, V33, P214, DOI 10.1177/0333102412468680; Goadsby PJ, 1997, J ANAT, V190, P367, DOI 10.1046/j.1469-7580.1997.19030367.x; Green AL, 2003, J CLIN NEUROSCI, V10, P512, DOI 10.1016/S0967-5868(03)00088-2; Green MW, 2003, HEADACHE, V43, P479, DOI 10.1046/j.1526-4610.2003.03093.x; Hamani C, 2006, PAIN, V125, P188, DOI 10.1016/j.pain.2006.05.019; Hammer M, 2001, NEUROMODULATION, V4, P47, DOI 10.1046/j.1525-1403.2001.00047.x; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hasegawa T, 1996, SPINE, V21, P1005, DOI 10.1097/00007632-199605010-00001; HASEGAWA T, 1993, SEMIN ULTRASOUND CT, V14, P404, DOI 10.1016/S0887-2171(05)80034-4; Hayek SM, 2009, PAIN PHYSICIAN, V12, P867; Holsheimer J, 1998, NEUROMODULATION, V1, P129, DOI 10.1111/j.1525-1403.1998.tb00006.x; Hord ED, 2003, J PAIN, V4, P530, DOI 10.1016/j.jpain.2003.08.001; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; HOSOBUCHI Y, 1973, ARCH NEUROL-CHICAGO, V29, P158, DOI 10.1001/archneur.1973.00490270040005; HOSOBUCHI Y, 1986, J NEUROSURG, V64, P543, DOI 10.3171/jns.1986.64.4.0543; Hosobuchi Y, 1993, Adv Neurol, V63, P215; HOSOBUCHI Y, 1987, PACE, V10, P213, DOI 10.1111/j.1540-8159.1987.tb05951.x; Hosobuchi Y, 1974, J NEUROSURG, V41, P740, DOI [DOI 10.3171/JNS.1974.41.6.0740, 10.3171/jns.1974.41.6.0740]; Jasper JF, 2008, PAIN PHYSICIAN, V11, P187; Nguyen JP, 2011, NAT REV NEUROL, V7, P699, DOI 10.1038/nrneurol.2011.138; Jenkins B, 2011, HEADACHE, V51, P1254, DOI 10.1111/j.1526-4610.2011.01966.x; Johnson MD, 2004, NEUROSURGERY, V55, P135, DOI 10.1227/01.NEU.0000126874.08468.89; Johnstone CSH, 2006, NEUROMODULATION, V9, P41, DOI 10.1111/j.1525-1403.2006.00041.x; Kapural L, 2005, ANESTH ANALG, V101, P171, DOI 10.1213/01.ANE.0000156207.73396.8E; Katayama Y, 1998, J NEUROSURG, V89, P585, DOI 10.3171/jns.1998.89.4.0585; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Kotsis SV, 2013, PLAST RECONSTR SURG, V131, P1194, DOI 10.1097/PRS.0b013e318287a0b3; Krames E, 2009, NEUROMODULATION, V12, P104, DOI 10.1111/j.1525-1403.2009.00197.x; Krames ES, 2011, NEUROMODULATION, V14, P299, DOI 10.1111/j.1525-1403.2011.00373.x; Kumar K, 2006, NEUROSURGERY, V58, P481, DOI 10.1227/01.NEU.0000192162.99567.96; Kumar K, 1998, SURG NEUROL, V50, P110, DOI 10.1016/S0090-3019(98)00012-3; KUMAR K, 1990, NEUROSURGERY, V26, P774, DOI 10.1227/00006123-199005000-00007; Leone M, 2004, CEPHALALGIA, V24, P934, DOI 10.1111/j.1468-2982.2004.00742.x; Leone M, 2003, NEUROL SCI, V24, pS143; LEVY RM, 1987, NEUROSURGERY, V21, P885, DOI 10.1227/00006123-198712000-00017; Levy R, 2010, PAIN PHYSICIAN, V13, P157; Liem L, 2013, NEUROMODULATION, V16, P471, DOI 10.1111/ner.12072; Lord SM, 1996, NEW ENGL J MED, V335, P1721, DOI 10.1056/NEJM199612053352302; Luedtke K, 2012, CLIN J PAIN, V28, P452, DOI 10.1097/AJP.0b013e31823853e3; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; Manchikanti L, 2000, Pain Physician, V3, P374; Manola L, 2005, MED BIOL ENG COMPUT, V43, P335, DOI 10.1007/BF02345810; Matharu MS, 2004, BRAIN, V127, P220, DOI 10.1093/brain/awh022; Matsunaga K, 2004, CLIN NEUROPHYSIOL, V115, P456, DOI 10.1016/S1388-2457(03)00362-6; Mauskop A, 2005, CEPHALALGIA, V25, P82, DOI 10.1111/j.1468-2982.2005.00611.x; McAuley J, 2013, NEUROMODULATION, V16, P530, DOI 10.1111/j.1525-1403.2012.00513.x; Medtronic Neurologic, MRI GUID; Melvin Eugene A Jr, 2007, Pain Physician, V10, P453; MEYERSON BA, 1993, ACTA NEUROCHIR, P150; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Mironer YE, 2011, NEUROMODULATION, V14, P151, DOI 10.1111/j.1525-1403.2010.00316.x; Monn MF, 2013, J SURG EDUC, V70, P180, DOI 10.1016/j.jsurg.2012.11.006; Muller PA, 2012, BRAIN STIMUL, V5, P320, DOI 10.1016/j.brs.2011.05.003; Narouze S, 2009, PAIN MED, V10, P221; Narouze S., 2009, TECH REG ANESTH PAIN, V13, P198; NASH TP, 1986, PAIN, V24, P67, DOI 10.1016/0304-3959(86)90027-8; Navarro RM, 2012, NEUROMODULATION, V15, P124, DOI 10.1111/j.1525-1403.2011.00422.x; Nesbitt A, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-S1-P230; Nesbitt AD, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-S1-P231; Neuman SA, 2011, CLIN J PAIN, V27, P556, DOI 10.1097/AJP.0b013e31820d276d; Nguyen JP, 2003, PAIN RES CL, V15, P197; Nguyen JP, 1997, ADV STER F, V12, P54; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; North RB, 2006, NEUROMODULATION, V9, P56, DOI 10.1111/j.1525-1403.2006.00043.x; Nuti C, 2005, PAIN, V118, P43, DOI 10.1016/j.pain.2005.07.020; Oh MY, 2004, NEUROMODULATION, V7, P103, DOI 10.1111/j.1094-7159.2004.04014.x; Oluigbo CO, 2011, PROG NEUROL SURG, V24, P171, DOI 10.1159/000323049; Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x; Oshinsky ML, 2012, HEADACHE, V52, P1336, DOI 10.1111/j.1526-4610.2012.02247.x; Owen SLF, 2007, ACTA NEUROCHIR SUPPL, V97, P111; Paulus W, 2004, CLIN NEUROPHYSIOL, V57, P708, DOI DOI 10.1016/S1567-424X(09)70411-8; Pereira Erlick A C, 2013, Handb Clin Neurol, V116, P277, DOI 10.1016/B978-0-444-53497-2.00023-1; Perryman L, 2013, 11 WORLD C INT NEUR; Pirotte B, 2008, NEUROSURGERY, V62, P941, DOI [10.1227/01.NEU.0000144837.31665.29, 10.1227/01.neu.0000333762.38500.ac]; PLOTKIN R, 1982, APPL NEUROPHYSIOL, V45, P173; Plow EB, 2012, J PAIN, V13, P411, DOI 10.1016/j.jpain.2012.02.001; Popeney CA, 2003, HEADACHE, V43, P369, DOI 10.1046/j.1526-4610.2003.03072.x; Rainov NG, 1997, CLIN NEUROL NEUROSUR, V99, P205, DOI 10.1016/S0303-8467(97)00017-6; Rapoport AM, 2013, 11 WORLD C INT NEUR; Rasche Dirk, 2006, Neurosurg Focus, V21, pE8; Ray C D, 1980, Acta Neurochir Suppl (Wien), V30, P289; Reed KL, 2010, CEPHALALGIA, V30, P260, DOI 10.1111/j.1468-2982.2009.01996.x; Richardson W. S., 2000, EVIDENCE BASED MED P, V2nd; Rodrigo-Royo MD, 2005, NEUROMODULATION, V8, P241, DOI 10.1111/j.1525-1403.2005.00032.x; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sadler RM, 2002, CEPHALALGIA, V22, P482, DOI 10.1046/j.1468-2982.2002.00387.x; Saitoh Y, 2001, Neurosurg Focus, V11, pE1; Saitoh Y, 2003, ACTA NEUROCHIR SUPPL, V87, P149; Saitoh Y, 2000, J NEUROSURG, V92, P150, DOI 10.3171/jns.2000.92.1.0150; Sandwell Stephen E, 2011, Surg Neurol Int, V2, P128, DOI 10.4103/2152-7806.85467; Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Schwedt TJ, 2007, CEPHALALGIA, V27, P153, DOI 10.1111/j.1468-2982.2007.01272.x; Schwedt TJ, 2006, CEPHALALGIA, V26, P1025, DOI 10.1111/j.1468-2982.2006.01142.x; Serra G, 2012, PAIN PHYSICIAN, V15, P245; Sharan AD, 2003, NEUROSURG CLIN N AM, V14, P437, DOI 10.1016/S1042-3680(03)00014-7; Sheng SR, 2010, EUR SPINE J, V19, P46, DOI 10.1007/s00586-009-1192-5; Silberstein S, 2008, CEPHALALGIA, V28, P484, DOI 10.1111/j.1468-2982.2008.01555.x; Silberstein SD, 2012, CEPHALALGIA, V32, P1165, DOI 10.1177/0333102412462642; Simopoulos T, 2010, HEADACHE, V50, P1064, DOI 10.1111/j.1526-4610.2010.01694.x; Sjoqvist O, 1939, Yale J Biol Med, V11, P593; Slavin KV, 2006, NEUROSURGERY, V58, P112, DOI 10.1227/01.NEU.0000192163.55428.62; Slavin KV, 2005, NEUROMODULATION, V8, P7, DOI 10.1111/j.1094-7159.2005.05215.x; Smith H, 2001, Neurosurg Focus, V11, pE2; Sol JC, 2001, STEREOT FUNCT NEUROS, V77, P172, DOI 10.1159/000064616; Son BC, 2003, J NEUROSURG, V98, P175, DOI 10.3171/jns.2003.98.1.0175; Sparkes E, 2012, CHRONIC ILLN, V8, P239, DOI 10.1177/1742395311433132; Sparkes E, 2010, PAIN, V150, P284, DOI 10.1016/j.pain.2010.05.001; Taha JM, 1996, NEUROSURGERY, V38, P865, DOI 10.1097/00006123-199605000-00001; Tani N, 2004, J NEUROSURG, V101, P687, DOI 10.3171/jns.2004.101.4.0687; Taub E, 1997, J NEUROSURG, V86, P197, DOI 10.3171/jns.1997.86.2.0197; Tomycz ND, 2011, HEADACHE, V51, P418, DOI 10.1111/j.1526-4610.2010.01829.x; Trentman TL, 2008, HEADACHE, V48, P319, DOI 10.1111/j.1526-4610.2007.01023.x; Trentman TL, 2008, PAIN PHYSICIAN, V11, P253; Trescher WH, 2008, NEUROLOGY CLIN PRACT; Tsubokawa T, 1991, Acta Neurochir Suppl (Wien), V52, P137; TSUBOKAWA T, 1991, PACE, V14, P131, DOI 10.1111/j.1540-8159.1991.tb04058.x; Vad VB, 2002, SPINE, V27, P11, DOI 10.1097/00007632-200201010-00005; Vaisman J, 2012, NEUROMODULATION, V15, P374, DOI 10.1111/j.1525-1403.2012.00455.x; Van Zundert J, 2007, PAIN, V127, P173, DOI 10.1016/j.pain.2006.09.002; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Weiner RL, 1999, NEUROMODULATION, V2, P217, DOI 10.1046/j.1525-1403.1999.00217.x; Yakovlev AE, 2010, NEUROMODULATION, V13, P137, DOI 10.1111/j.1525-1403.2009.00249.x; Young RF, 1996, NEUROSURGERY CHRONIC	185	40	41	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	AUG	2014	17	6					551	570		10.1111/ner.12215			20	Medicine, Research & Experimental; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	AN3PK	WOS:000340500200004	25112890				2022-02-06	
J	Weiner, MW; Veitch, DP; Hayes, J; Neylan, T; Grafman, J; Aisen, PS; Petersen, RC; Jack, C; Jagust, W; Trojanowski, JQ; Shaw, LM; Saykin, AJ; Green, RC; Harvey, D; Toga, AW; Friedl, KE; Pacifico, A; Sheline, Y; Yaffe, K; Mohlenoff, B				Weiner, Michael W.; Veitch, Dallas P.; Hayes, Jacqueline; Neylan, Thomas; Grafman, Jordan; Aisen, Paul S.; Petersen, Ronald C.; Jack, Clifford; Jagust, William; Trojanowski, John Q.; Shaw, Leslie M.; Saykin, Andrew J.; Green, Robert C.; Harvey, Danielle; Toga, Arthur W.; Friedl, Karl E.; Pacifico, Anthony; Sheline, Yvette; Yaffe, Kristine; Mohlenoff, Brian		Dept Def Alzheimer's Dis	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative	ALZHEIMERS & DEMENTIA			English	Article						Traumatic brain injury; Posttraumatic stress disorder; Alzheimer's disease; Veterans; Neuroimaging	AMYLOID PROTEIN DEPOSITION; MILD COGNITIVE IMPAIRMENT; ADDICTION SEVERITY INDEX; HEAD-INJURY; APOLIPOPROTEIN-E; CEREBROSPINAL-FLUID; BIOMARKER SIGNATURE; N-ACETYLASPARTATE; FLORBETAPIR F-18; TERM SURVIVORS	Both traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are common problems resulting from military service, and both have been associated with increased risk of cognitive decline and dementia resulting from Alzheimer's disease (AD) or other causes. This study aims to use imaging techniques and biomarker analysis to determine whether traumatic brain injury (TBI) and/or PTSD resulting from combat or other traumas increase the risk for AD and decrease cognitive reserve in Veteran subjects, after accounting for age. Using military and Department of Veterans Affairs records, 65 Vietnam War veterans with a history of moderate or severe TBI with or without PTSD, 65 with ongoing PTSD without TBI, and 65 control subjects are being enrolled in this study at 19 sites. The study aims to select subject groups that are comparable in age, gender, ethnicity, and education. Subjects with mild cognitive impairment (MCI) or dementia are being excluded. However, a new study just beginning, and similar in size, will study subjects with TBI, subjects with PTSD, and control subjects with MCI. Baseline measurements of cognition, function, blood, and cerebrospinal fluid biomarkers; magnetic resonance images (structural, diffusion tensor, and resting state blood-level oxygen dependent (BOLD) functional magnetic resonance imaging); and amyloid positron emission tomographic (PET) images with florbetapir are being obtained. One-year follow-up measurements will be collected for most of the baseline procedures, with the exception of the lumbar puncture, the PET imaging, and apolipoprotein E genotyping. To date, 19 subjects with TBI only, 46 with PTSD only, and 15 with TBI and PTSD have been recruited and referred to 13 clinics to undergo the study protocol. It is expected that cohorts will be fully recruited by October 2014. This study is a first step toward the design and statistical powering of an AD prevention trial using at-risk veterans as subjects, and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans. (C) 2014 Published by Elsevier Inc. on behalf of The Alzheimer's Association.	[Weiner, Michael W.; Veitch, Dallas P.; Hayes, Jacqueline] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Weiner, Michael W.; Neylan, Thomas; Yaffe, Kristine; Mohlenoff, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Weiner, Michael W.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA; [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Jack, Clifford] Mayo Clin, Dept Radiol, Rochester, MN USA; [Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Udall Parkinsons Res Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Shaw, Leslie M.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Harvey, Danielle] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA; [Toga, Arthur W.] Univ So Calif, Inst Neuroimaging & Informat, Lab Neuroimaging, Los Angeles, CA USA; [Pacifico, Anthony] US Army Med Res & Mat Command, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Sheline, Yvette] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA		Weiner, MW (corresponding author), Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94143 USA.	michael.weiner@ucsf.edu	Friedl, Karl/M-1803-2019; Harvey, Danielle/A-5496-2017; Jagust, William/ABE-6426-2020; Jack, Clifford R/F-2508-2010; Saykin, Andrew/A-1318-2007	Friedl, Karl/0000-0002-3134-8427; Jack, Clifford R/0000-0001-7916-622X; Saykin, Andrew/0000-0002-1376-8532; Veitch, Dallas/0000-0002-9918-0640	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); DODUnited States Department of Defense [W81XWH-12-2-0012]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH060482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, U24AG021886, U19AG010483] Funding Source: NIH RePORTER	ADNI is funded by the National Institute on Aging and National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Avid Radiopharmaceuticals, Inc; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization for ADNI is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI DOD data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. We thank all the veterans for their generous participation in this ADNI DOD study. This research was also supported by DOD award number W81XWH-12-2-0012.	Ahmadi N, 2011, AM J CARDIOL, V108, P29, DOI 10.1016/j.amjcard.2011.02.340; Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Bilbul M, 2011, CAN J NEUROL SCI, V38, P580, DOI 10.1017/S0317167100012129; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Derogatis L. R., 1994, USE PSYCHOL TESTING, P217; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; ELASHOFF JD, 2000, NQUERY ADVISOR VERSI; Farias ST, 2008, NEUROPSYCHOLOGY, V22, P531, DOI 10.1037/0894-4105.22.4.531; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Forsberg A, 2008, NEUROBIOL AGING, V29, P1456, DOI 10.1016/j.neurobiolaging.2007.03.029; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Furst AJ, 2012, NEUROBIOL AGING, V33, P215, DOI 10.1016/j.neurobiolaging.2010.03.011; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Institute NC, 2011, DICT CANC TERMS PACK; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c; Jagust WJ, 2010, ALZHEIMERS DEMENT, V6, P221, DOI 10.1016/j.jalz.2010.03.003; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kaplan E, 1983, BOSTON NAMING TEST; Katzman R, 1996, NEUROLOGY, V46, P889; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Kessler R. B., 1995, ARCH GEN PSYCHIAT, V5, P1048, DOI DOI 10.1001/ARCHPSYC.1995.03950240066012; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lister-James J, 2011, SEMIN NUCL MED, V41, P300, DOI 10.1053/j.semnuclmed.2011.03.001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mattsson N, 2011, ALZHEIMERS DEMENT, V7, P386, DOI 10.1016/j.jalz.2011.05.2243; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCFALL ME, 1991, J NERV MENT DIS, V179, P33, DOI 10.1097/00005053-199101000-00007; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Nasreddine ZS, 2003, CAN J NEUROL SCI, V30, P30; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Okamura N, 2010, IDRUGS, V13, P890; Olsson A, 2005, CLIN CHEM, V51, P336, DOI 10.1373/clinchem.2004.039347; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Pfeffer RI, 1982, GERONTOLOGY, V37, P323, DOI DOI 10.1093/GER0NJ/37.3.323; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007; Salloway S, 2011, ARCH NEUROL-CHICAGO, V68, P19, DOI 10.1001/archneurol.2010.344; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Samuelson KW, 2009, J INT NEUROPSYCH SOC, V15, P853, DOI 10.1017/S1355617709990282; Saykin AJ, 2010, ALZHEIMERS DEMENT, V6, P265, DOI 10.1016/j.jalz.2010.03.013; Schoenborn CA, 2003, SERIES 10 DATA NATL, V214, P1; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Schuff N, 1997, ANN NY ACAD SCI, V821, P516, DOI 10.1111/j.1749-6632.1997.tb48319.x; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shaw LM, 2008, NEUROSIGNALS, V16, P19, DOI 10.1159/000109755; Shaw LM, 2011, ACTA NEUROPATHOL, V121, P597, DOI 10.1007/s00401-011-0808-0; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Shen L, 2010, NEUROIMAGE, V53, P1051, DOI 10.1016/j.neuroimage.2010.01.042; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith TC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-69; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Subramanian SV, 2006, AM J EPIDEMIOL, V164, P823, DOI 10.1093/aje/kwj313; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wechsler D, 1987, MEMORY SCALE REVISED; Weiner Michael W, 2013, Alzheimers Dement, V9, pe111, DOI [10.1016/j.jalz.2011.09.172, 10.1016/j.jalz.2013.05.1769]; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Williams John W, 2010, Evid Rep Technol Assess (Full Rep), P1; Wolk DA, 2009, ANN NEUROL, V65, P557, DOI 10.1002/ana.21598; Wong DF, 2010, J NUCL MED, V51, P913, DOI 10.2967/jnumed.109.069088; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yehuda R, 2007, NEURON, V56, P19, DOI 10.1016/j.neuron.2007.09.006	114	40	42	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S226	S235		10.1016/j.jalz.2014.04.005			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP8GM	WOS:000360130700016	24924673	Green Published, Green Accepted, hybrid			2022-02-06	
J	Lesniak, M; Polanowska, K; Seniow, J; Czlonkowska, A				Lesniak, Marcin; Polanowska, Katarzyna; Seniow, Joanna; Czlonkowska, Anna			Effects of Repeated Anodal tDCS Coupled With Cognitive Training for Patients With Severe Traumatic Brain Injury: A Pilot Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; transcranial direct current stimulation; traumatic brain injury	DIRECT-CURRENT STIMULATION; TRANSCRANIAL DC-STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; PRIMARY MOTOR CORTEX; WORKING-MEMORY; HEALTHY-INDIVIDUALS; PARKINSONS-DISEASE; STROKE PATIENTS; EXCITABILITY; REHABILITATION	Objective: To determine whether cumulative anodal transcranial direct current stimulation (A-tDCS) of the left dorsolateral prefrontal cortex (DLPFC) could enhance rehabilitation of memory and attention in patients with traumatic brain injury (TBI). Setting: Inpatient and outpatient neurorehabilitation unit. Participants: Twenty-three adult patients, 4- to 92- months post severe TBI. Design: Participants were randomly allocated to 2 groups. The experimental group received A-tDCS (10 minutes; 1 mA; in the DLPFC), followed by rehabilitative cognitive training, daily for 15 days. Controls received A-tDCS for 25 seconds (sham condition) with the same rehabilitation. Main Measures: Battery of memory and attention tests, which included visual and auditory modalities. Participants were tested twice before beginning rehabilitation (to control for spontaneous recovery), after rehabilitation completion, and 4 months later. Results: Tests scores in both groups were similar at 3 weeks before and immediately before treatment. After treatment, the experimental group exhibited larger effect sizes in 6 of 8 cognitive outcome measures, but they were not significantly different from controls. At follow-up, differences remained insignificant. Conclusion: In contrast to previous studies, our study did not provide sufficient evidence to support the efficacy of repeated A-tDCS for enhancing rehabilitation of memory and attention in patients after severe TBI.	[Lesniak, Marcin; Polanowska, Katarzyna; Seniow, Joanna; Czlonkowska, Anna] Inst Psychiat & Neurol, Dept Neurol 2, PL-02957 Warsaw, Poland; [Czlonkowska, Anna] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland		Lesniak, M (corresponding author), Inst Psychiat & Neurol, Dept Neurol 2, 9 Sobieskiego St, PL-02957 Warsaw, Poland.	lesniak@ipin.edu.pl	LUO, JINGJING/AAZ-6697-2021	LUO, JINGJING/0000-0002-3222-1276; Lesniak, Marcin/0000-0001-9924-9620; Polanowska, Katarzyna/0000-0002-8410-9884; Czlonkowska, Anna/0000-0002-1956-1866; Seniow, Joanna Seniow/0000-0002-1017-4819	Polish National Science Centre grant [1611/B/P01/2009/37]	The study was supported by Polish National Science Centre grant no. 1611/B/P01/2009/37.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andrews SC, 2011, BRAIN STIMUL, V4, P84, DOI 10.1016/j.brs.2010.06.004; Backhaus S, 2011, ENCY CLIN NEUROPSYCH; Barnes M, 2006, TXB NEURAL REPAIR RE; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; Berryhill ME, 2012, NEUROSCI LETT, V521, P148, DOI 10.1016/j.neulet.2012.05.074; Berryhill ME, 2010, NEUROSCI LETT, V479, P312, DOI 10.1016/j.neulet.2010.05.087; Blumenfeld RS, 2011, J COGNITIVE NEUROSCI, V23, P257, DOI 10.1162/jocn.2010.21459; Boggio PS, 2009, J NEUROL NEUROSUR PS, V80, P444, DOI 10.1136/jnnp.2007.141853; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Chi RP, 2010, BRAIN RES, V1353, P168, DOI 10.1016/j.brainres.2010.07.062; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Forn C, 2011, J CLIN EXP NEUROPSYC, V33, P42, DOI 10.1080/13803395.2010.481620; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fridriksson J, 2011, STROKE, V42, P819, DOI 10.1161/STROKEAHA.110.600288; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gigi A, 2010, J NEUROIMAGING, V20, P163, DOI 10.1111/j.1552-6569.2009.00386.x; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hammer A, 2011, BMC NEUROSC, V12; Israel SL, 2010, J COGNITIVE NEUROSCI, V22, P513, DOI 10.1162/jocn.2009.21198; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kessler SK, 2012, BRAIN STIMUL, V5, P155, DOI 10.1016/j.brs.2011.02.007; Khedr EM, 2006, MOVEMENT DISORD, V21, P2201, DOI 10.1002/mds.21089; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lang N, 2011, J NEUROPHYSIOL, V105, P2802, DOI 10.1152/jn.00617.2010; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Penolazzi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010623; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Stagg CJ, 2011, NEUROPSYCHOLOGIA, V49, P800, DOI 10.1016/j.neuropsychologia.2011.02.009; Tanaka S, 2011, NEUROREHAB NEURAL RE, V25, P565, DOI 10.1177/1545968311402091; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Vallar G, 2011, NEUROPSYCHOL REHABIL, V21, P618, DOI 10.1080/09602011.2011.574050; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Wang L, 2010, J COGNITIVE NEUROSCI, V22, P543, DOI 10.1162/jocn.2009.21210; Wilson B, 2009, MEMORY REHABILITATIO; Wise EK, 2010, ARCH PHYS MED REHAB, V91, P1357, DOI 10.1016/j.apmr.2010.06.009	52	40	41	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					E20	E29		10.1097/HTR.0b013e318292a4c2			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100003	23756431				2022-02-06	
J	Kirkwood, MW; Peterson, RL; Connery, AK; Baker, DA; Grubenhoff, JA				Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.; Grubenhoff, Joseph A.			Postconcussive Symptom Exaggeration After Pediatric Mild Traumatic Brain Injury	PEDIATRICS			English	Article						mild TBI; concussion; postconcussive symptoms; postconcussion syndrome; symptom exaggeration; feigning; neuropsychological; validity testing; pediatrics	POST-CONCUSSIVE SYMPTOMS; VALIDITY TEST FAILURE; HEAD-INJURY; TEST-PERFORMANCE; NEUROPSYCHOLOGICAL TESTS; NEUROCOGNITIVE OUTCOMES; MILITARY SAMPLE; CASE SERIES; CHILDREN; METAANALYSIS	BACKGROUND: A minority of pediatric patients who have mild traumatic brain injury (mTBI) report persistent postconcussive symptoms. In adults, failure on validity tests, which help to detect exaggerated or feigned problems, is associated with symptom complaints. No pediatric studies have examined the relationship between validity test performance and symptom report. We hypothesized that children failing a validity test would report significantly more postconcussive symptoms than those passing. METHODS: Using a consecutive clinical case series design, we examined 191 patients aged 8 to 17 years seen for neuropsychological evaluation after mTBI. Participants were administered a validity test (Medical Symptom Validity Test; MSVT) and completed a graded symptom scale as part of a neuropsychological battery. RESULTS: A total of 23 participants (12%) failed the MSVT. The Fail group endorsed significantly more postconcussive symptoms than the Pass group, with a large effect size (P < .001; d = 1.1). MSVT performance remained a robust unique predictor of symptom report even after controlling for other influential factors (eg, female gender, premorbid psychiatric problems). CONCLUSIONS: A subset of children who had persistent complaints after mTBI may be exaggerating or feigning symptoms. If such negative response bias remains undetected, errors in etiologic statements and less than optimal treatment may occur. Because the detection of invalid responding is well established in neuropsychology, clinical neuropsychologists should be incorporated routinely into clinical care for patients who have persistent complaints. To better control for noninjury effects in future pediatric mTBI studies, researchers should add validity tests to neurobehavioral outcome batteries.	[Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Grubenhoff, Joseph A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Grubenhoff, Joseph A.] Childrens Hosp Colorado, Aurora, CO 80045 USA		Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Concuss Program, B285,13123 East 16th Ave, Aurora, CO 80045 USA.	michael.kirkwood@childrenscolorado.org	Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064			Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BIJUR PE, 1990, PEDIATRICS, V86, P337; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz M, 2011, APPL NEUROPSYCHOL, V18, P143, DOI 10.1080/09084282.2011.570619; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Conti RP, 2004, PSYCHOL REP, V94, P987; DeRight J, 2015, CHILD NEUROPSYCHOL, V21, P1, DOI 10.1080/09297049.2013.864383; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Flaro L, 2007, PEDIAT FORENSIC NEUR, P139; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2011, J PERS ASSESS, V93, P508, DOI 10.1080/00223891.2011.594132; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P, 2001, NEUROREHABILITATION, V16, P231; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2004, MANUAL MED SYMPTOM V; Green P, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P201, DOI 10.1007/978-1-4614-0442-2_6; GREENFELD D, 1987, HOSP COMMUNITY PSYCH, V38, P73; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kirkwood M. W, 2012, PEDIAT FORENSIC NEUR, P136; Kirkwood MW, 2014, CHILD NEUROPSYCHOL, V20, P245, DOI 10.1080/09297049.2012.759553; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Libow JA, 2000, PEDIATRICS, V105, P336, DOI 10.1542/peds.105.2.336; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stutts JT, 2003, J DEV BEHAV PEDIATR, V24, P276, DOI 10.1097/00004703-200308000-00009; Sweet JJ, 2013, J EXP PSYCHOPATHOL, V4, P6, DOI 10.5127/jep.022311; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vu JA, 2011, EXCEPT CHILDREN, V77, P263, DOI 10.1177/001440291107700301; Wechsler D., 2011, WECHSLER ABBREVIATED; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates K. O., 2012, MILD TRAUMATIC BRAIN, P124; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	75	40	40	0	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2014	133	4					643	650		10.1542/peds.2013-3195			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	AG3TU	WOS:000335343500011	24616360				2022-02-06	
J	Huang, BR; Chang, PC; Yeh, WL; Lee, CH; Tsai, CF; Lin, CJ; Lin, HY; Liu, YS; Wu, CYJ; Ko, PY; Huang, SS; Hsu, HC; Lu, DY				Huang, Bor-Ren; Chang, Pei-Chun; Yeh, Wei-Lan; Lee, Chih-Hao; Tsai, Cheng-Fang; Lin, Chingju; Lin, Hsiao-Yun; Liu, Yu-Shu; Wu, Caren Yu-Ju; Ko, Pei-Ying; Huang, Shiang-Suo; Hsu, Horng-Chaung; Lu, Dah-Yuu			Anti-Neuroinflammatory Effects of the Calcium Channel Blocker Nicardipine on Microglial Cells: Implications for Neuroprotection	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; FACTOR-KAPPA-B; SIGNALING PATHWAY; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE	Background/Objective: Nicardipine is a calcium channel blocker that has been widely used to control blood pressure in severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage. However, accumulating evidence suggests that inflammatory processes in the central nervous system that are mediated by microglial activation play important roles in neurodegeneration, and the effect of nicardipine on microglial activation remains unresolved. Methodology/Principal Findings: In the present study, using murine BV-2 microglia, we demonstrated that nicardipine significantly inhibits microglia-related neuroinflammatory responses. Treatment with nicardipine inhibited microglial cell migration. Nicardipine also significantly inhibited LPS plus IFN-gamma-induced release of nitric oxide (NO), and the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Furthermore, nicardipine also inhibited microglial activation by peptidoglycan, the major component of the Gram-positive bacterium cell wall. Notably, nicardipine also showed significant anti-neuroinflammatory effects on microglial activation in mice in vivo. Conclusion/Significance: The present study is the first to report a novel inhibitory role of nicardipine on neuroinflammation and provides a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases.	[Huang, Bor-Ren; Hsu, Horng-Chaung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Huang, Bor-Ren] Taichung Tzu Chi Hosp, Neurosurg Dept, Buddhist Tzu Chi Med Fdn, Taichung, Taiwan; [Huang, Bor-Ren] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chang, Pei-Chun] Asia Univ, Dept Bioinformat, Taichung, Taiwan; [Yeh, Wei-Lan] Changhua Christian Hosp, Dept Cell & Tissue Engn, Changhua, Taiwan; [Lee, Chih-Hao] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Tsai, Cheng-Fang] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Lin, Chingju] China Med Univ, Sch Med, Dept Physiol, Taichung, Taiwan; [Lin, Hsiao-Yun] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Liu, Yu-Shu; Wu, Caren Yu-Ju] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Ko, Pei-Ying] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Huang, Shiang-Suo] Chung Shan Med Univ, Dept Pharmacol, Coll Med, Taichung, Taiwan; [Huang, Shiang-Suo] Chung Shan Med Univ, Inst Med, Coll Med, Taichung, Taiwan; [Hsu, Horng-Chaung] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan; [Lu, Dah-Yuu] China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan		Lu, DY (corresponding author), China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan.	dahyuu@mail.cmu.edu.tw	Lu, Dah-Yuu/P-2563-2015		National Science CouncilMinistry of Science and Technology, Taiwan [NSC 101-2320-B-039-048-MY2, NSC 102-2320-B-039-051-MY3, NSC 102-2320-B-039-026-MY3]; Taichung Tzu Chi Hospital; Buddhist Tzu Chi Medical Foundation [TTCRD 101-03]; China Medical UniversityChina Medical University [CMU101-ASIA-10]; Asia University [99-A-01]	This work was supported by grants from the National Science Council (NSC 101-2320-B-039-048-MY2, NSC 102-2320-B-039-051-MY3 and NSC 102-2320-B-039-026-MY3), Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TTCRD 101-03), China Medical University (CMU101-ASIA-10), and Asia University (99-A-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amenta F, 2004, CLIN EXP HYPERTENS, V26, P351, DOI 10.1081/CEH-120034139; Amenta F, 1996, J HYPERTENS, V14, pS29, DOI 10.1097/00004872-199610003-00006; Amenta F, 2008, CLIN EXP HYPERTENS, V30, P808, DOI 10.1080/10641960802580190; Babu CS, 2011, INT J DEV NEUROSCI, V29, P93, DOI 10.1016/j.ijdevneu.2010.08.001; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Casamassima F, 2010, AM J MED GENET B, V153B, P1373, DOI 10.1002/ajmg.b.31122; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; Chen JH, 2012, INT IMMUNOPHARMACOL, V12, P94, DOI 10.1016/j.intimp.2011.10.019; Chen JH, 2011, J CELL BIOCHEM, V112, P2931, DOI 10.1002/jcb.23209; Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989; Degoute CS, 2007, DRUGS, V67, P1053, DOI 10.2165/00003495-200767070-00007; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Gasior M, 1996, J NEURAL TRANSM, V103, P819, DOI 10.1007/BF01273360; Gianino John W, 2012, Mo Med, V109, P384; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; Hashioka S, 2012, NEUROPHARMACOLOGY, V63, P685, DOI 10.1016/j.neuropharm.2012.05.033; Hayashi M, 2000, HYPERTENS RES, V23, P521, DOI 10.1291/hypres.23.521; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Huang BR, 2013, TOXICOL APPL PHARM, V269, P43, DOI 10.1016/j.taap.2013.03.004; Huang SM, 2011, J CELL BIOCHEM, V112, P643, DOI 10.1002/jcb.22966; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Kim Sang Yong, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P84, DOI 10.7461/jcen.2012.14.2.84; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Koizumi S, 2002, LIFE SCI, V72, P431, DOI 10.1016/S0024-3205(02)02273-7; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Komagiri Y, 2011, CELL CALCIUM, V49, P35, DOI 10.1016/j.ceca.2010.11.006; Leung YM, 2013, BIOMEDICINE-TAIWAN, V3, P130, DOI 10.1016/j.biomed.2012.11.003; Leung YM, 2011, BIOMEDICINE-TAIWAN, V1, P16, DOI 10.1016/j.biomed.2011.10.003; Liang X, 2007, J MOL NEUROSCI, V33, P94, DOI 10.1007/s12031-007-0058-8; Lin C, 2013, NEUROSCIENCE, V231, P216, DOI 10.1016/j.neuroscience.2012.11.051; Lin HY, 2014, NEUROBIOL AGING, V35, P191, DOI 10.1016/j.neurobiolaging.2013.06.020; Lin HY, 2011, J CELL PHYSIOL, V226, P1573, DOI 10.1002/jcp.22489; Lin HY, 2010, INT IMMUNOPHARMACOL, V10, P883, DOI 10.1016/j.intimp.2010.04.026; Liu YX, 2011, NEUROPHARMACOLOGY, V60, P373, DOI 10.1016/j.neuropharm.2010.10.002; Loihl AK, 1998, PROG BRAIN RES, V118, P253; Lu DY, 2007, BRIT J PHARMACOL, V151, P396, DOI 10.1038/sj.bjp.0707187; Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038; Lu DY, 2013, INT J NEUROPSYCHOPH, V16, P433, DOI 10.1017/S1461145712000338; Lu DY, 2012, NEURO-ONCOLOGY, V14, P1367, DOI 10.1093/neuonc/nos262; Lu DY, 2010, BIOCHEM PHARMACOL, V80, P1201, DOI 10.1016/j.bcp.2010.06.046; Lu DY, 2010, J CELL BIOCHEM, V110, P697, DOI 10.1002/jcb.22580; Lu DY, 2009, EUR J PHARMACOL, V613, P146, DOI 10.1016/j.ejphar.2009.03.001; Maa MC, 2013, BIOMEDICINE-TAIWAN, V3, P1, DOI 10.1016/j.biomed.2012.12.006; Matsui T, 2010, BIOCHEM BIOPH RES CO, V396, P566, DOI 10.1016/j.bbrc.2010.04.149; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Mikami C, 2001, CEREBROVASC DIS, V11, P44, DOI 10.1159/000047610; Narotam PK, 2008, J NEUROSURG, V109, P1065, DOI 10.3171/JNS.2008.109.12.1065; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Qureshi AI, 2011, NEUROCRIT CARE, V15, P559, DOI 10.1007/s12028-011-9538-3; Qureshi AI, 2006, CRIT CARE MED, V34, P1975, DOI 10.1097/01.CCM.0000220763.85974.E8; Qureshi Ai, 2012, J Vasc Interv Neurol, V5, P6; Rasmuson S., 2011, INT PSYCHOGERIATR, V18, P1; Saijonmaa Outi, 1997, Blood Pressure, V6, P24, DOI 10.3109/08037059709086442; Sanz JM, 2012, BRIT J PHARMACOL, V167, P1702, DOI 10.1111/j.1476-5381.2012.02112.x; Sato Shoichiro, 2012, Rinsho Shinkeigaku, V52, P642; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schut Ewout S, 2008, Pract Neurol, V8, P8, DOI 10.1136/jnnp.2007.139725; Su PY, 2013, BIOMEDICINE-TAIWAN, V3, P181, DOI 10.1016/j.biomed.2013.08.001; Tejada JG, 2007, AM J NEURORADIOL, V28, P844; Triggle DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI 10.1016/j.bcp.2007.01.016; Tsai CF, 2012, INT J MOL SCI, V13, P9877, DOI 10.3390/ijms13089877; Uslu S, 2012, NEUROCHEM RES, V37, P1554, DOI 10.1007/s11064-012-0750-0; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Yermakova A, 2000, CURR PHARM DESIGN, V6, P1755, DOI 10.2174/1381612003398672; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; Zhang XL, 2012, J INT MED RES, V40, P1036, DOI 10.1177/147323001204000322; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	76	40	44	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e91167	10.1371/journal.pone.0091167			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	WOS:000332845300055	24621589	gold, Green Published, Green Submitted			2022-02-06	
J	Bahraini, NH; Breshears, RE; Hernandez, TD; Schneider, AL; Forster, JE; Brenner, LA				Bahraini, Nazanin H.; Breshears, Ryan E.; Hernandez, Theresa D.; Schneider, Alexandra L.; Forster, Jeri E.; Brenner, Lisa A.			Traumatic Brain Injury and Posttraumatic Stress Disorder	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Brain injury; Posttraumatic stress; Imaging; Pathophysiology; Evaluation; Treatment	1ST 6 MONTHS; COMBAT VETERANS; ENDURING FREEDOM; HEAD-INJURY; AXIS-I; PSYCHIATRIC-DISORDERS; SERVICE MEMBERS; SOCIAL SUPPORT; RISK-FACTORS; PTSD	Given the upsurge of research in posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI), much of which has focused on military samples who served in Iraq and Afghanistan, the purpose of this article is to review the literature published after September 11th, 2001 that addresses the epidemiology, pathophysiology, evaluation, and treatment of PTSD in the context of TBI.	[Bahraini, Nazanin H.; Hernandez, Theresa D.; Schneider, Alexandra L.; Forster, Jeri E.; Brenner, Lisa A.] VISN, MIRECC 19, Dept Vet Affairs, Denver, CO 80220 USA; [Bahraini, Nazanin H.; Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA; [Breshears, Ryan E.] Wellstar Hlth Syst, Psychol Serv, Marietta, GA 30060 USA; [Breshears, Ryan E.] Univ Georgia, Dept Counseling & Human Dev, Athens, GA 30602 USA; [Hernandez, Theresa D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Forster, Jeri E.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO 80045 USA		Bahraini, NH (corresponding author), VISN, MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA.	nazanin.bahraini@va.gov	Brenner, Lisa A./AAG-2442-2019				American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Amstadter AB, 2009, PSYCHIATRY, V72, P360, DOI 10.1521/psyc.2009.72.4.360; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bahraini NH, 2009, MIL MED, V174, P1005, DOI 10.7205/MILMED-D-00-9509; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Briere J., 1995, TRAUMA SYMPTOM INVEN; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Department of Veterans Affairs and Department of Defense, 2010, VA DOD CLIN PRACT GU; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M, 2010, TRAUMATIC BRAIN INJU; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Jovanovic T, 2010, AM J PSYCHIAT, V167, P648, DOI 10.1176/appi.ajp.2009.09071074; KEANE TM, 1985, J CONSULT CLIN PSYCH, V53, P95, DOI 10.1037/0022-006X.53.1.95; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Ragsdale KA, 2013, J ANXIETY DISORD, V27, P420, DOI 10.1016/j.janxdis.2013.04.003; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; RAND Center for Military Health Policy Research, 2008, INVISIBLE WOUNDS WAR; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Raskind MA, 2013, AM J PSYCHIAT, V170, P1003, DOI 10.1176/appi.ajp.2013.12081133; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schoenfeld FB, 2012, J REHABIL RES DEV, V49, P729, DOI 10.1682/JRRD.2011.09.0164; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Silver JM, 2012, AM J PSYCHIAT, V169, P1230, DOI 10.1176/appi.ajp.2012.12091230; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wei WH, 2005, ARCH PHYS MED REHAB, V86, P905, DOI 10.1016/j.apmr.2004.09.026; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313	102	40	40	1	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					55	+		10.1016/j.psc.2013.11.002			22	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	AD8UM	WOS:000333541200005	24529423				2022-02-06	
J	Hook, GR; Yu, J; Sipes, N; Pierschbacher, MD; Hook, V; Kindy, MS				Hook, Gregory R.; Yu, Jin; Sipes, Nancy; Pierschbacher, Michael D.; Hook, Vivian; Kindy, Mark S.			The Cysteine Protease Cathepsin B Is a Key Drug Target and Cysteine Protease Inhibitors Are Potential Therapeutics for Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cathepsin B; cysteine protease inhibitor; motor function; traumatic brain injury	CELL-FREE DNA; MITOCHONDRIAL-DNA; PREDICTIVE MARKER; RAT-BRAIN; DAMAGE; REPAIR; NUCLEAR; DEATH	There are currently no effective therapeutic agents for traumatic brain injury (TBI), but drug treatments for TBI can be developed by validation of new drug targets and demonstration that compounds directed to such targets are efficacious in TBI animal models using a clinically relevant route of drug administration. The cysteine protease, cathepsin B, has been implicated in mediating TBI, but it has not been validated by gene knockout (KO) studies. Therefore, this investigation evaluated mice with deletion of the cathepsin B gene receiving controlled cortical impact TBI trauma. Results indicated that KO of the cathepsin B gene resulted in amelioration of TBI, shown by significant improvement in motor dysfunction, reduced brain lesion volume, greater neuronal density in brain, and lack of increased proapoptotic Bax levels. Notably, oral administration of the small-molecule cysteine protease inhibitor, E64d, immediately after TBI resulted in recovery of TBI-mediated motor dysfunction and reduced the increase in cathepsin B activity induced by TBI. E64d outcomes were as effective as cathepsin B gene deletion for improving TBI. E64d treatment was effective even when administered 8h after injury, indicating a clinically plausible time period for acute therapeutic intervention. These data demonstrate that a cysteine protease inhibitor can be orally efficacious in a TBI animal model when administered at a clinically relevant time point post-trauma, and that E64d-mediated improvement of TBI is primarily the result of inhibition of cathepsin B activity. These results validate cathepsin B as a new TBI therapeutic target.	[Hook, Gregory R.; Sipes, Nancy; Pierschbacher, Michael D.] Amer Life Sci Pharmaceut, San Diego, CA USA; [Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Yu, Jin; Kindy, Mark S.] Appl Neurotechnol Inc, Charleston, SC USA; [Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA		Kindy, MS (corresponding author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA.	kindyms@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44AG032784, 5R01ES016774-02]; VA Merit ReviewUS Department of Veterans Affairs [1I01RX000331-01]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES016774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG032784] Funding Source: NIH RePORTER	The authors thank Christoph Peters, MD, of Albert Ludwig University (Freiburg, Germany) for providing the cathepsin B-deficient mice and Lawrence Marshall, MD, for reviewing the manuscript. This work was supported, in part, by NIH grants R44AG032784 (to American Life Science Pharmaceuticals; ALSP) and 5R01ES016774-02 (to M. S. K.) and VA Merit Review 1I01RX000331-01 (to M.S.K.).	Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Coppede F, 2009, CURR ALZHEIMER RES, V6, P36, DOI 10.2174/156720509787313970; Goldshtein H, 2009, ANN CLIN BIOCHEM, V46, P488, DOI 10.1258/acb.2009.009002; Jiang YL, 2008, CANCER RES, V68, P6425, DOI 10.1158/0008-5472.CAN-08-1173; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lan J, 2003, J CEREBR BLOOD F MET, V23, P1324, DOI 10.1097/01.WCB.0000091540.60196.F2; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li WJ, 2006, J CEREBR BLOOD F MET, V26, P181, DOI 10.1038/sj.jcbfm.9600180; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Martin LJ, 2010, PHARMACEUTICALS, V3, P839, DOI 10.3390/ph3040839; Ohayon S, 2012, J NEUROTRAUM, V29, P261, DOI 10.1089/neu.2011.1938; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Santos RX, 2012, FREE RADICAL RES, V46, P565, DOI 10.3109/10715762.2011.648188; Swarup V, 2011, DNA CELL BIOL, V30, P389, DOI 10.1089/dna.2010.1165; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028; Vasko MR, 2011, DNA REPAIR, V10, P942, DOI 10.1016/j.dnarep.2011.06.004; Wang J, 2005, J NEUROCHEM, V93, P953, DOI 10.1111/j.1471-4159.2005.03053.x; Wang JYJ, 2001, CELL DEATH DIFFER, V8, P1047, DOI 10.1038/sj.cdd.4400938; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Widyarini S, 2006, J VET SCI, V7, P217, DOI 10.4142/jvs.2006.7.3.217; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zhou BR, 2008, PHOTODERMATOL PHOTO, V24, P175, DOI 10.1111/j.1600-0781.2008.00356.x	31	40	40	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					515	529		10.1089/NEU.2013.2944			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600250	24083575	Green Published			2022-02-06	
J	Barbey, AK; Colom, R; Paul, E; Forbes, C; Krueger, F; Goldman, D; Grafman, J				Barbey, Aron K.; Colom, Roberto; Paul, Erick; Forbes, Chad; Krueger, Frank; Goldman, David; Grafman, Jordan			Preservation of General Intelligence following Traumatic Brain Injury: Contributions of the Met66 Brain-Derived Neurotrophic Factor	PLOS ONE			English	Article							BDNF VAL66MET POLYMORPHISM; ACTIVITY-DEPENDENT SECRETION; FAMILY-BASED ASSOCIATION; CARD SORTING TEST; ALZHEIMERS-DISEASE; NEURONAL DEVELOPMENT; RECEPTOR SORTILIN; BIPOLAR DISORDER; EPISODIC MEMORY; WORKING-MEMORY	Brain-derived neurotrophic factor (BDNF) promotes survival and synaptic plasticity in the human brain. The Val66Met polymorphism of the BDNF gene interferes with intracellular trafficking, packaging, and regulated secretion of this neurotrophin. The human prefrontal cortex (PFC) shows lifelong neuroplastic adaption implicating the Val66Met BDNF polymorphism in the recovery of higher-order executive functions after traumatic brain injury (TBI). In this study, we examined the effect of this BDNF polymorphism on the preservation of general intelligence following TBI. We genotyped a sample of male Vietnam combat veterans (n = 156) consisting of a frontal lobe lesion group with focal penetrating head injuries for the Val66Met BDNF polymorphism. Val/Met did not differ from Val/Val genotypes in general cognitive ability before TBI. However, we found substantial average differences between these groups in general intelligence (approximate to half a standard deviation or 8 IQ points), verbal comprehension (6 IQ points), perceptual organization (6 IQ points), working memory (8 IQ points), and processing speed (8 IQ points) after TBI. These results support the conclusion that Val/Met genotypes preserve general cognitive functioning, whereas Val/Val genotypes are largely susceptible to TBI.	[Barbey, Aron K.; Paul, Erick] Univ Illinois, Decis Neurosci Lab, Urbana, IL 61801 USA; [Barbey, Aron K.; Paul, Erick] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Barbey, Aron K.] Univ Illinois, Dept Internal Med, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Psychol, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Neurosci Program, Champaign, IL 61820 USA; [Colom, Roberto] Univ Autonoma Madrid, Fdn CIEN, Fdn Reina Sofia, Madrid, Spain; [Forbes, Chad] Univ Delaware, Dept Psychol, Delaware, MD USA; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA USA; [Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Traumat Brain Injury Res Lab, Chicago, IL 60611 USA		Barbey, AK (corresponding author), Univ Illinois, Decis Neurosci Lab, Urbana, IL 61801 USA.	barbey@illinois.edu; jgrafman@ric.edu	Barbey, Aron/L-7312-2015; Colom, Roberto/F-8779-2010; Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010	Barbey, Aron/0000-0002-6092-0912; Colom, Roberto/0000-0001-5865-163X; Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]; Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] [PSI2010-20364]; Universidad Autonoma de Madrid [CEMU-2012-004]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675). R. Colom was supported by grant PSI2010-20364 from Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] and and CEMU-2012-004 [Universidad Autonoma de Madrid]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Shawi R, 2008, EUR J NEUROSCI, V27, P2103, DOI 10.1111/j.1460-9568.2008.06152.x; Arbuckle J. L, 2006, AMOS VERSION 7 0 COM; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Barbey AK, 2012, CORTEX; Barbey AK, 2011, CEREB CORTEX, V21, P789, DOI 10.1093/cercor/bhq153; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beste C, 2010, NEUROSCIENCE, V166, P178, DOI 10.1016/j.neuroscience.2009.12.022; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Frustaci A, 2008, NEUROPSYCHOBIOLOGY, V58, P163, DOI 10.1159/000182892; Gratacos M, 2007, BIOL PSYCHIAT, V61, P911, DOI 10.1016/j.biopsych.2006.08.025; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Ho BC, 2007, AM J PSYCHIAT, V164, P1890, DOI 10.1176/appi.ajp.2007.05111903; Ho BC, 2006, ARCH GEN PSYCHIAT, V63, P731, DOI 10.1001/archpsyc.63.7.731; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Kunugi H, 2001, MOL PSYCHIATR, V6, P83, DOI 10.1038/sj.mp.4000792; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; Montag C, 2009, PSYCHOL MED, V39, P1831, DOI 10.1017/S0033291709005509; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Riemenschneider M, 2002, MOL PSYCHIATR, V7, P782, DOI 10.1038/sj.mp.4001073; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x; Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Ventriglia M, 2002, MOL PSYCHIATR, V7, P136, DOI 10.1038/sj.mp.4000952; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189	59	40	40	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2014	9	2							e88733	10.1371/journal.pone.0088733			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC3BC	WOS:000332389000017	24586380	gold, Green Submitted, Green Published			2022-02-06	
J	Kiechle, K; Bazarian, JJ; Merchant-Borna, K; Stoecklein, V; Rozen, E; Blyth, B; Huang, JH; Dayawansa, S; Kanz, K; Biberthaler, P				Kiechle, Karin; Bazarian, Jeffrey J.; Merchant-Borna, Kian; Stoecklein, Veit; Rozen, Eric; Blyth, Brian; Huang, Jason H.; Dayawansa, Samantha; Kanz, Karl; Biberthaler, Peter			Subject-Specific Increases in Serum S-100B Distinguish Sports-Related Concussion from Sports-Related Exertion	PLOS ONE			English	Article							NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; BIOCHEMICAL MARKERS; COMPUTED-TOMOGRAPHY; S100 PROTEINS; ELITE PLAYERS; DAMAGE S-100B; EPIDEMIOLOGY	Background: The on-field diagnosis of sports-related concussion (SRC) is complicated by the lack of an accurate and objective marker of brain injury. Purpose: To compare subject-specific changes in the astroglial protein, S100B, before and after SRC among collegiate and semi-professional contact sport athletes, and compare these changes to differences in S100B before and after non-contact exertion. Study Design: Longitudinal cohort study. Methods: From 2009-2011, we performed a prospective study of athletes from Munich, Germany, and Rochester, New York, USA. Serum S100B was measured in all SRC athletes at pre-season baseline, within 3 hours of injury, and at days 2, 3 and 7 post-SRC. Among a subset of athletes, S100B was measured after non-contact exertion but before injury. All samples were collected identically and analyzed using an automated electrochemiluminescent assay to quantify serum S100B levels. Results: Forty-six athletes (30 Munich, 16 Rochester) underwent baseline testing. Thirty underwent additional post-exertion S100B testing. Twenty-two athletes (16 Rochester, 6 Munich) sustained a SRC, and 17 had S100B testing within 3 hours post-injury. The mean 3-hour post-SRC S100B was significantly higher than pre-season baseline (0.099+/-0.008 mu g/L vs. 0.058+/-0.006 mu g/L, p = 0.0002). Mean post-exertion S100B was not significantly different than the preseason baseline. S100B levels at post-injury days 2, 3 and 7 were significantly lower than the 3-hour level, and not different than baseline. Both the absolute change and proportional increase in S100B 3-hour post-injury were accurate discriminators of SRC from non-contact exertion without SRC (AUC 0.772 and 0.904, respectively). A 3-hour post-concussion S100B >0.122 mu g/L and a proportional S100B increase of >45.9% over baseline were both 96.7% specific for SRC. Conclusions: Relative and absolute increases in serum S100B can accurately distinguish SRC from sports-related exertion, and may be a useful adjunct to the diagnosis of SRC.	[Kiechle, Karin; Kanz, Karl] Univ Munich, Dept Trauma Surg, Klinikum Univ Munchen, Munich, Germany; [Bazarian, Jeffrey J.; Merchant-Borna, Kian; Blyth, Brian] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Stoecklein, Veit] Univ Munich, Dept Neurosurg, Klinikum Univ Munchen, Munich, Germany; [Rozen, Eric] Univ Rochester, Dept Athlet & Recreat, Rochester, NY USA; [Huang, Jason H.; Dayawansa, Samantha] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Biberthaler, Peter] Tech Univ Munich, Dept Trauma Surg, D-80290 Munich, Germany		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24HD064754]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health grant K24HD064754. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bonham VL, 2010, NEW ENGL J MED, V363, P997, DOI 10.1056/NEJMp1007639; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FierceBiomarkers, 2012, A STARS I MICR SFC F; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pham N, 2010, PLOS ONE, V5, DOI DOI 10.1371/ANN0TATI0N/BDCB41F2-A320-4401-A6AB-86E71738597E].PL0S; Prevention CCfDC, 2007, MMWR-MORBID MORTAL W, V56, P733; Rickels E, 2011, UNFALLCHIRURG, V114, P417, DOI 10.1007/s00113-010-1872-y; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tang W, 2012, APPL CATEGORICAL COU; Towend W, 2006, J NEUROTRAUM, V23, P149; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	29	40	41	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e84977	10.1371/journal.pone.0084977			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291WL	WOS:000329862500199	24416325	gold, Green Published, Green Submitted			2022-02-06	
J	Andrewes, HE; Walker, V; O'Neill, B				Andrewes, H. E.; Walker, V.; O'Neill, B.			Exploring the use of positive psychology interventions in brain injury survivors with challenging behaviour	BRAIN INJURY			English	Article						Depression; positive psychology; traumatic brain injury; treatment	SELF-CONCEPT; NEUROPSYCHOLOGIC REHABILITATION; DEPRESSION; IDENTITY; THERAPY; ANXIETY	Objective: To investigate the feasibility and effectiveness of conducting two positive psychology interventions to improve mood and self-concept with survivors of traumatic brain injury (TBI), within a neuro-rehabilitation hospital. Method and procedures: Ten patients with brain injury were randomly allocated to an intervention and control group. The efficacy of the first intervention, `three positive things in life' was measured via Seligman's Authentic Happiness Index (AHI), at base-line, directly following the intervention and at the end of the 12-week group programme. The second intervention, the `Value in Action (VIA) signature strengths intervention' was measured by the Head Injury Semantic Differential Scale (HISDS) at baseline and at the end of the group. Results: Compared to baseline and control group scores, the AHI index showed an increase in the intervention group's happiness following the intervention and at the end of the 12-week programme, albeit the latter increase was non-significant. The HISDS showed non-significant improvement in self-concept and reduction in polarization of the self in the present, future and past in the second intervention. Anecdotal evidence revealed a clear improved mood following the interventions. Conclusion: This study shows promising results for the effectiveness of Positive Psychology interventions and methods to improve feasibility when applying this treatment within a hospital setting.	[Andrewes, H. E.; Walker, V.; O'Neill, B.] Brain Injury Rehabil Trust, Glasgow, Lanark, Scotland; [O'Neill, B.] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland		Andrewes, HE (corresponding author), Brain Injury Rehabil Trust, Graham Anderson House, Glasgow, Lanark, Scotland.	hollya@student.unimelb.edu.au					Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bateman A, 2013, NEUROPAGE INTRO; Ben-Yishay Y, 2008, NEUROPSYCHOL REHABIL, V18, P513, DOI 10.1080/09602010802141525; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Dewar BK, 2007, NEUROPSYCHOL REHABIL, V17, P602, DOI 10.1080/09602010601051610; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Evans JJ, 2013, BRAIN IMPAIR, V12, P117; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; Myles SS, 2007, INT J PSYCHOL PSYCHO, V4, P487; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Osgood C, 1957, MEASUREMENT MEANING, P77; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Peterson C., 2004, CHARACTER STRENGTHS; ROBINSON RG, 1985, PSYCHOSOMATICS, V26, P769, DOI 10.1016/S0033-3182(85)72790-9; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Schueller SM, 2010, J POSIT PSYCHOL, V5, P253, DOI 10.1080/17439761003794130; Seligman M., 2006, AUTHENTIC HAPPINESS; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Snaith R.P., 1994, ACTA PSYCHIAT SCAND, V67, P361; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Tyerman A, 1987, THESIS U LONDON; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	40	42	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					965	971		10.3109/02699052.2014.888764			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600011	24826958				2022-02-06	
J	Dinkel, J; Drier, A; Khalilzadeh, O; Perlbarg, V; Czernecki, V; Gupta, R; Gomas, F; Sanchez, P; Dormont, D; Galanaud, D; Stevens, RD; Puybasset, L				Dinkel, J.; Drier, A.; Khalilzadeh, O.; Perlbarg, V.; Czernecki, V.; Gupta, R.; Gomas, F.; Sanchez, P.; Dormont, D.; Galanaud, D.; Stevens, R. D.; Puybasset, L.		NICER Neuro Imaging Coma Emergence	Long-Term White Matter Changes after Severe Traumatic Brain Injury: A 5-Year Prospective	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							AXONAL INJURY; SPATIAL STATISTICS; DIFFUSION; NEUROPLASTICITY; MODERATE; TIME	The authors used DTI to study posttraumatic white matter changes over a 5-year period. Thirteen patients with severe injuries acutely showed significant fractional anisotropy decreases in the corpus callosum and corona radiata when compared with controls. These abnormalities progressed at 2 years and then remained stable until 5 years. The DTI abnormalities correlated with sequelae such as amnesia, aphasia, and dyspraxia. BACKGROUND AND PURPOSE: Extensive white matter damage has been documented in patients with severe traumatic brain injury, yet how this damage evolves in the long term is not well understood. We used DTI to study white matter changes at 5 years after traumatic brain injury. MATERIALS AND METHODS: There were 8 healthy control participants and 13 patients with severe traumatic brain injury who were enrolled in a prospective observational study, which included clinical assessment and brain MR imaging in the acute setting (< 6 weeks) and 2 years and 5 years after injury. Only subjects with mild to moderate disability or no disability at 1 year were included in this analysis. DTI parameters were measured in 20 different brain regions and were normalized to values obtained in an age-matched control group. RESULTS: In the acute setting, fractional anisotropy was significantly lower in the genu and body of the corpus callosum and in the bilateral corona radiata in patients compared with control participants, whereas radial diffusivity was significantly (P < .05) higher in these tracts. At 2 years, fractional anisotropy in these tracts had further decreased and radial diffusivity had increased. No significant changes were detected between 2 and 5 years after injury. The baseline radial diffusivity and fractional anisotropy values in the anterior aspect of the brain stem, genu and body of the corpus callosum, and the right and left corona radiata were significantly (P < .05) associated with neurocognitive sequelae (including amnesia, aphasia, and dyspraxia) at year 5. CONCLUSIONS: DTI changes in major white matter tracts persist up to 5 years after severe traumatic brain injury and are most pronounced in the corpus callosum and corona radiata. Limited structural change is noted in the interval between 2 and 5 years.	[Dinkel, J.; Khalilzadeh, O.; Gupta, R.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Dinkel, J.] Univ Heidelberg Hosp, Dept Radiol, Heidelberg, Germany; [Drier, A.; Dormont, D.; Galanaud, D.] Grp Hosp Pitie Salpetriere, AP HP, Dept Neuroradiol, Paris, France; [Czernecki, V.] Grp Hosp Pitie Salpetriere, AP HP, Dept Neurol, Paris, France; [Sanchez, P.; Puybasset, L.] Grp Hosp Pitie Salpetriere, AP HP, Dept Anesthesiol & Intens Care, Paris, France; [Perlbarg, V.] Univ Paris 06, INSERM, UMRS 678, F-75013 Paris, France; [Czernecki, V.] Univ Paris 06, INSERM, CRICM UMR S975, F-75013 Paris, France; [Gomas, F.] Louis Mourier Hosp, Dept Anesthesiol & Intens Care, Colombes, France; [Stevens, R. D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Div Neurosci Crit Care, Baltimore, MD USA		Puybasset, L (corresponding author), Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Anesthesie Reanimat, 47-83 Bd Hop, F-75013 Paris, France.	louis.puybasset@psl.aphp.fr			French Ministry of Health [P051061 [2005]]; Assistance Publique-Hopitaux de Paris	This study was funded by a grant from the French Ministry of Health (Projet Hospitalier de Recherche Clinique registration # P051061 [2005]) and from departmental funds from the Assistance Publique-Hopitaux de Paris.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mori S, 2005, MRI ATLAS HUMAN WHIT; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Young JA, 2011, AM J THER, V18, P70, DOI 10.1097/MJT.0b013e3181e0f1a4; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	30	40	41	0	5	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2014	35	1					23	29		10.3174/ajnr.A3616			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AD9ER	WOS:000333568100007	23846796	Green Submitted, Green Published, hybrid			2022-02-06	
J	Doti, N; Reuther, C; Scognamiglio, PL; Dolga, AM; Plesnila, N; Ruvo, M; Culmsee, C				Doti, N.; Reuther, C.; Scognamiglio, P. L.; Dolga, A. M.; Plesnila, N.; Ruvo, M.; Culmsee, C.			Inhibition of the AIF/CypA complex protects against intrinsic death pathways induced by oxidative stress	CELL DEATH & DISEASE			English	Article						AIF/CypA complex; mitochondria; neuronal death; oxidative stress; peptide inhibitor	NEURONAL CELL-DEATH; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYCLOPHILIN-A; NUCLEAR TRANSLOCATION; APOPTOSIS; AIF; MITOCHONDRIA; NEUROPROTECTION	Delayed neuronal cell death largely contributes to the progressive infarct development and associated functional impairments after cerebral ischemia or brain trauma. Previous studies exposed a key role for the interaction of the mitochondrial protein apoptosis-inducing factor (AIF) and cytosolic cyclophilin A (CypA) in pathways of programmed cell death in neurons in vitro and in vivo. These studies suggested that pro-apoptotic activities of AIF, such as its translocation to the nucleus and subsequent DNA degradation, depend on the physical interaction of AIF with CypA. Hence, this protein complex may represent a new pharmacological target for inhibiting the lethal action of AIF on the brain tissue. In this study, we show that the AIF amino-acid residues 370-394 mediate the protein complex formation of AIF with CypA. The synthetic AIF(370-394) peptide inhibited AIF/CypA complex formation in vitro by binding CypA with a K-D of 12 mu M. Further, the peptide exerted pronounced neuroprotective effects in a model of glutamate-induced oxidative stress in cultured HT-22 cells. In this model system of AIF-dependent cell death, the AIF(370-394) peptide preserved mitochondrial integrity, as detected by measurements of the mitochondrial membrane potential and quantification of mitochondrial fragmentation. Further, the AIF(370-394) peptide inhibited perinuclear accumulation of fragmented mitochondria, mitochondrial release of AIF to the nucleus and glutamate-induced cell death to a similar extent as CypA-siRNA. These data indicate that the targeting of the AIF-CypA axis is an effective strategy of neuroprotection.	[Doti, N.; Scognamiglio, P. L.; Ruvo, M.] CNR, IBB, CIRPEB, I-80134 Naples, Italy; [Doti, N.; Reuther, C.; Dolga, A. M.; Culmsee, C.] Univ Marburg, Inst Pharmacol & Clin Pharm, D-35032 Marburg, Germany; [Doti, N.; Plesnila, N.] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Plesnila, N.] Univ Munich, Sch Med, Inst Stroke & Dementia Res ISD, D-81377 Munich, Germany		Doti, N (corresponding author), CNR, IBB, CIRPEB, Via Mezzocannone 16, I-80134 Naples, Italy.	nunzianna.doti@cnr.it; nikolaus.plesnila@med.uni-muenchen.de; culmsee@staff.uni-marburg.de	Dolga, Amalia/C-9664-2018; Doti, Nunzianna/ABC-9948-2020; Plesnila, Nikolaus/T-7522-2019; Culmsee, Carsten/ABC-3120-2021; Scognamiglio, Pasqualina Liana/X-9429-2019	Culmsee, Carsten/0000-0002-5121-5015; Scognamiglio, Pasqualina Liana/0000-0002-1444-8039; Dolga, Amalia/0000-0001-5400-5614	National Biophotonics and Imaging Platform Ireland (NBIPI); career enhancement and mobility programme (CEMP); Irish Higher Education Authority (HEA); FIRB MERITMinistry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB) [RBNE08NKH7]; PROGETTO CAMPUS from Campania Region	We thank Alexander Seiler (Roche Diagnostics GmbH) for providing the xCELLigence system, Dr. Julia Grohm and Mrs. Katharina Elsasser for the excellent technical support. Furthermore, we thank Mrs. Emma Esser for careful editing of the manuscript. This work has been supported by 'The National Biophotonics and Imaging Platform Ireland (NBIPI), career enhancement and mobility programme (CEMP) a Marie Curie co-funded scheme with the Irish Higher Education Authority (HEA) Program for Third Level Institutions Cycle 4 and the Italian National Research Council'. The project was also partly supported by FIRB MERIT project no. RBNE08NKH7 and 'PROGETTO CAMPUS' from Campania Region to MR.	Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Diemert S, 2012, J NEUROSCI METH, V203, P69, DOI 10.1016/j.jneumeth.2011.09.012; Dolga AM, 2012, GLIA, V60, P2050, DOI 10.1002/glia.22419; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fukui M, 2009, EUR J PHARMACOL, V617, P1, DOI 10.1016/j.ejphar.2009.06.059; Goldner FM, 1996, J COMP NEUROL, V372, P283; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; Grohm J, 2010, BRAIN BEHAV IMMUN, V24, P831, DOI 10.1016/j.bbi.2009.11.015; Guo XW, 2012, J BIOPHOTONICS, V5, P483, DOI 10.1002/jbio.201200015; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hangen E, 2010, TRENDS BIOCHEM SCI, V35, P278, DOI 10.1016/j.tibs.2009.12.008; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Myszka DG, 2004, ANAL BIOCHEM, V329, P316, DOI 10.1016/j.ab.2004.03.028; Pallast S, 2010, J CEREBR BLOOD F MET, V30, P1157, DOI 10.1038/jcbfm.2009.281; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Sevrioukova IF, 2011, ANTIOXID REDOX SIGN, V14, P2545, DOI 10.1089/ars.2010.3445; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thal SE, 2011, NEUROSCI LETT, V499, P1, DOI 10.1016/j.neulet.2011.05.016; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Tremper-Wells B, 2005, J BIOL CHEM, V280, P2165, DOI 10.1074/jbc.M410591200; Utkina-Sosunova IV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062448; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; xler EM, 2012, APOPTOSIS, V17, P1027; Xu JM, 2013, MICROSC RES TECHNIQ, V76, P612, DOI 10.1002/jemt.22207; Yu SW, 2009, ASN NEURO, V1, DOI 10.1042/AN20090046; Zhang XC, 2013, FEBS LETT, V587, P666, DOI 10.1016/j.febslet.2013.01.028; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193	42	40	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	JAN	2014	5								e993	10.1038/cddis.2013.518			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AC0YZ	WOS:000332222700017	24434516	gold, Green Published			2022-02-06	
J	Frith, M; Togher, L; Ferguson, A; Levick, W; Docking, K				Frith, Matthew; Togher, Leanne; Ferguson, Alison; Levick, Wayne; Docking, Kimberley			Assessment practices of speech-language pathologists for cognitive communication disorders following traumatic brain injury in adults: An international survey	BRAIN INJURY			English	Article						Assessment; cognitive; language; survey	CLINICAL NEUROPSYCHOLOGISTS; DISCOURSE; APHASIA; MANAGEMENT; DEFICITS; SCALE; MTBI	Primary objective: This study's objective was to examine the current assessment practices of SLPs working with adults with acquired cognitive communication impairments following a TBI. Methods and procedures: Two hundred and sixty-five SLPs from the UK, the US, Canada, Australia and New Zealand responded to the online survey stating the areas of communication frequently assessed and the assessment tools they use. Main outcomes and results: SLPs reported that they routinely assessed functional communication (78.8%), whereas domains such as discourse were routinely assessed by less than half of the group (44.3%). Clinicians used aphasia and cognitive communication/high level language tools and tools assessing functional performance, discourse, pragmatic skills or informal assessments were used by less than 10% of the group. The country and setting of service delivery influenced choice of assessment tools used in clinical practice. Conclusions: These findings have implications for training of SLPs in a more diverse range of assessment tools for this clinical group. The findings raise questions regarding the statistical validity and reliability of assessments currently used in clinical practice. It highlights the need for further research into how SLPs can be supported in translating current evidence about the use of assessment tools into clinical practice.	[Frith, Matthew] Hunter New England Local Hlth Dist, Kaleidoscope Children Young People & Families, Sydney, NSW, Australia; [Frith, Matthew; Togher, Leanne; Docking, Kimberley] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Frith, Matthew; Togher, Leanne; Docking, Kimberley] NHMRC Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Ferguson, Alison] Univ Newcastle, Sch Humanities & Social Sci, Newcastle, NSW 2300, Australia; [Levick, Wayne] Univ Newcastle, Sch Psychol, Newcastle, NSW 2300, Australia		Frith, M (corresponding author), Kaleidoscope, HNE LHD POB 2563 Dangar, Dangar, NSW 2309, Australia.	matthew.frith@hnehealth.nsw.gov.au	Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748; Docking, Kimberley/0000-0001-9996-7235			Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Speech-Language-Hearing Association, 2003, EV TREAT COMM COGN D; Bernicot J, 2001, INT J LANG COMM DIS, V36, P245; Blais Jean-Guy, 2011, J Appl Meas, V12, P370; Blyth T, 2012, BRAIN INJURY, V26, P234, DOI 10.3109/02699052.2012.654587; Bowers L, 2005, WORLD TEST; Christie J, 1986, MOUNT WILGA HIGH LEV; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; College of Audiologists and Speech-Language Pathologists of Ontario, 2002, PREF PRACT GUID COGN; Douglas J, 2000, TROBE COMMUNICATION; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Ellmo W, 1995, MEASURE COGNITIVE LI; Ellmo W, 1997, J NEW JERSEY SPEECH, V6, P17; Frank EM, 1996, J MED SPEECH-LANG PA, V4, P81; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Helm-Estabrooks N., 2001, COGNITIVE LINGUISTIC; Hofmans J, 2009, QUAL QUANT, V43, P703, DOI 10.1007/s11135-007-9154-7; Holland A., 1999, COMMUNICATION ACTIVI; Howard D, 2004, COMPREHENSIVE APHASI; HOWELL DC, 1995, FUNDAMENTAL STAT BEH; Hughes J, 2007, CAN J SPEECH-LANG PA, V31, P134; Isaki E, 2000, BRAIN INJURY, V14, P441; Kaplan E., 2001, BOSTON NAMING TEST; Katz RC, 2000, INT J LANG COMM DIS, V35, P303; Kay J, 1992, PSCHOLINGUISTIC ASSE; Kertesz A., 2006, W APHASIA BATTERY RE; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; Lee JW, 2002, RES NURS HEALTH, V25, P295, DOI 10.1002/nur.10041; MacDonald S., 2003, FUNCTIONAL ASSESSMEN; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S., 2002, AWARENESS SOCIAL INF; McGrane SA, 2000, BRAIN INJURY, V14, P975; Morgan AT, 2011, J EVAL CLIN PRACT, V17, P275, DOI 10.1111/j.1365-2753.2010.01436.x; Parkin A E, 2001, Aust J Rural Health, V9, P297, DOI 10.1046/j.1038-5282.2001.00383.x; Parrish C., 2009, SIG 2 PERSPECTIVES N, V19, P47, DOI [DOI 10.1044/NNS1D19.2.47, 10.1044/nnsld19.2.47, DOI 10.1044/NNSLD19.2.47]; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Randolph C., 2001, REPEATABLE BATTERY A; Ross-Swain DG., 1996, ROSS INFORM PROCESSI; Royal College of Speech and Language Therapists, 2005, RCSLT CLIN GUID; Shiel A, 2000, WESSEX HEADN INJURY; Simmons-Mackie N, 2005, J COMMUN DISORD, V38, P1, DOI 10.1016/j.jcomdis.2004.03.007; Steel J, 2013, BRAIN INJURY, V27, P819, DOI 10.3109/02699052.2013.775492; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; Turkstra KM., 2005, SEMINARS SPEECH LANG, V26, P213; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Uniform Data System for Medical Rehabilitation, 1996, FUNCT INF MEAS FIM; Verna A, 2009, INT J SPEECH-LANG PA, V11, P191, DOI 10.1080/17549500902726059; Vogel AP, 2010, J EVAL CLIN PRACT, V16, P1183, DOI 10.1111/j.1365-2753.2009.01291.x; Wertheimer JC, 2008, J HEAD TRAUMA REHAB, V23, P273, DOI 10.1097/01.HTR.0000336840.76209.a1; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wilson FC, 2007, DISABIL REHABIL, V29, P1751, DOI 10.1080/09638280601118432; Wong MN, 2010, APHASIOLOGY, V24, P1155, DOI 10.1080/02687030903168212; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV	58	40	41	1	55	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	13-14					1657	1666		10.3109/02699052.2014.947619			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AT1LY	WOS:000344696600004	25158134				2022-02-06	
J	Joseph, B; Aziz, H; Zangbar, B; Kulvatunyou, N; Pandit, V; O'Keeffe, T; Tang, A; Wynne, J; Friese, RS; Rhee, P				Joseph, Bellal; Aziz, Hassan; Zangbar, Bardiya; Kulvatunyou, Narong; Pandit, Viraj; O'Keeffe, Terence; Tang, Andrew; Wynne, Julie; Friese, Randall S.; Rhee, Peter			Acquired coagulopathy of traumatic brain injury defined by routine laboratory tests: Which laboratory values matter?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; coagulopathy and platelet count; progression of intracranial hemorrhage; neurosurgical intervention; mortality	PROTHROMBIN COMPLEX CONCENTRATE; HEAD TRAUMA; INTRACRANIAL HEMORRHAGE; PROGRESSIVE HEMORRHAGE; PROGNOSTIC VALUE; THROMBOCYTOPENIA; PREDICTORS; CHILDREN; IMPACT	BACKGROUND: Coagulopathy is a major determinant of disability and death in patients with traumatic intracranial hemorrhage. However, the correlation between coagulopathy defined by routine coagulation tests and clinical outcomes in traumatic brain injury (TBI) is not well defined. The aim of our study was to determine the effect of coagulopathy diagnosed by routine laboratory tests on outcomes in TBI patients. METHODS: We performed a retrospective cohort analysis of all isolated TBI patients exclusive of prehospital antiplatelet and anticoagulants with coagulation tests, namely, international normalized ratio (INR), platelet count, and partial thromboplastin time at admission. We defined coagulopathy by an INR of 1.5 or greater, partial thromboplastin time of 35 or greater, or platelet count of 100 x 10(3)/mu L or less. Outcome measures were progression on repeat head computed tomography (RHCT), need for neurosurgical intervention, and mortality. RESULTS: A total of 591 patients were enrolled, with a mean (SD) age of 47.4 (26.5) years and 67% being male. Of the patients, 13.3% were coagulopathic at admission. Platelet count of 100 x 10(3)/mu L or less was an independent predictor of progression on RHCT (odd ratio [OR], 4; 95% confidence interval [CI], 1.7-10), need for neurosurgical intervention (OR, 3.6; 95% CI, 1.2-6.1), and mortality (OR, 2.6; 95% CI, 1.1-4.8). INR was an independent predictor of progression on RHCT (OR, 2; 95% CI, 1.1-4.3). CONCLUSION: Routine bedside coagulation parameters at admission play an important role in predicting outcomes in blunt TBI. Platelet count is the strongest predictor for progression of initial insult on RHCT, need for neurosurgical intervention, and mortality. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Zangbar, Bardiya; Kulvatunyou, Narong; Pandit, Viraj; O'Keeffe, Terence; Tang, Andrew; Wynne, Julie; Friese, Randall S.; Rhee, Peter] Univ Arizona, Coll Med, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021; Zangbar, Bardiya/K-7147-2014	Aziz, Hassan/0000-0003-0406-1946; Zangbar, Bardiya/0000-0003-1215-1693			Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Dzik WH, 2007, TRANSFUSION MED, V17, P367, DOI 10.1111/j.1365-3148.2007.00795.x; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Fries D, 2006, BRIT J ANAESTH, V97, P460, DOI 10.1093/bja/ael191; Joseph B, 2014, J SURG RES, V186, P287, DOI 10.1016/j.jss.2013.08.009; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e	24	40	46	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					121	125		10.1097/TA.0b013e3182a9cc95			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200024	24368366				2022-02-06	
J	Kelso, ML; Gendelman, HE				Kelso, Matthew L.; Gendelman, Howard E.			Bridge Between Neuroimmunity and Traumatic Brain Injury	CURRENT PHARMACEUTICAL DESIGN			English	Article						Traumatic brain injury; neuroimmunity; mononuclear phagocytes; astrocytes; neurodegeneration; inflammation	REGULATORY T-CELLS; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; COLONY-STIMULATING FACTOR; NICOTINIC ACETYLCHOLINE-RECEPTOR; GLUTAMATE TRANSPORTER PROTEINS; EXPERIMENTAL MYASTHENIA-GRAVIS; AMYOTROPHIC-LATERAL-SCLEROSIS; FOCAL CEREBRAL-ISCHEMIA	The pathophysiology of degenerative, infectious, inflammatory and traumatic diseases of the central nervous system includes a significant immune component. As to the latter, damage to the cerebral vasculature and neural cell bodies, caused by traumatic brain injury (TBI) activates innate immunity with concomitant infiltration of immunocytes into the damaged nervous system. This leads to pro-inflammatory cytokine and prostaglandin production and lost synaptic integrity and more generalized neurotoxicity. Engagement of adaptive immune responses follows including the production of antibodies and lymphocyte proliferation. These affect the tempo of disease along with tissue repair and as such provide a number of potential targets for pharmacological treatments for TBI. However, despite a large body of research, no such treatment intervention is currently available. In this review we will discuss the immune response initiated following brain injuries, drawing on knowledge gained from a broad array of experimental and clinical studies. Our discussion seeks to address potential therapeutic targets and propose ways in which the immune system can be controlled to promote neuroprotection.	[Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA; [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Coll Med, Omaha, NE 68198 USA		Kelso, ML (corresponding author), Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA.	mkelso@unmc.edu			Carol Swarts Neuroscience Research Laboratory; Frances and Louie Blumkin Foundation; Department of DefenseUnited States Department of Defense [W81XWH11-1-0700]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P20 GM103480, P01 NS43985]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P01MH064570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036126, P01NS031492, P01NS043985, R01NS034239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA028555] Funding Source: NIH RePORTER	The authors would like to acknowledge Mrs. Robin Taylor for her assistance with the figures and Dr. JoEllyn McMillan for her editorial comments. This work was supported by the Carol Swarts Neuroscience Research Laboratory, the Frances and Louie Blumkin Foundation, Department of Defense Grant W81XWH11-1-0700, and National Institutes of Health grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P20 GM103480 and P01 NS43985.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; [Anonymous], NEUROSURGERY; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Banerjee R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002740; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Berry JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061177; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brynskikh AM, NANOMEDICINE LOND, V5, P379; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Choi SH, 2010, PHARMACOGENOMICS J, V10, P448, DOI 10.1038/tpj.2009.68; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cosentino M, 2013, J NEUROIMMUNE PHARM, V8, P1, DOI 10.1007/s11481-013-9440-1; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; DeFelipe J, 2002, J NEUROCYTOL, V31, P299, DOI 10.1023/A:1024130211265; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fagan SC, 2010, STROKE, V41, P2283, DOI 10.1161/STROKEAHA.110.582601; Faul M, 2010, TRAUMATIC BRAIN INJU; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Ferretti MT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-62; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Ghorpade A, 2008, NEUROIMMUNE PHARM, P89; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hercus TR, 2012, GROWTH FACTORS, V30, P63, DOI 10.3109/08977194.2011.649919; Hickey RW, 2007, PEDIAT RES; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hu WH, 2003, GLIA, V44, P13, DOI 10.1002/glia.10268; Huang Y.L., 2008, NEUROIMMUNE PHARMACO, V15, P183; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P277, DOI 10.1007/978-3-7091-0693-8_46; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Klyachko NL, 2012, NANOMED-NANOTECHNOL, V8, P119, DOI 10.1016/j.nano.2011.05.010; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kong T, 2009, J NEUROSURG, V111, P155, DOI 10.3171/2008.12.JNS08172; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Liu JU, 2009, J IMMUNOL, V182, P3855, DOI 10.4049/jimmunol.0803330; Liu YW, 2006, NAT MED, V12, P518, DOI 10.1038/nm1402; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lu DC, 2011, J NEUROTRAUM; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matyszak MK, 1996, NEUROSCIENCE, V74, P599, DOI 10.1016/0306-4522(96)00160-1; Meissner A, 2003, BLOOD, V102, P2724, DOI 10.1182/blood-2003-01-0007; Menalled LB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009793; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Montiel T, 2005, NEUROSCIENCE, V133, P667, DOI 10.1016/j.neuroscience.2004.11.020; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Mosley RL, 2006, CLIN NEUROSCI RES, V6, P261, DOI 10.1016/j.cnr.2006.09.006; Mrakovcic-Sutic I, 2010, SCAND J IMMUNOL, V72, P57, DOI 10.1111/j.1365-3083.2010.02407.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Olivecrona M, 2012, BRAIN INJURY, V26, P67, DOI 10.3109/02699052.2011.635351; Olivecrona M, 2009, J NEUROTRAUM, V26, P1251, DOI [10.1089/neu.2008.0605, 10.1089/neu.2008-0605]; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296; Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852; Ridwan S, 2012, J NEURAL TRANSM, V119, P1389, DOI 10.1007/s00702-012-0794-y; Rosenbaugh EG, 2010, BIOMATERIALS, V31, P5218, DOI 10.1016/j.biomaterials.2010.03.026; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Rumbaugh JA, 2007, J NEUROVIROL, V13, P168, DOI 10.1080/13550280601178218; Schabitz WR, 2008, J CEREBR BLOOD F MET, V28, P29, DOI 10.1038/sj.jcbfm.9600496; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Schwarz H, 2010, MOVEMENT DISORD, V25, P2219, DOI 10.1002/mds.23236; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sheng JR, 2008, CLIN IMMUNOL, V128, P172, DOI 10.1016/j.clim.2008.03.509; Sheng JR, 2011, J NEUROIMMUNOL, V240, P65, DOI 10.1016/j.jneuroim.2011.10.010; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Soares HD, 1995, J NEUROSCI, V15, P8223; Srivastava MVP, 2012, NEUROL INDIA, V60, P23, DOI 10.4103/0028-3886.93584; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Trajkovic V, 2004, GLIA, V47, P168, DOI 10.1002/glia.20046; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yi JH, 2007, BRAIN RES, V1154, P200, DOI 10.1016/j.brainres.2007.04.011; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhao Y, J NANOMED NONOTECHNO, pS4; Zou T, 2011, TRANSFUSION, V51, p160S, DOI 10.1111/j.1537-2995.2011.03379.x	182	40	42	0	12	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2014	20	26					4284	4298					15	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AK6AA	WOS:000338508000014	24025052				2022-02-06	
J	Tajiri, N; Duncan, K; Antoine, A; Pabon, M; Acosta, SA; de la Pena, I; Hernadez-Ontiveros, DG; Shinozuka, K; Ishikawa, H; Kaneko, Y; Yankee, E; McGrogan, M; Case, C; Borlongan, CV				Tajiri, Naoki; Duncan, Kelsey; Antoine, Alesia; Pabon, Mibel; Acosta, Sandra A.; de la Pena, Ike; Hernadez-Ontiveros, Diana G.; Shinozuka, Kazutaka; Ishikawa, Hiroto; Kaneko, Yuji; Yankee, Ernest; McGrogan, Michael; Case, Casey; Borlongan, Cesar V.			Stem cell-paved biobridge facilitates neural repair in traumatic brain injury	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						trauma; cell transplantation; regenerative medicine; neurogenesis; extracellular matrix	VENTRAL MESENCEPHALIC GRAFTS; PROGENITOR CELLS; MODEL; NEURONS; NEUROPROTECTION; DIFFERENTIATION; TRANSPLANTATION; NEUROGENESIS; PLASTICITY; MIGRATION	Modified mesenchymal stromal cells (MSCs) display a unique mechanism of action during the repair phase of traumatic brain injury by exhibiting the ability to build a biobridge between the neurogenic niche and the site of injury. Immunohistochemistry and laser capture assay have visualized this biobridge in the area between the neurogenic subventricular zone and the injured cortex. This biobridge expresses high levels of extracellular matrix metalloproteinases (MMPs), which are initially co-localized with a stream of transplanted MSCs, but later this region contains only few to non-detectable grafts and becomes overgrown by newly recruited host cells. We have reported that long-distance migration of host cells from the neurogenic niche to the injured brain site can be attained via these transplanted stem cell-paved biobridges, which serve as a key regenerative process for the initiation of endogenous repair mechanisms. Thus, far the two major schools of discipline in stem cell repair mechanisms support the idea of "cell replacement" and the bystander effects of "trophic factor secretion." Our novel observation of stem cell-paved biobridges as pathways for directed migration of host cells from neurogenic niche toward the injured brain site adds another mode of action underlying stem cell therapy. More in-depth investigations on graft-host interaction will likely aid translational research focused on advancing this stem cell-paved biobridge from its current place, as an equally potent repair mechanism as cell replacement and trophic factor secretion, into a new treatment strategy for traumatic brain injury and other neurological disorders.	[Tajiri, Naoki; Duncan, Kelsey; Antoine, Alesia; Pabon, Mibel; Acosta, Sandra A.; de la Pena, Ike; Hernadez-Ontiveros, Diana G.; Shinozuka, Kazutaka; Ishikawa, Hiroto; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Ctr Excellence Aging & Brain Repair, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Yankee, Ernest; McGrogan, Michael; Case, Casey] Sanbio Inc, Mountain View, CA USA		Tajiri, N (corresponding author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	ntaiiri@health.usf.edu; cborlong@health.usf.edu		Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203; dela Pena, Ike/0000-0003-2046-522X	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 1R01NS071956-01]; James, and Esther King Biomedical Research Program [09KB-01-23123, 1KG01-33966]	This work was supported by NIH NINDS RO1 1R01NS071956-01 (Cesar V. Borlongan), James, and Esther King Biomedical Research Program 09KB-01-23123 (Cesar V. Borlongan) and 1KG01-33966 (Cesar V. Borlongan).	Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Alvarez-Buylla A, 2008, COLD SH Q B, V73, P357, DOI 10.1101/sqb.2008.73.019; Andres RH, 2011, BRAIN, V134, P1777, DOI 10.1093/brain/awr094; Barbour HR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-106; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Carrero R, 2012, STEM CELL REV REP, V8, P905, DOI 10.1007/s12015-012-9364-9; Chiang YH, 2001, BRAIN RES, V889, P200, DOI 10.1016/S0006-8993(00)03133-4; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Hassani Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050444; He BR, 2014, MOL NEUROBIOL, V49, P1501, DOI 10.1007/s12035-013-8588-2; Hong SH, 2011, CELL STEM CELL, V9, P24, DOI 10.1016/j.stem.2011.06.002; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Kim Y, 2011, SCIENCE, V334, P1706, DOI 10.1126/science.1211222; Lee HS, 2010, STEM CELLS, V28, P501, DOI 10.1002/stem.294; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Lin CH, 2013, NEUROBIOL DIS, V58, P76, DOI 10.1016/j.nbd.2013.05.006; Liu ZW, 2011, STROKE, V42, P740, DOI 10.1161/STROKEAHA.110.607226; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Mazzocchi-Jones D, 2009, EUR J NEUROSCI, V30, P2134, DOI 10.1111/j.1460-9568.2009.07006.x; Mezey E, 2011, J CELL BIOCHEM, V112, P2683, DOI 10.1002/jcb.23216; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; Pastori C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002754; Pollock K, 2006, EXP NEUROL, V199, P143, DOI 10.1016/j.expneurol.2005.12.011; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Roet KCD, 2013, J NEUROSCI, V33, P11116, DOI 10.1523/JNEUROSCI.1002-13.2013; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Seol HJ, 2011, CANCER LETT, V311, P152, DOI 10.1016/j.canlet.2011.07.001; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Sobrino T, 2012, J NEUROSCI RES, V90, P1788, DOI 10.1002/jnr.23068; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tajiri N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043779; Tang FI, 1998, EXP BRAIN RES, V119, P287, DOI 10.1007/s002210050344; Trueman R. C., 2012, CURR TOP BEHAV NEURO, V15, P357, DOI [DOI 10.1007/7854, 10.1007/7854_2012_223, DOI 10.1007/7854_]; Wang L, 2011, J CEREBR BLOOD F MET, V31, P640, DOI 10.1038/jcbfm.2010.138; Wang XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038932, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0045036, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0040711, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0040084]; Wang Y, 1996, CELL TISSUE RES, V286, P225, DOI 10.1007/s004410050691; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1	50	40	42	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.		2014	8								116	10.3389/fnsys.2014.00116			6	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V19XW	WOS:000214852700116	25009475	gold, Green Published			2022-02-06	
J	Li, Q; Tian, Y; Wang, ZF; Liu, SB; Mi, WL; Ma, HJ; Wu, GC; Wang, J; Yu, J; Wang, YQ				Li, Q.; Tian, Y.; Wang, Z. -F.; Liu, S. -B.; Mi, W. -L.; Ma, H-J; Wu, G. -C.; Wang, J.; Yu, J.; Wang, Y. -Q.			INVOLVEMENT OF THE SPINAL NALP1 INFLAMMASOME IN NEUROPATHIC PAIN AND ASPIRIN-TRIGGERED-15-EPI-LIPDXIN A4 INDUCED ANALGESIA	NEUROSCIENCE			English	Article						NALP1 inflammasome; interleukin; neuropathic pain; aspirin-triggered-15-epi-lipoxin A4; caspase	TRAUMATIC BRAIN-INJURY; MOLECULAR PLATFORM; LIPID MEDIATORS; NERVE INJURY; LIPOXIN; CYTOKINES; RATS; IL-1-BETA; MINOCYCLINE; ACTIVATION	Neuroinflammation plays an important role in nerve-injury-induced neuropathic pain, but the explicit molecular mechanisms of neuroinflammation in neuropathic pain remain unclear. As one of the most critical inflammatory cytokines, interleukin-113 (IL-ID) has been regarded as broadly involved in the pathology of neuropathic pain. The inflammasome caspase-1 platform is one primary mechanism responsible for the maturation of IL-ID. Lipoxins, a type of endogenous anti-inflammatory lipid, have proved to be effective in relieving neuropathic pain behaviors. The present study was designed to examine whether the inflammasome caspase-1 IL-ID platform is involved in chronic constriction injury (CCI)-induced neuropathic pain and in lipoxin-induced analgesia. After rats were subjected to the CCI surgery, mature IL-ID was significantly increased in the ipsilateral spinal cord, and the inflammasome platform consisting of NALP1 (NAcht leucine-rich-repeat protein 1), caspase-1 and ASC (apoptosis-associated speck-like protein containing a caspase-activating recruitment domain) was also activated in spinal astrocytes and neurons, especially at the superficial laminae of the spinal dorsal horn; The aspirin-triggered-15epi-lipoxin A4 (ATL), which shares the potent actions of the endogenous lipoxins, was administered to the CCI rats. Repeated intrathecal injection with ATL markedly attenuated the CCI-induced thermal hyperalgesia and significantly inhibited NALP1 inflammasome activation, caspase-1 cleavage, and IL-10 maturation. These results suggested that spinal NALP1 inflammasome was involved in the CCI-induced neuropathic pain and that the analgesic effect of ATL was associated with suppressing NALP1 inflammasome activation. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	Shanghai Med Coll, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, Shanghai, Peoples R China; Inst Brain Sci, Inst Acupuncture Res, Shanghai, Peoples R China; Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China		Wang, YQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Integrat Med & Neurobiol, Mail Box 291,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.	wangyanqing@shmu.edu.cn	Mi, Wenli/P-5541-2019		National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [2013CB531906]; Excellent Doctoral Graduate Research Program of Fudan University [30970975, 31000495, 81171045, 81072875, 81371247, 31121061]; Ministry of Education of ChinaMinistry of Education, China [20100071120046, 20100071120042]	This work was supported by the National Key Basic Research program of China (2013CB531906), the National Natural Science Fund of China (30970975, 31000495, 81171045, 81072875, 81371247 and 31121061), the Excellent Doctoral Graduate Research Program of Fudan University and the Doctoral Fund of the Ministry of Education of China (Nos. 20100071120046, 20100071120042).	Alexander GM, 2005, PAIN, V116, P213, DOI 10.1016/j.pain.2005.04.013; Amin B, 2012, NEUROSCIENCE, V224, P15, DOI 10.1016/j.neuroscience.2012.07.058; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cunha TM, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-63; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hu S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-278; Jha Mithilesh Kumar, 2012, Immune Netw, V12, P41, DOI 10.4110/in.2012.12.2.41; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kleibeuker W, 2008, BRAIN BEHAV IMMUN, V22, P200, DOI 10.1016/j.bbi.2007.07.009; Kohno T, 2003, J PHYSIOL-LONDON, V548, P131, DOI 10.1113/jphysiol.2002.036186; Liao KC, 2009, INFECT IMMUN, V77, P4455, DOI 10.1128/IAI.00276-09; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mawhinney LJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-123; McCarberg B, 2006, AM J MANAG CARE, V12, pS263; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Romano M, 2010, THESCIENTIFICWORLDJO, V10, P1048, DOI 10.1100/tsw.2010.113; Salminen A, 2008, J CELL MOL MED, V12, P2255, DOI 10.1111/j.1582-4934.2008.00496.x; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Shi XY, 2011, ANESTH ANALG, V113, P175, DOI 10.1213/ANE.0b013e31821a0258; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Sonetti D, 2004, ACTA BIOL HUNG, V55, P273, DOI 10.1556/ABiol.55.2004.1-4.33; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Sun T, 2012, EUR J PAIN, V16, P18, DOI 10.1016/j.ejpain.2011.05.005; Sung CS, 2012, GLIA, V60, P2004, DOI 10.1002/glia.22415; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xu JJ, 2006, ANESTH ANALG, V103, P714, DOI 10.1213/01.ane.0000226100.46866.ea; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zou J, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00077	42	40	47	0	36	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 19	2013	254						230	240		10.1016/j.neuroscience.2013.09.028			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255ZN	WOS:000327279400021	24076348				2022-02-06	
J	Farooqui, A; Hiser, B; Barnes, SL; Litofsky, NS				Farooqui, Ali; Hiser, Bradley; Barnes, Stephen L.; Litofsky, N. Scott			Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						deep venous thrombosis; traumatic brain injury; chemoprophylaxis; Lovenox; heparin	MOLECULAR-WEIGHT HEPARIN; DEEP VENOUS THROMBOSIS; ENOXAPARIN PROPHYLAXIS; HEAD; NEUROSURGERY; PREVENTION; EVENT	Object. Patients with traumatic brain injury (TBI) are at risk for development of thromboembolic disease. The use of chemoprophylaxis in this patient group has not fully been characterized. The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious. Methods. In May 2009, a protocol was instituted for patients with TBI where chemoprophylaxis for thromboembolic disease (either 30 mg of Lovenox twice daily or 5000 U of heparin 3 times a day) was initiated 24 hours after an intracranial hemorrhage (ICH) was demonstrated as stable on head CT image. Two cohorts were evaluated: Cohort A included patients from May 2008 through April 2009 who had no routine administration of chemoprophylaxis, and Cohort B included patients from May 2009 through May 2010 after the protocol was instituted. The groups were compared, with the major outcomes being deep venous thrombosis (DVT), pulmonary embolism, and increase in size of ICH. Results. Of the 312 patients with TBI who were seen during the study course, 236 patients met criteria for inclusion in the study: 107 patients in Cohort A and 129 patients in Cohort B. The DVT rate was 6 occurrences (5.61%) in Cohort A and 0 occurrences (0%) in Cohort B, which was a statistically significant difference (p = 0.0080). Pulmonary embolism was found in 4 patients (3.74%) in Cohort A and 1 patient (0.78%) in Cohort B, a difference that did not reach statistical significance (p = 0.18). Three instances (2.8%) in Cohort A and 1 instance (0.7%) in Cohort B of increased ICH occurred after starting anticoagulation for chemoprophylaxis; this was not statistically different (p = 0.33). Conclusions. Use of chemoprophylaxis in TBI 24 hours after stable head CT is safe and decreases the rate of DVT formation.	[Farooqui, Ali; Litofsky, N. Scott] Univ Missouri, Sch Med, Div Neurol Surg, Columbia, MO 65212 USA; [Barnes, Stephen L.] Univ Missouri, Sch Med, Div Acute Care Surg, Columbia, MO 65212 USA; [Hiser, Bradley] St Lukes Med Ctr, Kansas City, MO USA		Litofsky, NS (corresponding author), Univ Missouri, Sch Med, Div Neurol Surg, 1 Hosp Dr,MC 321, Columbia, MO 65212 USA.	litofskyn@health.missouri.edu		Barnes, Stephen/0000-0001-6186-1435	Division of Neurological Surgery, University of Missouri-Columbia School of Medicine	This work was supported by research funds from the Division of Neurological Surgery, University of Missouri-Columbia School of Medicine. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Barmparas G, 2012, AM SURGEON, V78, P1166; Cage TA, 2009, J NEURO-ONCOL, V93, P151, DOI 10.1007/s11060-009-9886-4; Chibbaro S, 2008, SURG NEUROL, V70, P117, DOI 10.1016/j.surneu.2007.06.081; Collen JF, 2008, CHEST, V134, P237, DOI 10.1378/chest.08-0023; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Khaldi A, 2011, J NEUROSURG, V114, P40, DOI 10.3171/2010.8.JNS10332; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Kwiatt ME, 2012, J TRAUMA ACUTE CARE, V73, P625, DOI 10.1097/TA.0b013e318265cab9; Minshall CT, 2011, J TRAUMA, V71, P396, DOI 10.1097/TA.0b013e31822734c9; Mohseni Shahin, 2012, J Emerg Trauma Shock, V5, P11, DOI 10.4103/0974-2700.93102; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; O'Carroll CB, 2011, NEUROLOGIST, V17, P232, DOI 10.1097/NRL.0b013e318222d6c0; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Saadeh Y, 2012, J TRAUMA ACUTE CARE, V73, P426, DOI 10.1097/TA.0b013e31825a758b; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Thorson CM, 2012, CRIT CARE MED, V40, P2967, DOI 10.1097/CCM.0b013e31825bcb60	23	40	41	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2013	119	6					1576	1582		10.3171/2013.8.JNS13424			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	257EU	WOS:000327367200031	24053504				2022-02-06	
J	Fakhran, S; Yaeger, K; Alhilali, L				Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea			Symptomatic White Matter Changes in Mild Traumatic Brain Injury Resemble Pathologic Features of Early Alzheimer Dementia	RADIOLOGY			English	Article							SLEEP-WAKE DISTURBANCES; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; TENSOR IMAGING FINDINGS; COGNITIVE IMPAIRMENT; SPATIAL STATISTICS; AXONAL INJURY; DISEASE; IMPACT; SPECIFICITY	Purpose: To evaluate white matter integrity in patients with mild traumatic brain injury (TBI) who did not have morphologic abnormalities at conventional magnetic resonance (MR) imaging with diffusion-tensor imaging to determine any relationship between patterns of white matter injury and severity of postconcussion symptoms. Materials and Methods: The institutional review board approved this study, with waiver of informed consent. Diffusion-tensor images from 64 consecutive patients with mild TBI obtained with conventional MR imaging were evaluated retrospectively. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity. All patients underwent a neurocognitive evaluation. Correlations between skeletonized FA values in white matter, total concussion symptom score, and findings of sleep and wake disturbances were analyzed with regression analysis that used tract-based spatial statistics. Results: Total concussion symptom scores varied from 2 to 97 (mean 6 standard deviation, 32.7 +/- 24.4), with 34 patients demonstrating sleep and wake disturbances. Tract-based spatial statistics showed a significant correlation between high total concussion symptom score and reduced FA at the gray matter-white matter junction (P < .05), most prominently in the auditory cortex (P < .05). FA in the parahippocampal gyri was significantly decreased in patients with sleep and wake disturbances relative to patients without such disturbances (0.26 and 0.37, respectively; P < .05). Conclusion: The distribution of white matter abnormalities in patients with symptomatic mild TBI is strikingly similar to the distribution of pathologic abnormalities in patients with early Alzheimer dementia, a finding that may help direct research strategies. (C) RSNA, 2013	[Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA		Fakhran, S (corresponding author), Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Presby South Tower,8th Floor,8 Nor, Pittsburgh, PA 15213 USA.	fakhrans@upmc.edu					Baloyannis SJ, 2011, ACTA OTO-LARYNGOL, V131, P610, DOI 10.3109/00016489.2010.539626; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Ginestroni A, 2009, J NEUROL, V256, P925, DOI 10.1007/s00415-009-5044-3; Golob EJ, 2007, BRAIN, V130, P740, DOI 10.1093/brain/awl375; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Huang YF, 2012, ARCH NEUROL-CHICAGO, V69, P51, DOI 10.1001/archneurol.2011.235; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Romito-DiGiacomo RR, 2007, J NEUROSCI, V27, P8496, DOI 10.1523/JNEUROSCI.1008-07.2007; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Van Hoesen GW, 2000, ANN NY ACAD SCI, V911, P254; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Viswanathan A, 2006, STROKE, V37, P2690, DOI 10.1161/01.STR.0000245091.28429.6a; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Yallampalli R, 2010, J NEUROIMAGING; Yoshiura T, 2006, ACAD RADIOL, V13, P1460, DOI 10.1016/j.acra.2006.09.042	42	40	40	0	27	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2013	269	1					249	257		10.1148/radiol.13122343			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	225YH	WOS:000325000700028	23781117	Bronze			2022-02-06	
J	Hue, CD; Cao, SQ; Haider, SF; Vo, KV; Effgen, GB; Vogel, E; Panzer, MB; Bass, CR; Meaney, DF; Morrison, B				Hue, Christopher D.; Cao, Siqi; Haider, Syed F.; Vo, Kiet V.; Effgen, Gwen B.; Vogel, Edward, III; Panzer, Matthew B.; Bass, Cameron R. 'Dale'; Meaney, David F.; Morrison, Barclay, III			Blood-Brain Barrier Dysfunction after Primary Blast Injury in vitro	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; endothelial cells; primary blast injury; shock tube	CAPILLARY ENDOTHELIAL-CELLS; CLOSED-HEAD INJURY; TIGHT JUNCTIONS; GADOLINIUM-DTPA; SHOCK-WAVES; RAT MODEL; PERMEABILITY; EXPOSURE; EDEMA; DISRUPTION	The incidence of blast-induced traumatic brain injury (bTBI) has increased substantially in recent military conflicts. However, the consequences of bTBI on the blood-brain barrier (BBB), a specialized cerebrovascular structure essential for brain homeostasis, remain unknown. In this study, we utilized a shock tube driven by compressed gas to generate operationally relevant, ideal pressure profiles consistent with improvised explosive devices (IEDs). By multiple measures, the barrier function of an in vitro BBB model was disrupted following exposure to a range of controlled blast loading conditions. Trans-endothelial electrical resistance (TEER) decreased acutely in a dose-dependent manner that was most strongly correlated with impulse, as opposed to peak overpressure or duration. Significantly increased hydraulic conductivity and solute permeability post-injury further confirmed acute alterations in barrier function. Compromised ZO-1 immunostaining identified a structural basis for BBB breakdown. After blast exposure, TEER remained significantly depressed 2 days post-injury, followed by spontaneous recovery to pre-injury control levels at day 3. This study is the first to report immediate disruption of an in vitro BBB model following primary blast exposure, which may be important for the development of novel helmet designs to help mitigate the effects of blast on the BBB.	[Hue, Christopher D.; Cao, Siqi; Vo, Kiet V.; Effgen, Gwen B.; Vogel, Edward, III; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Panzer, Matthew B.; Bass, Cameron R. 'Dale'] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Haider, Syed F.] CUNY City Coll, Dept Biol, New York, NY 10031 USA		Morrison, B (corresponding author), Columbia Univ, 351 Engn Terrace,MC8904 1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122; Vo, Kiet/0000-0002-6293-2386; , Siqi/0000-0001-9779-4174	Multidisciplinary University Research Initiative from the Army Research Office [W911MF-10-1-0526]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE-07-07425]	We would like to thank Aaron Huang and Charles Levin for their assistance with experimental setup and operation of the blast injury device. This work was supported by a Multidisciplinary University Research Initiative from the Army Research Office (W911MF-10-1-0526) and a National Science Foundation Graduate Research Fellowship (to C.D.H.; DGE-07-07425). Portions of this work were previously presented at the 2012 International Research Council on the Biomechanics of Injury (IRCOBI), the 2012 National Neurotrauma Symposium, and the 2012 Annual Biomedical Research Conference for Minority Students (ABRCMS). The current manuscript has been significantly improved and expanded upon with new data compared to prior conference presentations of this work.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bershad EM, 2008, SEMIN NEUROL, V28, P690, DOI 10.1055/s-0028-1105968; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d; Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; DELI MA, 1995, J NEUROSCI RES, V41, P717, DOI 10.1002/jnr.490410602; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Effgen G. B., 2012, FRONT NEUROL, V3, P1; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; ENTERS EK, 1992, BRAIN RES, V576, P271; Fanning AS, 2007, MOL BIOL CELL, V18, P721, DOI 10.1091/mbc.E06-08-0764; FENSTERMACHER JD, 1984, EDEMA, P383; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gaillard PJ, 2001, EUR J PHARM SCI, V12, P215, DOI 10.1016/S0928-0987(00)00123-8; GAMBIHLER S, 1992, NATURWISSENSCHAFTEN, V79, P328, DOI 10.1007/BF01138714; Garcia AN, 2011, METHODS MOL BIOL, V763, P333, DOI 10.1007/978-1-61779-191-8_23; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gumbleton M, 2001, J PHARM SCI-US, V90, P1681, DOI 10.1002/jps.1119; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; HAWKINS CP, 1990, BRAIN, V113, P365, DOI 10.1093/brain/113.2.365; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Hyde D. W., 2004, CONWEP 2 1 0 8; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LARSSON HBW, 1990, MAGNET RESON MED, V16, P117, DOI 10.1002/mrm.1910160111; Li GL, 2010, ANN BIOMED ENG, V38, P2499, DOI 10.1007/s10439-010-0023-5; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Naik P, 2012, J PHARM SCI-US, V101, P1337, DOI 10.1002/jps.23022; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; OHNO K, 1978, AM J PHYSIOL, V235, pH299, DOI 10.1152/ajpheart.1978.235.3.H299; Olson JE, 1997, ACAD EMERG MED, V4, P662, DOI 10.1111/j.1553-2712.1997.tb03757.x; Omidi Y, 2003, BRAIN RES, V990, P95, DOI 10.1016/S0006-8993(03)03443-7; Panzer M. B., 2012, FRONT NEUROL, V3, P1; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer MB, 2012, J TRAUMA ACUTE CARE, V72, P454, DOI 10.1097/TA.0b013e31821e8270; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SILL HW, 1995, AM J PHYSIOL-HEART C, V268, pH535, DOI 10.1152/ajpheart.1995.268.2.H535; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simon MJ, 2011, ANN BIOMED ENG, V39, P394, DOI 10.1007/s10439-010-0144-x; Sonden A, 2000, LASER SURG MED, V26, P364, DOI 10.1002/(SICI)1096-9101(2000)26:4<364::AID-LSM4>3.0.CO;2-T; Sonden A, 2002, LASER SURG MED, V31, P233, DOI 10.1002/lsm.10093; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; vanAsperen J, 1997, J PHARM SCI, V86, P881, DOI 10.1021/js9701364; Victorino GP, 2003, SHOCK, V20, P171, DOI 10.1097/01.shk.0000079424.52617.92; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Willis CL, 2004, GLIA, V45, P325, DOI 10.1002/glia.10333; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Yuan W, 2010, MICROVASC RES, V80, P148, DOI 10.1016/j.mvr.2010.03.011	83	40	43	2	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1652	1663		10.1089/neu.2012.2773			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800006	23581482				2022-02-06	
J	Schreuder, M; Riccio, A; Risetti, M; Dahne, S; Ramsay, A; Williamson, J; Mattia, D; Tangermann, M				Schreuder, Martijn; Riccio, Angela; Risetti, Monica; Daehne, Sven; Ramsay, Andrew; Williamson, John; Mattia, Donatella; Tangermann, Michael			User-centered design in brain-computer interfaces-A case study	ARTIFICIAL INTELLIGENCE IN MEDICINE			English	Article						Brain-computer interface; Event-related potentials; Auditory evoked potentials; Linear discriminant analysis; User-centered design; Assistive technology; Stroke; Traumatic brain injury; Locked-in syndrome	AMYOTROPHIC-LATERAL-SCLEROSIS; LONG-TERM SURVIVAL; LOCKED-IN SYNDROME; COGNITIVE IMPAIRMENT; SPATIAL HEARING; INJURY; ATTENTION; PATTERNS; PEOPLE; HEAD	Objective: The array of available brain-computer interface (BCI) paradigms has continued to grow, and so has the corresponding set of machine learning methods which are at the core of BCI systems. The latter have evolved to provide more robust data analysis solutions, and as a consequence the proportion of healthy BCI users who can use a BCI successfully is growing. With this development the chances have increased that the needs and abilities of specific patients, the end-users, can be covered by an existing BCI approach. However, most end-users who have experienced the use of a BCI system at all have encountered a single paradigm only. This paradigm is typically the one that is being tested in the study that the end-user happens to be enrolled in, along with other end-users. Though this corresponds to the preferred study arrangement for basic research, it does not ensure that the end-user experiences a working BCI. In this study, a different approach was taken; that of a user-centered design. It is the prevailing process in traditional assistive technology. Given an individual user with a particular clinical profile, several available BCI approaches are tested and - if necessary - adapted to him/her until a suitable BCI system is found. Methods: Described is the case of a 48-year-old woman who suffered from an ischemic brain stem stroke, leading to a severe motor- and communication deficit. She was enrolled in studies with two different BCI systems before a suitable system was found. The first was an auditory event-related potential (ERP) paradigm and the second a visual ERP paradigm, both of which are established in literature. Results: The auditory paradigm did not work successfully, despite favorable preconditions. The visual paradigm worked flawlessly, as found over several sessions. This discrepancy in performance can possibly be explained by the user's clinical deficit in several key neuropsychological indicators, such as attention and working memory. While the auditory paradigm relies on both categories, the visual paradigm could be used with lower cognitive workload. Besides attention and working memory, several other neurophysiological and -psychological indicators - and the role they play in the BCIs at hand - are discussed. Conclusion: The user's performance on the first BCI paradigm would typically have excluded her from further ERP-based BCI studies. However, this study clearly shows that, with the numerous paradigms now at our disposal, the pursuit for a functioning BCI system should not be stopped after an initial failed attempt. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.	[Schreuder, Martijn; Daehne, Sven] Berlin Inst Technol, Machine Learning Lab, D-10587 Berlin, Germany; [Riccio, Angela; Risetti, Monica; Mattia, Donatella] Fdn Santa Lucia, Neuroelect Imaging & Brain Comp Interface Lab, I-00142 Rome, Italy; [Riccio, Angela] Univ Roma La Sapienza, Dept Psychol, I-00183 Rome, Italy; [Ramsay, Andrew; Williamson, John] Univ Glasgow, Sch Comp Sci, Glasgow G12 8QQ, Lanark, Scotland; [Tangermann, Michael] Univ Freiburg, BrainLinks BrainTools Excellence Cluster, D-79104 Freiburg, Germany		Schreuder, M (corresponding author), Berlin Inst Technol, Machine Learning Lab, Marchsstr 23, D-10587 Berlin, Germany.	schreuder@tu-berlin.de; a.riccio@hsantalucia.it	Tangermann, Michael/ABE-4178-2020; Riccio, Angela/K-2745-2016; Mattia, Donatella/D-7569-2012	Riccio, Angela/0000-0002-4098-9461; Mattia, Donatella/0000-0002-3092-2511; Schreuder, Evert-Jan Martijn/0000-0002-7239-9909	European ICT Programme Project [FP7-224631, BFNT 01GQ0850]; BrainLinks-BrainTools Cluster of Excellence; German Research Foundation (DFG)German Research Foundation (DFG) [EXC 1086]	This work is supported by the European ICT Programme Project FP7-224631, BFNT 01GQ0850, and the BrainLinks-BrainTools Cluster of Excellence funded by the German Research Foundation (DFG, grant number EXC 1086). This paper only reflects the authors' views and funding agencies are not liable for any use that may be made of the information contained herein.	BAUER G, 1979, J NEUROL, V221, P77, DOI 10.1007/BF00313105; Bianchi L, 2010, BRAIN TOPOGR, V23, P180, DOI 10.1007/s10548-010-0143-0; Blankertz B, 2011, NEUROIMAGE, V56, P814, DOI 10.1016/j.neuroimage.2010.06.048; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Brown AW, 2004, NEUROREHABILITATION, V19, P37; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; Corsi P. M., 1972, THESIS MCGILL U MONT; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; Halder S, 2010, CLIN NEUROPHYSIOL, V121, P516, DOI 10.1016/j.clinph.2009.11.087; HART S G, 1988, P139; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 2000, WCST WISCONSIN CARD; Hill N. J., 2005, ADV NEURAL INFORM PR, V17, P569; Kaufmann T, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056016; Kubler A, 2009, ANN NY ACAD SCI, V1157, P90, DOI 10.1111/j.1749-6632.2008.04122.x; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Ledoit O, 2004, J MULTIVARIATE ANAL, V88, P365, DOI 10.1016/S0047-259X(03)00096-4; Lemm S, 2011, NEUROIMAGE, V56, P387, DOI 10.1016/j.neuroimage.2010.11.004; Leon-Carrion J, 2002, BRAIN INJURY, V16, P555, DOI 10.1080/02699050110119466; Magni E, 1996, EUR J NEUROL, V3, P198, DOI 10.1111/j.1468-1331.1996.tb00423.x; Mun inger JI, 2010, FRONTIERS NEUROSCIEN, P4; Murguialday AR, 2011, CLIN NEUROPHYSIOL, V122, P925, DOI 10.1016/j.clinph.2010.08.019; Nijboer F, 2008, CLIN NEUROPHYSIOL, V119, P1909, DOI 10.1016/j.clinph.2008.03.034; Nijboer F, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00055; Orsini A., 2003, B PSICOL APPL, V239, P73; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Phukan J, 2012, J NEUROL NEUROSUR PS, V83, P102, DOI 10.1136/jnnp-2011-300188; Riccio A, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/045001; Ringholz GM, 2005, NEUROLOGY, V65, P586, DOI 10.1212/01.wnl.0000172911.39167.b6; Sarro L, 2011, AM J NEURORADIOL, V32, P1866, DOI 10.3174/ajnr.A2658; Schreuder M, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00112; Schreuder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009813; Sellers EW, 2006, CLIN NEUROPHYSIOL, V117, P538, DOI 10.1016/j.clinph.2005.06.027; SPINNLER H, 1987, ITALIAN J NEUROLOGIC; Tangermann M, 2011, INT J BIOELECTROMAGN, V13, P119; Townsend G, 2010, CLIN NEUROPHYSIOL, V121, P1109, DOI 10.1016/j.clinph.2010.01.030; Treder MS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066003; Treder MS, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-28; Vianello A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.06.003; Wightman FL, 1999, J ACOUST SOC AM, V105, P2841, DOI 10.1121/1.426899; Zickler C, 2009, ASSIST TECHNOL RES S, V25, P185, DOI 10.3233/978.1.60750.042.1.185; Zimmermann P, 1995, TEST ATTENTIONAL PER; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	44	40	42	0	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0933-3657	1873-2860		ARTIF INTELL MED	Artif. Intell. Med.	OCT	2013	59	2			SI		71	80		10.1016/j.artmed.2013.07.005			10	Computer Science, Artificial Intelligence; Engineering, Biomedical; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Medical Informatics	256DT	WOS:000327290600003	24076341	hybrid, Green Accepted			2022-02-06	
J	Sheehan, B; Nigrovic, LE; Dayan, PS; Kuppermann, N; Ballard, DW; Alessandrini, E; Bajaj, L; Goldberg, H; Hoffman, J; Offerman, SR; Mark, DG; Swietlik, M; Tham, E; Tzimenatos, L; Vinson, DR; Jones, GS; Bakken, S				Sheehan, Barbara; Nigrovic, Lise E.; Dayan, Peter S.; Kuppermann, Nathan; Ballard, Dustin W.; Alessandrini, Evaline; Bajaj, Lalit; Goldberg, Howard; Hoffman, Jeffrey; Offerman, Steven R.; Mark, Dustin G.; Swietlik, Marguerite; Tham, Eric; Tzimenatos, Leah; Vinson, David R.; Jones, Grant S.; Bakken, Suzanne		Pediat Emergency Care Appl Res Net	Informing the design of clinical decision support services for evaluation of children with minor blunt head trauma in the emergency department: A sociotechnical analysis	JOURNAL OF BIOMEDICAL INFORMATICS			English	Article						Clinical decision support; Prediction rules; Traumatic brain injury; Emergency department; Pediatrics	HEALTH-CARE; ORDER-ENTRY; UNINTENDED CONSEQUENCES; INFORMATION-TECHNOLOGY; SYSTEMS; PRINCIPLES; QUALITY	Integration of clinical decision support services (CDSS) into electronic health records (EHRs) may be integral to widespread dissemination and use of clinical prediction rules in the emergency department (ED). However, the best way to design such services to maximize their usefulness in such a complex setting is poorly understood. We conducted a multi-site cross-sectional qualitative study whose aim was to describe the sociotechnical environment in the ED to inform the design of a CDSS intervention to implement the Pediatric Emergency Care Applied Research Network (PECARN) clinical prediction rules for children with minor blunt head trauma. Informed by a sociotechnical model consisting of eight dimensions, we conducted focus groups, individual interviews and workflow observations in 11 EDs, of which 5 were located in academic medical centers and 6 were in community hospitals. A total of 126 ED clinicians, information technology specialists, and administrators participated. We clustered data into 19 categories of sociotechnical factors through a process of thematic analysis and subsequently organized the categories into a sociotechnical matrix consisting of three high-level sociotechnical dimensions (workflow and communication, organizational factors, human factors) and three themes (interdisciplinary assessment processes, clinical practices related to prediction rules, EHR as a decision support tool). Design challenges that emerged from the analysis included the need to use structured data fields to support data capture and re-use while maintaining efficient care processes, supporting interdisciplinary communication, and facilitating family-clinician interaction for decision-making. (C) 2013 Elsevier Inc. All rights reserved.	[Sheehan, Barbara] Columbia Univ, Med Ctr, Fac Pract Org, New York, NY 10032 USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Dayan, Peter S.; Jones, Grant S.] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Emergency Med, New York, NY 10032 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat & Emergency Med, Sacramento, CA 95817 USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr, San Rafael, CA USA; [Alessandrini, Evaline] Univ Cincinnati, Coll Med, Dept Pediat, Div Emergency Med,Cincinnati Childrens Hosp & Med, Cincinnati, OH USA; [Bajaj, Lalit; Swietlik, Marguerite; Tham, Eric] Univ Colorado Denver, Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA; [Goldberg, Howard] Partners HealthCare Syst, Boston, MA USA; [Hoffman, Jeffrey] Nationwide Childrens Hosp, Dept Pediat, Div Emergency Med, Columbus, OH USA; [Offerman, Steven R.] Kaiser Permanente, South Sacramento Med Ctr, Sacramento, CA USA; [Mark, Dustin G.] Kaiser Permanente, Oakland Med Ctr, Oakland, CA USA; [Tzimenatos, Leah] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Vinson, David R.] Kaiser Permanente, Roseville Med Ctr, Roseville, NSW, Australia; [Vinson, David R.] Columbia Univ, Sch Nursing, New York, NY 10032 USA; [Vinson, David R.] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA		Sheehan, B (corresponding author), Columbia Univ, Med Ctr, Fac Pract Org, 51 Audubon Ave,6th Floor, New York, NY 10032 USA.	bs584@columbia.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858; Nigrovic, Lise/0000-0002-6369-3997; Holubkov, Richard/0000-0003-0431-3381	American Recovery and Reinvestment Act-Office of the Secretary (ARRA OS) [S02MC19289-01-00]; Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This work was supported by the American Recovery and Reinvestment Act-Office of the Secretary (ARRA OS): Grant #S02MC19289-01-00.; PECARN is supported by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685.	Agency for Healthcare Research and Quality (AHRQ), 2001, TRANSL RES PRACT TRI; Anderson NR, 2007, INT J MED INFORM, V76, P821, DOI 10.1016/j.ijmedinf.2006.09.022; Asaro PV, 2006, ACAD EMERG MED, V13, P452, DOI 10.1197/j.aem.2005.09.015; Ash JS, 2007, J AM MED INFORM ASSN, V14, P415, DOI 10.1197/jamia.M2373; Ash JS, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-6; Ash JS, 2004, J AM MED INFORM ASSN, V11, P104, DOI 10.1197/jamia.M1471; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Berg M, 1999, INT J MED INFORM, V55, P87, DOI 10.1016/S1386-5056(99)00011-8; Berg M, 2003, METHOD INFORM MED, V42, P297; BERNER ES, 2009, CLIN DECISION SUPPOR, P4; BEYER H, 2009, REPRESENTING WORK PU; Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450; CHERNS A, 1976, HUM RELAT, V29, P783, DOI 10.1177/001872677602900806; Clegg CW, 2000, APPL ERGON, V31, P463, DOI 10.1016/S0003-6870(00)00009-0; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Gooch P, 2011, J AM MED INFORM ASSN, V18, P738, DOI 10.1136/amiajnl-2010-000033; Griffey RT, 2012, J AM MED INFORM ASSN, V19, P86, DOI 10.1136/amiajnl-2011-000124; Handler JA, 2004, ACAD EMERG MED, V11, P1135, DOI 10.1197/j.aem.2004.08.007; Holtzblatt K., 2005, RAPID CONTEXTUAL DES; *KAIS PERM, CLIN RES EM SERV TRE; Karsh BT, 2009, CLIN PRACTICE IMPROV; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lin CP, 2008, J AM MED INFORM ASSN, V15, P620, DOI 10.1197/jamia.M2453; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Payne TH, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P602; Payne TH, 2010, J AM MED INFORM ASSN, V17, P108, DOI 10.1197/jamia.M3173; Peleg M, 2009, INT J MED INFORM, V78, P482, DOI 10.1016/j.ijmedinf.2009.02.008; Porter SC, 2006, PEDIATRICS, V117, pE33, DOI 10.1542/peds.2005-0906; Porter SC, 2004, J AM MED INFORM ASSN, V11, P458, DOI 10.1197/jamia.M1569; Sittig DF, 2010, QUAL SAF HEALTH CARE, V19, pI68, DOI 10.1136/qshc.2010.042085; Terrell KM, 2009, J AM GERIATR SOC, V57, P1388, DOI 10.1111/j.1532-5415.2009.02352.x; Wagholikar KB, 2012, J AM MED INFORM ASSN, V19, P833, DOI 10.1136/amiajnl-2012-000820; Walker GH, 2008, THEOR ISS ERGON SCI, V9, P479, DOI 10.1080/14639220701635470; Wright A, 2008, J BIOMED INFORM, V41, P982, DOI 10.1016/j.jbi.2008.03.009	34	40	41	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1532-0464	1532-0480		J BIOMED INFORM	J. Biomed. Inform.	OCT	2013	46	5					905	913		10.1016/j.jbi.2013.07.005			9	Computer Science, Interdisciplinary Applications; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science; Medical Informatics	223YO	WOS:000324848600016	23892207	Bronze			2022-02-06	
J	Testoni, D; Hornik, CP; Smith, PB; Benjamin, DK; McKinney, RE				Testoni, Daniela; Hornik, Christoph P.; Smith, P. Brian; Benjamin, Daniel K., Jr.; McKinney, Ross E., Jr.			Sports Medicine and Ethics	AMERICAN JOURNAL OF BIOETHICS			English	Article						sports medicine; ethics; conflict of interest; sports; football; athletes	LOCAL-ANESTHETIC INJECTIONS; INFORMED-CONSENT; PROFESSIONAL FOOTBALL; DECISION-MAKING; PHYSICIAN; RETURN; PLAY; PARTICIPATION; CONCUSSION	Physicians working in the world of competitive sports face unique ethical challenges, many of which center around conflicts of interest. Team-employed physicians have obligations to act in the club's best interest while caring for the individual athlete. As such, they must balance issues like protecting versus sharing health information, as well as issues regarding autonomous informed consent versus paternalistic decision making in determining whether an athlete may compete safely. Moreover, the physician has to deal with an athlete's decisions about performance enhancement and return to play, pursuit of which may not be in the athlete's long-term best interests but may benefit the athlete and team in the short term. These difficult tasks are complicated by the lack of evidence-based standards in a field influenced by the lure of financial gains for multiple parties involved. In this article, we review ethical issues in sports medicine with specific attention paid to American professional football.	[Testoni, Daniela] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Hornik, Christoph P.; Smith, P. Brian; Benjamin, Daniel K., Jr.; McKinney, Ross E., Jr.] Duke Univ, Med Ctr, Durham, NC 27710 USA		McKinney, RE (corresponding author), Duke Univ, Med Ctr, DUMC Box 3461, Durham, NC 27710 USA.	ross.mckinney@duke.edu	Smith, Phillip B/I-5565-2014; NOBRE, DANIELA TESTONI COSTA/D-6657-2017	NOBRE, DANIELA TESTONI COSTA/0000-0001-7629-4904	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057956, K23HD060040, K24HD058735] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HHSN275201000003I, K24 HD058735, R01 HD057956, K23 HD060040] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [HHSN267200700051C] Funding Source: Medline		Anderson L, 2008, J MED ETHICS, V34, DOI 10.1136/jme.2008.024794; Anderson LC, 2005, J MED ETHICS, V31, P88, DOI 10.1136/jme.2002.000836; Attarian DE, 2001, J BONE JOINT SURG AM, V83A, P293, DOI 10.2106/00004623-200102000-00020; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belson K, 2012, NY TIMES; Bernstein J, 2000, CLIN ORTHOP RELAT R, P50; Bowen M., 2011, NATL FOOTBALL POST; Bunch WH, 2004, CLIN SPORT MED, V23, P183, DOI 10.1016/j.csm.2004.01.004; Burgess T. L., 2011, South African Journal of Sports Medicine, V23, P138; Capozzi JD, 2000, J BONE JOINT SURG AM, V82A, P1668, DOI 10.2106/00004623-200011000-00022; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Dunn WR, 2007, AM J SPORT MED, V35, P840, DOI 10.1177/0363546506295177; Federation International de Medecine Sportive, 2009, PRINC ETH GUID HLTH; Federation International de Medecine Sportive, 2009, POS STAT DOP SPORT; Finnoff JT, 2010, PM&R, V2, P285, DOI 10.1016/j.pmrj.2010.03.016; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Hall DE, 2012, CAN MED ASSOC J, V184, P533, DOI 10.1503/cmaj.112120; Holm S, 2011, BRIT J SPORT MED, V45, P1170, DOI 10.1136/bjsm.2011.086124; Hopper KD, 1998, SURGERY, V123, P496, DOI 10.1067/msy.1998.87236; HYLAND DA, 1979, HASTINGS CENT REP, V9, P5, DOI 10.2307/3560268; Johnson DL, 2008, ORTHOPEDICS, V31, P534, DOI 10.3928/01477447-20080601-16; Johnson R, 2004, CLIN SPORT MED, V23, P175, DOI 10.1016/j.csm.2004.01.003; King N. M. P., 2008, STUDIES ETHICS LAW T, V1, P1; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Magee J. T., 2003, SPORTS MED UPDAT MAR; McNamee MJ, 2009, SPORTS MED, V39, P339, DOI 10.2165/00007256-200939050-00001; Meisel A, 1996, ARCH INTERN MED, V156, P2521, DOI 10.1001/archinte.156.22.2521; National Football League, 2012, LEAG POL PLAYERS; Nemeth P., 2009, MICHIGAN BAR J, P42; Orchard J, 2001, BRIT J SPORT MED, V35, P212, DOI 10.1136/bjsm.35.4.212; Orchard JW, 2010, AM J SPORT MED, V38, P2259, DOI 10.1177/0363546510372796; Orchard JW, 2002, BRIT J SPORT MED, V36, P209, DOI 10.1136/bjsm.36.3.209; Pelliccia A, 2005, EUR HEART J, V26, P1422, DOI 10.1093/eurheartj/ehi325; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Polsky S, 1998, J Contemp Health Law Policy, V14, P503; Ross JR, 2012, J BONE JOINT SURG AM, V94A, P95, DOI 10.2106/JBJS.K.01423; Savulescu J, 2005, BRIT J SPORT MED, V39, P472, DOI 10.1136/bjsm.2005.017954; SIM J, 1993, BRIT J SPORT MED, V27, P95, DOI 10.1136/bjsm.27.2.95; Sjoqvist F, 2008, LANCET, V371, P1872, DOI 10.1016/S0140-6736(08)60801-6; Stoljar N, 2011, J MED PHILOS, V36, P375, DOI 10.1093/jmp/jhr029; Stovitz Steven D, 2006, Curr Sports Med Rep, V5, P120; Trusty Jane M, 2004, AACN Clin Issues, V15, P432, DOI 10.1097/00044067-200407000-00010; Tucker AM, 2004, CLIN SPORT MED, V23, P227, DOI 10.1016/j.csm.2004.01.001; Waddington I, 2002, BRIT J SPORT MED, V36, P118, DOI 10.1136/bjsm.36.2.118; Weir DR., 2009, NATL FOOTBALL LEAGUE; Whitney SN, 2004, ANN INTERN MED, V140, P54, DOI 10.7326/0003-4819-140-1-200401060-00012; Williams J., 2009, WORLD MED ASS MED ET, V23; World Anti-Doping Agency, 2009, WORLD ANT COD; World Health Organization, 2012, CLASS HLTH WORK; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	52	40	41	0	47	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1526-5161	1536-0075		AM J BIOETHICS	Am. J. Bioeth.	OCT 1	2013	13	10					4	12		10.1080/15265161.2013.828114			9	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	217FV	WOS:000324345300002	24024796	Green Accepted			2022-02-06	
J	Bedi, SS; Smith, P; Hetz, RA; Xue, HS; Cox, CS				Bedi, Supinder S.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Cox, Charles S.			Immunomagnetic enrichment and flow cytometric characterization of mouse microglia	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Microglia; Neuroinflammation; Flow cytometry	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; CELL PERMEABILIZATION; ACTIVATION; RESPONSES; BRAIN; IDENTIFICATION; MACROPHAGES; VIVO	Background: The inflammatory response after a CNS injury is regulated by microglia/macrophages. Changes in the ratio of M1 classically activated pro-inflammatory cells versus M2 alternatively activated anti-inflammatory cells reveal the direction of the immune response. These cells are routinely identified and enumerated by morphology and cell-surface markers using immunohistochemistry. New method: We used a controlled cortical impact (CCI) mouse model for traumatic brain injury (TBI), then isolated microglia/macrophages from neural cell suspensions using magnetic beads conjugated to CD11b monoclonal antibody to obtain the entire myeloid population. Polarization states of CD11b(+)CD45(lo) microglia were evaluated by expression of M1 surface marker F-c gamma RII/III and M2 surface marker CD206. Results: After TBI, we observed an increase in M1:M2 ratio in the ipsilateral hemisphere when compared to the contralateral side, indicating that 24h after CCI, a shift in microglia polarization occurs localized to the hemisphere of injury. Comparison with existing method(s): The major impetus for developing and refining the methods was the need to accurately quantify microglial activation states without reliance on manual morphometric counting of serial immunohistochemistry slides. Flow cytometric analysis of enriched cell suspensions provides quantitative measurement of microglial polarization states complementary to existing methods, but for entire populations of cells. Conclusions: In summary, we used immunomagnetic beads to isolate myeloid cells from injured brain, then stained surface antigens to flow cytometrically identify and categorize microglia as either classically activated M1 or alternatively activated M2, generating a ratio of M1:M2 cells which is useful in studying attempts to reduce or redirect neuroinflammation. (C) 2013 Elsevier B.V. All rights reserved.	[Bedi, Supinder S.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hetz, Robert A.; Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Cox, Charles S.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA		Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS077511] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44 NS077511] Funding Source: Medline		David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; FORD AL, 1995, J IMMUNOL, V154, P4309; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Nikodemova M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-147; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Papagno L, 2007, J IMMUNOL METHODS, V328, P182, DOI 10.1016/j.jim.2007.09.001; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Verdier M, 2000, CYTOMETRY, V41, P55, DOI 10.1002/1097-0320(20000901)41:1<55::AID-CYTO8>3.0.CO;2-A; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228	21	40	41	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2013	219	1					176	182		10.1016/j.jneumeth.2013.07.017			7	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	222HX	WOS:000324722900020	23928152	Green Accepted			2022-02-06	
J	Samini, F; Samarghandian, S; Borji, A; Mohammadi, G; Bakaian, M				Samini, Fariborz; Samarghandian, Saeed; Borji, Abasalt; Mohammadi, Gholamreza; Bakaian, Mandi			Curcumin pretreatment attenuates brain lesion size and improves neurological function following traumatic brain injury in the rat	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Curcumin; Brain injury; Rotarod; Inclined-plane test; Rat; Weight drop	FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; ANTIOXIDANT ENZYMES; RADICAL SCAVENGERS; LIPID-PEROXIDATION; HEMORRHAGE; MODEL; MICE; EXCITOTOXICITY	Turmeric has been in use since ancient times as a condiment and due to its medicinal properties. Curcumin, the yellow coloring principle in turmeric, is a polyphenolic and a major active constituent Besides anti-inflammatory, thrombolytic and anti-carcinogenic activities, curcumin also possesses strong antioxidant property. The neuroprotective effects of curcumin were evaluated in a weight drop model of cortical contusion trauma in rat. Male Wistar rats (350-400 g, n = 9) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and subjected to head injury. Five days before injury, animals randomly received an i.p. bolus of either curcumin (50 and 100 mg/kg/day, n = 9) or vehicle (n = 9). Two weeks after the injury and drug treatment, animals were sacrificed and a series of brain sections, stained with hematoxylin and eosin (H&E) were evaluated for quantitative brain lesion volume. Two weeks after the injury, oxidative stress parameter (malondialdehyde) was also measured in the brain. Curcumin (100 mg/kg) significantly reduced the size of brain injury-induced lesions (P < 0.05). Neurological examinations (rotarod and inclined-plane tests) were performed on days 1, 3, 7 and 14 post-brain injury. Control injured rats had a significant neurological deficit during 2 weeks (P < 0.001). The injury increased brain levels of the malondialdehyde by 35.6% and these increases were attenuated by curcumin (100 mg/kg). Curcumin treatment significantly improved the neurological status evaluated during 2 weeks after brain injury. The study demonstrates the protective efficacy of curcumin in rat traumatic brain injury model. (C) 2013 Elsevier Inc. All rights reserved.	[Samini, Fariborz; Bakaian, Mandi] Mashhad Univ Med Sci, Fac Med, Dept Neurosurg, Mashhad, Iran; [Samarghandian, Saeed; Borji, Abasalt] Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur, Iran; [Mohammadi, Gholamreza] Neyshabur Univ Med Sci, Hlth Strateg Res Ctr, Neyshabur, Iran		Samarghandian, S (corresponding author), Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur, Iran.	samarghandians@mums.ac.ir			Research Affairs of Neyshabur University of Medical Sciences	The authors would like to thank the Research Affairs of Neyshabur University of Medical Sciences for financially supporting this work.	Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Barone F C, 1997, Expert Opin Investig Drugs, V6, P501, DOI 10.1517/13543784.6.5.501; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Cartiera MS, 2010, MOL PHARMACEUT, V7, P86, DOI 10.1021/mp900138a; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Farahmand SK, 2013, BIOGERONTOLOGY, V14, P63, DOI 10.1007/s10522-012-9409-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Genet S, 2002, MOL CELL BIOCHEM, V236, P7, DOI 10.1023/A:1016103131408; Ghorbani A, 2012, AVICENNA J PHYTOMEDI, V2, P4; Gill SS, 2010, PLANT PHYSIOL BIOCH, V48, P909, DOI 10.1016/j.plaphy.2010.08.016; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Khurana S, 2012, HUM EXP TOXICOL, V31, P686, DOI 10.1177/0960327111433897; Kumar P, 2007, METHOD FIND EXP CLIN, V29, P19, DOI 10.1358/mf.2007.29.1.1063492; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Matteucci A, 2005, EXP BRAIN RES, V167, P641, DOI 10.1007/s00221-005-0068-0; McIntosh TK, 1996, LAB INVEST, V74, P315; Merrell JG, 2009, CLIN EXP PHARMACOL P, V36, P1149, DOI 10.1111/j.1440-1681.2009.05216.x; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; Nagaraju GP, 2012, INTEGR BIOL-UK, V4, P996, DOI 10.1039/c2ib20088k; Nishio S, 1997, ACT NEUR S, V70, P84; Pari L, 2007, FUND CLIN PHARMACOL, V21, P665, DOI 10.1111/j.1472-8206.2007.00542.x; PAXINOS G, 1990, RAT BRAIN STEREOTAXI; Pierre S, 1999, NEUROREPORT, V10, P47, DOI 10.1097/00001756-199901180-00009; Priyadarsini KI, 1997, FREE RADICAL BIO MED, V23, P838, DOI 10.1016/S0891-5849(97)00026-9; Sadeghnia HR, 2012, AFR J PHARM PHARMACO, V6, P2464, DOI 10.5897/AJPP12.085; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Sharma Deepak, 2012, Anesthesiol Clin, V30, P333, DOI 10.1016/j.anclin.2012.04.003; Sharma V, 2010, METHOD FIND EXP CLIN, V32, P227, DOI 10.1358/mf.2010.32.4.1452090; Shen L, 2009, BIOORG MED CHEM LETT, V19, P5990, DOI 10.1016/j.bmcl.2009.09.076; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Sood PK, 2011, NEUROTOX RES, V20, P351, DOI 10.1007/s12640-011-9249-8; Sun YH, 2011, J NEUROTRAUM, V28, P2513, DOI 10.1089/neu.2011.1958; Tamaddonfard E, 2012, AVICENNA J PHYTOMEDI, V2, P97; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wang YL, 2013, AM J CHINESE MED, V41, P59, DOI 10.1142/S0192415X13500055; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	47	40	42	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2013	110						238	244		10.1016/j.pbb.2013.07.019			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	253TM	WOS:000327112200031	23932920				2022-02-06	
J	Tang, HL; Hua, F; Wang, J; Sayeed, I; Wang, XJ; Chen, ZJ; Yousuf, S; Atif, F; Stein, DG				Tang, Huiling; Hua, Fang; Wang, Jun; Sayeed, Iqbal; Wang, Xiaojing; Chen, Zhengjia; Yousuf, Seema; Atif, Fahim; Stein, Donald G.			Progesterone and vitamin D: Improvement after traumatic brain injury in middle-aged rats	HORMONES AND BEHAVIOR			English	Article						Aging; Combination treatments; Functional repair; Progesterone; Traumatic brain injury; Vitamin D deficiency; Vitamin D3 hormone	D DEFICIENCY; D HORMONE; WORKING-MEMORY; NEUROPROTECTION; STROKE; SEX; PREVALENCE; EXPRESSION; CYTOKINES; RESPONSES	Progesterone (PROG) and vitamin D hormone (VDH) have both shown promise in treating traumatic brain injury (TBI). Both modulate apoptosis, inflammation, oxidative stress, and excitotoxicity. We investigated whether 21 days of VDH deficiency would alter cognitive behavior after TBI and whether combined PROG and VDH would improve behavioral and morphological outcomes more than either hormone alone in VDH-deficient middle-aged rats given bilateral contusions of the medial frontal cortex. PROG (16 mg/kg) and VDH (5 mu g/kg) were injected intraperitoneally 1 h post-injury. Eight additional doses of PROG were injected subcutaneously over 7 days post-injury. VDH deficiency itself did not significantly reduce baseline behavioral functions or aggravate impaired cognitive outcomes. Combination therapy showed moderate improvement in preserving spatial and reference memory but was not significantly better than PROG monotherapy. However, combination therapy significantly reduced neuronal loss and the proliferation of reactive astrocytes, and showed better efficacy compared to VDH or PROG alone in preventing MAP-2 degradation. VDH + PROG combination therapy may attenuate some of the potential long-term, subtle, pathophysiological consequences of brain injury in older subjects. (c) 2013 Elsevier Inc. All rights reserved.	[Tang, Huiling; Hua, Fang; Wang, Jun; Sayeed, Iqbal; Yousuf, Seema; Atif, Fahim; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Wang, Xiaojing; Chen, Zhengjia] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER	This work was supported by NIH grant 1R01HD061971 to DGS. The authors would like to thank Leslie McCann for the invaluable editorial assistance and Jason S. Lee and Kristen Carroll for their contribution to the paper.	Annweiler C, 2010, NEUROLOGY, V74, P27, DOI 10.1212/WNL.0b013e3181beecd3; Atalay B, 2007, BRIT J NEUROSURG, V21, P281, DOI 10.1080/02688690701364781; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Balden R, 2012, ENDOCRINOLOGY, V153, P2420, DOI 10.1210/en.2011-1783; Baldi E, 2005, NEUROSCI LETT, V378, P176, DOI 10.1016/j.neulet.2004.12.029; Becker A, 2005, BEHAV BRAIN RES, V161, P306, DOI 10.1016/j.bbr.2005.02.015; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Briones TL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-244; Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carroll JC, 2010, ENDOCRINOLOGY, V151, P2713, DOI 10.1210/en.2009-1487; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Chatterjee M, 2001, MUTAT RES-FUND MOL M, V475, P69, DOI 10.1016/S0027-5107(01)00080-X; Chisholm NC, 2013, BRAIN RES, V1514, P40, DOI 10.1016/j.brainres.2013.02.020; Chisholm NC, 2012, ENDOCRINOLOGY, V153, P4874, DOI 10.1210/en.2012-1412; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; de Abreu DAF, 2010, BEHAV BRAIN RES, V208, P603, DOI 10.1016/j.bbr.2010.01.005; DeLuca GC, 2013, NEUROPATH APPL NEURO, V39, P458, DOI 10.1111/nan.12020; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Diamond TH, 2005, MED J AUSTRALIA, V183, P10, DOI 10.5694/j.1326-5377.2005.tb06879.x; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Evatt ML, 2008, ARCH NEUROL-CHICAGO, V65, P1348, DOI 10.1001/archneur.65.10.1348; Evatt ML, 2011, ARCH NEUROL-CHICAGO, V68, P314, DOI 10.1001/archneurol.2011.30; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Felmingham KL, 2012, PSYCHONEUROENDOCRINO, V37, P1896, DOI 10.1016/j.psyneuen.2012.03.026; Frick KM, 2000, NEUROSCIENCE, V95, P293; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; GAGE FH, 1989, NEUROBIOL AGING, V10, P347, DOI 10.1016/0197-4580(89)90047-X; Galea LAM, 2000, HORM BEHAV, V37, P86, DOI 10.1006/hbeh.1999.1560; Gallagher M, 1997, ANNU REV PSYCHOL, V48, P339, DOI 10.1146/annurev.psych.48.1.339; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Heaney RP, 2004, AM J CLIN NUTR, V80, p1706S, DOI 10.1093/ajcn/80.6.1706S; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Holick MF, 2005, AM J KIDNEY DIS, V45, P1119, DOI 10.1053/j.ajkd.2005.04.015; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Kojima G, 2012, STROKE, V43, P2163, DOI 10.1161/STROKEAHA.112.651752; Kuningas M, 2009, NEUROBIOL AGING, V30, P466, DOI 10.1016/j.neurobiolaging.2007.07.001; Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Luckhaus C, 2009, J NEURAL TRANSM, V116, P905, DOI 10.1007/s00702-009-0241-x; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Markham JA, 2002, NEUROBIOL AGING, V23, P579, DOI 10.1016/S0197-4580(02)00004-0; MARKOWSKA AL, 1989, NEUROBIOL AGING, V10, P31, DOI 10.1016/S0197-4580(89)80008-9; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; Minasyan A, 2007, J STEROID BIOCHEM, V104, P274, DOI 10.1016/j.jsbmb.2007.03.032; Narayanan R, 2004, BONE, V35, P134, DOI 10.1016/j.bone.2004.02.014; Newmark HL, 2007, MOVEMENT DISORD, V22, P461, DOI 10.1002/mds.21317; Paris JJ, 2011, BRAIN RES, V1379, P149, DOI 10.1016/j.brainres.2010.10.099; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; SHARMA N, 1994, CELL MOTIL CYTOSKEL, V27, P234, DOI 10.1002/cm.970270305; Solomon JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029354; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; Stein DG, 2011, PM&R, V3, pS100, DOI 10.1016/j.pmrj.2011.03.010; Sun Q, 2012, STROKE, V43, P1470, DOI 10.1161/STROKEAHA.111.636910; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Valtuena J., 2013, CARDIORESPIRATORY FI, DOI DOI 10.1093/QJMED/HCT089; Veliskova J, 2013, HORM BEHAV, V63, P267, DOI 10.1016/j.yhbeh.2012.03.018; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579	69	40	45	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X	1095-6867		HORM BEHAV	Horm. Behav.	AUG	2013	64	3					527	538		10.1016/j.yhbeh.2013.06.009			12	Behavioral Sciences; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Endocrinology & Metabolism	235QM	WOS:000325735800014	23896206	Green Accepted			2022-02-06	
J	Liu, M; Gross, DW; Wheatley, BM; Concha, L; Beaulieu, C				Liu, Min; Gross, Donald W.; Wheatley, B. Matt; Concha, Luis; Beaulieu, Christian			The acute phase of Wallerian degeneration: Longitudinal diffusion tensor imaging of the fornix following temporal lobe surgery	NEUROIMAGE			English	Article						Wallerian degeneration; Diffusion tensor imaging; Epilepsy; Parallel diffusivity; Perpendicular diffusivity; Fractional anisotropy	RAT SPINAL-CORD; TRAUMATIC AXONAL INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MOUSE MODEL; RETINAL ISCHEMIA; WATER DIFFUSION; OPTIC-NERVE; EPILEPSY; LOBECTOMY	Numerous animal studies have shown the applicability of diffusion tensor imaging (DTI) to track Wallerian degeneration that occurs after injury to the neural fiber. Non-invasive biomarkers that may differentiate the early axonal breakdown and later myelin degradation have been attributed to either reduced parallel and elevated perpendicular diffusivity, respectively. While several human DTI studies have shown this potential at subacute and chronic time points, the diffusion changes that occur within the first week are unknown. Anterior temporal lobectomy (i.e. resection of hippocampus) is the standard surgical treatment of medically refractory temporal lobe epilepsy. The concomitant transection of the fimbria-fornix serves as a unique opportunity to examine the process of Wallerian degeneration since the timing is known. Six temporal lobe epilepsy patients underwent brain DTI before the surgery, three to four times within the first week post-operatively, and at one to four months following surgery. Both parallel and perpendicular diffusivities decreased markedly by a similar amount in the ipsilateral fornix within the first two days post-surgery. Approaching the end of the first week, perpendicular (but not parallel) diffusivity pseudo-recovered towards its pre-surgical value, but then increased dramatically months later. Fractional anisotropy, as a result of the combined action of the parallel and perpendicular diffusivities, stayed relatively stable within the first week and only reduced drastically at the chronic stage. DTI demonstrated acute water diffusion changes within days of transection that are not just limited to parallel diffusivity. While the chronic diffusion changes in the fornix are compatible with myelin degradation, the acute changes may reflect beading and swelling of axolemma, granular disintegration of the axonal neurofilaments, ischemia induced cytotoxic edema, and/or changes in the extra-axonal space including inflammatory changes and gliosis. (C) 2013 Elsevier Inc. All rights reserved.	[Liu, Min; Beaulieu, Christian] Univ Alberta, Dept Biomed Engn, Fac Med & Dent, Edmonton, AB T6G 2V2, Canada; [Gross, Donald W.] Univ Alberta, Fac Med & Dent, Dept Med, Div Neurol, Edmonton, AB T6G 2V2, Canada; [Wheatley, B. Matt] Univ Alberta, Fac Med & Dent, Dept Surg, Div Neurosurg, Edmonton, AB T6G 2V2, Canada; [Concha, Luis] Univ Nacl Autonoma Mexico, Inst Neurobiol, Queretaro, Mexico		Beaulieu, C (corresponding author), Univ Alberta, Dept Biomed Engn, Res Transit Facil 1098, Edmonton, AB T6G 2V2, Canada.	christian.beaulieu@ualberta.ca	Concha, Luis/G-5161-2011; Liu, Min/C-7301-2012; Concha, Luis/M-5720-2019; , DWG/AAF-9259-2020; Beaulieu, Christian/E-9796-2011	Concha, Luis/0000-0002-7842-3869; Liu, Min/0000-0002-4377-5864; Beaulieu, Christian/0000-0002-2342-3298; Gross, Donald/0000-0003-1344-4092	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Innovates-Health Solutions; China Scholarship CouncilChina Scholarship Council	This work was supported by Canadian Institutes of Health Research (D.W.G. and C.B.); Alberta Innovates-Health Solutions (C.B.); and China Scholarship Council (M.L.).	Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Concha L, 2005, ANN NEUROL, V57, P188, DOI 10.1002/ana.20334; Concha L, 2009, J NEUROL NEUROSUR PS, V80, P312, DOI 10.1136/jnnp.2007.139287; Concha L, 2007, EPILEPSIA, V48, P931, DOI 10.1111/j.1528-1167.2007.01006.x; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Concha L, 2010, J NEUROSCI, V30, P996, DOI 10.1523/JNEUROSCI.1619-09.2010; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; McDonald CR, 2010, NEUROLOGY, V75, P1631, DOI 10.1212/WNL.0b013e3181fb44db; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nguyen D, 2011, EPILEPSY RES, V94, P189, DOI 10.1016/j.eplepsyres.2011.02.001; Papadakis NG, 2002, MAGNET RESON MED, V48, P394, DOI 10.1002/mrm.10204; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Schoene-Bake JC, 2009, NEUROIMAGE, V46, P569, DOI 10.1016/j.neuroimage.2009.03.013; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Taoka T, 2005, AM J NEURORADIOL, V26, P797; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vercauteren T, 2009, NEUROIMAGE, V45, pS61, DOI 10.1016/j.neuroimage.2008.10.040; Wheatley BM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E4; Wieshmann UC, 1999, EPILEPSIA, V40, P1155, DOI 10.1111/j.1528-1157.1999.tb00834.x; Xu JQ, 2008, NMR BIOMED, V21, P928, DOI 10.1002/nbm.1307; Yogarajah M, 2010, BRAIN, V133, P2348, DOI 10.1093/brain/awq175; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	40	40	41	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JUL 1	2013	74						128	139		10.1016/j.neuroimage.2013.01.069			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	124CL	WOS:000317441300014	23396161				2022-02-06	
J	Veenith, TV; Carter, E; Grossac, J; Newcombe, VFJ; Outtrim, JG; Lupson, V; Williams, GB; Menon, DK; Coles, JP				Veenith, Tonny V.; Carter, Eleanor; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne G.; Lupson, Victoria; Williams, Guy B.; Menon, David K.; Coles, Jonathan P.			Inter Subject Variability and Reproducibility of Diffusion Tensor Imaging within and between Different Imaging Sessions	PLOS ONE			English	Article							PRINCIPAL EIGENVECTOR MEASUREMENTS; TRAUMATIC BRAIN-INJURY; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; TRACTOGRAPHY; MR; DEGENERATION; MULTICENTER; SCANNER	The aim of these studies was to provide reference data on intersubject variability and reproducibility of diffusion tensor imaging. Healthy volunteers underwent imaging on two occasions using the same 3T Siemens Verio magnetic resonance scanner. At each session two identical diffusion tensor sequences were obtained along with standard structural imaging. Fractional anisotropy, apparent diffusion coefficient, axial and radial diffusivity maps were created and regions of interest applied in normalised space. The baseline data from all 26 volunteers were used to calculate the intersubject variability, while within session and between session reproducibility were calculated from all the available data. The reproducibility of measurements were used to calculate the overall and within session 95% prediction interval for zero change. The within and between session reproducibility data were lower than the values for intersubject variability, and were different across the brain. The regional mean (range) coefficient of variation figures for within session reproducibility were 2.1 (0.9-5.5%), 1.2 (0.4-3.9%), 1.2 (0.4-3.8%) and 1.8 (0.4-4.3%) for fractional anisotropy, apparent diffusion coefficient, axial and radial diffusivity, and were lower than between session reproducibility measurements (2.4 (1.1-5.9%), 1.9 (0.7-5.7%), 1.7 (0.7-4.7%) and 2.4 (0.9-5.8%); p < 0.001). The calculated overall and within session 95% prediction intervals for zero change were similar. This study provides additional reference data concerning intersubject variability and reproducibility of diffusion tensor imaging conducted within the same imaging session and different imaging sessions. These data can be utilised in interventional studies to quantify change within a single imaging session, or to assess the significance of change in longitudinal studies of brain injury and disease.	[Veenith, Tonny V.; Carter, Eleanor; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne G.; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Div Anaesthesia, Cambridge, Cambs, England; [Lupson, Victoria; Williams, Guy B.] Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, Cambs, England		Coles, JP (corresponding author), Univ Cambridge, Div Anaesthesia, Cambridge, Cambs, England.	jpc44@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020; Veenith, Tonny V/A-9948-2010	Veenith, Tonny/0000-0002-4125-8804; Veenith, Tonny V/0000-0002-4125-8804; Outtrim, Joanne/0000-0001-8118-6430; Coles, Jonathan/0000-0003-4013-679X; Newcombe, Virginia/0000-0001-6044-9035	National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship; NIHRNational Institute for Health Research (NIHR); Wellcome trustWellcome TrustEuropean Commission; Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G0701532, G9439390, G1000183B, G0001354, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0512-10090] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0701532, G0600986] Funding Source: UKRI	Dr. TV Veenith was supported by clinical research training fellowship from the National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship. VFJN is supported by an NIHR academic clinical fellowship. JPC was supported by Wellcome trust project grant. DKM is supported by an NIHR Senior Investigator Award. This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Alves GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052859; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bisdas S, 2008, AM J NEURORADIOL, V29, P1128, DOI 10.3174/ajnr.A1044; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Brander A, 2010, ACTA RADIOL, V51, P800, DOI 10.3109/02841851.2010.495351; Cassol E, 2004, MULT SCLER J, V10, P188, DOI 10.1191/1352458504ms997oa; Cercignani M, 2003, AM J NEURORADIOL, V24, P638; Ciccarelli O, 2003, NEUROIMAGE, V19, P1545, DOI 10.1016/S1053-8119(03)00190-3; Ciccarelli O, 2003, NEUROIMAGE, V18, P348, DOI 10.1016/S1053-8119(02)00042-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Danielian LE, 2010, NEUROIMAGE, V49, P1572, DOI 10.1016/j.neuroimage.2009.08.062; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FRISTON KJ, 1995, CLIN NEUROSCI, V3, P89; Hannoun S, 2012, AM J NEURORADIOL, V33, P1363, DOI 10.3174/ajnr.A2983; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Jansen JFA, 2007, INVEST RADIOL, V42, P327, DOI 10.1097/01.rli.0000262757.10271.e5; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; Lemkaddem A, 2012, NEUROIMAGE, V62, P87, DOI 10.1016/j.neuroimage.2012.04.045; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Pfefferbaum A, 2003, J MAGN RESON IMAGING, V18, P427, DOI 10.1002/jmri.10377; Senda J, 2012, J NEUROL SCI, V319, P105, DOI 10.1016/j.jns.2012.04.019; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stamatakis EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014496; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Takao H, 2011, HUM BRAIN MAPP, V32, P1762, DOI 10.1002/hbm.21145; Takao H, 2011, NEUROIMAGE, V54, P1053, DOI 10.1016/j.neuroimage.2010.09.023; Teipel SJ, 2011, PSYCHIAT RES-NEUROIM, V194, P363, DOI [10.1016/j.pscychresns2011.05.012, 10.1016/j.pscychresns.2011.05.012]; Vollmar C, 2010, NEUROIMAGE, V51, P1384, DOI 10.1016/j.neuroimage.2010.03.046; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010	43	40	40	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e65941	10.1371/journal.pone.0065941			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	WOS:000321148400008	23840380	gold, Green Published, Green Submitted			2022-02-06	
J	Furman, GR; Lin, CC; Bellanca, JL; Marchetti, GF; Collins, MW; Whitney, SL				Furman, Gabriel R.; Lin, Chia-Cheng; Bellanca, Jennica L.; Marchetti, Gregory F.; Collins, Michael W.; Whitney, Susan L.			Comparison of the Balance Accelerometer Measure and Balance Error Scoring System in Adolescent Concussions in Sports	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; balance; postural sway; accelerometer	PREDICT PROTRACTED RECOVERY; TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; SYMPTOMS	Background: High-technology methods demonstrate that balance problems may persist up to 30 days after a concussion, whereas with low-technology methods such as the Balance Error Scoring System (BESS), performance becomes normal after only 3 days based on previously published studies in collegiate and high school athletes. Purpose: To compare the National Institutes of Health's Balance Accelerometer Measure (BAM) with the BESS regarding the ability to detect differences in postural sway between adolescents with sports concussions and age-matched controls. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Forty-three patients with concussions and 27 control participants were tested with the standard BAM protocol, while sway was quantified using the normalized path length (mG/s) of pelvic accelerations in the anterior-posterior direction. The BESS was scored by experts using video recordings. Results: The BAM was not able to discriminate between healthy and concussed adolescents, whereas the BESS, especially the tandem stance conditions, was good at discriminating between healthy and concussed adolescents. A total BESS score of 21 or more errors optimally identified patients in the acute concussion group versus healthy participants at 60% sensitivity and 82% specificity. Conclusion: The BAM is not as effective as the BESS in identifying abnormal postural control in adolescents with sports concussions. The BESS, a simple and economical method of assessing postural control, was effective in discriminating between young adults with acute concussions and young healthy people, suggesting that the test has value in the assessment of acute concussions.	[Furman, Gabriel R.; Lin, Chia-Cheng; Bellanca, Jennica L.; Marchetti, Gregory F.; Collins, Michael W.; Whitney, Susan L.] Univ Pittsburgh, Ctr Sports Med, Pittsburgh, PA 15261 USA		Whitney, SL (corresponding author), Univ Pittsburgh, Dept Phys Therapy, 6035 Forbes Tower, Pittsburgh, PA 15261 USA.	whitney@pitt.edu			Department of Physical Therapy at the University of Pittsburgh; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER	This study was sponsored by the Department of Physical Therapy at the University of Pittsburgh.	Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Monsell EM, 1997, OTOLARYNG HEAD NECK, V117, P394, DOI 10.1016/S0194-5998(97)70132-3; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rine RM, 2013, NEUROLOGY, V80, pS25, DOI 10.1212/WNL.0b013e3182872c6a; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543	22	40	40	4	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2013	41	6					1404	1410		10.1177/0363546513484446			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	301HN	WOS:000330523500024	23585486	Green Accepted			2022-02-06	
J	Liu, W; Wang, BQ; Wolfowitz, R; Yeh, PH; Nathan, DE; Graner, J; Tang, HY; Pan, H; Harper, J; Pham, D; Oakes, TR; French, LM; Riedy, G				Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Graner, John; Tang, Haiying; Pan, Hai; Harper, Jamie; Dzung Pham; Oakes, Terrence R.; French, Louis M.; Riedy, Gerard			Perfusion deficits in patients with mild traumatic brain injury characterized by dynamic susceptibility contrast MRI	NMR IN BIOMEDICINE			English	Article						dynamic susceptibility-weighted MRI; perfusion; arterial input function; relative cerebral flood flow; traumatic brain injury	CEREBRAL-BLOOD-FLOW; ARTERIAL INPUT FUNCTION; POSTTRAUMATIC-STRESS-DISORDER; HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; NEUROPSYCHOLOGICAL OUTCOMES; ANTERIOR CINGULATE; SPECT; BLAST; IRAQ	Perfusion deficits in patients with mild traumatic brain injury (TBI) from a military population were characterized by dynamic susceptibility contrast perfusion imaging. Relative cerebral blood flow (rCBF) was calculated by a model-independent deconvolution approach from the tracer concentration curves following a bolus injection of gadolinium diethylenetriaminepentaacetate (Gd-DTPA) using both manually and automatically selected arterial input functions (AIFs). Linear regression analysis of the mean values of rCBF from selected regions of interest showed a very good agreement between the two approaches, with a regression coefficient of R=0.88 and a slope of 0.88. The BlandAltman plot also illustrated the good agreement between the two approaches, with a mean difference of 0.6 +/- 12.4mL/100g/min. Voxelwise analysis of rCBF maps from both approaches demonstrated multiple clusters of decreased perfusion (p<0.01) in the cerebellum, cuneus, cingulate and temporal gyrus in the group with mild TBI relative to the controls. MRI perfusion deficits in the cerebellum and anterior cingulate also correlated (p<0.01) with neurocognitive results, including the mean reaction time in the Automated Neuropsychological Assessment Metrics and commission error and detection T-scores in the Continuous Performance Test, as well as neurobehavioral scores in the Post-traumatic Stress Disorder ChecklistCivilian Version. In conclusion, rCBF calculated using AIFs selected from an automated approach demonstrated a good agreement with the corresponding results using manually selected AIFs. Group analysis of patients with mild TBI from a military population demonstrated scattered perfusion deficits, which showed significant correlations with measures of verbal memory, speed of reaction time and self-report of stress symptoms. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.	[Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Graner, John; Pan, Hai; Harper, Jamie; Oakes, Terrence R.; Riedy, Gerard] NCNC, Bethesda, MD USA; [Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Pan, Hai] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Wolfowitz, Rachel; Graner, John; Harper, Jamie; Oakes, Terrence R.; Riedy, Gerard] Natl Intrepid Ctr Excellence NICoE, Bethesda, MD USA; [Tang, Haiying; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Dzung Pham; French, Louis M.] CNRM, Rockville, MD USA; [French, Louis M.] WRNMMC, Bethesda, MD USA		Riedy, G (corresponding author), Natl Intrepid Ctr Excellence, Bethesda, MD 20889 USA.	Gerard.riedy@med.navy.mil	Pham, Dzung/AAR-8263-2020; french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [33333]; Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [PT074437]	This research was supported by Center for Neuroscience and Regenerative Medicine (CNRM) grant #33333 and Congressionally Directed Medical Research Programs (CDMRP) grant PT074437. The authors would like to thank Dr. John A. Butman for providing the method for automated AIF selection and Dr Robert W. Cox, Dr Daniel Glen, Dr Richard Reynolds and Dr Ziad Saad for their support with the AFNI software.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bjornerud A, 2010, J CEREBR BLOOD F MET, V30, P1066, DOI 10.1038/jcbfm.2010.4; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Borghammer P, 2009, NEUROIMAGE, V45, P249, DOI 10.1016/j.neuroimage.2008.07.042; Bradshaw BGD, 2008, TBI TASK FORCE REPOR; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Butman JA, 2005, P INT SOC MAGN RESON, V13, P1126; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Carroll TJ, 2003, RADIOLOGY, V227, P593, DOI 10.1148/radiol.2272020092; Casey BJ, 1997, DEV PSYCHOBIOL, V30, P61, DOI 10.1002/(SICI)1098-2302(199701)30:1<61::AID-DEV6>3.0.CO;2-T; Conturo TE, 2005, J MAGN RESON IMAGING, V22, P697, DOI 10.1002/jmri.20457; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Field AS, 2003, RADIOLOGY, V227, P129, DOI 10.1148/radiol.2271012173; Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Graner J, 2011, P INT SOC MAGN RESON, V3662; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Grunder G, 2009, NEUROIMAGE, V45, P258, DOI 10.1016/j.neuroimage.2008.10.042; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUBOTA K, 1983, STROKE, V14, P720, DOI 10.1161/01.STR.14.5.720; LAMMERTSMA AA, 1984, J CEREBR BLOOD F MET, V4, P317, DOI 10.1038/jcbfm.1984.47; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; MEIER P, 1954, J APPL PHYSIOL, V6, P731, DOI 10.1152/jappl.1954.6.12.731; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miao Y, 2011, AM J NEURORADIOL, V32, P1280, DOI 10.3174/ajnr.A2540; Mlynash M, 2005, AM J NEURORADIOL, V26, P1479; Mukherjee P, 2003, AM J NEURORADIOL, V24, P862; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P425, DOI 10.1097/00004647-199804000-00011; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Peruzzo D, 2011, COMPUT METH PROG BIO, V104, pE148, DOI 10.1016/j.cmpb.2011.02.012; Rausch M, 2000, MAGN RESON IMAGING, V18, P1235, DOI 10.1016/S0730-725X(00)00219-8; REMPP KA, 1994, RADIOLOGY, V193, P637, DOI 10.1148/radiology.193.3.7972800; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruminski J, 2005, ADV SOFT COMP, P671, DOI 10.1007/3-540-32390-2_79; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Van Laere KJ, 2002, J NUCL MED, V43, P458; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vlassenko A, 2004, J NEUROPSYCH CLIN N, V16, P360, DOI 10.1176/appi.neuropsych.16.3.360; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEISSKOFF RM, 1994, MAGNET RESON MED, V31, P601, DOI 10.1002/mrm.1910310605; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMASHITA K, 1988, GERONTOLOGY, V34, P199, DOI 10.1159/000212953; Zasler ND, 2006, BRAIN INJURY MED PRI, P333; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	79	40	40	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	JUN	2013	26	6					651	663		10.1002/nbm.2910			13	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	134RJ	WOS:000318231700007	23456696				2022-02-06	
J	Newcombe, VFJ; Williams, GB; Outtrim, JG; Chatfield, D; Abate, MG; Geeraerts, T; Manktelow, A; Room, H; Mariappen, L; Hutchinson, PJ; Coles, JP; Menon, DK				Newcombe, Virginia F. J.; Williams, Guy B.; Outtrim, Joanne G.; Chatfield, Doris; Abate, M. Gulia; Geeraerts, Thomas; Manktelow, Anne; Room, Hywel; Mariappen, Leela; Hutchinson, Peter J.; Coles, Jonathan P.; Menon, David K.			Microstructural basis of contusion expansion in traumatic brain injury: insights from diffusion tensor imaging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						contusions; diffusion tensor imaging; traumatic brain injury	HEAD-INJURY; TIME-COURSE; CEREBRAL CONTUSION; EDEMA; COEFFICIENT; PERFUSION; STROKE; PROGRESSION; TOMOGRAPHY; MECHANISMS	Traumatic brain injury (TBI) is often exacerbated by events that lead to secondary brain injury, and represent potentially modifiable causes of mortality and morbidity. Diffusion tensor imaging was used to characterize tissue at-risk in a group of 35 patients scanned at a median of 50 hours after injury. Injury progression was assessed in a subset of 16 patients with two scans. All contusions within the first few days of injury showed a core of restricted diffusion, surrounded by an area of raised apparent diffusion coefficient (ADC). In addition to these two well-defined regions, a thinner rim of reduced ADC was observed surrounding the region of increased ADC in 91% of patients scanned within the first 3 days after injury. In patients who underwent serial imaging, the rim of ADC hypointensity was subsumed into the high ADC region as the contusion enlarged. Overall contusion enlargement tended to be more frequent with early lesions, but its extent was unrelated to the time of initial imaging, initial contusion size, or the presence of hemostatic abnormalities. This rim of hypointensity may characterize a region of microvascular failure resulting in cytotoxic edema, and may represent a 'traumatic penumbra' which may be rescued by effective therapy.	[Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris; Abate, M. Gulia; Geeraerts, Thomas; Manktelow, Anne; Room, Hywel; Mariappen, Leela; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Anaesthesia, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Williams, Guy B.; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Abate, M. Gulia] San Gerardo Hosp, Dept Perioperat Med & Intens Care, Milan, Italy; [Geeraerts, Thomas] Univ Toulouse 3, Univ Hosp Toulouse, Anesthesiol & Crit Care Dept, F-31062 Toulouse, France; [Hutchinson, Peter J.] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England		Newcombe, VFJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	vfjn2@cam.ac.uk		Newcombe, Virginia/0000-0001-6044-9035; Coles, Jonathan/0000-0003-4013-679X; Outtrim, Joanne/0000-0001-8118-6430	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; NIHRNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G1000183B, G9439390, G0001354, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0512-10090] Funding Source: researchfish	This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. VFJN is supported by an NIHR academic clinical fellowship. PJAH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. DKM is supported by an NIHR Senior Investigator Award. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Copen WA, 2001, RADIOLOGY, V221, P27, DOI 10.1148/radiol.2211001397; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fiehler J, 2004, STROKE, V35, P514, DOI 10.1161/01.STR.0000114873.28023.C2; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kuroiwa T, 2000, ACT NEUR S, V76, P191; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Liu KF, 2001, STROKE, V32, P1897, DOI 10.1161/01.STR.32.8.1897; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Rae CL, 2012, NEUROIMAGE, V62, P1675, DOI 10.1016/j.neuroimage.2012.06.012; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; WAGNER DP, 1984, MED DECIS MAKING, V4, P297, DOI 10.1177/0272989X8400400305; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	40	40	42	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2013	33	6					855	862		10.1038/jcbfm.2013.11			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	156KP	WOS:000319821100008	23423189	Green Published, Bronze			2022-02-06	
J	Yan, ZJ; Zhang, P; Hu, YQ; Zhang, HT; Hong, SQ; Zhou, HL; Zhang, MY; Xu, RX				Yan, Zhong-Jie; Zhang, Peng; Hu, Yu-Qin; Zhang, Hong-Tian; Hong, Sun-Quan; Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Ru-Xiang			Neural Stem-Like Cells Derived from Human Amnion Tissue are Effective in Treating Traumatic Brain Injury in Rat	NEUROCHEMICAL RESEARCH			English	Article						Amnion; Neural differentiation; Neural stem cells; Transplantation; Traumatic brain injury	NEUROTROPHIC FACTORS; PROGENITOR CELLS; MESENCHYMAL CELLS; CORD BLOOD; TRANSPLANTATION; EXPRESSION; DEFICITS; MODEL; DIFFERENTIATION; MEMBRANE	Although human amnion derived mesenchymal stem cells (AMSC) are a promising source of stem cells, their therapeutic potential for traumatic brain injury (TBI) has not been widely investigated. In this study, we evaluated the therapeutic potential of AMSC using a rat TBI model. AMSC were isolated from human amniotic membrane and characterized by flow cytometry. After induction, AMSC differentiated in vitro into neural stem-like cells (AM-NSC) that expressed higher levels of the neural stem cell markers, nestin, sox2 and musashi, in comparison to undifferentiated AMSC. Interestingly, the neurotrophic factors, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), glial cell derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) were markedly upregulated after neural stem cell induction. Following transplantation in a rat TBI model, significant improvements in neurological function, brain tissue morphology, and higher levels of BDNF, NGF, NT-3, GDNF and CNTF, were observed in the AM-NSC group compared with the AMSC and Matrigel groups. However, few grafted cells survived with minimal differentiation into neural-like cells. Together, our results suggest that transplantation of AM-NSC promotes functional rehabilitation of rats with TBI, with enhanced expression of neurotrophic factors a likely mechanistic pathway.	[Yan, Zhong-Jie; Zhang, Peng; Hong, Sun-Quan; Zhou, Hong-Long; Zhang, Mao-Ying] Southern Med Univ, Zhujiang Hosp, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Yan, Zhong-Jie; Zhang, Peng; Zhang, Hong-Tian; Zhou, Hong-Long; Zhang, Mao-Ying; Xu, Ru-Xiang] Southern Med Univ, Bayi Clin Med Inst, Mil Gen Hosp Beijing PLA, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China; [Hu, Yu-Qin] Southern Med Univ, Affiliated Hexian Mem Hosp, Dept Gynecol & Obstet, Guangzhou 511400, Guangdong, Peoples R China		Xu, RX (corresponding author), Southern Med Univ, Bayi Clin Med Inst, Mil Gen Hosp Beijing PLA, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China.	xuruxiang_neuron@126.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U0632008, 81100916]	We thank Health & Biotech (Guangdong, Guangzhou, China) for their kindly presenting human amnion derived mesenchymal stem cells. This research was supported by the Natural Science Foundation of China (U0632008, 81100916).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang YJ, 2010, CELLS TISSUES ORGANS, V192, P93, DOI 10.1159/000295774; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fisher-Shoval Y, 2012, J MOL NEUROSCI, V48, P176, DOI 10.1007/s12031-012-9805-6; Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22-5-649; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hayase M, 2009, J CEREBR BLOOD F MET, V29, P1409, DOI 10.1038/jcbfm.2009.62; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Jiang JJ, 2010, NEUROSCI RES, V66, P46, DOI 10.1016/j.neures.2009.09.1711; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Magatti M, 2009, CELL TRANSPLANT, V18, P899, DOI 10.3727/096368909X471314; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; PAXINOS G, 2005, RAT BRAIN STEREOTAXI, P98; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Qian DX, 2010, NEUROCHEM RES, V35, P572, DOI 10.1007/s11064-009-0101-y; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Soncini M, 2007, J TISSUE ENG REGEN M, V1, P296, DOI 10.1002/term.40; Tao J, 2012, BRAIN RES, V1448, P1, DOI 10.1016/j.brainres.2012.01.069; Tsai MS, 2007, STEM CELLS, V25, P2511, DOI 10.1634/stemcells.2007-0023; Tsuji H, 2010, CIRC RES, V106, P1613, DOI 10.1161/CIRCRESAHA.109.205260; Warrier S, 2012, PLACENTA, V33, P850, DOI 10.1016/j.placenta.2012.07.001; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yaghoobi MM, 2008, BRAIN RES, V1203, P26, DOI 10.1016/j.brainres.2008.01.086; Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098; Zhang HT, 2009, NEUROSCI LETT, V458, P116, DOI 10.1016/j.neulet.2009.04.045; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x; Zhu RS, 2007, J NEUROSCI RES, V85, P3064, DOI 10.1002/jnr.21426	40	40	42	1	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2013	38	5					1022	1033		10.1007/s11064-013-1012-5			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	116SO	WOS:000316903200014	23475428				2022-02-06	
J	Brandstack, N; Kurki, T; Tenovuo, O				Brandstack, Nina; Kurki, Timo; Tenovuo, Olli			Quantitative Diffusion-Tensor Tractography of Long Association Tracts in Patients with Traumatic Brain Injury without Associated Findings at Routine MR Imaging	RADIOLOGY			English	Article							WHITE-MATTER INJURY; AXONAL INJURY; FIBER TRACTOGRAPHY; HEAD-INJURY; INTEGRITY; ABNORMALITIES; IMPAIRMENT; DISABILITY; DISTORTION; SEQUELAE	Purpose: To evaluate whether quantitative diffusion-tensor tractography can show abnormalities in long association tracts of subjects with symptoms after traumatic brain injury without any visible signs of intracranial or intraparenchymal abnormalities of obvious traumatic origin at routine magnetic resonance (MR) imaging and to determine the number and type of these abnormalities. Materials and Methods: The study was approved by the local ethics committee, and informed consent was obtained from all subjects. Diffusion-tensor tractography was performed at 3.0 T in 106 consecutive clinical patients with traumatic brain injury without abnormalities at conventional MR imaging (age, 16-56 years) and 62 age- and sex-matched control subjects. Volume, mean apparent diffusion coefficient (ADC), and mean fractional anisotropy (FA) were measured in the following tracts: uncinate fasciculus, superior cingulum, temporal cingulum, superior longitudinal fasciculus, arcuate fasciculus, inferior fronto-occipital fasciculus, and inferior longitudinal fasciculus. Statistical analyses were based on repeated-measures analysis of covariance. Results: In control subjects, tract volumes showed large variability whereas FA and ADC showed small variability. In several tracts, mean FA values correlated negatively with the respective volumes. In patients with brain injury, FA values were reduced in both uncinate fasciculi, both inferior fronto-occipital fasciculi, and in the right inferior longitudinal fasciculus compared with control subjects (P < .05). Diffusivity was increased in half of the tracts (P < .05). The tract volumes were not significantly reduced. Conclusion: Quantitative diffusion-tensor tractography is able to show posttraumatic FA and ADC abnormalities in patients with normal findings at conventional MR imaging in several association tracts, most commonly the uncinate fasciculus. (C)RSNA, 2013	[Brandstack, Nina; Kurki, Timo] Turku Univ Hosp, Dept Radiol, FIN-20520 Turku, Finland; [Tenovuo, Olli] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland; [Kurki, Timo] Pulssi Med Ctr, Dept Radiol, Turku, Finland		Brandstack, N (corresponding author), Helsinki Univ Hosp, Dept Radiol, PL 340, Helsinki 00029, HUS, Finland.	nimabr@utu.fi		Kurki, Timo/0000-0001-5532-3534			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Borich MR, 2012, NEUROIMAGE, V59, P2393, DOI 10.1016/j.neuroimage.2011.09.009; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Catani M, 2008, CORTEX, V44, P953, DOI 10.1016/j.cortex.2008.04.002; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Duffau H, 2009, J NEUROL, V256, P382, DOI 10.1007/s00415-009-0053-9; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Hasan KM, 2010, BRAIN STRUCT FUNCT, V214, P361, DOI 10.1007/s00429-009-0238-0; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	39	40	40	0	12	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	2013	267	1					231	239		10.1148/radiol.12112570			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	112AX	WOS:000316565000024	23297328	Bronze			2022-02-06	
J	Kim, N; Branch, CA; Kim, M; Lipton, ML				Kim, Namhee; Branch, Craig A.; Kim, Mimi; Lipton, Michael L.			Whole Brain Approaches for Identification of Microstructural Abnormalities in Individual Patients: Comparison of Techniques Applied to Mild Traumatic Brain Injury	PLOS ONE			English	Article							DIFFUSION TENSOR IMAGES; WHITE-MATTER INTEGRITY; AXONAL INJURY; FRACTIONAL ANISOTROPY; PERSONALIZED MEDICINE; VOXELWISE ANALYSIS; CORPUS-CALLOSUM; REGISTRATION; BIOMARKERS; PHARMACOGENOMICS	Purpose: Group-wise analyses of DTI in mTBI have demonstrated evidence of traumatic axonal injury (TAI), associated with adverse clinical outcomes. Although mTBI is likely to have a unique spatial pattern in each patient, group analyses implicitly assume that location of injury will be the same across patients. The purpose of this study was to optimize and validate a procedure for analysis of DTI images acquired in individual patients, which could detect inter-individual differences and be applied in the clinical setting, where patients must be assessed as individuals. Materials and Methods: After informed consent and in compliance with HIPAA, 34 mTBI patients and 42 normal subjects underwent 3.0 Tesla DTI. Four voxelwise assessment methods (standard Z-score, "one vs. many" t-test, Family-Wise Error Rate control using pseudo t-distribution, EZ-MAP) for use in individual patients, were applied to each patient's fractional anisotropy (FA) maps and tested for its ability to discriminate patients from controls. Receiver Operating Characteristic (ROC) analyses were used to define optimal thresholds (voxel-level significance and spatial extent) for reliable and robust detection of mTBI pathology. Results: ROC analyses showed EZ-MAP (specificity 71%, sensitivity 71%), "one vs. many" t-test and standard Z-score (sensitivity 65%, specificity 76% for both methods) resulted in a significant area under the curve (AUC) score for discriminating mTBI patients from controls in terms of the total number of abnormal white matter voxels detected while the FWER test was not significant. EZ-MAP is demonstrated to be robust to assumptions of Gaussian behavior and may serve as an alternative to methods that require strict Gaussian assumptions. Conclusion: EZ-MAP provides a robust approach for delineation of regional abnormal anisotropy in individual mTBI patients.	[Kim, Namhee; Branch, Craig A.; Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA; [Kim, Namhee; Branch, Craig A.; Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Radiol, Bronx, NY USA; [Branch, Craig A.] Yeshiva Univ, Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY USA; [Kim, Mimi] Yeshiva Univ, Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA; [Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY USA; [Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA		Lipton, ML (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu			Dana Foundation; David Mahoney Neuroimaging Program; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS082432]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	This work was supported by The Dana Foundation, David Mahoney Neuroimaging Program and by National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01 NS082432). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Becla L, 2011, INT J TECHNOL ASSESS, V27, P118, DOI 10.1017/S026646231100002X; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Curran ME, 2011, PHARMACOGENOMICS, V12, P465, DOI 10.2217/pgs.11.9; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar D, 2011, ANN I SUPER SANITA, V47, P31, DOI 10.4415/ANN_11_01_08; Li C, 2011, CLIN GENET, V79, P403, DOI 10.1111/j.1399-0004.2010.01609.x; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Muller HP, 2009, MAGN RESON IMAGING, V27, P324, DOI 10.1016/j.mri.2008.07.003; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Patel SA, 2007, J MAGN RESON IMAGING, V26, P552, DOI 10.1002/jmri.21076; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Plas J, 1999, REV NEUROL, V155, P569; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sato Y, 2010, CURR PHARM DESIGN, V16, P2232, DOI 10.2174/138161210791792886; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Viviani R, 2007, HUM BRAIN MAPP, V28, P1075, DOI 10.1002/hbm.20332; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058	44	40	40	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2013	8	3							e59382	10.1371/journal.pone.0059382			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123VE	WOS:000317418500037	23555665	Green Published, gold, Green Submitted			2022-02-06	
J	Hendrix, S; Kramer, P; Pehl, D; Warnke, K; Boato, F; Nelissen, S; Lemmens, E; Pejler, G; Metz, M; Siebenhaar, F; Maurer, M				Hendrix, Sven; Kramer, Peter; Pehl, Debora; Warnke, Katharina; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi; Pejler, Gunnar; Metz, Martin; Siebenhaar, Frank; Maurer, Marcus			Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4	FASEB JOURNAL			English	Article						entorhinal cortex lesion; mMCP-4; protease; T cells	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-ISCHEMIA; EARLY RESPONDERS; MICE; ACTIVATION; PROTEASES; BIOLOGY; MOUSE	Mast cells (MCs) are found abundantly in the brain and the meninges and play a complex role in neuroinflammatory diseases, such as stroke and multiple sclerosis. Here, we show that MC-deficient Kit(W)/Kit(W-v) mice display increased neurodegeneration in the lesion area after brain trauma. Furthermore, MC-deficient mice display significantly more brain inflammation, namely an increased presence of macrophages/microglia, as well as dramatically increased T-cell infiltration at days 4 and 14 after injury, combined with increased astrogliosis at day 14 following injury. The number of proliferating Ki67(+) macrophages/microglia and astrocytes around the lesion area is more than doubled in these MC-deficient mice. In parallel, MC-deficient Kit(W-sh/W-sh) mice display increased presence of macrophages/microglia at day 4, and persistent astrogliosis at day 4 and 14 after brain trauma. Further analysis of mice deficient in one of the most relevant MC proteases, i.e., mouse mast cell protease 4 (mMCP-4), revealed that astrogliosis and T-cell infiltration are significantly increased in mMCP-4-knockout mice. Finally, treatment with an inhibitor of mMCP-4 significantly increased macrophage/microglia numbers and astrogliosis. These data suggest that MCs exert protective functions after trauma, at least in part via mMCP-4, by suppressing exacerbated inflammation via their proteases.-Hendrix, S., Kramer, P., Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., Maurer, M. Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. FASEB J. 27, 920-929 (2013). www.fasebj.org	[Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Dept Morphol, Diepenbeek, Belgium; [Hendrix, Sven; Boato, Francesco; Nelissen, Sofie; Lemmens, Evi] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium; [Kramer, Peter; Pehl, Debora; Warnke, Katharina] Charite, Ctr Anat Cell Biol & Neurobiol, D-13353 Berlin, Germany; [Metz, Martin; Siebenhaar, Frank; Maurer, Marcus] Charite, Dept Dermatol, D-13353 Berlin, Germany; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden		Hendrix, S (corresponding author), Dept Morphol, Agoralaan Gebouw D, BE-3590 Diepenbeek, Belgium.	sven.hendrix@uhasselt.be	Metz, Martin/M-5237-2013; Hendrix, Sven/F-4059-2010; Metz, Martin/B-8799-2009	Metz, Martin/0000-0002-4070-9976; Hendrix, Sven/0000-0003-2344-7369; Metz, Martin/0000-0002-4070-9976; Boato, Francesco/0000-0001-9741-8021; Lemmens, Evi/0000-0001-6044-5659; Maurer, Marcus/0000-0002-4121-481X; Kramer, Peter/0000-0003-4780-5271; Siebenhaar, Frank/0000-0003-4532-1644	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SPP1394]; Fonds Wetenschappelijk Onderzoek-VlaanderenFWO [G.0834.11N, G.0389.12]	The authors are indebted to Doreen Ludecke and Julia Konig for their engaged and skillful technical assistance, to Nathalie Geurts for performing the FACS analyses and to Dearbhaile Dooley for editing the text. P.K. was a member of GRK1258. This study was supported in part by grants from Deutsche Forschungsgemeinschaft (SPP1394) and from Fonds Wetenschappelijk Onderzoek-Vlaanderen (G.0834.11N, G.0389.12) to S.H. The authors declare no conflicts of interests.	Bennett JL, 2009, J IMMUNOL, V182, P5507, DOI 10.4049/jimmunol.0801485; Berghmans N, 2011, J INTERF CYTOK RES, V31, P575, DOI 10.1089/jir.2010.0137; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Brown MA, 2002, MOL IMMUNOL, V38, P1373, DOI 10.1016/S0161-5890(02)00091-3; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; DROPP JJ, 1972, ANAT REC, V174, P227, DOI 10.1002/ar.1091740207; Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hendrix S, 2006, NEUROSCI LETT, V392, P174, DOI 10.1016/j.neulet.2005.09.029; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Kwidzinski E, 2003, J NEURAL TRANSM-SUPP, P29, DOI 10.1007/978-3-7091-0643-3_2; Li HM, 2011, J IMMUNOL, V187, P274, DOI 10.4049/jimmunol.1003603; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Manni L, 1998, INT J DEV NEUROSCI, V16, P1, DOI 10.1016/S0736-5748(98)00003-3; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; Robbie-Ryan M, 2003, J IMMUNOL, V170, P1630, DOI 10.4049/jimmunol.170.4.1630; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Skaper SD, 2001, J NEUROCHEM, V76, P47, DOI 10.1046/j.1471-4159.2001.00008.x; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Strbian D, 2007, J CEREBR BLOOD F MET, V27, P795, DOI 10.1038/sj.jcbfm.9600387; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Taiwo OB, 2005, PAIN, V114, P131, DOI 10.1016/j.pain.2004.12.002; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Waskow C, 2004, BLOOD, V104, P1688, DOI 10.1182/blood-2004-04-1247; Zappulla JP, 2002, J NEUROIMMUNOL, V131, P5, DOI 10.1016/S0165-5728(02)00250-3; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	38	40	42	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2013	27	3					920	929		10.1096/fj.12-204800			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	098YO	WOS:000315585200008	23193170				2022-02-06	
J	Franceschini, M; Rampello, A; Agosti, M; Massucci, M; Bovolenta, F; Sale, P				Franceschini, Marco; Rampello, Anais; Agosti, Maurizio; Massucci, Maurizio; Bovolenta, Federica; Sale, Patrizio			Walking Performance: Correlation between Energy Cost of Walking and Walking Participation. New Statistical Approach Concerning Outcome Measurement	PLOS ONE			English	Article							COMMUNITY AMBULATION; STROKE PATIENTS; LEVEL WALKING; OLDER-ADULTS; GAIT; REHABILITATION; POPULATION; PARAMETERS; MOBILITY; INJURY	Walking ability, though important for quality of life and participation in social and economic activities, can be adversely affected by neurological disorders, such as Spinal Cord Injury, Stroke, Multiple Sclerosis or Traumatic Brain Injury. The aim of this study is to evaluate if the energy cost of walking (CW), in a mixed group of chronic patients with neurological diseases almost 6 months after discharge from rehabilitation wards, can predict the walking performance and any walking restriction on community activities, as indicated by Walking Handicap Scale categories (WHS). One hundred and seven subjects were included in the study, 31 suffering from Stroke, 26 from Spinal Cord Injury and 50 from Multiple Sclerosis. The multivariable binary logistical regression analysis has produced a statistical model with good characteristics of fit and good predictability. This model generated a cut-off value of. 40, which enabled us to classify correctly the cases with a percentage of 85.0%. Our research reveal that, in our subjects, CW is the only predictor of the walking performance of in the community, to be compared with the score of WHS. We have been also identifying a cut-off value of CW cost, which makes a distinction between those who can walk in the community and those who cannot do it. In particular, these values could be used to predict the ability to walk in the community when discharged from the rehabilitation units, and to adjust the rehabilitative treatment to improve the performance.	[Franceschini, Marco; Sale, Patrizio] IRCCS San Raffale, Dept NeuroRehabilitat, Rome, Italy; [Rampello, Anais; Agosti, Maurizio] Univ Hosp, Dept Rehabil, Parma, Italy; [Massucci, Maurizio] Hosp Passignano, Rehabil Unit, Perugia, Italy; [Bovolenta, Federica] Med Rehabil NOCSAE Hosp AUSL Modena, Modena, Italy		Sale, P (corresponding author), IRCCS San Raffale, Dept NeuroRehabilitat, Rome, Italy.	patrizio.sale@gmail.com	Sale, Patrizio/K-8757-2016; Sale, Patrizio/J-3276-2019	Sale, Patrizio/0000-0002-4850-3673; Sale, Patrizio/0000-0002-4850-3673; Franceschini, Marco/0000-0002-2131-1583; Agosti, Maurizio/0000-0003-2365-3488			BAMBER D, 1975, J MATH PSYCHOL, V12, P387, DOI 10.1016/0022-2496(75)90001-2; Barbeau H, 2001, CURR OPIN NEUROL, V14, P735, DOI 10.1097/00019052-200112000-00009; Bernardi M, 1999, J ELECTROMYOGR KINES, V9, P149, DOI 10.1016/S1050-6411(98)00046-7; Blessey R L, 1976, Phys Ther, V56, P1019; Bregman DJJ, 2010, PROSTHET ORTHOT INT, V34, P293, DOI 10.3109/03093646.2010.495969; Corrigan R, 2008, DISABIL REHABIL, V30, P1079, DOI 10.1080/09638280701623158; Cunha IT, 2002, AM J PHYS MED REHAB, V81, P848, DOI 10.1097/00002060-200211000-00008; Delextrat A, 2011, HUM MOVEMENT SCI, V30, P115, DOI 10.1016/j.humov.2010.10.004; Duffy CM, 1997, DEV MED CHILD NEUROL, V39, P234; Eriksson JS, 2012, EUR J APPL PHYSIOL, V112, P345, DOI 10.1007/s00421-011-1985-1; Finlayson ML, 2010, PHYS MED REH CLIN N, V21, P357, DOI 10.1016/j.pmr.2009.12.003; Franceschini M, 2003, CLIN REHABIL, V17, P368, DOI 10.1191/0269215503cr622oa; Ijzerman MJ, 2002, ARCH PHYS MED REHAB, V83, P1777, DOI 10.1053/apmr.2002.35655; Kelly JO, 2003, ARCH PHYS MED REHAB, V84, P1780, DOI 10.1016/S0003-9993(03)00376-9; Lapointe R, 2001, SPINAL CORD, V39, P327, DOI 10.1038/sj.sc.3101167; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; Maclean N, 2000, SOC SCI MED, V50, P495; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Mudge S, 2009, ARCH PHYS MED REHAB, V90, P296, DOI 10.1016/j.apmr.2008.07.025; Pang MYC, 2007, PHYS THER, V87, P282, DOI 10.2522/ptj.20060142; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Peyrot N, 2009, J APPL PHYSIOL, V106, P1763, DOI 10.1152/japplphysiol.91240.2008; Rosdahl H, 2010, EUR J APPL PHYSIOL, V109, P159, DOI 10.1007/s00421-009-1326-9; SCHAFER H, 1989, STAT MED, V8, P1381, DOI 10.1002/sim.4780081110; Shumway-Cook A, 2002, PHYS THER, V82, P670, DOI 10.1093/ptj/82.7.670; Snook EM, 2009, NEUROREHAB NEURAL RE, V23, P108, DOI 10.1177/1545968308320641; van de Port IG, 2008, J REHABIL MED, V40, P23, DOI 10.2340/16501977-0114; van Hedel HJA, 2010, RESTOR NEUROL NEUROS, V28, P123, DOI 10.3233/RNN-2010-0508; WATERS R L, 1983, Journal of Orthopaedic Research, V1, P73, DOI 10.1002/jor.1100010110; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P756; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; World Health Organization/Regional Office for Europe. Vienna Declaration on Nutrition and Noncommunicable Diseases in the Context of Health, 2013, WHO EUR MIN C NUTR N, P5, DOI [10.1136/bmj.f4417, DOI 10.1136/BMJ.F4417]; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zamparo P., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P348; Zamparo P, 1998, SCAND J MED SCI SPOR, V8, P222; ZWEIG MH, 1993, CLIN CHEM, V39, P561	37	40	40	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e56669	10.1371/journal.pone.0056669			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	WOS:000315524900030	23468871	gold, Green Published, Green Submitted			2022-02-06	
J	Hendricks, AM; Amara, J; Baker, E; Charns, MP; Gardner, JA; Iverson, KM; Kimerling, R; Krengel, M; Meterko, M; Pogoda, TK; Stolzmann, KL; Lew, HL				Hendricks, Ann M.; Amara, Jomana; Baker, Errol; Charns, Martin P.; Gardner, John A.; Iverson, Katherine M.; Kimerling, Rachel; Krengel, Maxine; Meterko, Mark; Pogoda, Terri K.; Stolzmann, Kelly L.; Lew, Henry L.			Screening for mild traumatic brain injury in OEF-OIF deployed US military: An empirical assessment of VHA's experience	BRAIN INJURY			English	Article						Afghanistan; blast injuries; brain injuries; depression; Iraq; non-blast injuries; post-traumatic stress disorder; screening; Veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MENTAL-HEALTH PROBLEMS; VETERANS; IRAQ; AFGHANISTAN; TBI; CHALLENGES; DIAGNOSES; OUTCOMES	Background: VHA screens for traumatic brain injury (TBI) among patients formerly deployed to Afghanistan or Iraq, referring those who screen positive for a Comprehensive TBI Evaluation (CTBIE). Methods: To assess the programme, rates were calculated of positive screens for potential TBI in the population of patients screened in VHA between October 2007 through March 2009. Rates were derived of TBI confirmed by comprehensive evaluations from October 2008 through July 2009. Patient characteristics were obtained from Department of Defense and VHA administrative data. Results: In the study population, 21.6% screened positive for potential TBI and 54.6% of these had electronic records of a CTBIE. Of those with CTBIE records, evaluators confirmed TBI in 57.7%, yielding a best estimate that 6.8% of all those screened were confirmed to have TBI. Three quarters of all screened patients and virtually all those evaluated (whether TBI was confirmed or not) had VHA care the following year. Conclusions: VHA's TBI screening process is inclusive and has utility in referring patients with current symptoms to appropriate care. More than 90% of those evaluated received further VHA care and confirmatory evaluations were associated with significantly higher average utilization. Generalizability is limited to those who seek VHA healthcare.	[Hendricks, Ann M.; Baker, Errol; Charns, Martin P.; Gardner, John A.; Iverson, Katherine M.; Krengel, Maxine; Meterko, Mark; Pogoda, Terri K.; Stolzmann, Kelly L.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Hendricks, Ann M.; Charns, Martin P.; Meterko, Mark; Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Amara, Jomana] USN, Postgrad Sch, DRMI, Monterey, CA USA; [Iverson, Katherine M.; Krengel, Maxine] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA; [Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Lew, Henry L.] Univ Hawaii Manoa, Honolulu, HI 96822 USA		Hendricks, AM (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave,152 H, Boston, MA 02130 USA.	ahendricksphd@gmail.com	; Pogoda, Terri/F-6243-2012	Krengel, Maxine/0000-0001-7632-590X; Charns, Martin/0000-0002-7102-5331; Pogoda, Terri/0000-0003-1397-8780; Kimerling, Rachel/0000-0003-0996-4212	Office of Research and Development, Health Services R&D Service, Department of Veterans AffairsUS Department of Veterans Affairs [SDR 08-405]	This paper is based on work supported by the Office of Research and Development, Health Services R&D Service, Department of Veterans Affairs, through SDR 08-405. The opinions expressed in this article are the authors' and do not reflect those of the Department of Veterans Affairs, the Veterans Health Administration, Health Services Research and Development, the Defense and Veterans Brain Injury Center or the Department of Defense. We thank Douglas Bidelspach, David Cifu, Carlos Tun and three anonymous reviewers for comments on prior versions of this paper.	Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Committee on Gulf War and Health, 2008, BRAIN INJ VET LONG T, V7; Department of Defense, NUMBERS TRAUMATIC BR; Department of Veterans Affairs, 2011, VA ANN BUDG REQ FY 2; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU, P32; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Golding H, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0081; Hendricks A., 2012, PTSD MILD TRAUMATIC, P260; Hendricks A, 2011, HSR D 2011 NAT M WAS; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kupersmith J, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0079; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2007, AM J PHYS MED REHAB, V86, P1035, DOI 10.1097/01.phm.0000297446.70510.d4; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lew HL, 2007, J REHABILITATION RES, V44, P179; Lew HL, 2006, ARCH PHYS MED REHAB, V87, pe6; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Office of Rehabilitation Services Veterans Health Administration, 2010, STAT COMPR TBI EV; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pogoda TK, 2009, AM J PHYS MED REHAB, V88, P1043, DOI 10.1097/PHM.0b013e3181c1eef5; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; U.S. Government Accountability Office, 2008, 08276 GAO; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	41	40	40	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2013	27	2					125	134		10.3109/02699052.2012.729284			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	083PX	WOS:000314478500001	23384211				2022-02-06	
J	Li, SX; Sun, Y; Shan, D; Feng, B; Xing, JJ; Duan, YJ; Dai, JP; Lei, H; Zhou, YW				Li, Shangxun; Sun, Yan; Shan, Dai; Feng, Bin; Xing, Jingjun; Duan, Yijie; Dai, Jiapei; Lei, Hao; Zhou, Yiwu			Temporal profiles of axonal injury following impact acceleration traumatic brain injury in rats-a comparative study with diffusion tensor imaging and morphological analysis	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Traumatic brain injury; Traumatic axonal injury; Diffusion tensor imaging; Biomarker; beta-Amyloid precursor protein; Neurofilament	INTRAAXONAL NEUROFILAMENT COMPACTION; AMYLOID PRECURSOR PROTEIN; EARLY-DIAGNOSIS; SPINAL-CORD; MOUSE MODEL; DAMAGE; ACCUMULATION; TRANSPORT; RECOVERY; MILD	Traumatic axonal injury (TAI) plays a major role in the development of neurological impairments after traumatic brain injury (TBI), but it is commonly difficult to evaluate it precisely and early with conventional histological biomarkers, especially when the patients experience short-term survival after TBI. Diffusion tensor imaging (DTI) has shown some promise in detecting TAI, but longitudinal studies on the compromised white matter with DTI at early time points (a parts per thousand currency sign72 h) following impact acceleration TBI are still absent. In the present study, rats were subjected to the Marmarou model and imaged with DTI at 3, 12, 24, and 72 h (n = 5 each) post-injury. Using a region-of-interest-based approach, the regions of interest including the corpus callosum, bilateral external capsule, internal capsule, and pyramidal tract were studied. Two DTI parameters, fraction anisotropy and axial diffusivity, were significantly reduced from 3 to 72 h in each region after trauma, corresponding to the gradient of axonal damage demonstrated by immunohistochemical staining of beta-amyloid precursor protein and neurofilament light chain. Remarkably, DTI changes predicted the approximate time in the acute phase following TBI. These results indicate that the temporal profiles of diffusion parameters in DTI may be able to provide a tool for early diagnosis of TAI following impact acceleration TBI.	[Li, Shangxun; Xing, Jingjun; Duan, Yijie; Zhou, Yiwu] Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Forens Med, Wuhan 430030, Peoples R China; [Sun, Yan; Feng, Bin; Dai, Jiapei] S Cent Univ Nationlities, Wuhan Inst Neurosci & Neuroengn, Wuhan 430074, Peoples R China; [Shan, Dai; Lei, Hao] Chinese Acad Sci, State Key Lab Magnet Resonance & Atom & Mol Phys, Wuhan Ctr Magnet Resonance, Wuhan Inst Phys & Math, Wuhan 430071, Peoples R China		Zhou, YW (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Forens Med, Wuhan 430030, Peoples R China.	jdai@mail.scuec.edu.cn; leihao@wipm.ac.cn; yiwuhedi@sina.com	, 雷皓/H-8147-2019; Lei, Hao/A-7004-2008	, 雷皓/0000-0003-3412-1241; Lei, Hao/0000-0003-3412-1241; Dai, Jiapei/0000-0002-1474-5754	Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870674, 20921004, 31070961]; Research Foundation for the Key Laboratory of Neuroscience and Neuroengineering from South Central University for Nationalities [XJS09001]	This work was supported by the Scientific Research Foundation for the Returned Overseas Chinese Scholars from State Education Ministry and the National Natural Science Foundation of China (Grant Nos. 30870674, 20921004, and 31070961) and partly by the Research Foundation for the Key Laboratory of Neuroscience and Neuroengineering from South Central University for Nationalities (XJS09001).	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Ogata Mamoru, 2007, Legal Medicine, V9, P105, DOI 10.1016/j.legalmed.2006.11.013; Paxinos G, 1997, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	46	40	41	3	27	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JAN	2013	127	1					159	167		10.1007/s00414-012-0712-8			9	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	065QR	WOS:000313164100023	22573358				2022-02-06	
J	Macera, CA; Aralis, HJ; Rauh, MJ; MacGregor, AJ				Macera, Caroline A.; Aralis, Hilary J.; Rauh, Mitchell J.; MacGregor, Andrew J.			Do Sleep Problems Mediate the Relationship between Traumatic Brain Injury and Development of Mental Health Symptoms after Deployment?	SLEEP			English	Article						Posttraumatic stress disorder; sleep problems; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; DISTURBANCE; INSOMNIA; IRAQ; DEPRESSION; PREVALENCE; PATTERNS; PREDICTS	Study Objectives: Military members screening positive for blast-related traumatic brain injury (TBI) may subsequently screen positive for posttraumatic stress disorder (PTSD) or depression. The role of sleep as a mediating factor in the development of mental health symptoms was explored. Design: Prospective study with symptoms evaluated at two time points. Setting: Postdeployment service in Iraq, Afghanistan, or Kuwait during 2008 and 2009. Participants: There were 29,640 US Navy and Marine Corps men (29,019 who did not screen positive for PTSD at baseline, 27,702 who did not screen positive for depression at baseline, and 27,320 who did not screen positive at baseline for either condition). Measurements and Results: After controlling for sleep problems, the adjusted odds of receiving a positive PTSD screening at follow-up decreased from 1.61 (95% confidence interval [CI] 1.21-2.14) to 1.32 (95% CI 0.99-1.77) for a subject screening positive for TBI relative to a subject screening negative, suggesting that sleep problems mediated 26% of TBI's effect on development of PTSD. Likewise, after controlling for sleep problems, the adjusted odds of receiving a positive depression screening decreased from 1.41 (95% CI 1.11-1.80) to 1.15 (95% CI 0.90-1.47), suggesting that sleep problems mediated 41% of TBI's effect on development of depression. Results were similar for those with either PTSD or depression (37% mediated). Conclusions: These results suggest that sleep problems mediate the effect of a positive TBI screening on the development of mental health disorders, and sleep problems may be an early indicator of risk for PTSD or depression.	[Macera, Caroline A.] USN, Dept Warfighter Performance, Hlth Res Ctr, DHAPP, San Diego, CA 92106 USA		Macera, CA (corresponding author), USN, Dept Warfighter Performance, Hlth Res Ctr, DHAPP, 140 Sylvester Rd, San Diego, CA 92106 USA.	carol.macera@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	U.S. Navy Bureau of Medicine and Surgery [60818]	This work was supported by the U.S. Navy Bureau of Medicine and Surgery under Work Unit No. 60818. The views expressed are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. This research was conducted in compliance with all applicable federal regulations governing the protection of human subjects (protocol NHRC. 2009.0020).	Asmundson GJG, 2000, BEHAV RES THER, V38, P203, DOI 10.1016/S0005-7967(99)00061-3; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Deployment Health Clinical Center, ASD HA MEM IMPL REV; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Herr, MEDIATION DICHOTOMOU; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI 10.1177/0193841X9301700202; MACKINNON DP, 1995, MULTIVAR BEHAV RES, V30, P41, DOI 10.1207/s15327906mbr3001_3; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Picchioni D, 2010, MIL PSYCHOL, V22, P340, DOI 10.1080/08995605.2010.491844; PREACHER KJ, CALCULATION SOBEL TE; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Wright KM, 2008, MIL MED, V173, P411, DOI 10.7205/MILMED.173.5.411; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	33	40	42	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	JAN 1	2013	36	1					83	90		10.5665/sleep.2306			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	063LT	WOS:000313001200013	23288974	Green Published, Bronze			2022-02-06	
J	Mukherjee, S; Zeitouni, S; Cavarsan, CF; Shapiro, LA				Mukherjee, Sanjib; Zeitouni, Suzanne; Cavarsan, Clarissa Fantin; Shapiro, Lee A.			Increased seizure susceptibility in mice 30 days after fluid percussion injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; post-traumatic epilepsy; pentylenetetrazole; mouse models	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; COGNITIVE DYSFUNCTION; PENTYLENETETRAZOLE; MICROGLIA; IMPACT; MODEL; RATS; TBI	Traumatic brain injury (TBI) has been reported to increase seizure susceptibility and also contribute to the development of epilepsy. However, the mechanistic basis of the development of increased seizure susceptibility and epilepsy is not clear. Though there is substantial work done using rats, data are lacking regarding the use of mice in the fluid percussion injury (FPI) model. It is unclear if mice, like rats, will experience increased seizure susceptibility following FPI. The availability of a mouse model of increased seizure susceptibility after FPI would provide a basis for the use of genetically modified mice to study mechanism(s) of the development of post-traumatic epilepsy. Therefore, this study was designed to test the hypothesis that, mice subjected to a FPI develop increased seizure susceptibility to a subconvulsive dose of the chemoconvulsant, pentylenetetrazole (PTZ). Three groups of mice were used: FPI, sham, and naive controls. On day 30 after FPI, mice from the three groups were injected with PTZ. The results showed that FPI mice exhibited an increased severity, frequency, and duration of seizures in response to PTZ injection compared with the sham and naive control groups. Histopathological assessment was used to characterize the injury at 1, 3, 7, and 30 days after FPI. The results show that mice subjected to the FPI had a pronounced lesion and glial response that was centered at the FPI focus and peaked at 3 days. By 30 days, only minimal evidence of a lesion is observed, although there is evidence of a chronic glial response. These data are the first to demonstrate an early increase in seizure susceptibility following FPI in mice. Therefore, future studies can incorporate transgenic mice into this model to further elucidate mechanisms of TB I-induced increases in seizure susceptibility.	[Mukherjee, Sanjib; Cavarsan, Clarissa Fantin; Shapiro, Lee A.] Scott & White Hosp, Dept Surg, Temple, TX USA; [Mukherjee, Sanjib; Zeitouni, Suzanne; Cavarsan, Clarissa Fantin; Shapiro, Lee A.] Cent Texas Vet Hlth Care Syst, Temple, TX USA; [Zeitouni, Suzanne; Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX USA; Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Temple, TX USA		Shapiro, LA (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Bldg 205,1901 South 1st St, Temple, TX 76504 USA.	lshapiro@medicine.tamhsc.edu	Cavarsan, Clarissa F./J-9221-2013	Cavarsan, Clarissa F./0000-0002-6687-2130	Scott and White Hospital (RGP) [90347]; Central Texas Veterans Health Care System, Temple, TX, USA	We are also grateful for the funding support from Scott and White Hospital (RGP#90347). This material is the result of work supported with resources, including a SHEEP grant and the use of facilities at the Central Texas Veterans Health Care System, Temple, TX, USA. We are also grateful to Megan Ruch for her technical support. We would like to thank Drs. Richard Robertson and Pier Di Patre for their meaningful comments regarding the histology data.	Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Arisi GM, 2011, AGING DIS, V2, P294; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Jain S, 2011, N-S ARCH PHARMACOL, V383, P385, DOI 10.1007/s00210-011-0606-1; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kramer K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041476; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pitkanen A., 2012, JASPERS BASIC MECH E, P331; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; Shapiro LA, 2009, BRAIN RES, V1266, P29, DOI 10.1016/j.brainres.2009.02.031; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wilhelm EA, 2012, LIFE SCI, V90, P666, DOI 10.1016/j.lfs.2012.03.005; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	30	40	40	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								28	10.3389/fneur.2013.00028			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000028	23519723	Green Published, gold			2022-02-06	
J	Ono, M; Zheng, YY; Joshi, B; Sigl, JC; Hogue, CW				Ono, Masahiro; Zheng, Yueying; Joshi, Brijen; Sigl, Jeffrey C.; Hogue, Charles W.			Validation of a Stand-Alone Near-Infrared Spectroscopy System for Monitoring Cerebral Autoregulation During Cardiac Surgery	ANESTHESIA AND ANALGESIA			English	Article							BLOOD-FLOW AUTOREGULATION; TRAUMATIC BRAIN-INJURY; CARDIOPULMONARY BYPASS; CEREBROVASCULAR AUTOREGULATION; PERFUSION-PRESSURE; REACTIVITY; STROKE; TIME; SATURATION	BACKGROUND: Individualizing arterial blood pressure (ABP) targets during cardiopulmonary bypass (CPB) based on cerebral blood flow (CBF) autoregulation monitoring may provide a more effective means for preventing cerebral hypoperfusion than the current standard of care. Autoregulation can be monitored in real time with transcranial Doppler (TCD). We have previously demonstrated that near-infrared spectroscopy (NIRS)-derived regional cerebral oxygen saturation (rS(c)O(2)) provides a clinically suitable surrogate of CBF for autoregulation monitoring. The purpose of this study was to determine the accuracy of a stand-alone "plug-and-play" investigational system for autoregulation monitoring that uses a commercially available NIRS monitor with TCD methods. METHODS: TCD monitoring of middle cerebral artery CBF velocity and NIRS monitoring were performed in 70 patients during CPB. Indices of autoregulation were computed by both a personal computer-based system and an investigational prototype NIRS-based monitor. A moving linear correlation coefficient between slow waves of ABP and CBF velocity (mean velocity index [Mx]) and between ABP and rS(c)O(2), (cerebral oximetry index [COx]) were calculated. When CBF is autoregulated, there is no correlation between CBF and ABP; when CBF is dysregulated, Mx and COx approach 1 (i.e., CBF and ABP are correlated). Linear regression and bias analysis were performed between time-averaged values of Mx and COx derived from the personal computer-based system and from COx measured with the prototype monitor. Values for Mx and COx were categorized in 5 mm Hg bins of ABP for each patient. The lower limit of CBF autoregulation was defined as the ABP where Mx incrementally increased to >= 0.4. RESULTS: There was correlation and good agreement between COx derived from the prototype monitor and Mx (r = 0.510; 95% confidence interval, 0.414-0.595; P < 0.001; bias, -0.07 +/- 0.19). The correlation and bias between the personal computer based COx and the COx from the prototype NIRS monitor were r = 0.957 (95% confidence interval, 0.945-0.966; P < 0.001 and 0.06 +/- 0.06, respectively). The average ABP at the lower limit of autoregulation was 63 +/- 11 mm Hg (95% prediction interval, 52-74 mm Hg). Although the mean ABP at the COx-determined lower limit of autoregulation determined with the prototype monitor was statistically different from that determined by Mx (59 9 mm Hg; 95% prediction interval, 50-68 mm Hg; P = 0.026), the difference was not likely clinically meaningful. CONCLUSIONS: Monitoring CBF autoregulation with an investigational stand-alone NIRS monitor is correlated and in good agreement with TCD-based methods. The availability of such a device would allow widespread autoregulation monitoring as a means of individualizing ABP targets during CPB. (Anesth Analg 2013;116:198-204)	[Ono, Masahiro] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA; [Zheng, Yueying] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Anesthesiol, Hangzhou 310003, Zhejiang, Peoples R China; [Joshi, Brijen] Johns Hopkins Univ, Sch Med, Dept Internal Med, Sinai Med Ctr, Baltimore, MD USA		Hogue, CW (corresponding author), Johns Hopkins Univ Hosp, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Tower 711, Baltimore, MD 21287 USA.	chogue2@jhmi.edu	Ono, Masahiro/AAE-3939-2019		Mid-Atlantic Affiliate of the American Heart AssociationAmerican Heart Association [103363]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL092259]; Somanetics Corp/Covidien PLC, Boulder, CO; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	This study was supported in part by the Mid-Atlantic Affiliate of the American Heart Association (grant-in-aid no. 103363), by the National Institutes of Health (grant no. R01HL092259, to C. W. H.), and by a direct research grant from Somanetics Corp/Covidien PLC, Boulder, CO. Clinical Trials Registration NCT00769691 at www.clinicaltrials.gov. Covidien has licensed aspects of the investigational software from The Johns Hopkins University.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Barodka VM, 2011, ANESTH ANALG, V112, P1048, DOI 10.1213/ANE.0b013e3182147e3c; Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DAVIS SM, 1983, NEUROLOGY, V33, P391, DOI 10.1212/WNL.33.4.391; Drummond JC, 1997, ANESTHESIOLOGY, V86, P1431, DOI 10.1097/00000542-199706000-00034; Gottesman RF, 2006, STROKE, V37, P2306, DOI 10.1161/01.STR.0000236024.68020.3a; Joshi B, 2012, ANESTH ANALG, V114, P503, DOI 10.1213/ANE.0b013e31823d292a; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Kim MB, 2000, J CLIN MONIT COMPUT, V16, P191, DOI 10.1023/A:1009940031063; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lavinio A, 2007, STROKE, V38, P402, DOI 10.1161/01.STR.0000254551.92209.5c; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Minhas PS, 2004, NEUROSURGERY, V55, P63, DOI 10.1227/01.NEU.0000126876.10254.05; Moraca R, 2006, J THORAC CARDIOV SUR, V131, P540, DOI 10.1016/j.jtcvs.2005.10.046; MUHONEN MG, 1992, STROKE, V23, P988, DOI 10.1161/01.STR.23.7.988; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; MUTCH WAC, 1994, J CEREBR BLOOD F MET, V14, P510, DOI 10.1038/jcbfm.1994.63; Newman MF, 1996, CIRCULATION, V94, P353; Olsen KS, 1996, J NEUROSURG ANESTH, V8, P280, DOI 10.1097/00008506-199610000-00004; Ono M, 2012, BRIT J ANAESTH, V109, P391, DOI 10.1093/bja/aes148; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Reinhard M, 2004, STROKE, V35, P1381, DOI 10.1161/01.STR.0000127533.46914.31; SCHELL RM, 1993, ANESTH ANALG, V76, P849; SCHWARTZ AE, 1995, ANN THORAC SURG, V60, P165; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Taylor K M, 1990, Semin Thorac Cardiovasc Surg, V2, P300; YAMAMOTO M, 1980, ARCH NEUROL-CHICAGO, V37, P489, DOI 10.1001/archneur.1980.00500570037005; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	34	40	41	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2013	116	1					198	204		10.1213/ANE.0b013e318271fb10			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	065JT	WOS:000313145300025	23223100	Green Accepted			2022-02-06	
J	Wittwer, JE; Webster, KE; Hill, K				Wittwer, Joanne E.; Webster, Kate E.; Hill, Keith			Rhythmic auditory cueing to improve walking in patients with neurological conditions other than Parkinson's disease - what is the evidence?	DISABILITY AND REHABILITATION			English	Article						Acoustic simulation; gait; neurologic gait disorder; rhythmic auditory cueing	RANDOMIZED CLINICAL-TRIALS; GAIT VARIABILITY; PHYSICAL-THERAPY; RETEST RELIABILITY; MOVEMENT-DISORDERS; SYSTEMATIC REVIEWS; SYNCHRONOUS MUSIC; ATTENTIONAL COST; STIMULATION RAS; OLDER-ADULTS	Purpose: To investigate whether synchronising over-ground walking to rhythmic auditory cues improves temporal and spatial gait measures in adults with neurological clinical conditions other than Parkinson's disease. Method: A search was performed in June 2011 using the computerised databases AGELINE, AMED, AMI, CINAHL, Current Contents, EMBASE, MEDLINE, PsycINFO and PUBMED, and extended using hand-searching of relevant journals and article reference lists. Methodological quality was independently assessed by two reviewers. A best evidence synthesis was applied to rate levels of evidence. Results: Fourteen studies, four of which were randomized controlled trials (RCTs), met the inclusion criteria. Patient groups included those with stroke (six studies); Huntington's disease and spinal cord injury (two studies each); traumatic brain injury, dementia, multiple sclerosis and normal pressure hydrocephalus (one study each). The best evidence synthesis found moderate evidence of improved velocity and stride length of people with stroke following gait training with rhythmic music. Insufficient evidence was found for other included neurological disorders due to low study numbers and poor methodological quality of some studies. Conclusion: Synchronising walking to rhythmic auditory cues can result in short-term improvement in gait measures of people with stroke. Further high quality studies are needed before recommendations for clinical practice can be made.	[Wittwer, Joanne E.; Webster, Kate E.] La Trobe Univ, Fac Hlth Sci, Musculoskeletal Res Ctr, Bundoora, Vic 3086, Australia; [Wittwer, Joanne E.] La Trobe Univ, Sch Physiotherapy, Bundoora, Vic 3086, Australia; [Hill, Keith] Curtin Univ Technol, Sch Physiotherapy, Perth, WA, Australia		Wittwer, JE (corresponding author), La Trobe Univ, Fac Hlth Sci, Musculoskeletal Res Ctr, Room 216, Bundoora, Vic 3086, Australia.	J.Wittwer@latrobe.edu.au	Wittwer, Joanne/M-9909-2015; Hill, Keith D/L-6398-2017	Wittwer, Joanne/0000-0002-7884-4356; Hill, Keith D/0000-0002-2191-0308			Amatachaya S, 2009, SPINAL CORD, V47, P668, DOI 10.1038/sc.2008.168; Baker K, 2008, PARKINSONISM RELAT D, V14, P314, DOI 10.1016/j.parkreldis.2007.09.008; Baker K, 2007, ARCH PHYS MED REHAB, V88, P1593, DOI 10.1016/j.apmr.2007.07.026; Brach JS, 2007, J GERONTOL A-BIOL, V62, P983, DOI 10.1093/gerona/62.9.983; Bradt J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006787.pub2; Brown LA, 2009, ARCH PHYS MED REHAB, V90, P1578, DOI 10.1016/j.apmr.2009.03.009; Clair AA, 2006, J MUSIC THER, V43, P154, DOI 10.1093/jmt/43.2.154; Conklyn D, 2010, NEUROREHAB NEURAL RE, V24, P835, DOI 10.1177/1545968310372139; de Bruin N, 2010, PARKINSONS DIS, P9; de I'Etoile SK, 2008, INT J REHABIL RES, V31, P155, DOI 10.1097/MRR.0b013e3282fc0f44; del Olmo MF, 2005, PARKINSONISM RELAT D, V11, P25, DOI 10.1016/j.parkreldis.2004.09.002; Delval A, 2008, MOVEMENT DISORD, V23, P1446, DOI 10.1002/mds.22125; Frenkel-Toledo S, 2005, MOVEMENT DISORD, V20, P1109, DOI 10.1002/mds.20507; Green J, 2002, CLIN REHABIL, V16, P306, DOI 10.1191/0269215502cr495oa; Hausdorff JM, 2007, EUR J NEUROSCI, V26, P2369, DOI 10.1111/j.1460-9568.2007.05810.x; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hayden R, 2009, INT J NEUROSCI, V119, P2183, DOI 10.3109/00207450903152609; Herbert Robert D., 2001, Physiotherapy Theory and Practice, V17, P201, DOI 10.1080/095939801317077650; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Karageorghis CI, 2009, J SPORT EXERCISE PSY, V31, P18, DOI 10.1123/jsep.31.1.18; Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Lim I, 2005, CLIN REHABIL, V19, P695, DOI 10.1191/0269215505cr906oa; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Morris ME, 2000, PHYS THER, V80, P578, DOI 10.1093/ptj/80.6.578; Morris ME, 2010, PHYS THER, V90, P280, DOI 10.2522/ptj.20090091; Nieuwboer A, 2007, J NEUROL NEUROSUR PS, V78, P134, DOI 10.1136/jnnp.200X.097923; Nieuwboer A, 2009, NEUROREHAB NEURAL RE, V23, P831, DOI 10.1177/1545968309337136; Park IM, 2010, J PHYS THER SCI, V22, P295, DOI 10.1589/jpts.22.295; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; Rochester L, 2007, J NEURAL TRANSM, V114, P1243, DOI 10.1007/s00702-007-0756-y; Rochester L, 2011, MOVEMENT DISORD, V26, P430, DOI 10.1002/mds.23450; Rochester L, 2009, MOVEMENT DISORD, V24, P839, DOI 10.1002/mds.22400; Royal Dutch Society for Physical Therapy, 2004, KNGF EV BAS CLIN PRA; Schmidt RA., 1991, CONT MANAGEMENT MOTO, P49; Simpson SD, 2006, J SPORT SCI, V24, P1095, DOI 10.1080/02640410500432789; Snijders AH, 2007, LANCET NEUROL, V6, P63, DOI 10.1016/S1474-4422(06)70678-0; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Stolze H, 2001, J NEUROL NEUROSUR PS, V70, P289, DOI 10.1136/jnnp.70.3.289; Styns F, 2007, HUM MOVEMENT SCI, V26, P769, DOI 10.1016/j.humov.2007.07.007; Terrier P, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-12; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Thaut M., 1997, INT J ARTS MED, V5, P4, DOI [10.1016/B978-0-12-679270-6.50031-0, DOI 10.1016/B978-0-12-679270-6.50031-0]; Thaut M, 2008, RHYTHM MUSIC BRAIN S; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 1999, MOVEMENT DISORD, V14, P808, DOI 10.1002/1531-8257(199909)14:5<808::AID-MDS1014>3.0.CO;2-J; Thaut MH, 1999, IEEE ENG MED BIOL, V18, P101, DOI 10.1109/51.752991; Thaut MH, 1993, J NEUROL REHABIL, V7, P9, DOI DOI 10.1177/136140969300700103; Thaut MH, 2010, MUSIC PERCEPT, V27, P263, DOI 10.1525/MP.2010.27.4.263; Thaut MH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002312; Urquhart DM, 1999, ARCH PHYS MED REHAB, V80, P696, DOI 10.1016/S0003-9993(99)90175-2; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Wittwer JE, 2008, GAIT POSTURE, V28, P392, DOI 10.1016/j.gaitpost.2008.01.007; Zatorre RJ, 2007, NAT REV NEUROSCI, V8, P547, DOI 10.1038/nrn2152	57	40	41	0	63	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	2					164	176		10.3109/09638288.2012.690495			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	067JX	WOS:000313291200010	22681598				2022-02-06	
J	Grujicic, M; Yavari, R; Snipes, JS; Ramaswami, S; Runt, J; Tarter, J; Dillon, G				Grujicic, M.; Yavari, R.; Snipes, J. S.; Ramaswami, S.; Runt, J.; Tarter, J.; Dillon, G.			Molecular-level computational investigation of shock-wave mitigation capability of polyurea	JOURNAL OF MATERIALS SCIENCE			English	Article							MATERIAL MODEL; DEFORMATION; TRANSITION; DYNAMICS; GLASS	Various static and (equilibrium and non-equilibrium) dynamic molecular-level computational methods and tools are utilized in order to investigate the basic shock-wave physics and shock-wave material interactions in polyurea (a nano-phase segregated elastomeric co-polymer). The main goal of this investigation was to establish relationships between the nano-segregated polyurea microstructure (consisting of rod-shaped, discrete, so-called "hard domains" embedded into a highly compliant, so-called soft matrix) and the experimentally established superior capability of this material to disperse and attenuate resident shock waves (e.g., those generated as a result of blast-wave impact). By analyzing molecular-level interactions of the shock waves with polyurea, an attempt was made to identify and quantify main phenomena and viscous/inelastic deformation and microstructure-altering processes taking place at the shock front, which are most likely responsible for the superior shock-mitigation behavior of polyurea. Direct molecular-level simulations of shock-wave generation and propagation in the "strong-shock" regime are utilized in order to construct the appropriate shock-Hugoniot relations (relations which are used in the construction of the associated continuum-level material models). Extension of these relations into the "weak-shock" regime of interest from the traumatic brain injury prevention point of view is also discussed.	[Grujicic, M.; Yavari, R.; Snipes, J. S.; Ramaswami, S.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA; [Runt, J.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16082 USA; [Tarter, J.; Dillon, G.] Penn State Univ, Appl Res Labs, University Pk, PA 16082 USA		Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, 241 Engn Innovat Bldg, Clemson, SC 29634 USA.	gmica@clemson.edu			Office of Naval Research (ONR) through the Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]; Office of Naval Research (ONR) through Army Research Office (ARO) [W911NF-09-1-0513]; Office of Naval Research (ONR) through Army Research Laboratory (ARL) [W911NF-06-2-0042]	The material presented in this paper is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head", Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University, the Army Research Office (ARO) research contract entitled "Multilength Scale Material Model Development for Armor-grade Composites", Contract Number W911NF-09-1-0513, and the Army Research Laboratory (ARL) research contract entitled "Computational Analysis and Modeling of Various Phenomena Accompanying Detonation Explosives Shallow-Buried in Soil" Contract Number W911NF-06-2-0042. The authors are indebted to Drs. Roshdy Barsoum of ONR and Larry C. Russell, Jr. of ARO for their continuing support and interest in this study.	Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; Arman B, 2012, MACROMOLECULES, V45, P3247, DOI 10.1021/ma3001934; Bogoslovov RB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2745212; Castagna AM, 2012, MACROMOLECULES UNPUB; Choi T, 2012, MACROMOLECULES, V45, P3581, DOI 10.1021/ma300128d; Davison L, 2008, SHOCK WAVE HIGH PRES, P1; Grujicic A, 2012, J MATER ENG PERFORM, V21, P1562, DOI 10.1007/s11665-011-0065-3; Grujicic M, 2008, SOIL DYN EARTHQ ENG, V28, P20, DOI 10.1016/j.soildyn.2007.05.001; Grujicic M, 2004, MAT SCI ENG B-SOLID, V107, P204, DOI 10.1016/j.mseb.2003.11.012; Grujicic M, 2011, MULTIDISCIP MODEL MA, V7, P96, DOI 10.1108/15736101111157064; Grujicic M, 2012, MATER DESIGN, V35, P144, DOI 10.1016/j.matdes.2011.08.031; Grujicic M, 2011, J MATER SCI, V46, P7298, DOI 10.1007/s10853-011-5691-5; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2012, J MATER ENG PERFORM, V21, P2, DOI 10.1007/s11665-011-9875-6; Grujicic M, 2011, MAT SCI ENG A-STRUCT, V528, P3799, DOI 10.1016/j.msea.2011.01.081; Grujicic M, 2010, MAT SCI ENG A-STRUCT, V527, P7741, DOI 10.1016/j.msea.2010.08.042; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2007, MULTIDISCIP MODEL MA, V3, P287, DOI 10.1163/157361107781389562; Grujicic M, 2009, APPL SURF SCI, V253; Grujicic M, 2012, MULTIDISCIP MODEL MA, V8; Grujicic M, 2011, J MATER SCI, V46, P1767, DOI 10.1007/s10853-010-4998-y; HOLIAN BL, 1979, PHYS REV LETT, V43, P1598, DOI 10.1103/PhysRevLett.43.1598; HOLIAN BL, 1980, PHYS REV A, V22, P2798, DOI 10.1103/PhysRevA.22.2798; Mock W, 2009, AIP CONF PROC, V1195, P1241; Qiao J, 2011, MECH MATER, V43, P598, DOI 10.1016/j.mechmat.2011.06.012; Runt J, 2012, IN PRESS; Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v; THEODOROU DN, 1986, MACROMOLECULES, V19, P139, DOI 10.1021/ma00155a022	28	40	41	0	62	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-2461	1573-4803		J MATER SCI	J. Mater. Sci.	DEC	2012	47	23					8197	8215		10.1007/s10853-012-6716-4			19	Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	005BX	WOS:000308726500027					2022-02-06	
J	Mott, TF; McConnon, ML; Rieger, BP				Mott, Timothy F.; McConnon, Michael L.; Rieger, Brian P.			Subacute to Chronic Mild Traumatic Brain Injury	AMERICAN FAMILY PHYSICIAN			English	Article							TASK-FORCE; NEUROPSYCHOLOGY; MANAGEMENT; HEAD; PAIN	Although a universally accepted definition is lacking, mild traumatic brain injury and concussion are classified by transient loss of consciousness, amnesia, altered mental status, a Glasgow Coma Score of 13 to 15, and focal neurologic deficits following an acute closed head injury. Most patients recover quickly, with a predictable clinical course of recovery within the first one to two weeks following traumatic brain injury. Persistent physical, cognitive, or behavioral postconcussive symptoms may be noted in 5 to 20 percent of persons who have mild traumatic brain injury. Physical symptoms include headaches, dizziness, and nausea, and changes in coordination, balance, appetite, sleep, vision, and hearing. Cognitive and behavioral symptoms include fatigue, anxiety, depression, and irritability, and problems with memory, concentration and decision making. Women, older adults, less educated persons, and those with a previous mental health diagnosis are more likely to have persistent symptoms. The diagnostic workup for subacute to chronic mild traumatic brain injury focuses on the history and physical examination, with continuing observation for the development of red flags such as the progression of physical, cognitive, and behavioral symptoms, seizure, progressive vomiting, and altered mental status. Early patient and family education should include information on diagnosis and prognosis, symptoms, and further injury prevention. Symptom-specific treatment, gradual return to activity, and multidisciplinary coordination of care lead to the best outcomes. Psychiatric and medical comorbidities, psychosocial issues, and legal or compensatory incentives should be explored in patients resistant to treatment. (Am Fam Physician. 2012;86(11):1045-1051. Copyright (C) 2012 American Academy of Family Physicians.)	[Mott, Timothy F.] Naval Hosp Pensacola, Family Med Residency Program, Pensacola, FL USA; [Rieger, Brian P.] State Univ New York Upstate Med Univ, Concuss Management Program, Syracuse, NY USA; [Rieger, Brian P.] State Univ New York Upstate Med Univ, Cent New York Concuss Ctr, Syracuse, NY USA		Mott, TF (corresponding author), Pensacola Family Med Residency, 6000 W Hwy 98, Pensacola, FL 32515 USA.	timothy.mott@med.navy.mil		Mott, Timothy/0000-0003-1560-3501			Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Coronado Victor G, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; *MILD TRAUM BRAIN, 1997, NEUROLOGY, V48, P581; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Quinlan JD, 2010, AM FAM PHYSICIAN, V82, P43; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357	31	40	40	1	27	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	DEC 1	2012	86	11					1045	1051					7	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	047YL	WOS:000311877300013	23198672				2022-02-06	
J	Chuang, TJ; Lin, KC; Chio, CC; Wang, CC; Chang, CP; Kuo, JR				Chuang, Tai-Jen; Lin, Kao-Chang; Chio, Chung-Ching; Wang, Che-Chuan; Chang, Chin-Ping; Kuo, Jinn-Rung			Effects of secretome obtained from normoxia-preconditioned human mesenchymal stem cells in traumatic brain injury rats	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Secretome; human mesenchymal stem cell; fluid percussion injury; cell apoptosis; Sprague-Dawley rats	MARROW STROMAL CELLS; BONE; EXPRESSION; ANGIOGENESIS; VEGF; TRANSPLANTATION; NEUROGENESIS; HYPOXIA; STROKE; MACROPHAGES	BACKGROUND: The aim of the present study was to investigate whether secretome obtained from normoxia-preconditioned human mesenchymal stem cells causes attenuation of traumatic brain injury (TBI), induced by fluid percussion injury. METHODS: Anaesthetized male Sprague-Dawley rats, immediately after the onset of fluid percussion TBI, were divided into two major groups and given the vehicle solution (1 mL) or secretome (500 mu g) intravenously. Another group of rats was used as sham-operated controls. The functional outcome such as motor (maximum grasp angle) was evaluated by an inclined plane test. Cellular infarction volume was calculated by triphenyltetrazolium chloride staining. Neuronal loss, apoptosis, and neurotrophic factor such as vascular epithelial growth factor (VEGF) expression in the cortex were measured by immunofluorescence staining. All the parameters were assessed on Day 3 after injury. RESULTS: Compared with those of the sham-operated controls, the motor deficits and cerebral infarction of rats after TBI were significantly attenuated by secretome therapy. The TBI-induced neuronal loss and apoptosis were also significantly reduced by secretome therapy. Furthermore, VEGF-positive cells in the ischemic cortex after TBI were further significantly increased by secretome therapy. CONCLUSION: Our results demonstrate that intravenous injection of secretome from normoxia-preconditioned human mesenchymal stem cells may ameliorate TBI-induced rats by reducing neuronal cell loss and apoptosis and promoting VEGF production, resulting in functional outcome improvement. We also recommend that secretome from normoxia-preconditioned human mesenchymal stem cells could be a promising treatment strategy for traumatic brain injury. (J Trauma Acute Care Surg. 2012; 73: 1161-1167. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan 708, Taiwan; [Chuang, Tai-Jen] Liou Ying Chi Mei Med Ctr, Dept Intens Care Unit, Tainan, Taiwan; [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Neurol, Tainan 708, Taiwan; [Lin, Kao-Chang; Chang, Chin-Ping; Kuo, Jinn-Rung] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan		Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, 901 Jong Hwa Rd, Tainan 708, Taiwan.	cmh7520@mail.chimei.org.tw		Chang, Ching-Ping/0000-0003-0890-9414	 [CLFHR10101]	The project was supported by CLFHR10101.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890-197404000-00001; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harichandan A, 2011, BEST PRACT RES CL HA, V24, P25, DOI 10.1016/j.beha.2011.01.001; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kim HJ, 2008, J NEUROTRAUM, V10, P2008; Kooreman NG, 2010, J R SOC INTERFACE, V7, pS753, DOI 10.1098/rsif.2010.0353.focus; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Manoonkitiwongsa PS, 2001, J CEREBR BLOOD F MET, V21, P1223, DOI 10.1097/00004647-200110000-00011; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Modo M, 2003, NEUROREPORT, V14, P39, DOI 10.1097/00001756-200301200-00007; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oh JS, 2010, NEUROSCI LETT, V472, P215, DOI 10.1016/j.neulet.2010.02.008; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 2007, CLIN PHARMACOL THER, V82, P241, DOI 10.1038/sj.clpt.6100313; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tipoe George L., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P199, DOI 10.2174/187152506777698290; van Zanten ARH, 2005, CRIT CARE MED, V33, P1449, DOI 10.1097/01.CCM.0000166710.64724.34	39	40	43	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73	5					1161	1167		10.1097/TA.0b013e318265d128			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	043VF	WOS:000311577100023	22976425				2022-02-06	
J	Hilario, A; Ramos, A; Millan, JM; Salvador, E; Gomez, PA; Cicuendez, M; Diez-Lobato, R; Lagares, A				Hilario, A.; Ramos, A.; Millan, J. M.; Salvador, E.; Gomez, P. A.; Cicuendez, M.; Diez-Lobato, R.; Lagares, A.			Severe Traumatic Head Injury: Prognostic Value of Brain Stem Injuries Detected at MRI	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							GLASGOW OUTCOME SCALE; DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE; VEGETATIVE STATE; LESIONS; CLASSIFICATION; MODERATE	BACKGROUND AND PURPOSE: Traumatic brain injuries represent an important cause of death for young people. The main objectives of this work are to correlate brain stem injuries detected at MR imaging with outcome at 6 months in patients with severe TBI, and to determine which MR imaging findings could be related to a worse prognosis. MATERIALS AND METHODS: One hundred and eight patients with severe TBI were studied by MR imaging in the first 30 days after trauma. Brain stem injury was categorized as anterior or posterior, hemorrhagic or nonhemorrhagic, and unilateral or bilateral. Outcome measures were GOSE and Barthel Index 6 months postinjury. The relationship between MR imaging findings of brain stem injuries, outcome, and disability was explored by univariate analysis. Prognostic capability of MR imaging findings was also explored by calculation of sensitivity, specificity, and area under the ROC curve for poor and good outcome. RESULTS: Brain stem lesions were detected in 51 patients, of whom 66% showed a poor outcome, as expressed by the GOSE scale. Bilateral involvement was strongly associated with poor outcome (P < .05). Posterior location showed the best discriminatory capability in terms of outcome (OR 6.8, P < .05) and disability (OR 4.8, P < .01). The addition of nonhemorrhagic and anterior lesions or unilateral injuries showed the highest odds and best discriminatory capacity for good outcome. CONCLUSIONS: The prognosis worsens in direct relationship to the extent of traumatic injury. Posterior and bilateral brain stem injuries detected at MR imaging are poor prognostic signs. Nonhemorrhagic injuries showed the highest positive predictive value for good outcome.	[Hilario, A.; Ramos, A.; Millan, J. M.; Salvador, E.] Hosp 12 Octubre, Dept Radiol, E-28041 Madrid, Spain; [Gomez, P. A.; Cicuendez, M.; Diez-Lobato, R.; Lagares, A.] Hosp 12 Octubre, Dept Neurosurg, E-28041 Madrid, Spain		Hilario, A (corresponding author), Hosp 12 Octubre, Dept Radiol, Ave Cordoba S-N, E-28041 Madrid, Spain.	amayahilario@yahoo.es	Lagares, Alfonso/B-2969-2011; Gomez, Pedro/N-5051-2019	Lagares, Alfonso/0000-0003-3996-0554; Gomez, Pedro/0000-0002-4185-5238; Salvador, Elena/0000-0002-8324-6502			Aguas J, 2005, NEUROCIRUGIA, V16, P14; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; JENKINS A, 1986, LANCET, V2, P445; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; MAHONEY F I, 1965, Md State Med J, V14, P61; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	30	40	43	0	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV	2012	33	10					1925	1931		10.3174/ajnr.A3092			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	045QH	WOS:000311711400016	22576887	Green Published, hybrid			2022-02-06	
J	Schoknecht, K; Shalev, H				Schoknecht, Karl; Shalev, Hadar			Blood-brain barrier dysfunction in brain diseases: Clinical experience	EPILEPSIA			English	Article						Blood-brain barrier; Epilepsy; Stroke; Traumatic brain injury; Schizophrenia	ACUTE ISCHEMIC-STROKE; TEMPORAL-LOBE EPILEPSY; SERUM S100B LEVELS; THROMBOLYTIC THERAPY; MAJOR DEPRESSION; HEMORRHAGIC TRANSFORMATION; SCHIZOPHRENIC-PATIENTS; S100-BETA PROTEIN; RISK-FACTORS; INJURY	The bloodbrain barrier, a unique feature of the cerebral vasculature, is gaining attention as a feature in common neurologic disorders including stroke, traumatic brain injury, epilepsy, and schizophrenia. Although acute bloodbrain barrier dysfunction can induce cerebral edema, seizures, or neuropsychiatric symptoms, epileptogenesis and cognitive decline are among the chronic effects. The mechanisms underlying bloodbrain barrier dysfunction are diverse and may range from physical endothelial damage in traumatic brain injury to degradation of extracellular matrix proteins via matrix metalloproteinases as part of an inflammatory response. Clinically, bloodbrain barrier dysfunction is often detected using contrast-enhanced imaging. However, these techniques do not give any insights into the underlying mechanism. Elucidating the specific pathways of bloodbrain barrier dysfunction at different time points and in different brain diseases using novel imaging techniques promises a more accurate bloodbrain barrier terminology as well as new treatment options and personalized treatment.	[Schoknecht, Karl] Charite, Inst Neurophysiol, D-13347 Berlin, Germany; [Shalev, Hadar] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Psychiat, IL-84105 Beer Sheva, Israel; [Shalev, Hadar] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel		Schoknecht, K (corresponding author), Charite, Inst Neurophysiol, Oudenarder St 16, D-13347 Berlin, Germany.	karl.schoknecht@charite.de					Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Arolt V, 2003, EUR NEUROPSYCHOPHARM, V13, P235, DOI 10.1016/S0924-977X(03)00016-6; Austinat M, 2009, STROKE, V28, P5; Balami JS, 2011, LANCET NEUROL, V10, P357, DOI 10.1016/S1474-4422(10)70313-6; Beer C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-71; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Castellanos M, 2007, STROKE, V38, P1855, DOI 10.1161/STROKEAHA.106.481556; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dassan P, 2009, CEREBROVASC DIS, V27, P295, DOI 10.1159/000199468; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; de Klerk OL, 2010, PSYCHIAT RES-NEUROIM, V183, P151, DOI 10.1016/j.pscychresns.2010.05.002; Esposito G, 2006, LIFE SCI, V78, P2707, DOI 10.1016/j.lfs.2005.10.023; Gama CS, 2006, PROG NEURO-PSYCHOPH, V30, P512, DOI 10.1016/j.pnpbp.2005.11.009; Gattaz WF, 2000, SCHIZOPHR RES, V43, P91, DOI 10.1016/S0920-9964(99)00146-2; Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Herman ST, 2011, NEUROLOGY, V77, P1776, DOI 10.1212/WNL.0b013e31823b4e73; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Ivens S, 2010, J NEUROL, V257, P615, DOI 10.1007/s00415-009-5384-z; Jang BS, 2008, PSYCHIAT INVEST, V5, P193, DOI 10.4306/pi.2008.5.3.193; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kim SY, 2012, EPILEPSIA, V53, P37, DOI 10.1111/j.1528-1167.2012.03701.x; Kumar S, 2010, LANCET NEUROL, V9, P105, DOI 10.1016/S1474-4422(09)70266-2; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Levi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039636; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018200; Marchi N, 2010, BRAIN RES, V1353, P176, DOI 10.1016/j.brainres.2010.06.051; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; MULLER N, 1995, SCHIZOPHR RES, V14, P223, DOI 10.1016/0920-9964(94)00045-A; Neumann-Haefelin C, 2002, STROKE, V33, P1392, DOI 10.1161/01.STR.0000014619.59851.65; Pascoe MC, 2011, INT J STROKE, V6, P128, DOI 10.1111/j.1747-4949.2010.00565.x; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rothermundt M, 2004, NEUROPSYCHOPHARMACOL, V29, P1004, DOI 10.1038/sj.npp.1300403; Rothermundt M, 2009, GEN PHYSIOL BIOPHYS, V28, pF76; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008; Sarandol A, 2007, PROG NEURO-PSYCHOPH, V31, P1164, DOI 10.1016/j.pnpbp.2007.03.008; Schroeter ML, 2008, J AFFECT DISORDERS, V111, P271, DOI 10.1016/j.jad.2008.03.005; Schroeter ML, 2002, NEUROREPORT, V13, P1675, DOI 10.1097/00001756-200209160-00021; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shalev H., 2009, CARDIOVASC PSYCHIAT, V2009, P27853, DOI [DOI 10.1155/2009/278531, 10.1155/2009/278531]; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Slot KB, 2009, STROKE, V40, P1585, DOI 10.1161/STROKEAHA.108.531533; Sotgiu S, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-84; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Sutcigil L, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/76396; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vezzani A, 2008, EPILEPSIA, V49, P24, DOI 10.1111/j.1528-1167.2008.01490.x; Warach S, 2004, STROKE, V35, P2659, DOI 10.1161/01.STR.0000144051.32131.09; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; Wunder A, 2012, EPILEPSIA, V53, P14, DOI 10.1111/j.1528-1167.2012.03698.x; Yang Y, 2011, STROKE, V332, P3; Zhang XY, 2010, J PSYCHIATR RES, V44, P1236, DOI 10.1016/j.jpsychires.2010.04.023	72	40	41	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2012	53			6	SI		7	13		10.1111/j.1528-1167.2012.03697.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	033LI	WOS:000310797400002	23134490	Bronze			2022-02-06	
J	Taylor, C; Jan, S; Curtis, K; Tzannes, A; Li, Q; Palmer, C; Dickson, C; Myburgh, J				Taylor, Colman; Jan, Stephen; Curtis, Kate; Tzannes, Alex; Li, Qiang; Palmer, Cameron; Dickson, Cara; Myburgh, John			The cost-effectiveness of physician staffed Helicopter Emergency Medical Service (HEMS) transport to a major trauma centre in NSW, Australia	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Helicopter Emergency Medical Services; Primary scene response; Cost-effectiveness; Health economics; Trauma care; Trauma system	WILLINGNESS-TO-PAY; INJURED PATIENTS; BRAIN-INJURY; EMS; MORTALITY; IMPACT; CARE	Background and context: Helicopter Emergency Medical Services (HEMS) are highly resource-intensive facilities that are well established as part of trauma systems in many high-income countries. We evaluated the cost-effectiveness of a physician-staffed HEMS intervention in combination with treatment at a major trauma centre versus ground ambulance or indirect transport (via a referral hospital) in New South Wales (NSW), Australia. Methods: Cost and effectiveness estimates were derived from a cohort of trauma patients arriving at St George Hospital in NSW, Australia during an 11-year period. Adjusted estimates of in-hospital mortality were derived using logistic regression and adjusted hospital costs were estimated through a general linear model incorporating a gamma distribution and log link. These estimates along with other assumptions were incorporated into a Markov model with an annual cycle length to estimate a cost per life saved and a cost per life-year saved at one year and over a patient's lifetime respectively in three patient groups (all patients; patients with serious injury [Injury Severity Score > 12]; patients with traumatic brain injury [TBI]). Results: Results showed HEMS to be more costly but more effective at reducing in-hospital mortality leading to a cost per life saved of $1,566,379, $533,781 and $519,787 in all patients, patients with serious injury and patients with TBI respectively. When modelled over a patient's lifetime, the improved mortality associated with HEMS led to a cost per life year saved of $96,524, $50,035 and $49,159 in the three patient groups respectively. Sensitivity analyses revealed a higher probability of HEMS being cost-effective in patients with serious injury and TBI. Conclusion: Our investigation confirms a HEMS intervention is associated with improved mortality in trauma patients, especially in patients with serious injury and TBI. The improved benefit of HEMS in patients with serious injury and TBI leads to improved estimated cost-effectiveness. (C) 2012 Elsevier Ltd. All rights reserved.	[Taylor, Colman; Jan, Stephen; Curtis, Kate; Li, Qiang; Myburgh, John] George Inst Global Hlth, Sydney, NSW, Australia; [Taylor, Colman] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Curtis, Kate] Univ Sydney, Sydney Nursing Sch, Sydney, NSW 2006, Australia; [Curtis, Kate; Tzannes, Alex; Dickson, Cara; Myburgh, John] St George Hosp, Sydney, NSW, Australia; [Tzannes, Alex] Ambulance Serv NSW, Sydney, NSW, Australia; [Myburgh, John] Univ NSW, Fac Med, Sydney, NSW, Australia; [Palmer, Cameron] Royal Childrens Hosp Melbourne, Trauma Serv, Melbourne, Vic, Australia; [Palmer, Cameron] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia		Taylor, C (corresponding author), POB M201,Missenden Rd, Camperdown, NSW 2050, Australia.	ctaylor@georgeinstitute.org.au	black, deborah/C-2829-2017; Jan, Stephen/AAG-3333-2021	black, deborah/0000-0001-9174-1565; Jan, Stephen/0000-0003-2839-1405	NSW Department of Health	Co-authors Curtis, Tzannes, Dickson and Myburgh and all paid employees of the NSW Department of Health, which funds Helicopter Emergency Medical Services. The primary author (C. Taylor) has a paid part-time position with Novartis Pharmaceuticals.	Access Economics , 2009, EC COST SPIN CORD IN; Access Economics, 2007, HLTH NAT VAL STAT LI; Ambulance Service of New South Wales, 2008, PROT T1 PREH MAN MAJ; Australian Bureau of Statistics, 2011, ABS LIF TABL; Australian Bureau of Statistics, 2011, CONS PRIC IND AUSTR; Australian Government Department of Health and Ageing, 2008, GUID PREP SUBM PHARM; Australian Institute of Health and Welfare, 2010, HLTH WELF EXP SER; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Botker MA, 2009, SCANDINAVIAN J TRAUM, V5, P17; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P8; Garner Alan A, 2004, Emerg Med Australas, V16, P318, DOI 10.1111/j.1742-6723.2004.00636.x; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hensher DA, 2009, TRANSPORT RES A-POL, V43, P692, DOI 10.1016/j.tra.2009.06.001; Independent Pricing and Regulatory Tribunal of New South Wales, 2005, REV FIN ASP AMB SERV; Lerner EB, 2006, ANN EMERG MED, V47, P515, DOI 10.1016/j.annemergmed.2006.01.012; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Meltzer D, 1997, J HEALTH ECON, V16, P33, DOI 10.1016/S0167-6296(96)00507-3; NSW Health, 2010, NSW COSTS CAR STAND; NSW Health, 2011, SEL SPEC STAT SERV P; NSW Health Department, 2006, NSW PROGR PROD DAT C; Olsen JA, 1998, SOC SCI MED, V46, P1, DOI 10.1016/S0277-9536(97)00129-9; Palmer CS, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-29; Rinburg AN, 2009, BRIT J SURG, V96, P1365, DOI 10.1002/bjs.6720; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Ringburg A, 2009, PREHOSP EMERG CARE, V13, P37, DOI 10.1080/10903120802472004; Ringburg AN, 2009, PREHOSP EMERG CARE, V13, P2009; Shepherd MV, 2008, EMERG MED AUSTRALAS, V20, P494, DOI 10.1111/j.1742-6723.2008.01135.x; Taylor CB, 2011, INJURY, V42, P1088, DOI 10.1016/j.injury.2011.02.013; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P242, DOI 10.1080/10903120290938634; Thomas SH, 2007, PREHOSP EMERG CARE, V11, P477, DOI 10.1080/10903120701537097; Thomas Stephen H, 2003, Curr Opin Anaesthesiol, V16, P153, DOI 10.1097/00001503-200304000-00008; Thomas Stephen H, 2004, Prehosp Emerg Care, V8, P322; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P359, DOI 10.1080/10903120290938508	41	40	42	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1843	1849		10.1016/j.injury.2012.07.184			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300012	22898559				2022-02-06	
J	Boucher, PA; Joos, B; Morris, CE				Boucher, Pierre-Alexandre; Joos, Bela; Morris, Catherine E.			Coupled left-shift of Nav channels: modeling the Na+-loading and dysfunctional excitability of damaged axons	JOURNAL OF COMPUTATIONAL NEUROSCIENCE			English	Article						Hodgkin-Huxley; Diffuse axonal injury; Myelinated; Arrhythmia; Neuropathic pain; Na/K-ATPase; Extracellular space	GATED SODIUM-CHANNELS; TRAUMATIC BRAIN-INJURY; NEUROPATHIC PAIN; LATENT ADDITION; STRETCH-INJURY; SENSORY AXONS; MEMBRANE; NEURONS; CURRENTS; OSCILLATIONS	Injury to neural tissue renders voltage-gated Na+ (Nav) channels leaky. Even mild axonal trauma initiates Na+ -loading, leading to secondary Ca2+-loading and white matter degeneration. The nodal isoform is Nav1.6 and for Nav1.6-expressing HEK-cells, traumatic whole cell stretch causes an immediate tetrodotoxin-sensitive Na+-leak. In stretch-damaged oocyte patches, Nav1.6 current undergoes damage-intensity dependent hyperpolarizing- (left-) shifts, but whether left-shift underlies injured-axon Nav-leak is uncertain. Nav1.6 inactivation (availability) is kinetically limited by (coupled to) Nav activation, yielding coupled left-shift (CLS) of the two processes: CLS should move the steady-state Nav1.6 "window conductance" closer to typical firing thresholds. Here we simulated excitability and ion homeostasis in free-running nodes of Ranvier to assess if hallmark injured-axon behaviors-Na+-loading, ectopic excitation, propagation block-would occur with Nav-CLS. Intact/traumatized axolemma ratios were varied, and for some simulations Na/K pumps were included, with varied in/outside volumes. We simulated saltatory propagation with one mid-axon node variously traumatized. While dissipating the [Na+] gradient and hyperactivating the Na/K pump, Nav-CLS generated neuropathic pain-like ectopic bursts. Depending on CLS magnitude, fraction of Nav channels affected, and pump intensity, tonic or burst firing or nodal inexcitability occurred, with [Na+] and [K+] fluctuating. Severe CLS-induced inexcitability did not preclude Na+-loading; in fact, the steady-state Na+-leaks elicited large pump currents. At a mid-axon node, mild CLS perturbed normal anterograde propagation, and severe CLS blocked saltatory propagation. These results suggest that in damaged excitable cells, Nav-CLS could initiate cellular deterioration with attendant hyper- or hypo-excitability. Healthy-cell versions of Nav-CLS, however, could contribute to physiological rhythmic firing.	[Boucher, Pierre-Alexandre; Joos, Bela] Univ Ottawa, Dept Phys, Ottawa, ON K1N 6N5, Canada; [Morris, Catherine E.] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8M5, Canada		Joos, B (corresponding author), Univ Ottawa, Dept Phys, 150 Louis Pasteur, Ottawa, ON K1N 6N5, Canada.	pbouc040@uottawa.ca; bjoos@uottawa.ca; cmorris@uottawa.ca		Joos, Bela/0000-0001-8576-5579; Morris, Catherine/0000-0002-7401-6545	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); HSF; CIHRCanadian Institutes of Health Research (CIHR)	We thank Andre Longtin and Na Yu for helpful discussions during the preparation of this manuscript. Our research was supported by funds from NSERC, HSF and CIHR.	Allen DG, 2010, ADV EXP MED BIOL, V682, P297, DOI 10.1007/978-1-4419-6366-6_17; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Banderali U, 2010, CHANNELS, V4, P12, DOI 10.4161/chan.4.1.10260; Beyder A, 2010, J PHYSIOL-LONDON, V588, P4969, DOI 10.1113/jphysiol.2010.199034; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Borjesson SI, 2010, BIOPHYS J, V98, P396, DOI 10.1016/j.bpj.2009.10.026; Bostock H, 1997, J PHYSIOL-LONDON, V498, P277, DOI 10.1113/jphysiol.1997.sp021857; Bruno MJ, 2007, P NATL ACAD SCI USA, V104, P9638, DOI 10.1073/pnas.0701015104; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Coggan JS, 2010, P NATL ACAD SCI USA, V107, P20602, DOI 10.1073/pnas.1013798107; Devor M, 2009, EXP BRAIN RES, V196, P115, DOI 10.1007/s00221-009-1724-6; Di X, 2000, ACT NEUR S, V76, P379; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Duflocq A, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-66; Finol-Urdaneta RK, 2010, BIOPHYS J, V98, P762, DOI 10.1016/j.bpj.2009.10.053; Fried K, 2011, PAIN, V152, P2685, DOI 10.1016/j.pain.2011.08.004; Gu C, 2011, J BIOL CHEM, V286, P25835, DOI 10.1074/jbc.M111.219113; Hirn C, 2008, J GEN PHYSIOL, V132, P199, DOI 10.1085/jgp.200810024; HODGKIN AL, 1948, J PHYSIOL-LONDON, V107, P165, DOI 10.1113/jphysiol.1948.sp004260; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hogg RC, 2002, EUR J NEUROSCI, V16, P242, DOI 10.1046/j.1460-9568.2002.02071.x; Huff TB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017176; Isose S, 2010, CLIN NEUROPHYSIOL, V121, P719, DOI 10.1016/j.clinph.2009.12.034; Izhikevich EM, 2001, NEURAL NETWORKS, V14, P883, DOI 10.1016/S0893-6080(01)00078-8; Kager H, 2000, J NEUROPHYSIOL, V84, P495, DOI 10.1152/jn.2000.84.1.495; Kimelberg HK, 2004, ADV EXP MED BIOL, V559, P157; Kole MHP, 2011, NEURON, V71, P671, DOI 10.1016/j.neuron.2011.06.024; Kovalsky Y, 2009, J NEUROPHYSIOL, V102, P1430, DOI 10.1152/jn.00005.2009; Krepkiy D, 2009, NATURE, V462, P473, DOI 10.1038/nature08542; Krishnan GP, 2011, J NEUROSCI, V31, P8870, DOI 10.1523/JNEUROSCI.6200-10.2011; Kuwabara S, 2006, CLIN NEUROPHYSIOL, V117, P810, DOI 10.1016/j.clinph.2005.11.018; LAUGER P, 1991, DISTINGUISHED LECT S, V5; LEMIEUX DR, 1992, J THEOR BIOL, V154, P335, DOI 10.1016/S0022-5193(05)80175-4; Lenkey N, 2011, NEUROPHARMACOLOGY, V60, P191, DOI 10.1016/j.neuropharm.2010.08.005; Li GR, 2009, CARDIOVASC RES, V81, P286, DOI 10.1093/cvr/cvn322; Lorincz A, 2010, SCIENCE, V328, P906, DOI 10.1126/science.1187958; Mantegazza M, 2010, LANCET NEUROL, V9, P413, DOI 10.1016/S1474-4422(10)70059-4; Marques A., 1988, BIOCHEM PHARMACOL, V15, P601; Massimini M, 2009, PROG BRAIN RES, V177, P201, DOI 10.1016/S0079-6123(09)17714-2; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Misawa S, 2009, J PERIPHER NERV SYST, V14, P279, DOI 10.1111/j.1529-8027.2009.00239.x; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; Morris C.E., 2011, CELL PHYSL SOURCE BO, P493; Morris C. E., 2011, CARDIAC MECHANOELECT, P42; Morris CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00019; Morris CE, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00025; Ochab-Marcinek A, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011904; Prescott SA, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000198; Ritter AM, 2009, NEUROSCI LETT, V452, P28, DOI 10.1016/j.neulet.2008.12.051; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schmidt D, 2008, P NATL ACAD SCI USA, V105, P19276, DOI 10.1073/pnas.0810187105; Seifert G, 2009, J NEUROSCI, V29, P7474, DOI 10.1523/JNEUROSCI.3790-08.2009; Shi RY, 2011, NEUROSCI BULL, V27, P36, DOI 10.1007/s12264-011-1048-y; Smit JE, 2009, BIOL CYBERN, V100, P49, DOI 10.1007/s00422-008-0280-7; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Sun GC, 2006, ACTA PHARMACOL SIN, V27, P1537, DOI 10.1111/j.1745-7254.2006.00452.x; Tabarean IV, 1999, BIOPHYS J, V77, P758, DOI 10.1016/S0006-3495(99)76930-4; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Thomas EA, 2009, ANN NEUROL, V66, P219, DOI 10.1002/ana.21712; Tokuno HA, 2003, MUSCLE NERVE, V28, P212, DOI 10.1002/mus.10421; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Volman V, 2011, P NATL ACAD SCI USA, V108, P15402, DOI 10.1073/pnas.1112066108; Vucic S, 2010, J NEUROL NEUROSUR PS, V81, P222, DOI 10.1136/jnnp.2009.183079; Wan XD, 1999, AM J PHYSIOL-CELL PH, V276, pC318, DOI 10.1152/ajpcell.1999.276.2.C318; Wang JA, 2009, AM J PHYSIOL-CELL PH, V297, pC823, DOI 10.1152/ajpcell.00505.2008; Weiss S, 2010, BRIT J PHARMACOL, V160, P1072, DOI 10.1111/j.1476-5381.2010.00766.x; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	75	40	41	0	12	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0929-5313			J COMPUT NEUROSCI	J. Comput. Neurosci.	OCT	2012	33	2					301	319		10.1007/s10827-012-0387-7			19	Mathematical & Computational Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Neurosciences & Neurology	005BN	WOS:000308725400005	22476614				2022-02-06	
J	Grande, PO; Romner, B				Graende, Per-Olof; Romner, Bertil			Osmotherapy in Brain Edema: A Questionable Therapy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain edema; mannitol; hypertonic saline; osmotherapy; rebound phenomenon; renal failure; traumatic brain injury	ELEVATED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; HYPERTONIC SALINE; INTRACEREBRAL HEMORRHAGE; CEREBRAL EDEMA; VOLUME REGULATION; MANNITOL; MANAGEMENT; RESUSCITATION; TRANSPORT	Despite the fact that it has been used since the 1960s in diseases associated with brain edema and has been investigated in > 150 publications on head injury, very little has been published on the outcome of osmotherapy. We can only speculate whether osmotherapy improves outcome, has no effect on outcome, or leads to worse outcome. Here we describe the action and potentially beneficial and adverse effects of the 2 most commonly used osmotic solutions, mannitol and hypertonic saline, and present some critical aspects of their use. There is a well-documented transient intracranial pressure (ICP)-reducing effect of osmotherapy, but an adverse rebound increase in ICP after its withdrawal has been discussed extensively in the literature and is an expected pathophysiological phenomenon. From side effects related to renal and pulmonary failure, electrolyte disturbances, and a rebound increase in ICP, osmotherapy can be negative for outcome, which may explain why we lack scientific support for its use. These drawbacks, and the fact that the most recent Cochrane meta-analyses of osmotherapy in brain edema and stroke could not find any beneficial effects on outcome, make routine use of osmotherapy in brain edema doubtful. Nevertheless, the use of osmotherapy as a temporary measure may be justified to acutely prevent brain stem compression until other measures, such as evacuation of space-occupying lesions or decompressive craniotomy, can be performed. This article is the Con part in a Pro-Con debate in the present journal on the general routine use of osmotherapy in brain edema.	[Graende, Per-Olof] Univ Lund Hosp, Dept Anesthesia & Intens Care, SE-22185 Lund, Sweden; [Romner, Bertil] Univ Lund Hosp, Dept Neurosurg, SE-22185 Lund, Sweden; [Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark		Grande, PO (corresponding author), Univ Lund Hosp, Dept Anesthesia & Intens Care, SE-22185 Lund, Sweden.	per-olof.grande@med.lu.se			Swedish Research Council, StockholmSwedish Research Council [11581]; Medical Faculty of Lund University; Region Skane (ALF), Lund, Sweden	Supported by Grants from the Swedish Research Council (#11581), Stockholm, the Medical Faculty of Lund University, and Region Skane (ALF), Lund, Sweden.	ANDREWS RJ, 1993, SURG NEUROL, V39, P218, DOI 10.1016/0090-3019(93)90186-5; Bereczki D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001153.pub2; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1995, New Horiz, V3, P448; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Davis M, 1994, J Neurosci Nurs, V26, P170; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Fang L, 2010, RENAL FAILURE, V32, P673, DOI 10.3109/0886022X.2010.486492; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Georgiadis Alexandros L, 2003, Curr Neurol Neurosci Rep, V3, P524, DOI 10.1007/s11910-003-0058-1; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Holbeck S, 2002, CRIT CARE MED, V30, P212, DOI 10.1097/00003246-200201000-00030; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Kamat Pradip, 2003, Pediatr Crit Care Med, V4, P239, DOI 10.1097/01.PCC.0000059340.19010.CE; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Levick JR, 1997, INT J MICROCIRC, V17, P241, DOI 10.1159/000179236; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; LUNDVALL J, 1969, ACTA PHYSIOL SCAND, V77, P224, DOI 10.1111/j.1748-1716.1969.tb04566.x; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; MAZZONI MC, 1989, J CELL PHYSIOL, V140, P272, DOI 10.1002/jcp.1041400212; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Misra UK, 2005, J NEUROL SCI, V234, P41, DOI 10.1016/j.jns.2005.03.038; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Node Y, 1990, Adv Neurol, V52, P359; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; OKEN DE, 1994, RENAL FAILURE, V16, P147, DOI 10.3109/08860229409044856; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RABETOY GM, 1993, ANN PHARMACOTHER, V27, P25, DOI 10.1177/106002809302700105; RAVUSSIN P, 1986, J NEUROSURG, V64, P104, DOI 10.3171/jns.1986.64.1.0104; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 2007, BRIT MED J, V334, P392, DOI 10.1136/bmj.39118.480023.BE; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sakellaridis N, 2011, J NEUROSURG, V114, P543; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; WEAVER A, 1987, NEPHRON, V45, P233, DOI 10.1159/000184124; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WINKLER SR, 1995, SURG NEUROL, V43, P59, DOI 10.1016/0090-3019(95)80039-J; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	61	40	41	2	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2012	24	4					407	412					6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	013GR	WOS:000309294400023	22955195				2022-02-06	
J	Adams, RS; Larson, MJ; Corrigan, JD; Horgan, CM; Williams, TV				Adams, Rachel Sayko; Larson, Mary Jo; Corrigan, John D.; Horgan, Constance M.; Williams, Thomas V.			Frequent Binge Drinking After Combat-Acquired Traumatic Brain Injury Among Active Duty Military Personnel With a Past Year Combat Deployment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						binge drinking; combat; deployment; military personnel; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ALCOHOL-USE; PRIMARY-CARE; DEPRESSIVE-DISORDERS; SERVICE MEMBERS; US MILITARY; IRAQ; VETERANS	Objective: To determine whether combat-acquired traumatic brain injury (TBI) is associated with postdeployment frequent binge drinking among a random sample of active duty military personnel. Participants: Active duty military personnel who returned home within the past year from deployment to a combat theater of operations and completed a survey health assessment (N = 7155). Methods: Cross-sectional observational study with multivariate analysis of responses to the 2008 Department of Defense Survey of Health Related Behaviors Among Active Duty Military Personnel, an anonymous, random, population-based assessment of the armed forces. Main Measures: Frequent binge drinking: 5 or more drinks on the same occasion, at least once per week, in the past 30 days. TBI-AC: self-reported altered consciousness only; loss of consciousness (LOC) of less than 1 minute (TBI-LOC <1); and LOC of 1 minute or greater (TBI-LOC 1+) after combat injury event exposure. Results: Of active duty military personnel who had a past year combat deployment, 25.6% were frequent binge drinkers and 13.9% reported experiencing a TBI on the deployment, primarily TBI-AC (7.5%). In regression models adjusting for demographics and positive screen for posttraumatic stress disorder, active duty military personnel with TBI had increased odds of frequent binge drinking compared with those with no injury exposure or without TBI: TBI-AC (adjusted odds ratio, 1.48; 95% confidence interval, 1.18-1.84); TBI-LOC 1+ (adjusted odds ratio, 1.67; 95% confidence interval, 1.002.79). Conclusions: Traumatic brain injury was significantly associated with past month frequent binge drinking after controlling for posttraumatic stress disorder, combat exposure, and other covariates.	[Adams, Rachel Sayko; Larson, Mary Jo; Horgan, Constance M.] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02454 USA; [Larson, Mary Jo; Horgan, Constance M.] Brandeis Univ, Inst Behav Hlth, Waltham, MA 02454 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Williams, Thomas V.] Long Term Studies Def Hlth Cost Assessment & Prog, TRICARE Management Act, Dept Def, Falls Church, VA USA		Adams, RS (corresponding author), Brandeis Univ, Heller Sch Social Policy & Management, 415 South St,Mailstop 035, Waltham, MA 02454 USA.	radams@brandeis.edu	Adams, Rachel/AAH-4653-2020		Ruth L. Kirschstein National Research Service Award from the National Institute on Alcohol Abuse and Alcoholism [F31 AA021030, T32 AA007567]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F31AA021030, T32AA007567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA030150] Funding Source: NIH RePORTER	Ms Adams conducted this research with predoctoral fellowship dissertation support from a Ruth L. Kirschstein National Research Service Award from the National Institute on Alcohol Abuse and Alcoholism (F31 AA021030) and an institutional training grant (T32 AA007567). Ms Adams acknowledges the support of dissertation committee members Drs Grant Ritter and Robert M. Bray for their review of her research proposal as well as the programming support of Mr Lee Panas.	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; [Anonymous], 2007, STAT STAT SOFTW COMP; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bray R, 2009, DEP DEFENSE SURVEY H; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; Brewer RD, 2005, JAMA-J AM MED ASSOC, V294, P616, DOI 10.1001/jama.294.5.616; Brown JM, 2007, 2006 UNIT LEVEL INFL; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DOD Deployment Health Clinical Center, 2010, ENH POSTD HLTH ASS P; Federman EB, 2000, MIL PSYCHOL, V12, P205, DOI 10.1207/S15327876MP1203_3; Ferrier-Auerbach AG, 2009, ADDICT BEHAV, V34, P625, DOI 10.1016/j.addbeh.2009.03.027; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FRENCH LM, 2010, MILITARY NEUROPSYCHO, P101; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hingson RW, 2009, PEDIATRICS, V123, P1477, DOI 10.1542/peds.2008-2176; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2008, GULF WAR HLTH, V7; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Kaner EFS, 2009, DRUG ALCOHOL REV, V28, P301, DOI 10.1111/j.1465-3362.2009.00071.x; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Larson MJ, 2012, J SOC WORK PRACT ADD, V12, P6, DOI 10.1080/1533256X.2012.647586; Mattiko MJ, 2011, ADDICT BEHAV, V36, P608, DOI 10.1016/j.addbeh.2011.01.023; McQueen J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005191.pub3, 10.1002/14651858.CD005191]; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Naimi TS, 2009, AM J PREV MED, V37, P314, DOI 10.1016/j.amepre.2009.06.013; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; Ong AL, 2008, MIL MED, V173, P871, DOI 10.7205/MILMED.173.9.871; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Ramchand R, 2011, MIL PSYCHOL, V23, P6, DOI 10.1080/08995605.2011.534407; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shen YC, 2012, AM J PUBLIC HEALTH, V102, pS80, DOI 10.2105/AJPH.2011.300425; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; Spera C, 2011, J STUD ALCOHOL DRUGS, V72, P5, DOI 10.15288/jsad.2011.72.5; Stahre MA, 2009, AM J PREV MED, V36, P208, DOI 10.1016/j.amepre.2008.10.017; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The Center for Substance Abuse Research, 2009, CESAR FAX, V7; Tourangeau R, 1996, PUBLIC OPIN QUART, V60, P275, DOI 10.1086/297751; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; [No title captured]	58	40	40	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2012	27	5					349	360		10.1097/HTR.0b013e318268db94			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	004OQ	WOS:000308691400089	22955100	Green Accepted			2022-02-06	
J	Gallaway, MS; Fink, DS; Millikan, AM; Bell, MR				Gallaway, Michael Shayne; Fink, David S.; Millikan, Amy M.; Bell, Michael R.			Factors Associated With Physical Aggression Among US Army Soldiers	AGGRESSIVE BEHAVIOR			English	Article						aggression; military; deployment; combat	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; INTIMATE PARTNER VIOLENCE; AFGHANISTAN WAR VETERANS; COMBAT VETERANS; ALCOHOL-PROBLEMS; SPOUSE ABUSE; IRAQ WAR; DEPLOYMENT; MILITARY	There are a growing number of studies that have approximated levels of aggression and associated outcomes among combat veterans returning from Iraq and Afghanistan using brief screening assessments. However, further research to evaluate the relative role of combat exposures and overt physical behaviors is required to further elucidate potential associations between military service, combat deployment, and overt physical aggression. The purpose of the current study was to assess the prevalence of self-reported physical aggression in a sample of US Army soldiers using an adaptation of the Revised Conflict Tactics Scale (CTS2), and examine factors associated with higher levels of aggression. A population-based cross-sectional study was conducted at a single US Army Installation within a sample of active duty US Army soldiers (n = 6,128) from two large units. Anonymous surveys were collected 6 months following deployment to measure overt aggressive behaviors, posttraumatic stress disorder, anxiety, depression, traumatic brain injury, and misuse of alcohol. There were a relatively higher number of minor and severe physical overt aggressive actions reported among soldiers who previously deployed, notably highest among deployed soldiers reporting the highest levels of combat intensity. Soldiers screening positive for the misuse of alcohol were also significantly more likely to report relatively higher levels of physical aggression. This study quantified overt aggressive behaviors and associated factors, showing increasing combat exposures may result in increased physical aggression. Clinicians treating service members returning from combat may consider assessing relative levels of combat. Aggr. Behav. 38:357-367, 2012. Published 2012 Wiley Periodicals, Inc.	[Gallaway, Michael Shayne; Fink, David S.; Millikan, Amy M.] USA, BSHOP, Inst Publ Hlth, Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA; [Bell, Michael R.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Gallaway, MS (corresponding author), USA, BSHOP, Inst Publ Hlth, Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA.	shayne.gallaway@us.army.mil	Fink, David S./F-1634-2014	Fink, David S./0000-0003-1531-1525			Acierno R., 2000, SCREENING MEASURES D; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Baron RA., 1994, HUMAN AGGRESSION; Bell NS, 2006, ALCOHOL CLIN EXP RES, V30, P1721, DOI 10.1111/j.1530-0277.2006.00214.x; Bell NS, 2004, ALCOHOL CLIN EXP RES, V28, P1890, DOI 10.1097/01.ALC.0000148102.89841.9B; Bohannon J R, 1995, Violence Vict, V10, P133; Booth-Kewley S, 2010, AGGRESSIVE BEHAV, V36, P330, DOI 10.1002/ab.20355; Bulmer, 1979, PRINCIPLES STAT; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; CASTRO CA, 2000, INT REV ARMED FORCES, V73, P191; Cherpitel CJ, 2002, ALCOHOL CLIN EXP RES, V26, P1686, DOI 10.1097/01.ALC.0000036300.26619.78; Elbogen EB, 2010, AM J PSYCHIAT, V167, P1051, DOI 10.1176/appi.ajp.2010.09050739; Foran HM, 2011, J CONSULT CLIN PSYCH, V79, P391, DOI 10.1037/a0022962; Forgey MA, 2006, J FAM VIOLENCE, V21, P369, DOI 10.1007/s10896-006-9033-3; Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-00008; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Heyman RE, 1999, J CONSULT CLIN PSYCH, V67, P239, DOI 10.1037/0022-006X.67.2.239; Hodge J., 2004, PUBLIC HLTH PRACTICE; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Martin C. B., 2007, MSMR MED SURVEILLANC, V14, P2; Millikan AM, 2008, 14HKOB1U09 EP CONS; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Newby JH, 2005, MIL MED, V170, P643, DOI 10.7205/MILMED.170.8.643; Office of the Surgeon General United States Army Medical Command & Office of the Command Surgeon HQ US-CENTCOM & Office of the Command Surgeon US Forces Afghanistan (USFOR-A), 2011, JOINT MENT HLTH ADV; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Slep AMS, 2010, J COMMUN HEALTH, V35, P375, DOI 10.1007/s10900-010-9264-3; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sontag D., 2008, WAR TORN 1; Straus M. A., 2003, CONFLICT TACTICS SCA; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Taft CT, 2007, J FAM PSYCHOL, V21, P270, DOI 10.1037/0893-3200.21.2.270; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of Health and Human Services National Institute of Health (NIH), 2003, NAT I HLTH NIH PUBL; Zoricic Z, 2003, EUR J PSYCHIAT, V17, P243; [No title captured]	40	40	42	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0096-140X			AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2012	38	5					357	367		10.1002/ab.21436			11	Behavioral Sciences; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology	989MP	WOS:000307564500003	22898873				2022-02-06	
J	Sander, AM; Maestas, KL; Pappadis, MR; Sherer, M; Hammond, FM; Hanks, R				Sander, Angelle M.; Maestas, Kacey Little; Pappadis, Monique R.; Sherer, Mark; Hammond, Flora M.; Hanks, Robin		Traumatic Brain Injury Model Syst	Sexual Functioning 1 Year After Traumatic Brain Injury: Findings From a Prospective Traumatic Brain Injury Model Systems Collaborative Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation	HEAD-INJURY; ADENOCARCINOMA; PRETREATMENT; BEHAVIOR; IMPACT	Sander AM, Maestas KL, Pappadis MR, Sherer M, Hammond FM, Hanks R, and the NIDRR Traumatic Brain Injury Model Systems Module Project on Sexuality After TBI. Sexual functioning 1 year after traumatic brain injury: findings from a prospective Traumatic Brain Injury Model Systems collaborative study. Arch Phys Med Rehabil 2012;93:1331-7. Objective: To investigate the incidence and types of sexual difficulties in men and women with traumatic brain injury (TBI) 1 year after injury, as well as their comfort level in discussing problems with health care professionals. Design: Prospective cohort study. Setting Community. Participants: Persons with TBI (N = 223; 165 men and 58 women) who had been treated at I of 6 participating TBI Model 5) stems inpatient rehabilitation units and were living in the community. Interventions: None. Main Outcome Measures: Derogatis Interview for Sexual Functioning-self-report (DISF-SR); Global Sexual Satisfaction Index (GSSI); structured interview regarding changes in sexual functioning; and comfort level discussing sexuality with health care professionals. Results: Women with TBI scored significantly below the normative; sample for all subscales of the DISF-SR, including sexual cognition/fantasy, arousal, sexual behavior/experience, and orgasm. Men scored significantly below the normative sample on all scales except arousal. Women reported greater dysfunction than men for sexual cognition/fantasy and arousal. Twenty-nine percent of participants reported dissatisfaction with sexual functioning on the GSSI, with a greater percentage of men reporting dissatisfaction. Sixty-eight percent of participants indicated that they would spontaneously raise issues of sexual difficulties with health care professionals, while the remainder would either bring it up only if directly asked or would not discuss it at all. Conclusions: Sexual difficulties were present in a substantial portion of community-dwelling people with TB! at 1 year after injury. Educational interventions to increase awareness among people with TBI and rehabilitation professionals are warranted, as well as interventions to improve sexual functioning.	[Sander, Angelle M.; Maestas, Kacey Little; Pappadis, Monique R.; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Maestas, Kacey Little] Harris Cty Hosp Dist, Houston, TX USA; [Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Pappadis, Monique R.] Univ Houston, Grad Coll Social Work, Houston, TX USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Hanks, Robin] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Hanks, Robin] Rehabil Inst Michigan, Detroit, MI USA		Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133B090023, H133A070043, H133A080014, H133P080007]	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133B090023, H133A070043, H133A080014, and H133P080007).	Aloni A, 2003, SEXUAL DIFFICULTIES; Aloni R, 1999, BRAIN INJURY, V13, P269, DOI 10.1080/026990599121647; Blackerby WF., 1990, J HEAD TRAUMA REHAB, V5, P73, DOI [10.1097/00001199-199005020-00012, DOI 10.1097/00001199-199005020-00012]; Derogatis L, 1987, DEROGATIS INTERVIEW; Derogatis L. R., 1975, DEROGATIS SEXUAL FUN; Derogatis LR, 1997, J SEX MARITAL THER, V23, P291; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gervasio AH, 1999, SEXUALITY SEXUAL DYS; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Nicolosi A, 2006, J SEX MARITAL THER, V32, P331, DOI 10.1080/00926230600666469; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pistoia F, 2006, PHARMACOL RES, V54, P11, DOI 10.1016/j.phrs.2006.01.010; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Rankin TM, 1999, NIH CONS DEV C REH P; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Sandel ME, 2007, SEXUALITY REPROD NEU; Strauss D, 1991, SEX DISABIL, V9, P49; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Zasler ND, 1995, STATE ART REV PHYSIC, P361; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P729, DOI 10.1016/0360-3016(90)90503-C; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P1001, DOI 10.1016/0360-3016(90)90025-F	27	40	41	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1331	1337		10.1016/j.apmr.2012.03.037			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700006	22840831				2022-02-06	
J	Yuan, F; Ding, J; Chen, H; Guo, Y; Wang, G; Gao, WW; Chen, SW; Tian, HL				Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li			Predicting Progressive Hemorrhagic Injury after Traumatic Brain Injury: Derivation and Validation of a Risk Score Based on Admission Characteristics	JOURNAL OF NEUROTRAUMA			English	Article						prognostic model; progressive hemorrhagic injury; risk score; traumatic brain injury; validation	HEAD TRAUMA; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; COAGULOPATHY	Previous studies have demonstrated that patients with traumatic brain injury (TBI) who also have progressive hemorrhagic injury (PHI), have a higher risk of clinical deterioration and worse outcomes than do TBI patients without PHI. Therefore, the early prediction of PHI occurrence is useful to evaluate the status of patients with TBI and to improve outcomes. The objective of this study was to develop and validate a prognostic model that uses information available at admission to determine the likelihood of PHI after TBI. Retrospectively collected data were used to develop a PHI prognostic model with a logistic regression analysis. The prediction model was validated in 114 patients from a separate hospital. Eight independent prognostic factors were identified: age >= 57 years (5 points), intra-axial bleeding/brain contusion (4 points), midline shift 5 mm (6 points), platelet (PLT) count <100 x 10(9)/L (10 points), PLT count >= 100 but <150 x 10(9)/L (4 points), prothrombin time > 14 sec (7 points), D-dimer >= 5 mg/L (12 points), and glucose >= 10 mmol/L (10 points). Each patient was assigned a number of points proportional to the regression coefficient. We calculated risk scores for each patient and defined three risk groups: low risk (0-13 points), intermediate risk (14-22 points), and high risk (23-54 points). In the development cohort, the PHI rates after TBI for these three groups were 10.3%, 47.3%, and 85.2%, respectively. In the validation cohort, the corresponding PHI rates were 10.9%, 47.3%, and 86.9%. The C-statistic for the point system was 0.864 (p=0.509 by the Hosmer-Lemeshow test) in the development cohort, and 0.862 (p=0.589 by the Hosmer-Lemeshow test) in the validation cohort. In conclusion, a relatively simple risk score using admission predictors accurately predicted the risk for PHI after TBI.	[Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200030, Peoples R China		Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, 600 Yishan Rd, Shanghai 200030, Peoples R China.	tianhengli1964@yahoo.com.cn			Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1412500]	This study was supported in part by a grant from the Shanghai Science and Technology Committee (grant no. 10JC1412500). We would like to thank Dong-Qing Shen, Department of Neurosurgery at Fengxian Center Hospital, for making the external validation data available for analysis.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; BOLLINGER O, 1891, INT BEITRAGE WEISSEN, P457; Brain Trauma Foundation. American Association of Neurological Surgeons & Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pi, DOI DOI 10.1089/NEU.2007.9999; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Doughty R.G., 1938, SOUTH MED J, V31, P254; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Hiroshi T., 1997, J NEUROSURG, V86, P768; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3	20	40	46	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2137	2142		10.1089/neu.2011.2233			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900003	22568757	Green Published			2022-02-06	
J	Smith, BA; Xie, BW; van Beek, ER; Que, I; Blankevoort, V; Xiao, SZ; Cole, EL; Hoehn, M; Kaijzel, EL; Lowik, CWGM; Smith, BD				Smith, Bryan A.; Xie, Bang-Wen; van Beek, Ermond R.; Que, Ivo; Blankevoort, Vicky; Xiao, Shuzhang; Cole, Erin L.; Hoehn, Mathias; Kaijzel, Eric L.; Lowik, Clemens W. G. M.; Smith, Bradley D.			Multicolor Fluorescence Imaging of Traumatic Brain Injury in a Cryolesion Mouse Model	ACS CHEMICAL NEUROSCIENCE			English	Article						Traumatic brain injury; multicolor fluorescence imaging; cell death imaging; blood-brain-barrier; annexin V; zinc(II)-dipicolylamine	IN-VIVO; BARRIER PERMEABILITY; MOLECULAR PROBE; REAL-TIME; APOPTOSIS; MICE; PHOSPHATIDYLSERINE; RECOGNITION; DISRUPTION; INFECTION	Traumatic brain injury is characterized by initial tissue damage, which then can lead to secondary processes such as cell death and blood-brain-barrier disruption. Clinical and preclinical studies of traumatic brain injury typically employ anatomical imaging techniques and there is a need for new molecular imaging methods that provide complementary biochemical information. Here, we assess the ability of a targeted, near-infrared fluorescent probe, named PSS-794, to detect cell death in a brain cryolesion mouse model that replicates certain features of traumatic brain injury. In short, the model involves brief contact of a cold rod to the head of a living, anesthetized mouse. Using noninvasive whole-body fluorescence imaging, PSS-794 permitted visualization of the cryolesion in the living animal. Ex vivo imaging and histological analysis confirmed PSS-794 localization to site of brain cell death. The nontargeted, deep-red Tracer-653 was validated as a tracer dye for monitoring blood-brain-barrier disruption, and a binary mixture of PSS-794 and Tracer-653 was employed for multicolor imaging of cell death and blood-brain-barrier permeability in a single animal. The imaging data indicates that at 3 days after brain cryoinjury the amount of cell death had decreased significantly, but the integrity of the blood-brain-barrier was still impaired; at 7 days, the blood-brain-barrier was still three times more permeable than before cryoinjury.	[Xie, Bang-Wen; van Beek, Ermond R.; Que, Ivo; Blankevoort, Vicky; Kaijzel, Eric L.; Lowik, Clemens W. G. M.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands; [Smith, Bryan A.; Xiao, Shuzhang; Cole, Erin L.; Smith, Bradley D.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Hoehn, Mathias] Max Planck Inst Neurol Res, D-50931 Cologne, Germany		Lowik, CWGM (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	c.w.g.m.lowik@lumc.nl; smith.115@nd.edu		Kaijzel, Eric/0000-0003-3118-9910	Center for Translational Molecular Medicine, project MUSIS [03O-202]; NIH GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM059078, T32GM075762]; Volkswagen Grant [183443]; ENCITE project [201842]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075762, R01GM059078] Funding Source: NIH RePORTER	This study was supported by the Center for Translational Molecular Medicine, project MUSIS (Grant 03O-202); NIH Grants R01GM059078 (B.D.S.) and T32GM075762 (B.A.S.), Volkswagen Grant 183443, and the ENCITE project 201842.	Abulrob A, 2008, MOL IMAGING, V7, P248, DOI 10.2310/7290.2008.00025; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Bahamni P., 2011, J CEREB BLOOD FLOW M, V31, P1311; Beekman CAC, 2011, APPL RADIAT ISOTOPES, V69, P656, DOI 10.1016/j.apradiso.2010.12.012; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Blankenberg FG, 2008, J NUCL MED, V49, p81S, DOI 10.2967/jnumed.107.045898; Burtea C, 2009, MOL PHARMACEUT, V6, P1903, DOI 10.1021/mp900106m; Chapon C, 2009, MAGN RESON MATER PHY, V22, P167, DOI 10.1007/s10334-008-0161-z; Cole E. L., 2011, ORG BIOMOL CHEM, DOI 10/1039/c20606783h; del Valle J, 2008, J NEUROSCI METH, V174, P42, DOI 10.1016/j.jneumeth.2008.06.025; Eriskat J, 2003, ACTA NEUROCHIR SUPPL, V86, P265; Faul M, 2010, TRAUMATIC BRAIN INJU, P1; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hanshaw RG, 2005, BIOORGAN MED CHEM, V13, P5035, DOI 10.1016/j.bmc.2005.04.071; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kobayashi H, 2007, NANO LETT, V7, P1711, DOI 10.1021/nl0707003; Kosaka N, 2009, J INVEST DERMATOL, V129, P2818, DOI 10.1038/jid.2009.161; Leblond F, 2010, J PHOTOCH PHOTOBIO B, V98, P77, DOI 10.1016/j.jphotobiol.2009.11.007; Lederle W, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-26; Leevy WM, 2006, J AM CHEM SOC, V128, P16476, DOI 10.1021/ja0665592; Lin KJ, 2012, ANN NUCL MED, V26, P272, DOI 10.1007/s12149-012-0571-x; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mitsunaga M, 2011, CANCER PREV RES, V4, P767, DOI 10.1158/1940-6207.CAPR-10-0334; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Netherlands Inspectorate for Health Protection Commodities and Veterinary Public Health, 1999, COD PRACT AN EXP CAN, P1; Niu G, 2010, J NUCL MED, V51, P1659, DOI 10.2967/jnumed.110.078584; Ntziachristos V, 2004, P NATL ACAD SCI USA, V101, P12294, DOI 10.1073/pnas.0401137101; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; O'Neil EJ, 2006, COORDIN CHEM REV, V250, P3068, DOI 10.1016/j.ccr.2006.04.006; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith BA, 2011, APOPTOSIS, V16, P722, DOI 10.1007/s10495-011-0601-5; Smith BA, 2011, MOL PHARMACEUT, V8, P583, DOI 10.1021/mp100395u; Smith BA, 2010, J AM CHEM SOC, V132, P67, DOI 10.1021/ja908467y; Spaeth N, 2004, J NUCL MED, V45, P1931; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderheyden JL, 2006, NUCL MED BIOL, V33, P135, DOI 10.1016/j.nucmedbio.2005.09.002; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson JRF, 2009, EUR J TRAUMA EMERG S, V35, P176, DOI 10.1007/s00068-008-8095-8; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Xiong CY, 2011, J MED CHEM, V54, P1825, DOI 10.1021/jm101477d; Yamamoto N, 2011, INT J CLIN ONCOL, V16, P84, DOI 10.1007/s10147-011-0201-y; Yang M, 2007, CANCER RES, V67, P5195, DOI 10.1158/0008-5472.CAN-06-4590; Zhao M, 2009, ANTI-CANCER AGENT ME, V9, P1018, DOI 10.2174/187152009789377691; Zheng H, 2011, J AM CHEM SOC, V133, P15280, DOI 10.1021/ja205911n	51	40	40	0	30	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	JUL	2012	3	7					530	537		10.1021/cn3000197			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	975VO	WOS:000306539800006	22860222	Green Published			2022-02-06	
J	Rockhill, CM; Jaffe, K; Zhou, C; Fan, MY; Katon, W; Fann, JR				Rockhill, Carol Mary; Jaffe, Kenneth; Zhou, Chuan; Fan, Ming-Yu; Katon, Wayne; Fann, Jesse R.			Health Care Costs Associated with Traumatic Brain Injury and Psychiatric Illness in Adults	JOURNAL OF NEUROTRAUMA			English	Article						cost; health care; psychiatry; traumatic brain injury	MEDICAL COSTS; IMPACT; POPULATION; DISORDERS; ADHERENCE; SYMPTOMS; CHILDREN; MODELS	A cohort design was used to determine the contribution of traumatic brain injury (TBI) and psychiatric illness to health care costs for adolescents and adults in the 3 years following mild or moderate-to-severe TBI compared to a matched cohort without TBI, controlling for confounders. In all, 3756 subjects 15 years or older from a large health maintenance organization database were examined. We identified subjects who sustained a TBI in 1993 (n = 939) and selected three control subjects per TBI-exposed subject (n = 2817), matched for age, sex, and enrollment at the time of injury. Unadjusted mean costs in 2009-adjusted dollars were compared using Kruskal-Wallis tests and Mann-Whitney U tests, and adjusted mean costs were compared using gamma regression analyses. Average costs were 76% higher in the 3 years after injury for the mild TBI group, and 5.75 times greater for the moderate-to-severe TBI group compared to controls. The presence of psychiatric illness was associated with more than doubling of total costs for both inpatient and outpatient non-mental health care. Gamma regression analyses confirmed significantly higher costs in patients with TBI or psychiatric illness. A significant interaction between moderate-to-severe TBI and psychiatric illness indicated a 3.39 times greater cost among patients with both exposures compared with those exposed to moderate-to-severe TBI without psychiatric illness. TBI and psychiatric illness were each associated with significant increases in health care costs; those with the combination of moderate-to-severe TBI and psychiatric illness had much higher costs than any other group.	[Rockhill, Carol Mary; Fan, Ming-Yu; Katon, Wayne; Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98115 USA; [Jaffe, Kenneth] Childrens Hosp & Med Ctr, Dept Rehabil Med, Seattle, WA 98105 USA; [Zhou, Chuan] Univ Washington, Dept Pediat, Seattle, WA 98115 USA		Rockhill, CM (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific Ave NE,Box 359300 W3636, Seattle, WA 98115 USA.	rockhill@uw.edu	Zhou, Chuan/AAJ-1935-2020; MUNOZ, ROSA ANA/H-3964-2018	MUNOZ, ROSA ANA/0000-0002-7504-2163	National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia	This research was supported by a grant to the last author from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. The funding organization's role was limited to review of the design of the study. We thank David Rubanowice, B.S., for his computer programming assistance, William Hollingsworth, Ph.D., for guidance regarding cost analyses, and Leighton Chan, M.D., M.P.H., for his expertise with Medicare and rehabilitation service payment policies.	American Medical Rehabilitation Providers Association (AMRPA), 2010, STAT FIELD; Appleton R., 2006, MANAGEMENT BRAIN INJ; Asche CV, 2010, CURR MED RES OPIN, V26, P1843, DOI 10.1185/03007995.2010.488037; Ashman TA, 2006, MT SINAI J MED, V73, P999; Blough DK, 1999, J HEALTH ECON, V18, P153, DOI 10.1016/S0167-6296(98)00032-0; Bombardier C., 2010, JAMA-J AM MED ASSOC, V301, P1938; Brouwer WBF, 2005, BRIT MED J, V331, P446, DOI 10.1136/bmj.331.7514.446; Centers for Disease Control and Prevention, 2010, NAT CTR INJ PREV CON; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; COOK RD, 1983, BIOMETRIKA, V70, P1, DOI 10.1093/biomet/70.1.1; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Dobrez D, 2010, ARCH PHYS MED REHAB, V91, P184, DOI 10.1016/j.apmr.2009.10.020; Dobrez DG, 2004, ARCH PHYS MED REHAB, V85, P1909, DOI 10.1016/j.apmr.2004.06.064; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul M, 2010, TRAUMATIC BRAIN INJU; Gold M., 1996, COST EFFECTIVENESS H; Halpern R, 2011, J MANAGE CARE PHARM, V17, P25, DOI 10.18553/jmcp.2011.17.1.25; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Katon WJ, 2003, ARCH GEN PSYCHIAT, V60, P897, DOI 10.1001/archpsyc.60.9.897; Lofgren R, 2006, ACAD MED, V81, P713, DOI 10.1097/00001888-200608000-00007; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Medicare Payment Advisory Commission (MedPAC), 2010, INP REH FAC SERV ASS; National Center for Health Statistics, 1991, NAT CTR HLTH STAT PU; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Ortendahl M, 2002, J CLIN EPIDEMIOL, V55, P843, DOI 10.1016/S0895-4356(02)00447-X; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smith M.S., 1994, MANAG CARE Q, V2, P21; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP LAB BUR LA, 2006, CONS PRIC IND; Walker EA, 2003, ARCH GEN PSYCHIAT, V60, P369, DOI 10.1001/archpsyc.60.4.369; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Weiner J P, 1992, HMO Pract, V6, P13	42	40	40	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1038	1046		10.1089/neu.2010.1562			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100002	22142264				2022-02-06	
J	Clausen, F; Marklund, N; Lewen, A; Enblad, P; Basu, S; Hillered, L				Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Enblad, Per; Basu, Samar; Hillered, Lars			Interstitial F-2-Isoprostane 8-Iso-PGF(2 alpha) As a Biomarker of Oxidative Stress after Severe Human Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; microdialysis; oxidative stress; traumatic brain injury	CEREBRAL MICRODIALYSIS; LIPID-PEROXIDATION; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; SYSTEM X(C)(-); FREE-RADICALS; GLYCEROL; DAMAGE; RATS	Oxidative stress is a major contributor to the secondary injury process after experimental traumatic brain injury (TBI). The importance of oxidative stress in the pathobiology of human TBI is largely unknown. The F-2-isoprostane 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)), synthesized in vivo through non-enzymatic free radical catalyzed peroxidation of arachidonic acid, is a widely used biomarker of oxidative stress in multiple disease states, including TBI and cerebral ischemia/reperfusion. Our hypothesis is that harvesting of biomarkers directly in the injured brain by cerebral microdialysis (MD) is advantageous because of its high spatial and temporal resolution compared to blood or cerebrospinal fluid sampling. The aim of this study was to test the feasibility of measuring 8-iso-PGF(2 alpha) in MD, ventricular cerebrospinal fluid (vCSF), and plasma samples collected from patients with severe TBI, and to compare the MD signals with MD-glycerol, implicated as a biomarker of oxidative stress, as well as MD-glutamate, a biomarker of excitotoxicity. Six patients (4 men, 2 women) were included in the study, three of whom had a focal/mixed TBI, and three a diffuse axonal injury (DAI). Following the bedside analysis of routine MD biomarkers (glucose, lactate: pyruvate ratio, glycerol, and glutamate), two 12-hMD samples per day were used to analyze 8-iso-PGF(2 alpha) from 24 h up to 8 days post-injury. The interstitial levels of 8-iso-PGF(2 alpha) were markedly higher than the levels obtained from plasma and vCSF (p < 0.05), supporting our hypothesis. The MD-8-iso-PGF(2 alpha) levels correlated strongly (p < 0.05) with MD-glycerol and MD-glutamate, which are widely used biomarkers of membrane phospholipid degradation/oxidative stress and excitotoxicity, respectively. This study demonstrates the feasibility of analyzing 8-iso-PGF(2 alpha) in MD samples from the human brain. Our results support a close relationship between oxidative stress and excitotoxicity following human TBI. MD-8-iso-PGF(2 alpha) in combination with MD-glycerol may be useful biomarkers of oxidative stress in the neurointensive care setting.	[Clausen, Fredrik] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; [Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Enblad, Per; Hillered, Lars] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; [Basu, Samar] Uppsala Univ, Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci Oxidat Stress & Infla, S-75185 Uppsala, Sweden; [Basu, Samar] Univ Auvergne, Fac Pharm, Lab Biochim Biol Mol & Nutr, Clermont Ferrand, France		Clausen, F (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	Fredrik.clausen@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292; Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Uppsala University Hospital; Selander Foundation; Ahlen Foundation	This study was supported by the Swedish Research Council, the Swedish Brain Foundation, Uppsala University Hospital, the Selander Foundation, and the Ahlen Foundation.	AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bachi A, 1997, BRIT J PHARMACOL, V121, P1770, DOI 10.1038/sj.bjp.0701321; Basu S, 1998, PROSTAG LEUKOTR ESS, V58, P319, DOI 10.1016/S0952-3278(98)90042-4; Basu S, 2000, FEBS LETT, V470, P1, DOI 10.1016/S0014-5793(00)01279-5; Basu S, 2008, ANTIOXID REDOX SIGN, V10, P1405, DOI 10.1089/ars.2007.1956; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2008, CRIT CARE, V12, DOI 10.1186/cc6779; Belton O, 2000, CIRCULATION, V102, P840; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FREEMAN BA, 1982, LAB INVEST, V47, P412; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Idris AH, 2005, CRIT CARE MED, V33, P2043, DOI 10.1097/01.CCM.0000174104.50799.BD; JACOBSON I, 1985, J NEUROSCI METH, V15, P263, DOI 10.1016/0165-0270(85)90107-4; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; Nguyen NHT, 2007, J NEUROCHEM, V101, P1694, DOI 10.1111/j.1471-4159.2006.04433.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Sato H, 2002, J NEUROSCI, V22, P8028; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Sjogren P, 2005, ARTERIOSCL THROM VAS, V25, P2580, DOI 10.1161/01.ATV.0000190675.08857.3d; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; Sumbria RK, 2011, NEUROCHEM RES, V36, P109, DOI 10.1007/s11064-010-0276-2; TEASDALE G, 1974, LANCET, V2, P81; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wiklund L, 2005, ANN NY ACAD SCI, V1053, P205, DOI 10.1196/annals.1344.019; ZALBA, 2007, CEREBROVASC DIS, V24, P24	61	40	42	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					766	775		10.1089/neu.2011.1754			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900007	21639729				2022-02-06	
J	Micklewright, JL; King, TZ; O'Toole, K; Henrich, C; Floyd, FJ				Micklewright, Jackie L.; King, Tricia Z.; O'Toole, Kathleen; Henrich, Chris; Floyd, Frank J.			Parental Distress, Parenting Practices, and Child Adaptive Outcomes Following Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Head injury; Family; Adolescence; Recovery; Adaptive outcomes; Indirect effects	SHORT-TERM; FAMILY BURDEN; ADAPTATION; BEHAVIOR; MODERATOR	Moderate and severe pediatric traumatic brain injuries (TBI) are associated with significant familial distress and child adaptive sequelae. Our aim was to examine the relationship between parental psychological distress, parenting practices (authoritarian, permissive, authoritative), and child adaptive functioning 12-36 months following TBI or orthopedic injury (OI). Injury type was hypothesized to moderate the relationship between parental distress and child adaptive functioning, demonstrating a significantly stronger relationship in the TBI relative to OI group. Authoritarian parenting practices were hypothesized to mediate relationship between parental distress and child adaptive functioning across groups. Groups (TBI n=21, OI n=23) did not differ significantly on age at injury, time since injury, sex, race, or SES. Parents completed the Brief Symptom Inventory, Parenting Practices Questionnaire, and Vineland-II. Moderation and mediation hypotheses were tested using hierarchical multiple regression and a bootstrapping approach, respectively. Results supported moderation and revealed that higher parental psychological distress was associated with lower child adaptive functioning in the TBI group only. Mediation results indicated that higher parental distress was associated with authoritarian parenting practices and lower adaptive functioning across groups. Results suggest that parenting practices are an important area of focus for studies attempting to elucidate the relationship between parent and child functioning following TBI. (JINS, 2012, 18, 343-350)	[Micklewright, Jackie L.] Hennepin Cty Med Ctr, Dept Neuropsychol, Minneapolis, MN 55415 USA; [Micklewright, Jackie L.; King, Tricia Z.; Henrich, Chris] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA; [O'Toole, Kathleen] Childrens Healthcare Atlanta Scottish Rite, Dept Neuropsychol, Atlanta, GA USA; [Floyd, Frank J.] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA		Micklewright, JL (corresponding author), Hennepin Cty Med Ctr, Dept Neuropsychol, 701 Pk Ave S, Minneapolis, MN 55415 USA.	jmicklewright1@gmail.com			American Psychological Association; Georgia State University Research Foundation; Georgia State University; North American Brain Injury Society	We are greateful to our participants and their families who gave their time to make this research possible. The research described in this study was supported by dissertation grants to Jackie Micklewright from the American Psychological Association and Georgia State University Research Foundation. Funding for Jackie Micklewright was also provided by the Georgia State University Brains & Behavior Research Fellowship. This research was also recognized by Division 22 of the American Psychological Association, the Department of Veterans Affairs Rehabilitation Research and Development Service, and the North American Brain Injury Society's Charles W. Haynes Fellowship Award. There are no conflicts of interest associated with the current study.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI 10.1111/j.1467-8624.1966.tb05416.x; Bornstein MH, 2003, MON PARENT, P29; Centers for Disease Control and Prevention Division of Injury and Disability Outcomes and Progress, 2004, TRAUM BRAIN INJ US E; Chapieski L, 2005, EPILEPSY BEHAV, V7, P246, DOI 10.1016/j.yebeh.2005.05.002; de Bildt A, 2005, J AUTISM DEV DISORD, V35, P53, DOI 10.1007/s10803-004-1033-7; Derogatis L.R., 1993, BSI BRIEF SYMPTOM IN; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fletcher J., 1998, HDB PEDIAT PSYCHOL, P258; Gamble WC, 2007, EARLY CHILD RES Q, V22, P72, DOI 10.1016/j.ecresq.2006.11.004; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Locke LM, 2002, CLIN PSYCHOL REV, V22, P895, DOI 10.1016/S0272-7358(02)00133-2; Lucas J.A., 2006, CLIN NEUROPSYCHOLOGY, V2nd ed., P351; McNett Molly, 2007, J Neurosci Nurs, V39, P68; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Patterson, 1982, SOCIAL LEARNING APPR, V3; Patterson G. R., 1983, STRESS COPING DEV CH; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Sattler J. M., 2006, ASSESSMENT CHILDREN; Sparrow S.S., 2005, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Whaley SE, 1999, J CONSULT CLIN PSYCH, V67, P826, DOI 10.1037/0022-006X.67.6.826; Winsler A, 2005, EARLY CHILD RES Q, V20, P1, DOI 10.1016/j.ecresq.2005.01.007; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	38	40	41	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2012	18	2					343	350		10.1017/S1355617711001792			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	899DI	WOS:000300794600018	22314012	Green Submitted			2022-02-06	
J	Zollman, FS; Larson, EB; Wasek-Throm, LK; Cyborski, CM; Bode, RK				Zollman, Felise S.; Larson, Eric B.; Wasek-Throm, Laura K.; Cyborski, Cherina M.; Bode, Rita K.			Acupuncture for Treatment of Insomnia in Patients With Traumatic Brain Injury: A Pilot Intervention Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						actigraphy; acupuncture; insomnia; sleep; TBI; traumatic brain injury	MELATONIN SECRETION; SLEEP; RECOVERY; ACTIGRAPHY; DEPRESSION; QUALITY	Objectives: To assess the efficacy of acupuncture in treating insomnia in traumatic brain injury (TBI) survivors as compared to medication, to determine whether acupuncture has fewer cognitive and affective adverse effects than does medication. Participants: Twenty-four adult TBI survivors, randomized to acupuncture or control arms. Setting: Outpatient rehabilitation clinic. Measures: Insomnia Severity Index (degree of insomnia); actigraphy (sleep time); Hamilton Depression Rating Scale (depression); Repeatable Battery for the Assessment of Neuropsychological Status and Paced Auditory Serial Addition Test (cognitive function) administered at baseline and postintervention. Results: Sleep time did not differ between the treatment and control groups after intervention, whereas cognition improved in the former but not the latter. Conclusion: Acupuncture has a beneficial effect on perception of sleep or sleep quality and on cognition in our small sample of patients with TBI. Further studies of this treatment modality are warranted to validate these findings and to explore factors that contribute to treatment efficacy.	[Zollman, Felise S.; Larson, Eric B.; Cyborski, Cherina M.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Wasek-Throm, Laura K.] Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA		Zollman, FS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA.	f-zollman@northwestern.edu	Larson, Eric/AAD-9567-2021		CDMRP (US Army Medical Research and Material Command) [W81XWH-08-1-0752]	This work was supported by CDMRP (US Army Medical Research and Material Command #W81XWH-08-1-0752).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 2004, NCCAM PUBL D; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; He Jing, 2005, J Tradit Chin Med, V25, P171; HELMS JM, 1995, ACUPUNCTURE ENERGETI; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kim YS, 2004, AM J CHINESE MED, V32, P771, DOI 10.1142/S0192415X04002399; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Li Y, 1993, J Tradit Chin Med, V13, P5; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCall WV, 2000, J SLEEP RES, V9, P43, DOI 10.1046/j.1365-2869.2000.00186.x; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Phillips K D, 2001, J Assoc Nurses AIDS Care, V12, P27, DOI 10.1016/S1055-3290(06)60168-4; Randolph C., 1998, REPEATABLE BATTERY A; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; SADEH A, 1995, SLEEP, V18, P288, DOI 10.1093/sleep/18.4.288; Sok SR, 2003, J ADV NURS, V44, P375, DOI 10.1046/j.0309-2402.2003.02816.x; Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19; Tang NKY, 2004, BEHAV RES THER, V42, P27, DOI 10.1016/S0005-7967(03)00068-8; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; THAXTON L, 2007, BRAIN INJURY MED PRI, P557; Tsay SL, 2004, AM J CHINESE MED, V32, P407, DOI 10.1142/S0192415X04002065; VANHILTEN JJ, 1993, SLEEP, V16, P146, DOI 10.1093/sleep/16.2.146; WANG X, 1988, Journal of Traditional Chinese Medicine, V8, P127; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167	39	40	40	3	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					135	142		10.1097/HTR.0b013e3182051397			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100006	21386714				2022-02-06	
J	Mota, BC; Pereira, L; Souza, MA; Silva, LFA; Magni, DV; Ferreira, APO; Oliveira, MS; Furian, AF; Mazzardo-Martins, L; da Silva, MD; Santos, ARS; Ferreira, J; Fighera, MR; Royes, LFF				Mota, Bibiana Castagna; Pereira, Leticia; Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Magni, Danieli Valnes; Oliveira Ferreira, Ana Paula; Oliveira, Mauro Schneider; Furian, Ana Flavia; Mazzardo-Martins, Leidiane; da Silva, Morgana Duarte; Soares Santos, Adair Roberto; Ferreira, Juliano; Fighera, Michele Rechia; Freire Royes, Luiz Fernando			Exercise Pre-conditioning Reduces Brain Inflammation and Protects against Toxicity Induced by Traumatic Brain Injury: Behavioral and Neurochemical Approach	NEUROTOXICITY RESEARCH			English	Article						Traumatic brain injury; Physical exercise; Inflammation; Na+K+-ATPase	NA+,K+-ATPASE ACTIVITY; HEAD-INJURY; PHYSICAL-ACTIVITY; RAT HIPPOCAMPUS; TNF-ALPHA; MICE; BARRIER; IL-6; EDEMA; INHIBITION	Although the favorable effects of physical exercise in neurorehabilitation after traumatic brain injury (TBI) are well known, detailed pathologic and functional alterations exerted by previous physical exercise on post-traumatic cerebral inflammation have been limited. In the present study, it is showed that fluid percussion brain injury (FPI) induced motor function impairment, followed by increased plasma fluorescein extravasation and cerebral-inflammation characterized by interleukin-1 beta, tumor necrosis factor-alpha (TNF-alpha) increase, and decreased IL-10. In addition, myeloperoxidase (MPO) increase and Na+,K+-ATPase activity inhibition after FPI suggest that the opening of blood-brain barrier (BBB) followed by neurtrophils infiltration and cerebral inflammation may contribute to the failure of selected targets leading to secondary damage. In fact, Pearson's correlation analysis revealed strong correlation of MPO activity increase with Na+,K+-ATPase activity inhibition in sedentary rats. Statistical analysis also revealed that previous running exercise (4 weeks) protected against FPI-induced motor function impairment and fluorescein extravasation. Previous physical training also induced IL-10 increase per se and protected against cerebral IL-1 beta, and TNF-alpha increase and IL-10 decrease induced by FPI. This protocol of physical training was effective against MPO activity increase and Na+,K+-ATPase activity inhibition after FPI. The present protection correlated with MPO activity decrease suggests that the alteration of cerebral inflammatory status profile elicited by previous physical training reduces initial damage and limits long-term secondary degeneration after TBI. This prophylactic effect may facilitate functional recovery in patients suffering from brain injury induced by TBI.	[Mota, Bibiana Castagna; Pereira, Leticia; Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Oliveira Ferreira, Ana Paula; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Lab Bioquim Exercicio, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Souza, Mauren Assis; Almeida Silva, Luiz Fernando; Magni, Danieli Valnes; Oliveira Ferreira, Ana Paula; Oliveira, Mauro Schneider; Ferreira, Juliano; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia] Univ Fed Pampa, BR-97650000 Itaqui, RS, Brazil; [Fighera, Michele Rechia] PUC RS, Hosp Sao Lucas, Serv Neurol, Inst Cerebro, Porto Alegre, RS, Brazil; [Mazzardo-Martins, Leidiane; da Silva, Morgana Duarte; Soares Santos, Adair Roberto] Univ Fed Santa Catarina, Dept Ciencias Fisiol, Ctr Ciencias Biol, Florianopolis, SC, Brazil		Royes, LFF (corresponding author), Univ Fed Santa Maria, Lab Bioquim Exercicio, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Ferreira, Juliano/A-9803-2013; Souza, Mauren/A-7990-2015; da Silva, Morgana D/D-4942-2015; Fighera, Michele R/J-9576-2014; Santos, Adair/C-5565-2013; Oliveira, Mauro Schneider/G-3437-2012	Ferreira, Juliano/0000-0002-9562-0602; da Silva, Morgana D/0000-0002-2487-236X; Santos, Adair/0000-0002-6435-4698; Oliveira, Mauro Schneider/0000-0002-5381-1208; Fighera, Michele/0000-0002-3111-7530; Almeida Silva, Luiz Fernando/0000-0002-7621-4836			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Arida RM, 2007, PHYSIOL BEHAV, V90, P629, DOI 10.1016/j.physbeh.2006.11.016; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chow JW, 2010, BRAIN INJURY, V24, P1575, DOI 10.3109/02699052.2010.523053; Costa T, 2010, J NEUROSCI RES, V88, P1329, DOI 10.1002/jnr.22300; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Ding YH, 2006, CURR NEUROVASC RES, V3, P263, DOI 10.2174/156720206778792911; DISHMAN RK, 1988, PHYSIOL BEHAV, V43, P541, DOI 10.1016/0031-9384(88)90206-5; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres M, 2003, ANN NEUROL, V54, P582, DOI 10.1002/ana.10722; Erickson KI, 2007, NEUROBIOL AGING, V28, P179, DOI 10.1016/j.neurobiolaging.2005.11.016; FAN L, 1995, MOL BRAIN RES, V30, P125; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Funk JA, 2011, BRAIN BEHAV IMMUN, V25, P1063, DOI 10.1016/j.bbi.2011.03.012; Gobatto CA, 2001, COMP BIOCHEM PHYS A, V130, P21, DOI 10.1016/S1095-6433(01)00362-2; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM TM, 1990, J NEUROPHYSIOL, V63, P395, DOI 10.1152/jn.1990.63.3.395; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; Ivashkova Y, 2006, J TRAUMA, V61, P879, DOI 10.1097/01.ta.0000234722.98537.01; Jamme I, 1995, NEUROREPORT, V7, P333; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Juliet PAR, 2008, BRAIN RES, V1210, P230, DOI 10.1016/j.brainres.2008.02.099; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEES GJ, 1990, NEUROSCI LETT, V120, P159, DOI 10.1016/0304-3940(90)90027-7; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Marquezi ML, 2003, INT J SPORT NUTR EXE, V13, P65, DOI 10.1123/ijsnem.13.1.65; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Oliveira MS, 2009, J NEUROCHEM, V109, P416, DOI 10.1111/j.1471-4159.2009.05961.x; Olsen AL, 2007, ANTIVIR RES, V75, P104, DOI 10.1016/j.antiviral.2006.11.013; Parachikova A, 2008, NEUROBIOL DIS, V30, P121, DOI 10.1016/j.nbd.2007.12.008; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Potts Mathew B, 2006, NeuroRx, V3, P143; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2003, EXERC IMMUNOL REV, V9, P40; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; TILG H, 1994, BLOOD, V83, P113; Unterberg AW, 1997, ACT NEUR S, V70, P106; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Woods JA, 2005, BRAIN BEHAV IMMUN, V19, P369, DOI 10.1016/j.bbi.2005.04.007; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	63	40	41	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	FEB	2012	21	2					175	184		10.1007/s12640-011-9257-8			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	869NK	WOS:000298604700004	21735317				2022-02-06	
J	Lopez, NE; Krzyzaniak, MJ; Blow, C; Putnam, J; Ortiz-Pomales, Y; Hageny, AM; Eliceiri, B; Coimbra, R; Bansal, V				Lopez, Nicole E.; Krzyzaniak, Michael J.; Blow, Chelsea; Putnam, James; Ortiz-Pomales, Yan; Hageny, Ann-Marie; Eliceiri, Brian; Coimbra, Raul; Bansal, Vishal			Ghrelin Prevents Disruption of the Blood-Brain Barrier after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; blood-brain barrier; ghrelin; traumatic brain injury	PRO-INFLAMMATORY CYTOKINES; PHORBOL-MYRISTATE ACETATE; V1A RECEPTOR ANTAGONIST; HEAD-INJURY; CELL-DEATH; NEUTROPHIL INFILTRATION; HIPPOCAMPAL-NEURONS; EDEMA; RATS; AQUAPORIN-4	Significant effort has been focused on reducing neuronal damage from post-traumatic brain injury (TBI) inflammation and blood-brain barrier (BBB)-mediated edema. The orexigenic hormone ghrelin decreases inflammation in sepsis models, and has recently been shown to be neuroprotective following subarachnoid hemorrhage. We hypothesized that ghrelin modulates cerebral vascular permeability and mediates BBB breakdown following TBI. Using a weight-drop model, TBI was created in three groups of mice: sham, TBI, and TBI/ghrelin. The BBB was investigated by examining its permeability to FITC-dextran and through quantification of perivascualar aquaporin-4 (AQP-4). Finally, we immunoblotted for serum S100B as a marker of brain injury. Compared to sham, TBI caused significant histologic neuronal degeneration, increases in vascular permeability, perivascular expression of AQP-4, and serum levels of S100B. Treatment with ghrelin mitigated these effects; after TBI, ghrelin-treated mice had vascular permeability and perivascular AQP-4 and S100B levels that were similar to sham. Our data suggest that ghrelin prevents BBB disruption after TBI. This is evident by a decrease in vascular permeability that is linked to a decrease in AQP-4. This decrease in vascular permeability may diminish post-TBI brain tissue damage was evident by decreased S100B.	[Bansal, Vishal] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA		Bansal, V (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	v3bansal@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Lopez, Nicole/0000-0002-4807-7360; Eliceiri, Brian/0000-0003-1811-1916	American Surgical Association Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	Funding for this work was supported partly by American Surgical Association Foundation.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Bansal V., 2010, J NEUROTRAUMA; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Finkelstein E., 2006, INCIDENCE EC BURDEN; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hinson SR, 2010, NEUROSCIENCE, V168, P1009, DOI 10.1016/j.neuroscience.2009.08.032; Huber JD, 2006, AM J PHYSIOL-HEART C, V290, pH732, DOI 10.1152/ajpheart.00747.2005; Iseri SO, 2008, REGUL PEPTIDES, V146, P73, DOI 10.1016/j.regpep.2007.08.014; Jacob A, 2010, FASEB J, V24, P1682, DOI 10.1096/fj.09-138834; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kwan R, 2010, J ELECTR COMPUT ENG, V2010, DOI [10.1097/TA.0b013e3181bb9878, 10.1155/2010/273486]; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Lee J, 2010, CANCER RES, V70, P10131, DOI 10.1158/0008-5472.CAN-10-2740; Liu YJ, 2006, CHINESE J PHYSIOL, V49, P244; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marmarou A, 2003, ACT NEUR S, V86, P7; Miao YY, 2007, BIOCHEM BIOPH RES CO, V359, P795, DOI 10.1016/j.bbrc.2007.05.192; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Patel TH, 2008, NEUROSCI LETT, V444, P222, DOI 10.1016/j.neulet.2008.08.020; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Qi X, 2008, J CLIN INVEST, V118, P173, DOI 10.1172/JCI32636; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Sehirli O, 2008, PEPTIDES, V29, P1231, DOI 10.1016/j.peptides.2008.02.012; Simard M, 2003, J NEUROSCI, V23, P9254; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Xu JJ, 2009, NEUROSCI LETT, V453, P58, DOI 10.1016/j.neulet.2009.01.067; Zelenina M, 2010, NEUROCHEM INT, V57, P468, DOI 10.1016/j.neuint.2010.03.022	49	40	45	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					385	393		10.1089/neu.2011.2053			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300017	21939391	Green Published			2022-02-06	
J	Batchelor, JS; Grayson, A				Batchelor, John S.; Grayson, Alan			A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracramal haemorrhage	BMJ OPEN			English	Article							INTRACEREBRAL HEMORRHAGE; BRAIN-INJURY; HEAD-INJURY; EMERGENCY REVERSAL; ELDERLY-PATIENTS; ASPIRIN; THERAPY; AGENTS; MILD; RISK	Objectives: The aim of this study was to evaluate by meta-analysis the current level of evidence in order to establish the impact of a platelet transfusion on survival in patients on pre-injury antiplatelet agents who sustain an intracranial haemorrhage (either spontaneous or traumatic). Design: This was a meta-analysis; the MEDLINE Database was searched using the PubMed interface and the Ovid interface. CINAHL and EM BASE Databases were also searched. The search was performed to identify randomised controlled trials (RCT)'s case-controlled studies or nested case-controlled studies. Comparing the outcome (death or survival) of patients with intracranial haemorrhage (ICH) and pre-injury antiplatelet agents who received a platelet transfusion against a similar cohort of patients who did not receive a platelet transfusion. Results: 499 citations were obtained from the PubMed search. 31 full articles were reviewed from 34 abstracts. 6 studies were found suitable for the meta-analysis. No randomised controlled studies were identified. 2 of the six studies were in patients with spontaneous ICH. The remaining four studies were in patients with traumatic intracranial haemorrhage. Significant heterogeneity was present between the studies, I-2=58.276. The random effects model was therefore the preferred model, this produced a pooled OR for survival of 0.773 (95% Cl 0.414 to 1.442). Conclusions: The results of this meta-analysis has shown, based upon six small studies, that there was no clear benefit in terms of survival in the administration of a platelet transfusion to patients with antiplatelet-associated ICH. Further work is required in order to establish any potential benefit in the administration of a platelet transfusion in patients with spontaneous or traumatic intracranial haemorrhage who were on pre-injury antiplatelet agents.	[Batchelor, John S.; Grayson, Alan] Manchester Royal Infirm, Dept Emergency Med, Manchester M13 9WL, Lancs, England		Batchelor, JS (corresponding author), Manchester Royal Infirm, Dept Emergency Med, Oxford Rd, Manchester M13 9WL, Lancs, England.	johnbatchelor@msn.com					Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Beshay JE, 2010, J NEUROSURG, V112, P307, DOI 10.3171/2009.7.JNS0982; Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; de Gans K, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-19; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Fabbri A, 2010, J NEUROL NEUROSUR PS, V81, P1275, DOI 10.1136/jnnp.2009.197467; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Sansing LH, 2009, NEUROLOGY, V72, P1397, DOI 10.1212/01.wnl.0000342709.31341.88; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	20	40	40	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2012	2	2							e000588	10.1136/bmjopen-2011-000588			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	091IF	WOS:000315042100030	22492383	Green Published, gold			2022-02-06	
J	Golaszewski, SM; Bergmann, J; Christova, M; Kunz, AB; Kronbichler, M; Rafolt, D; Gallasch, E; Staffen, W; Trinka, E; Nardone, R				Golaszewski, Stefan M.; Bergmann, Juergen; Christova, Monica; Kunz, Alexander B.; Kronbichler, Martin; Rafolt, Dietmar; Gallasch, Eugen; Staffen, Wolfgang; Trinka, Eugen; Nardone, Raffaele			Modulation of motor cortex excitability by different levels of whole-hand afferent electrical stimulation	CLINICAL NEUROPHYSIOLOGY			English	Article						Transcranial magnetic stimulation; Mesh-glove; Motor cortex excitability; Somatosensory stimulation; Neuroplasticity	PERIPHERAL-NERVE STIMULATION; CORTICAL PLASTICITY; INHIBITION; ATTENTION; INPUT; TENS	Objective: In a previous transcranial magnetic stimulation (TMS) study we demonstrated that suprathreshold mesh-glove (MG) whole-hand stimulation elicits lasting changes in motor cortical excitability. Currently, there is no consensus with regard to the optimal parameters for the induction of sensorimotor cortical plasticity using peripheral electrical stimulation. Thus, in the present study we explore the modulatory effects of MG stimulation at different stimulus intensities and different frequencies in order to identify an optimal stimulation protocol. Methods: MG stimulation was performed on 12 healthy subjects in separate sessions at different stimulation levels: sub-sensory at 50 Hz, sensory at 50 Hz and motor at 2 Hz. To verify if stimulation at lower frequencies is less effective, an additional experiment at sensory level with 2 Hz was performed. TMS was used to assess motor threshold (MT), motor evoked potentials (MEPs) recruitment curve (RC), short latency intracortical inhibition (SICI) and intracortical facilitation (ICF) to paired-pulse TMS at baseline (T0), immediately after (T1) and 1 h (T2) after 30 min of MG stimulation. F-wave studies were performed to assess spinal motoneuron excitability. Results: MG stimulation at sub-sensory/50 Hz and sensory/2 Hz level determines no significant cortical excitability changes; at sensory/50 Hz level and at motor/2 Hz level we found decreased MT, increased MEP RC as well as reduced SICI and increased ICF at T1 and T2. Conclusions: MG stimulation at sensory/50 Hz and motor/2 Hz level induces similar long-lasting modulatory effects on motor cortical excitability. Both the strength of the corticospinal projections and the intracortical networks are influenced to the same extend. Significance: The study provides further evidence that stimulation intensity and frequency can independently modulate motor cortical plasticity. The selection of optimal stimulation parameters has potentially important implications for the neurorehabilitation of patients after brain damage (e. g. stroke, traumatic brain injury) with hand motor deficits. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Golaszewski, Stefan M.; Kunz, Alexander B.; Staffen, Wolfgang; Trinka, Eugen; Nardone, Raffaele] Paracelsus Med Univ Salzburg, Dept Neurol, A-5020 Salzburg, Austria; [Golaszewski, Stefan M.; Bergmann, Juergen; Kunz, Alexander B.; Kronbichler, Martin; Staffen, Wolfgang] Paracelsus Med Univ Salzburg, Inst Neurosci, A-5020 Salzburg, Austria; [Golaszewski, Stefan M.] Med Univ Innsbruck, Dept Psychiat, fMRI Lab, Innsbruck, Austria; [Bergmann, Juergen; Kronbichler, Martin] Paris Lodron Univ Salzburg, Dept Psychol, Salzburg, Austria; [Bergmann, Juergen; Kronbichler, Martin] Paris Lodron Univ Salzburg, Ctr Neurocognit Res, Salzburg, Austria; [Christova, Monica; Gallasch, Eugen] Med Univ Graz, Inst Physiol, Graz, Austria; [Rafolt, Dietmar] Med Univ Vienna, Ctr Biomed Engn & Med Phys, Vienna, Austria; [Nardone, Raffaele] F Tappeiner Hosp, Dept Neurol, Meran, Italy		Golaszewski, SM (corresponding author), Paracelsus Med Univ Salzburg, Dept Neurol, Ignaz Harrer Str 79, A-5020 Salzburg, Austria.	S.Golaszewski@salk.at	LUO, JINGJING/AAZ-6697-2021; Kronbichler, Martin/AAY-1519-2021; Kronbichler, Martin/A-5599-2008	LUO, JINGJING/0000-0002-3222-1276; Kronbichler, Martin/0000-0003-2240-2812; Kronbichler, Martin/0000-0003-2240-2812; Kunz, Alexander/0000-0002-8455-8436; Trinka, Eugen/0000-0002-5950-2692; Nardone, Raffaele/0000-0001-5243-6760	Austrian National Bank [13221, 10109]; Paracelsus Medical University Salzburg, Austria [05/02/011]; Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas, USA	This work was supported by Grants Nos. 13221 and 10109 from the Austrian National Bank and by a Grant No. 05/02/011 from the Paracelsus Medical University Salzburg, Austria. The authors wish to thank Dr. Meta and Prof. Dr. Milan Dimitrijevic from the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas, USA, for their support and continuous encouragement while working on this study.	Charlton CS, 2003, J NEUROL SCI, V208, P79, DOI 10.1016/S0022-510X(02)00443-4; Chipchase LS, 2011, CLIN NEUROPHYSIOL, V122, P456, DOI 10.1016/j.clinph.2010.07.025; CHRISTOVA M, 2011, EUR J APPL PHYSL; DENGLER R, 1992, MUSCLE NERVE, V15, P1138, DOI 10.1002/mus.880151013; Fernandez-del-Olmo M, 2008, CLIN NEUROPHYSIOL, V119, P1834, DOI 10.1016/j.clinph.2008.04.002; Fraser C, 2002, NEURON, V34, P831, DOI 10.1016/S0896-6273(02)00705-5; Golaszewski S, 1999, SCAND J REHABIL MED, V31, P165; Golaszewski SM, 2004, NEUROLOGY, V62, P2262, DOI 10.1212/WNL.62.12.2262; Golaszewski SM, 2010, CLIN NEUROPHYSIOL, V121, P248, DOI 10.1016/j.clinph.2009.09.024; Hallett M, 1999, EEG CL N SU, V50, P85; Kaelin-Lang A, 2002, J PHYSIOL-LONDON, V540, P623, DOI 10.1113/jphysiol.2001.012801; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lin JZ, 2004, MUSCLE NERVE, V30, P289, DOI 10.1002/mus.20110; Mima T, 2004, NEUROSCI LETT, V355, P85, DOI 10.1016/j.neulet.2003.10.045; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ridding MC, 2005, EXP BRAIN RES, V163, P335, DOI 10.1007/s00221-004-2176-7; Ridding MC, 2000, EXP BRAIN RES, V131, P135, DOI 10.1007/s002219900269; Rosenkranz K, 2004, J PHYSIOL-LONDON, V561, P307, DOI 10.1113/jphysiol.2004.069328; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Tinazzi M, 2005, EXP BRAIN RES, V161, P457, DOI 10.1007/s00221-004-2091-y; Zittel S, 2007, EXP BRAIN RES, V176, P425, DOI 10.1007/s00221-006-0624-2	21	40	40	0	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2012	123	1					193	199		10.1016/j.clinph.2011.06.010			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865QG	WOS:000298324800025	21764634				2022-02-06	
J	Shahrokhi, N; Haddad, MK; Joukar, S; Shabani, M; Keshavarzi, Z; Shahozehi, B				Shahrokhi, Nader; Haddad, Mohammad Khaksari; Joukar, Siavash; Shabani, Mohammad; Keshavarzi, Zekie; Shahozehi, Bidoallah			Neuroprotective antioxidant effect of sex steroid hormones in traumatic brain injury	PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						TBI; sex steroids; estrogen; progesterone; GPx; SOD; MDA; neuroprotection	OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; EDEMA FORMATION; FREE-RADICALS; IN-VITRO; RATS; PROGESTERONE; ESTROGEN; PROTECTS; DAMAGE	The aim of the present study was to evaluate the effect of different doses of sex steroid hormones on brain edema, BBB permeability, brain antioxidant enzyme activity, and MDA level after traumatic brain injury (TBI) in ovarectomized (OVX) rats. Female rats were divided into six (One sham and 5 TBI) groups including: vehicle, estrogen in physiologic (33.3 mu g/kg) and pharmacologic (1 mg/kg) doses, progesterone in physiologic (1.7 mg/kg) and pharmacological doses (8 mg/kg). The results showed that compared to vehicle group, estrogen and progesterone groups showed significantly lower brain water content (P<0.001). Evans blue content was significantly lower in both estrogen doses and in progesterone physiologic dose (P<0.001). Evans blue content was significantly higher in progesterone pharmacologic dose (P<0.001). Superoxide dismutase (SOD) activity was significantly higher in estrogen and progesterone pharmacologic doses (P<0.001). Glutathione peroxidase (GPx) activity was significantly lower in estrogen physiologic dose (P<0.001). It was concluded that the neuroprotective effect of different doses of sex steroid hormones after TBI, may be mediated by changes in oxidant agent activity.	[Haddad, Mohammad Khaksari; Joukar, Siavash; Shahozehi, Bidoallah] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Shahrokhi, Nader; Shabani, Mohammad] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Keshavarzi, Zekie] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran		Haddad, MK (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran.	nshahrokhisa@yahoo.com	Shahrokhi, Nader/AAV-3747-2020; Shabani, Mohammad/AAZ-3682-2020; Haddad, Mohammad Khaksari/AAB-9025-2019	Shahrokhi, Nader/0000-0002-0149-7819; Shabani, Mohammad/0000-0002-2082-5849; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Joukar, Siyavash/0000-0002-9937-6985			Calegare BFA, 2010, PSYCHONEUROENDOCRINO, V35, P775, DOI 10.1016/j.psyneuen.2009.11.004; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Behl C, 2002, J STEROID BIOCHEM, V83, P195, DOI 10.1016/S0960-0760(02)00271-6; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Dhote VV, 2007, LIFE SCI, V81, P188, DOI 10.1016/j.lfs.2007.05.010; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Huang CY, 2010, J SURG RES, V164, pE1, DOI 10.1016/j.jss.2010.07.041; Kasimay O, 2009, RENAL FAILURE, V31, P711, DOI 10.3109/08860220903134563; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kerksick C, 2008, MED SCI SPORT EXER, V40, P1772, DOI 10.1249/MSS.0b013e31817d1cce; Kuebler JF, 2003, CRIT CARE MED, V31, P1786, DOI 10.1097/01.CCM.0000063441.41446.23; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Pajovic SB, 2003, PHYSIOL RES, V52, P189; Palomar-Morales M, 2010, PANCREAS, V39, P193, DOI 10.1097/MPA.0b013e3181c156d9; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Soylemez S, 2008, VASC PHARMACOL, V49, P97, DOI 10.1016/j.vph.2008.06.006; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; SUN Y, 1988, CLIN CHEM, V34, P497; Traupe T, 2007, HYPERTENSION, V49, P1364, DOI 10.1161/HYPERTENSIONAHA.106.081554; Unfer TC, 2006, CLIN CHIM ACTA, V369, P73, DOI 10.1016/j.cca.2006.01.006; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Verma Y, 2008, ARH HIG RADA TOKSIKO, V59, P1, DOI 10.2478/10004-1254-59-2008-1835; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Zandi PP, 2004, ARCH NEUROL-CHICAGO, V61, P82, DOI 10.1001/archneur.61.1.82	39	40	46	0	4	UNIV KARACHI	KARACHI	UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN	1011-601X			PAK J PHARM SCI	Pak. J. Pharm. Sci.	JAN	2012	25	1					219	225					7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	889JV	WOS:000300070900033	22186333				2022-02-06	
J	Viano, DC; Halstead, D				Viano, David C.; Halstead, David			Change in Size and Impact Performance of Football Helmets from the 1970s to 2010	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Protective headgear; Recreation and sport; Concussion; Helmets; Sport equipment	PROFESSIONAL FOOTBALL; GAME IMPACTS; NECK INJURY; CONCUSSION; HEAD; PLAYER; BIOMECHANICS	Linear impactor tests were conducted on football helmets from the 1970s-1980s to complement recently reported tests on 1990s and 2010s helmets. Helmets were placed on the Hybrid III head with an array of accelerometers to determine translational and rotational acceleration. Impacts were at four sites on the helmet shell at 3.6-11.2 m/s. The four generations of helmets show a continuous improvement in response from bare head impacts in terms of Head Injury Criterion (HIC), peak head acceleration and peak rotational acceleration. Helmets of 2010s weigh 1.95 +/- 0.2 kg and are 2.7 times heavier than 1970s designs. They are also 4.3 cm longer, 7.6 cm higher, and 4.9 cm wider. The extra size and weight allow the use of energy absorbing padding that lowers forces in helmet impacts. For frontal impacts at 7.4 m/s, the four best performing 2010s helmets have HIC of 148 +/- 23 compared to 179 +/- 42 for the 1990s baseline, 231 +/- 27 for the 1980s, 253 +/- 22 for the 1970s helmets, and 354 +/- 3 for the bare head. The additional size and padding of the best 2010s helmets provide superior attenuation of impact forces in normal play and in conditions associated with concussion than helmets of the 1970s-1990s.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Halstead, David] Univ Tennessee, Coll Engn, Sports Biomech Impact Res Lab, Knoxville, TN 37996 USA; [Halstead, David] So Impact Res Ctr LLC, Rockford, TN 37853 USA		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			National Football League	Funding for this research was provided by the National Football League. SIRC has previous and ongoing relationships with some of the helmet manufacturers, NOCSAE and others. These were acknowledged at the onset. The testing reported here was completed while the lead author was a member of the NFL's MTBI Committee and oversaw the evaluations. The views presented here are those of the authors and not necessarily those of the sponsor or any helmet manufacturer. The impact testing and data were collected by Ms. Elizabeth McCalley at SIRC; her assistance is greatly appreciated. The data was analyzed by ProBiomechanics LLC without the involvement of SIRC. Dr. Chantal Parenteau merged, tabulated and analyzed the data at ProBiomechanics LLC; her assistance is also greatly appreciated.	[Anonymous], 1998, 00298M03 NOCSAE; [Anonymous], 1998, 02198M05 NOCSAE; [Anonymous], 2004, 00104M05 NOCSAE; Backaitis S. H., 1994, HYBRID; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; Casson IR, 2008, NEUROSURGERY, V62, P204, DOI 10.1227/01.NEU.0000311079.65895.3E; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Hodgson V. R., 1980, INTERSCHOL ATHLETIC, V7, P11; Hodgson V. R., 1972, 16 STAPP CAR CRASH C, V45, P1; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR., 1970, 14 STAPP CAR CRASH C; HODGSON VR, 1985, UTILITY HEAD INJURY; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; Mertz H. J., 1996, 960099 SAE; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Myers Thomas J., 1993, Bio-Medical Materials and Engineering, V3, P15; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S., 2009, J BIOMECH ENG, V131, P610; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	31	40	40	0	30	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		175	184		10.1007/s10439-011-0395-1			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700016	21994057				2022-02-06	
J	Zhang, ZR; Zhang, ZY; Wu, YZ; Schluesener, HJ				Zhang, Zhiren; Zhang, Zhi-Yuan; Wu, Yuzhang; Schluesener, Hermann J.			Immunolocalization of Toll-Like Receptors 2 and 4 as well as Their Endogenous Ligand, Heat Shock Protein 70, in Rat Traumatic Brain Injury	NEUROIMMUNOMODULATION			English	Article						Traumatic brain injury; Toll-like receptor 2; Toll-like receptor 4; Myeloid differentiation factor 88; Heat shock protein 70; Innate immunity	CENTRAL-NERVOUS-SYSTEM; HEAT-SHOCK PROTEINS; INNATE IMMUNE-SYSTEM; CEREBRAL ISCHEMIA/REPERFUSION; EXPERIMENTAL STROKE; HEME OXYGENASE-1; HSP70; INFLAMMATION; EXPRESSION; ISCHEMIA	Objective: Toll-like receptors (TLRs) are essential to the innate immune system for recognizing not only microbial pathogens but also endogenous ligands from injured cells, suggesting that TLRs are a sensitive detection system to tissue injury and play roles in initiating tissue degeneration/regeneration. In this study, the effects of traumatic brain injury (TBI) on lesional expression of TLR2, TLR4, their most common adaptor molecule myeloid differentiation factor 88 (MyD88) and their endogenous ligand, heat shock protein 70 (HSP70), were investigated. Methods: Rat TBI was induced using an open-skull weight-drop model. TLR2, TLR4, MyD88 and HSP70 expression was studied by immunohistochemistry. Results: TLR2, TLR4, HSP70 and MyD88 were mainly found in lesioned regions and subcortical white matter. While infiltration of TLR2+ cells became significant on day 2, significant accumulation of TLR4+, MyD88+ and HSP70+ cells was already seen on day 1, and the numbers of immunopositive cells increased continuously until day 4. Furthermore, double staining together with morphological classification showed that major cellular sources for TLR2, TLR4 and MyD88 were macrophages/microglia in lesioned areas and astrocytes in subcortical white matter. But for HSP70, the major cellular sources were neurons in perilesion and macrophages/microglia in lesion areas and astrocytes in subcortical white matter. Discussion: In summary, our data reveal distinct patterns of localization of TLR+ resident and infiltrating cells in TBI rat brain. Infiltrating activated monocytic cells are the major source of TLR+ cells. These findings warrant further investigation of the roles of TLRs in controlling immune and degenerative/regenerative processes after TBI. Copyright (C) 2011 S. Karger AG, Basel	[Zhang, Zhiren; Wu, Yuzhang] Third Mil Univ PLA, Inst Immunol, Chongqing, Peoples R China; [Zhang, Zhiren; Zhang, Zhi-Yuan; Schluesener, Hermann J.] Univ Tubingen, Inst Brain Res, Tubingen, Germany		Zhang, ZR (corresponding author), Third Mil Med Univ PLA, Inst Immunol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835; Wu, Yuzhang/0000-0002-4049-0214; Zhang, Zhi-Yuan/0000-0001-9067-0670	Natural Science Foundation of CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]	This research was partly supported by the Natural Science Foundation Project of CQ CSTC (contract No. 2010BB5025).	Ahn TB, 2006, BRAIN RES, V1087, P159, DOI 10.1016/j.brainres.2006.02.097; Aravalli RN, 2007, J NEUROIMMUNE PHARM, V2, P297, DOI 10.1007/s11481-007-9071-5; Arumugam TV, 2009, SHOCK, V32, P4, DOI 10.1097/SHK.0b013e318193e333; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bhat R, 2009, NEURON, V64, P123, DOI 10.1016/j.neuron.2009.09.015; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Brown MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1201, DOI 10.2741/1304; Carpentier PA, 2008, BRAIN BEHAV IMMUN, V22, P140, DOI 10.1016/j.bbi.2007.08.011; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Crack PJ, 2007, IMMUNOL CELL BIOL, V85, P476, DOI 10.1038/sj.icb.7100103; DeGracia DJ, 2007, NEUROL RES, V29, P356, DOI 10.1179/016164107X204666; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; Kinoshita Y, 2001, J NEUROTRAUM, V18, P435, DOI 10.1089/089771501750171038; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Kumar H, 2009, BIOCHEM BIOPH RES CO, V388, P621, DOI 10.1016/j.bbrc.2009.08.062; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Mautes AEM, 2000, BRAIN RES, V883, P233, DOI 10.1016/S0006-8993(00)02846-8; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Papadimitraki ED, 2007, J AUTOIMMUN, V29, P310, DOI 10.1016/j.jaut.2007.09.001; Park C, 2008, NEUROSCI LETT, V431, P123, DOI 10.1016/j.neulet.2007.11.057; Pavlik A, 2007, PROG BRAIN RES, V162, P417, DOI 10.1016/S0079-6123(06)62020-7; Pineau I, 2009, GLIA, V57, P351, DOI 10.1002/glia.20763; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Reddy SJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E4; Reynolds LPR, 2003, CEREBELLUM, V2, P171, DOI 10.1080/14734220310016114; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Shirali AC, 2008, CURR OPIN ORGAN TRAN, V13, P20, DOI 10.1097/MOT.0b013e3282f3df04; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tanaka S, 2002, J NEUROSCI RES, V67, P37, DOI 10.1002/jnr.10078; Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Noort JM, 2009, PROG BRAIN RES, V175, P139, DOI 10.1016/S0079-6123(09)17509-X; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zhang ZY, 2009, NEUROSCIENCE, V159, P136, DOI 10.1016/j.neuroscience.2008.12.034; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	49	40	45	1	18	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2012	19	1					10	19		10.1159/000326771			10	Endocrinology & Metabolism; Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	844MH	WOS:000296750800002	22067617				2022-02-06	
J	Zhang, Z; Francisco, EM; Holden, JK; Dennis, RG; Tommerdahl, M				Zhang, Zheng; Francisco, Eric M.; Holden, Jameson K.; Dennis, Robert G.; Tommerdahl, Mark			Somatosensory information processing in the aging population	FRONTIERS IN AGING NEUROSCIENCE			English	Article						aging; sensory; plasticity; adaptation; tactile; somatosensory	STIMULUS-DRIVEN SYNCHRONIZATION; WHITE-MATTER INTEGRITY; VIBROTACTILE THRESHOLDS; REACTION-TIME; OLDER-ADULTS; CORTICAL REORGANIZATION; INDIVIDUAL-DIFFERENCES; AGE; BRAIN; VARIABILITY	While it is well known that skin physiology - and consequently sensitivity to peripheral stimuli - degrades with age, what is less appreciated is that centrally mediated mechanisms allow for maintenance of the same degree of functionality in processing these peripheral inputs and interacting with the external environment. In order to demonstrate this concept, we obtained observations of processing speed, sensitivity (thresholds), discriminative capacity, and adaptation metrics on subjects ranging in age from 18 to 70. The results indicate that although reaction speed and sensory thresholds change with age, discriminative capacity, and adaptation metrics do not. The significance of these findings is that similar metrics of adaptation have been demonstrated to change significantly when the central nervous system (CNS) is compromised. Such compromise has been demonstrated in subject populations with autism, chronic pain, acute NMDA receptor block, concussion, and with tactile-thermal interactions. If the metric of adaptation parallels cortical plasticity, the results of the current study suggest that the CNS in the aging population is still capable of plastic changes, and this cortical plasticity could be the mechanism that compensates for the degradations that are known to naturally occur with age. Thus, these quantitative measures - since they can be obtained efficiently and objectively, and appear to deviate from normative values significantly with systemic cortical alterations - could be useful indicators of cerebral cortical health.	[Zhang, Zheng; Francisco, Eric M.; Holden, Jameson K.; Dennis, Robert G.; Tommerdahl, Mark] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA		Tommerdahl, M (corresponding author), Univ N Carolina, Dept Biomed Engn, CB 7575, Chapel Hill, NC 27599 USA.	tommerda@med.unc.edu			Department of Defense, Congressionally Directed Medical Research Program (CDMRP) [W81XWH-07-1-0287, NIH 1-R21-NS072811-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072811] Funding Source: NIH RePORTER	This work was supported, in part by the Department of Defense, Congressionally Directed Medical Research Program (CDMRP) W81XWH-07-1-0287, and NIH 1-R21-NS072811-01A1.	Bartzokis G, 2003, ARCH NEUROL-CHICAGO, V60, P393, DOI 10.1001/archneur.60.3.393; Bunce D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013567; Deary IJ, 2006, NEUROLOGY, V66, P505, DOI 10.1212/01.wnl.0000199954.81900.e2; Dinse HR, 2005, ACTA NEUROCHIR SUPPL, V93, P79; Dinse HR, 2006, PROG BRAIN RES, V157, P57, DOI 10.1016/S0079-6123(06)57005-0; Dinse HR, 2006, ANN NEUROL, V60, P88, DOI 10.1002/ana.20862; Driscoll I, 2009, NEUROLOGY, V72, P1906, DOI 10.1212/WNL.0b013e3181a82634; Favorov OV, 2011, J NEUROPHYSIOL, V105, P1342, DOI 10.1152/jn.00708.2010; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Folger SE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-87; FOZARD JL, 1994, J GERONTOL, V49, pP179, DOI 10.1093/geronj/49.4.P179; Francisco E, 2008, EXP BRAIN RES, V191, P49, DOI 10.1007/s00221-008-1494-6; Friedman RM, 2008, J NEUROPHYSIOL, V100, P3185, DOI 10.1152/jn.90278.2008; GESCHEIDER GA, 1994, SOMATOSENS MOT RES, V11, P345, DOI 10.3109/08990229409028878; Gorus E, 2008, J GERIATR PSYCH NEUR, V21, P204, DOI 10.1177/0891988708320973; Greenwood PM, 2007, NEUROPSYCHOLOGY, V21, P657, DOI 10.1037/0894-4105.21.6.657; Greenwood PM, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00150; Gunning-Dixon FM, 2009, INT J GERIATR PSYCH, V24, P109, DOI 10.1002/gps.2087; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Hilbig H, 2002, J CHEM NEUROANAT, V23, P199, DOI 10.1016/S0891-0618(01)00159-4; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Kalisch T, 2008, CLIN INTERV AGING, V3, P673, DOI 10.2147/CIA.S3174; Kalisch T, 2009, CEREB CORTEX, V19, P1530, DOI 10.1093/cercor/bhn190; Kattenstroth JC, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00031; KENSHALO DR, 1986, J GERONTOL, V41, P732, DOI 10.1093/geronj/41.6.732; Kohn A, 2007, J NEUROPHYSIOL, V97, P3155, DOI 10.1152/jn.00086.2007; LEE CJ, 1992, CEREB CORTEX, V2, P81, DOI 10.1093/cercor/2.2.81; LEE CJ, 1992, CEREB CORTEX, V2, P107, DOI 10.1093/cercor/2.2.107; Li SC, 2002, NEUROSCI BIOBEHAV R, V26, P729, DOI 10.1016/S0149-7634(02)00059-3; Lin YH, 2005, J PERIPHER NERV SYST, V10, P269, DOI 10.1111/j.1085-9489.2005.10305.x; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; MAEDA S, 1994, ERGONOMICS, V37, P1391, DOI 10.1080/00140139408964917; Morioka M, 2002, INT ARCH OCC ENV HEA, V75, P78; MORSE CK, 1993, PSYCHOL AGING, V8, P156, DOI 10.1037/0882-7974.8.2.156; Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010; Ratcliff R, 2001, PSYCHOL AGING, V16, P323, DOI 10.1037//0882-7974.16.2.323; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Resnick SM, 2003, J NEUROSCI, V23, P3295; Simons SB, 2007, J NEUROPHYSIOL, V97, P2121, DOI 10.1152/jn.00513.2006; Simons SB, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-43; Tannan V, 2007, BRAIN RES, V1186, P164, DOI 10.1016/j.brainres.2007.10.024; Tannan V, 2007, J NEUROSCI METH, V164, P131, DOI 10.1016/j.jneumeth.2007.04.011; Tannan V, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-18; Tannan V, 2005, J NEUROSCI METH, V147, P75, DOI 10.1016/j.jneumeth.2005.05.001; Tannan V, 2006, BRAIN RES, V1102, P109, DOI 10.1016/j.brainres.2006.05.037; Tannan V, 2008, AUTISM RES, V1, P223, DOI 10.1002/aur.34; THORNBURY JM, 1981, J GERONTOL, V36, P34, DOI 10.1093/geronj/36.1.34; Tommerdahl M, 2007, BRAIN RES, V1154, P116, DOI 10.1016/j.brainres.2007.04.032; Tommerdahl M, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-19; Tommerdahl M, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-61; Tommerdahl M, 2010, NEUROSCI BIOBEHAV R, V34, P160, DOI 10.1016/j.neubiorev.2009.08.009; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1313, DOI 10.1016/j.neuropsychologia.2004.02.009; Vernooij MW, 2009, ARCH GEN PSYCHIAT, V66, P545, DOI 10.1001/archgenpsychiatry.2009.5; VERRILLO RT, 1980, J GERONTOL, V35, P185, DOI 10.1093/geronj/35.2.185; Verrillo RT, 2002, SOMATOSENS MOT RES, V19, P238, DOI 10.1080/0899022021000009161; VERRILLO RT, 1977, B PSYCHONOMIC SOC, V9, P197, DOI 10.3758/BF03336973; VERRILLO RT, 1979, SENS PROCESS, V3, P49; VERRILLO RT, 1982, PERCEPT PSYCHOPHYS, V32, P61, DOI 10.3758/BF03204869; Wilson RS, 2002, PSYCHOL AGING, V17, P179, DOI 10.1037/0882-7974.17.2.179; Zhang Z, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-12; Zhang Z, 2011, CLIN J PAIN, V27, P755, DOI 10.1097/AJP.0b013e31821c98ec; Zhang Z, 2009, BRAIN RES, V1302, P97, DOI 10.1016/j.brainres.2009.09.037	63	40	40	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	DEC 8	2011	3								18	10.3389/fnagi.2011.00018			9	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	054KD	WOS:000312341500001	22163221	gold, Green Published			2022-02-06	
J	Rabago, CA; Wilken, JM				Rabago, Christopher A.; Wilken, Jason M.			Application of a Mild Traumatic Brain Injury Rehabilitation Program in a Virtual Realty Environment: A Case Study	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						mild traumatic brain injury; postconcussive syndrome military; rehabilitation; virtual reality; visual vertigo	STABILITY FOLLOWING CONCUSSION; SPATIAL ORIENTATION; POSTURAL STABILITY; VISUAL VERTIGO; HEAD-INJURY; BALANCE; REALITY; RELIABILITY; VALIDITY	Background and Purpose: Mild traumatic brain injury (mTBI) can compromise reaction time, visual perception, memory, attention, balance, and gait. These deficits, especially if persistent, can restrict participation in daily activities and the resumption of personal and profession roles. The purpose of this case study is to describe an mTBI-specific clinical assessment and rehabilitation intervention administered in a virtual reality environment. Case Description: The case involved a 31-year-old male service member who had sustained an mTBI (concussion) during a recreational softball game 36 days prior to physical therapist evaluation. He had complaints of severe visual and physical motion intolerance. He demonstrated impaired static balance and was restricted from full military duty. Interventions: The assessment included measurements of postural and gait balance during cognitive, visual, and vestibular challenges within a Computer-Assisted Rehabilitation Environment. Phase 1 of the intervention consisted of clinical techniques (ie, optokinetic stimulation/habituation, visual/physical perturbations, and postural stability exercises) targeting specific impairments. Phase 2 training consisted of weapon handling and target recognition tasks to simulate the requirements of his military occupation. Outcomes: At the conclusion of 6 treatments, the patient demonstrated significant increases in postural and gait balance with a near complete resolution of all postconcussion symptoms. He successfully returned to full duty and training for combat deployment. Discussion: Service members and civilians exhibit similar impairments, limitations, and restrictions following mTBI. A rehabilitation program delivered in a virtual-reality environment can be structured to manage complex mTBI symptoms through the integration of multiple treatment modalities specific to a patient's personal and professional roles.	[Rabago, Christopher A.; Wilken, Jason M.] Brooke Army Med Ctr, Dept Orthoped & Rehabil, Ctr Intrepid, Ft Sam Houston, TX 78234 USA		Rabago, CA (corresponding author), Brooke Army Med Ctr, Dept Orthoped & Rehabil, Ctr Intrepid, 3851 Roger Brooke Drv, Ft Sam Houston, TX 78234 USA.	Christopher.Rabago@amedd.army.mil		Rabago, Christopher/0000-0002-4484-0613; Wilken, Jason/0000-0002-5556-7667	Medical Research and Material Command's Military Operational Medicine Research Program; Brooke Army Medical Center's traumatic brain injury service	Support provided by Medical Research and Material Command's Military Operational Medicine Research Program (to J.M.W.).; We thank our CAREN application designer, Michael Vernon, for his technical expertise in the development of treatment applications; Mustafa Shinta for data collection assistance; Dr Tedesco-Evans and Mrs Marina LeBlanc for the patient referral; and all the providers at Brooke Army Medical Center's traumatic brain injury service for their support.	Akin FW, 2003, J REHABIL RES DEV, V40, P415, DOI 10.1682/JRRD.2003.09.0415; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Chang CP, 2008, CYBERPSYCHOL BEHAV, V11, P495, DOI 10.1089/cpb.2007.0075; Clendaniel RA, 2010, J NEUROL PHYS THER, V34, P111, DOI 10.1097/NPT.0b013e3181deca01; Cox DJ, 2010, MIL MED, V175, P411, DOI 10.7205/MILMED-D-09-00081; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Guerraz M, 2001, BRAIN, V124, P1646, DOI 10.1093/brain/124.8.1646; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keshner EA, 2009, STUD HEALTH TECHNOL, V145, P209, DOI 10.3233/978-1-60750-018-6-209; Lovell M, 2009, PHYS MED REH CLIN N, V20, P39, DOI 10.1016/j.pmr.2008.10.003; McAndrew PM, 2010, J BIOMECH, V43, P1470, DOI 10.1016/j.jbiomech.2010.02.003; McComas Joan, 2002, J NEUROLOGIC PHYS TH, V26, P55; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van der Eerden WJ, 1999, ST HEAL T, V62, P373; Whitney SL, 2007, ARCH PHYS MED REHAB, V88, P99, DOI 10.1016/j.apmr.2006.10.027; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D	30	40	44	2	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	DEC	2011	35	4					185	193		10.1097/NPT.0b013e318235d7e6			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	890YU	WOS:000300183800006	22027473				2022-02-06	
J	Timmons, SD; Bee, T; Webb, S; Diaz-Arrastia, RR; Hesdorffer, D				Timmons, Shelly D.; Bee, Tiffany; Webb, Sharon; Diaz-Arrastia, Ramon R.; Hesdorffer, Dale			Using the Abbreviated Injury Severity and Glasgow Coma Scale Scores to Predict 2-Week Mortality After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Abbreviated Injury Severity Score; Glasgow Coma Scale; Mortality; Prediction; Outcome	SEVERE HEAD-INJURY; ADMISSION CHARACTERISTICS; CLASSIFICATION; VALIDATION; REVISION; OUTCOMES; TRIALS	Background: Prediction of outcome after traumatic brain injury (TBI) remains elusive. We tested the use of a single hospital Glasgow Coma Scale (GCS) Score, GCS Motor Score, and the Head component of the Abbreviated Injury Scale (AIS) Score to predict 2-week cumulative mortality in a large cohort of TBI patients admitted to the eight U. S. Level I trauma centers in the TBI Clinical Trials Network. Methods: Data on 2,808 TBI patients were entered into a centralized database. These TBI patients were categorized as severe (GCS score, 3-8), moderate (9-12), or complicated mild (13-15 with positive computed tomography findings). Intubation and chemical paralysis were recorded. The cumulative incidence of mortality in the first 2 weeks after head injury was calculated using Kaplan-Meier survival analysis. Cox proportional hazards regression was used to estimate the magnitude of the risk for 2-week mortality. Results: Two-week cumulative mortality was independently predicted by GCS, GCS Motor Score, and Head AIS. GCS Severity Category and GCS Motor Score were stronger predictors of 2-week mortality than Head AIS. There was also an independent effect of age (<60 vs. >60) on mortality after controlling for both GCS and Head AIS Scores. Conclusions: Anatomic and physiologic scales are useful in the prediction of mortality after TBI. We did not demonstrate any added benefit to combining the total GCS or GCS Motor Scores with the Head AIS Score in the short-term prediction of death after TBI.	[Timmons, Shelly D.] Semmes Murphey Clin, Dept Neurosurg, Memphis, TN USA; [Bee, Tiffany] Univ Tennessee Hlth Sci Ctr, Dept Surg, Memphis, TN USA; [Webb, Sharon] Univ S Carolina, Dept Neurosurg, Columbia, SC 29208 USA; [Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Hesdorffer, Dale] Columbia Univ Gertrude H Sergievsky Ctr, New York, NY USA; [Hesdorffer, Dale] Dept Epidemiol, New York, NY USA		Timmons, SD (corresponding author), Geisinger Hlth Syst, MC 14-05, Danville, PA 17822 USA.	stimmons@mac.com		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Traumatic Brain Injury Clinical Trials Network, National Institute of Child Health and Human Development, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS) [HD042823]	Supported by Traumatic Brain Injury Clinical Trials Network, National Institute of Child Health and Human Development, National Institutes of Health Grant Number HD042823.	Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Clark DE, 2002, HEALTH SERV RES, V37, P631, DOI 10.1111/1475-6773.00041; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2001, J AM COLL SURGEONS, V193, P250, DOI 10.1016/S1072-7515(01)00993-0; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JONES IS, 1989, J TRAUMA, V29, P646, DOI 10.1097/00005373-198905000-00020; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LISTED NA, 1971, JAMA-J AM MED ASSOC, V215, P277; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170	25	40	41	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1172	1178		10.1097/TA.0b013e31822b0f4b			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849IG	WOS:000297118600020	22071922				2022-02-06	
J	Shear, DA; Lu, XCM; Pedersen, R; Wei, G; Chen, ZY; Davis, A; Yao, CP; Dave, J; Tortella, FC				Shear, Deborah A.; Lu, Xi-Chun May; Pedersen, Rebecca; Wei, Guo; Chen, Zhiyong; Davis, Angela; Yao, Changping; Dave, Jitendra; Tortella, Frank C.			Severity Profile of Penetrating Ballistic-Like Brain Injury on Neurofunctional Outcome, Blood-Brain Barrier Permeability, and Brain Edema Formation	JOURNAL OF NEUROTRAUMA			English	Article						BBB; cognitive function; edema; PBBI; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; CAUDATE-PUTAMEN LESIONS; CEREBROSPINAL-FLUID; HEAD-INJURY; WATER-MAZE; QUINOLINIC ACID; DORSAL STRIATUM; CELL-DEATH; RAT; DEFICITS	This study evaluated the injury severity profile of unilateral, frontal penetrating ballistic-like brain injury (PBBI) on neurofunctional outcome, blood-brain barrier (BBB) permeability, and brain edema formation. The degree of injury severity was determined by the delivery of a water-pressure pulse designed to produce a temporary cavity by rapid (< 40 ms) expansion of the probe's elastic balloon calibrated to equal 5%, 10%, 12.5%, or 15% of total rat brain volume (control groups consisted of sham surgery or insertion of the probe only). Neurofunctional assessments revealed motor and cognitive deficits related to the degree of injury severity, with the most clear-cut profile of PBBI injury severity depicted by the Morris water maze (MWM) results. A biphasic pattern of BBB leakage was detected in the injured hemisphere at all injury severity levels at 4 h post-injury, and again at 48-72 h post-injury, which remained evident out to 7 days post-PBBI in the 10% and 12.5% PBBI groups. Likewise, significant brain edema was detected in the injured hemisphere by 4 h post-injury and remained elevated out to 7 days post-injury in the 10% and 12.5% PBBI groups. However, following 5% PBBI, significant levels of edema were only detected from 24 h to 48h post-injury. These results identify an injury severity profile of BBB permeability, brain edema, and neurofunctional impairment that provides sensitive and clinically relevant outcome metrics for studying potential therapeutics.	[Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, MRMC UWI C, Silver Spring, MD 20910 USA		Shear, DA (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, MRMC UWI C, Bldg 503-2W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Dave, Jitendra R/A-8940-2011; Shear, Deborah/B-3607-2011				Adelson PD, 1998, ACT NEUR S, V71, P104; BAKAY RAE, 1986, NEUROSURGERY, V18, P376, DOI 10.1227/00006123-198603000-00026; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Choi-Lundberg DL, 1998, EXP NEUROL, V154, P261, DOI 10.1006/exnr.1998.6887; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; De Leonibus E, 2003, BEHAV NEUROSCI, V117, P685, DOI 10.1037/0735-7044.117.4.685; Devan BD, 1999, J NEUROSCI, V19, P2789; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KLATZO I, 1985, BRIT J ANAESTH, V57, P18, DOI 10.1093/bja/57.1.18; Lorberboym M, 2003, J NUCL MED, V44, P1898; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Marmarou A, 2000, ACT NEUR S, V76, P349; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shear DA, 1998, EXP NEUROL, V150, P305, DOI 10.1006/exnr.1998.6767; Shear DA, 1998, PROG NEURO-PSYCHOPH, V22, P1217, DOI 10.1016/S0278-5846(98)00070-0; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; Tomkins O., 2011, CARDIOVASC PSYC 0222; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whishaw IQ, 1996, HIPPOCAMPUS, V6, P513, DOI 10.1002/(SICI)1098-1063(1996)6:5<513::AID-HIPO4>3.0.CO;2-J; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	46	40	40	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2185	2195		10.1089/neu.2011.1916			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500018	21644814				2022-02-06	
J	Anderson, GD; Farin, FM; Bammler, TK; Beyer, RP; Swan, AA; Wilkerson, HW; Kantor, ED; Hoane, MR				Anderson, Gail D.; Farin, Federico M.; Bammler, Theo K.; Beyer, Richard P.; Swan, Alicia A.; Wilkerson, Hui-Wen; Kantor, Eric D.; Hoane, Michael R.			The Effect of Progesterone Dose on Gene Expression after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CCI injury model; gene expression; neurotrauma; progesterone	INTERLEUKIN-1 RECEPTOR ANTAGONIST; CELL-DEATH; ALLOPREGNANOLONE; NEUROPROTECTION; INFLAMMATION; RECOVERY; CORTEX; MODERATE; PATHWAYS; PEPTIDE	Microarray-based transcriptional profiling was used to determine the effect of progesterone in the cortical contusion (CCI) model. Gene ontology (GO) analysis then evaluated the effect of dose on relevant biological pathways. Treatment (vehicle, progesterone 10 mg/kg or 20 mg/kg given i.p.) was started 4 h post-injury and administered every 12 h post-injury for up to 72 h, with the last injection 12 hr prior to death for the 24 h and 72 h groups. In the CCI-injured vehicle group compared to non-injured animals, expression of 1,114, 4,229, and 291 distinct genes changed > 1.5-fold (p < 0.05) at 24 h, 72 h, and 7 days, respectively. At 24 h, the effect of low-dose progesterone on differentially expressed genes was < 20% the effect of higher dose compared to vehicle. GO analysis identified a significant effect of low-and high-dose progesterone treatment compared to vehicle on DNA damage response. At 72 h, high-dose progesterone treatment compared to vehicle affected expression of almost twice as many genes as did low-dose progesterone. Both low-and high-dose progesterone resulted in expression of genes regulating inflammatory response and apoptosis. At 7 days, there was only a modest difference in high-dose progesterone compared to vehicle, with only 14 differentially expressed genes. In contrast, low-dose progesterone resulted in 551 differentially expressed genes compared to vehicle. GO analysis identified genes for the low-dose treatment involved in positive regulation of cell proliferation, innate immune response, positive regulation of anti-apoptosis, and blood vessel remodeling.	[Anderson, Gail D.; Kantor, Eric D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Farin, Federico M.; Bammler, Theo K.; Beyer, Richard P.; Wilkerson, Hui-Wen] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Swan, Alicia A.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA		Anderson, GD (corresponding author), Univ Washington, Dept Pharm, Box 357630,Hlth Sci Complex H-361A, Seattle, WA 98195 USA.	gaila@washington.edu	Swan, Alicia A/O-3536-2018	Swan, Alicia A/0000-0003-2412-0499; Hoane, Michael/0000-0001-7779-2657	National Institutes of Health/National Institute of Child, Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 HD061944-01]; UW NIEHS [P30ES07033]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES007033] Funding Source: NIH RePORTER	This research was supported by a grant from the National Institutes of Health/National Institute of Child, Health and Development (R01 HD061944-01). ). This work was also supported in part by the UW NIEHS sponsored Center for Ecogenetics & Environmental Health (P30ES07033).	Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; Aragones G, 2010, ATHEROSCLEROSIS, V213, P329, DOI 10.1016/j.atherosclerosis.2010.07.026; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Camon E, 2004, NUCLEIC ACIDS RES, V32, pD262, DOI 10.1093/nar/gkh021; *CDC, 2011, INJ PREV CONTR TRAUM; Chesik D, 2010, NEUROSCI LETT, V468, P178, DOI 10.1016/j.neulet.2009.10.051; Choi JS, 2008, NEUROSCI LETT, V438, P233, DOI 10.1016/j.neulet.2008.04.026; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Cui LL, 2010, BRAIN RES, V1325, P164, DOI 10.1016/j.brainres.2010.02.036; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DABNEY A, 2006, BIOCONDUCTORS QVALUE; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fairfax BP, 2010, HUM MOL GENET, V19, P720, DOI 10.1093/hmg/ddp530; Galasko D, 2010, BIOMARK MED, V4, P27, DOI 10.2217/BMM.09.89; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Halks-Miller M, 2003, ANN NEUROL, V54, P638, DOI 10.1002/ana.10733; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy A, 2009, J NEUROTRAUM, V26, P1521, DOI 10.1089/neu.2008.0746; Li J, 2008, BRAIN RES, V1196, P22, DOI 10.1016/j.brainres.2007.12.028; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; McKallip RJ, 2002, INT IMMUNOL, V14, P1015, DOI 10.1093/intimm/dxf068; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Perez-Martin M, 2010, EUR J NEUROSCI, V31, P1533, DOI 10.1111/j.1460-9568.2010.07220.x; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Smyth GK., 2004, STAT APPL GENET MOL, V3, pArticl, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; SNEED TB, 1994, CELL IMMUNOL, V153, P456, DOI 10.1006/cimm.1994.1042; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yasuda M, 2002, HISTOL HISTOPATHOL, V17, P945, DOI 10.14670/HH-17.945	76	40	41	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1827	1843		10.1089/neu.2011.1911			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000014	21770760	Green Published			2022-02-06	
J	Braun, M; Tupper, D; Kaufmann, P; McCrea, M; Postal, K; Westerveld, M; Wills, K; Deer, T				Braun, Michelle; Tupper, David; Kaufmann, Paul; McCrea, Michael; Postal, Karen; Westerveld, Michael; Wills, Karen; Deer, Teresa			Neuropsychological Assessment: A Valuable Tool in the Diagnosis and Management of Neurological, Neurodevelopmental, Medical, and Psychiatric Disorders	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						neuropsychological assessment; diagnosis; neurological disorders; neurodevelopmental disorders; clinical management	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; OLDER-ADULTS; PSYCHOLOGICAL-ASSESSMENT; NEUROCOGNITIVE OUTCOMES; ECOLOGICAL VALIDITY; FUNCTIONAL OUTCOMES; FINANCIAL CAPACITY; AMERICAN-ACADEMY	For both children and adults with neurological, neurodevelopmental, medical, or psychiatric disorders, neuropsychological assessment can be a valuable tool in determining diagnosis, prognosis, and functional abilities as well as informing clinical management. This review summarizes the contributions of neuropsychological assessment to clinical care across diagnostic categories, with the goal of helping clinicians determine its utility for individual patients.	[Braun, Michelle] Wheaton Franciscan Healthcare, Dept Neurol & Neurosurg, Racine, WI 53405 USA; [McCrea, Michael] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Deer, Teresa] Neuropsychol Consultants, Kenosha, WI USA; [Tupper, David] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Wills, Karen] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Kaufmann, Paul] Univ Nebraska, Dept Hlth & Human Serv, Lincoln, NE USA; [Postal, Karen] Neuropsychol Consultants, Andover, MA USA; [Westerveld, Michael] Florida Hosp, Orlando, FL USA		Braun, M (corresponding author), Wheaton Franciscan Healthcare, Dept Neurol & Neurosurg, 3805B Spring St,Ste 320, Racine, WI 53405 USA.	michelle.braun@wfhc.org	Postal, Karen/AAA-3184-2020				Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Alosco ML, 2011, J CARDIOVASC NURS; Amato MP, 2008, NEUROLOGY, V71, P632, DOI 10.1212/01.wnl.0000324621.58447.00; American Academy of Clinical Neuropsychology, 2010, AACN RESP AMA PCPI D; [Anonymous], 1996, Neurology, V47, P592; Antony SP, 2010, NEUROPSYCHOL TRENDS, P37, DOI 10.7358/neur-2010-007-anto; Areza-Fegyveres Renata, 2010, Dement. neuropsychol., V4, P14, DOI 10.1590/S1980-57642010DN40100003; Attix DK, 2009, CLIN NEUROPSYCHOL, V23, P21, DOI 10.1080/13854040801945078; Baars MAE, 2009, DEMENT GERIATR COGN, V27, P173, DOI 10.1159/000200465; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Balthazar MLF, 2010, J INT NEUROPSYCH SOC, V16, P205, DOI 10.1017/S1355617709990956; Barker-Collo S, 2010, NEUROLOGY, V75, P1608, DOI 10.1212/WNL.0b013e3181fb44c8; Barker-Collo S, 2006, NEUROPSYCHOL REV, V16, P53, DOI 10.1007/s11065-006-9007-5; Bearden CE, 2010, CURR PSYCHIAT REP, V12, P499, DOI 10.1007/s11920-010-0151-5; Benedict RHB, 2007, J NEUROL, V254, P22, DOI 10.1007/s00415-007-2007-4; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Bronstein JM, 2011, ARCH NEUROL-CHICAGO, V68, P165, DOI 10.1001/archneurol.2010.260; Chan AS, 2004, NEUROPSYCHOLOGY, V18, P700, DOI 10.1037/0894-4105.18.4.700; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Clusmann H, 2008, SEMIN ULTRASOUND CT, V29, P60, DOI 10.1053/j.sult.2007.11.004; Cohen R. A., 2010, NEUROPSYCHOLOGY CARD; Cosentino S, 2011, INT J ALZHEIMERS DIS; CULLUM CM, 1993, J CLIN EXP NEUROPSYC, V15, P321, DOI 10.1080/01688639308402566; Cummings J, 2010, J ALZHEIMERS DIS, V21, P843, DOI 10.3233/JAD-2010-100078; Damholdt MF, 2012, ACTA NEUROL SCAND, V125, P311, DOI 10.1111/j.1600-0404.2011.01561.x; de Jager CA, 2009, AGE AGEING, V38, P455, DOI 10.1093/ageing/afp068; Depp CA, 2008, J CLIN PSYCHOPHARM, V28, P225, DOI 10.1097/JCP.0b013e318166dfed; Devos H, 2011, NEUROLOGY, V76, P747, DOI 10.1212/WNL.0b013e31820d6300; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Diller L, 1992, NEUROPSYCHOLOGY, V6, P357; Duinkerke Anja, 2004, Cogn Behav Neurol, V17, P179, DOI 10.1097/01.wnn.0000124916.16017.6a; Eack S. M., 2010, PSYCHOL MED, P1; Edwards Christopher L, 2007, Neuropsychiatr Dis Treat, V3, P705; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Elamin M, 2011, NEUROLOGY, V76, P1263, DOI 10.1212/WNL.0b013e318214359f; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; Fasano A, 2010, BRAIN, V133, P2664, DOI 10.1093/brain/awq221; Feigin VL, 2008, INT J STROKE, V3, P33, DOI 10.1111/j.1747-4949.2008.00177.x; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Fletcher JM, 1999, PEDIATR CLIN N AM, V46, P885, DOI 10.1016/S0031-3955(05)70161-9; Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543; Gasquoine PG, 2011, J CLIN EXP NEUROPSYC, V33, P486, DOI 10.1080/13803395.2010.536759; Gavett BE, 2010, J INT NEUROPSYCH SOC, V16, P651, DOI 10.1017/S1355617710000421; Gavett BE, 2009, J INT NEUROPSYCH SOC, V15, P121, DOI 10.1017/S1355617708090176; Gelb SR, 2010, NEUROPSYCHOLOGY, V24, P514, DOI 10.1037/a0018670; Geroldi C, 2008, ALZ DIS ASSOC DIS, V22, P309, DOI 10.1097/WAD.0b013e3181871a47; Gilman S, 2005, EXP NEUROL, V191, pS95, DOI 10.1016/j.expneurol.2004.06.017; Godefroy O, 2009, EUR NEUROL, V61, P223, DOI 10.1159/000197107; Gold JI, 2008, PEDIATR HEMAT ONCOL, V25, P409, DOI 10.1080/08880010802107497; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Gorman AA, 2009, NEUROPSYCHOL REV, V19, P186, DOI 10.1007/s11065-009-9095-0; Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2; Graydon FJX, 2001, EPILEPSY BEHAV, V2, P140, DOI 10.1006/ebeh.2001.0163; Gure TR, 2010, J GERONTOL A-BIOL, V65, P434, DOI 10.1093/gerona/glp197; Gustaw-Rothenberg K, 2008, DEMENT GERIATR COGN, V26, P165, DOI 10.1159/000150443; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanna-Pladdy B, 2010, INT J NEUROSCI, V120, P538, DOI 10.3109/00207454.2010.496539; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Helmstaedter C, 2004, EPILEPSY BEHAV, V5, pS45, DOI 10.1016/j.yebeh.2003.11.006; Henry TR, 2011, EPILEPSY BEHAV, V20, P194, DOI 10.1016/j.yebeh.2010.12.008; Hentschel F, 2005, INT J GERIATR PSYCH, V20, P645, DOI 10.1002/gps.1333; Hermann B, 2007, J INT NEUROPSYCH SOC, V13, P12, DOI 10.1017/S135561770707004X; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; Herrmann N, 2011, EXPERT OPIN PHARMACO, V12, P787, DOI 10.1517/14656566.2011.558006; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Hoth KF, 2008, COGN BEHAV NEUROL, V21, P65, DOI 10.1097/WNN.0b013e3181799dc8; Humphrey L, 2003, CLIN NEUROPSYCHOLOGY; Jak AJ, 2009, J INT NEUROPSYCH SOC, V15, P890, DOI 10.1017/S1355617709090638; Jak AJ, 2009, AM J GERIAT PSYCHIAT, V17, P368, DOI 10.1097/JGP.0b013e31819431d5; Jerskey BA, 2009, J INT NEUROPSYCH SOC, V15, P137, DOI 10.1017/S1355617708090073; Jones B L, 2000, Semin Clin Neuropsychiatry, V5, P157, DOI 10.1053/scnp.2000.6726; Kalirao P, 2011, AM J KIDNEY DIS, V57, P612, DOI 10.1053/j.ajkd.2010.11.026; Kalmar JH, 2008, NEUROPSYCHOLOGY, V22, P442, DOI 10.1037/0894-4105.22.4.442; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim SH, 2010, DEMENT GERIATR COGN, V29, P213, DOI 10.1159/000278422; Knopman DS, 2009, ALZHEIMERS DEMENT, V5, P207, DOI 10.1016/j.jalz.2009.01.027; Kozora E, 2004, ARTHRIT RHEUM-ARTHR, V51, P810, DOI 10.1002/art.20692; Di Legge Silvia, 2010, Dement. neuropsychol., V4, P4, DOI 10.1590/S1980-57642010DN40100002; Leung AWS, 2010, NEUROREHABILITATION, V27, P351, DOI 10.3233/NRE-2010-0619; Libon DJ, 2007, NEUROLOGY, V68, P369, DOI 10.1212/01.wnl.0000252820.81313.9b; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Mackin RS, 2009, J INT NEUROPSYCH SOC, V15, P793, DOI 10.1017/S1355617709990300; Marcotte T. D., 2010, NEUROPSYCHOLOGY EVER; Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x; Martino DJ, 2011, J NERV MENT DIS, V199, P459, DOI 10.1097/NMD.0b013e3182214190; Masson JD, 2010, J INTELL DISABIL RES, V54, P457, DOI 10.1111/j.1365-2788.2010.01280.x; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McLennan SN, 2010, J CARDIOVASC NURS, V25, P390, DOI 10.1097/JCN.0b013e3181dae445; Mendez MF, 2007, AM J GERIAT PSYCHIAT, V15, P84, DOI 10.1097/01.JGP.0000231744.69631.33; Messier C, 2010, J CLIN EXP NEUROPSYC, V32, P809, DOI 10.1080/13803390903540323; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Meyers CA, 2006, J CLIN ONCOL, V24, P1305, DOI 10.1200/JCO.2005.04.6086; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Morgan J. E., 2008, TXB CLIN NEUROPSYCHO; Morris DM, 2006, NEUROREHABILITATION, V21, P131; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Naskar S, 2010, BRAIN RES REV, V65, P1, DOI 10.1016/j.brainresrev.2010.04.010; Nordlund A, 2007, NEUROPSYCHOLOGY, V21, P706, DOI 10.1037/0894-4105.21.6.706; Novack TA, 2010, HDB REHABILITATION P; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Oda H, 2009, PSYCHOGERIATRICS, V9, P85, DOI 10.1111/j.1479-8301.2009.00283.x; Okun MS, 2007, CLIN NEUROPSYCHOL, V21, P162, DOI 10.1080/13825580601025940; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Pfiffner LJ, 2006, J ABNORM CHILD PSYCH, V34, P725, DOI 10.1007/s10802-006-9060-9; Posner J, 2007, ACAD PSYCHIATR, V31, P479, DOI 10.1176/appi.ap.31.6.479; Quiske A, 2007, EPILEPSY BEHAV, V10, P328, DOI 10.1016/j.yebeh.2006.12.009; Randolph C, 2009, LIVER INT, V29, P629, DOI 10.1111/j.1478-3231.2009.02009.x; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Razani J, 2011, J GERIATR PSYCH NEUR, V24, P23, DOI 10.1177/0891988710390812; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ris MD, 2007, J INT NEUROPSYCH SOC, V13, P50, DOI 10.1017/S1355617707070087; Robottom BJ, 2009, INT REV NEUROBIOL, V84, P229, DOI 10.1016/S0074-7742(09)00412-7; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; ROURKE BP, 1994, FRAMES REFERENCE ASS; Sabsevitz DS, 2001, EPILEPSIA, V42, P1408, DOI 10.1046/j.1528-1157.2001.38500.x; Sachdev PS, 2006, DEMENT GERIATR COGN, V21, P300, DOI 10.1159/000091438; Salmon DP, 2009, ANNU REV PSYCHOL, V60, P257, DOI 10.1146/annurev.psych.57.102904.190024; Sauer AM, 2009, J ANESTH, V23, P256, DOI 10.1007/s00540-009-0744-5; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Schatz David Beck, 2006, J Atten Disord, V10, P141, DOI 10.1177/1087054706286698; Scott JC, 2011, NEUROPSYCHOLOGY, V25, P511, DOI 10.1037/a0022491; Shrivastava A, 2011, J PSYCHIATR PRACT, V17, P194, DOI 10.1097/01.pra.0000398412.67115.5c; Sirven JI, 2000, NEUROLOGY, V54, P2166, DOI 10.1212/WNL.54.11.2166; Smith G. E., 2008, TXB CLIN NEUROPSYCHO; Spaan PEJ, 2010, BEHAV NEUROL, V23, P203, DOI [10.3233/BEN-2010-0295, 10.1155/2010/946315]; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Stephan BCM, 2010, NAT REV NEUROL, V6, P318, DOI 10.1038/nrneurol.2010.54; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Tabert MH, 2006, ARCH GEN PSYCHIAT, V63, P916, DOI 10.1001/archpsyc.63.8.916; Talacchi A, 2011, J NEURO-ONCOL, V103, P541, DOI 10.1007/s11060-010-0417-0; Temple RO, 2006, ARCH CLIN NEUROPSYCH, V21, P371, DOI 10.1016/j.acn.2006.05.002; Tierney MC, 2005, NEUROLOGY, V64, P1853, DOI 10.1212/01.WNL.0000163773.21794.0B; Toniolo Silvia, 2011, G Ital Med Lav Ergon, V33, pA29; Towgood K, 2004, J INT NEUROPSYCH SOC, V10, P114; Trepanier LL, 2000, BRAIN COGNITION, V42, P324, DOI 10.1006/brcg.1999.1108; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5; von Rhein M, 2011, J PEDIATR-US, V158, P984, DOI 10.1016/j.jpeds.2010.11.040; Wagle J, 2011, DEMENT GERIATR COGN, V31, P379, DOI 10.1159/000328970; Wahlin TBR, 2007, NEUROPSYCHOLOGY, V21, P31, DOI 10.1037/0894-4105.21.1.31; Waldstein SR, 2010, HANDBOOK OF MEDICAL NEUROPSYCHOLOGY: APPLICATIONS OF COGNITIVE NEUROSCIENCE, P69, DOI 10.1007/978-1-4419-1364-7_5; Waldstein SR, 2010, J ALZHEIMERS DIS, V20, P833, DOI 10.3233/JAD-2010-091591; Weimer DL, 2009, ALZHEIMERS DEMENT, V5, P215, DOI 10.1016/j.jalz.2009.01.028; Weinberg DG, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1150; Wilson BA, 1999, APPL PREV PSYCHOL, V2, P209; Wright SL, 2007, J GERIATR PSYCH NEUR, V20, P189, DOI 10.1177/0891988707308801; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ylikoski R, 2000, ARCH GERONTOL GERIAT, V30, P115, DOI 10.1016/S0167-4943(00)00045-5; Zihl J, 2010, APPL NEUROPSYCHOL, V17, P44, DOI 10.1080/09084280903526133	159	40	40	1	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2011	24	3					107	114		10.1097/WNN.0b013e3182351289			8	Behavioral Sciences; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	823YB	WOS:000295162800001	21945982				2022-02-06	
J	Kirkham, FJ; Haywood, P; Kashyape, P; Borbone, J; Lording, A; Pryde, K; Cox, M; Keslake, J; Smith, M; Cuthbertson, L; Murugan, V; Mackie, S; Thomas, NH; Whitney, A; Forrest, KM; Parker, A; Forsyth, R; Kipps, CM				Kirkham, F. J.; Haywood, P.; Kashyape, P.; Borbone, J.; Lording, A.; Pryde, K.; Cox, M.; Keslake, J.; Smith, M.; Cuthbertson, L.; Murugan, V.; Mackie, S.; Thomas, N. H.; Whitney, A.; Forrest, K. M.; Parker, A.; Forsyth, R.; Kipps, C. M.			Movement disorder emergencies in childhood	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article; Proceedings Paper	9th European-Pediatric-Neurology-Society Congress	MAY 11-14, 2011	Cavtat, CROATIA	European Pediat Neurol Soc		Chorea; Dystonia; Status dystonicus; Paroxysmal Autonomic Instability with Dystonia; Sandifer syndrome; Myoclonus; Opsoclonus; Tremor; Parkinsonism; Drugs; Neuroleptic malignant syndrome; Metabolic; Infection; Sydenham's chorea; Systemic lupus erythematosus; Cardiopulmonary bypass; Wilson's disease; Organic aciduria; Biotin; Creatine	OPSOCLONUS-MYOCLONUS SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE NECROTIZING ENCEPHALOPATHY; NEUROLEPTIC MALIGNANT SYNDROME; TRAUMATIC BRAIN-INJURY; PAROXYSMAL AUTONOMIC INSTABILITY; CONGENITAL HEART-DISEASE; CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; SYDENHAMS-CHOREA	The literature on paediatric acute-onset movement disorders is scattered. In a prospective cohort of 52 children (21 male; age range 2mo-15y), the commonest were chorea, dystonia, tremor, myoclonus, and Parkinsonism in descending order of frequency. In this series of mainly previously well children with cryptogenic acute movement disorders, three groups were recognised: (1) Psychogenic disorders (n = 12), typically >10 years of age, more likely to be female and to have tremor and myoclonus (2) Inflammatory or autoimmune disorders (n = 22), including N-methyl-D-aspartate receptor encephalitis, opsoclonus-myoclonus, Sydenham chorea, systemic lupus erythematosus, acute necrotizing encephalopathy (which may be autosomal dominant), and other encephalitides and (3) Non-inflammatory disorders (n = 18), including drug-induced movement disorder, post-pump chorea, metabolic, e.g. glutaric aciduria, and vascular disease, e.g. moyamoya. Other important noninflammatory movement disorders, typically seen in symptomatic children with underlying aetiologies such as trauma, severe cerebral palsy, epileptic encephalopathy, Down syndrome and Rett syndrome, include dystonic posturing secondary to gastro-oesophageal reflux (Sandifer syndrome) and Paroxysmal Autonomic Instability with Dystonia (PAID) or autonomic 'storming'. Status dystonicus may present in children with known extrapyramidal disorders, such as cerebral palsy or during changes in management e.g. introduction or withdrawal of neuroleptic drugs or failure of intrathecal baclofen infusion; the main risk in terms of mortality is renal failure from rhabdomyolysis. Although the evidence base is weak, as many of the inflammatory/autoimmune conditions are treatable with steroids, immunoglobulin, plasmapheresis, or cyclophosphamide, it is important to make an early diagnosis where possible. Outcome in survivors is variable. Using illustrative case histories, this review draws attention to the practical difficulties in diagnosis and management of this important group of patients. (C) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Kirkham, F. J.] UCL Inst Child Hlth, London, England; [Kirkham, F. J.; Haywood, P.; Kashyape, P.; Borbone, J.; Lording, A.; Pryde, K.; Cox, M.; Keslake, J.; Smith, M.; Cuthbertson, L.; Murugan, V.; Mackie, S.; Thomas, N. H.; Whitney, A.; Forrest, K. M.; Kipps, C. M.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [Kirkham, F. J.] Univ Southampton, Southampton SO9 5NH, Hants, England; [Haywood, P.; Smith, M.] Community Child Hlth, Southampton, Hants, England; [Parker, A.] Addenbrookes Hosp, Cambridge, England; [Forsyth, R.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England		Kirkham, FJ (corresponding author), UCL Inst Child Hlth, London, England.	fk@soton.ac.uk	Kirkham, Fenella/C-2442-2009; Kipps, Christopher/AAB-1053-2020; Forsyth, Rob/H-9193-2019; Forsyth, Rob J/I-9226-2012	Kirkham, Fenella/0000-0002-2443-7958; Kipps, Christopher/0000-0002-5205-9712; Forsyth, Rob/0000-0002-5657-4180; Forsyth, Rob J/0000-0002-5657-4180; kashyape, pawan/0000-0001-7164-7256			Acampa M, 2008, NEUROSCI LETT, V432, P69, DOI 10.1016/j.neulet.2007.12.030; Agrawal S, 2010, ARCH DIS CHILD, V95, P312, DOI 10.1136/adc.2009.164889; Ashtekar CS, 2003, DEV MED CHILD NEUROL, V45, P634, DOI 10.1017/S0012162203001154; Avcin T, 2008, ARTHRIT RHEUM-ARTHR, V59, P206, DOI 10.1002/art.23334; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Baik JS, 2010, MOVEMENT DISORD, V25, P1482, DOI 10.1002/mds.23130; Barash J, 2005, PEDIATR NEUROL, V32, P205, DOI 10.1016/j.pediatrneurol.2004.09.012; Beleza P, 2008, EUR J PAEDIATR NEURO, V12, P505, DOI 10.1016/j.ejpn.2007.11.005; Bell J, 2008, PEDIATR BLOOD CANCER, V50, P370, DOI 10.1002/pbc.20899; Ben-Pazi H, 2003, J PEDIATR-US, V143, P267, DOI 10.1067/S0022-3476(03)00366-4; Benseler SM, 2007, LUPUS, V16, P564, DOI 10.1177/0961203307078971; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BORBONE J, 2009, EUR J PAED NEUROL S1, V13, pS20; Borghi E, 2005, J MED VIROL, V75, P427, DOI 10.1002/jmv.20285; BRUYN GW, 1984, EUR NEUROL, V23, P278, DOI 10.1159/000115743; Burke MJ, 2008, PEDIATR BLOOD CANCER, V50, P679, DOI 10.1002/pbc.21009; Cardoso F, 2000, EUR J NEUROL, V7, P467, DOI 10.1046/j.1468-1331.2000.t01-1-00100.x; Catsman-Berrevoets CE, 2009, PEDIATR BLOOD CANCER, V53, P1048, DOI 10.1002/pbc.22226; Choi IS, 1999, EUR NEUROL, V42, P141, DOI 10.1159/000008088; Corapcioglu F, 2008, PEDIATR HEMAT ONCOL, V25, P756, DOI 10.1080/08880010802341690; CURLESS RG, 1994, J PEDIATR-US, V124, P737, DOI 10.1016/S0022-3476(05)81365-4; Dale RC, 2005, DEV MED CHILD NEUROL, V47, P785, DOI 10.1017/S0012162205001647; Dale RC, 2004, ARCH DIS CHILD, V89, P604, DOI 10.1136/adc.2003.031856; Dale RC, 2004, BRAIN, V127, P21, DOI 10.1093/brain/awh008; Dale RC, 2001, ANN NEUROL, V50, P588, DOI 10.1002/ana.1250; Dale RC, 2007, MOVEMENT DISORD, V22, P2281, DOI 10.1002/mds.21664; Dale RC, 2010, DEV MED CHILD NEUROL, V52, P739, DOI 10.1111/j.1469-8749.2009.03598.x; Dale RC, 2009, ANN NEUROL, V66, P704, DOI 10.1002/ana.21807; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Deconinck N, 2006, PEDIATR NEUROL, V34, P312, DOI 10.1016/j.pediatrneurol.2005.08.034; DELEON S, 1990, ANN THORAC SURG, V50, P714, DOI 10.1016/0003-4975(90)90668-V; Demiroren K, 2007, J CHILD NEUROL, V22, P550, DOI 10.1177/0883073807302614; Dimova PS, 2006, MOVEMENT DISORD, V21, P564, DOI 10.1002/mds.20742; du Plessis AJ, 2002, PEDIATR NEUROL, V27, P9, DOI 10.1016/S0887-8994(02)00382-X; EDWARDS PD, 1975, J NEUROL NEUROSUR PS, V38, P729, DOI 10.1136/jnnp.38.8.729; Ertekin V, 2010, PEDIATR NEUROL, V42, P441, DOI 10.1016/j.pediatrneurol.2010.02.009; Ertle F, 2008, PEDIATR BLOOD CANCER, V50, P683, DOI 10.1002/pbc.21107; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; FREILINGER M, 2011, EUR J PAEDIAT NEU S1, V15, pS18; Frucht S, 2000, MOVEMENT DISORD, V15, P1; Gable MS, 2009, EUR J CLIN MICROBIOL, V28, P1421, DOI 10.1007/s10096-009-0799-0; Gamboa E T, 1973, Trans Am Neurol Assoc, V98, P177; Garvey MA, 2005, J CHILD NEUROL, V20, P424, DOI 10.1177/08830738050200050601; GASCON GG, 1994, BRAIN DEV-JPN, V16, P94, DOI 10.1016/0387-7604(94)90102-3; Ghosh J B, 2005, Indian J Pediatr, V72, P85, DOI 10.1007/BF02760591; Gika AD, 2010, MOVEMENT DISORD, V25, P385, DOI 10.1002/mds.22926; Gika AD, 2010, DEV MED CHILD NEUROL, V52, P99, DOI 10.1111/j.1469-8749.2009.03405.x; Gouider-Khouja N, 2010, EUR J PAEDIATR NEURO, V14, P304, DOI 10.1016/j.ejpn.2009.11.005; Green C, 2002, PEDIATR NEUROL, V26, P318, DOI 10.1016/S0887-8994(01)00396-4; GROOTHUIS JR, 1977, AM J DIS CHILD, V131, P1131, DOI 10.1001/archpedi.1977.02120230077014; Guerrini R, 2007, NEUROLOGY, V69, P427, DOI 10.1212/01.wnl.0000266594.16202.c1; Guideri F, 2005, PEDIATR CARDIOL, V26, P574, DOI 10.1007/s00246-005-0784-z; Gupta A, 2009, CURR OPIN NEUROL, V22, P430, DOI 10.1097/WCO.0b013e32832dc169; HAYWOOD P, 2009, EUR J PAED NEUROL S1, V13, pS33; HAYWOOD P, 2009, EUR J PAED NEUROL S1, V13, pS32; Holden KR, 1998, J PEDIATR-US, V132, P162, DOI 10.1016/S0022-3476(98)70505-0; Huber BM, 2010, EUR J PEDIATR, V169, P441, DOI 10.1007/s00431-009-1048-3; HUNTLEY DT, 1993, DEV MED CHILD NEUROL, V35, P631; Jech R, 2009, MOVEMENT DISORD, V24, P2291, DOI 10.1002/mds.22764; Kabakus N, 2006, PEDIATR INT, V48, P622, DOI 10.1111/j.1442-200X.2006.02280.x; Khan MR, 2011, JCPSP-J COLL PHYSICI, V21, P119, DOI 02.2011/JCPSP.119120; Kiechl-Kohlendorfer U, 1999, NEUROPEDIATRICS, V30, P96, DOI 10.1055/s-2007-973468; Kim JH, 2004, KOREAN J RADIOL, V5, P171, DOI 10.3348/kjr.2004.5.3.171; KIM JS, 1995, MOVEMENT DISORD, V10, P510, DOI 10.1002/mds.870100419; KIM KH, 2009, KOREAN J PEDIAT, V2010, P616; Kipps CM, 2005, MOVEMENT DISORD, V20, P322, DOI 10.1002/mds.20325; Klein A, 2007, EUR J PEDIATR, V166, P359, DOI 10.1007/s00431-006-0247-4; KOMATSU H, 1992, BRAIN DEV-JPN, V14, P400, DOI 10.1016/S0387-7604(12)80348-2; Kotagal P, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e46; Krug P, 2010, EUR J PAEDIATR NEURO, V14, P400, DOI 10.1016/j.ejpn.2009.12.005; Kurian MA, 2011, DEV MED CHILD NEUROL, V53, P394, DOI 10.1111/j.1469-8749.2011.03955.x; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Levin DA, 2005, PEDIATR CARDIOL, V26, P34, DOI 10.1007/s00246-004-0669-6; Lo SE, 2005, NEUROCRIT CARE, V3, P139, DOI 10.1385/NCC:3:2:139; Long SS, 2005, ADV EXP MED BIOL, V568, P1; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Manji H, 1998, BRAIN, V121, P243, DOI 10.1093/brain/121.2.243; Mariotti P, 2007, MOVEMENT DISORD, V22, P963, DOI 10.1002/mds.21471; Mariotti P, 2010, LANCET, V376, P388, DOI 10.1016/S0140-6736(10)60711-8; McCarthy JE, 2009, PARKINSONISM RELAT D, V15, P792, DOI 10.1016/j.parkreldis.2009.04.002; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; MEDLOCK MD, 1993, ANN NEUROL, V34, P820, DOI 10.1002/ana.410340611; MILLER G, 1995, ARCH PEDIAT ADOL MED, V149, P764, DOI 10.1001/archpedi.1995.02170200054008; Neuhut R, 2009, J CHILD ADOL PSYCHOP, V19, P415, DOI 10.1089/cap.2008.0130; OKANO S, 1992, PEDIATR NEUROL, V8, P72, DOI 10.1016/0887-8994(92)90058-7; Olfat M, 2004, CLIN RHEUMATOL, V23, P395, DOI 10.1007/s10067-004-0898-3; Oosterveer DM, 2010, PEDIATR NEUROL, V43, P1, DOI 10.1016/j.pediatrneurol.2009.11.015; Paliwal VK, 2010, J NEURAL TRANSM, V117, P613, DOI 10.1007/s00702-010-0366-y; Pandey P, 2010, J NEUROSURG-PEDIATR, V6, P559, DOI 10.3171/2010.9.PEDS10192; Pang KK, 2010, EUR J PAEDIATR NEURO, V14, P156, DOI 10.1016/j.ejpn.2009.03.002; Parodi S, 2009, NEUROPEDIATRICS, V40, P103; Paviour DC, 2004, MOVEMENT DISORD, V19, P123, DOI 10.1002/mds.10644; Paz JA, 2006, PEDIATR NEUROL, V34, P264, DOI 10.1016/j.pediatrneurol.2005.08.028; Piekutowska-Abramczuk D, 2009, CLIN GENET, V76, P195, DOI 10.1111/j.1399-0004.2009.01195.x; Poloni C, 2010, DEV MED CHILD NEUROL, V52, pe78, DOI 10.1111/j.1469-8749.2009.03542.x; POWELL FC, 1994, STROKE, V25, P117, DOI 10.1161/01.STR.25.1.117; Pradhan S, 1999, NEUROLOGY, V53, P1781, DOI 10.1212/WNL.53.8.1781; Pranzatelli MR, 2010, J PEDIAT HEMATOL ONC, V32, pE167, DOI 10.1097/MPH.0b013e3181cf0726; Pranzatelli MR, 2009, J CHILD NEUROL, V24, P316, DOI 10.1177/0883073808324217; PRANZATELLI MR, 1994, PEDIATR NEUROL, V10, P131, DOI 10.1016/0887-8994(94)90045-0; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Prockop LD, 2005, J NEUROIMAGING, V15, P144, DOI 10.1177/1051228404273819; PRONICKA E, 1984, J INHERIT METAB DIS, V7, P113; Pronicka E, 2001, J INHERIT METAB DIS, V24, P707, DOI 10.1023/A:1012937204315; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; RAMANAN PV, 2009, J INDIAN MED ASSOC, V107, P253; ROBINSON RO, 1988, ARCH DIS CHILD, V63, P1466, DOI 10.1136/adc.63.12.1466; Rostasy K, 2006, NEUROPEDIATRICS, V37, P291, DOI 10.1055/s-2006-955931; Rothenberg AB, 2009, PEDIATR RADIOL, V39, P723, DOI 10.1007/s00247-009-1282-x; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Schwingenschuh P, 2008, MOVEMENT DISORD, V23, P1882, DOI 10.1002/mds.22280; SEBIRE G, 1992, J PEDIATR-US, V121, P845, DOI 10.1016/S0022-3476(05)80326-9; Sibbitt WL, 2002, J RHEUMATOL, V29, P1536; Silva RR, 1999, J AM ACAD CHILD PSY, V38, P187, DOI 10.1097/00004583-199902000-00018; Singer HS, 1997, MOVEMENT DISORD, V12, P588, DOI 10.1002/mds.870120417; Smith Steven M, 2010, Paediatr Drugs, V12, P285, DOI 10.2165/11532530-000000000-00000; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; STEINLIN MI, 1995, PEDIATR NEUROL, V13, P191, DOI 10.1016/0887-8994(95)00110-2; Teive HAG, 2005, ARQ NEURO-PSIQUIAT, V63, P26, DOI 10.1590/S0004-282X2005000100005; Teixeira AL, 2005, PARKINSONISM RELAT D, V11, P327, DOI 10.1016/j.parkreldis.2005.02.007; Uc Ergun Y, 2003, Semin Pediatr Neurol, V10, P62; van Toorn R, 2005, EUR J PAEDIATR NEURO, V9, P423, DOI 10.1016/j.ejpn.2005.06.007; VAN TR, 2004, EUR J PAEDIATR NEURO, V8, P211; Wait SD, 2009, J NEUROSURG-PEDIATR, V4, P217, DOI 10.3171/2009.4.PEDS08444; Walker Kathleen G, 2010, Ther Adv Neurol Disord, V3, P301, DOI 10.1177/1756285610382063; Walker KG, 2005, DEV MED CHILD NEUROL, V47, P771, DOI 10.1017/S0012162205001611; WALLACH S, 1994, AM J MED, V97, P494, DOI 10.1016/0002-9343(94)90336-0; Wasserman JK, 2010, MOVEMENT DISORD, V25, P1754, DOI 10.1002/mds.23161; WICAL BS, 1990, PEDIATR NEUROL, V6, P202; Wilken B, 2008, EUR J PAEDIATR NEURO, V12, P51, DOI 10.1016/j.ejpn.2007.05.005; WONG PC, 1992, CIRCULATION, V86, P118; Zomorrodi A, 2006, PEDIATRICS, V117, pE675, DOI 10.1542/peds.2005-1573	137	40	40	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	SEP	2011	15	5					390	404		10.1016/j.ejpn.2011.04.005			15	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pediatrics	830LN	WOS:000295658600002	21835657				2022-02-06	
J	Dikeos, D; Georgantopoulos, G				Dikeos, Dimitris; Georgantopoulos, Georgios			Medical comorbidity of sleep disorders	CURRENT OPINION IN PSYCHIATRY			English	Article						excessive daytime sleepiness; hypersomnia; insomnia; periodic leg movements in sleep; rapid eye movement behaviour disorder; restless legs syndrome; sleep-related limb movements	RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; LIMB MOVEMENT-DISORDER; TRAUMATIC BRAIN-INJURY; BEHAVIOR DISORDER; CARDIOVASCULAR-DISEASE; CLINICAL-FEATURES; PARKINSONS-DISEASE; CHRONIC INSOMNIA; IMPACT	Purpose of review Recently published literature indicates that sleep disorders present with medical comorbidities quite frequently. The coexistence of a sleep disorder with a medical disorder has a substantial impact for both the patient and the health system. Recent findings Insomnia and hypersomnia are highly comorbid with medical conditions, such as chronic pain and diabetes, as well as with various cardiovascular, respiratory, gastrointestinal, urinary and neurological disorders. Restless legs syndrome and periodic leg movement syndrome have been associated with iron deficiency, kidney disease, diabetes, and neurological, autoimmune, cardiovascular and respiratory disorders. Rapid eye movement behaviour disorder has been described as an early manifestation of serious central nervous system diseases; thus, close neurological monitoring of patients referring with this complaint is indicated. Summary Identification and management of any sleep disorder in medical patients is important for optimizing the course and prognosis. Of equal importance is the search for undetected medical disorder in patients presenting with sleep disorders.	[Dikeos, Dimitris; Georgantopoulos, Georgios] Univ Athens, Sch Med, Dept Psychiat 1, Athens 11528, Greece		Dikeos, D (corresponding author), Univ Athens, Sch Med, Eginit Hosp, Dept Psychiat 1, 72 Vas Sofias Ave, Athens 11528, Greece.	ddikeos@med.uoa.gr					Abad VC, 2008, SLEEP MED REV, V12, P211, DOI 10.1016/j.smrv.2007.09.001; Abbott RD, 2005, NEUROLOGY, V65, P1442, DOI 10.1212/01.wnl.0000183056.89590.0d; Al-Jahdali Hamdan H, 2010, J Circadian Rhythms, V8, P7, DOI 10.1186/1740-3391-8-7; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Allen RP, 2005, ARCH INTERN MED, V165, P1286, DOI 10.1001/archinte.165.11.1286; *AM SLEEP DIS ASS, 1997, PER LIMB MOV DIS, P65; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Ancoli-Israel S, 2006, AM J MANAG CARE, V12, pS221; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Benediktsdottir B, 2010, SLEEP MED, V11, P1043, DOI 10.1016/j.sleep.2010.08.006; Bliwise DL, 2010, ANN NEUROL, V68, P353, DOI 10.1002/ana.22076; Bliwise DL, 2009, SLEEP MED, V10, P540, DOI 10.1016/j.sleep.2008.04.002; Bodkin CL, 2009, J WOMENS HEALTH, V18, P1955, DOI 10.1089/jwh.2008.1348; Bosco D, 2009, J NEUROL SCI, V287, P60, DOI 10.1016/j.jns.2009.09.008; Boulos MI, 2010, CAN J NEUROL SCI, V37, P167, DOI 10.1017/S0317167100009896; Brotini S, 2004, SLEEP MED, V5, P169, DOI 10.1016/j.sleep.2003.10.012; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Cengic B., 2010, INT UROL NEPHROL; Chasens ER, 2009, DIABETES EDUCATOR, V35, P455, DOI 10.1177/0145721709333857; Chokroverty S, 2010, INDIAN J MED RES, V131, P126; Cuellar NG, 2008, DIABETES EDUCATOR, V34, P218, DOI 10.1177/0145721708314180; Cuellar NG, 2008, J CLIN SLEEP MED, V4, P50; Dang D, 2010, J NEUROL SCI, V290, P146, DOI 10.1016/j.jns.2009.12.007; Dembe AE, 2005, OCCUP ENVIRON MED, V62, P588, DOI 10.1136/oem.2004.016667; Ekbom K, 2009, J INTERN MED, V266, P419, DOI 10.1111/j.1365-2796.2009.02159.x; Ellmore TM, 2010, PARKINSONISM RELAT D, V16, P645, DOI 10.1016/j.parkreldis.2010.08.014; Ferentinos P, 2009, J PSYCHOSOM RES, V66, P37, DOI 10.1016/j.jpsychores.2008.07.009; Focke NK, 2010, SLEEP, V33, P731, DOI 10.1093/sleep/33.6.731; Foley KA, 2010, BEHAV SLEEP MED, V8, P90, DOI 10.1080/15402001003622842; Gagnon JF, 2006, LANCET NEUROL, V5, P424, DOI 10.1016/S1474-4422(06)70441-0; Gao XA, 2010, MOVEMENT DISORD, V25, P2654, DOI 10.1002/mds.23256; Gao X, 2009, NEUROLOGY, V72, P1255, DOI 10.1212/01.wnl.0000345673.35676.1c; Gemignani F, 2007, J PERIPHER NERV SYST, V12, P50, DOI 10.1111/j.1529-8027.2007.00116.x; George CFP, 2003, DRUGS, V63, P379, DOI 10.2165/00003495-200363040-00004; Gjerstad MD, 2002, NEUROLOGY, V58, P1544, DOI 10.1212/WNL.58.10.1544; Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863; Gureje O, 2009, INT J GERIATR PSYCH, V24, P686, DOI 10.1002/gps.2180; Hanly PJ, 2003, AM J KIDNEY DIS, V41, P403, DOI 10.1053/ajkd.2003.50066; HANYU H, 2010, EUR J NEUROL; Hening WA, 2008, SEMIN ARTHRITIS RHEU, V38, P55, DOI 10.1016/j.semarthrit.2007.09.001; Hornyak M, 2006, SLEEP MED REV, V10, P169, DOI 10.1016/j.smrv.2005.12.003; Ikehara S, 2009, SLEEP, V32, P295, DOI 10.1093/sleep/32.3.295; Iranzo A, 2009, SLEEP MED REV, V13, P385, DOI 10.1016/j.smrv.2008.11.003; Iwanami M, 2010, SLEEP MED, V11, P361, DOI 10.1016/j.sleep.2009.12.006; Kaplan Y, 2008, CAN J NEUROL SCI, V35, P352, DOI 10.1017/S0317167100008957; Katz DA, 1998, ARCH INTERN MED, V158, P1099, DOI 10.1001/archinte.158.10.1099; Kosmadakis GC, 2008, INT J ARTIF ORGANS, V31, P919, DOI 10.1177/039139880803101101; Koutsourelakis I, 2009, EUR RESPIR J, V34, P687, DOI 10.1183/09031936.00124708; Krouse HJ, 2008, J ASTHMA, V45, P389, DOI 10.1080/02770900801971800; Kushida C, 2007, QUAL LIFE RES, V16, P617, DOI 10.1007/s11136-006-9142-8; Lee K, 2004, SLEEP MED REV, V8, P199, DOI 10.1016/j.smrv.2003.10.001; Leger D, 2002, SLEEP, V25, P625; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Liu LQ, 2008, PSYCHIAT ANN, V38, P627, DOI 10.3928/00485713-20080901-01; Lo Coco D, 2010, MOVEMENT DISORD, V25, P2658, DOI 10.1002/mds.23261; Lo Coco D, 2009, SLEEP MED, V10, P572, DOI 10.1016/j.sleep.2008.04.014; Longstreth WT, 2009, SLEEP MED, V10, P422, DOI 10.1016/j.sleep.2008.05.009; Loo HV, 2008, J NEUROL SCI, V266, P145, DOI 10.1016/j.jns.2007.09.033; Lopes LA, 2005, DIABETES CARE, V28, P2633, DOI 10.2337/diacare.28.11.2633; Mahowald MW, 2005, PRINCIPLES PRACTICE, P897; McWhirter Dewey, 2007, Psychiatry (Edgmont), V4, P26; Merlino G, 2007, SLEEP, V30, P866, DOI 10.1093/sleep/30.7.866; Miyamoto T, 2008, SLEEP, V31, P717, DOI 10.1093/sleep/31.5.717; Nielsen TA, 2005, PRINCIPLES PRACTICE, P936, DOI DOI 10.1016/B0-72-160797-7/50085-9; Novak M, 2004, J PSYCHOSOM RES, V56, P527, DOI 10.1016/j.jpsychores.2004.02.007; Ohayon MM, 2006, ARCH INTERN MED, V166, P1262, DOI 10.1001/archinte.166.12.1262; Ohayon MM, 1997, SLEEP, V20, P340, DOI 10.1093/sleep/20.5.340; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P547, DOI 10.1016/S0022-3999(02)00443-9; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-531; Paparrigopoulos T, 2009, GEN HOSP PSYCHIAT, V31, P175, DOI 10.1016/j.genhosppsych.2008.09.016; Paparrigopoulos TJ, 2005, INT REV PSYCHIATR, V17, P293, DOI 10.1080/09540260500104540; Parish JM, 2009, CHEST, V135, P563, DOI 10.1378/chest.08-0934; Parker KP, 2003, AM J KIDNEY DIS, V41, P394, DOI 10.1053/ajkd.2003.50049; Peacock J, 2010, INDIAN J MED RES, V131, P338; Pierratos A, 2011, BLOOD PURIFICAT, V31, P146, DOI 10.1159/000321859; POLLMACHER T, 1993, SLEEP, V16, P572; Polydefkis M, 2000, NEUROLOGY, V55, P1115, DOI 10.1212/WNL.55.8.1115; Poryazova R, 2010, EUR NEUROL, V63, P129, DOI 10.1159/000276402; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Postuma RB, 2010, MOVEMENT DISORD, V25, P2304, DOI 10.1002/mds.23347; Rijsman RM, 1999, SLEEP MED REV, V3, P147, DOI 10.1016/S1087-0792(99)90021-7; Roth T, 2007, SLEEP MED, V8, pS1, DOI 10.1016/S1389-9457(08)70001-7; Roth T, 2009, AM J MANAG CARE, V15, pS6; Sabanayagam C, 2010, SLEEP, V33, P1037, DOI 10.1093/sleep/33.8.1037; Sagberg F, 2006, ACCIDENT ANAL PREV, V38, P28, DOI 10.1016/j.aap.2005.06.018; SALIH AM, 1994, BRIT J RHEUMATOL, V33, P60; Scherfler C, 2011, ANN NEUROL, V69, P400, DOI 10.1002/ana.22245; Schiza SE, 2010, SLEEP MED, V11, P149, DOI 10.1016/j.sleep.2009.07.016; Schlesinger I, 2009, MOVEMENT DISORD, V24, P1587, DOI 10.1002/mds.22486; Shaheen NJ, 2008, DIGEST DIS SCI, V53, P1493, DOI 10.1007/s10620-007-0057-1; Shneerson JM, 2005, SLEEP MED GUIDE SLEE, P125; Sivertsen B, 2009, J PSYCHOSOM RES, V67, P109, DOI 10.1016/j.jpsychores.2009.05.001; Skaer TL, 2010, PHARMACOECONOMICS, V28, P1015, DOI 10.2165/11537390-000000000-00000; Skomro RP, 2001, SLEEP MED, V2, P417, DOI 10.1016/S1389-9457(01)00110-1; Soldatos CR, 2000, J PSYCHOSOM RES, V48, P555, DOI 10.1016/S0022-3999(00)00095-7; Soldatos CR, 2005, SLEEP MED, V6, P5, DOI 10.1016/j.sleep.2004.10.006; Stockner H, 2009, MOVEMENT DISORD, V24, P1906, DOI 10.1002/mds.22483; Stroe AF, 2010, SLEEP MED, V11, P890, DOI 10.1016/j.sleep.2010.04.010; Sundberg R, 2010, RESP MED, V104, P337, DOI 10.1016/j.rmed.2009.10.017; Suzuki K, 2008, J NEUROL SCI, V271, P47, DOI 10.1016/j.jns.2008.03.008; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Taylor-Gjevre RM, 2010, JCR-J CLIN RHEUMATOL, V16, P255, DOI 10.1097/RHU.0b013e3181eeb2df; Taylor-Gjevre RM, 2009, JCR-J CLIN RHEUMATOL, V15, P12, DOI 10.1097/RHU.0b013e318190f94c; Ton TGN, 2009, NEUROEPIDEMIOLOGY, V32, P114, DOI 10.1159/000177037; Ulfberg J, 2007, SLEEP MED, V8, P768, DOI 10.1016/j.sleep.2006.11.015; van der Klaauw AA, 2007, J CLIN ENDOCR METAB, V92, P3898, DOI 10.1210/jc.2007-0944; Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284; Walters AS, 2009, SLEEP, V32, P589, DOI 10.1093/sleep/32.5.589; Watson NF, 2005, J CLIN SLEEP MED, V1, P41; Winkelman JW, 2008, NEUROLOGY, V70, P35, DOI 10.1212/01.wnl.0000287072.93277.c9; Winkelman JW, 2006, SLEEP MED, V7, P545, DOI 10.1016/j.sleep.2006.01.004; Yoo SS, 2010, KOREAN J UROL, V51, P757, DOI 10.4111/kju.2010.51.11.757; Zambelis T, 2002, J NEUROL NEUROSUR PS, V72, P821, DOI 10.1136/jnnp.72.6.821; Zervas IM, 2009, MENOPAUSE, V16, P837, DOI 10.1097/gme.0b013e318196063e; Zoccolella S, 2011, SLEEP MED REV, V15, P41, DOI 10.1016/j.smrv.2010.02.004	116	40	40	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0951-7367	1473-6578		CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	JUL	2011	24	4					346	354		10.1097/YCO.0b013e3283473375			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	769PS	WOS:000291030800015	21587079				2022-02-06	
J	Jin, W; Kong, J; Wang, HD; Wu, J; Lu, TY; Jiang, J; Ni, HB; Liang, WB				Jin, Wei; Kong, Jie; Wang, Handong; Wu, Jun; Lu, Tianyu; Jiang, Jian; Ni, Hongbin; Liang, Weibang			Protective effect of tert-butylhydroquinone on cerebral inflammatory response following traumatic brain injury in mice	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						tBHQ; Traumatic brain injury; Nrf2; Inflammatory response	NF-KAPPA-B; NRF2-DRIVEN ANTIOXIDANT RESPONSE; GLUTATHIONE-S-TRANSFERASE; OXIDATIVE STRESS; IN-VIVO; CELL-DEATH; INDUCTION; NRF2; ACTIVATION; TBHQ	Aim: Antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown in our previous studies to play a crucial role in protection against TBI induced inflammatory response in the brain. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), a novel Nrf2 activator, can protect mice brain against TBI-induced inflammatory damage. Methods: Adult male ICR mice were randomly divided into three groups: (1) sham + vehicle group; (2) TBI + vehicle group; and (3) TBI + tBHQ group (n = 12 per group). Closed head injury was adopted using Hall's weight-dropping method. We measured Nrf2 and nuclear factor kappa B (NF-kappa B) binding activities by electrophoretic mobility shift assay (EMSA), concentrations of tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA), brain oedema by wet/dry weight method, and cortical apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) analysis. Results: Induction of the Nrf2 activity by tBHQ markedly decreased NF-kappa B activation and inflammatory cytokine production in the injured brain. Administration of tBHQ also significantly attenuated TBI-induced brain oedema and cortical apoptosis. Conclusion: Pre-treatment with tBHQ could attenuate the cerebral inflammatory response after TBI. (C) 2011 Elsevier Ltd. All rights reserved.	[Jin, Wei; Kong, Jie; Wu, Jun; Lu, Tianyu; Jiang, Jian; Ni, Hongbin; Liang, Weibang] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China; [Wang, Handong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China		Ni, HB (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu Prov, Peoples R China.	glyy110@163.com; njneurosurgery@yahoo.com.cn			Drum Tower Hospital of China	This work was supported by grants from Drum Tower Hospital of China. We thank Dr. Li-zhi Xu for technical assistance.	Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baines J, 1999, WHO TECH REP SER, V884, P1; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chen F, 1999, CLIN CHEM, V45, P7; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Keum YS, 2006, PHARM RES, V23, P2586, DOI 10.1007/s11095-006-9094-2; Koh K, 2009, BIOCHEM BIOPH RES CO, V380, P449, DOI 10.1016/j.bbrc.2009.01.082; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lamb JG, 2000, DRUG METAB DISPOS, V28, P1018; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nishizono S, 2000, BIOSCI BIOTECH BIOCH, V64, P1153, DOI 10.1271/bbb.64.1153; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Yan D, 2010, BIOCHEM PHARMACOL, V80, P144, DOI 10.1016/j.bcp.2010.03.004	35	40	41	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	2011	42	7					714	718		10.1016/j.injury.2011.03.009			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	772OL	WOS:000291243100017	21466884				2022-02-06	
J	Mrazik, M; Bawani, F; Krol, AL				Mrazik, Martin; Bawani, Farzad; Krol, Andrea L.			Sport-Related Concussions: Knowledge Translation Among Minor Hockey Coaches	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussions; symptoms; pediatric; mild traumatic brain injury; knowledge	TRAUMATIC BRAIN-INJURY; TO-PLAY GUIDELINES; RETURN; MANAGEMENT; CHILD	Objective: The objective of this study was to investigate minor hockey coaches' knowledge base of sport-related concussions. Design: Cross-sectional survey. Setting: Subjects independently completed the written survey at preseason organizational meetings. Participants: One hundred seventy-eight active coaches spanning 5 age levels (ages 5-15 years). Coaches reported 2.62 +/- 3.73 years of coaching experience. Main Outcome Measures: Resources where coaches obtained information about concussions, perceptions of variables associated with concussions, knowledge level of issues associated with concussions, and decision-making practices. Results: Newspapers and magazines were the most frequent source of information regarding concussions, yet were rated as not very helpful. Family physicians were less frequently sought but were rated as most helpful. A majority of coaches reported limited knowledge about concussions but rated this knowledge as being important. There was a significant relationship between head coaching experience and concussion knowledge [R(2)= 0.09, F3,156 = 4.41, P = 0.005]. Most coaches demonstrated a good knowledge base of common issues associated with concussions, and a majority of individuals correctly identified return-to-play practices. Conclusions: A majority of minor hockey coaches correctly recognized and understood issues related to sport-related concussions. Results suggested that knowledge translation through various formal and informal sources has had a positive effect. However, a majority of coaches reported having limited knowledge about concussions yet consider it an important topic.	[Mrazik, Martin; Bawani, Farzad; Krol, Andrea L.] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2G5, Canada		Mrazik, M (corresponding author), Univ Alberta, Dept Educ Psychol, 6-135 Educ Bldg N, Edmonton, AB T6G 2G5, Canada.	mrazik@ualberta.ca			Alberta Centre for Injury Control Research	Supported by the Alberta Centre for Injury Control Research operating grant. The authors report no conflicts of interest.	Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Centers for Disease Control and Prevention, 2017, INJ PREV CONTR TRAUM; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	20	40	40	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2011	21	4					315	319		10.1097/JSM.0b013e31821e2b78			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	786DY	WOS:000292284700006	21694594				2022-02-06	
J	Helfer, TM; Jordan, NN; Lee, RB; Pietrusiak, P; Cave, K; Schairer, K				Helfer, Thomas M.; Jordan, Nikki N.; Lee, Robyn B.; Pietrusiak, Paul; Cave, Kara; Schairer, Kim			Noise-Induced Hearing Injury and Comorbidities Among Postdeployment U.S. Army Soldiers: April 2003-June 2009	AMERICAN JOURNAL OF AUDIOLOGY			English	Article						noise-induced hearing injury; mild traumatic brain injury; posttraumatic stress disorder; blast trauma; speech-language disorders	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; LOSS PREVENTION PROGRAMS; BLAST; IRAQ; POPULATIONS; UPDATE; TEAM; DUTY; EAR	Purpose: To evaluate noise-induced hearing injury (NIHI) and blast-related comorbidities among U.S. Army soldiers in an effort to understand the morbidity burden and future health service requirements for wounded war fighters returning from the Central Command Area of Responsibility, predominantly from Iraq and Afghanistan deployments. Method: Inpatient and outpatient records with diagnosed NIHI or blast-related comorbidities (e.g., significant threshold shift [STS], noise-induced hearing loss, tinnitus, sensorineural hearing loss, eardrum perforations, mild traumatic brain injury, and posttraumatic stress disorder) were extracted for active duty soldiers returning from combat deployments. Records were limited to those within 6 months of the soldier's return date from April 2003 through June 2009. To account for changes in STS coding practice, STS rates observed after October 1, 2006, were used to extrapolate prior probable postdeployment STS. Results: Statistically significant increases were observed for tinnitus, dizziness, eardrum perforations, and speech-language disorders. The combination of observed and extrapolated STS yielded a conservative estimate of 27,427 cases. Conclusions: Estimates can be used to forecast resource requirements for hearing services among veterans. This article could serve as a guide for resourcing and innovating prevention measures and treatment in this population. Data provided may also serve as a baseline for evaluating prevention measures.	[Helfer, Thomas M.; Jordan, Nikki N.; Lee, Robyn B.; Pietrusiak, Paul] USA, Publ Hlth Command Provis, Inst Publ Hlth, Gunpowder, MD USA; [Cave, Kara] Blanchfield Army Community Hosp, Ft Campbell, KY USA; [Schairer, Kim] Univ Wisconsin, Madison, WI 53706 USA		Helfer, TM (corresponding author), USA, Publ Hlth Command Provis, Inst Publ Hlth, Gunpowder, MD USA.	thomas.helfer@us.army.mil					Adera T, 2000, AM IND HYG ASSOC J, V61, P11, DOI 10.1080/778879047; ADERA T, 1993, J OCCUP ENVIRON MED, V35, P568, DOI 10.1097/00043764-199306000-00012; Adera T, 1995, J Am Acad Audiol, V6, P302; Adera T, 1997, AM J IND MED, V31, P243, DOI 10.1002/(SICI)1097-0274(199702)31:2<243::AID-AJIM14>3.0.CO;2-1; Adera T, 2000, AM IND HYG ASSOC J, V61, P161, DOI 10.1202/0002-8894(2000)061<0161:TTAOHL>2.0.CO;2; ADERA T, 1993, MIL MED, V11, P697; *ARM FORC HLTH SUR, 2008, MED SURVEILLANCE MON, V15, P36; *ARM FORC HLTH SUR, 2010, 2009 TBI CAT PEN SEV; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Durch, 2006, NOISE MILITARY SERVI; Fagelson Marc A, 2007, Am J Audiol, V16, P107, DOI 10.1044/1059-0889(2007/015); Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; HELFER T, 2009, FORC HLTH PROT C ALB; HELFER T, 2008, FORC HLTH PROT C ALB; Helfer T M, 2000, Am J Audiol, V9, P75, DOI 10.1044/1059-0889(2000/008); Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helmick KM, 2007, FEDERAL PRACTITIONER, V24, P58; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *I MED NAT AC SCI, 2010, PREL ASS READJ NEEDS; *I MED NAT AC SCI, 1999, MEAS HLTH PERF PUBL; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jordan Nikki N., 2009, Seminars in Hearing, V30, P28, DOI 10.1055/s-0028-1111104; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lewine JD, 2002, AM J PSYCHIAT, V159, P1689, DOI 10.1176/appi.ajp.159.10.1689; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Metzger LJ, 2009, PSYCHOPHYSIOLOGY, V46, P172, DOI 10.1111/j.1469-8986.2008.00720.x; Meyer JD, 2002, OCCUP MED-OXFORD, V52, P75, DOI 10.1093/occmed/52.2.75; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PAIGE SR, 1990, BIOL PSYCHIAT, V27, P419, DOI 10.1016/0006-3223(90)90552-D; Schulz T. Y., 2004, HEARING HLTH, V21, P18; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tufts JB, 2009, J AM ACAD AUDIOL, V20, P539, DOI 10.3766/jaaa.20.9.3; *UN BIOST UT WORK, 2009, COD GUID; *US DEP ARM, 2006, PRED HEAR READ TEST; *US DEP ARM, 2006, CONC SOLD BATTL; *US DEP ARM, 2009, POSTD AUD; *US DEP DEF, 2008, POSTD HLTH ASS; *US DEP DEF, 2004, DOD HEAR CONS PROGR; *US DEP HHS, 2008, INT CLASS DIS 9 REV; *USA, 2009, FREQ ASK QUEST TRAUM; Verbeek JH, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006396.pub2; WALBY AP, 1986, J LARYNGOL OTOL, V100, P411, DOI 10.1017/S0022215100099412; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YETISER S, 1993, MIL MED, V158, P803, DOI 10.1093/milmed/158.12.803	53	40	42	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1059-0889	1558-9137		AM J AUDIOL	Am. J. Audiol.	JUN	2011	20	1					33	41		10.1044/1059-0889(2011/10-0033)			9	Audiology & Speech-Language Pathology; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Otorhinolaryngology	782IP	WOS:000292002000005	21474555				2022-02-06	
J	Kean, J; Malec, JF; Altman, IM; Swick, S				Kean, Jacob; Malec, James F.; Altman, Irwin M.; Swick, Shannon			Rasch Measurement Analysis of the Mayo-Portland Adaptability Inventory (MPAI-4) in a Community-Based Rehabilitation Sample	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; rehabilitation; TBI	BRAIN-INJURY; VALIDITY; MODEL; DIF	The precise measurement of patient outcomes depends upon clearly articulated constructs and refined clinical assessment instruments that work equally well for all subgroups within a population. This is a challenging task in those with acquired brain injury (ABI) because of the marked heterogeneity of the disorder and subsequent outcomes. Alhough essential, the iterative process of instrument refinement is often neglected. This present study was undertaken to examine validity, reliability, dimensionality and item estimate invariance of the Mayo-Portland Adaptability Inventory -4 (MPAI-4), an outcome measure for persons with ABI. The sampled population included 603 persons with traumatic ABI participating in a home-and community-based rehabilitation program. Results indicated that the MPAI-4 is a valid, reliable measure of outcome following traumatic ABI, which measures a broad but unitary core construct of outcome after ABI. Further, the MPAI-4 is composed of items that are unbiased toward selected subgroups except where differences could be expected [ e. g., more chronic traumatic brain injury (TBI) patients are better able to negotiate demands of transportation than more acute TBI patients]. We address the trade-offs between strict unidimensionality and clinical applicability in measuring outcome, and illustrate the advantages and disadvantages of applying single-parameter measurement models to broad constructs.	[Kean, Jacob; Malec, James F.] Indiana Univ, Sch Med, Dept PM&R, Indianapolis, IN 46254 USA; [Altman, Irwin M.] Gent Rehab Walls, Phoenix, AZ USA; [Swick, Shannon] Gent Rehab Walls, Marshall, MI USA		Kean, J (corresponding author), Indiana Univ, Sch Med, Dept PM&R, 4141 Shore Dr, Indianapolis, IN 46254 USA.	jakean@indiana.edu		Kean, Jacob/0000-0002-8577-0586	National Institute for Neurological Diseases and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	This manuscript was prepared with support from a Small Business Technology Transfer (STTR) grant from the National Institute for Neurological Diseases and Stroke (NINDS).	Baghaei P., 2008, RASCH MEASUREMENT T, V22, P1145; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; Lezak, 2008, MANUAL MAYO PORTLAND; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Linacre J, 1994, RASCH MEAS T, V7, P328; Linacre JM, 2008, WINSTEPS RASCH MODEL; Linacre JMWB, 1994, RASCH MEASUREMENT T, V8, P360, DOI DOI 10.HTTPS://D0I.0RG/10.1177/097340820900300217; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Marais Ida, 2008, J Appl Meas, V9, P200; PEARSON JD, 1995, J ACOUST SOC AM, V97, P1196, DOI 10.1121/1.412231; Scott NW, 2009, J CLIN EPIDEMIOL, V62, P288, DOI 10.1016/j.jclinepi.2008.06.003; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith RM, 2003, J APPL MEAS, V4, P198; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; WILSON M, 1989, PSYCHOL BULL, V105, P276, DOI 10.1037/0033-2909.105.2.276; Zwick R, 1999, J EDUC MEAS, V36, P1, DOI 10.1111/j.1745-3984.1999.tb00543.x	23	40	40	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					745	753		10.1089/neu.2010.1573			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100275	21332409	Green Published			2022-02-06	
J	Ben-David, BM; Nguyen, LLT; van Lieshout, PHHM				Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.			Stroop Effects in Persons with Traumatic Brain Injury: Selective Attention, Speed of Processing, or Color-Naming? A Meta-analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Stroop; Head injury; Selective attention; Information processing; Color perception; Executive function	CLOSED-HEAD-INJURY; ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL; WORD TEST; DIVIDED ATTENTION; SENSORY ORIGIN; FOLLOW-UP; INFORMATION; TASK; DEFICITS	The color word Stroop test is the most common tool used to assess selective attention in persons with traumatic brain injury (TBI). A larger Stroop effect for TBI patients, as compared to controls, is generally interpreted as reflecting a decrease in selective attention. Alternatively, it has been suggested that this increase in Stroop effects is influenced by group differences in generalized speed of processing (SOP). The current study describes an overview and meta-analysis of 10 studies, where persons with TBI (N = 324) were compared to matched controls (N = 501) on the Stroop task. The findings confirmed that Stroop interference was significantly larger for TBI groups (p = .008). However, these differences may be strongly biased by TBI-related slowdown in generalized SOP (r(2) = .81 in a Brinley analysis). We also found that TBI-related changes in sensory processing may affect group differences. Mainly, a TBI-related increase in the latency difference between reading and naming the font color of a color-neutral word (r(2) = .96) was linked to Stroop effects. Our results suggest that, in using Stroop, it seems prudent to control for both sensory factors and SOP to differentiate potential changes in selective attention from other changes following TBI. (JINS, 2011, 17,354-363)	[Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.] Univ Toronto, Dept Speech Language Pathol, Oral Dynam Lab, Toronto, ON M5G 1V7, Canada; [Ben-David, Boaz M.; van Lieshout, Pascal H. H. M.] Toronto Rehabil Inst, Toronto, ON, Canada; [Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.] Univ Toronto Mississauga, Dept Psychol, Toronto, ON, Canada; [van Lieshout, Pascal H. H. M.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada		Ben-David, BM (corresponding author), Univ Toronto, Dept Speech Language Pathol, Oral Dynam Lab, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	boaz.ben.david@utoronto.ca	van Lieshout, Pascal HHM/A-1371-2008	van Lieshout, Pascal HHM/0000-0001-8139-8900; Ben-David, Boaz/0000-0002-0392-962X	Ontario Neurotrauma Foundation [2008-ABI-PDF-659]; Canada Research Chairs programCanada Research Chairs [303712CRC]	B.M. Ben-David was partially supported by a grant from the Ontario Neurotrauma Foundation (2008-ABI-PDF-659). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program (303712CRC) awarded to P.H.H.M. van Lieshout.	Alferes V, 2003, METAANALYSIS FIXED R; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Balota DA, 2010, PSYCHOL AGING, V25, P208, DOI 10.1037/a0017474; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Ben-David BM, 2011, BRAIN INJURY, V25, P206, DOI 10.3109/02699052.2010.536197; Ben-David BM, 2010, AGING NEUROPSYCHOL C, V17, P730, DOI 10.1080/13825585.2010.510553; Ben-David BM, 2009, AGING NEUROPSYCHOL C, V16, P505, DOI 10.1080/13825580902855862; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; Brinley JF, 1965, BEHAV AGING NERVOUS, P114; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; CERELLA J, 1994, ACTA PSYCHOL, V86, P109, DOI 10.1016/0001-6918(94)90002-7; CERELLA J, 1990, HDB PSYCHOL AGING, P00201, DOI DOI 10.1016/B978-0-12-101280-9.50018-8; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eidels A, 2010, COGNITION, V114, P129, DOI 10.1016/j.cognition.2009.08.008; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; FERRARO RF, 1996, BRAIN COGNITION, V32, P429; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goethals I, 2004, J NEUROTRAUM, V21, P1059, DOI 10.1089/0897715041651051; Golden CJ, 1978, STROOP COLOR WORD TE; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hedges L.V., 1985, STAT METHODS META AN; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Koh SB, 2008, EUR NEUROL, V60, P174, DOI 10.1159/000148244; Lannoo E, 1997, PSYCHOL BELG, V37, P141; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MACLEOD CM, 1992, J EXP PSYCHOL GEN, V121, P12, DOI 10.1037/0096-3445.121.1.12; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mani TM, 2007, NEUROCASE, V13, P229, DOI 10.1080/13554790701594862; MCDOWD JM, 2000, HDB AGING COGNITION, P00221; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Melara RD, 2003, PSYCHOL REV, V110, P422, DOI 10.1037/0033-295X.110.3.422; MILLER EM, 1994, PERS INDIV DIFFER, V17, P803, DOI 10.1016/0191-8869(94)90049-3; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1975, LOYOLA S, P55; RANDOLPH A, 1988, ARCH BIOCHEM BIOPHYS, V267, P46, DOI 10.1016/0003-9861(88)90006-9; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Sabri M, 2001, J EXP PSYCHOL HUMAN, V27, P515, DOI 10.1037/0096-1523.27.3.515; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schmitter-Edgecombe M, 1996, J Int Neuropsychol Soc, V2, P111; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Verhaeghen P, 2002, NEUROSCI BIOBEHAV R, V26, P849, DOI 10.1016/S0149-7634(02)00071-4; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	72	40	40	1	48	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					354	363		10.1017/S135561771000175X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900016	21320377				2022-02-06	
J	Graham, MR; Myers, T; Evans, P; Davies, B; Cooper, SM; Bhattacharya, K; Grace, FM; Baker, JS				Graham, M. R.; Myers, T.; Evans, P.; Davies, B.; Cooper, S. M.; Bhattacharya, K.; Grace, F. M.; Baker, J. S.			DIRECT HITS TO THE HEAD DURING AMATEUR BOXING IS ASSOCIATED WITH A RISE IN SERUM BIOMARKERS FOR BRAIN INJURY	INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY			English	Article						boxing; brain injury; S100-B; Neuron-specific enolase (NSE)	NEURON-SPECIFIC ENOLASE; BIOCHEMICAL MARKERS; S-100B PROTEIN; DAMAGE; CONCUSSION; SPORTS; TISSUE; PLASMA; CELLS	Boxing exposes participants to the physiological response to high intensity exercise and also to direct body and brain trauma. Amateur boxing is increasing and females have also been included in the Olympics. The aim of this study is to assess the stress response and possible brain injury incurred during a match by measuring serum biomarkers associated with stress and cellular brain injury before and after combat. Sixteen male amateur boxers were studied retrospectively. The study population was divided into two groups: (a) a group that received predominantly punches to the head (PTH) and (b) a group that received predominantly punches to the body (PTB). Blood samples were taken before and five minutes after each contest. They were analysed for S-100B, neuron-specific enolase (NSE), creatine kinase (CK) and cortisol. The PTH group received direct contacts to the head (not blocked, parried or avoided) and to the body (n=8, age: 17.6 +/- 5.3, years; height: 1.68 +/- 0.13, meters; mass: 65.4 +/- 20.3, kg). The PTB group received punches to the body including blocked and parried punches, but received no direct punches to the head, (n=8, mean +/- SD, age: 19.1 +/- 3.2 years; height: 1.70 +/- 0.75, meters; mass: 68.5 +/- 15 kg). Significant increases (P<0.05) were observed between pre- and post-combat serum concentrations in serum concentrations in PTH of S-100B (0.35 +/- 0.61 vs. 0.54 +/- 0.73, mu g.L(-1)) NSE (19.7 +/- 14 vs.31.1 +/- 26.6, ng.ml(-1)) and cortisol (373 +/- 202 vs. 756 +/- 93, nmol.L(-1)). Significant increases (P<0.05) of creatine kinase were recorded in both groups. This study demonstrates significant elevations in neurochemical biomarkers in boxers who received direct blows to the head. However, further work is required to quantify this volumetric brain damage and long term clinical sequelae.	[Graham, M. R.] Glyndwr Univ, Wrexham LL11 2AW, Wales; [Graham, M. R.; Myers, T.] Newman Univ Coll, Birmingham, W Midlands, England; [Evans, P.] Royal Gwent Hosp, Newport NPT 2VB, Gwent, Wales; [Davies, B.] Univ Glamorgan, Pontypridd CF37 1DL, M Glam, Wales; [Cooper, S. M.] Univ Wales Inst, Cardiff, S Glam, Wales; [Bhattacharya, K.] Royal Infirm Edinburgh NHS Trust, Dept Cardiovasc Surg, Edinburgh, Midlothian, Scotland; [Grace, F. M.; Baker, J. S.] Univ W Scotland, Sch Sci, Hamilton, Scotland		Graham, MR (corresponding author), Glyndwr Univ, Wrexham LL11 2AW, Wales.	drgraham.ac.uk@live.co.uk	Grace, Fergal/N-7324-2016	Grace, Fergal/0000-0002-3144-5999			*AIBA, 2003, RUL INT COMP TOURN; *AM BOX ASS ENGL L, 2009, GUID WOM GIRLS START, P1; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; Duval F, 2006, PSYCHONEUROENDOCRINO, V31, P876, DOI 10.1016/j.psyneuen.2006.04.003; Foy K, 2009, BRIT J HOSP MED, V70, P440, DOI 10.12968/hmed.2009.70.8.43536; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jordan BD, 2009, CLIN SPORT MED, V28, P561, DOI 10.1016/j.csm.2009.07.005; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Kosakevitch-Ricbourg L, 2006, Rev Stomatol Chir Maxillofac, V107, P211, DOI 10.1016/S0035-1768(06)77043-7; Loosemore Mike, 2008, Br J Sports Med, V42, P564; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Shave R, 2010, J AM COLL CARDIOL, V56, P169, DOI 10.1016/j.jacc.2010.03.037; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Springborg Jtiaocnob Bertram, 2009, Ugeskr Laeger, V171, P978; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; White C, 2007, BRIT MED J, V335, P469, DOI 10.1136/bmj.39328.486100.DB; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zazryn TR, 2009, PHYS MED REH CLIN N, V20, P227, DOI 10.1016/j.pmr.2008.10.004; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	29	40	40	1	24	BIOLIFE SAS	SILVA MARINA (TE)	VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY	0394-6320			INT J IMMUNOPATH PH	Int. J. Immunopathol. Pharmacol.	JAN-MAR	2011	24	1					119	125		10.1177/039463201102400114			7	Immunology; Pathology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pathology; Pharmacology & Pharmacy	761BQ	WOS:000290370100014	21496394	Bronze			2022-02-06	
J	Hasiloglu, ZI; Albayram, S; Selcuk, H; Ceyhan, E; Delil, S; Arkan, B; Baskoy, L				Hasiloglu, Z. I.; Albayram, S.; Selcuk, H.; Ceyhan, E.; Delil, S.; Arkan, B.; Baskoy, L.			Cerebral Microhemorrhages Detected by Susceptibility-Weighted Imaging in Amateur Boxers	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PROFESSIONAL BOXERS; HEAD-INJURY; DAMAGE; CHILDREN; LESIONS; MRI	BACKGROUND AND PURPOSE: SWI is a new technique for evaluating diffuse axonal injury associated with punctate hemorrhages. The aim of our study was to determine the prevalence of cerebral microhemorrhages in amateur boxers compared with nonboxers by using SWI and to evaluate the sensitivity of SWI compared with T2 FSE and T2*GE sequences. MATERIALS AND METHODS: We performed cranial MR imaging with a 1.5T scanner in 21 amateur boxers and 21 control subjects. The study protocol included conventional MR images, T2 FSE, T2*GE, and SWI sequences. The proportions of boxers and controls having CSP, DPVS, cerebral atrophy, cerebellar atrophy, ventricular dilation. PSWMD, and microhemorrhages were computed and were compared by using the chi(2) test of proportions. The relationship between microhemorrhages and boxing-related covariates was assessed by using the Wilcoxon rank sum test. The association between the categories was tested by using the Fisher exact test. RESULTS: Using SWI, microhemorrhages were found in 2 (9.52%) of 21 boxers. The microhemorrhages were not visible on T2 FSE or T2*GE images. The proportion of subjects with microhemorrhages did not differ significantly between the boxers and control subjects (chi(2) = 0.525, df = 1, P = .4688). The prevalence of CSP and DPVS was significantly higher in the boxers than in the control subjects. CONCLUSIONS: More microhemorrhages were detected in amateur boxers than in controls, but this difference was not statistically significant.	[Hasiloglu, Z. I.; Albayram, S.] Istanbul Univ, Cerrahpasa Med Sch, Div Neuroradiol, Dept Radiol, TR-34300 Kmp Istanbul, Turkey; [Delil, S.] Istanbul Univ, Cerrahpasa Med Sch, Dept Neurol, TR-34300 Kmp Istanbul, Turkey; [Selcuk, H.] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Radiol, Istanbul, Turkey; [Ceyhan, E.] Koc Univ, Dept Math, Istanbul, Turkey		Albayram, S (corresponding author), Istanbul Univ, Cerrahpasa Med Sch, Div Neuroradiol, Dept Radiol, TR-34300 Kmp Istanbul, Turkey.	salbayram@hotmail.com	Selcuk, Hakan/AAL-2052-2020; Delil, Memet Sakir/AAP-9301-2021; Baskoy, Lutfullah/AAY-3245-2020	Selcuk, Hakan/0000-0001-5606-4423; 			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CORSELLIS JAN, 1989, BMJ-BRIT MED J, P105; Hahnel S, 2008, AM J NEURORADIOL, V29, P388, DOI 10.3174/ajnr.A0799; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	20	40	45	0	10	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2011	32	1					99	102		10.3174/ajnr.A2250			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	717BC	WOS:000287016200017	20966064	hybrid, Green Published			2022-02-06	
J	Hayward, NMEA; Tuunanen, PI; Immonen, R; Ndode-Ekane, XE; Pitkanen, A; Grohn, O				Hayward, Nick Mark Edward Alexander; Tuunanen, Pasi I.; Immonen, Riikka; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla; Grohn, Olli			Magnetic resonance imaging of regional hemodynamic and cerebrovascular recovery after lateral fluid-percussion brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; arterial spin labeling; cerebral hemodynamics; magnetic resonance imaging; traumatic brain injury; vascular density	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; PERFUSION; METABOLISM; TRAUMA; HYPOPERFUSION; CONTUSION; ISCHEMIA; EPILEPSY; HYPOXIA	Hemodynamic and cerebrovascular factors are crucially involved in secondary damage after traumatic brain injury (TBI). With magnetic resonance imaging, this study aimed to quantify regional cerebral blood flow (CBF) by arterial spin labeling and cerebral blood volume by using an intravascular contrast agent, during 14 days after lateral fluid-percussion injury (LFPI) in rats. Immunohistochemical analysis of vessel density was used to evaluate the contribution of vascular damage. Results show widespread ipsilateral and contralateral hypoperfusion, including both the cortex and the hippocampus bilaterally, as well as the ipsilateral thalamus. Hemodynamic unrest may partly be explained by an increase in blood vessel density over a period of 2 weeks in the ipsilateral hippocampus and perilesional cortex. Furthermore, three phases of perilesional alterations in CBF, progressing from hypoperfusion to normal and back to hypoperfusion within 2 weeks were shown for the first time in a rat TBI model. These three phases were similar to hemodynamic fluctuations reported in TBI patients. This makes it feasible to use LFPI in rats to study mechanisms behind hemodynamic changes and to explore novel therapeutic approaches for secondary brain damage after TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 166-177; doi:10.1038/jcbfm.2010.67; published online 19 May 2010	[Hayward, Nick Mark Edward Alexander; Tuunanen, Pasi I.; Immonen, Riikka; Grohn, Olli] Univ Eastern Finland, Biomed Imaging Unit, Dept Neurobiol, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, Dept Neurobiol, Epilepsy Res Grp, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Grohn, O (corresponding author), Univ Eastern Finland, Biomed Imaging Unit, Dept Neurobiol, AI Virtanen Inst, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uef.fi		Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632; Hayward, Nick/0000-0001-9496-7332	Marie Curie Early Stage Trainee Research Fellowship [MEST-CT-2005-019217]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation	This study was funded by a Marie Curie Early Stage Trainee Research Fellowship MEST-CT-2005-019217, by The Academy of Finland (AP, OG) and by The Sigrid Juselius Foundation (AP).	Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dunn JF, 2004, MAGN RESON MED, V51, P55, DOI 10.1002/mrm.10660; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Robertson CL, 2000, ACT NEUR S, V76, P187; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	47	40	41	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2011	31	1					166	177		10.1038/jcbfm.2010.67			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	702BX	WOS:000285870700019	20485295	Green Published, Bronze			2022-02-06	
J	Liu, MC; Kobeissy, F; Zheng, WR; Zhang, ZQ; Hayes, RL; Wang, KKW				Liu, Ming Cheng; Kobeissy, Firas; Zheng, Wenrong; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Kevin K. W.			Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions	ASN NEURO			English	Article						cell death; neurodegeneration; protease; tau protein; tauopathy; traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; ACID 5-METHOXY-3-OXAPENTYL ESTER; DIFFUSE AXONAL INJURY; ALPHA-II-SPECTRIN; ALZHEIMERS-DISEASE; NEURONAL DAMAGE; RAT-BRAIN; C-TAU; APOPTOSIS; PROTEIN	Axonally specific microtubule-associated protein tau is an important component of neurofibrillary tangles found in AD (Alzheimer's disease) and other tauopathy diseases such as CTE (chronic traumatic encephalopathy). Such tau aggregate is found to be hyperphosphorylated and often proteolytically fragmented. Similarly, tau is degraded following TBI (traumatic brain injury). In the present study, we examined the dual vulnerability of tau to calpain and caspase-3 under neurotoxic and neurodegenerative conditions. We first identified three novel calpain cleavage sites in rat tau (four-repeat isoform) as Ser(130)down arrow Lys(131), Gly(157)down arrow Ala(158) and Arg(380)down arrow Glu(381). Fragment-specific antibodies to target the major calpain-mediated TauBDP-35K (35 kDa tau-breakdown product) and the caspase-mediated TauBDP-45K respectively were developed. In rat cerebrocortical cultures treated with excitotoxin [NMDA (N-methyl-D-aspartate)], tau is significantly degraded into multiple fragments, including a dominant signal of calpain-mediated TauBDP-35K with minimal caspase-mediated TauBDP-45K. Following apoptosis-inducing EDTA treatment, tau was truncated only to TauBDP-48K/45K-exclusively by caspase. Cultures treated with another apoptosis inducer STS (staurosporine), dual fragmentation by calpain (TauBDP-35K) and caspase-3 (TauBDP-45K) was observed. Tau was also fragmented in injured rat cortex following TBI in vivo to BDPs of 45-42 kDa (minor), 35 kDa and 15 kDa, followed by TauBDP-25K. Calpain-mediated TauBDP-35K-specific antibody confirmed robust signals in the injured cortex, while caspase-mediated TauBDP-45K-specific antibody only detected faint signals. Furthermore, intravenous administration of a calpain-specific inhibitor SNJ-1945 strongly suppressed the TauBDP-35K formation. Taken together, these results suggest that tau protein is dually vulnerable to calpain and caspase-3 proteolysis under different neurotoxic and injury conditions.	[Liu, Ming Cheng; Kobeissy, Firas; Zheng, Wenrong; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Kobeissy, Firas; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL 32610 USA		Liu, MC (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	mcLiu@banyanbio.com; kwang@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	NINDS-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R21NS052322, R01 NS049175]; Department of Defense (DoD)United States Department of Defense [DAMD17-03-1-0066]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052322, R01NS049175] Funding Source: NIH RePORTER	This work was supported by NINDS-NIH [1R21NS052322] (to M. C. L.), [R01 NS049175] (to K. K. W.); Department of Defense (DoD) [Grant No. DAMD17-03-1-0066] (to R.L.H.).	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Avila J, 2004, CURR ALZHEIMER RES, V1, P97, DOI 10.2174/1567205043332207; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Canu N, 1998, J NEUROSCI, V18, P7061; Chiesa R, 1998, J NEUROCHEM, V70, P1474; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Delobel P, 2005, FEBS LETT, V579, P1, DOI 10.1016/j.febslet.2004.11.018; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOSIK KS, 1987, J NEUROSCI, V7, P3142; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Krishnamurthy S, 2002, ADV ANAT PATHOL, V9, P185, DOI 10.1097/00125480-200205000-00002; LITERSKY JM, 1993, BRAIN RES, V604, P32, DOI 10.1016/0006-8993(93)90349-R; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; McIntosh TK, 1996, LAB INVEST, V74, P315; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Oka T, 2006, NEUROSCIENCE, V141, P2139, DOI 10.1016/j.neuroscience.2006.05.060; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rohn TT, 2002, DRUG NEWS PERSPECT, V15, P549, DOI 10.1358/dnp.2002.15.9.740233; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Shimohama S, 1999, BIOCHEM BIOPH RES CO, V256, P381, DOI 10.1006/bbrc.1999.0344; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Sinjoanu RC, 2008, NEUROCHEM INT, V53, P79, DOI 10.1016/j.neuint.2008.06.003; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2007, INT J NEUROPSYPHARM, V9, P1; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x; Yen S, 1999, FEBS LETT, V461, P91, DOI 10.1016/S0014-5793(99)01427-1; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang JY, 2009, J ALZHEIMERS DIS, V16, P39, DOI 10.3233/JAD-2009-0908; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	71	40	43	0	9	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	1759-0914			ASN NEURO	ASN Neuro		2011	3	1					25	36	e00051	10.1042/AN20100012			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	759QQ	WOS:000290263600003	21359008	Green Published, Green Submitted, gold			2022-02-06	
J	Mukherjee, S; Katki, K; Arisi, GM; Foresti, ML; Shapiro, LA				Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.			Early TBI-induced cytokine alterations are similarly detected by two distinct methods of multiplex assay	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						cytokine; TBI; fluid percussion injury; multiplex assay		Annually, more than a million persons experience traumatic brain injury (TBI) in the US and a substantial proportion of this population develop debilitating neurological disorders, such as, paralysis, cognitive deficits, and epilepsy. Despite the long-standing knowledge of the risks associated with TBI, no effective biomarkers or interventions exist. Recent evidence suggests a role for inflammatory modulators in TBI-induced neurological impairments. Current technological advances allow for the simultaneous analysis of the precise spatial and temporal expression patterns of numerous proteins in single samples which ultimately can lead to the development of novel treatments. Thus, the present study examined 23 different cytokines, including chemokines, in the ipsi and contralateral cerebral cortex of rats at 24 h after a fluid percussion injury (FPI). Furthermore, the estimation of cytokines were performed in a newly developed multiplex assay instrument, MAGPIX (Luminex Corp), and compared with an established instrument, Bio-Plex (Bio-Rad), in order to validate the newly developed instrument. The results show numerous inflammatory changes in the ipsi and contralateral side after FPI that were consistently reported by both technologies.	[Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.] Scott & White Hosp, Neurosci Res Inst, Temple, TX USA; [Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.] Cent Texas Vet Hlth Syst, Temple, TX USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosurg, Temple, TX 76504 USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Temple, TX 76504 USA		Shapiro, LA (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Bldg 205,1901 South 1st St, Temple, TX 76504 USA.	lshapiro@medicine.tamhsc.edu	Foresti, Maira Licia/D-8292-2015; Arisi, Gabriel/J-8714-2012	Arisi, Gabriel/0000-0002-6832-3389	Foundation CIEN-Reina Sofia; FISInstituto de Salud Carlos III [PS09/00684]; CIBERNED, ISC-III from Spain	We would especially like to thank Dr. M.-X. Silveyra for her contribution, and M.-T. Garcia-Hedo and C. Serra-Basante for technical assistance. This work was supported by grants from Foundation CIEN-Reina Sofia, FIS (Grant PS09/00684), and CIBERNED, ISC-III from Spain to Javier Saez-Valero.	ARENDT T, 1992, NEUROCHEM INT, V21, P381, DOI 10.1016/0197-0186(92)90189-X; ATACK JR, 1986, J NEUROCHEM, V47, P263; ATACK JR, 1987, J NEUROCHEM, V48, P1687, DOI 10.1111/j.1471-4159.1987.tb05724.x; ATACK JR, 1983, NEUROSCI LETT, V40, P199, DOI 10.1016/0304-3940(83)90302-6; Ballard Clive G., 2005, Current Alzheimer Research, V2, P307; Basun H, 2002, DEMENT GERIATR COGN, V14, P156, DOI 10.1159/000063605; Berson A, 2008, BRAIN, V131, P109, DOI 10.1093/brain/awm276; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Brimijoin S, 1999, ENVIRON HEALTH PERSP, V107, P59, DOI 10.2307/3434472; BROCKMAN SK, 1986, J BIOL CHEM, V261, P1201; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; CHIAPPA S, 1995, BIOCHEM PHARMACOL, V49, P955, DOI 10.1016/0006-2952(95)00004-J; Clarke NA, 2001, INT J GERIATR PSYCH, V16, P1104, DOI 10.1002/gps.472; Cribbs D. H., 1995, ALZHEIMERS RES, V1, P197; Darreh-Shori T, 2006, J NEURAL TRANSM, V113, P1791, DOI 10.1007/s00702-006-0526-2; Davidsson P, 2001, NEUROSCI LETT, V300, P157, DOI 10.1016/S0304-3940(01)01586-5; DAVIES P, 1976, LANCET, V2, P1403; Davis AA, 2010, J NEUROSCI, V30, P4190, DOI 10.1523/JNEUROSCI.6393-09.2010; Dong HX, 2009, BRAIN RES, V1303, P169, DOI 10.1016/j.brainres.2009.09.097; Dori A, 2005, CEREB CORTEX, V15, P419, DOI 10.1093/cercor/bhh145; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FISHMAN EB, 1986, ANN NEUROL, V19, P246, DOI 10.1002/ana.410190305; Fodero LR, 2002, J NEUROCHEM, V81, P441, DOI 10.1046/j.1471-4159.2002.00902.x; Fodero LR, 2001, J NEUROCHEM, V79, P1022, DOI 10.1046/j.1471-4159.2001.00640.x; Fu HJ, 2008, BIOCHEM BIOPH RES CO, V366, P631, DOI 10.1016/j.bbrc.2007.11.068; Garcia-Ayllon MS, 2007, J NEUROCHEM, V101, P1701, DOI 10.1111/j.1471-4159.2007.04461.x; Garcia-Ayllon MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008701; Garcia-Ayllon MS, 2006, HEPATOLOGY, V43, P444, DOI 10.1002/hep.21071; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; Giacobini E, 2002, J NEURAL TRANSM-SUPP, P181; Greenberg DS, 2010, NEURODEGENER DIS, V7, P60, DOI 10.1159/000285507; Greenfield SA, 2008, FEBS J, V275, P604, DOI 10.1111/j.1742-4658.2007.06235.x; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guevara J, 1998, J NEUROPATH EXP NEUR, V57, P905, DOI 10.1097/00005072-199810000-00003; HAMMOND P, 1988, J NEUROCHEM, V50, P1111, DOI 10.1111/j.1471-4159.1988.tb10580.x; HECKERS S, 1992, NEUROBIOL AGING, V13, P455, DOI 10.1016/0197-4580(92)90072-6; Hu W, 2003, J NEUROCHEM, V86, P470, DOI 10.1046/j.1471-4159.2003.01855.x; INESTROSA NC, 1981, J NEUROSCI, V1, P1260; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Inestrosa NC, 2008, FEBS J, V275, P625, DOI 10.1111/j.1742-4658.2007.06238.x; Kaduszkiewicz H, 2005, BMJ-BRIT MED J, V331, P321, DOI 10.1136/bmj.331.7512.321; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kang J., 1987, NATURE, P19; Kanninen K, 2004, NEUROSCI LETT, V367, P235, DOI 10.1016/j.neulet.2004.06.013; Kasa P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Lahiri D K, 1997, Ann N Y Acad Sci, V826, P416, DOI 10.1111/j.1749-6632.1997.tb48495.x; Lahiri DK, 2007, J PHARMACOL EXP THER, V320, P386, DOI 10.1124/jpet.106.112102; LAHIRI DK, 1994, J NEUROSCI RES, V37, P777, DOI 10.1002/jnr.490370612; LAYER PG, 1995, ALZ DIS ASSOC DIS, V9, P29, DOI 10.1097/00002093-199501002-00006; Li QQ, 2010, EXP GERONTOL, V45, P842, DOI 10.1016/j.exger.2010.06.008; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matrone C, 2008, P NATL ACAD SCI USA, V105, P13139, DOI 10.1073/pnas.0806133105; Melo JB, 2003, NEUROSCI RES, V45, P117, DOI 10.1016/S0168-0102(02)00201-8; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Mesulam M M, 1990, Adv Neurol, V51, P235; Mesulam MM, 2004, PROG BRAIN RES, V145, P67, DOI 10.1016/S0079-6123(03)45004-8; MESULAM MM, 1987, ANN NEUROL, V22, P223, DOI 10.1002/ana.410220206; Moreno RD, 1998, INT J DEV NEUROSCI, V16, P123, DOI 10.1016/S0736-5748(98)00008-2; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; MULLER F, 1985, BRAIN RES, V331, P295, DOI 10.1016/0006-8993(85)91555-0; Munoz-Torrero D, 2008, CURR MED CHEM, V15, P2433, DOI 10.2174/092986708785909067; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OGANE N, 1992, NEUROCHEM RES, V17, P489, DOI 10.1007/BF00969897; Pakaski M., 2001, Neurobiology (Budapest), V9, P55; Paraoanu LE, 2006, J MOL NEUROSCI, V30, P201, DOI 10.1385/JMN:30:1:201; Parnetti L, 2011, ACTA NEUROL SCAND, V124, P122, DOI 10.1111/j.1600-0404.2010.01435.x; Peng Y, 2006, J NEUROSCI RES, V84, P903, DOI 10.1002/jnr.20987; Pepeu G, 2009, CURR ALZHEIMER RES, V6, P86, DOI 10.2174/156720509787602861; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2005, J NEUROCHEM, V94, P629, DOI 10.1111/j.1471-4159.2005.03140.x; PERRY EK, 1977, LANCET, V1, P189; PERRY EK, 1986, J NEUROCHEM, V47, P1262; PERRY RH, 1980, AGE AGEING, V9, P9, DOI 10.1093/ageing/9.1.9; Rakonczay Z, 2003, ACTA BIOL HUNG, V54, P183, DOI 10.1556/ABiol.54.2003.2.7; Rees T, 2003, NEUROBIOL AGING, V24, P777, DOI 10.1016/S0197-4580(02)00230-0; Rees TM, 2003, DRUG TODAY, V39, P75, DOI 10.1358/dot.2003.39.1.740206; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; Rossner S, 1998, PROG NEUROBIOL, V56, P541, DOI 10.1016/S0301-0082(98)00044-6; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Saez-Valero J, 2000, J NEUROL NEUROSUR PS, V69, P664, DOI 10.1136/jnnp.69.5.664; Saez-Valero J, 1999, J NEUROCHEM, V72, P1600, DOI 10.1046/j.1471-4159.1999.721600.x; Saez-Valero J, 2002, NEUROSCI LETT, V325, P199, DOI 10.1016/S0304-3940(02)00282-3; Saez-Valero J, 2000, ACTA NEUROL SCAND, V102, P49, DOI 10.1034/j.1600-0404.2000.00307.x; SaezValero J, 1997, LANCET, V350, P929, DOI 10.1016/S0140-6736(97)24039-0; Sberna G, 1998, J NEUROCHEM, V71, P723; Sberna G, 1997, J NEUROCHEM, V69, P1177; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; Sihlbom C, 2008, NEUROCHEM RES, V33, P1332, DOI 10.1007/s11064-008-9588-x; Silman I, 2005, CURR OPIN PHARMACOL, V5, P293, DOI 10.1016/j.coph.2005.01.014; Silveyra M. X., 2011, NEUROBIOL AGING, DOI [10.1016/j.neurobiolaging.2011.04.006, DOI 10.1016/J.NEUROBIOLAGING.2011.04.006.[]; Silveyra M. X., 2011, NEUROBIOL AGING, DOI [10.1016/j.neurobiolaging.2011.03.006, DOI 10.1016/J.NEUROBIOLAGING.2011.03.006.[]; Silveyra MX, 2008, MOL CELL BIOL, V28, P2908, DOI 10.1128/MCB.02065-07; Silveyra MX, 2006, J NEUROCHEM, V96, P97, DOI 10.1111/j.1471-4159.2005.03514.x; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; STIEGER S, 1987, J NEUROCHEM, V49, P460, DOI 10.1111/j.1471-4159.1987.tb02887.x; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; SUNG SC, 1983, NEUROCHEM RES, V8, P303, DOI 10.1007/BF00965720; Talesa VN, 2001, MECH AGEING DEV, V122, P1961, DOI 10.1016/S0047-6374(01)00309-8; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Toiber D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003108; ULRICH J, 1990, ACTA NEUROPATHOL, V80, P624, DOI 10.1007/BF00307630; White AR, 2003, BRAIN RES, V966, P231, DOI 10.1016/S0006-8993(02)04173-2; WRIGHT CI, 1993, ANN NEUROL, V34, P373, DOI 10.1002/ana.410340312; Xie HDQ, 2010, J BIOL CHEM, V285, P11537, DOI 10.1074/jbc.M109.038711; YOUNKIN SG, 1986, FASEB J, V45, P2982; ZAKUT H, 1985, J NEUROCHEM, V45, P382, DOI 10.1111/j.1471-4159.1985.tb03999.x; Zhang Y, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-4; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x; Zimmermann M, 2005, NEUROBIOL DIS, V19, P237, DOI 10.1016/j.nbd.2005.01.002	117	40	40	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.		2011	4								21	10.3389/fnmol.2011.00021			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V38VE	WOS:000209370100019	21954376	Green Published, gold			2022-02-06	
J	Bansal, V; Ryu, SY; Blow, C; Costantini, T; Loomis, W; Eliceiri, B; Baird, A; Wolf, P; Coimbra, R				Bansal, Vishal; Ryu, Seok Yong; Blow, Chelsea; Costantini, Todd; Loomis, William; Eliceiri, Brian; Baird, Andrew; Wolf, Paul; Coimbra, Raul			The Hormone Ghrelin Prevents Traumatic Brain Injury Induced Intestinal Dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						ghrelin; intestinal permeability; tight junctions; traumatic brain injury	DELAYED GASTROINTESTINAL TRANSIT; DORSAL MOTOR NUCLEUS; KAPPA-B; BARRIER DYSFUNCTION; TIGHT JUNCTION; PERMEABILITY; INFLAMMATION; CYTOKINES; PIPELINE; PEPTIDE	Intestinal barrier breakdown following traumatic brain injury (TBI) is characterized by increased intestinal permeability, leading to bacterial translocation, and inflammation. The hormone ghrelin may prevent intestinal injury and have anti-inflammatory properties. We hypothesized that exogenous ghrelin prevents intestinal injury following TBI. A weight-drop model created severe TBI in three groups of anesthetized Balb/c mice. Group TBI: animals underwent TBI only; Group TBI/ghrelin: animals were given 10 mu g of ghrelin intraperitoneally prior and 1 h following TBI; Group sham: no TBI or ghrelin injection. Intestinal permeability was measured 6 h following TBI by detecting serum levels of FITC-Dextran after injection into the intact ileum. The terminal ileum was harvested for histology, expression of the tight junction protein MLCK and inflammatory cytokine TNF-alpha. Permeability increased in the TBI group compared to the sham group (109.7 +/- 21.8 mu g/mL vs. 32.2 +/- 10.1 mu g/mL; p<0.002). Ghrelin prevented TBI-induced permeability (28.3 +/- 4.2 mu g/mL vs. 109.7 +/- 21.8 mu g/mL; p<0.001). The intestines of the TBI group showed blunting and necrosis of villi compared to the sham group, while ghrelin injection preserved intestinal architecture. Intestinal MLCK increased 73% compared to the sham group (p<0.03). Ghrelin prevented TBI-induced MLCK expression to sham levels. Intestinal TNF-alpha increased following TBI compared to the sham group (46.2 +/- 7.1 pg/mL vs. 24.4 +/- 2.2 pg/mL p<0.001). Ghrelin reduced TNF-a to sham levels (29.2 +/- 5.0 pg/mL; p = NS). We therefore conclude that ghrelin prevents TBI-induced injury, as determined by intestinal permeability, histology, and intestinal levels of TNF-alpha. The mechanism for ghrelin mediating intestinal protection is likely multifactorial, and further studies are needed to delineate these possibilities.	[Bansal, Vishal; Ryu, Seok Yong; Blow, Chelsea; Costantini, Todd; Loomis, William; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Sanggye Paik Hosp, Dept Emergency Med, Gimhae, South Korea; [Wolf, Paul] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA		Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Baird, Andrew/0000-0003-0027-9905; Eliceiri, Brian/0000-0003-1811-1916	Inje Research and Scholarship Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	This research was supported in part by the 2009 Inje Research and Scholarship Foundation.	Ammori JB, 2008, SURGERY, V144, P159, DOI 10.1016/j.surg.2008.03.008; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Camilleri M, 2008, GASTROENTEROLOGY, V135, P1877, DOI 10.1053/j.gastro.2008.09.005; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Costantini TW, 2009, J TRAUMA, V67, P1162, DOI 10.1097/TA.0b013e3181ba3577; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Costantini TW, 2009, J TRAUMA, V66, P17, DOI 10.1097/TA.0b013e318191bb1f; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Gonzalez-Rey E, 2006, GASTROENTEROLOGY, V130, P1707, DOI 10.1053/j.gastro.2006.01.041; Graham WV, 2006, J BIOL CHEM, V281, P26205, DOI 10.1074/jbc.M602164200; Grimal R., 2010, PRESENTATION ENQUETE, P1; Gura T, 2003, SCIENCE, V299, P849, DOI 10.1126/science.299.5608.849; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; KOCH A, 2010, CRIT CARE, V14; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Miao YY, 2007, BIOCHEM BIOPH RES CO, V359, P795, DOI 10.1016/j.bbrc.2007.05.192; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; Sallam HS, 2007, AM J PHYSIOL-REG I, V292, pR253, DOI 10.1152/ajpregu.00100.2006; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; van der Lely AJ, 2009, HORM RES, V71, P129, DOI 10.1159/000178055; Waseern T, 2008, SURGERY, V143, P334, DOI 10.1016/j.surg.2007.09.039; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121	39	40	43	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2255	2260		10.1089/neu.2010.1372			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400014	20858122	Green Published			2022-02-06	
J	Carlson, AP; Ramirez, P; Kennedy, G; McLean, AR; Murray-Krezan, C; Stippler, M				Carlson, Andrew P.; Ramirez, Pedro; Kennedy, George; McLean, A. Robb; Murray-Krezan, Cristina; Stippler, Martina			Low rate of delayed deterioration requiring surgical treatment in patients transferred to a tertiary care center for mild traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						mild traumatic brain injury; cortical contusion; skull fracture; traumatic subarachnoid hemorrhage; subdural hematoma; brain concussion	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; NEUROSURGERY; MANAGEMENT; RULE; CT; TELERADIOLOGY; CONSULTATION; TELEMEDICINE	Object. Patients with mild traumatic brain injury (mTBI) only rarely need neurosurgical intervention; however, there is a subset of patients whose condition will deteriorate. Given the high resource utilization required for interhospital transfer and the relative infrequency of the need for intervention, this study was undertaken to determine how often patients who were transferred required intervention and if there were factors that could predict that need. Methods. The authors performed a retrospective review of cases involving patients who were transferred to the University of New Mexico Level 1 trauma center for evaluation of mTBI between January 2005 and December 2009. Information including demographic data, lesion type, need for neurosurgical intervention, and short-term outcome was recorded. Results. During the 4-year study period, 292 patients (age range newborn to 92 years) were transferred for evaluation of mTBI. Of these 292 patients, 182 (62.3%) had an acute traumatic finding of some kind; 110 (60.4%) of these had a follow-up CT to evaluate progression, whereas 60 (33.0%) did not require a follow-up CT. In 15 cases (5.1% overall), the patients were taken immediately to the operating room (either before or after the first CT). Only 4 patients (1.5% overall) had either clinical or radiographic deterioration requiring delayed surgical intervention after the second CT scan. Epidural hematoma (EDH) and subdural hematoma (SDH) were both found to be significantly associated with the need for surgery (OR 29.5 for EDH, 95% CI 6.6-131.8; OR 9.7 for SDH, 95% CI 2.4-39.1). There were no in-hospital deaths in the series, and 97% of patients were discharged with a Glasgow Coma Scale score of 15. Conclusions. Most patients who are transferred with mTBI who need neurosurgical intervention have a surgical lesion initially. Only a very small percentage will have a delayed deterioration requiring surgery, with EDH and SDH being more concerning lesions. In most cases of mTBI, triage can be performed by a neurosurgeon and the patient can be observed without interhospital transfer. (DOI: 10.3171/2010.8.FOCUS10182)	[Carlson, Andrew P.; Ramirez, Pedro; Stippler, Martina] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Kennedy, George; McLean, A. Robb] Univ New Mexico, Dept Emergency Med, Albuquerque, NM 87131 USA; [Murray-Krezan, Cristina] Univ New Mexico, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA		Stippler, M (corresponding author), Univ New Mexico, Dept Neurosurg, MSC10-5615,1 Univ New Mexico, Albuquerque, NM 87131 USA.	mstippler@salud.unm.edu	Carlson, Andrew P/B-4369-2012; Murray-Krezan, Cristina/O-3834-2016	Carlson, Andrew P/0000-0003-2189-3699; Murray-Krezan, Cristina/0000-0002-5488-1080	Clinical Translational Science Center at UNM	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Statistical analysis was supported via a grant through the Clinical Translational Science Center at UNM.	Ashkenazi I, 2007, EMERG MED J, V24, P550, DOI 10.1136/emj.2006.044461; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Edmonds Marcia, 2006, Evid Based Med, V11, P61, DOI 10.1136/ebm.11.2.61; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Gray WP, 1998, NEUROSURGERY, V42, P103, DOI 10.1097/00006123-199801000-00020; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hebb MO, 2007, CAN J SURG, V50, P187; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Houkin K, 1999, NEUROL MED-CHIR, V39, P773, DOI 10.2176/nmc.39.773; Huynh T, 2006, AM SURGEON, V72, P1162; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kreutzer J, 2008, J TELEMED TELECARE, V14, P67, DOI 10.1258/jtt.2007.060605; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Newgard CD, 2005, EMERG MED J, V22, P855, DOI 10.1136/emj.2004.020206; Ng WH, 2007, SURG NEUROL, V67, P338, DOI 10.1016/j.surneu.2006.10.056; Pirris SM, 2010, NEUROSURGERY, V66, P999, DOI 10.1227/01.NEU.0000368443.43565.2A; Qushmaq Ismael, 2006, ACP J Club, V144, P53; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Schulmeyer FJ, 1999, ST HEAL T, V64, P115; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Smith Eric E, 2008, Crit Pathw Cardiol, V7, P173, DOI 10.1097/HPC.0b013e318184e2bc; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Urban V, 1996, Eur J Emerg Med, V3, P5, DOI 10.1097/00063110-199603000-00001; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Waran V, 2008, J TRAUMA, V64, P362, DOI 10.1097/TA.0b013e318070cc88; Wong HT, 2006, NEUROSURGERY, V59, P607, DOI 10.1227/01.NEU.0000228926.13395.F9	33	40	41	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E3	10.3171/2010.8.FOCUS10182			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900004	21039137	Green Accepted			2022-02-06	
J	Thomale, UW; Graetz, D; Vajkoczy, P; Sarrafzadeh, AS				Thomale, Ulrich-Wilhelm; Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.			Severe traumatic brain injury in children-a single center experience regarding therapy and long-term outcome	CHILDS NERVOUS SYSTEM			English	Article						Severe brain injury; Intracranial hypertension; ICP; Decompressive craniectomy; Glasgow Outcome Score	EARLY DECOMPRESSIVE CRANIECTOMY; CEREBRAL-BLOOD-FLOW; REFRACTORY INTRACRANIAL HYPERTENSION; HEAD-INJURY; PERFUSION-PRESSURE; HYPERVENTILATION; CRANIOTOMY; MANAGEMENT; TUMORS; TRIAL	Object The impact of intracranial pressure (ICP), decompressive craniectomy (DC), extent of ICP therapy, and extracranial complications on long-term outcome in a single-center pediatric patient population with severe traumatic brain injury (TBI) is examined. Methods Data of pediatric (<= 16 years) TBI patients were retrospectively reviewed using a prospectively acquired database on neurosurgical interventions between April 1996 and March 2007 at the Charite Berlin. The patients' records, neuroimages, admission Glasgow Coma Scale (GCS) score, the time to craniectomy for hematoma evacuation/DC, and the extent of ICP therapy were reviewed. Twelve-month and long-term outcome was evaluated (Glasgow Outcome Scale). Results Fifty-three pediatric TBI patients [mean age 8.41 (0-16) years] were studied. Patients were categorized into two groups, with DC (n=14) and without DC (n=39). DC was performed 3 +/- 3.98 median, quartiles 2 (0-3.75) days post-trauma. In the majority of children (n=9; 64%), surgical decompression was performed early within 2 days post-trauma. (0.8 +/- 0.9 days). The DC group tended to be older (median age 12 vs. 7 years, p=0.052), had a lower GCS (3 vs. 6.5, p<0.01), and had a 3-fold longer stay on the ICU (20 vs. 6.5 days, p<0.03) compared to the conservatively treated group. Mean follow-up duration (n=30) was 5.2 +/- 2.4 years (range 1-10.5). At the most recent follow-up examination, 92% of survivors had returned to school. Conclusion Though initial GCS was worse in pediatric TBI patients who underwent decompressive craniectomy compared to the conservatively treated patients, long-term outcome was comparable. In children, decompressive craniectomy might be favored early in the management of uncontrollable ICP.	[Sarrafzadeh, Asita S.] Univ Med Berlin, Dept Neurosurg, Charite Virchow Med Ctr, D-13353 Berlin, Germany; [Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.] Univ Med Berlin, Charite, Campus Virchow Klinikum, Dept Neurosurg, D-13353 Berlin, Germany		Sarrafzadeh, AS (corresponding author), Univ Med Berlin, Dept Neurosurg, Charite Virchow Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chambers Iain R, 2003, Neurosurg Focus, V15, pE3; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; *FDN BT, 2003, PEDIATR CRIT CARE ME, V4, P45; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jagannathan J, 2007, J NEUROSURG, V106, pA761; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kunze E, 1998, ACT NEUR S, V71, P16; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Spiller WG, 1906, J AMER MED ASSOC, V47, P679; Suzuki K., 1990, NAGOYA MED J, V34, P159; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	43	40	43	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	NOV	2010	26	11					1563	1573		10.1007/s00381-010-1103-4			11	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	683IY	WOS:000284470700018	20177687				2022-02-06	
J	King, C; Robinson, T; Dixon, CE; Rao, GR; Larnard, D; Nemoto, CEM				King, Christopher; Robinson, Timothy; Dixon, C. Edward; Rao, Gutti R.; Larnard, Donald; Nemoto, C. Edwin M.			Brain Temperature Profiles during Epidural Cooling with the ChillerPad in a Monkey Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; non-human primate; selective brain cooling; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; TERM MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; SELECTIVE HYPOTHERMIA; MARKED PROTECTION; CORTICAL IMPACT; SAFETY; HEAD; NEUROPROTECTION; 15-DEGREES-C	Therapeutic hypothermia remains a promising treatment for patients with severe traumatic brain injury (TBI). Multiple animal studies have suggested that hypothermia is neuroprotective after TBI, but clinical trials have been inconclusive. Systemic hypothermia, the method used in almost all major clinical trials, is limited by the time to target temperature, the depth of hypothermia, and complications, problems that may be solved by selective brain cooling. We evaluated the effects on brain temperature of a cooling device called the ChillerPad,(TM) which is applied to the dura in a non-human primate TBI model using controlled cortical impact (CCI). The cortical surface was rapidly cooled to approximately 15 degrees C and maintained at that level for 24 h, followed by rewarming over about 10 h. Brain temperatures fell to 34-35 degrees C at a depth of 15 mm at the cortical gray/white matter interface, and to 28-32 degrees C at 10 mm deep. Intracranial pressure was mildly elevated (8-12 mm Hg) after cooling and rewarming, likely due to TBI. Other physiological variables were unchanged. Cooling was rapidly diminished at points distant from the cooling pad. The ChillerPad may be useful for highly localized cooling of the brain in circumstances in which a craniotomy is clinically indicated. However, because of the delay required by the craniotomy, other methods that are more readily available for inducing hypothermia may be used as a bridge between the time of injury to placement of the ChillerPad.	[King, Christopher] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Rao, Gutti R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; [Robinson, Timothy] Tiroconsulting, Sandown, NH USA; [Larnard, Donald] Mantis Enterprises LLC, N Hampton, NH USA; [Nemoto, C. Edwin M.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA		King, C (corresponding author), Univ Pittsburgh, Dept Emergency Med, Forbes Tower,Suite 10028, Pittsburgh, PA 15260 USA.	kingcc@upmc.edu			Seacoast Technologies, Portsmouth, New Hampshire	The authors wish to thank Dr. Geoffrey Manley (Department of Neurosurgery, University of California-San Francisco) for his helpful advice on the setting and timing for the use of the controlled cortical impact device in the monkey. This study was funded by a grant from Seacoast Technologies, Portsmouth, New Hampshire.	Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Clark DL, 2009, EXP NEUROL, V220, P391, DOI 10.1016/j.expneurol.2009.10.002; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; Covaciu L, 2008, RESUSCITATION, V76, P83, DOI 10.1016/j.resuscitation.2007.07.002; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Finkelstein E., 2006, INCIDENCE EC BURDEN; HOFMAN MA, 1988, BRAIN BEHAV EVOLUT, V32, P17, DOI 10.1159/000116529; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mascio CE, 2009, ASAIO J, V55, P287, DOI 10.1097/MAT.0b013e3181964861; Nemoto EM, 2006, ADV EXP MED BIOL, V578, P317; Nemoto EM, 2006, ADV EXP MED BIOL, V578, P311; OHTA T, 1992, NEUROSURGERY, V31, P1049, DOI 10.1227/00006123-199212000-00010; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; Percy A, 2009, ANN THORAC SURG, V87, P117, DOI 10.1016/j.athoracsur.2008.10.025; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2001, J NEUROSURG, V94, P853; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu Wu-si, 2006, Chin J Traumatol, V9, P238; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SCHRECKINGER M, 2009, NEUROCRIT CARE; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Schwartz AE, 1996, NEUROSURGERY, V39, P577; Schwartz ID, 1996, PEDIATR RES, V39, P577; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; SYDENHAM E, 2009, COCHRANE DATABASE SY; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wagner KR, 2005, NEUROL RES, V27, P238, DOI 10.1179/016164105X25261; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wei G, 2008, J NEUROTRAUM, V25, P549, DOI 10.1089/neu.2007.0498; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zhang LH, 2007, SURG NEUROL, V67, P117, DOI 10.1016/j.surneu.2006.05.064; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	52	40	43	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1895	1903		10.1089/neu.2009.1178			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600013	20684677				2022-02-06	
J	Berman, M; Ali, A; Ashley, E; Freed, D; Clarke, K; Tsui, S; Parameshwar, J; Large, S				Berman, Marius; Ali, Ayyaz; Ashley, Euan; Freed, Darren; Clarke, Kieran; Tsui, Steven; Parameshwar, Jayan; Large, Stephen			Is stress cardiomyopathy the underlying cause of ventricular dysfunction associated with brain death?	JOURNAL OF HEART AND LUNG TRANSPLANTATION			English	Article						heart transplantation; graft dysfunction; RV dysfunction; stress cardiomyopathy; Takotsubo cardiomyopathy	WALL-MOTION ABNORMALITIES; MYOCARDIAL DYSFUNCTION; HUMAN DONOR; TAKOTSUBO CARDIOMYOPATHY; SUBARACHNOID HEMORRHAGE; INJURY; HEART	Most deaths in the first 30 days after cardiac transplantation are due to failure of the donor heart, often with the clinical picture of right ventricular failure. Indeed, there is a significant reduction in contractility of the human donor heart and loss of contractile reserve before and soon after transplantation. This myocardial insult appears in association with brain death in the donor and follows a "catecholamine storm" associated with a rapidly rising intracranial pressure. Microscopy of the myocardium in organ donors shows a picture typical of catecholamine-induced injury and similar to changes found in endomyocardial specimens of stress cardiomyopathy (catecholamine-induced cardiomyopathy, or Takotsubo cardiomyopathy). There are 3 common features between stress cardiomyopathy and the heart of a brain-dead donor: exposure of the heart to unusually high catecholamine levels, ventricular dysfunction, and prompt recovery. Stress cardiomyopathy is a temporary myocardial dysfunction that has been described after sub-arachnoid hemorrhage, traumatic head injury, pheochromocytoma, acute emotional distress, exogenous administration of catecholamines, and non-related surgery. Given the common features of this catecholamine-mediated myocardial insult, we ask if brain-dead donor heart dysfunction is an extreme variant of stress cardiomyopathy? And, if so is it, like stress cardiomyopathy, reversible? Can we therefore expect recovery of the dysfunctional donor heart over time, thereby permitting increased use of hearts offered for transplantation? J Heart Lung Transplant 2010;29:957-65 (C) 2010 International Society for Heart and Lung Transplantation All rights reserved.	[Berman, Marius; Ali, Ayyaz; Tsui, Steven; Parameshwar, Jayan; Large, Stephen] Papworth Hosp, Dept Cardiothorac Surg, Cambridge CB23 3RE, England; [Ashley, Euan] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Freed, Darren] Univ Manitoba, Dept Surg, Sch Med, Winnipeg, MB R3T 2N2, Canada; [Clarke, Kieran] Univ Oxford, Dept Physiol, Oxford, England		Large, S (corresponding author), Papworth Hosp, Dept Cardiothorac Surg, Cambridge CB23 3RE, England.	Stephen.Large@papworth.nhs.uk	Large, Stephen/AAW-4872-2021	Large, Stephen/0000-0002-3201-6344; Freed, Darren/0000-0002-6239-1444			Abraham J, 2009, J AM COLL CARDIOL, V53, P1320, DOI 10.1016/j.jacc.2009.02.020; Akashi YJ, 2008, CIRCULATION, V118, P2754, DOI 10.1161/CIRCULATIONAHA.108.767012; Ako J, 2006, AM J MED, V119, P10, DOI 10.1016/j.amjmed.2005.08.022; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; BHATIA SJS, 1987, CIRCULATION, V76, P819, DOI 10.1161/01.CIR.76.4.819; Brandspiegel HZ, 1998, CIRCULATION, V98, P1349, DOI 10.1161/01.CIR.98.13.1349; Bybee KA, 2004, ANN INTERN MED, V141, P858, DOI 10.7326/0003-4819-141-11-200412070-00010; Dujardin KS, 2001, J HEART LUNG TRANSPL, V20, P350, DOI 10.1016/S1053-2498(00)00193-5; Elesber AA, 2006, J AM COLL CARDIOL, V47, P1082, DOI 10.1016/j.jacc.2005.12.004; Ellison GM, 2007, J BIOL CHEM, V282, P11397, DOI 10.1074/jbc.M607391200; Hurst RT, 2006, J AM COLL CARDIOL, V48, P579, DOI 10.1016/j.jacc.2006.06.015; Kneale BJ, 2000, J AM COLL CARDIOL, V36, P1233, DOI 10.1016/S0735-1097(00)00849-4; Kothavale A, 2006, NEUROCRIT CARE, V4, P199, DOI 10.1385/NCC:4:3:199; Lee VH, 2006, J NEUROSURG, V105, P264, DOI 10.3171/jns.2006.105.2.264; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MAYER SA, 1995, J NEUROSURG, V83, P889, DOI 10.3171/jns.1995.83.5.0889; MORI H, 1993, CARDIOVASC RES, V27, P192, DOI 10.1093/cvr/27.2.192; NOVITZKY D, 1989, TRANSPLANT P, V21, P2567; NOVITZKY D, 1986, ANN THORAC SURG, V41, P520, DOI 10.1016/S0003-4975(10)63032-9; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Riera Maria, 2010, J Trauma, V68, pE13, DOI 10.1097/TA.0b013e3181469d5b; Sanchez-Recalde A, 2006, CIRCULATION, V113, pE738, DOI 10.1161/CIRCULATIONAHA.105.581108; Sato M, 2006, CIRC J, V70, P947, DOI 10.1253/circj.70.947; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Stoica SC, 2004, TRANSPLANTATION, V78, P1193, DOI 10.1097/01.TP.0000137792.74940.4F; Stoica SC, 2003, EUR J CARDIO-THORAC, V23, P503, DOI 10.1016/S1010-7940(03)00019-8; Stoica SC, 2006, J THORAC CARDIOV SUR, V132, P116, DOI 10.1016/j.jtcvs.2005.12.061; Szabo G, 1998, EUR J CARDIO-THORAC, V13, P449, DOI 10.1016/S1010-7940(98)00049-9; TALAJ JA, 2007, J AM COLL CARDIOL, V50, P1064; Taylor DO, 2008, J HEART LUNG TRANSPL, V27, P943, DOI 10.1016/j.healun.2008.06.017; Van de Walle SOA, 2006, MAYO CLIN PROC, V81, P1499, DOI 10.4065/81.11.1499; VANTRIGT P, 1995, ANN SURG, V221, P666; VANVLIET PD, 1966, NEW ENGL J MED, V274, P1102, DOI 10.1056/NEJM196605192742002; WHITE M, 1995, CIRCULATION, V92, P2183, DOI 10.1161/01.CIR.92.8.2183; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; Yoshikawa D, 1999, ANESTH ANALG, V89, P962; Zaroff JG, 2006, STROKE, V37, P1680, DOI 10.1161/01.STR.0000226461.52423.dd	39	40	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1053-2498	1557-3117		J HEART LUNG TRANSPL	J. Heart Lung Transplant.	SEP	2010	29	9					957	965		10.1016/j.healun.2010.04.008			9	Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation	645VR	WOS:000281494800001	20627624				2022-02-06	
J	Broglio, SP; Vagnozzi, R; Sabin, M; Signoretti, S; Tavazzi, B; Lazzarino, G				Broglio, Steven P.; Vagnozzi, Roberto; Sabin, Matthew; Signoretti, Stefano; Tavazzi, Barbara; Lazzarino, Giuseppe			Concussion occurrence and knowledge in Italian football (soccer)	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						Mild traumatic brain injury; symptoms	HIGH-SCHOOL FOOTBALL; METABOLIC BRAIN VULNERABILITY; FOR-DISEASE-CONTROL; RECURRENT CONCUSSION; INTERNATIONAL-CONFERENCE; NEUROCOGNITIVE FUNCTION; TEMPORAL WINDOW; SPORT; PLAYERS; EPIDEMIOLOGY	The purpose of the study was to investigate concussion history, knowledge, injury identification, and management strategies among athletes, coaches, and medical staff in Italian club level football (soccer) clubs. Surveys (N= 727) were distributed among Italian football clubs. Athletes' surveys were designed to evaluate athlete knowledge of concussive signs and symptoms and injury reporting. Coaches' surveys explored the understanding of concussive signs and symptoms and management practices. Medical staff surveys explored the standard of care regarding concussions. A total of 342 surveys were returned, for a 47% response rate. Descriptive analyses indicated 10% of athletes sustaining a concussion in the past year and 62% of these injuries were not reported, primarily due to the athletes not thinking the injury was serious enough. Coaches consistently identified non-concussion related symptoms (98.7%), but were unable to identify symptoms associated with concussion (38.9%). Most understood that loss of consciousness is not the sole indicator of injury (82.6%). Medical staff reported a heavy reliance on the clinical exam (92%) and athlete symptom reports (92%) to make the concussion diagnosis and return to play decision, with little use of neurocognitive (16.7%) or balance (0.0%) testing. Italian football athletes appear to report concussions at a rate similar to American football players, with a slightly higher rate of unreported injuries. Most of these athletes were aware they were concussed, but did not feel the injury was serious enough to report. Although coaches served as the primary person to whom concussions were reported, the majority of coaches were unable to accurately identify concussion related symptoms. With little use for neurocognitive and postural control assessments, the medical personnel may be missing injuries or returning athletes to play too soon. Collectively, these findings suggest that athletes, coaches, and medical personnel would benefit from concussion based educational materials on the signs, symptoms, and evaluative techniques of concussion.	[Broglio, Steven P.; Sabin, Matthew] Univ Illinois, Neurotrauma Res Lab, Urbana, IL USA; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Rome, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy		Broglio, SP (corresponding author), Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61820 USA.	broglio@illinois.edu	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279	William and Flora Hewlett Foundation; Italian Ministry of University and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [2007JBHZ5F]	The authors would like to thank the William and Flora Hewlett Foundation for supporting Dr. Broglio and the Italian Ministry of University and Research [(MIUR) PRIN 2007JBHZ5F] for their support of Dr. Vagnozzi and Dr. Tavazzi. In addition, we would like to thank Eren Havrilak for her assistance.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P934; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; *FIFA, 2008, BIG COUNT; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Onate JA., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	34	40	40	0	19	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	SEP	2010	9	3					418	430					13	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	748AF	WOS:000289361700010	24149636				2022-02-06	
J	Chevignard, MP; Catroppa, C; Galvin, J; Anderson, V				Chevignard, Mathilde P.; Catroppa, Cathy; Galvin, Jane; Anderson, Vicki			Development and Evaluation of an Ecological Task to Assess Executive Functioning Post Childhood TBI: The Children's Cooking Task	BRAIN IMPAIRMENT			English	Article						child; traumatic brain injury; executive functions; ecological assessment; naturalistic task; validity	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; PERFORMANCE-BASED MEASURES; FRONTAL-LOBE DAMAGE; YOUNG-CHILDREN; HEAD TRAUMA; OUTCOMES; VALIDITY; TESTS; DEFICITS	Purpose: Traumatic brain injury (TBI) often leads to executive functions deficits, which may be responsible for severe and longstanding disabilities in everyday activities. Sensitivity and ecological validity of neuropsychological tests of executive functions have been questioned. The aims of this study were to pilot an ecological open-ended assessment of executive functions in children, the 'Children's Cooking Task' (CCT), specifically to report its reliability, discriminant validity and concurrent validity. Methods: Twenty-five children with mild (n = 10) or moderate-to-severe TBI (n = 15), and 21 matched controls (aged 8 to 20 years) participated in the study. An open-ended cooking task was designed to test multi-tasking abilities. It required the preparation of two simple recipes using specific instructions. Outcome measures included the number of errors and an overall qualitative analysis of the task. Validating measures of executive functions included the Delis Kaplan Executive Function System, the Six-Part Test and two questionnaires completed by the child's primary care-giver: the Behavior Rating Inventory of Executive Function and the Dysexecutive Questionnaire for Children. Results: Internal consistency of the Children's Cooking Task was high (Cronbach's alpha = .86), as was test-retest reliability (ICC = .89). Children with moderate-to-severe TBI, as well as children with mild TBI made significantly more errors in the Children's Cooking Task in comparison to controls (p < .001). The CCT was correlated with several tests and one questionnaire of executive functioning (Trails, verbal fluency, sorting, 20 questions, Dysexecutive Questionnaire). Discussion and Conclusion: The Children's Cooking Task has good interrater and test-retest reliability, as well as good discriminant and concurrent validity.	[Chevignard, Mathilde P.] Hop Natl St Maurice, Rehabil Dept Children Acquired Brain Injuries, 14 Rue Val dOsne, F-94410 St Maurice, France; [Chevignard, Mathilde P.] Univ Paris 06, Grp Hosp Pitie, ER UPMC 6, F-75252 Paris 05, France; [Chevignard, Mathilde P.; Catroppa, Cathy; Galvin, Jane; Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Galvin, Jane] La Trobe Univ, Sch Occupat Therapy, Melbourne, Vic, Australia; [Galvin, Jane] Royal Childrens Hosp, Victorian Paediat Rehabil Serv, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic 3010, Australia		Chevignard, MP (corresponding author), Hop Natl St Maurice, Rehabil Dept Children Acquired Brain Injuries, 14 Rue Val dOsne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436	Hopital National de Saint Maurice, France; University Paris 6; 'France Traumatisme Cranien - Societe Francaise de Medecine Physique et de Readaptation' (FTC-SOFMER); 'Societe Francophone d'Etude et de Recherche sur les Handicaps de l'Enfance' (SFERHE)	This work was supported by the Hopital National de Saint Maurice, France; by the University Paris 6, and by two grants awarded by 'France Traumatisme Cranien - Societe Francaise de Medecine Physique et de Readaptation' (FTC-SOFMER) and 'Societe Francophone d'Etude et de Recherche sur les Handicaps de l'Enfance' (SFERHE).	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Atchison BT, 1998, AM J OCCUP THER, V52, P843, DOI 10.5014/ajot.52.10.843; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Chapparo C., 1997, OCCUPATIONAL PERFORM, V1, P189; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cohen J., 2013, STAT POWER ANAL BEHA; Crowe L., 2009, INT NEUR SOC MIDY M, P51; Daniel A., 1983, POWER PRIVILEGE PRES; Delis DC., 2001, DELIS KAPLAN EXECUTI; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Emslie H, 2003, BEHAV ASSESMENT DYSE; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fry K, 2002, AUSTR OCCUPATIONAL T, V49, P182, DOI 10.1046/j.1440-1630.2002.00337.x; Garth J, 1997, Pediatr Rehabil, V1, P99; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA IP, 2000, BEHAV RATING INVENTO; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Masson F, 1996, ARCH PEDIATRIE, V3, P651, DOI 10.1016/0929-693X(96)87085-0; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Nybo T, 1999, BRAIN INJURY, V13, P759; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Rocke K, 2008, AM J OCCUP THER, V62, P528, DOI 10.5014/ajot.62.5.528; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sharples PM, 1998, INJURY YOUNG, V263-299; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sullivan J, 2006, FORTUNE, V154, P21; TEASDALE G, 1974, LANCET, V2, P81; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129	67	40	40	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	SEP	2010	11	2			SI		125	143		10.1375/brim.11.2.125			19	Clinical Neurology; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	V24IS	WOS:000208404700004					2022-02-06	
J	Ferraris, VA; Ferraris, SP; Saha, SP				Ferraris, Victor A.; Ferraris, Suellen P.; Saha, Sibu P.			The Relationship Between Mortality and Preexisting Cardiac Disease in 5,971 Trauma Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	94th Annual Clinical Congress of the American-College-of-Surgeons (ACS) / 63rd Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical Problems	OCT 12-16, 2008	San Francisco, CA	Amer Coll Surg (ACS)		Trauma; Cardiac risk factors; Mortality; Logistic regression; Propensity score; Congestive heart failure; Adrenergic beta-antagonists; Warfarin; Clopidogrel	PREINJURY WARFARIN USE; BETA-BLOCKER EXPOSURE; ACTIVATED FACTOR-VII; INTENSIVE-CARE-UNIT; INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; BRAIN-INJURY; HEAD-INJURIES; ANTICOAGULATION; EFFICACY	Background: We observed significant morbidity and mortality in patients with preexisting cardiac disease who suffer severe traumatic injuries. We wondered about the types of injury seen and about the cardiac risks factors that predispose to worse outcomes in these patients. Our hypothesis is that significant cardiac comorbidity is associated with adverse trauma outcomes. Methods: We reviewed 10,144 trauma admissions to the University of Kentucky during a 5-year period (2002-2007) in patients 21 years or older. The types and extent of injuries were characterized, and risk factors for poor outcome were assessed. Propensity analysis assessed variable interaction and adjusted for important multivariate cardiovascular risk factors. Results: Of the 10,144 adult trauma patients, there was adequate cardiovascular history before emergency treatment in 5,971 patients (58.9%). Of the 700 trauma deaths, 236 (33.7%) had adequate medical history to allow accurate assessment of cardiovascular disease. Significant multivariate predictors of trauma-related death included older age (odds ratio [OR] = 0.938), injury severity score (OR = 0.893 per unit score), major burn (OR = 5.907), assault with a weapon (OR = 3.205), systolic blood pressure divided by Glasgow coma score (OR = 0.958 per score unit), and female (OR = 1.629). In the cohort of 236 deaths with adequate medical history, severe head and chest injuries caused death in 187 patients (79.2%). Significant propensity-adjusted cardiovascular risks of trauma death included preinjury warfarin use (OR = 2.309, p = 0.001), congestive heart failure (CHF) (OR = 2.060, p = 0.011), and preinjury beta-blocker use (OR = 2.62, p = 0.001). The highest mortality rates occurred in patients with combinations of these cardiovascular risk factors. For example, patients on warfarin with CHF had a 26.3% mortality rate, whereas patients on warfarin and beta-blocker had a 27.3% mortality rate. Conclusions: Preinjury cardiac risk factors, especially preinjury warfarin, beta-blocker use, and CHF, are independent multivariate predictors of mortality in patients suffering significant trauma. Although head and chest injuries are the most frequent causes of death, patients with more than one preinjury cardiac risk factor have 5 to 10 times the mortality risk compared with those without cardiac risks.	[Ferraris, Victor A.] Univ Kentucky, Div Cardiovasc & Thorac Surg, Kentucky Clin A301, Dept Surg, Lexington, KY 40536 USA; [Ferraris, Victor A.; Ferraris, Suellen P.] Lexington Vet Affairs Med Ctr, Dept Surg, Lexington, KY USA		Ferraris, VA (corresponding author), Univ Kentucky, Div Cardiovasc & Thorac Surg, Kentucky Clin A301, Dept Surg, 740 S Limestone, Lexington, KY 40536 USA.	ferraris@earthlink.net					Alexander JQ, 2000, AM SURGEON, V66, P855; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Asensio JA, 2001, AM J SURG, V182, P743, DOI 10.1016/S0002-9610(01)00809-1; Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329; Blow O, 1999, J TRAUMA, V47, P964, DOI 10.1097/00005373-199911000-00028; Chang MC, 2000, J TRAUMA, V49, P26, DOI 10.1097/00005373-200007000-00004; Chiu W, 2007, J TRAUMA, V63, P510; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Enderson BL, 2007, J TRAUMA, V62, P33; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Friese RS, 2008, J TRAUMA, V64, P1061, DOI 10.1097/TA.0b013e3181684cf0; Gage BF, 2006, ARCH INTERN MED, V166, P241, DOI 10.1001/archinte.166.2.241; Grandhi R, 2008, AM SURGEON, V74, P802; Hardy JF, 2008, ANN THORAC SURG, V86, P1038, DOI 10.1016/j.athoracsur.2008.05.013; Hui T, 2002, AM SURGEON, V68, P1111; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ityas C, 2008, J CLIN ANESTH, V20, P276, DOI 10.1016/j.jclinane.2007.12.012; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Jafary FH, 2005, ACTA CARDIOL, V60, P557, DOI 10.2143/AC.60.5.2004980; Kalina M, 2008, AM SURGEON, V74, P858; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; London JA, 2006, SURG CLIN N AM, V86, P1503, DOI 10.1016/j.suc.2006.08.003; Macdonald DJM, 2006, POSTGRAD MED J, V82, DOI 10.1136/pgmj.2006.047381; Mallarkey G, 2008, DRUGS, V68, P1665, DOI 10.2165/00003495-200868120-00005; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Neideen T, 2008, J TRAUMA, V65, P1016, DOI 10.1097/TA.0b013e3181897eac; Paladino L, 2008, RESUSCITATION, V77, P363, DOI 10.1016/j.resuscitation.2008.01.022; Parmar K. A., 2006, SMJ Singapore Medical Journal, V47, P676; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pryor JP, 2007, J TRAUMA, V62, P61; Raff T, 1996, Acta Chir Plast, V38, P122; Ranucci M, 2008, ARCH SURG-CHICAGO, V143, P296, DOI 10.1001/archsurg.2007.66; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Stanworth SJ, 2007, COCHRANE DB SYST REV, V2; Tharmarajah P, 2007, J ORTHOP TRAUMA, V21, P26, DOI 10.1097/BOT.0b013e31802c4f3c; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; You H, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub2	48	40	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					645	652		10.1097/TA.0b013e3181d8941d			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	649HX	WOS:000281760800040	20526211				2022-02-06	
J	Dhawan, J; Benveniste, H; Nawrocky, M; Smith, SD; Biegon, A				Dhawan, Jasbeer; Benveniste, Helene; Nawrocky, Marta; Smith, S. David; Biegon, Anat			Transient focal ischemia results in persistent and widespread neuroinflammation and loss of glutamate NMDA receptors	NEUROIMAGE			English	Article						Stroke; Autoradiography; beta-imager; [H-3]PK11195; [H-3]MK801; Microglia; Neuroinflammation	MIDDLE CEREBRAL-ARTERY; METHYL-D-ASPARTATE; CLOSED-HEAD INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; POSITRON-EMISSION-TOMOGRAPHY; BINDING-SITES; IN-VIVO; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; BRAIN-LESIONS	Stroke is accompanied by neuroinflammation in humans and animal models. To examine the temporal and anatomical profile of neuroinflammation and NMDA receptors (NMDAR) in a stroke model, rats (N=17) were subjected to a 90 min occlusion of the middle cerebral artery (MCAO) and compared to sham (N=5) and intact (N=4) controls. Striatal and parietal cortical infarction was confirmed by MRI 24 h after reperfusion. Animals were killed 14 or 30-40 days later and consecutive coronal cryostat sections were processed for quantitative autoradiography with the neuroinflammation marker [H-3]PK11195 and the NMDAR antagonist [H-3]MK801. Significantly increased specific binding of [H-3]PK11195 relative to nonischemic controls was observed in the ipsilateral striatum (>3 fold, p 0.0001), substantia innominata (>2 fold) with smaller (20%-80%) but statistically significant (p = 0.002-0.04) ipsilateral increases in other regions partially involved in the infarct such as the parietal and piriform cortex, and in the lateral septum, which was not involved in the infarct. Trends for increases in PBR density were also observed in the contralateral hemisphere. In the same animals, NMDAR specific binding was significantly decreased bilaterally in the septum, substantia innominata and ventral pallidum. Significant decreases were also seen in the ipsilateral striatum, accumbens, frontal and parietal cortex. The different anatomical distribution of the two phenomena suggests that neuroinflammation does not cause the observed reduction in NMDAR, though loss of NMDAR may be locally augmented in ipsilateral regions with intense neuroinflammation. Persistent, bilateral loss of NMDAR, probably reflecting receptor down regulation and internalization, may be responsible for some of the effects of stroke on cognitive function which cannot be explained by infarction alone. Published by Elsevier Inc.	[Dhawan, Jasbeer; Benveniste, Helene; Nawrocky, Marta; Smith, S. David; Biegon, Anat] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; [Benveniste, Helene] SUNY Stony Brook, Dept Anesthesia, Stony Brook, NY 11794 USA		Biegon, A (corresponding author), Brookhaven Natl Lab, Dept Med, Bldg 490, Upton, NY 11973 USA.	biegon@bnl.gov			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 N5050285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	Supported in part by NIH RO1 N5050285 to Anat Biegon.	Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; BENAVIDES J, 1983, J NEUROCHEM, V41, P1744, DOI 10.1111/j.1471-4159.1983.tb00888.x; BENVENISTE H, 1991, STROKE, V22, P259, DOI 10.1161/01.STR.22.2.259; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Dalkara T, 1996, STROKE, V27, P127, DOI 10.1161/01.STR.27.1.127; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; Emsley HCA, 2008, NEUROCRIT CARE, V9, P125, DOI 10.1007/s12028-007-9035-x; FIORELLI M, 1991, J NEUROL SCI, V104, P135, DOI 10.1016/0022-510X(91)90302-N; Gerhard A, 2000, NEUROREPORT, V11, P2957, DOI 10.1097/00001756-200009110-00025; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; HAEFELIN TN, 2000, STROKE, V31, P1965; Hochstenbach J, 1998, CLIN REHABIL, V12, P514, DOI 10.1191/026921598666870672; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P128, DOI 10.1016/0165-6147(91)90527-Y; Koizumi J, 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Li S, 2010, NEUROSCI LETT, V470, P106, DOI 10.1016/j.neulet.2009.12.064; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; OGAWA N, 1991, NEUROCHEM RES, V16, P519, DOI 10.1007/BF00974869; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; PENNEY JB, 1990, J NEUROL NEUROSUR PS, V53, P314, DOI 10.1136/jnnp.53.4.314; Pera J, 2004, J NEUROSCI RES, V78, P132, DOI 10.1002/jnr.20232; Peters O, 1998, J CEREBR BLOOD F MET, V18, P196, DOI 10.1097/00004647-199802000-00011; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rojas S, 2007, J CEREBR BLOOD F MET, V27, P1975, DOI 10.1038/sj.jcbfm.9600500; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rossini PM, 2003, LANCET NEUROL, V2, P493, DOI 10.1016/S1474-4422(03)00485-X; RYCK MD, 2000, NEUROPHARMACOLOGY, V39, P691; Schroeter M, 2009, J CEREBR BLOOD F MET, V29, P1216, DOI 10.1038/jcbfm.2009.36; SETTE G, 1993, STROKE, V24, P2046, DOI 10.1161/01.STR.24.12.2046; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sobesky J, 2005, J CEREBR BLOOD F MET, V25, P1685, DOI 10.1038/sj.jcbfm.9600162; Spratt NJ, 2006, J NEUROSCI METH, V155, P285, DOI 10.1016/j.jneumeth.2006.01.020; Sunderland A, 1999, STROKE, V30, P949, DOI 10.1161/01.STR.30.5.949; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tsubokawa T, 2006, J NEUROSCI RES, V84, P832, DOI 10.1002/jnr.20977; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; WANG KM, 2000, STROKE, V31, P2055; Weber R, 2006, J CEREBR BLOOD F MET, V26, P591, DOI 10.1038/sj.jcbfm.9600241; Wiart M, 2007, STROKE, V38, P131, DOI 10.1161/01.STR.0000252159.05702.00; Wu O, 2007, J CEREBR BLOOD F MET, V27, P196, DOI 10.1038/sj.jcbfm.9600328; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhu DM, 2005, J NEUROSCI RES, V80, P104, DOI 10.1002/jnr.20422	57	40	46	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUN	2010	51	2					599	605		10.1016/j.neuroimage.2010.02.073			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	589IT	WOS:000277141200010	20206701	Green Accepted			2022-02-06	
J	Tanriverdi, F; Unluhizarci, K; Karaca, Z; Casanueva, FF; Kelestimur, F				Tanriverdi, F.; Unluhizarci, K.; Karaca, Z.; Casanueva, F. F.; Kelestimur, F.			Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers	PITUITARY			English	Article						Boxing; Traumatic brain injury; Growth hormone; Head trauma; Hypopituitarism	GH DEFICIENCY; BRAIN-INJURY; ADULTS	Traumatic brain injury (TBI) has been recently recognized as a leading cause of pituitary dysfunction. Current data clearly demonstrated that sports related head trauma due to boxing, kickboxing, and soccer might results in pituitary hormone deficiencies, isolated growth hormone (GH) deficiency in particular. In the present report physiologic dose GH replacement therapy (GHRT) was performed in two GH deficient retired amateur boxers for the first time. The boxers received recombinant GH for 6 months. After 6 months of GHRT there were substantial improvements, but not complete normalization, in the body composition parameters, lipid profiles and quality of life scores in both boxers. These preliminary results suggest that GHRT may have beneficial effects in retired boxers with severe isolated GH deficiency due to sports related head trauma. But more data with higher number of boxers and longer GHRT duration are warranted.	[Tanriverdi, F.; Unluhizarci, K.; Karaca, Z.; Kelestimur, F.] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Casanueva, F. F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	Karaca, Zuleyha/ABB-7891-2021; kelestimur, f/ABE-9873-2021				[Anonymous], 1998, J CLIN ENDOCRINOL ME, V83, P379; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi Fatih, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P131, DOI 10.1586/14737167.6.2.131; Tanriverdi F, 2008, OBES METAB-MILAN, V4, P118; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x	10	40	41	1	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	JUN	2010	13	2					111	114		10.1007/s11102-009-0204-0			4	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	584RS	WOS:000276770900003	19847653				2022-02-06	
J	Thomas, BW; Mejia, VA; Maxwell, RA; Dart, BW; Smith, PW; Gallagher, MR; Claar, SC; Greer, SH; Barker, DE				Thomas, Bradley W.; Mejia, Vicente A.; Maxwell, Robert A.; Dart, Benjamin W.; Smith, Philip W.; Gallagher, Michael R.; Claar, Sean C.; Greer, Stephen H.; Barker, Donald E.			Scheduled Repeat CT Scanning for Traumatic Brain Injury Remains Important in Assessing Head Injury Progression	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	121st Annual Meeting of the Southern-Surgical-Association	DEC, 2009	Hot Springs, VA	SE Surg Assoc			SERIAL COMPUTED-TOMOGRAPHY; HEMORRHAGE; MANAGEMENT; HEMATOMAS; UTILITY; CLASSIFICATION; DIAGNOSIS; CHILDREN; MODERATE; SCANS	BACKGROUND: Scheduled repeat brain CT (SRBCT) is used to monitor progression of traumatic brain injury (TBI). Previous studies have suggested that routine SRBCT can be replaced by an unscheduled repeat brain CT after deterioration on serial neurological examination. In this study, we evaluated if SRBCT has a role in the management of TBI. STUDY DESIGN: Retrospective observational study of 1,019 consecutive adult patients admitted to a Level I trauma center with CT evidence of TBI on initial brain CT (IBCT). All patients with intracranial pathology on IBCT were scheduled for SRBCT and underwent sequential neurological physical examinations. Interventions (surgical or medical) after IBCT SRBCT, or neurological change were recorded. RESULTS: One thousand nineteen patients with IBCT evidence of TBI were identified from the trauma registry during a 50-month study period beginning in November 2001. Eighty-six (8.9%) of these patients went directly for craniotomy. After exclusions, 887 patients were analyzed. A total of 692 (78%) patients had a no worse first SRBCT and neurologic changes requiring intervention later developed in 11 (1.6%) of these patients. One hundred ninety-five (22%) patients had a worse first SRBCT, with 14 (7.2%) requiring immediate intervention. Seven (3.6%) worse first SRBCT patients had a subsequent SRBCT that worsened, leading to an intervention. A neurologic change that precipitated an intervention developed subsequently in an additional 19 (9.7%) patients with a worse first SRBCT. Chi-square analysis demonstrated that a first SRBCT that was worse was more likely to result in an intervention than if the first SRBCT was no worse. CONCLUSIONS: A worse SRBCT is more likely to result in neurologic intervention. SRBCT remains useful in assessing patients with TBI. (J Am Coll Surg 2010;210:824-832. (C) 2010 by the American College of Surgeons)	[Thomas, Bradley W.; Mejia, Vicente A.; Maxwell, Robert A.; Dart, Benjamin W.; Smith, Philip W.; Gallagher, Michael R.; Claar, Sean C.; Greer, Stephen H.; Barker, Donald E.] Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, Chattanooga, TN 37401 USA		Thomas, BW (corresponding author), Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, 979 E 3rd St,Suite 401, Chattanooga, TN 37401 USA.	bradley.w.thomas@gmail.com					Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Camins M B, 1996, Bull Am Coll Surg, V81, P16; Camins MB, 1996, B AM COLL SURG, V81, P47; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Cooper P R, 1992, Neurosurg Clin N Am, V3, P659; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; HUNEIDI AHS, 1992, ANN ROY COLL SURG, V74, P345; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PARK H, 2009, BR J NEUROSURG  0804, P1; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Shackford SR, 2004, J TRAUMA, V56, P480; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sinson G, 2001, J TRAUMA, V51, P875; Stearley H E, 1998, Am J Crit Care, V7, P282; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; TEASDALE G, 1974, LANCET, V2, P81; Vano E, 1998, BRIT J RADIOL, V71, P728, DOI 10.1259/bjr.71.847.9771383; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; 2006, MMWR MORB MORTAL WKL, V55, P201	48	40	45	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2010	210	5					824	830		10.1016/j.jamcollsurg.2009.12.039			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	594HZ	WOS:000277528700058	20421059				2022-02-06	
J	Levy, AS; Salottolo, K; Bar-Or, R; Offner, P; Mains, C; Sullivan, M; Bar-Or, D				Levy, Andrew Stewart; Salottolo, Kristin; Bar-Or, Raphael; Offner, Patrick; Mains, Charles; Sullivan, Michael; Bar-Or, David			Pharmacologic Thromboprophylaxis Is a Risk Factor for Hemorrhage Progression in a Subset of Patients With Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Prophylaxis; Traumatic brain injury; Thromboembolism; Lovenox; Intracranial hemorrhage	VENOUS THROMBOEMBOLISM PROPHYLAXIS; MOLECULAR-WEIGHT HEPARIN; HEAD COMPUTED-TOMOGRAPHY; NONOPERATIVE MANAGEMENT; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; DATA-BANK; SAFETY; PATTERNS; FAILURE	Background: Pharmacologic thromboprophylaxis (PTP) may exacerbate intracranial hemorrhage (ICH) in patients with traumatic brain injury (TBI). We examined risk factors for hemorrhage progression in patients with blunt TBI and hypothesized that PTP would increase ICH progression in a subset of these patients. Methods: We retrospectively studied patients with TBI admitted to our level I trauma center during 19 months. Progression of hemorrhage was examined in two populations: patients with a stable initial follow-up (F/U) computed tomography (CT) and patients with hemorrhage progression on initial F/U CT. Risk factors potentially associated with hemorrhage progression were analyzed using logistic regression. Timing of PTP was defined two ways: exposed to PTP versus not exposed; early (<72 hours), late (>= 72 hours), or no PTP. Results: Three hundred forty patients with TBI were reviewed and hemorrhage progression occurred in 32.4% (n = 110) of patients of which 59.1% were considered clinically significant. In patients with ICH progression on initial F/U CT, predictors of subsequent hemorrhage progression include exposure to PTP (odds ratio [OR]: 13.07, p = 0.01), extradural/subdural hemorrhage (OR: 5.15, p = 0.03), Glasgow Coma Score 3-8 (OR: 4.64, p = 0.03), and body mass index >= 25 (OR = 4.32, p = 0.03). PTP was not significantly associated with hemorrhage progression in patients with a stable initial F/U CT. Conclusions: These findings suggest that PTP use is associated with a 13-fold increased odds of further hemorrhage progression in patients whose F/U CT within 1 day of admission showed ICH progression; 16% of this risk can be attributed to receiving PTP. Conversely, PTP may be safe in a subgroup of patients with TBI with no ICH progression on initial F/U CT.	[Salottolo, Kristin; Bar-Or, Raphael; Sullivan, Michael; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Salottolo, Kristin; Bar-Or, Raphael; Offner, Patrick; Mains, Charles; Sullivan, Michael; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Offner, Patrick; Mains, Charles] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Mains, Charles; Bar-Or, David] Rocky Vista Univ, Aurora, CO USA		Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020				*BRAIN TRAUM FDN A, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Peitzman A, 2000, J TRAUMA, V48, P374; Rogers SO, 2007, J TRAUMA, V62, P562; Shackford SR, 2004, ANN SURG, V240, P496; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	20	40	41	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					886	892		10.1097/TA.0b013e3181d27dd5			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	583GY	WOS:000276663100026	20386284				2022-02-06	
J	Garden, N; Sullivan, KA; Lange, RT				Garden, Natalie; Sullivan, Karen A.; Lange, Rael T.			The Relationship Between Personality Characteristics and Postconcussion Symptoms in a Nonclinical Sample	NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; postconcussion syndrome; personality; MMCI-III; BC-PSI	TRAUMATIC BRAIN-INJURY; CLINICAL MULTIAXIAL INVENTORY; POST-CONCUSSION SYNDROME; EMOTIONAL RISK-FACTORS; COMPLAINT BASE RATES; MILD HEAD-INJURY; MCMI-III; MISERABLE MINORITY; CHRONIC PAIN; DEPRESSION	Postconcussion symptoms are relatively common in the acute recovery period following mild traumatic brain injury. However, for a small subset of patients, self reported postconcussion symptoms continue long after injury. Many factors have been proposed to account for the presence of persistent postconcussion symptoms. The influence of personality traits has been proposed as one explanation, The purpose of this study was to examine the relation between postconcussion-like symptom reporting and personality traits in a sample of 96 healthy participants. Participants completed the British Columbia Postconcussion Symptom Inventory and the Millon Clinical Multiaxial Inventory III (MCMI-III). There was a strong positive relation between the majority of MCMI-III scales and postconcussion-like symptom reporting. Approximately half of the sample met the International Classification of Diseases-10 Criterion C symptoms for Postconcussional Syndrome. Compared with those participants who did not meet this criterion, the PCS group had significant elevations on the negativistic, depression, major depression, dysthymia, anxiety, dependent, sadistic, somatic, and borderline scales of the MCMI-Ill. These findings support the hypothesis that personality traits can play a contributing role in self reported postconcussion symptoms.	[Garden, Natalie; Sullivan, Karen A.] Queensland Univ Technol, Sch Psychol & Counselling, Clin Neuropsychol Res Grp, Kelvin Grove 4059, Australia; [Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove 4059, Australia; [Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada		Sullivan, KA (corresponding author), Queensland Univ Technol, Sch Psychol & Counselling, Clin Neuropsychol Res Grp, Victoria Pk Rd, Kelvin Grove 4059, Australia.	karen.sullivan@qut.edu.au			School of Psychology and Counselling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (Approval No. 0700000965) approved all research documented in this report. Funding for this project was provided by the School of Psychology and Counselling, Queensland University of Technology. We acknowledge the generous assistance of Patricia Obst, statistics consultant, Queensland University of Technology.	Aluja A, 2007, INT J CLIN HLTH PSYC, V7, P307; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blood L, 2008, J FORENSIC PSYCHOL P, V8, P24, DOI 10.1080/15228930801947286; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 2013, STAT POWER ANAL BEHA; Craig R.J., 2005, NEW DIRECTIONS INTER; Craig RJ, 1997, SUBST USE MISUSE, V32, P1385, DOI 10.3109/10826089709039384; CRAIG RJ, 1992, J SUBST ABUSE TREAT, V9, P249, DOI 10.1016/0740-5472(92)90068-Y; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GARDEN NA, APPL NEUROP IN PRESS; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gondolf EW, 1999, J FAM VIOLENCE, V14, P1, DOI 10.1023/A:1022843324943; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HAGGARD R, 2008, J PAIN, V9, P67; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; HOLLIMAN NB, 1989, J CLIN PSYCHOL, V45, P373, DOI 10.1002/1097-4679(198905)45:3<373::AID-JCLP2270450305>3.0.CO;2-R; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; King AR, 1998, J PERS ASSESS, V71, P253, DOI 10.1207/s15327752jpa7102_12; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Manchikanti Laxmaiah, 2002, Pain Physician, V5, P40; McCann J.T., 2001, J FORENSIC PSYCHOL P, V1, P27, DOI [https://doi.org/10.1300/J158v01n02_02, DOI 10.1300/J158V01N02_02]; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Millon T., 2006, MILLON CLIN MULTIAXI, VThird; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; REPKO GP, 1985, J CLIN PSYCHOL, V43, P478; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruocco AC, 2007, BRAIN INJURY, V21, P1233, DOI 10.1080/02699050701716919; Ruocco AC, 2007, J NEUROPSYCH CLIN N, V19, P27, DOI 10.1176/appi.neuropsych.19.1.27; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Rush BK, 2004, REHABIL PSYCHOL, V49, P275, DOI 10.1037/0090-5550.49.4.275; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; TUOKKO H, 1991, Brain Injury, V5, P287, DOI 10.3109/02699059109008098; VANEM P, 2007, SCAND J PSYCHOL, V49, P83; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WATSON DC, 1995, PERS INDIV DIFFER, V19, P817, DOI 10.1016/S0191-8869(95)00130-1; WIERZBICKI M, 1993, J CLIN PSYCHOL, V49, P204, DOI 10.1002/1097-4679(199303)49:2<204::AID-JCLP2270490211>3.0.CO;2-W; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2004, ICD 10 INT STAT CLAS	74	40	40	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					168	175		10.1037/a0017431			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100005	20230111	Green Submitted			2022-02-06	
J	Helton, WS; Weil, L; Middlemiss, A; Sawers, A				Helton, William S.; Weil, Lena; Middlemiss, Annette; Sawers, Andrew			Global interference and spatial uncertainty in the Sustained Attention to Response Task (SART)	CONSCIOUSNESS AND COGNITION			English	Article						Attention; Impulsivity; Mindlessness; Speed-accuracy trade-offs; Sustained attention; Vigilance	TRAUMATIC BRAIN-INJURY; SENSITIVITY DECREMENT; SIGNAL SALIENCE; VIGILANCE; MINDLESSNESS; PERFORMANCE; LAPSES; MIND; PERCEPTION; FAILURES	The Sustained Attention to Response Task (SART) is a Go-No-Go signal detection task developed to measure lapses of sustained conscious attention. In this Study, we examined the impact global interference and spatial uncertainty has oil SART performance. Tell participants performed either a SART (high-Go) or a traditionally formatted (low-Go) version of a global-local stimuli detection task with spatially certain and uncertain signals Reaction time in the SART was insensitive to global interference and spatial uncertainty, whereas reaction time in the low-Go task was sensitive Spatial uncertainty increased errors of omission in the SART, which was not expected if the SART measures mindlessness There was a high correlation between participants' errors of commission rate and their reaction time in the SART The results. overall. support the view that the SART IF, a better measure of response strategy than lapses in sustained attention or mindlessness (C) 2010 Elsevier Inc All rights reserved	[Helton, William S.; Weil, Lena; Middlemiss, Annette; Sawers, Andrew] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand		Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.						BARTLETT MS, 1947, BIOMETRICS, V3, P39, DOI 10.2307/3001536; Cheyne J. A., 2009, CONSCIOUSNESS COGNIT; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Davies DR., 1982, PSYCHOL VIGILANCE; DICKMAN S, 1985, J PERS SOC PSYCHOL, V48, P133, DOI 10.1037/0022-3514.48.1.133; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Forster S, 2009, COGNITION, V111, P345, DOI 10.1016/j.cognition.2009.02.006; GIAMBRA LM, 1995, CONSCIOUS COGN, V4, P1, DOI 10.1006/ccog.1995.1001; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Grier RA, 2003, HUM FACTORS, V45, P349, DOI 10.1518/hfes.45.3.349.27253; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, ACTA PSYCHOL, V130, P204, DOI 10.1016/j.actpsy.2008.12.006; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Hitchcock EM, 1999, HUM FACTORS, V41, P365, DOI 10.1518/001872099779610987; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; MACKWORTH NH, 1950, 2680 MED RES COUNC; MacLean KA, 2009, ATTEN PERCEPT PSYCHO, V71, P1042, DOI 10.3758/APP.71.5.1042; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Matthews Gerald, 2000, HUMAN PERFORMANCE CO; Maxwell S., 2004, DESIGNING EXPT ANAL; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scerbo M. W., 1998, VIEWING PSYCHOL WHOL, P145, DOI [DOI 10.1037/10290-006, 10.1037/10290-006]; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm J. S., 1984, SUSTAINED ATTENTION, P1; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; WARM JS, 2008, PERFORMANCE STRESS, P116; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wickens C. D., 1993, WORKLOAD TRANSITION, P139; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	39	40	40	2	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100			CONSCIOUS COGN	Conscious. Cogn.	MAR	2010	19	1					77	85		10.1016/j.concog.2010.01.006			9	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	572FV	WOS:000275813800007	20138552				2022-02-06	
J	Bener, A; Omar, AOK; Ahmad, AE; Al-Mulla, FH; Rahman, YSA				Bener, Abdulbari; Omar, Azhar O. Kh.; Ahmad, Amal E.; Al-Mulla, Fatma H.; Rahman, Yassir S. Abdul			The pattern of traumatic brain injuries: A country undergoing rapid development	BRAIN INJURY			English	Article						Epidemiology and incidence; traumatic brain injury; morbidity; rehabilitation; mortality	EPIDEMIOLOGY	Background: Traumatic brain injuries (TBIs) remain an important public health problem in most industrial developed and especially in developing countries. This may also result in temporary or permanent disability. Objective: The aim of this study was to examine the trends in the distribution of traumatic brain injuries by gender, age, severity of injury and outcome and describe the incidence in the injury patterns. Design: This is a retrospective, descriptive, hospital-based study that included all cases of TBI during the period from January 2003 to December 2007. Patients and methods: This study is a retrospective analysis of 1919 patients with traumatic brain injury attended and treated at the Accident and Emergency Department of the Hamad General Hospital and other Trauma Centers of the Hamad Medical Corporation. Details of all TBI cases were extracted from the database of the Emergency Medical Services (EMS). Severity of TBI was assessed by Glasgow Coma Scale (GCS). Results: This study was based on 1919 patients suffering from traumatic brain injury, where 154 died and 97 (5.1%) of them died in the intensive care unit. The number of TBI cases increased remarkably in 2007 by 69.7%. However, the incidence rate was nearly stable across the years (4.2-4.9/10000 population). Of the total TBI cases, the majority of them were non-Qataris (72.7%) and men (88.6%). There was a significant increase in number of TBI cases between 2003 and 2007 in terms of age group (p = 0.003), nationality (p = 0.004) and severity of injuries (p = 0.05). The highest peak rate of TBI cases was observed among the population over 65 years old, followed by 15-24 year olds. Falls caused most TBIs in the 1-14 years age group, road traffic accidents in the age group 15-24 years and sports and recreation in the age group 25-34 years. Conclusion: The present study findings revealed that traumatic brain injury is a major public health problem, especially among young adults and older people. Although there was a sharp increase found in the number of TBI cases, the incidence rate of TBI took a stable trend during the study period.	[Bener, Abdulbari] Hamad Med Corp, Dept Epidemiol & Med Stat, Weill Cornell Med Coll, Hamad Gen Hosp, Doha, Qatar; [Bener, Abdulbari] Univ Manchester, Dept Evidence Populat Hlth Unit, Sch Epidemiol & Hlth Sci, Manchester, Lancs, England; [Omar, Azhar O. Kh.; Al-Mulla, Fatma H.] Hamad Med Corp, Dept Pediat, Doha, Qatar; [Ahmad, Amal E.] Hamad Med Corp, Speech Therapy Unit, Rehabil Dept, Doha, Qatar; [Rahman, Yassir S. Abdul] Hamad Med Corp, Dept Trauma Surg, Doha, Qatar		Bener, A (corresponding author), Hamad Med Corp, Dept Epidemiol & Med Stat, Weill Cornell Med Coll, Hamad Gen Hosp, POB 3050, Doha, Qatar.	abener@hmc.org.qa	BENER, ABDULBARI/AAC-4436-2020				Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bener Abdulbari, 2009, Int Emerg Nurs, V17, P52, DOI 10.1016/j.ienj.2008.07.007; Bener Abdulbari, 2007, Int J Inj Contr Saf Promot, V14, P103, DOI 10.1080/17457300701212033; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; HAMAD BA, 2008, ANN HLTH REPORT; Hannay HJ, 2004, NEUROPHYSIOLOGICAL A, P158; HANNAY HJ, NEUROPSYCHOLOGICAL A; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KLAUBER MR, 1978, AM J EPIDEMIOL, V1981, P500; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Melo JRT, 2004, ARQ NEURO-PSIQUIAT, V62, P711, DOI 10.1590/S0004-282X2004000400027; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tsai WC, 2004, J CLIN NEUROSCI, V11, P126, DOI 10.1016/S0967-5868(03)00156-5; *US DEP HHS, 1997, INT CLASS DIS; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zitnay GA, 2005, ACT NEUR S, V93, P131	25	40	41	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					74	80		10.3109/02699050903508192			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500002	20085444				2022-02-06	
J	Claus, CP; Tsuru-Aoyagi, K; Adwanikar, H; Walker, B; Whetstone, W; Noble-Haeusslein, LJ				Claus, Catherine P.; Tsuru-Aoyagi, Kyoko; Adwanikar, Hita; Walker, Breset; Whetstone, William; Noble-Haeusslein, Linda J.			Age Is a Determinant of Leukocyte Infiltration and Loss of Cortical Volume after Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Inflammation; Traumatic brain injury; Developing brain; Cell death	NITRIC-OXIDE SYNTHASE; GLUTATHIONE-PEROXIDASE ACTIVITY; HEME OXYGENASE-2 PROTEIN; IMMATURE BRAIN; RAT-BRAIN; REGIONAL VULNERABILITY; SUPEROXIDE-DISMUTASE; BARRIER PERMEABILITY; MOUSE-BRAIN; HEAD-INJURY	There is increasing evidence that the inflammatory response differs in the injured developing brain as compared to the adult brain. Here we compared cerebral blood flow and profiled the inflammatory response in mice that had been subjected to traumatic brain injury (TBI) at postnatal day (P)21 or at adulthood. Relative blood flow, determined by laser Doppler, revealed a 30% decrease in flow immediately after injury followed by prominent hyperemia between 7 and 35 days after injury in both age groups. The animals were euthanized at 1-35 days after injury and the brains prepared for the immunolocalization and quantification of CD45-, GR-1-, CD4- and CD8-positive (+) cells. On average, the number of CD45+ leukocytes in the cortex was significantly higher in the P21 as compared to the adult group. A similar trend was seen for GR-1+ granulocytes, whereas no age-related differences were noted for CD4+ and CD8+ cells. While CD45+ and GR-1+ cells in the P21 group remained elevated, relative to shams, over the first 2 weeks after injury, the adult group showed a time course limited to the first 3 days after injury. The loss of ipsilateral cortical volumes at 2 weeks after injury was significantly greater in the adult relative to the P21 group. While the adult group showed no further change in cortical volumes, there was a significant loss of cortical volumes between 2 and 5 weeks after injury in the P21 group, reaching values similar to that of the adult group by 5 weeks after injury. Together, these findings demonstrate age-dependent temporal patterns of leukocyte infiltration and loss of cortical volume after TBI. Copyright (C) 2010 S. Karger AG, Basel	[Claus, Catherine P.; Tsuru-Aoyagi, Kyoko; Adwanikar, Hita; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Walker, Breset; Whetstone, William] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabilitat Sci, San Francisco, CA 94143 USA		Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.	Linda.Noble@ucsf.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R21NS065937]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS065937, R01NS050159] Funding Source: NIH RePORTER	The authors thank Seong E. Koh (MD) and Hovhannes Manvelyan (MD) for their contributions to this project. The study was supported by NIH/NINDS grants No. R01NS050159 and R21NS065937.	Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LAWSON LJ, 1995, EUR J NEUROSCI, V7, P1584, DOI 10.1111/j.1460-9568.1995.tb01154.x; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maines MD, 1996, BRAIN RES, V722, P83, DOI 10.1016/0006-8993(96)00184-9; Mischel RE, 1997, NEUROSCI LETT, V231, P17, DOI 10.1016/S0304-3940(97)00531-4; Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, pR8; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Reed MG, 1998, J MICROSC-OXFORD, V190, P350; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Yoneyama-Sarnecky T, 2010, DEV NEUROSCI-BASEL, V32, P81, DOI 10.1159/000258700	45	40	40	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					454	465		10.1159/000316805			12	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900013	20847543	Green Published, Bronze			2022-02-06	
J	Couillet, J; Soury, S; Lebornec, G; Asloun, S; Joseph, PA; Mazaux, JM; Azouvi, P				Couillet, Josette; Soury, Stephane; Lebornec, Gaelle; Asloun, Sybille; Joseph, Pierre-Alain; Mazaux, Jean-Michel; Azouvi, Philippe			Rehabilitation of divided attention after severe traumatic brain injury: A randomised trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Divided attention; Traumatic brain injury; Cognitive rehabilitation	DUAL-TASK PERFORMANCE; WORKING-MEMORY; DEFICITS; IMPAIRMENTS	Patients with severe traumatic brain injury (TBI) frequently suffer from a difficulty in dealing with two tasks simultaneously. However, there has been little research on the rehabilitation of divided attention. The objective of the present study was to assess the effectiveness of a rehabilitation programme for divided attention after severe TBI. Twelve patients at a subacute/chronic stage after a severe TBI were included. A randomised AB vs. BA cross-over design was used. Training lasted six weeks, with four one-hour sessions per week. It was compared to a non-specific (control) cognitive training. During experimental treatment, patients were trained to perform two concurrent tasks simultaneously. Each one of the two tasks was first trained as a single task, then both tasks were given simultaneously. A progressive hierarchical order of difficulty was used, by progressively increasing task difficulty following each patient's individual improvement. Patients were randomised in two groups: one starting with dual-task training, the other with control training. Outcome measures included target dual-task measures, executive and working memory tasks, non-target tasks, and the Rating Scale of Attentional Behaviour addressing attentional problems in everyday life. Assessment was not blind to treatment condition. A significant training-related effect was found on dual-task measures and on the divided attention item of the Rating Scale of Attentional Behaviour. There was only little effect on executive measures, and no significant effect on non-target measures. These results suggest that training had specific effects on divided attention and helped patients to deal more rapidly and more accurately with dual-task situations.	[Couillet, Josette; Lebornec, Gaelle; Asloun, Sybille; Azouvi, Philippe] Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France; [Soury, Stephane; Joseph, Pierre-Alain; Mazaux, Jean-Michel] Hop Pellegrin, Serv Med Phys & Readaptat, CHU Bordeaux, F-33076 Bordeaux, France; [Azouvi, Philippe] UPMC, ER 6, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France		Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr			Programme Hospitalier de Recherche Clinique (PHRC) [AOM01025]; Assistance Publique-Hopitaux de Paris (AP-HP) [P01120]	This work was supported by grants from the Programme Hospitalier de Recherche Clinique (PHRC National 2001, AOM01025) and by Assistance Publique-Hopitaux de Paris (AP-HP, P01120).	Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Duval J, 2008, NEUROPSYCHOL REHABIL, V18, P430, DOI 10.1080/09602010701573950; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Leclercq M., 2007, BATTERIE ATTENTION W; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J., 2008, COGNITIVE NEUROREHAB, P507; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sturm W, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P365; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; TEASDALE G, 1974, LANCET, V2, P81; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; Zimmermann P, 1995, TEST ATTENTIONAL PER	39	40	42	1	31	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	3					321	339	PII 919145662	10.1080/09602010903467746			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	598RZ	WOS:000277857200001	20146136				2022-02-06	
J	Ekmark-Lewen, S; Lewen, A; Israelsson, C; Li, GL; Farooque, M; Olsson, Y; Ebendal, T; Hillered, L				Ekmark-Lewen, Sara; Lewen, Anders; Israelsson, Charlotte; Li, Gui Lin; Farooque, Mohammad; Olsson, Yngve; Ebendal, Ted; Hillered, Lars			Vimentin and GFAP responses in astrocytes after contusion trauma to the murine brain	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; rat; mouse; astrocytes; gliosis	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; GLIAL REACTION; INJURY; RAT; IMMUNOREACTIVITY; PROLIFERATION; ALPHA	Purpose: Astroglial responses after traumatic brain injury are difficult to detect with routine morphological methods. The aims for this study were to compare the temporal and spatial expression pattern of vimentin-and glial fibrillary acidic protein (GFAP) in a weight drop model of mild cerebral contusion injury in the rat. We also wanted to study the vimentin response with immunohistochemistry and vimentin mRNA RT-PCR analysis in severe cortical contusion injury produced by the controlled cortical impact in the mouse. Methods: Vimentin and GFAP immunohistochemistry (1day, 3 days and 7 days) combined with vimentin mRNA RT-PCR analysis (1 h, 4 h, 22 h, 3 days and 7 days) were used after experimental traumatic brain injury in the rat and mouse. Results: Increases in post-traumatic vimentin mRNA levels in the cortex and in the hippocampus appeared together with vimentin immunoreactivity in astrocytes in the perimeter of the cortical lesion, in the subcortical white matter and in the hippocampus starting at one day after severe trauma. GFAP immunostaining revealed hypertrophic astrocytes peaking at day 3 in the perifocal cortical region. There was no significant increase in GFAP immunoreactivity in the white matter in the rat. However, in the mouse there was a slight increase in the number of GFAP positive cells in this region, 3 days after trauma. Overall the pattern of vimentin immunoreactivity was very similar in the rat and mouse. Conclusions: Vimentin immunoreactivity was more sensitive than the GFAP staining method to demonstrate the distribution and time course of astrocyte reactions after a contusion injury, especially in the white matter distant from the cortical lesion.	[Ekmark-Lewen, Sara; Lewen, Anders; Hillered, Lars] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden; [Israelsson, Charlotte; Ebendal, Ted] Uppsala Univ, Dept Neurosci, Biomed Ctr, SE-75185 Uppsala, Sweden; [Li, Gui Lin; Farooque, Mohammad; Olsson, Yngve] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden		Lewen, A (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden.	anders.lewen@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [7888, 0320]; Swedish Brain Foundation; Fredrik and Ingrid Thuring's Foundation; Swedish Association of Neurologically Disabled; Tore Nilsson's Foundation; A. Wiberg's Foundation; Ahlen's Foundation; Emil and Wera Cornell Foundation; Laerdal Foundation for Acute Medicine; O E and Edla Johansson's Foundation; King Gustaf V and Queen Victorias Foundation; Foundation for Stroke Research	We would like to thank Madeleine Jarild, Gunilla Tibbling, Khaled Ahmad Ata and Ulla Karlsson for their excellent technical help. Supported by grants from the Swedish Medical Research Council (projects no. 7888 and 0320), The Swedish Brain Foundation, Fredrik and Ingrid Thuring's Foundation, The Swedish Association of Neurologically Disabled, Tore Nilsson's Foundation, A. Wiberg's Foundation, Ahlen's Foundation, Emil and Wera Cornell Foundation, the Laerdal Foundation for Acute Medicine, O E and Edla Johansson's Foundation, King Gustaf V and Queen Victorias Foundation, and 1987 Foundation for Stroke Research.	Baldwin SA, 1996, GLIA, V16, P266; Bignami A., 1991, DISCUSS NEUROSCI, V111, P9; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; DAHL D, 1981, EXP NEUROL, V73, P496, DOI 10.1016/0014-4886(81)90283-1; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; ENG LF, 1992, PROGR BRAIN RES, V94; GIULIAN D, 1988, J NEUROSCI, V8, P709; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Motohashi O, 1997, J NEUROTRAUM, V14, P747, DOI 10.1089/neu.1997.14.747; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SELMAJ K, 1991, J NEUROCHEM, V57, P823, DOI 10.1111/j.1471-4159.1991.tb08225.x; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4	25	40	45	1	13	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2010	28	3					311	321		10.3233/RNN-2010-0529			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606QP	WOS:000278442500002	20479526				2022-02-06	
J	Hajek, CA; Yeates, KO; Taylor, HG; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M				Hajek, Christine A.; Yeates, Keith Owen; Taylor, H. Gerry; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha			Relationships among post-concussive symptoms and symptoms of PTSD in children following mild traumatic brain injury	BRAIN INJURY			English	Article						Pediatric; closed head injury; outcome	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; CONSEQUENCES; ADOLESCENTS; AMNESIA	Primary objective: To investigate the occurrence of post-concussive symptoms (PCS) and symptoms of post-traumatic stress disorder (PTSD) in children following mild traumatic brain injuries (TBI). Research design: Longitudinal study comparing the outcomes of mild TBI and orthopaedic injuries (OI) in children aged 8-15. Methods and procedures: One hundred and eighty-six children with mild TBI and 99 with OI were recruited prospectively. Parents rated children's PCS and symptoms of PTSD at 2 weeks, 3 months and 12 months post-injury. One hundred and sixty-seven with mild TBI and 84 with OI completed all assessments. Main outcomes and results: Controlling for symptoms of PTSD, the mild TBI group demonstrated more PCS than the OI group, although the magnitude of group differences diminished with time. Controlling for PCS, the OI group displayed more symptoms of PTSD than the mild TBI group at baseline, but not thereafter. Symptoms of PTSD and PCS were correlated significantly, but more highly in the OI group than the mild TBI group. Conclusions: Although PCS and symptoms of PTSD are correlated, children with mild TBI are more distinguishable from children with OI based on PCS than on symptoms of PTSD. The latter symptoms, moreover, do not account for increased PCS following mild TBI in children.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Hajek, Christine A.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Hajek, Christine A.; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Columbus, OH USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The research reported here served as the basis for a thesis submitted by the first author to The Ohio State University in partial fulfilment of the requirements for a master's degree. Portions of the research were presented at the annual meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 2008 and the annual meeting of the Society for Developmental and Behavioral Pediatrics, Cincinnati, Ohio, October 2008. The larger study on which the research was based was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development and the National Center for Medical Rehabilitation Research to Keith Owen Yeates. The authors wish to acknowledge the contributions of Lauren Ayr, Anne Birnbaum, Amy Clemens, Taryn Fay, Kalaichelvi Ganesalingham, Amanda Lininger, Melissa Ginn, Katie Pestro, Elizabeth Roth, Elizabeth Shaver and Heidi Walker in conducting the study.	Aaron J, 1999, J PEDIATR PSYCHOL, V24, P335, DOI 10.1093/jpepsy/24.4.335; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; *AM MED ASS, 1997, INT CLASS DIS; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Davis L, 2000, Clin Child Fam Psychol Rev, V3, P135, DOI 10.1023/A:1009564724720; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Foa EB, 2001, J CLIN CHILD PSYCHOL, V30, P376, DOI 10.1207/S15374424JCCP3003_9; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Keppel-Benson JM, 2002, J CHILD PSYCHOL PSYC, V43, P203, DOI 10.1111/1469-7610.00013; KIRKWOOD MW, 2007, CLIN NEUROPSYCHOL, V24, P1; Landolt MA, 2003, J CHILD PSYCHOL PSYC, V44, P1199, DOI 10.1111/1469-7610.00201; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McNally RJ, 1996, J SCHOOL PSYCHOL, V34, P147, DOI 10.1016/0022-4405(96)00004-0; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Strand VC, 2005, TRAUMA VIOLENCE ABUS, V6, P55, DOI 10.1177/1524838004272559; TAYLOR HG, NEUROPSYCHO IN PRESS; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	39	40	40	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					100	109		10.3109/02699050903508226			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500005	20085447	Green Accepted			2022-02-06	
J	Han, SJ; Guo, Y; Granger-Donetti, B; Vicci, VR; Alvarez, TL				Han, Sang J.; Guo, Yi; Granger-Donetti, Berangere; Vicci, Vincent R.; Alvarez, Tara L.			Quantification of heterophoria and phoria adaptation using an automated objective system compared to clinical methods	OPHTHALMIC AND PHYSIOLOGICAL OPTICS			English	Article						dissociated phoria; eye-movements; heterophoria measurement; phoria adaptation; sustained convergence	TRAUMATIC BRAIN-INJURY; COVER TEST; VERGENCE ADAPTATION; PRISM ADAPTATION; INTEREXAMINER REPEATABILITY; EYE-MOVEMENTS; ACCOMMODATION; CONVERGENCE; DISTANCE; STIMULI	Purpose: To develop a system with which to quantify objectively the heterophoria to be measured throughout eye movement experiments. This study compared precision, resolution and accuracy characteristics of a limbus eye movement tracking system to the alternate cover test and the Maddox rod. Methods: Precision testing was performed using each technique with binocularly-normal subjects at different test sessions. Resolution was measured and compared between the three systems. The heterophoria or phoria was measured from 40 cm/16 inches objectively with the limbus eye movement system and the Maddox rod during a sustained convergence-induced phoria adaptation experiment using physical and haploscope visual targets to compare accuracy. Results: Precision testing quantified that the responses objectively recorded using the limbus tracking system exhibited similar standard deviations to the Maddox rod and the alternate cover test techniques. The limbus tracking method has the ability to quantify the response decay to phoria and has better resolution when compared to the clinical methods. When physical targets were used to induce phoria adaptation, the correlation was significant between the limbus eye movement tracking system and the Maddox rod after near and far adaptation, where the Maddox rod measurements were slightly more esophoric compared to those measured with the limbus tracking system. Conclusion: This objective limbus tracking system offers a better means by which to study the phoria and its adaptation throughout an eye movement experiment. The broader aim of this research is to establish a tool that will further the basic science of oculomotor control and binocular dysfunctions.	[Han, Sang J.; Guo, Yi; Alvarez, Tara L.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Granger-Donetti, Berangere] Essilor Inc Corp, St Maur, France; [Vicci, Vincent R.] Westfield & Kessler Rehabil, W Orange, NJ USA; [Vicci, Vincent R.] Westfield & Kessler Rehabil, Chester, NJ USA; [Vicci, Vincent R.] Westfield & Kessler Rehabil, Saddle Brook, NJ USA		Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu		Guo, Yi/0000-0003-3103-6447; Alvarez, Tara/0000-0002-8797-1613	Essilor International; National Science Foundation CAREERNational Science Foundation (NSF) [BES-0447713]	This study was funded by Essilor International and the National Science Foundation CAREER BES-0447713 to TLA.	Baker FJ, 2003, OPHTHAL PHYSL OPT, V23, P507, DOI 10.1046/j.1475-1313.2003.00145.x; BARNARD NAS, 1995, OPHTHAL PHYSL OPT, V15, P413, DOI 10.1016/0275-5408(95)00053-G; BIRNBAUM MH, 1985, AM J OPTOM PHYS OPT, V62, P732; BIRNBAUM MH, 1998, MYOPIA NEARWORK, P162; Brautaset RL, 2005, OPHTHAL PHYSL OPT, V25, P215, DOI 10.1111/j.1475-1313.2005.00276.x; Casillas EC, 2006, OPTOMETRY VISION SCI, V83, P237, DOI 10.1097/01.opx.0000214316.50270.24; Cheng D, 2008, OPHTHAL PHYSL OPT, V28, P225, DOI 10.1111/j.1475-1313.2008.00560.x; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; COOPER J, 1992, OPTOMETRY VISION SCI, V69, P300, DOI 10.1097/00006324-199204000-00008; EHRLICH DL, 1987, OPHTHAL PHYSL OPT, V7, P353, DOI 10.1016/0275-5408(87)90054-8; Fogt N, 2001, OPTOMETRY VISION SCI, V78, P815, DOI 10.1097/00006324-200111000-00011; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Goss D A, 1999, J Am Optom Assoc, V70, P764; GOSS DA, 1990, OPTOMETRY VISION SCI, V67, P637, DOI 10.1097/00006324-199008000-00015; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HIRSCH M J, 1948, Am J Optom Arch Am Acad Optom, V25, P492; Howarth PA, 2000, OPTOMETRY VISION SCI, V77, P616, DOI 10.1097/00006324-200011000-00013; Jaschinski W, 2007, OPHTHAL PHYSL OPT, V27, P85, DOI 10.1111/j.1475-1313.2006.00448.x; Jiang Bai-Chuan, 2007, Optometry, V78, P129, DOI 10.1016/j.optm.2006.08.017; Johns HA, 2004, OPTOMETRY VISION SCI, V81, P939; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KRAN BS, 1988, AM J OPTOM PHYS OPT, V65, P703; Lam AKC, 2005, OPHTHAL PHYSL OPT, V25, P162, DOI 10.1111/j.1475-1313.2005.00270.x; MORLEY JW, 1992, J NEUROPHYSIOL, V67, P1475, DOI 10.1152/jn.1992.67.6.1475; MORRIS F M, 1960, Am J Optom Arch Am Acad Optom, V37, P327; NORTH RV, 1993, OPHTHAL PHYSL OPT, V13, P239, DOI 10.1111/j.1475-1313.1993.tb00465.x; OSHEA WF, 1988, AM J OPTOM PHYS OPT, V65, P787; OWENS DA, 1992, INVEST OPHTH VIS SCI, V33, P2733; PELI E, 1983, AM J OPTOM PHYS OPT, V60, P712; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Rainey BB, 1998, OPTOMETRY VISION SCI, V75, P719, DOI 10.1097/00006324-199810000-00016; ROMANO PE, 1971, AM J OPHTHALMOL, V72, P10, DOI 10.1016/0002-9394(71)91585-6; Scheiman M, 2001, VISUAL VESTIBULAR CO, P89; SCHOR CM, 1979, VISION RES, V19, P757, DOI 10.1016/0042-6989(79)90151-2; SCHOR CM, 1982, AM J OPTOM PHYS OPT, V59, P774; Schroeder TL, 1996, OPTOMETRY VISION SCI, V73, P389, DOI 10.1097/00006324-199606000-00006; SCOBEE RG, 1947, T AM ACAD OPHTHALMOL, V40, P179; SETHI B, 1986, OPHTHAL PHYSL OPT, V6, P151, DOI 10.1016/0275-5408(86)90006-2; SHEBILSKE WL, 1983, J EXP PSYCHOL HUMAN, V9, P270, DOI 10.1037/0096-1523.9.2.270; Spierer A, 1997, GRAEF ARCH CLIN EXP, V235, P345, DOI 10.1007/BF00937281; Wong EPF, 2002, OPTOMETRY VISION SCI, V79, P370, DOI 10.1097/00006324-200206000-00010; Ying SH, 2006, EXP BRAIN RES, V171, P297, DOI 10.1007/s00221-005-0267-8	43	40	40	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-5408	1475-1313		OPHTHAL PHYSL OPT	Ophthalmic Physiol. Opt.	JAN	2010	30	1					95	107		10.1111/j.1475-1313.2009.00681.x			13	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	531JE	WOS:000272660500010	19682268				2022-02-06	
J	Skoglund, K; Enblad, P; Marklund, N				Skoglund, Karin; Enblad, Per; Marklund, Niklas			Effects of the Neurological Wake-Up Test on Intracranial Pressure and Cerebral Perfusion Pressure in Brain-Injured Patients	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Cerebral perfusion pressure; Sedation; Propofol; Wake-up test; Neurological examination; Reaction Level Scale; Glasgow Coma Scale	INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; VENTILATOR BUNDLE; SEDATION; EFFICACY; IMPACT; DETERIORATION; NEUROTRAUMA; MANAGEMENT; RECOVERY	To evaluate the effects of the neurological "wake-up test" (NWT), defined as interruption of continuous propofol sedation and evaluation of the patient's level of consciousness, on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in patients with severe subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI). A total of 127 NWT procedures in 21 severely brain-injured adult patients with either TBI (n = 12) or SAH (n = 9) were evaluated. ICP and CPP levels prior to, during and after the NWT procedure were recorded. During the NWT, ICP increased from 13.4 +/- A 6 mmHg at baseline to 22.7 +/- A 12 (P < 0.05) and the CPP increased from 75.6 +/- A 11 to 79.1 +/- A 21 mmHg (P < 0.05) in TBI patients. Eight patients showed a reduced CPP during the NWT due to increased ICP. In SAH patients, ICP increased from 10.6 +/- A 5 to 16.8 +/- A 8 mmHg (P < 0.05) and the CPP increased from 76.9 +/- A 13 to 84.6 +/- A 15 mmHg (P < 0.05). When continuous propofol sedation was interrupted and NWT was performed in severely brain-injured patients, the mean ICP and CPP levels were modestly increased. A subset of patients showed more pronounced changes. To date, the role of the NWT in the neurointensive care of TBI and SAH patients is unclear. Although the NWT is safe in the majority of patients and may provide useful clinical information about the patient's level of consciousness, alternate monitoring methods are suggested in patients showing marked ICP and/or CPP changes during NWT.	[Skoglund, Karin; Enblad, Per; Marklund, Niklas] Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Marklund, Niklas/0000-0002-9797-5626	Laerdal Foundation for Acute Medicine; Swedish Research CouncilSwedish Research CouncilEuropean Commission	The authors are grateful to Monica Edberg, the NICU nurse staff, Dr. Tim Howells, and Dr. Camilla Frojd for excellent support during the study. This study was supported by the Laerdal Foundation for Acute Medicine and the Swedish Research Council.	Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blamoun J, 2009, AM J INFECT CONTROL, V37, P172, DOI 10.1016/j.ajic.2008.05.010; Bruder N, 2002, ANESTH ANALG, V94, P650, DOI 10.1097/00000539-200203000-00031; Bruder N, 1999, ANESTH ANALG, V89, P674, DOI 10.1097/00000539-199909000-00027; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrasco G, 2000, CRIT CARE, V4, P217, DOI 10.1186/cc697; Cesarini KG, 1999, J NEUROSURG, V90, P664, DOI 10.3171/jns.1999.90.4.0664; Citerio Giuseppe, 2003, Curr Opin Crit Care, V9, P120, DOI 10.1097/00075198-200304000-00007; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Deogaonkar A, 2004, CRIT CARE MED, V32, P2403, DOI 10.1097/01.CCM.0000147442.14921.A5; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Gemma M, 2002, J NEUROSURG ANESTH, V14, P50, DOI 10.1097/00008506-200201000-00010; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Grande PO, 2002, INTENS CARE MED, V28, P529, DOI 10.1007/s00134-002-1236-3; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kerr ME, 1999, CRIT CARE MED, V27, P2776, DOI 10.1097/00003246-199912000-00028; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; REILLY P, 1997, HEAD INJURY, P385; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; Ryttlefors M, 2007, NEUROSURGERY, V61, P704, DOI 10.1227/01.NEU.0000298898.38979.E3; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; SKOGLUND K, 2009, 10 QUADR C WORLD FED; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; STROMGREN M, 2003, 7 QUADR C EUR ASS NE; TEASDALE G, 1974, LANCET, V2, P81; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Wittbrodt ET, 2005, PHARMACOTHERAPY, V25, p3S, DOI 10.1592/phco.2005.25.5_Part_2.3S; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2	50	40	42	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					135	142		10.1007/s12028-009-9255-3			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300002	19644774				2022-02-06	
J	Garon, BR; Sierzant, T; Ormiston, C				Garon, Bernard R.; Sierzant, Tess; Ormiston, Charles			Silent Aspiration: Results of 2,000 Video Fluoroscopic Evaluations	JOURNAL OF NEUROSCIENCE NURSING			English	Article							FIBEROPTIC ENDOSCOPIC EVALUATION; ACUTE-STROKE; DETECTING ASPIRATION; SWALLOWING DISORDERS; CLINICAL EXAMINATION; ELDERLY-PATIENTS; PULSE OXIMETRY; DYSPHAGIA; RISK; HEAD	The purpose of this retrospective study of aspiration and the lack of a protective cough reflex at the vocal folds (silent aspiration) was to increase the awareness of nursing staffs of the diagnostic pathology groups associated with silent aspiration. Of the 2,000 patients evaluated in this study, 51% aspirated on the video fluoroscopic evaluation. Of the patients who aspirated, 55% had no protective cough reflex (silent aspiration). The diagnostic pathology groups with the highest rates of silent aspiration were brain cancer, brainstem stroke, head-neck cancer, pneumonia, dementia/Alzheimer, chronic obstructive lung disease, seizures, myocardial infarcts, neurodegenerative pathologies, right hemisphere stroke, closed head injury, and left hemisphere stroke. It is of high concern that the diagnostic groups identified in this research as having the highest risk of silent aspiration be viewed as "red-flag" patients by the nursing staff caring for them. Early nursing dysphagia screens, with close attention to the clinical symptoms associated with silent aspiration, and early referral for formal dysphagia evaluation are stressed.	[Garon, Bernard R.] HealthE St Josephs Hosp, Dept Phys Med, St Paul, MN USA; [Sierzant, Tess; Ormiston, Charles] HealthE St Josephs Hosp, Natl Brain Aneurysm Ctr, St Paul, MN USA		Garon, BR (corresponding author), HealthE St Josephs Hosp, Dept Phys Med, St Paul, MN USA.	brgaron@healtheast.org					Argon M, 2004, EUR J NUCL MED MOL I, V31, P94, DOI 10.1007/s00259-003-1276-0; ARVEDSON J, 1994, INT J PEDIATR OTORHI, V28, P173, DOI 10.1016/0165-5876(94)90009-4; Aviv JE, 2002, DYSPHAGIA, V17, P219, DOI 10.1007/s00455-002-0055-6; Belafsky PC, 2003, LARYNGOSCOPE, V113, P1969, DOI 10.1097/00005537-200311000-00021; BLITZER A, 1990, Dysphagia, V5, P129, DOI 10.1007/BF02412635; Borr C, 2007, DYSPHAGIA, V22, P225, DOI 10.1007/s00455-007-9078-3; Chan ED, 1998, CHEST, V114, P1704, DOI 10.1378/chest.114.6.1704; Cook I J, 1989, Dysphagia, V4, P8, DOI 10.1007/BF02407397; Daniels SK, 2000, ARCH PHYS MED REHAB, V81, P1030, DOI 10.1053/apmr.2000.6301; DeMatteo C, 2005, DEV MED CHILD NEUROL, V47, P149, DOI 10.1017/S0012162205000289; DEPIPPO KL, 1994, NEUROLOGY, V44, P1655, DOI 10.1212/WNL.44.9.1655; Doggett David L, 2002, Curr Atheroscler Rep, V4, P311; Donzelli J, 2005, DYSPHAGIA, V20, P283, DOI 10.1007/s00455-005-0027-8; Dusick Anna, 2003, Semin Pediatr Neurol, V10, P255, DOI 10.1016/S1071-9091(03)00071-8; Eibling DE, 2001, J OTOLARYNGOL, V30, P235, DOI 10.2310/7070.2001.20174; FEINBERG MJ, 1992, RADIOLOGY, V183, P811, DOI 10.1148/radiology.183.3.1584939; Goeleven A, 2006, AMYOTROPH LATERAL SC, V7, P235, DOI 10.1080/17482960600664870; Groher ME, 1986, DYSPHAGIA, V1, P3, DOI DOI 10.1007/BF02408233; Halvorsen RA, 2002, ABDOM IMAGING, V28, P244, DOI 10.1007/s00261-002-0034-2; Higo R, 2003, ANN OTO RHINOL LARYN, V112, P630, DOI 10.1177/000348940311200710; Higo R, 2003, EUR ARCH OTO-RHINO-L, V260, P124, DOI 10.1007/s00405-002-0527-1; Hiss SG, 2003, LARYNGOSCOPE, V113, P1386, DOI 10.1097/00005537-200308000-00023; HORNER J, 1991, ARCH NEUROL-CHICAGO, V48, P1170, DOI 10.1001/archneur.1991.00530230078026; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; Hudspeth MP, 2006, PEDIATRICS, V118, pE530, DOI 10.1542/peds.2006-0043; HUMPHREYS B, 1987, LARYNGOSCOPE, V97, P25; Keeling WB, 2007, ANN THORAC SURG, V83, P193, DOI 10.1016/j.athoracsur.2006.08.008; Kelly AM, 2006, CLIN OTOLARYNGOL, V31, P425, DOI 10.1111/j.1749-4486.2006.01292.x; Kelly AM, 2007, LARYNGOSCOPE, V117, P1723, DOI 10.1097/MLG.0b013e318123ee6a; Kendall KA, 2004, DYSPHAGIA, V19, P65, DOI 10.1007/s00455-003-0500-1; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251, DOI 10.1164/ajrccm.150.1.8025758; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; Leder SB, 2000, DYSPHAGIA, V15, P201, DOI 10.1007/s004550000028; Leder SB, 2004, DYSPHAGIA, V19, P177, DOI 10.1007/s00455-004-0009-2; Leder SB, 2005, DYSPHAGIA, V20, P157, DOI 10.1007/s00455-005-0009-x; Leder SB, 2002, DYSPHAGIA, V17, P214, DOI 10.1007/s00455-002-0054-7; Leslie P, 2004, DYSPHAGIA, V19, P231, DOI 10.1007/s00455-004-0007-4; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; LOGEMANN JA, 1985, ANN OTO RHINOL LARYN, V94, P373; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; Marik PE, 2003, CHEST, V124, P328, DOI 10.1378/chest.124.1.328; MCCONNEL FMS, 1988, LARYNGOSCOPE, V98, P705; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); McCullough GH, 2001, J COMMUN DISORD, V34, P55, DOI 10.1016/S0021-9924(00)00041-1; McGowan SL, 2007, NEUROCRIT CARE, V6, P90, DOI 10.1007/s12028-007-0024-x; Meyer KC, 2001, RESP PHYSIOL, V128, P23, DOI 10.1016/S0034-5687(01)00261-4; Miyazaki Y, 2002, YAKUGAKU ZASSHI, V122, P97, DOI 10.1248/yakushi.122.97; MUZ J, 1987, LARYNGOSCOPE, V97, P1180; Perlman PW, 2004, OTOLARYNG HEAD NECK, V130, P80, DOI 10.1016/j.otohns.2003.09.026; Perry L, 2001, DYSPHAGIA, V16, P7, DOI 10.1007/s004550000047; Ramsey D, 2005, DYSPHAGIA, V20, P218, DOI 10.1007/s00455-005-0018-9; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; Ravelli AM, 2006, CHEST, V130, P1520, DOI 10.1378/chest.130.5.1520; Rosenbek JC, 2004, J COMMUN DISORD, V37, P437, DOI 10.1016/j.jcomdis.2004.04.007; Rosenthal DI, 2006, J CLIN ONCOL, V24, P2636, DOI 10.1200/JCO.2006.06.0079; Schindler JS, 2002, LARYNGOSCOPE, V112, P589, DOI 10.1097/00005537-200204000-00001; SHAWKER TH, 1984, INVEST RADIOL, V19, P82, DOI 10.1097/00004424-198403000-00003; Simental Alfred A, 2004, Curr Oncol Rep, V6, P162, DOI 10.1007/s11912-004-0028-z; Siraj Q H, 2004, J Pak Med Assoc, V54, P219; Smith CH, 1999, DYSPHAGIA, V14, P1, DOI 10.1007/PL00009579; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; Svartengren M, 2005, EUR RESPIR J, V26, P609, DOI 10.1183/09031936.05.00002105; Tohara H, 2003, DYSPHAGIA, V18, P126, DOI 10.1007/s00455-002-0095-y; Trapl M, 2007, STROKE, V38, P2948, DOI 10.1161/STROKEAHA.107.483933; Wang TG, 2005, ARCH PHYS MED REHAB, V86, P730, DOI 10.1016/j.apmr.2004.10.021; Westergren A, 2006, INT NURS REV, V53, P143, DOI 10.1111/j.1466-7657.2006.00460.x; Yoshikawa M, 2005, J GERONTOL A-BIOL, V60, P506, DOI 10.1093/gerona/60.4.506; Zaugg M, 2000, Anesthesiol Clin North Am, V18, P47, DOI 10.1016/S0889-8537(05)70148-6	68	40	41	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	AUG	2009	41	4					178	185		10.1097/JNN.0b013e3181aaaade			8	Clinical Neurology; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Nursing	516XM	WOS:000271576700002	19678503				2022-02-06	
J	Noori, AJ; Al-Obaidi, WA				Noori, Arass Jalal; Al-Obaidi, Wesal Ali			Traumatic dental injuries among primary school children in Sulaimani city, Iraq	DENTAL TRAUMATOLOGY			English	Article							PERMANENT INCISORS; SCHOOLCHILDREN; BRAZIL; PREVALENCE; TEETH	A cross-sectional survey was carried out through clinical examination of anterior teeth among 4015, 6- to 13-year-old children enrolled in 20 public primary schools of Sulaimani city, northern Iraq. The prevalence and pattern of traumatized anterior teeth were studied in relation to age, gender, type of injury, dental treatment needs, place and cause of the trauma in addition to occlusal relation and upper lip position. The prevalence of children with traumatic dental injuries was found to be 6.1% (243 children) of the total sample. Age and gender were highly significantly associated with dental trauma (P < 0.001). Males were more affected than females and the prevalence increased with age. Simple enamel fracture was the most common type of injury followed by enamel-dentine fracture and concussion. The maxillary central incisors were found to be most affected by trauma followed by mandibular central incisors and the maxillary lateral incisors. The number of injured teeth per child was 1.38 (totally 336 anterior teeth were found with dental trauma) and single tooth trauma was the most common type (69.5%). Results showed that only 7% of the traumatized anterior teeth received treatment and about half (48.7%) of the remaining traumatized teeth did not need dental treatments, while the least treatment type needed was extraction (3.5%). The highest proportions of traumatized children were found with class II division 1 malocclusion and inadequate upper lip coverage. Falls and playing were the most common causes of dental injury, while home was the most common place of trauma occurrence. The present study revealed a relatively low prevalence of dental trauma, but still this figure represents a large number of children. Therefore, educational programs are to be initiated for the community regarding causes, prevention and treatments of traumatic dental injuries.	[Noori, Arass Jalal] Univ Sulaimani, Coll Dent, Sulaimani, Iraq; [Al-Obaidi, Wesal Ali] Univ Baghdad, Coll Dent, Baghdad, Iraq		Noori, AJ (corresponding author), Univ Sulaimani, Coll Dent, Sulaimani, Iraq.	dr.arass@yahoo.com	Noori, Arass/Y-5247-2019	Noori, Arass/0000-0001-9968-6978			Al-Jundi SH, 2002, DENT TRAUMATOL, V18, P181, DOI 10.1034/j.1600-9657.2002.02081.x; Al-Obaidi W, 2002, IRAQI DENT J, V30, P207; Al-Obaidi W, 2002, IRAQI DENT J, V29, P299; ALHAYALI A, 1998, THESIS U BAGHDAD BAG; ALKASSAB AG, 2005, THESIS U BAGHDAD BAG; ALSAYYAB M, 1992, IRAQI DENT J, V1, P37; Andreasen JO, 1981, TRAUMATIC INJURIES T, P19; Baghdady VS, 1981, J DENT RES, V2, P67; Brin I, 1984, Pediatr Dent, V6, P78; Cortes MID, 2002, COMMUNITY DENT ORAL, V30, P193; Cortes MIS, 2001, DENT TRAUMATOL, V17, P22, DOI 10.1034/j.1600-9657.2001.170105.x; ELSAMARRAI S, 1989, THESIS U BAGHDAD BAG; FALOMO B, 1986, J DENT CHILD, V53, P119; GARCIA-GODOY F, 1981, Journal of Pedodontics, V5, P295; Jackson D., 1962, BRIT DENT J, V112, P147; JARVINEN S, 1978, ACTA ODONTOL SCAND, V36, P359, DOI 10.3109/00016357809029088; Kania MJ, 1996, ANGLE ORTHOD, V66, P423; Marcenes W, 2000, INT DENT J, V50, P87, DOI 10.1002/j.1875-595X.2000.tb00804.x; McDonald RE, 2004, DENT CHILD ADOLESCEN; Millichap J., 1987, PEDIAT NEUROL BRIEFS, V1, P18; Petersson HG, 1996, EUR J ORAL SCI, V104, P436; Rai S B, 1998, J Indian Soc Pedod Prev Dent, V16, P44; Sennhenn-Kirchner S, 2006, DENT TRAUMATOL, V22, P237, DOI 10.1111/j.1600-9657.2006.00383.x; Skaare AB, 2003, DENT TRAUMATOL, V19, P304, DOI 10.1046/j.1600-9657.2003.00211.x; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x; Sullivan Debra D, 2002, JAAPA, V15, P48; Traebert Jefferson, 2003, Oral Health Prev Dent, V1, P317; Traebert J, 2006, DENT TRAUMATOL, V22, P173, DOI 10.1111/j.1600-9657.2006.00359.x; Wilson S, 1997, PEDIATR EMERG CARE, V13, P12, DOI 10.1097/00006565-199702000-00004; YAGOT KH, 1988, COMMUNITY DENT ORAL, V16, P292, DOI 10.1111/j.1600-0528.1988.tb01778.x	30	40	44	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	AUG	2009	25	4					442	446		10.1111/j.1600-9657.2009.00791.x			5	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	469FP	WOS:000267881600015	19496800				2022-02-06	
J	Svoboda, E; Richards, B				Svoboda, Eva; Richards, Brian			Compensating for anterograde amnesia: A new training method that capitalizes on emerging smartphone technologies	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Memory disorders; Rehabilitation; Technology; Neuropsychology; Program evaluation; Cognition	TRAUMATIC BRAIN-INJURY; MEMORY AID; IMPAIRED PATIENTS; FOLLOW-UP; REHABILITATION; ACQUISITION; PEOPLE; SKILL; DISCRIMINATION; INDIVIDUALS	Following a neuropathological event, individuals left with moderate-to-severe memory Impairment are unable to reliably form new memories. The most common challenges involve the capacity to perform a task in the future and to consciously recall a recent event. Disruption of these memory processes leaves the individual trapped in the present,, unable to stay oil track, and alienated from ongoing events. Memory research has demonstrated that implicit memory is often preserved despite severe explicit memory impairment and that preserved memory systems call provide avenues for acquiring new skills and knowledge. A within-subject single-case A(1)-B(1)-A(2)-B(2) experimental design was used to introduce ail established theory-driven training program of technology use for individuals with moderate-to-severe memory impairment. We describe its application to enabling RR, all individual with memory impairment postcolloid cyst removal, to independently support her memory using a commercial smartphone. RR showed successful outcome on both objective and qualitative measures of memory functioning. Moreover, she demonstrated consistent and creative generalization of acquired smartphone skills across a broad range of real-life memory-demanding Circumstances. Our findings suggest that individuals with moderate-to-severe memory impairment are able to capitalize oil emerging commercial technology to support their memory. (JINS, 2009, 15, 629-638.)	[Svoboda, Eva; Richards, Brian] Baycrest, Cognit & Behav Hlth Program, Toronto, ON M6A 2E1, Canada		Svoboda, E (corresponding author), Baycrest, Cognit & Behav Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; Cullen C. N., 1976, NURS TIMES, V72, P45; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Henson RNA, 2003, PROG NEUROBIOL, V70, P53, DOI 10.1016/S0301-0082(03)00086-8; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; Moscovitch M., 1982, AGING COGNITIVE PROC, P55; Oddy M, 2004, NEUROPSYCHOL REHABIL, V14, P481, DOI 10.1080/09602010343000309; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; Schacter Daniel, 1994, P1; Schacter DL, 2004, NAT REV NEUROSCI, V5, P853, DOI 10.1038/nrn1534; SIDMAN M, 1967, J EXP ANAL BEHAV, V10, P3, DOI 10.1901/jeab.1967.10-3; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; Troyer AK, 2002, J GERONTOL B-PSYCHOL, V57, pP19, DOI 10.1093/geronb/57.1.P19; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wu M., 2007, UNIVERSAL USABILITY, P317; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	38	40	42	0	28	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2009	15	4					629	638		10.1017/S1355617709090791			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	470EU	WOS:000267958600017	19588540				2022-02-06	
J	San-Juan, OD; Chiappa, KH; Costello, DJ; Cole, AJ				San-juan, O. D.; Chiappa, K. H.; Costello, D. J.; Cole, A. J.			Periodic epileptiform discharges in hypoxic encephalopathy: BiPLEDs and GPEDs as a poor prognosis for survival	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						PLEDs; BiPLEDs; GPEDs; Hypoxic encephalopathy; Prognosis	TRAUMATIC ENCEPHALOPATHIES; CLINICAL-SIGNIFICANCE; POSTANOXIC COMA; EEG PATTERNS; NEUROLOGY; ARREST	Introduction: Electrophysiologic tests in hypoxic encephalopathy consist of EEG and evoked/event-related potential studies. In most studies the generalized periodic epileptiform complexes have been reported combined with other EEG patterns and were indicators of a poor outcome in different etiologies of hypoxic encephalopathy (HE), but these have rarely been examined independently. Methodology: We analyzed from 2000 to 2007 the outcome of patients with HE and generalized periodic epileptiform complexes. We abstracted and tabulated clinical information, imaging findings, and outcome from the medical records. Results: We found 52 patients in our database. Fourteen patients (eight BiPLEDs and six GPEDs) were associated with HE. Patients with BIPLEDs were 68 +/- 19.4 years old, 5 female (62%) and 3 (38%) men. GPEDs patients were 52.5 +/- 19.1 years old, 2 women (20%) and 4 (80%) men. Myocardial infarction and ventricular tachycardia were responsible of 57% of the HE cases. Neuroimaging studies in both groups showed cortical structural lesions in 84%. All patients were comatose and died. Two GPEDs patients developed status epilepticus. Conclusion: GPEDs and BIPLEDs after an anoxic insult carried a poor prognosis for survival. Aggressive treatment of patients may not be warranted when these EEG patterns are seen after anoxic brain injury. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[San-juan, O. D.; Chiappa, K. H.; Costello, D. J.; Cole, A. J.] Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, Boston, MA 02114 USA		San-Juan, OD (corresponding author), Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, 55 Furit St, Boston, MA 02114 USA.	pegaso31@yahoo.com	San Juan, Daniel/AAU-3348-2020	San Juan, Daniel/0000-0001-6685-5851; Costello, Daniel/0000-0001-6023-8246	Foundation Mexico (FMH) in Harvard; FMH Fellowship	The study was funded by grant from the Foundation Mexico (FMH) in Harvard. San-Juan OD is Supported by FMH Fellowship.	BASSETTI C, 1987, EEG-EMG-Z ELEK ELEKT, V18, P97; BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; Fitzpatrick W, 2007, CAN J NEUROL SCI, V34, P443, DOI 10.1017/S0317167100007332; Fushimi M, 2003, ACTA NEUROL SCAND, V108, P55, DOI 10.1034/j.1600-0404.2003.00084.x; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; KUROIWA Y, 1980, ARCH NEUROL-CHICAGO, V37, P15, DOI 10.1001/archneur.1980.00500500045005; Nicolai J, 2001, CLIN NEUROPHYSIOL, V112, P1726, DOI 10.1016/S1388-2457(01)00602-2; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; TREIMAN DM, 1997, J CLIN NEUROPHYSIOL, V14, P159; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Yemisci M, 2003, SEIZURE-EUR J EPILEP, V12, P465, DOI 10.1016/S1059-1311(02)00351-5; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P354, DOI 10.1097/00004691-199907000-00008; Young GB, 2005, NEUROCRIT CARE, V2, P5, DOI 10.1385/NCC:2:1:005; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379	20	40	42	0	3	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	JUN	2009	18	5					365	368		10.1016/j.seizure.2009.01.003			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	453VM	WOS:000266641000011	19196524	Bronze			2022-02-06	
J	Wade, SL; Walz, NC; Carey, JC; Williams, KM				Wade, Shari L.; Walz, Nicolay Chertkoff; Carey, JoAnne C.; Williams, Kendra M.			Brief Report: Description of Feasibility and Satisfaction Findings from an Innovative Online Family Problem-solving Intervention for Adolescents following Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	New Frontiers in Pediatric Brain Injury Meeting	2007	San Diego, CA			acquired brain injury; adolescent; telehealth	CHILDREN	ObjectiveTo describe feasibility and satisfaction findings from an innovative online family problem-solving intervention for adolescents with traumatic brain injury (TBI).MethodsNine adolescents who sustained a moderate to severe TBI in the previous 24 months and their families participated in a novel, online, manualized treatment program (Teen Online Problem Solving, TOPS) consisting of 10 web-based sessions providing information and interactive exercises on cognitive, social, and behavioral skills typically affected by TBI. Web-based sessions were followed by synchronous video conferences with a therapist to review target skills and apply the problem-solving process to family goals.ResultsAll teens and consenting parents completed at least 10 sessions. The website and videoconferences received moderate to high ratings on helpfulness and ease of use. Parents and teens reported increased knowledge regarding targeted knowledge and skills. ConclusionsFindings support the acceptability of TOPS for adolescent TBI.	[Wade, Shari L.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA		Wade, SL (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			NHGRI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [HG133G050239] Funding Source: Medline		Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; GOODMAN SH, 1995, J ABNORM CHILD PSYCH, V23, P473, DOI 10.1007/BF01447209; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Norman S, 2006, J PSYCHIATR MENT HLT, V13, P771, DOI 10.1111/j.1365-2850.2006.01033.x; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Spence SH, 2003, J CONSULT CLIN PSYCH, V71, P3, DOI 10.1037/0022-006X.71.1.3; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; 2007, PARENT TEENAGER INTE	14	40	40	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2009	34	5					517	522		10.1093/jpepsy/jsn081			6	Psychology, Developmental	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	449TH	WOS:000266352400008	18667477	Bronze, Green Published			2022-02-06	
J	Homaifar, BY; Brenner, LA; Gutierrez, PM; Harwood, JF; Thompson, C; Filley, CM; Kelly, JP; Adler, LE				Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Harwood, Jeri F.; Thompson, Caitlin; Filley, Christopher M.; Kelly, James P.; Adler, Lawrence E.			Sensitivity and Specificity of the Beck Depression Inventory-II in Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	5th Annual Conference of the American-Academy-of-Clinical-Neuropsychology	JUN 07-09, 2007	Denver, CO	Amer Acad Clin Neuropsychol		Brain injuries; Depression; Rehabilitation; Veterans	FOLLOW-UP; AXIS-I; PSYCHIATRIC-DISORDERS; EMOTIONAL ADJUSTMENT; AWARENESS; INDIVIDUALS; CHALLENGES	Homaifar BY, Brenner LA, Gutierrez PM, Harwood JF, Thompson C, Filley CM, Kelly JP, Adler LE. Sensitivity and specificity of the Beck Depression Inventory-II in persons with traumatic brain injury. Arch Phys Med Rehabil 2009,90:652-6. Objectives: Our objective was to examine the Beck Depression Inventory-II (BDI-II) in a traumatic brain injury (TBI) sample using a receiver operating characteristic (ROC) Curve to determine how well the BDI-II identifies depression. An ROC curve allows for analysis of the sensitivity and specificity of a diagnostic test using various cutoff points to determine the number of true positives, true negatives, false positives, and false negatives. Design: This was a secondary analysis of data gathered from an observational study. We examined BDI-II scores in a sample of 52 veterans with remote histories of TBI. Setting: This study was completed at a Veterans Affairs (VA) Medical Center. Participants: Participants were veterans eligible to receive VA health care services. Interventions: Not applicable. Main Outcome Measures: Outcome measures included the BDI-II and the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). Results: We generated an ROC curve to determine how well the BDI-II identifies depression using the SCID-TV as the criterion standard for diagnosing depression, defined here as a diagnosis of major depressive disorder. Results indicated a cutoff score of at least 19 if one has a mild TBI or at least 35 if one has a moderate or severe TBI. These scores maximize sensitivity (87%) and specificity (79%). Conclusions: Clinicians working with persons with TBI can use the BDI-II to determine whether depressive symptoms warrant further assessment.	[Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Adler, Lawrence E.] Vet Affairs VISN 19 Mental Illness Res Educ & Cli, Denver, CO USA; [Brenner, Lisa A.; Kelly, James P.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Filley, Christopher M.; Adler, Lawrence E.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Harwood, Jeri F.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Brenner, Lisa A.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; [Thompson, Caitlin] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA; [Homaifar, Beeta Y.; Filley, Christopher M.] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA; [Harwood, Jeri F.] Sch Publ Hlth, Dept Biostat & Informat, Denver, CO USA		Homaifar, BY (corresponding author), VA Eastern Colorado Hlth Care Syst, MIRECC VISN 19,1055 Clermont St, Denver, CO 80220 USA.	beeta.homaifar1@va.gov	Gutierrez, Peter/K-8905-2019; Brenner, Lisa A./AAG-2442-2019	Gutierrez, Peter/0000-0001-8981-8404; 	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH020061] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH020061] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BRENNER LA, MILITARY ME IN PRESS; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; CONDER R, 1992, MANUAL COMPUTERIZED; *DEP VET AFF, 2004, VETEESA138 SP; Felicetti T, 2005, PROF CASE MANAG, V10, P264; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Spitzer R, 1995, STRUCTURED CLIN INTE; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ., 1995, GUIDELINES SURVEILLA; TRUDEL TM, 2005, BRAIN INJURY PROFESS, V2, P16	34	40	41	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					652	656		10.1016/j.apmr.2008.10.028			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	432TD	WOS:000265156200017	19345782	Green Accepted			2022-02-06	
J	Onyszchuk, G; LeVine, SM; Brooks, WM; Berman, NEJ				Onyszchuk, Gregory; LeVine, Steven M.; Brooks, William M.; Berman, Nancy E. J.			Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study	NEUROSCIENCE LETTERS			English	Article						T2 hypointensky; Iron; Traumatic brain injury; GFAP; Iba1	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; T2 HYPOINTENSITY; MOUSE MODEL; RAT; MATTER; DEFEROXAMINE; ASTROCYTES; CHELATORS; TOXICITY	Traumatic brain injury (TBI) is a major cause of neurological disability across all ages, but the elderly are particularly vulnerable and have a worse prognosis than younger individuals. To advance the understanding of long-term pathogenesis induced by TBI in the elderly, aged mice (21-24 months) were given a controlled cortical impact (CCI) injury to the sensorimotor cortex, and their brains were analyzed by MRI and histopathology at 1 and 2 months after CCI injury, a post-acute period. A T2 hypointensity was observed in the ipsilateral thalamus but not in the contralateral thalamus or in the thalamus of sham operated, control mice. The hypointensity was co-localized with increased histochemical staining of iron, a paramagnetic substance that causes a shortening of the T2 relaxation time. Since iron catalyzes reactions that lead to toxic free radicals, the deposition of iron in the thalamus raises the possibility that it promotes pathogenesis following TBI. Astrocyte gliosis and microgliosis were also observed in the ipsilateral thalamus in the post-acute period. The ipsilateral internal capsule displayed a trend for a 12 hypointensity, however, unlike the thalamus it did not have an increase of iron or GFAP staining, but it did have evidence of microgliosis. In summary, areas of T2 hypointensity were revealed in both the thalamus and internal capsule during the post-acute period following CCI injury, but the underlying pathology appeared to be distinct between these regions. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; LeVine, Steven M.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA; [Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA		Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd,Mail Stop 3038, Kansas City, KS 66160 USA.	nberman@kumc.edu	Ritter, Stefanie L/D-9312-2012	brooks, william/0000-0001-6227-7636	Steve Palermo Endowment; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG026482, R01 NS039123, P20 RR016475, P30 HD 02528]; Hoglund Family Foundation;  [C76 HF00201];  [R21HD050534];  [R21AG029615];  [R03AG026374];  [P20RR015563]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD050534] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015563, P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482, R21AG029615, R01AG031140, R03AG026374] Funding Source: NIH RePORTER	We thank Dr. Yong-Yue He for assistance with the CCI procedures. The study was supported in part by the Steve Palermo Endowment and grants from the National Institutes of Health (R21 AG026482, R01 NS039123, P20 RR016475 and P30 HD 02528). The Hoglund Brain Imaging Center is supported by C76 HF00201 and the Hoglund Family Foundation. Dr. Brooks is supported by R21HD050534, R21AG029615, R03AG026374 and P20RR015563.	Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Barnabe N, 2002, FREE RADICAL BIO MED, V33, P266, DOI 10.1016/S0891-5849(02)00873-0; Bermel RA, 2005, ARCH NEUROL-CHICAGO, V62, P1371, DOI 10.1001/archneur.62.9.1371; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brass SD, 2006, MULT SCLER J, V12, P437, DOI 10.1191/135248506ms1301oa; Brass Steven D, 2006, Top Magn Reson Imaging, V17, P31, DOI 10.1097/01.rmr.0000245459.82782.e4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; CHENOUFI N, 1995, J HEPATOL, V23, P166, DOI 10.1016/0168-8278(95)80331-9; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Eybl V, 2002, TOXICOL LETT, V128, P169, DOI 10.1016/S0378-4274(01)00541-0; Forge JK, 1998, LIFE SCI, V63, P2271, DOI 10.1016/S0024-3205(98)00512-8; Fredenburg AM, 1996, TOXICOLOGY, V108, P191, DOI 10.1016/0300-483X(95)03301-U; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Glickstein H, 2006, BLOOD, V108, P3195, DOI 10.1182/blood-2006-05-020867; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HE W, 2005, 65 US CURRENT POPULA; Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009; LEVINE SM, 1991, J NEUROSCI RES, V29, P413, DOI 10.1002/jnr.490290317; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Meguro R, 2007, ARCH HISTOL CYTOL, V70, P1, DOI 10.1679/aohc.70.1; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Takeuchi Y, 2002, J NEUROL NEUROSUR PS, V72, P543; TODORICH, GLIA IN PRESS; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Young JK, 2004, J HISTOCHEM CYTOCHEM, V52, P1519, DOI 10.1369/jhc.4A6375.2004; Zamboni P, 2006, J ROY SOC MED, V99, P589, DOI 10.1258/jrsm.99.11.589; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhang Y, 2007, MULT SCLER J, V13, P880, DOI 10.1177/1352458507076411	36	40	40	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 13	2009	452	2					204	208		10.1016/j.neulet.2009.01.049			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	422ZM	WOS:000264466200025	19383440	Green Accepted			2022-02-06	
J	Brennan, LK; Rubin, D; Christianm, CW; Duhaime, AC; Mirchandani, HG; Rorke-Adams, LB				Brennan, Laura K.; Rubin, David; Christianm, Cindy W.; Duhaime, Ann-Christine; Mirchandani, Haresh G.; Rorke-Adams, Lucy B.			Neck injuries in young pediatric homicide victims Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						abusive head trauma; cervical cord injury; neck injury	SHAKEN BABY SYNDROME; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NONACCIDENTAL HEAD-INJURY; CHILD-ABUSE; RADIOGRAPHIC ABNORMALITY; INFANT SYNDROME; NEUROPATHOLOGY; SHAKING; DAMAGE	Object. In this study, the authors estimate the prevalence of injuries to the soft tissue of the neck, cervical vertebrae, and cervical spinal cord among victims of abusive head trauma to better understand these injuries and their relationship to other pathophysiological findings commonly found in children with fatal abusive head trauma. Methods. The population included all homicide victims 2 years of age and younger from the city of Philadelphia, Pennysivania, who underwent a comprehensive postmortem examination at the Office of the Medical Examiner between 1995 and 2003. A retrospective review of all available postmortem records was performed, and data regarding numerous pathological findings, as well as the patient's clinical history and demographic information, were abstracted. Data were described using means and standard deviations for continuous variables, and frequency and ranges for categorical variables. Chi-square analyses were used to test for the association of neck injuries with different types of brain injury. Results. The sample included 52 children, 41 (79%) of whom died of abusive head trauma. Of these, 29 (71%) had primary cervical cord injuries: in 21 there were parenchymal injuries, in 24 meningeal hemorrhages, and in 16, nerve root avulsion/dorsal root ganglion hemorrhage were evident. Six children with abusive head trauma had no evidence of an impact to the head, and all 6 had primary cervical spinal cord injury (SCI). No child had a spinal fracture. Six of 29 children (21%) with primary cervical SCIs had soft-tissue (ligamentous or muscular) injuries to the neck, and 14 (48%) had brainstem injuries. There was a significant association of primary cervical SCI with cerebral edema (p = 0.036) but not with hypoxia-ischemia, infarction, or herniation. Conclusions. Cervical SCI is a frequent but not universal finding in young children with fatal abusive head trauma. In the present study, parenchymal and/or root injury usually occurred without evidence of muscular or ligamentous damage, or of bone dislocation or fracture. Moreover, associated brainstem injuries were not always seen. Although there was a significant association of primary cervical cord injury with cerebral edema, there was no direct relationship to brainstem herniation, hypoxia-ischemia, or infarction. This suggests that cervical spinal trauma is only 1 factor in the pathogenesis of these lesions. (DOI: 10.3171/2008.11.PEDS0835)	[Brennan, Laura K.; Rubin, David; Christianm, Cindy W.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Brennan, Laura K.; Rubin, David; Christianm, Cindy W.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Duhaime, Ann-Christine] Dartmouth Hitchcock Med Ctr, Dept Neurosurg, Lebanon, NH 03766 USA; [Mirchandani, Haresh G.; Rorke-Adams, Lucy B.] Off Med Examiner City Philadelphia, Philadelphia, PA USA; [Rorke-Adams, Lucy B.] Childrens Hosp Philadelphia, Div Anat Pathol, Philadelphia, PA 19104 USA		Brennan, LK (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	brennanl@email.chop.edu					Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; Gleckman AM, 2000, J FORENSIC SCI, V45, P1151; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; Graham E M, 1997, J Matern Fetal Med, V6, P1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Judkins AR, 2004, AM J FOREN MED PATH, V25, P29, DOI 10.1097/01.paf.0000113811.85110.54; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; KEWALRAMANI LS, 1980, PARAPLEGIA, V18, P206, DOI 10.1038/sc.1980.36; King WJ, 2003, CAN MED ASSOC J, V168, P155; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Margulies S, 2006, FORENSIC SCI INT, V164, P278, DOI 10.1016/j.forsciint.2005.12.018; MCGRORY BE, 1977, ANN NEUROL, V2, P82, DOI 10.1002/ana.410020116; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PIATT JH, 1995, PEDIATRICS, V96, P780; Ranjith RK, 2002, J PEDIATR ORTHOP B, V11, P329, DOI 10.1097/00009957-200210000-00011; Rooks VJ, 1998, PEDIATR RADIOL, V28, P193, DOI 10.1007/s002470050330; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SNEED RC, 1988, AM J DIS CHILD, V142, P965, DOI 10.1001/archpedi.1988.02150090063023; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; SWISCHUK LE, 1969, RADIOLOGY, V92, P733, DOI 10.1148/92.4.733; Thomas NH, 1995, PEDIATR NEUROSURG, V23, P188, DOI 10.1159/000120957; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596	46	40	40	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	MAR	2009	3	3					232	239		10.3171/2008.11.PEDS0835			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	414MO	WOS:000263868300014	19338471				2022-02-06	
J	Catena, RD; van Donkelaar, P; Halterman, CI; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Halterman, Charlene I.; Chou, Li-Shan			Spatial orientation of attention and obstacle avoidance following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						Spatial orientation of attention; Concussion; Obstacle avoidance; Trip	TRAUMATIC BRAIN-INJURY; DIVIDED ATTENTION; AUTOMATIC AVOIDANCE; DEFICITS; COORDINATION; BEHAVIOR; STEP	Re-injury to the brain during recovery from an initial concussion leads to increased probability of permanent brain damage or death. Recovery from concussion has been proposed to be ongoing even up to a month post-injury. The goal of the current study was to investigate the relationship between the visuospatial orientation of attention and obstacle avoidance during gait in individuals that have recently suffered a concussion (mTBI) over a month post-injury. MTBI subjects and matched control subjects performed the attentional network test (ANT), designed to isolate several different components of attention. Obstacle crossing during gait with and without a concurrent attention dividing task was also performed. Reaction times from the ANT and obstacle clearance measurements were the main dependent variables. We observed that concussed individuals had statistically more obstacle contacts than controls. The ability to orient attention in space was also statistically deficient immediately after a concussion, and this was correlated with lower obstacle clearances of the leading foot. Similar correlations could also be found between both leading and trailing foot avoidance and spatial orientation of attention in participants with concussion when attention was divided during obstacle crossing, and these relationships gradually weakened as recovery progressed. By contrast, spatial attention and obstacle clearance were not significantly correlated in control subjects. These findings indicate that patients with mTBI who display greater spatial attention deficits cross over the obstacle with a lower clearance than patients with less or without spatial attention deficits, leading to an increased probability of obstacle contact.	[Catena, Robert D.; van Donkelaar, Paul; Halterman, Charlene I.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	chou@uoregon.edu	Catena, Robert/AAT-1510-2021	Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors gratefully acknowledge the assistance of Tonya M. Parker Ph.D. with data collection.	BELL R, 1977, AM FAM PHYSICIAN, V16, P145; BORG J, 2004, J REHABIL MED, V43, pS61; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Drew T, 2008, BRAIN RES REV, V57, P199, DOI 10.1016/j.brainresrev.2007.07.017; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Humphreys GW, 2004, NAT NEUROSCI, V7, P693, DOI 10.1038/nn0704-693; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johansson RS, 2001, J NEUROSCI, V21, P6917, DOI 10.1523/JNEUROSCI.21-17-06917.2001; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; McIntosh RD, 2004, P ROY SOC B-BIOL SCI, V271, P15, DOI 10.1098/rspb.2003.2545; Mohagheghi AA, 2004, EXP BRAIN RES, V155, P459, DOI 10.1007/s00221-003-1751-7; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Patla AE, 1997, NEUROREPORT, V8, P3661, DOI 10.1097/00001756-199712010-00002; Peker T, 1997, Morphologie, V81, P13; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1984, J NEUROSCI, V4, P1863; Rice NJ, 2006, EXP BRAIN RES, V174, P176, DOI 10.1007/s00221-006-0435-5; Santangelo V, 2007, PERCEPTION, V36, P1497, DOI 10.1068/p5848; Santangelo V, 2007, J EXP PSYCHOL HUMAN, V33, P137, DOI 10.1037/0096-1523.33.1.137; Schindler I, 2004, NAT NEUROSCI, V7, P779, DOI 10.1038/nn1273; Tresilian JR, 1998, EXP BRAIN RES, V120, P352, DOI 10.1007/s002210050409; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WIJERS AA, 1989, BIOL PSYCHOL, V29, P213, DOI 10.1016/0301-0511(89)90021-5; WIJERS AA, 1987, BIOL PSYCHOL, V25, P33, DOI 10.1016/0301-0511(87)90066-4; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	40	40	41	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	MAR	2009	194	1					67	77		10.1007/s00221-008-1669-1			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	416YR	WOS:000264041900006	19082819				2022-02-06	
J	Sena, MJ; Rivers, RM; Muizelaar, JP; Battistella, FD; Utter, GH				Sena, Matthew J.; Rivers, Ryan M.; Muizelaar, J. Paul; Battistella, Felix D.; Utter, Garth H.			Transfusion practices for acute traumatic brain injury: a survey of physicians at US trauma centers	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	36th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 18-21, 2007	Orlando, FL	Soc Critical Care Med		Anemia; Transfusion; Traumatic brain injury; Survey	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; CRITICALLY-ILL; OXYGENATION; ANEMIA; IMPACT; AGE; VASORESPONSIVITY; HEMODILUTION; MORTALITY	To determine whether physician specialty influences transfusion threshold in patients with acute severe traumatic brain injury (TBI). We surveyed transfusion preferences of chiefs of trauma surgery, chairs of neurosurgery, and surgical and neurosurgical ICU directors at all 187 US Level I trauma centers using a scenario-based, multiple-choice instrument administered by mail. We evaluated the hemoglobin value used as a transfusion threshold for patients with severe acute TBI in several scenarios as well as opinions regarding the rationale for transfusion. The response rate was 58% (312/534). Mean time in practice was 17 +/- A 8 years and 65% were board certified in critical care. Neurosurgeons (NS) used a greater mean hemoglobin threshold for transfusion of TBI patients than trauma surgeons (TS) and non-surgeon intensivists (CC) whether the intracranial pressure was normal (8.3 +/- A 1.2, 7.5 +/- A 1.0, and 7.5 +/- A 0.8 g/dL; NS, TS, and CC, respectively, P < 0.001) or elevated (8.9 +/- A 1.1, 8.0 +/- A 1.1, and 8.4 +/- A 1.1 g/dL; NS, TS, and CC, respectively, P < 0.001). All three groups commonly believed that secondary ischemic injury is an important problem following TBI (74, 66, and 63%, P = 0.32), but fewer NS believed that transfusions have important immunodulatory effects (25, 91, and 83%, P < 0.001). Neurosurgeons prefer more liberal transfusion of TBI patients than TS and CC, suggesting that actual practice may depend largely on which specialist is primarily managing care. The observed clinical equipoise would justify a randomized trial of liberal versus restrictive transfusion strategies in patients with TBI.	[Sena, Matthew J.; Rivers, Ryan M.; Battistella, Felix D.; Utter, Garth H.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA; [Muizelaar, J. Paul] Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sacramento, CA 95817 USA		Sena, MJ (corresponding author), Univ Calif Davis, Med Ctr, Dept Surg, 2315 Stockton Blvd,Room 4206, Sacramento, CA 95817 USA.	matthew.sena@ucdmc.ucdavis.edu		Utter, Garth/0000-0001-7747-3429			*ACS, 2006, ACS SURG PRINC PRACT; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Claridge JA, 2002, AM SURGEON, V68, P566; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2005, CRIT CARE MED, V33, P7, DOI 10.1097/01.CCM.0000151047.33912.A3; KRAUS J, 2005, EPIDEMIOLOGY TXB TRA, P3; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; LEE SH, 1994, J NEUROSURG, V80, P469, DOI 10.3171/jns.1994.80.3.0469; Longhi L, 2002, ACT NEUR S, V81, P315; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Peabody JW, 2004, ANN INTERN MED, V141, P771, DOI 10.7326/0003-4819-141-10-200411160-00008; Purdy FR, 1997, CAN J ANAESTH, V44, P1256, DOI 10.1007/BF03012772; Raghavan M, 2005, CHEST, V127, P295, DOI 10.1378/chest.127.1.295; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Reasoner DK, 1996, ANESTH ANALG, V82, P61, DOI 10.1097/00000539-199601000-00011; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Taylor RW, 2002, CRIT CARE MED, V30, P2249, DOI 10.1097/00003246-200210000-00012; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023; Winn HR, 2004, YOUMANS NEUROLOGICAL, V5; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	35	40	42	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2009	35	3					480	488		10.1007/s00134-008-1289-z			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	408FR	WOS:000263421400012	18854976				2022-02-06	
J	Tagliaferri, F; Compagnone, C; Yoganandan, N; Gennarelli, TA				Tagliaferri, Fernanda; Compagnone, Christian; Yoganandan, Narayan; Gennarelli, Thomas A.			Traumatic Brain Injury After Frontal Crashes: Relationship With Body Mass Index	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Frontal crashes; Motor-vehicle accidents; Body mass index; Obesity	OBESITY; HABITUS; DEATH	Background: Previous studies had demonstrated that injury severity and risk of death after motor-vehicle crashes are related to human body characteristics. The purpose of this study was to clarify the relationship between body mass index (BMI) and head injury severity in front seat passengers after a frontal collision. Methods: Data from all front seat occupants with at least one injury, older than 16 years old involved in a frontal collision from 1993 to 2005 were retrieved from the National Automotive Sampling System (NASS) database. Patient and collision characteristics were analyzed. Two cohorts were defined according to BMI < or >= 30 kg/m(2). Results: A total of 6,977 patients were included in this study, 5,918 (85%) had complete data on weight and height. Patient's mean age was 37 18 years old, the median ISS was 6, interquartile range (IQR) 15, and 61 % were men. The mortality rate was positively associated to the crash delta velocity (DV) (p < 0.0001). The use of restraint system reduced the risk of death (p = 0.01). There was a significant increase in fatal outcome (p < 0.0001; RR 1.84 95% CI 1.61-2.1) and injury severity (ISS >25 p < 0.0001; RR 1.36 95% CI 1.19-1.54) in the obese cohort. Obese patients had higher chances of halving a maximum head injury (Abbreviated Injury Score head = 6) than those not obese (p = 0.003; RR 1.97 95% CI 1.522.55). Conclusion: Obese passengers are more likely to suffer a more severe head trauma after a frontal collision. Further studies with computational models are needed to determine the precise role of BMI on brain injury-related biomechanical metrics.	[Tagliaferri, Fernanda] Osped Cesare Magati, Scandiano, Italy; [Compagnone, Christian] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; [Yoganandan, Narayan; Gennarelli, Thomas A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA		Gennarelli, TA (corresponding author), 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	tgenn@mcw.edu		Compagnone, Christian/0000-0001-9951-5503			Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Ford ES, 2005, OBES RES, V13, P118, DOI 10.1038/oby.2005.15; Larsson I, 2004, INT J OBESITY, V28, P1317, DOI 10.1038/sj.ijo.0802732; Mock CN, 2002, ACCIDENT ANAL PREV, V34, P221, DOI 10.1016/S0001-4575(01)00017-3; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Moran SG, 2002, J TRAUMA, V52, P1116, DOI 10.1097/00005373-200206000-00015; ROSS R, 1994, AM J CLIN NUTR, V59, P1277, DOI 10.1093/ajcn/59.6.1277; Wang Stewart C, 2003, Annu Proc Assoc Adv Automot Med, V47, P545	11	40	40	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2009	66	3					727	729		10.1097/TA.0b013e31815edefd			3	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	419ZU	WOS:000264259000023	19276745				2022-02-06	
J	Hutchinson, P; O'Connell, M; Seal, A; Nortje, J; Timofeev, I; Al-Rawi, P; Coles, J; Fryer, T; Menon, D; Pickard, J; Carpenter, K				Hutchinson, Peter J.; O'Connell, Mark T.; Seal, Alex; Nortje, Jurgens; Timofeev, Ivan; Al-Rawi, Pippa G.; Coles, Jonathan P.; Fryer, Timothy D.; Menon, David K.; Pickard, John D.; Carpenter, Keri L. H.			A combined microdialysis and FDG-PET study of glucose metabolism in head injury	ACTA NEUROCHIRURGICA			English	Article						Microdialysis; Positron emission tomography; Cerebral metabolism; Glucose; Glycolysis; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; PENTOSE-PHOSPHATE PATHWAY; CEREBRAL-BLOOD-FLOW; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; ENERGY-METABOLISM; ISCHEMIA; FLUX; MECHANISMS	Microdialysis continuously monitors the chemistry of a small focal volume of the cerebral extracellular space. Positron emission tomography (PET) establishes metabolism of the whole brain but only for the scan's duration. This study's objective was to apply these techniques together, in patients with traumatic brain injury, to assess the relationship between microdialysis (extracellular glucose, lactate, pyruvate, and the lactate/pyruvate (L/P) ratio as a marker of anaerobic metabolism) and PET parameters of glucose metabolism using the glucose analogue [F-18]-fluorodeoxyglucose (FDG). In particular, we aimed to determine the fate of glucose in terms of differential metabolism to pyruvate and lactate. Microdialysis catheters (CMA70 or CMA71) were inserted into the cerebral cortex of 17 patients with major head injury. Microdialysis was performed during FDG-PET scans with regions of interest for PET analysis defined by the location of the gold-tipped microdialysis catheter. Microdialysate analysis was performed on a CMA600 analyser. There was significant linear relationship between the PET-derived parameter of glucose metabolism (regional cerebral metabolic rate of glucose; CMRglc) and levels of lactate (r = 0.778, p < 0.0001) and pyruvate (r = 0.799, p < 0.0001), but not with the L/P ratio. The results suggest that in this population of patients, glucose was metabolised to both lactate and pyruvate, but was not associated with an increase in the L/P ratio. This suggests an increase in glucose metabolism to both lactate and pyruvate, as opposed to a shift towards anaerobic metabolism.	[Hutchinson, Peter J.; O'Connell, Mark T.; Seal, Alex; Timofeev, Ivan; Al-Rawi, Pippa G.; Pickard, John D.; Carpenter, Keri L. H.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Nortje, Jurgens; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England; [Hutchinson, Peter J.; O'Connell, Mark T.; Nortje, Jurgens; Coles, Jonathan P.; Fryer, Timothy D.; Menon, David K.; Pickard, John D.; Carpenter, Keri L. H.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 0QQ, England		Carpenter, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	pjah2@cam.ac.uk; mark.oconnell@probescientific.com; aseal@interchange.ubc.ca; jurgens.nortje@nnuh.nhs.uk; it227@cam.ac.uk; pga20@medschl.cam.ac.uk; jpc44@wbic.cam.ac.uk; tdf21@wbic.cam.ac.uk; dkm13@wbic.cam.ac.uk; jdp1000@wbic.cam.ac.uk; klc1000@wbic.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	O'Connell, Mark/0000-0001-6272-8767; Coles, Jonathan/0000-0003-4013-679X; Timofeev, Ivan/0000-0002-1168-0393; Carpenter, Keri/0000-0001-8236-7727	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; Academy of Medical Sciences /Health Foundation; KLHC; MRC (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research Biomedical Research Centre, Cambridge. ITNational Institute for Health Research (NIHR); Codman and the Evelyn Trus; PGA; Stroke Association, UK; PJH, Academy of Medical Sciences / Health Foundation Senior Surgical Scientist Fellowship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We gratefully acknowledge the following. Study support: the Medical Research Council (Grant No G9439390 ID 65883) and the Academy of Medical Sciences /Health Foundation. Authors' support: KLHC, the MRC (Acute Brain Injury Programme Grant) and the National Institute for Health Research Biomedical Research Centre, Cambridge. IT, Codman and the Evelyn Trust; PGA, the Stroke Association, UK; PJH, Academy of Medical Sciences / Health Foundation Senior Surgical Scientist Fellowship. Technical assistance: L Maskell. Statistical advice: H Richards.	ARCHER DP, 1990, J CEREBR BLOOD F MET, V10, P624, DOI 10.1038/jcbfm.1990.114; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dohmen C, 2005, BRAIN RES, V1037, P43, DOI 10.1016/j.brainres.2004.12.046; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Feng DG, 1995, IEEE T MED IMAGING, V14, P697, DOI 10.1109/42.476111; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Hattori N, 2003, J NUCL MED, V44, P1709; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Lee JY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0002.2001; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Noske DP, 2005, SURG NEUROL, V64, P109, DOI 10.1016/j.surneu.2004.09.036; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Shulman RG, 1999, P NATL ACAD SCI USA, V96, P3245, DOI 10.1073/pnas.96.6.3245; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Spanaki MV, 1999, NEUROLOGY, V53, P1518, DOI 10.1212/WNL.53.7.1518; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; 1992, LANCET, V339, P1326	43	40	41	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2009	151	1					51	61		10.1007/s00701-008-0169-1			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	399EY	WOS:000262784400006	19099177				2022-02-06	
J	Silver, JM; Koumaras, B; Meng, XY; Potkin, SG; Reyes, PF; Harvey, PD; Katz, DI; Gunay, I; Arciniegas, DB				Silver, Jonathan M.; Koumaras, Barbara; Meng, Xiangyi; Potkin, Steven G.; Reyes, Patricio F.; Harvey, Philip D.; Katz, Douglas I.; Gunay, Ibrahim; Arciniegas, David B.			Long-term effects of rivastigmine capsules in patients with traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; open-label extension; rivastigmine; safety; efficacy	HEAD-INJURY; CHOLINE-ACETYLTRANSFERASE; ALZHEIMERS-DISEASE; FOLLOW-UP; DYSFUNCTION; FOREBRAIN; ATTENTION; MEMORY	Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study. Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (12 mg/day). Patients were assessed using a range of cognitive tests including the Hopkins Verbal Learning Test (HVLT) and the Cambridge Neuropsychological Test Automated Battery Rapid Visual Information Processing (CANTAB RVIP) A' sub-test. Safety measures included monitoring of adverse events. Results: In the extension study (n = 127), the mean duration of rivastigmine treatment was 23.8 weeks and the mean final dosage was 7.9 mg/day. Approximately 40% of patients were responders (1.0 SD improvement from baseline) on CANTAB RVIP A' or HVLT total score at week 38 or endpoint. Statistically significant changes from week 12 at week 38 were observed for CANTAB-RVIP A' and HVLT-total word recall for the sub-group of ex-placebo patients with greater severity of initial impairment. The safety profile of rivastigmine capsules was consistent with the label. Conclusions: Treatment with rivastigmine for up to 38 weeks was safe in patients with TBI and cognitive impairment.	[Koumaras, Barbara; Meng, Xiangyi; Gunay, Ibrahim] Novartis Pharmaceut, E Hanover, NJ 07936 USA; [Silver, Jonathan M.] NYU, Sch Med, New York, NY USA; [Potkin, Steven G.] Univ Calif, Irvine Med Ctr, Orange, CA USA; [Reyes, Patricio F.] Creighton Univ, Sch Med, Omaha, NE USA; [Harvey, Philip D.] Mt Sinai Sch Med, New York, NY USA; [Katz, Douglas I.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Arciniegas, David B.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Aurora, CO USA		Gunay, I (corresponding author), Novartis Pharmaceut, 1 Hlth Plaza, E Hanover, NJ 07936 USA.	ibrahim.gunay@novartis.com	Potkin, Steven G/A-2021-2013; Arciniegas, David/A-3792-2009	Potkin, Steven/0000-0003-1028-1013; Katz, Douglas/0000-0002-7502-8505	Novartis Pharmaceuticals CorporationNovartis	The authors B. Koumaras, X. Meng and I. Gunay are all employees of Novartis Pharmaceuticals Corporation. Dr Harvey was compensated by Novartis Pharmaceuticals during the clinical trial for research assistance. He received no compensation for the preparation of this paper. This study was supported by Novartis Pharmaceuticals Corporation.	Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Corey-Bloom J, 1998, INT J GERIATR PSYCHO, V1, P55; Cummings Jeffrey, 2007, Expert Rev Neurother, V7, P1457, DOI 10.1586/14737175.7.11.1457; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; *NOV PHARM CORP, 2000, EX RIV TARTR CAPS; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Winblad B, 2007, INT J GERIATR PSYCH, V22, P456, DOI 10.1002/gps.1788; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	25	40	43	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					123	132	PII 908444636	10.1080/02699050802649696			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200006	19191091				2022-02-06	
J	Kreitschmann-Andermahr, I; Poll, EM; Reineke, A; Gilsbach, JM; Brabant, G; Buchfelder, M; Fassbender, W; Faust, M; Kann, PH; Wallaschofski, H				Kreitschmann-Andermahr, I.; Poll, E. M.; Reineke, A.; Gilsbach, J. M.; Brabant, G.; Buchfelder, M.; Fassbender, W.; Faust, M.; Kann, P. H.; Wallaschofski, H.			Growth hormone deficient patients after traumatic brain injury - Baseline characteristics and benefits after growth hormone replacement - An analysis of the German KIMS database	GROWTH HORMONE & IGF RESEARCH			English	Article						Traumatic brain injury; Hypopituitarism; Quality of life; Growth hormone deficiency; Pituitary	QUALITY-OF-LIFE; PITUITARY-FUNCTION; CHILDHOOD-ONSET; ADULT-ONSET; FACTOR-I; HYPOPITUITARISM; DYSFUNCTION; CHOLESTEROL; PREVALENCE; INSUFFICIENCY	Objective: In recent years, traumatic brain in jury (TBI) has been identified as a significant cause of growth hormone deficiency (GHD). The aim of the present study was to characterize adult TBI patients with GHD to elucidate the effect of human growth hormone (hGH) replacement in TBI patients as documented in the German Pfizer International Metabolic (KIMS) database. Design: As of October 2006, 84 TBI patients had been included in the German KIMS database (n = 28 childhood-onset and 54 adult-onset GHD). All 84 TBI patients were matched with 84 patients with GHD due to non-functioning pituitary adenoma (NFPA) also included in this database. Analysis of clinical and outcome variables was performed, with comparisons of childhood vs. adult TBI. and TBI vs. NFPA patients, at baseline and one-year follow-up. Results: TBI patients with GHD were significantly younger at the onset Of pituitary disease and exhibited a significantly longer time span between GHD diagnosis and KIMS entry than NFPA patients. Those KIMS patients who had Sustained their TBI in childhood were of significantly shorter stature than adult-onset. TBI patients. At 1-year follow-up, insulin-like growth factor I (IGF-1) standard deviation score levels had returned to the normal range and quality of life (QoL), as measured by QoL- Assessment of Growth Hormone Deficiency in Adults (AGHDA) questionnaire, improved significantly in TBI as in NFPA patients. Conclusion: This analysis provides preliminary data that TBI patients with GHD benefit from hGH replacement in terms of improved QoL in a similar Fashion as do NFPA patients. Moreover. it suggests that belated diagnosis and treatment in childhood-onset GHD due to TBI might be related to a shorter final height in these children. (C) 2008 Elsevier Ltd. All rights reserved.	[Kreitschmann-Andermahr, I.; Poll, E. M.; Reineke, A.; Gilsbach, J. M.] Univ Aachen, Rhein Westfal TH Aachen, Dept Neurosurg, D-52074 Aachen, Germany; [Brabant, G.] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England; [Buchfelder, M.] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Fassbender, W.] Dept Internal Med Kempen, Kempen, Germany; [Faust, M.] Univ Cologne, Dept Internal Med 2, D-5000 Cologne 41, Germany; [Kann, P. H.] Univ Marburg, Div Endocrinol & Diabetol, D-35032 Marburg, Germany; [Wallaschofski, H.] Ernst Moritz Arndt Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, D-17487 Greifswald, Germany		Kreitschmann-Andermahr, I (corresponding author), Univ Aachen, Rhein Westfal TH Aachen, Dept Neurosurg, Pauwelsstr 30, D-52074 Aachen, Germany.	ikreitschmann-andermahr@ukaachen.de					ACERINI CL, 2007, PITUITARY; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hesse V, 1997, SOZIALPADIATRIE, V19, P20; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kendall-Taylor P, 2005, EUR J ENDOCRINOL, V152, P557, DOI 10.1530/eje.1.01877; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LIE RF, 1976, CLIN CHEM, V22, P1627; Lissett CA, 2002, CLIN ENDOCRINOL, V57, P35, DOI 10.1046/j.1365-2265.2002.01556.x; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Mukherjee A, 2003, J CLIN ENDOCR METAB, V88, P5865, DOI 10.1210/jc.2002-021741; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2006, EUR J ENDOCRINOL, V155, P553, DOI 10.1530/eje.1.02258; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476	27	40	41	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	DEC	2008	18	6					472	478		10.1016/j.ghir.2008.08.007			7	Cell Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Endocrinology & Metabolism	386KH	WOS:000261881600002	18829359				2022-02-06	
J	Kumar, A; Lalwani, S; Agrawal, D; Rautji, R; Dogra, TD				Kumar, Arvind; Lalwani, Sanjeev; Agrawal, Deepak; Rautji, Ravi; Dogra, T. D.			Fatal road traffic accidents and their relationship with head injuries: An epidemiological survey of five years	INDIAN JOURNAL OF NEUROTRAUMA			English	Article						fatal vehicular accidents; fracture; head injury		In depth studies of fatal vehicular accidents provide valuable data for implementing effective emergency services to reduce the trauma related mortality and strengthening legal measures in peak hours of fatal accidents. We aimed to study, pattern of injuries especially fatal traumatic brain injuries occurring in vehicular accidents. Postmortem reports and clinical records of victims of road traffic accident autopsied during the period of 2001-2005 at Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi, were analyzed retrospectively. Out of total 7008 medico legal autopsies conducted during the study period, 2472 (35.27 %) were of vehicular accidents. The male/female ratio was 7.49: 1. Commonest age group affected was between 21-40 years involving 1341 (54.24%) cases. Pre-hospital mortality was in 985 (39.84 %) cases. Fatal traumatic brain injuries were seen in 1699 (68.73%) cases. Skull fractures were found in 1183 (69.63%) cases of head injury; most common bone fractured was temporal bone (n= 559, 47.25%). The commonest variety of intracranial hemorrhage was subdural hemorrhage (n= 1514, 89.11%). The craniotomy was done in 297 (17.48%) cases; maximum mortality (41.07%) was seen within 4-14 days. Most commonly injured abdominal organ was liver (n= 532, 21.52%). No significant difference was evident in incidence of fatal vehicular accident on weekends and weekdays. However November month took maximum toll of deaths (n= 273, 11.04%) of total vehicular accident fatalities in five year duration. 53.20% of fatal accident occurred between 6 PM and 6 AM. The results of study emphasize the need to improve the pre hospital care with provision of trauma services at site and to establish neurosurgical facilities with trauma registry.	[Kumar, Arvind; Lalwani, Sanjeev; Dogra, T. D.] All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi 110029, India; [Agrawal, Deepak] All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India; [Rautji, Ravi] Armed Forces Med Coll, Dept Forens Med & Toxicol, Pune, Maharashtra, India		Lalwani, S (corresponding author), All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi 110029, India.	sanjulalwani2001@yahoo.com	/AAG-3032-2021; Dogra, Tirath Das/R-6517-2019	/0000-0002-5499-0746; Dogra, Tirath Das/0000-0002-5398-2285			Akang EEU, 2002, MED SCI LAW, V42, P160, DOI 10.1177/002580240204200207; [Anonymous], EC SURV DELH 2001 02, P14; [Anonymous], 2005, PROF FAT INJ S AFR 6; [Anonymous], 2004, REGIONAL HLTH FORUM; [Anonymous], 2004, INJ PREV, V10, P67; [Anonymous], 2007, EC SURV DELH 2007 08; Banthia P, 2006, JNMA J Nepal Med Assoc, V45, P238; CHANDRA J, 1979, MED SCI LAW, V19, P186, DOI 10.1177/002580247901900309; Elesha S O, 2002, Niger Postgrad Med J, V9, P38; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Friedman R, INJURIES RELATED ALL; Friedman Z, 1996, AM J FOREN MED PATH, V17, P233, DOI 10.1097/00000433-199609000-00011; Ghosh P K, 1992, J Indian Med Assoc, V90, P309; Henriksson E, 2001, ACCIDENT ANAL PREV, V33, P467, DOI 10.1016/S0001-4575(00)00060-9; Malhotra C, 2005, INTERNET J FORENSIC, V6; Meel BL, 2007, MED SCI LAW, V47, P64, DOI 10.1258/rsmmsl.47.1.64; MEHTA SP, 1968, INDIAN J MED RES, V56, P456; Menon Anand, 2008, J Forensic Leg Med, V15, P75, DOI 10.1016/j.jflm.2007.06.001; Montazeri A, 2004, PUBLIC HEALTH, V118, P110, DOI 10.1016/S0033-3506(03)00173-2; NCRB, 2005, NAT CRIM REC BUR MIN; Peden M, 2004, INJURY PREV, V10, P67, DOI 10.1136/ip.2004.005405; SAHDEV P, 1994, ACCIDENT ANAL PREV, V26, P377, DOI 10.1016/0001-4575(94)90011-6; SALGADO MSL, 1988, FORENSIC SCI INT, V36, P91, DOI 10.1016/0379-0738(88)90219-8; Sharma BR, 2001, MED SCI LAW, V41, P266, DOI 10.1177/002580240104100311	24	40	40	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0973-0508	2213-3739		INDIAN J NEUROTRAUM	Indian J. Neurotrauma	DEC	2008	5	2					63	67		10.1016/S0973-0508(08)80002-0			5	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V3M0P	WOS:000218379000002					2022-02-06	
J	Tian, HL; Geng, Z; Cui, YH; Hu, J; Xu, T; Cao, HL; Chen, SW; Chen, H				Tian, Heng-Li; Geng, Zhi; Cui, Yu-Hui; Hu, Jin; Xu, Tao; Cao, He-Li; Chen, Shi-Wen; Chen, Hao			Risk factors for posttraumatic cerebral infarction in patients with moderate or severe head trauma	NEUROSURGICAL REVIEW			English	Article						posttraumatic cerebral infarction; traumatic brain injury; risk factor; logistic regression analysis	DECOMPRESSIVE CRANIECTOMY; ISCHEMIC-STROKE; ARTERIAL SPASM; INJURY; BRAIN; HYDROCEPHALUS; HYPERTENSION; CIRCULATION; HERNIATION; VASOSPASM	We examined the incidence and timing of posttraumatic cerebral infarction (PTCI) and provide predictive factors for the development of PTCI in patients with moderate or severe traumatic brain injury. Three hundred and fifty-three consecutive patients with moderate or severe head trauma were retrospectively reviewed to determine the incidence and timing of PTCI and to evaluate the effects of age, gender, admission Glasgow Coma Scores (GCS), decompressive craniectomy, brain herniation, and low systolic blood pressure (BP) on the development of cerebral infarction. Risk factors for posttraumatic cerebral infarction were evaluated using logistic regression analysis. PTCI was observed in 36 (11.96%) of the 353 patients, and in a majority of cases, cerebral infarction developed within 2 weeks after injury. Poor admission GCS (P<0.01), low systolic BP (P<0.01), brain herniation (P<0.05), and decompression craniotomy (P<0.05) were significantly associated with the development of PTCI. No relationship was found between PTCI and gender or increased age. Posttraumatic cerebral infarction is a relatively common complication in patients with head trauma that develops early in the clinical course. Low GCS, low systolic BP, brain herniation, and decompression craniotomy may be risk factors for PTCI in patients with moderate or severe traumatic brain injury.	[Tian, Heng-Li; Cui, Yu-Hui; Hu, Jin; Xu, Tao; Cao, He-Li; Chen, Hao] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Geng, Zhi] Shanghai Jiao Tong Univ, Dept Neurol, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Chen, Shi-Wen] Shanghai Jiao Tong Univ, Dept Radiol, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China		Chen, H (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China.	chenhao_316@yahoo.com.cn		Chen, Hao/0000-0002-9943-9237	Shanghai Municipal Health Bureau [054011]; Shanghai Science and Technology Council [03ZR14059]	This study was supported by the Shanghai Municipal Health Bureau (grant no. 054011) and Shanghai Science and Technology Council (grant no. 03ZR14059).	Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Droste DW, 2003, ACTA NEUROL SCAND, V107, P241, DOI 10.1034/j.1600-0404.2003.00098.x; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Ivanusa M, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-26; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Moulin T, 1997, EUR NEUROL, V38, P10, DOI 10.1159/000112896; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; PHILLIPS SJ, 1992, ARCH INTERN MED, V152, P938, DOI 10.1001/archinte.152.5.938; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SACCO RL, 1995, NEUROLOGY, V45, pS10; SATO M, 1986, NEUROSURGERY, V18, P300, DOI 10.1227/00006123-198603000-00007; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Tomberg T A, 1989, Zh Vopr Neirokhir Im N N Burdenko, P23; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; WEISBERG LA, 1979, COMPUT TOMOGR, V3, P15, DOI 10.1016/0363-8235(75)90004-6; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Yang Xiao-feng, 2005, J Zhejiang Univ Sci B, V6, P644, DOI 10.1631/jzus.2005.B0644; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763	25	40	54	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607			NEUROSURG REV	Neurosurg. Rev.	OCT	2008	31	4					431	436		10.1007/s10143-008-0153-5			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	344YF	WOS:000258962500015	18704527				2022-02-06	
J	Cartagena, CM; Ahmed, F; Burns, MP; Pajoohesh-Ganji, A; Pak, DT; Faden, AI; Rebeck, GW				Cartagena, Casandra M.; Ahmed, Farid; Burns, Mark P.; Pajoohesh-Ganji, Ahdeah; Pak, Daniel T.; Faden, Alan I.; Rebeck, G. William			Cortical Injury Increases Cholesterol 24S Hydroxylase (Cyp46) Levels in the Rat Brain	JOURNAL OF NEUROTRAUMA			English	Article						glia cell response to injury; neurodegenerative disorders; traumatic brain injury	LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN-CHOLESTEROL; E-BASED PEPTIDE; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; IN-VITRO; CEREBROSPINAL-FLUID; GENE-EXPRESSION; NERVOUS-SYSTEM; HEAD-INJURY	In traumatic brain injury (TBI), cellular loss from initial impact as well as secondary neurodegeneration leads to increased cholesterol and lipid debris at the site of injury. Cholesterol accumulation in the periphery can trigger inflammatory mechanisms while cholesterol clearance may be anti-inflammatory. Here we investigated whether TBI altered the regulation of cholesterol 24S-hydroxylase (Cyp46), an enzyme that converts cholesterol to the more hydrophilic 24S-hydroxycholesterol. We examined by Western blot and immunohistochemistry changes in Cyp46 expression following fluid percussion injury. Under normal conditions, most Cyp46 was present in neurons, with very little measurable in glia. Cyp46 levels were significantly increased at 7 days post-injury, and cell type specific analysis at 3 days post-injury showed a significant increase in levels of Cyp46 (84%) in microglia. Since 24-hydroxycholesterol induces activation of genes through the liver X receptor (LXR), we examined protein levels of ATP-binding cassette transporter A1 and apolipoprotein E, two LXR regulated cholesterol homeostasis proteins. Apolipoprotein E and ATP-binding cassette transporter A1 were increased at 7 days post-injury, indicating that increased LXR activity coincided with increased Cyp46 levels. We found that activation of primary rat microglia by LPS in vitro caused increased Cyp46 levels. These data suggest that increased microglial Cyp46 activity is part of a system for removal of damaged cell membranes post-injury, by conversion of cholesterol to 24-hydroxycholesterol and by activation of LXR-regulated gene transcription.	[Cartagena, Casandra M.; Ahmed, Farid; Burns, Mark P.; Pajoohesh-Ganji, Ahdeah; Faden, Alan I.; Rebeck, G. William] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; [Pak, Daniel T.] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA		Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Burns, Mark P/0000-0003-4750-2000	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AG14473, F31-AG025676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F31AG025676, R01AG014473] Funding Source: NIH RePORTER	We thank Dr. Suzana Petanceska for providing the anti-Cyp46 antibody and Dr. David Russell for providing the Cyp46 cDNA and CYP46 knock-out brain tissue. This research was supported by the National Institutes of Health (R01-AG14473, F31-AG025676).	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007; Ansell Benjamin J, 2007, Curr Atheroscler Rep, V9, P57, DOI 10.1007/BF02693941; Bar-On P, 2008, J NEUROCHEM, V105, P1656, DOI 10.1111/j.1471-4159.2008.05254.x; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Bonotis K, 2008, J NEUROIMMUNOL, V193, P183, DOI 10.1016/j.jneuroim.2007.10.020; Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Gasparovic C, 2001, NEUROSCI LETT, V301, P87, DOI 10.1016/S0304-3940(01)01616-0; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Kamada H, 2003, NEUROSCI RES, V45, P91, DOI 10.1016/S0168-0102(02)00203-1; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kim HJ, 2008, P NATL ACAD SCI USA, V105, P2094, DOI 10.1073/pnas.0711599105; Langley B, 2004, J NEUROSCI RES, V77, P621, DOI 10.1002/jnr.20210; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; McGeer PL, 2008, MOVEMENT DISORD, V23, P474, DOI 10.1002/mds.21751; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Navab Mohamad, 2007, Curr Atheroscler Rep, V9, P244, DOI 10.1007/s11883-007-0026-3; *NINDS, 2002, NIH PUBL; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605; Rebeck GW, 2004, NEUROBIOL LIPIDS, V3, P1; Reynolds AD, 2008, J NEUROCHEM, V104, P1504, DOI 10.1111/j.1471-4159.2007.05087.x; Rojo LE, 2008, ARCH MED RES, V39, P1, DOI 10.1016/j.arcmed.2007.10.001; Sanossian N, 2007, STROKE, V38, P1104, DOI 10.1161/01.STR.0000258347.19449.0F; Stannard AK, 2001, J BIOL CHEM, V276, P46011, DOI 10.1074/jbc.M104812200; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Teunissen CE, 2007, J NEUROSCI RES, V85, P1499, DOI 10.1002/jnr.21266; Turley SD, 1996, J LIPID RES, V37, P1953; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Walcher D, 2006, ARTERIOSCL THROM VAS, V26, P1022, DOI 10.1161/01.ATV.0000210278.67076.8f; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Z, 2008, NEUROPATH APPL NEURO, V34, P330, DOI 10.1111/j.1365-2990.2007.00893.x	63	40	40	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1087	1098		10.1089/neu.2007.0444			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900005	18729719	Green Accepted, Green Published			2022-02-06	
J	Neumann, JO; Chambers, IR; Citerio, G; Enblad, P; Gregson, BA; Howells, T; Mattern, J; Nilsson, P; Piper, I; Ragauskas, A; Sahuquillo, J; Yau, YH; Kiening, K				Neumann, J. -O.; Chambers, I. R.; Citerio, G.; Enblad, P.; Gregson, B. A.; Howells, T.; Mattern, J.; Nilsson, P.; Piper, I.; Ragauskas, A.; Sahuquillo, J.; Yau, Y. H.; Kiening, K.		BrainIT Grp	The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hyperventilation	CEREBRAL-BLOOD-FLOW; HEAD-INJURY; MANAGEMENT; METABOLISM; OXYGENATION; ISCHEMIA	Objective: To assess the use of hyperventilation and the adherence to Brain Trauma Foundation-Guidelines (BTF-G) after traumatic brain injury (TBI). Setting: Twenty-two European centers are participating in the BrainIT initiative. Design: Retrospective analysis of monitoring data. Patients and participants: One hundred and fifty-one patients with a known time of trauma and at least one recorded arterial blood-gas (ABG) analysis. Measurements and results: A total number of 7,703 ABGs, representing 2,269 ventilation episodes (VE) were included in the analysis. Related minute-by-minute ICP data were taken from a 30 min time window around each ABG collection. Data are given as mean with standard deviation. (1) Patients without elevated intracranial pressure (ICP) (< 20 mmHg) manifested a statistically significant higher PaCO2 (36 +/- 5.7 mmHg) in comparison to patients with elevated ICP (< 20 mmHg; PaCO2: 34 +/- 5.4 mmHg, P < 0.001). (2) Intensified forced hyperventilation (PaCO2 <= 25 mmHg) in the absence of elevated ICP was found in only 49 VE (2%). (3) Early prophylactic hyperventilation (< 24 h after TBI; PaCO2 <= 35 mmHg, ICP < 20 mmHg) was used in 1,224 VE (54%). (4) During forced hyperventilation (PaCO2 <= 30 mmHg), simultaneous monitoring of brain tissue pO(2) or SjvO2 was used in only 204 VE (9%). Conclusion: While overall adherence to current BTF-G seems to be the rule, its recommendations on early prophylactic hyperventilation as well as the use of additional cerebral oxygenation monitoring during forced hyperventilation are not followed in this sample of European TBI centers. Descriptor: Neurotrauma.	[Neumann, J. -O.; Mattern, J.; Kiening, K.] Univ Klinikum Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; [Chambers, I. R.] James Cook Univ Hosp, Dept Reg Med Phys, Middlesbrough, Cleveland, England; [Citerio, G.] Hosp San Gerardo, NeuroICU, Dept Perioperat Med & Intens Care, Monza, Italy; [Enblad, P.; Howells, T.; Nilsson, P.] Univ Uppsala Hosp, Dept Clin Neurosci, Neurosurg Sect, Uppsala, Sweden; [Gregson, B. A.] Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Piper, I.] So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; [Ragauskas, A.] Kaunas Univ Technol, Telemat Sci Lab, Kaunas, Lithuania; [Sahuquillo, J.] Vall Hebron Univ Hosp, Neurotraumatol Res Unit, Dept Neurosurg, Barcelona, Spain; [Yau, Y. H.] Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland		Neumann, JO (corresponding author), Univ Klinikum Heidelberg, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Jan-Oliver.Neumann@med.uni-heidelberg.de	Citerio, Giuseppe/B-1839-2015; Sahuquillo, Juan/B-3577-2008; Ragauskas, Art/J-7486-2016	Citerio, Giuseppe/0000-0002-5374-3161; Sahuquillo, Juan/0000-0003-0713-5875; Ragauskas, Art/0000-0002-3536-554X; Gregson, Barbara/0000-0003-4868-9137			Barnes J, 2005, ACT NEUR S, V95, P39; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK MR, 2007, J NEUROTRAUMA S1, V24, pS87; BULLOCK MR, 2000, J NEUROTRAUM, V17, P513; Chambers IR, 2006, ACTA NEUROCHIR SUPPL, V96, P7; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Kerr ME, 1996, CRIT CARE MED, V24, P785, DOI 10.1097/00003246-199605000-00010; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oertel M, 2002, ACT NEUR S, V81, P71; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	22	40	44	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	SEP	2008	34	9					1676	1682		10.1007/s00134-008-1123-7			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339FF	WOS:000258562800019	18449528				2022-02-06	
J	Hoane, MR; Pierce, JL; Holland, MA; Anderson, GD				Hoane, M. R.; Pierce, J. L.; Holland, M. A.; Anderson, G. D.			Nicotinamide treatment induces behavioral recovery when administered up to 4 hours following cortical contusion injury in the rat	NEUROSCIENCE			English	Article						traumatic brain injury; therapy; window of opportunity; vitamin; recovery of function	IMPROVES FUNCTIONAL RECOVERY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; INFARCT VOLUME; PERFORMANCE	Recent studies have demonstrated nicotinamide (NAM), a soluble B-group vitamin, to be an effective treatment in experimental models of traumatic brain injury (TBI). However, research on this compound has been limited to administration regimens starting shortly after injury. This study was conducted to establish the window of opportunity for NAM administration following controlled cortical impact (CCI) injury to the frontal cortex. Groups of rats were assigned to NAM (50 mg/kg), saline (1 ml/kg), or sham conditions and received contusion injuries or sham procedures. Injections of NAM or saline were administered at 15 min, 4 h, or 8 h post-injury, followed by five boosters at 24 h intervals. Following the last injection, blood was taken for serum NAM analysis. Animals were tested on a variety of tasks to assess somatosensory performance (bilateral tactile adhesive removal and vibrissae-forelimb placement) and cognitive performance (reference and working memory) in the Morris water maze. The results of the serum NAM analysis showed that NAM levels were significantly elevated in treated animals. Behavioral analysis on the tactile removal test showed that all NAM-treated groups facilitated recovery of function compared with saline treatment. On the vibrissae-forelimb placing test all NAM-treated groups also were significantly different from the saline-treated group. However, the acquisition of reference memory was only significantly improved in the 15-min and 4-h groups. In the working memory task both the 15-min and 4-h groups also improved working memory compared with saline treatment. The window of opportunity for NAM treatment is task-dependent and extends to 8 h for the sensorimotor tests but only extends to 4 h post-injury in the cognitive tests. These results suggest that a 50 mg/kg treatment regimen starting at the clinically relevant time point of 4 h may result in attenuated injury severity in the human TBI population. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Hoane, M. R.; Pierce, J. L.; Holland, M. A.] So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA; [Anderson, G. D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA		Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15 NS045647, R15 NS045647-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Burkle A, 2001, CHEMBIOCHEM, V2, P725, DOI 10.1002/1439-7633(20011001)2:10<725::AID-CBIC725>3.0.CO;2-3; Chang ML, 2002, NEUROSCI LETT, V322, P137, DOI 10.1016/S0304-3940(01)02520-4; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Gilligan JE, 1999, MED J AUSTRALIA, V171, P617, DOI 10.5694/j.1326-5377.1999.tb123822.x; Gillmor HA, 1999, BIOMED CHROMATOGR, V13, P360, DOI 10.1002/(SICI)1099-0801(199908)13:5<360::AID-BMC893>3.0.CO;2-S; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 2005, BEHAV LAB RAT, P129; Tam D, 2005, ANN NY ACAD SCI, V1053, P258, DOI 10.1196/annals.1344.023; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483	27	40	42	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 26	2008	154	3					861	868		10.1016/j.neuroscience.2008.04.044			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	319OE	WOS:000257172500001	18514428	Green Accepted			2022-02-06	
J	Bryant, RA; Creamer, M; O'Donnell, ML; Silove, D; McFarlane, AC				Bryant, Richard A.; Creamer, Mark; O'Donnell, Meaghan L.; Silove, Derrick; McFarlane, Alexander C.			A multisite study of the capacity of acute stress disorder diagnosis to predict posttraumatic stress disorder	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; SEPTEMBER-11 TERRORIST ATTACKS; 2-YEAR PROSPECTIVE EVALUATION; NEW-YORK-CITY; BURN INJURY; SELF-REPORT; HEART-RATE; SURVIVORS; PTSD	Objective: Previous studies investigating the relationship between acute stress disorder (ASD) and posuraumatic stress disorder (PTSD) have reported mixed findings and have been flawed by small sample sizes and single sites. This study addresses these limitations by conducting a large-scale and multisite study to evaluate the extent to which ASD predicts subsequent PTSD. Method: Between April 2004 and April 2005, patients admitted consecutively to 4 major trauma hospitals across Australia (N = 597) were randomly selected and assessed for ASD (DSM-IV criteria) during hospital admission (within I month of trauma exposure) and were subsequently reassessed for PTSD 3 months after the initial assessment (N = 507). Results: Thirty-three patients (6%) met criteria for ASD, and 49 patients (10%) met criteria for PTSD at the 3-month follow-up assessment. Fifteen patients (45%) diagnosed with ASD and 34 patients (7%) not diagnosed with ASD subsequently met criteria for PTSD. The positive predictive power of PTSD criteria in the acute phase (0.60) was a better predictor of chronic PTSD than the positive predictive power of ASD (0.46). Conclusions: The majority of people who develop PTSD do not initially meet criteria for ASD. These data challenge the proposition that the ASD diagnosis is an adequate tool to predict chronic PTSD.	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Silove, Derrick] Univ New S Wales, Psychiat Res & Teaching Unit, Sch Psychiat, Sydney, NSW 2052, Australia; [Silove, Derrick] Univ New S Wales, Ctr Populat Mental Hlth Res, Sch Psychiat, Sydney, NSW 2052, Australia; [Creamer, Mark] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3010, Australia; [O'Donnell, Meaghan L.] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [McFarlane, Alexander C.] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA 5005, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unswedu.au	Young, Alexander/A-1523-2009; Bryant, Richard/AAA-6479-2019	Young, Alexander/0000-0002-9367-9213; Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2007, J ANXIETY DISORD, V21, P183, DOI 10.1016/j.janxdis.2006.09.012; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; Difede J, 2002, PSYCHOSOM MED, V64, P826, DOI 10.1097/01.PSY.0000024237.11538.08; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Engelhard IM, 2002, BEHAV RES THER, V40, P1415, DOI 10.1016/S0005-7967(02)00018-9; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Galea S, 2003, AM J EPIDEMIOL, V158, P514, DOI 10.1093/aje/kwg187; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; Guthrie R, 2000, BEHAV RES THER, V38, P899, DOI 10.1016/S0005-7967(99)00120-5; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; Kangas M, 2005, J CONSULT CLIN PSYCH, V73, P360, DOI 10.1037/0022-006X.73.2.360; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; O'Donnell ML, 2007, J TRAUMA STRESS, V20, P173, DOI 10.1002/jts.20198; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PAULSEN AS, 1988, ARCH GEN PSYCHIAT, V45, P62; PERRY S, 1992, AM J PSYCHIAT, V149, P931; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Silove D, 2003, J NERV MENT DIS, V191, P604, DOI 10.1097/01.nmd.0000087187.13408.e1; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb05251.x; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; ZATZICK DF, 1994, J NERV MENT DIS, V182, P576, DOI 10.1097/00005053-199410000-00008; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	60	40	40	0	10	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	JUN	2008	69	6					923	929		10.4088/JCP.v69n0606			7	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	318LI	WOS:000257092800006	18422396				2022-02-06	
J	Kivlin, JD; Currie, ML; Greenbaum, VJ; Simons, KB; Jentzen, J				Kivlin, Jane D.; Currie, Melissa L.; Greenbaum, V. Jordan; Simons, Kenneth B.; Jentzen, Jeffrey			Retinal hemorrhages in children following fatal motor vehicle crashes - A case series	ARCHIVES OF OPHTHALMOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SHAKEN-BABY-SYNDROME; PEDIATRIC HEAD-INJURIES; YOUNG-CHILDREN; ABUSE VICTIMS; CARDIOPULMONARY-RESUSCITATION; OPHTHALMOLOGIC FINDINGS; VALSALVA RETINOPATHY; NONACCIDENTAL INJURY; SUBDURAL HEMATOMAS	Objective: To demonstrate the severity of ocular findings in young children who died of injuries due to motor vehicle crashes. Methods: Case series of 10 children younger than 3 years who were fatally injured in motor vehicle crashes between January 1, 1994, and December 31, 2002. All children underwent autopsy that included eye examination. All available medical and autopsy records, pathology slides and photographs, and police and traffic department reports were reviewed for each case. Results: Eight patients had retinal hemorrhages, which extended into the periphery in 13 eyes and were bilateral in 7 patients. Three patients had elevated circular retinal folds. Six patients had hemorrhages below the internal limiting membrane, but no patients had deeper splitting of the retina. Nine patients had optic nerve sheath hemorrhages. Conclusion: The association of extensive, sometimes severe, ocular hemorrhages with fatal accidental trauma, compared with previous reports of accidental trauma with no or few hemorrhages, indicates the severity of injury required to cause hemorrhages of this magnitude.	[Kivlin, Jane D.; Simons, Kenneth B.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA; [Simons, Kenneth B.; Jentzen, Jeffrey] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Jentzen, Jeffrey] Milwaukee Cty Med Examiners Off, Milwaukee, WI USA; [Currie, Melissa L.] Univ Louisville, Dept Pediat, Louisville, KY 40292 USA; [Greenbaum, V. Jordan] Childrens Healthcare Atlanta, Atlanta, GA USA		Kivlin, JD (corresponding author), Med Coll Wisconsin, Dept Ophthalmol, 925 N 87th St, Milwaukee, WI 53226 USA.	jkivlin@mcw.edu					Adams G, 2004, EYE, V18, P795, DOI 10.1038/sj.eye.6701643; ALARIO A, 1990, AJDC, V140, P445; Bechtel K, 2005, PEDIATRICS, V115, P192, DOI 10.1542/peds.2004-2150; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; Chandra P, 2005, EYE, V19, P914, DOI 10.1038/sj.eye.6701665; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Duane T D, 1972, Trans Am Ophthalmol Soc, V70, P298; DUHAIME AC, 1992, PEDIATRICS, V90, P179; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HANIGAN WC, 1987, PEDIATRICS, V80, P618; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; KOSER M, 1995, ARCH PEDIAT ADOL MED, V149, P1275, DOI 10.1001/archpedi.1995.02170240093016; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; LUERSSEN TG, 1991, CONC PED N, V11, P87; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; Mehlman CT, 2000, J BONE JOINT SURG AM, V82A, P895, DOI 10.2106/00004623-200006000-00021; Meier P, 2005, GRAEF ARCH CLIN EXP, V243, P824, DOI 10.1007/s00417-005-1213-y; Mills M, 1998, J AAPOS, V2, P67, DOI 10.1016/S1091-8531(98)90066-0; MORRIS R, 1994, OPHTHALMOLOGY, V1, P101; Ness T, 2005, GRAEF ARCH CLIN EXP, V243, P859, DOI 10.1007/s00417-005-1131-z; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Plunkett J, 2001, AM J FOREN MED PATH, V22, P417, DOI 10.1097/00000433-200112000-00020; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Sandramouli S, 1997, ARCH DIS CHILD, V76, P449, DOI 10.1136/adc.76.5.449; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039; Shugerman RP, 1996, PEDIATRICS, V97, P664; Shukla D, 2005, AM J OPHTHALMOL, V140, P134, DOI 10.1016/j.ajo.2004.12.026; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, PRESSE MED, V33, P1174, DOI 10.1016/S0755-4982(04)98886-0; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; VINCHON M, 2004, CHILD NERV SYST, V20, P279; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	65	40	42	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9950	1538-3601		ARCH OPHTHALMOL-CHIC	Arch. Ophthalmol.	JUN	2008	126	6					800	804		10.1001/archopht.126.6.800			5	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	310RX	WOS:000256548900005	18541842	Bronze			2022-02-06	
J	Yager, PH; You, Z; Qin, T; Kim, HH; Takahashi, K; Ezekowitz, AB; Stahl, GL; Carroll, MC; Whalen, MJ				Yager, Phoebe H.; You, Zerong; Qin, Tao; Kim, Hyung-Hwan; Takahashi, Kazue; Ezekowitz, Alan B.; Stahl, Gregory L.; Carroll, Michael C.; Whalen, Michael J.			Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell death; complement; inflammation; lectins; mice; traumatic brain injury	CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; NITRIC-OXIDE; COMPLEMENT INHIBITION; ISCHEMIA-REPERFUSION; SPATIAL MEMORY; WATER MAZE; RATS; NEURODEGENERATION; DISEASE	Mannose binding lectin (MBL) initiates complement activation and exacerbates tissue damage after systemic ischemia/reperfusion. We tested the hypothesis that MBL activates complement and worsens outcome using two levels of controlled cortical impact (CCI) in mice. After moderate CCI (0.6 mm depth), MBL immunostaining was detected on injured endothelial cells of wild-type (WT) mice and C3d was detected in MBL KO (deficient in MBL A/C) and WT mice, suggesting that MBL is dispensable for terminal complement activation after CCI. Brain neutrophils, edema, blood-brain barrier permeability, gross histopathology, and motor dysfunction were similar in injured MBL KO and WT mice. In mice subjected to mild CCI (0.2 mm), MBL KO mice had almost two-fold increased acute CA3 cell degeneration at 6 h (P< 0.01 versus WT). Naive MBL KO mice had decreased brain volume but performed similar to WT mice in two distinct Morris water maze (MWM) paradigms. However, injured MBL KO mice had impaired performance in cued platform trials (P< 0.05 versus WT), suggesting a transient nonspatial learning deficit in injured MBL KO mice. The data suggest that MBL deficiency increases susceptibility to CCI through C3-independent mechanisms and that MBL-deficient patients may be at increased risk of poor outcome after traumatic brain injury.	[Yager, Phoebe H.; You, Zerong; Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA USA; [Yager, Phoebe H.; You, Zerong; Qin, Tao; Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Kim, Hyung-Hwan] Harvard Med Sch, Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA USA; [Takahashi, Kazue; Ezekowitz, Alan B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Dev Immunol Lab, Charlestown, MA USA; [Stahl, Gregory L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA; [Carroll, Michael C.] Harvard Med Sch, CBR Inst Biomed Res Inc, Boston, MA USA		Whalen, MJ (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA USA.	mwhalen@partners.org		Stahl, Gregory/0000-0002-4805-8119	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL052886, R01HL056086, R56HL056086, R29HL052886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI042788, R01AI042788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, P30NS045776] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL56086, HL52886] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI42788-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS045776, R01NS47447] Funding Source: Medline		Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chan RK, 2006, J IMMUNOL, V177, P8080, DOI 10.4049/jimmunol.177.11.8080; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; de la Torre JC, 2005, J CEREBR BLOOD F MET, V25, P663, DOI 10.1038/sj.jcbfm.9600057; Garthwaite G, 2006, J NEUROSCI, V26, P7730, DOI 10.1523/JNEUROSCI.1528-06.2006; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Gong MN, 2007, CRIT CARE MED, V35, P48, DOI 10.1097/01.CCM.0000251132.10689.F3; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LEHMANN S, 1993, BRAIN RES BULL, V30, P515, DOI 10.1016/0361-9230(93)90286-K; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Liu H, 2001, SCAND J IMMUNOL, V53, P489, DOI 10.1046/j.1365-3083.2001.00908.x; Madsen HO, 1998, J IMMUNOL, V161, P3169; Micheau J, 2004, BEHAV NEUROSCI, V118, P1022, DOI 10.1037/0735-7044.118.5.1022; Moller-Kristensen M, 2006, J IMMUNOL, V176, P1769, DOI 10.4049/jimmunol.176.3.1769; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; Moller-Kristensen M, 2007, J INVEST DERMATOL, V127, P1524, DOI 10.1038/sj.jid.5700748; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Steffensen R, 2000, J IMMUNOL METHODS, V241, P33, DOI 10.1016/S0022-1759(00)00198-8; Takahashi K, 2006, CURR OPIN IMMUNOL, V18, P16, DOI 10.1016/j.coi.2005.11.014; Tong XK, 2005, J NEUROSCI, V25, P11165, DOI 10.1523/JNEUROSCI.4031-05.2005; Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462; Walsh MC, 2005, J IMMUNOL, V175, P541, DOI 10.4049/jimmunol.175.1.541; Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060; Wellmer A, 2000, NEUROSCI LETT, V296, P137, DOI 10.1016/S0304-3940(00)01645-1; White MK, 2002, EXP CELL RES, V280, P270, DOI 10.1006/excr.2002.5646; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zanetta J P, 2003, Prog Mol Subcell Biol, V32, P75; Zhang M, 2006, J IMMUNOL, V177, P4727, DOI 10.4049/jimmunol.177.7.4727	42	40	40	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2008	28	5					1030	1039		10.1038/sj.jcbfm.9600605			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	292JC	WOS:000255261300017	18183030	Bronze			2022-02-06	
J	Runyan, DK				Runyan, Desmond K.			The challenges of assessing the incidence of inflicted traumatic brain injury - A world perspective	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							SHAKEN BABY SYNDROME; CHILDREN	Objective: Commentary on the methods available for ascertaining the incidence of inflicted traumatic brain injury (inflicted TBI) and the difficulties involved in defining and measuring this condition in young children. Design: Review of published and unpublished international data regarding parental shaking of infants compared to studies assessing incidence. Results: Review of parental report data reveal that the shaking of young children is a surprisingly common act in a wide variety of countries and cultures. While 2.6% of parents of children aged under 2 years in the U.S. report shaking their child as an act of "discipline," survey data from lesser-developed countries on four continents indicate that shaking, as a form of discipline, may be many times more common among infants in their countries and that the consequences, short of hospitalization or death, are inadequately studied. Methodologic challenges to epidemiologic work to develop better estimates are discussed. Conclusions: These data highlight the challenges faced in ascertaining the epidemiology of inflicted TBI in young children. While there is scientific evidence that the shaking of young children can produce profound destruction of children's brains and lives, these data reveal that there are many other children who are shaken by their caregivers but escape the acute clinical presentation of "shaken baby syndrome" or for whom the injuries are not recognized as due to inflicted TBI. The impact of these private acts must be further studied as there may be other long-lasting and serious intracranial impacts that have not been characterized.	Univ N Carolina, Dept Social Med, Chapel Hill, NC 27599 USA		Runyan, DK (corresponding author), Univ N Carolina, Dept Social Med, Campus Box 7240, Chapel Hill, NC 27599 USA.	drunyan@unc.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029			CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; *GALL ORG, 1996, DISC CHILDR AM; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; MINNS R, 2006, SHAKEN BABY SYNDROME; Minns RA, 2005, J ROY COLL PHYS EDIN, V35, P5; Runyan DK, 2002, WORLD REPORT VIOLENC; Straus MA, 1998, CHILD ABUSE NEGLECT, V22, P249, DOI 10.1016/S0145-2134(97)00174-9; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; *UNICEF STAT, 2005, MULT IND CLUST SURV	14	40	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S112	S115		10.1016/j.amepre.2008.01.011			4	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300003	18374259				2022-02-06	
J	Gaylord, KM; Cooper, DB; Mercado, JM; Kennedy, JE; Yoder, LH; Holcomb, JB				Gaylord, Kathryn M.; Cooper, Douglas B.; Mercado, Janyna M.; Kennedy, Jan E.; Yoder, Linda H.; Holcomb, John B.			Incidence of posttraumatic stress disorder and mild traumatic brain injury in burned service members: Preliminary report	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						burn injury; blast injury; PTSD; mild TBI	MENTAL-DISORDERS; HEALTH-PROBLEMS; BLAST INJURY; SYMPTOMS; OUTCOMES; IRAQ; AFGHANISTAN; OPERATIONS; MILITARY; CARE	Background: Although sustaining physical injury in theater increases service members' risk for posttraumatic stress disorder (PTSD), exposure to explosive munitions may increase the risk of mild traumatic brain injury (mTBI). We hypothesized a higher incidence of PTSD and mTBI in service members who sustained both burn and explosion injuries than in nonexplosion exposed service members. Methods: A retrospective review of PTSD and mTBI assessments was completed on burned service members between September 2005 and August 2006. Subjects were divided into cohort groups: (1) PTSD and mTBI, (2) PTSD and no mTBI, (3) mTBI and no PTSD, (4) no mTBI and no PTSD. Specific criteria used for group classification were based on subjects' total score on Posttraumatic Stress Disorder Checklist, Military version (PCL-M), clinical interview, and record review to meet American Congress of Rehabilitation Medicine criteria for mTBI. Descriptive analyses were used. Results: Seventy-six service members met the inclusion criteria. The incidence rate of PTSD was 32% and mTBI was 41%. Eighteen percent screened positive for PTSD and mTBI; 13% screened positive for PTSD, but not mTBI; 23% screened positive for mTBI but not PTSD; 46% did not screen positive for either PTSD or mTBI. Conclusion: Given the high incidence of these disorders in burned service members, further screening of PTSD and TBI appears warranted. Because symptom presentation in PTSD and mTBI is clinically similar in acute and subacute stages, and treatments can vary widely, further research investigating symptom profiles of PTSD and mTBI is warranted.	[Gaylord, Kathryn M.; Holcomb, John B.] USAISR, Ft Sam Houston, TX 78234 USA; [Cooper, Douglas B.; Mercado, Janyna M.] Brooke Army Med Ctr, Dept Behav Med, Ft Sam Houston, TX 78234 USA; [Kennedy, Jan E.] Wilford Hall USAF Med Ctr, Dept Neurol, Def & Vet Brain Injury Ctr, Lackland AFB, TX 78236 USA; [Yoder, Linda H.] Univ Texas Austin, Sch Nursing, Austin, TX 78712 USA		Gaylord, KM (corresponding author), USAISR, 3400 Rawley E Chambers Rd, Ft Sam Houston, TX 78234 USA.	kathryn.gaylord@amedd.army.mil					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Baur KM, 1998, J BURN CARE REHABIL, V19, P230, DOI 10.1097/00004630-199805000-00009; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cancio LC, 2005, J BURN CARE REHABIL, V26, P151, DOI 10.1097/01.BCR.0000155540.31879.FB; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Defense and Veterans Brain Injury Center Working Group, 2006, AC MAN MILD TRAUM BR; Dobie DJ, 2004, ARCH INTERN MED, V164, P394, DOI 10.1001/archinte.164.4.394; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Hoge CW, 2006, JAMA-J AM MED ASSOC, V296, P2678, DOI 10.1001/jama.296.22.2678-b; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Kraus J. F., 1999, REHABILITATION ADULT, P3; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; TEASDALE G, 1974, LANCET, V2, P81; Van Loey NEE, 2003, J TRAUMA STRESS, V16, P361, DOI 10.1023/A:1024465902416; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F, 1995, TRAUMATIC STRESS THE, P103	29	40	41	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2		S			S200	S204		10.1097/TA.0b013e318160ba42			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	265UJ	WOS:000253386200054	18376167				2022-02-06	
J	Corrigan, JD; Deutschle, JJ				Corrigan, John D.; Deutschle, James J., Jr.			The presence and impact of traumatic brain injury among clients in treatment for co-occurring mental illness and substance abuse	BRAIN INJURY			English	Article						traumatic brain injury; substance abuse; mental illness	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; ASSOCIATION; DEPRESSION; MANIA; PSYCHOPATHOLOGY; INDIVIDUALS; RELIABILITY; PREVALENCE	Objectives: To compare diagnostic and treatment-related differences between persons participating in treatment for dually diagnosed substance use disorders and severe mental illness who have or do not have a history of traumatic brain injury (TBI). Design: Prospective cohort. Interventions: Not applicable. Primary measures: Demographic information, diagnostic data, pre-treatment status, treatment participation and staff assessment of functioning. Results: Seventy-two percent of participants in treatment for dually diagnosed substance use disorders and severe mental illness reported a history of at least one TBI. Participants with TBI had greater morbidity as reflected in more complex psychiatric diagnoses and greater likelihood of being diagnosed with an Axis II personality disorder. Participants with a TBI showed tendencies toward earlier onset of substance use and worse current functioning. Both a greater number of injuries and earlier age at first TBI showed some indications of being associated with worse morbidity. Conclusions: Individuals dually diagnosed with substance use disorders and severe mental illness may have a high rate of TBI, which in turn could contribute to important clinical and treatment differences. Results also suggested the need for validated methods of identifying aspects of a prior history of TBI that provide more information than presence/absence.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Deutschle, James J., Jr.] Hopewell Counseling & Consultat, Newark, OH USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011		CSAT SAMHSA HHS [H79TI12708] Funding Source: Medline		ALTERMAN AI, 1985, J STUD ALCOHOL, V46, P256, DOI 10.15288/jsa.1985.46.256; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; Corrigan J.D., 2005, REHABILITATION TRAUM, P133; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Deb S, 1999, AM J PSYCHIAT, V156, P374; *DEP HLTH HUM SERV, 2005, RES 2005 NAT SURV DR; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Drake RE, 2001, PSYCHIAT SERV, V52, P469, DOI 10.1176/appi.ps.52.4.469; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; GORDON W, 2002, AM C REH MED PHIL PA; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holtzer R, 2000, BRAIN INJURY, V14, P959, DOI 10.1080/02699050050191904; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LYONS J, 1998, GEN HOSP PSYCHIAT, V10, P292; MALLOY P, 1990, ADDICT BEHAV, V15, P431, DOI 10.1016/0306-4603(90)90029-W; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mueser KT, 2003, INTEGRATED TREATMENT; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RIESS H, 1987, J CLIN PSYCHIAT, V48, P29; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sacks S., 2005, SUBSTANCE ABUSE TREA; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; STREETER CC, 1995, J NERV MENT DIS, V183, P577, DOI 10.1097/00005053-199509000-00003; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; TOWNSEND W, 1999, EMERGING BEST PRACTI; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANREEKUM R, 1993, J PSYCHIATR NEUROSCI, V18, P121; WALKER R, 2001, FUNCTIONALITY SCALE; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	49	40	40	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					223	231		10.1080/02699050801938967			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500003	18297594				2022-02-06	
J	McHugh, L; Wood, RL				McHugh, Louise; Wood, Rodger L.			Using a temporal discounting paradigm to measure decision-making and impulsivity following traumatic brain injury: A pilot study	BRAIN INJURY			English	Article						temporal discounting; traumatic brain injury; decision-making; impulsivity	DELAY; REWARDS; PERSONALITY; BEHAVIOR; AMYGDALA; CHOICE	Primary objective: This study reports on a pilot study using a temporal discounting paradigm and a standardized impulsivity questionnaire to examine decision-making in a group of brain injured patients and age matched controls. Methods and procedures: Participants were asked to choose between a larger reward available at a specified time in the future and smaller reward available immediately. Outcome and results: Each of the two groups demonstrated temporal discounting; that is, the subjective value of the reward decreased with increasing delay. However, the TBI group discounted more than the controls, suggesting that their decision-making was more impulsive. Conclusion: The results suggest that a temporal discounting paradigm might be a useful method of assessing decision-making after head trauma, especially in cases where capacity to make decisions about financial awards is an issue or in respect of money management generally.	[McHugh, Louise] Univ Wales Swansea, Sch Human Sci, Brain Injury Res Grp, Dept Psychol, Swansea SA2 8PP, W Glam, Wales		McHugh, L (corresponding author), Univ Wales Swansea, Sch Human Sci, Brain Injury Res Grp, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	l.mchugh@swansea.ac.uk		McHugh, Louise/0000-0002-2526-4649			Ainslie G., 2001, BREAKDOWN WILL; Bechara A, 2003, ANN NY ACAD SCI, V985, P356, DOI 10.1111/j.1749-6632.2003.tb07094.x; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC, P21; Crean JP, 2000, EXP CLIN PSYCHOPHARM, V8, P155, DOI 10.1037/1064-1297.8.2.155; Critchfield TS, 2001, J APPL BEHAV ANAL, V34, P101, DOI 10.1901/jaba.2001.34-101; Dixon MR, 2005, BEHAV INTERVENT, V20, P101, DOI 10.1002/bin.173; FEINGOLD A, 1994, PSYCHOL BULL, V116, P429, DOI 10.1037/0033-2909.116.3.429; Fossati A, 2002, PERCEPT MOTOR SKILL, V95, P621, DOI 10.2466/PMS.95.6.621-635; Green L, 1999, J EXP PSYCHOL LEARN, V25, P418, DOI 10.1037/0278-7393.25.2.418; GREEN L, 1993, BEHAV PHILOS, V21, P37; Greve KW, 2001, BRAIN INJURY, V15, P255; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Johnson MW, 2002, J EXP ANAL BEHAV, V77, P129, DOI 10.1901/jeab.2002.77-129; Kirby KN, 1996, PSYCHON B REV, V3, P100, DOI 10.3758/BF03210748; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; MISCHEL W, 1989, SCIENCE, V244, P933, DOI 10.1126/science.2658056; Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x; MYERSON J, 1995, J EXP ANAL BEHAV, V64, P263, DOI 10.1901/jeab.1995.64-263; PATTERSON CM, 1993, PSYCHOL REV, V100, P716, DOI 10.1037/0033-295X.100.4.716; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; RACHLIN H, 1972, J EXP ANAL BEHAV, V17, P15, DOI 10.1901/jeab.1972.17-15; Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121; Weber EU, 2007, PSYCHOL SCI, V18, P516, DOI 10.1111/j.1467-9280.2007.01932.x; Wood RL, 2001, BRAIN DAM B, P3; Yarkoni T, 2005, J EXP ANAL BEHAV, V84, P537, DOI 10.1901/jeab.2005.121-04	29	40	41	1	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					715	721		10.1080/02699050802263027			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600009	18608202				2022-02-06	
J	Perez-Barcena, J; Llompart-Pou, JA; Homar, J; Abadal, JM; Raurich, JM; Frontera, G; Brell, M; Ibanez, J; Ibanez, J				Perez-Barcena, Jon; Llompart-Pou, Juan A.; Homar, Javier; Abadal, Josep M.; Raurich, Joan M.; Frontera, Guillem; Brell, Marta; Ibanez, Javier; Ibanez, Jordi			Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial	CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; LIPID-PEROXIDATION; INTENSIVE-CARE; PROTECTION; DRAINAGE	Introduction Experimental research has demonstrated that the level of neuroprotection conferred by the various barbiturates is not equal. Until now no controlled studies have been conducted to compare their effectiveness, even though the Brain Trauma Foundation Guidelines recommend that such studies be undertaken. The objectives of the present study were to assess the effectiveness of pentobarbital and thiopental in terms of controlling refractory intracranial hypertension in patients with severe traumatic brain injury, and to evaluate the adverse effects of treatment. Methods This was a prospective, randomized, cohort study comparing two treatments: pentobarbital and thiopental. Patients who had suffered a severe traumatic brain injury (Glasgow Coma Scale score after resuscitation <= 8 points or neurological deterioration during the first week after trauma) and with refractory intracranial hypertension (intracranial pressure > 20 mmHg) first-tier measures, in accordance with the Brain Trauma Foundation Guidelines. Results A total of 44 patients (22 in each group) were included over a 5-year period. There were no statistically significant differences in ' baseline characteristics, except for admission computed cranial tomography characteristics, using the Traumatic Coma Data Bank classification. Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03). Under logistic regression analysis -undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital -thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027). There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection. Conclusions Thiopental appeared to be more effective than pentobarbital in controlling intracranial hypertension refractory to first-tier measures. These findings should be interpreted with caution because of the imbalance in cranial tomography characteristics and the different dosages employed in the two arms of the study. The incidence of adverse effects was similar in both groups. Trial Registration (Trial registration: US Clinical Trials registry NCT00622570.)	[Perez-Barcena, Jon; Llompart-Pou, Juan A.; Homar, Javier; Abadal, Josep M.; Raurich, Joan M.; Ibanez, Jordi] Son Dureta Univ Hosp, Intens Care Med Dept, Palma de Mallorca 07014, Spain; [Perez-Barcena, Jon] Univ Autonoma Barcelona, Dept Surg, Bellaterra 08193, Spain; [Frontera, Guillem] Son Dureta Univ Hosp, Invest Unit, Palma de Mallorca 07014, Spain; [Brell, Marta; Ibanez, Javier] Son Dureta Univ Hosp, Dept Neurosurg, Palma de Mallorca 07014, Spain		Perez-Barcena, J (corresponding author), Son Dureta Univ Hosp, Intens Care Med Dept, Andrea Doria 55, Palma de Mallorca 07014, Spain.	jperez@hsd.es		Ibanez, Javier/0000-0003-3735-8332	Spanish government's Fondo de Investigacion SanitariaInstituto de Salud Carlos III [FIS PI020642]	This research was supported by a public grant from the Spanish government's Fondo de Investigacion Sanitaria (FIS PI020642), awarded to Dr J Perez Barcena. This public institution will not gain or lose financially from the publication of this manuscript in any way.	Abadal-Centellas JM, 2007, J TRAUMA, V62, P282, DOI 10.1097/01.ta.0000199422.01949.78; Almaas R, 2000, ANESTHESIOLOGY, V92, P764, DOI 10.1097/00000542-200003000-00020; Bratton S L, 2007, J NEUROTRAUMA S1, V24, pS71, DOI DOI 10.1089/NEU.2007.9985; Cole DJ, 2001, CAN J ANAESTH, V48, P807, DOI 10.1007/BF03016699; Drummond JC, 1996, ANESTHESIOLOGY, V85, P1504, DOI 10.1097/00000542-199612000-00050; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HATANO Y, 1989, ANESTHESIOLOGY, V71, P80, DOI 10.1097/00000542-198907000-00015; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; Munch EC, 2001, CRIT CARE MED, V29, P976; Perez-Barcena J, 2005, NEUROCIRUGIA, V16, P5; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; ROESCH C, 1983, ANESTH ANALG, V62, P49; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Shibuta S, 1998, BRIT J PHARMACOL, V124, P804, DOI 10.1038/sj.bjp.0701884; SMITH DS, 1980, ANESTHESIOLOGY, V53, P186, DOI 10.1097/00000542-198009000-00002; STEEN PA, 1980, ANESTHESIOLOGY, V53, P183; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537	23	40	40	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	4							R112	10.1186/cc6999			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360UF	WOS:000260082700028	18759980	Green Published, gold			2022-02-06	
J	Ponsford, JL; Myles, PS; Cooper, DJ; Mcdermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SA				Ponsford, Jennie L.; Myles, Paul S.; Cooper, D. James; Mcdermott, Francis T.; Murray, Lynnette J.; Laidlaw, John; Cooper, Gregory; Tremayne, Ann B.; Bernard, Stephen A.			Gender differences in outcome in patients with hypotension and severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						traumatic brain injury; gender; outcome	SEVERE HEAD-INJURY; RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; SEX-RELATED DIFFERENCES; POSTMENOPAUSAL WOMEN; FEMALE RATS; REHABILITATION; EXPERIENCE; HORMONES	Background: Animal studies have identified hormonal influences on responses to injury and recovery, creating a potential gender effect on outcome. Progesterone and oestrogen are thought to afford protection in the immediate post-injury period, suggesting females have an advantage, although there has been Limited evidence of this in human outcome studies. Methods: This study examined the influence of gender on outcome in 229 adults (151 males), aged > 17 years, with severe blunt head trauma, initial GCS < 9 and hypotension, recruited into a randomised controlled trial of pre-hospital, hypertonic saline resuscitation versus conventional fluid management. Outcome was measured by survival and Glasgow Outcome Scale-Extended version (GOS-E) scores at 6 months post-injury. Results: Females recruited into the study had a higher mean age. Females were more likely to be injured as passengers and pedestrians and mates as drivers or motorcyclists. There were no gender differences in GCS or injury severity scores, ICP, cerebral perfusion pressure, gas exchange (PaO2/FiO(2) ratio), or duration of mechanical ventilation. After controlling for GCS, age and cause of injury, females had a lower rate of survival. They also showed a lower rate of good outcome (GOS-E score > 4) at 6 months, but this appeared to reflect the lower rate of initial survival. Those females surviving had similar outcomes to mates. Conclusions: The study provides no evidence that females fare better than mates following severe TBI, suggesting rather that females may fare worse. (c) 2007 Elsevier Ltd. All rights reserved.	[Ponsford, Jennie L.] Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia; [Myles, Paul S.] Monash Univ, Alfred Hosp, Dept Anesthesia, Clayton, Vic 3168, Australia; [Cooper, D. James; Murray, Lynnette J.] Monash Univ, Alfred Hosp, Dept Intens Care, Clayton, Vic 3168, Australia; [Laidlaw, John] Royal Melbourne Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Cooper, Gregory; Bernard, Stephen A.] Metropolitan Ambulance Serv, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au; p.myles@alfred.org.au; j.cooper@alfred.com.au; mcdf@ozemail.com.au; l.murray@alfred.org.au; John.Laidlaw@mh.org.au; Greg.cooper@mas.vic.gov.au; annt2@bigpond.com; Stephen.bernard@dhs.vic.gov.au	Myles, Paul/AAU-9524-2020; Cooper, D. James/G-7961-2013	Myles, Paul/0000-0002-3324-5456; Cooper, D. James/0000-0002-5872-9051			Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Forgie ML, 2003, BEHAV NEUROSCI, V117, P257, DOI 10.1037/0735-7044.117.2.257; Forgie ML, 1998, BEHAV NEUROSCI, V112, P141, DOI 10.1037/0735-7044.112.1.141; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; Juraska JM, 1990, CEREBRAL CORTEX RAT, P483; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; KRAUS JF, 2000, NEUROSURG FOCUS ARTI, V5, P8; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STEWART J, 1994, BRAIN RES, V654, P149, DOI 10.1016/0006-8993(94)91581-4; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	33	40	42	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2008	39	1					67	76		10.1016/j.injury.2007.08.028			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	264GE	WOS:000253274700010	18164301				2022-02-06	
J	Sacco, K; Angeleri, R; Bosco, FM; Colle, L; Mate, D; Bara, BG				Sacco, K.; Angeleri, R.; Bosco, F. M.; Colle, L.; Mate, D.; Bara, B. G.			Assessment Battery for Communication - ABaCo: A new Instrument for the Evaluation of Pragmatic Abilities	JOURNAL OF COGNITIVE SCIENCE			English	Article						Assessment; Communication; Pragmatic abilities; Battery; Cognitive Pragmatics		The Assessment Battery for Communication (ABaCo) is a new clinical instrument for the evaluation of communicative abilities in patients with neuropsychological and psychiatric disorders, such as aphasia, right hemispheric damage, closed head injury, autism and schizophrenia. ABaCo consists of 5 scales, investigating comprehension and production of linguistic and extralinguistic acts, paralinguistic expressions, appropriateness with respect to discourse and social norms, and management of conversation. Validity measures (content and construct validity) and reliability measures (inter-rater reliability and internal consistency) were computed. The experts' content validity evaluations indicate an excellent match between test items and the measurement of pragmatic abilities, as well as the suitability of the battery for both children and adults. Regarding the other psychometric measures, computed on 390 normal children in different age groups, factor analysis shows the validity of the underlying theoretical construct. Reliability analyses show a high inter-rater agreement, suggesting that the battery can be administered and scored by any trained judge, and a good internal consistency, suggesting that the various items that make up each scale are coherent and contribute to the measurement of communicative abilities.	[Sacco, K.; Angeleri, R.; Bosco, F. M.; Colle, L.; Mate, D.; Bara, B. G.] Univ Turin, Ctr Cognit Sci, Turin, Italy; [Sacco, K.; Angeleri, R.; Bosco, F. M.; Colle, L.; Mate, D.; Bara, B. G.] Univ Turin, Dept Psychol, Turin, Italy; [Sacco, K.] Koelliker Hosp, Neuroradiol, CCS FMRI, Turin, Italy; [Sacco, K.] Univ Turin, Dept Psychol, Turin, Italy; [Sacco, K.; Bosco, F. M.; Colle, L.; Bara, B. G.] Inst Neurosci, Turin, Italy		Angeleri, R (corresponding author), Univ Turin, Ctr Cognit Sci, Turin, Italy.	angeleri@psych.unito.it	bosco, francesca marina/B-6746-2013	bosco, francesca marina/0000-0001-6101-8587	Fondazione Cassa di Risparmio di Torino, CRT Foundation, Italy	We thank Gianluca Bo, Marco Del Giudice and Marco Zuffranieri for statistical assistance, and Ivan Enrici for participating in the initial stages of this project, and all the participants in this study. This research has been supported by Fondazione Cassa di Risparmio di Torino, CRT Foundation, Italy.	AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1207/s15516709cog1702_2; AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Austin JL., 1962, DO THINGS WORDS, V2; Bara B.G., 1999, P 3 EUR C COGN SCI R, P285; Bara BG, 2000, BRAIN COGNITION, V43, P21; Bara BG, 1999, BRAIN LANG, V68, P507, DOI 10.1006/brln.1999.2125; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2000, BRAIN LANG, V71, P10, DOI 10.1006/brln.1999.2198; Bara BG, 2001, BRAIN LANG, V77, P216, DOI 10.1006/brln.2000.2429; Bara BG, 1999, PROCEEDINGS OF THE TWENTY FIRST ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P55; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; BARA BG, 2008, COGNITIVE PRAGMATICS; Becchio C, 2006, CONSCIOUS COGN, V15, P64, DOI 10.1016/j.concog.2005.03.006; Bishop DVM, 1998, J CHILD PSYCHOL PSYC, V39, P879, DOI 10.1017/S0021963098002832; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Brown G., 1983, DISCOURSE ANAL SOCIO; Bryan K., 1995, RIGHT HEMISPHERE LAN, V2nd ed.; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Carlomagno S, 2000, NEUROPSYCHOL REHABIL, V10, P337, DOI 10.1080/096020100389183; Carlomagno S., 1994, PRAGMATIC APPROACHES; Clark Herbert H., 1996, USING LANGUAGE; CLARK HH, 1986, COGNITION, V22, P1, DOI 10.1016/0010-0277(86)90010-7; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COHEN M, 1990, BRAIN LANG, V38, P122, DOI 10.1016/0093-934X(90)90105-P; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Cutica I., 2005, P 27 INT C COGN SCI; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; Davis G. A., 1985, ADULT APHASIA REHABI; DeVellis R.F., 1991, SCALE DEV; Emmorey K, 2003, NEUROPSYCHOLOGIA, V41, P85, DOI 10.1016/S0028-3932(02)00089-1; Frattali C. M., 1995, AM SPEECH LANGUAGE H; Gardner H, 1986, RIGHT HEMISPHERE COM; Gibbs Raymond W., 1994, POETICS MIND FIGURAT; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Grice H.P., 1989, STUDIES WAYS WORDS; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; Hinde R.A., 1972, NONVERBAL COMMUNICAT; Holland A., 1998, COMMUNICATION ACTIVI; Holland A., 1980, COMMUNICATIVE ABILIT; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; Kasher A., 1981, FESTSCHRIFT NATIVE S, P93; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Letts C, 2001, INT J LANG COMM DIS, V36, P307; Likert R.A., 1932, TECHNIQUE MEASUREMEN, V140, P1; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; Noveck IA, 2001, COGNITION, V78, P165, DOI 10.1016/S0010-0277(00)00114-1; Nunnaly J.C., 1978, PSYCHOMETRIC THEORY; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; Penn C, 1985, S Afr J Commun Disord, V32, P18; Pickering MJ, 2004, BEHAV BRAIN SCI, V27, P169; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Rinaldi MC, 2004, CORTEX, V40, P479, DOI 10.1016/S0010-9452(08)70141-2; Sarno M. T., 1969, FUNCTIONAL COMMUNICA; Schegloff EA., 1978, STUDIES ORG CONVERSA, P7, DOI DOI 10.1016/B978-0-12-623550-0.50008-2; Searle J. R., 1969, SPEECH ACTS ESSAY PH; Spector CC, 1996, LANG SPEECH HEAR SER, V27, P307, DOI 10.1044/0161-1461.2704.307; Surian L, 1996, Cogn Neuropsychiatry, V1, P55, DOI 10.1080/135468096396703; Tager-Flusberg H, 2000, UNDERSTANDING OTHER, P124; Tirassa M, 1999, BRAIN LANG, V68, P419, DOI 10.1006/brln.1999.2121; Walter H, 2004, J COGNITIVE NEUROSCI, V16, P1854, DOI 10.1162/0898929042947838; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Zanini S, 2005, NEUROL SCI, V26, P13, DOI 10.1007/s10072-005-0377-x; Zanini S., 2003, BATTERIA LINGUAGGIO	69	40	40	1	6	SEOUL NATL UNIV, INST COGNITIVE SCIENCE	SEOUL	SEOUL NATL UNIV, SEOUL, 151-742, SOUTH KOREA	1598-2327			J COGN SCI	J. Cogn. Sci.		2008	9	2					111	157					47	Linguistics	Emerging Sources Citation Index (ESCI)	Linguistics	V2U8Q	WOS:000217931900002					2022-02-06	
J	Tolonen, A; Turkka, J; Salonen, O; Ahoniemi, E; Alaranta, H				Tolonen, Anu; Turkka, Jukka; Salonen, Oili; Ahoniemi, Eija; Alaranta, Hannu			Traumatic brain injury is under-diagnosed in patients with spinal cord injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; spinal cord injury; co-occurrence; rehabilitation	CLOSED-HEAD-INJURY; FUNCTIONAL CLASSIFICATION; INTERNATIONAL STANDARDS; CONSCIOUSNESS; DEFICITS; AMNESIA; SCALE	Objective: To investigate the occurrence and severity of traumatic brain injury in patients with traumatic spinal cord injury. Design: Cross-sectional study with prospective neurological, neuropsychological and neuroradiological examinations and retrospective medical record review. Patients: Thirty-one consecutive, traumatic spinal cord injury patients on their first post-acute rehabilitation period in a national rehabilitation centre. Methods: The American Congress of Rehabilitation Medicine diagnostic criteria for mild traumatic brain injury were applied. Assessments were performed with neurological and neuropsychological examinations and magnetic resonance imaging 1.5T. Results: Twenty-three of the 31 patients with spinal cord injury (74%) met the diagnostic criteria for traumatic brain injury. Nineteen patients had sustained a loss of consciousness or post-traumatic amnesia. Four patients had a focal neurological finding and 21 had neuropsychological findings apparently due to traumatic brain injury. Trauma-related magnetic resonance imaging abnormalities were detected in 10 patients. Traumatic brain injury was classified as moderate or severe in 17 patients and mild in 6 patients. Conclusion: The results suggest a high frequency of traumatic brain injury in patients with traumatic spinal cord injury, and stress a special diagnostic issue to be considered in this patient group.	Finnish Associat People Mobil Disabilit, Kapyla Rehabil Ctr, FI-00251 Helsinki, Finland; Univ Helsinki, Dept Radiol, Helsinki, Finland		Tolonen, A (corresponding author), Finnish Associat People Mobil Disabilit, Kapyla Rehabil Ctr, POB 103, FI-00251 Helsinki, Finland.	anu.tolonen@invalidiliitto.fi					Ahmed S, 2000, BRAIN INJURY, V14, P765; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; AYYOUB Z, 2002, SPINAL CORD MED PRIN; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MAHMOUD A, 1999, INJURY REHABIL, V5, P42; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; OJANEN M, 1993, RESPIRATION, V60, P96; OJANEN M, 1997, EVALUATION, V3, P135; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED	25	40	45	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2007	39	8					622	626		10.2340/16501977-0101			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	225UK	WOS:000250543400006	17896053	Green Submitted, gold			2022-02-06	
J	Innes, CRH; Jones, RD; Dalrymple-Alford, JC; Hayes, S; Hollobon, S; Severinsen, J; Smith, G; Nicholls, A; Anderson, TJ				Innes, Carrie R. H.; Jones, Richard D.; Dalrymple-Alford, John C.; Hayes, Sarah; Hollobon, Sue; Severinsen, Julie; Smith, Gwyneth; Nicholls, Angela; Anderson, Tim J.			Sensory-motor and cognitive tests predict driving ability of persons with brain disorders	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						driving; brain disorders; prediction; sensory-motor; cognitive; human performance	IDENTIFY OLDER DRIVERS; SIMULATED CAR CRASHES; ON-ROAD; PERFORMANCE; IMPAIRMENT; BATTERY; DEMENTIA; VALIDITY; DEFICITS; RISK	Objective: Brain disorders can lead to a decreased ability to perform the physical and cognitive functions necessary for safe driving. This study aimed to determine how accurately a battery of computerized sensory-motor and cognitive tests (SMCTests(TM)) could predict driving abilities in persons with brain disorders. Methods: SMCTests and an independent on-road driving assessment were applied to 50 experienced drivers with brain disorders referred to a hospital-based driving assessment service. The patients comprised 36 males and 14 females, a mean age of 71.3 years (range 43-85 years) and diagnoses of 35 stroke, 4 traumatic brain injury, 4 Alzheimer's disease, and 7 other. Binary logistic regression (BLR) and nonlinear causal resource analysis (NCRA) were used to build model equations for prediction of on-road driving ability based on SMCTests performance. Results: BLR and NCRA correctly classified 94% and 90% of referrals respectively as on-road pass or fail. Leave-one-out cross-validation estimated that BLR and NCRA would correctly predict the classification of 86% and 76% respectively of an independent referral group as on-road pass or fail. Conclusions: Compared with other studies, SMCTests have shown the highest predictive accuracy against true on-road driving ability as estimated in an independent data set and in persons with brain disorders. SMCTests also have the advantage of being able to comprehensively and objectively assess both sensory-motor and higher cognitive functions related to driving. (c) 2007 Elsevier B.V. All rights reserved.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand; Univ Canterbury, Dept Elect & Comp Engn, Christchurch 1, New Zealand; Univ Canterbury, Dept Psychol, Christchurch, New Zealand; Burwood Hosp, Dept Occupat, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand		Innes, CRH (corresponding author), Van Veer Inst Parkinsons & Brain Res, 66 Stewart St, Christchurch, New Zealand.	carrie.innes@vanderveer.org.nz		Innes, Carrie/0000-0003-4230-7791; Jones, Richard/0000-0003-2287-3358			Ball K, 1993, J Am Optom Assoc, V64, P71; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; Dalrymple-Alford JC, 2003, J STUD ALCOHOL, V64, P93, DOI 10.15288/jsa.2003.64.93; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DAWSON B, 2001, STAT METHODS MULTIPL; De Raedt R, 2000, J AM GERIATR SOC, V48, P1664, DOI 10.1111/j.1532-5415.2000.tb03880.x; DOBBS AR, 2000, CAN FAM PHYSICIAN, V46, P142; DOBBS AR, 1997, EVALUATIONS RISK EXP; DOBBS AR, 2005, CAN MUTL ROAD SAF C; Fischer CA, 2002, P ANN INT IEEE EMBS, P2473, DOI 10.1109/IEMBS.2002.1053382; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; Graydon FX, 2004, TRANSPORT RES F-TRAF, V7, P271, DOI 10.1016/j.trf.2004.09.006; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hoffman JD, 2002, TRANSPORT RES REC, P59; HOPKINS WG, 2000, NEW VIEW STAT, V2004; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; Johnson J E, 1999, J Gerontol Nurs, V25, P12; Jones R., 2006, 2006 IEEE Power Engineering Society General Meeting; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Jones R D, 1990, Int Disabil Stud, V12, P141; Jones RD, 2002, HUM MOVEMENT SCI, V21, P603, DOI 10.1016/S0167-9457(02)00165-3; JONES RD, 1992, MOVEMENT DISORD, V7, P232, DOI 10.1002/mds.870070308; Jones RD, 1996, IEEE T BIO-MED ENG, V43, P1001, DOI 10.1109/10.536901; JONES RD, 1989, BRAIN, V112, P113, DOI 10.1093/brain/112.1.113; JONES RD, 1995, J NEUROL SCI, V131, P43, DOI 10.1016/0022-510X(95)00043-2; KONDRASKE GV, 2006, ELEMENTAL RESOURCE M, P1; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lee HC, 2003, ACCIDENT ANAL PREV, V35, P797, DOI 10.1016/S0001-4575(02)00083-0; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Lings S, 1991, Int Disabil Stud, V13, P74; LIU L, 1999, CYBERPSYCHOL BEHAV, V2, P1; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Marottoli RA, 1998, J AM GERIATR SOC, V46, P562, DOI 10.1111/j.1532-5415.1998.tb01071.x; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McKenna P, 2004, BRIT J CLIN PSYCHOL, V43, P325, DOI 10.1348/0144665031752952; McKnight AJ, 1999, ACCIDENT ANAL PREV, V31, P445, DOI 10.1016/S0001-4575(98)00082-7; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Nouri F M, 1987, Int Disabil Stud, V9, P110; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Sims RV, 2000, J GERONTOL A-BIOL, V55, pM22; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Stolwyk RJ, 2006, J CLIN EXP NEUROPSYC, V28, P898, DOI 10.1080/13803390591000909; Uc EY, 2006, J NEUROL SCI, V251, P35, DOI 10.1016/j.jns.2006.08.011; *US DEP TRANSP, 1999, SAF MOB OLD PEOP NOT; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; WITTON IH, 1999, CREDIBILITY EVALUATI, P119; Wood JM, 2005, J NEUROL NEUROSUR PS, V76, P176, DOI 10.1136/jnnp.2004.047118; 2002, MED ASPECTS FITNESS	59	40	41	1	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	SEP 15	2007	260	1-2					188	198		10.1016/j.jns.2007.04.052			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	208JG	WOS:000249315000029	17544448				2022-02-06	
J	Pearson, BC; Armitage, KR; Horner, CWM; Carpenter, RHS				Pearson, B. C.; Armitage, K. R.; Horner, C. W. M.; Carpenter, R. H. S.			Saccadometry: the possible application of latency distribution measurement for monitoring concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CLOSED-HEAD INJURY; EYE-MOVEMENTS; RECOVERY; SACCADES; DEFICITS	Premature return to play after concussion may have debilitating or even fatal consequences. Computerised neuropsychological test batteries are widely used to monitor recovery, but none meet all specified criteria. One possible alternative is to measure saccadic reaction time or latency. Latency reflects the operation of cerebral decision mechanisms, and is strongly influenced by many agents that impair cortical function. A portable, micro-miniature device ( saccadometer) was used to record the eye movements of amateur boxers before and after competitive bouts. Individual latency distributions were significantly affected after blows to the head, though the effects seemed to be reversible, with recovery over a few days. This quantitative, objective and easy to use technique should perhaps be deployed more widely to evaluate its potential in monitoring the effects of sports-related head injuries.	Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England		Pearson, BC (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	bcp22@cam.ac.uk		Carpenter, Roger/0000-0003-2572-1448			Ali FR, 2006, EXP BRAIN RES, V169, P237, DOI 10.1007/s00221-005-0143-6; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; CARPENTER RHS, 1994, J PHYSL, V480, P4; CARPENTER RHS, 2006, LATER; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Leigh RJ, 2004, BRAIN, V127, P460, DOI 10.1093/brain/awh035; Nouraei SAR, 2003, BRIT J ANAESTH, V91, P175, DOI 10.1093/bja/aeg158; Ober JK, 2003, MODELLING MEASUREMEN, P187; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reddi BAJ, 2000, NAT NEUROSCI, V3, P827, DOI 10.1038/77739; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2	13	40	40	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2007	41	9							610	10.1136/bjsm.2007.036731			3	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	204VP	WOS:000249072400021	17496064	Green Published			2022-02-06	
J	Riordan, WP; Cotton, BA; Norris, PR; Waitman, LR; Jenkins, JM; Morris, JA				Riordan, William P.; Cotton, Bryan A.; Norris, Patrick R.; Waitman, Lemuel R.; Jenkins, Judith M.; Morris, John A.			beta-blocker exposure in patients with severe traumatic brain injury (TBI) and cardiac uncoupling	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		heart rate variability; cardiac uncoupling; beta-blocker; trauma; brain injury	HEART-RATE-VARIABILITY; SUBARACHNOID HEMORRHAGE; ORGAN DYSFUNCTION; SPECTRAL-ANALYSIS; DEATH; CATECHOLAMINES; COMPLICATIONS; PROPRANOLOL; PREDICTOR; PRESSURE	Background: Cardiac uncoupling and reduced heart rate (HR) variability are associated with increased mortality after severe traumatic brain injury (TBI). Recent data has shown beta-blocker (beta B) exposure is associated with improved survival in this patient population. The purpose of the present study was to evaluate the effect of beta B exposure on the mortality risk of patients with severe TBI and early cardiac uncoupling. Methods: From December 2000 to October 2005, 4,116 patients were admitted to the trauma intensive care unit. Four hundred forty-six patients (12%) had head Abbreviated Injury Scale score : 5 without neck injury and had continuous HR data for the first 24 hours. One hundred forty-one patients (29%) received beta B. Cardiac uncoupling was calculated as the percent of time that 5-minute HR standard deviation was between 0.3 bpm and 0.6 bpm on postinjury day 1. Results: A relationship between beta B and survival was observed when the population was considered irrespective of length of stay or beta B start time (p < 0.001). Cardiac uncoupling appears to stratify patients into groups who might receive additional benefit from beta B, and identifies patients with increasing mortality. However, the association of beta B with survival was attenuated when analyses accounted for selection bias in beta B administration. Conclusions: beta B exposure was associated with reduced mortality among patients with severe TBI. Though loss of HR variability has previously been associated with an increase in mortality, beta B exposure appears to be associated with increased survival across all stratifications of cardiac uncoupling. Key Words. Heart rate variability, Cardiac uncoupling, beta-Blocker, Trauma, Brain injury.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37212 USA		Riordan, WP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	william.riordan@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ARBABI S, 2006, 65 ANN M AAST SEP 28; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; COTTON BA, 2007, J TRAUMA, V62, P1; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; Fathizadeh P, 2004, CRIT CARE MED, V32, P1300, DOI 10.1097/01.CCM.0000127776.78490.E4; FEIBEL JH, 1981, ANN NEUROL, V9, P340, DOI 10.1002/ana.410090405; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P228, DOI 10.1097/00003246-199302000-00014; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grogan EL, 2004, ANN SURG, V240, P547, DOI 10.1097/01.sla.0000137143.65540.9c; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Kemp CD, 2006, J AM COLL SURGEONS, V203, pS36, DOI 10.1016/j.jamcollsurg.2006.05.090; King ML, 1997, BRAIN INJURY, V11, P445; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Korpelainen JT, 1996, STROKE, V27, P2059, DOI 10.1161/01.STR.27.11.2059; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; Lampert R, 2003, AM J CARDIOL, V91, P137, DOI 10.1016/S0002-9149(02)03098-9; LOWENSOHN RI, 1977, LANCET, V1, P626; MALING HM, 1958, AM J PHYSIOL, V194, P590, DOI 10.1152/ajplegacy.1958.194.3.590; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MOREL DR, 1984, INTENS CARE MED, V10, P133, DOI 10.1007/BF00265802; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; MOWERY NT, 2006, AM ASS SURG TRAUM 65; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Neil-Dwyer G, 1990, Acta Neurochir Suppl (Wien), V47, P102; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RIORDAN WP, 2007, SOC CRIT CAR MED 36; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SPARKS HV, 1970, CARDIOVASC RES, V4, P363, DOI 10.1093/cvr/4.3.363; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	63	40	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					503	510		10.1097/TA.0b013e3181271c34			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	211DA	WOS:000249503300004	18073593				2022-02-06	
J	Ubiali, F; Nava, S; Nessi, V; Frigerio, S; Parati, E; Bernasconi, P; Mantegazza, R; Baggi, F				Ubiali, Federica; Nava, Sara; Nessi, Valeria; Frigerio, Simona; Parati, Eugenio; Bernasconi, Pia; Mantegazza, Renato; Baggi, Fulvio			Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation	INTERNATIONAL IMMUNOLOGY			English	Article						NSC; one-way MLR; transplantation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CLASS-I; STEM/PROGENITOR CELLS; HUMAN MYOBLASTS; MUSCLE-CELLS; TRANSPLANTATION; DIFFERENTIATION; VITRO; STIMULATION	Neural stem cells (NSCs) transplantation has been proposed as a means of restoring damaged brain tissue, a possibility rendered more likely by reports of low NSCs immunogenicity in various experimental models because of low expression of MHC class I and II as well as co- stimulatory molecules. We investigated the immunogenicity of a human NSC line grown in normal culture conditions and in the presence of pro- inflammatory cytokines IFN-gamma and tumor necrosis factor alpha by one-way mixed lymphocyte reaction (MLR) experiments with peripheral blood lymphocytes from eight HLA-incompatible donors. NSCs stimulated lymphocyte proliferation in almost all donors tested, with stimulation indices in the range of the low-end distribution curve of MLR between donors. The healthy subject that gave negative MLR results was the best compatible donor with respect to NSC haplotype. Since we observed low MLR responses overall, we studied if NSCs might exert any immunomodulatory activity. We detected transcription and release of the immunomodulatory molecule transforming growth factor beta (TGF-beta)-1; moreover, the addition of TGF-beta 1 in MLR experiments down-regulated proliferative responses. To further confirm the immunological potential of human NSCs, we studied xenogeneic recognition of NSCs by immunocompetent cells derived from C57BL/6 mice, showing that NSCs can elicit an allo(xeno) response ex vivo. Our data indicate that NSCs have low but not negligible immunogenic potential that is sufficient to activate peripheral lymphocytes. Secretion of TGF-b1 might balance the immunogenicity of NSCs. Nevertheless, the possibility that allo-NSCs grafting might induce in the long term an immune activation, thus vanishing their therapeutical effect, should not be overlooked and deserves further investigation.	Neurol Inst Fdn Carlo Besta, I-20133 Milan, Italy		Baggi, F (corresponding author), Neurol Inst Fdn Carlo Besta, Via Celoria 11, I-20133 Milan, Italy.	baggi@istituto-besta.it	Parati, Eugenio Agostino/AAN-5893-2021; Baggi, Fulvio/AAX-4132-2020; Nava, Sara/J-8740-2016; Bernasconi, Pia/AAB-7590-2019; Frigerio, Simona/AAI-3264-2021; Mantegazza, Renato/AAB-7569-2019; Parati, Eugenio A/G-8765-2011	Parati, Eugenio Agostino/0000-0001-5020-6523; Baggi, Fulvio/0000-0002-4618-0102; Nava, Sara/0000-0001-9912-8255; Frigerio, Simona/0000-0001-7078-075X; Mantegazza, Renato/0000-0002-9810-5737; Bernasconi, Pia/0000-0003-0869-2104			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; BAGGI F, 1993, J NEUROIMMUNOL, V46, P57, DOI 10.1016/0165-5728(93)90233-O; BARKER CF, 1977, ADV IMMUNOL, V25, P1; Bernasconi P, 1998, J NEUROIMMUNOL, V85, P52, DOI 10.1016/S0165-5728(97)00254-3; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Curnow SJ, 1998, J NEUROIMMUNOL, V86, P53, DOI 10.1016/S0165-5728(98)00013-7; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Duan WM, 2002, NEUROSCIENCE, V115, P495, DOI 10.1016/S0306-4522(02)00382-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; GOEBELS N, 1992, J IMMUNOL, V149, P661; Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037; Holzer U, 2006, J AUTOIMMUN, V26, P241, DOI 10.1016/j.jaut.2006.03.006; Imitola J, 2004, AM J PATHOL, V164, P1615, DOI 10.1016/S0002-9440(10)63720-0; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Isacson O, 2003, LANCET NEUROL, V2, P417, DOI 10.1016/S1474-4422(03)00437-X; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Mammolenti M, 2004, STEM CELLS, V22, P1101, DOI 10.1634/stemcells.22-6-1101; Mantegazza R, 1996, J NEUROIMMUNOL, V68, P53, DOI 10.1016/0165-5728(96)00068-9; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McLaren FH, 2001, J NEUROIMMUNOL, V112, P35, DOI 10.1016/S0165-5728(00)00410-0; Mickelson EM, 1996, TISSUE ANTIGENS, V47, P27, DOI 10.1111/j.1399-0039.1996.tb02511.x; Modo M, 2003, NEUROSCI LETT, V337, P85, DOI 10.1016/S0304-3940(02)01301-0; Muraoka K, 2006, EXP NEUROL, V199, P311, DOI 10.1016/j.expneurol.2005.12.004; Odeberg J, 2005, J NEUROIMMUNOL, V161, P1, DOI 10.1016/j.jneuroim.2004.11.016; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Parati E A, 2004, J Endocrinol Invest, V27, P64; Parati EA, 2002, BRAIN RES, V925, P213, DOI 10.1016/S0006-8993(01)03291-7; Petersdorf EW, 2003, TISSUE ANTIGENS, V61, P1, DOI 10.1034/j.1399-0039.2003.610101.x; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Poltavtseva RA, 2002, DEV BRAIN RES, V134, P149, DOI 10.1016/S0165-3806(02)00274-2; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sung JL, 2003, INT IMMUNOPHARMACOL, V3, P233, DOI 10.1016/S1567-5769(02)00276-X; Tambur AR, 2004, NEUROL RES, V26, P243, DOI 10.1179/016164104225013932; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088	37	40	42	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0953-8178			INT IMMUNOL	Int. Immunol.	SEP	2007	19	9					1063	1074		10.1093/intimm/dxm079			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	227TV	WOS:000250681600004	17660500	Bronze			2022-02-06	
J	Warren, MW; Larner, SF; Kobeissy, FH; Brezing, CA; Jeung, JA; Hayes, RL; Gold, MS; Wang, KKW				Warren, Matthew W.; Larner, Stephen F.; Kobeissy, Firas H.; Brezing, Christina A.; Jeung, Jennifer A.; Hayes, Ronald L.; Gold, Mark S.; Wang, Kevin K. W.			Calpain and caspase proteolytic markers co-localize with rat cortical neurons after exposure to methamphetamine and MDMA	ACTA NEUROPATHOLOGICA			English	Article						calpain; caspase; MDMA; methamphetamine; spectrin	TRAUMATIC BRAIN-INJURY; INCREASED EXPRESSION; INDUCED APOPTOSIS; II-SPECTRIN; DOPAMINE; NEUROTOXICITY; ACTIVATION; ECSTASY; SEROTONIN; DEATH	Abuse of the club drugs Methamphetamine (Meth) and Ecstasy (MDMA) is an international problem. The seriousness of this problem is the result of what appears to be programmed cell death (PCD) occurring within the brain following their use. This follow up study focused on determining which cell types, neurons and/or glial cells, were affected in the brains of drug-injected rats. Two proteolytic enzyme families involved in PCD, calpains and caspases, were previously shown to be activated and to degrade the brain cytoskeletal associated protein all-spectrin. Using methods employed and confirmed in traumatic brain injury (TBI) studies, rat brain tissues were examined, 24 and 48 h after Meth and MDMA exposure, for the activation of calpain-1 and caspase-3, and their subsequent alpha II-spectrin cleavage breakdown products (SBDPs), SBDP145, and SBDP120, respectively. Based upon our previous studies we know that activated calpain-1 and caspase-3 were up-regulated after drug use as were the levels of their cleaved SBDPs, SBDP145, and SBDP120, respectively, which is indicative of PCD. Here we show that activated calpain-1 and caspase-3 increases could be localized to neurons in the cortex where the products of their cleaved targets were found to be concentrated, particularly, to the axonal regions. These findings support the hypothesis that calpains and caspases mediate PCD in cortical neurons following club drug abuse and, more importantly, appear to contribute to the neuropathology suffered by abusers.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA		Warren, MW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Box 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	warren@ufl.edu; kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; Fumagalli F, 1999, J NEUROSCI, V19, P2424; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Hirata H, 1997, BRAIN RES, V768, P345, DOI 10.1016/S0006-8993(97)00798-1; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Kanthasamy A, 2006, ANN NY ACAD SCI, V1074, P234, DOI 10.1196/annals.1369.022; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larsen KE, 2002, J NEUROSCI, V22, P8951; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; McKay R, 1988, Ann N Y Acad Sci, V540, P47, DOI 10.1111/j.1749-6632.1988.tb27050.x; Meyer JS, 2004, INT J DEV NEUROSCI, V22, P261, DOI 10.1016/j.ijdevneu.2004.04.007; NASH JF, 1991, EUR J PHARMACOL, V200, P53, DOI 10.1016/0014-2999(91)90664-C; *NAT I DRUG AB, 2005, NAT SURV RES DRUG US; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; O'Dell SJ, 2000, SYNAPSE, V37, P32, DOI 10.1002/(SICI)1098-2396(200007)37:1<32::AID-SYN4>3.0.CO;2-X; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; PU CF, 1994, BRAIN RES, V649, P217, DOI 10.1016/0006-8993(94)91067-7; Rawson RA, 2002, J SUBST ABUSE TREAT, V23, P145, DOI 10.1016/S0740-5472(02)00256-8; Ricaurte G A, 1989, NIDA Res Monogr, V94, P306; SCHMIDT CJ, 1987, BIOCHEM PHARMACOL, V36, P4095, DOI 10.1016/0006-2952(87)90566-1; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; Simantov R, 1997, FASEB J, V11, P141, DOI 10.1096/fasebj.11.2.9039956; STUFFLEBEAM R, 2006, NEURONS SYNAPSES NEU; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Substance Abuse and Mental Health Services Administration, 2004, DHHS PUBL; Tamburini I, 2006, ANN NY ACAD SCI, V1074, P377, DOI 10.1196/annals.1369.037; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Thomas DM, 2004, NEUROSCI LETT, V367, P349, DOI 10.1016/j.neulet.2004.06.065; Wallace TL, 1999, J NEUROSCI, V19, P9141, DOI 10.1523/JNEUROSCI.19-20-09141.1999; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2006, INT J NEUROPSYCHOPH, P1; WHITE SR, 1994, NEUROSCIENCE, V62, P41, DOI 10.1016/0306-4522(94)90313-1; Xu WJ, 2005, SYNAPSE, V58, P110, DOI 10.1002/syn.20185; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x; Zhu JPQ, 2006, NEUROSCIENCE, V140, P607, DOI 10.1016/j.neuroscience.2006.02.055; Zhu JPQ, 2005, BRAIN RES, V1049, P171, DOI 10.1016/j.brainres.2005.04.089	51	40	40	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2007	114	3					277	286		10.1007/s00401-007-0259-9			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	205XT	WOS:000249149200009	17647000				2022-02-06	
J	Myhre, MC; Grogaard, JB; Dyb, GA; Sandvik, L; Nordhov, M				Myhre, M. C.; Grogaard, J. B.; Dyb, G. A.; Sandvik, L.; Nordhov, M.			Traumatic head injury in infants and toddlers	ACTA PAEDIATRICA			English	Article						child abuse; head injury; infants and children; neglect; risk factors	YOUNG-CHILDREN; BRAIN-INJURY; HEMORRHAGE	Aim: To describe the presenting characteristics, type of injury and hospital course in young children with traumatic head injury, and to identify characteristics indicating that the trauma was inflicted. Methods: A retrospective medical record review of 91children less than 3 years of age who were admitted to a tertiary teaching hospital in Norway from 1995 through 2005 with a traumatic head injury. Patients were identified by diagnostic codes, and categorized by type of injury as skull fractures (n = 39), epidural haemorrhage (EDH) (n = 12), subdural haemorrhage (n = 27) and parenchymal brain injury (n = 13). Further the cases were classified as inflicted injury (n = 17), accident (n = 35) or indeterminate (n = 39). Results: The mechanism of injury was similar for EDHs and isolated skull fractures, and none were classified as inflicted. Sixty-three percent of the cases with subdural haematoma were classified as inflicted. When compared to the accident group, children in the inflicted group more frequently had subdural haemorrhage without a skull fracture (OR = 6.9, CI = 1.7-28.2), and seizures (OR = 9.5, CI = 2.1-43.3). Conclusions: Inflicted and accidental head injuries differed in presenting characteristics and injury type. Nearly two-third of the subdural haemorrhages were classified as inflicted, but none of the epidural EDHs or skull fractures. Inflicted injuries tended to present with seizures.	Ullevaal Univ Hosp, Dept Paediat Intens Care, N-0407 Oslo, Norway; Norwegian Ctr Violence & Traumat Strees Studies, Oslo, Norway; Ullevaal Univ Hosp, Clin Res Ctr, Oslo, Norway; Univ Hosp, Dept Paediat, Tromso, Norway		Myhre, MC (corresponding author), Ullevaal Univ Hosp, Dept Paediat Intens Care, N-0407 Oslo, Norway.	mimy@uus.no					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GRAHREMAN A, 2005, J NEUROSURG, V103, P213; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; King WJ, 2003, CAN MED ASSOC J, V168, P155; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Shugerman RP, 1996, PEDIATRICS, V97, P664; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380	22	40	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	AUG	2007	96	8					1159	1163		10.1111/j.1651-2227.2007.00356.x			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	193OD	WOS:000248282500013	17578493	Green Published			2022-02-06	
J	Pasco, A; Lemaire, L; Franconi, F; Lefur, Y; Noury, F; Saint-Andre, JP; Benoit, JP; Cozzone, PJ; Le Jeune, JJ				Pasco, Anne; Lemaire, Laurent; Franconi, Florence; Lefur, Yann; Noury, Fanny; Saint-Andre, Jean-Paul; Benoit, Jean-Pierre; Cozzone, Patrick J.; Le Jeune, Jean-Jacques			Perfusional deficit and the dynamics of cerebral edemas in experimental traumatic brain injury using perfusion and diffusion-weighted magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						ADC; diffusion; DSC; edema; fluid lateral percussion; perfusion; quantitative magnetic resonance imaging; traumatic brain injury	HIGH-RESOLUTION MEASUREMENT; FLUID PERCUSSION INJURY; TRACER BOLUS PASSAGES; CLOSED-HEAD INJURY; BLOOD-FLOW; SECONDARY HYPOXIA; PUBLIC-HEALTH; MRI; RATS; METABOLISM	The aim of this work was to characterize edema dynamics, cerebral blood volume, and flow alterations in an experimental model of brain trauma using quantitative diffusion and perfusion magnetic resonance imaging (MRI). Associated with an influx of water in the intracellular space 1-5 h post-trauma as demonstrated by the 40% reduction in apparent diffusion coefficient, a 70-80% reduction in cerebral blood flow was measured within the lesioned region. Transient hypoperfusion (40-50%) was also observed in the non-traumatized contralateral hemisphere, although there was no evidence of edema formation. After the initial cytotoxic edema, a clear evolution toward extracellular water accumulation was observed, demonstrated by an increase in apparent diffusion coefficient.	INSERM, U 646, F-49100 Angers, France; Univ Angers, F-49100 Angers, France; Univ Angers, Serv Commun Anal Spectroscop, Angers, France; Ctr Resonance Magnet Biol & Med, CNRS, UMR 6612, Marseille, France; CHU Angers, Anat Pathol Lab, Angers, France		Lemaire, L (corresponding author), INSERM, U 646, 10 Rue Andre Boquel, F-49100 Angers, France.	laurent.lemaire@univ-angers.fr	LEMAIRE, Laurent/A-3100-2011; FRANCONI, Florence/K-4258-2015; NOURY, Fanny/N-8177-2015; Benoit, Jean-Pierre/K-4387-2015	LEMAIRE, Laurent/0000-0002-1308-9345; FRANCONI, Florence/0000-0001-6725-0803; BENOIT, Jean-Pierre/0000-0002-6178-7199			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauman RA, 2005, BEHAV BRAIN RES, V160, P25, DOI 10.1016/j.bbr.2004.11.031; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; HAASE A, 1990, MAGN RESON MED, V13, P77, DOI 10.1002/mrm.1910130109; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; LAURER HL, 2000, EUR J TRAUMA, V26, P995; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lythgoe MF, 1997, MAGN RESON MED, V38, P662, DOI 10.1002/mrm.1910380421; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Mathe JF, 2005, ANN FR ANESTH, V24, P688, DOI 10.1016/j.annfar.2005.03.029; Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P425, DOI 10.1097/00004647-199804000-00011; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1336, DOI 10.1038/sj.jcbfm.9600126; Simonsen CZ, 1999, JMRI-J MAGN RESON IM, V9, P342, DOI 10.1002/(SICI)1522-2586(199902)9:2<342::AID-JMRI29>3.0.CO;2-B; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; Vonarbourg A, 2004, MAGN RESON MATER PHY, V17, P133, DOI 10.1007/s10334-004-0049-5; WINDLE V, 2001, EXP NEUROL, P324; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	45	40	42	1	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1321	1330		10.1089/neu.2006.0136			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500003	17711393	Green Accepted, Green Submitted			2022-02-06	
J	Ramos-Mandujano, G; Vazquez-Juarez, E; Hernandez-Benitez, R; Pasantes-Morales, H				Ramos-Mandujano, Gerardo; Vazquez-Juarez, Erika; Hernandez-Benitez, Reyna; Pasantes-Morales, Herminia			Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes	GLIA			English	Article						intracerebral hemorrhage; PAR-1; volume-sensitive anion channel; DCPIB; tamoxifen; astrocyte swelling	PROTEASE-ACTIVATED RECEPTORS; SH-SY5Y NEUROBLASTOMA-CELLS; MUSCARINIC CHOLINERGIC-RECEPTORS; ISCHEMIC NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; G-BETA-GAMMA; CEREBRAL-ISCHEMIA; RAT ASTROCYTES; TAURINE RELEASE; POTENTIATION	High concentrations of thrombin (Thr) have been linked to neuronal damage in cerebral ischemia and traumatic brain injury. In the present study we found that Thr markedly enhanced swelling-activated efflux of H-3-glutamate from cultured astrocytes exposed to hyposmotic medium. Thr (0.5-5 U/mL) elicited small H-3-glutamate efflux under isosmotic conditions and increased the hyposmotic glutamate efflux by 5- to 10-fold, the maximum effect being observed at 15% osmolarity reduction. These Thr effects involve its protease activity and are fully mimicked by SFFLRN, the synthetic peptide activating protease-activated receptor-1. Thr potentiation of 3H-glutamate efflux was largely dependent on a Thr-elicited increases in cytosolic Ca 21 (Ca(2+)i) concentration ([Ca 21],). Preventing Ca(t+)i rise by treatment with EGTA-AM or with the phospholipase C blocker U73122 reduced the Thr-increased glutamate efflux by 68%. The protein kinase C blockers Go6976 or chelerythrine reduced the Thr effect by 19%-22%, while Ca/calmodulin blocker W7 caused a 63% inhibition. In addition to this Ca2+-sensitive pathway, Thr effect on glutamate efflux also involved activation of phosphoinositide-3 kinase (PI3K), since it was reduced by the PI3K inhibitor wortmannin (51% inhibition). Treating cells with EGTA-AM plus wortmannin essentially abolished Thr-dependent glutamate efflux. Thr-activated glutamate release was potently inhibited by the blockers of the volume-sensitive anion permeability pathway, NPPB (IC50 15.8 mu M), DCPIB (IC50 4.2 mu M), and tamoxifen (IC50 6.6 mu M). These results suggest that Thr may contribute to the excitotoxic neuronal injury by elevating extracellular glutamate release from glial cells. Therefore, this work may aid in search of neuroprotective strategies for treating cerebral ischemia and brain trauma. (C) 2007 Wiley-Liss, Inc.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biofis, Mexico City 04510, DF, Mexico		Pasantes-Morales, H (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biofis, Ciudad Univ, Mexico City 04510, DF, Mexico.	hpasante@ifc.unam.mx	Vazquez-Juarez, Erika/D-8183-2017	Vazquez-Juarez, Erika/0000-0003-1810-9621; Hernandez-Benitez, Reyna/0000-0003-2546-8956			Abdullaev IF, 2006, J PHYSIOL-LONDON, V572, P677, DOI 10.1113/jphysiol.2005.103820; AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cardin V, 2003, GLIA, V44, P119, DOI 10.1002/glia.10271; Cheema TA, 2005, J PHARMACOL EXP THER, V315, P755, DOI 10.1124/jpet.105.090787; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Decher T, 2001, BRIT J PHARMACOL, V134, P1467; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; Franco R, 2004, PFLUG ARCH EUR J PHY, V449, P159, DOI 10.1007/s00424-004-1322-1; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Heacock AM, 2004, J PHARMACOL EXP THER, V311, P1097, DOI 10.1124/jpet.104.072553; Heacock AM, 2006, J PHARMACOL EXP THER, V317, P685, DOI 10.1124/jpet.105.098467; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Karabiyikoglu M, 2004, J CEREBR BLOOD F MET, V24, P159, DOI 10.1097/01.WCB.0000100062.36077.84; Kawai H, 1996, J PHARMACOL EXP THER, V278, P780; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; Loveday D, 2003, J NEUROCHEM, V87, P476, DOI 10.1046/j.1471-4159.2003.02021.x; Manolopoulos VG, 1997, BIOCHEM BIOPH RES CO, V232, P74, DOI 10.1006/bbrc.1997.6222; Mongin AA, 2005, AM J PHYSIOL-CELL PH, V288, pC204, DOI 10.1152/ajpcell.00330.2004; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Pike CJ, 1996, J NEUROCHEM, V66, P1374; Ribeiro MD, 2006, EXP NEUROL, V198, P199, DOI 10.1016/j.expneurol.2005.11.017; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; THOROED SM, 1995, J EXP BIOL, V198, P311; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Weinstein JR, 2005, J NEUROCHEM, V95, P1177, DOI 10.1111/j.1471-4159.2005.03499.x; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Xi GH, 2002, STROKE, V33, P399; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	35	40	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2007	55	9					917	925		10.1002/glia.20513			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	173EM	WOS:000246856300003	17437307				2022-02-06	
J	Haileyesus, T; Annest, JL; Dellinger, AM				Haileyesus, Tadesse; Annest, Joseph L.; Dellinger, Ann M.			Cyclists injured while sharing the road with motor vehicles	INJURY PREVENTION			English	Article								Objective: To provide national estimates of non-fatal cyclist injuries treated in US hospital emergency departments (EDs) resulting from an encounter with a motor vehicle (MV) on the road. Methods: Non-fatal injury data for 2001 - 4 from the National Electronic Injury Surveillance System All Injury Program were analyzed. Results: An estimated 62 267 persons (21.5 per 100 000 population; 95% CI 14.3 to 28.7) were treated annually in US hospital EDs for unintentional non-fatal cyclist injuries involving an MV on the road. Among these cases, children aged 10 14 years (65.8 per 100 000) and males (35.3 per 100 000) had the highest injury rates. Many injuries involved the extremities (41.9%). The head was the primary body part affected for 38.6% of hospitalized/ transferred patients, of which about 84.7% had a principal diagnosis of a concussion or internal head injury. Conclusions: Effective road environmental interventions (eg, bicycle- friendly roadway design, intersections and crossings) along with efforts to promote safe personal behavior ( eg, helmet use and following rules of the road) are needed to help reduce injuries among cyclists while sharing the road.	Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30340 USA; Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Annest, JL (corresponding author), Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, 4770 Buford Highway MS K59, Atlanta, GA 30340 USA.	lannest@cdc.gov					*AM AC PED COMM AC, 1990, PEDIATRICS, V85, P229; [Anonymous], 1998, PUBL FED HIGHW ADM, VFHWA-RD-97-148; C. for Disease Control Prevention, 2003, WEB BAS INJ STAT QUE; *CDC, 2004, US CENS POP BRIDG RA; *CDC, 1995, J SCH HLTH, V65, P133; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P340; EilertPetersson E, 1997, ACCIDENT ANAL PREV, V29, P363, DOI 10.1016/S0001-4575(97)00002-X; Elvik R., 2004, HDB ROAD SAFETY MEAS; *FED HIGHW ADM, 2003, DES GUID ACC BIC PED; Gerberich S G, 1994, Minn Med, V77, P27; Jacobsen PL, 2015, INJURY PREV, V21, P271, DOI 10.1136/ip.9.3.205rep; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Karkhaneh M, 2006, INJURY PREV, V12, P76, DOI 10.1136/ip.2005.010942; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; Kwan I, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003438; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; *NAT BIC DEAL ASS, 2005, IND OV 2005; *NAT CTR STAT AN, 2005, PED TRAFF SAF FACTS; Quinlan KP, 1999, ANN EMERG MED, V34, P637, DOI 10.1016/S0196-0644(99)70166-6; Schroeder T., 2001, NEISS ALL INJURY PRO; SCOTT D, 2005, INJURY B         APR; Stutts JC, 1999, ACCIDENT ANAL PREV, V31, P505, DOI 10.1016/S0001-4575(99)00007-X; *US BUR CENS, 2006, AM FACTFINDER; Watson L., 2006, 251 MON U ACC RES CT	24	40	40	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2007	13	3					202	206		10.1136/ip.2006.014019			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	178MO	WOS:000247225000014	17567979	Green Published			2022-02-06	
J	Jakola, AS; Muller, K; Larsen, M; Waterloo, K; Romner, B; Ingebrigtsen, T				Jakola, A. S.; Muller, K.; Larsen, M.; Waterloo, K.; Romner, B.; Ingebrigtsen, T.			Five-year outcome after mild head injury: a prospective controlled study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						neuropsychology; neurosurgery; trauma	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN MEASUREMENTS; QUALITY-OF-LIFE; PREDICTION; COMPLAINTS; RECOVERY; HEALTH	Objectives - To study the prevalence of post-concussion symptoms (PCS) 5-7 years after mild head injury (MHI) and to investigate whether patients suffer from more symptoms than the normal population. Methods - We conducted a 5- to 7-year follow-up of patients (n = 89) with MHI. Post-concussion symptoms were quantified with the Rivermead Post Concussion Symptoms Questionnaire (RPQ) and health-related quality of life (HRQL) was measured with the EuroQol-5D (EQ-5D). We also quantified subjective general health state with the EuroQol Visual Analogue Scale (EQ-VAS). An age- and sex-matched, but otherwise randomly chosen control group of 89 persons was recruited from the National Population Registry for a cross-sectional comparison. Twerity-eight patients (30%) and 27 (30%) controls responded. Results - Patients reported significantly (P = 0.017) more PCS (median RPQ score 10, 95% CI 2-20) than controls (median 2, 95% CI 0-4). They also reported significantly (P = 0.008) lower HRQL (median EQ-5D score 0.866, 95% CI 0.796-1.000) than controls (1.000, 95% CI 1.000 - 1.000), but there was no difference between the groups in their subjective ratings of general health state. Conclusions - Patients reported significantly more PCS and lower HRQL 5 to 7 years after MHI than age- and sex-matched controls from the normal population.	Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway; Univ Tromso, Fac Med, Tromso, Norway; Univ Tromso, Fac Psychol, Tromso, Norway; Univ Tromso, Dept Neurol, Tromso, Norway		Muller, K (corresponding author), Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway.	kay.muller@unn.no	Jakola, Asgeir S/J-1738-2018	Jakola, Asgeir S/0000-0002-2860-9331; Ingebrigtsen, Tor/0000-0001-5966-9786			BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; NORD E, 1991, HEALTH POLICY, V18, P25, DOI 10.1016/0168-8510(91)90141-J; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WANG Y, 2006, ARCH CLIN NEUROPSYCH; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	28	40	40	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	JUN	2007	115	6					398	402		10.1111/j.1600-0404.2007.00827.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	174RK	WOS:000246960300005	17511848				2022-02-06	
J	Zhang, ZY; Zhang, ZR; Artelt, M; Burnet, M; Schluesener, HJ				Zhang, Zhiyuan; Zhang, Zhiren; Artelt, Matthias; Burnet, Michael; Schluesener, Hermann J.			Dexamethasone attenuates early expression of three molecules associated with microglia/macrophages activation following rat traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						dexamethasone; traumatic brain injury; EMAP-II; P2X4R; AIF-1; microglia/macrophages	INFLAMMATORY FACTOR-I; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; MICROGLIAL CELLS; POLYPEPTIDE-II; MACROPHAGES/MICROGLIAL CELLS; RECEPTOR ACTIVATION; LESIONAL EXPRESSION	Corticosteroids have been used in the treatment of human traumatic brain injury ( TBI), which is a leading cause of death and disability, but their efficiency is still a matter of debate. Dexamethasone was considered to delay post-traumatic inflammation and retard neuronal degeneration, resulting in attenuation of secondary injury following experimental TBI. In a rat TBI model, we have investigated the effects of dexamethasone on expression patterns of markers of inflammatory activation of microglia/macrophages by immunohistochemistry. Endothelial-monocyte activating polypeptide II (EMAP-II), P2X4 receptor (P2X4R) and allograft-inflammatory factor-1 (AIF-1) were reported to be associated with the activation of microglia/macrophages post central nervous system (CNS) injury and may play roles in inflammatory cascades of secondary brain damage. Dexamethasone significantly suppressed the accumulation of EMAP-II+, P2X4R(+) or AIF(+) cells at Day-1 and 2 post-brain-trauma but not on Days 4 and 6, which is in accordance with the reported short- but not long-term protective effects of dexamethasone in TBI. These findings indicate a rather rapid but transient anti-inflammatory effect of dexamethasone in TBI.	Univ Tubingen, Brain Res Inst, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany		Zhang, ZY (corresponding author), Univ Tubingen, Brain Res Inst, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzy@gmx.de	Burnet, Michael/AAB-2958-2019; zhang, zhiren/I-1046-2014; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835			Adelson PD, 1998, ACT NEUR S, V71, P104; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; BOSSCHER KD, 1997, P NATL ACAD SCI USA, V94, P13504; Brough D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/mcne.2001.1054; CARLOS TM, 1994, BLOOD, V84, P2068; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colton CA, 1996, NEUROCHEM INT, V29, P43, DOI 10.1016/0197-0186(95)00139-5; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; Deininger MH, 2000, ACTA NEUROPATHOL, V100, P673, DOI 10.1007/s004010000233; Deininger MH, 2002, FEBS LETT, V514, P115, DOI 10.1016/S0014-5793(02)02430-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fauser S, 2001, ACTA NEUROPATHOL, V101, P565; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Gahm C, 2005, ACTA NEUROCHIR, V147, P1071, DOI 10.1007/s00701-005-0590-7; Gendron FP, 2003, J NEUROCHEM, V87, P344, DOI 10.1046/j.1471-4159.2003.01995.x; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Gottschall PE, 1996, NEUROREPORT, V7, P3077, DOI 10.1097/00001756-199611250-00057; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; Haynes LE, 2001, NEUROSCIENCE, V104, P57, DOI 10.1016/S0306-4522(01)00070-7; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KAO J, 1992, J BIOL CHEM, V267, P20239; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lehrmann E, 1997, J COMP NEUROL, V386, P461; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mitchell IJ, 1998, NEUROSCIENCE, V84, P489, DOI 10.1016/S0306-4522(97)00534-4; MORI N, 1992, EPILEPSIA, V33, P994, DOI 10.1111/j.1528-1157.1992.tb01749.x; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Postler E, 2000, J NEUROIMMUNOL, V104, P85, DOI 10.1016/S0165-5728(99)00222-2; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schluesener HJ, 2001, J NEUROIMMUNOL, V113, P89, DOI 10.1016/S0165-5728(00)00428-8; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schwab JM, 2001, J NEUROIMMUNOL, V119, P214, DOI 10.1016/S0165-5728(01)00375-7; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.3.CO;2-U; Tanaka S, 1998, J NEUROSCI, V18, P6358; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang XQ, 2006, PLASMA SCI TECHNOL, V8, P141, DOI 10.1088/1009-0630/8/2/04; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015	67	40	40	0	10	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2007	113	6					675	682		10.1007/s00401-007-0195-8			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	171IO	WOS:000246729600006	17265048				2022-02-06	
J	Mishra, MK; Koli, P; Bhowmick, S; Basu, A				Mishra, Manoj Kumar; Koli, Preeti; Bhowmick, Sourojit; Basu, Anirban			Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis	NEUROCHEMISTRY INTERNATIONAL			English	Article						astrocytes; Japanese encephalitis virus; glutamate transporters; ceruloplasmin; neurotrophic factors; reactive oxygen species	CILIARY NEUROTROPHIC FACTOR; TRAUMATIC BRAIN-INJURY; VIRUS-INFECTION; SPINAL-CORD; PROINFLAMMATORY MEDIATORS; REACTIVE ASTROCYTES; CEREBROSPINAL-FLUID; FACTOR EXPRESSION; OXIDATIVE STRESS; TYPE-1 RECEPTOR	Astrocytes play a key role in regulating aspects of inflammation and in the homeostatic maintenance of the central nervous system (CNS). However, the role of astrocytes in viral encephalitis mediated inflammation is not well documented. As Japanese encephalitis virus (JEV) infection is localized to neurons and considering the importance of astrocytes in supporting neuronal survival and function, we have exploited an experimental model of Japanese encephalitis (JE) to better understand the role of astrocytes in JE. Suckling mice pups were inoculated with the virus and 2 and 4 days later we analyzed a panel of molecules characteristic of reactive astrogliosis. We show that JEV infection increases the expression of astrocyte-specific glial fibrillary acidic protein (GFAP), the glutamate aspartate transporter (GLAST), glutamate transporter-1 (GLT-1) and ceruloplasmin (CP). The transcript levels of growth factors produced predominantly by activated astrocytes such as nerve growth factor (NGF) and ciliary neurotrophin factor (CNTF) were elevated following JEV infection. The transcript level of brain-derived neurotrophic factor (BDNF) was also elevated following JEV infection. Both NGF and CNTF were capable of preventing ROS mediated neuronal death following in vitro JEV infection to a certain extent. Taken altogether, these data indicate that increased astrogliosis following JEV infection is accompanied by the enhanced ability of astrocytes to detoxify glutamate, inactivate free radical and produce neurotrophic factors that are involved in neuronal protection. However, this elevated physiological state of astrocyte is insufficient in conferring neuroprotection, as infected animals eventually succumb to infection. The response of astrocytes to JE can be amplified to modulate the adaptive response of brain to induce neuroprotection. (c) 2007 Elsevier Ltd. All rights reserved.	Natl Brain Res Ctr, Manesar 122050, Haryana, India		Basu, A (corresponding author), Natl Brain Res Ctr, Manesar 122050, Haryana, India.	anirban@nbrc.res.in	Mishra, Manoj/A-7105-2018; BASU, ANIRBAN/C-1166-2009	Mishra, Manoj/0000-0001-9636-4930; Basu, Anirban/0000-0002-5200-2054			ALBRECHT M, 2002, SILICO BIOL, V2, P1; Appaiahgari MB, 2006, MICROBES INFECT, V8, P92, DOI 10.1016/j.micinf.2005.05.023; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Aschner M, 1998, NEUROTOXICOLOGY, V19, P7; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3; BIGNAMI A, 1989, INT J DEV NEUROSCI, V7, P343, DOI 10.1016/0736-5748(89)90056-7; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CHATURVEDI UC, 1979, CLIN EXP IMMUNOL, V38, P492; Chen CJ, 2002, J GEN VIROL, V83, P1897, DOI 10.1099/0022-1317-83-8-1897; Chen J, 2000, Health Rep, V11, P9; Chiaretti A, 2004, ACTA PAEDIATR, V93, P1178, DOI 10.1080/08035250410031314; Ciriolo MR, 2005, ANTIOXID REDOX SIGN, V7, P432, DOI 10.1089/ars.2005.7.432; Delaney CL, 1996, J NEUROSCI, V16, P6908; Dreyfus CF, 1999, J NEUROSCI RES, V56, P1, DOI 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DRINGEN R, 1995, DEV NEUROSCI-BASEL, V17, P63, DOI 10.1159/000111275; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; ENG LF, 1992, PROG BRAIN RES, V94, P353; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HASE T, 1992, VIRCHOWS ARCH B, V63, P25; Ichiyama T, 2000, J NEUROL SCI, V177, P146, DOI 10.1016/S0022-510X(00)00366-X; Kaur N, 2005, J NEUROCHEM, V92, P1521, DOI 10.1111/j.1471-4159.2004.02990.x; Kaur R, 2003, J NEUROVIROL, V9, P421, DOI 10.1080/13550280390218454; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Liu HL, 2003, J NEUROCHEM, V86, P1553, DOI 10.1046/j.1471-4159.2003.01978.x; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; MATHUR A, 1988, BRIT J EXP PATHOL, V69, P423; MATHUR A, 1992, INT J EXP PATHOL, V73, P603; Messersmith DJ, 2000, J NEUROSCI RES, V62, P241, DOI 10.1002/1097-4547(20001015)62:2<241::AID-JNR9>3.0.CO;2-D; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Patel BN, 2002, J NEUROSCI, V22, P6578; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Reier P J, 1988, Adv Neurol, V47, P87; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUDGE JS, 1995, J NEUROSCI, V15, P6856; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHWARTZ JP, 1994, PERSPECT DEV NEUROBI, V2, P251; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; SPRANGERS SA, 1990, ENDOCRINOLOGY, V126, P1133, DOI 10.1210/endo-126-2-1133; TRAUGOTT U, 1988, J NEUROL SCI, V84, P257, DOI 10.1016/0022-510X(88)90130-X; Uchida K, 1998, J NEUROL, V245, P781, DOI 10.1007/s004150050287; Vrati S, 1999, J GEN VIROL, V80, P1665, DOI 10.1099/0022-1317-80-7-1665; Vrati S, 1999, AM J TROP MED HYG, V61, P677, DOI 10.4269/ajtmh.1999.61.677; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149	66	40	44	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	APR	2007	50	5					764	773		10.1016/j.neuint.2007.01.014			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	160QC	WOS:000245956400012	17353066				2022-02-06	
J	Macdonald, S; Cherpitel, CJ; DeSouza, A; Stockwell, T; Borges, G; Giesbrecht, N				Macdonald, Scott; Cherpitel, Cheryl J.; DeSouza, Amanda; Stockwell, Tim; Borges, Guilherme; Giesbrecht, Norman			Variations of alcohol impairment in different types, causes and contexts of injuries: Results of emergency room studies from 16 countries	ACCIDENT ANALYSIS AND PREVENTION			English	Article						injury; alcohol; violence; severity; location	RISK-FACTOR; ABUSE; DEATH; FALLS; WORK	Objective: The purpose of this paper is to document alcohol impairment (based on a blood alcohol content (BAC) of at least 80 mg%) for different types, causes and location contexts of injuries. Design and setting: Data from 45 studies with 11,536 injury patients were merged to determine variations in the percent of alcohol impairment among injury patients. In each study, emergency room (ER) injury patients were given a short interview on the circumstances of their injury and BAC was measured. Results: Injury severity, measured by number of body regions injured was significantly associated with BACs over 80 mg%. The highest percentage of injury type to involve alcohol was head injury/concussion. In terms of causes of injuries, patients with alcohol impairment were significantly more likely to be involved in violence than any other cause (i.e., vehicle, failing, poisoning or burns). Finally, injuries occurring at a bar or restaurant were significantly more likely to involve alcohol impairment than any other setting. Conclusions: The results demonstrate considerable variation in the circumstances where alcohol is involved in injuries. These results may be useful for the development of prevention initiatives. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Victoria, Ctr Addict Res BC, Victoria, BC V8W 2Y2, Canada; Univ Victoria, Sch Hlth Informat Sci, Victoria, BC V8W 2Y2, Canada; Inst Publ Hlth, Alcohol Res Grp, Berkeley, CA 94709 USA; Ctr Addict & Mental Hlth, London, ON N6G 4X8, Canada; Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada; Univ Autsnoma Metropoilitana Xochimilco, Mexico City 14370, DF, Mexico; Inst Nacl Psiquiatria, Mexico City 14370, DF, Mexico; Ctr Addict & Mental Hlth, Toronto, ON, Canada		Macdonald, S (corresponding author), Univ Victoria, Ctr Addict Res BC, BP POB 1700 STN CSC, Victoria, BC V8W 2Y2, Canada.	scottmac@uvic.ca		Borges, Guilherme/0000-0002-3269-0507; Stockwell, Tim/0000-0002-5696-6803			Boles SM, 2003, AGGRESS VIOLENT BEH, V8, P155, DOI 10.1016/S1359-1789(01)00057-X; BORGES G, 1994, DRUG ALCOHOL DEPEN, V36, P1, DOI 10.1016/0376-8716(94)90002-7; Cherpitel CJ, 2003, ADDICTION, V98, P1277, DOI 10.1046/j.1360-0443.2003.00459.x; COMPTON RP, 2002, ALCOHOL DRUGS TRAFFI; DONELSON AC, 1988, SOCIAL CONTROL DRINK, P3; Graham K, 1998, ADDICTION, V93, P659, DOI 10.1046/j.1360-0443.1998.9356593.x; Graham K, 2000, ADDICTION, V95, P847, DOI 10.1046/j.1360-0443.2000.9568473.x; HINGSON R, 1993, ADDICTION, V88, P877, DOI 10.1111/j.1360-0443.1993.tb02105.x; HINGSON R, 1987, J STUD ALCOHOL, V48, P212, DOI 10.15288/jsa.1987.48.212; Hoaken PNS, 2003, ADDICT BEHAV, V28, P1533, DOI 10.1016/j.addbeh.2003.08.033; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Langley J, 1996, ADDICTION, V91, P985, DOI 10.1111/j.1360-0443.1996.tb03595.x; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Macdonald S, 2005, ADDICT BEHAV, V30, P103, DOI 10.1016/j.addbeh.2004.04.016; Macdonald S, 1998, ACCIDENT ANAL PREV, V30, P21, DOI 10.1016/S0001-4575(97)00058-4; MacDonald S, 1997, DRUG ALCOHOL REV, V16, P251, DOI 10.1080/09595239800187431; McLeod R, 2003, ACCIDENT ANAL PREV, V35, P71, DOI 10.1016/S0001-4575(01)00091-4; *NAT HIGHW TRAFF S, 2004, TRAFF SAF FACTS COMP; NORTON RN, 1989, ALCOHOL ALCOHOLISM, V24, P565, DOI 10.1093/oxfordjournals.alcalc.a044960; Rehm J, 2003, EUR ADDICT RES, V9, P157, DOI 10.1159/000072222; ROWE B, 1992, CAN MED ASSOC J, V146, P147; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2; STALLONES L, 1993, ADDICTION, V88, P945, DOI 10.1111/j.1360-0443.1993.tb02112.x; WALSH ME, 1983, INJURY, V15, P62, DOI 10.1016/0020-1383(83)90165-1; Watt K, 2005, ALCOHOL ALCOHOLISM, V40, P263, DOI 10.1093/alcalc/agh164; WEBB GR, 1994, J STUD ALCOHOL, V55, P434, DOI 10.15288/jsa.1994.55.434; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Young DJ, 2004, J STUD ALCOHOL, V65, P605, DOI 10.15288/jsa.2004.65.605	29	40	42	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	2006	38	6					1107	1112		10.1016/j.aap.2006.04.019			6	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	103AB	WOS:000241854300010	16828047				2022-02-06	
J	Mulhern, S; McMillan, TM				Mulhern, Sharon; McMillan, Thomas M.			Knowledge and expectation of postconcussion symptoms in the general population	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						mild brain injury; postconcussion syndrome	POST-CONCUSSIONAL SYNDROME; MILD HEAD-INJURY; BRAIN INJURY; BASE RATES; ANXIETY; DEPRESSION; COMPLAINTS; STRESS; DISORDER; ABILITY	Objective: Beliefs about mild traumatic brain injury (MTBI) may affect complaints and their persistence. This study investigates the relationships between knowledge, experience, and expectation in the general population. Methods: One hundred seventy-one people reported symptoms expected from vignettes about MTBI, depression, posttraumatic stress disorder (PTSD), and orthopedic injury. Then they completed a postconcussional syndrome (PCS) checklist about these vignettes and about personal symptoms. Results: The ability to generate symptoms from vignettes was poor for PCs, depression, and PTSD, and was greatly improved using a PCs checklist, probably by symptom guessing. No postconcussion symptoms were associated specifically with MTBI. Those with more personal symptoms expected more symptoms. Past experience of MTBI did not improve symptom knowledge. Beliefs about the 'undesirability' of conditions were associated with expected outcomes. Conclusions: People know little about PCs. Expectations about MTBI are influenced by psychological factors that are relevant if we consider information given in hospitals. Symptom overlap means that psychological conditions such as depression may be misdiagnosed as PCs, and checklists should not be used for diagnosis. (c) 2006 Elsevier Inc. All rights reserved.	Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; ALVES WM, 1993, PHYS MED REHABIL, V6, P21; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; BADDELEY AD, 1992, MANUAL SPEED CAPACIT; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Burges C, 2001, BRIT J CLIN PSYCHOL, V40, P209, DOI 10.1348/014466501163544; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hochstrasser B, 1996, EUR ARCH PSY CLIN N, V246, P261, DOI 10.1007/BF02190278; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEVENTHAL H, 1997, PERCEPTIONS HLTH ILL, P00001; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ross Michael, 1986, HDB MOTIVATION COGNI, P122; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN; SEEMILLERSMITH L, 2003, BRAIN INJURY, V17, P199; *SPSS INC, 1997, STAT PACK SOC SCI VE; Stern RA, 1996, J NEUROPSYCH CLIN N, V8, P181; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	40	42	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	OCT	2006	61	4					439	445		10.1016/j.jpsychores.2006.03.004			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	094SP	WOS:000241259600003	17011350				2022-02-06	
J	Patrick, PD; Blackman, JA; Mabry, JL; Buck, ML; Gurka, MJ; Conaway, MR				Patrick, Peter D.; Blackman, James A.; Mabry, Jennifer L.; Buck, Marcia L.; Gurka, Matthew J.; Conaway, Mark R.			Dopamine agonist therapy in low-response children following traumatic brain injury	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	59th Annual Meeting of the American-Academy-for-Cerebral-Palsy-and-Developmental-Medicine	SEP 14-17, 2005	Orlando, FL	Amer Acad Cerebral Palsy & Dev Med			VEGETATIVE STATE; CLINICAL-USE; AMANTADINE; COMA	The objective of this study was to determine whether a dopamine agonist could improve mental status among children in a low-response state following traumatic brain injury. In an 8-week, prospective, double-blind, randomized trial, 10 children and adolescents ages 8 to 21 years ((X) over bar = 16.7 years) with traumatic brain injury sustained at least 1 month previously and remaining in a low-response state (Rancho Los Amigos Scale level <= 3) received pramipexole or amantadine. Medication dosage was increased over 4 weeks, weaned over 2 weeks, and then discontinued. At baseline and weekly during the study, subjects were evaluated with the Coma Near Coma Scale, Western NeuroSensory Stimulation Profile, and Disability Rating Scale. Scores improved significantly from baseline to the medication phase on the Coma Near Coma Scale, Western NeuroSensory Stimulation Profile, and Disability Rating Scale (P < .005). The weekly rate of change was significantly better for all three measures on medication than off medication (P < .05). Rancho Los Amigos Scale levels improved significantly on medication as well (P < .05). There was no difference in efficacy between amantadine and pramipexole. No unexpected or significant side effects were observed with either drug.	Univ Virginia, Childrens Hosp, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22901 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA		Blackman, JA (corresponding author), Univ Virginia, Childrens Hosp, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22901 USA.	jab5u@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R24HD039631] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Gerlach M, 2003, J NEURAL TRANSM, V110, P1119, DOI 10.1007/s00702-003-0027-5; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hagen C, 1979, LEVELS COGNITIVE FUN; Hollander M, 1973, NONPARAMETRIC STAT M; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kieburtz K, 1997, JAMA-J AM MED ASSOC, V278, P125; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; ODELL MW, 1996, MED REHABILITATION T, P103; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; PENNEY JB, 1996, NEUROPSYCHIATRY, P145; Povlishock J T, 2000, Clin Neurosurg, V46, P113; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHATZBERG AF, 2003, TXB PSYCHOPHARMACOLO; Schneider WN, 1999, BRAIN INJURY, V13, P863; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Waxham M., 1999, FUNDAMENTAL NEUROSCI, P235	28	40	44	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	OCT	2006	21	10					879	885		10.1177/08830738060210100901			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pediatrics	122DU	WOS:000243206700009	17005105				2022-02-06	
J	Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM; Kadyan, V				Mysiw, W. Jerry; Bogner, Jennifer A.; Corrigan, John D.; Fugate, Lisa P.; Clinchot, Daniel M.; Kadyan, Vivek			The impact of acute care medications on rehabilitation outcome after traumatic brain injury	BRAIN INJURY			English	Article						brain trauma; rehabilitation; agitation; post traumatic amnesia	HEAD-INJURY; RECOVERY; AGITATION; STROKE; NOREPINEPHRINE; DOPAMINE; DRUGS; EDEMA	Objectives: To examine the impact of medications with known central nervous system (CNS) mechanisms of action, given during the acute care stages after traumatic brain injury (TBI), on the extent of cognitive and motor recovery during inpatient rehabilitation. Design: Retrospective extraction of data utilizing an inception cohort of moderate and severe TBI survivors. Methods: The records of 182 consecutive moderate and severe TBI survivors admitted to a single, large, Midwestern level I trauma centre and subsequently transferred for acute inpatient rehabilitation were abstracted for the presence of 11 categories of medication, three measures of injury severity (worst 24 hour Glasgow Coma Scale, worst pupillary response, intra-cranial hypertension), three measures of outcome (Function Independence Measure (FIM) Motor and Cognitive scores at both rehabilitation admission and discharge and duration of post-traumatic amnesia (PTA)). Main outcome and results: The narcotics, benzodiazepines and neuroleptics were the most common categories of CNS active medications (92%, 67% and 43%, respectively). The three categories of medications appeared to have no significant outcome on the FIM outcome variables. The neuroleptics affected cognitive recovery with almost 7 more days required to clear PTA in the neuroleptic treated group. The presence of benzodiazepines did tend to obscure the impact of neuroleptics on PTA duration but the negative impact of neuroleptics on PTA duration remained significant. Conclusions: The results suggest that the use of neuroleptics during the acute care stage of recovery has a negative impact on recovery of cognitive function at discharge from inpatient rehabilitation. Due to the paucity of subjects with hemiplegia in this cohort, conclusions could not be drawn as to the impact of acute care medications on motor recovery.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Mysiw, WJ (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 W 9th Ave,Dodd Hall, Columbus, OH 43210 USA.	mysiw.1@osu.edu	Bogner, Jennifer/E-2773-2011; Mysiw, Walter/E-3724-2011; Corrigan, John D./E-2921-2011	Clinchot, Daniel/0000-0002-2810-7227			Beaumont A, 2000, ACT NEUR S, V76, P147; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Dam M, 1996, STROKE, V27, P2145; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; O'Neill MJ, 1998, EUR J PHARMACOL, V352, P37, DOI 10.1016/S0014-2999(98)00333-1; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	40	40	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2006	20	9					905	911		10.1080/02699050600743972			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100003	17062422				2022-02-06	
J	Wijnen, VJM; Heutink, M; van Boxtel, GJM; Eilander, HJ; de Gelder, B				Wijnen, Viona J. M.; Heutink, Matagne; van Boxtel, Geert J. M.; Eilander, Henk J.; de Gelder, Beatrice			Autonomic reactivity to sensory stimulation is related to consciousness level after severe traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						severe traumatic brain injury; autonomic nervous system; consciousness; vegetative state; minimally conscious state; sensory stimulation	HEART-RATE-VARIABILITY; POWER SPECTRUM ANALYSIS; VEGETATIVE STATE; EVOKED-POTENTIALS; CINGULATE CORTEX; PROGNOSTIC VALUE; COMA; SCALE; CONNECTIVITY; DISABILITY	Objective: To examine changes in the activity of the autonomic nervous system (ANS) that are related to recovery to consciousness in the post-acute phase after severe traumatic brain injury (sTBI). Methods: Skin conductance and heart rate reactivity to sensory stimulation were recorded every 2 weeks for an average period of 3.5 months in 16 adolescent patients, during the assessment of their level of consciousness (LoC), and their cognitive and functional behaviour. Results: Both heart rate variability (HRV) and skin conductance level (SCL) in reaction to sensory stimulation changed with recovery to consciousness. Indices of HRV and SCL that represent sympathetic activity of the autonomic nervous system (ANS) increased with recovery, whereas indices that represent parasympathetic activity decreased. In addition, we observed an increase in sympathovagal balance of the ANS with recovery. Conclusions: Recovery to consciousness determined by clinical observation in sTBI in the post-acute phase is related to changes in SCL and HRV during sensory stimulation. ANS reactivity to environmental stimulation can therefore give objective supplementary information about the clinical state of sTBI patients, and can contribute to decision-making in the treatment policy of unresponsive patients. Significance: These findings demonstrate that autonomic reactivity can be informative concerning how a severely damaged nervous system reacts to environmental stimulation and how, in a recovering nervous system, this reactivity changes. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Tilburg Univ, Dept Psychol & Hlth, Cognit Neurosci Lab, NL-5000 LE Tilburg, Netherlands; Rehabil Ctr Leipk, Tilburg, Netherlands; Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA		Wijnen, VJM (corresponding author), Warandelaan 2,POB 90153, NL-5000 LE Tilburg, Netherlands.	v.j.m.wijnen@gmail.com	Wijnen, Viona/G-1328-2016; Eilander, Henk/D-9643-2016; Wijnen, Viona/AAX-3041-2021	Wijnen, Viona/0000-0001-7797-1882; van Boxtel, Geert/0000-0002-9105-7963			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, W NEUROSENSORY STIMU, V24; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; BERNTSON GG, 1991, PSYCHOL REV, V98, P459, DOI 10.1037/0033-295X.98.4.459; BERNTSON GG, 1995, PSYCHOPHYSIOLOGY, V32, P162, DOI 10.1111/j.1469-8986.1995.tb03308.x; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boucsein W., 1992, ELECTRODERMAL ACTIVI; Camm AJ, 1996, CIRCULATION, V93, P1043; *CDC INJ PREV, TRAUM BRAIN INJ FACT; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; EILANDER HJ, 2005, BRAIN INJURY, V20, P46; EILANDER HJ, UNPUB RELIABILITY VA; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2005, NEUROPSYCHOL REHABIL, V15, P372, DOI 10.1080/09602010443000434; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Hagen C., 1972, LEVELS COGNITIVE FUN; Hildebrandt H, 1998, EUR ARCH PSY CLIN N, V248, P46, DOI 10.1007/s004060050016; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1996, NEUROTRAUMA, P3; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Keselman HJ, 2001, BRIT J MATH STAT PSY, V54, P1, DOI 10.1348/000711001159357; King ML, 1997, BRAIN INJURY, V11, P445; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEHRER PM, 1989, PSYCHOPHYSIOLOGY, V26, P668, DOI 10.1111/j.1469-8986.1989.tb03169.x; Liu I, 2005, TEST-SPAIN, V14, P1, DOI 10.1007/BF02595397; LOWENSOHN RI, 1977, LANCET, V1, P626; Lyeth BG, 2001, HEAD TRAUMA, P115; Malliani A, 1998, CIRCULATION, V98, P2640; Matthews SC, 2004, NEUROIMAGE, V22, P1151, DOI 10.1016/j.neuroimage.2004.03.005; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; MULDER LJM, 1992, BIOL PSYCHOL, V34, P205, DOI 10.1016/0301-0511(92)90016-N; Neumann N, 2004, BRAIN RES PROTOC, V14, P25, DOI 10.1016/j.brainresprot.2004.09.001; Ohman A., 2000, HDB PSYCHOPHYSIOLOGY, V2nd, P533; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; PLUM F, DIAGNOSIS STUPOR COM; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; TEASDALE G, 1974, LANCET, V2, P81; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WIJNEN VJM, 2005, BRAIN INJURY, V20, P107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	74	40	40	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	AUG	2006	117	8					1794	1807	SICI d0.1016/j.clinph.2006.03.006	10.1016/j.clinph.2006.03.006			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	075HY	WOS:000239876700018	16793340				2022-02-06	
J	Sang, Q; Kim, MH; Kumar, S; Bye, N; Morganti-Kossman, MC; Gunnersen, J; Fuller, S; Howitt, J; Hyde, L; Beissbarth, T; Scott, HS; Silke, J; Tan, SS				Sang, Qian; Kim, Mary H.; Kumar, Sharad; Bye, Nicole; Morganti-Kossman, Maria C.; Gunnersen, Jenny; Fuller, Stephanie; Howitt, Jason; Hyde, Lavinia; Beissbarth, Tim; Scott, Hamish S.; Silke, John; Tan, Seong-Seng			Nedd4-WW domain-binding protein 5 (Ndfip1) is associated with neuronal survival after acute cortical brain injury	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; cerebral cortex; SAGE; ubiquitination; differential gene expression; apoptosis	GENE-EXPRESSION; IDENTIFICATION; APOPTOSIS; PROFILE; CORTEX; NEUROPROTECTION; UBIQUITINATION; PROTOONCOGENE; PREVENTION; FAMILY	Understanding the transcriptional response to neuronal injury after trauma is a necessary prelude to formulation of therapeutic strategies. We used Serial Analysis of Gene Expression (SAGE) to identify 50,000 sequence tags representing 18,000 expressed genes in the cortex 2 h after traumatic brain injury (TBI). Asimilar tag library was obtained from sham-operated cortex. The SAGE data were validated on biological replicates using quantitative real-time-PCR on multiple samples at 2, 6, 12, and 24 h after TBI. This analysis revealed that the vast majority of genes showed a downward trend in their pattern of expression over 24 h. This was confirmed for a subset of genes using in situ hybridization and immunocytochemistry on brain sections. Of the overexpressed genes in the trauma library, Nedd4-WW (neural precursor cell expressed, developmentally downregulated) domain-binding protein 5 (N4WBP5) (also known as Ndfip1) is strongly expressed in surviving neurons around the site of injury. Overexpression of N4WBP5 in cultured cortical neurons increased the number of surviving neurons after gene transfection and growth factor starvation compared with control transfections. These results identify N4WBP5 as a neuroprotective protein and, based on its known interaction with the ubiquitin ligase Nedd4, would suggest protein ubiquitination as a possible survival strategy in neuronal injury.	Univ Melbourne, Howard Florey Inst, Brain Dev Lab, Parkville, Vic 3010, Australia; Monash Univ, Alfred Hosp, Trauma Res Inst, Melbourne, Vic 3004, Australia; Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia		Tan, SS (corresponding author), Univ Melbourne, Howard Florey Inst, Brain Dev Lab, Parkville, Vic 3010, Australia.	stan@hfi.unimelb.edu.au	Scott, Hamish/B-2122-2009; Kumar, Sharad/AAX-7787-2020; Beissbarth, Tim/B-3129-2013; Silke, John/B-7622-2008	Scott, Hamish/0000-0002-5813-631X; Kumar, Sharad/0000-0001-7126-9814; Beissbarth, Tim/0000-0001-6509-2143; Silke, John/0000-0002-7611-5774; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Gunnersen, Jenny/0000-0002-6310-7724; Howitt, Jason/0000-0001-9922-7931			ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beissbarth T, 2004, BIOINFORMATICS, V20, P31, DOI 10.1093/bioinformatics/bth924; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Boon WM, 2004, P NATL ACAD SCI USA, V101, P14972, DOI 10.1073/pnas.0406296101; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti AC, 1998, J NEUROSCI, V18, P5663; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Heng JIT, 2003, BIOESSAYS, V25, P709, DOI 10.1002/bies.10299; Herbert C, 1997, EUR J CANCER PREV, V6, P44, DOI 10.1097/00008469-199702000-00008; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844	37	40	44	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 5	2006	26	27					7234	7244		10.1523/JNEUROSCI.1398-06.2006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	060LW	WOS:000238804700018	16822981	Bronze, Green Published			2022-02-06	
J	Cioni, M; Esquenazi, A; Hirai, B				Cioni, Matteo; Esquenazi, Alberto; Hirai, Barbara			Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						botulinum toxin; temporospatial parameters; gait; equinovarus foot	TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; HEMIPARETIC PATIENTS; HEMIPLEGIC GAIT; WALKING SPEED; SPASTIC FOOT; STROKE; PARAMETERS; INJECTION; EFFICACY	Objective: The aim of this study was to identify if botulinum toxin type A is a drug able to modify walking velocity, step length, and width of the base of support of adult patients with dynamic equinovarus foot deformity resulting from upper motor neuron syndrome. Design: This retrospective study analyzed data from 20 patients' files selected from 448 consecutive charts. The main Inclusion criteria were the presence of dynamic equinovarus foot deformity due to upper motor neuron syndrome, age between 20 and 80 yrs, evaluation of temporo-spatial parameters of gait by the Gait Mat 11 before and 4 wks after botulinum toxin type A injection to the calf muscles, and the ability to walk barefoot, unassisted, and without braces. For data analysis, based on walking velocity, we divided the patients into two groups, slow walking velocity (0.18-0.49 m/sec) and medium walking velocity (0.50-0.99 m/sec). Results: Width of the base of support was significantly reduced after botulinum toxin type A treatment, both for the affected (P < 0.005) and the unaffected limbs (P < 0.002), in the group of subjects walking at medium velocity. Walking velocity or step length of either group of patients was not significantly modified by botulinum toxin type A treatment. Conclusions: Based on this study, a significant effect of botulinum toxin type A on width of the base of support is evident and seems to be the result of a better position of the affected foot during the stance phase of locomotion leading to increased body stability and consequent reduction of width of the base of support of the unaffected limb. No change was evident in step length or walking velocity for this patient population.	Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, I-95125 Catania, Italy; IRCCS, Oasi Inst Res Mental Retardat & Brain Aging, Troina, Italy; Moss Rehabil Hosp, Gait & Mot Anal Lab, Philadelphia, PA USA		Cioni, M (corresponding author), Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, V A Doria 6, I-95125 Catania, Italy.			CIONI, Matteo/0000-0002-7594-6939			Barker S, 2006, MED ENG PHYS, V28, P460, DOI 10.1016/j.medengphy.2005.07.017; Bird AR, 1999, J AM PODIAT MED ASSN, V89, P405, DOI 10.7547/87507315-89-8-405; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BRIN MF, 1997, MUSCLE NERVE       S, V6, P208; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; Esquenazi A., 2001, PHYS MED REHABILITAT, P93; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Gooch JL, 2004, ARCH PHYS MED REHAB, V85, P1121, DOI 10.1016/j.apmr.2003.09.032; Hesse S, 2001, DRUG AGING, V18, P255, DOI 10.2165/00002512-200118040-00003; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; Johnson CA, 2004, ARCH PHYS MED REHAB, V85, P902, DOI 10.1016/j.apmr.2003.08.081; Mancini F, 2005, NEUROL SCI, V26, P26, DOI 10.1007/s10072-005-0378-9; Mayer NH, 1997, MUSCLE NERVE, pS21; MOLTENI F, 2000, GAIT ANAL STATE ART, P263; MURRAY MP, 1978, AM J PHYS MED REHAB, V57, P278; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Ofluoglu D, 2003, AM J PHYS MED REHAB, V82, P832, DOI 10.1097/01.PHM.0000091986.32078.CD; OLNEY SJ, 1996, GAIT POSTURE, V4, P136, DOI 10.1016/0966-6362(96)01063-6; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Pomeroy VM, 2004, CLIN REHABIL, V18, P222, DOI 10.1191/0269215504cr725oa; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P128, DOI 10.1097/00002060-199703000-00008; Rousseaux M, 2005, J NEUROL SCI, V232, P51, DOI 10.1016/j.jns.2005.01.009; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; WAAGFJORD J, 1990, PHYS THER, V70, P549, DOI 10.1093/ptj/70.9.549; WAGENAAR RC, 1992, J BIOMECH, V25, P1007, DOI 10.1016/0021-9290(92)90036-Z; Whittle M, 1991, GAIT ANAL INTRO, P91; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45	30	40	46	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2006	85	7					600	606		10.1097/01.phm.0000223216.50068.bc			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	059IC	WOS:000238725500007	16788391				2022-02-06	
J	Sviri, GE; Soustiel, JF; Zaaroor, M				Sviri, GE; Soustiel, JF; Zaaroor, M			Alteration in brain natriuretic peptide (BNP) plasma concentration following severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						brain natriuretic peptide; head injury; intracranial hypertension; subarachnoid hemorrhage	CEREBRAL VASOSPASM; SUBARACHNOID HEMORRHAGE; EDEMA; HYPONATREMIA; SYSTEM	Background. Brain natriuretic peptide (BNP) is a potent natriuretic and vasodilator factor which, by its systemic effects, can decrease cerebral blood flow (CBF). In aneurysmal subarchnoid hemorrhage (aSAH), BNP plasma concentrations were found to be associated with hyponatremia and were progressively elevated in patients who eventually developed delayed ischemic deficit secondary to vasospasm. The purpose of the present study was to evaluate trends in BNP plasma concentrations during the acute phase following severe (traumatic brain injury) TBI. Methods. BNP plasma concentration was evaluated in 30 patients with severe isolated head injury (GCS < 8 on admission) in four time periods after the injury (period 1: days 1-2; period 2: days 4-5; period 3: days 7-8; period 4: days 10-11). All patients were monitored for ICP during the first week after the injury. Findings. The initial BNP plasma concentrations (42 +/- 36.9 pg/ml) were 7.3 fold (p < 0.01) higher in TBI patients as compared to the control group (5.78 +/- 1.90pg/ml). BNP plasma concentrations were progressively elevated through days 7-8 after the injury in patients with diffused SAH as compared to patients with mild or no SAH (p < 0.001) and in patients with elevated ICP as compared to patients without elevated ICP (p < 0.001). Furthermore, trends in BNP plasma concentrations were significantly and positively associated with poor outcome. Interpretation. BNP plasma concentrations are elevated shortly after head injury and are continuously elevated during the acute phase in patients with more extensive SAH and in those with elevated ICP, and correlate with poor outcomes. Further studies should be undertaken to evaluate the role of BNP in TBI pathophysiology.	Technion Israel Inst Technol, Dept Neurosurg, Rambam Maimonides Med Ctr, Haifa, Israel		Sviri, GE (corresponding author), Rambam Maimonides Med Ctr, Dept Neurol Surg, POB 9602, IL-31096 Haifa, Israel.						Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Donati-Genet PCM, 2001, J PEDIATR SURG, V36, P1094, DOI 10.1053/jpsu.2001.24770; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fukui S, 2004, J CLIN NEUROSCI, V11, P507, DOI 10.1016/S0967-5868(03)00111-5; HOFFMAN A, 1991, AM J HYPERTENS, V4, P597, DOI 10.1093/ajh/4.7.597; JENNETT B, 1975, LANCET, V1, P480; Kuwahara K, 1998, J CARDIOVASC PHARM, V31, pS354, DOI 10.1097/00005344-199800001-00099; Levin ER, 1998, NEW ENGL J MED, V339, P321; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; MINAMIKAWA J, 1994, ACTA NEUROCHIR, P104; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V155, P740, DOI 10.1016/S0006-291X(88)80557-6; MORINAGA K, 1992, Neurological Surgery, V20, P45; Morinaga K, 1994, No To Shinkei, V46, P545; ROSENBERG GA, 1995, STROKE, V26, P874, DOI 10.1161/01.STR.26.5.874; Sviri GE, 2000, STROKE, V31, P118, DOI 10.1161/01.STR.31.1.118; Sviri GE, 2001, ACT NEUR S, V77, P41; TEASDALE G, 1974, LANCET, V2, P81; Tomida M, 1998, STROKE, V29, P1584, DOI 10.1161/01.STR.29.8.1584; Tsubokawa T, 2004, NEUROL RES, V26, P893, DOI 10.1179/016164104225017776; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; Wijdicks EFM, 1997, J NEUROSURG, V87, P275, DOI 10.3171/jns.1997.87.2.0275; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P540, DOI 10.1016/S0003-9993(97)90173-8	23	40	50	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2006	148	5					529	533		10.1007/s00701-005-0666-4			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	034GG	WOS:000236916400009	16322908				2022-02-06	
J	Popma, A; Raine, A				Popma, A; Raine, A			Will future forensic assessment be neurobiologic?	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; LOW SALIVARY CORTISOL; HEART-RATE LEVEL; AGE 11 YEARS; ANTISOCIAL-BEHAVIOR; AGGRESSIVE-BEHAVIOR; ADOLESCENTS; CHILDREN; VIOLENCE; GENE	During the past two decades, research on the role of biologic factors in antisocial behavior has made great progress. This article discusses recent findings and their possible implications for future forensic assessment and treatment. In addition, some relevant philosophical, ethical, and political questions are brought forward.	Vrije Univ Amsterdam, Med Ctr, Dept Child & Adolescent Psychiat, NL-1115 ZG Amsterdam, Netherlands; Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA		Popma, A (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Child & Adolescent Psychiat, P-A Bascule,Rijksstraatweg 145PB, NL-1115 ZG Amsterdam, Netherlands.	a.popma@debascule.com					ARCHER J, 1991, BRIT J PSYCHOL, V82, P1, DOI 10.1111/j.2044-8295.1991.tb02379.x; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Button TMM, 2005, BEHAV GENET, V35, P115, DOI 10.1007/s10519-004-0826-y; Cacioppo JT, 2000, PSYCHOL BULL, V126, P829, DOI 10.1037//0033-2909.126.6.829; Cacioppo JT, 2003, J PERS SOC PSYCHOL, V85, P650, DOI 10.1037/0022-3514.85.4.650; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; CLONINGER CR, 1982, ARCH GEN PSYCHIAT, V39, P1242; Coccaro EF, 1997, PSYCHIAT RES, V73, P1, DOI 10.1016/S0165-1781(97)00108-X; Connor D.F., 2002, AGGRESSION ANTISOCIA; CRISTIANSEN KO, 1977, BIOSOCIAL BASIS CRIM, P89; DAHL RE, 1998, ANN PROGR CHILD PSYC, P3; Damasio A., 1994, DESCARTES ERROR EMOT; Eley TC, 2003, DEV PSYCHOPATHOL, V15, P383, DOI 10.1017/S095457940300021X; EYSENCK HJ, 1977, CRIME PERSONALITY; Farrington DP, 1997, NATO ADV SCI I A-LIF, V292, P89; FISHER PA, 2002, INT C INF STUD TOR O; Foley DL, 2004, ARCH GEN PSYCHIAT, V61, P738, DOI 10.1001/archpsyc.61.7.738; FOWLES DC, 1993, ELECTRODERMAL ACTIVI; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; GRISSO T, 2004, DOUBLE JEOPARDY ADOL; Haberstick BC, 2005, AM J MED GENET B, V135B, P59, DOI 10.1002/ajmg.b.30176; Hugdahl K, 1998, PSYCHOPHYSIOLOGY, V35, P170; Hux D, 1998, BRAIN INJURY, V12, P667; Ishikawa SS, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P277; Kendler KS, 2005, AM J PSYCHIAT, V162, P433, DOI 10.1176/appi.ajp.162.3.433; Kendler KS, 2005, AM J PSYCHIAT, V162, P1243, DOI 10.1176/appi.ajp.162.7.1243; Kruesi MJP, 2004, PSYCHIAT RES-NEUROIM, V132, P1, DOI 10.1016/j.pscychresns.2004.07.002; LAHEY BB, 1995, CONDUCT DISORDERS CH; Lee TMC, 2002, HUM BRAIN MAPP, V15, P157, DOI 10.1002/hbm.10020; Lorber MF, 2004, PSYCHOL BULL, V130, P531, DOI 10.1037/0033-2909.130.4.531; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McBurnett K, 2000, ARCH GEN PSYCHIAT, V57, P38, DOI 10.1001/archpsyc.57.1.38; McBurnett K, 2005, BIOL PSYCHIAT, V57, P1109, DOI 10.1016/j.biopsych.2005.01.041; Mednick S, 1977, BIOSOCIAL BASES CRIM, P1; Mitchell S. D., 2003, BIOL COMPLEXITY INTE; Moffitt TE, 2001, DEV PSYCHOPATHOL, V13, P355, DOI 10.1017/S0954579401002097; Monastra VJ, 2005, APPL PSYCHOPHYS BIOF, V30, P95, DOI 10.1007/s10484-005-4305-x; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Newman TK, 2005, BIOL PSYCHIAT, V57, P167, DOI 10.1016/j.biopsych.2004.10.012; OCONNOR K, 1985, BRIT J PSYCHOL, V76, P187, DOI 10.1111/j.2044-8295.1985.tb01942.x; Ortiz J, 2004, J AM ACAD CHILD PSY, V43, P154, DOI 10.1097/00004583-200402000-00010; PARKER LS, 1995, TRENDS GENET, V11, P520, DOI 10.1016/S0168-9525(00)89164-7; Plomin R, 2003, ANNU REV PSYCHOL, V54, P205, DOI 10.1146/annurev.psych.54.101601.145108; Porter RJ, 2003, PSYCHOPHARMACOLOGY, V165, P216, DOI 10.1007/s00213-002-1282-0; Prichep LS, 2002, CLIN ELECTROENCEPHAL, V33, P8, DOI 10.1177/155005940203300104; QUAY HC, 1965, AM J PSYCHIAT, V122, P180, DOI 10.1176/ajp.122.2.180; RAINE A, 1984, BIOL PSYCHOL, V18, P123, DOI 10.1016/0301-0511(84)90015-2; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Raine A, 1997, J AM ACAD CHILD PSY, V36, P1457, DOI 10.1097/00004583-199710000-00029; Raine A, 2003, AM J PSYCHIAT, V160, P1627, DOI 10.1176/appi.ajp.160.9.1627; RAINE A, 1990, AM J PSYCHIAT, V147, P933; Raine A, 2001, AGGRESSIVE BEHAV, V27, P111, DOI 10.1002/ab.4; Raine A, 2001, PSYCHOPHYSIOLOGY, V38, P254, DOI 10.1111/1469-8986.3820254; RAINE A, 1990, PSYCHIAT RES, V31, P85, DOI 10.1016/0165-1781(90)90111-H; Raine A, 1993, PSYCHOPATHOLOGY CRIM; Raine A., 1997, BIOSOCIAL BASES VIOL; RAINE A, 1999, CEREBRUM, V1, P15; Rhee SH, 2002, PSYCHOL BULL, V128, P490, DOI 10.1037//0033-2909.128.3.490; ROWE DC, 2001, BIOL CRIME; Rutter ML, 1997, AM PSYCHOL, V52, P390; Sapolsky RM, 2004, PHILOS T R SOC B, V359, P1787, DOI 10.1098/rstb.2004.1547; Scarpa A, 2003, J COMMUNITY PSYCHOL, V31, P321, DOI 10.1002/jcop.10058; Shirtcliff EA, 2005, DEV PSYCHOPATHOL, V17, P167, DOI 10.1017/S0954579405050091; Shoal GD, 2003, J AM ACAD CHILD PSY, V42, P1101, DOI 10.1097/01.CHI.0000070246.24125.6D; Sterzer P, 2005, BIOL PSYCHIAT, V57, P7, DOI 10.1016/j.biopsych.2004.10.008; Susman EJ, 1996, ANN NY ACAD SCI, V794, P18, DOI 10.1111/j.1749-6632.1996.tb32506.x; van de Wiel NMH, 2004, J AM ACAD CHILD PSY, V43, P1011, DOI 10.1097/01.chi.0000126976.56955.43; van Goozen SHM, 2000, J AM ACAD CHILD PSY, V39, P1438, DOI 10.1097/00004583-200011000-00019; Vermeiren R, 2003, CLIN PSYCHOL REV, V23, P277, DOI 10.1016/S0272-7358(02)00227-1; Volavka J, 1999, J NEUROPSYCH CLIN N, V11, P307, DOI 10.1176/jnp.11.3.307; Yang YL, 2005, BRIT J PSYCHIAT, V187, P320, DOI 10.1192/bjp.187.4.320	72	40	42	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1056-4993	1558-0490		CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	APR	2006	15	2					429	+		10.1016/j.chc.2005.11.004			17	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	028YE	WOS:000236523900010	16527664	Green Submitted			2022-02-06	
J	Gordon, WA; Cantor, J; Ashman, T; Brown, M				Gordon, WA; Cantor, J; Ashman, T; Brown, M			Treatmeant of post-TBI executive dysfunction - Application of theory to clinical practice	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		emotional regulation; executive functions; rehabilitation; theory; traumatic brain injury; problem solving	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY INTEGRATION; GOAL MANAGEMENT; ATTENTION; INDIVIDUALS; PROGRAM; DEFICITS; OUTPATIENTS; IMPAIRMENT	The authors propose a theory-based model for the treatment of post-traumatic brain injury executive dysfunction that integrates (1) theories of cerebral function and organization, (2) cognitive-behavioral theory of problem solving, and (3) learning theory. The model delineates appropriate targets of and methods for the treatment of executive dysfunction. A practical application of the theoretical model is described in the form of a comprehensive day treatment program, Executive Plus. A test of the model is also discussed, focused on the comparison of Executive Plus and a standard day treatment program along parameters dictated by the model.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA		Gordon, WA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.		Ashman, Teresa/B-1621-2013				Beck A.T, 1976, COGNITIVE THERAPY EM; Benson D.F., 1986, FRONTAL LOBES; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; BENYISHAY Y, 1971, J ABNORM PSYCHOL, V78, P17, DOI 10.1037/h0031481; Burgess P, 1996, BEHAV ASSESSMENT DYS; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Conners C. K., 2000, CONNERS CONTINUOUS P; D'Zurilla T. J., 1988, HDB COGNITIVE BEHAV; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Gagne R. M, 1965, CONDITIONS LEARNING; GOLDBERG E, 1986, HDB CLIN MEMORY ASSE; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Gordon WA, 1987, NEUROPSYCHOL REHABIL, P111; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; GORDON WA, 1991, NEUROBEHAVIOURAL SEQ, P175; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loeb, 1996, INDEPENDENT LIVING S; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria AR, 1963, RESTORATION FUNCTION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; MATEER CA, 1992, REHABILITATION POSTC, P143; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1981, BRIT MED BULL, V37, P187, DOI 10.1093/oxfordjournals.bmb.a071699; Simon D, 2001, REHABIL PSYCHOL, V46, P330; Sohlberg M, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2001, ATTENTION PROCESS TR; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Stuss D. T., 1987, J NEUROLOGICAL REHAB, V1, P19, DOI DOI 10.1177/136140968700100105; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P64; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; YLVISAKER M, 2004, 4 ANN GALV TBI C GAL	62	40	41	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					156	167		10.1097/00001199-200603000-00008			12	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300007	16569989				2022-02-06	
J	Creamer, M; O'Donnell, ML; Pattison, P				Creamer, M; O'Donnell, ML; Pattison, P			Amnesia, traumatic brain injury, and posttraumatic stress disorder: a methodological inquiry	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; MTBI; amnesia	MOTOR-VEHICLE ACCIDENTS; CONSCIOUSNESS; CONSEQUENCES; SYMPTOMS; SCALE	This study explored the relationship between mild traumatic brain injury (MTBI), amnesia, and posttraumatic stress disorder (PTSD). MTBI status and amnesia for the event were assessed in 307 consecutive admissions to a Level 1 Trauma Center. Amnesia did not always occur concurrently with MTBI: 18% of those with MTBI had full recall and over half had partial recall of the event. Just over 10% of participants developed PTSD by 12 months post-injury, with prevalence comparable across MTBI and non-MTBI groups. Non-significant differences in incidence of PTSD were apparent between those with full recall (9%), partial recall (14%) and no recall (7%). These data highlight the fact that PTSD may develop following trauma despite amnesia for the event, and illustrate the importance in both clinical and research settings of carefully examining the extent of amnesia. (c) 2005 Elsevier Ltd. All rights reserved.	Australian Ctr Posttraumat Mental Hlth, Heidelberg, Vic 3081, Australia; Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia		Creamer, M (corresponding author), Australian Ctr Posttraumat Mental Hlth, ARMC Repat Campus,POB 5444, Heidelberg, Vic 3081, Australia.	markcc@unimelb.edu.au		Pattison, Philippa/0000-0001-9626-2897; O'Donnell, Meaghan/0000-0003-4349-0022			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; MAROSSZEKY NEV, 1998, PTA PROTOCOLL GUIDEL; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; TEASDALE G, 1974, LANCET, V2, P81	19	40	40	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967	1873-622X		BEHAV RES THER	Behav. Res. Ther.	OCT	2005	43	10					1383	1389		10.1016/j.brat.2004.11.001			7	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	971CT	WOS:000232359500010	16086988				2022-02-06	
J	McAllister, TW; Rhodes, CH; Flashman, LA; McDonald, BC; Belloni, D; Saykin, AJ				McAllister, TW; Rhodes, CH; Flashman, LA; McDonald, BC; Belloni, D; Saykin, AJ			Effect of the dopamine D2 receptor T allele on response latency after mild traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							DRD2; GENE; BINDING	Objective: The authors tested the hypothesis that the dopamine D2 receptor T allele ( formerly described as the A1 allele) would be associated with poorer performance on memory and attention tasks following mild traumatic brain injury. Method: Thirty-nine patients with mild traumatic brain injury and 27 comparison subjects were genotyped. All subjects completed memory and attention tests, including the California Verbal Learning Test recognition task and the Continuous Performance Test. Results: In both groups the T allele was associated with poorer performance on the California Verbal Learning Test recognition task. There was also a significant diagnosis-by-allele interaction on measures of response latency ( Continuous Performance Test): the subjects with mild traumatic brain injury and the T allele had the worst performance. Conclusions: Genetic polymorphisms modulating central dopaminergic tone can affect cognitive outcome following mild traumatic brain injury.	Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH 03756 USA		McAllister, TW (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-40472-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; First M., 1997, STRUCTURED CLIN INTE; Gordon N, 1996, EUR J DISORDER COMM, V31, P359; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCALLISTER TW, 2003, J NEUROPSYCHIATRY CL, V15, P278; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; TEASDALE G, 1974, LANCET, V2, P81; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME	16	40	43	0	1	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	SEP	2005	162	9					1749	1751		10.1176/appi.ajp.162.9.1749			3	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	959ZT	WOS:000231559300028	16135640				2022-02-06	
J	Maxwell, WL; Watson, A; Queen, R; Conway, B; Russell, D; Neilson, M; Graham, DI				Maxwell, WL; Watson, A; Queen, R; Conway, B; Russell, D; Neilson, M; Graham, DI			Slow, medium, or fast re-warming following post-traumatic hypothermia therapy? An ultrastructural perspective	JOURNAL OF NEUROTRAUMA			English	Article						post-traumatic hypothermia; re-warming; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; NONDISRUPTIVE AXONAL INJURY; NEUROFILAMENT DISTRIBUTIONS; CYTOSKELETAL CHANGES; OPTIC-NERVE; DAMAGE; MICROTUBULES; MODEL	It was hypothesized that rapid rather than slow re-warming following traumatic brain injury (TBI) and short-term hypothermia results in secondary, ultrastructural pathology. After stretch injury to the right optic nerve, adult guinea pigs were randomly allocated to one of six experimental groups. Either (1) sham (all procedures but not stretch-injured; n = 4); injured and (2) maintained at normal temporalis core temperature (38.5 degrees C) for 8 hours (n = 6); (3) cooled rapidly to 32.5 degrees C (temporalis temperature), maintained for 4 h and re-warmed to 38.5 degrees C at 1 degrees C rise every 10 min (fast; n = 6); (4) cooled and re-warmed at 1 degrees C rise every 20 min (medium; n = 6); (5) cooled and re-warmed at 1 degrees C rise every 40 min (slow; n = 6) before being killed 8 h after injury; and (6) uninjured animals (n = 6) cooled to 32.5 degrees C for 4 h and then re-warmed at 1 degrees C every 10 min before killing 4 h later. Tissue was processed for light immunocytochemistry (beta-APP and RMO-14) and ultrastructural stereology. In both uninjured and injured fast re-warmed animals, there was almost total loss of axonal microtubules (MT) and an increased number of neurofilaments (NF) within the axoplasm. In the former, there was also compaction of NF. The number of MT was reduced to 40% of control values, NFs were increased but were not compacted after medium rate re-warming. Following slow re-warming the axonal cytoskeleton did not differ from that in control animals. It is concluded that re-warming faster than 1 degrees C every 40 min following mild post-traumatic hypothermia induces secondary axonal pathology.	Univ Glasgow, IBLS, Glasgow G12 8QQ, Lanark, Scotland; So Gen Hosp, Univ Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland		Maxwell, WL (corresponding author), Univ Glasgow, IBLS, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	w.maxwell@bio.gla.ac.uk					Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; DONAGHY M, 1988, J NEUROCYTOL, V17, P197, DOI 10.1007/BF01674207; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GUY J, 1989, J COMP NEUROL, V287, P446, DOI 10.1002/cne.902870404; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kumar S, 2002, J NEUROSCI RES, V68, P681, DOI 10.1002/jnr.10249; Kumar S, 2002, BIOPHYS J, V82, P2360, DOI 10.1016/S0006-3495(02)75581-1; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OHNISHI A, 1976, J NEUROPATH EXP NEUR, V35, P167, DOI 10.1097/00005072-197603000-00004; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; WEGNER JE, 1976, BIOL GUINEA PIG	28	40	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					873	884		10.1089/neu.2005.22.873			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900003	16083354				2022-02-06	
J	Nguyen, XV; Masse, J; Kumar, A; Vijitruth, R; Kulik, C; Liu, M; Choi, DY; Foster, TC; Usynin, I; Bakalkin, G; Bing, GY				Nguyen, XV; Masse, J; Kumar, A; Vijitruth, R; Kulik, C; Liu, M; Choi, DY; Foster, TC; Usynin, I; Bakalkin, G; Bing, GY			Prodynorphin knockout mice demonstrate diminished age-associated impairment in spatial water maze performance	BEHAVIOURAL BRAIN RESEARCH			English	Article						dynorphin; opioid; aging; Morris water maze; learning; memory; spatial; knockout mice	KAPPA-OPIOID RECEPTOR; GUINEA-PIG HIPPOCAMPUS; DENTATE GYRUS; DYNORPHIN PEPTIDES; SPINAL-CORD; RATS; MEMORY; EXPRESSION; BRAIN; BLOCK	Dynorphins, endogenous kappa-opioid agonists widely expressed in the central nervous system, have been reported to increase following diverse pathophysiological processes, including excitotoxicity, chronic inflammation. and traumatic injury. These peptides have been implicated in cognitive impairment, especially that associated with aging. To determine whether absence of dynorphin confers any beneficial effect on spatial learning and memory, knockout mice lacking the coding exons of the gene encoding its precursor prodynorphin (Pdyn) were tested in a water maze task. Learning and memory assessment using a 3-day water maze protocol demonstrated that aged Pdyn knockout mice (13-17 months) perform comparatively better than similarly aged wild-type (WT) mice, based on acquisition and retention probe trial indices. There was no genotype effect on performance in the cued version of the swim task nor on average swim speed, suggesting the observed genotype effects are likely attributable to differences in cognitive rather than motor function. Young (3-6 months) mice performed significantly better than aged mice, but in young mice, no genotype difference was observed. To investigate the relationship between aging and brain dynorphin expression in mice, we examined dynorphin peptide levels at varying ages in hippocampus and frontal cortex of WT 129SvEv mice. Quantitative radioimmunoassay demonstrated that dynorphin A levels in frontal cortex, but not hippocampus, of 12- and 24-month mice were significantly elevated compared to 3-month mice. Although the underlying mechanisms have yet to be elucidated, the results suggest that chronic increases in endogenous dynorphin expression with age, especially in frontal cortex, may adversely affect learning and memory. (c) 2005 Elsevier B.V. All rights reserved.	Univ Kentucky, Ctr Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden		Bing, GY (corresponding author), Univ Kentucky, Ctr Med, Dept Anat & Neurobiol, 800 Rose St,310 Whitney Henrickson Facil, Lexington, KY 40536 USA.	gbing@uky.edu	Nguyen, Xuan V/G-5532-2012; bing, guoying/F-7084-2012; Usynin, Ivan F/A-4945-2017	Nguyen, Xuan V/0000-0002-2617-1938; Bing, Guoying/0000-0003-0609-8152; Usynin, Ivan/0000-0003-1752-9034; Bakalkin, Georgy/0000-0002-8074-9833	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG14979] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65055-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 044157] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F30MH065055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014979] Funding Source: NIH RePORTER		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; Chen L, 1998, J PHARMACOL EXP THER, V284, P826; CHEN L, 1995, J NEUROSCI, V15, P4602; CHRISTENSSONNYLANDER I, 1985, NEUROPEPTIDES, V6, P391, DOI 10.1016/0143-4179(85)90137-4; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Croll SD, 1999, PHARMACOL BIOCHEM BE, V64, P625, DOI 10.1016/S0091-3057(99)00122-7; Diez M, 2000, NEUROSCIENCE, V100, P259, DOI 10.1016/S0306-4522(00)00261-X; Foster TC, 1999, BRAIN RES REV, V30, P236, DOI 10.1016/S0165-0173(99)00017-X; Fugger HN, 1998, HORM BEHAV, V34, P163, DOI 10.1006/hbeh.1998.1475; GAGE FH, 1984, NEUROBIOL AGING, V5, P43, DOI 10.1016/0197-4580(84)90084-8; GALLAGHER M, 1993, BEHAV BRAIN RES, V57, P155, DOI 10.1016/0166-4328(93)90131-9; GARZON J, 1984, BRAIN RES, V302, P392, DOI 10.1016/0006-8993(84)90256-7; Hauser KF, 1999, EXP NEUROL, V160, P361, DOI 10.1006/exnr.1999.7235; Heron A, 1996, NEUROPEPTIDES, V30, P355, DOI 10.1016/S0143-4179(96)90024-4; HILLER JM, 1987, BRAIN RES, V406, P17, DOI 10.1016/0006-8993(87)90764-5; Hurd YL, 1999, ANN NY ACAD SCI, V877, P499, DOI 10.1111/j.1749-6632.1999.tb09285.x; INTROINICOLLISON IB, 1987, PSYCHOBIOLOGY, V15, P171; JARRARD LE, 1978, J COMP PHYSIOL PSYCH, V92, P1119, DOI 10.1037/h0077516; JIANG HK, 1989, P NATL ACAD SCI USA, V86, P2948, DOI 10.1073/pnas.86.8.2948; Kessels RPC, 2000, NEUROPSYCHOL REV, V10, P101, DOI 10.1023/A:1009016820717; KHACHATURIAN H, 1982, PEPTIDES, V3, P941, DOI 10.1016/0196-9781(82)90063-8; Kotz CM, 2004, NEUROBIOL AGING, V25, P1343, DOI 10.1016/j.neurobiolaging.2004.02.025; Magnusson KR, 2003, BEHAV NEUROSCI, V117, P485, DOI 10.1037/0735-7044.117.3.485; MCDANIEL KL, 1990, PHARMACOL BIOCHEM BE, V35, P429, DOI 10.1016/0091-3057(90)90180-P; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NYLANDER I, 1991, NEUROPHARMACOLOGY, V30, P1219, DOI 10.1016/0028-3908(91)90168-B; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; Pliakas AM, 2001, J NEUROSCI, V21, P7397, DOI 10.1523/JNEUROSCI.21-18-07397.2001; Ploj K, 2001, PHARMACOL BIOCHEM BE, V69, P173, DOI 10.1016/S0091-3057(01)00511-1; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; Redell JB, 2003, EXP BIOL MED, V228, P261, DOI 10.1177/153537020322800304; REISBERG B, 1983, NEW ENGL J MED, V308, P721; Risser D, 1996, NEUROSCI LETT, V203, P111, DOI 10.1016/0304-3940(95)12275-3; Sandin J, 1998, NEUROSCIENCE, V85, P375, DOI 10.1016/S0306-4522(97)00605-2; Sharifi N, 2001, MOL BRAIN RES, V86, P70, DOI 10.1016/S0169-328X(00)00264-3; Tan-No K, 2001, EXP CELL RES, V269, P54, DOI 10.1006/excr.2001.5309; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; TERMAN GW, 1994, J NEUROSCI, V14, P4740; Terman GW, 2000, J NEUROSCI, V20, P4379, DOI 10.1523/JNEUROSCI.20-12-04379.2000; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WAGNER JJ, 1992, J NEUROSCI, V12, P132; WATSON SJ, 1982, LIFE SCI, V31, P1773, DOI 10.1016/0024-3205(82)90207-7; WATSON SJ, 1982, SCIENCE, V218, P1134, DOI 10.1126/science.6128790; WEISSKOPF MG, 1993, NATURE, V365, P188, DOI 10.1038/365188a0; Woods A, 2001, NEUROCHEM RES, V26, P395, DOI 10.1023/A:1010903215566; ZAMIR N, 1985, NEUROSCIENCE, V15, P1025, DOI 10.1016/0306-4522(85)90251-9	50	40	41	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 20	2005	161	2					254	262		10.1016/j.bbr.2005.02.010			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	935UT	WOS:000229809600011	15922052				2022-02-06	
J	Godbout, L; Grenier, MC; Braun, CMJ; Gagnon, S				Godbout, L; Grenier, MC; Braun, CMJ; Gagnon, S			Cognitive structure of executive deficits in patients with frontal lesions performing activities of daily living	BRAIN INJURY			English	Article						ageing; scripts; executive functions; activities of daily living	CLOSED-HEAD INJURY; TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; PROSPECTIVE MEMORY; WORKING-MEMORY; EVERYDAY MEMORY; DAMAGE; IMPAIRMENTS; LOBE; ATTENTION	Objective. Executive function in activities of daily living (ADL) were investigated in 10 patients with excised frontal lobe tumours. Method. The patients with frontal lesions were compared to 10 normal controls with a neuropsychological test battery, a script generation task and a realistic implementation of complex multi-task ADL (planning and preparing a meal). Results. The patients manifested numerous basic executive deficits on the paper-pencil tests, were unimpaired on the script generation task despite an aberrant semantic structure and manifested marked anomalies in the meal preparation task. Conclusion. Frontal lobe deficits in lengthy complex multi-task ADL can be explained by impairment of several executive functions, generalized slowness of performance and paucity of behaviour.	Univ Quebec, Dept Psychol, Ctr Neurosci Cognit, Montreal, PQ H3C 3P8, Canada; Univ Quebec, Dept Psychol, Lab Neuropsychol Expt & Comparee, Quebec City, PQ, Canada; Univ Ottawa, Ecole Psychol, Ottawa, ON, Canada		Braun, CMJ (corresponding author), Univ Quebec, Dept Psychol, Ctr Neurosci Cognit, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	braun.claude@uqam.ca					Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; ARTHUR G, 1947, POINT SCALE PERFORMA, V2; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Baddeley A.D., 1986, WORKING MEMORY; BAILLARGEON J, 1994, UNPUB ADAPTATION FRA; BASSETT SS, 1991, PSYCHOL MED, V21, P77, DOI 10.1017/S0033291700014677; Benson D.F., 1986, FRONTAL LOBES; BISSIACHI PS, 1996, PROSPECTIVE MEMORY T, P297; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Carlson MC, 1999, J GERONTOL B-PSYCHOL, V54, pS262, DOI 10.1093/geronb/54B.5.S262; CHATELOIS J, 1993, UNPUB TEST STROOP RE; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COOPER R, 1995, FR ART INT, V27, P27; CROVITZ HF, 1984, B PSYCHONOMIC SOC, V22, P413; Crozier S, 1999, NEUROPSYCHOLOGIA, V37, P1469, DOI 10.1016/S0028-3932(99)00054-8; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duyckaerts C, 1998, REV NEUROL-FRANCE, V154, pS8; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EUSTACHE F, 1996, MANUEL NEUROPSYCHOLO; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GABRIELI JDE, 1993, BEHAV NEUROSCI, V107, P899, DOI 10.1037/0735-7044.107.6.899; Gil R., 1996, NEUROPSYCHOLOGIE; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Godbout L, 2000, BRAIN COGNITION, V44, P490, DOI 10.1006/brcg.2000.1213; GODBOUT L, 2004, IN PRESS J CLIN EXPT; GODBOUT L, 2004, IN PRESS PHYS OCCUPA; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Grafman J., 1989, INTEGRATING THEORY P, P93; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Katai S, 1999, Rinsho Shinkeigaku, V39, P913; KEITH V, 1973, NONPARAMETRIC DESIGN; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; KOLB B, 1989, FONDAMENTALS HUMAN N; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luria A.R., 1966, HIGHER CORTICAL FUNC; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; McDaniel M. A., 1992, ADV LEARNING BEHAV D, V1, P23; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; Neisser U., 1982, MEMORY OBSERVED REME, P327; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Partiot A, 1996, NEUROREPORT, V7, P761, DOI 10.1097/00001756-199602290-00020; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Reitan RM, 1985, HALSTEADREITAN NEURO; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Sala SD, 1995, ANN NY ACAD SCI, V769, P161, DOI 10.1111/j.1749-6632.1995.tb38137.x; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Shapiro JK, 1998, BRAIN COGNITION, V37, P175; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; Thurstone L. L, 1962, PRIMARY MENTAL ABILI; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler, 1997, WECHSLER ADULT INTEL; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; WINOGRAD E, 1978, PRACTICAL ASPECTS ME, P348; WISE SP, 1996, NEUROSCIENCE, V8, P39; [No title captured]	78	40	42	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2005	19	5					337	348		10.1080/02699050400005093			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	932JH	WOS:000229549500004	16094781				2022-02-06	
J	Sturms, LM; van der Sluis, CK; Stewart, RE; Groothoff, JW; ten Duis, HJ; Eisma, WH				Sturms, LM; van der Sluis, CK; Stewart, RE; Groothoff, JW; ten Duis, HJ; Eisma, WH			A prospective study on paediatric traffic injuries: health-related quality of life and post-traumatic stress	CLINICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; EVENT SCALE; PSYCHOLOGICAL CONSEQUENCES; CHILDREN; DISORDER; IMPACT; ADOLESCENTS; CHILDHOOD; PARENTS	Objectives: To examine children's reports of their health- related quality of life ( HRQoL) following paediatric traffic injury, to explore child and parental post- traumatic stress, and to identify children and parents with adverse outcomes. Design: Prospective cohort study. Assessments: shortly after the injury, three months and six months post injury. Setting: Department of Traumatology, University Hospital. Subjects: Fifty- one young traffic injury victims aged 8 - 15 years. Main measures: TNO- AZL Children's Quality of Life questionnaire and the Impact of Event Scale. Results: Short- term adverse changes in the child's HRQoL were observed for the child's motor functioning and autonomy. At three months, 12% of the children and 16% of the parents reported serious post- traumatic stress symptoms. Increased stress at three months, or across follow- up, was observed among hospitalized children, children with head injuries, and children injured in a motor vehicle accident. Parental stress was related to low socioeconomic status and the seriousness of the child's injury and accident ( hospitalization, head injury, serious injury, motor vehicle involved, others injured). Conclusions: The children reported only temporary effects in their motor functioning and autonomy. Post- traumatic stress symptoms following paediatric traffic injury were not only experienced by the children, but also by their parents.	Univ Groningen Hosp, Dept Rehabil Med, NL-9700 RB Groningen, Netherlands; Univ Groningen, No Ctr Healthcare Res, Groningen, Netherlands; Univ Groningen Hosp, Dept Surg, Traumatol Sect, Groningen, Netherlands		van der Sluis, CK (corresponding author), Univ Groningen Hosp, Dept Rehabil Med, POB 30-001, NL-9700 RB Groningen, Netherlands.	c.k.van.der.sluis@rev.umcg.nl		Stewart, Roy/0000-0001-9227-433X			Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Beers SR, 2002, AM J PSYCHIAT, V159, P483, DOI 10.1176/appi.ajp.159.3.483; Brom D., 1985, NEDERLANDS TIJDSCHRI, V40, P164; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; CANTERBURY J, 1997, AFTERMATH ROAD ACCID; Commission on Professional and Hospital Activities, 1978, INT CLASS DIS 9 REV; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Dyregrov A, 1996, SCAND J PSYCHOL, V37, P339, DOI 10.1111/j.1467-9450.1996.tb00667.x; Eiser C, 2001, Health Technol Assess, V5, P1; Famularo R, 1996, CHILD ABUSE NEGLECT, V20, P1245, DOI 10.1016/S0145-2134(96)00119-6; FIGLEY CR, 1995, TRAUMA CULTURAL SOC, P75, DOI DOI 10.1007/978-1-4757-9421-2_5; FOY DW, 1996, J SCH PSYCHOL, V34, P113; Gofin R, 1999, J TRAUMA, V47, P15, DOI 10.1097/00005373-199907000-00004; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Keppel-Benson JM, 2002, J CHILD PSYCHOL PSYC, V43, P203, DOI 10.1111/1469-7610.00013; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Landolt MA, 1998, J PAEDIATR CHILD H, V34, P539, DOI 10.1046/j.1440-1754.1998.00303.x; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McDermott BM, 2000, AUST NZ J PSYCHIAT, V34, P446, DOI 10.1080/j.1440-1614.2000.00753.x; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; NADER K, 1990, AM J PSYCHIAT, V147, P1526; Scheeringa MS, 2001, J TRAUMA STRESS, V14, P799, DOI 10.1023/A:1013002507972; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Sturms LM, 2002, J TRAUMA, V52, P88, DOI 10.1097/00005373-200201000-00016; Sturms LM, 2003, ARCH PHYS MED REHAB, V84, P431, DOI 10.1053/apmr.2003.50015; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Theunissen NCM, 1998, QUAL LIFE RES, V7, P387, DOI 10.1023/A:1008801802877; Verrips EGH, 1999, EUR J PUBLIC HEALTH, V9, P188, DOI 10.1093/eurpub/9.3.188; Vogels T, 2000, TACQOL MANUAL PARENT; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015; Winje D, 1998, J CHILD PSYCHOL PSYC, V39, P635, DOI 10.1017/S0021963098002479; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; YULE W, 1991, BRIT J CLIN PSYCHOL, V30, P131, DOI 10.1111/j.2044-8260.1991.tb00928.x; YULE W, 1999, POST TRAUMATIC STRES; Yule W, 1990, J TRAUMA STRESS, V3, P279, DOI DOI 10.1002/JTS.2490030209; YULE W, 1999, INT HDB ROAD TRAFFIC	47	40	43	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAY	2005	19	3					312	322		10.1191/0269215505cr867oa			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	907QU	WOS:000227733800010	15859532	Green Submitted			2022-02-06	
J	Di Russo, F; Incoccia, C; Formisano, R; Sabatini, U; Zoccolotti, P				Di Russo, F; Incoccia, C; Formisano, R; Sabatini, U; Zoccolotti, P			Abnormal motor preparation in severe traumatic brain injury with good recovery	JOURNAL OF NEUROTRAUMA			English	Article						MRCP; readiness potentials; source analysis; TBI	CLOSED-HEAD-INJURY; CORTICAL POTENTIALS; PARKINSONS-DISEASE; ATTENTIONAL PROCESSES; INTRACEREBRAL HEMORRHAGE; REACTION-TIME; MOVEMENT; TOPOGRAPHY; SCALE; AREA	Movement-related cortical potentials (MRCPs) were examined in seven patients with severe traumatic brain injury (TBI) and 12 matched control subjects. All patients had clinically established good recovery by the time of testing. Flexion movements of the index finger of the left or right hand were recorded in two (alternating and repetitive) self-paced conditions and in one externally triggered condition. In control subjects, the bereitschaftspotential (BP) component of MRCP was detected approximately 2000 msec prior to movement onset in the self-paced conditions and was larger and earlier in the alternating compared to the repetitive condition. The BP component was absent in the externally triggered condition. In TBI patients, the BP was greatly reduced and no difference between the alternating-repetitive conditions was detected; in contrast, only small differences were present in the controls for the negative slope (NS) and MP components and no difference for the reafferent positivity (RAP) component. A dipole analysis indicated the supplementary motor area and the premotor area as the likely generators of BP and NS' components, respectively. Gradient-recalled echo magnetic resonance imaging allowed the detection of a number of small hypointense lesions primarily located in the frontal lobes, as in diffuse axonal injury. This pattern of results indicates a selective deficit in motor preparation and a relatively spared pattern of activation during and following movement in these patients. Imaging data appear generally consistent with the pattern of MRCPs observed in the patient group. Implications of these results for the problem of slowness in TBI patients are discussed.	Fdz Santa Lucia, Ctr Ric Neuropsicol, I-00179 Rome, Italy; IUSM, Rome, Italy; Univ Rome, Dept Psychol, Rome, Italy		Di Russo, F (corresponding author), Fdz Santa Lucia, Ctr Ric Neuropsicol, Via Ardeatina,36, I-00179 Rome, Italy.	fdirusso@iusm.it	Zoccolotti, Pierluigi/H-4437-2019; Sabatini, Umberto/K-4659-2016; Di Russo, Francesco/N-6686-2015; Sabatini, Umberto/A-8484-2010	Zoccolotti, Pierluigi/0000-0002-6351-2455; Sabatini, Umberto/0000-0001-5321-8626; Di Russo, Francesco/0000-0002-3127-9433; Incoccia, Chiara/0000-0003-4068-6548			Adams R. D., 1976, PRINCIPLES NEUROLOGY; ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Becker W, 1980, Prog Brain Res, V54, P189, DOI 10.1016/S0079-6123(08)61624-6; BOTZEL K, 1993, ELECTROEN CLIN NEURO, V89, P187, DOI 10.1016/0168-5597(93)90132-9; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DICK JPR, 1989, BRAIN, V112, P233, DOI 10.1093/brain/112.1.233; Dirnberger G, 2002, CLIN NEUROPHYSIOL, V113, P254, DOI 10.1016/S1388-2457(01)00728-3; Dirnberger G, 2000, EXP BRAIN RES, V135, P231, DOI 10.1007/s002210000522; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Filipovic SR, 1997, J NEUROL SCI, V147, P177, DOI 10.1016/S0022-510X(96)05344-0; Gerstenbrand F., 1967, APALLISCHE SYNDROM; Graham D.I., 1996, NEUROTRAUMA, P43; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Jellinger K, 1966, Wien Z Nervenheilkd Grenzgeb, V23, P40; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1974, LANCET, V13, P81; Kuzma BB, 2000, SURG NEUROL, V53, P400; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; Miller E, 1970, Cortex, V6, P121; MILTNER W, 1994, ELECTROEN CLIN NEURO, V91, P295, DOI 10.1016/0013-4694(94)90193-7; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Niedermeyer E, 1993, ELECTROENCEPHALOGRAP; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patel MR, 1999, AM J ROENTGENOL, V173, P479, DOI 10.2214/ajr.173.2.10430158; Peppe A, 1998, ELECTROEN CLIN NEURO, V106, P374, DOI 10.1016/S0013-4694(97)00075-8; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Sabatini U, 2000, BRAIN, V123, P394, DOI 10.1093/brain/123.2.394; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; TARKKA IM, 1991, J CLIN NEUROPHYSIOL, V8, P331, DOI 10.1097/00004691-199107010-00009; TARKKA IM, 1994, INT J PSYCHOPHYSIOL, V16, P81, DOI 10.1016/0167-8760(94)90044-2; Toma K, 2002, NEUROIMAGE, V17, P161, DOI 10.1006/nimg.2002.1165; TORO C, 1993, ELECTROEN CLIN NEURO, V86, P167, DOI 10.1016/0013-4694(93)90004-F; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOL AT; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; [No title captured]	43	40	40	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					297	312					16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400009	15716635				2022-02-06	
J	Komjati, K; Besson, VC; Szabo, C				Komjati, Katalin; Besson, Valerie C.; Szabo, Csaba			Poly (ADP-Ribose) Polymerase Inhibitors as Potential Therapeutic Agents in Stroke and Neurotrauma	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Poly(ADP-ribose) polymerase; ischemia; necrosis; apoptosis; inflammation; CNS; stroke; spinal cord injury	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE; INDUCED CELL-DEATH; POLY(ADP-RIBOSE) SYNTHETASE ACTIVATION; DIABETIC ENDOTHELIAL DYSFUNCTION; FLUID PERCUSSION INJURY; CORTICAL IMPACT INJURY	Poly (ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding protein that is primarily activated by nicks in the DNA molecule. It regulates the activity of various enzymes - including itself- that are involved in the control of DNA metabolism. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor proteins including histones, transcription factors and PARP itself. Poly(ADP-ribosylation) contributes to DNA repair and to the maintenance of genomic stability. Evidence obtained with pharmacological PARP inhibitors of various structural classes, as well as animals lacking the PARP-1 enzyme indicate that PARP plays an important role in cerebral ischemia/reperfusion, stroke and neurotrauma. Overactivation of PARP consumes NAD(+) and ATP culminating in cell dysfunction and necrosis. PARP activation can also act as a signal that initiates cell death programs, for instance through AIF (apoptosis inducing factor) translocation. PARP has also been shown to associate with and regulate the function of several transcription factors. Of special interest is the enhancement by PARP of NF-kappa B-mediated transcription, which plays a central role in the expression of inflammatory cytokines, chemokines, adhesion molecules and inflammatory mediators. Via this mechanism, PARP is involved in the up-regulation of numerous pro-inflammatory genes that play a pathogenetic role in the later stage of stroke and neurotrauma. Here we review the roles of PARP in DNA damage signaling and cell death, and summarize the pathogenetic role of PARP in stroke and neurotrauma.	[Komjati, Katalin; Szabo, Csaba] Inotek Pharmaceut Corp, Beverly, MA 01915 USA; [Besson, Valerie C.] Univ Rene Decartes, Lab Pharmacol Circulat Cerebrale, Paris, France; [Szabo, Csaba] Semmelweis Univ, Dept Human Physiol & Clin Expt Res, Budapest, Hungary		Szabo, C (corresponding author), INOTEK Pharmaceut, 100 Cummings Ctr,Suite 419E, Beverly, MA 01915 USA.	szabocsaba@aol.com	besson, valerie C/L-7388-2017; BESSON, VALERIE/AAZ-9989-2020; Szabo, Csaba/ABG-2644-2021	besson, valerie C/0000-0002-1491-2380; BESSON, VALERIE/0000-0002-1491-2380; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Hungarian Ministry of Health	The work in the authors' laboratories is supported by grants from the National Institutes of Health and the Hungarian Ministry of Health.	Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Affar E, 2002, P NATL ACAD SCI USA, V99, P245, DOI 10.1073/pnas.012460399; Aito H, 2004, BRAIN RES, V1013, P117, DOI 10.1016/j.brainres.2004.04.014; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Barc S, 2001, NEUROSCI LETT, V314, P82, DOI 10.1016/S0304-3940(01)02273-X; Beneke S, 2004, INT J CANCER, V111, P813, DOI 10.1002/ijc.20342; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Chiang SKS, 2000, INVEST OPHTH VIS SCI, V41, P3210; Chiarugi A, 2003, J PHARMACOL EXP THER, V305, P943, DOI 10.1124/jpet.103.048934; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Colak A, 2003, J NEUROSURG, V98, P275, DOI 10.3171/spi.2003.98.3.0275; Cole KK, 2002, J NEUROCHEM, V82, P19, DOI 10.1046/j.1471-4159.2002.00935.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cosi C, 2002, EXPERT OPIN THER PAT, V12, P1047, DOI 10.1517/13543776.12.7.1047; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/0006-8993(96)00571-9; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; Cuzzocrea S, 2004, CURR MED CHEM, V9, P1147; Czapski GA, 2004, NEUROSCI LETT, V356, P45, DOI 10.1016/j.neulet.2003.11.022; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DEMURCIA G, 2000, DNA DAMAGE STRESS SI; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Didier M, 1996, J NEUROSCI, V16, P2238; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Dyker AG, 1998, STROKE, V29, P535, DOI 10.1161/01.STR.29.2.535; Ehrlich W, 1995, RHEUMATOL INT, V15, P171, DOI 10.1007/BF00301776; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FAGNI L, 1994, PROG BRAIN RES, V103, P381; Falsig J, 2004, EUR J PHARMACOL, V497, P7, DOI 10.1016/j.ejphar.2004.06.042; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Ferraris D, 2003, BIOORGAN MED CHEM, V11, P3695, DOI 10.1016/S0968-0896(03)00333-X; Flentjar NJ, 2002, EXP NEUROL, V177, P9, DOI 10.1006/exnr.2002.7927; Genovese T, 2005, J PHARMACOL EXP THER, V312, P449, DOI 10.1124/jpet.104.076711; Giovanelli L, J CEREB BLOOD FLOW M, V22, P697; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; GROTTA J, 1994, CEREBROVASC DIS, V4, P115, DOI 10.1159/000108466; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Gupta S, 2004, NEUROL RES, V26, P103, DOI 10.1179/016164104773026624; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; HAMMER B, 1993, NEUROREPORT, V5, P72, DOI 10.1097/00001756-199310000-00018; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HIROMATSU Y, 1992, CLIN ENDOCRINOL, V36, P91, DOI 10.1111/j.1365-2265.1992.tb02907.x; Hivert B, 1998, NEUROREPORT, V9, P1835, DOI 10.1097/00001756-199806010-00031; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Huang FN, 2004, BRAIN RES, V997, P79, DOI 10.1016/j.brainres.2003.10.051; Hung TH, 2002, CIRC RES, V90, P1274, DOI 10.1161/01.RES.0000024411.22110.AA; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kabra DG, 2004, BRAIN RES BULL, V62, P425, DOI 10.1016/j.brainresbull.2003.11.001; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kaminski S.G, 1999, NEUROREPORT, V10, P3347; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Klaidman LK, 2001, BBA-GEN SUBJECTS, V1525, P136, DOI 10.1016/S0304-4165(00)00181-1; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Koh SH, 2004, EUR J NEUROSCI, V20, P1461, DOI 10.1111/j.1460-9568.2004.03632.x; Komjati K, 2004, INT J MOL MED, V13, P373; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lacza Z, 2003, INT J MOL MED, V12, P153; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lee YS, 2004, FREE RADICAL BIO MED, V36, P330, DOI 10.1016/j.freeradbiomed.2003.11.006; Lee YW, 2001, NEUROCHEM RES, V26, P337, DOI 10.1023/A:1010993428770; Lees K.R., 2002, CEREBROVASC DIS, P430; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li F, 2004, DIABETOLOGIA, V47, P710, DOI 10.1007/s00125-004-1356-0; Lin SH, 2000, J CEREBR BLOOD F MET, V20, P1380, DOI 10.1097/00004647-200009000-00013; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; MAYNARD KI, 2002, SCI MED          SEP, P260; Mazzon E, 2001, EUR J PHARMACOL, V415, P85, DOI 10.1016/S0014-2999(01)00809-3; McCulloch J, 2002, CEREBROVASC DIS, P404; Meier HL, 1999, ANN NY ACAD SCI, V890, P330, DOI 10.1111/j.1749-6632.1999.tb08010.x; Meli E, 2004, MOL CELL NEUROSCI, V25, P172, DOI 10.1016/j.mcn.2003.09.016; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Minchenko AG, 2003, FASEB J, V17, P1514, DOI 10.1096/fj.03-0013fje; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Nakajima H, 2005, J PHARMACOL EXP THER, V312, P472, DOI 10.1124/jpet.104.075465; Nishio S, 1997, ACT NEUR S, V70, P84; Nucci C, 2000, BIOCHEM BIOPH RES CO, V278, P360, DOI 10.1006/bbrc.2000.3811; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Oka M, 2000, NEUROPHARMACOLOGY, V39, P1319, DOI 10.1016/S0028-3908(99)00197-5; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Pacher P, 2002, BIOCHEM PHARMACOL, V64, P1785, DOI 10.1016/S0006-2952(02)01421-1; Pacher P, 2002, BRIT J PHARMACOL, V135, P1347, DOI 10.1038/sj.bjp.0704627; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Pacher P, 2002, J PHARMACOL EXP THER, V300, P862, DOI 10.1124/jpet.300.3.862; Pacher P, 2002, INT J MOL MED, V9, P659; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; PARK SD, 1983, ENVIRON MUTAGEN, V5, P515, DOI 10.1002/em.2860050402; Park WS, 2001, NEUROL RES, V23, P410, DOI 10.1179/016164101101198640; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; PAYAN HM, 1977, STROKE, V8, P194, DOI 10.1161/01.STR.8.2.194; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Plaschke K, 2000, ANN NY ACAD SCI, V903, P299, DOI 10.1111/j.1749-6632.2000.tb06380.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; RINK A, 1995, AM J PATHOL, V147, P1575; Rudat V, 1998, INT J RADIAT BIOL, V73, P325, DOI 10.1080/095530098142428; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Satoh M, 2001, STROKE, V32, P225, DOI 10.1161/01.STR.32.1.225; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Scott GS, 2004, J NEUROTRAUM, V21, P1255, DOI 10.1089/neu.2004.21.1255; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharma HS, 2003, ACT NEUR S, V86, P415; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Shimoda K, 2003, AM J PHYSIOL-LUNG C, V285, pL240, DOI 10.1152/ajplung.00319.2002; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 2001, NUCLEIC ACIDS RES, V29, P841, DOI 10.1093/nar/29.3.841; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Snyder SH, 1996, NAT MED, V2, P965, DOI 10.1038/nm0996-965; Sonee M, 2002, NEUROTOX RES, V4, P595, DOI 10.1080/1029842021000045480; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Soriano FG, 2001, CIRC RES, V89, P684, DOI 10.1161/hh2001.097797; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sugawara T, 2002, FASEB J, V16, P1997, DOI 10.1096/fj.02-0251fje; Suh SW, 2003, J NEUROSCI, V23, P10681; Sun AY, 1998, ACTA PHARMACOL SIN, V19, P104; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 2003, INTENS CARE MED, V29, P863, DOI 10.1007/s00134-003-1737-8; Szabo C, 2002, CIRCULATION, V106, P2680, DOI 10.1161/01.CIR.0000038365.78031.9C; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; SZABO C, 2000, CELL DEATH ROLE PARP; Szabo E, 2001, FASEB J, V15, pA942; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Tabuchi K, 2001, ANN OTO RHINOL LARYN, V110, P118; Takahashi G, 2003, J THORAC CARDIOV SUR, V126, P1461, DOI 10.1016/S0022-5223(03)00693-7; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tasker RC, 1998, J CEREBR BLOOD F MET, V18, P1346, DOI 10.1097/00004647-199812000-00009; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri ND, 2004, BRAIN RES, V995, P76, DOI 10.1016/j.brainres.2003.09.056; Verrecchia C, 2000, RECENT RES DEV NEURO, V3, P237; Virag L, 1999, MOL PHARMACOL, V56, P824; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; Wullner U, 1997, NEUROSCIENCE, V81, P721, DOI 10.1016/S0306-4522(97)00181-4; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YAMANAKA K, 1995, NEUROSCI LETT, V194, P124, DOI 10.1016/0304-3940(95)11715-9; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZHANG J, 2002, THERAPEUTIC IMPLICAT; Zhang YM, 2004, EUR J NEUROSCI, V20, P1727, DOI 10.1111/j.1460-9568.2004.03651.x; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	239	40	45	0	2	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2005	4	2					179	194		10.2174/1568007053544138			16	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5XF	WOS:000497842000010	15857303				2022-02-06	
J	Graham, DI; Smith, C; Reichard, R; Leclercq, PD; Gentleman, SM				Graham, DI; Smith, C; Reichard, R; Leclercq, PD; Gentleman, SM			Trials and tribulations of using beta-amyloid precursor protein immunohistochemistry to evaluate traumatic brain injury in adults	FORENSIC SCIENCE INTERNATIONAL			English	Article						traumatic brain injury; hypoglycaemia; CO poisoning; beta APP immunohistochemistry	DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; CALPAIN ACTIVATION; DIAGNOSIS; APP; NEUROPATHOLOGY; HYPOXIA	Axonal pathology is increasingly identified by P-amyloid precursor protein (PAPP) immunohistochemistry in the brains of patients who may or may not have a history of trauma. The presence of betaAPP-IR+ has been variously interpreted as either that diffuse traumatic axonal injury (TAI) is indeed a universal finding in cases of fatal traumatic brain injury (TBI) or there are other causes of betaAPP-IR+ axons which under certain circumstances may be sufficient to mimic TBI and therefore make the medicolegal interpretation of certain cases very difficult. To address some of the uncertainties we have undertaken a detailed analysis of the amount and distribution of PAPP immunohistochemistry in 63 cases of fatal TBI, 17 cases of patients dying after cardiac arrest, 12 cases dying in association with status epilepticus, 3 cases of carbon monoxide (CO) poisoning, 13 cases of hypoglycaemia and in 60 controls. Three patterns of betaAPP-IR+ were identified. First, diffuse multi-focal, second, corresponding to the outline of an infarct or haematoma, and thirdly a mixture of the two. The first pattern was seen in cases of the lesser grades of TAI, CO poisoning, and hypoglycaemia, the second pattern in cases in which there was evidence of raised intracranial pressure and the third in cases of severe TAL It is concluded that the proper interpretation of cases requires the examination of a sufficient number of blocks (n = 15), processing using standardised protocols including PAPP immunohistochemistry and in some cases the mapping of any IR+ on anatomical line diagrams. PAPP carried out on a small number of randomly taken blocks is likely to lead to misinterpretation of the clinico-pathological correlations and possibly to a miscarriage of justice. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	So Gen Hosp, NHS Trust, Inst Neurol Sci, Div Clin Neurosci,Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Pathol, Edinburgh EH4 2XU3, Midlothian, Scotland; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ London Imperial Coll Sci Technol & Med, Dept Neuroinflammat, Div Neurosci & Psychol Disorders, London W6 8RP, England		Graham, DI (corresponding author), So Gen Hosp, NHS Trust, Inst Neurol Sci, Div Clin Neurosci,Acad Unit Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	d.graham@clinmed.gla.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Dolinak D, 2000, NEUROPATH APPL NEURO, V26, P448, DOI 10.1046/j.1365-2990.2000.00273.x; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; [No title captured]	28	40	46	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC 16	2004	146	2-3					89	96		10.1016/S0379-0738(03)00274-3			8	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	879OZ	WOS:000225728400004	15542268				2022-02-06	
J	McManus, T; Sadgrove, M; Pringle, AK; Chad, JE; Sundstrom, LE				McManus, T; Sadgrove, M; Pringle, AK; Chad, JE; Sundstrom, LE			Intraischaemic hypothermia reduces free radical production and protects against ischaemic insults in cultured hippocampal slices	JOURNAL OF NEUROCHEMISTRY			English	Article						cerebral ischaemia; free radical; hypothermia; neuroprotection; nitric oxide	FOCAL CEREBRAL-ISCHEMIA; NMDA RECEPTOR ANTAGONISTS; TRANSIENT GLOBAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; NITRIC-OXIDE SYNTHESIS; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; NEURONAL DAMAGE; IN-VITRO	Hypothermia has been demonstrated to be an effective neuroprotective strategy in a number of models of ischaemic and excitotoxic neurodegeneration in vitro and in vivo. Reduced glutamate release and free radical production have been postulated as potential mechanisms underlying this effect but no definitive mechanism has yet been reported. In the current study, we have used oxygen-glucose deprivation in organotypic hippocampal slice cultures as an in vitro model of cerebral ischaemia. When assessed by propidium iodide fluorescence, reducing the temperature during oxygen-glucose deprivation to 31-33degreesC was significantly neuroprotective but this effect was lost if the initiation of hypothermia was delayed until the post-insult recovery period. The neuroprotective effects of hypothermia were associated with a significant decrease in both nitric oxide production, as assessed by 3-amino-4-aminomethyl-2',7'-difluorofluorescein fluorescence, and superoxide formation. Further, hypothermia significantly attenuated NMDA-induced nitric oxide formation in the absence of hypoxia/hypoglycaemia. We conclude that the neuroprotective effects of hypothermia are mediated through a reduction in nitric oxide and superoxide formation and that this effect is likely to be downstream of NMDA receptor activation.	Univ Southampton, Sch Med, Div Clin Neurosci, Southampton SO16 7PX, Hants, England; Univ Southampton, Sch Biol Sci, Neurosci Grp, Southampton, Hants, England		Pringle, AK (corresponding author), Univ Southampton, Sch Med, Div Clin Neurosci, Biomed Sci Bldg,Bassett Crescent E, Southampton SO16 7PX, Hants, England.	akp1@soton.ac.uk		Pringle, Ashley/0000-0003-2421-4380			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Amorim P, 1999, BRAIN RES, V844, P143, DOI 10.1016/S0006-8993(99)01944-7; Barth A, 1996, EXP NEUROL, V141, P330, DOI 10.1006/exnr.1996.0168; Berger C, 2002, STROKE, V33, P519, DOI 10.1161/hs0102.100878; Berman F W, 1996, J Biochem Toxicol, V11, P111, DOI 10.1002/(SICI)1522-7146(1996)11:3<111::AID-JBT2>3.0.CO;2-N; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BUCHAN A, 1990, J NEUROSCI, V10, P311; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Corbett D, 2000, BRAIN PATHOL, V10, P145; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Dietrich WD, 1996, ADV NEUROL, V71, P177; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Greiner C, 1998, BRAIN RES, V786, P267, DOI 10.1016/S0006-8993(97)01465-0; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; Keynes RG, 2004, EUR J NEUROSCI, V19, P1163, DOI 10.1111/j.1460-9568.2004.03217.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; LOUGHEED WM, 1955, J NEUROSURG, V12, P240, DOI 10.3171/jns.1955.12.3.0240; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion Donald W, 2002, Curr Opin Crit Care, V8, P111, DOI 10.1097/00075198-200204000-00004; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Nedergaard M, 1996, ADV NEUROL, V71, P75; NEWELL DW, 1995, BRAIN RES, V675, P38, DOI 10.1016/0006-8993(95)00039-S; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; Pringle AK, 2000, EUR J NEUROSCI, V12, P3833, DOI 10.1046/j.1460-9568.2000.00272.x; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Ren YB, 2004, J CEREBR BLOOD F MET, V24, P42, DOI 10.1097/01.WCB.0000095802.98378.91; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schuppe H, 2002, J NEUROBIOL, V53, P361, DOI 10.1002/neu.10117; Shima H, 2003, J NEUROTRAUM, V20, P1179, DOI 10.1089/089771503770802862; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; Takei Y, 2004, BRAIN DEV-JPN, V26, P176, DOI 10.1016/S0387-7604(03)00123-2; TANIMOTO M, 1987, BRAIN RES, V417, P239, DOI 10.1016/0006-8993(87)90448-3; TAYLOR CP, 1993, NEUROSCIENCE, V52, P555, DOI 10.1016/0306-4522(93)90405-5; Taylor CP, 1999, J NEUROSCI, V19, P619; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tymianski M, 1998, J CEREBR BLOOD F MET, V18, P848, DOI 10.1097/00004647-199808000-00005; Venturini G, 1999, NITRIC OXIDE-BIOL CH, V3, P375, DOI 10.1006/niox.1999.0250; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WIDMANN R, 1993, J NEUROCHEM, V61, P200, DOI 10.1111/j.1471-4159.1993.tb03556.x; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yamamoto H, 1999, NEUROSCIENCE, V91, P501, DOI 10.1016/S0306-4522(98)00648-4; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; Zhao W, 1996, J NEUROSCI RES, V45, P282, DOI 10.1002/(SICI)1097-4547(19960801)45:3<282::AID-JNR10>3.0.CO;2-6; Zimmer J, 2000, AMINO ACIDS, V19, P7, DOI 10.1007/s007260070029	74	40	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2004	91	2					327	336		10.1111/j.1471-4159.2004.02711.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	856UH	WOS:000224070100008	15447666	Bronze			2022-02-06	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM			Interpersonal stressors and resources as predictors, of parental adaptation following pediatric traumatic injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							BRAIN-INJURY; SOCIAL SUPPORT; FAMILY BURDEN; INITIAL YEAR; CHILDREN; IMPACT; ADOLESCENTS; DEPRESSION; RECOVERY; BEHAVIOR	The authors examined the relationship of preinjury interpersonal resources and stressors to parental adaptation following pediatric traumatic brain injury (TBI) and orthopedic injury. Parents of children with severe TBI (n = 53), moderate TBI (n = 56), and orthopedic injuries (n = 80) were assessed soon after injury, 6 and 12 months after the initial evaluation, and at an extended follow-up with a mean of 4 years postinjury. General linear model analyses provide support for both main and moderating effects of stressors and resources on parental adjustment. Support from friends and spouse was associated with less psychological distress, whereas family and spouse stressors were associated with greater distress. The results also reveal a marked decline in injury-related stress over follow-up for families in the severe TBI group who reported a combination of high stressors and high resources. The decline suggests that interpersonal resources attenuated long-term family burden because of severe TBI. The findings are discussed in terms of their implications for intervention following TBI.	Cincinnati Childrens Hosp Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Univ Hosp Hlth Syst, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Cleveland, OH 44109 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline		ABBEY A, 1995, J PERS SOC PSYCHOL, V68, P455, DOI 10.1037/0022-3514.68.3.455; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN GW, 1986, PSYCHOL MED, V16, P813, DOI 10.1017/S0033291700011831; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; CRINIC KA, 1983, CHILD DEV, V54, P209; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; DUNKELSCHETTER C, 1984, J SOC ISSUES, V40, P77, DOI 10.1111/j.1540-4560.1984.tb01108.x; EWART CK, 1991, HEALTH PSYCHOL, V10, P155, DOI 10.1037/0278-6133.10.3.155; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FINCH JF, 1989, AM J COMMUN PSYCHOL, V17, P585, DOI 10.1007/BF00922637; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Harris T, 1999, BRIT J PSYCHIAT, V174, P225, DOI 10.1192/bjp.174.3.225; Holahan CJ, 1997, J PERS SOC PSYCHOL, V72, P918, DOI 10.1037/0022-3514.72.4.918; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; JENNETT B, 1975, LANCET, V1, P480; KIECOLTGLASER JK, 1988, AM J COMMUN PSYCHOL, V16, P825, DOI 10.1007/BF00930895; KIECOLTGLASER JK, 1993, PSYCHOSOM MED, V55, P395, DOI 10.1097/00006842-199309000-00001; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; MASTEN AS, 1988, J CHILD PSYCHOL PSYC, V29, P745, DOI 10.1111/j.1469-7610.1988.tb00751.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Moos RH, 1998, J FAM PSYCHOL, V12, P326, DOI 10.1037/0893-3200.12.3.326; Moos RH, 1994, LIFE STRESSORS SOCIA; MORGANDL, 1997, J CLIN GEROPSYCHOLOG, V3, P73; NORRIS VK, 1990, GERONTOLOGIST, V30, P535, DOI 10.1093/geront/30.4.535; PAGEL MD, 1987, J PERS SOC PSYCHOL, V53, P793, DOI 10.1037/0022-3514.53.4.793; RHODES JE, 1995, J COMMUNITY PSYCHOL, V23, P74, DOI 10.1002/1520-6629(199501)23:1<74::AID-JCOP2290230107>3.0.CO;2-D; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROOK KS, 1992, SER CLIN C, P157; ROOK KS, 1990, J SOC CLIN PSYCHOL, V9, P118, DOI 10.1521/jscp.1990.9.1.118; ROOK KS, 1984, J PERS SOC PSYCHOL, V46, P1097, DOI 10.1037/0022-3514.46.5.1097; Rook KS, 1998, DARK SIDE OF CLOSE RELATIONSHIPS, P369; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; *SAS I, 1990, STAT AN SYST VERS 6; Schafer JL, 1997, ANAL INCOMPLETE MULT; SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489; SCHUSTER TL, 1990, AM J COMMUN PSYCHOL, V18, P423, DOI 10.1007/BF00938116; Smith Carol E., 1994, Annals of Behavioral Medicine, V16, P352; Stein R, 1985, PACTS PAPERS AECOM T; STEPHENS MAP, 1987, PSYCHOL AGING, V2, P125, DOI 10.1037/0882-7974.2.2.125; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	62	40	40	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	OCT	2004	72	5					776	784		10.1037/0022-006X.72.5.776			9	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	858TU	WOS:000224215600004	15482036				2022-02-06	
J	Bardach, NS; Olson, SJ; Elkins, JS; Smith, WS; Lawton, MT; Johnston, SC				Bardach, NS; Olson, SJ; Elkins, JS; Smith, WS; Lawton, MT; Johnston, SC			Regionalization of treatment for subarachnoid hemorrhage - A cost-utility analysis	CIRCULATION			English	Article						cost-benefit analysis; quality of health care; hemorrhage, subarachnoid	UNRUPTURED CEREBRAL ANEURYSMS; TRAUMATIC BRAIN-INJURY; INTERHOSPITAL TRANSPORT; HOSPITALS; VOLUME; STROKE; CARE; HELICOPTER; MORTALITY; PROPHYLAXIS	Background-Previous studies have shown that for the treatment of subarachnoid hemorrhage (SAH), outcomes are improved but costs are higher at hospitals with a high volume of admissions for SAH. Whether regionalization of care for SAH is cost-effective is unknown. Methods and Results-In a cost-utility analysis, health outcomes for patients with SAH were modeled for 2 scenarios: 1 representing the current practice in California in which most patients with SAH are treated at the closest hospital and 1 representing the regionalization of care in which patients at hospitals with <20 SAH admissions annually ( low volume) would be transferred to hospitals with >= 20 SAH admissions annually ( high volume). Using a Markov model, we compared net quality-adjusted life-years (QALYs) and cost per QALY. Inputs were chosen from the literature and derived from a cohort study in California. Transferring a patient with SAH from a low- to a high-volume hospital would result in a gain of 1.60 QALYs at a cost of $10 548/QALY. For transfer to result in only borderline cost-effectiveness ($50 000/QALY), differences in case fatality rates between low- and high-volume hospitals would have to be one fifth as large (2.2%) or risk of death during transfer would have to be 5 times greater (9.8%) than estimated in the base case. Conclusions-Transfer of patients with SAH from low- to high-volume hospitals appears to be cost-effective, and regionalization of care may be justified. However, current estimates of the impact of hospital volume on outcome require confirmation in more detailed cohort studies.	Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Neurol Surg, San Francisco, CA 94143 USA; Univ Calif Berkeley, Richard & Rhoda Goldman Sch Publ Policy, Berkeley, CA 94720 USA		Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, Box 0114,505 Parnassus Ave, San Francisco, CA 94143 USA.	clay.johnston@ucsfmedctr.org		Bardach, Naomi/0000-0002-5178-0719	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002254] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02 NS 02254] Funding Source: Medline		Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Arfken CL, 1998, J TRAUMA, V45, P785, DOI 10.1097/00005373-199810000-00031; Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B; Berman MF, 2003, STROKE, V34, P2200, DOI 10.1161/01.STR.0000086528.32334.06; *CDC, MORT DAT; Dewhurst AT, 2001, ANAESTHESIA, V56, P882, DOI 10.1046/j.1365-2044.2001.02059-2.x; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; EHRENWERTH J, 1986, CRIT CARE MED, V14, P543, DOI 10.1097/00003246-198606000-00005; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; Gebremichael M, 2000, CRIT CARE MED, V28, P79, DOI 10.1097/00003246-200001000-00013; Gold M., 1996, COST EFFECTIVENESS H; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; Johansson M, 2001, STROKE, V32, P2845, DOI 10.1161/hs1201.099416; Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799; Johnston SC, 1999, NEUROLOGY, V52, P1806, DOI 10.1212/WNL.52.9.1806; KANTER RK, 1989, PEDIATRICS, V84, P43; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Matz PG, 2003, STROKE, V34, P2206, DOI 10.1161/01.STR.0000089683.66849.5E; Naimark D, 1997, MED DECIS MAKING, V17, P152, DOI 10.1177/0272989X9701700205; *OFF STAT PLANN DE, 1999, CAL HOSP DISCH DAT R; Prencipe M, 1998, STROKE, V29, P126, DOI 10.1161/01.STR.29.1.126; RIDLEY S, 1989, ANAESTHESIA, V44, P822, DOI 10.1111/j.1365-2044.1989.tb09099.x; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; Selevan JS, 1999, ANN EMERG MED, V33, P33, DOI 10.1016/S0196-0644(99)70414-2; Solomon RA, 1996, STROKE, V27, P13, DOI 10.1161/01.STR.27.1.13; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Taylor CL, 1997, J NEUROSURG, V86, P583, DOI 10.3171/jns.1997.86.4.0583; Werman HA, 1999, AM J EMERG MED, V17, P130, DOI 10.1016/S0735-6757(99)90043-8; Wuerz R, 1994, Prehosp Disaster Med, V9, P50	34	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-7322	1524-4539		CIRCULATION	Circulation	MAY 11	2004	109	18					2207	2212		10.1161/01.CIR.0000126433.12527.E6			6	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	819NU	WOS:000221322600011	15117848	Bronze, Green Submitted			2022-02-06	
J	Steiner, J; Rafols, D; Park, HK; Katar, MS; Rafols, JA; Petrov, T				Steiner, J; Rafols, D; Park, HK; Katar, MS; Rafols, JA; Petrov, T			Attenuation of iNOS mRNA exacerbates hypoperfusion and upregulates endothelin-1 expression in hippocampus and cortex after brain trauma	NITRIC OXIDE-BIOLOGY AND CHEMISTRY			English	Article						brain; endothelin-1; iNOS; microcirculation; antisense mRNA; in situ hybridization	NITRIC-OXIDE SYNTHASE; PROTEIN-SYNTHESIS; CEREBRAL-CIRCULATION; NEURONAL NOS; HEAD TRAUMA; BLOOD-FLOW; INJURY; RAT; PHOSPHORYLATION; HYPOTENSION	Nitric oxide (NO, a vasodilator) and endothelin-1 (ET-1, a powerful vasoconstrictor) participate in the regulation of brain's microcirculation influencing each other's expression and synthesis. Following injury to the brain, NO is derived largely from the inducible form of nitric oxide synthase (NOS). We used Marmarou's model of traumatic brain injury (TBI) to study the cerebral blood flow and expression (mRNA) of ET-1 in rats that were pretreated with antisense iNOS oligodeoxynucleotides (ODNs). Intracerebroventricular application of iNOS ODNs resulted in reduced synthesis of iNOS as detected by Western blot analysis. The cerebral blood flow (measured by laser Doppler flowmetry), generally decreased after TBI, was further markedly reduced in the treated animals and remained at low levels up to 48 It post-TBI. The expression of ET-1 (detected by in situ hybridization in cortex and hippocampus) was increased 2-3-fold following TBI alone and this increase reached 5-6-fold in animals pretreated with antisense iNOS ODNs. The results indicate that most likely, NO, generated primarily by iNOS, suppresses ET-1 production and that a decrease of NO results in upregulation of ET-I via transcriptional and translational mechanisms. Increased availability of ET-1 at the vascular bed and the neuropil may contribute to the altered microvascular reactivity and reduced perfusion of the brain following TBI. (C) 2004 Elsevier Inc. All rights reserved.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA		Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	tpetrov@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; Atkins CM, 1999, J NEUROSCI, V19, P7241, DOI 10.1523/JNEUROSCI.19-17-07241.1999; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; CAZABON SM, 1998, INTRO BLOOD BRAIN BA, P338; Chen Y, 2003, AM J PHYSIOL-CELL PH, V284, pC243, DOI 10.1152/ajpcell.00305.2002; CHIASSON BJ, 1994, CELL MOL NEUROBIOL, V14, P507, DOI 10.1007/BF02088834; Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; HIROSE H, 1995, EUR J PHARMACOL, V277, P77, DOI 10.1016/0014-2999(95)00070-2; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Lavallee M, 2001, Heart Fail Rev, V6, P265; LEFFLER CW, 1986, CIRC RES, V59, P562, DOI 10.1161/01.RES.59.5.562; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; PARK HK, 1999, J MENTAL HLTH, V3, P32; PETROV T, 1995, NEUROPHARMACOLOGY, V34, P509, DOI 10.1016/0028-3908(95)00002-N; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T, 2003, J NEUROL SCI, V209, P31, DOI 10.1016/S0022-510X(02)00461-6; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Sventek P, 1996, HYPERTENSION, V27, P49, DOI 10.1161/01.HYP.27.1.49; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZYMKOWSKI DE, 2002, DRUG DISCOV TODAY, V7, P107, DOI DOI 10.1016/S1359-6446(01)02123-7; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	37	40	46	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1089-8603	1089-8611		NITRIC OXIDE-BIOL CH	Nitric Oxide-Biol. Chem.	MAY	2004	10	3					162	169		10.1016/j.niox.2004.03.005			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	828LG	WOS:000221974200006	15158696				2022-02-06	
J	Gracias, VH; Guillamondegui, OD; Stiefel, MF; Wilensky, EM; Bloom, S; Gupta, R; Pryor, JP; Reilly, PM; Leroux, PD; Schwab, CW				Gracias, VH; Guillamondegui, OD; Stiefel, MF; Wilensky, EM; Bloom, S; Gupta, R; Pryor, JP; Reilly, PM; Leroux, PD; Schwab, CW			Cerebral cortical oxygenation: A pilot study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		traumatic brain injury; intracranial pressure; cerebral perfusion pressure; cerebral hypoxia; brain tissue oxygenation	BRAIN-TISSUE OXYGEN; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; ANEURYSM SURGERY; PRESSURE; AUTOREGULATION; EXPERIENCE; REACTIVITY; TENSION	Background. Cerebral hypoxia (cerebral cortical oxygenation [PbrO(2)] < 20 mm Hg) monitored by direct measurement has been shown in animal and small clinical studies to be associated with poor outcome. We present our preliminary results observing PbrO(2) in patients with traumatic brain injury (TBI). Methods. A prospective observational cohort study was performed. Institutional review board approval was obtained. All patients with TBI who required measurement of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbrO(2) because of a Glasgow Coma Scale score < 8 were enrolled. Data sets (ICP, CPP, PbrO(2), positive end-expiratory pressure (PEEP), PaO2, and PaCO2) were recorded during routine manipulation. Episodes of cerebral hypoxia were compared with episodes without. Results are displayed as mean SEM; t test, chi(2), and Fisher's exact test were used to answer questions of interest. Results: One hundred eighty-one data sets were abstracted from 20 patients. Thirty-five episodes of regional cerebral hypoxia were identified in 14 patients. Compared with episodes of acceptable cerebral oxygenation, episodes of cerebral hypoxia were noted to be associated with a significantly lower mean PaO2 (144 +/- 14 vs. 165 +/- 8; p < 0.01) and higher mean PEEP (8.8 +/- 0.7 vs. 7.1 +/- 0.3; p < 0.01). Mean ICP and CPP measurements were similar between groups. In a univariate analysis, cerebral hypoxic episodes were associated with PaO2 :5 100 mm Hg (p < 0.01) and PEEP > 5 cm H2O (p < 0.01), but not ICP > 20 mm Hg, CPP less than or equal to 65 mm Hg, or PaCO2 less than or equal to 35 mm Hg. Conclusion: Cerebral oxymetry is confirmed safe in the patient with multiple injuries with TBI. Occult cerebral hypoxia is present in the traumatic brain injured patient despite normal traditional measurements of cerebral perfusion. Further research is necessary to determine whether management protocols aimed at the prevention of cerebral cortical hypoxia will affect outcome.	Univ Penn, Sch Med, Dept Surg, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Gracias, VH (corresponding author), Univ Penn, Sch Med, Dept Surg, Div Traumatol & Surg Crit Care, 3440 Mkt St,1st Floor, Philadelphia, PA 19104 USA.	graciasv@uphs.upenn.edu					CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Gelabert-Gonzalez M, 2002, ACTA NEUROCHIR, V144, P863, DOI 10.1007/s00701-002-0975-9; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 2000, ANESTHESIOLOGY, V92, P442, DOI 10.1097/00000542-200002000-00026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201, DOI 10.1093/neurosurgery/46.1.201; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Khaldi A, 2001, NEUROSURGERY, V49, P33; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	18	40	40	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					469	472		10.1097/01.TA.0000114274.95423.C0			4	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	808CM	WOS:000220547200001	15128115				2022-02-06	
J	Koh, JO; Cassidy, JD				Koh, JO; Cassidy, JD			Incidence study of head blows and concussions in competition taekwondo	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head blow; concussion; incidence; competition taekwondo	FOOTBALL PLAYERS; WORLD; CHAMPIONSHIPS; MANAGEMENT; INJURIES; SPORTS	Objective: To examine the incidence of head blows and concussions in competition taekwondo. Design: Incidence cohort design. Setting: Tackwondo tournament in 2001, in South Korea. Participants: A total of 2328 competitors (female, 676; male, 1652; age, 11-19 years) from 424 schools participated in the tournament. All recipients of head blows were interviewed immediately after the match. All matches were recorded on videotape. Main Outcome Measures: Head blow and concussion rates were calculated. Also, factors associated with head blows and concussions were analyzed. Results: The incidence of head blows and concussions was 226 and 50 per 1000 athlete exposures, respectively. Only 17% of competitors reported that they had had a concussion in the last 12 months. A multinomial logistic model showed that head blows and concussions were associated with young age and a lack of blocking skills. Conclusions: The incidence of head blows and concussions is high in competition taekwondo. Promoting blocking skills to prevent head blows could decrease concussions in taekwondo,	Yonsei Univ, Dept Sport & Leisure Studies, Seoul 120749, South Korea; Univ Toronto, Toronto Western Res Inst, Hlth Network, Div Outcomes & Populat Hlth, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON, Canada		Koh, JO (corresponding author), Yonsei Univ, Dept Sport & Leisure Studies, 134 Shinchon Dong, Seoul 120749, South Korea.	sunshinejkoh@hanmail.net		Koh, Jae Ok/0000-0002-3639-0739			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gordis L, 2000, EPIDEMIOLOGY; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MASTER EJ, 1999, JAMA-J AM MED ASSOC, V282, P971; MASTER EJT, 2000, PHYSICIAN SPORTSMED, V28, P87; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; *SPSS, 2002, SPSS COMP PROGR VERS; *STAT CORP, 2002, STAT COMP PROGR VERS; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; ZEMPER ED, 1994, AM SOC TEST MATER, V1229, P116, DOI 10.1520/STP12808S	24	40	42	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2004	14	2					72	79		10.1097/00042752-200403000-00004			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	943BO	WOS:000230327000004	15014340				2022-02-06	
J	Nolle, C; Todt, I; Seidl, RO; Ernst, A				Nolle, C; Todt, I; Seidl, RO; Ernst, A			Pathophysiological changes of the central auditory pathway after blunt trauma of the head	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; hearing disorder; MTBI; otoacoustic emissions	EVOKED OTOACOUSTIC EMISSIONS; CONTRALATERAL ACOUSTIC STIMULATION; HEARING-LOSS; AXONAL INJURY; SUPPRESSION; CONCUSSION; DIZZINESS; TINNITUS; HUMANS; NOISE	It is the aim of the present paper to correlate clinical symptoms of auditory dysfunction (tinnitus, hyperacusis, hearing loss) one year on average after a blunt trauma of the head with objective audiological test results (otoacoustic emission and auditory brainstem response testing, impedance audiometry) and to compare these findings to controls without history of head trauma. Thirty-one patients (24-56 years) were included. They were largely female (n = 26). The clinical and otolaryngological examination (including otoscopy) of all patients revealed no pathological abnormalities. Pure-tone audiograms were normal with one exception (pre-existing noise-induced hearing loss) as well as tympanograms. The main auditory symptoms were tinnitus (n = 9), hyperacusis (n = 2) and a reported transient hearing loss immediately after the trauma (n = 16) (which had improved at the time of examination). The results of testing the central auditory pathway showed that the transiently evoked otoacoustic emissions (otoemissions) revealed statistically significant differences between amplitude differences of all patients as well as patients with tinnitus and controls in the linear, but not in the non-linear stimulation mode. A complete loss of stapedial reflex responses was found in 12 of the patients and a partial (irregular) loss (in at least more than two frequencies) in four additional patients. Auditory brainstem responses (ABR) were normal in all patients, but 76% had lowered loudness discomfort levels (LDL). Blunt trauma of the head can lead to auditory dyfunction, probably as a result of diffuse axonal injury of the central auditory pathway. An initial sensorineural hearing loss after the trauma (as a result of the inner ear fluid concussion) was transiently reported only. Auditory symptoms play a minor role in the so-called "post-concussive syndrome," but should be considered and evaluated fully.	UKB, Dept Otolaryngol, D-12683 Berlin, Germany; Hosp Univ Berlin, UKB, Dept Otolaryngol, D-12683 Berlin, Germany		Ernst, A (corresponding author), UKB, Dept Otolaryngol, Warener Str 7, D-12683 Berlin, Germany.	ArneborgE@ukb.de					Anari M, 1999, SCAND AUDIOL, V28, P219, DOI 10.1080/010503999424653; Bamiou DE, 2000, AUDIOLOGY, V39, P168; BERLIN CI, 1995, HEARING RES, V87, P96, DOI 10.1016/0378-5955(95)00082-F; BERLIN CI, 1993, HEARING RES, V71, P1, DOI 10.1016/0378-5955(93)90015-S; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Brors M, 2001, NEURORADIOLOGY, V43, P144, DOI 10.1007/PL00006045; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; Cohen M, 1996, SCAND AUDIOL, V25, P133, DOI 10.3109/01050399609047995; COLLET L, 1994, BRIT J AUDIOL, V28, P213, DOI 10.3109/03005369409086570; De Ceulaer G, 2001, OTOL NEUROTOL, V22, P350, DOI 10.1097/00129492-200105000-00013; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; FRANKLIN DJ, 1992, EAR HEARING, V13, P417, DOI 10.1097/00003446-199212000-00008; GELFAND SA, 1982, J EAR HEAR, V3, P93; JANNI NN, 1991, J NEUROSURG, V29, P206; Katzenell U, 2001, OTOL NEUROTOL, V22, P321, DOI 10.1097/00129492-200105000-00009; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meriot P, 1999, J RADIOL, V80, P1780; Nolle C, 2000, OTO RHINO LARYN NOVA, V10, P194, DOI 10.1159/000054817; NORMAN M, 1993, BRIT J AUDIOL, V27, P281, DOI 10.3109/03005369309076705; PLINKERT PK, 1992, LARYNGO RHINO OTOL, V71, P74, DOI 10.1055/s-2007-997249; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRASHER D, 1994, BRIT J AUDIOL, V28, P247, DOI 10.3109/03005369409086574; RAJAN R, 1990, J HEAR RES, V45, P137; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; VEUILLET E, 1991, J NEUROPHYSIOL, V65, P724, DOI 10.1152/jn.1991.65.3.724; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WILLIAMS EA, 1994, ACTA OTO-LARYNGOL, V114, P121, DOI 10.3109/00016489409126029	31	40	43	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					251	258		10.1089/089771504322972040			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600003	15115600				2022-02-06	
J	Alban, JP; Hopson, MM; Ly, V; Whyte, J				Alban, JP; Hopson, MM; Ly, V; Whyte, J			Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; methylphenidate; vital signs; adverse effects	DOUBLE-BLIND; PLACEBO; ADOLESCENTS	Objective: To study methylphenidate's adverse effects and impact on vital signs within the adult traumatic brain injury population. Design: Thirty-five adults with traumatic brain injury enrolled in a double-blind, placebo-controlled, 6-wk crossover study of methylphenidate, given in a dose of 0.3 mg/kg/dose, twice a day. Vital signs were taken by trained clinicians and research assistants. Participants filled out weekly questionnaires pertaining to the adverse effects. Results: Poor appetite was the only adverse effect related to methylphenidate. Other adverse effects commonly associated with methylphenidate, such as insomnia, rapid heart rate, and anxiety, were not found to be significantly related to the medication. The average rise in mean arterial pressure on methylphenidate was 2.5 mm. Methylphenidate showed a stronger impact on pulse, with an average increase of 7 beats/min. Baseline vital signs did not predict the degree of increase on methylphenidate. Conclusion: Methylphenidate appears to be safe for the adult population with traumatic brain injury. However, because a few individuals experienced significant changes in vital signs and adverse effects, all patients should be monitored.	Thomas Jefferson Univ, Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19141 USA		Whyte, J (corresponding author), Thomas Jefferson Univ, Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd,Korman Bldg,Suite 213, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			BARNHART E, 1991, PHYS DESK REFERENCE, P865; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Glenn MB, 1998, J HEAD TRAUMA REHAB, V13, P87, DOI 10.1097/00001199-199810000-00010; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Jansen IHM, 2001, J AM GERIATR SOC, V49, P474, DOI 10.1046/j.1532-5415.2001.49092.x; JOHNSON ML, 1992, AM J PHYS MED REHAB, V71, P239, DOI 10.1097/00002060-199208000-00008; KLORMAN R, 1987, J AM ACAD CHILD PSY, V26, P363, DOI 10.1097/00004583-198705000-00015; LINGAM VR, 1988, J CLIN PSYCHIAT, V49, P151; LOWE TL, 1982, JAMA-J AM MED ASSOC, V247, P1729, DOI 10.1001/jama.247.12.1729; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; ROSENBERG PB, 1991, J CLIN PSYCHIAT, V52, P263; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; VARLEY CK, 1983, J AM ACAD CHILD PSY, V22, P351, DOI 10.1016/S0002-7138(09)60671-3; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	18	40	40	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2004	83	2					131	137		10.1097/01.phm.0000112308.68586.1d			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	767AP	WOS:000188416600007	14758299				2022-02-06	
J	Peloso, PM; Von Holst, H; Borg, J				Peloso, PM; Von Holst, H; Borg, J			Mild traumatic brain injuries presenting to Swedish hospitals in 1987-2000	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; incidence; aetiology	EXTERNAL CAUSES; HEAD-INJURY; EPIDEMIOLOGY; RESTRAINT; COMMUNITY; INCREASE; SEVERITY; OUTCOMES; CHILDREN; SWEDEN	Objective: To evaluate the incidence and causes of mild traumatic brain injury in Sweden. Design: Retrospective, population-based incidence cohort study. Subjects: All persons presenting to hospitals in Sweden between 1987 and 2000 with a discharge diagnosis of ICD-9 code 850 and ICD-10 code S0.60. Methods: Data source was the Hospital Discharge Register at the National Board of Health and Welfare ( Sweden). Incidence rates are stratified by age, gender, mechanism of injury and length of hospital stay. Results: Men had a mean of 209 mild traumatic brain injuries per 100,000 inhabitants and women averaged 148 per 100,000. Men had more mild traumatic brain injury than women at all ages. There were 2 incidence peaks, in the age strata 16-20 years and those over 65 years. Falls were the most common cause of mild traumatic brain injury overall and occurred commonly under the age of 10 years and over the age of 65 years. Motor vehicle and bicycle injuries were the second and third most common causes of mild traumatic brain injury, and had their peak incidence in those aged 16 35 years. Conclusion: Preventative strategies for mild traumatic brain injury should be age and gender specific.	Univ Iowa Hlth Care, Roy & Lucille Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden		Peloso, PM (corresponding author), Univ Iowa Hlth Care, Roy & Lucille Carver Coll Med, Dept Internal Med, Room E 330 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	paul-peloso@uiowa.edu		Borg, Jorgen/0000-0002-2372-7478			BRITTON M, 2000, 153 SBU SWED COUNC T; CARLSSON G, 1991, ACCIDENT ANAL PREV, V23, P175, DOI 10.1016/0001-4575(91)90047-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *CTR EP SWED NAT B, 2002, SWED HOSP DISCH REG; Ekman R, 2001, ACCIDENT ANAL PREV, V33, P793, DOI 10.1016/S0001-4575(00)00093-2; Ekman R, 1997, ACCIDENT ANAL PREV, V29, P321, DOI 10.1016/S0001-4575(96)00086-3; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; GILLESPIE LD, 2001, COCHRANE DB SYST REV, V3; Hung C C, 1991, J Formos Med Assoc, V90, P1227; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; SCHELP L, 1990, PUBLIC HEALTH, V104, P55, DOI 10.1016/S0033-3506(05)80346-4; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Wilmoth JR, 2000, SCIENCE, V289, P2366, DOI 10.1126/science.289.5488.2366	23	40	40	0	0	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			22	27		10.1080/16501960410023714			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300006	15083869	gold			2022-02-06	
J	Suzuki, T; Bramlett, HM; Dietrich, WD				Suzuki, T; Bramlett, HM; Dietrich, WD			The importance of gender on the beneficial effects of posttraumatic hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; gender; hormones; histopathology; hypothermia	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; ESTROGEN-RECEPTOR; CORTICAL IMPACT; FOCAL ISCHEMIA; DAMAGE	The authors studied the importance of gender on the consequences of mild posttraumatic hypothermia following parasagittal fluid-percussion (F-P) brain injury in rats. After traumatic brain injury (TBI), brain temperature was maintained at nonnothermia (37degreesC) or reduced to 33degreesC for 4 h starting 30 min after the insult followed by a 1.5-h slow rewarming period. Animals (n = 48) were allowed to survive for 3 days before quantitative histopathological and immunocytochemical examination. As previously reported, contusion volume in nonnothermic animals (37degreesC) was smaller (P < 0.05) in intact females compared to males. In addition, numbers of NeuN-positive cortical neurons were greater in females versus males after TBI. Posttraumatic hypothermia significantly reduced overall contusion volume in males (P < 0.05), while not significantly reducing contusion volume in females. Likewise, hypothermia protected against the loss of cortical neurons in males but had no effect in females. Ovariectomized females showed contusion volumes and neuronal cell counts comparable to those seen in males as well as a significant reduction in contusion volumes and greater neuronal counts following posttraumatic hypothermia. These data are the first to demonstrate that posttraumatic hypothermia (4 h) does not affect short-term histopathological outcomes in female rats. Potential mechanisms underlying this gender difference are discussed. Finally, these experimental findings may have important implications in terms of clinical trials using therapeutic hypothermia targeting patients with central nervous system (CNS) injury. (C) 2003 Elsevier Inc. All rights reserved.	Univ Miami, Sch Med, Neurotrauma Res Ctr, Dept Neurol Surg,Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043233, P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS43233, NS42133] Funding Source: Medline		Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dubal DB, 1999, J NEUROSCI, V19, P6385; Farace E, 2001, J NEUROSURG, V94, P863; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HAYASHI N, 1996, J CRIT MED, V8, P295; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; WAGNER AK, 2002, J NEUROTRAUM, V19, P1367; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; ZILLES L, 1985, CORTEX RAT STEREOTAX	60	40	42	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2003	184	2					1017	1026		10.1016/S0014-4886(03)00389-3			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	758KW	WOS:000187634400050	14769396				2022-02-06	
J	Kang, SK; Jun, ES; Bae, YC; Jung, JS				Kang, SK; Jun, ES; Bae, YC; Jung, JS			Interactions between human adipose stromal cells and mouse neural stem cells in vitro	DEVELOPMENTAL BRAIN RESEARCH			English	Article						neural stem cell; adipose stromal cell; neuron; differentiation; proliferation	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR PRODUCTION; ADULT MAMMALIAN BRAIN; BONE-MARROW; NEURONAL DIFFERENTIATION; DOPAMINERGIC-NEURONS; FUNCTIONAL RECOVERY; RAT; TRANSPLANTATION; MICE	Transplantation of adult mesenchymal stem cells (MSCs) into adult rat brain has been known to reduce functional deficits associated with stroke and traumatic brain injury. However, in injured brains, there is no evidence that transplanted MSCs replace lost host brain tissue. In this study, we determined in vitro interaction between human adipose tissue stromal cells (hATSCs), a kind of MSC, and neural stem cells (NSCs). hATSCs were isolated and proliferated from human adipose tissues, and NSCs from the subventricular zone of postnatal mice. When NSCs were cultured on mitomycin-treated hATSC monolayers, their proliferation was decreased, but neuronal differentiation was significantly induced. The percentage of neurons significantly increased in 7 days in cultures of NSCs on hATSCs feeder as compared to NSCs cultured on laminin-coated dishes. When the duration of the cultures was extended to 14 days, hATSCs supported the survival of neurons derived from NSCs. To determine the role of soluble factors from hATSCs, NSCs were cultured with hATSCs conditioned medium or co-cultured with permeable filter on which hATSCs were grown. Although proliferation of NSCs significantly decreased and glial differentiation increased under these experimental conditions, their neuronal differentiation was not affected, indicating that direct physical contact between hATSCs and NSCs is required for induction of neuronal differentiation. These data indicate that hATSCs may provide supportive roles on endogenous neural stem cells, when they are transplanted into damaged brain. (C) 2003 Elsevier B.V. All rights reserved.	Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Dept Plast Surg, Pusan 602739, South Korea		Jung, JS (corresponding author), Pusan Natl Univ, Coll Med, Dept Physiol, 1 Ga Ami Dong, Pusan 602739, South Korea.	jsjung@pusan.ac.kr					Blondel O, 2000, J NEUROSCI, V20, P8012; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; Imura T, 2003, J NEUROSCI, V23, P2824; Kang SK, 2001, NEUROSCI RES COMMUN, V29, P183, DOI 10.1002/nrc.10011; KANG SK, IN PRESS EXP NEUROL; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lou SJ, 2003, BRAIN RES, V968, P114, DOI 10.1016/S0006-8993(03)02224-8; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MICHAEL AS, 2002, DEV BRAIN RES, V137, P115; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; PARK LW, 2000, NEUROSCI RES, V40, P615; PETTERSSON P, 1984, ACTA MED SCAND, V215, P447; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; TOMQVIST N, 2000, EXP NEUROL, V164, P130; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	44	40	42	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	OCT 10	2003	145	1					141	149		10.1016/S0165-3806(03)00224-4			9	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	733RG	WOS:000186014000013	14519500				2022-02-06	
J	Schuhmann, MU; Mokhtarzadeh, M; Stichtenoth, DO; Skardelly, M; Klinge, PA; Gutzki, FM; Samii, M; Brinker, T				Schuhmann, MU; Mokhtarzadeh, M; Stichtenoth, DO; Skardelly, M; Klinge, PA; Gutzki, FM; Samii, M; Brinker, T			Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	52nd Annual Meeting of the German-Neurosurgical-Society	2001	BIELEFELD, GERMANY	German Neurosurg Soc		brain edema; cerebral contusion; leukotrienes; inflammation; LTB4; LTC4; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MAGNETIC-RESONANCE-SPECTROSCOPY; SUBARACHNOID HEMORRHAGE; BARRIER PERMEABILITY; FOCAL ISCHEMIA; RAT-BRAIN; POLYMORPHONUCLEAR LEUKOCYTES; NEUTROPHIL ACCUMULATION; CYSTEINYL-LEUKOTRIENES; PERITONEAL-MACROPHAGES	The post-traumatic changes of leukotrienes LTC4, LTD4, LTE4, and LTB4 in cerebrospinal fluid of rats from 10 min to 7 days were investigated after controlled cortical impact in relation to brain edema and cellular inflammatory response. LTC4 increased five-fold at 4 h, normalized at 24 h, and showed another tour-told increase at 7 days. The same pattern was observed for LTD4 and LTE4. LTB4 however, behaved differently: concentrations were lower and levels peaked two-fold at 24 h. Edema in the injured hemisphere increased continuously up to 24 h without change contralaterally. Leukocyte infiltration, macrophage presence and microglia activation were most prominent at 24 h, 7 days and 24 h respectively. Leukotriene changes in CSF seem to reflect those in the affected tissue, with a time delay and in lower concentrations, and were not linearly correlated to brain edema. The initially high leukotriene levels are rather likely to contribute to the cytotoxic edema than to enhance a vasogenic edema component. The profile of LTB4 was parallel to the time course of leukocyte infiltration, indicating initiation of infiltration as well as prolonged production by leukocytes themselves. The second leukotriene peak at 7 days is likely to follow a different pathway and might be related to a production in macrophages or activated glia.	Hannover Med Sch, Dept Neurosurg, D-3000 Hannover, Germany; Hannover Med Sch, Dept Clin Pharmacol, D-3000 Hannover, Germany; Nordstadt Hosp, Dept Neurosurg, Hannover, Germany		Schuhmann, MU (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurg, Johannisallee 34, D-04103 Leipzig, Germany.	mschuh@gmx.de	Skardelly, Marco/AAF-8680-2021				ABE M, 1992, PROSTAG LEUKOTR ESS, V45, P59, DOI 10.1016/0952-3278(92)90103-P; ABE M, 1990, BIOCHEM BIOPH RES CO, V171, P1344, DOI 10.1016/0006-291X(90)90834-A; AKTAN S, 1991, PROSTAG LEUKOTR ESS, V43, P247, DOI 10.1016/0952-3278(91)90037-6; BABA T, 1992, J NEUROSURG, V77, P403, DOI 10.3171/jns.1992.77.3.0403; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BLACK KL, 1994, J NEUROSURG, V81, P745, DOI 10.3171/jns.1994.81.5.0745; BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; Brock TG, 1998, BIOCHEM J, V329, P519; CENEDELLA RJ, 1975, LIPIDS, V10, P290, DOI 10.1007/BF02532702; CHEN S, 2003, IN PRESS EXP NEUROL; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DEMPSEY R J, 1986, Neurological Research, V8, P53; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DOROVINIZIS K, 1992, J NEUROPATH EXP NEUR, V51, P194, DOI 10.1097/00005072-199203000-00009; Dreher W, 1998, MAGNET RESON MED, V39, P878, DOI 10.1002/mrm.1910390605; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; FAULER J, 1991, CLIN SCI, V80, P497, DOI 10.1042/cs0800497; GAETANI P, 1992, ACTA NEUROL SCAND, V86, P184, DOI 10.1111/j.1600-0404.1992.tb05063.x; GAETANI P, 1991, NEUROSURGERY, V28, P853, DOI 10.1227/00006123-199106000-00011; Girard J, 1996, EUR J PHARMACOL, V300, P43, DOI 10.1016/0014-2999(95)00804-7; HARIRI RJ, 1989, J TRAUMA, V29, P1203, DOI 10.1097/00005373-198909000-00003; HAUPTS M, 1992, ACTA NEUROL SCAND, V85, P365; HOEHNBERLAGE M, 1995, MAGN RESON MED, V34, P824, DOI 10.1002/mrm.1910340607; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; HYNES N, 1991, BRAIN RES, V553, P4, DOI 10.1016/0006-8993(91)90222-H; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; KAEVER V, 1990, BIOCHEM PHARMACOL, V39, P1313, DOI 10.1016/0006-2952(90)90007-8; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MABE H, 1990, Neurological Research, V12, P165; MAMOT C, 1995, MOL BRAIN RES, V33, P79, DOI 10.1016/0169-328X(95)00108-5; Marmarou A, 2000, ACT NEUR S, V76, P349; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MINAMI N, 1991, ACTA NEUROPATHOL, V81, P401, DOI 10.1007/BF00293461; MINAMISAWA H, 1988, STROKE, V19, P372, DOI 10.1161/01.STR.19.3.372; NAMURA Y, 1994, ACTA NEUROCHIR, P296; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PALMBLAD J, 1981, BLOOD, V58, P658; PAOLETTI P, 1988, J NEUROSURG, V69, P488, DOI 10.3171/jns.1988.69.4.0488; Portella G, 2000, ACT NEUR S, V76, P273; REID GK, 1990, J BIOL CHEM, V265, P19818; Rosnowska M, 1997, Pol Merkur Lekarski, V2, P254; SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; SCHUHMANN MU, 2002, THESIS MED HOCHSCHUL; SEREGI A, 1990, J PHARM PHARMACOL, V42, P191, DOI 10.1111/j.2042-7158.1990.tb05383.x; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIMMET T, 1990, J NEUROCHEM, V54, P2091, DOI 10.1111/j.1471-4159.1990.tb04915.x; Stroop R, 1998, ACT NEUR S, V71, P303; Tsikas D, 1996, ANAL BIOCHEM, V236, P175, DOI 10.1006/abio.1996.0149; TSIKAS D, 1993, J CHROMATOGR-BIOMED, V622, P1, DOI 10.1016/0378-4347(93)80242-V; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Whalen MJ, 1998, ACT NEUR S, V71, P212; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874; Winking M, 1996, J CEREBR BLOOD F MET, V16, P737, DOI 10.1097/00004647-199607000-00026; Winking M, 1997, ACTA NEUROCHIR, V139, P764, DOI 10.1007/BF01420051; WINKING M, 1992, EICOSANOIDS OTHER BI	75	40	43	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2003	25	5					481	491		10.1179/016164103101201896			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	704PP	WOS:000184348900008	12866196				2022-02-06	
J	Malik, AS; Narayan, RK; Wendling, WW; Cole, RW; Pashko, LL; Schwartz, AG; Strauss, KI				Malik, AS; Narayan, RK; Wendling, WW; Cole, RW; Pashko, LL; Schwartz, AG; Strauss, KI			A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model	JOURNAL OF NEUROTRAUMA			English	Article						cyclooxygenase-2; neurosteroid; rat traumatic brain injury	SYSTEMIC-LUPUS-ERYTHEMATOSUS; BOVINE CEREBRAL-ARTERIES; INDUCIBLE CYCLOOXYGENASE; LIPID-PEROXIDATION; SULFATE; INHIBITION; NEURONS; MEMORY; MICE; STEROIDS	The purpose of this study was to investigate the efficacy of a novel steroid, fluasterone (DHEF, a dehydroepiandrosterone (DHEA) analog), at improving functional recovery in a rat model of traumatic brain injury (TBI). The lateral cortical impact model was utilized in two studies of efficacy and therapeutic window. DHEF was given (25 mg/kg, intraperitoneally) at the initial time point and once a day for 2 more days. Study A included four groups: sham injury, vehicle treated (n = 22); injured, vehicle treated (n = 30); injured, pretreated (5-10 min prior to injury, n = 24); and injured, posttreated (initial dose 30 min postinjury, n = 15). Study B (therapeutic window) included five groups: sham injury, vehicle treated (n = 17); injured, vehicle treated (n = 26); and three post-treatment groups: initial dose at 30 min (n = 18), 2 h (n = 23), or 12 h (n = 16) postinjury. Three criteria were used to grade functional recovery. In study A, DHEF improved beam walk performance both with pretreatment (79%) and 30-min posttreatment group (54%; p < 0.01, Dunnett vs. injured vehicle). In study B, the 12-h posttreatment group showed a 97% improvement in beam walk performance (p < 0.01, Dunnett). The 30-min and 12-h posttreatment groups showed a decreased incidence of falls from the beam, which reached statistical significance (p < 0.05, Dunnett). Tests of memory (Morris water maze) and neurological reflexes both revealed significant improvements in all DHEF treatment groups. In cultured rat mesangial cells, DHEF (and DHEA) potently inhibited interleukin-1beta-induced cyclooxygenase-2 (COX2) mRNA and prostaglandin (PGE2) production. In contrast, DHEF treatment did not alter injury-induced COX2 mRNA levels in the cortex or hippocampus. However, DHEF (and DHEA) relaxed ex vivo bovine middle cerebral artery preparations by about 30%, with an IC50 approximate to 40 muM. This was a direct effect on the vascular smooth muscle, independent of the endothelial cell layer. Fluasterone (DHEF) treatments improved functional recovery in a rat TBI model. Possible mechanisms of action for this novel DHEA analog are discussed. These findings suggest an exciting potential use for this agent in the clinical treatment of traumatic brain injury.	Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Temple Univ, Sch Med, Dept Anesthesia, Philadelphia, PA 19122 USA; Temple Univ, Sch Med, Fels Inst, Philadelphia, PA 19122 USA		Strauss, KI (corresponding author), 231 Albert Sabin Way ML515, Cincinnati, OH 45267 USA.	kstrauss@uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38654, R01 NS038654] Funding Source: Medline		Aragno M, 2000, BIOCHEM PHARMACOL, V60, P389, DOI 10.1016/S0006-2952(00)00327-0; BABIOR BM, 1982, CAN J PHYSIOL PHARM, V60, P1353, DOI 10.1139/y82-202; Baulieu EE, 1996, J ENDOCRINOL, V150, pS221; Boccuzzi G, 1997, FREE RADICAL BIO MED, V22, P1289, DOI 10.1016/S0891-5849(96)00543-6; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; BREEN RA, 1961, J COMP PHYSIOL PSYCH, V54, P498, DOI 10.1037/h0046436; CERRO SD, 1995, GLIA, V14, P65; Derksen RHWM, 1998, SEMIN ARTHRITIS RHEU, V27, P335, DOI 10.1016/S0049-0172(98)80013-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; FENG JF, 1995, NEURAL PROCESS LETT, V2, P9, DOI 10.1007/BF02309009; FLOOD JF, 1988, BRAIN RES, V448, P178, DOI 10.1016/0006-8993(88)91116-X; FLOOD JF, 1988, BRAIN RES, V447, P269, DOI 10.1016/0006-8993(88)91129-8; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199; HALL ED, 1996, NEUROTRAUMA, P1405; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HASTINGS LA, 1988, CARCINOGENESIS, V9, P1099, DOI 10.1093/carcin/9.6.1099; Hata T, 1996, ACTA OBSTET GYN SCAN, V75, P343, DOI 10.3109/00016349609033328; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; HEUSER G, 1961, ENDOCRINOLOGY, V69, P915, DOI 10.1210/endo-69-5-915; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Imamura M, 1998, BIOCHEM BIOPH RES CO, V243, P771, DOI 10.1006/bbrc.1998.8177; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IRWIN S, 1966, SCIENCE, V152, P100, DOI 10.1126/science.152.3718.100; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Kipper-Galperin M, 1999, INT J DEV NEUROSCI, V17, P765, DOI 10.1016/S0736-5748(99)00067-2; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Li H, 2001, BRAIN RES, V888, P263, DOI 10.1016/S0006-8993(00)03077-8; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; MARCZYNSKI TJ, 1994, NEUROBIOL AGING, V15, P69, DOI 10.1016/0197-4580(94)90146-5; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; Maurice T, 1997, BEHAV BRAIN RES, V83, P159, DOI 10.1016/S0166-4328(97)86061-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mei J. M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P585; Moore SA, 1999, ADV EXP MED BIOL, V469, P125; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PASHKO LL, 1991, CARCINOGENESIS, V12, P2189, DOI 10.1093/carcin/12.11.2189; RAINERI R, 1970, BIOCHEMISTRY-US, V9, P2233, DOI 10.1021/bi00813a003; RATKO TA, 1991, CANCER RES, V51, P481; Reddy DS, 1998, BRAIN RES, V791, P108, DOI 10.1016/S0006-8993(98)00085-7; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Robertson C. S., 1996, NEUROTRAUMA, P487; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; SADOWSKI IJ, 1985, INT J BIOCHEM, V17, P1023, DOI 10.1016/0020-711X(85)90250-2; SARA SJ, 1994, BRAIN RES BULL, V35, P457, DOI 10.1016/0361-9230(94)90159-7; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; SCHWARTZ AG, 1994, J GERONTOL, V49, pB37, DOI 10.1093/geronj/49.2.B37; SCHWARTZ AG, 1988, CANCER RES, V48, P4817; SCHWARTZ AG, 1993, J CELL BIOCHEM, P73; SCHWARTZ AG, 1989, CARCINOGENESIS, V10, P1809; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Soares HD, 1995, J NEUROSCI, V15, P8223; SPIVAK CE, 1994, SYNAPSE, V16, P113, DOI 10.1002/syn.890160205; STANTON PK, 1985, J NEUROSCI, V5, P2169; STEIN D, 1990, NEUROSCIENTIST, V4, P435; STRAUSS K, 1998, TRAUMA Q, V13, P353; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; van Vollenhoven RF, 1998, J RHEUMATOL, V25, P285; VANVOLLENHOVEN RF, 1994, ARTHRITIS RHEUM, V37, P1305, DOI 10.1002/art.1780370906; vanVollenhoven RF, 1995, ARTHRITIS RHEUM, V38, P1826, DOI 10.1002/art.1780381216; WENDLING WW, 1987, STROKE, V18, P591, DOI 10.1161/01.STR.18.3.591; WENDLING WW, 1991, STROKE, V22, P66, DOI 10.1161/01.STR.22.1.66; WENDLING WW, 1994, J NEUROSURG ANESTH, V6, P186; Williams PJ, 1997, ARTHRITIS RHEUM-US, V40, P907, DOI 10.1002/art.1780400519; Wolkowitz OM, 1995, ANN NY ACAD SCI, V774, P337; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	74	40	41	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					463	476		10.1089/089771503765355531			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900006	12803978	Green Accepted			2022-02-06	
J	Carbonell, WS; Mandell, JW				Carbonell, WS; Mandell, JW			Transient neuronal but persistent astroglial activation of ERK/MAP kinase after focal brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; C57bl/6 mice; extracellular signal-regulated kinase; forebrain stab lesion; gliosis; MAP kinase; traumatic brain injury	PROTEIN-KINASE; MAP KINASE; IN-VIVO; RAT; TRAUMA; ASTROCYTES; ISCHEMIA; CELL; TRANSCRIPTION; FOREBRAIN	Astrogliosis is a nearly ubiquitous response to a variety of insults to the central nervous system (CNS). This reaction is triggered rapidly, but can persist for years after the initial trauma. Little is known about the signaling mechanisms responsible for this activation and its chronic maintenance. Extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) activation is implicated in several functions important to the reactive glial phenotype such as cellular proliferation and motility. Here we utilize immunohistochemistry with a phosphorylation state-specific antibody (pERK) to characterize the temporal and spatial pattern of ERK/MAPK activation in neurons and glia following a forebrain stab lesion (FSL) in mice. Early activation (1 h) was primarily in perilesional neuronal elements, particularly of the hippocampus. Occasional perilesional glia were also positive for pERK. Additionally, ependymal cells bilaterally stained prominently for pERK. These patterns of pERK immunoreactivity at 1 h were abolished by pretreatment with the selective MEK inhibitor, SL327. ERK/MAPK activation at later time points between 1 day (d) and 30d was primarily restricted to perilesional astrocytes with maximum labeling at 3d. However, pERK-positive astrocytes represented only a subset of total GFAP-positive cells and were found more proximal to the lesion suggesting specific functional activation of these cells. Finally, immunostaining for the phosphorylated form of cAMP response element-binding (CREB) protein, a downstream target of the ERK/MAPK cascade, was increased in perilesional glia 7d after FSL. Sustained activation of the ERK/MAPK signaling pathway in perilesional reactive glia suggests a critical role for this cascade in astrogliosis.	Univ Virginia, Sch Med, Dept Pathol Neuropathol, HSC, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Grad Program Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Med Scientist Training Program, Charlottesville, VA 22908 USA		Mandell, JW (corresponding author), Univ Virginia, Sch Med, Dept Pathol Neuropathol, HSC, POB 800904, Charlottesville, VA 22908 USA.	jwm2m@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002065] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5 T32 GM07267-23] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02 NS02065] Funding Source: Medline		ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Crepel V, 1998, J NEUROSCI, V18, P1196; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Garrido YCS, 1998, BRAIN RES BULL, V47, P223, DOI 10.1016/S0361-9230(98)00075-6; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LAPING NJ, 1994, BRAIN PATHOL, V4, P259, DOI 10.1111/j.1750-3639.1994.tb00841.x; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Lee WJ, 2003, GLIA, V41, P15, DOI 10.1002/glia.10131; Lin BW, 1998, ACTA NEUROPATHOL, V95, P511, DOI 10.1007/s004010050832; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Miura T, 2000, EXP NEUROL, V166, P115, DOI 10.1006/exnr.2000.7493; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Rajan P, 1998, J NEUROSCI, V18, P3620; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUZUKI T, 1995, NEUROSCI RES, V22, P277, DOI 10.1016/0168-0102(95)00902-6; Varga AW, 2000, LEARN MEMORY, V7, P321, DOI 10.1101/lm.35300; Wang H, 2001, BIOCHEM BIOPH RES CO, V286, P869, DOI 10.1006/bbrc.2001.5482; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; [No title captured]	43	40	42	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					327	336		10.1089/089771503765172282			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900002	12866812				2022-02-06	
J	Dempsey, RJ; Rao, VLR				Dempsey, RJ; Rao, VLR			Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats	JOURNAL OF NEUROSURGERY			English	Article						cytidinediphosphocholine; controlled cortical impact; hippocampus; neuroprotection; phospholipase; secondary neuronal death; rat	GLUTAMATE TRANSPORTER GLT-1; NITRIC-OXIDE SYNTHASE; BARRIER BREAKDOWN; CDP-CHOLINE; CITICOLINE; COMBINATION; ACTIVATION; DEFICITS; IMPACT; EDEMA	Object. In previous studies at their laboratory the authors showed that cytidinediphosphocholine (CDP-choline), an intermediate of phosphatidylcholine synthesis, decreases edema formation and blood-brain barrier disruption following traumatic brain injury (TBI). In the present study the authors investigate whether CDP-choline protects hippocampal neurons after controlled cortical impact (CCI)-induced TBI in adult rats. Methods. After adult male Sprague-Dawley rats had been anesthetized with halothane, a moderate-grade TBI was induced with the aid of a CCI device set at a velocity of 3 m/second, creating a 2-mm deformation. Sham-operated rats, which underwent craniectomy without impact served as controls. The CDP-choline (100, 200, and 400 mg/kg body weight) or saline was injected into the animals twice (once immediately postinjury and once 6 hours postinjury). Seven days after the injury, the rats were neurologically evaluated and killed, and the number of hippocampal neurons was estimated by examining thionine-stained brain sections. By 7 days postinjury, there was a significant amount of neuronal death in the ipsilateral hippocampus in the CA2 (by 53 +/- 7%, p < 0.05) and CA3 (by 59 +/- 9%, p < 0.05) regions and a contusion (volume 34 +/- 8 mm(3)) in the ipsilateral cortex compared with sham-operated control animals. Rats subjected to TBI also displayed severe neurological deficit at 7 days postinjury. Treating rats with CDP-choline (200 and 400 mg/kg, intraperitoneally) significantly prevented TBI-induced neuronal loss in the hippocampus, decreased cortical contusion volume, and improved neurological recovery. Conclusions. Treatment with CDP-choline decreased brain damage following TBI.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA		Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, K4-818 CSC,600 Highland Ave, Madison, WI 53792 USA.	Dempsey@neurosurg.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28000, NS31220] Funding Source: Medline		Adibhatla RM, 2002, J NEUROCHEM, V80, P12; Alkan T., 2001, Archives of Physiology and Biochemistry, V109, P161, DOI 10.1076/apab.109.2.161.4273; Andersen M, 1999, STROKE, V30, P1464, DOI 10.1161/01.STR.30.7.1464; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bonventre JV, 1997, J LIPID MEDIAT CELL, V16, P199; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.0.CO;2-B; RAO AM, 2001, STROKE, V32, P2376; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2001, BRAIN RES, V911, P96; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shuaib A, 2000, EXP NEUROL, V161, P733, DOI 10.1006/exnr.1999.7314; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	45	40	45	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2003	98	4					867	873		10.3171/jns.2003.98.4.0867			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	662AD	WOS:000181922400021	12691414				2022-02-06	
J	Strauss, DJ; Day, SM; Shavelle, RM; Wu, YW				Strauss, DJ; Day, SM; Shavelle, RM; Wu, YW			Remote symptomatic epilepsy - Does seizure severity increase mortality?	NEUROLOGY			English	Article							LIFE EXPECTANCY; LONG-TERM; COHORT; CHILDREN; DEATH	Objective: To investigate the excess mortality due to remote symptomatic epilepsy, taking account of frequency and type of seizures. Methods: The authors compared mortality in persons with (n = 8,156) and without (n = 72,526) history of epilepsy in a 1988 to 1999 California population of persons with mild developmental disabilities. Subjects had traumatic brain injury, cerebral palsy, Down syndrome, autism, or no identifiable condition. There were 506,204 person-years of data, with 1,523 deaths. Excess death rates and standardized mortality ratios were computed for the persons in the study with epilepsy, relative to those in the study without epilepsy. Controlled comparisons were made using logistic regression on person-years. Results: Compared to subjects with no epilepsy, the excess mortality was six (deaths per 1,000 persons per year) for persons with a recent (<12 months) history of status epilepticus, five for a recent history of generalized tonic-clonic seizure, three for a recent history of nonconvulsive seizures, and less than one for a history of epilepsy but no recent events. Proportion in remission and excess mortality showed no change over the 12-year study period. Conclusions: Persistent seizures are associated with increased mortality in remote symptomatic epilepsy. Mortality is highest among individuals with status epilepticus or generalized convulsions.	Univ Calif San Francisco, Life Expectancy Project, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA		Day, SM (corresponding author), 1439 17th Ave, San Francisco, CA 94122 USA.		Day, Steven/P-1002-2019	Day, Marc/0000-0002-1711-3963; Day, Steven/0000-0001-8305-5813			AGRESTI A, 1990, CATEGORICAL DATA ANA, P366; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; Bak S, 2000, Ugeskr Laeger, V162, P3578; Bell GS, 2001, SEIZURE-EUR J EPILEP, V10, P306, DOI 10.1053/seiz.2001.0584; BRACKENRIDGE RDC, 1998, MED SELECTION LIFE R; *CAL DEP DEV SERV, 1986, CLIENT DEV EV REP; *CIT ASS, 1998, IND EV DEP DEV SERV; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; *DEP HLTH SERV CTR, 1983, STAT CAL 1983 1997 A; HARRIS CW, 1982, INTERRATER RELIABILI; HARVEY AS, 1993, EPILEPSIA, V34, P597, DOI 10.1111/j.1528-1157.1993.tb00434.x; Kahn HA, 1989, STAT METHODS EPIDEMI, P97; Lew EA, 1990, MED RISKS TRENDS MOR; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lindsten H, 2000, EPILEPSIA, V41, P1469, DOI 10.1111/j.1528-1157.2000.tb00124.x; Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Olafsson E, 1998, EPILEPSIA, V39, P89, DOI 10.1111/j.1528-1157.1998.tb01279.x; PRESTON TW, 1965, J I ACTUARIES, V92, P27; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636; Shackleton DP, 2002, EPILEPSIA, V43, P445, DOI 10.1046/j.1528-1157.2002.10301.x; Shinnar S, 2002, J CHILD NEUROL, V17, pS4, DOI 10.1177/08830738020170010201; *SOC ACT ASS LIF I, 1986, MED IMP STUD 1983, V1; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; *STAT CAL DEP FIN, 1988, STAT CAL DEP FIN RAC; Strauss D, 2000, J Insur Med, V32, P217; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; WIDAMANT KF, 1984, 92 ANN M AM PSYCH AS	33	40	41	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 11	2003	60	3					395	399		10.1212/WNL.60.3.395			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	646BG	WOS:000181014500007	12578917				2022-02-06	
J	Visser-Keizer, AC; Meyboom-De Jong, B; Deelman, BG; Berg, IJ; Gerritsen, MJJ				Visser-Keizer, AC; Meyboom-De Jong, B; Deelman, BG; Berg, IJ; Gerritsen, MJJ			Subjective changes in emotion, cognition and behaviour after stroke: Factors affecting the perception of patients and partners	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; HOSPITAL ANXIETY; DEPRESSION SCALE; AWARENESS; UNAWARENESS; ANOSOGNOSIA; DISABILITY; LESIONS	The presence and severity of changes in emotion and cognition experienced by left- and right-sided stroke patients and observed by their partners were compared at 3 months poststroke. The results showed that, regardless of the side of stroke, several changes were reported by half of the stroke patients and their partners. It appeared that while left hemisphere stroke patients agreed with their partners on the number and severity of most changes, partners of right hemisphere patients reported more frequent and more severe changes than the patients themselves. The level of observability of the altered behaviour, distress of the partner, distress of left-sided stroke patients and hemispatial neglect of right-sided stroke patients emerged a factors related to disagreement between stroke patient and partner.	Univ Groningen, Dept Gen Practice, NL-9713 BZ Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol & Gerontol, Groningen, Netherlands		Visser-Keizer, AC (corresponding author), Univ Groningen, Dept Gen Practice, Bloemsingel 1, NL-9713 BZ Groningen, Netherlands.						Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; Damasio A., 1999, FEELING WHAT HAPPENS; *DEP NEUR, 1986, DE 15 WOORD TEST 15; GAINOTTI G, 1993, COGNITION EMOTION, V7, P71, DOI 10.1080/02699939308409178; Gerritsen M, 2001, Tijdschr Gerontol Geriatr, V32, P24; GERRITSEN M, 2000, Z NEUROPSYCHOLOGIE, V10, P229; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; HIBBARD MR, 1992, REHABIL PSYCHOL, V37, P103, DOI 10.1037/0090-5550.37.2.103; Hochstenbach J, 1997, TSG, V75, P479; HOCHSTENBACH J, 1999, COGNITIVE EMOTIONAL; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; JOHNSON BFG, 1995, CHEM-EUR J, V1, P252, DOI 10.1002/chem.19950010409; Knapp P, 1999, STROKE, V30, P934, DOI 10.1161/01.STR.30.5.934; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAHONEY F I, 1965, Md State Med J, V14, P61; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOTOMURA N, 1988, JPN J PSYCHIAT NEUR, V42, P747; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rolls E.T., 1999, BRAIN EMOTION; SCHURE LM, 1995, PARTNERS CVA PATIENT; Snijders J. T, 1988, SNIJDERS OOMEN NIET; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; WILLANGER R, 1981, ACTA NEUROL SCAND, V64, P310; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	40	40	0	11	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					1032	1045		10.1076/jcen.24.8.1032.8383			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100005	12650229				2022-02-06	
